<SEC-DOCUMENT>0000950123-20-007024.txt : 20200924
<SEC-HEADER>0000950123-20-007024.hdr.sgml : 20200924
<ACCEPTANCE-DATETIME>20200717171053
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-20-007024
CONFORMED SUBMISSION TYPE:	DRS
PUBLIC DOCUMENT COUNT:		44
FILED AS OF DATE:		20200717
<PUBLIC-REL-DATE>20200924
DATE AS OF CHANGE:		20200903

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Opthea Ltd
		CENTRAL INDEX KEY:			0001815620
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		DRS
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-03304
		FILM NUMBER:		201034351

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 4
		STREET 2:		650 CHAPEL STREET
		CITY:			SOUTH YARRA, VICTORIA
		STATE:			C3
		ZIP:			3141
		BUSINESS PHONE:		61 3 9826 0399

	MAIL ADDRESS:	
		STREET 1:		LEVEL 4
		STREET 2:		650 CHAPEL STREET
		CITY:			SOUTH YARRA, VICTORIA
		STATE:			C3
		ZIP:			3141
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>Draft Registration Statement</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>As confidentially submitted to the United States Securities and Exchange Commission
on July&nbsp;17, 2020. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registration No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:16%">&nbsp;</P></center> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B><FONT
STYLE="white-space:nowrap">FORM&nbsp;F-1</FONT> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>REGISTRATION STATEMENT </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B><I>UNDER </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B><I>THE SECURITIES ACT OF&nbsp;1933 </I></B></FONT></P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:16%">&nbsp;</P></center> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>Opthea
Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:16%">&nbsp;</P></center>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Australia</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2836</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not Applicable</B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction of</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>incorporation or organization)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Primary Standard Industrial</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Classification Code Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S.&nbsp;Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification&nbsp;Number)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Opthea Limited
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Level&nbsp;4 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>650 Chapel Street </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>South Yarra, Victoria 3141 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Australia </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>+ 61 3 9826 0399 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Address, including zip code, and telephone number, including area code, of registrant&#146;s principal executive offices) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Corporation Service Company </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1180 Avenue of the Americas, Suite 210 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>New York, New York 10036 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Name, address, including zip code, and
telephone number, including area code, of agent for service) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:16%">&nbsp;</P></center> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Copies to: </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Ferish Patel</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>John McKenna</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Milson Yu</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cooley LLP</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Ocean Financial Centre</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>10 Collyer Quay</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Raffles Place</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Singapore 049315</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>+65 6962 7500</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Divakar Gupta</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Brent Siler</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cooley LLP</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>55 Hudson Yards</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>New York, NY&nbsp;10001</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(212)
<FONT STYLE="white-space:nowrap">479-6000</FONT></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Craig Semple</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Gilbert + Tobin</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Level&nbsp;22, 101 Collins Street</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Melbourne, Victoria 3000</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Australia</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>+61 3 8656 3300</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Edwin&nbsp;O&#146;Connor</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Seo Salimi</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Goodwin&nbsp;Procter&nbsp;LLP</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>620 8th Avenue</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>New York, NY&nbsp;10018</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(212)
<FONT STYLE="white-space:nowrap">813-8800</FONT></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Michael&nbsp;Ziegelaar</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Herbert&nbsp;Smith&nbsp;Freehills</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Level&nbsp;42, 101 Collins
Street</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Melbourne, Victoria 3000</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Australia</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>+61 3 9288 1234</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Approximate date of commencement of proposed sale to the
public</B>: As soon as practicable after this Registration Statement becomes effective. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act, check the following box:&nbsp;&nbsp;&#9744;
</FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If this Form is filed to register additional securities for an offering pursuant to
Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If this Form is a post-effective amendment filed pursuant to
Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If this Form is a post-effective amendment filed pursuant to
Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Emerging growth company&nbsp;&nbsp;&#9746; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards&#134; provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&#9746; </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Calculation of Registration Fee </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>


<TR STYLE="font-size:1px">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Title of Each Class&nbsp;of</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Securities to be Registered<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></B></FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Proposed<BR>Maximum<BR>Aggregate<BR>Offering&nbsp;Price<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Amount&nbsp;of<BR>Registration&nbsp;
Fee<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP></B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ordinary shares, no par value</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">All ordinary shares in the offering will be in the form of American Depositary Shares, or ADSs, with each ADS representing
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares. ADSs issuable upon deposit of the ordinary shares registered hereby are being registered pursuant to a separate registration statement
on Form <FONT STYLE="white-space:nowrap">F-6.</FONT> </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes ordinary shares (which may be in the form of ADSs) that the underwriters have an option to purchase. See &#147;Underwriting.&#148; </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Estimated solely for the purpose of computing the amount of the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended, based on an
estimate of the proposed maximum offering price. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:16%">&nbsp;</P></center> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until
the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the Registration
Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:16%">&nbsp;</P></center> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#134;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The term &#147;new or revised financial accounting standard&#148; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards
Codification after April&nbsp;5, 2012. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXPLANATORY NOTE </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the applicable provisions of the Fixing America&#146;s Surface Transportation Act, we are omitting
our financial statements (and related financial information) as of and for the fiscal year ended June&nbsp;30, 2018 and as of and for the six months ended December&nbsp;31, 2019 and 2018 because they relate to historical periods that we believe will
not be required to be included in the prospectus at the time of the contemplated offering. We intend to amend this registration statement to include all required financial information&nbsp;at the date of such amendment before distributing a
preliminary prospectus to investors. </FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2" COLOR="#cc062a"><B>The information in this preliminary prospectus is not complete and may be changed. We may not
sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and we are not soliciting an offer to buy these securities in
any jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2" COLOR="#cc062a"><B>SUBJECT TO COMPLETION, DATED &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PRELIMINARY PROSPECTUS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g04e62.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;American Depositary Shares </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>representing &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ordinary Shares
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per American Depositary
Share </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This is the initial public offering of our American
depositary shares, or ADSs, in the United States, representing &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares of Opthea Limited. Each ADS represents
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares, no par value, deposited with &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, as
depositary, and the ADSs may be evidenced by American depositary receipts. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have granted the underwriters an option to purchase up to an additional&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADSs to cover over-allotments, if
any. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have applied to list the ADSs on the
Nasdaq Global Market under the symbol &#147;OPT.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our ordinary shares are listed on the Australian Securities Exchange under the symbol &#147;OPT.&#148; On &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2020, the last reported sale price of our ordinary shares on the Australian Securities Exchange was A$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share, equivalent to a price of
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS, after giving effect to the Australian dollar/U.S. dollar exchange rate of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, and an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-to-1. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The final offering price per ADS in U.S. dollars and the
corresponding offering price per ordinary share in Australian dollars will be determined through negotiations between us and the representatives of the underwriters and by reference to the prevailing market prices of our ordinary shares on the
Australian Securities Exchange after taking into account market conditions and other factors. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:16%">&nbsp;</P></center> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Investing in the ADSs involves a high degree of risk. See &#147;<A HREF="#cov947560_100">Risk Factors</A>&#148; beginning on
page&nbsp;11 of this prospectus. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are an
&#147;emerging growth company&#148; as that term is used in the Jumpstart Our Business Startups Act of 2012 and, as such, have elected to comply with certain reduced public company reporting requirements. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Neither the U.S. Securities and Exchange Commission nor
any U.S. state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Per&nbsp;ADS</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Public offering price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Underwriting discounts and commissions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds, before expenses, to Opthea Limited</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have agreed to reimburse the underwriters for certain expenses. See &#147;Underwriting.&#148; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The underwriters expect to deliver the ADSs to purchasers on or
about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020 through the book-entry facilities of The Depository Trust Company. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Citigroup</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SVB Leerink</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020. </FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Page</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_1">Prospectus Summary</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_2">The Offering</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_3">Summary Consolidated Financial Data</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_4">Risk Factors</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_5">Special Note Regarding Forward-Looking Statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">69</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_6">Industry and Market Data</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">71</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_7">Use of Proceeds</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">72</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_8">Dividend Policy</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">73</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_9">Capitalization</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_10">Dilution</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">75</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_11">Selected Consolidated Financial Data</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">77</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_12">Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">79</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_13">Business</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">94</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_14">Management</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">143</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_15">Certain Relationships and Related Party Transactions</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">152</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_16">Principal Shareholders</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">154</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_17">Description of Share Capital</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">156</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_18">Description of American Depositary Shares</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">163</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_19">Shares and American Depositary Shares Eligible for Future Sale</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">174</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_20">Material United States Federal Income and Australian Tax Considerations</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">176</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_21">Enforcement of Civil Liabilities</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">186</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_22">Underwriting</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">187</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_23">Expenses Relating to the Offering</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">195</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_24">Legal Matters</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">195</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_25">Experts</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">195</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_26">Where You Can Find More Information</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">195</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom947560_27">Index to Consolidated Financial Statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">F-1</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>We are responsible for the information contained in this
prospectus and any free writing prospectus we prepare or authorize. We and the underwriters have not authorized anyone to provide you with different information. We and the underwriters take no responsibility for, and can provide no assurance as to
the reliability of, any other information others may give you. We are not, and the underwriters are not, making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should not assume that the
information contained in this prospectus is accurate as of any date other than its date. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>For investors outside the United States: neither we nor any of the underwriters have done anything that would permit this offering or possession or distribution of this prospectus or any free writing
prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus or any free writing prospectus must inform themselves about, and
observe any restrictions relating to, the offering of the ADSs and the distribution of this prospectus and any free writing prospectus outside the United States. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are incorporated under the laws of Australia, and a
majority of our outstanding ordinary shares are owned <FONT STYLE="white-space:nowrap">by&nbsp;non-U.S.&nbsp;residents.</FONT> Under the rules of the U.S. Securities and Exchange Commission, or the SEC, we are eligible for treatment as a
&#147;foreign private issuer.&#148; As a foreign private issuer, we will not be required to file periodic reports and financial statements with the SEC as frequently or as promptly as domestic registrants whose securities are registered under
the&nbsp;Securities Exchange Act of 1934, as amended, or the Exchange Act. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">i </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our reporting and functional currency is the Australian dollar, and our financial
statements included elsewhere in this prospectus are presented in Australian dollars. The consolidated financial statements and related notes included elsewhere in this prospectus have been prepared under the International Financial Reporting
Standards, or IFRS, as issued by the International Accounting Standards Board, or IASB, which differs in certain significant respects from U.S. Generally Accepted Accounting Principles, or GAAP. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All references in this prospectus to &#147;US$,&#148;
&#147;U.S. dollars,&#148; and &#147;dollars&#148; mean U.S. dollars and all references to &#147;A$&#148; mean Australian dollars, unless otherwise noted. Throughout this prospectus, all references to &#147;ADSs&#148; mean American depositary shares,
each of which represents&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of our ordinary shares, no par value, and all references to &#147;ADRs&#148; mean the American depositary receipts that evidence
the ADSs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus contains translations
of some Australian dollar amounts into U.S. dollars. Except as otherwise stated in this prospectus, all translations from Australian dollars to U.S. dollars are based on the rate published by the Reserve Bank of Australia as of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020. No representation is made that the Australian dollar amounts referred to in this prospectus could have been or could be converted into U.S.
dollars at such rate. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Opthea,&#148; the Opthea logo and other trademarks or service marks of Opthea appearing in this prospectus are
the property of Opthea or its subsidiary. Solely for convenience, the trademarks, service marks and trade names referred to in this prospectus are listed without the <FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and <FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT> symbols, but such
references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their right thereto. All other trademarks, trade names and service marks appearing in this prospectus are
the property of their respective owners. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">ii </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_1"></A>PROSPECTUS SUMMARY </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>This summary highlights selected information contained
elsewhere in this prospectus. This summary does not contain all of the information you should consider before investing in our ADSs. You should read this entire prospectus, and the registration statement of which this prospectus is a part, including
&#147;Risk Factors,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; and our consolidated financial statements and the related notes included elsewhere in this prospectus, before making an
investment decision. Unless otherwise indicated or the context otherwise requires, &#147;Opthea,&#148; the &#147;Company,&#148; &#147;our company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to Opthea Limited and its consolidated
subsidiary, taken as a whole. </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Overview
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a clinical stage biopharmaceutical
company developing a novel therapy for the treatment of highly prevalent and progressive retinal diseases. We are developing our Phase <FONT STYLE="white-space:nowrap">3-ready</FONT> product candidate,
<FONT STYLE="white-space:nowrap">OPT-302,</FONT> a biologic designed to inhibit <FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D,</FONT> to complement <FONT STYLE="white-space:nowrap">VEGF-A</FONT>
inhibitors for the treatment of ophthalmic diseases. <FONT STYLE="white-space:nowrap">Anti-VEGF-A</FONT> therapies represent the standard of care for wet <FONT STYLE="white-space:nowrap">age-related</FONT> macular degeneration, or AMD, and other
retinal diseases; however, there remains a significant unmet medical need as many patients do not adequately respond to these treatments. As the only biologic inhibitor of <FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT
STYLE="white-space:nowrap">VEGF-D</FONT> in clinical development, <FONT STYLE="white-space:nowrap">OPT-302</FONT> differs from standard of care therapies and when administered in combination with a <FONT STYLE="white-space:nowrap">VEGF-A</FONT>
inhibitor, is designed to achieve broader inhibition of the vascular endothelial growth factor, or VEGF, family and target a mechanism of clinical resistance to improve visual acuity. Our lead indication for
<FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy is wet AMD, a chronic, progressive disease and the leading cause of vision loss for individuals over the age of 50. In a 366-patient Phase 2b clinical trial for the treatment of wet
AMD, <FONT STYLE="white-space:nowrap">OPT-302,</FONT> in combination with a standard of care <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy, ranibizumab (Lucentis), demonstrated a statistically significant superior mean gain in visual
acuity over ranibizumab monotherapy at week 24. We intend to initiate two pivotal Phase 3 clinical trials in treatment-naive patients with wet AMD to evaluate the efficacy and safety of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination
with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy compared to <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapy in the first half of 2021. We expect to report topline data from these Phase 3 clinical trials in 2023. In
addition to our clinical trials in wet AMD, we have observed evidence of improved clinical outcomes in a Phase 1b/2a clinical trial of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with another standard of care <FONT
STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy, aflibercept (Eylea), in patients with treatment-refractory diabetic macular edema, or DME. We retain worldwide rights to develop and commercialize <FONT STYLE="white-space:nowrap">OPT-302</FONT>
for the treatment of wet AMD and DME and believe that the novel treatment mechanism of <FONT STYLE="white-space:nowrap">OPT-302</FONT> has the potential to provide therapeutic benefit for other progressive eye diseases. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Wet AMD is a rapidly progressing disease with loss of central
vision developing over a period of weeks to months in which abnormal new blood vessels form in the back of the eye in a process called choroidal neovascularization. These newly formed vessels are highly permeable, leaking exudate leading to fluid
accumulation and retinal lesion formation. This, in turn, adversely affects sensory cells in the retina and if left untreated, results in rapid loss of visual acuity. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Wet AMD affects approximately one million people in the
United States and 2.5&nbsp;million people in Europe. The standard of care for wet AMD and other ocular neovascular diseases is the administration of monotherapies that primarily inhibit <FONT STYLE="white-space:nowrap">VEGF-A.</FONT> These
therapeutic agents, which include ranibizumab and aflibercept, prevent <FONT STYLE="white-space:nowrap">VEGF-A</FONT> molecules from binding to, and activating, VEGF receptors and thereby inhibit the formation and permeability of blood vessels.
Ranibizumab and aflibercept had combined annual worldwide sales of over $11.9&nbsp;billion in 2019. As the risk of developing wet AMD increases with age, it is predicted that the overall aging of the population will result in a significant increase
in the number of wet AMD cases, both in the United States and worldwide. Given the suboptimal clinical responses that many patients experience despite receiving standard </FONT></P>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
of care treatments, we believe there is a significant and expanding market opportunity for novel therapies that can improve vision in patients with wet AMD. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">OPT-302</FONT> is designed
to address a deficiency in the treatment paradigm for wet AMD and other retinal diseases, such as DME, by targeting alternate members of the VEGF family, namely <FONT STYLE="white-space:nowrap">VEGF-C</FONT> and
<FONT STYLE="white-space:nowrap">VEGF-D,</FONT> which are not targeted by current standard of care therapies. <FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D</FONT> function in parallel with <FONT
STYLE="white-space:nowrap">VEGF-A</FONT> to drive neovascularization and vascular leakage, which are key hallmarks of both wet AMD and DME. In addition, treatment with <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors leads to upregulation
of <FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D</FONT> to compensate for <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibition, which may represent an important mechanism of clinical resistance to <FONT
STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapy. We are developing <FONT STYLE="white-space:nowrap">OPT-302</FONT> to be used in combination with standard of care <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapies to achieve
broader inhibition of the VEGF family, with the goal of improving overall efficacy and demonstrating superior vision gains over that which can be achieved by inhibiting <FONT STYLE="white-space:nowrap">VEGF-A</FONT> alone. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In our completed Phase 2b wet AMD clinical trial, <FONT
STYLE="white-space:nowrap">OPT-302</FONT> in combination with ranibizumab demonstrated a statistically significant superior mean gain in visual acuity at week 24 compared to patients treated with ranibizumab with a sham injection, which we refer to
as ranibizumab monotherapy. The trial was an international, multi-center, double-masked trial in 366 treatment-naive patients with wet AMD. Patients were randomized into three groups and received intravitreal injections every four weeks of either
0.5 mg or 2.0 mg <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with 0.5 mg ranibizumab or 0.5 mg ranibizumab monotherapy. Patients treated with 2.0 mg <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy demonstrated
a statistically significant improvement in visual acuity compared to patients treated with ranibizumab monotherapy. In the patients that received 2.0 mg <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy, visual acuity improved at
week 24 from baseline by a mean of +14.2 letters compared to +10.8 letters for those treated with ranibizumab monotherapy, a statistically significant benefit of +3.4 letters. Patients that received 2.0 mg
<FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy also demonstrated improvements in retinal anatomy which were consistent with the visual acuity gains observed in the trial, including reductions in retinal fluid and lesion size by
week 24. In a <FONT STYLE="white-space:nowrap">pre-specified</FONT> subgroup analysis, greater activity of <FONT STYLE="white-space:nowrap">OPT-302</FONT> was observed in lesion types that are considered more difficult to treat with <FONT
STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy. Our clinical experience to date, which includes administration of over 1,850 doses of <FONT STYLE="white-space:nowrap">OPT-302</FONT> to 399 patients with retinal disease, indicates that <FONT
STYLE="white-space:nowrap">OPT-302</FONT> intravitreal injections are well tolerated, with the incidence of treatment-emergent adverse events comparable to <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapy in our clinical trials.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are planning to initiate two concurrent
pivotal Phase 3 clinical trials for the treatment of treatment-naive patients with wet AMD. These double-masked, sham-controlled Phase 3 clinical trials will assess the efficacy and safety of 2.0 mg of <FONT STYLE="white-space:nowrap">OPT-302</FONT>
in combination with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy for treatment-naive patients with wet AMD compared to a standard of care <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapy. We intend to finalize the Phase
3 trial protocols following the completion of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-Phase</FONT></FONT> 2 regulatory meetings with the U.S. Food and Drug Administration, or the FDA, and the European Medicines
Agency, or the EMA. We expect to initiate the trials in the first half of 2021 and to report topline data in 2023. If the results of the Phase 3 clinical trials are favorable, we intend to file for marketing approval for <FONT
STYLE="white-space:nowrap">OPT-302</FONT> for the treatment of wet AMD in the United States, European Union and other territories. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are also investigating the therapeutic potential of <FONT STYLE="white-space:nowrap">OPT-302</FONT> for DME. DME is a progressive eye
disease and a complication of diabetic retinopathy, or DR, a condition caused by chronically elevated glucose levels in diabetics that damages the retina. DME can cause blurred vision, severe vision loss and blindness. Wet AMD and DME share a
similar underlying pathophysiology, including retinal neovascularization and increased vascular permeability, and as a result, <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors are also considered the standard of care treatment for DME.
Based on its mechanism of action and clinical results to date, we believe that <FONT STYLE="white-space:nowrap">OPT-302</FONT> also has the potential to deliver therapeutic benefit in DME patients. In our Phase 1b/2a clinical trial of <FONT
STYLE="white-space:nowrap">OPT-302</FONT> in combination with aflibercept in patients with treatment-refractory DME, we observed evidence of improved clinical outcomes following <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy in
this indication. </FONT></P>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also believe that our novel treatment mechanism has the potential to provide
therapeutic benefit for other progressive retinal diseases beyond wet AMD and DME. We may further investigate the efficacy of <FONT STYLE="white-space:nowrap">OPT-302</FONT> to improve clinical outcomes in patients with polypoidal choroidal
vasculopathy, a form of wet AMD that is highly prevalent in Asian populations and less responsive to <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy than other wet AMD subtypes. Beyond wet AMD and DME, we may explore applications of <FONT
STYLE="white-space:nowrap">OPT-302</FONT> in other retinal diseases in which a <FONT STYLE="white-space:nowrap">VEGF-C</FONT> or <FONT STYLE="white-space:nowrap">VEGF-D</FONT> inhibitor could have therapeutic potential, such as retinal vein
occlusion. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our Pipeline </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes the stage of clinical
development and status of our product candidate, <FONT STYLE="white-space:nowrap">OPT-302.</FONT> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g61r81.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">*</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">Phase 3 clinical trial designs to be finalized following completion of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-Phase</FONT></FONT> 2
meetings with U.S. and European regulatory agencies, including the FDA and EMA. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Our Strategy </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our goal is to become a leader in developing and commercializing therapeutics for the treatment of retinal diseases. The key elements of our strategy are to: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Advance <FONT STYLE="white-space:nowrap">OPT-302</FONT> through two concurrent Phase 3 trials for the treatment of wet AMD.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Maximize the commercial potential <FONT STYLE="white-space:nowrap">of&nbsp;OPT-302</FONT> through commercialization independently and opportunistic
collaborations with third parties. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Optimize <FONT STYLE="white-space:nowrap">OPT-302</FONT> administration and potential to reduce injection burden for patients.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expand clinical development of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in wet AMD, DME and other retinal diseases.
</FONT></P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Associated with Our Business </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our business is subject to numerous risks and uncertainties,
including those described in &#147;Risk Factors&#148; and elsewhere in this prospectus. You should carefully consider these risks before making an investment. These risks include, among others, the following: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a clinical stage biopharmaceutical company with no products approved for commercial sale. We have incurred net losses since our inception, we
expect to incur significant losses and increasing operating losses for the foreseeable future, and we may never be profitable. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently have no source of product revenue and may never become profitable. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will require substantial additional capital to finance our operations, which may not be available to us on acceptable terms, or at all. As a result,
we may not complete the development and commercialization of <FONT STYLE="white-space:nowrap">OPT-302</FONT> or develop new product candidates. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our business substantially depends on the success of <FONT STYLE="white-space:nowrap">OPT-302,</FONT> our only product candidate under clinical
development, which has not completed a pivotal Phase 3 clinical trial. If we are unable to obtain regulatory approval for and successfully commercialize <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates, or we
experience significant delays in doing so, our business will be harmed. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical drug development involves a lengthy and expensive process with uncertain timelines and uncertain outcomes. Our clinical trials may fail to
adequately demonstrate the safety and efficacy of <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we experience delays in clinical testing, our commercial prospects will be harmed, our costs may increase and our business may be harmed.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we encounter difficulties in enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise negatively
affected. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidates may cause undesirable side effects or have other properties that
could delay or prevent their regulatory approval or limit the commercial profile of an approved label. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Even if we complete the necessary Phase 3 pivotal clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may
prevent us or any future collaboration partners from obtaining approvals for the commercialization of <FONT STYLE="white-space:nowrap">OPT-302</FONT> for the treatment of wet AMD or any other indication as well as for any other product candidate we
develop. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidates may not achieve adequate market acceptance among physicians,
patients, healthcare payors and others in the medical community necessary for commercial success. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lack of efficacy, adverse events or undesirable side effects may emerge in clinical trials conducted by third parties with product candidates for wet
AMD or DME, which could negatively affect our stock price, our ability to attract additional capital and our development program. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The results of completed clinical trials may not be predictive of future results. Data from our clinical trials to date may not be indicative of
results obtained when these trials are completed or in later stage trials. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become
available and are subject to audit and verification procedures that could result in material changes in the final data. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may face substantial competition, which may result in others discovering, developing or commercializing competing products before or more
successfully than us. </FONT></P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our business could be negatively affected by the effects of health epidemics, including the evolving effects of the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, in regions where we or third parties on which we rely have significant manufacturing facilities, concentrations of clinical trial sites or other business operations.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have relied on, and expect to continue to rely on, third-party manufacturers to produce <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any
future product candidates. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our success depends upon our ability to obtain and maintain intellectual property protection for our products and technologies.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">There has been no prior market for our ADSs and an active and liquid market for our securities may fail to develop, which could harm the market price
of the ADSs. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we fail to implement and maintain an effective system of internal controls to remediate our material weaknesses over financial reporting, we may be
unable to accurately report our results of operations, meet our reporting obligations or prevent fraud, and investor confidence in our company and the market price of the ADSs may be negatively impacted. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we are unable to adequately address these and other risks
we face, our business may be harmed. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Corporate
Information </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We were incorporated under the
laws of Australia in 1984 under the name Circadian Technologies Limited. In 1985, we completed an initial public offering of our ordinary shares and the listing of our ordinary shares on the Australian Securities Exchange, or the ASX. In December
2015, we changed the name of our company to Opthea Limited. Our headquarters and registered offices are located at Suite 0403, Level&nbsp;4, 650 Chapel Street, South Yarra, VIC 3141, Australia. Our telephone number is +61 3 9826 0399. Our agent for
service of process in the United States is Corporation Service Company, located at 1180 Avenue of the Americas, Suite 210, New York, NY 10036. Our website address is www.opthea.com. The reference to our website is an inactive textual reference only
and information contained in, or that can be assessed through, our website is not part of this prospectus. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Implications of Being an Emerging Growth Company </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a company with less than $1.07&nbsp;billion in revenue
during our last fiscal year, we qualify as an &#147;emerging growth company&#148; as defined in the JOBS Act. As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable
generally to public companies. These provisions include: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">exemption from the auditor attestation requirement of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, in the assessment
of our internal controls over financial reporting; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to the extent that we no longer qualify as a foreign private issuer, (i)&nbsp;reduced disclosure obligations regarding executive compensation in our
periodic reports and proxy statements and (ii)&nbsp;exemptions from the requirements of holding <FONT STYLE="white-space:nowrap">a&nbsp;non-binding&nbsp;advisory</FONT> vote on executive compensation, including golden parachute compensation.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may take advantage of these
exemptions until such time that we are no longer an emerging growth company. Accordingly, the information that we provide shareholders and holders of our ADSs may be different than you might obtain from other public companies. We will cease to be an
emerging growth company upon the earliest to occur of (i)&nbsp;the last day of the fiscal year in which we have more than $1.07&nbsp;billion in annual revenue; (ii)&nbsp;the last day of the fiscal year in which we qualify as a &#147;large
accelerated filer&#148;; (iii)&nbsp;the date on which we have, during the previous three-year period, issued more than $1.0&nbsp;billion <FONT STYLE="white-space:nowrap">in&nbsp;non-convertible&nbsp;debt</FONT> securities;&nbsp;and (iv)&nbsp;the
last day of the fiscal year in which the fifth anniversary of this offering occurs. </FONT></P>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, Section&nbsp;107 of the JOBS Act provides that an emerging growth company
can use the extended transition period provided in Section&nbsp;7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. Given that we currently report and expect to continue to report under IFRS, as issued by the
IASB, we have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required by the IASB.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Implications of Being a Foreign Private Issuer
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are also considered a &#147;foreign
private issuer&#148; under U.S. securities laws. In our capacity as a foreign private issuer, we are exempt from certain rules under the Exchange Act that impose certain disclosure obligations and procedural requirements for proxy solicitations
under Section&nbsp;14 of the Exchange Act. In addition, our senior management, the members of our board of directors and our principal shareholders are exempt from the reporting and &#147;short-swing&#148; profit recovery provisions of
Section&nbsp;16 of the Exchange Act and the rules under the Exchange Act with respect to their purchases and sales of our securities. Moreover, we are not required to file periodic reports and financial statements with the SEC as frequently or as
promptly as U.S. companies whose securities are registered under the Exchange Act. In addition, we are not required to comply with Regulation FD, which restricts the selective disclosure of material information. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may take advantage of these exemptions until such time as
we are no longer a foreign private issuer. We will remain a foreign private issuer until such time that 50% or more of our outstanding voting securities are held by U.S. residents and any of the following three circumstances applies: (i)&nbsp;the
majority of the members of board of directors or our senior management are U.S. citizens or residents; (ii)&nbsp;more than 50% of our assets are located in the United States; or (iii)&nbsp;our business is administered principally in the United
States. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have taken advantage of certain
reduced reporting and other requirements in this prospectus. Accordingly, the information contained herein may be different from the information you receive from other public companies. </FONT></P>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_2"></A>THE OFFERING </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">ADSs offered by us </FONT></P></TD>
<TD><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADSs. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Option to purchase additional ADSs </FONT></P></TD>
<TD><FONT STYLE="font-family:Times New Roman" SIZE="2">The underwriters have an option for a period of 30 days from the date of this prospectus to purchase up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional
ADSs. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ordinary shares to be outstanding after this offering, including shares underlying ADSs </FONT></P></TD>

<TD><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares (or
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares if the underwriters exercise their option to purchase
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional ADSs in full). </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">American depositary shares </FONT></P></TD>
<TD><FONT STYLE="font-family:Times New Roman" SIZE="2">Each ADS represents &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares, no par value. The ADSs are evidenced by ADRs as issued by
the depositary. You will have the rights of an ADS holder as provided in the deposit agreement among us, the depositary and all holders and beneficial owners of ADSs issued thereunder. The depositary will be the holder of the ordinary shares
underlying the ADSs. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">You may surrender your ADSs to the depositary to withdraw the ordinary shares underlying your ADSs. The depositary will charge you a fee for such an exchange.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may amend or terminate the deposit agreement for any reason without your consent. Any amendment that imposes or increases fees or charges or which materially
prejudices any substantial existing right you have as an ADS holder will not become effective as to outstanding ADSs until 30 days after notice of the amendment is given to ADS holders. If an amendment becomes effective, you will be bound by the
deposit agreement as amended if you continue to hold your ADSs. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To better understand the terms of the ADSs, you should carefully read the section titled &#147;Description of American Depositary Shares.&#148; We also encourage you to
read the deposit agreement, which is filed as an exhibit to the registration statement of which this prospectus forms a part. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depositary </FONT></P></TD>
<TD><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Use of proceeds </FONT></P></TD>
<TD><FONT STYLE="font-family:Times New Roman" SIZE="2">We estimate that the net proceeds from the sale of the ADSs that we are selling in this offering will be approximately
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million (or approximately US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the
underwriters&#146; option to purchase additional ADSs is exercised in full), based upon an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS, the U.S.
dollar equivalent of the last reported sale price of our ordinary shares on the ASX on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, after giving effect to the Australian dollar/U.S. dollar
exchange rate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, and an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-to-1,</FONT></FONT> after deducting underwriting discounts and commissions and
estimated offering expenses payable by us. </FONT></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">We intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, to advance the clinical development of <FONT
STYLE="white-space:nowrap">OPT-302</FONT> for the treatment of wet AMD, including the initiation of two pivotal Phase 3 clinical trials, and to fund other research and development activities for <FONT STYLE="white-space:nowrap">OPT-302</FONT> in
potential additional indications, including DME, and for working capital and other general corporate purposes. See &#147;Use of Proceeds&#148; for additional information. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Risk factors </FONT></P></TD>
<TD><FONT STYLE="font-family:Times New Roman" SIZE="2">See &#147;Risk Factors&#148; and the other information included in this prospectus for a discussion of the risks you should carefully consider before investing in the ADSs.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposed Nasdaq Global Market&nbsp;symbol for the ADSs </FONT></P></TD>
<TD><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;OPT&#148; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Australian Stock Exchange symbol for our ordinary shares </FONT></P></TD>
<TD><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;OPT&#148; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The number of ordinary shares (including ordinary shares underlying ADSs) that will be outstanding after this offering is based on 269,157,769&nbsp;ordinary shares outstanding as of June&nbsp;30, 2020,
and excludes: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,044,000 ordinary shares issuable upon the exercise of outstanding options as of June&nbsp;30, 2020 with a weighted-average exercise price of A$0.68
per ordinary share under our equity incentive plans; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,446,777&nbsp;ordinary shares reserved for future issuance under our Long Term Incentive Plan. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, unless we specifically state otherwise, all
information in this prospectus assumes (i)&nbsp;no exercise by the underwriters of their option to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional ADSs and (ii)&nbsp;no
exercise of outstanding options to purchase ordinary shares. </FONT></P>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_3"></A>SUMMARY CONSOLIDATED FINANCIAL DATA </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following tables summarize our consolidated financial and
other data. The summary consolidated statement of profit or loss and other comprehensive income data for the years ended June&nbsp;30, 2019 and 2020 have been derived from our audited consolidated financial statements included elsewhere in this
prospectus. Our audited consolidated financial statements have been prepared in accordance with IFRS, as issued by the IASB, as of and for the years ended June&nbsp;30, 2019 and 2020. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You should read the consolidated financial and other data set forth below in conjunction with our consolidated
financial statements and the accompanying notes, the information in &#147;Selected Consolidated Financial and Other Data&#148; and the information in &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations&#148; contained elsewhere in this prospectus. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Consolidated Statement of Profit or Loss and Other Comprehensive Income Data </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2020</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in&nbsp;thousands,&nbsp;except<BR>per&nbsp;share&nbsp;data)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">159</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">837</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(31,348</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patent expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(161</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Intellectual property costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(113</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Administrative expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,175</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Occupancy expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net foreign exchange gain (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">363</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss before income tax</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(35,547</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income tax benefit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,637</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss for the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,910</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other comprehensive income:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Items that will not be reclassified subsequently to profit or loss:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value gains on investments in financial assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">260</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other comprehensive income for the period, net of tax</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">260</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total comprehensive loss for the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total comprehensive loss for the year is attributable to:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Owners of the Company</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss per share attributable to Owners of the Company &#150; basic and diluted (in cents)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8.98</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income primarily comprises finance income from interest on bank deposits and, for the fiscal year ended June&nbsp;30, 2019, funding under a <FONT
STYLE="white-space:nowrap">one-time</FONT> Australian government grant from the Commonwealth Scientific and Industrial Research Organization. </FONT></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Consolidated Statement of Financial Position Data </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As of June&nbsp;30, 2020</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Actual</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As<BR>Adjusted<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)(2)</SUP></B></FONT></TD>

<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Working capital</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated losses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The as adjusted statement of financial position data give effect to our receipt of net proceeds from the issuance and sale
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADSs at the assumed initial offering price of US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
ADS, the U.S. dollar equivalent of the last reported sale price of our ordinary shares on the ASX on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, after giving effect to the Australian
dollar/U.S. dollar exchange rate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, and an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-to-1,</FONT></FONT> after deducting underwriting commissions and estimated offering
expenses payable by us. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each $1.00 increase or decrease in the assumed initial public offering price of
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS, the U.S. dollar equivalent of the last reported sale price of our ordinary shares on the ASX
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, after giving effect to the Australian dollar/U.S. dollar exchange rate
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;as of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, and an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-to-1,</FONT></FONT> would increase or decrease, respectively, the amount of cash and
cash equivalents, working capital, total assets and total equity by A$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million (or
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million), assuming the number of ADSs offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting
underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of ADSs we are offering. An increase or decrease of 1,000,000 in the number of ADSs we are offering would increase or
decrease the amount of cash and cash equivalents, working capital, total assets and total equity by A$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million (or
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million), assuming the assumed initial public offering price per ADS remains the same and after deducting underwriting discounts and commissions. The
as adjusted information is illustrative only and will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Working capital is defined as current assets less current liabilities. </FONT></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_4"></A><A NAME="cov947560_100"></A>RISK FACTORS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Investing in our ADSs involves a high degree of risk. You
should consider and read carefully all of the risks and uncertainties described below, as well as other information included in this prospectus, including our consolidated financial statements and related notes included elsewhere in this prospectus,
before making an investment decision. If any of the following risks actually occur, it could harm our business, prospects, results of operations and financial condition. In such event, the trading price of our ADSs could decline and you might lose
all or part of your investment. </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Our
Financial Position and Need for Capital </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We are a clinical stage biopharmaceutical company with no products approved for commercial sale. We have incurred net losses since
our inception, we expect to incur significant losses and increasing operating losses for the foreseeable future, and we may never be profitable. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a clinical stage biopharmaceutical company with no products approved for commercial sale. To date, our operations have been limited
to organizing and staffing our company, business planning, raising capital, developing our product candidate, <FONT STYLE="white-space:nowrap">OPT-302,</FONT> and licensing certain related technology, conducting research and development activities,
including preclinical studies and clinical trials, and providing general and administrative support for these operations. Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital
expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effect and/or an acceptable safety profile, gain regulatory approval and become commercially viable. We have not generated any revenue from
product sales to date, and we continue to incur significant research and development and other expenses related to our ongoing operations. We are not profitable and have incurred net losses since our inception. Our total comprehensive losses were
$20.7&nbsp;million and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million for the years ended June&nbsp;30, 2019 and 2020. As of June&nbsp;30, 2020, we had an accumulated loss of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million. We have spent, and expect to continue to spend, significant resources to fund research and development of, and seek regulatory approvals for, <FONT
STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidates. We expect to incur substantial and increasing operating losses over the next several years as our research, development, manufacturing and clinical trial activities
increase. Additionally, if <FONT STYLE="white-space:nowrap">OPT-302</FONT> is approved for commercial sale, our commercialization expenses will increase significantly as we establish sales, marketing, distribution, manufacturing, supply chain and
other commercial infrastructure. As a result, our accumulated losses will also increase significantly. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may negatively affect our business. The
size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have a negative impact on our total
(deficit) equity and working capital. The net losses we incur may fluctuate significantly from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">quarter-to-quarter</FONT></FONT> such that a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">period-to-period</FONT></FONT> comparison of our results of operations may not be a good indication of our future performance. Even if we eventually generate product revenue, we may never be profitable and, if we do
achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We currently have no source of product revenue and may never become profitable. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">OPT-302</FONT> has not been
approved for commercial sale, and we expect it to be several years before <FONT STYLE="white-space:nowrap">OPT-302</FONT> is approved, if ever, and we are able to commence sales of <FONT STYLE="white-space:nowrap">OPT-302.</FONT> To date, we have
not generated any revenue from the licensing or commercialization of <FONT STYLE="white-space:nowrap">OPT-302</FONT> and do not expect to receive revenue from it for a number of years, if ever. We will not be able to generate product revenue unless
and until <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidate, alone or with future partners, successfully completes clinical trials, receives regulatory approval and is successfully commercialized. Although we may seek
to obtain revenue from collaboration or licensing agreements with third parties, we currently have no such agreements that could provide us with material, ongoing future revenue and we may never enter into any such agreements. Our ability to
generate future product revenue </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
from <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates also depends on a number of additional factors, including our or our future partners&#146; ability to:
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">successfully complete research and clinical development of <FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidates and obtain
regulatory approvals for commercialization; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">maintain supply and manufacturing relationships with third parties, and ensure adequate and legally compliant manufacturing of bulk drug substances and
drug products to maintain that supply, including any scale up of manufacturing processes for <FONT STYLE="white-space:nowrap">OPT-302</FONT> to support our planned Phase 3 clinical program of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in
combination with anti-vascular endothelial growth factor-A, or <FONT STYLE="white-space:nowrap">anti-VEGF-A,</FONT> therapy for the treatment of wet <FONT STYLE="white-space:nowrap">age-related</FONT> macular degeneration, or AMD;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">launch and commercialize future product candidates for which we obtain marketing approval, if any, and, if launched independently, successfully
establish a sales force, marketing and distribution infrastructure; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">demonstrate the necessary safety data post-approval to ensure continued regulatory approval; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">obtain coverage and adequate product reimbursement from third-party payors, including government payors; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">achieve market acceptance for our or our future partners&#146; products, if any; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">establish, maintain, protect and enforce our intellectual property rights; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">attract, hire and retain qualified personnel. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, because of the numerous risks and uncertainties
associated with biologic product development, including that <FONT STYLE="white-space:nowrap">OPT-302</FONT> may not advance through development, achieve the endpoints of applicable clinical trials or receive approval for use in combination with one
or more approved therapies, we are unable to predict the timing or amount of increased expenses, or if or when we will achieve or maintain profitability. In addition, our expenses could increase beyond expectations if we decide, or are required by
the U.S. Food and Drug Administration, or the FDA, or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities, including the European Medicines Agency, or the EMA, to perform studies or trials in addition to those that we
currently anticipate. Even if we complete the development and regulatory processes described above, we anticipate incurring significant costs associated with launching and commercializing these products. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Even if we generate revenue from the sale of any of our
product candidates that may be approved, we may not become profitable and may need to obtain additional funding to continue operations. If we fail to become profitable or do not sustain profitability on a continuing basis, then we may be unable to
continue our operations at planned levels and be forced to reduce our operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>We will require substantial additional capital to finance our operations, which may not be available to us on acceptable terms, or at all. As a result, we may not complete the development and
commercialization of <FONT STYLE="white-space:nowrap">OPT-302</FONT> or develop new product candidates. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a clinical-stage biopharmaceutical company, our operations have consumed significant amounts of cash since our inception. We expect our
research and development expenses to increase substantially in connection with our ongoing activities, particularly as we prepare to initiate our planned Phase 3 clinical trials of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with <FONT
STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy for the treatment of wet AMD and continue clinical development of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with aflibercept for the treatment of persistent diabetic macular
edema, or DME, and other retinal diseases. Even if we are able to obtain regulatory approval for <FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidates that we may develop, we will require substantial additional capital to
commercialize such product candidates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe
that the net proceeds from this offering, together with our existing cash and cash equivalents, will fund our projected operating requirements until&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. Our
forecast of the period of time through which </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
our financial resources will adequately support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of
factors, including the factors discussed elsewhere in this &#147;Risk Factors&#148; section. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect.
Our future funding requirements, both short and long-term, will depend on many factors, including: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the initiation, progress, timing, costs and results of clinical trials for <FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product
candidates we may develop, including whether the FDA or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities require additional clinical trials beyond our proposed Phase 3 clinical trials of <FONT
STYLE="white-space:nowrap">OPT-302</FONT> in combination with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy for the treatment of wet AMD to support an approved label of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination
with multiple existing <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the initiation, progress, timing, costs and results of additional clinical trials and studies to evaluate the potential for <FONT
STYLE="white-space:nowrap">co-formulation</FONT> of <FONT STYLE="white-space:nowrap">OPT-302</FONT> with approved and/or biosimilar forms of <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors to provide flexibility of treatment options for
physicians and to reduce the frequency and number of injections for patients; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the outcome, timing and cost of seeking and obtaining regulatory approvals from the FDA and comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
regulatory authorities; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">if approved, the costs of commercialization activities for <FONT STYLE="white-space:nowrap">OPT-302,</FONT> or any other product candidate that
receives regulatory approval; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the cost to establish, maintain, expand, enforce and defend the scope of our intellectual property portfolio, including the amount and timing of any
payments we may be required to make, or that we may receive, in connection with licensing, preparing, filing, prosecuting, defending and enforcing of any patents or other intellectual property rights; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our headcount growth and associated costs as we expand our research and development capabilities and establish a commercial infrastructure;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">market acceptance of any approved product candidates, including product pricing and adequate reimbursement by third-party payors;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the cost of acquiring, licensing or investing in additional businesses, products, product candidates and technologies; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the cost of establishing sales, marketing and distribution capabilities for <FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product
candidates for which we may receive regulatory approval and that we determine to commercialize ourselves or in collaboration with our future partners; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the costs of operating as a public company with securities listed in both Australia and the United States. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will require additional capital to develop, obtain
regulatory approval for and commercialize <FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidates. In particular, we will require additional capital to progress our ongoing and future planned clinical trials without delays,
including payments in connection with the achievement of certain regulatory milestones. We do not have any committed external source of funds. We expect to finance future cash needs through public or private equity or debt offerings or
collaborations. We also intend to continue to apply for tax incentives under the Research and Development Tax Incentive scheme provided by the Australian government. See &#147;&#151;Risks Related to Development and Commercialization of Our Product
Candidates&#151;We have received tax credits under the Research and Development Tax Incentive scheme in Australia that may become repayable if we did not or do not comply with the rules of the scheme, or we may become ineligible for tax credits in
our current or future tax years, which could harm our business, financial condition and results of operations.&#148; Additional capital may not be available in sufficient amounts or on reasonable terms, if at all. If we are not able to raise
additional capital, we may not be able to expand our operations or otherwise capitalize on our business opportunities, and our business and financial condition will be negatively impacted. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Raising additional capital may cause dilution to holders purchasing ADSs in this
offering, restrict our operations or require us to relinquish rights to our technologies or product candidates. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Holders purchasing ADSs in this offering could suffer dilution or be negatively affected by fixed payment obligations we may incur if we
raise additional funds through the issuance of additional equity securities or debt. Further, these securities may have rights senior to those of our ordinary shares and could contain covenants or protective rights that would restrict our operations
and potentially impair our competitiveness, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could negatively
impact our ability to conduct our business. If we need to secure additional financing, such additional fundraising efforts may divert our management and research efforts from our
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may negatively affect our ability to develop and commercialize <FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product
candidates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To the extent we obtain additional
funding through product collaborations, these arrangements would generally require us to relinquish rights to some of our technologies, product candidates or products, and we may not be able to enter into such agreements, on acceptable terms, if at
all. If we are unable to obtain additional funding on a timely basis, we may be required to curtail or terminate some or all of our development programs or product candidates. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Development and Commercialization of Our Product
Candidates </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our business substantially
depends on the success of <FONT STYLE="white-space:nowrap">OPT-302,</FONT> our only product candidate under clinical development, which has not completed a pivotal Phase 3 clinical trial. If we are unable to obtain regulatory approval for and
successfully commercialize <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates, or we experience significant delays in doing so, our business will be harmed. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To date, the primary focus of our product development has
been <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy for the treatment of patients with wet AMD and DME. Currently, <FONT STYLE="white-space:nowrap">OPT-302</FONT> is
our only product candidate under clinical development. This may make an investment in our company riskier than similar companies that have multiple product candidates in active development and that therefore may be able to better sustain a failure
of a lead candidate. Successful continued development and ultimate regulatory approval of <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy for the treatment of wet AMD, DME or other indications is critical to the future success of
our business. We have invested, and will continue to invest, a significant portion of our time and financial resources in the clinical development of <FONT STYLE="white-space:nowrap">OPT-302.</FONT> If we cannot successfully develop, obtain
regulatory approval for and commercialize <FONT STYLE="white-space:nowrap">OPT-302,</FONT> we may not be able to continue our operations. The future regulatory and commercial success of <FONT STYLE="white-space:nowrap">OPT-302</FONT> is subject to a
number of risks, including the following: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may not have sufficient financial and other resources to complete the necessary clinical trials for <FONT STYLE="white-space:nowrap">OPT-302,</FONT>
including, but not limited to, the pivotal clinical trials needed to obtain drug approval; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may not be able to obtain adequate evidence from clinical trials of efficacy and safety for <FONT STYLE="white-space:nowrap">OPT-302</FONT>
combination therapy for the treatment of wet AMD, DME or other indications; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">in our clinical trials for <FONT STYLE="white-space:nowrap">OPT-302,</FONT> we may need to adjust our clinical trial procedures and may need additional
clinical trial sites, which could delay our clinical trial progress; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the results of our clinical trials may not meet the level of statistical or clinical significance required by the FDA or comparable <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities for marketing approval; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the standards implemented by clinical or regulatory agencies may change at any time and we cannot be certain what regulatory agencies may require in
pivotal clinical trials for the approval of <FONT STYLE="white-space:nowrap">OPT-302;</FONT> </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the results of later stage clinical trials may not be as favorable as the results we have observed to date in our preclinical studies and early
clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we cannot be certain of the number and type of clinical trials and <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies that the FDA or
comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory agencies will require in order to approve <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:Times New Roman" SIZE="2">
for the treatment of wet AMD, DME or any other indication, including an approved label for use of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with multiple <FONT
STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies for the treatment of wet AMD; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">establishing sales, marketing and distribution capabilities and launching commercial sales of our products, if and when approved, whether alone or in
collaboration with others; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">acceptance of our products, if and when approved, by patients, the medical community and third-party payors; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">obtaining and maintaining third-party coverage and adequate reimbursement; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">maintaining a continued acceptable safety profile of our products following approval, including when used in combination with existing therapies;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">effectively competing with other therapies; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">enforcing and defending intellectual property rights and claims. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Many of these risks are beyond our control, including the
risks related to clinical development, the regulatory submission process, potential threats to our intellectual property rights and the manufacturing, marketing and sales efforts of any future collaborator. Of the large number of drugs in
development in the pharmaceutical industry, only a small percentage result in the submission of a new drug application or a biologics license application, or BLA, to the FDA and even fewer are approved for commercialization. Furthermore, even if we
do receive regulatory approval to market <FONT STYLE="white-space:nowrap">OPT-302,</FONT> any such approval may be subject to limitations on the indicated uses or patient populations for which we may market the products. Accordingly, even if we are
able to obtain the requisite financing to continue to fund our development programs, we may be unable to successfully develop or commercialize <FONT STYLE="white-space:nowrap">OPT-302.</FONT> If we or any of our future development collaborators are
unable to develop, or obtain regulatory approval for, or, if approved, successfully commercialize <FONT STYLE="white-space:nowrap">OPT-302,</FONT> we may not be able to generate sufficient revenue to continue our business. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Clinical drug development involves a lengthy and
expensive process with uncertain timelines and uncertain outcomes. Our clinical trials may fail to adequately demonstrate the safety and efficacy of <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates.
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidates will be subject to rigorous and extensive clinical
trials and extensive regulatory approval processes implemented by the FDA and comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities before obtaining marketing approval from these regulatory authorities. The drug
development and approval process is lengthy and expensive, and approval is never certain. Investigational new drugs, such as <FONT STYLE="white-space:nowrap">OPT-302,</FONT> may not prove to be safe and effective in clinical trials. We have no
direct experience as a company in conducting pivotal stage clinical trials required to obtain regulatory approval. We may be unable to conduct clinical trials at preferred sites, enlist clinical investigators, enroll sufficient numbers of
participants or begin or successfully complete clinical trials in a timely fashion, if at all. In addition, the design of a clinical trial can determine whether its results will support approval of a product, and flaws in the design of a clinical
trial may not become apparent until the clinical trial is well advanced. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The protocols for our planned Phase&nbsp;3 clinical trials for <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy are subject
to review by the FDA and comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities. The FDA is not obligated to comment on our protocols within any specified time period or at all or to affirmatively clear or approve our
Phase&nbsp;3 clinical program. We have submitted summaries of the protocols for our Phase&nbsp;3 clinical trials to the FDA and comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities, including the EMA. The FDA or other
regulatory authorities may request additional information, require us to conduct additional <FONT STYLE="white-space:nowrap">non-clinical</FONT> trials or require us to modify our proposed Phase&nbsp;3 clinical program, including its endpoints,
patient enrollment criteria or selection of <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies, to receive clearance to initiate such program or to continue such program once initiated. In addition, the FDA or other regulatory authorities
may disagree with all or a portion of our proposed trial protocols, including whether our Phase 3 clinical trial protocol is sufficient for approval of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
combination with two or more approved <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies for the treatment of wet AMD. Any such limitations could reduce the market acceptance of <FONT
STYLE="white-space:nowrap">OPT-302</FONT> and harm our business, financial condition and results of operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we experience delays in clinical testing, our commercial prospects will be harmed, our costs may increase and our business may be
harmed. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Conducting clinical studies for
any product candidates in the United States requires filing an investigational new drug application, or IND, and reaching agreement with the FDA on clinical protocols, finding appropriate clinical sites and clinical investigators, securing approvals
for such studies from the institutional review board at each such site, manufacturing clinical quantities of product candidates and supplying drug product to clinical sites. Currently, we have an active IND with the FDA in the United States for <FONT
STYLE="white-space:nowrap">OPT-302.</FONT> If any such future IND is not approved by the FDA, our clinical development timeline may be negatively impacted and any future clinical programs may be delayed or terminated. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We cannot guarantee that we will be able to successfully
accomplish required regulatory activities or all of the other activities necessary to initiate and complete clinical trials. As a result, our clinical trials may be extended, delayed or terminated, and we may be unable to obtain regulatory approvals
or successfully commercialize our products. We do not know whether any other clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Our product development costs will increase if we
experience delays in clinical testing. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize <FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidates
or allow our competitors to bring products to market before we do, which would impair our ability to successfully commercialize <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates and may harm our business, results of
operations and prospects. Events that may result in a delay or unsuccessful completion of clinical development include: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the unavailability of financial resources to commence and completed planned trials; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delays in reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">revisions to labeling, including adding limitations on approved uses or the additions of additional warnings, contraindications or other safety
information including boxed warnings; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">ongoing discussions with the FDA or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities regarding the scope or design of
our clinical trials, including our planned pivotal Phase 3 clinical trials of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy for the treatment of wet AMD;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">deviations from the trial protocol by clinical trial sites and investigators, or failures to conduct the trial in accordance with regulatory
requirements; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the need to repeat clinical trials as a result of inconclusive or negative results or poorly executed testing or changes in required endpoints by the
FDA or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> authorities; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">unfavorable FDA inspection and review of a clinical trial site or records of any clinical or preclinical investigation; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the placement of a clinical hold on a clinical trial by the FDA or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> authorities;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delays in obtaining, or the inability to obtain, required approvals from institutional review boards or other governing entities at clinical sites
selected for participation in our clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">failure of third parties, such as CROs, to satisfy their contractual duties to us or meet expected deadlines; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delays in the testing, validation, manufacturing and delivery of the product candidates to the clinical sites; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">insufficient supply or deficient quality of product candidate materials or other materials necessary to conduct our clinical trials, including of drugs
to be used in the proposed combination therapy with our product candidates; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delays in enrolling participants into our clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delays in patients completing a trial or returning for post-treatment <FONT STYLE="white-space:nowrap">follow-up;</FONT> </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delays caused by patients dropping out of a trial due to side effects, disease progression or otherwise; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">serious and unexpected drug-related adverse effects experienced by participants in our clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">implementation of new, or changes to, guidance or interpretations from the FDA or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
authorities with respect to approval pathways for any product candidates we are pursuing; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in government regulations or administrative actions or lack of adequate funding to continue the clinical trials. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our or our future collaborators&#146; inability to timely
complete clinical trials could result in additional costs to us as well as impair our ability to generate product revenue, continue development, commercialize <FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidates and
receive royalties on product sales. In addition, if we make changes to a product candidate, we may need to conduct additional nonclinical studies or clinical trials to bridge or demonstrate the comparability of our modified product candidate to
earlier versions, which could delay our clinical development plan or marketing approval for our current product candidate and any future product candidates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we encounter difficulties in enrolling patients in our clinical trials, our clinical development activities could be delayed or
otherwise negatively affected. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
timely completion of clinical trials largely depends on patient enrollment. We may encounter delays in enrolling, or be unable to enroll, a sufficient number of patients to complete any of our clinical trials, and even once enrolled, we may be
unable to retain a sufficient number of patients to complete any of our trials. Many factors affect patient enrollment, including: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the size and nature of the patient population, which may be limited due to eligibility requirements; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the number and location of clinical sites; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">competition with other companies for clinical sites or patients; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the availability and amount of any patient stipend; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the eligibility and exclusion criteria for the trial; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the design of the clinical trial; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to recruit clinical trial investigators with the appropriate competencies and experience; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">inability to obtain and maintain patient consents; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">significant adverse events or other side effects observed, if any; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">risk that enrolled participants will drop out before completion; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">competing clinical trials and clinicians&#146; and patients&#146; perceptions as to the potential advantages of the drug being studied in relation to
other available therapies. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In
addition, other companies are conducting clinical trials for the same indications and seek to enroll patients in their trials that may otherwise be eligible for our clinical studies or trials, which could lead to slow recruitment and delays in our
clinical programs. Further, since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which could further reduce the number of
patients who are available for our clinical trials in these sites. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. If we are unable to
enroll a sufficient number </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
of patients that will complete clinical testing, we will be unable to seek or gain marketing approval for <FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidates and our
business will be harmed. Even if we are able to enroll a sufficient number of patients in our clinical studies or trials, delays in patient enrollment may result in increased costs or may affect the timing or outcome of our clinical trials, which
could prevent completion of these trials and negatively affect our ability to advance the development of <FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidates may cause undesirable
side effects or have other properties that could delay or prevent their regulatory approval or limit the commercial profile of an approved label. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Undesirable side effects caused by <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy or any future product candidates
could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities. Additional clinical studies may be required to evaluate the safety profile of <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy or any future product
candidates. We have no clinical safety data on patient exposure to <FONT STYLE="white-space:nowrap">OPT-302</FONT> administered in combination with an <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy for longer than 24 weeks. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Future results of our trials could reveal a high and
unacceptable severity and prevalence of side effects or unexpected characteristics, including, for example, immunogenicity. In such an event, we could suspend or terminate our trials or the FDA or comparable
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities could order us to cease clinical trials or deny approval of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with
<FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy or any future product candidates for any or all targeted indications. Drug-related side effects could affect patient recruitment or the ability of enrolled subjects to complete the trial or
result in potential product liability claims. Any of these occurrences could materially and negatively affect our business, financial condition, results of operations and prospects. While <FONT STYLE="white-space:nowrap">OPT-302</FONT> has been well
tolerated in our completed clinical trials, dosed patients have experienced certain adverse events, including potentially treatment-related serious adverse events, or SAEs, of myocardial infarction, endophthalmitis and vitritis in our Phase 2b
clinical trial of <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy for the treatment of wet AMD, and a potentially treatment-related SAE of stroke for one patient in our Phase 1b/2a clinical trial of
<FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy for the treatment of DME. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">It may be difficult to discern whether certain events or symptoms observed during our clinical trials or by patients using our approved products are related to
<FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates or approved products, including <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies used in combination with <FONT STYLE="white-space:nowrap">OPT-302,</FONT>
or some other factor. As a result, we and our development programs may be negatively affected even if such events or symptoms are ultimately determined to be unlikely related to <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product
candidates or approved products. We are developing <FONT STYLE="white-space:nowrap">OPT-302</FONT> to complement existing <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors, including ranibizumab and aflibercept. There are some potential side
effects associated with intravitreal <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies such as intraocular hemorrhage, intraocular pressure elevation, retinal detachment, inflammation, vasculitis, artery occlusion or infection inside the
eye and over-inhibition of VEGF, as well as the potential for potential systemic side effects such as heart attack, stroke, wound healing problems and high blood pressure.&nbsp;Further, <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination
with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies for the treatment of wet AMD is administered as sequential intravitreal injections over several weeks. There are risks inherent in the intravitreal injection procedure of drugs such
as existing <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies in combination with <FONT STYLE="white-space:nowrap">OPT-302</FONT> which can cause injury to the eye and other complications including conjunctival hemorrhage, punctate
keratitis, eye pain, conjunctival hyperemia, which results in a discharge, intra-ocular inflammation and inflammation of the interior of the eye. For example, in our completed clinical trials, patients dosed with
<FONT STYLE="white-space:nowrap">OPT-302</FONT> have experienced potentially treatment-related ocular adverse events such as eye pain, vitreous floaters, eye irritation and raised intraocular pressure. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We cannot assure you that additional or more severe adverse
side effects than those observed to date related to <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy or any future product candidates will not be observed in our clinical trials or in the commercial setting. If observed, such
adverse side effects could delay or preclude regulatory approval of <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy or any future product candidates, limit commercial use or result in the withdrawal of previously granted
marketing approvals. If we or others identify undesirable or unacceptable side effects caused by <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy or any future product candidates or products: </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may be required to modify, suspend or terminate our clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may be required to modify or include additional dosage and administration instructions, warnings and precautions, contraindications, boxed warnings,
limitations, restrictions or other statements in the product label for our approved products, or issue field alerts to physicians and pharmacies; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we, or any future collaborators, may be required to create a risk evaluation and mitigation strategy, or REMS, which could include a medication guide
outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers, and/or other elements to assure safe use; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may be required to conduct costly additional clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may be subject to limitations on how we may promote our approved products; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">sales of our approved products may decrease significantly; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">regulatory authorities may require us to take our approved products off the market; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may be subject to regulatory investigations, government enforcement actions, litigation or product liability claims; and
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our products may become less competitive or our reputation may suffer. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any of these results could decrease or prevent any sales of our approved product or substantially increase the
costs and expenses of commercializing and marketing our product. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Even if we complete the necessary Phase 3 pivotal clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent us or any future collaboration partners
from obtaining approvals for the commercialization of <FONT STYLE="white-space:nowrap">OPT-302</FONT> for the treatment of wet AMD or any other indication as well as for any other product candidate we develop. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any product candidate we may develop and the activities
associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive
regulation by the FDA and other regulatory authorities in the United States and by comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities. Failure to obtain marketing approval for a product candidate will prevent us from
commercializing the product candidate in a given jurisdiction. We have not received approval to market any product candidates from regulatory authorities in any jurisdiction and it is possible that none of the product candidates we may seek to
develop in the future will ever obtain regulatory approval. While we expect to expand our internal regulatory function to support the marketing approval process for <FONT STYLE="white-space:nowrap">OPT-302,</FONT> we have no prior experience in
filing and supporting the applications necessary to gain marketing approvals and expect to rely in part on third-party CROs or regulatory consultants to assist us in this process. Securing regulatory approval requires the submission of extensive
preclinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish the biologic product candidate&#146;s safety, purity, efficacy and potency. Securing regulatory approval also
requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Any product candidates we develop may not be effective, may be only moderately
effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The process of obtaining marketing approvals, both in the
United States and in other jurisdictions, is expensive, may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and
novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product
application, may cause delays in the approval or rejection of an application. The FDA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">19 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical
and clinical testing could delay, limit, or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not
commercially viable. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we experience delays in
obtaining approval or if we fail to obtain approval of any product candidates we may develop, the commercial prospects for those product candidates, including for <FONT STYLE="white-space:nowrap">OPT-302</FONT> in other indications, may be harmed,
and our ability to generate revenues will be materially impaired. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Lack of efficacy, adverse events or undesirable side effects may emerge in clinical trials conducted by third parties with product candidates for wet AMD or DME, which could negatively affect our
stock price, our ability to attract additional capital and our development program. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Lack of efficacy, adverse events or undesirable side effects may emerge in clinical trials conducted by third parties developing product candidates for wet AMD or DME. In addition, other companies have
developed products for wet AMD and DME, including product candidates administered in combination with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies, and have suffered setbacks and clinical trial failures in the past, including
failures of primary endpoints in Phase 3 pivotal clinical trials following positive data from Phase 1 and 2 trials. Lack of efficacy, adverse events or undesirable side effects experienced by subjects in third party clinical trials currently being
conducted or previously conducted could negatively affect our stock price, our ability to attract additional capital and our development of <FONT STYLE="white-space:nowrap">OPT-302</FONT> or even the viability of
<FONT STYLE="white-space:nowrap">OPT-302</FONT> as a product candidate. In addition, any such adverse events or undesirable side effects may lead to increased regulatory requirements for, or additional regulatory review of, <FONT
STYLE="white-space:nowrap">OPT-302,</FONT> which may result in delays in development and commercialization of <FONT STYLE="white-space:nowrap">OPT-302</FONT> and harm our business, financial condition and results of operations. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The results of completed clinical trials may not be
predictive of future results. Data from our clinical trials to date may not be indicative of results obtained when these trials are completed or in later stage trials. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There is a high failure rate for drugs and biologic products
proceeding through clinical trials. Failure can occur at any time during the clinical trial process. The results of completed clinical trials of <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidate may not be predictive of
the results of later-stage clinical trials, including our planned Phase 3 trials of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy for the treatment of wet AMD, and the
results of trials in certain patients may not be predictive of those obtained in another. In fact, many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late stage clinical trials even after
achieving promising results in earlier stage clinical trials. In addition, data obtained from clinical activities is subject to varying interpretations, which may delay, limit or prevent regulatory approval. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The results of our Phase 2b clinical trial of <FONT
STYLE="white-space:nowrap">OPT-302</FONT> combination therapy may not be predictive of the results of our Phase 3 clinical program due, in part, to the fact that we have no clinical data on <FONT STYLE="white-space:nowrap">OPT-302</FONT> in
combination with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy in any clinical trial longer than 24 weeks and that we plan to conduct our Phase 3 clinical trials at many clinical centers that were not included in our Phase 2b clinical
trial. The number of patients exposed to product candidates and the average exposure time in prior clinical trials may be inadequate to detect rare adverse events or findings that may only be detected once a product candidate is administered to more
patients and for greater periods of time. In addition, if a combination of <FONT STYLE="white-space:nowrap">OPT-302</FONT> with an <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy in our Phase 3 clinical program for the treatment of wet
AMD does not achieve superiority over <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapy with statistical significance on the primary endpoints of our Phase 3 clinical trials, or the FDA or a comparable
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authority requires additional clinical trials beyond our Phase 3 clinical program to support an approved label of <FONT STYLE="white-space:nowrap">OPT-302</FONT> used in combination with
multiple <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies, our ability to successfully commercialize <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy for the
treatment of wet AMD would be harmed. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">20 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Interim, topline and preliminary data from our clinical trials that we announce
or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">From time to time, we may publicly disclose preliminary or
topline data from our clinical trials, which are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the
particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline
results that we report may differ from future results of the same studies or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and
verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. From time to time, we
may also disclose interim data from our clinical trials. In addition, we may report interim analyses of only certain endpoints rather than all endpoints. Interim data from clinical trials that we may complete are subject to the risk that one or more
of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, adverse changes between interim data and final data could significantly harm our business and prospects. Additional
disclosure of interim data by us or by our competitors in the future could also result in volatility in the price of the ADSs and our ordinary shares after this offering. Further, others, including regulatory agencies, may not accept or agree with
our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product
candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with
what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views,
activities or otherwise regarding a particular product candidate or our business. If the topline data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to
obtain approval for, and commercialize, <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates may be harmed, which could harm our business, financial condition, results of operations and prospects. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may face substantial competition, which may result
in others discovering, developing or commercializing competing products before or more successfully than us. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The biopharmaceutical industry is intensely competitive and subject to rapid innovation and significant technological advancements. We
believe the key competitive factors that will affect the development and commercial success of <FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidates are efficacy, safety and tolerability profile, reliability, convenience
of dosing, price, the level of generic competition and reimbursement. Our competitors include multinational pharmaceutical companies, specialized biotechnology companies, universities and other research institutions. A number of biotechnology and
pharmaceutical companies are pursuing the development or marketing of pharmaceuticals that target the same diseases that we are targeting. Smaller or earlier-stage companies may also prove to be significant competitors, particularly through
collaborative arrangements with large, established companies. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">There are a number of large pharmaceutical and biotechnology companies that are currently pursuing the development of products for the treatment of wet AMD and DME, or have commercially approved products
for the treatment of wet AMD or DME, including Roche,&nbsp;Regeneron&nbsp;and Novartis. The current standard of care for wet AMD is monotherapy administration of <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies, including ranibizumab
and aflibercept, as well as <FONT STYLE="white-space:nowrap">off-label</FONT> use of bevacizumab. These drugs are well established therapies and are widely accepted by physicians, patients and third-party payors, which may make it difficult to
convince these parties to switch to </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">21 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
<FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy. In addition to competition from other companies directly targeting wet AMD or DME, any products we may develop may also face
competition from other types of therapies. In addition, many companies are developing new therapeutics, and we cannot predict what the standard of care will be as <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates
progress through clinical development. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If our
competitors market products that are more effective, safer or cheaper than our products, that are more durable or have reduced injection burden compared to our products (including <FONT STYLE="white-space:nowrap">OPT-302),</FONT> or that reach the
market sooner than our products, we may not achieve commercial success. In addition, the biopharmaceutical industry is characterized by rapid technological change. If we fail to stay at the forefront of technological change, we may be unable to
compete effectively. Technological advances or products developed by our competitors may render our technologies, products or product candidates obsolete, less competitive or not economical. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Many of our competitors have substantially greater financial, technical, human and other resources than we do
and may be better equipped to develop, manufacture and market technologically superior products. In addition, many of these competitors have significantly longer operating histories and greater experience than we have in undertaking nonclinical
studies and human clinical trials of new pharmaceutical products and in obtaining regulatory approvals of human therapeutic products. Clinical trials for the treatment of wet AMD and DME may be relatively costly and time consuming. The requirements
for approval by the FDA and comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities may change over time and this may require changes to ongoing or future clinical trial designs that could impact timelines and cost.
Further, many of our competitors have established distribution channels for the commercialization of their products, whereas we have no such channel or capabilities. In addition, many competitors have greater name recognition and more extensive
collaborative relationships. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a result, our
competitors may obtain regulatory approval of their products more rapidly than we do or may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize our product candidate or any future product
candidates. Our competitors may also develop and succeed in obtaining approval for drugs that are more effective, more convenient, more widely used and less costly or have a better safety profile than our products and these competitors may also be
more successful than we are in manufacturing and marketing their products. If we are unable to compete effectively against these companies, then we may not be able to commercialize our product candidate or any future product candidates or achieve a
competitive position in the market. This would negatively affect our ability to generate revenue. Our competitors also compete with us in recruiting and retaining qualified scientific, management and commercial personnel, establishing clinical trial
sites and enrolling patients for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our inability to compete effectively in any of these aspects of our business could harm our business, financial
condition, results of operations and prospects. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may encounter difficulties in managing our growth, which could negatively impact our operations. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As we advance our clinical development programs for product
candidates, seek regulatory approval in the United States and elsewhere and increase the number of ongoing product development programs, we anticipate that we will need to increase our product development, scientific and administrative headcount. In
particular, as we progress our Phase 3 clinical trials for <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy for the treatment of wet AMD, we will require additional key
staff for clinical development operations as well as additional key financial and administrative personnel. We will also need to establish commercial capabilities in order to commercialize any product candidates that may be approved. Such an
evolution may impact our strategic focus and our deployment and allocation of resources. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our ability to manage our operations and growth effectively depends upon the continual improvement of our procedures, reporting systems and operational, financial and management controls. We may not be
able to implement administrative and operational improvements in an efficient or timely manner and may discover deficiencies in existing systems and controls. If we do not meet these challenges, we may be unable to execute our business strategies
and may be forced to expend more resources than anticipated addressing these issues. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">22 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may acquire additional technology and complementary businesses in the future.
Acquisitions involve many risks, any of which could materially harm our business, including the diversion of management&#146;s attention from core business concerns, failure to effectively exploit acquired technologies, failure to successfully
integrate the acquired business or realize expected synergies or the loss of key employees from either our business or the acquired businesses. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, in order to continue to meet our obligations as a public listed company in both Australia and the United States and to
support our anticipated long-term growth, we will need to increase our general and administrative capabilities. Our management, personnel and systems may not be adequate to support this future growth. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we are unable to successfully manage our growth and the
increased complexity of our operations, our business, financial position, results of operations and prospects may be harmed. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>A fast track designation by the FDA, even if granted for <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any other future product
candidates, may not lead to a faster development or regulatory review or approval process and does not increase the likelihood that our product candidates will receive marketing approval. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If a drug or biologic is intended for the treatment of a
serious or life-threatening condition and the product demonstrates the potential to address unmet medical needs for this condition, the sponsor may apply for FDA fast track designation for a particular indication. We may seek fast track designation
for certain of our current or future product candidates, including <FONT STYLE="white-space:nowrap">OPT-302,</FONT> but there is no assurance that the FDA will grant this status to any of our proposed product candidates. If granted, fast track
designation makes a product eligible for more frequent interactions with FDA to discuss the development plan and clinical trial design, as well as rolling review of the application, which means that the company can submit completed sections of its
marketing application for review prior to completion of the entire submission. Marketing applications of products candidates with fast track designation may qualify for priority review under the policies and procedures offered by the FDA, but the
fast track designation does not assure any such qualification or ultimate marketing approval by the FDA. The FDA has broad discretion whether or not to grant fast track designation, so even if we believe a particular product candidate is eligible
for this designation, there can be no assurance that the FDA would decide to grant it. Even if we do receive fast track designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures, and
receiving a fast track designation does not provide any assurance of ultimate FDA approval. In addition, the FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development
program. In addition, the FDA may withdraw any fast track designation at any time. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors and others in the medical
community necessary for commercial success. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Even if our product candidates receive regulatory approval, they may not gain adequate market acceptance among physicians, patients, healthcare payors and others in the medical community. Given the number
of drugs in development or currently approved for the treatment of wet AMD and DME, if we are unsuccessful in achieving a differentiated profile with <FONT STYLE="white-space:nowrap">OPT-302,</FONT> including in combination with existing therapies,
based on efficacy, safety and tolerability, dosing and administration, market acceptance will be limited. For example, current treatments for wet AMD, including ranibizumab, aflibercept and low cost, <FONT STYLE="white-space:nowrap">off-label</FONT>
use of bevacizumab, are well established in the medical community and perceived as demonstrating meaningful clinical response in many cases. As a result, doctors may continue to rely on these treatments without
<FONT STYLE="white-space:nowrap">OPT-302</FONT> or may continue to use such existing treatments as first-line therapies. The medical community may also resist adopting a combination therapy over monotherapy for any of our targeted indications. In
particular, recent clinical development has focused on maintaining vision gains with a <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitor while reducing the number of injections. While we plan to evaluate the potential for <FONT
STYLE="white-space:nowrap">co-formulation</FONT> of <FONT STYLE="white-space:nowrap">OPT-302</FONT> with approved and/or </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">23 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
biosimilar forms of <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors to provide flexibility of treatment options for physicians and to reduce the frequency and number of injections for
patients, there can be no assurance that we will be successful or that any <FONT STYLE="white-space:nowrap">co-formulated</FONT> product will have a favorable safety profile. If we are unable to reduce the injection burden of <FONT
STYLE="white-space:nowrap">OPT-302</FONT> combination therapy or a <FONT STYLE="white-space:nowrap">co-formulation</FONT> of <FONT STYLE="white-space:nowrap">OPT-302</FONT> for patients or otherwise increase the duration of efficacy of <FONT
STYLE="white-space:nowrap">OPT-302</FONT> doses, or if physicians determine that a more frequent regimen is necessary, the market acceptance of <FONT STYLE="white-space:nowrap">OPT-302</FONT> may be limited which would harm our business, financial
condition and results of operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition,
the potential market opportunity for <FONT STYLE="white-space:nowrap">OPT-302</FONT> is difficult to estimate precisely. If <FONT STYLE="white-space:nowrap">OPT-302</FONT> receives marketing approval for the treatment of wet AMD, it will be approved
solely for use in combination with one or more <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies, and may be limited to use with only one <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy for the treatment of wet AMD depending
on the protocol for our planned Phase 3 clinical trials or whether the results from each of our Phase 3 clinical trials support an approved label for use of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with more than one <FONT
STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy. The market opportunity for <FONT STYLE="white-space:nowrap">OPT-302</FONT> will be dependent upon the continued use of <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies in the
treatment of wet AMD and the market share of such <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies for which <FONT STYLE="white-space:nowrap">OPT-302</FONT> is approved as a combination therapy. The degree of market acceptance of any of
our approved product candidates will depend on a number of factors, including: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the efficacy, safety and dosing profile of the product candidate as demonstrated in clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the timing of market introduction of the product candidate as well as competitive products; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the clinical indications for which the product candidate is approved; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the imposition of a REMS which may include distribution or use restrictions; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any restrictions on the use of our products to a subgroup of patients; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">acceptance of the product candidate as a safe and effective treatment by physicians and patients; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the potential and perceived advantages of the product candidate over alternative treatments, including any similar generic treatments;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the cost of treatment in relation to alternative treatments; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the availability of coverage and adequate reimbursement and pricing by third parties and government authorities; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">patients&#146; willingness to pay <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> in the absence of
coverage and/or adequate reimbursement from third-party payors; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the relative convenience and ease of administration; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the frequency and severity of adverse events; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the effectiveness of sales and marketing efforts; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">unfavorable publicity relating to the product candidate. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sales of medical products also depend on the willingness of
physicians to prescribe the treatment, which is likely to be based on a determination by these physicians that the products are safe, therapeutically effective and cost effective. In addition, the inclusion or exclusion of products from treatment
guidelines established by various physician groups and the viewpoints of influential physicians can affect the willingness of other physicians to prescribe the treatment. We cannot predict whether physicians, physicians&#146; organizations,
hospitals, other healthcare providers, government agencies or private insurers will determine that our products are safe, therapeutically effective and cost effective as compared with competing treatments. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Efforts to educate the medical community and third-party
payors on the benefits of <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy may require significant resources and may not be successful. Demonstrating the safety and efficacy of
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
our product candidates and obtaining regulatory approvals will not guarantee future revenue. Our commercial success also depends on coverage and adequate reimbursement of our product candidates
by third-party payors, including government payors, which may be difficult or time-consuming to obtain, may be limited in scope and may not be obtained in all jurisdictions in which we may seek to market our products. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If the market opportunities for any product that we or
our strategic collaborators develop are smaller than we believe they are, our revenue may be negatively affected and our business may suffer. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We intend to focus our product candidate development on therapies for the treatment of wet AMD and additional retinal disease indications
such as DME or retinal vein occlusion, or RVO. Our projections of addressable patient populations that have the potential to benefit from treatment with our product candidate are based on estimates. These estimates have been derived from a variety
of sources, including the scientific literature, surveys of clinics, patient foundations or market research, and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of
patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for our product candidates may not ultimately be amenable to treatment with our product candidates. Our market opportunity may also be
limited by future competitor treatments that enter the market. If any of our estimates are inaccurate, the market opportunities for any of our product candidates could be significantly diminished and have an adverse impact on our business.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If
<FONT STYLE="white-space:nowrap">OPT-302</FONT> is approved by the FDA as a combination therapy for the treatment of wet AMD, the approval will be limited to this specific indication and, unless we seek regulatory approval for additional
indications, we will be prohibited from marketing <FONT STYLE="white-space:nowrap">OPT-302</FONT> for other indications. We may be subject to fines, penalties or injunctions if we are determined to have promoted or be promoting the use of <FONT
STYLE="white-space:nowrap">OPT-302</FONT> for unapproved or <FONT STYLE="white-space:nowrap">&#147;off-label&#148;</FONT> uses, resulting in damage to our reputation and business. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If <FONT STYLE="white-space:nowrap">OPT-302</FONT> receives marketing approval for the treatment of wet AMD, it
will be approved solely for use in combination with one or more <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies, and may be limited to only one <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy for the treatment of wet AMD
depending on the protocols for our planned pivotal Phase 3 clinical trials. Although we are also developing <FONT STYLE="white-space:nowrap">OPT-302</FONT> for other retinal diseases, any regulatory approval of
<FONT STYLE="white-space:nowrap">OPT-302</FONT> for wet AMD would not be cover the treatment of any other indication. As a result, we would be prohibited from promoting <FONT STYLE="white-space:nowrap">OPT-302</FONT> for the treatment of DME unless
we are granted FDA approval for such indication. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA strictly regulates the promotional claims that may be made about prescription products. While physicians may choose to prescribe
products for uses that are not described in the product&#146;s labeling and for uses that differ from those tested in clinical trials and approved by the regulatory authorities, we are prohibited from marketing and promoting the products for
indications that are not specifically approved by the FDA or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities. These <FONT STYLE="white-space:nowrap">&#147;off-label&#148;</FONT> uses are common across medical
specialties and may constitute an appropriate treatment for some patients in varied circumstances. Regulatory authorities in the United States generally do not restrict or regulate the behavior of physicians in their choice of treatment within the
practice of medicine. Regulatory authorities do, however, restrict communications by biotechnology or pharmaceutical companies on <FONT STYLE="white-space:nowrap">off-label</FONT> use. If the FDA determines that our promotional activities constitute
promotion of an <FONT STYLE="white-space:nowrap">off-label</FONT> use, it could request that we modify our promotional materials and subject us to FDA regulatory or enforcement actions as well as actions by other agencies, including issuance of
warning letters or untitled letters, suspension or withdrawal of an approved product from the market, mandatory or voluntary recalls, civil fines, disgorgement of money, operating restrictions, additional reporting requirements and/or oversight if
we become subject to a corporate integrity agreement or similar agreement, injunctions or criminal prosecution, any of which could significantly harm our business. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">25 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">OPT-302</FONT> is being developed to be used as
a combination therapy for use with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies, which exposes us to additional risks. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are developing <FONT STYLE="white-space:nowrap">OPT-302</FONT> to be used in combination with currently approved <FONT
STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors. Even if <FONT STYLE="white-space:nowrap">OPT-302</FONT> were to receive marketing approval or be commercialized, we would continue to be subject to the risks that the FDA or similar regulatory
authorities could revoke approval of some or all approved <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies for safety, efficacy, manufacturing or supply issues. This could result in <FONT STYLE="white-space:nowrap">OPT-302</FONT> being
restricted from commercialization or being less commercially successful. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We may also evaluate <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any other future product candidates in combination with one or more other product candidates that have not yet been approved for
marketing by the FDA or similar foreign regulatory authorities. We will not be able to market and sell <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any product candidate we develop in combination with any such unapproved therapies that do not
ultimately obtain marketing approval. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the FDA
or similar foreign regulatory authorities do not approve these other product candidates or revoke their approval of, or if safety, efficacy, manufacturing, or supply issues arise with, the drugs we choose to evaluate in combination with <FONT
STYLE="white-space:nowrap">OPT-302</FONT> or any product candidate we develop, we may be unable to obtain approval of or market <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any product candidate we develop. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we fail to develop and commercialize additional
product candidates, we may be unable to grow our business. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Although the development and commercialization of <FONT STYLE="white-space:nowrap">OPT-302</FONT> is currently our primary focus, as part of our longer-term growth strategy, we plan to evaluate the
development and commercialization of other therapies related to retinal diseases. The success of this strategy depends primarily upon our ability to identify and validate new therapeutic candidates, and to identify, develop and commercialize new
drugs and biologics. Our research efforts may initially show promise in discovering potential new drugs and biologics, yet fail to yield product candidates for clinical development for a number of reasons, including: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may need to rely on third parties to generate molecules for some of our product candidate programs; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may encounter product manufacturing difficulties that limit yield or produce undesirable characteristics that increase the cost of manufacturing our
product candidates, cause delays or make our product candidates unmarketable; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">product candidates may cause adverse effects in patients or subjects, even after successful initial toxicology studies, which may make the product
candidates unmarketable; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">product candidates may not demonstrate a meaningful benefit to patients or subjects; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our future collaboration partners may change their development profiles or plans for potential product candidates or abandon a therapeutic area or the
development of a partnered product. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If any of these events occur, we may be forced to abandon our development efforts for one or more programs, which could harm our business, operating results and prospects and could potentially cause us to
cease operations. Future research programs to identify new product candidates may require substantial technical, financial and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately prove
to be unsuccessful. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Product candidates may
require additional, time-consuming development efforts prior to commercial sale, including preclinical studies, clinical trials and approval by the FDA and/or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities. All
product candidates are prone to the risks of failure that are inherent in pharmaceutical product development, including the possibility that the product candidate will not be shown to be sufficiently safe and effective for approval by regulatory
authorities. In addition, we cannot assure you that any such products that are approved will be manufactured or produced economically, be successfully commercialized, be widely accepted in the marketplace or be more effective than other commercially
available alternatives. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">26 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may expend our limited resources to pursue one or more particular indications
and fail to capitalize on indications that may be more profitable or for which there is a greater likelihood of success. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have limited financial and management resources. As a result, we may forego or delay pursuit of opportunities with other indications
that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future development programs for
specific indications may not yield any commercially viable products. Any such failures would negatively affect our business and results of operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We must attract and retain highly skilled employees in order to succeed. If we are not able to retain our current senior management
team and our scientific advisors or continue to attract and retain qualified scientific, technical and business personnel, our business will suffer. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may not be able to attract or retain qualified personnel and consultants due to the intense competition for such individuals among in
the biotechnology and pharmaceutical industries. If we are not able to attract and retain necessary personnel and consultants to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our
development and commercial objectives, our ability to raise additional capital and our ability to implement our business strategy. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our industry has experienced a high rate of turnover of management personnel in recent years. We are highly dependent on the development,
regulatory, commercialization and business development expertise of the members of our executive team, as well as other key employees and consultants. If we lose one or more of our executive officers or other key employees or consultants, our
ability to implement our business strategy successfully could be seriously harmed. Any of our executive officers or other key employees or consultants may terminate their employment at any time with three months&#146; notice, subject to certain
exceptions, and replacing such individuals may be difficult and time-consuming because of the limited number of individuals in our industry with the necessary breadth of skills and experience. Competition to hire and retain employees and consultants
from this limited pool is intense, and we may be unable to hire, train, retain or motivate such individuals. Additionally, we do not currently maintain &#147;key person&#148; life insurance on the lives of our executives or any of our employees.
This lack of insurance means that we may not receive adequate compensation for the loss of the services of these individuals. If we are unable to continue to attract and retain high-quality personnel, the rate and success with which we can discover
and develop product candidates and our business will be limited. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>As we evolve from a company that is primarily involved in clinical development to a company that is also involved in preparing for commercialization, we may encounter difficulties in expanding our
operations successfully. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As we advance
our product candidates through clinical trials, we will need to expand our development, regulatory, manufacturing and marketing and sales capabilities and may need to further contract with third parties to provide these capabilities, such as
collaborators, distributors, marketers and additional suppliers. We currently have no experience as a company in or infrastructure for sales, marketing and distribution, and our operations are currently limited to clinical development activities and
as our operations expand, we likely will need to manage additional relationships with such third parties. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidate is approved, we intend either to establish a sales and
organization with technical expertise and supporting distribution capabilities to commercialize <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidate or to outsource such functions to one or more third parties. Either of
these options would be expensive and time-consuming. Some or all of these costs may be incurred in advance of any approval of <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidate. In addition, we may not be able to hire a
sales force that is sufficient in size or has adequate expertise in the medical markets that we intend to target. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">27 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Factors that may inhibit our efforts to commercialize our products on our own include:
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the inability of sales personnel to obtain access to physicians or attain adequate numbers of physicians to prescribe any drugs;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the inability to obtain sufficient access and reimbursement for our product candidate, if approved; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">unforeseen costs and expenses associated with creating a sales and marketing organization. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any failure or delay in the development of our internal
sales, marketing and distribution capabilities would negatively affect the commercialization of <FONT STYLE="white-space:nowrap">OPT-302</FONT> and other future product candidates. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Maintaining third-party relationships for these purposes will
impose significant added responsibilities on members of our management and other personnel. We must be able to effectively manage our development efforts, recruit and train sales and marketing personnel, effectively manage our participation in the
clinical trials in which our product candidates are involved and improve our managerial, development, operational and finance systems, all of which may impose a strain on our administrative and operational infrastructure. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we enter into arrangements with third parties to perform
sales, marketing or distribution services, any product revenues that we receive, or the profitability of these product revenues to us, are likely to be lower than if we were to market and sell any products that we develop without the involvement of
these third parties. In addition, we may not be successful in entering into arrangements with third parties to sell and market our products and can provide no assurance that the terms of any such arrangements will remain favorable for us over time.
We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish sales and marketing capabilities successfully,
either on our own or in collaboration with third parties, we will not be successful in commercializing our products. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our business could be negatively affected by the effects of health epidemics, including the evolving effects of the COVID-19
pandemic, in regions where we or third parties on which we rely have significant manufacturing facilities, concentrations of clinical trial sites or other business operations. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Health epidemics in regions where we have concentrations of clinical trial sites or other business operations
could negatively affect our business, including by causing significant disruption in the operations of third-party manufacturers and CROs upon whom we rely. For example, the novel coronavirus disease 2019, or
<FONT STYLE="white-space:nowrap">COVID-19,</FONT> pandemic has presented a substantial public health and economic challenge around the world and is affecting employees, patients, communities and business operations, as well as the U.S. economy and
financial markets. Based on guidance issued by Australian federal and state governments, we transitioned to a remote work environment for all of our employees. In connection with these measures, we may be subject to claims based upon, arising out
of, or related to <FONT STYLE="white-space:nowrap">COVID-19</FONT> and our actions and responses thereto, including any determinations that we may make to continue to operate or to <FONT STYLE="white-space:nowrap">re-open</FONT> our facilities.
Further, the effects of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">shelter-in-place</FONT></FONT> orders in Australia and across the world and our work-from-home policies may negatively impact productivity, disrupt our
business and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. These and
similar, and perhaps more severe, disruptions in our operations could negatively impact our business, financial condition, results of operations and growth prospects. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As the pandemic continues, we may experience a negative
impact on our ability to initiate clinical trial sites, maintain patient enrollment and enroll new patients which may impact timelines in the future. Our ability to attract additional clinical trial sites and principal investigators to conduct our
clinical trials and to conduct the necessary clinical trial site initiation procedures may be impacted by quarantines, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">shelter-in-place</FONT></FONT> and similar restrictions imposed
by federal, state and local governments. These restrictions may also prohibit patients from enrolling in, or continuing to participate in, our clinical trials. Principal investigators and clinical trial site staff,
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">28 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
as healthcare providers, may have heightened exposure to COVID-19 and if their health is impacted by <FONT STYLE="white-space:nowrap">COVID-19</FONT> it could negatively impact the conduct of our
clinical trials at their sites. Similarly, potential participants in our clinical trials, many of whom are medically vulnerable, may be unwilling to enroll in, and enrolled patients may be unwilling to continue to participate in, our clinical trials
due to an unwillingness to travel to sites for required screening and clinical trial visits and procedures. Enrolled patients may be unable to comply with clinical trial protocols if quarantines, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">shelter-in-place</FONT></FONT> and similar restrictions continue to impede patient movement or interrupt healthcare services. In addition, we may be required to develop and implement additional clinical study policies and
procedures designed to help protect patients from the <FONT STYLE="white-space:nowrap">COVID-19</FONT> disease, which may include using telemedicine visits, remote monitoring of patients and clinical trial sites, and measures designed to ensure that
data from clinical trials that may be disrupted as result of the pandemic are collected pursuant to the study protocol and consistent with cGCPs, with any significant protocol deviation reviewed and approved by the clinical trial site institutional
review board, or IRB, all or any of which could materially and negatively affect our clinical development timelines and our ability to obtain regulatory approvals of our product candidates, and could significantly increase our costs. We could also
see an impact on our ability to report clinical trial results, or interact with regulators, ethics committees or other important agencies due to limitations in regulatory authority employee resources or otherwise. In addition, the FDA or comparable <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities may refuse to accept data from clinical trials conducted in geographies experiencing heightened impact from <FONT STYLE="white-space:nowrap">COVID-19.</FONT> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Moreover, we rely on third-party CROs and other third parties
to assist us with clinical development activities, and we cannot guarantee that they will continue to perform their contractual duties in a timely and satisfactory manner as a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic.
In addition, quarantines, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">shelter-in-place</FONT></FONT> and similar government orders could impact personnel at third-party manufacturing facilities in the United States and other
countries, or the availability or cost of materials, which would disrupt our supply chain. In particular, some of our suppliers of certain materials used in the production of our drug products are located in Europe. In any event, if the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic continues and persists for an extended period of time or more acutely impacts geographies with particular impact on our business, we could experience significant disruptions to our clinical
development timelines, which would harm our business, financial condition, results of operations and growth prospects. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, while the potential economic impact brought by, and the duration of, the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic may be difficult to assess or predict, the pandemic could result in significant and prolonged disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In
addition, a recession or market correction resulting from the spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> could harm our business and the value of our ordinary shares and ADSs offered hereby following this offering. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Disruptions at the FDA and other government agencies
caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, otherwise prevent new products from being developed, approved or commercialized in a timely manner or at all, or
otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The ability of the FDA to review and approve new products
can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, statutory, regulatory and policy changes, and other events that may otherwise
affect the FDA&#146;s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies on which our operations may rely, including
those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary
government agencies, which would adversely affect our business. For example, in </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">29 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
recent years, including in 2018 and 2019, the U.S. government shut down several times and certain regulatory agencies, such as the FDA, had to furlough critical employees and stop critical
activities. Separately, in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, in March 2020, the FDA announced its intention to postpone most inspections of foreign manufacturing facilities and products through April 2020.
Also in March 2020, the FDA announced its intention to temporarily postpone routine surveillance inspections of domestic manufacturing facilities. Regulatory authorities outside the United States may adopt similar restrictions or other policy
measures in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic or issue guidance materially affecting the conduct of clinical trials. If a prolonged government shutdown occurs, or if global health concerns continue to prevent
the FDA or other regulatory authorities from conducting their regular inspections, reviews or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have
a material adverse effect on our business. Further, upon completion of this offering and in our operations as a public company, future government shutdowns or delays could impact our ability to access the public markets and obtain necessary capital
in order to properly capitalize and continue our operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Even if we commercialize <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidate, we may face challenges to achieving profitability such as our products becoming subject to
unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which could harm our business. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the United States and in other countries, patients who are prescribed treatment for their conditions generally rely on third-party
payors to reimburse all or part of the costs associated with their treatment. The availability of coverage and adequacy of reimbursement for our products by third-party payors, including government health care programs (e.g., Medicare, Medicaid,
TRICARE), managed care providers, private health insurers, health maintenance organizations and other organizations is essential for most patients to be able to afford medical services and pharmaceutical products such as <FONT
STYLE="white-space:nowrap">OPT-302</FONT> or any our product candidates. Third-party payors decide which medications they will pay for and establish reimbursement levels. The availability of coverage and extent of reimbursement by governmental and
other third-party payors is essential for most patients to be able to afford treatments such as <FONT STYLE="white-space:nowrap">OPT-302.</FONT> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for
Medicare&nbsp;&amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, or HHS. CMS decides whether and to what extent our products will be covered and reimbursed under Medicare and private payors tend to
follow CMS to a substantial degree. Factors payors consider in determining reimbursement are based on whether the product is: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a covered benefit under its health plan; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">safe, effective and medically necessary; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">appropriate for the specific patient; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">cost-effective; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">neither experimental nor investigational. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our ability to commercialize any products successfully will depend in part on the extent to which coverage and adequate reimbursement for
these products and related treatments will be available from third-party payors, including government health care programs and private health insurers. Moreover, a payor&#146;s decision to provide coverage for a drug product does not imply that an
adequate reimbursement rate will be approved. If coverage and adequate reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the
approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the United States, no uniform policy for coverage and reimbursement for products exists among third-party payors. Therefore, coverage
and reimbursement for our products can differ significantly from payor to </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">30 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
payor. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the reimbursement rate that the payor will pay for the product.
One payor&#146;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product. Third-party payors may also limit coverage to specific products on an approved list, or
formulary, which might not include all of the <FONT STYLE="white-space:nowrap">FDA-approved</FONT> products for a particular indication. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Government authorities and other third-party payors in the United States and abroad have attempted to control costs by limiting coverage
and the amount of reimbursement for particular medications and for newly approved products, and as a result, they may not cover or provide adequate payment for <FONT STYLE="white-space:nowrap">OPT-302</FONT> and future product candidates.
Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that coverage and reimbursement will be
available for any product that we or our future collaborators commercialize and, if reimbursement is available, what the level of reimbursement will be. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for
which we or our future collaborators obtain marketing approval. If coverage and reimbursement are not available or reimbursement is available only to limited levels, we and our future collaborators may not be able to successfully commercialize any
product candidate for which marketing approval is obtained. A decision by a third-party payor not to cover or not to separately reimburse for our medical products or therapies using our products could reduce physician utilization of our products
once approved. Assuming there is coverage for our product candidates, or therapies using our product candidates by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require
<FONT STYLE="white-space:nowrap">co-payments</FONT> that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States will be available for <FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future
product candidates and any reimbursement that may become available may not be adequate or may be decreased or eliminated in the future. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than
the purposes for which the drug is approved by the FDA or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all
cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may only be temporary.
Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net
prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at
lower prices than in the United States. Our inability to promptly obtain coverage and profitable reimbursement rates from both government-funded and private payors for any approved products that we develop could harm our operating results, our
ability to raise capital needed to commercialize products and our overall financial condition. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The regulations that govern marketing approvals, pricing and reimbursement for new drug products vary widely from country to country. Current and future legislation may significantly change the approval
requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after
marketing or product licensing approval is granted. In some <FONT STYLE="white-space:nowrap">non-U.S.</FONT> markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a
result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay or limit our commercial launch of the product, possibly for lengthy time periods, which could negatively impact the
revenue we generate from the sale of the product in that particular country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To become and remain profitable, we or any
potential future collaborator must develop and eventually commercialize <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates with significant market potential at an adequate profit margin after cost of goods sold and
other expenses. Commercialization of <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">31 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
candidates may entail a substantial cost of goods sold and there can be no assurance that we will be able to achieve a suitable gross margin with respect to sales of <FONT
STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Changes in U.S. healthcare law and implementing regulations, as well as changes in healthcare policy, may impact our business in ways that we cannot currently predict and may harm our business and
results of operations. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There have been,
and likely will continue to be, several executive, legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval
activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval. Among policy makers and payors in the United States there is significant interest in promoting changes in healthcare systems with the
stated goals of containing healthcare costs, improving quality and/or expanding access and the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Patient Protection and Affordable Care Act, as amended by
the Health Care and Education Reconciliation Act of 2010, collectively referred to as the Affordable Care Act, substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S.
pharmaceutical industry. The Affordable Care Act, among other things: (1)&nbsp;introduced a new average manufacturer price definition for drugs and biologics that are inhaled, infused, instilled, implanted or injected and not generally dispensed
through retail community pharmacies; (2)&nbsp;increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and expanded rebate liability from
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fee-for-service</FONT></FONT> Medicaid utilization to include the utilization of Medicaid managed care organizations as well; (3)&nbsp;established a branded prescription drug fee that
pharmaceutical manufacturers of branded prescription drugs must pay to the federal government; (4)&nbsp;expanded the list of covered entities eligible to participate in the 340B drug pricing program by adding new entities eligible for the program;
(5)&nbsp;established a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (increased to 70% pursuant to the Bipartisan Budget Act of 2018, or BBA, effective as of January 2019) <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable branded drugs to eligible beneficiaries during their coverage gap period, as a condition for the
manufacturer&#146;s outpatient drugs to be covered under Medicare Part D; (6)&nbsp;extended manufacturers&#146; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;
(7)&nbsp;expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals, including individuals with income at or below 133% of the federal poverty level, thereby
potentially increasing manufacturers&#146; Medicaid rebate liability; (8)&nbsp;created a licensure framework for <FONT STYLE="white-space:nowrap">follow-on</FONT> biologic products; and (9)&nbsp;established a Center for Medicare and Medicaid
Innovation at the CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There remain judicial and Congressional challenges to certain aspects of the Affordable Care Act, as well as efforts by the Trump
administration to repeal or replace certain aspects of the Affordable Care Act. For example, the Tax Cuts and Jobs Act of 2017, or the TCJA, was enacted, which included a provision that repealed, effective January&nbsp;1, 2019, the <FONT
STYLE="white-space:nowrap">tax-based</FONT> shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the
&#147;individual mandate.&#148; On December&nbsp;14, 2018, a U.S. District Court Judge in the Northern District of Texas ruled that the individual mandate is a critical and inseverable feature of the Affordable Care Act, and therefore, because it
was repealed as part of the TCJA, the remaining provisions of the Affordable Care Act are invalid as well. On December&nbsp;18, 2019, the U.S. Court of Appeals for the 5th Circuit ruled that the individual mandate was unconstitutional but remanded
the case back to the District Court to determine whether the remaining provisions of the Affordable Care Act are invalid as well. On March&nbsp;2, 2020, the U.S. Supreme Court granted the petitions for writs of certiorari to review the case,
although it is unclear when a decision will be made or how the Supreme Court will rule. In addition, there may be other efforts to challenge, repeal or replace the Affordable Care Act. We are continuing to monitor any changes to the Affordable Care
Act that, in turn, may potentially impact our business in the future. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">32 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other legislative changes have been proposed and adopted since the Affordable Care Act
was enacted. These changes include aggregate reductions to Medicare payments to providers of 2% per fiscal year pursuant to the Budget Control Act of 2011 and subsequent laws, which began in 2013 and will remain in effect through 2030, unless
additional Congressional action is taken. These Medicare sequester reductions will be suspended from May&nbsp;1, 2020 through December&nbsp;31, 2020 due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. In January 2013, the American
Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations
period for the government to recover overpayments to providers from three to five years. New laws may result in additional reductions in Medicare and other healthcare funding, which may materially negatively affect customer demand and affordability
for our products and, accordingly, the results of our financial operations. Also, there has been heightened governmental scrutiny recently over the manner in which pharmaceutical companies set prices for their marketed products, which have resulted
in several Congressional inquiries and proposed federal legislation, as well as state efforts, designed to, among other things, bring more transparency to product pricing, reduce the cost of prescription drugs under Medicare, review the relationship
between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. For example, at the federal level, the Trump administration&#146;s budget proposal for fiscal year 2021 includes a
$135&nbsp;billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> drug costs for patients, and
increase patient access to lower-cost generic and biosimilar drugs. On March&nbsp;10, 2020, the Trump administration sent &#147;principles&#148; for drug pricing to Congress, calling for legislation that would, among other things, cap Medicare Part
D beneficiary <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> pharmacy expenses, provide an option to cap Medicare Part D beneficiary monthly <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses, and place limits on pharmaceutical price increases. Further, the Trump administration previously released a &#147;Blueprint,&#148; or plan, to lower drug prices and reduce out of
pocket costs of drugs that contained proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out
of pocket costs of drug products paid by consumers. HHS has solicited feedback on some of these measures and has implemented others under its existing authority. For example, in May 2019, CMS issued a final rule to allow Medicare Advantage plans the
option to use step therapy for Part B drugs beginning January&nbsp;1, 2020. This final rule codified CMS&#146;s policy change that was effective January&nbsp;1, 2019. While some of these and other measures may require additional authorization to
become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. At the state level, individual states in the United States are
increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and
marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions on
coverage or access could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical
products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates that we successfully commercialize or put pressure on our product pricing.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect that these and other healthcare reform
measures that may be adopted in the future, may result in more rigorous coverage criteria and lower reimbursement, and put additional downward pressure on the price that we receive for any approved product. It is possible that additional
governmental action is taken to address the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. Any reduction in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private
payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our drugs, once marketing approval is obtained. We cannot predict the
likelihood, nature or extent of government regulation that may arise from future legislation or administrative action in the United States. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or
the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">33 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been
obtained and we may not achieve or sustain profitability </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>As a company primarily based outside of the United States, our business is subject to economic, political, regulatory and other risks associated with international operations. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a company with substantial operations in Australia and an
international clinical trial program, our business is subject to risks associated with conducting business outside the United States. Many of our suppliers and clinical trial relationships are located outside the United States. Accordingly, our
future results could be harmed by a variety of factors, including: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">economic weakness, including inflation, or political instability in particular <FONT STYLE="white-space:nowrap">non-U.S.</FONT> economies and markets;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">differing and changing regulatory requirements for product approvals; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">differing jurisdictions could present different issues for securing, maintaining or obtaining freedom to operate in such jurisdictions;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">potentially reduced protection for intellectual property rights; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">difficulties in compliance with different, complex and changing laws, regulations and court systems of multiple jurisdictions and compliance with a
wide variety of foreign laws, treaties and regulations; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulations and customs, tariffs and trade barriers; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> currency exchange rates, Australian dollar, U.S. dollar, euro and currency controls;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in a specific country&#146;s or region&#146;s political or economic environment; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">trade protection measures, import or export licensing requirements or other restrictive actions by governments; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">differing reimbursement regimes and price controls in certain <FONT STYLE="white-space:nowrap">non-U.S.</FONT> markets; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">negative consequences from changes in tax laws; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">workforce uncertainty in countries where labor unrest is more common than in the United States; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">litigation or administrative actions resulting from claims against us by current or former employees or consultants individually or as part of class
actions, including claims of wrongful terminations, discrimination, misclassification or other violations of labor law or other alleged conduct; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">difficulties associated with staffing and managing international operations, including differing labor relations; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">business interruptions resulting from <FONT STYLE="white-space:nowrap">geo-political</FONT> actions, including war and terrorism, health epidemics, or
natural disasters including earthquakes, typhoons, floods and fires. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we fail to comply with <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory requirements governing human clinical trials and marketing approval for drugs, we could be prevented from
selling our product candidates in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> markets, which may negatively affect our operating results and financial condition. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The requirements governing the conduct of clinical trials,
product licensing, pricing and reimbursement for marketing our product candidates outside the United States vary greatly from country to country and may require additional testing. We expect that our future clinical development of our product
candidates will involve a number of clinical trials in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions. We have no direct experience as a company in obtaining </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">34 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory approvals. The time required to obtain approvals outside the United States may differ from that required to obtain FDA approval. We may
not obtain <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory approvals on a timely basis, if at all. Approval by the FDA does not guarantee approval by comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities, and
approval by one <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authority does not ensure approval by regulatory authorities in other countries or by the FDA. Failure to comply with these regulatory requirements or obtain required
approvals could impair our ability to develop <FONT STYLE="white-space:nowrap">non-U.S.</FONT> markets for our product candidates and may harm our results of operations and financial condition. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Price controls may be imposed in <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> markets, which may negatively affect our future profitability. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In some countries, particularly EU member states, Japan, Australia and Canada, the pricing of prescription drugs is subject to
governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a product. In addition, there can be considerable pressure by governments and other
stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement
has been obtained. Reference pricing used by various EU member states and parallel distribution, or arbitrage between <FONT STYLE="white-space:nowrap">low-priced</FONT> and high-priced member states, can further reduce prices. In some countries, we
or our collaborators may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval.
Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of our products is unavailable or limited in
scope or amount, or if pricing is set at unsatisfactory levels, our business, revenues or profitability could be harmed. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We have received tax incentives under the Research and Development Tax Incentive scheme in Australia that may become repayable if we
did not or do not comply with the rules of the scheme, or we may become ineligible for tax incentives in our current or future tax years, which could harm our business, financial condition and results of operations. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have received cash incentives in the past under the
Research and Development Tax Incentive scheme, or the R&amp;D Scheme, to offset the costs of our clinical trials and other qualifying expenses incurred both in Australia and other jurisdictions. Certain research and development costs that we incur
in the future may be ineligible for cash incentives under the R&amp;D Scheme. For example, costs incurred outside Australia in connection with our future clinical trials are generally not eligible for cash incentives under the R&amp;D Scheme. In
addition, the federal government of Australia and the Australian Taxation Office, or ATO, could change the rules of the regulatory regime or amend past tax returns and, as a result, amounts paid to us may become repayable to the ATO including the
amount of tax incentives in respect of our fiscal year ended June&nbsp;30, 2020 included as current receivables in our consolidated financial statements. Any rule changes made to reduce the amount we are able to claim under the R&amp;D Scheme
currently or in future and any retrospective changes made to the R&amp;D Scheme that reduce the incentives that we have claimed in past tax years could harm our business, financial condition and results of operations. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Legal, political and economic uncertainty surrounding
the planned exit of the U.K. from the EU are a source of instability and uncertainty. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On June&nbsp;23, 2016, the U.K. held a referendum in which a majority of the eligible members of the electorate voted for the U.K. to leave the EU. The U.K&#146;s withdrawal from the EU is commonly
referred to as &#147;Brexit.&#148; The U.K. and the EU have agreed to a withdrawal agreement, or the Withdrawal Agreement, which was approved by the U.K. Parliament on January&nbsp;24, 2020. Under the Withdrawal Agreement, the U.K. is subject to a
transition period until December&nbsp;31, 2020, or the Transition Period, during which EU rules will continue to apply. Negotiations between the U.K. and the EU are expected to continue in relation to the customs and trading relationship between the
U.K. and the EU following the expiration of the Transition Period. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">35 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The uncertainty concerning the U.K&#146;s legal, political and economic relationship
with the EU after the Transition Period may be a source of instability in the international markets, create significant currency fluctuations, and/or otherwise negatively affect trading agreements or similar cross-border cooperation arrangements
(whether economic, tax, fiscal, legal, regulatory or otherwise). These developments, or the perception that any of them could occur, have had, and may continue to have, a significant negative impact on global economic conditions and the stability of
global financial markets, and could significantly reduce global market liquidity and limit the ability of key market participants to operate in certain financial markets. In particular, it could also lead to a period of considerable uncertainty in
relation to the regulatory process in Europe. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Brexit has created political and economic uncertainty, particularly in the U.K. and the EU, and this uncertainty may persist for years. A
withdrawal could, among other outcomes, disrupt the free movement of goods, services and people between the U.K. and the EU, and result in increased legal and regulatory complexities, as well as potentially higher costs of conducting business in
Europe. The U.K.&#146;s vote to exit the EU could also result in similar referendums or votes in other European countries in which we do business. Given the lack of comparable precedent, it is unclear what financial, trade and legal implications the
withdrawal of the U.K. from the EU would have and how such withdrawal would affect us. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Any new regulations could add time and expense to the conduct of our business, as well as the process by which our product candidate receives regulatory approval in the U.K., the EU and elsewhere. In
addition, the announcement of Brexit and the withdrawal of the U.K. from the EU have had and may continue to negatively affect global economic conditions and the stability of global financial markets, and may significantly reduce global market
liquidity and restrict the ability of key market participants to operate in certain financial markets. Any of these effects of Brexit, among others, could harm our business, our results of operations, liquidity and financial condition. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Product liability lawsuits against us could cause us to
incur substantial liabilities and to limit commercialization of any products that we may develop. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will
face an even greater risk if we commercialize any resulting products. Product liability claims may be brought against us by subjects enrolled in our clinical trials, patients, or others using our products. If we cannot successfully defend ourselves
against claims that our product candidates or products that we may develop caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">decreased demand for any product candidates or products that we may develop; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">product recalls or a change in the indications for which products may be used; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">termination of clinical trial sites or entire trial programs; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">injury to our reputation and significant negative media attention; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">withdrawal of clinical trial participants; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">significant costs to defend the related litigation; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">substantial monetary awards to trial subjects or patients; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">loss of revenue; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">diversion of management and scientific resources from our business operations; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the inability to commercialize any products that we may develop. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">36 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our clinical trial liability insurance coverage may not adequately cover all
liabilities that we may incur. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. Our inability to obtain product liability insurance at an acceptable cost or to
otherwise protect against potential product liability claims could prevent or delay the commercialization of any products or product candidates that we develop. We intend to expand our insurance coverage for products to include the sale of
commercial products if we obtain marketing approval for our product candidates in development, but we may be unable to obtain commercially reasonable product liability insurance for any products approved for marketing. Large judgments have been
awarded in class action lawsuits based on drugs that had unanticipated side effects. If we are sued for any injury caused by our products, product candidates or processes, our liability could exceed our product liability insurance coverage and our
total assets. Claims against us, regardless of their merit or potential outcome, may also generate negative publicity or harm our ability to obtain physician endorsement of our products or expand our business. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our employees, contractors, vendors, principal
investigators, consultants and future partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are exposed to the risk of fraud or other misconduct by
our employees, contractors, vendors, principal investigators, consultants or future partners. Misconduct by these parties could include failures to comply with FDA or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> authority regulations,
to provide accurate information to the FDA or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulators, to comply with U.S. federal and state and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> healthcare fraud and abuse laws and
regulations, to report financial information or data timely, completely or accurately, or to disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws
and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer
incentive programs and other business arrangements. Third-party misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation.
Although we have adopted a Code of Conduct, it is not always possible to identify and deter misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in
protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us resulting from this misconduct and we are not successful in
defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. If we or our future partners market products in a manner that violates
fraud and abuse and other healthcare laws, or if we or our future partners violate government price reporting laws, we or our future partners may be subject to administrative civil and/or criminal penalties, among other sanctions. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Most states also have statutes or regulations similar to
these federal laws, which may apply to items such as pharmaceutical products and services reimbursed by private insurers. We and/or our future partners may be subject to administrative, civil and criminal sanctions for violations of any of these
federal and state laws. Pharmaceutical and other healthcare companies have been prosecuted under these laws for a variety of promotional and marketing activities, such as: providing free trips, free goods, sham consulting fees and grants and other
monetary benefits to prescribers; reporting to pricing services inflated average wholesale prices that were then used by federal programs to set reimbursement rates; engaging in <FONT STYLE="white-space:nowrap">off-label</FONT> promotion; and
submitting inflated best price information to the Medicaid Rebate Program to reduce liability for Medicaid rebates. Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and
regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and
abuse or other healthcare laws and regulations. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">37 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our business operations and relationships with investigators, healthcare
professionals, consultants, third-party payors, patient organizations and customers are subject to broadly applicable healthcare laws and regulations, which could expose us civil to penalties, criminal sanctions, contractual damages, reputational
harm and diminished profits and future earnings. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any product candidate for which we obtain regulatory approval. Our current and
future arrangements may expose us to broadly applicable fraud and abuse and other healthcare laws that may constrain the business or financial arrangements and relationships through which we would market, sell and distribute our products. In
particular, the research of our product candidates, as well as the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws designed to
prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs
and other business or financial arrangements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Such laws include, but are not limited to, the following: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering,
receiving or providing remuneration (including any kickback, bribe or rebate), directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or
recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid. The term &#147;remuneration&#148; has been broadly interpreted to include
anything of value. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly. Practices that involve remuneration that may
be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. A person or entity does not need to have actual knowledge of the federal Anti-Kickback
Statute or specific intent to violate it to have committed a violation. The Anti-Kickback Statute has been interpreted to apply to arrangements between biopharmaceutical manufacturers, on the one hand, and prescribers, purchasers and formulary
managers, among others, on the other. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False
Claims Act; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the federal criminal and civil false claims laws, including the False Claims Act, which imposes criminal and civil penalties, including through civil
whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent, knowingly making, using or causing to be made or
used, a false record or statement material to a false or fraudulent claim, or knowingly making or causing to be made, a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. Manufacturers can be held
liable under the False Claims Act even when they do not submit claims directly to government payors if they are deemed to &#147;cause&#148; the submission of false or fraudulent claims. When an entity is determined to have violated the False Claims
Act, the government may impose civil fines and penalties for each false claim, plus treble damages, and exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, among other things,
knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or making false or fraudulent statements relating to healthcare matters; similar to the federal Anti-Kickback Statute, a person or entity
does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, which also
impose obligations, including mandatory </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">38 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:Times New Roman" SIZE="2">
contractual terms, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information on health plans, health care clearing houses, and certain
healthcare providers and their business associates, defined as independent contractors or agents of covered entities that create, receive or obtain protected health information in connection with providing a service for or on behalf of a covered
entity. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or
injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#146; fees and costs associated with pursuing federal civil actions. In addition, there may be additional federal, state and
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> laws which govern the privacy and security of health and other personally identifiable information, or personal information or personal data, in certain circumstances, many of which differ from each
other in significant ways and may not have the same effect, thus complicating compliance efforts; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment
is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) to report annually to the government information related to payments or other &#147;transfers of value&#148; made to physicians, as
defined by law, and teaching hospitals, and requires applicable manufacturers and group purchasing organizations to report annually to the ownership and investment interests held by such physicians and their immediate family members and payments or
other &#147;transfers of value&#148; to such physician owners (covered manufacturers are required to submit reports to CMS by the 90th day of each calendar year). Effective January&nbsp;1, 2022, these reporting obligations will extend to include
transfers of value made in the previous year to certain <FONT STYLE="white-space:nowrap">non-physician</FONT> providers such as physician assistants and nurse practitioners; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">analogous state and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> laws and regulations, such as state anti-kickback and false claims laws, which may
apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT>
third-party payors, including private insurers, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; and state laws that require pharmaceutical companies to comply with the pharmaceutical
industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, and state laws that require drug manufacturers to report information related to payments and other transfers of value to
physicians and other healthcare providers, marketing expenditures or drug pricing; and state and local laws require the registration of pharmaceutical sales representatives; and state and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> laws
governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pharmaceutical and other healthcare companies have been
prosecuted under these laws for a variety of promotional and marketing activities, such as: providing free trips, free goods, sham consulting fees and grants and other monetary benefits to prescribers; reporting to pricing services inflated average
wholesale prices that were then used by federal programs to set reimbursement rates; engaging in <FONT STYLE="white-space:nowrap">off-label</FONT> promotion; and submitting inflated best price information to the Medicaid Rebate Program to reduce
liability for Medicaid rebates. Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental
authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The global data protection landscape is rapidly evolving, and
we may be affected by or subject to new, amended or existing laws and regulations in the future, including as our operations continue to expand or if we operate in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions. Several <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions, including the European Union, or EU, its member states, the United Kingdom, Japan and Australia, among others, have adopted legislation and regulations that increase or change the
requirements governing the collection, use, disclosure and transfer of the personal information of individuals in these jurisdictions. Additionally, certain countries have passed or are considering
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">39 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
passing laws that require local data residency and/or restrict the international transfer of data and/or impose data localization requirements with respect to certain personal information. These
laws have the potential to increase costs of compliance, risks of noncompliance and penalties for noncompliance. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will
involve substantial costs. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages,
disgorgement, fines, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, additional oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings,
and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, that person or entity may be subject
to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We depend on our information technology systems and those of our third-party collaborators, service providers, contractors or
consultants. Our internal computer systems, or those of our third-party collaborators, service providers, contractors or consultants, may fail or suffer security breaches, disruptions, or incidents, which could result in a material disruption of our
development programs or loss of data or compromise the privacy, security, integrity or confidentiality of sensitive information related to our business and could harm our reputation, business, financial condition or results of operations.
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the ordinary course of our business,
we collect, store and transmit large amounts of confidential information, including intellectual property, proprietary business information and personal information. Our internal technology systems and infrastructure, and those of our current or
future third-party collaborators, service providers, contractors and consultants are vulnerable to damage from computer viruses, unauthorized access or use resulting from malware, natural disasters, terrorism, war and telecommunication and
electrical failures, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">denial-of-service</FONT></FONT> attacks, cyber-attacks or cyber-intrusions over the Internet, hacking, phishing and other social engineering attacks, persons
inside our organizations (including employees or contractors), loss or theft, or persons with access to systems inside our organization. Attacks on information technology systems are increasing in their frequency, levels of persistence,
sophistication and intensity, and they are being conducted by increasingly sophisticated and organized <FONT STYLE="white-space:nowrap">non-U.S.</FONT> governments, groups and individuals with a wide range of motives and expertise. For example, in
June 2020, a coordinated cyber security attack targeted Australian government entities and companies. In addition to extracting or accessing sensitive information, such attacks could include the deployment of harmful malware, ransomware, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">denial-of-service</FONT></FONT> attacks, social engineering and other means to affect service reliability and threaten the security, confidentiality, integrity and availability of
information. The prevalent use of mobile devices that access sensitive information also increases the risk of data security incidents which could lead to such sensitive information (which may include confidential information, other intellectual
property or personal information) being subject to unauthorized access or otherwise compromised. While to our knowledge we have not experienced any material system failure, accident or security breach to date, if such an event were to occur and
cause interruptions in our operations or the operations of third-party collaborators, service providers, contractors and consultants, it could result in a material disruption of our development programs and significant reputational, financial,
legal, regulatory, business or operational harm. The costs to us to mitigate, investigate and respond to potential security incidents, breaches, disruptions, network security problems, bugs, viruses, worms, malicious software programs and security
vulnerabilities could be significant, and while we have implemented security measures to protect our data security and information technology systems, our efforts to address these problems may not be successful, and these problems could result in
unexpected interruptions, delays, cessation of service and other harm to our business and our competitive position. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For example, the loss of clinical trial data from completed, ongoing or planned clinical trials for our product candidates could result in
delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any real or perceived security breach affects our systems (or those of our
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">40 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
third-party collaborators, service providers, contractors or consultants), or results in the loss of or accidental, unlawful or unauthorized access to, use of, release of, or other processing of
personal information or damage to our data or applications or other data or applications relating to our technology or product candidates, or inappropriate disclosure of confidential or proprietary information, we could incur liabilities and the
further development of our product candidates could be delayed. Such a breach may require notification to governmental agencies, the media or individuals pursuant to various <FONT STYLE="white-space:nowrap">non-U.S.</FONT> domestic (federal and
state) privacy and security laws, if applicable, including HIPAA, as amended by HITECH, and its implementing rules and regulations, as well as regulations promulgated by the Federal Trade Commission and state breach notification laws. In addition,
our liability insurance may not be sufficient in type or amount to cover us against all losses and claims related to security breaches, cyberattacks and other related incidents. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any failure or perceived failure by us or any third-party
collaborators, service providers, contractors or consultants to comply with our privacy, confidentiality, data security or similar obligations, or any data security incidents or other security breaches that result in the accidental, unlawful or
unauthorized access to, use of, release of, processing of, or transfer of sensitive information, including personal information, may result in negative publicity, harm to our reputation, governmental investigations, enforcement actions, regulatory
fines, litigation or public statements against us, could cause third parties to lose trust in us or could result in claims by third parties, including those that assert that we have breached our privacy, confidentiality, data security or similar
obligations, any of which could harm our reputation, business, financial condition or results of operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To the extent we maintain individually identifiable health information, we could be subject to fines and penalties (including civil and
criminal) under HIPAA for any failure by us or our business associates to comply with HIPAA&#146;s requirements. Moreover, data security incidents and other security breaches can be difficult to detect, and any delay in identifying them may lead to
increased harm. While we have implemented data security measures intended to protect our information, data, information technology systems, applications and infrastructure, there can be no assurance that such measures will successfully prevent
service interruptions or data security incidents. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>European data collection is governed by restrictive regulations governing the collection, use, processing and cross-border transfer
of personal information. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may collect,
process, use or transfer personal information from individuals located in the European Economic Area in connection with our business, including in connection with conducting clinical trials in the European Economic Area, or the EEA. Additionally, if
any of our product candidates are approved, we may seek to commercialize those products in the European Economic Area. The collection and use of personal health data in the European Economic Area is governed by the provisions of the General Data
Protection Regulation ((EU) 2016/679), or the GDPR, along with other European Union and country-specific laws and regulations. The United Kingdom and Switzerland have also adopted data protection laws and regulations. These legislative acts
(together with regulations and guidelines) impose requirements relating to having legal bases for processing personal data relating to identifiable individuals and transferring such data outside of the European Economic Area, including to the United
States, providing details to those individuals regarding the processing of their personal data, keeping personal data secure, having data processing agreements with third parties who process personal data, responding to individuals&#146; requests to
exercise their rights in respect of their personal data, reporting security breaches involving personal data to the competent national data protection authority and affected individuals, appointing data protection officers or corporate
representatives, conducting data protection impact assessments and record-keeping. The GDPR imposes additional responsibilities and liabilities in relation to personal data that we process and we may be required to put in place additional mechanisms
ensuring compliance with the new data protection rules. Failure to comply with the requirements of the GDPR and related national data protection laws of the member states of the European Economic Area and other states in the European Economic Area
may result in substantial penalties, including potential fines of up to &#128;20&nbsp;million or 4% of annual global revenues, whichever is greater, other administrative penalties and civil claims being brought against us, which could harm our
business, financial condition and results of operations. European data </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">41 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
protection authorities may interpret the GDPR and national laws differently and may impose additional requirements, which adds to the complexity of processing personal data in or from the EEA or
United Kingdom. Guidance on implementation and compliance practices are often updated or otherwise revised. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our insurance policies are expensive and only protect us from some business risks, leaving us exposed to significant uninsured
liabilities. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We do not carry insurance
for all categories of risk that our business may encounter. We believe that we maintain insurance customary for businesses of our size and type, including clinical trial liability insurance. However, there are types of losses we may incur that
cannot be insured against or that we believe are not economically reasonable to insure. Moreover, any loss incurred could exceed policy limits and policy payments made to us may not be made on a timely basis. Such losses could negatively affect our
business prospects, results of operations, cash flows and financial condition. We do not know if our current levels of coverage are adequate or if we will be able to obtain insurance with adequate levels of coverage in the future, if at all. Any
significant uninsured liability may require us to pay substantial amounts, which could negatively impact our financial position and results of operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Disputes under key agreements or conflicts of interest with our scientific advisors or clinical investigators could delay or prevent
development or commercialization of our product candidates. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Any agreements we have or may enter into with third parties, such as collaboration, license, formulation supplier, manufacturing, clinical research organization or clinical trial agreements, may give rise
to disputes regarding the rights and obligations of the parties. Disagreements could develop over contract interpretation, rights to ownership or use of intellectual property, the scope and direction of research and development, the approach for
regulatory approvals or commercialization strategy. We intend to conduct research programs in a range of therapeutic areas, but our pursuit of these opportunities could result in conflicts with the other parties to these agreements that may be
developing or selling pharmaceuticals or conducting other activities in these same therapeutic areas. Any disputes or commercial conflicts could lead to the termination of our agreements, delay progress of our product development programs,
compromise our ability to renew agreements or obtain future agreements, lead to the loss of intellectual property rights, result in increased financial obligations for us or result in costly litigation. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We work with outside scientific advisors and collaborators at
academic and other institutions that assist us in our research and development efforts. Our scientific advisors are not our employees and may have other commitments that limit their availability to us. If a conflict of interest between their work
for us and their work for another entity arises, we may lose their services. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Unstable market and economic conditions may have serious adverse consequences on our business and financial condition. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Global credit and financial markets have experienced extreme
disruptions at various points over the last few decades, characterized by diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic
stability. If another such disruption in credit and financial markets and deterioration of confidence in economic conditions occurs, our business may be harmed. If the equity and credit markets were to deteriorate significantly in the future, it may
make any necessary debt or equity financing more difficult to complete, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could harm our growth strategy, financial performance and
share price and could require us to delay or abandon development or commercialization plans. In addition, there is a risk that one or more of our service providers, manufacturers or other partners would not survive or be able to meet their
commitments to us under such circumstances, which could directly affect our ability to attain our operating goals on schedule and on budget. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">42 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we fail to implement and maintain an effective system of internal controls to
remediate our material weaknesses over financial reporting, we may be unable to accurately report our results of operations, meet our reporting obligations or prevent fraud, and investor confidence in our company and the market price of the ADSs may
be negatively impacted. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;404(a) of the&nbsp;Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, requires that our management assess and report
annually on the effectiveness of our internal controls over financial reporting and identify any material weaknesses in our internal controls over financial reporting. During the audit of our consolidated financial statements for the fiscal year
ended June&nbsp;30, 2019, material weaknesses were identified in our internal control over financial reporting. Under standards established by the PCAOB, a &#147;material weakness&#148; is a deficiency, or combination of deficiencies in internal
control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. The material weaknesses that have been
identified relate to our lack of (i)&nbsp;sufficient accounting and financial reporting personnel with requisite knowledge of and experience in application of SEC rules and regulations and (ii)&nbsp;adequate controls to address segregation of
duties. We and our independent registered public accounting firm were not required to perform an evaluation of our internal control over financial reporting as of June&nbsp;30, 2019 and 2020 in accordance with the provisions of the Sarbanes-Oxley
Act. Accordingly, we cannot assure you that we have identified all, or that we will not in the future have additional, material weaknesses. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are in the process of implementing a number of measures to address the material weaknesses that have been identified including:
(i)&nbsp;hiring additional accounting and financial reporting personnel with SEC reporting experience, (ii)&nbsp;expanding the capabilities of existing accounting and financial reporting personnel through continuous training and education in the
accounting and reporting requirements under International Financial Reporting Standards, or IFRS, and SEC rules and regulations, (iii)&nbsp;establishing effective monitoring and oversight controls for
<FONT STYLE="white-space:nowrap">non-recurring</FONT> and complex transactions to ensure the accuracy and completeness of our company&#146;s consolidated financial statements and related disclosures and (iv)&nbsp;implementing formal processes and
controls to identify, monitor and mitigate segregation of duties conflicts. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The presence of material weaknesses could result in financial statement errors which, in turn, could lead to errors in our financial reports or delays in our financial reporting, which could require us to
restate our operating results or result in our auditors issuing a qualified audit report. In order to establish and maintain effective disclosure controls and procedures and internal controls over financial reporting, we will need to expend
significant resources and provide significant management oversight. Developing, implementing and testing changes to our internal controls may require specific compliance training of our directors and employees, entail substantial costs in order to
modify our existing accounting systems, take a significant period of time to complete and divert management&#146;s attention from other business concerns. These changes may not, however, be effective in establishing and maintaining adequate internal
controls. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If either we are unable to conclude
that we have effective internal controls over financial reporting or our independent auditors are unwilling or unable to provide us with an unqualified report on the effectiveness of our internal controls over financial reporting as required by
Section&nbsp;404(b) of the Sarbanes-Oxley Act, investors may lose confidence in our operating results, the price of the ADSs could decline and we may be subject to litigation or regulatory enforcement actions. In addition, if we are unable to meet
the requirements of Section&nbsp;404 of the Sarbanes-Oxley Act, we may not be able to remain listed on The Nasdaq Global Market, or Nasdaq. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Regulatory Approvals </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we are not able to obtain required regulatory approvals, we will not be able to commercialize
<FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidate, and our ability to generate product revenue will be impaired. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidate that we may develop, as well as the activities associated
with their development and commercialization, including their design, research, testing, manufacture, safety, efficacy, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">43 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
recordkeeping, labeling, packaging, storage, approval, advertising, promotion, sale and distribution are subject to comprehensive regulation by the FDA and other regulatory agencies in the United
States and by similar regulatory authorities outside the United States. Failure to obtain marketing approval for, and thus commercialize any product candidate, could negatively impact our ability to generate any revenue from product sales.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have not received approval from regulatory
authorities to market any product candidate in any jurisdiction, and it is possible that our product candidate will never obtain the appropriate regulatory approvals necessary for us to commence product sales. Neither we nor any collaborator is
permitted to market our product candidate in the United States or any other jurisdiction until we receive regulatory approval of a BLA from the FDA or similar application from regulatory authorities outside of the United States. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The time required to obtain approval of a BLA by the FDA or
similar application from regulatory authorities outside of the United States is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the
regulatory authority. Prior to submitting a BLA to the FDA or any comparable application to any other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities for approval of any product candidate, we will need to complete pivotal
Phase 3 clinical trials and demonstrate favorable results with respect to safety, tolerability and efficacy. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course
of a product candidate&#146;s clinical development and may vary among jurisdictions. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Securing marketing approvals requires the submission of extensive nonclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the safety
and efficacy of our product candidate for the specified indications. We expect to rely on third-party CROs, consultants and our collaborators to assist us in filing and supporting the applications necessary to gain marketing approvals. Securing
marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, regulatory authorities. Errors in the submission of applications for marketing approval or
issues, including those related to gathering the appropriate data and the inspection process, may ultimately delay or affect our ability to obtain regulatory approval, commercialize our product candidate and generate product revenue. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our failure to obtain regulatory approval in
international jurisdictions would prevent us from marketing our product candidates outside the United States. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we succeed in developing any products, we intend to market them in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions in
addition to the United States. In order to market and sell our products in other jurisdictions, we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. We may not obtain <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> regulatory approvals on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions. Approval by one regulatory authority outside
the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. If we fail to obtain approval of any of our product candidates by regulatory authorities in another country we will be unable to
commercialize our product in that country, and the commercial prospects of that product candidate and our business prospects could decline. The approval procedure varies among countries and can involve additional testing. The time required to obtain
approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside
the United States, we must secure product reimbursement approvals before regulatory authorities will approve the product for sale in that country. Obtaining <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory approvals and compliance with <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. Further, clinical trials conducted
in one country may not be accepted by regulatory authorities in other countries and regulatory approval in one country does not ensure approval in any other country, while a failure or delay in obtaining regulatory approval in one country may have a
negative effect on the regulatory approval process in others. Also, regulatory approval for any of our product candidates may be withdrawn if we </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">44 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
fail to comply with regulatory requirements, if problems occur after the product candidate reaches the market or for other reasons. If we fail to comply with the regulatory requirements in
international markets and fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed and our business will be negatively affected.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Even if
<FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy or any future product candidate receives regulatory approval, it may still face future development and regulatory difficulties. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Even if we obtained regulatory approval for a product
candidate, it would be subject to ongoing requirements by the FDA and comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities governing the manufacture, quality control, further development, labeling, packaging, storage,
distribution, safety surveillance, import, export, advertising, promotion, recordkeeping and reporting of safety and other post-market information. The FDA and comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities will
continue to closely monitor the safety profile of any product even after approval. If the FDA, or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities, become aware of new safety information after approval of any of our
product candidates, it may require labeling changes or establishment of a risk evaluation and mitigation strategy or similar strategy, impose significant restrictions on a product&#146;s indicated uses or marketing or impose ongoing requirements for
potentially costly post-approval studies or post-market surveillance. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with current good
manufacturing practices, or cGMP, regulations and standards. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the
product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. If we, our product
candidates or the manufacturing facilities for our product candidates fail to comply with applicable regulatory requirements, or undesirable side effects caused by such products are identified, a regulatory agency may: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings about such product;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">mandate modifications to promotional materials or require us to provide corrective information to healthcare practitioners;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">revise labeling, including adding limitations on approved uses or the additions of additional warnings, contraindications or other safety information
including boxed warnings; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">impose a REMS which may include distribution on or use restrictions; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">require that we conduct post-marketing studies; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">require us to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due dates for
specific actions and penalties for noncompliance; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">seek an injunction or impose civil or criminal penalties or monetary fines; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">suspend marketing of, withdraw regulatory approval of or recall such product; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">suspend any ongoing clinical studies; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">refuse to approve pending applications or supplements to applications filed by us; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">suspend or impose restrictions on operations, including costly new manufacturing requirements; or </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">seize or detain products, refuse to permit the import or export of products or require us to initiate a product recall. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">45 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The occurrence of any event or penalty described above may inhibit our ability to
commercialize our products and generate product revenue. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Advertising and promotion of any product candidate that obtains approval in the United States will be heavily scrutinized by the FDA, the Department of Justice, the Department of Health and Human
Services&#146; Office of Inspector General, state attorneys general, members of Congress and the public. Violations, including promotion of our products for unapproved (or <FONT STYLE="white-space:nowrap">off-label)</FONT> uses, are subject to
enforcement letters, inquiries and investigations and significant civil and criminal sanctions by the government. In the United States, engaging in the impermissible promotion of our products for <FONT STYLE="white-space:nowrap">off-label</FONT>
uses can also subject us to false claims litigation under federal and state statutes, which can lead to significant civil and criminal penalties. Additionally, comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities will
heavily scrutinize advertising and promotion of any product candidate that obtains approval outside of the United States. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA&#146;s policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory
approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval
that we may have obtained, which would negatively affect our business, prospects and ability to achieve or sustain profitability. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Our Reliance on Third Parties </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We have relied on, and expect to continue to rely on, third-party manufacturers to produce
<FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates. Any failure by a third-party manufacturer to produce acceptable product candidates for us pursuant to our specifications and regulatory standards may delay or impair
our ability to initiate or complete our clinical trials, obtain and maintain regulatory approvals or commercialize approved products. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The manufacturing of biologic drugs such as <FONT STYLE="white-space:nowrap">OPT-302</FONT> is complex and the process of identifying the
qualifying suppliers takes a significant investment of time and money. We do not own or operate manufacturing facilities for the production of clinical or commercial quantities of our product candidates, and we lack the resources and the
capabilities to do so. As a result, we currently rely, and expect to rely for the foreseeable future, on third-party manufacturers to supply us with <FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidates. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently have a sole source relationship with Patheon
N.V., a division of Thermo Fisher Scientific Inc., pursuant to which they supply us with <FONT STYLE="white-space:nowrap">OPT-302</FONT> drug substance and drug product. If there should be any disruption in our supply arrangement with Patheon,
including any adverse events affecting Patheon or Thermo Fisher Scientific, it could have a negative effect on the clinical development of <FONT STYLE="white-space:nowrap">OPT-302</FONT> and other operations while we work to identify and qualify an
alternate supply source. In addition, we do not have a long-term supply arrangement to purchase <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy for use in combination with <FONT STYLE="white-space:nowrap">OPT-302</FONT> in our clinical
trials and acquire such drug product on a purchase order basis. Any complications with our existing suppliers of <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies could considerably delay our clinical trials for <FONT
STYLE="white-space:nowrap">OPT-302,</FONT> including our Phase 3 pivotal clinical program of <FONT STYLE="white-space:nowrap">OPT-302</FONT> for the treatment of wet AMD, or the regulatory approvals of
<FONT STYLE="white-space:nowrap">OPT-302.</FONT> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reliance on third-party suppliers and manufacturers entails risks to which we would not be subject if we manufacture product candidates or
products ourselves. For example, if we do not maintain our key manufacturing relationships, including with Patheon, we may fail to find replacement manufacturers or develop our own manufacturing capabilities in a timely manner or at all, which could
delay or impair our ability to obtain regulatory approval for our products and substantially increase our costs or deplete profit margins, if any. If we do find replacement manufacturers, we may not be able to enter into agreements with them on
terms and conditions favorable to us in a timely manner, if at all, and there could be a substantial delay before new facilities could be qualified and registered with or licensed by the FDA and other comparable
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">46 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Even if we are able to establish agreements with third-party manufacturers, reliance on
third-party manufacturers entails additional risks, including: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">failure of the third party to manufacture product candidates according to our schedule, or at all, including if our third-party contractors give
greater priority to the supply of other products over our product candidates or otherwise do not satisfactorily perform according to the terms of the agreements between us and them; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">breach of the manufacturing agreement by the third party because of factors beyond our control (including a failure to manufacture product candidates
in accordance with our product specifications); </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the failure of the third-party manufacturer to comply with applicable regulatory requirements and reliance on third-parties for manufacturing process
development, regulatory compliance and quality assurance; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">mislabeling of clinical supplies, potentially resulting in the wrong dose amounts being supplied or active drug or placebo not being properly
identified; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions, or of drug supplies not being distributed to
commercial vendors in a timely manner, resulting in lost sales; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">misappropriation of our proprietary information, including our trade secrets and <FONT STYLE="white-space:nowrap">know-how;</FONT>
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reliance on the third party for regulatory compliance, quality assurance and safety and pharmacovigilance reporting. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA and other comparable
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities require manufacturers to register manufacturing facilities. The FDA and other comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities also inspect
these facilities to confirm compliance with cGMP. Contract manufacturers may face manufacturing or quality control problems causing drug substance production and shipment delays or a situation where the contractor may not be able to maintain
compliance with the applicable cGMP requirements. We may have little to no control regarding the occurrence of third-party manufacturer incidents. Failure by our third-party manufacturers and suppliers to pass such inspections and otherwise
satisfactorily complete the FDA approval regimen with respect to our product candidate may result in regulatory actions such as the issuance of FDA Form 483 notices of observations, warning letters or injunctions or the loss of operating licenses.
In addition, our third-party manufacturers and suppliers are subject to numerous environmental, health and safety laws and regulations, including those governing the handling, use, storage, treatment and disposal of waste products, and failure to
comply with such laws and regulations could result in significant costs associated with civil or criminal fines and penalties for such third parties. Any failure to comply with cGMP requirements or other FDA or comparable <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> regulatory requirements could negatively impact our clinical research activities and our ability to develop <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates and market our
products following approval. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If <FONT
STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates are approved by the FDA or other comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities for commercial sale, we may need to manufacture such
product candidate in larger quantities. We intend to use third-party manufacturers for commercial quantities of <FONT STYLE="white-space:nowrap">OPT-302</FONT> to the extent we advance this product candidate and other product candidates. Our
manufacturers may not be able to successfully increase the manufacturing capacity for any of our product candidates in a timely or efficient manner, or at all. If we are unable to successfully increase the manufacturing capacity for a product
candidate, the regulatory approval or commercial launch of that product candidate may be delayed or there may be a shortage in the supply of the product candidate. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, the operations of our third-party manufacturers
may be subject to earthquakes, power shortages, telecommunications failures, failures or breaches of information technology systems, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics, such as the
recent <FONT STYLE="white-space:nowrap">COVID-19</FONT> </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">47 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
pandemic, and other natural or <FONT STYLE="white-space:nowrap">man-made</FONT> disasters or business interruptions. Damage or extended periods of interruption to our facilities due to fire,
natural disaster, power loss, communications failure, unauthorized entry or other events could cause us to cease or delay development of some or all of our product candidates. Our ability to obtain clinical supplies of our product candidates could
be disrupted if the operations of these suppliers are affected by a <FONT STYLE="white-space:nowrap">man-made</FONT> or natural disaster or other business interruption. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our current and anticipated future dependence upon others for
the manufacture of our product candidates may negatively affect our future profit margins and our ability to develop our product candidates and commercialize any products that receive regulatory approval on a timely basis. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In some cases, the technical skills or technology required to
manufacture our product candidates may be unique or proprietary to the original manufacturer, we may have difficulty transferring such skills or technology to another third party and a feasible alternative many not exist. These factors would
increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third party manufacture our product candidates. If we are required to change manufacturers for any reason, we will be
required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines and the manufacturer may be required to obtain applicable licenses or approvals.
The delays associated with the verification of a new manufacturer, if we are able to identify an alternative source, could negatively affect our ability to develop product candidates in a timely manner or within budget. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The manufacture of biologic products is complex and we
are subject to many manufacturing risks, any of which could substantially increase our costs and limit supply of our products. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The manufacture of biologic products is complex and requires significant expertise and capital investment, including the development of
advanced manufacturing techniques and process controls. Manufacturers of biologic products often encounter difficulties in production, particularly in scaling up and validating initial production and ensuring the avoidance of contamination. These
problems include difficulties with production costs and yields, quality control, including stability of the product, quality assurance testing, operator error and shortages of qualified personnel, as well as compliance with strictly enforced
federal, state and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulations. We cannot assure you that any stability or other issues relating to the manufacture of <FONT STYLE="white-space:nowrap">OPT-302</FONT> will not occur in the future.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The process of manufacturing <FONT
STYLE="white-space:nowrap">OPT-302</FONT> is complex, highly regulated and subject to several risks, including: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the process of manufacturing biologics is susceptible to product loss due to contamination, equipment failure, improper installation or operation of
equipment, vendor or operator error and improper storage conditions. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other
contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, the manufacturing facilities may need to be closed for an extended period of time to investigate and eliminate the
contamination; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the manufacturing facilities in which our products are made could be negatively affected by equipment failures, labor and raw material shortages,
financial difficulties of our contract manufacturers, natural disasters, power failures, local political unrest and numerous other factors; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any adverse developments affecting manufacturing operations for our product candidates may result in shipment delays, inventory shortages, lot
failures, and for any approved products, product withdrawals, or recalls or other interruptions in the supply of our products. We may also have to record inventory write-offs and incur other charges and expenses for products that fail to meet
specifications, undertake costly remediation efforts or seek costlier manufacturing alternatives. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">48 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To date, <FONT STYLE="white-space:nowrap">OPT-302</FONT> has been manufactured by a
single third-party manufacturer, Patheon, solely for preclinical studies and Phase 1 and 2 trials. This manufacturer may not be able to scale production to the larger quantities required for large clinical trials, including our planned Phase 3
clinical trials of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy for the treatment of wet AMD, and to commercialize <FONT STYLE="white-space:nowrap">OPT-302,</FONT> on
a timely basis or at all. Any such failure will require us to seek alternative manufacturing sources, which may result in considerable additional expense and delays in our planned clinical trials. We have limited process development capabilities and
have access only to external manufacturing capabilities. We do not have and we do not currently plan to acquire or develop the facilities or capabilities to manufacture bulk drug substance or filled drug product for use in human clinical trials or
commercialization. Any delay or interruption in the supply of clinical trial materials, including as a result of breach by us or Patheon of our agreement with Patheon, or our inability to agree to the terms of supply or related services in any
statement of work, could delay the completion of clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, require us to commence new clinical trials at additional expense or
terminate clinical trials completely. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As product candidates proceed through nonclinical studies to
late-stage clinical trials towards potential approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize processes
and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidate to perform differently and affect the
results of planned clinical trials or other future clinical trials conducted with the altered materials. Such changes may also require additional testing, FDA notification or FDA approval. This could delay completion of clinical trials, require the
conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidate or jeopardize our ability to
commence sales and generate revenue. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We
rely on third parties to conduct our clinical trials and some aspects of our research and development activities, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research
or testing. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently rely on, and
expect to continue to rely on, third parties, such as CROs, clinical data management organizations, medical institutions, consultants and clinical investigators, to conduct our clinical trials and certain aspects of our research and development
activities. Any of these third parties may terminate their engagements with us at any time. If we need to enter into alternative arrangements, it would delay our product development activities and such alternative arrangements may not be available
on terms acceptable to us. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our reliance on these
third parties for research and development activities will reduce our control over these activities, but will not relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted
in accordance with the general investigational plan and clinical trial protocols. Moreover, the FDA requires us to comply with standards, commonly referred to as current Good Clinical Practices, for conducting, recording and reporting the results of
clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. We are also required to register ongoing clinical trials and post the results
of completed clinical trials on a government-sponsored database within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Furthermore, these third parties may also have relationships
with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements, standard
operating procedures or clinical trial protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">49 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
<FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also expect to rely on other third parties to
store and distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development, marketing approval and/or commercialization of <FONT STYLE="white-space:nowrap">OPT-302</FONT> or
any future product candidates, producing additional losses and depriving us of potential revenue. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may seek to establish commercial collaborations for our product candidates, and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development and
commercialization plans. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our drug
development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses. We may decide to collaborate with other pharmaceutical and biotechnology companies for the development and
potential commercialization of our product candidates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the
collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#146;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the
likelihood of approval by the FDA or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities, the potential market for the product candidate, the costs and complexities of manufacturing and delivering such product
candidate to patients, the potential of competing products and the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and
industry and market conditions generally. The collaborators may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive
than the one with us for our product candidate. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of business
combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have
to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any
sales or marketing activities or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may
need to obtain additional capital, which may not be available to us on acceptable terms, or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product
revenue. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Relating to Intellectual Property
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our success depends upon our ability
to obtain and maintain intellectual property protection for our products and technologies. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our success will depend in significant part on our current or future licensors&#146;, licensees&#146; or collaborators&#146; ability to establish and maintain adequate protection of our owned and licensed
intellectual property covering the product candidates we plan to develop, and the ability to develop these product candidates and commercialize the products resulting therefrom, without infringing the intellectual property rights of others. In
addition to taking other steps to protect our intellectual property, we hold issued patents, we have applied for patents, and we intend </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">50 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
to continue to apply for, patents with claims covering our technologies, processes and product candidates when and where we deem it appropriate to do so. We have filed patent applications both in
the United States and in certain <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions to obtain patent rights to inventions we have developed, with claims directed to compositions of matter, methods of use and other technologies relating
to our programs. There can be no assurance that any of these patent applications will issue as patents or, for those applications that do mature into patents, that the claims of the patents will exclude others from making, using or selling our
product candidates or products that compete with or are similar to our product candidates. In countries where we have not sought and do not seek patent protection, third parties may be able to manufacture and sell our product candidates without our
permission, and we may not be able to stop them from doing so. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">With respect to patent rights, we do not know whether any of the pending patent applications for any of our product candidates will result in the issuance of patents that effectively protect our
technologies, processes and product candidates, or if any of our issued patents or our current or future licensors&#146;, licensees&#146; or collaborators&#146; issued patents will effectively prevent others from commercializing competitive
technologies, processes and products. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months
after filing or in some cases not at all, until they are issued as a patent. Therefore, we cannot be certain that we or our current or future licensors, licensees or collaborators were the first to make the inventions claimed in our owned or
licensed patents or pending patent applications, or that we or our current or future licensors, licensees or collaborators were the first to file for patent protection of such inventions. For a description of our patent portfolio, see
&#147;Business&#151;Intellectual Property.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any changes we make to <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates to cause them to have what we view
as more advantageous properties may not be covered by our existing patents and patent applications, and we may be required to file new applications and/or seek other forms of protection for any such altered product candidates. The patent landscape
surrounding the technology underlying our product candidates is potentially crowded, and there can be no assurance that we would be able to secure patent protection that would adequately cover an alternative to
<FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The patent prosecution process is expensive and time-consuming, and we and our current or future licensors, licensees or collaborators may not be able to prepare, file and prosecute all necessary or
desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we or our current or future licensors, licensees or collaborators will fail to identify patentable aspects of inventions made in the course of
development and commercialization activities before it is too late to obtain patent protection for them. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to
maintain or enforce the patents, covering technology that we license from or license to third parties and may be reliant on our current or future licensors, licensees or collaborators to perform these activities, which means that these patent
applications may not be prosecuted, and these patents enforced, in a manner consistent with the best interests of our business. If our current or future licensors, licensees or collaborators fail to establish, maintain, protect or enforce such
patents and other intellectual property rights, such rights may be reduced or eliminated. If our current or future licensors, licensees or collaborators are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement
of any patent rights, such patent rights could be compromised. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Similar to the patent rights of other biotechnology companies, the scope, validity and enforceability of our owned and licensed patent rights generally are highly uncertain and involve complex legal and
factual questions. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. In recent years, these areas
have been the subject of much litigation in the industry. As a result, the issuance, scope, validity, enforceability and commercial value of our and our current or future licensors&#146;, licensees&#146; or collaborators&#146; patent rights are
highly uncertain. Our and our current or future licensors&#146;, licensees&#146; or collaborators&#146; pending and future patent applications may not result in patents being issued that protect our technology or product candidates, or products
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">51 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
resulting therefrom, in whole or in part, or that effectively prevent others from commercializing competitive technologies and products. The patent examination process may require us or our
current or future licensors, licensees or collaborators to narrow the scope of the claims of pending and future patent applications, which would limit the scope of patent protection that is obtained, if any. Our and our current or future
licensors&#146;, licensees&#146; or collaborators&#146; patent applications cannot be enforced against third parties practicing the technology that is currently claimed in such applications unless and until a patent issues from such applications,
and then only to the extent the claims that issue are broad enough to cover the technology being practiced by those third parties. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Furthermore, given the amount of time required for the development, testing and regulatory review of new product candidates, patents
protecting such candidates might expire before or shortly after the resulting products are commercialized. As a result, our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents may not provide us with sufficient rights to exclude
others from commercializing products similar or identical to ours. We expect to seek extensions of patent terms for our issued patents, where available. This includes in the United States under the Hatch-Waxman Act, which permits a patent term
extension of up to five years beyond the original expiration date of the patent as compensation for regulatory delays. However, such a patent term extension cannot lengthen the remaining term of a patent beyond a total of 14 years from the
product&#146;s approval date. Only one patent applicable to each regulatory review period may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended, with extended rights
limited to the approved product, its approved uses and/or its manufacture. During the period of patent term extension, the claims of a patent are not enforceable for their full scope, but are instead limited to the scope of the approved product. In
addition, the applicable authorities, including the FDA in the United States, and any comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities, may not agree with our assessment of whether such extensions are available, and
may refuse to grant extensions to our patents, or may grant more limited extensions than we request. In addition, we may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to the
expiration of relevant patents or otherwise failing to satisfy applicable requirements. If this occurs, any period during which we have the right to exclusively market our product will be shorter than we would otherwise expect, and our competitors
may obtain approval of and launch products earlier than might otherwise be the case. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may not be able to protect our intellectual property rights throughout the world. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The legal protection afforded to inventors and owners of intellectual property in countries outside of the United States may not be as
protective or effective as that in the United States and we may, therefore, be unable to acquire and enforce intellectual property rights outside the United States to the same extent as in the United States. Whether filed in the United States or
abroad, our patent applications may be challenged or may fail to result in issued patents. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition, our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from practicing our technologies or from developing or commercializing competing
products. Furthermore, others may independently develop or commercialize similar or alternative technologies or drugs, or design around our patents. Our patents may be challenged, invalidated, circumvented or narrowed, or fail to provide us with any
competitive advantages. In many <FONT STYLE="white-space:nowrap">non-U.S.</FONT> countries, patent applications and/or issued patents, or parts thereof, must be translated into the native language. If our patent applications or issued patents are
translated incorrectly, they may not adequately cover our technologies; in some countries, it may not be possible to rectify an incorrect translation, which may result in patent protection that does not adequately cover our technologies in those
countries. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Filing, prosecuting, enforcing and
defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States may be less extensive than those in the United States.
In addition, the laws of some <FONT STYLE="white-space:nowrap">non-U.S.</FONT> countries do not protect intellectual property rights to the same extent as federal and certain state laws in the United States. Consequently, we may not be able to
prevent third parties from practicing our inventions in all countries outside </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">52 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use technologies in jurisdictions where we
have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products
may compete with <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Many companies have encountered significant problems in
protecting and defending intellectual property rights in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and
other intellectual property protection, particularly those relating to biopharmaceuticals. This could make it difficult for us to stop the infringement of our patents or the marketing of competing products in violation of our proprietary rights,
generally. Proceedings to enforce our patent rights in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at
risk of being invalidated or interpreted narrowly, could place our patent applications at risk of not issuing and could provoke third parties to assert claims against us or our collaborator. We may not prevail in any lawsuits that we initiate and
the damages or other remedies awarded, if any, may not be commercially meaningful. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The requirements for patentability differ and certain countries have heightened requirements for patentability, requiring more disclosure in the patent application. In addition, certain countries have
compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, we may have limited remedies if patents are infringed or if we are compelled to grant a license to a third party, which
could materially diminish the value of those patents. This could limit our potential revenue opportunities. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries,
the patent owner may have limited remedies, which could materially diminish the value of such patent. Accordingly, our efforts to enforce intellectual property rights around the world may be inadequate to obtain a significant commercial advantage
from the intellectual property that we own or license. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect <FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidates.
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As is the case with other biotechnology
and pharmaceutical companies, our success is heavily dependent on intellectual property rights, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves technological and legal complexity, and obtaining and
enforcing biopharmaceutical patents is costly, time-consuming and inherently uncertain. The U.S. Supreme Court in recent years has issued rulings either narrowing the scope of patent protection available in certain circumstances or weakening the
rights of patent owners in certain situations or ruling that certain subject matter is not eligible for patent protection. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events
has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress, the federal courts, the USPTO and equivalent bodies in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions, the laws and
regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce existing patents and patents we may obtain in the future. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patent reform laws, such as the Leahy-Smith America Invents Act, or the Leahy-Smith Act, as well as changes in
how patent laws are interpreted, could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. The Leahy-Smith Act made a number of significant changes to U.S.
patent law. These include provisions that affect the filing and prosecution strategies associated with patent applications, including a change from a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-invent&#148;</FONT></FONT> to a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-inventor-to-file&#148;</FONT></FONT> patent system, and a
change allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO-administered post-grant proceedings, including post-grant review, <I>inter partes
</I>review and derivation proceedings. The USPTO has developed regulations and procedures to govern administration of the Leahy-Smith Act, and many of the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">53 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
substantive changes to patent law associated with the Leahy-Smith Act and, in particular, the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-inventor-to-file&#148;</FONT></FONT> provisions, became effective in 2013. The Leahy-Smith Act and its implementation may increase the uncertainties and costs surrounding
the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have harm our business, financial condition and results of operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may be unable to obtain intellectual property rights or technology necessary to develop and
commercialize <FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidates. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The patent landscape around our programs is complex, and there may be one or more third-party patents and patent applications containing
subject matter that might be relevant to <FONT STYLE="white-space:nowrap">OPT-302.</FONT> Depending on what claims may ultimately issue from these patent applications, and how courts construe the issued patent claims, as well as depending on the
ultimate formulation and method of use of <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates, we may need to obtain a license to practice the technology claimed in such patents. There can be no assurance that such
licenses will be available on commercially reasonable terms, or at all. If a third party does not offer us a necessary license or offers a license only on terms that are unattractive or unacceptable to us, we might be unable to develop and
commercialize one or more of our product candidates, which would harm our business, financial condition and results of operations. Moreover, even if we obtain licenses to such intellectual property, but subsequently fail to meet our obligations
under the relevant license agreements, or such license agreements are terminated for any other reasons, we may lose our rights to the technologies licensed under those agreements. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The licensing or acquisition of third-party intellectual
property rights is an area in which many companies operate that have interests that are in conflict with ours, and several more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may
consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us
to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment, or at all. If
we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which
could harm our business, financial condition, results of operations and prospects. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may become involved in lawsuits or other proceedings to protect or enforce our intellectual property, which could be expensive, time-consuming and unsuccessful and have a negative effect on the
success of our business. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Third parties
may infringe our patents or misappropriate or otherwise violate our intellectual property rights. In the future, we may initiate legal proceedings to enforce or defend our intellectual property rights, to protect our trade secrets or to determine
the validity or scope of intellectual property rights we own or control. Also, third parties may initiate legal proceedings against us to challenge the validity or scope of intellectual property rights we own, control or to which we have rights. For
example, generic or biosimilar drug manufacturers or other competitors or third parties may challenge the scope, validity or enforceability of our patents, requiring us to engage in complex, lengthy and costly litigation or other proceedings. These
proceedings can be expensive and time-consuming and many of our adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we can. Accordingly, despite our efforts, we
may not be able to prevent third parties from infringing upon or misappropriating intellectual property rights we own, control or have rights to, particularly in countries where the laws may not protect those rights as fully as in the United States.
Litigation could result in substantial costs and diversion of management resources, which could harm our business and financial results. In addition, if we initiated legal proceedings against a third party to enforce a patent covering a product
candidate, the defendant could counterclaim that such patent is invalid or unenforceable. In patent litigation in the United States, defendants usually assert counterclaims alleging </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">54 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
invalidity or unenforceability. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or <FONT
STYLE="white-space:nowrap">non-enablement.</FONT> Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement,
during prosecution. In an infringement or declaratory judgment proceeding, a court may decide that a patent owned by or licensed to us is invalid or unenforceable, or may refuse to stop the other party from using the subject matter alleged to be
infringing on the grounds that our patents do not cover that subject matter. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated, narrowed, held unenforceable or interpreted in such a
manner that would not preclude third parties from entering the market with competing products. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Third-party <FONT STYLE="white-space:nowrap">pre-issuance</FONT> submission of prior art to the USPTO, or opposition, derivation, revocation, reexamination, <I>inter partes </I>review or interference
proceedings, or other <FONT STYLE="white-space:nowrap">pre-issuance</FONT> or post-grant proceedings or other patent office proceedings or litigation in the United States or other jurisdictions provoked by third parties or brought by us, may be
necessary to determine the inventorship, priority, patentability or validity of inventions with respect to our patents or patent applications. An unfavorable outcome could leave our technology or product candidates without patent protection, allow
third parties to commercialize our technology or product candidates and compete directly with us, without payment to us, or could require us to obtain license rights from the prevailing party in order to be able to manufacture or commercialize our
product candidates without infringing third-party patent rights. Our business could be harmed if the prevailing party in such a case does not offer us a license on commercially reasonable terms, or at all. Even if we obtain a license, it may be <FONT
STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same technologies licensed to us. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it
could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. Even if we successfully defend such litigation or proceeding, we may incur substantial costs and our defense may distract
our management and other employees. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition,
many <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions have rules of discovery that are different than those in the United States and that may make defending or enforcing our patents extremely difficult. There could also be public
announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could negatively affect the price of the ADSs and our ordinary shares.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Third parties may initiate legal
proceedings against us alleging that we infringe their intellectual property rights or we may initiate legal proceedings against third parties to challenge the validity or scope of intellectual property rights controlled by third parties, the
outcome of which would be uncertain and could harm our business. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our commercial success depends upon our ability to develop, manufacture, market and sell <FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidates that we may develop and use our
proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property and proprietary rights of third parties. The biotechnology and pharmaceutical industries are characterized by extensive litigation
regarding patents and other intellectual property rights. Third parties may initiate legal proceedings against us alleging that we infringe their intellectual property rights or we may initiate legal proceedings against third parties to challenge
the validity or scope of intellectual property rights controlled by third parties, including in oppositions, interferences, revocations, reexaminations, <I>inter partes </I>review or derivation proceedings before the USPTO or its counterparts in
other jurisdictions. These proceedings can be expensive and time-consuming and many of our adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we can. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">55 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We could be found liable for monetary damages, including treble damages and
attorneys&#146; fees, if we are found to have willfully infringed a patent of a third party. A finding of infringement could prevent us from commercializing <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates or force us
to cease some of our business operations, which could materially harm our business. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We may not be aware of all third-party intellectual property rights potentially relating to <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates and technologies. We are not
aware of any facts that would lead us to conclude that the valid and enforceable claims of any third-party patents would reasonably be interpreted to cover our product candidates. As to pending third-party applications, we cannot predict with any
certainty which claims will issue, if any, or the scope of such issued claims. Even if we believe third-party intellectual property claims are without merit, there is no assurance that a court would find in our favor on questions of infringement,
validity, enforceability or priority. A court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, which could materially and negatively affect our ability to commercialize any product candidates
we may develop and any other product candidates or technologies covered by the asserted third-party patents. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of
validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such
U.S. patent. If any such third-party patents (including those that may issue from such applications) were successfully asserted against us or other commercialization partners and we were unable to successfully challenge the validity or
enforceability of any such asserted patents, then we and other commercialization partners may be prevented from commercializing our product candidates, or may be required to pay significant damages, including treble damages and attorneys&#146; fees
if we are found to willfully infringe the asserted patents, or obtain a license to such patents, which may not be available on commercially reasonable terms, or at all. Even if we were able to obtain a license, it could be <FONT
STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. Any of the foregoing
would harm our business, financial condition and operating results. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Although we have reviewed certain third-party patents and patent filings that we believe may be relevant to our therapeutic candidates or products, we have not conducted a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">freedom-to-operate</FONT></FONT> search or analysis for any of our therapeutic candidates or products, and we may not be aware of patents or pending or future patent applications
that, if issued, would block us from commercializing our therapeutic candidates or products. Thus, we cannot guarantee that our therapeutic candidates or products, or our commercialization thereof, do not and will not infringe any third party&#146;s
intellectual property. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may be subject to
claims by third parties asserting misappropriation of intellectual property, or claiming ownership of what we regard as our own intellectual property. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Although we seek to ensure that our employees do not use the proprietary information or <FONT STYLE="white-space:nowrap">know-how</FONT>
of others in their work for us, we may be subject to claims that we or these employees have used or disclosed confidential information or intellectual property, including trade secrets or other proprietary information, of any such employee&#146;s
former employer, or that third parties have an interest in our patents as an inventor or <FONT STYLE="white-space:nowrap">co-inventor.</FONT> Litigation may be necessary to defend against these claims. If we fail in prosecuting or defending any such
claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or the services of personnel or sustain other damages. Such intellectual property rights could be awarded to a third party, and we could be required to
obtain a license from such third party to commercialize our technology or products. Such a license may not be available on commercially reasonable terms, or at all. Even if we successfully prosecute or defend against such claims, litigation could
result in substantial costs and distract management. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual
property to </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">56 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual
property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our
intellectual property. Such claims could harm our business, financial condition, results of operations and prospects. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our inability to protect our confidential information and trade secrets would harm our business and competitive position.
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to seeking patents for some
of our technology and product candidates, we also rely substantially on trade secrets, including unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> technology and other proprietary materials and information, to maintain our competitive
position. We seek to protect these trade secrets, in part, by entering into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators,
outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. However, these steps may be
inadequate, we may fail to enter into agreements with all such parties or any of these parties may breach the agreements and disclose our trade secrets and there may be no adequate remedy available for such breach of an agreement. We cannot assure
you that our trade secrets will not be disclosed or that we can meaningfully protect our trade secrets. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time consuming, and the outcome
is unpredictable. In addition, some courts both within and outside the United States may be less willing, or unwilling, to protect trade secrets. If a competitor lawfully obtained or independently developed any technology or information that we
protect as trade secret, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Intellectual property rights do not necessarily address
all potential threats. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The degree of
future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">others may be able to make products that are similar to <FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidates we may
develop or utilize similar technology but that are not covered by the claims of the patents that we exclusively license or may own in the future; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we, our licensors or our future collaborators, might not have been the first to make the inventions covered by the issued patents and pending patent
applications that we exclusively license or may own in the future; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we, our licensors or our future collaborators, might not have been the first to file patent applications covering certain of our or their inventions;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or exclusively
licensed intellectual property rights; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">it is possible that our pending patent applications or those that we may file in the future, including those that we have licensed, will not result in
issued patents; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">issued patents to which we hold rights may be held invalid or unenforceable, including as a result of legal challenges by our competitors;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned
from such activities to develop competitive products for sale in major commercial markets in which we do not have sufficient patent rights to stop such sales; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may not develop additional proprietary technologies that are patentable; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">57 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the patents of others may be asserted against our product candidates and technologies in a manner that harms our business; and
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may choose not to file a patent application in order to maintain certain trade secrets or <FONT STYLE="white-space:nowrap">know-how,</FONT> and a
third party may subsequently file a patent covering such trade secrets or <FONT STYLE="white-space:nowrap">know-how.</FONT> </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Should any of these events occur, they could harm our business, financial condition, results of operations and prospects. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If our trademarks and trade names are not maintained
and adequately protected, we may not be able to build name recognition in our markets of interest, and our business may be negatively affected. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Failure to obtain trademark registrations in the future, could limit our ability to protect and enforce our trademarks and impede our
marketing efforts in the countries in which we operate. We may not be able to protect our rights to trademarks and trade names which we may need to build name recognition with potential partners or customers in our markets of interest. As a means to
enforce any future trademark rights and prevent infringement, we may be required to file trademark claims against third parties or initiate trademark opposition proceedings. This can be expensive and time consuming and can strain the financial
resources of a company of our size, and we may not be successful in enforcing our trademark rights. In addition, our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented, declared generic or determined to
be infringing on other marks. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Future trademark
applications in the United States and in other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions where we may file may not be allowed or may subsequently be opposed. Even if these applications result in registration of trademarks, third
parties may challenge our use or registration of these trademarks in the future. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our
business may be negatively affected. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our
product candidates may face competition sooner than anticipated from biosimilar products. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Even if we are successful in achieving regulatory approval to commercialize a product candidate faster than our competitors, our product candidates may face competition from biosimilar products. In the
United States, our product candidates are regulated by the FDA. The Biologics Price Competition and Innovation Act of 2009, or BPCIA, created an abbreviated pathway for the approval of biosimilar and interchangeable biologic products. The
abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#147;interchangeable&#148; based on its similarity to an existing brand
product. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the original branded product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA.
As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect
on the future commercial prospects for our product candidates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">There is a risk that any exclusivity we may be afforded if any of our product candidates are approved as a biologic product under a BLA could be shortened due to congressional action or otherwise, or that
the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic or biosimilar competition sooner than anticipated. Moreover, the extent to which a biosimilar product,
once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for <FONT STYLE="white-space:nowrap">non-biologic</FONT> products is not yet clear, and will depend on a number of
marketplace and regulatory factors that are still developing. In addition, a competitor could decide to forego the biosimilar approval path and submit a full BLA after completing its own preclinical studies and clinical trials. In such cases, any
exclusivity to which we may be eligible under the BPCIA would not prevent the competitor from marketing its product as soon as it is approved. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">58 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In Europe, the European Commission has granted marketing authorizations for several
biosimilar products pursuant to a set of general and product class-specific guidelines for biosimilar approvals issued over the past few years. In Europe, a competitor may reference data supporting approval of an innovative biological product, but
will not be able to market it until 10 years after the time of approval of the innovative product. This <FONT STYLE="white-space:nowrap">10-year</FONT> marketing exclusivity period may be extended to 11 years if, during the first eight of those 10
years, the marketing authorization holder obtains an approval for one or more new therapeutic indications that bring significant clinical benefits compared with existing therapies. In addition, companies may be developing biosimilar products in
other countries that could compete with our products, if approved. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If competitors are able to obtain marketing approval for biosimilars referencing our product candidates, if approved, such products may become subject to competition from such biosimilars, with the
attendant competitive pressure and potential adverse consequences. Such competitive products may be able to immediately compete with us in each indication for which our product candidates may have received approval. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Ownership of the ADSs and this Offering </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>There has been no prior market for our ADSs and an
active and liquid market for our securities may fail to develop, which could harm the market price of the ADSs. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">While our ordinary shares have been listed on the Australian Securities Exchange, or ASX, since 1985, prior to this offering, there has
been no public market on a U.S. national securities exchange for our ordinary shares or ADSs. Although we anticipate that the ADSs will be approved for listing on Nasdaq, an active trading market for the ADSs may never develop or be sustained
following this offering. The initial offering price of the ADSs will be determined through negotiations between us and the underwriters. This offering price may not be indicative of the market price of the ADSs after this offering. In the absence of
an active trading market for the ADSs, investors may not be able to sell their ADSs at or above the offering price or at the time that they would like to sell. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The trading price and volume of the ADSs may be volatile, and purchasers of the ADSs could incur substantial losses.
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The price and trading volumes of our
ordinary shares and ADSs may be significantly affected by events such as announcements regarding scientific and clinical results concerning product candidates currently being developed by us, our collaboration partners or our main competitors,
changes in market conditions related to our sector of activity, announcements of new contracts, technological innovations and collaborations by us or our main competitors, developments concerning intellectual property rights, as well as the
development, regulatory approval and commercialization of new products by us or our main competitors and changes in our financial results. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, equity markets may be subject to considerable price and trading volume fluctuations, and often, these movements do not
reflect the operational and financial performance of the listed companies concerned. In particular, biotechnology companies&#146; share prices have been highly volatile in the past and may continue to be highly volatile in the future. As we operate
in a single industry, we are especially vulnerable to these factors to the extent that they affect our industry. Fluctuations in the stock market as well as the macroeconomic environment could significantly affect the price of the ADSs. As a result
of this volatility, investors may not be able to sell their ADSs at or above the price originally paid for the security. The market price and trading volume for the ADSs may be influenced by many factors, including: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">actual or anticipated fluctuations in our financial condition and operating results; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">actual or anticipated changes in our growth rate relative to our competitors; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">competition from existing products or new products that may emerge; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">59 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">announcements by us or our competitors of significant acquisitions, divestitures, spin-offs, strategic partnerships, joint ventures, collaborations,
capital commitments or changes in business strategy; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">adverse results of delays in our or any of our competitors&#146; preclinical studies or clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">adverse regulatory decisions, including failure to receive regulatory approval for any of our product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the termination of a strategic alliance or the inability to establish additional strategic alliances; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">failure to meet or exceed financial estimates and projections of the investment community or that we provide to the public;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">issuance of new or updated research or reports by securities analysts; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">fluctuations in the valuation of companies perceived by investors to be comparable to us; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">ADS price and volume fluctuations attributable to inconsistent trading volume levels of the ADSs; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">price and volume fluctuations in trading of our ordinary shares on the ASX; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">short selling or other market manipulation activities; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">fluctuations of exchange rates between the U.S. dollar and the Australian dollar; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">additions or departures of key management or scientific personnel; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">disruptions in our supply or manufacturing arrangements; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">disputes or other developments related to proprietary rights, including patents, litigation matters and our ability to obtain patent and other
intellectual property protection for our technologies; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes to coverage policies or reimbursement levels by commercial third-party payors and government payors and any announcements relating to coverage
policies or reimbursement levels; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">litigation involving our company; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">announcement or expectation of additional debt or equity financing efforts; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">natural disasters or other calamities or disease outbreaks, such as the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">sales of the ADSs by us, our affiliates or our other shareholders; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">general economic and market conditions. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">These and other market and industry factors may cause the market price and demand for the ADSs to fluctuate, regardless of our actual
operating performance, which may limit or prevent investors from readily selling their ADSs and may otherwise negatively affect the liquidity of the trading market for the ADSs. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If securities or industry analysts do not publish
research or publish inaccurate or unfavorable research about our business, the price of the ADSs and their trading volume could decline. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The trading market for the ADSs depends in part on the research and reports that securities or industry analysts publish about us or our
business. As a public listed company in Australia since 1985, our equity securities are currently subject to coverage by a number of analysts. If fewer securities or industry analysts cover our company, the trading price for the ADSs could be
negatively impacted. If one or more of the analysts who covers us downgrades our equity securities or publishes incorrect or unfavorable research about our business, the price of the ADSs would likely decline. If one or more of these analysts ceases
coverage of our company or fails to publish reports on us regularly, or downgrades our securities, demand for the ADSs could decrease, which could cause the price of the ADSs or their trading volume to decline. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">60 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We do not currently intend to pay dividends on our securities and, consequently,
your ability to achieve a return on your investment will depend on appreciation in the price of the ADSs. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have never declared or paid any cash dividends on our ordinary shares and do not currently intend to do so for the foreseeable future.
We currently intend to invest our future earnings, if any, to fund our operations and growth. Therefore, you are not likely to receive any dividends on your ADSs for the foreseeable future and the success of an investment in the ADSs will depend
upon any future appreciation in its value. Consequently, investors may need to sell all or part of their holdings of the ADSs after price appreciation, which may never occur, as the only way to realize any future gains on their investment. There is
no guarantee that the ADSs will appreciate in value or even maintain the price at which our shareholders have purchased them. Investors seeking cash dividends should consider not purchasing the ADSs. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">While we do not anticipate paying any cash dividends on our
ordinary shares in the foreseeable future, if such a dividend is declared, the depositary for the ADSs has agreed to pay to you the cash dividends or other distributions it or the custodian receives on our ordinary shares or other deposited
securities after deducting its fees and expenses. You will receive these distributions in proportion to the number of our ordinary shares your ADSs represent. However, in accordance with the limitations set forth in the deposit agreement, it may be
unlawful or impractical to make a distribution available to holders of ADSs. We have no obligation to take any other action to permit the distribution of the ADSs, ordinary shares, rights or anything else to holders of the ADSs. This means that you
may not receive the distributions we make on our ordinary shares or any value from them if it is unlawful or impractical to make them available to you. These restrictions may negatively impact the value of your ADSs. In addition, exchange rate
fluctuations may affect the amount of Australian dollars that we are able to distribute, and the amount in U.S. dollars that our shareholders receive upon the payment of cash dividends or other distributions we declare and pay in Australian dollars,
if any. These factors could harm the value of the ADSs, and, in turn, the U.S. dollar proceeds that holders receive from the sale of the ADSs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>You will experience immediate and substantial dilution in the net tangible book value of the ADSs you purchase in this offering.
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The assumed initial public offering
price of the ADSs is substantially higher than the net tangible book value per ADS or per ordinary share immediately after this offering. If you purchase ADSs in this offering, you will suffer immediate dilution of
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS (or US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share), or
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS (or US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share) if the
underwriters exercise their option to purchase additional shares in full, representing the difference between our as adjusted net tangible book value per ADS or per ordinary share after giving effect to the sale of ADSs in this offering and the
assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS, the U.S. dollar equivalent of the last reported sale of price of our ordinary shares on the ASX on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;2020, after giving effect to the Australian dollar/U.S. dollar exchange rate of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, and an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-to-1. See &#147;Dilution.&#148; If outstanding options are exercised in the
future, you will experience additional dilution. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We have broad discretion in the use of the net proceeds from this offering and may not use them effectively. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will have broad discretion in the application of the net
proceeds that we receive from this offering as well as of our existing cash and cash equivalents and <FONT STYLE="white-space:nowrap">non-current</FONT> financial assets, and we may spend or invest these funds in a way with which our shareholders or
holders of the ADSs disagree. Our failure to apply these funds effectively could harm our business and financial condition. Pending their use, we may invest the net proceeds from the offering in a manner that does not produce income or that loses
value. These investments may not yield a favorable return to our investors. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Future sales of ordinary shares or ADSs by existing holders could depress the market price of the ordinary shares or ADSs. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on 269,157,769&nbsp;ordinary shares outstanding as of June&nbsp;30, 2020, upon the closing of this
offering, we will have outstanding a total of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares (including ordinary shares represented by ADSs),
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">61 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
assuming no exercise of the underwriters&#146; option to purchase additional ADSs and no exercise of outstanding options. Each member of our senior management and board of directors and their
affiliates are subject <FONT STYLE="white-space:nowrap">to&nbsp;lock-up&nbsp;agreements</FONT> with the underwriters that restrict their ability to transfer ordinary shares, options and other securities convertible into, exchangeable for, or
exercisable for ordinary shares during the period ending on, and including, the 90th day after the date of this prospectus, subject to specified exceptions. Citigroup Global Markets Inc.&nbsp;and SVB Leerink LLC&nbsp;may, in their discretion, permit
our shareholders who are subject to <FONT STYLE="white-space:nowrap">these&nbsp;lock-up&nbsp;agreements</FONT> to sell securities prior to the expiration of <FONT STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;agreements.</FONT> As of the date of
this prospectus, the exercise of all outstanding options exercisable for ordinary shares would enable the subscription of new ordinary shares representing approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the diluted share capital. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">After <FONT STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;agreements</FONT> pertaining to this offering expire, and based on the number
of ordinary shares outstanding upon the closing of this offering, including ordinary shares represented by ADSs, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional ordinary shares will be
eligible for sale in the public market, all of which ordinary shares are held by members of our senior management and board of directors and will be subject to volume limitations under Rule 144 under the Securities Act of 1933, as amended, or the
Securities Act. In addition, the ordinary shares subject to subscription under outstanding options exercisable for ordinary shares will become eligible for sale in the public market in the future, subject to certain legal and contractual
limitations. Sales of a large number of the ordinary shares in the public market could depress the market price of the ADSs. See &#147;Shares and American Depository Shares Eligible for Future Sale&#148; for a more detailed description of sales that
may occur in the future. If these additional ordinary shares are sold, or if it is perceived that they will be sold, in the public market, the trading price of the ordinary shares and ADSs could decline substantially, which could impair our ability
to raise additional capital through the issuance of ordinary shares, ADSs or other securities in the future. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The dual listing of our ordinary shares and the ADSs following this offering may negatively impact the liquidity and value of the
ADSs. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Following this offering and after
the ADSs are listed on Nasdaq, our ordinary shares will continue to be listed on the ASX. We cannot predict the effect of this dual listing on the value of our ordinary shares and ADSs. However, the dual listing of our ordinary shares and ADSs may
dilute the liquidity of these securities in one or both markets and may negatively impact the development of an active trading market for the ADSs in the United States. The price of the ADSs could also be negatively impacted by trading in our
ordinary shares on the ASX. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We are subject
to risks associated with currency fluctuations, and changes in foreign currency exchange rates could impact our results of operations. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our ordinary shares are quoted in Australian dollars on the ASX and the ADSs will be quoted in U.S. dollars. In the past year, the
Australian dollar has generally weakened against the U.S. dollar; however, this trend may not continue and may be reversed. As such, any significant change in the value of the Australian dollar may have a negative effect on the value of our ADSs in
U.S. dollars. In addition, if the Australian dollar weakens against the U.S. dollar, then, if we decide to convert our Australian dollars into U.S. dollars for any business purpose, appreciation of the U.S. dollar against the Australian dollar would
have a negative effect on the U.S. dollar amount available to us. While we engage in limited hedging transactions to manage our foreign exchange risk, these activities may not be effective in limiting or eliminating foreign exchange losses. To the
extent that we need to convert U.S. dollars we receive from this offering into Australian dollars for our operations, appreciation of the Australian dollar against the U.S. dollar would have a negative effect on the Australian dollar amount we would
receive from the conversion. Consequently, appreciation or depreciation in the value of the Australian dollar relative to the U.S. dollar would affect our financial results reported in U.S. dollar terms without giving effect to any underlying change
in our business or results of operations. As a result of such foreign currency fluctuations, it could be more difficult to detect underlying trends in our business and results of operations. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">62 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We will incur significant increased costs as a result of operating as a company
with ADSs that are publicly traded in the United States, and our management will be required to devote substantial time to new compliance initiatives. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a company whose ADSs will be publicly traded in the United States, we will incur significant legal, accounting, insurance and other
expenses that we did not previously incur. In addition, the Sarbanes-Oxley Act, Dodd-Frank Wall Street Reform and Consumer Protection Act and related rules implemented by the SEC and Nasdaq have imposed various requirements on public companies
listed in the United States including requiring establishment and maintenance of effective disclosure and financial controls. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives, and we
will need to add additional personnel and build our internal compliance infrastructure. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. These
laws and regulations could also make it more difficult and expensive for us to attract and retain qualified persons to serve on our board of directors, our board committees or as our senior management. Furthermore, if we are unable to satisfy our
obligations as a public company listed in the United States, we could be subject to delisting of the ADSs, fines, sanctions and other regulatory action and potentially civil litigation. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>U.S. investors may have difficulty enforcing civil liabilities against our company, our directors or
members of senior management and the experts named in this prospectus. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Certain members of our senior management and board of directors named in this prospectus are <FONT STYLE="white-space:nowrap">non-residents</FONT> of the United States, and a substantial portion of the
assets of such persons are located outside the United States. As a result, it may be impracticable to serve process on such persons in the United States or to enforce judgments obtained in U.S. courts against them based on civil liability provisions
of the securities laws of the United States. Even if you are successful in bringing such an action, there is doubt as to whether Australian courts would enforce certain civil liabilities under U.S. securities laws in original actions or judgments of
U.S. courts based upon these civil liability provisions. In addition, awards of punitive damages in actions brought in the United States or elsewhere may be unenforceable in Australia or elsewhere outside the United States. An award for monetary
damages under U.S. securities laws would be considered punitive if it does not seek to compensate the claimant for loss or damage suffered and is intended to punish the defendant. The enforceability of any judgment in Australia will depend on the
particular facts of the case as well as the laws and treaties in effect at the time. The United States and Australia do not currently have a treaty or statute providing for recognition and enforcement of the judgments of the other country (other
than arbitration awards) in civil and commercial matters. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As a result, our public shareholders may have more difficulty in protecting their interests through actions against us, our management or our directors than would shareholders of a corporation
incorporated in a jurisdiction in the United States. In addition, as a company incorporated in Australia, the provisions of the Corporations Act 2001 (Cth), or the Corporations Act, regulate the circumstances in which shareholder derivative actions
may be commenced which may be different, and in many ways less permissive, than for companies incorporated in the United States. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Australian takeover laws may discourage takeover offers being made for us or may discourage the acquisition of a significant
position in our ordinary shares or ADSs. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are incorporated in Australia and are subject to the takeover laws of Australia. Among other things, we are subject to the Corporations
Act. Subject to a range of exceptions, the Corporations Act prohibits the acquisition of a direct or indirect interest in our issued voting shares if the acquisition of that interest will lead to a person&#146;s voting power in us increasing to more
than 20%, or increasing from a starting point that is above 20% and below 90%. Australian takeover laws may discourage takeover offers being made for us or may discourage the acquisition of a significant position in our ordinary shares. This may
have the ancillary effect of entrenching our board of directors and may deprive or limit our shareholders&#146; opportunity to sell their ordinary shares and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">63 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
may further restrict the ability of our shareholders to obtain a premium from such transactions. See &#147;Description of Share Capital&#151;Change of Control.&#148; </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our Constitution and Australian laws and regulations
applicable to us may adversely affect our ability to take actions that could be beneficial to our shareholders. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As an Australian company we are subject to different corporate requirements than a corporation organized under the laws of the United
States. Our Constitution, as well as the Corporations Act, sets forth various rights and obligations that apply to us as an Australian company and which may not apply to a U.S. corporation. These requirements may operate differently than those of
many U.S. companies. You should carefully review the summary of these matters set forth under &#147;Description of Share Capital&#148; as well as our Constitution, which is included as an exhibit to the registration statement of which this
prospectus forms a part, prior to investing in the ADSs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Purchasers of ADSs in this offering will not be directly holding our ordinary shares. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A holder of ADSs will not be treated as one of our shareholders and will not have direct shareholder rights. Our Constitution and
Australian law govern our shareholder rights. The depositary, through the custodian or the custodian&#146;s nominee, will be the holder of the ordinary shares underlying ADSs held by purchasers of ADSs in this offering. Purchasers of ADSs in this
offering will have ADS holder rights. The deposit agreement among us, the depositary and purchasers of ADSs in this offering, as an ADS holder, and all other persons directly and indirectly holding ADSs, sets out ADS holder rights, as well as the
rights and obligations of us and the depositary. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Your right as a holder of ADSs to participate in any future preferential subscription rights offering or to elect to receive
dividends in ordinary shares may be limited, which may cause dilution to your holdings. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The deposit agreement provides<B><I></I></B>&nbsp;that the depositary will not make rights available to you unless the distribution to ADS holders of both the<B><I></I></B>&nbsp;rights and any related
securities are either registered under the Securities Act or exempted from registration<B><I></I></B>&nbsp;under the Securities Act. If we offer holders of our ordinary shares the option to receive&nbsp;dividends in either cash or shares, under the
deposit agreement the depositary may require satisfactory<B><I></I></B>&nbsp;assurances from us that extending the offer to holders of ADSs does not require registration of any<B><I></I></B>&nbsp;securities under the Securities Act before making the
option available to holders of ADSs. We are under<B><I></I></B>&nbsp;no obligation to file a registration statement with respect to any such rights or securities or to endeavor to<B><I></I></B>&nbsp;cause such a registration statement to be declared
effective. Moreover, we may not be able to establish an<B><I></I></B>&nbsp;exemption from registration under the Securities Act. Accordingly, ADS holders may be unable to<B><I></I></B>&nbsp;participate in our rights offerings or to elect to receive
dividends in shares and may experience dilution in<B><I></I></B>&nbsp;their holdings. In addition, if the depositary is unable to sell rights that are not exercised or not distributed<B><I></I></B>&nbsp;or if the sale is not lawful or reasonably
practicable, it will allow the rights to lapse, in which case you<B><I></I></B>&nbsp;will receive no value for these rights. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>You may not be able to exercise your right to vote the ordinary shares underlying your ADSs. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Holders of ADSs may exercise voting rights with respect to
the ordinary shares represented by the ADSs only in accordance with the provisions of the deposit agreement. The deposit agreement provides that, upon receipt of notice of any meeting of holders of our ordinary shares, the depositary will fix a
record date for the determination of ADS holders who shall be entitled to give instructions for the exercise of voting rights. Upon timely receipt of notice from us, if we so request, the depositary shall distribute to the holders as of the record
date (i)&nbsp;the notice of the meeting or solicitation of consent or proxy sent by us and (ii)&nbsp;a statement as to the manner in which instructions may be given by the holders. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You may instruct the depositary of your ADSs to vote the
ordinary shares underlying your ADSs. Otherwise, you will not be able to exercise your right to vote, unless you withdraw the ordinary shares underlying the ADSs you hold. However, you may not know about the meeting far enough in advance to
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">64 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
withdraw those ordinary shares. If we ask for your instructions, the depositary, upon timely notice from us, will notify you of the upcoming vote and arrange to deliver our voting materials to
you. We cannot guarantee you that you will receive the voting materials in time to ensure that you can instruct the depositary to vote your ordinary shares or to withdraw your ordinary shares so that you can vote them yourself. If the depositary
does not receive timely voting instructions from you, it may give a proxy to a person designated by us to vote the ordinary shares underlying your ADSs. In addition, the depositary and its agents are not responsible for failing to carry out voting
instructions or for the manner of carrying out voting instructions. This means that you may not be able to exercise your right to vote, and there may be nothing you can do if the ordinary shares underlying your ADSs are not voted as you requested.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under our Constitution, any resolution to be
considered at a meeting of the shareholders shall be decided on a show of hands unless a poll is demanded in accordance with the terms of our Constitution. A poll may be demanded before a vote is taken, or, in the case of a vote taken on a show of
hands, immediately before or immediately after, the declaration of the result of the show of hands. Under voting by a show of hands, multiple &#147;yes&#148; votes by ADS holders will only count as one &#147;yes&#148; vote and will be negated by a
single &#147;no&#148; vote, unless a poll is demanded. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>You may be subject to limitations on the transfer of your ADSs and the withdrawal of the underlying ordinary shares. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Your ADSs are transferable on the books of the depositary.
However, the depositary may close its books at any time or from time to time when it deems expedient in connection with the performance of its duties. The depositary may refuse to deliver, transfer or register transfers of your ADSs generally when
our books or the books of the depositary are closed, or at any time if we or the depositary think it is advisable to do so because of any requirement of law, government or governmental body, or under any provision of the deposit agreement, or for
any other reason subject to your right to cancel your ADSs and withdraw the underlying ordinary shares. Temporary delays in the cancellation of your ADSs and withdrawal of the underlying ordinary shares may arise because the depositary has closed
its transfer books or we have closed our transfer books, the transfer of ordinary shares is blocked to permit voting at a shareholders&#146; meeting or we are paying a dividend on our ordinary shares. In addition, you may not be able to cancel your
ADSs and withdraw the underlying ordinary shares when you owe money for fees, taxes and similar charges and when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the
withdrawal of ordinary shares or other deposited securities. See &#147;Description of American Depositary Shares.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Holders of ADSs are not treated as holders of our ordinary shares. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">By participating in this offering you will become a holder of ADSs with underlying ordinary shares in an
Australian public listed company. Holders of ADSs are not treated as holders of our ordinary shares, unless they withdraw the ordinary shares underlying their ADSs in accordance with the deposit agreement and applicable laws and regulations. The
depositary is the holder of the ordinary shares underlying the ADSs. Holders of ADSs therefore do not have any rights as holders of our ordinary shares, other than the rights that they have pursuant to the deposit agreement. See &#147;Description of
American Depositary Shares.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We
currently report our financial results under IFRS, which differs in certain significant respect from U.S. generally accepted accounting principles, or U.S. GAAP. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Currently we report our financial statements under IFRS.
There have been and there may in the future be certain significant differences between IFRS and U.S. GAAP, including differences related to revenue recognition, intangible assets, share-based compensation expense, income tax and earnings per share.
As a result, our financial information and reported earnings for historical or future periods could be significantly different if they were prepared in accordance with U.S. GAAP. In addition, we do not intend to provide a reconciliation between IFRS
and U.S. GAAP unless it is required under applicable law. As a result, you may not be able to meaningfully compare our financial statements under IFRS with those companies that prepare financial statements under U.S. GAAP. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">65 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>As a foreign private issuer, we are exempt from a number of rules under the U.S.
securities laws and are permitted to file less information with the SEC than a U.S. company. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a foreign private issuer, as defined in the SEC&#146;s rules and regulations and, consequently, we are not subject to all of the
disclosure requirements applicable to public companies organized within the United States. For example, we are exempt from certain rules under the Exchange Act that regulate disclosure obligations and procedural requirements related to the
solicitation of proxies, consents or authorizations applicable to a security registered under the Exchange Act, including the U.S. proxy rules under Section&nbsp;14 of the Exchange Act. In addition, our senior management and directors are exempt
from the reporting and &#147;short-swing&#148; profit recovery provisions of Section&nbsp;16 of the Exchange Act and related rules with respect to their purchases and sales of our securities. Moreover, while we currently make annual and semi-annual
filings with respect to our listing on the ASX and expect to file financial reports on an annual and semi-annual basis, we will not be required to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S.
public companies and will not be required to file quarterly reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q&nbsp;or</FONT> current reports on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K&nbsp;under</FONT> the Exchange Act. In addition,
foreign private issuers are not required to file their annual report <FONT STYLE="white-space:nowrap">on&nbsp;Form&nbsp;20-F&nbsp;until</FONT> four months after the end of each fiscal year. Accordingly, there may be less publicly available
information concerning our company than there would be if we were not a foreign private issuer. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>As a foreign private issuer, we are permitted to adopt certain home country practices in relation to corporate governance matters that differ significantly from Nasdaq corporate governance listing
standards and these practices may afford less protection to shareholders than they would enjoy if we complied fully with Nasdaq&nbsp;corporate governance listing standards. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a foreign private issuer listed on Nasdaq, we will be subject to their corporate governance listing
standards. However, Nasdaq rules permit foreign private issuers to follow the corporate governance practices of its home country. Some corporate governance practices in Australia may differ from Nasdaq&nbsp;corporate governance listing standards.
For example, we could <FONT STYLE="white-space:nowrap">include&nbsp;non-independent&nbsp;directors</FONT> as members of our Remuneration and Nomination committees, and our independent directors may not necessarily hold regularly scheduled meetings
at which only independent members of the board of directors are present. Currently, we intend to follow home country practice to the maximum extent possible. Therefore, our shareholders may be afforded less protection than they otherwise would have
under corporate governance listing standards applicable to U.S. domestic issuers. For an overview of our corporate governance practices, see &#147;Management.&#148; </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may lose our foreign private issuer status in the
future, which could result in significant additional cost and expense. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">While we currently qualify as a foreign private issuer, the determination of foreign private issuer status is made annually on the last business day of an issuer&#146;s most recently completed second
fiscal quarter and, accordingly, our next determination will be made on June&nbsp;30, 2021. In the future, we would lose our foreign private issuer status if we to fail to meet the requirements necessary to maintain our foreign private issuer status
as of the relevant determination date. For example, if 50% or more of our securities are held by U.S. residents and more than 50% of our senior management or directors are residents or citizens of the United States, we could lose our foreign private
issuer status. Immediately following the closing of this offering, approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding ordinary shares (including ordinary shares in the
form of ADSs) will likely be held by U.S. residents (assuming that all purchasers in this offering are residents of the United States). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The regulatory and compliance costs to us under U.S. securities laws as a U.S. domestic issuer may be significantly more than costs we
incur as a foreign private issuer. If we are not a foreign private issuer, we will be required to file periodic reports and registration statements on U.S. domestic issuer forms with the SEC, which are more detailed and extensive in certain respects
than the forms available to a foreign private issuer. We would be required under current SEC rules to prepare our financial statements in accordance with U.S. GAAP rather than IFRS, and modify certain of our policies to comply with corporate
governance practices required of U.S. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">66 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
domestic issuers. Such conversion of our financial statements to U.S. GAAP would involve significant time and cost. In addition, we may lose our ability to rely upon exemptions from certain
corporate governance requirements on U.S. stock exchanges that are available to foreign private issuers such as the ones described above and exemptions from procedural requirements related to the solicitation of proxies. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We are an &#147;emerging growth company&#148; under the
JOBS Act and will be able to avail ourselves of reduced disclosure requirements applicable to emerging growth companies, which could make our ordinary shares ADSs less attractive to investors. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are an &#147;emerging growth company,&#148; as defined in
the JOBS Act, and we intend to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not &#147;emerging growth companies,&#148; including not being required to comply with the
auditor attestation requirements of Section&nbsp;404(b) of the Sarbanes-Oxley Act, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not
previously approved. In addition, Section&nbsp;107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in Section&nbsp;7(a)(2)(B) of the Securities Act, for complying with new
or revised accounting standards. We will not take advantage of the extended transition period provided under Section&nbsp;7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We cannot predict if investors will find the ordinary shares
or ADSs less attractive because we may rely on these exemptions. If some investors find the ordinary shares or ADSs less attractive as a result, there may be a less active trading market for the ordinary shares or ADSs and the price of the ordinary
shares or ADSs may be more volatile. We may take advantage of these exemptions until such time that we are no longer an emerging growth company. We would cease to be an emerging growth company upon the earliest to occur of (i)&nbsp;the last day of
the fiscal year in which we have more than $1.07&nbsp;billion in annual revenue; (ii)&nbsp;the last day of the fiscal year in which we qualify as a &#147;large accelerated filer&#148;; (iii)&nbsp;the date on which we have, during the previous
three-year period, issued more than $1.0&nbsp;billion <FONT STYLE="white-space:nowrap">in&nbsp;non-convertible&nbsp;debt</FONT> securities;&nbsp;and (iv)&nbsp;the last day of the fiscal year in which the fifth anniversary of this offering occurs.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we are a passive foreign investment
company, there could be adverse U.S. federal income tax consequences to U.S. holders. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Based on the nature and composition of our income, assets, activities and market capitalization for our taxable year ended June&nbsp;30, 2019, we believe that we were not classified as a passive foreign
investment company, or PFIC, for the taxable year ended June&nbsp;30, 2019. Based on the expected nature and composition of our income, assets, activities and market capitalization for our taxable year ended June&nbsp;30, 2020, we believe that we
will not be classified as a PFIC for the taxable year ended June&nbsp;30, 2020. However, there can be no assurance that we will not be considered a PFIC in the current year or for any future taxable year. A separate determination must be made after
the close of each taxable year as to whether we are a PFIC for that year. As a result, our PFIC status may change from year to year. Our status as a PFIC will depend on the composition of our income (including whether we receive certain grants or
subsidies and whether such amounts will constitute gross income for purposes of the PFIC income test) and the composition and value of our assets, which may be determined in large part by reference to the market value of the ADSs and our ordinary
shares, which may be volatile, from time to time. Our status may also depend, in part, on how quickly we utilize the cash proceeds from this offering in our business. Our U.S. counsel expresses no opinion regarding our conclusions or our
expectations regarding our PFIC status. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the
Code, <FONT STYLE="white-space:nowrap">a&nbsp;non-U.S.&nbsp;company</FONT> will be considered a PFIC for any taxable year in which (1) 75% or more of its gross income consists of passive income or (2) 50% or more of the average quarterly value of
its assets consists of assets that produce, or are held for the production of, passive income. For purposes of these tests, passive income includes dividends, interest, gains from the sale or exchange of investment property and
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">67 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
certain rents and royalties. In addition, for purposes of the above calculations, <FONT STYLE="white-space:nowrap">a&nbsp;non-U.S.&nbsp;corporation</FONT> that directly or indirectly owns at
least 25% by value of the shares of another corporation is treated as if it held its proportionate share of the assets and received directly its proportionate share of the income of such other corporation. If we are a PFIC for any taxable year
during which a U.S. holder (as defined in the section titled &#147;Material United States Federal Income Tax and Australian Tax Considerations&#151;Material United States Federal Income Tax Considerations&#148;) holds our ordinary shares or ADSs, we
will continue to be treated as a PFIC with respect to such U.S. holder in all succeeding years during which the U.S. holder owns the ordinary shares or ADSs, regardless of whether we continue to meet the PFIC test described above, unless the U.S.
holder is eligible to make and makes a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election or makes a specified election once we cease to be a PFIC. If we are classified as a PFIC for any taxable
year during which a U.S. holder holds our ordinary shares or ADSs, the U.S. holder may be subject to adverse tax consequences regardless of whether we continue to qualify as a PFIC, including ineligibility for any preferred tax rates on capital
gains or on actual or deemed dividends, interest charges on certain taxes treated as deferred, and additional reporting requirements. For further discussion of the PFIC rules and the adverse U.S. federal income tax consequences in the event we are
classified as a PFIC, see &#147;Material United States Federal Income Tax and Australian Tax Considerations&#151;Material United States Federal Income Tax Considerations.&#148; </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If a United States person is treated as owning at least
10% of our ordinary shares, such holder may be subject to adverse U.S. federal income tax consequences. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If a U.S. holder is treated as owning, directly, indirectly or constructively, at least 10% of the value or voting power of our ordinary
shares or ADSs, such U.S. holder may be treated as a &#147;United States shareholder&#148; with respect to each &#147;controlled foreign corporation&#148; in our group, if any. While our group does not currently include any U.S. subsidiaries, if we
form or acquire any U.S. subsidiaries in the future any of our <FONT STYLE="white-space:nowrap">current&nbsp;non-U.S.&nbsp;subsidiaries</FONT> and any future newly formed or
<FONT STYLE="white-space:nowrap">acquired&nbsp;non-U.S.&nbsp;subsidiaries</FONT> will be treated as controlled foreign corporations, regardless of whether we are treated as a controlled foreign corporation. A United States shareholder of a
controlled foreign corporation may be required to annually report and include in its U.S. taxable income its pro rata share of &#147;Subpart F income,&#148; &#147;global
<FONT STYLE="white-space:nowrap">intangible&nbsp;low-taxed&nbsp;income&#148;</FONT> and investments in U.S. property by controlled foreign corporations, regardless of whether we make any distributions. An individual that is a United States
shareholder with respect to a controlled foreign corporation generally would not be allowed certain tax deductions or foreign tax credits that would be allowed to a United States shareholder that is a U.S. corporation. Failure to comply with
controlled foreign corporation reporting obligations may subject a United States shareholder to significant monetary penalties. We cannot provide any assurances that we will furnish to any United States shareholder information that may be necessary
to comply with the reporting and tax paying obligations applicable under the controlled foreign corporation rules of the Code. U.S. holders should consult their tax advisors regarding the potential application of these rules to their investment in
our ordinary shares or ADSs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Future changes
to tax laws could materially adversely affect our company and reduce net returns to our shareholders. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our tax treatment is subject to the enactment of, or changes in, tax laws, regulations and treaties, or the interpretation thereof, tax
policy initiatives and reforms under consideration and the practices of tax authorities in jurisdictions in which we operate, including those related to the Organization for Economic <FONT STYLE="white-space:nowrap">Co-Operation</FONT> and
Development&#146;s Base Erosion and Profit Shifting Project, the European Commission&#146;s state aid investigations and other initiatives. Such changes may include (but are not limited to) the taxation of operating income, investment income,
dividends received or (in the specific context of withholding tax) dividends paid. We are unable to predict what tax reform may be proposed or enacted in the future or what effect such changes would have on our business, but such changes, to the
extent they are brought into tax legislation, regulations, policies or practices, could affect our financial position and overall or effective tax rates in the future in countries where we have operations, reduce
<FONT STYLE="white-space:nowrap">post-tax</FONT> returns to our shareholders, and increase the complexity, burden and cost of tax compliance. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">68 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_5"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus contains forward-looking
statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this prospectus, including statements regarding our future results of operations, financial
condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as &#147;anticipate,&#148;
&#147;believe,&#148; &#147;contemplate,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148;
&#147;should,&#148; &#147;target,&#148; &#147;will,&#148; or &#147;would,&#148; or the negative of these words or other similar terms or expressions. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we
believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of known and unknown risks, uncertainties, other factors and assumptions, including
the risks described in &#147;Risk Factors&#148; and elsewhere in this prospectus, regarding, among other things: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the success, cost and timing of our product development activities and clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our expectations about the timing or likelihood of achieving regulatory approval and the cost of our development programs;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our reliance on the success of <FONT STYLE="white-space:nowrap">OPT-302</FONT> as our only product candidate; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to obtain funding for our operations, including funding necessary to complete further development and commercialization of our product
candidates; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the commercialization of our product candidates, if approved; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our plans to research, develop and commercialize our product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to maintain, expand, protect and enforce our intellectual property portfolio; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights of third parties;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to attract collaborators with development, regulatory and commercialization expertise; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">business disruptions affecting the initiation, patient enrollment, development and operation of our clinical trials, including as a result of a public
health emergency, such as the global outbreak of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidate; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">future agreements with third parties in connection with the commercialization of our product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the size and growth potential of the markets for our product candidates, and our ability to serve those markets; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the rate and degree of market acceptance of our product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">regulatory developments in the United States, Australia and other jurisdictions; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the success of competing therapies that are or may become available; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to attract and retain key scientific or management personnel; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">69 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our expectations regarding the period during which we qualify as an emerging growth company under the JOBS Act; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our use of the proceeds from this offering; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the future trading price of the ADSs and impact of securities analysts&#146; reports on these prices; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">other risks and uncertainties, including those listed under &#147;Risk Factors.&#148; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">These risks are not exhaustive. Other sections of this
prospectus may include additional factors that could harm our business and financial performance. New risk factors may emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of
all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You should not rely on forward-looking statements as
predictions of future events. We have based the forward-looking statements contained in this prospectus primarily on our current expectations and projections about future events and trends that we believe may affect our business, financial condition
and operating results. We undertake no obligation to update any forward-looking statements made in this prospectus to reflect events or circumstances after the date of this prospectus or to reflect new information or the occurrence of unanticipated
events, except as required by law. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Our forward-looking
statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, statements that &#147;we believe&#148; and similar statements reflect our beliefs and opinions on the relevant subject. These
statements are based on information available to us as of the date of this prospectus. While we believe that information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements should not be
read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You should read this prospectus and the documents that we
reference in this prospectus and have filed as exhibits to the registration statement of which this prospectus is a part with the understanding that our actual future results, levels of activity, performance and achievements may be different from
what we expect. We qualify all of our forward-looking statements by these cautionary statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">70 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_6"></A>INDUSTRY AND MARKET DATA </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus contains estimates and information
concerning our industry and our business, including estimated market size and projected growth rates of the markets for our product candidates. Unless otherwise expressly stated, we obtained this industry, business, market, medical and other
information from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This information involves a number of assumptions and
limitations. Although we are responsible for all of the disclosure contained in this prospectus and we believe the third-party market position, market opportunity and market size data included in this prospectus are reliable, we have not
independently verified the accuracy or completeness of this third-party data. In addition, projections, assumptions and estimates of our future performance and the future performance of the industry in which we operate are necessarily subject to a
high degree of uncertainty and risk due to a variety of factors, including those described in &#147;Risk Factors.&#148; These and other factors could cause results to differ materially from those expressed in these publications and reports.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">71 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_7"></A>USE OF PROCEEDS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We estimate that the net proceeds to us from the sale of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADSs in this offering will be approximately US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million
(or approximately US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters exercise their option to purchase
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional ADSs in full), based on the assumed initial public offering price of
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS, the U.S. dollar equivalent of the last reported sale price of our ordinary shares on the ASX on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, after giving effect to the Australian dollar/U.S. dollar exchange rate of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, and an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-to-1, after deducting underwriting discounts and commissions and estimated
offering expenses payable by us. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each US$1.00
increase (decrease) in the assumed initial offering price of US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS, the U.S. dollar equivalent of the last reported sale price of our ordinary
shares on the ASX on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, after giving effect to the Australian dollar/U.S. dollar exchange rate of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, and an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-to-1, would increase (decrease) the net proceeds to us from this offering by
approximately US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the number of ADSs offered by us, as set forth on the cover page of this prospectus, remains the same and after
deducting underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, an increase (decrease) of 1,000,000 ADSs offered by us would increase (decrease) the net proceeds to us by
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the assumed initial public offering price of
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS, the U.S. dollar equivalent of the last reported sale price of our ordinary shares on the ASX on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, after giving effect to the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-to-1, remains the same and after deducting underwriting discounts and commissions. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect to use the net proceeds from this offering,
together with our existing cash and cash equivalents, as follows: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">approximately US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to advance the clinical development of <FONT STYLE="white-space:nowrap">OPT-302</FONT> for the treatment of wet AMD, including the initiation
of two pivotal Phase 3 clinical trials; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the remaining proceeds for other research and development activities for <FONT STYLE="white-space:nowrap">OPT-302</FONT> in potential additional
indications, including persistent DME, and for working capital and general corporate purposes. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">However, due to the uncertainties inherent in the product development process, it is difficult to estimate with certainty the exact
amounts of the net proceeds from this offering that may be used for the above purposes. Our management will have broad discretion over the use of the net proceeds from this offering. The amounts and timing of our expenditures will depend upon
numerous factors including the results of our research and development efforts, the timing and success of preclinical studies and any ongoing clinical trials or clinical trials we may commence in the future, the timing of regulatory submissions and
the amount of cash obtained through future collaborations, if any. Following this offering, we will require additional funding in order to complete clinical development and commercialize our lead product candidate,
<FONT STYLE="white-space:nowrap">OPT-302,</FONT> in any indication. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We believe opportunities may exist from time to time to expand our current business through acquisitions or <FONT STYLE="white-space:nowrap">in-licensing</FONT> of complementary companies, medicines or
technologies. While we have no current agreements, commitments or understandings for any specific acquisitions or <FONT STYLE="white-space:nowrap">in-licensing</FONT> at this time, we may use a portion of the net proceeds for these purposes.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of June&nbsp;30, 2020, we had cash and cash
equivalents of A$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million (or US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million). We believe our
cash and cash equivalents, together with the net proceeds of this offering, will be sufficient to fund our operations until &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We cannot predict with certainty all of the particular uses
for the proceeds of this offering or the amounts that we will actually spend on the uses set forth above. Accordingly, our management will have broad discretion in applying the net proceeds of this offering. The timing and amount of our actual
expenditures will be based on many factors, including cash flows from operations and the anticipated growth of our business.&nbsp;Pending our use of the net proceeds from this offering, we intend to invest the net proceeds in a variety of capital
preservation investments, including short-term, investment-grade, interest-bearing instruments. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">72 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_8"></A>DIVIDEND POLICY </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have never declared or paid any dividends on our ordinary
shares. We intend to retain any earnings for use in our business and do not currently intend to pay cash dividends on our ordinary shares. Dividends, if any, on our outstanding ordinary shares will be declared by and subject to the discretion of our
board of directors, and subject to Australian law. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any dividend we declare will be paid to the holders of ADSs, subject to the terms of the deposit agreement, to the same extent as holders
of our ordinary shares, to the extent permitted by applicable law and regulations, less the fees and expenses payable under the deposit agreement. Any dividend we declare will be distributed by the depositary bank to the holders of our ADSs, subject
to the terms of the deposit agreement. See &#147;Description of American Depositary Shares&#151;Dividends and Distributions.&#148; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">73 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_9"></A>CAPITALIZATION </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth our cash and our
capitalization as of June&nbsp;30, 2020, on: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an actual basis; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an as adjusted basis to give effect to the issuance and sale of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADSs in this offering at the assumed initial public offering price of
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS, the U.S. dollar equivalent of the last reported sale price of our ordinary shares on the ASX on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, after giving effect to the Australian dollar/U.S. dollar exchange rate of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, and an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-to-1, after deducting underwriting discounts and commissions and estimated
offering expenses payable by us. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You should read this information in conjunction with our consolidated financial statements and the related notes included elsewhere in
this prospectus, the information set forth in &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and other financial information contained elsewhere in this prospectus. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As of June&nbsp;30, 2020</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Actual<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As&nbsp;
Adjusted<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)(2)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;data)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contributed equity: 269,157,769&nbsp;ordinary shares, no par value, outstanding, actual;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares, no par value, outstanding, as adjusted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated losses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reserves</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total capitalization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amounts have been translated from Australian dollars to U.S. dollars at an assumed exchange rate of
A$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per US1.00, which was the official exchange rate published by the Reserve Bank of Australia
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each US$1.00 increase (decrease) in the assumed initial public offering price of
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS, the U.S. dollar equivalent of the last reported sale price of our ordinary shares on the ASX
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2020, after giving effect to the Australian dollar/U.S. dollar exchange rate
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;as of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, and an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-to-1, would increase (decrease) each of cash and cash equivalents, contributed
equity, total equity and total capitalization by A$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million (or
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million), assuming the number of ADSs offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting
underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, an increase (decrease) of 1,000,000 ADSs offered by us would increase (decrease) each of cash and cash equivalents, contributed equity, total equity and
total capitalization by A$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million (or US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million),
assuming the assumed initial public offering price of US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS, the U.S. dollar equivalent of the last reported sale price of our ordinary shares on
the ASX on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2020, after giving effect to the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-to-1, remains the same, and after deducting underwriting discounts and commissions. The as adjusted information is illustrative only and will depend
on the actual initial public offering price, number of ADSs offered and other terms of this offering determined at pricing. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The outstanding ordinary share information in the table above is based on 269,157,769&nbsp;ordinary shares outstanding as of June&nbsp;30,
2020, and excludes: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,044,000 ordinary shares issuable upon the exercise of outstanding options as of June&nbsp;30, 2020 with a weighted-average exercise price of A$0.68
per ordinary share under our equity incentive plans; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,446,777&nbsp;ordinary shares reserved for future issuance under our Long Term Incentive Plan. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">74 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_10"></A>DILUTION </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you invest in the ADSs in this offering, your ownership
interest will be immediately diluted to the extent of the difference between the initial public offering price per ADS and the as adjusted net tangible book value per ordinary share or ADS immediately after this offering. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of June&nbsp;30, 2020, our historical net tangible book
value was A$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million (or US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million), or
A$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (or US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ) per ADS. Historical net tangible book value
per ADS represents our total tangible assets less total liabilities, divided by the number of ordinary shares outstanding as of June&nbsp;30, 2020, converted to ADSs at an
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">-to-1.</FONT></FONT> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">After giving effect to the receipt of the net proceeds from our sale of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADSs in this offering at an assumed initial public offering price of
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS, the U.S. dollar equivalent of the last reported sale price of our ordinary shares on the ASX on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, after giving effect to the Australian dollar/U.S. dollar exchange rate of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, and an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-to-1, after deducting underwriting discounts and commissions and estimated
offering expenses payable by us, our as adjusted net tangible book value as of June&nbsp;30, 2020 was A$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million (or
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million), or A$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(or
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)&nbsp;per ADS, equivalent to A$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(or
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) per ordinary share, in each case based on an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share
ratio of <FONT STYLE="white-space:nowrap">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-to-1.</FONT> This represents an immediate increase in net tangible book value of
A$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(or US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) per ADS, equivalent to
A$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;or (US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) per ordinary share, to our existing
shareholders and immediate dilution of A$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(or
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)&nbsp;per ADS, equivalent to
A$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)&nbsp;per ordinary share, to investors purchasing
ADSs in this offering, in each case based on an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio of
<FONT STYLE="white-space:nowrap">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-to-1.</FONT> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table illustrates this dilution on a per ADS basis, assuming all ordinary shares outstanding as of June&nbsp;30, 2020
converted to ADSs at an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">-to-1:</FONT></FONT> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Assumed initial public offering price per ADS</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Historical net tangible book value per ADS as of June&nbsp;30, 2020</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Increase in net tangible book value per ADS attributed to investors purchasing ADSs in this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">As adjusted net tangible book value per ADS after this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dilution in net tangible book value per ADS to investors in this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each US$1.00 increase
(decrease) in the assumed initial public offering price of US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS, the U.S. dollar equivalent of the last reported sale price of our ordinary shares
on the ASX on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, after giving effect to the Australian dollar/U.S. dollar exchange rate of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, and an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-to-1, would increase (decrease) the as adjusted net tangible book value per ADS
after this offering by US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and dilution to investors in this offering by
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS, assuming that the number of ADSs offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting
underwriting discounts and commissions. An increase of 1,000,000 ADSs offered by us would increase the as adjusted net tangible book value by US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS
and the dilution to investors in this offering would decrease by US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS, assuming the assumed initial public offering price remains the same and
after deducting underwriting discounts and commissions. A decrease of 1,000,000 ADSs offered by us would decrease the as adjusted net tangible book value by
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS and the dilution to investors in this offering would increase by
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS, assuming the assumed initial public offering price remains the same and after deducting underwriting discounts and commissions. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the underwriters exercise their option to purchase
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional ADSs in full, the as adjusted net tangible book value after the offering would be
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS, the increase in net tangible book value per ADS to existing shareholders would be
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS and the dilution per ADS to new investors in </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">75 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
this offering would be US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS, in each case assuming an initial public offering price of
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS, the U.S. dollar equivalent of the last reported sale price of our ordinary shares on the ASX on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, after giving effect to the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-to-1. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The dilution information above is for illustration purposes only. Our as adjusted net tangible book value following the closing of this
offering will depend on the actual initial public offering price and other terms of this offering determined at pricing. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes, as of June&nbsp;30, 2020: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the total number of ordinary shares purchased from us by existing shareholders and the equivalent number of ordinary shares underlying ADSs purchased
by investors in this offering; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the total consideration paid to us by our existing shareholders and by investors purchasing ADSs in this offering, assuming an initial public offering
price of US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS, the U.S. dollar equivalent of the last reported sale price of our ordinary shares on the ASX on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, after giving effect to the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-to-1, before deducting underwriting discounts and commissions and estimated offering expenses payable by us in connection with this offering; and
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the average price per ordinary share paid by existing shareholders and the average price per ADS or equivalent number of ordinary shares.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Ordinary Shares<BR>(Directly or in the<BR>Form of ADSs)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total&nbsp;Consideration</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Average<BR>Price<BR>Per&nbsp;Share</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Average<BR>Price&nbsp;per<BR>ADS</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percent</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percent</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Existing shareholders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchasers of ADSs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the underwriters exercise
their option to purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional ADSs in full, our existing shareholders would
own&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% and investors in this offering would own&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the
total number of ordinary shares outstanding (including shares underlying ADSs) upon the closing of this offering. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each US$1.00 increase (decrease) in the assumed initial public offering price of
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS, the U.S. dollar equivalent of the last reported sale price of our ordinary shares on the ASX on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, after giving effect to the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-to-1, would increase (decrease) the total consideration paid by investors in this offering by
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million and increase (decrease) the total consideration paid by investors in this offering
by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;%, assuming that the number of ADSs offered by us, as set forth on the cover page of this prospectus, remains the same and before deducting
underwriting discounts and commissions. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
outstanding ordinary share information in the tables above is based on 269,157,769&nbsp;ordinary shares as of June&nbsp;30, 2020, and excludes: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,044,000 ordinary shares issuable upon the exercise of outstanding options as of June&nbsp;30, 2020, with a weighted-average exercise price of A$0.68
per ordinary share under our equity incentive plans; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,446,777 ordinary shares reserved for future issuance under our Long Term Incentive Plan. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To the extent any outstanding options are exercised, there
will be further dilution to investors purchasing in this offering. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">76 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_11"></A>SELECTED CONSOLIDATED FINANCIAL DATA </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following tables summarize our consolidated financial
and other data. The summary consolidated statement of profit or loss and other comprehensive income data for the years ended June&nbsp;30, 2019 and 2020 have been derived from our audited consolidated financial statements included elsewhere in this
prospectus. Our audited consolidated financial statements have been prepared in accordance with IFRS, as issued by the IASB, as of and for the years ended June&nbsp;30, 2019 and 2020. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You should read the consolidated financial and other data set forth below in conjunction with our consolidated
financial statements and the accompanying notes and the information in &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; contained elsewhere in this prospectus. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Consolidated Statement of Profit or Loss and Other Comprehensive Income
Data </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2020</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in&nbsp;thousands,&nbsp;except&nbsp;per&nbsp;share&nbsp;data)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">159</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">837</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(31,348</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patent expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(161</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Intellectual property costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(113</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Administrative expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,175</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Occupancy expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net foreign exchange gain (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">363</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss before income tax</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(35,547</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income tax benefit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,637</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss for the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,910</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other comprehensive income:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Items that will not be reclassified subsequently to profit or loss:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value gains on investments in financial assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">260</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other comprehensive income for the period, net of tax</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">260</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total comprehensive loss for the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total comprehensive loss for the year is attributable to:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Owners of the Company</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss per share attributable to Owners of the Company&#151;basic and diluted (in&nbsp;cents)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8.98</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income primarily comprises finance income from interest on bank deposits and, for the fiscal year ended June&nbsp;30, 2019, funding under a <FONT
STYLE="white-space:nowrap">one-time</FONT> Australian government grant from the Commonwealth Scientific and Industrial Research Organization. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">77 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Consolidated Statement of Financial Position Data </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As of June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2020</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in&nbsp;thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Working capital</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated losses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Working capital is defined as current assets less current liabilities. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">78 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_12"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>The following &#147;Management&#146;s Discussion and
Analysis of Financial Condition and Results of Operations&#148; should be read together the section titled &#147;Selected Consolidated Financial Data&#148; and our consolidated financial statements and the accompanying notes included elsewhere in
this prospectus. This discussion includes both historical information and forward-looking information based upon current expectations that involve risk, uncertainties and assumptions. Our actual results may differ materially from management&#146;s
expectations as a result of various factors, including, but not limited to, those discussed in &#147;Risk Factors&#148; and elsewhere in this prospectus. </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Overview </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a clinical stage biopharmaceutical company developing a novel therapy for the treatment of highly prevalent and progressive retinal
diseases. We are developing our Phase <FONT STYLE="white-space:nowrap">3-ready</FONT> product candidate, <FONT STYLE="white-space:nowrap">OPT-302,</FONT> a biologic designed to inhibit <FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT
STYLE="white-space:nowrap">VEGF-D,</FONT> to complement <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors for the treatment of ophthalmic diseases. <FONT STYLE="white-space:nowrap">Anti-VEGF-A</FONT> therapies represent the standard of care
for wet <FONT STYLE="white-space:nowrap">age-related</FONT> macular degeneration, or AMD, and other retinal diseases; however, there remains a significant unmet medical need as many patients do not adequately respond to these treatments. As the only
biologic inhibitor of <FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D</FONT> in clinical development, <FONT STYLE="white-space:nowrap">OPT-302</FONT> differs from standard of care therapies and when
administered in combination with a <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitor, is designed to achieve broader inhibition of the vascular endothelial growth factor, or VEGF, family and target a mechanism of clinical resistance to
improve visual acuity. Our lead indication for <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy is wet AMD, a chronic, progressive disease and the leading cause of vision loss for individuals over the age of 50. In a <FONT
STYLE="white-space:nowrap">366-patient</FONT> Phase 2b clinical trial for the treatment of wet AMD, <FONT STYLE="white-space:nowrap">OPT-302,</FONT> in combination with a standard of care <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy,
ranibizumab (Lucentis), demonstrated a statistically significant superior mean gain in visual acuity over ranibizumab monotherapy at week 24. We intend to initiate two pivotal Phase 3 clinical trials in treatment-naive patients with wet AMD to
evaluate the efficacy and safety of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy compared to <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapy in the
first half of 2021. We expect to report topline data from these Phase 3 clinical trials in 2023. In addition to our clinical trials in wet AMD, we have observed evidence of improved clinical outcomes in a Phase 1b/2a clinical trial of <FONT
STYLE="white-space:nowrap">OPT-302</FONT> in combination with another standard of care <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy, aflibercept (Eylea), in patients with treatment-refractory diabetic macular edema, or DME. We retain
worldwide rights to develop and commercialize <FONT STYLE="white-space:nowrap">OPT-302</FONT> for the treatment of wet AMD and DME and believe that the novel treatment mechanism of <FONT STYLE="white-space:nowrap">OPT-302</FONT> has the potential to
provide therapeutic benefit for other progressive eye diseases. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We were founded in 1984 and completed our initial public offering and listing of ordinary shares on the Australian Securities Exchange in 1985. In April 2007, we acquired intellectual property relating to
VEGF receptor 3 and subsequently developed the intellectual property for our lead product candidate, <FONT STYLE="white-space:nowrap">OPT-302.</FONT> Our development focus on the treatment of retinal diseases began in 2013. Since then, we have
devoted substantially all of our efforts to organizing and staffing our company, business planning, raising capital, developing and manufacturing our lead product candidate, <FONT STYLE="white-space:nowrap">OPT-302,</FONT> conducting research and
development activities, including preclinical studies and clinical trials, and providing general and administrative support for these operations. Our operations relating to the development of <FONT STYLE="white-space:nowrap">OPT-302</FONT> have been
financed primarily through the issuance and sale of new ordinary shares totaling A$112.7&nbsp;million through June&nbsp;30, 2020. We have also received an aggregate of A$35.1&nbsp;million in cash tax incentives in the five fiscal years ended
June&nbsp;30, 2019 under the Research and Development, or R&amp;D, Tax Incentive Scheme for the funding of the development of and clinical trials for <FONT STYLE="white-space:nowrap">OPT-302.</FONT> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have incurred operating losses since 2013. Our ability to
generate product revenue sufficient to achieve profitability will be dependent on the successful development and eventual commercialization of <FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidates. Our total comprehensive
loss was A$20.7&nbsp;million and A$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million for the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">79 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
years ended June&nbsp;30, 2019 and 2020, respectively. As of June&nbsp;30, 2020, we had an accumulated loss of
A$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million. We expect to continue to incur significant expenses for at least the next several years as we advance
<FONT STYLE="white-space:nowrap">OPT-302</FONT> through late-stage clinical development, including our planned pivotal Phase 3 trials of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with anti-VEGF-A therapy for the treatment of wet
AMD, and, if these results are favorable, seek regulatory approval for <FONT STYLE="white-space:nowrap">OPT-302.</FONT> In addition, we may also pursue development of <FONT STYLE="white-space:nowrap">OPT-302</FONT> for the treatment of additional
indications, including DME, retinal vein occlusion and other indications in which <FONT STYLE="white-space:nowrap">OPT-302</FONT> has the potential to provide therapeutic benefit. In addition, if we obtain marketing approval for <FONT
STYLE="white-space:nowrap">OPT-302,</FONT> we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. Upon the completion of this offering, we expect to incur additional costs
associated with operating as a public company in the United States, including significant additional legal, accounting, investor relations, compliance and other expenses. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a result, we will need substantial additional funding to
support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt financings, or other capital
sources, which may include collaborations with other companies or other strategic transactions as well as Australian research and development tax incentives. We may be unable to raise additional funds or enter into such other agreements or
arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development and commercialization of <FONT
STYLE="white-space:nowrap">OPT-302.</FONT> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because of the numerous risks and uncertainties associated with the development of biopharmaceutical product candidates, we are unable to
predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may never become profitable. If we fail to become profitable or are unable to
sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to scale back or discontinue our operations. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of June&nbsp;30, 2020, we had cash and cash equivalents of
A$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million. We believe that the anticipated net proceeds from this offering, together with our existing cash and cash equivalents as of June&nbsp;30,
2020, will enable us to fund our operating and research and development expenses through &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have based this estimate on assumptions that may prove to
be wrong, and we could exhaust our available capital resources sooner than we expect. See &#147;&#151;Liquidity and Capital Resources.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are closely monitoring how the spread of <FONT
STYLE="white-space:nowrap">COVID-19</FONT> is affecting our employees, business, preclinical studies and clinical trials. In response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, all of our employees have transitioned to working
remotely and travel has been restricted.&nbsp;Although operations to date have not been materially affected by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, at this time, there is significant uncertainty relating to the trajectory
of the pandemic. The impact of related responses and disruptions caused by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic may result in difficulties or delays in initiating, enrolling, conducting or completing our planned clinical
trials and the incurrence of unforeseen costs as a result of disruptions in clinical supply or clinical trial delays. The impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> on our future results will largely depend on future developments,
which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the pandemic, travel restrictions and social distancing in Australia, the United States and other countries,
business closures or business disruptions, the ultimate impact on financial markets and the global economy and the effectiveness of actions taken in Australia, the United States and other countries to contain and treat the disease. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Components of Our Results of Operations </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Revenue </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue consists of sales-based royalties in connection with
the <FONT STYLE="white-space:nowrap">out-licensing</FONT> of certain intellectual property assets that are unrelated to our core business and the development of <FONT STYLE="white-space:nowrap">OPT-302</FONT> and are not currently
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">80 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
under development. These licenses are primarily used by third-party licensees for research purposes, and we expect revenue from these <FONT STYLE="white-space:nowrap">out-licensing</FONT>
arrangements to be nominal in future periods. These are variable consideration amounts and are recognized when the sales by our license partners to third parties occur, as the performance obligation to transfer the intellectual property to the
license partner is already satisfied. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To date, we
have not generated any revenue from sales of approved products.&nbsp;Because of the numerous risks and uncertainties associated with product development and regulatory approval, we are unable to predict the amount, timing or whether we will be able
to obtain revenue from sales of approved products, and we may never succeed in obtaining regulatory approval for <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any other product candidate. If our development efforts for <FONT
STYLE="white-space:nowrap">OPT-302</FONT> are successful and result in an approved and marketed product, or if we enter into additional collaboration or license agreements with third parties, we may generate revenue in the future from a combination
of product sales or payments from such collaboration or license agreements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other Income </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Other income primarily comprises finance income from interest on bank deposits and funding under a <FONT STYLE="white-space:nowrap">one-time</FONT> Australian government grant from the Commonwealth
Scientific and Industrial Research Organization, or the CSIRO. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Operating Expenses </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Research and Development Expenses.</I>&nbsp;&nbsp;&nbsp;&nbsp;Research and development expenses comprise the research project costs related to the development programs, including clinical trials, for <FONT
STYLE="white-space:nowrap">OPT-302</FONT> for the treatment of wet AMD and DME. R&amp;D expenses also include: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">expenses incurred in connection with the clinical development of our product candidates, including under agreements with third parties, such as
consultants and contract research organizations, or CROs; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the cost of manufacturing and purchasing drug products for use in our clinical trials, including under agreements with third parties, such as
consultants and contract manufacturing organizations, or CMOs; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">facilities, depreciation and other expenses, which include direct or allocated expenses for rent, maintenance of facilities and insurance;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">costs related to compliance with regulatory requirements; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">clinical trial insurance. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expense R&amp;D costs as incurred and have not capitalized any amounts of R&amp;D costs as of June&nbsp;30, 2019. For the year ended
June&nbsp;30, 2019, we did not make any advance payments for goods or services to be received in future periods for use in R&amp;D activities. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our direct R&amp;D expenses are tracked on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis for our product candidate and consist primarily of external costs, such as fees paid to CROs, CMOs, research laboratories and outside
consultants in connection with our process development, manufacturing and clinical development activities. We do not allocate employee costs associated with our research efforts, laboratory supplies and facilities, including depreciation and other
indirect costs, to specific programs because these costs are deployed across multiple development activities and indications for <FONT STYLE="white-space:nowrap">OPT-302</FONT> and, as such, are not separately classified. We use internal resources
primarily to conduct our research activities as well as for managing our process development, manufacturing and clinical development activities. These employees work across multiple development programs and, therefore, we do not track these costs by
program. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">R&amp;D expenses in fiscal years after
June&nbsp;30, 2019 are expected to comprise costs of a similar nature to that recorded to date. Product candidates in later stages of clinical development, such as <FONT STYLE="white-space:nowrap">OPT-302,</FONT> generally have
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">81 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our R&amp;D expenses
will continue to increase in connection with our planned clinical development, manufacturing and regulatory approval activities in the near term and in the future, including as we initiate our planned pivotal Phase 3 clinical trials of <FONT
STYLE="white-space:nowrap">OPT-302</FONT> in combination with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy for the treatment of wet AMD. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At this time, we cannot accurately estimate or know the nature, timing and costs of the efforts that will be necessary to complete the
clinical development of <FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidates. We may never succeed in achieving regulatory approval for any of our product candidates. The duration, costs and timing of clinical trials and
development of our product candidates will depend on a variety of factors, including: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the scope, rate of progress and expense of our planned clinical trials as well as other R&amp;D activities; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">clinical trial results; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the terms and timing of regulatory approvals; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the expense of filing, maintaining, prosecuting, defending and enforcing patent claims and other intellectual property rights;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the ability to raise necessary additional funds; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the ability to obtain and maintain third-party insurance coverage and adequate reimbursement; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the ability to market, commercialize and achieve market acceptance for any products that receive regulatory approval; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a continued acceptable safety profile of <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy following approval in any indication; and
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">establishing and maintaining agreements with third-party suppliers and manufacturers for clinical supply and commercial manufacturing of <FONT
STYLE="white-space:nowrap">OPT-302,</FONT> or any other product candidate, if approved. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A change in the outcome of any of these factors with respect to the development of <FONT STYLE="white-space:nowrap">OPT-302</FONT> could
significantly change the duration, costs and timing associated with clinical trials and development of <FONT STYLE="white-space:nowrap">OPT-302.</FONT> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Patent Expenses.</I>&nbsp;&nbsp;&nbsp;&nbsp;Patent expenses comprise the cost of outside patent attorneys to manage and prosecute our
patent portfolio. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Intellectual Property Costs.</I>&nbsp;&nbsp;&nbsp;&nbsp;Intellectual property costs relate to the license and patent assignment costs in respect of our
<FONT STYLE="white-space:nowrap">in-license</FONT> agreements for certain technologies not currently under development and unrelated to our <FONT STYLE="white-space:nowrap">out-licensing</FONT> arrangements under which we receive sales-based
royalties. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Administrative
Expenses.</I>&nbsp;&nbsp;&nbsp;&nbsp;Administrative expenses comprise employee benefit expenses, including share-based payment expenses; investor relations expenses; insurance costs; audit, accountancy and legal fees; other personnel-related
expenses; and depreciation expense. We anticipate that our administrative expenses will increase in the future as we increase our headcount to support development of <FONT STYLE="white-space:nowrap">OPT-302</FONT> and our continued research
activities. We also anticipate that we will incur increased accounting, audit, legal, regulatory, compliance and director and officer insurance costs as well as investor and public relations expenses associated with being a public company in the
United States. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Occupancy
Expenses.</I>&nbsp;&nbsp;&nbsp;&nbsp;Occupancy expenses represent the costs relating to our headquarters in Melbourne, Australia, including lease rental and incidental costs. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">82 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Net Foreign Exchange Gain (Loss) </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net foreign exchange gain (loss) represents the impact of
the variance in exchange rates between the Australian dollar and the U.S. dollar, Euro, British Pound and Canadian dollar on our cash and cash equivalents, financial assets, financial liabilities and foreign currency denominated transactions.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Income Tax Benefit </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income tax benefit represents the cash incentive amount
receivable under the R&amp;D Tax Incentive Scheme, an Australian Federal Government program under which eligible companies with annual aggregated revenue of less than A$20.0&nbsp;million can receive cash amounts equal to 43.5% of eligible R&amp;D
expenditures from the Australian Taxation Office, or the ATO. The R&amp;D Tax Incentive Scheme incentive relates to eligible expenditures incurred in Australia and, under certain circumstances, in other countries in connection with the development
of <FONT STYLE="white-space:nowrap">OPT-302.</FONT> The R&amp;D tax incentive is applied annually to eligible expenditures incurred during the fiscal year following an annual application and subsequent filing of our income tax return subsequent to
fiscal year end. We estimate the amount of R&amp;D tax incentive after the completion of a fiscal year based on eligible Australia and overseas expenditures incurred during that year. We expect to continue applying for the R&amp;D tax incentive as
we further develop <FONT STYLE="white-space:nowrap">OPT-302.</FONT> In particular, we intend to apply for the costs expected to be incurred in Australia related to our planned pivotal Phase 3 clinical trials of
<FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy for the treatment of wet AMD to be eligible for the R&amp;D tax incentive for future fiscal years once incurred. However,
there can be no assurance that the ATO will allow these costs to be eligible for the tax incentive. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Results of Operations for the Fiscal Years Ended June&nbsp;30, 2019 and 2020 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth a summary of our consolidated statement of profit or loss and other comprehensive income for the periods
presented. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year&nbsp;Ended&nbsp;June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2019<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2020</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">159</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">837</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(31,348</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patent expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(161</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Intellectual property costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(113</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Administrative expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,175</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Occupancy expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net foreign exchange gain (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">363</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss before income tax</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(35,547</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income tax benefit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,637</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss for the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,910</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other comprehensive income:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Items that will not be reclassified subsequently to profit or loss:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value gains on investments in financial assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">260</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other comprehensive income for the period, net of tax</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">260</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total comprehensive loss for the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The consolidated statement of profit or loss and other comprehensive income for the year ended June&nbsp;30, 2019 reflects the impact of the adoption of IFRS 15
&#147;Revenue from Contracts with Customers&#148; and IFRS&nbsp;9 &#147;Financial Instruments,&#148; which became applicable on January&nbsp;1, 2018. The impact of the adoption of IFRS&nbsp;15 and IFRS 9 is not material to the consolidated statement
of profit or loss and other comprehensive income. The details on the impact of the transition are presented in note 5 to our consolidated financial statements appearing elsewhere in this prospectus. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">83 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Revenue </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue was A$159&nbsp;thousand for the year ended June&nbsp;30, 2019 and consisted of sales-based royalties in
connection with the <FONT STYLE="white-space:nowrap">out-licensing</FONT> of certain intellectual property assets that are unrelated to our core business and the development of <FONT STYLE="white-space:nowrap">OPT-302</FONT> and are not currently
under development. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other Income
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income was A$837&nbsp;thousand for
the year ended June&nbsp;30, 2019 and consisted of A$756&nbsp;thousand of finance income from interest on bank deposits, A$78&nbsp;thousand in funding under a <FONT STYLE="white-space:nowrap">one-time</FONT> Australian government grant from the
CSIRO and A$3 thousand of other income. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and Development Expenses </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expenses were A$31.3&nbsp;million for the year ended June&nbsp;30, 2019. Our research and development expenses
are broken down as set forth in the table below: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year&nbsp;Ended&nbsp;June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2020</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Costs related to the Phase 2b clinical trial of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in wet AMD</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,718</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Costs related to the Phase 1b/2a clinical trial of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in DME</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,646</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chemistry manufacturing and controls</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">675</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other direct <FONT STYLE="white-space:nowrap">non-clinical</FONT> expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">309</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31,348</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Patent Expenses
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patent expenses were A$161&nbsp;thousand
for the year ended June&nbsp;30, 2019 and consisted of the cost of outside patent attorneys to manage and prosecute our patent portfolio. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Intellectual Property Costs </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Intellectual property costs were A$113&nbsp;thousand for the year ended June&nbsp;30, 2019 and consisted of the license and patent
assignment costs in respect of our <FONT STYLE="white-space:nowrap">in-license</FONT> agreements for certain technologies not currently under development and unrelated to our <FONT STYLE="white-space:nowrap">out-licensing</FONT> arrangements under
which we receive sales-based royalties. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Administrative Expenses </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Administrative expenses were A$5.2&nbsp;million for the year ended June&nbsp;30, 2019 and consisted primarily of A$3.7&nbsp;million for
employee benefit expenses, including A$2.7&nbsp;million for employee remuneration and A$968&nbsp;thousand for share-based payments, as well as A$572&nbsp;thousand of professional fees and expenses, A$572&nbsp;thousand for personnel-related expenses,
A$33&nbsp;thousand for depreciation expense and A$377&nbsp;thousand for insurance costs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Occupancy Expenses </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Occupancy expenses were A$109&nbsp;thousand for the year ended June&nbsp;30, 2019 and consisted of A$79&nbsp;thousand in lease rental costs and A$30&nbsp;thousand in lease incidental costs, in each case
related to the lease for our headquarters in Melbourne, Australia. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">84 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Net Foreign Exchange Gain (Loss) </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net foreign exchange gain was A$363&nbsp;thousand for the
year ended June&nbsp;30, 2019, primarily as a result of a net gain from the variance of the exchange rate between the Australian dollar and U.S. dollar on U.S. dollar-denominated cash and cash equivalents, financial assets, financial liabilities and
foreign currency denominated transactions. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Income Tax Benefit </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income tax benefit was A$14.6&nbsp;million for the year ended June&nbsp;30, 2019 and consisted of an R&amp;D tax incentive receivable
recognized for the fiscal year. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Liquidity and Capital
Resources </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The liquidity and capital
resources discussion that follows contains certain estimates as of the date of this prospectus of our estimated future sources and uses of liquidity (including estimated future capital resources and capital expenditures) and future financial and
operating results. These estimates reflect numerous assumptions made by us with respect to industry performance, general business, economic, regulatory, market and financial conditions and other future events, and matters specific to our businesses,
all of which are difficult or impossible to predict and many of which are beyond our control. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Sources and Uses of Liquidity </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our operations relating to the development of <FONT STYLE="white-space:nowrap">OPT-302</FONT> have been financed primarily through the issuance and sale of new ordinary shares totaling
A$112.7&nbsp;million through June&nbsp;30, 2020. We have also received an aggregate of A$35.1&nbsp;million in the five fiscal years ended June&nbsp;30, 2019 under the R&amp;D Tax Incentive Scheme for the funding of the development and clinical
trials of <FONT STYLE="white-space:nowrap">OPT-302.</FONT> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As of June&nbsp;30, 2020, we had cash and cash equivalents of A$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to fund the manufacturing of
sufficient clinical grade <FONT STYLE="white-space:nowrap">OPT-302</FONT> drug product and complete the regulatory and clinical preparation activities to initiate our planned pivotal Phase 3 clinical trials of
<FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy for the treatment of wet AMD. As of June&nbsp;30, 2020, we had an accumulated loss of
A$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Funding Requirements </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe that the net proceeds from this offering, together with our existing cash and cash equivalents, will enable us to fund our
operating and research and development expenses through &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have based this estimate on assumptions that may prove to be wrong, and we could use our
capital resources sooner than we currently expect. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development of,
continue or initiate clinical trials of, and seek marketing approval for, <FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidates. In addition, if we obtain marketing approval for
<FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidates, we expect to incur significant commercialization expenses related to sales, marketing, manufacturing and distribution to the extent that such sales, marketing and
distribution are not the responsibility of any future collaborators. Further, following the completion of this offering, we expect to incur additional costs associated with operating as a public company in the United States. Accordingly, we will
need to obtain substantial additional funding in connection with our continuing operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Until we can generate a sufficient amount of revenue from the sale of approved products, if ever, we expect to finance our operating activities through our existing liquidity, the net proceeds from this
offering and future financing activities, including a combination of equity offerings, debt financings, collaborations, strategic </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">85 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the
terms of these securities may include liquidation or other preferences that adversely affect your rights as a holder of ADSs. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take
specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable
rights to our technologies, intellectual property, future revenue streams or product candidates. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our
product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our present and future funding requirements will depend on
many factors, including, among other things:&nbsp;&nbsp;&nbsp;&nbsp; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the initiation, progress, timing, costs and results of our clinical trials for <FONT STYLE="white-space:nowrap">OPT-302,</FONT> including our planned
pivotal Phase 3 clinical trials of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy for the treatment of wet AMD, and any future product candidates we may develop;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">costs associated with expanding our organization, including our management infrastructure; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the costs involved in filing patent applications and maintaining and enforcing patents or defending against claims of infringement raised by third
parties; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the time and costs involved in obtaining regulatory approval for our product candidates and any delays we may encounter as a result of evolving
regulatory requirements or adverse results with respect to any of these product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">selling and marketing activities undertaken in connection with the commercialization of <FONT STYLE="white-space:nowrap">OPT-302,</FONT> together with
the costs involved in the creation of a sales and marketing organization; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the costs of operating as a public listed company in both Australia and the United States. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Conducting clinical trials is a time-consuming, expensive and
uncertain process that takes many years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future
product candidate, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of <FONT STYLE="white-space:nowrap">OPT-302</FONT> and any future product candidate that we do not expect to be
commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. For
more information as to the risks associated with our future funding needs, see &#147;Risk Factors&#151;Risks Related to Our Financial Position and Need for Capital.&#148; </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Cash Flows </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes our cash flows for the
periods presented: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year&nbsp;Ended&nbsp;June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2020</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash used in operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(24,185</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash provided by investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">321</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash provided by financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,630</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net decrease in cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11,234</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">86 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Operating Activities </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the year ended June&nbsp;30, 2019, net cash used in
operating activities was A$24.2&nbsp;million, attributable to a net loss of A$20.9&nbsp;million adjusted for A$13.9&nbsp;million in <FONT STYLE="white-space:nowrap">non-cash</FONT> items as well as a net cash outflow from changes in operating assets
and liabilities of A$1.4&nbsp;million, partially offset by a R&amp;D tax incentive of A$12.0&nbsp;million. <FONT STYLE="white-space:nowrap">Non-cash</FONT> adjustments of A$13.9&nbsp;million consisted of A$14.6&nbsp;million in income tax benefit
recognized in profit or loss and A$259&nbsp;thousand in net exchange differences, partially offset by A$967&nbsp;thousand in share-based payments and A$33&nbsp;thousand in depreciation expense. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Investing Activities </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the year ended June&nbsp;30, 2019, net cash provided by
investing activities was A$321&nbsp;thousand, attributable to A$339&nbsp;thousand in cash received on disposal of our financial asset of shares and options in Antisense Therapeutics Ltd., an <FONT STYLE="white-space:nowrap">ASX-listed</FONT>
company, offset by cash payments of A$18&nbsp;thousand for the purchase of computer equipment. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Financing Activities </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">For the year ended June&nbsp;30, 2019, net cash provided by financing activities was A$12.6&nbsp;million from the issuance of new ordinary shares on the exercise of options previously issued in connection
with a capital raise. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contractual Obligations </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes our contractual obligations
as of June&nbsp;30, 2019: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Payments Due By Period</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Less&nbsp;than&nbsp;1<BR>Year</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B><FONT STYLE="white-space:nowrap">1-3&nbsp;Years</FONT></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B><FONT STYLE="white-space:nowrap">3-5&nbsp;Years</FONT></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>More&nbsp;than<BR>5 Years</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating lease commitments</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchase obligations</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">330</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">330</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">License agreements</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">316</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">102</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">85</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">128</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">653</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">439</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">85</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">128</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amounts represent payments due under the lease for our headquarters in Melbourne, Australia, which expires in July 2022. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amounts consist of purchase obligations of <FONT STYLE="white-space:nowrap">OPT-302</FONT> drug product under our manufacturing services agreement with Patheon
Biologics Company Australia Pty Ltd. and Patheon Biologics Company B.V. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amounts represent payments due under <FONT STYLE="white-space:nowrap">in-license</FONT> agreements with the Schepens Eye Research Institute and the University of Siena
for technologies not currently under development and unrelated to our <FONT STYLE="white-space:nowrap">out-licensing</FONT> arrangements under which we receive sales-based royalties. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The commitment amounts in the table above are associated with
contracts that are enforceable and legally binding and that specify all significant terms, including fixed or minimum services to be used, fixed, minimum or variable price provisions, and the approximate timing of the actions under the contracts.
The table does not include obligations under agreements that we can cancel without a significant penalty. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We enter into agreements in the normal course of business with contract research organizations for clinical trials and with vendors for
other services and products for operating purposes which are cancelable at any time by us. These payments are not included in this table of contractual obligations. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Commercial License Agreement with Selexis SA
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In October 2013, we entered into a
commercial license agreement, or the Selexis Agreement, with Selexis SA, or Selexis, under which Selexis granted us a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide, sublicensable license under certain
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">87 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
patents, <FONT STYLE="white-space:nowrap">know-how</FONT> and other intellectual property controlled by Selexis to use certain cell lines, deliverables and materials provided by Selexis to
manufacture <FONT STYLE="white-space:nowrap">OPT-302</FONT> and related products and to use, sell and otherwise exploit such products. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We paid Selexis a nominal upfront payment upon entering into the Selexis Agreement. We are also required to make certain payments under
the Selexis Agreement totaling approximately US$1.3&nbsp;million upon the achievement of certain development and commercial milestones. We are also obligated to pay a low single-digit running royalty on worldwide net sales of the licensed products.
Our royalty obligations will continue, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT>
basis, until the expiration of the relevant patents, but will not extend beyond October 2024 in any event. After the expiration of the royalty term, our license will continue and become full paid, perpetual and irrevocable. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Selexis Agreement will expire on the date of expiration
of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> of the license patents. Either party may terminate the Selexis Agreement for the other party&#146;s uncured material breach or bankruptcy. We may
also terminate the Selexis Agreement at any time upon prior notice to Selexis. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the periods presented, we did not, and we do not currently, engage in <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet
financing arrangements as defined under SEC rules, such as relationships with other entities or financial partnerships, which are often referred to as structured finance or special purpose entities, established for the purpose of facilitating
financing transactions that are not required to be reflected on our consolidated statement of financial position. In addition, we do not engage in trading activities involving <FONT STYLE="white-space:nowrap">non-exchange</FONT> traded contracts.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Critical Accounting Policies and Estimates </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe that the following accounting policies involve a
high degree of judgment and complexity. Accordingly, these are the policies we believe are the most critical to aid in fully understanding and evaluating our consolidated financial condition and results of our operations. See note 3 to our
consolidated financial statements appearing elsewhere in this prospectus for a description of our other significant accounting policies. The preparation of our consolidated financial statements in conformity with IFRS requires us to make estimates
and judgments that affect the amounts reported in those financial statements and accompanying notes. Although we believe that the estimates we use are reasonable, due to the inherent uncertainty involved in making those estimates, actual results
reported in future periods could differ from those estimates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and Development Costs </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The majority of our expenditures is incurred as a result of our clinical trials for <FONT STYLE="white-space:nowrap">OPT-302.</FONT> During the year ended June&nbsp;30, 2019, we progressed a Phase 2b
clinical trial of <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy for the treatment of wet AMD and a Phase 1b/2a clinical trial of <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy for the treatment of DME. A
key measure of our performance is the level of expenditures incurred on the research and development of <FONT STYLE="white-space:nowrap">OPT-302.</FONT> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Judgement is required in relation to: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the classification of expenses in the income statement between research and development costs and operating expenses; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether costs relate to research or development, and consequently if they meet the capitalization criteria under International Accounting Standards, or
IAS, 38 &#147;Intangible Assets.&#148; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have determined that we are still in a research phase, and accordingly, no development costs have been capitalized as of June&nbsp;30, 2019. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">88 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Share-based Payment Transactions </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We provide benefits to our directors and employees
(including key management personnel) in the form of share-based payments, whereby employees render services in exchange for ordinary shares or rights over ordinary shares (equity-settled transactions). The cost of these equity-settled transactions
with employees is measured by reference to the fair value at the date at which they are granted. Binomial models are used to value the options issued, with key assumptions being the listed price per ordinary share on the grant date, the option
exercise price, expected volatility of the underlying ordinary shares based on the historical share price volatility and the risk-free interest rate. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The cost of the equity-settled transactions is recognized, together with a corresponding increase in equity, over the period in which the
performance conditions are fulfilled (the vesting period), ending on the date on which the relevant employees become fully entitled to the award (the vesting date). The charge to profit or loss for the period is the cumulative amount less the
amounts already charged in previous periods. There is a corresponding credit to equity. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Until an award has vested, any amounts recorded are contingent and will be adjusted if more or fewer awards vest than were originally anticipated to do so. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Income Tax&#151;Research and Development Tax Incentive
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The R&amp;D Tax Incentive Scheme is an
Australian Federal Government program under which eligible companies with annual aggregated revenue of less than A$20&nbsp;million can receive cash amounts equal to 43.5% of eligible research and development expenditures from the ATO. The R&amp;D
Tax Incentive Scheme incentive relates to eligible expenditures incurred in Australia and, under certain circumstances, overseas on the development of our lead candidate <FONT STYLE="white-space:nowrap">OPT-302.</FONT> The R&amp;D tax incentive is
applied annually to eligible expenditures incurred during our financial year following an annual application and subsequent filing of our income tax return after the financial year end. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We estimate the amount of R&amp;D tax incentive after the completion of the financial year based on eligible
Australia and overseas expenditures incurred during that year. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have presented incentives in respect of the R&amp;D Tax Incentive Scheme within income tax benefit in the Statement of Profit or Loss and Other Comprehensive Income by analogizing with IAS 12
&#147;Income Taxes.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Judgment is required as
to the eligibility for the R&amp;D tax incentive in respect of: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to make claims and its continued compliance under the scheme; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">research and development and other supporting costs previously approved by Australian tax authorities; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">estimated amounts, timing and geographical location of future costs related to the projects for which applications have been approved to date; and
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">assessment of whether expenditure on projects for which approval has been given by Australian tax authorities relate to Australian or overseas
expenditure. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the year ended
June&nbsp;30, 2019, we have recognized an R&amp;D tax incentive receivable of A$14.6&nbsp;million within our consolidated statement of financial position with a corresponding amount recognized within income tax benefit within the consolidated
statement of profit or loss and other comprehensive income. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Investment tax credits such as the R&amp;D tax incentive are outside of the scope of IAS 12 &#147;Income Taxes&#148; and IAS 20 &#147;Accounting for Government Grants and Disclosure of Government
Assistance.&#148; Based on the guidance in IAS 8 &#147;Accounting Policies, Changes in Accounting Estimates and Errors,&#148; companies need to make </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">89 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
an accounting policy choice on how to present these incentives, which in practice is done by either analogizing with IAS 12 or with IAS 20. We have determined that the R&amp;D tax incentive
should be presented by analogizing to IAS 12 because the nature of the incentive is considered to be more closely aligned to income taxes, based on the following considerations: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The R&amp;D tax incentive is considered an income tax offset which will be offset against our tax obligation if and when we return to a net tax payable
position. In addition, while we are currently eligible to receive cash payments under the Scheme since our consolidated revenue is currently below A$20&nbsp;million, if and when we generate revenue in excess of A$20&nbsp;million, the R&amp;D tax
incentive will become <FONT STYLE="white-space:nowrap">non-refundable</FONT> and can only be offset against any future income tax payable by us.</FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The ATO, which is the tax authority in Australia, manages the annual claims process as the R&amp;D tax incentive is included in our annual income tax
return. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The ATO is also responsible for making the R&amp;D tax incentive cash payment if a company is eligible for a cash refund under the program, oversees
compliance with the requirements of the R&amp;D tax incentive scheme and performs <FONT STYLE="white-space:nowrap">pre-issuance</FONT> reviews. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Recently Adopted Accounting Pronouncements </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Amendments to Accounting Standards that are
Mandatorily Effective for the Current Year </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have adopted all of the new and revised Standards and Interpretations issued by the IASB that are relevant to its operations and
effective for the current year. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">New and revised
Standards and amendments thereof and Interpretations effective for the current year that are relevant to us include: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">IFRS 9 &#147;Financial Instruments&#148; and related amending Standards; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">IFRS 15 &#147;Revenue from Contracts with Customers&#148; and related amending Standards; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendments to IFRS 2 &#147;Classification and Measurement of Share-based Payment Transactions;&#148; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Annual Improvements to IFRS 2014-2016 Cycle; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">IFRIC 22 &#147;Foreign Currency Transactions and Advance Consideration.&#148; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>IFRS 9 &#147;Financial Instruments&#148; and Related
Amending Standards </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the year ended
June&nbsp;30, 2019, we have applied IFRS 9 &#147;Financial Instruments&#148; (as amended) and the related consequential amendments to other Accounting Standards that are effective for an annual period that begins on or after January&nbsp;1, 2018.
The transition provisions of IFRS 9 allow an entity to not restate comparatives. We have taken advantage of this exemption with respect to classification and measurement (including impairment) changes. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additionally, we adopted consequential amendments to IFRS 7
&#147;Financial Instruments&#148; that were applied to the disclosures about the financial year ended June&nbsp;30, 2019 and to the comparative period. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IFRS 9 introduced new requirements for: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The classification and measurement of financial assets and financial liabilities; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Impairment of financial assets; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">General hedge accounting. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">90 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The expected credit loss model requires us to account for expected credit losses and
changes in those expected credit losses at each reporting date to reflect changes in credit risk since initial recognition of the financial assets. We have applied the simplified approach when calculating the expected credit loss as part of its
accounting policy which has not materially impacted the accounts. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our directors reviewed and assessed our existing financial assets as of July&nbsp;1, 2018 based on the facts and circumstances that existed at that date. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our investments in equity instruments (neither held for
trading nor a contingent consideration arising from a business combination) that were previously classified as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> financial assets and were measured at
fair value at each reporting date under IAS 39 &#147;Financial Instruments: Recognition and Measurement&#148; have been designated as FVTOCI. The change in fair value on these equity instruments continues to be accumulated in the investment
revaluation reserve. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other receivables which were
carried at amortized cost under IAS 39 continue to be carried at amortized cost under IFRS 9. IFRS 9 has had no impact on the classification of financial liabilities. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, IFRS 9 requires an expected credit loss model as
opposed to an incurred credit loss model under IAS 39. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">There were no differences in the carrying amounts of financial assets and financial liabilities resulting from the adoption of IFRS 9 recognized in retained earnings and reserves as of July&nbsp;1, 2018.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>IFRS 15 &#147;Revenue from Contracts with
Customers&#148; and Related Amending Standards </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">During the year ended June&nbsp;30, 2019, we applied IFRS 15 &#147;Revenue from Contracts with Customers&#148; (as amended) which is effective for an annual period that begins on or after January&nbsp;1,
2018. IFRS 15 introduced a five-step approach to revenue recognition. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The application of IFRS 15 has not had a significant impact on our financial position and/or financial performance; however, our accounting policies for revenue have changed and are disclosed in detail in
note 3 to the consolidated financial statements included elsewhere in this prospectus. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other Pronouncements Adopted in the Year Ended June&nbsp;30, 2019 </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the year ended June&nbsp;30, 2019, we applied a number of amendments to IFRS and Interpretations issued by the IASB that are
effective for an annual period that begins on or after January&nbsp;1, 2018. Their adoption has not had any material impact on the disclosures or on the amounts reported in our financial statements. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>New and Revised International Financial Reporting
Standards and Interpretations on Issue But not Yet Effective </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>IFRS 16 Leases</I> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">IFRS 16 &#147;Leases&#148; introduces a single, <FONT STYLE="white-space:nowrap">on-balance</FONT> lease sheet accounting model for lessees. A lessee recognizes a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset representing its right to use the underlying asset and a lease liability representing its obligation to make lease payments. There are optional exemptions for short-term leases and leases
of low value items. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IFRS 16 is effective for
annual periods beginning on or after January&nbsp;1, 2019. We will apply IFRS 16 initially on July&nbsp;1, 2019. We have assessed the potential impact on its consolidated financial statements and determined that there will not be a material impact
on its consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">91 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IFRS 16 will change how we account for leases previously classified as operating leases
under IAS 17 &#147;Leases,&#148; which were <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet. On initial application of IFRS 16 for all leases (except as noted below), we will: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Recognize <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and lease liabilities in the consolidated
statement of financial position, initially measured at the present value of the future lease payments; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Recognize depreciation of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and interest on lease
liabilities in the consolidated statement of profit or loss and other comprehensive income; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Separate the total amount of cash paid into a principal portion (presented within financing activities) and interest (presented within operating
activities) in the consolidated statement of cash flows. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Lease incentives (e.g., rent-free period) will be recognized as part of the measurement of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and lease
liabilities whereas under IAS 17 they resulted in the recognition of a lease liability incentive, amortized as a reduction of rental expenses on a straight-line basis. Under IFRS 16,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets will be tested for impairment in accordance with IAS 36 &#147;Impairment of Assets.&#148; This will replace the previous requirement to recognize a
provision for onerous lease contracts. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For
short-term leases (lease term of 12 months or less) and leases of <FONT STYLE="white-space:nowrap">low-value</FONT> assets (such as office equipment), we have elected to apply the recognition exemption as permitted by IFRS 16. The lease payments
associated with those leases will be recognized as an expense on a straight-line basis over the lease term. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Given our current premises lease for our headquarters expires on July&nbsp;14, 2019, the adoption of IFRS 16 is not expected to have any
material impact on us at the transition date. We entered into a new lease agreement for our existing premises on July&nbsp;15, 2019 and a preliminary assessment indicates we will recognize a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset of A$365&nbsp;thousand and a corresponding lease liability of A$365&nbsp;thousand on this date. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Qualitative and Quantitative Disclosures about Market Risk </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are exposed to market risks in the ordinary course of our
business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily the result of fluctuations in interest rates and foreign
currency exchange rate risk. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Interest Rate
Risk </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of June&nbsp;30, 2020, we had
cash and cash equivalents of A$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million. We have limited exposure to interest rate risk.&nbsp;Our exposure to market interest rates relates primarily to
the short-term deposits. The deposits are held with two of Australia&#146;s largest banks. Our cash and cash equivalents are not locked into long-term deposits at fixed rates so as to mitigate the risk of earning interest below the current floating
rate. We do not have any credit facilities bearing variable interest rates.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Foreign Currency Exchange Rate Risk </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As a result of services provided by <FONT STYLE="white-space:nowrap">non-related</FONT> entities in the United States, Canada, United Kingdom and Europe, part of our financial assets and liabilities and
foreign currency denominated transactions are affected by movements in the applicable exchange rate. We do not enter into any hedging transactions. We are primarily exposed to foreign exchange risk inherent in U.S. dollar-denominated contracts
related to our clinical development activities. As of June&nbsp;30, 2019, we had A$4.5&nbsp;million in net exposure to the U.S. dollar, primarily in payables. An increase or decrease of the Australian dollar to U.S. dollar exchange rate by 10% would
increase our after tax loss by A$285&nbsp;thousand or decrease our after tax loss by A$349&nbsp;thousand, respectively. As we continue our clinical development activities, we expect to face continued exposure to exchange rate risk from the U.S.
dollar. There was minimal or insignificant exposure to the British Pound, Euro and Canadian dollar during the year ended June&nbsp;30, 2019. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">92 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Emerging Growth Company Status </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a company with less than $1.07&nbsp;billion in revenue during our last fiscal year, we qualify as an
&#147;emerging growth company&#148; as defined in the JOBS Act. As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These provisions
include: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">exemption from the auditor attestation requirement of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, in the assessment
of our internal controls over financial reporting; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to the extent that we no longer qualify as a foreign private issuer, (i)&nbsp;reduced disclosure obligations regarding executive compensation in our
periodic reports and proxy statements and (ii)&nbsp;exemptions from the requirements of holding <FONT STYLE="white-space:nowrap">a&nbsp;non-binding&nbsp;advisory</FONT> vote on executive compensation, including golden parachute compensation.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may take advantage of these
exemptions until such time that we are no longer an emerging growth company. Accordingly, the information that we provide shareholders and holders of our ADSs may be different than you might obtain from other public companies. We will cease to be an
emerging growth company upon the earliest to occur of (i)&nbsp;the last day of the fiscal year in which we have more than $1.07&nbsp;billion in annual revenue; (ii)&nbsp;the last day of the fiscal year in which we qualify as a &#147;large
accelerated filer&#148;; (iii)&nbsp;the date on which we have, during the previous three-year period, issued more than $1.0&nbsp;billion <FONT STYLE="white-space:nowrap">in&nbsp;non-convertible&nbsp;debt</FONT> securities; and (iv)&nbsp;the last day
of the fiscal year in which the fifth anniversary of this offering occurs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition, Section&nbsp;107 of the JOBS Act provides that an emerging growth company can use the extended transition period provided in Section&nbsp;7(a)(2)(B) of the Securities Act for complying with
new or revised accounting standards. Given that we currently report and expect to continue to report under IFRS, as issued by the IASB, we have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will
adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required by the IASB. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Foreign Private Issuer Status </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are also considered a &#147;foreign private issuer&#148; under U.S. securities laws. In our capacity as a foreign private issuer, we
are exempt from certain rules under the Securities Exchange Act of 1934, as amended, that impose certain disclosure obligations and procedural requirements for proxy solicitations under Section&nbsp;14 of the Exchange Act. In addition, our senior
management, the members of our board of directors and our principal shareholders are exempt from the reporting and &#147;short-swing&#148; profit recovery provisions of Section&nbsp;16 of the Exchange Act and the rules under the Exchange Act with
respect to their purchases and sales of our securities. Moreover, we are not required to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange
Act. In addition, we are not required to comply with Regulation FD, which restricts the selective disclosure of material information. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may take advantage of these exemptions until such time as we are no longer a foreign private issuer. We will remain a foreign private
issuer until such time that 50% or more of our outstanding voting securities are held by U.S. residents and any of the following three circumstances applies: (i)&nbsp;the majority of the members of board of directors or our senior management are
U.S. citizens or residents; (ii)&nbsp;more than 50% of our assets are located in the United States; or (iii)&nbsp;our business is administered principally in the United States. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have taken advantage of certain reduced reporting and
other requirements in this prospectus. Accordingly, the information contained herein may be different from the information you receive from other public companies. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">93 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_13"></A>BUSINESS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Overview </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a clinical stage biopharmaceutical company developing a novel therapy for the treatment of highly
prevalent and progressive retinal diseases. We are developing our Phase <FONT STYLE="white-space:nowrap">3-ready</FONT> product candidate, <FONT STYLE="white-space:nowrap">OPT-302,</FONT> a biologic designed to inhibit
<FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D,</FONT> to complement <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors for the treatment of ophthalmic diseases.
<FONT STYLE="white-space:nowrap">Anti-VEGF-A</FONT> therapies represent the standard of care for wet <FONT STYLE="white-space:nowrap">age-related</FONT> macular degeneration, or AMD, and other retinal diseases; however, there remains a significant
unmet medical need as many patients do not adequately respond to these treatments. As the only biologic inhibitor of <FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D</FONT> in clinical development, <FONT
STYLE="white-space:nowrap">OPT-302</FONT> differs from standard of care therapies and when administered in combination with a <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitor, is designed to achieve broader inhibition of the vascular
endothelial growth factor, or VEGF, family and target a mechanism of clinical resistance to improve visual acuity. Our lead indication for <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy is wet AMD, a chronic, progressive disease
and the leading cause of vision loss for individuals over the age of 50. In a <FONT STYLE="white-space:nowrap">366-patient</FONT> Phase 2b clinical trial for the treatment of wet AMD, <FONT STYLE="white-space:nowrap">OPT-302,</FONT> in combination
with a standard of care <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy, ranibizumab (Lucentis), demonstrated a statistically significant superior mean gain in visual acuity over ranibizumab monotherapy at week 24. We intend to initiate
two pivotal Phase 3 clinical trials in treatment-naive patients with wet AMD to evaluate the efficacy and safety of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy
compared to <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapy in the first half of 2021. We expect to report topline data from these Phase 3 clinical trials in 2023. In addition to our clinical trials in wet AMD, we have observed
evidence of improved clinical outcomes in a Phase 1b/2a clinical trial of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with another standard of care <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy, aflibercept (Eylea),
in patients with treatment-refractory diabetic macular edema, or DME. We retain worldwide rights to develop and commercialize <FONT STYLE="white-space:nowrap">OPT-302</FONT> for the treatment of wet AMD and DME and believe that the novel treatment
mechanism of <FONT STYLE="white-space:nowrap">OPT-302</FONT> has the potential to provide therapeutic benefit for other progressive eye diseases. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Wet AMD is a rapidly progressing disease with loss of central vision developing over a period of weeks to months in which abnormal new
blood vessels form in the back of the eye in a process called choroidal neovascularization, or CNV. These newly formed vessels are highly permeable, leaking exudate leading to fluid accumulation and retinal lesion formation. This, in turn, adversely
affects sensory cells in the retina and if left untreated, results in rapid loss of visual acuity. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Wet AMD affects approximately one million people in the United States and 2.5&nbsp;million people in Europe. The standard of care for wet AMD and other ocular neovascular diseases is the administration of
monotherapies that primarily inhibit <FONT STYLE="white-space:nowrap">VEGF-A.</FONT> These therapeutic agents, which include ranibizumab and aflibercept, prevent <FONT STYLE="white-space:nowrap">VEGF-A</FONT> molecules from binding to, and
activating, VEGF receptors and thereby inhibit the formation and permeability of blood vessels. Ranibizumab and aflibercept had combined annual worldwide sales of over $11.9&nbsp;billion in 2019. As the risk of developing wet AMD increases with age,
it is predicted that the overall aging of the population will result in a significant increase in the number of wet AMD cases, both in the United States and worldwide. Given the suboptimal clinical responses that many patients experience despite
receiving standard of care treatments, we believe there is a significant and expanding market opportunity for novel therapies that can improve vision in patients with wet AMD. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Despite the widespread use and commercial success of <FONT
STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors, at least 45% of wet AMD patients treated with a <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitor experience some degree of suboptimal clinical response, with a majority of patients failing
to achieve 20/40 vision after 12 months of treatment, providing further opportunity for visual acuity improvement. Furthermore, many patients have persistent retinal fluid and insufficient gains in visual acuity to resume routine daily activities
such as driving and reading following regular treatment with a <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitor. In addition, improvements in visual acuity following regular administration of <FONT STYLE="white-space:nowrap">VEGF-A</FONT>
monotherapy are often not sustained with long-term use. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">94 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">OPT-302</FONT> is designed to address a deficiency in
the treatment paradigm for wet AMD and other retinal diseases, such as DME, by targeting alternate members of the VEGF family, namely <FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D,</FONT> which are not
targeted by current standard of care therapies. <FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D</FONT> function in parallel with <FONT STYLE="white-space:nowrap">VEGF-A</FONT> to drive neovascularization
and vascular leakage, which are key hallmarks of both wet AMD and DME. In addition, treatment with <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors leads to upregulation of <FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT
STYLE="white-space:nowrap">VEGF-D</FONT> to compensate for <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibition, which may represent an important mechanism of clinical resistance to <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT>
monotherapy. We are developing <FONT STYLE="white-space:nowrap">OPT-302</FONT> to be used in combination with standard of care <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapies to achieve broader inhibition of the VEGF family, with
the goal of improving overall efficacy and demonstrating superior vision gains over that which can be achieved by inhibiting <FONT STYLE="white-space:nowrap">VEGF-A</FONT> alone. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In our completed Phase 2b wet AMD clinical trial, <FONT
STYLE="white-space:nowrap">OPT-302</FONT> in combination with ranibizumab demonstrated a statistically significant superior mean gain in visual acuity at week 24 compared to patients treated with ranibizumab with a sham injection, which we refer to
as ranibizumab monotherapy. The trial was an international, multi-center, double-masked trial in 366 treatment-naive patients with wet AMD. Patients were randomized into three groups and received intravitreal injections every four weeks of either
0.5 mg or 2.0 mg <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with 0.5 mg ranibizumab or 0.5 mg ranibizumab monotherapy. Treatments were administered by intravitreal injections once every four weeks for 20 weeks (six treatments in
total). The primary endpoint was the mean change at week 24 in best corrected visual acuity, or BCVA, from baseline on the Early Treatment of Diabetic Retinopathy Study, or ETDRS, standardized eye chart, which we refer to as visual acuity. Patients
treated with 2.0 mg <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy demonstrated a statistically significant improvement in visual acuity compared to patients treated with ranibizumab monotherapy. In the patients that received
2.0 mg <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy, visual acuity improved at week 24 from baseline by a mean of +14.2 letters compared to +10.8 letters for those treated with ranibizumab monotherapy, a statistically
significant benefit of +3.4 letters. Patients that received 2.0 mg <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy also demonstrated improvements in retinal anatomy which were consistent with the visual acuity gains observed in
the trial, including reductions in retinal fluid and lesion size by week 24. In a <FONT STYLE="white-space:nowrap">pre-specified</FONT> subgroup analysis, greater activity of <FONT STYLE="white-space:nowrap">OPT-302</FONT> was observed in lesion
types that are considered more difficult to treat with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy. Our clinical experience to date, which includes administration of over 1,850 doses of <FONT STYLE="white-space:nowrap">OPT-302</FONT>
to 399 patients with retinal disease, indicates that <FONT STYLE="white-space:nowrap">OPT-302</FONT> intravitreal injections are well tolerated, with the incidence of treatment-emergent adverse events, or TEAEs, comparable to <FONT
STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapy in our clinical trials. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are planning to initiate two concurrent pivotal Phase 3 clinical trials for the treatment of treatment-naive patients with wet AMD. These double-masked, sham-controlled Phase 3 clinical trials will
assess the efficacy and safety of 2.0 mg of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy for treatment-naive patients with wet AMD compared to a standard of care <FONT
STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapy. The primary endpoint of both trials will be the mean change in visual acuity from baseline at week 52. Patients will continue to be dosed until week 96 to further assess long-term safety at
week 100. We intend to finalize the Phase 3 trial protocols following the completion of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-Phase</FONT></FONT> 2 regulatory meetings with the U.S. Food and Drug Administration, or
the FDA, and European Medicines Agency, or the EMA. We expect to initiate the trials in the first half of 2021 and to report topline data in 2023. If the results of the Phase 3 clinical trials are favorable, we intend to file for marketing approval
for <FONT STYLE="white-space:nowrap">OPT-302</FONT> for the treatment of wet AMD in the United States, European Union and other territories. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are also investigating the therapeutic potential of <FONT STYLE="white-space:nowrap">OPT-302</FONT> for DME. DME is a progressive eye
disease and a complication of diabetic retinopathy, or DR, a condition caused by chronically elevated glucose levels in diabetics that damages the retina. DME can cause blurred vision, severe vision loss and blindness. Wet AMD and DME share a
similar underlying pathophysiology, including retinal neovascularization and increased vascular permeability, and as a result, <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors are also considered the standard of care treatment for DME.
Based on its mechanism of action and clinical results to date, we believe that <FONT STYLE="white-space:nowrap">OPT-302</FONT> also has the potential to deliver therapeutic benefit in DME patients. In our Phase 1b/2a clinical trial of <FONT
STYLE="white-space:nowrap">OPT-302</FONT> in combination with aflibercept in patients with treatment-refractory DME, we observed evidence of improved clinical outcomes following <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy in
this indication. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">95 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also believe that our novel treatment mechanism has the potential to provide
therapeutic benefit for other progressive retinal diseases beyond wet AMD and DME. We may further investigate the efficacy of <FONT STYLE="white-space:nowrap">OPT-302</FONT> to improve clinical outcomes in patients with polypoidal choroidal
vasculopathy, or PCV, a form of wet AMD that is highly prevalent in Asian populations and less responsive to <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy than other wet AMD subtypes. Beyond wet AMD and DME, we may explore applications
of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in other retinal diseases in which a <FONT STYLE="white-space:nowrap">VEGF-C</FONT> or <FONT STYLE="white-space:nowrap">VEGF-D</FONT> inhibitor could have therapeutic potential, such as retinal vein
occlusion, or RVO. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our Company </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a public company listed on the Australian Securities
Exchange. We have assembled a team of experts with deep scientific, clinical and business expertise in biotechnology and specifically in neovascular disease. Megan Baldwin, Ph.D., our Chief Executive Officer and Managing Director, has over 20 years
of research and development and biopharmaceutical industry experience on neovascularization and therapeutic strategies in ophthalmic indications and cancer. Prior to joining our company, she was a postdoctoral research fellow and an associate market
planning manager at Genentech, where she conducted angiogenesis research before joining the anti-angiogenic therapy commercial group. Mike Tonroe, our Chief Financial Officer and Company Secretary, was previously Chief Financial Officer of the
Australian Synchrotron in Melbourne and has over 20 years of experience in financial management, including as Chief Financial Officer to other companies as well as board-level positions for private and listed companies in Australia, United Kingdom,
the United States and Canada. We believe that the breadth of experience and successful track record of our senior management, combined with our established relationships with leaders in the industry and medical community, provide us with unique
insights into biologic drug development for the treatment of neovascular disease. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Our Strategy </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our goal is to become a leader in developing and commercializing therapeutics for the treatment of retinal diseases. The key elements of our strategy are to: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Advance <FONT STYLE="white-space:nowrap">OPT-302</FONT> through two concurrent Phase 3 trials for the treatment of wet
AMD.&nbsp;&nbsp;&nbsp;&nbsp;</B>Based on the positive results of our Phase 2b trial in wet AMD, we plan to initiate two concurrent pivotal Phase 3 clinical trials in treatment-naive patients with wet AMD to evaluate the efficacy and safety of <FONT
STYLE="white-space:nowrap">OPT-302</FONT> in combination with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy. We expect to initiate these trials in the first half of 2021 with <FONT STYLE="white-space:nowrap">top-line</FONT> results in
2023. If these results are favorable, we plan to file for marketing approval for <FONT STYLE="white-space:nowrap">OPT-302</FONT> for the treatment of wet AMD in the United States, European Union and other territories. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Maximize the commercial potential of</B><B></B><B><FONT STYLE="white-space:nowrap">&nbsp;OPT-302.&nbsp;&nbsp;&nbsp;&nbsp;</FONT></B>We retain
worldwide rights for the development and commercialization of <FONT STYLE="white-space:nowrap">OPT-302.</FONT> If <FONT STYLE="white-space:nowrap">OPT-302</FONT> receives marketing approval in the United States and European Union for wet AMD or any
other retinal indications we are pursuing, we intend to establish our own commercial organization in these key territories. We may also enter into collaborations where we believe there is an opportunity to accelerate the development and
commercialization of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in select territories. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Optimize <FONT STYLE="white-space:nowrap">OPT-302</FONT> administration and potential to reduce injection burden for
patients.</B>&nbsp;&nbsp;&nbsp;&nbsp;Currently, <FONT STYLE="white-space:nowrap">OPT-302</FONT> is administered as an injection following intravitreal administration of a <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitor. We plan to
investigate the efficacy and durability of less frequent administration of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in clinical trials based on <FONT STYLE="white-space:nowrap">OPT-302&#146;s</FONT> pharmacokinetic profile, structural
similarity to aflibercept and potential for improved and prolonged clinical efficacy over time. In addition, we plan to evaluate the potential for <FONT STYLE="white-space:nowrap">co-formulation</FONT> of
<FONT STYLE="white-space:nowrap">OPT-302</FONT> with approved and/or biosimilar forms of <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors to provide flexibility of treatment options for physicians and to reduce the frequency and number of
injections for patients. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Expand clinical development of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in wet AMD, DME and other retinal
diseases</B>.&nbsp;&nbsp;&nbsp;&nbsp;Due to similarities in the underlying pathophysiology, we anticipate that <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with <FONT STYLE="white-space:nowrap">VEGF-A</FONT>
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">96 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:Times New Roman" SIZE="2">
inhibitors may provide therapeutic benefit to patients with other neovascular ophthalmic diseases, such as DME. We reported positive data from a Phase 1b/2a trial of <FONT
STYLE="white-space:nowrap">OPT-302</FONT> in combination with aflibercept for the treatment of DME, and we plan to continue further development in this indication. We also continue to explore the potential benefit of
<FONT STYLE="white-space:nowrap">OPT-302</FONT> in PCV and other ocular diseases, such as RVO and DR, in which there is a strong scientific and clinical rationale. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our Pipeline </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes the stage of clinical development and status of our product candidate,
<FONT STYLE="white-space:nowrap">OPT-302.</FONT> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g61r81.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">*</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">Phase 3 clinical trial designs to be finalized following completion of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-Phase</FONT></FONT> 2
meetings with U.S. and European regulatory agencies, including the FDA and EMA. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>VEGFs in Ocular Diseases </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Multiple ophthalmic diseases and conditions, including wet AMD and DME, involve aberrant blood vessel formation and growth, as well as vascular permeability and resulting leakage that contributes to
disease progression. In wet AMD, lesions consist of newly formed blood vessels that are typically fragile and leak, leading to the accumulation of fluid in the retinal tissue at the back of the eye. As shown in the figure below, if left untreated,
this fluid can cause retinal swelling that disrupts the local architecture and function of sensory cells and neurons in the eye, resulting in vision loss. In patients with DME, high blood glucose levels drive physiological changes resulting in
vascular permeability that also result in fluid accumulation, or edema, in the macula, the central region of the retina, and loss of visual acuity. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">97 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Neovascularization and Vascular Permeability are Key Hallmarks of a Number of Retinal
Diseases, Leading to Lesion Formation, Edema and Distortion of the Retina Photoreceptor Layer Causing Loss of Vision </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g20b36.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Neovascularization and
vascular permeability associated with retinal disease progression are driven by a family of related growth factors known as VEGFs. Members of the VEGF family, including <FONT STYLE="white-space:nowrap">VEGF-A,</FONT>
<FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D,</FONT> exert their activity by binding and activating VEGF receptors referred to as <FONT STYLE="white-space:nowrap">VEGFR-1,</FONT> <FONT
STYLE="white-space:nowrap">VEGFR-2,</FONT> and <FONT STYLE="white-space:nowrap">VEGFR-3.</FONT> Receptor activation triggers signaling pathways that lead to the development of new blood vessels, a process known as angiogenesis, as well as vascular
permeability. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">98 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Members of the VEGF Family of Growth Factors Have Overlapping but Distinct
Specificities for VEGFRs </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g01v78.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">*</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">Lymphangiogenesis refers to the proliferation of lymphatic vessels from <FONT STYLE="white-space:nowrap">pre-existing</FONT> lymphatic vessels.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><FONT STYLE="white-space:nowrap">VEGF-A</FONT> </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">VEGF-A</FONT> is the most
well-characterized member of the VEGF family of growth factors and was the first to be targeted for therapeutic intervention. <FONT STYLE="white-space:nowrap">VEGF-A</FONT> is a potent growth factor and its relevance in ophthalmic neovascularization
has been well-established. Overexpression of <FONT STYLE="white-space:nowrap">VEGF-A</FONT> in animal models has shown <FONT STYLE="white-space:nowrap">VEGF-A</FONT> to be a causal factor in the development of neovascularization and vascular
permeability, which are key hallmarks in the progression of wet AMD. In wet AMD patients, <FONT STYLE="white-space:nowrap">VEGF-A</FONT> levels are shown to be elevated in the aqueous humor fluid of the eye.
<FONT STYLE="white-space:nowrap">VEGF-A</FONT> binds to <FONT STYLE="white-space:nowrap">VEGFR-1,</FONT> which acts to regulate <FONT STYLE="white-space:nowrap">VEGF-A</FONT> activity, and <FONT STYLE="white-space:nowrap">VEGFR-2,</FONT> which is a
key driver of neovascularization and vascular permeability. Several inhibitors of <FONT STYLE="white-space:nowrap">VEGF-A</FONT> have been approved to treat a number of neovascular ocular diseases. The two leading ocular <FONT
STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors by revenue, ranibizumab and aflibercept, had combined annual worldwide sales of over $11.9&nbsp;billion in 2019. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT
STYLE="white-space:nowrap">VEGF-D</FONT> </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT
STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D</FONT> contribute to the development and persistence of neovascular diseases, as evidenced by their elevated levels in multiple pathological conditions. Both <FONT
STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D</FONT> can stimulate neovascularization and <FONT STYLE="white-space:nowrap">VEGF-C</FONT> can induce permeability by binding to
<FONT STYLE="white-space:nowrap">VEGFR-2,</FONT> independent of <FONT STYLE="white-space:nowrap">VEGF-A</FONT> activity. Additionally, <FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D</FONT> bind to <FONT
STYLE="white-space:nowrap">VEGFR-3,</FONT> a receptor that is not activated by <FONT STYLE="white-space:nowrap">VEGF-A,</FONT> which confers biological activities to both <FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT
STYLE="white-space:nowrap">VEGF-D</FONT> that are distinct from those of <FONT STYLE="white-space:nowrap">VEGF-A.</FONT> Activation of <FONT STYLE="white-space:nowrap">VEGFR-3</FONT> can stimulate vascular proliferation and modulate vascular
permeability, vascular leakage and edema formation. The receptor binding profiles and the distinct biological activities of <FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D</FONT> suggest that inhibiting <FONT
STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D</FONT> may have therapeutic potential in ocular diseases by acting independently of, and in tandem with, the activity of
<FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors. There are currently no other therapies either approved or in clinical development that are designed to specifically target <FONT STYLE="white-space:nowrap">VEGF-C</FONT> or <FONT
STYLE="white-space:nowrap">VEGF-D.</FONT> </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99 </FONT></P>


</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Resistance to <FONT STYLE="white-space:nowrap">VEGF-A</FONT> Therapies May be Driven
by <FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D</FONT> </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Standard of care treatments for wet AMD and DME inhibit <FONT STYLE="white-space:nowrap">VEGF-A</FONT> activation of its receptors that
are typically expressed on vascular endothelium. This can lead to inhibition of blood vessel growth and leakage which can stabilize disease and improve clinical outcomes, including visual acuity, in patients with retinal eye conditions. However, not
all patients fully respond to <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibition. A substantial proportion of patients with wet AMD and DME have further opportunity for visual acuity gain and/or a need for resolution of persistent retinal
fluid following <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> treatment. Furthermore, gains in visual acuity are often not sustained over the long term, even when <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies are administered
regularly. This resistance may occur as <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapies do not fully address the multifactorial pathogenesis of wet AMD and DME, including having no activity to block
<FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D.</FONT> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D</FONT> are implicated in the development of resistance to clinical use of
<FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies. Levels of <FONT STYLE="white-space:nowrap">VEGF-C</FONT> and/or <FONT STYLE="white-space:nowrap">VEGF-D</FONT> have been observed to be upregulated in response to <FONT
STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies, most notably in patients with wet AMD. In a study conducted by third-party researchers in wet AMD patients, a 66% increase in the level of <FONT STYLE="white-space:nowrap">VEGF-C</FONT> in the
aqueous humor fluid in eyes was observed following two monthly doses of the <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitor, bevacizumab (Avastin). This is illustrated in the figure below. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><FONT STYLE="white-space:nowrap">VEGF-C</FONT> Levels are
Increased in Aqueous Fluid of the Eye in Wet AMD Patients Treated with Monthly Intravitreal Bevacizumab </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g02v46.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Study conducted by Cabral
et al. (2018) </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upregulation of <FONT
STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D</FONT> can continue to drive signaling through <FONT STYLE="white-space:nowrap">VEGFR-2,</FONT> even in the presence of a
<FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitor, as well as signal through <FONT STYLE="white-space:nowrap">VEGFR-3,</FONT> both of which may contribute to ongoing angiogenesis and vascular permeability associated with persistent wet AMD. <FONT
STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D</FONT> mediated activation of <FONT STYLE="white-space:nowrap">VEGFR-2</FONT> and <FONT STYLE="white-space:nowrap">VEGFR-3,</FONT> as well as their compensatory
elevation following <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibition, may contribute to <FONT STYLE="white-space:nowrap">sub-optimal</FONT> clinical response to <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapy. We believe <FONT
STYLE="white-space:nowrap">OPT-302</FONT> in combination with a <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitor can address a key mechanism of clinical <FONT STYLE="white-space:nowrap">sub-responsiveness</FONT> to standard of care
treatments for serious retinal eye diseases by broad blockade of the VEGF family of growth factors which is not achieved by <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapies. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><FONT STYLE="white-space:nowrap">OPT-302</FONT> </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are developing our Phase
<FONT STYLE="white-space:nowrap">3-ready</FONT> product candidate, <FONT STYLE="white-space:nowrap">OPT-302,</FONT> a biologic designed to inhibit <FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D,</FONT> to
complement existing <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors, for the treatment of ophthalmic diseases, including wet AMD and DME. <FONT STYLE="white-space:nowrap">Anti-VEGF-A</FONT> therapies represent the standard of care for wet
AMD and other retinal </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">100
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
diseases. However, there remains a significant unmet need as many patients do not adequately respond to these treatments. As the only biologic inhibitor of
<FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D</FONT> in clinical development, <FONT STYLE="white-space:nowrap">OPT-302</FONT> differs from standard of care <FONT STYLE="white-space:nowrap">VEGF-A</FONT>
inhibitors, and in combination with a <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitor, is designed to address the <FONT STYLE="white-space:nowrap">sub-optimal</FONT> clinical responses of <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT>
monotherapies by achieving broader inhibition of the VEGF family to improve visual acuity over standard of care <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapies. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2019, we completed a
<FONT STYLE="white-space:nowrap">366-patient</FONT> Phase 2b clinical trial of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with ranibizumab for the treatment of wet AMD, which demonstrated a statistically significant superior mean
gain in visual acuity over ranibizumab monotherapy at week 24. We intend to initiate two pivotal Phase 3 clinical trials in treatment-naive patients with wet AMD to evaluate the efficacy and safety of <FONT STYLE="white-space:nowrap">OPT-302</FONT>
in combination with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy compared to a standard of care monotherapy. We intend to finalize our Phase 3 clinical trial protocols following completion of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">end-of-Phase</FONT></FONT> 2 regulatory meetings with the FDA and EMA and expect to initiate the trials in the first half of 2021 and to report topline data in 2023. In addition, in our Phase 1b/2a clinical trial of <FONT
STYLE="white-space:nowrap">OPT-302</FONT> in combination with aflibercept for the treatment of persistent DME, we observed evidence of clinical activity and improvements in visual acuity outcomes compared to aflibercept monotherapy. <FONT
STYLE="white-space:nowrap">OPT-302</FONT> was observed to be well tolerated across Phase 1 and Phase 2 clinical studies in two disease indications following intravitreal administration of over 1,850 doses of
<FONT STYLE="white-space:nowrap">OPT-302</FONT> to 399 patients either as monotherapy or in combination with standard of care <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">OPT-302</FONT> Mechanism of Action </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">We have designed <FONT
STYLE="white-space:nowrap">OPT-302</FONT> to function as a ligand trap, capable of binding and sequestering <FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D,</FONT> thereby preventing these growth factors
from activating <FONT STYLE="white-space:nowrap">VEGFR-2</FONT> and <FONT STYLE="white-space:nowrap">VEGFR-3.</FONT> <FONT STYLE="white-space:nowrap">OPT-302</FONT> is comprised of the first three extracellular domains of human <FONT
STYLE="white-space:nowrap">VEGFR-3,</FONT> fused to the Fc domain, or the constant fragment of human immunoglobulin
G</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUB STYLE="vertical-align:baseline; position:relative; top:.4ex">1</SUB></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">, or IgG</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUB STYLE="vertical-align:baseline; position:relative; top:.4ex">1</SUB></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">, as illustrated in the figure below.
<FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D</FONT> function independent of, but in parallel with, <FONT STYLE="white-space:nowrap">VEGF-A</FONT> to drive neovascularization and vascular leakage, key
hallmarks of both wet AMD and DME. In addition, treatment with <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors leads to upregulation of <FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D</FONT> to
compensate for <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibition, which may represent an important mechanism of clinical resistance to <FONT STYLE="white-space:nowrap">VEGF-A</FONT> monotherapy. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Structure of
<FONT STYLE="white-space:nowrap">OPT-302</FONT> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g03q94.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ligand trap therapeutics
that include the receptor-binding domains for other ligands have been approved for a number of indications. One such agent is aflibercept, marketed as Eylea, a ligand trap consisting of extracellular domains of
<FONT STYLE="white-space:nowrap">VEGFR-1</FONT> and <FONT STYLE="white-space:nowrap">VEGFR-2,</FONT> which primarily mediates its activity by binding and inhibiting <FONT STYLE="white-space:nowrap">VEGF-A.</FONT> Aflibercept has marketing approval
for the treatment of wet AMD, DME, macular edema secondary to RVO and DR. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">101
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Wet AMD </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AMD is a chronic, progressive disease of the macula, a part of the retina containing the greatest concentration
of light-sensing cells responsible for detailed, high visual acuity and central vision. The development of AMD is strongly associated with age, affecting up to 40% of individuals over the age of 75. There are two forms of AMD, dry AMD and wet AMD.
Dry AMD is the most common form, representing approximately 85% to 90% of all AMD cases. However, dry AMD can develop into wet AMD, and wet AMD accounts for 90% of the severe vision loss associated with the disease. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Wet AMD is a rapidly progressing disease with loss of central
vision developing over a period of weeks to months, and is the leading cause of vision loss for individuals over the age of 50. The most common symptoms of wet AMD are loss of central vision, distortion of objects or blurred vision. Peripheral
vision usually remains intact. The disease typically affects patients initially in one eye, with a high likelihood of it occurring in the second eye over time. If left untreated, wet AMD can lead to rapid loss of visual acuity and blindness,
adversely impacting the patient&#146;s ability to conduct daily activities, such as driving and reading. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Wet AMD occurs when new blood vessels in the choroid, or the vascular layer in the eye just under the retina, intrude into the retinal
layers and leak fluid. The formation of these new blood vessels is referred to as CNV. These newly formed vessels are highly permeable, which can lead to fluid accumulation and adversely affect sensory cells in the retina. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Wet AMD can be classified as occult or classic, based on the
neovascular pattern within lesions. In occult lesions, all of the blood vessels are below the retinal pigment epithelium, or RPE, and the areas on angiograms have a stippled appearance. Classic lesions, by contrast, appear as well-demarcated areas
on angiograms due to neovascular blood vessels being located above the RPE. Classic lesions are further subdivided into predominantly classic if 50% or more of the blood vessels are above the RPE, and minimally classic, if greater than 0% and less
than 50% of the blood vessels are below the RPE. Classic-containing lesions tend to be the most responsive to <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Classifications of Wet AMD Based on Neovascular Lesion
Pattern </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g37q51.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There is a further <FONT
STYLE="white-space:nowrap">sub-type</FONT> of wet AMD lesion referred to as retinal angiomatous proliferation, or RAP. RAP lesions are a type of CNV in which neovascularization in the retina protrudes into the
<FONT STYLE="white-space:nowrap">sub-retinal</FONT> space and connects to the choroidal circulation. Between 10% and 21% of wet AMD patients have RAP lesions which are more commonly found in older Caucasian patients. Although there are no therapies
specifically approved to treat RAP lesions, patients are typically treated with <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">PCV is a further <FONT STYLE="white-space:nowrap">sub-type</FONT> of wet AMD. PCV is an abnormality of inner choroidal vessels that causes
dilations in the blood vessels in the retina that resemble polyps, known as polypoidal protrusions. PCV typically </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">102
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
does not respond well to <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitor therapies and many patients are diagnosed with PCV only after they fail to respond to these therapies. There is a
high prevalence of PCV in Asian countries, with between 23% and 54% of patients with presumed cases of wet AMD in Japan having PCV. Prevalence rates of between 4% and 10% have been reported in Caucasian patients with presumed cases of wet AMD.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Current Treatments for Wet AMD and Their
Limitations </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There are four <FONT
STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors approved by the FDA for the treatment of wet AMD, all of which are administered by regular intravitreal injections as monotherapy. These <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors
include: the <FONT STYLE="white-space:nowrap">VEGF-A</FONT> specific antibody ranibizumab, the antibody fragment brolucizumab (Beovu) and the VEGFR-based ligand trap aflibercept. The <FONT STYLE="white-space:nowrap">VEGF-A</FONT> antibody,
bevacizumab, an FDA approved therapy for colorectal and other cancers, is also used <FONT STYLE="white-space:nowrap">off-label</FONT> by many physicians to treat wet AMD. In addition, pegaptanib sodium (Macugen) is an aptamer or antibody-like RNA
construct that inhibits <FONT STYLE="white-space:nowrap">VEGF-A</FONT> but is now infrequently administered following the approval of biologic <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors. Recent clinical development has focused on
maintaining vision gains with a <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitor whilst reducing the number of injections. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors stabilize loss vision in over 90% of wet AMD patients. However, the
effectiveness of these therapies in many patients is limited. Improvements of <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>15 letters of visual acuity typically occur in less than 40% of treated patients. In addition, despite regular treatment with
a <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitor, many patients have insufficient gains in visual acuity to resume routine daily activities such as driving and reading. Chronic vision loss can also occur despite ongoing treatment with an <FONT
STYLE="white-space:nowrap">anti-VEGF-A</FONT> inhibitor. Retrospective and prospective analyses of patients treated with <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitor therapies for five years have found that, after initial gains in visual
function following one year of treatment, many patients then had a gradual decline in visual acuity in subsequent years, resulting in the eventual reversal of the majority of gains. Treatment options are limited for patients who do not respond
adequately or experience visual decline despite ongoing therapy with standard of care <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors, and typically involve switching treatment from one <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT>
monotherapy to another with minimal additional visual benefit achieved. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Market Opportunity for the Treatment of Wet AMD </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Wet AMD affects approximately 1&nbsp;million people in the United States and 2.5&nbsp;million in Europe. Combined annual worldwide sales
of ranibizumab and aflibercept were over $11.9&nbsp;billion in 2019. In addition, nearly half of wet AMD patients are treated with bevacizumab as a lower cost alternative <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy. As the risk of
developing wet AMD increases with age, it is predicted that the overall aging of the population will result in a significant increase in the number of wet AMD cases, both in the United States and worldwide. Given the suboptimal clinical responses
that many patients experience despite receiving standard of care treatments, we believe there is a significant and expanding market opportunity for novel therapies that can improve vision in patients with wet AMD. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe that
<FONT STYLE="white-space:nowrap">OPT-302,</FONT> used in combination with standard of care <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors, can address the significant unmet need for wet AMD patients by providing improved outcomes over
that which can be achieved by inhibiting <FONT STYLE="white-space:nowrap">VEGF-A</FONT> alone. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Phase 1/2a Clinical Trial Results in Wet AMD </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2017, we completed a Phase 1/2a clinical trial of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in wet AMD patients under an
investigational new drug, or IND, application accepted by the FDA in 2015. The trial was divided into two parts. Part 1 was a Phase 1 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> <FONT
STYLE="white-space:nowrap">20-patient</FONT> dose-escalation study in which <FONT STYLE="white-space:nowrap">OPT-302</FONT> was administered at three escalating doses (0.3 mg, 1.0 mg or 2.0 mg), either in combination with 0.5 mg ranibizumab or alone
as a 2.0 mg monotherapy, once every four weeks for a total of three doses, with a <FONT STYLE="white-space:nowrap">follow-up</FONT> visit at week 12. Part 2 was a Phase 2a <FONT STYLE="white-space:nowrap">31-patient</FONT> dose-expansion trial in
which 2.0 mg <FONT STYLE="white-space:nowrap">OPT-302</FONT> was administered in combination with ranibizumab or as a monotherapy once every four weeks for a total of three doses, with a <FONT STYLE="white-space:nowrap">follow-up</FONT> visit at
week </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">103
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
12. Of the 51 patients dosed, 49% were treatment naive and 51% were previously treated with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy. The previously-treated patients had
received an average of 17 prior treatments, equating to prior treatment over an average of 1.3 years, of an intravitreal <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitor prior to enrolling in the trial. The Phase 1/2a trial was conducted at
14 trial sites in the United States. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT
STYLE="white-space:nowrap">OPT-302</FONT> was well tolerated up to the highest dose tested both in combination with ranibizumab and as a monotherapy. No dose-limiting toxicities, or DLTs, were observed and the maximum tolerated dose, or MTD, was not
reached. There were no treatment-related serious adverse events, or SAEs. The most common TEAEs were conjunctival hemorrhage, eye pain and corneal inflammation mainly related to the intravitreal injection procedure. TEAEs did not lead to permanent
discontinuation of the study for any patient. The pharmacokinetic profile of <FONT STYLE="white-space:nowrap">OPT-302</FONT> was similar in the absence or presence of ranibizumab, and there was no evidence of
<FONT STYLE="white-space:nowrap">OPT-302</FONT> immunogenicity in this clinical trial. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Although the focus of this trial was safety, we also observed preliminary signals of clinical benefit. Improvements in visual acuity were observed in treatment-naive patients as well as patients
previously treated with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy, as measured by the number of letters that could be read on a standard eye chart following <FONT STYLE="white-space:nowrap">OPT-302</FONT> monotherapy and <FONT
STYLE="white-space:nowrap">OPT-302</FONT> combination therapy. As illustrated in the figure below, after 12 weeks, in patients across all dose groups, the mean change in visual acuity from baseline increased by +10.8 letters in treatment-naive
patients and +4.9 letters in previously treated patients who received <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy. While this <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT>
trial did not have a ranibizumab monotherapy group, published historical results from the pivotal ranibizumab monotherapy Phase 3 MARINA trial reported a +5.9 letter improvement in visual acuity in treatment-naive patients at week 12. The Phase 3
MARINA trial recruited patients with similar lesion types as those recruited into our Phase 2a trial. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Mean Change in Visual Acuity from Baseline to Week 12 in Treatment-Naive and Previously-Treated Wet AMD Patients Administered <FONT
STYLE="white-space:nowrap">OPT-302</FONT> in Combination with Ranibizumab </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g02f26.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, improvements
in visual acuity following treatment with <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy were consistent with anatomical outcomes, such as reductions in intraretinal and subretinal fluid. Retinal thickness, which is assessed by
spectral domain optical coherence tomography, or <FONT STYLE="white-space:nowrap">SD-OCT,</FONT> using a standard criterion called central subfield thickness, or CST, was also reduced following <FONT STYLE="white-space:nowrap">OPT-302</FONT>
combination therapy. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">104
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Phase 2b Clinical Trial Results in Wet AMD </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on the positive results of the Phase 1/2a trial, we
completed an international, multi-center, double-masked Phase 2b clinical trial of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with ranibizumab in a total of 366 treatment-naive patients in August 2019. As illustrated in the
figure below, patients were randomized into three groups to receive either 0.5 mg or 2.0 mg <FONT STYLE="white-space:nowrap">OPT-302</FONT> with 0.5 mg ranibizumab or ranibizumab monotherapy, which included a sham injection. A sham intravitreal
injection involves pressing a syringe hub against the surface of the eye to mimic an intravitreal injection so that the patient remains masked to the treatment group to which they have been randomized. Administration was by intravitreal injection
once every four weeks for 20 weeks (six treatments in total). The primary endpoint of the clinical trial was the mean change in BCVA from baseline on the ETDRS standardized eye chart at week 24. Secondary outcome measures included the proportion of
patients gaining <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>15 letters in BCVA, changes in retinal thickness, change in intraretinal and subretinal fluid and proportion of patients losing <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>15 letters
in BCVA. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Design of the Phase 2b Clinical Trial
of <FONT STYLE="white-space:nowrap">OPT-302</FONT> with Ranibizumab in Wet AMD </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g58w10.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As illustrated in the
figure below, 366 treatment-naive patients were randomized 1:1:1 to each of the three treatment groups. We used data from the 362 patients who had a baseline assessment of their visual acuity and completed at least one post-dose visit as the
modified intent to treat population, or mITT, in all analyses. Key inclusion criteria for patients in the trial included CNV classified as either occult, minimally classic or predominantly classic, and BCVA on the ETDRS standardized eye chart of <FONT
STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>25 and <FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT>60 letters. The Phase 2b trial was conducted at 109 trial sites in the United States, Europe, Israel and the United Kingdom. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">105
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Patient Distribution in the Phase 2b Clinical Trial in Wet AMD </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g59e21.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Q4W refers to
administration every four weeks. IVT refers to administration by intravitreal injection. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Improvements in Visual Acuity </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Phase 2b clinical trial met the primary endpoint, demonstrating a statistically significant superior mean gain in visual acuity at week 24 compared to baseline in the 2.0 mg <FONT
STYLE="white-space:nowrap">OPT-302</FONT> combination therapy group compared to the ranibizumab monotherapy group. The figure below illustrates patients in the 2.0 mg <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy group had a
mean visual acuity improvement of +14.22 letters relative to baseline, compared to +10.84 letters for those treated with ranibizumab monotherapy at week 24 (p=0.0107). This represents a statistically significant benefit of +3.4 letters and a greater
than 30% relative improvement in vision outcomes in the <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination group compared to ranibizumab monotherapy. Evidence of improved visual acuity was observed beginning as early as week 8 and continued
throughout the course of the trial to week 24. Mean visual acuity in the lower dose 0.5 mg <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy group was not significantly different from the ranibizumab monotherapy group. However,
evidence of a dose response was observed between the 2.0 mg and 0.5 mg <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy groups on several anatomical outcomes, such as retinal thickness and the proportion of patients with
intraretinal and subretinal fluid at week 24. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">106
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Mean Change in Visual Acuity from Baseline to Week 24 in Treatment-Naive Wet AMD
Patients Administered Ranibizumab Monotherapy or <FONT STYLE="white-space:nowrap">OPT-302</FONT> Combination Therapy </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g60r81.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Error bars shown in all
figures represent the SEM, or the standard error of the mean. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Secondary outcome measurements from the trial were also supportive of the primary endpoint. As illustrated in the figure below, we observed a greater proportion of patients gaining <FONT
STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>15, <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>10 and <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>5 letters in the 2.0 mg <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy group compared
to the ranibizumab monotherapy group. In addition, the proportion of patients losing <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>15, <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>10 and <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>5 letters was
lower in the 2.0 mg <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy group compared to the ranibizumab monotherapy group. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">107
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Greater Proportion of Patients Gaining, and Fewer Patients Losing, </B><FONT
STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT><B></B><B>15, </B><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT><B></B><B>10 and </B><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT><B></B><B>5 Letters with <FONT STYLE="white-space:nowrap">OPT-302</FONT>
Combination Therapy Compared to Ranibizumab Monotherapy </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g61k18.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Reductions in Retinal
Thickness and Fluid </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to the
statistically significant improvement in visual acuity, treatment with <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy led to greater reductions in retinal thickness. The reductions in retinal thickness in patients is consistent
with less fluid accumulation in the retina and reduced disease severity as increased fluid accumulation in the retina is associated with the loss of visual acuity in wet AMD patients. The figure below depicts the greater mean reduction in retinal
thickness in the <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy group compared to the ranibizumab monotherapy group at week 24. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">108
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Greater Reduction in Retinal Thickness from Baseline to Week 24 following <FONT
STYLE="white-space:nowrap">OPT-302</FONT> Combination Therapy Compared to Ranibizumab Monotherapy </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g12r10.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fewer patients in the <FONT
STYLE="white-space:nowrap">OPT-302</FONT> combination therapy group had subretinal fluid and intraretinal fluid present compared to the ranibizumab monotherapy group. The presence of subretinal fluid is a hallmark of wet AMD and its resolution is
referred to as &#147;drying&#148; of the retina while intraretinal fluid is a prognostic biomarker for poor visual acuity and <FONT STYLE="white-space:nowrap">sub-optimal</FONT> response to <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT>
therapies. As illustrated in the figure below, there were approximately 10% fewer patients with subretinal fluid and 5% fewer patients with intraretinal fluid following administration of <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination
therapy compared to ranibizumab monotherapy. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Fewer Patients with Subretinal and Intraretinal Fluid Present at Week 24 Following <FONT STYLE="white-space:nowrap">OPT-302</FONT>
Combination Therapy Compared to Ranibizumab Monotherapy </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g12q20.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">109
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Greater improvements in anatomical indicators of disease severity, including on
exploratory endpoints of mean reduction in total lesion area and CNV area, were observed in the <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy group compared to ranibizumab monotherapy. As illustrated in the figure below, the
patients treated with <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy had an approximately 39% further reduction in both total lesion area and CNV area compared to ranibizumab monotherapy. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Greater Reduction in Total Lesion Area and CNV Area from
Baseline to Week 24 following <FONT STYLE="white-space:nowrap">OPT-302</FONT> Combination Therapy Compared to Ranibizumab Monotherapy </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g17z07.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Improved Therapeutic
Outcomes in Wet AMD Lesion Subtypes </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A number
of <FONT STYLE="white-space:nowrap">pre-specified</FONT> subgroup and exploratory analyses were incorporated into the Phase 2b trial design in order to identify those wet AMD patients who may respond best to
<FONT STYLE="white-space:nowrap">OPT-302.</FONT> The Phase 2b trial randomized patients with a broad range of lesion morphologies including occult, minimally classic and predominantly classic lesions. In addition, the Phase 2b trial investigated
efficacy in post-hoc analyses in other wet AMD subtypes, including PCV and RAP. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Patients enrolled in our Phase 2b trial consisted of 44% occult, 43% minimally classic and 13% predominantly classic lesion types, which is similar to the distribution reported in treatment-naive wet AMD
patients. Predominantly classic patients typically respond well to <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitor therapy and an additive benefit of <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy could not be discerned
in this small patient group of only 15 patients per treatment arm. The majority of patients randomized in the Phase 2b trial had occult or minimally classic lesions. These patients did not respond as well to ranibizumab monotherapy as those with
predominantly classic lesions. Patients with occult and minimally classic lesions treated with <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy experienced improvement in visual acuity beginning at week 8 and persisting through
week 24 compared to ranibizumab monotherapy. The figure below illustrates the mean change in visual acuity over 24 weeks in each of the lesion classifications treated with <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy compared
to ranibizumab monotherapy. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">110
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Mean Change in Visual Acuity from Baseline to Week 24 in Wet AMD Lesion Types
Following <FONT STYLE="white-space:nowrap">OPT-302</FONT> Combination Therapy Compared to Ranibizumab Monotherapy </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g38g34.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In a post-hoc analysis, in
the occult lesion subgroup, the mean visual acuity gain from baseline to week 24 in the <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy group was +16.2 letters (n=53), compared to +10.2 letters in the ranibizumab monotherapy
group (n=51), a benefit of +6.0 letters. In addition, in the minimally classic subgroup, the mean visual acuity gain from baseline to week 24 in the <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy group was +13.7 letters (n=53),
compared to +11.1 letters in the ranibizumab monotherapy group (n=53), a benefit of +2.7 letters. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In particular, in the occult lesion subgroup, we observed a greater proportion of patients gaining <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>15 and <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>10
letters in the <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy group compared to the ranibizumab monotherapy group (approximately 22% and 19% over ranibizumab monotherapy, respectively). In the minimally classic subgroup, we
observed a greater proportion of patients (approximately 10% over ranibizumab monotherapy) gaining <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>10 letters in the <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy group compared to
the ranibizumab monotherapy group. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Gains in
Visual Acuity from Baseline to Week 24 in Patients with Occult and Minimally Classic Lesions Following <FONT STYLE="white-space:nowrap">OPT-302</FONT> Combination Therapy Compared to Ranibizumab Monotherapy </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g60u79.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">111
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In patients with occult lesions, treatment with
<FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy also led to a greater mean reduction in retinal thickness of <FONT STYLE="white-space:nowrap">-134.6</FONT> &micro;m from baseline compared to
<FONT STYLE="white-space:nowrap">-103.5</FONT> &micro;m for ranibizumab monotherapy. <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy did not have greater clinical benefit in the reduction of retinal thickness in minimally classic
lesions, compared to the ranibizumab monotherapy group. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In patients with occult lesions, approximately 13% and 12% fewer patients had subretinal fluid and intraretinal fluid, respectively, as compared to ranibizumab monotherapy at week 24. In patients with
minimally classic lesions, approximately 2% fewer patients treated with <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy had subretinal fluid and intraretinal fluid compared to patients treated with ranibizumab monotherapy at week
24. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As shown in the figures below, by week 24,
patients with occult and minimally classic lesions also had greater reductions in both wet AMD total lesion area and CNV area following <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy compared to patients receiving ranibizumab
monotherapy. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Greater Reduction in Total Lesion
Area from Baseline to Week 24 in Patients with Occult and Minimally Classic Lesions Following <FONT STYLE="white-space:nowrap">OPT-302</FONT> Combination Therapy Compared to Ranibizumab Monotherapy </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g70z93.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">112
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Greater Reduction in CNV Area from Baseline to Week 24 in Patients with Occult and
Minimally Classic Lesions Following <FONT STYLE="white-space:nowrap">OPT-302</FONT> Combination Therapy Compared to Ranibizumab Monotherapy </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g29f80.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Classification of lesions
following treatment with <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy or ranibizumab monotherapy suggests that virtually all lesions shifted toward an occult morphology or were either fibrotic with no active CNV or quiescent
by week 24. <FONT STYLE="white-space:nowrap">OPT-302</FONT> improved visual acuity to the greatest extent in occult lesions compared to ranibizumab monotherapy. While these results were generated in treatment-naive wet AMD patients, these results
suggest that <FONT STYLE="white-space:nowrap">OPT-302</FONT> has the potential to provide benefit to patients who have been previously treated with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>RAP and PCV Lesion Subtypes </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In our Phase 2b clinical trial, over 85% of patients
enrolled did not have RAP lesions detected at randomization and these patients responded better to <FONT STYLE="white-space:nowrap">OPT-302</FONT> than patients with RAP lesions. In patients without RAP lesions, the mean visual acuity gain from
baseline to week 24 was +15.0 letters (n=103) with <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy, compared to +10.6 letters for those treated with ranibizumab monotherapy (n=102), a benefit of +4.4 letters. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">113
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Mean Change in Visual Acuity from Baseline to Week 24 in Patients Without RAP Lesions
Following <FONT STYLE="white-space:nowrap">OPT-302</FONT> Combination Therapy Compared to Ranibizumab Monotherapy </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g02q76.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In patients without RAP
lesions who had occult or minimally classic lesions, the mean visual acuity gain from baseline to week 24 was +16.1 letters with <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy (n=88) compared to +10.3 letters for those treated
with ranibizumab monotherapy (n=87), a benefit of +5.7 letters. Patients with RAP absent occult lesions demonstrated a mean visual acuity gain at week 24 of +16.7 letters with <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy
(n=49) compared to +10.1 letters for those treated with ranibizumab monotherapy (n=47), a gain of +6.5 letters. Patients with RAP absent minimally classic lesions demonstrated a mean visual acuity gain at week 24 of +15.5 letters with <FONT
STYLE="white-space:nowrap">OPT-302</FONT> combination therapy (n=39) compared to +10.7 letters for those treated with ranibizumab monotherapy (n=40), a gain of +4.7 letters. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Improved Therapeutic Outcomes of <FONT
STYLE="white-space:nowrap">OPT-302</FONT> in PCV Lesions </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In patients with PCV lesions, the mean visual acuity gain from baseline to week 24 in the <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy group was +13.5 letters (n=22), compared to
+6.9 letters in the ranibizumab monotherapy group (n=20). This equates to a benefit of +6.7 letters and is almost a <FONT STYLE="white-space:nowrap">two-fold</FONT> improvement in visual acuity gain observed from baseline following <FONT
STYLE="white-space:nowrap">OPT-302</FONT> combination therapy. Ranibizumab monotherapy was not observed to be as effective in patients with PCV compared to other wet AMD subtypes. In patients without PCV, the mean visual acuity gain from baseline to
week 24 in the <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy group was +14.2 letters (n=99), compared to +11.5 letters in the ranibizumab monotherapy group (n=98), a benefit of +2.7 letters. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Safety and Tolerability </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">OPT-302</FONT> was well
tolerated in this Phase 2b trial with a very low incidence of ocular inflammation and no safety issues identified with addition of <FONT STYLE="white-space:nowrap">OPT-302</FONT> to ranibizumab intravitreal therapy. The incidence of ocular TEAEs was
similar in <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination groups compared to the ranibizumab monotherapy group. TEAEs were considered potentially treatment related in approximately 15% of patients. The most common treatment-related
TEAEs were eye pain, vitreous floaters, eye irritation and raised intraocular pressure. One patient discontinued from the trial due to a TEAE, which was not considered treatment related. Three patients treated with
<FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy had potentially treatment-related SAEs: one case each of vitritis, endophthalmitis and myocardial infarction. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">114
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Planned Pivotal Phase 3 Clinical Trials in Wet AMD </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are planning to initiate two concurrent pivotal Phase 3
clinical trials for the treatment of treatment-naive patients with wet AMD. These double-masked, sham-controlled Phase 3 clinical trials will assess the efficacy and safety of 2.0 mg of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination
with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy for treatment-naive patients with wet AMD compared to a standard of care <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapy. The primary endpoint of both trials will be
the mean change in visual acuity from baseline to week 52. Patients will continue to be dosed until week 96 to further assess long-term safety at week 100. We intend to finalize the Phase 3 trial protocols following the completion of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-Phase</FONT></FONT> 2 regulatory meetings with the FDA and the EMA. We expect to initiate the trials in the first half of 2021 and to report topline data in 2023. If the results of
the Phase 3 clinical trials are favorable, we intend to file for marketing approval for <FONT STYLE="white-space:nowrap">OPT-302</FONT> for the treatment of wet AMD in the United States, European Union and other territories. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Diabetic Macular Edema </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Diabetic macular edema is a complication of DR, a disease
affecting the blood vessels of the retina in diabetics. Chronically elevated blood glucose levels, or hyperglycemia, causes damage to the small blood vessels or capillaries in the retina in patients with diabetes. The consequent chronic decrease in
oxygen supply to retinal cells results in tissue damage that is referred to as DR. Approximately <FONT STYLE="white-space:nowrap">one-third</FONT> of patients with DR or up to 10% of diabetics develop DME, which is characterized by accumulation of
fluid and retinal thickening within the macula and is responsible for most of the central visual loss experienced in the diabetic population. Central-involved DME is diagnosed when swelling or edema occurs from fluid leaking into the central fovea
region of the macula. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Current Treatments
for DME and Their Limitations </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT
STYLE="white-space:nowrap">VEGF-A</FONT> inhibitor therapy is the first-line standard of care therapy for DME. Both ranibizumab and aflibercept are approved for the treatment of DME, and similarly to wet AMD, many patients receive bevacizumab as an <FONT
STYLE="white-space:nowrap">off-label,</FONT> lower cost alternative <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitor therapy. Many patients with central-involved DME require near-monthly administration of intravitreal <FONT
STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors during the first 12 months of treatment, with fewer injections needed in subsequent years to maintain clinical benefit. <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors have largely
replaced the use of laser photocoagulation as a treatment for DME. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The anti-inflammatory corticosteroid therapies dexamethasone (Ozurdex) and fluocinolone acetonide (Illuvian) are also approved for use in central-involved DME. These agents however, are rarely used as
first-line therapy due to inferior visual acuity outcomes compared to <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy. Patients with persistent DME and who are insufficiently responsive to
<FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy have shown some treatment benefit with intravitreal corticosteroids. However, as intravitreal corticosteroids are associated with high rates of ocular adverse events including cataract
progression and intraocular pressure elevation, switching to corticosteroids from an <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy with a <FONT STYLE="white-space:nowrap">sub-optimal</FONT> response needs to be carefully considered.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Despite the widespread use of treatments
targeting <FONT STYLE="white-space:nowrap">VEGF-A</FONT> in the management of DME, there is still a significant unmet need as many patients demonstrate a <FONT STYLE="white-space:nowrap">sub-optimal</FONT> response, remain treatment refractory or
require frequent injections for persistent leakage in the macula. A substantial proportion of patients with central-involved DME treated with <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors do not show reductions in the fluid or clinically
meaningful improvement in visual acuity. This resistance may occur as treatment selective <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapies do not fully address all of the factors involved in the pathogenesis of DME. As such,
combination therapies targeting alternative factors and pathways have the potential for improved clinical outcomes in DME patients. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Market Opportunity for the Treatment of DME </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">It is estimated that between 1.3&nbsp;million and
2.0&nbsp;million people worldwide, including 14% of Type 1 diabetics and 6% of Type 2 diabetics, have DME . The risk of developing DME increases with time. According </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">115
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
to the Wisconsin Epidemiologic Study of Diabetic Retinopathy, after 10 years of <FONT STYLE="white-space:nowrap">follow-up,</FONT> 20% of patients with Type 1 diabetes and 25% of those with Type
2 diabetes will have developed DME. Ranibizumab and aflibercept, two <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors approved for the treatment of DME, generated combined annual worldwide sales of over $11.9&nbsp;billion in 2019.
Approximately 22% of these sales are attributable to the treatment of DME. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Potential for <FONT STYLE="white-space:nowrap">OPT-302</FONT> in DME </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe that as a potent inhibitor of <FONT STYLE="white-space:nowrap">VEGF-C</FONT> and
<FONT STYLE="white-space:nowrap">VEGF-D,</FONT> <FONT STYLE="white-space:nowrap">OPT-302</FONT> has the potential to provide significant therapeutic benefit to patients affected by DME. Although the underlying causes of wet AMD and DME differ,
members of the VEGF family play a role in the progression of both diseases. <FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D</FONT> and their receptors are specifically implicated in the progression of
diabetes. For example, patients with diabetes have higher levels of <FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-A</FONT> and increased expression of both <FONT STYLE="white-space:nowrap">VEGFR-2</FONT>
and <FONT STYLE="white-space:nowrap">VEGFR-3</FONT> in the retina compared to <FONT STYLE="white-space:nowrap">non-diabetics.</FONT> The <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors ranibizumab and aflibercept, originally approved for
treatment of wet AMD patients, have also been approved for treatment of DME patients. Similar to wet AMD, bevacizumab is also frequently used <FONT STYLE="white-space:nowrap">off-label</FONT> as a treatment for DME. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In our completed Phase 1b dose escalation clinical trial in
patients with persistent DME, we observed promising evidence of a dose response of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with aflibercept, including further improvements in visual acuity despite patients&#146; having been
previously treated with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy. In our completed Phase 2a clinical trial, we observed improved visual acuity outcomes and evidence of a reduction in retinal thickness in treatment-refractory DME
patients following <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Phase 1b Clinical Trial of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in DME </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2018, we completed a Phase 1b dose-escalation clinical trial of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with
aflibercept in nine patients with persistent DME that were previously treated with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies. Patients were administered three escalating doses (0.3 mg, 1.0 mg or 2.0 mg) of <FONT
STYLE="white-space:nowrap">OPT-302</FONT> in combination with 2.0 mg aflibercept by intravitreal injections once every four weeks for a total of three doses. The primary analysis was conducted at week 12, four weeks after the final dose. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Across all nine patients in the Phase 1b trial, a mean gain
in visual acuity of +7.7 letters from baseline to week 12 was observed across all dose groups, with a clear dose response of improved visual acuity with increasing doses of <FONT STYLE="white-space:nowrap">OPT-302.</FONT> There was a corresponding
mean decrease in retinal thickness at week 12 of <FONT STYLE="white-space:nowrap">-71</FONT> &micro;m from baseline and six of nine (67%) patients had a <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>50% reduction in excess foveal thickness.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">116
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Dose-dependent Increases in Visual Acuity and Reduction in Retinal Thickness at Week
12 Following Treatment with <FONT STYLE="white-space:nowrap">OPT-302</FONT> in Combination with Aflibercept </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g95s99.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Five of the nine patients
in the Phase 1b trial had bilateral, persistent treatment-refractory DME. In these patients, study eyes received <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with aflibercept, and fellow eyes received standard of care <FONT
STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapy. In these bilateral disease patients, the mean change in visual acuity from baseline to week 12 was +10.0 letters in the study eye and +2.6 letters in the fellow eye. The corresponding
reduction in retinal thickness from baseline to week 12 was <FONT STYLE="white-space:nowrap">-80</FONT> &micro;m for <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination treated study eyes, compared to
<FONT STYLE="white-space:nowrap">-6</FONT> &micro;m in fellow eyes that received <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapy. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>In Patients with Bilateral DME, <FONT STYLE="white-space:nowrap">OPT-302</FONT> Combination Therapy Improved Visual Acuity and Reduced
Retinal Thickness Compared to Fellow Eyes Treated with <FONT STYLE="white-space:nowrap">Anti-VEGF-A</FONT> Monotherapy </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g29k54.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">* Patients with bilateral disease and persistent DME in the fellow eye receiving anti-VEGF-A
(ranibizumab or aflibercept) monotherapy. Prior anti-VEGF-A therapy in Fellow Eyes BL to Week 12 (5 patients): 3x Aflibercept, 3x Ranibizumab, 1x Ranibizumab, 4x Ranibizumab, 3x Aflibercept. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">117
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with aflibercept was
well tolerated at all dose levels, with no DLTs and the MTD was not reached. There were no treatment-related clinically significant changes in intraocular pressure, electrocardiograms or vital signs. The most common AEs were related to the
intravitreal injection procedure. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Phase 2a
Clinical Trial of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in DME </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Based on the positive results of our Phase 1b trial, we reported outcomes from a Phase 2a trial in persistent DME patients refractory to <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy in June
2020. Similar to the Phase 1b trial, this <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial was designed to investigate the ability of <FONT STYLE="white-space:nowrap">OPT-302</FONT> to improve
outcomes in persistent DME patients. The primary endpoints were clinical response rate in visual acuity as well as safety and tolerability. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Clinical Trial Design </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This Phase 2a trial was a randomized, double-masked, dose expansion trial that enrolled patients diagnosed with persistent center-involved
DME despite regular administration of prior <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapy. These patients are considered to be a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-treat</FONT></FONT>
patient population since they have received prior <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapy and experienced a suboptimal clinical response. In our trial, these patients were defined as having visual acuity between 20/40 and 20/320
Snellen equivalent, or <FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT>73 and <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>24 BCVA letters on the ETDRS standardized eye chart, and retinal thickness of <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>320
&micro;m on <FONT STYLE="white-space:nowrap">SD-OCT.</FONT> In this Phase 2a trial, the mean number of prior intravitreal <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> injections was eight in each of the treatment groups, reflecting that the
patients recruited into this trial were heavily <FONT STYLE="white-space:nowrap">pre-treated,</FONT> with a mean of 39 days since the immediate prior injection to the start of the trial. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Phase 2a trial was conducted at 53 trial sites in the United States, Israel, Australia and Latvia. Of the
144 patients randomized in the trial, 115 patients conformed sufficiently with the trial protocol and were included in our analyses of clinical efficacy. Patients were randomized 2:1 to receive either 2.0 mg
<FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with 2.0 mg aflibercept or a sham injection and 2.0 mg aflibercept. Patients received intravitreal injections once every four weeks for a total of three doses. The primary analysis was
conducted at week 12, four weeks after the final dose. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Design of the Phase 2a Clinical Trial of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in Combination with Aflibercept in Persistent Diabetic Macular Edema </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g44c18.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">PRN refers to <I>pro re
nata</I>, or treatment on an as needed basis. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Improvements in Visual Acuity </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The primary efficacy endpoint of the trial was the clinical response rate, defined as the proportion of patients receiving <FONT
STYLE="white-space:nowrap">OPT-302</FONT> combination therapy that achieved a <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>5 letter gain in visual acuity at week 12 compared to baseline. Our predefined measure of success was a response rate of
greater than or equal to 38%, based on historical observations that show limited ability to achieve a <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>5 letter improvement in DME patients on long-term <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT>
monotherapy. As an exploratory trial, this Phase 2a was not powered to detect statistical significance of <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy compared to aflibercept monotherapy. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">118
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We observed that 52.8% of patients treated with
<FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy achieved a <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>5 letter improvement in visual acuity at week 12 compared to baseline, meeting the
<FONT STYLE="white-space:nowrap">pre-specified</FONT> primary efficacy endpoint for this trial. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The mean change in visual acuity at week 12 compared to baseline was +5.9 letters in patients receiving <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy and +6.1 letters in the
aflibercept monotherapy group. In the <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy group, the percentage of patients with visual acuity gains of <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>10 and <FONT
STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>15 letters was higher, and the percentage of patients who lost <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>5 letters was lower than that in the aflibercept monotherapy group. These measures of visual
function are shown in the figure below. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Measures of Visual Acuity at Week 12 Following <FONT STYLE="white-space:nowrap">OPT-302</FONT> Combination Therapy and Aflibercept
Monotherapy </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g42m12.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patients treated with <FONT
STYLE="white-space:nowrap">OPT-302</FONT> combination therapy also had decreased retinal thickness compared to aflibercept monotherapy, as shown in the figure below. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Greater Reduction in Retinal Thickness from Baseline to
Week 12 following <FONT STYLE="white-space:nowrap">OPT-302</FONT> Combination Therapy Compared to Aflibercept Monotherapy </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g42j16.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">119
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Prior Treatment History in Persistent DME Patients </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior studies have shown that DME patients with mild visual
acuity loss of 20/40 or better at baseline, show similar outcomes to any of the <FONT STYLE="white-space:nowrap">VEGF-A</FONT> therapies: ranibizumab, aflibercept and bevacizumab. However, in patients with poorer baseline vision of 20/50 or worse,
aflibercept has better outcomes compared to ranibizumab and bevacizumab over the first 12 months of treatment. It has also been shown that DME patients who experience inadequate responses to ranibizumab have achieved further anatomical and
functional improvements upon switching to aflibercept. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Due to the challenge of enrolling a large group of patients with identical prior treatment histories, we designed our Phase&nbsp;2a trial to accelerate enrollment by randomizing patients with variable
prior treatment histories. This strategy allowed us to more broadly understand the prior treatment history in persistent DME patients, which will inform the design of our future trials in DME. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In order to explore the importance of differences in prior treatment history, we collected detailed <FONT
STYLE="white-space:nowrap">anti-VEGF-A</FONT> treatment histories for patients enrolled in our Phase&nbsp;2a DME trial. Patients randomized into our Phase 2a trial had variable prior treatment histories which included infrequent or irregular dosing
and/or therapy with aflibercept, ranibizumab and bevacizumab. Post-hoc analyses of the results from our Phase 2a trial suggest that some patients may have benefitted from the increased efficacy of aflibercept and/or from the switch to aflibercept
therapy as administered in our trial on an every four-week dosing cycle. In the subset of patients who had only received aflibercept for their three prior <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> treatments on a regular basis immediately
before trial enrollment, referred to as treatment history of prior aflibercept, the mean improvement in visual acuity observed for the aflibercept monotherapy group was +3.4 letters (n=13), compared to a mean improvement of +7.4 letters for those
patients with more variable prior treatment history who received aflibercept monotherapy (n=27). This suggests that the majority of patients enrolled in the trial had not achieved a maximal response to all
<FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies prior to enrolling in the trial. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Due to the observed increase in treatment benefit for patients with a variable treatment history who then received aflibercept every four weeks in the trial, the subset of patients with a treatment
history of prior aflibercept may represent the most stringent and least variable patient population in which to test the ability of <FONT STYLE="white-space:nowrap">OPT-302</FONT> to provide additional benefit. In this more homogeneous patient
population, as shown in the figure below, patients administered <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy demonstrated a mean improvement in visual acuity of +6.6 letters (n=22) from baseline to week 12, compared to +3.4
letters (n=13) in the aflibercept monotherapy group. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Greater Gains in Visual Acuity following <FONT STYLE="white-space:nowrap">OPT-302</FONT> Combination Therapy in Patients with a
Treatment History of Prior Aflibercept </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g01q44.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">120
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, 27.3% of patients gained <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>10
letters and 9.1% gained <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>15 letters of visual acuity from baseline to week 12 following <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy. There were no patients with a treatment history
of prior aflibercept that gained <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>10 letters of visual acuity in the aflibercept monotherapy group. Furthermore, the proportion of patients who lost <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>1 letters
was 9.1% in the <FONT STYLE="white-space:nowrap">OPT-302</FONT> combination therapy group and 23.1% in the aflibercept monotherapy group. We believe that these results, as shown in the figures below, strongly support the potential of <FONT
STYLE="white-space:nowrap">OPT-302</FONT> to improve the visual acuity in patients with persistent DME despite prior treatment with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapy. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Proportion of Patients with a Treatment History of Prior
Aflibercept Who Gained and Lost Visual Acuity from Baseline to Week 12 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g54a02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In this subgroup of
patients with a treatment history of prior aflibercept, anatomical changes were consistent with functional visual acuity outcomes. As shown in the figure below, a greater mean reduction in retinal thickness was observed in the <FONT
STYLE="white-space:nowrap">OPT-302</FONT> combination therapy group compared to the aflibercept monotherapy group at week 12. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Greater Mean Reduction in Retinal Thickness following <FONT STYLE="white-space:nowrap">OPT-302</FONT> Combination Therapy in Patients
with a Treatment History of Prior Aflibercept </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g02a85.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">121
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Safety and Tolerability </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">OPT-302</FONT> combination
therapy was well tolerated. There was one potentially treatment-related SAE of cerebrovascular accident, or stroke, resulting in one patient discontinuing treatment who remained in the study. The most common TEAEs were conjunctival hemorrhage and
increased intraocular pressure and were mainly related to the intravitreal injection procedure. TEAEs did not lead to discontinuation of the study for any patient. The incidence of intra-ocular inflammation was low, occurring in one patient for each
treatment group, and the observed events were manageable and able to be resolved. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We now have extensive global clinical dosing experience demonstrating a favorable safety profile following repeated intravitreal administration of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in 399
patients, with over 1,850 doses of <FONT STYLE="white-space:nowrap">OPT-302</FONT> administered across three international clinical studies in two disease indications and in combination with the two leading standard of care <FONT
STYLE="white-space:nowrap">anti-VEGF-A</FONT> therapies, ranibizumab and aflibercept. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Retinal Vein Occlusion </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Based on the positive clinical data from our clinical trials of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in wet AMD and DME, we intend to prioritize future development in these two indications
while exploring potential opportunities to develop <FONT STYLE="white-space:nowrap">OPT-302</FONT> in other ophthalmic indications such as RVO, DR and other diseases involving aberrant CNV. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">RVO is a sight-threatening visual disorder resulting from blockage of one of the veins carrying blood out of
the retina. This blocked vein can leak blood and fluid resulting in swelling that can cause macular edema. Persistent, inadequately-treated macular edema associated with RVO can blur vision, cause significant loss in visual acuity and eventually
lead to blindness. Macular edema is the most common cause of vision loss in people who suffer from RVO. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Similar to wet AMD and DME, the first-line standard of care to treat macular edema associated with RVO is intravitreal <FONT
STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapy. <FONT STYLE="white-space:nowrap">VEGF-A</FONT> inhibitors however, are only effective in significantly improving vision in approximately 30% to 40% of patients with macular edema associated
with RVO above sham control. The prevalence of RVO in people over the age of 50 has been reported to be 0.7%, or approximately 1.8&nbsp;million people in the United States and Europe. Over 500,000 individuals in the United States and Europe have
macular edema associated with RVO. We believe that <FONT STYLE="white-space:nowrap">OPT-302</FONT> has the potential to bring therapeutic benefit to patients suffering from macular edema secondary to RVO. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Competition </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The biotechnology and pharmaceutical industries, and the ophthalmic disease subsector, are characterized by
rapidly advancing technologies, evolving understanding of disease etiology, intense competition and a strong emphasis on intellectual property. While we believe that <FONT STYLE="white-space:nowrap">OPT-302</FONT> and our knowledge and experience
provide us with certain competitive advantages, we face substantial potential competition from many different sources, including large and specialty pharmaceutical and biotechnology companies, academic research institutions and governmental agencies
and public and private research institutions. Many of our current or potential competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, manufacturing, <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> studies, conducting clinical trials and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being
concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also
compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for,
our programs. Accordingly, our competitors may be more successful than we may be in developing, commercializing and achieving widespread market acceptance. In addition, our competitors&#146; products may be more effective or more effectively
marketed </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">122
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
and sold than any treatment we or our development partners may commercialize and may render our product candidates obsolete or noncompetitive before we can recover the expenses related to
developing and commercializing our product candidates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are developing <FONT STYLE="white-space:nowrap">OPT-302</FONT> for the treatment of wet AMD and additional retinal disease indications, such as DME and RVO, together with certain combination agents.
Companies that have products that may compete with <FONT STYLE="white-space:nowrap">OPT-302</FONT> include Roche Group, Regeneron Pharmaceuticals, Inc. and Novartis AG, which have marketed <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT>
therapies including ranibizumab (Lucentis) and aflibercept (Eylea), each a standard of care treatment for wet AMD, and brolucizumab (Beovu), as well as Ocugen, Inc., which has a product candidate in development for the treatment of wet AMD and DME.
We are also aware of other companies that are working on therapies for the whole eye, including Santen, Inc. and Ocular Therapeutix, Inc. In addition, bevacizumab (Avastin), marketed by Genentech, Inc., is used
<FONT STYLE="white-space:nowrap">off-label</FONT> to treat wet AMD. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">It is possible that our competitors will succeed in developing technologies that are more effective than our product candidates or that would render our technology obsolete or noncompetitive, or will
succeed in developing biosimilar or interchangeable products for our product candidates. We anticipate that we will continue to face increasing competition in the future as new companies enter our market and scientific developments surrounding
biosimilars and other retinal therapies continue to accelerate, particularly once ranibizumab and aflibercept approach loss of exclusivity. We cannot predict to what extent the entry of biosimilars or other competing products will impact potential
future sales of our products or our product candidates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">With respect to our current and potential future product candidates, we believe that our ability to compete effectively and develop products that can be manufactured cost-effectively and marketed
successfully will depend on our ability to: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">advance the development of <FONT STYLE="white-space:nowrap">OPT-302</FONT> and any other product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">license additional technology; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">complete clinical trials which position our products for regulatory and commercial success; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">maintain a proprietary position in our products; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">obtain required government and other public and private approvals on a timely basis; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">attract and retain key personnel; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">commercialize effectively; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">obtain reimbursement for our products in approved indications; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">establish efficient manufacturing processes and supply chain; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">comply with applicable laws, regulations and regulatory requirements and restrictions with respect to our business, including the commercialization of
our products, including with respect to any changed or increased regulatory restrictions; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">enter into additional collaborations to advance the development and commercialization of our product candidates. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our Commercial License Arrangement with Selexis SA </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In October 2013, we entered into a commercial license
agreement, or the Selexis Agreement, with Selexis SA, or Selexis, under which Selexis granted us a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide, sublicensable license under certain patents,
<FONT STYLE="white-space:nowrap">know-how</FONT> and other intellectual property controlled by Selexis to use certain cell lines, deliverables and materials provide by Selexis to manufacture <FONT STYLE="white-space:nowrap">OPT-302</FONT> and
related products and to use, sale and otherwise exploit such products. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">123
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We paid Selexis a nominal upfront payment upon entering into the Selexis Agreement. We
are also required to make certain payments under the Selexis Agreement totaling approximately US$1.3&nbsp;million upon the achievement of certain development and commercial milestones. We are also obligated to pay a low single-digit running royalty
on worldwide net sales of the licensed products. Our royalty obligations will continue, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, until the expiration of the relevant patents, but will not extend beyond October 2024 in any event. After the expiration of the royalty term, our license will continue and become
full paid, perpetual and irrevocable. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Selexis
Agreement will expire on the date of expiration of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> of the license patents. Either party may terminate the Selexis Agreement for the other party&#146;s
uncured material breach or bankruptcy. We may also terminate the Selexis Agreement at any time upon prior notice to Selexis. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Intellectual Property </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of June&nbsp;30, 2020, we have rights to over 22 issued U.S. patents, over four U.S. patent applications, over 75 issued <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> patents and over eight pending <FONT STYLE="white-space:nowrap">non-U.S.</FONT> applications. All of our current issued patents and patent applications are projected to expire between August 2021 and
November 2034. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our owned and licensed patents and
patent applications include patents and patent applications that are directed to soluble forms of <FONT STYLE="white-space:nowrap">VEFGR-3,</FONT> including <FONT STYLE="white-space:nowrap">OPT-302,</FONT> both in the form of composition of matter
and method of use claims, including claims directed at the treatment of eye diseases such as wet AMD. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">With respect to <FONT STYLE="white-space:nowrap">OPT-302,</FONT> we own a patent family with two issued U.S. patents with claims covering
the composition of matter of <FONT STYLE="white-space:nowrap">OPT-302</FONT> and its use and/or nucleic acids, vectors, and host cells for producing it, one pending U.S. patent application, one issued European patent validated in 38 countries, over
six issued <FONT STYLE="white-space:nowrap">non-U.S.</FONT> patents in various countries including Japan, Australia, Singapore and Russia, and over nine pending <FONT STYLE="white-space:nowrap">non-U.S.</FONT> patent applications in various
countries including China, Korea, Canada and India. The issued patents and pending patent applications, if issued, are expected to expire in 2034, without taking into account any patent term extension. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The actual protection afforded by a patent, which can vary
from country to country, depends on the type of patent, the scope of its coverage as determined by the patent office or courts in the country, and the availability of legal remedies in the country. The information in the above list is based on our
current assessment of patents that we own or control or have exclusively licensed. The information is subject to revision, for example, in the event of changes in the law or legal rulings affecting our patents or if we become aware of new
information. Significant legal issues remain unresolved as to the extent and scope of available patent protection for biotechnology products and processes in the United States and other important markets outside the United States. We expect that
litigation will likely be necessary to determine the term, validity, enforceability and/or scope of certain of our patents and other proprietary rights. An adverse decision or ruling with respect to one or more of our patents could result in the
loss of patent protection for a product and, in turn, the introduction of competitor products or <FONT STYLE="white-space:nowrap">follow-on</FONT> biologics to the market earlier than anticipated. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patents expire, on a country by country basis, at various
times depending on various factors, including the filing date of the corresponding patent application(s), the availability of patent term adjustment, patent term extension and supplemental protection certificates and requirements for terminal
disclaimers. In most countries, including the United States, the patent term is 20 years from the earliest claimed filing date of <FONT STYLE="white-space:nowrap">a&nbsp;non-provisional&nbsp;patent</FONT> application or its foreign equivalent in the
applicable country. In the United States, a patent&#146;s term may, in certain cases, be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO in examining and granting a patent, or may be
shortened if a patent is terminally disclaimed over a commonly owned patent or a patent naming a common inventor and having an earlier expiration date. In the United States, a patent may also be eligible for limited patent term extension under the
Drug Price Competition and Patent Term Restoration Act of 1984, or Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">124
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent
applicable to each regulatory review period may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended, with extended rights limited to the approved product, its approved
uses, and/or its manufacture. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Although we believe
our owned and licensed patents and patent applications provide us with a competitive advantage, the patent positions of biotechnology and pharmaceutical companies can be uncertain and involve complex legal and factual questions. We may not be able
to develop patentable products or processes or obtain patents from pending patent applications. In the event of patent issuance, the patents may not be sufficient to protect the proprietary technology owned by or licensed to us or our partners. Our
current patents, or patents that issue on pending applications, may be challenged, invalidated, infringed or circumvented. In addition, changes to patent laws in the United States or in other countries may limit our ability to defend or enforce our
patents, or may apply retroactively to affect the term and/or scope of our patents. Our patents have been and may in the future be challenged by third parties in post-issuance administrative proceedings or in litigation as invalid, not infringed or
unenforceable under U.S. or foreign laws, or they may be infringed by third parties. As a result, we are or may be from time to time involved in the defense and enforcement of our patent or other intellectual property rights in a court of law and
administrative tribunals, such as in USPTO <I>inter partes</I> review or reexamination proceedings, foreign opposition proceedings or related legal and administrative proceedings in the United States and elsewhere. The costs of defending our patents
or enforcing our proprietary rights in post-issuance administrative proceedings or litigation may be substantial and the outcome can be uncertain. An adverse outcome may allow third parties to use our proprietary technologies without a license from
us. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Furthermore, we rely upon trade secrets and <FONT
STYLE="white-space:nowrap">know-how</FONT> and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, by using confidentiality and invention assignment
agreements with its commercial partners, collaborators, employees and consultants. These agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to grant it ownership of technologies
that are developed through a relationship with a third party. These agreements may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by
competitors. To the extent that our commercial partners, collaborators, employees and consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting <FONT
STYLE="white-space:nowrap">know-how</FONT> and inventions. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our commercial success will also depend in part on not infringing upon the proprietary rights of third parties. It is uncertain whether the issuance of any third-party patent would require us to alter its
development or commercial strategies for our product candidates or processes, or to obtain licenses or cease certain activities. Our breach of any license agreements or failure to obtain a license to proprietary rights that it may require to develop
or commercialize its future products may have an adverse impact on us. If third parties prepare and file patent applications in the United States that also claim technology to which we have rights, we may have to participate in interference or
derivation proceedings in the USPTO to determine priority of invention. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As of June&nbsp;30, 2020, we or our subsidiary have registered and own &#147;Opthea&#148; as a trademark in nine jurisdictions, including the United States and Europe. Other than the registered trademark
listed above, we currently rely on our unregistered trademarks, trade names and service marks, as well as our domain names and logos, as appropriate, to market our brands and to build and maintain brand recognition. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Government Regulation </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA and other regulatory authorities at federal, state,
and local levels, as well as in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling,
packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring, and post-approval reporting of biologics such as </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">125
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
those we are developing. We, along with third-party contractors, will be required to navigate the various nonclinical, clinical and commercial approval requirements of the governing regulatory
agencies of the countries in which we wish to conduct studies or seek approval or licensure of <FONT STYLE="white-space:nowrap">OPT-302</FONT> or any future product candidate. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>U.S. Biological Product Development </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the United States, the FDA regulates biologics under both
the Federal Food, Drug and Cosmetic Act and the Public Health Services Act and their implementing regulations. Both drugs and biologics also are subject to other federal, state and local statutes and regulations. The process of obtaining regulatory
approvals and the subsequent compliance with appropriate federal, state and local statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time
during the product development process, approval process or post-market may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA&#146;s refusal to approve pending applications,
withdrawal of an approval, license revocation, a clinical hold, untitled or warning letters, product recalls or market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of
government contracts, restitution, disgorgement and civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our product candidates and any future biological product
candidates we develop must be approved by the FDA through a biologics license application, or BLA, process before they may be legally marketed in the United States. The BLA is a request for approval to market the biologic for one or more specified
indications and must contain proof of safety, purity and potency. The FDA review and approval process generally involves the following: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#146;s current Good Laboratory Practices
regulations; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">submission to the FDA of an IND, which must become effective before clinical trials may begin and must be updated annually or when significant changes
are made; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">approval by an institutional review board, or IRB, or ethics committee at each clinical site before the trial is commenced;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">performance of adequate and well-controlled human clinical trials to establish the safety, purity and potency of the proposed biologic product
candidate for its intended purpose; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">preparation of and submission to the FDA of a BLA after completion of all pivotal clinical trials that includes substantial evidence of safety, purity
and potency from results of nonclinical testing and clinical trials; satisfactory completion of an FDA advisory committee review, if applicable; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">satisfactory completion of an FDA <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of the manufacturing facility or facilities at which
the proposed product is produced to assess compliance with current good manufacturing practices, or cGMP, and to assure that the facilities, methods and controls are adequate to preserve the biological product&#146;s continued safety, purity and
potency, and of selected clinical investigation sites to assess compliance with GCP; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">FDA review and approval, or licensure, of the BLA to permit commercial marketing of the product for particular indications for use in the United
States. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Nonclinical
Studies and IND </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preclinical studies
include laboratory evaluation of product chemistry and formulation, as well as in vitro and animal studies to assess the potential for adverse events and in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies
is subject to federal regulations and requirements, including GLP regulations for safety/toxicology studies. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">126
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior to beginning the first clinical trial with a product candidate in the United
States, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the
protocol(s) for clinical studies. The IND also includes results of animal and in vitro studies assessing the toxicology, PK, pharmacology, and PD characteristics of the product candidate; chemistry, manufacturing, and controls information; and any
available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA,
within the <FONT STYLE="white-space:nowrap">30-day</FONT> time period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold until the IND sponsor and the FDA resolve the
outstanding concerns or questions. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Clinical Trials </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified
investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other
things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product
development and for any subsequent protocol amendments. For new indications, a separate new IND may be required. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical
trial and its informed consent form before the clinical trial begins at that site, and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a
finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study
sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines
that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries. For
purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the
clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of a BLA. The FDA will accept a well-designed and well-conducted foreign clinical study
not conducted under an IND if the study was conducted in accordance with GCP requirements, and the FDA is able to validate the data through an onsite inspection if deemed necessary. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Phase 1 &#151; The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These
studies are designed to test the safety, dosage tolerance, absorption, metabolism, distribution and elimination of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on
effectiveness. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Phase 2 &#151; The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the
preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3
clinical trials. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Phase 3 &#151; The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically
significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">127
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:Times New Roman" SIZE="2">
to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval and product labeling. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In some cases, the FDA may require, or companies may
voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These <FONT STYLE="white-space:nowrap">so-called</FONT> Phase 4 studies may be made a condition to approval of the BLA. Concurrent
with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate, and must finalize a process for manufacturing the product in commercial
quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality
and purity of the final product, or for biologics, the safety, purity and potency. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo
unacceptable deterioration over its shelf life. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>BLA Submission, Review and Approval </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Assuming successful completion of the clinical trials, the
results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from pertinent
preclinical and clinical studies, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#146;s chemistry, manufacturing, controls, and proposed labeling, among other things.
The submission of a BLA requires payment of a substantial application user fee to FDA, unless a waiver or exemption applies. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Once a BLA has been submitted, the FDA&#146;s goal is to review standard applications within ten months after it accepts the application
for filing (a <FONT STYLE="white-space:nowrap">60-day</FONT> process), or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. In both standard and priority reviews, the review process can
be significantly extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed,
packed, or held meets standards designed to assure the product&#146;s continued safety, purity and potency. The FDA may convene an advisory committee to provide clinical insight on application review questions. Before approving a BLA, the FDA will
typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to
assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. If the FDA determines that the application,
manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional
information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug
substance will be produced, the FDA may issue an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response
letter will describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response letter
without first conducting required inspections, testing submitted product lots, and/or reviewing proposed labeling. In issuing the Complete Response letter, the FDA may recommend actions that the applicant might take to place the BLA in condition for
approval, including requests for additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing
testing and surveillance to monitor safety or efficacy of a product. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">128
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If regulatory approval of a product is granted, such approval will be granted for
particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a Risk Evaluation and Mitigation Strategy, or REMS, to ensure the benefits of the product
outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides,
physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or
the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with <FONT STYLE="white-space:nowrap">pre-</FONT> and post-marketing requirements is not maintained or if problems occur
after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#146;s safety and effectiveness after commercialization, and may limit further
marketing of the product based on the results of these post-marketing studies. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Expedited Development and Review Programs </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any marketing application for a biologic submitted to the FDA for approval may be eligible for FDA programs intended to expedite the FDA
review and approval process, such as priority review, fast track designation, breakthrough therapy and accelerated approval. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A product is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative
therapy exists or to provide a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition compared to marketed products. For products containing new molecular entities, priority review designation means the
FDA&#146;s goal is to take action on the marketing application within six months of the <FONT STYLE="white-space:nowrap">60-day</FONT> filing date (compared with ten months under standard review). </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To be eligible for a fast track designation, the FDA must
determine, based on the request of a sponsor, that a product is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need by providing a therapy where none exists or a
therapy that may be potentially superior to existing therapy based on efficacy or safety factors. Fast track designation provides opportunities for frequent interactions with the FDA review team to expedite development and review of the product. The
FDA may also review sections of the BLA for a fast track product on a rolling basis before the complete application is submitted, if the sponsor and FDA agree on a schedule for the submission of the application sections, and the sponsor pays any
required user fees upon submission of the first section of the BLA. The review clock does not begin until the final section of the BLA is submitted. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, a sponsor can request designation of a product candidate as a &#147;breakthrough therapy.&#148; A breakthrough therapy is
defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug or biologic may
demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs or biologics designated as breakthrough therapies are
also eligible for accelerated approval. The FDA must take certain actions, such as holding timely meetings and providing advice, intended to expedite the development and review of an application for approval of a breakthrough therapy. The benefits
of breakthrough therapy designation include the same benefits as fast track designation, plus intensive guidance from the FDA to ensure an efficient drug development program. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additionally, products studied for their safety and
effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a
clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">129
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As
a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled post-marketing clinical studies to verify and describe the anticipated effect on irreversible morbidity or mortality or other
clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval <FONT STYLE="white-space:nowrap">pre-approval</FONT> of promotional materials, which could adversely impact the timing of the commercial launch of the
product. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Even if a product qualifies for one or
more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review and approval will not be shortened. Furthermore, priority review, fast track
designation, breakthrough therapy designation, and accelerated approval do not change the standards for approval but may expedite the development or approval process. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Orphan Drug Designation </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Orphan Drug Act, the FDA may grant orphan
designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States, or 200,000 or more individuals in the United States for which there is
no reasonable expectation that the cost of developing and making available in the United States a drug or biologic for this type of disease or condition will be recovered from sales in the United States for that drug or biologic. Orphan designation
must be requested before submitting a BLA. After the FDA grants orphan designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not convey any
advantage in, or automatically shorten the duration of, the regulatory review or approval process. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If a product that has orphan designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan exclusivity, which means that the
FDA may not approve any other applications, including a full BLA, to market the same product for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug
exclusivity. Orphan exclusivity does not prevent FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug
designation are tax credits for certain research and a waiver of the BLA application fee. A designated orphan product may not receive orphan exclusivity if it is approved for a use that is broader than the indication for which it received orphan
designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the
product to meet the needs of patients with the rare disease or condition. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Post-Approval Requirements </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to quality
control and quality assurance, record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as
adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under which FDA assesses an annual program fee for each product identified in an approved BLA. Biologic
manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which
impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before
being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">130
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of
production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the
product reaches the market. Later discovery of previously unknown problems with a product, including AEs of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in
revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other
potential consequences include, among other things: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">restrictions on the marketing or manufacturing of a product, mandated modification of promotional materials or issuance of corrective information,
issuance by FDA or other regulatory authorities of safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product, or complete withdrawal of the product from
the market or product recalls; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">fines, warning or untitled letters or holds on post-approval clinical studies; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">product seizure or detention, or refusal of the FDA to permit the import or export of products; or </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">injunctions, consent decrees or the imposition of civil or criminal penalties. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA closely regulates the marketing, labeling,
advertising and promotion of biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies
actively enforce the laws and regulations prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters,
corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#146;s labeling and that differ from those tested by us and approved by the FDA.
The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#146;s communications on the subject of <FONT STYLE="white-space:nowrap">off-label</FONT> use of their products.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Biosimilars and Reference Product
Exclusivity </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Affordable Care Act
signed into law in 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> reference biological product. To date, a number of biosimilars have been licensed under the BPCIA, and numerous biosimilars have been approved in Europe. The FDA has issued several guidance documents
outlining its approach to the review and approval of biosimilars. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through
analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as
the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing
safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are
manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">131
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the BPCIA, an application for a biosimilar product may not be submitted to the
FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was
first licensed. During this <FONT STYLE="white-space:nowrap">12-year</FONT> period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that
applicant&#146;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as
interchangeable products. At this juncture, it is unclear whether products deemed &#147;interchangeable&#148; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The BPCIA is complex and continues to be interpreted and
implemented by the FDA. In addition, government proposals have sought to reduce the <FONT STYLE="white-space:nowrap">12-year</FONT> reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity
provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation, and impact of the BPCIA is subject to significant uncertainty. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other U.S. Healthcare Laws and Compliance Requirements
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the United States, our current and
future operations are subject to regulation by various federal, state and local authorities in addition to the FDA, including but not limited to, CMS other divisions of the U.S. Department of Health and Human Services, or HHS (such as the Office of
Inspector General, Office for Civil Rights and the Health Resources and Service Administration), the U.S. Department of Justice, or DOJ, and individual U.S. Attorney offices within the DOJ, and state and local governments. For example, our clinical
research, sales, marketing and scientific/educational grant programs may have to comply with the anti-fraud and abuse provisions of the Social Security Act, the false claims laws, the privacy and security provisions of HIPAA and similar state laws,
each as amended, as applicable. Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors and customers may be subject to healthcare laws, regulations and enforcement by
the federal government and by authorities in the states and foreign jurisdictions in which we conduct our business. Such laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, privacy and security, price
reporting, and physician sunshine laws. Some of our <FONT STYLE="white-space:nowrap">pre-commercial</FONT> activities are subject to some of these laws. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying,
soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any item or service reimbursable, in
whole or in part, under Medicare, Medicaid or other federal healthcare programs. The term remuneration has been interpreted broadly to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between
therapeutic product manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. The exceptions
and safe harbors are drawn narrowly and practices that involve remuneration that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor.
Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on
a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis based on a cumulative review of all of its facts and circumstances. Our practices may not in all cases meet all of the criteria for protection under
a statutory exception or regulatory safe harbor. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additionally, the intent standard under the Anti-Kickback Statute was amended by the Affordable Care Act to a stricter standard such that
a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Further, courts have found that if &#147;one purpose&#148; of remuneration is to induce referrals,
the federal Anti-Kickback statute is violated. Violations of the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">132
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Anti-Kickback Statute can result in significant civil and criminal fines and penalties for each violation, imprisonment, and exclusion from federal healthcare programs. In addition, the
Affordable Care Act codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act, or the FCA, as
discussed below. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The federal false claims laws,
including the FCA, which can be enforced by private citizens through civil qui tam actions, and civil monetary penalty laws, prohibit any person or entity from, among other things, knowingly presenting, or causing to be presented, a false or
fraudulent claim for payment to, or approval by, the federal government, including federal healthcare programs, such as Medicare and Medicaid, knowingly making, using, or causing to be made or used a false record or statement material to a false or
fraudulent claim to the federal government, or knowingly making a false statement to improperly avoid, decrease or conceal an obligation to pay money to the federal government. A claim includes &#147;any request or demand&#148; for money or property
presented to the U.S. government. Pharmaceutical and other healthcare companies have been, and continue to be, prosecuted under these laws, among other things, for allegedly providing free product to customers with the expectation that the customers
would bill federal programs for the product and for causing false claims to be submitted because of the companies&#146; marketing of the product for unapproved, <FONT STYLE="white-space:nowrap">off-label,</FONT> and thus generally <FONT
STYLE="white-space:nowrap">non-reimbursable,</FONT> uses. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">HIPAA created additional federal criminal statutes that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or
fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party payors, willfully obstructing a criminal investigation of a
healthcare offense, and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for
healthcare benefits, items or services. Like the Anti-Kickback Statute, the Affordable Care Act amended the intent standard for certain healthcare fraud statutes under HIPAA such that a person or entity no longer needs to have actual knowledge of
the statute or specific intent to violate it in order to have committed a violation. When an entity is determined to have violated the FCA, the government may impose civil fines and penalties for each false claim, plus treble damages, and exclude
the entity from participation in Medicare, Medicaid and other federal healthcare programs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We may be subject to data privacy and security regulations by both the federal government and the states in which we conduct our business. HIPAA, as amended by HITECH, and its implementing regulations,
imposes requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates relating to the privacy, security and transmission of individually identifiable health
information. Among other things, HITECH makes HIPAA&#146;s privacy and security standards directly applicable to business associates, which are independent contractors or agents of covered entities that create, maintain, transmit, receive or obtain
protected health information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business
associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorneys&#146; fees and costs associated with pursuing federal civil actions. In addition, many
state laws govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways, are often not <FONT STYLE="white-space:nowrap">pre-empted</FONT> by HIPAA, and may have a more
prohibitive effect than HIPAA, thus complicating compliance efforts. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Additionally, the federal Physician Payments Sunshine Act, or the Sunshine Act, within the Affordable Care Act, and its implementing regulations, require that certain manufacturers of drugs, devices,
biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) report annually to CMS information related to certain payments or other transfers of
value made or distributed to physicians, as defined by such law, and teaching hospitals, or to entities </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">133
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals and to report annually certain ownership and investment interests held by physicians and their
immediate family members. Failure to report accurately could result in penalties. Effective January&nbsp;1, 2022, these reporting obligations will extend to include transfers of value made in the previous year to certain <FONT
STYLE="white-space:nowrap">non-physician</FONT> providers such as physician assistants and nurse practitioners. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Many states have similar statutes or regulations to the above federal laws that may be broader in scope and may apply regardless of payor.
We may also be subject to state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, and/or state
laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers, drug pricing or marketing expenditures. We may be subject to state and foreign laws governing
the privacy and security of health information, some of which may be more stringent than those in the United States (such as the GDPR, which was adopted by the EU and subsequently became effective in May 2018). These laws may differ from each other
in significant ways and may not have the same effect, further complicating compliance efforts. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In order to distribute products commercially, we must comply with state laws that require the registration of manufacturers and wholesale distributors of drug and biological products in a state,
including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements on manufacturers and
distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the distribution chain.
Several states have enacted legislation requiring pharmaceutical and biotechnology companies to establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical
trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical and biotechnology companies for use in
sales and marketing, and to prohibit certain other sales and marketing practices. All of our activities are potentially subject to federal and state consumer protection and unfair competition laws. Additionally, to the extent that we have business
operations in foreign countries or sell any of our products in foreign countries and jurisdictions, including Canada or the EU, we may be subject to additional regulation. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ensuring business arrangements with third parties comply with
applicable healthcare laws and regulations is a costly endeavor. If our operations are found to be in violation of any of the federal and state healthcare laws described above or any other current or future governmental regulations that apply to us,
we may be subject to penalties, including without limitation, significant civil, criminal and/or administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government programs, such as Medicare and
Medicaid, injunctions, private &#147;qui tam&#148; actions brought by individual whistleblowers in the name of the government, or refusal to allow us to enter into government contracts, contractual damages, reputational harm, administrative burdens,
diminished profits and future earnings, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with
these laws, and the curtailment or restructuring of our operations, any of which could adversely affect its ability to operate our business and results of operations. Any action against us for violation of these laws, even if we successfully defend
against it, could cause us to incur significant legal expenses and divert our management&#146;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to
comply with multiple jurisdictions with different compliance or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Coverage, Pricing and Reimbursement </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which
we may obtain regulatory approval. In the United States and in foreign markets, sales of any products for </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">134
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
which we receive regulatory approval for commercial sale will depend, in part, on the extent to which third-party payors provide coverage and establish adequate reimbursement levels for such
products. In the United States, third-party payors include federal and state healthcare programs, private managed care providers, health insurers and other organizations. Third-party payors decide which medications they will pay for and establish
reimbursement levels. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid in the United States, and commercial payors are critical to new product acceptance. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our ability to commercialize any products successfully also
will depend in part on the extent to which coverage and reimbursement for these products and related treatments will be available from third-party payors, which decide which therapeutics they will pay for and establish reimbursement levels. In the
United States, the principal decisions about reimbursement for new medicines are typically made by CMS, an agency within the U.S. Department of Health and Human Services, or HHS. CMS decides whether and to what extent our products will be covered
and reimbursed under Medicare and private payors tend to follow CMS to a substantial degree. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#146;s determination that use of a
therapeutic is: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a covered benefit under its health plan; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">safe, effective and medically necessary; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">appropriate for the specific patient; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">cost-effective; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">neither experimental nor investigational. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We cannot be sure that coverage or reimbursement will be available for any product that we commercialize and, if coverage and
reimbursement are available, what the level of reimbursement will be. Coverage may also be more limited than the purposes for which the product is approved by the FDA or comparable foreign regulatory authorities. Reimbursement may impact the demand
for, or the price of, any product for which we obtain regulatory approval. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We may develop products that, once approved, may be administered by a physician. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be
particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact
physician utilization. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Third-party payors are
increasingly challenging the price, examining the medical necessity, and reviewing the cost-effectiveness of medical products, therapies and services, in addition to questioning their safety and efficacy. Obtaining reimbursement for our products may
be particularly difficult because of the higher prices often associated with branded drugs and drugs administered under the supervision of a physician. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical
necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA approvals. Our product candidates may not be considered medically necessary or cost-effective. Obtaining coverage and reimbursement approval of a
product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to each payor supporting scientific, clinical and cost-effectiveness data for the use of our product on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">payor-by-payor</FONT></FONT> basis, with no assurance that coverage and adequate reimbursement will be obtained. A payor&#146;s decision to provide coverage for a product does not imply
that an adequate reimbursement rate will be approved. Further, one payor&#146;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not
be available to enable us to maintain price levels sufficient to realize an appropriate return on its investment in product development. If reimbursement is not available or is available only at limited levels, we may not be able to successfully
commercialize any product candidate that we successfully develops. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">135
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Different pricing and reimbursement schemes exist in other countries. In the EU,
governments influence the price of biopharmaceutical products through their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate
positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare
the cost effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to establish their own prices for medicines, but monitor and control company profits. The downward pressure on health care
costs has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from <FONT STYLE="white-space:nowrap">low-priced</FONT> markets exert a commercial
pressure on pricing within a country. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care, the
increasing influence of health maintenance organizations, and additional legislative changes in the United States has increased, and we expect will continue to increase, the pressure on healthcare pricing. The downward pressure on the rise in
healthcare costs in general, particularly prescription medicines, medical devices and surgical procedures and other treatments, has become very intense. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable
coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Healthcare Reform </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the United States and some foreign jurisdictions, there
have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities, and
affect the ability to profitably sell product candidates for which marketing approval is obtained. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the
stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative
initiatives. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For example, the Affordable Care Act
has substantially changed healthcare financing and delivery by both governmental and private insurers. Among the Affordable Care Act provisions of importance to the pharmaceutical and biotechnology industries, in addition to those otherwise
described above, are the following: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned
among these entities according to their market share in some government healthcare programs; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23% and 13% of the average manufacturer
price for most branded and generic drugs, respectively, and capped the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (increased to 70% pursuant to the Bipartisan Budget
Act of 2018, or BBA, effective as of January 2019) <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable branded drugs to eligible beneficiaries during their
coverage gap period, as a condition for the manufacturers&#146; outpatient drugs to be covered under Medicare Part D; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">extension of manufacturers&#146; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care
organizations; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">136
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals
and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#146; Medicaid rebate liability; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">expansion of the entities eligible for discounts under the 340B Drug Discount Program; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along
with funding for such research; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">expansion of healthcare fraud and abuse laws, including the FCA and the Anti-Kickback Statute, new government investigative powers, and enhanced
penalties for noncompliance; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused,
instilled, implanted, or injected; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">requirements to report certain financial arrangements with certain healthcare providers and teaching hospitals; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a requirement to annually report certain information regarding drug samples that manufacturers and distributors provide to physicians;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">establishment of a Center for Medicare and Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare and
Medicaid spending; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a licensure framework for follow on biologic products. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Since its enactment, there have been legal and political
challenges to certain aspects of the Affordable Care Act. By way of example, the TCJA included a provision that repealed, effective January&nbsp;1, 2019, the <FONT STYLE="white-space:nowrap">tax-based</FONT> shared responsibility payment imposed by
the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#147;individual mandate.&#148; On December&nbsp;14, 2018, a U.S. District Court Judge in
the Northern District of Texas ruled that the individual mandate is a critical and inseverable feature of the Affordable Care Act, and therefore, because it was repealed as part of the TCJA, the remaining provisions of the Affordable Care Act are
invalid as well. On December&nbsp;18, 2019, the U.S. Court of Appeals for the 5th Circuit ruled that the individual mandate was unconstitutional but remanded the case back to the District Court to determine whether the remaining provisions of the
Affordable Care Act are invalid as well. On March&nbsp;2, 2020, the U.S. Supreme Court granted the petitions for writs of certiorari to review the case, although it is unclear when a decision will be made or how the Supreme Court will rule. In
addition, there may be other efforts to challenge, repeal or replace the Affordable Care Act. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Further legislation or regulation could be passed that could harm our business, financial condition and results of operations. Other legislative changes have been proposed and adopted since the Affordable
Care Act was enacted. For example, in August 2011, President Obama signed into law the Budget Control Act of 2011, which, among other things, included aggregate reductions to Medicare payments to providers of 2% per fiscal year, which went into
effect beginning on April&nbsp;1, 2013 and will stay in effect through 2030 unless additional Congressional action is taken. These Medicare sequester reductions have been suspended from May&nbsp;1, 2020 through December&nbsp;31, 2020 due to the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals,
imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. In addition, the BBA amended the Affordable Care Act, effective
January&nbsp;1, 2019, by increasing the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and closing the coverage
gap in most Medicare drug plans, commonly referred to as the &#147;donut hole.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Additionally, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S.
Congressional inquiries and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">137
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
proposed federal legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between
pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. At the federal level, the Trump administration&#146;s budget proposal for fiscal year 2021 includes a $135&nbsp;billion allowance to
support legislative proposals seeking to reduce drug prices, increase competition, lower <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> drug costs for patients, and increase patient access to lower-cost
generic and biosimilar drugs. On March&nbsp;10, 2020, the Trump administration sent &#147;principles&#148; for drug pricing to Congress, calling for legislation that would, among other things, cap Medicare Part D beneficiary <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> pharmacy expenses, provide an option to cap Medicare Part D beneficiary monthly
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses, and place limits on pharmaceutical price increases. Further, the Trump administration previously released a &#147;Blueprint,&#148; or plan, to
lower drug prices and reduce out of pocket costs of drugs that contained proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of
their products, and reduce the out of pocket costs of drug products paid by consumers. HHS has solicited feedback on some of these measures and has implemented others under its existing authority. For example, in May 2019, CMS issued a final rule to
allow Medicare Advantage Plans the option of using step therapy for Part B drugs beginning January&nbsp;1, 2020. This final rule codified CMS&#146;s policy change that was effective January&nbsp;1, 2019. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">While some of these and other measures may require additional
authorization to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative or administrative measures to control drug costs. Individual states in the United States have also become
increasingly active in passing legislation and implementing regulations designed to control biopharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost
disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions on coverage or
access could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and
which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates that we successfully commercialize or put pressure on our product pricing. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect that these and other healthcare reform measures
that may be adopted in the future, may result in more rigorous coverage criteria and lower reimbursement, and in additional downward pressure on the price that we receive for any approved product. It is possible that additional governmental action
is taken to address the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payors. The implementation of
cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products. Such reforms could have an adverse effect on anticipated revenue from product candidates
that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>European Union Regulation </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the European Union, a clinical trial application must be
submitted to each country&#146;s national regulatory authority in which the clinical trial is to take place, together with an independent ethics committee, much like the FDA and IRB, respectively. It is expected, however, that the Clinical Trials
Regulation 536/2014 shall start to apply during the course of 2020. This new Regulation takes direct effect in each European Union Member State and seeks to simplify and streamline the approval of clinical trials in the European Union, for example,
by allowing the clinical trial sponsor to submit a single application for approval of a clinical trial across the EU via a new EU Portal. The new Regulation also aims to streamline and simplify the rules on safety reporting, and introduces enhanced
transparency requirements such as mandatory submission of a summary of the clinical trial results to a new EU Database. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">138
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Medicinal products can only be commercialized in the European Economic Area after a
marketing authorization, or MA, has been obtained. There are two types of marketing authorizations: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The centralized MA, which is issued by the European Commission through the Centralised Procedure, based on the opinion of the Committee for Medicinal
Products for Human Use of the European Medicines Agency, or EMA, and which is valid throughout the entirety of the EEA. The Centralised Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal
products, and medicinal products indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, auto immune and viral diseases. The Centralised Procedure is optional for products containing an active substance not authorized in
the EEA before 20&nbsp;May 2004, for products that constitute a significant therapeutic, scientific or technical innovation or for which a centralized authorization would be in the interest of patients. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available
for products not falling within the mandatory scope of the Centralised Procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in another Member State through the Mutual
Recognition Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the above described procedures, before granting the MA,
the EMA or the competent authorities of the Member States of the EEA make an assessment of the risk benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The European Union also provides opportunities for market
exclusivity. For example, in the European Union, upon receiving marketing authorization, innovative medicinal products generally receive eight years of data exclusivity and an additional two years of market exclusivity. If granted, data exclusivity
prevents regulatory authorities in the European Union from referencing the innovator&#146;s data to assess a generic or biosimilar application. During the additional <FONT STYLE="white-space:nowrap">two-year</FONT> period of market exclusivity, a
generic or biosimilar marketing authorization can be submitted, and the innovator&#146;s data may be referenced, but no generic or biosimilar product can be marketed until the expiration of the market exclusivity. Products receiving orphan
designation, can receive ten years of market exclusivity, during which time no similar medicinal product for the same indication may be placed on the market. An orphan product&#146;s market exclusivity may be reduced to six years if, at the end of
the fifth year, it is established that the criteria for orphan drug designation are no longer met, in other words, when it is shown on the basis of available evidence that the product is sufficiently profitable not to justify maintenance of market
exclusivity. Additionally, marketing authorization may be granted to a similar product for the same indication at any time if: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the applicant consents to a second orphan medicinal product application; or </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the applicant cannot supply sufficient quantities of the orphan medicinal product. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the EU, companies developing a new medicinal product must
agree to a Paediatric Investigation Plan, or a PIP, with the EMA and must conduct pediatric clinical trials in accordance with that PIP, unless a deferral or waiver applies (for example, because the relevant disease or condition occurs only in
adults). The MA application for the product must include the results of pediatric clinical trials conducted in accordance with the PIP, unless a waiver applies, or a deferral has been granted, in which case the pediatric clinical trials must be
completed at a later date. Products that are granted a marketing authorization on the basis of the pediatric clinical trials conducted in accordance with the PIP are eligible for a six month extension of the protection under a supplementary
protection certificate (if any is in effect at the time of approval) or, in the case of orphan medicinal products, a two year extension of the orphan market exclusivity. This pediatric reward is subject to specific conditions and is not
automatically available when data in compliance with the PIP are developed and submitted. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">139
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Coverage, Pricing and Reimbursement </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the European Union, pricing and reimbursement schemes
vary widely from country to country. Some countries provide that drug products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost effectiveness of a
particular drug candidate to currently available therapies. For example, the European Union provides options for its member states to restrict the range of drug products for which their national health insurance systems provide reimbursement and to
control the prices of medicinal products for human use. European Union member states may approve a specific price for a drug product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the drug
product on the market. Other member states allow companies to fix their own prices for drug products, but monitor and control company profits. The downward pressure on health care costs in general, particularly prescription drugs, has become
intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross border imports from low priced markets exert competitive pressure that may reduce pricing within a country. Any
country that has price controls or reimbursement limitations for drug products may not allow favorable reimbursement and pricing arrangements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Advertising Regulation </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All advertising and promotional activities for the product must be consistent with the approved summary of product characteristics, and
therefore all <FONT STYLE="white-space:nowrap">off-label</FONT> promotion is prohibited. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Direct-to-consumer</FONT></FONT> advertising of prescription medicines is also prohibited in
the European Union. Although general requirements for advertising and promotion of medicinal products are established under European Union directives, the details are governed by regulations in each European Union Member State and can differ from
one country to another. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we fail to comply with
applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Pharmacovigilance System </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The holder of a European MA must establish and maintain a
pharmacovigilance system and appoint an individual qualified person for pharmacovigilance, or QPPV, who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of
periodic safety update reports, or PSURs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All new
European MA applications must include a risk management plan, or RMP, describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. The regulatory
authorities may also impose specific obligations as a condition of the MA. Such risk-minimization measures or post-authorization obligations may include additional safety monitoring, more frequent submission of PSURs, or the conduct of additional
clinical trials or post-authorization safety studies. RMPs and PSURs are routinely available to third parties requesting access, subject to limited redactions. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Rest of the World Regulation </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For other countries outside of the EU and the United States, such as countries in Eastern Europe, Latin America or Asia, the requirements
governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. Additionally, the clinical trials must be conducted in accordance with GCP requirements and the applicable regulatory requirements
and the ethical principles that have their origin in the Declaration of Helsinki. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">140
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we fail to comply with applicable foreign regulatory requirements, we may be subject
to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Brexit and the Regulatory Framework in the United
Kingdom </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On June&nbsp;23, 2016, the
electorate in the United Kingdom, or UK, voted in favor of leaving the EU, commonly referred to as &#147;Brexit&#148; and the United Kingdom officially withdrew from the EU on January&nbsp;31, 2020. The United Kingdom and the EU are currently in a
transition period during which the United Kingdom and the EU are negotiating additional arrangements, including their future trading arrangement. The United Kingdom has stated that it wants the transition period to expire, and the future trading
terms to be agreed, by December&nbsp;31, 2020. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Since the regulatory framework for pharmaceutical products in the United Kingdom covering quality, safety and efficacy of pharmaceutical
products, clinical trials, marketing authorization, commercial sales and distribution of pharmaceutical products is derived from EU directives and regulations, immediately following Brexit, it is expected that the United Kingdom&#146;s regulatory
regime will remain aligned with EU regulations. It remains to be seen how, if at all, Brexit will impact regulatory requirements for product candidates and products in the United Kingdom. In the longer term, Brexit could materially impact the future
regulatory regime which applies to products and the approval of product candidates in the United Kingdom. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The Foreign Corrupt Practices Act </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FCPA prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of anything of value,
directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also
obligates companies whose securities are listed in the United States to comply with accounting provisions requiring us to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international
subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Additional Regulation </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the
Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern our use, handling and disposal of various biological, chemical and radioactive
substances used in, and wastes generated by, our operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. We believe that we are in
material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other Regulations </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are also subject to numerous federal, state and local
laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances. We may incur significant costs to comply with such laws
and regulations now or in the future. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition
to regulation in the United States and Europe, a variety of foreign regulations govern clinical trials, commercial sales and distribution of drugs. Pharmaceutical firms who wish to market their medicinal drugs
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">141
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
outside the European Union and the United States must submit marketing authorization application to the national authorities of the concerned countries, such as the Pharmaceutical and Medical
Device Agency, or PMDA in Japan. The approval process varies from jurisdiction to jurisdiction and the time to approval may be longer or shorter than that required by the FDA or European Commission. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Manufacturing and Supply </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are dependent on specialized third parties, who are
subject to cGMP requirements and regulations, for the supply and manufacture of <FONT STYLE="white-space:nowrap">OPT-302</FONT> drug substance and drug product. We do not have any internal manufacturing and control capabilities. We source the drug
substance for <FONT STYLE="white-space:nowrap">OPT-302</FONT> and our clinical trials on a purchase order basis. However, we believe that competitive pricing is achieved because there are a number of potential long-term replacements for our
suppliers of drug substance. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In October 2013, we
entered into a biopharmaceutical manufacturing agreement, or the Patheon Agreement, with Patheon Biologics Company, Austria Pty Ltd. and Patheon Biologics Company B.V., or collectively Patheon. The Patheon Agreement establishes the general terms and
conditions pursuant to which Patheon or its affiliates will manufacture <FONT STYLE="white-space:nowrap">OPT-302</FONT> drug product for us in accordance with cGMP requirements. Under the Patheon Agreement, Patheon granted us a perpetual,
royalty-free, fully <FONT STYLE="white-space:nowrap">paid-up,</FONT> <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide, transferable and sublicensable license, under all of Patheon&#146;s intellectual property rights embedded in the
development and manufacture process to the extent necessary for developing, making, using and selling <FONT STYLE="white-space:nowrap">OPT-302.</FONT> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Patheon Agreement will expire on the date that all of the manufacturing services to be performed by Patheon are completed. We may
terminate the Patheon Agreement for any reason upon prior written notice. Patheon may terminate the Patheon Agreement upon prior written notice if Patheon has not performed any activities under the Patheon Agreement for certain period of time or if,
despite Patheon&#146;s commercially reasonably best efforts, Patheon determines that the services cannot be completed according to specifications approved by us or within a reasonable time after the originally planned timeframe. Either party may
terminate the Patheon Agreement for the other party&#146;s uncured material breach or bankruptcy. In addition, the Patheon Agreement will terminate if the parties are unable to reach agreement regarding necessary changes to the services based on the
results of individual stage of development work. Upon termination of the Patheon Agreement, we are required to pay Patheon for services properly performed, including <FONT STYLE="white-space:nowrap">non-cancelable</FONT> costs. Based upon the timing
of the termination, we may also be required to pay Patheon certain close out cost for canceled services </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Employees </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As of June&nbsp;30, 2020, we had eight full-time employees, four of whom had an M.D. or Ph.D. degree. None of our employees are represented by collective bargaining agreements. We believe that our
management maintains good relations with our employees. As of June&nbsp;30, 2020, all of our employees were based in Australia, with four employees in our research and development department and four employees in our general and administrative
department. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Facilities </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We occupy approximately 591 square feet of office space in
South Yarra, Victoria, Australia under a lease that expires in July 2022. We believe that our existing facilities are adequate to meet our current needs and that suitable additional alternative facilities will be available in the future on
commercially reasonable terms to meet our future needs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Legal
Proceedings </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">From time to time, we may become
involved in legal proceedings arising in the ordinary course of our business. We are currently not a party to any material legal proceedings. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">142
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_14"></A>MANAGEMENT </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Directors and Senior Management </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth information relating to our
directors, senior management and key employees as of June&nbsp;30, 2020. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="63%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Age</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Position</B></FONT></P></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Senior Management and Key Employees</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Megan Baldwin, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer and Managing Director</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael Tonroe</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">53</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer and Company Secretary</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Richard Chadwick, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Head of Intellectual Property</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael Gerometta, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">56</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Head of Chemistry, Manufacturing and Controls Development</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clare Price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">51</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director of Clinical Development</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Annette Leahy</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director of Clinical Research</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Geoffrey Kempler</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">64</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chairperson</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael Sistenich</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The business addresses for
our senior management and board of directors is Opthea Limited, Suite 0403, Level&nbsp;4, 650 Chapel Street, South Yarra, VIC 3141, Australia. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Senior Management and Key Employees </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Megan Baldwin, Ph.D., </I>has served as our Chief
Executive Officer and Managing Director since February 2014. Since joining our company in 2008, Dr.&nbsp;Baldwin has held various positions, including Head of Preclinical R&amp;D from February 2009 to November 2012 and Chief Executive Officer of
Opthea Pty Ltd., previously a wholly-owned subsidiary, from November 2012 to December 2015. Dr.&nbsp;Baldwin has over 20 years of experience focusing on angiogenesis and therapeutic strategies for ophthalmic and cancer indications. Prior to joining
our company, Dr.&nbsp;Baldwin was employed at Genentech, Inc. (now a subsidiary of the Roche Group), a leader in the field of angiogenesis-based therapies for cancer and other diseases. Dr.&nbsp;Baldwin earned a Bachelor of Science Honours and Ph.D.
in Medicine from the University of Melbourne. We believe that Dr.&nbsp;Baldwin&#146;s business expertise and her daily insight into corporate matters as our Chief Executive Officer qualify her to serve on our board of directors. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Michael Tonroe</I> has served as our Chief Financial
Officer and Company Secretary since May 2014. From March 2011 to April 2014, Mr.&nbsp;Tonroe served as the Chief Financial Officer and Company Secretary of the Australian Synchrotron Co. Ltd. in Melbourne. Mr.&nbsp;Tonroe has over 20 years of
experience in financial management serving in board-level positions for private and listed companies in Australia, the United Kingdom, the United States and Canada. Mr.&nbsp;Tonroe is a fellow of the Institute of Chartered Accountants in England and
Wales and earned a Bachelor of Science in Business Studies from Buckingham University. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Richard Chadwick, Ph.D.,</I> has served as our Head of Intellectual Property since February 2008. From April 2003 to December 2007, Dr.&nbsp;Chadwick was a patent attorney at FB Rice&nbsp;&amp; Co., a
private law firm. Prior to FB Rice&nbsp;&amp; Co., Dr.&nbsp;Chadwick was a patent attorney at Wynne-Jones, Laine&nbsp;&amp; James, a private law firm, and also worked as an <FONT STYLE="white-space:nowrap">in-house</FONT> attorney at Dow Corning
Limited, a materials science company, and Unilever plc, a consumer goods company. Dr.&nbsp;Chadwick earned a Bachelor of Science in Biochemistry with Microbiology from </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">143
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
the University of St. Andrews and a Ph.D. in Biochemistry and Molecular Biology from the University of Manchester. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Michael Gerometta, Ph.D.,</I> has served as our Head of
Chemistry, Manufacturing and Controls Development since December 2008. Dr.&nbsp;Gerometta has over 30 years of experience in the Australian biotechnology industry, working with numerous contract manufacturing organizations overseas and locally in
all facets of translational CMC from concept through to Phase 2 studies. Dr.&nbsp;Gerometta earned a Bachelor of Science in Chemistry from the University of Technology, Sydney, and a Ph.D. in Biotechnology from the Queensland University of
Technology. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Clare Price</I> has served as our
Director of Clinical Development since July 2016. From February 2016 to July 2016, Ms.&nbsp;Price served as the Director of Clinical Development at Commercial Eyes Pty Ltd., a pharmaceutical consulting firm. From January 2007 to January 2016,
Ms.&nbsp;Price served in various roles, most recently as the Clinical Programme Director, at Starpharma Holdings Ltd, an Australian biotechnology company. Ms.&nbsp;Price earned a Bachelor of Pharmacy from Bath Spa University. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Annette Leahy </I>has served as our Director of Clinical
Research since August 2017. From May 2016 to August 2017, she was the Clinical Trials Manager at Swisse Wellness Pty Ltd., an Australian wellness company. From September 2014 to May 2016, she served in various roles, most recently as Senior Manager,
Learning and Development, at Novotech (Australia) Pty Ltd., an Australian clinical research organization. Ms Leahy earned a Bachelor of Health Information Management from La Trobe University. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Geoffrey Kempler </I>has served as the Chairperson of our
board of directors since November 2015. Mr.&nbsp;Kempler has also served as the Chairman of the board of directors since 1997 and as Chief Executive Officer since June 2005 of Alterity Therapeutics Ltd., a pharmaceutical development company listed
on both the Nasdaq Capital Market and the Australian Securities Exchange. Mr.&nbsp;Kempler earned a Bachelor of Science from Monash University and a Graduate Diploma in Applied Social Psychology from Swinburne University of Technology. We believe
Mr.&nbsp;Kempler&#146;s extensive experience in investment and business development qualify him to serve on our board of directors. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Michael Sistenich </I>has served as a member of our board of directors since November 2015. Since May 2017, Mr.&nbsp;Sistenich has
served as a <FONT STYLE="white-space:nowrap">co-founder</FONT> and partner of Aurenda Partners Pty Ltd., an investment firm. From August 2016 to February 2017, Mr.&nbsp;Sistenich served as the interim Chief Executive Officer of Nohla Therapeutics,
Inc., a cellular therapy company, and has also served as a member of the board of directors of Nohla Therapeutics, Inc. from March 2017 to June 2019. Mr.&nbsp;Sistenich has advised a wide range of global institutions, high net worth individuals and
companies on healthcare investments over the past 20 years. He is a healthcare specialist in international investment management and investment banking. Mr.&nbsp;Sistenich earned a Master of Science in Biochemistry from the University of Oxford. We
believe Mr.&nbsp;Sistenich&#146;s financial experience and his service on the boards of directors of several biotechnology companies qualify him to serve on our board of directors. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Board of Directors </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors currently consists of three members,
including Dr.&nbsp;Baldwin, our Chief Executive Officer and Managing Director. Directors are elected at our annual general meeting of shareholders. Under our Constitution, at the close of each annual general meeting
<FONT STYLE="white-space:nowrap">one-third</FONT> of the directors, other than the Managing Director, or if their number is not a multiple of three, then the number nearest to but not more than <FONT STYLE="white-space:nowrap">one-third</FONT> of
the directors must retire. In addition, a director, other than the managing director, must retire from office at the conclusion of the third annual general after the director was last elected, even if his or her retirement results in more than <FONT
STYLE="white-space:nowrap">one-third</FONT> of all directors retiring from office. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">144
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The membership of our board of directors is directed by the following requirements as
set forth in our Constitution and our Board Charter, as applicable: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">there will be a minimum of three directors and a maximum of 10, and our board of directors may determine the number of directors within those limits;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the majority of our board of directors should be independent; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our board of directors has the power to appoint any person to be a director, either to fill a vacancy or as an additional director (provided that the
total number of directors does not exceed the maximum number of directors permitted), and any director so appointed will hold office until the end of the next annual general meeting when he or she may be
<FONT STYLE="white-space:nowrap">re-elected;</FONT> and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our board of directors should, collectively, have the appropriate level of personal qualities, skills, experience and time commitment to properly
fulfill its responsibilities. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors has delegated responsibility for the management of our businesses to the Chief Executive Officer and Managing
Director but remains responsible for overseeing the performance of management. The principal roles and responsibilities of our board of directors include the following: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">review, evaluate, provide input into and approve our business plan; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">monitor senior management&#146;s performance and implementation of strategy, and ensure appropriate resources are available;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">review, evaluate and approve and monitor major resource allocations and capital investments, and acquisitions and divestitures;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">review, evaluate, approve and monitor major resource allocations and capital investments, and acquisitions and divestitures;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">review and monitor our financial and operating results; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">review, evaluate and approve the overall corporate organizational structure, the assignment of senior management responsibilities and plans for senior
management development and succession; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">review, evaluate and approve compensation strategy as it relates to our senior management; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">review and ratify systems of risk management and internal compliance and control, codes of conduct and legal compliance. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors has established delegated limits of
authority, which define the matters that are delegated to management and those that require board of director approval. Under the Corporations Act, at least two of our directors must be resident Australians. None of our <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors have any service contracts with us that provide for benefits upon termination of employment. Under our Board Charter, the board of directors is required to meet at least six times per year.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Board Committees </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To assist with the effective discharge of its duties, the
board of directors has established an Audit and Risk Committee, a Remuneration Committee and a Nomination Committee. Each committee operates under a charter approved by our board of directors, which sets forth the purposes and responsibilities of
the committees as well as qualifications for committee membership, committee structure and operations and committee reporting to the board of directors. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Audit and Risk Committee </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The members of our Audit and Risk Committee are Messrs. Kempler and Sistenich and Dr.&nbsp;Baldwin. Our board of directors has determined
that each of Messrs. Kempler and Sistenich satisfies the independence </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">145
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
requirements under Nasdaq listing standards and Rule <FONT STYLE="white-space:nowrap">10A-3(b)(1)</FONT> of the Exchange Act. The chairperson of our Audit and Risk Committee is
Mr.&nbsp;Sistenich. Our board of directors has determined that Mr.&nbsp;Sistenich is an &#147;audit committee financial expert&#148; within the meaning of SEC regulations. Each member of our Audit and Risk Committee can read and understand
fundamental financial statements in accordance with applicable requirements. In arriving at these determinations, our board of directors has examined each member&#146;s scope of experience and the nature of his or her employment. Under applicable
Nasdaq rules, we are permitted to phase in compliance with the audit committee composition and independence requirements set forth in Nasdaq Rule 5615(b)(1) and Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act, as follows:
(1)&nbsp;one independent member at the time of listing of the ADSs on Nasdaq; (2)&nbsp;a majority of independent members within 90 days of listing of the ADSs on Nasdaq; and (3)&nbsp;all independent members within one year of listing of the ADSs on
Nasdaq. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The charter for our Audit and Risk
Committee requires the committee to consist of at least three directors, each of whom must be <FONT STYLE="white-space:nowrap">non-employee</FONT> directors and a majority of which must be independent directors. Each of the members of our Audit and
Risk Committee other than Dr.&nbsp;Baldwin is independent under the committee charter. The chairperson of our Audit and Risk Committee must be an independent director and cannot be the chairperson of our board of directors. The Audit and Risk
Committee is required to hold at least two regular meetings each year and must review its charter at least annually. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The role of the Audit and Risk Committee is to advise our board of directors in discharging responsibilities of our board of directors
with respect to our financial reporting including accounting standards, internal control integrity and compliance, external audit activities including auditor appointment, independence, terms of engagement and fees and business risk management.
Specific responsibilities of our Audit and Risk Committee include: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewing accounting standards and half-year and annual financial statements prior to referral to the board of directors; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">monitor developments likely to affect financial reporting including legislative pronouncements or disclosure requirements, as they affect both current
and future years; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">review any unusual transactions, pending litigation, outstanding claims or contingencies which the management, auditors or legal counsel believe may
have a material effect on the financial position or operations and the manner in which these matters are disclosed in financial statements; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">evaluating internal control policies and procedures; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">making recommendations to the board of directors on the appointment, reappointment or replacement of external auditors; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">evaluating the independence and effectiveness of external auditors and preapprove all audit and material
<FONT STYLE="white-space:nowrap">non-audit</FONT> services provided by external auditors; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewing the results of the external audit and assess remedial action taken or proposed in audit reports; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewing all representation letters signed by management to ensure that the information presented is complete and appropriate;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">monitoring risks and establish risk management policies; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">making recommendations to the board of directors regarding proposed changes to our risk management framework; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewing the schedule of insurance annually. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Remuneration Committee </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The members of our Remuneration Committee are Messrs.
Kempler and Sistenich and Dr.&nbsp;Baldwin. The chairperson of our Remuneration Committee is Mr.&nbsp;Sistenich. The objectives of the Remuneration Committee are </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">146
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
to link remuneration to the creation of shareholder value, to offer competitive and appropriate remuneration for the business performance delivered and to put into place a remuneration framework
that reflects the responsibilities of senior management while being sufficiently competitive to attract and retain high caliber performers. The charter of our Remuneration Committee requires the committee to consist of at least three directors, a
majority of whom must be independent. The chairperson of our Remuneration Committee must be an independent director. The Remuneration Committee is required to hold at least one regular meeting each year. Specific responsibilities of our Remuneration
Committee include: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">overseeing our remuneration strategy; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">ensuring remuneration policies and practices enable us to attract, motivate and retain a diverse mix of directors and senior management;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">fairly and responsibly remunerating directors and senior management; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">at least annually, reviewing and reporting on diversity of our employee base; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">seeking information it considers necessary to fulfill its duties, including external advice. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Nomination Committee </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The members of our Nomination Committee are Messrs. Kempler
and Sistenich and Dr.&nbsp;Baldwin. The chairperson of our Nomination Committee is Mr.&nbsp;Sistenich. The role of the Nomination Committee is to assist our board of directors by identifying, reviewing and evaluating individuals qualified to become
members of our board of directors, reviewing and recommending the nomination of directors and assisting the board of directors with other related tasks. The charter of our Nomination Committee requires the committee to consist of at least three
directors, the majority of whom must meet the independence recommendations of the ASX Corporate Governance Council (as well as all applicable laws and regulations) and each of whom must be free of any relationship that, in the opinion of the board
of directors, would interfere with his or her exercise of independent judgment. The members of the Nomination Committee will be appointed annually by the board of directors. The Nomination Committee is required to hold at least one regular meeting
each year. Specific responsibilities of our Nomination Committee include: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">assisting in identifying, interviewing and recruiting candidates for the board of directors; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewing potential director qualifications; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">preparing a description of the role and capabilities required for a particular role; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">at least annually, presenting to the board of directors a list of individuals recommended for nomination for election to the board of directors at the
annual meeting of shareholders; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">planning succession of our directors; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">inducting and coordinating professional development programs for our directors; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">developing and implementing a process for evaluating the performance of the board of directors and its committees; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">managing the succession of our senior management; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewing and making recommendations about changes to the charter of the Nomination Committee as required in the Committee&#146;s opinion; and
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">annually review its own performance. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Foreign Private Issuer Exemption </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We qualify as a &#147;foreign private issuer&#148; as defined in Section&nbsp;405 of the Securities Act of 1933, as amended. As a foreign
private issuer, we are exempt from certain rules under the Exchange Act that impose disclosure </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">147
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
requirements as well as procedural requirements for proxy solicitations under Section&nbsp;14 of the Exchange Act. In addition, the members of our board of directors and senior management are not
subject to short-swing profit and insider trading reporting obligations under Section&nbsp;16 of the Exchange Act. They will, however, be subject to the obligations to report changes in share ownership under Section&nbsp;13 of the Exchange Act and
related SEC rules, to the extent applicable. The foreign private issuer exemption will also permit us to follow home country corporate governance practices instead of certain Nasdaq listing requirements. We intend to take all actions necessary for
us to maintain compliance as a foreign private issuer under the applicable corporate governance requirements of the Sarbanes-Oxley Act, the rules adopted by the SEC and the listing rules of Nasdaq. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">These exemptions do not modify the independence requirements
for our Audit and Risk Committee, and we intend to comply with the requirements of the Sarbanes-Oxley Act and the Nasdaq listing rules, which require that our Audit and Risk Committee be composed of at least three independent members. <FONT
STYLE="white-space:nowrap">Rule&nbsp;10A-3&nbsp;under</FONT> the Exchange Act provides that the Audit and Risk Committee must have direct responsibility for the nomination, compensation and choice of our auditors, as well as control over the
performance of their duties, management of complaints made, and selection of consultants. Under <FONT STYLE="white-space:nowrap">Rule&nbsp;10A-3,&nbsp;if</FONT> the laws of a foreign private issuer&#146;s home country require that any such matter be
approved by the board of directors or the shareholders of the Company, the Audit and Risk Committee&#146;s responsibilities or powers with respect to such matter may instead be advisory. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Code of Conduct </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have adopted a Code of Conduct applicable to all of our directors, officers and employees. Our Code of Conduct is available on our
website at www.opthea.com. We post on our website all disclosures that are required by law or the listing standards of Nasdaq concerning any amendments to, or waivers from, any provision of the Code of Conduct. The reference to our website address
does not constitute incorporation by reference of the information contained at or available through our website, and you should not consider it to be a part of, this prospectus. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Family Relationships </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There are no family relationships among any of the members
of our board of directors and our senior management. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Remuneration </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Overview </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our remuneration policy is to align director and senior management objectives with shareholder and business objectives by providing a
fixed remuneration component and typically offering long-term incentives based on key performance areas. Our board of directors believes the remuneration policy to be appropriate and effective in its ability to attract and retain the best executives
and directors to run and manage the consolidated entity, as well as create goal congruence between directors, executives and shareholders. Our board of directors and the Remuneration Committee are responsible for determining the appropriate
remuneration package for our senior management, including our Chief Executive Officer. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Australian executives and directors receive a superannuation guarantee contribution required under Australian law and do not receive any other retirement benefits. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Remuneration of Senior Management </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the fiscal year ended June&nbsp;30, 2020, the aggregate
cash remuneration paid to our senior management was A$970,099. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">148
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our senior management receive fixed compensation and performance-linked remuneration.
The level of fixed remuneration is set to provide a base level of compensation which is both appropriate to the applicable position and is competitive in the marketplace. The Remuneration Committee accesses external advice independent of senior
management if required. Fixed compensation is comprised of base salary and superannuation contribution and is reviewed every 12 months by the Remuneration Committee. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Performance-linked remuneration consists of short-term and
long-term incentives. The objective of short-term incentives is to link the achievement of our operational targets with the remuneration received by our senior management charged with meeting those targets. Total potential short-term incentives are
set at a level that we believe provides sufficient incentive to our senior management to achieve the operational targets at a cost to us that is reasonable under the circumstances. Short-term incentives may include cash bonuses based on the extent
to which specific targets set at the beginning of each fiscal year are met. The targets consist of a number of key performance indicators covering corporate objectives and individual measures of performance. Individual performance indicators are
linked to our development plans. Our Remuneration Committee determines, on an annual basis and after consideration of performance against the key performance indicators, the amount, if any, of short-term incentives payable to our senior management.
Payments of short-term incentive bonuses are made in the following reporting period. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We also provide long-term incentives through option grants under our Long Term Incentive Plan. The objective of the Long Term Incentive Plan is to reward our management and key employees in a manner that
aligns this element of compensation with the creation of shareholder wealth. Long Term Incentive Plan grants are made to senior management and employees who are able to influence the generation of shareholder wealth and have a direct impact on our
performance and development. Option vesting conditions are based on continued service to us. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In making remuneration determinations for our senior management, the Remuneration Committee considers operational contributions by our senior management as well as the following performance indicators:
revenue, loss before tax, tax benefit, loss after tax, basic loss per ordinary share, net tangible assets per share and changes in prevailing trading prices of our ordinary shares on the ASX. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Remuneration of <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our <FONT STYLE="white-space:nowrap">non-employee</FONT>
directors receive a fixed fee annually, which is reviewed by our board of directors on an annual basis. Mr.&nbsp;Kempler is entitled to an annual fixed fee of A$99,000 (inclusive of superannuation contributions, including for his service as
chairperson of the board of directors). Mr.&nbsp;Sistenich is entitled to an annual fixed fee of A$65,700 (inclusive of superannuation contributions). The fixed fees cover both service on the board of directors and committees of the board of
directors. The remuneration of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors is reviewed by our board of directors on an annual basis. <FONT STYLE="white-space:nowrap">Non-employee</FONT> directors are not provided with
retirement benefits apart from statutory superannuation, which is only applicable to Australian resident directors. <FONT STYLE="white-space:nowrap">Non-employee</FONT> directors are reimbursed for costs directly related to conducting business
related to their service on our board of directors. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We implemented a <FONT STYLE="white-space:nowrap">non-executive</FONT> director share and option plan, or the NED Plan, in 2014. Under the
NED Plan, present and future <FONT STYLE="white-space:nowrap">non-executive</FONT> directors may: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">elect to receive ordinary shares or options to purchase ordinary shares in lieu of receiving some or all of their annual fixed fee;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">be awarded ordinary shares or options to purchase ordinary shares in lieu of additional cash remuneration in respect of services provided to the
Company which in the opinion of the board of directors are outside the scope of the ordinary duties of the relevant director; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">otherwise be awarded ordinary shares or options to purchase ordinary shares as part of the directors&#146; remuneration in addition to any existing
cash remuneration paid to directors (if any). </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">149
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The NED Plan is designed to assist us in preserving our cash for use toward advancing
the clinical development of our product candidate and provide our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors an opportunity to demonstrate their commitment and support for us through sacrificing some or all of their cash fees for
ordinary shares or options. The NED Plan also provides us with further flexibility in the design of the directors&#146; remuneration packages and in turn assists us with retaining existing directors and attracting new additional directors with the
relevant experience and expertise. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the fiscal
year ended June&nbsp;30, 2020, the aggregate cash remuneration paid to our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors was A$167,447, including A$2,747&nbsp;in cash reimbursements. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Employment Agreements with Senior Management
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The key provisions of the employment
agreements are set out below for each member of our senior management. None of these employment agreements have termination dates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Officer</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Date of<BR>Agreement</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Base Salary</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Termination without Cause</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Benefits upon Termination
without<BR>Cause</B></FONT></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Megan Baldwin, Ph.D.<BR><I>Chief Executive Officer and Managing Director</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">April&nbsp;23,<BR>2014</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$440,000 per&nbsp;year</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Not less than three months&#146; notice (if by employee)</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Not less than three months&#146; notice or payment in lieu of notice period
(if by us)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon notice of termination by us, any options that have vested or will vest during the notice period will be released; all other options will lapse at the discretion of our board of
directors.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael Tonroe<BR><I>Chief Financial Officer and Company Secretary</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">May&nbsp;8,<BR>2014</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$256,844 per&nbsp;year</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Not less than three months&#146; notice (if by employee)</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Not less than three months&#146; notice or payment in lieu of notice period
(if by us)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Not applicable.</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon termination of
employment, our senior management are entitled to receive their statutory entitlements of accrued annual and long service leave, together with any superannuation benefits. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Remuneration of Members of Our Board of Directors and
Senior Management </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Details of the
remuneration of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors and senior management for the fiscal year ended June&nbsp;30, 2020 are set forth below. During the fiscal year ended June&nbsp;30, 2020, no options to purchase
ordinary shares were granted to any of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors or senior management. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Short-Term<BR>Incentive</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B><FONT STYLE="white-space:nowrap">Post-Employment</FONT></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Salary/Fees<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Cash&nbsp;
Bonus<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Superannuation</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Geoffrey Kempler</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">90,405</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,589</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">98,994</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael Sistenich</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,700</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">65,700</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Senior Management</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Megan Baldwin, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">440,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51,300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">591,300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael Tonroe</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">256,844</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">64,211</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">351,555</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">For our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, amounts set forth in this column include our reimbursement of expenses incurred in connection
with performance of services relating to board service. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Bonuses are paid in the fiscal year following the year in which they were earned. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">150
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Details of options held by our <FONT STYLE="white-space:nowrap">non-employee</FONT>
directors and senior management as of June&nbsp;30, 2020 are set forth below. None of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors or senior management exercised any options to purchase ordinary shares during the fiscal year
ended June&nbsp;30, 2020. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of<BR>Options</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Grant&nbsp;Date</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exercise<BR>Price</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percentage<BR>Vested<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Last&nbsp;Vesting<BR>Date</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Expiration<BR>Date</B></FONT></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Geoffrey Kempler</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,000,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/31/16</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A$0.480</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">100%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/7/18</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/7/21</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,500,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/15/19</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.855</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11/29/19</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11/29/22</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael Sistenich</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,000,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/31/16</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.480</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/7/18</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/7/21</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,500,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/15/19</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.855</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11/29/19</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11/29/22</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Senior Management</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Megan Baldwin, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,000,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/31/16</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.480</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/7/18</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/7/21</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,000,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/15/19</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.855</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11/29/19</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11/29/22</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael Tonroe</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">800,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/31/16</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.480</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/1/19</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/1/22</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">600,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4/3/19</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.855</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4/3/20</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4/3/23</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">No options lapsed or were forfeited during the fiscal year ended June&nbsp;30, 2020. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">151
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_15"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Other than compensation arrangements which
are described under &#147;Management&#151;Remuneration&#148; or as disclosed below, from July&nbsp;1, 2017 through the date of this prospectus, we did not enter into any transactions or loans with any: (i)&nbsp;enterprises that directly or
indirectly, through one or more intermediaries, control, are controlled by or are under common control with us; (ii)&nbsp;associates; (iii)&nbsp;individuals owning, directly or indirectly, an interest in our voting power that gives them significant
influence over us, and close members of any such individual&#146;s family; (iv)&nbsp;key management personnel and close members of such individuals&#146; families; or (v)&nbsp;enterprises in which a substantial interest in our voting power is owned,
directly or indirectly, by any person described in (iii)&nbsp;or (iv)&nbsp;or over which such person is able to exercise significant influence. </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Ordinary Share Private Financing </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In December 2019, we issued and sold to certain institutional investors, including Regal Funds Management Pty Ltd., approximately
18.9&nbsp;million ordinary shares at a purchase price of A$2.65 per share for an aggregate purchase price of A$50.0&nbsp;million. Regal Funds Management Pty Ltd., a holder of over 10% of our outstanding ordinary shares as of June&nbsp;30, 2020,
purchased approximately 2.8&nbsp;million shares for A$7.5&nbsp;million. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Director and Senior Management Compensation </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">See &#147;Management&#151;Remuneration&#148; for information regarding compensation of our senior management and directors. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Indemnification Agreements </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Constitution provides that, except to the extent
prohibited by law including under the Corporations Act and, to the extent that an officer is not otherwise indemnified by us pursuant to an indemnity, we will indemnify every person who is or has been an officer of the company against any liability
(other than legal costs that are unreasonable) incurred by that person as an officer. This includes any liability incurred by that person in their capacity as an officer of our subsidiary where we requested that person to accept that appointment.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have entered into Deeds of Indemnity,
Insurance and Access, or Indemnity Deeds, with Geoffrey Kempler and Michael Sistenich, each a <FONT STYLE="white-space:nowrap">non-employee</FONT> director. Under the Indemnity Deeds, we have agreed to indemnify (to the maximum extent permitted
under Australian law and our Constitution, subject to certain specified exceptions) each director against all liabilities incurred in their capacity as our or our subsidiaries&#146; director or officer and any and all costs and expenses relating to
such a claim or to any notified event incurred by such director , including costs and expenses reasonably and necessarily incurred to mitigate any liability for such a claim or any claim which may arise from such a notified event. The Indemnity
Deeds provide that the indemnities are unlimited as to amount, continuous and irrevocable. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Separately, we have obtained insurance for Messrs. Kempler and Sistenich, as required by the Indemnity Deeds. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling
us pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Related Person Transaction Policy </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We comply with Australian law and the rules and regulations
of the ASX regarding approval of transactions with related parties. Prior to the closing of this offering, we intend to adopt a related person transaction policy </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">152
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
that sets forth our procedures for the identification, review, consideration and approval or ratification of related person transactions. The policy will become effective upon the execution of
the underwriting agreement for this offering. For purposes of our policy, a related person transaction is a transaction, arrangement or similar contractual relationship, or any series of similar transactions, arrangements or relationships, in which
we and any related person are, were or will be participants and the amount involved in the transaction exceeds $120,000, with the exception of usual transactions concluded under normal conditions. A related person is any member of our board of
directors, our senior management or any beneficial owner of more than 5% of any class of our ordinary shares, including any of their immediate family members and any entity owned or controlled by such persons. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the policy, if a transaction has been identified as a
related person transaction, including any transaction that was not a related person transaction when originally consummated or any transaction that was not initially identified as a related person transaction prior to consummation, our senior
management must present information regarding the related person transaction to the board of directors for review, consideration and approval or ratification. The presentation must include a description of, among other things, the material facts,
the interests, direct and indirect, of the related persons, the benefits to us of the transaction and whether the transaction is on terms that are comparable to the terms available to or from, as the case may be, an unrelated third party or to or
from employees generally. Under the policy, we will collect information that we deem reasonably necessary from each member of our board of directors and, to the extent feasible, significant shareholder to enable us to identify any existing or
potential related-person transactions and to effectuate the terms of the policy. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">All of the transactions described above were entered into prior to the adoption of the written policy, but our board of directors evaluated and approved all transactions that were considered to be related
party transactions under Australian law and the rules and regulations of the ASX at the time at which they were consummated. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">153
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_16"></A>PRINCIPAL SHAREHOLDERS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth information with respect to
the beneficial ownership of our ordinary shares as of June&nbsp;30, 2020, for: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">each person or group of affiliated persons known by us to beneficially own more than 5% of our ordinary shares; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">each member of our senior management; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">each of our directors; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">all of our directors and senior management as a group. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To our knowledge, as of June&nbsp;30, 2020, approximately
374,934 ordinary shares, or 0.1% of our ordinary shares, were held of record by six residents of the United States. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have determined beneficial ownership in accordance with the rules and regulations of the SEC, and the information is not necessarily
indicative of beneficial ownership for any other purpose. Except as indicated by the footnotes below, we believe, based on information furnished to us, that the persons and entities named in the table below have sole voting and sole investment power
with respect to all shares that they beneficially own. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Applicable percentage ownership before the offering is based on 269,157,769 ordinary shares outstanding as of June&nbsp;30, 2020. Applicable percentage ownership after the offering is based on ordinary
shares outstanding immediately after the closing of this offering (after giving effect to the sale and issuance of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADSs representing
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares at an ADS-to-ordinary share ratio of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-to-1), assuming no exercise by the underwriters of their option to purchase additional ADSs. In computing the number of shares beneficially owned by a
person or entity and the percentage ownership of such person or entity, we deemed to be outstanding all shares subject to options held by the person or entity that are currently exercisable, or exercisable within 60 days of June&nbsp;30, 2020.
However, except as described above, we did not deem such shares outstanding for the purpose of computing the percentage ownership of any other person or entity. The information contained in the following table is not necessarily indicative of
beneficial ownership for any other purpose, and the inclusion of any shares in the table does not constitute an admission of beneficial ownership of those shares. Each of our shareholders is entitled to one vote per ordinary share. None of the
holders of our shares will have different voting rights from other holders of shares after the closing of this offering. We are not aware of any arrangement that may, at a subsequent date, result in a change of control of our company. For further
information regarding options to purchase ordinary shares held by our directors and senior management, see &#147;Management&#151;Remuneration.&#148; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">154
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless otherwise indicated, the address of each beneficial owner listed below is c/o
Opthea Limited, Suite 0403, Level&nbsp;4, 650 Chapel Street, South Yarra, VIC 3141, Australia. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percentage&nbsp;of&nbsp;Shares&nbsp;Beneficially&nbsp;Owned</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name of Beneficial Owner</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number of<BR>Ordinary&nbsp;Shares<BR>Beneficially<BR>Owned</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Before Offering</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>After Offering</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Principal Shareholders</I></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Regal Funds Management Pty Ltd.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32,661,678</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Baker Brothers Advisors L.P.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26,526,759</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Entities affiliated with the Liberman Family</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,228,128</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">KiFin Ltd.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(4)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,275,227</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Directors and Senior Management</I></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Megan Baldwin, Ph.D.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(5)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,987,723</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael Tonroe</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(6)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,400,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Geoffrey Kempler</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(7)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,400,960</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael Sistenich</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(8)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,020,178</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All directors and senior management as a group (four persons)</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(9)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,808,861</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Represents beneficial ownership of less than 1%. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of 32,661,678 ordinary shares beneficially owned. The address for Regal Funds Management Pty Ltd. is Level&nbsp;47, Gateway, 1 Macquarie Place, Sydney, NSW
2000, Australia. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of (i) 2,166,666 ordinary shares held by 667, L.P. and (ii) 24,360,093 ordinary shares held by Baker Brothers Life Sciences, L.P. We refer to 667, L.P. and
Baker Brothers Life Sciences, L.P. together as the Baker Entities. Julian C. Baker and Felix J. Baker are the controlling members of the ultimate general partners of the Baker Entities and each may be deemed to indirectly beneficially own the
securities held by the Baker Entities. Julian C. Baker and Felix J. Baker disclaim beneficial ownership of the ordinary shares directly owned by the Baker Entities. The address for the Baker Entities is 880 Washington Street, 3rd Floor, New York,
New York 10014. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of 19,228,128 ordinary shares beneficially owned. The address for the entities affiliated with the Liberman Family is 8 Oxford Street, South Yarra, VIC 3141,
Australia. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of 16,275,227 ordinary shares beneficially owned. The address for KiFin Ltd. is Geneva Place, 333 Waterfront Drive, Road Town, Tortola, British Virgin Islands.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of (i) 997,723 ordinary shares beneficially owned and (ii) 7,000,000 ordinary shares issuable upon the exercise of options that are exercisable within 60 days
of June&nbsp;30, 2020. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of 1,400,000 ordinary shares issuable upon the exercise of options that are exercisable within 60 days of June&nbsp;30, 2020. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of (i) 900,960 ordinary shares directly held by Mr.&nbsp;Kempler and (ii) 3,500,000 ordinary shares issuable upon the exercise of options that are exercisable
within 60 days of June&nbsp;30, 2020. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of (i) 520,178 ordinary shares directly held by Mr.&nbsp;Sistenich and (ii) 2,500,000 ordinary shares issuable upon the exercise of options that are
exercisable within 60 days of June&nbsp;30, 2020. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of (i) 2,418,861 ordinary shares beneficially owned and (ii) 14,400,000 ordinary shares issuable upon the exercise of options that are exercisable within 60
days of June&nbsp;30, 2020. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">155
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_17"></A>DESCRIPTION OF SHARE CAPITAL </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>General </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following description of our ordinary shares is only a summary. We encourage you to read our Constitution,
which is included as an exhibit to this registration statement, of which this prospectus forms a part. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a public company limited by shares incorporated under the Corporations Act by the Australian Securities and Investments Commission,
or ASIC. Our corporate affairs are principally governed by our Constitution, the Corporations Act and the Australian Securities Exchange, or ASX, Listing Rules. Our ordinary shares trade on the ASX. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Australian law applicable to our Constitution is not
significantly different than a U.S. company&#146;s charter documents except we do not have a limit on our authorized share capital, the concept of par value is not recognized under Australian law and as further discussed under &#147;&#151;Our
Constitution.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to any restrictions
on the issue of securities in our Constitution, the Corporations Act and the ASX Listing Rules and any other applicable law, we may from time to time issue shares and grant options on any terms, with the rights and restrictions and for the
consideration that our board of directors determine. The rights and restrictions attaching to ordinary shares are derived through a combination of our Constitution, the common law applicable in Australia, the ASX Listing Rules, the Corporations Act
and other applicable law. A general summary of some of the rights and restrictions attaching to our ordinary shares are summarized below. Each ordinary shareholder is entitled to receive notice of, and to be present, vote and speak at, general
meetings. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Changes to Our Share Capital </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of June&nbsp;30, 2020, we had (i)
269,157,769&nbsp;ordinary shares outstanding and (ii)&nbsp;outstanding options to purchase 18,044,000&nbsp;ordinary shares at a weighted-average exercise price of A$0.68&nbsp;per share. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">From July&nbsp;1, 2017, through the date of this prospectus, the following events have changed the number of
our issued and outstanding ordinary shares: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In December 2019, we issued 18,867,930 ordinary shares to institutional shareholders at an issue price of A$2.65 per share.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We issued the following ordinary shares upon the exercise of options over the following periods: </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">from July&nbsp;1, 2017 through June&nbsp;30, 2018, 2,063,518 ordinary shares upon the exercise of options granted in connection with capital raise
transactions; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">from July&nbsp;1, 2018 through June&nbsp;30, 2019, 46,776,951 ordinary shares upon the exercise of options granted in connection with capital raise
transactions; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">from July&nbsp;1, 2019 through June&nbsp;30, 2020, 875,000 ordinary shares upon the exercise of options granted to officers and employees.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our Constitution </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Constitution is similar in nature to the bylaws of a
U.S. corporation. It does not provide for or prescribe any specific objectives or purposes of our company. Our Constitution is subject to the terms of the Corporations Act. It may be amended or repealed and replaced by special resolution of
shareholders, which is a resolution passed by at least 75% of the votes cast by shareholders (in person or by proxy) entitled to vote on the resolution. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under Australian law, a company has the legal capacity and powers of an individual both within and outside Australia. The material
provisions of our Constitution are summarized below. This summary is not intended to be </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">156
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
complete nor to constitute a definitive statement of the rights and liabilities of our shareholders, and is qualified in its entirety by reference to the complete text of our Constitution, a copy
of which is on file with the Securities and Exchange Commission. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Interested Directors </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A director or that director&#146;s alternate who has a material personal interest in a matter that is being considered at a directors&#146; meeting must not be present while the matter is being considered
at the meeting or vote in respect of that matter according to our Constitution unless permitted to do so by the Corporations Act, in which case such director may (i)&nbsp;be counted in determining whether or not a quorum is present at any meeting of
directors considering that contract or arrangement or proposed contract or arrangement; (ii)&nbsp;sign or countersign any document relating to that contract or arrangement or proposed contract or arrangement; and (iii)&nbsp;vote in respect of, or in
respect of any matter arising out of, the contract or arrangement or proposed contract or arrangement. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless a relevant exception applies, the Corporations Act requires our directors to provide disclosure of any material personal interest,
and prohibits directors from voting on matters in which they have a material personal interest and from being present at the meeting while the matter is being considered, unless directors who do not have a material personal interest in the relevant
matter have passed a resolution that identifies the director, the nature and extent of the director&#146;s interest in the matter and its relation to our affairs and states that those directors are satisfied that the interest should not disqualify
the director from voting or being present. In addition, the Corporations Act and the ASX Listing Rules may require shareholder approval of any provision of related party benefits to our directors, unless a relevant exception applies. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Directors&#146; Compensation </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our <FONT STYLE="white-space:nowrap">non-employee</FONT>
directors are paid remuneration for their services as directors. Subject to the ASX Listing Rules, <FONT STYLE="white-space:nowrap">non-employee</FONT> directors as a whole may be paid or provided remuneration for their services a total amount or
value not to exceed $500,000 per annum. Subject to the ASX Listing Rules, the aggregate, capped sum for <FONT STYLE="white-space:nowrap">non-employee</FONT> directors&#146; remuneration is to be divided among the directors in such proportion as the
directors themselves agree and in accordance with our Constitution. The capped sum remuneration for <FONT STYLE="white-space:nowrap">non-employee</FONT> directors may not be increased except at a general meeting of shareholders and the particulars
of the proposed increase are required to have been provided to shareholders in the notice convening the meeting. In addition, our board of directors may fix the remuneration of each executive director, which may comprise salary or commission on or
participation in our profits (or comprising a combination of each) as our directors determine. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Fees payable to our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors must be by way of a fixed sum and not by way of a commission on or a percentage of profits or operating revenue.
Remuneration paid to our executive directors must also not include a commission or percentage of operating revenue. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to our Constitution, any director who performs extra services or makes any special exertions, whether in going or residing abroad
or otherwise for any of the purposes of the Company, that director may be paid an additional sum for those services and exertions. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to other remuneration provided in our Constitution, all of our directors are entitled to be paid by us for all travelling and
other expenses properly incurred by the directors in attending general meetings, board meetings, committee meetings or otherwise in connection with our business. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, in accordance with our Constitution, a director
may be paid a retirement benefit as determined by our board of directors subject to the requirements of the Corporations Act. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">157
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Borrowing Powers Exercisable by Directors </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to our Constitution, the management and control of
our business affairs are vested in our board of directors. Our board of directors has the power to raise or borrow money or obtain other financial accommodation for the purposes of the Company, and may grant security for the repayment of that sum or
sums or the payment, performance or fulfilment of any debts, liabilities, contracts or obligations incurred or undertaken by the Company in any manner and upon any terms and conditions as our board of directors deems appropriate. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Retirement of Directors </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to our Constitution,
<FONT STYLE="white-space:nowrap">one-third</FONT> of our directors, other than the managing director, must retire from office at every annual general meeting. If the number of directors is not a multiple of three, then the number nearest, to but not
exceeding, <FONT STYLE="white-space:nowrap">one-third</FONT> must retire from office. The directors who retire in this manner are required to be the directors or director longest in office since last being elected. A director, other than the
managing director, must retire from office at the conclusion of the third annual general meeting after which the director was elected. A retiring director remains in office until the end of the meeting and will be eligible for <FONT
STYLE="white-space:nowrap">re-election</FONT> at the meeting. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Rights and Restrictions on Classes of Shares </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The rights attaching to our ordinary shares are detailed in our Constitution. Our Constitution provides that, subject to the Corporations
Act, the ASX Listing Rules and our Constitution, our directors may issue shares with preferential, deferred or special rights, privileges or conditions or with any restrictions, whether in relation to dividends, voting, return of share capital, or
otherwise as our board of directors may determine. Subject to the Corporations Act, the ASX Listing Rules and our Constitution (see &#147;&#151;Change of Control&#148;), we may issue further shares on such terms and conditions as our board of
directors resolve. We may only issue preference shares if the rights attaching to the preference shares relating to repayment of capital, participation in surplus assets and profits, cumulative and
<FONT STYLE="white-space:nowrap">non-cumulative</FONT> dividends, voting and priority of payment of capital and dividends in respect of other shares (including ordinary shares) are set out in our constitution or otherwise approved by special
resolution passed at a general meeting. Our outstanding share capital consists of only one class of ordinary shares. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Dividend Rights </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Corporations Act, a company must not pay a dividend unless (a)&nbsp;the company&#146;s assets exceed its liabilities immediately
before the dividend is declared and the excess is sufficient for the payment of the dividend; (b)&nbsp;the payment of the dividend is fair and reasonable to the company&#146;s shareholders as a whole; and (c)&nbsp;the payment of the dividend does
not materially prejudice the company&#146;s ability to pay its creditors. Subject to this requirement, our board of directors may from time to time determine to pay and declare dividends to shareholders. All dividends unclaimed for one year after
the time for payment has passed may be invested or otherwise made use of by our board of directors for our benefit until claimed or until dealt with under any law relating to unclaimed moneys. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Voting Rights </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under our Constitution, and subject to any voting exclusions
imposed under the ASX Listing Rules (which typically exclude parties from voting on resolutions in which they have an interest), the rights and restrictions attaching to a class of shares, each shareholder has one vote on a show of hands at a
meeting of the shareholders unless a poll is demanded under the Constitution or the Corporations Act. On a poll vote, each shareholder shall have one vote for each fully paid share and a fractional vote for each share held by that shareholder that
is not fully paid, such fraction being equivalent to the proportion of the amount that has been paid to such date on that share. Shareholders may vote in person or by proxy, attorney or representative. Under Australian law, shareholders of a public
company are generally not permitted to approve corporate matters by written consent. Our Constitution does not provide for cumulative voting. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">158
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under Australian law, an ordinary resolution is passed if a majority of the votes cast
on the resolution (in person or by proxy) by members entitled to vote on the resolution are in favor of the resolution. Under Australian law, a special resolution is passed if at least 75% of the votes cast on the resolution (in person or by proxy)
are in favor of the resolution. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">ADS holders may
not directly vote at a meeting of the shareholders but may instruct the depositary to vote the number of deposited ordinary shares their ADSs represent. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Right to Share in Our Profits </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to our Constitution, our shareholders are entitled to participate in our profits only by payment of dividends. Our board of
directors may from time to time determine to pay dividends to the shareholders. However, any such dividend may only be payable in accordance with the requirements set out in the Corporations Act described above. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Rights to Share in the Surplus in the Event of Winding
Up </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Constitution provides for the
right of shareholders to participate in a surplus in the event of our winding up, subject to the rights attaching to a class of shares,. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>No Redemption Provision for Ordinary Shares </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There are no redemption provisions in our Constitution in
relation to ordinary shares. Under our Constitution, shares may be issued and allotted, which are liable to be redeemed. Under the Corporations Act, redeemable preference shares may only be redeemed if those preference shares are fully <FONT
STYLE="white-space:nowrap">paid-up</FONT> and payment in satisfaction of redemption is out of profits or the proceeds of a new issue of shares made for the purposes of the redemption. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Variation or Cancellation of Share Rights </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to the Corporations Act, the ASX Listing Rules and
the terms of issue of shares of that class, the rights and privileges attached to shares in a class of shares may only be varied or cancelled by a special resolution, together with either: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a special resolution passed at a meeting of members holding shares in the class; or </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the written consent of members with at least 75% of the shares in the class. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Directors May Make Calls </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Constitution provides that subject to compliance with
the Corporations Act and the terms on which partly paid shares are issued, directors may make calls on the holders of the shares for any money unpaid on them. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>General Meetings of Shareholders </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">General meetings of shareholders may be called by our board of directors. Except as permitted under the Corporations Act, shareholders may
not convene a meeting. The Corporations Act requires the directors to call and arrange to hold a general meeting on the request of shareholders with at least 5% of the votes that may be cast at a general meeting. Notice of the proposed meeting of
our shareholders is required at least 28 days prior to such meeting under the Corporations Act. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">159
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Foreign Ownership Regulation </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Constitution does not impose specific limitations on the
rights of <FONT STYLE="white-space:nowrap">non-residents</FONT> to own securities. However, acquisitions and proposed acquisitions of securities in Australian companies may be subject to review and approval by the Australian Federal Treasurer under
the Foreign Acquisitions and Takeovers Act 1975 (Cth), or the FATA, which generally applies to acquisitions or proposed acquisitions: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">by a foreign person (as defined in the FATA) or associated foreign persons that would result in such persons having an interest in 20% or more of the
issued shares of, or control of 20% or more of the voting power in, an Australian company; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">by <FONT STYLE="white-space:nowrap">non-associated</FONT> foreign persons that would result in such foreign persons having an aggregate interest in 40%
or more of the issued shares of, or control of 40% or more of the voting power in, an Australian company, where the Australian company is valued above the monetary threshold prescribed by FATA. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Due to the impacts of the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, the monetary thresholds for foreign investment proposals covered by the FATA and its associated regulations have been reduced to zero. This regime may revert in the future to the previous
regime, which, in general terms, provided that in respect of proposals for investment in <FONT STYLE="white-space:nowrap">non-sensitive</FONT> sectors, no such review or approval under the FATA is required if the foreign acquirer is a U.S. entity or
an entity from certain other countries and the value of the Australian target is less than A$1,192&nbsp;million. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Australian Federal Treasurer may prevent a proposed acquisition in the above categories or impose conditions on such acquisition if
the Treasurer is satisfied that the acquisition would be contrary to the national interest. If a foreign person acquires shares or an interest in shares in an Australian company in contravention of the FATA, the Australian Federal Treasurer may make
a range of orders including an order the divestiture of such person&#146;s shares or interest in shares in that Australian company. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Ownership Threshold </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There are no specific provisions in our Constitution that require a shareholder to disclose ownership above a certain threshold. The
Corporations Act, however, requires a shareholder to notify us and the ASX once it, together with its associates, acquires a 5% interest in our ordinary shares, at which point the shareholder will be considered to be a &#147;substantial&#148;
shareholder. Further, once a shareholder owns (alone or together with associates) a 5% interest in us, such shareholder must notify us and the ASX of any increase or decrease of 1% or more in its holding of our ordinary shares, and must also notify
us and the ASX on its ceasing to be a &#147;substantial&#148; shareholder. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Issues of Shares and Change in Capital </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Subject to our Constitution, the Corporations Act, the ASX Listing Rules and any other applicable law, we may at any time issue shares and give any person a call or option over any shares on any terms,
with preferential, deferred or other special rights, privileges or conditions or with restrictions and for the consideration and other terms that the directors determine. We may only issue preference shares if the rights attaching to the preference
shares relating to repayment of capital, participation in surplus assets and profits, cumulative and <FONT STYLE="white-space:nowrap">non-cumulative</FONT> dividends, voting and priority of payment of capital and dividends in respect of other shares
(including ordinary shares) are set out in our Constitution or otherwise approved by special resolution passed at a general meeting of shareholders. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to the requirements of our Constitution, the Corporations Act, the ASX Listing Rules and any other applicable law, including
relevant shareholder approvals, we may consolidate or divide our share capital into a larger or smaller number by resolution, reduce our share capital in any manner (provided that the reduction is fair and reasonable to our shareholders as a whole,
does not materially prejudice our ability to pay creditors and obtains the necessary shareholder approval) or buy back our ordinary shares whether under an equal access <FONT STYLE="white-space:nowrap">buy-back</FONT> or on a selective basis.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">160
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Change of Control </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Takeovers of listed Australian public companies, including
us, are regulated by the Corporations Act, which prohibits the acquisition of a &#147;relevant interest&#148; in issued voting shares in a listed company if the acquisition will lead to that person&#146;s or someone else&#146;s voting power in our
company increasing from 20% or below to more than 20% or increasing from a starting point that is above 20% and below 90%, which we refer to as the Takeovers Prohibition, subject to a range of exceptions. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Generally, a person will have a relevant interest in
securities if the person: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">is the holder of the securities (other than if the person holds those securities as a bare trustee); </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">has power to exercise, or control the exercise of, a right to vote attached to the securities; or </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">has the power to dispose of, or control the exercise of a power to dispose of, the securities. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If, at a particular time, </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a person has a relevant interest in issued securities; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the person (whether before or after acquiring the relevant interest) has: </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">entered or enters into an agreement with another person with respect to the securities; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">given or gives another person an enforceable right, or has been or is given an enforceable right by another person, in relation to the securities
(whether the right is enforceable presently or in the future and whether or not on the fulfillment of a condition); or </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">granted or grants an option to, or has been or is granted an option by, another person with respect to the securities; and
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the other person would have a relevant interest in the securities if the agreement were performed, the right enforced or the option exercised,
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">then the other person is taken
to have a relevant interest in the relevant securities. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">There are a number of exceptions to the Takeover Prohibition. In general terms, some of the more significant exceptions include: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">when the acquisition results from the acceptance of an offer under a formal takeover bid; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">when the acquisition is conducted on market by or on behalf of the bidder during the bid period for a full takeover bid that is unconditional or only
conditional on certain &#145;prescribed&#146; matters set out in the Corporations Act; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">when the acquisition has been previously approved by our shareholders by resolution passed at general meeting; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an acquisition by a person if, throughout the six months before the acquisition, that person or any other person has had voting power in our company of
at least 19% and, as a result of the acquisition, none of the relevant persons would have voting power in our company more than three percentage points higher than they had six months before the acquisition; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">when the acquisition results from the issue of securities under a rights issue; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">when the acquisition results from the issue of securities under a dividend reinvestment scheme or bonus share plan; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">when the acquisition results from the issue of securities under certain underwriting arrangements; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">when the acquisition results from the issue of securities through a will or through operation of law; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">161
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an acquisition that arises through the acquisition of a relevant interest in another listed company which is listed on a prescribed financial market or
a financial market approved by ASIC; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an acquisition arising from an auction of forfeited shares conducted <FONT STYLE="white-space:nowrap">on-market;</FONT> or
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an acquisition arising through a compromise, arrangement, liquidation or <FONT STYLE="white-space:nowrap">buy-back.</FONT>
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Breaches of the takeovers
provisions of the Corporations Act are criminal offenses. ASIC and the Australian Takeover Panel have a wide range of powers relating to breaches of takeover provisions, including the ability to make orders, canceling contracts, freezing transfers
of, and rights attached to, securities and forcing a party to dispose of securities. There are certain defenses to breaches of the Takeover Prohibition provided in the Corporations Act. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Access to and Inspection of Documents </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inspection of our records is governed by our Constitution
and the Corporations Act. Any member of the Company has the right to inspect or obtain copies of our share register on the payment of a prescribed fee. Our books containing the minutes of general meetings will be kept at our registered office and
will be open to inspection of members at all times when the office is required to be open to the public. Other corporate records, including minutes of directors&#146; meetings, financial records and other documents, are not open for inspection by
shareholders (who are not directors). Where a shareholder is acting in good faith and an inspection is deemed to be made for a proper purpose, a shareholder may apply to the court to make an order for inspection of our books. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Legal Name; Formation; Registered Office </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We were incorporated under the laws of Australia in 1984
under the name Circadian Technologies Limited. In 1985, we completed an initial public offering of our ordinary shares and the listing of our ordinary shares on the Australian Securities Exchange, or the ASX. In December 2015, we changed the name of
our company to Opthea Limited. Our headquarters and registered offices are located at Suite 0403, Level&nbsp;4, 650 Chapel Street, South Yarra, VIC 3141, Australia. Our agent for service of process in the United States is Corporation Service
Company, located at 1180 Avenue of the Americas, Suite 210, New York, New York 10036. Our website address is www.opthea.com. The reference to our website is an inactive textual reference only and information contained in, or that can be assessed
through, our website is not part of this prospectus. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Listing
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have applied to have our ADSs listed on
the Nasdaq Global Market under the symbol &#147;OPT.&#148; Our ordinary shares are listed on the ASX under the symbol &#147;OPT.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Transfer Agent and Registrar </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon the closing of this offering, the transfer agent and registrar for our ADSs will be
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. Computershare Investor Services Pty Limited is our transfer agent and registrar for our ordinary shares and currently maintains our share register for
our ordinary shares. The share register reflects only record owners of our ordinary shares. Holders of our ADSs will not be treated as one of our shareholders and their names will therefore not be entered in our share register. The depositary, the
custodian or their nominees will be the holder of the shares underlying the ADSs. Holders of our ADSs have a right to receive the ordinary shares underlying their ADSs. See &#147;Description of American Depositary Shares.&#148; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">162
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_18"></A>DESCRIPTION OF AMERICAN DEPOSITARY SHARES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;has agreed to act as the depositary bank for the ADSs.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#146;s depositary offices are located at &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. ADSs
represent ownership interests in securities that are on deposit with the depositary bank. ADSs may be represented by certificates that are commonly known as American Depositary Receipts. The depositary bank typically appoints a custodian to safekeep
the securities on deposit. In this case, the custodian is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We will appoint &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;as depositary bank pursuant to a deposit agreement. A copy of the deposit agreement has been
filed with the SEC under cover of a Registration Statement on <FONT STYLE="white-space:nowrap">Form&nbsp;F-6&nbsp;(Registration</FONT>
<FONT STYLE="white-space:nowrap">No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;).</FONT> You may obtain a copy of the deposit agreement from the SEC&#146;s website at www.sec.gov.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are providing you with a summary description
of the material terms of the ADSs and of your material rights as an owner of ADSs. Please remember that summaries by their nature lack the precision of the information summarized and that the rights and obligations of an owner of ADSs will be
determined by reference to the terms of the deposit agreement and not by this summary. We urge you to review the deposit agreement in its entirety. The portions of this summary description that are italicized describe matters that may be relevant to
the ownership of ADSs but that may not be contained in the deposit agreement. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Each ADS represents the right to receive, and to exercise the beneficial ownership interests in, one ordinary share<B></B>&nbsp;that is on deposit with the depositary bank and/or custodian. An ADS also
represents the right to receive, and to exercise the beneficial interests in, any other property received by the depositary bank or the custodian on behalf of the owner of the ADS but that has not been distributed to the owners of ADSs because of
legal restrictions or practical considerations. We and the depositary bank may agree to change <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">the&nbsp;ADS-to-ordinary</FONT></FONT> share&nbsp;ratio by amending the deposit
agreement. This amendment may give rise to, or change, the depositary fees payable by ADS owners. The custodian, the depositary bank and their respective nominees will hold all deposited property for the benefit of the holders and beneficial owners
of ADSs. The deposited property does not constitute the proprietary assets of the depositary bank, the custodian or their nominees.&nbsp;Beneficial ownership in the deposited property will under the terms of the deposit agreement be vested in the
beneficial owners of the ADSs. The depositary bank, the custodian and their respective nominees will be the record holders of the deposited property represented by the ADSs for the benefit of the holders and beneficial owners of the corresponding
ADSs.&nbsp;A beneficial owner of ADSs may or may not be the holder of ADSs. Beneficial owners of ADSs will be able to receive, and to exercise beneficial ownership interests in, the deposited property only through the registered holders of the ADSs,
the registered holders of the ADSs (on behalf of the applicable ADS owners) only through the depositary bank, and the depositary bank (on behalf of the owners of the corresponding ADSs) directly, or indirectly, through the custodian or their
respective nominees, in each case upon the terms of the deposit agreement. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If you become an owner of ADSs, you will become a party to the deposit agreement and therefore will be bound to its terms and to the terms of any ADR that represents your ADSs. The deposit agreement and
the ADR specify our rights and obligations as well as your rights and obligations as owner of ADSs and those of the depositary bank. As an ADS holder you appoint the depositary bank to act on your behalf in certain circumstances. The deposit
agreement and the ADRs are governed by New York law. However, our obligations to the holders of ordinary shares will continue to be governed by the laws of Australia, which may be different from the laws in the United States. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, applicable laws and regulations may require you
to satisfy reporting requirements and obtain regulatory approvals in certain circumstances. You are solely responsible for complying with such reporting requirements and obtaining such approvals. Neither the depositary bank, the custodian, us or any
of their or our respective agents or affiliates shall be required to take any actions whatsoever on your behalf to satisfy such reporting requirements or obtain such regulatory approvals under applicable laws and regulations. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">163
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>As an owner of ADSs, we will not treat you as one of our shareholders and you will
not have direct shareholder rights. The depositary bank will hold on your behalf the shareholder rights attached to the&nbsp;ordinary shares underlying your ADSs. As an owner of ADSs you will be able to exercise the shareholders rights for
the&nbsp;ordinary shares represented by your ADSs through the depositary bank only to the extent contemplated in the deposit agreement. To exercise any shareholder rights not contemplated in the deposit agreement you will, as an ADS owner, need to
arrange for the cancellation of your ADSs and become a direct shareholder. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The manner in which you own the ADSs (for example, in a brokerage account vs. as registered holder, or as holder of certificated versus uncertificated ADSs) may affect your rights and obligations, and the
manner in which, and extent to which, the depositary bank&#146;s services are made available to you. As an owner of ADSs, you may hold your ADSs either by means of an ADR registered in your name, through a brokerage or safekeeping account, or
through an account established by the depositary bank in your name reflecting the registration of uncertificated ADSs directly on the books of the depositary bank (commonly referred to as the &#147;direct registration system&#148; or
&#147;DRS&#148;). The direct registration system reflects the uncertificated (book-entry) registration of ownership of ADSs by the depositary bank. Under the direct registration system, ownership of ADSs is evidenced by periodic statements issued by
the depositary bank to the holders of the ADSs. The direct registration system includes automated transfers between the depositary bank and The Depository Trust Company, or DTC, the central book-entry clearing and settlement system for equity
securities in the United States. If you decide to hold your ADSs through your brokerage or safekeeping account, you must rely on the procedures of your broker or bank to assert your rights as ADS owner. Banks and brokers typically hold securities
such as the ADSs through clearing and settlement systems such as DTC. The procedures of such clearing and settlement systems may limit your ability to exercise your rights as an owner of ADSs. Please consult with your broker or bank if you have any
questions concerning these limitations and procedures. All ADSs held through DTC will be registered in the name of a nominee of DTC. This summary description assumes you have opted to own the ADSs directly by means of an ADS registered in your name
and, as such, we will refer to you as the &#147;holder.&#148; When we refer to &#147;you,&#148; we assume the reader owns ADSs and will own ADSs at the relevant time. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The registration of the ordinary shares in the name of the
depositary bank or the custodian shall, to the maximum extent permitted by applicable law, vest in the depositary bank or the custodian the record ownership in the applicable ordinary shares with the beneficial ownership rights and interests in such
ordinary shares being at all times vested with the beneficial owners of the ADSs representing the ordinary shares. The depositary bank or the custodian will at all times be entitled to exercise the beneficial ownership rights in all deposited
property, in each case only on behalf of the holders and beneficial owners of the ADSs representing the deposited property. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Dividends and Distributions </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a holder of ADSs, you generally have the right to receive the distributions we make on the securities deposited with the custodian.
Your receipt of these distributions may be limited, however, by practical considerations and legal limitations. Holders of ADSs will receive such distributions under the terms of the deposit agreement in proportion to the number of ADSs held as of
the specified record date, after deduction of the applicable fees, taxes and expenses. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Distributions of Cash </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Whenever we make a cash distribution for the securities on deposit with the custodian, we will deposit the funds with the custodian. Upon receipt of confirmation of the deposit of the requisite funds, the
depositary bank will arrange for the funds received in a currency other than U.S. dollars to be converted into U.S. dollars and for the distribution of the U.S. dollars to the holders, subject to Australian laws and regulations. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">164
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The conversion into U.S. dollars will take place only if practicable and if the U.S.
dollars are transferable to the United States. The depositary bank will apply the same method for distributing the proceeds of the sale of any property (such as undistributed rights) held by the custodian in respect of securities on deposit.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The distribution of cash will be made net of the
fees, expenses, taxes and governmental charges payable by holders under the terms of the deposit agreement. The depositary bank will hold any cash amounts it is unable to distribute in
<FONT STYLE="white-space:nowrap">a&nbsp;non-interest&nbsp;bearing</FONT> account for the benefit of the applicable holders and beneficial owners of ADSs until the distribution can be effected or the funds that the depositary bank holds must be
escheated as unclaimed property in accordance with the laws of the relevant states of the United States. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Distributions of Shares </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Whenever we make a free distribution of ordinary shares for the securities on deposit with the custodian, we will deposit the applicable
number of ordinary shares with the custodian. Upon receipt of confirmation of such deposit, the depositary bank will&nbsp;either&nbsp;distribute to holders new ADSs representing the ordinary shares deposited&nbsp;or&nbsp;modify <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">the&nbsp;ADS-to-ordinary</FONT></FONT> shares ratio, in which case each ADS you hold will represent rights and interests in the additional ordinary shares so deposited. Only whole new ADSs
will be distributed. Fractional entitlements will be sold and the proceeds of such sale will be distributed as in the case of a cash distribution. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The distribution of new ADSs or the modification of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">the&nbsp;ADS-to-ordinary</FONT></FONT> shares ratio upon a distribution of ordinary shares will be made net of the fees, expenses, taxes and governmental charges payable by holders
under the terms of the deposit agreement. To pay such taxes or governmental charges, the depositary bank may sell all or a portion of the new ordinary shares so distributed. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">No such distribution of new ADSs will be made if it would
violate a law (such as U.S. securities laws) or if it is not operationally practicable. If the depositary bank does not distribute new ADSs as described above, it may sell the ordinary shares received upon the terms described in the deposit
agreement and will distribute the proceeds of the sale as in the case of a distribution of cash. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Distributions of Rights </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Whenever we intend to distribute rights to subscribe for additional ordinary shares, we will give prior notice to the depositary bank and we will assist the depositary bank in determining whether it is
lawful and reasonably practicable to distribute rights to subscribe for additional ADSs to holders. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The depositary bank will establish procedures to distribute rights to subscribe for additional ADSs to holders and to enable such holders to exercise such rights if it is lawful and reasonably practicable
to make the rights available to holders of ADSs, and if we provide all of the documentation contemplated in the deposit agreement (such as opinions to address the lawfulness of the transaction). You may have to pay fees, expenses, taxes and other
governmental charges to subscribe for the new ADSs upon the exercise of your rights. The depositary bank is not obligated to establish procedures to facilitate the distribution and exercise by holders of rights to subscribe for new ordinary shares
other than in the form of ADSs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The depositary
bank will&nbsp;not distribute the rights to you if: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we do not timely request that the rights be distributed to you or we request that the rights not be distributed to you; or
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we fail to deliver satisfactory documents to the depositary bank; or </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">it is not reasonably practicable to distribute the rights. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The depositary bank will sell the rights that are not
exercised or not distributed if such sale is lawful and reasonably practicable. The proceeds of such sale will be distributed to holders as in the case of a cash distribution. If the depositary bank is unable to sell the rights, it will allow the
rights to lapse. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">165
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Elective Distributions </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Whenever we intend to distribute a dividend payable at the
election of shareholders either in cash or in additional shares, we will give prior notice thereof to the depositary bank and will indicate whether we wish the elective distribution to be made available to you. In such case, we will assist the
depositary bank in determining whether such distribution is lawful and reasonably practicable. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The depositary bank will make the election available to you only if it is reasonably practicable and if we have provided all of the documentation contemplated in the deposit agreement. In such case, the
depositary bank will establish procedures to enable you to elect to receive either cash or additional ADSs, in each case as described in the deposit agreement. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the election is not made available to you, you will receive either cash or additional ADSs, depending on what a shareholder in
Australia would receive upon failing to make an election, as more fully described in the deposit agreement. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other Distributions </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Whenever we intend to distribute property other than cash, ordinary shares or rights to subscribe for additional ordinary shares, we will
notify the depositary bank in advance and will indicate whether we wish such distribution to be made to you. If so, we will assist the depositary bank in determining whether such distribution to holders is lawful and reasonably practicable.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If it is reasonably practicable to distribute
such property to you and if we provide to the depositary bank all of the documentation contemplated in the deposit agreement, the depositary bank will distribute the property to the holders in a manner it deems practicable. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The distribution will be made net of fees, expenses, taxes
and governmental charges payable by holders under the terms of the deposit agreement. To pay such taxes and governmental charges, the depositary bank may sell all or a portion of the property received. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The depositary bank will&nbsp;not&nbsp;distribute the
property to you and will sell the property if: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we do not request that the property be distributed to you or if we request that the property not be distributed to you; or
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we do not deliver satisfactory documents to the depositary bank; or </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the depositary bank determines that all or a portion of the distribution to you is not reasonably practicable. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The proceeds of such a sale will be distributed to holders as
in the case of a cash distribution. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Redemption </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Whenever we decide to redeem any of the securities on
deposit with the custodian, we will notify the depositary bank in advance. If it is practicable and if we provide all of the documentation contemplated in the deposit agreement, the depositary bank will provide notice of the redemption to the
holders. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The custodian will be instructed to
surrender the shares being redeemed against payment of the applicable redemption price. The depositary bank will convert into U.S. dollars upon the terms of the deposit agreement the redemption funds received in a currency other than U.S. dollars
and will establish procedures to enable holders to receive the net proceeds from the redemption upon surrender of their ADSs to the depositary bank. You may have to pay fees, expenses, taxes and other governmental charges upon the redemption of your
ADSs. If less than all ADSs are being redeemed, the ADSs to be retired will be selected by lot or on a<I>&nbsp;pro rata</I>&nbsp;basis, as the depositary bank may determine. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">166
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Changes Affecting Ordinary Shares </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The ordinary shares held on deposit for your ADSs may change from time to time. For example, there may be a
change in nominal or par <FONT STYLE="white-space:nowrap">value,&nbsp;split-up,&nbsp;cancellation,</FONT> consolidation or any other reclassification of such ordinary shares or a recapitalization, reorganization, merger, consolidation or sale of
assets of the Company. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If any such change were to
occur, your ADSs would, to the extent permitted by law and the deposit agreement, represent the right to receive the property received or exchanged in respect of the ordinary shares held on deposit. The depositary bank may in such circumstances
deliver new ADSs to you, amend the deposit agreement, the ADRs and the applicable Registration Statement on <FONT STYLE="white-space:nowrap">Form&nbsp;F-6,&nbsp;call</FONT> for the exchange of your existing ADSs for new ADSs and take any other
actions that are appropriate to reflect as to the ADSs the change affecting the Shares. If the depositary bank may not lawfully distribute such property to you, the depositary bank may sell such property and distribute the net proceeds to you as in
the case of a cash distribution. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Issuance of ADSs upon Deposit
of Ordinary Shares </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon completion of the
offering, the ordinary shares being offered pursuant to the prospectus will be deposited by us with the custodian.&nbsp;Upon receipt of confirmation of such deposit, the depositary bank will issue ADSs to the underwriters named in the prospectus.
After the completion of the offering, the ordinary shares that are being offered for sale pursuant to the prospectus will be deposited by us with the custodian. Upon receipt of confirmation of such deposit, the depositary bank will issue ADSs to the
underwriters named in the prospectus. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Following
the closing of this offering, the depositary bank may create ADSs on your behalf if you or your broker deposit ordinary shares with the custodian. The depositary bank will deliver these ADSs to the person you indicate only after you pay any
applicable issuance fees and any charges and taxes payable for the transfer of the ordinary shares to the custodian. Your ability to deposit ordinary shares and receive ADSs may be limited by U.S. and Australian legal considerations applicable at
the time of deposit. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The issuance of ADSs may be
delayed until the depositary bank or the custodian receives confirmation that all required approvals have been given and that the ordinary shares have been duly transferred to the custodian. The depositary bank will only issue ADSs in whole numbers.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">When you make a deposit of ordinary shares, you
will be responsible for transferring good and valid title to the depositary bank. As such, you will be deemed to represent and warrant that: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The ordinary shares are duly authorized, validly issued, fully <FONT STYLE="white-space:nowrap">paid,&nbsp;non-assessable&nbsp;and</FONT> legally
obtained. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">All preemptive (and similar) rights, if any, with respect to such ordinary shares have been validly waived or exercised. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">You are duly authorized to deposit the ordinary shares. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The ordinary shares presented for deposit are free and clear of any lien, encumbrance, security interest, charge, mortgage or adverse claim, and are
not, and the ADSs issuable upon such deposit will not be, &#147;restricted securities&#148; (as defined in the deposit agreement). </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The ordinary shares presented for deposit have not been stripped of any rights or entitlements. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If any of the representations or warranties are incorrect in
any way, we and the depositary bank may, at your cost and expense, take any and all actions necessary to correct the consequences of the misrepresentations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Transfer, Combination and Split Up of ADRs </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As an ADR holder, you will be entitled to transfer, combine or split up your ADRs and the ADSs evidenced thereby. For transfers of ADRs,
you will have to surrender the ADRs to be transferred to the depositary bank and also must: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">ensure that the surrendered ADR is properly endorsed or otherwise in proper form for transfer; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">167
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">provide such proof of identity and genuineness of signatures as the depositary bank deems appropriate; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">provide any transfer stamps required by the State of New York or the United States; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">pay all applicable fees, charges, expenses, taxes and other government charges payable by ADR holders pursuant to the terms of the deposit agreement,
upon the transfer of ADRs. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To
have your ADRs either combined or split up, you must surrender the ADRs in question to the depositary bank with your request to have them combined or split up, and you must pay all applicable fees, charges and expenses payable by ADR holders,
pursuant to the terms of the deposit agreement, upon a combination or split up of ADRs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Withdrawal of Ordinary shares Upon Cancellation of ADSs </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a holder, you will be entitled to present your ADSs to the depositary bank for cancellation and then receive the corresponding number
of underlying ordinary shares<B></B>&nbsp;at the custodian&#146;s offices. Your ability to withdraw the ordinary shares held in respect of the ADSs may be limited by U.S. and Australian law considerations applicable at the time of withdrawal. To
withdraw the ordinary shares represented by your ADSs, you will be required to pay to the depositary bank the fees for cancellation of ADSs and any charges and taxes payable upon the transfer of the ordinary shares. You assume the risk for delivery
of all funds and securities upon withdrawal. Once canceled, the ADSs will not have any rights under the deposit agreement. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you hold ADSs registered in your name, the depositary bank may ask you to provide proof of identity and genuineness of any signature
and such other documents as the depositary bank may deem appropriate before it will cancel your ADSs. The withdrawal of the ordinary shares represented by your ADSs may be delayed until the depositary bank receives satisfactory evidence of
compliance with all applicable laws and regulations. Please keep in mind that the depositary bank will only accept ADSs for cancellation that represent a whole number of securities on deposit. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You will have the right to withdraw the securities represented by your ADSs at any time except for: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">temporary delays that may arise because (i)&nbsp;the transfer books for the ordinary shares or ADSs are closed or (ii)&nbsp;ordinary shares are
immobilized on account of a shareholders&#146; meeting or a payment of dividends; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">obligations to pay fees, taxes and similar charges; or </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">restrictions imposed because of laws or regulations applicable to ADSs or the withdrawal of securities on deposit. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The deposit agreement may not be modified to impair your
right to withdraw the securities represented by your ADSs except to comply with mandatory provisions of law. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Voting Rights </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As a holder, you generally have the right under the deposit agreement to instruct the depositary bank to exercise the voting rights for the ordinary shares represented by your ADSs. The voting rights of
holders of ordinary shares are described under &#147;Description of Share Capital&#151;Voting Rights.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At our request, the depositary bank will distribute to you any notice of shareholders&#146; meeting received from us together with
information explaining how to instruct the depositary bank to exercise the voting rights of the securities represented by ADSs. In lieu of distributing such materials, the depositary bank may distribute to holders of ADSs instructions on how to
retrieve such materials upon request. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the
depositary bank timely receives voting instructions from a holder of ADSs, it will endeavor to vote the securities (in person or by proxy) represented by the holder&#146;s ADSs in accordance with such voting instructions. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">168
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the depositary receives voting instructions from a holder of ADSs that fail to
specify the manner in which the depositary is to vote, the depositary will deem such holder (unless otherwise specified in the notice distributed to holders) to have instructed the depositary to vote in favor of all resolutions endorsed by our board
of directors. With respect to securities represented by ADSs for which no timely voting instructions are received by the depositary from the holder, the depositary will (unless otherwise specified in the notice distributed to holders) deem such
holder to have instructed the depositary to give a discretionary proxy to a person designated by us to vote the securities. However, no such discretionary proxy will be given by the depositary with respect to any matter to be voted upon as to which
we inform the depositary that we do not wish such proxy to be given, substantial opposition exists, or the rights of holders of securities may be materially adversely affected. The ability of the depositary bank to carry out voting instructions may
be limited by practical and legal limitations and the terms of the securities on deposit. We cannot assure you that you will receive voting materials in time to enable you to return voting instructions to the depositary bank in a timely manner.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Fees and Charges </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As an ADS holder, you will be required to pay the following
fees under the terms of the deposit agreement: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Service</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fees</B></FONT></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issuance of ADSs (such as an issuance of ADS upon a deposit of ordinary shares, upon a change in
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">the&nbsp;ADSs-to-shares</FONT></FONT> ratio, or for any other reason), excluding ADS issuances as a result of distributions of ordinary shares)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Up to U.S. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS issued</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cancellation of ADSs (such as a cancellation of ADSs for delivery of deposited property, upon a change in
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">the&nbsp;ADSs-to-shares</FONT></FONT> ratio, or for any other reason)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Up to U.S. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS cancelled</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Distribution of cash dividends or other cash distributions (such as upon a sale of rights and other entitlements)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Up to U.S. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS held</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Distribution of ADSs pursuant to (i)&nbsp;stock dividends or other free stock distributions or (ii)&nbsp;exercise of rights to purchase additional ADSs</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Up to U.S. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS held</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Distribution of securities other than ADSs or rights to purchase additional ADSs (such as upon <FONT STYLE="white-space:nowrap">a&nbsp;spin-off)</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Up to U.S. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS held</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">ADS services</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Up to U.S. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS held on the applicable record date established by the depositary bank</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Registration of ADS transfers (such as upon a registration of the transfer of registered ownership of ADSs, upon a transfer of ADSs into DTC and<I>&nbsp;vice versa</I>, or for any
other reason)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Up to U.S. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS (or fraction thereof) transferred</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Conversion of ADSs of one series for ADSs of another series (such as upon conversion of Partial Entitlement ADSs for Full Entitlement ADSs, or upon conversion of Restricted ADSs
(each as defined in the deposit agreement) into freely transferable ADSs, and&nbsp;vice versa).</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Up to U.S. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS (or fraction thereof) converted</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As an ADS holder you will
also be responsible to pay certain charges such as: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">taxes (including applicable interest and penalties) and other governmental charges; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the registration fees as may from time to time be in effect for the registration of ordinary shares on the share register and applicable to transfers
of ordinary shares to or from the name of the custodian, the depositary bank or any nominees upon the making of deposits and withdrawals, respectively; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">169
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">certain cable, telex and facsimile transmission and delivery expenses; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the fees, expenses, spreads, taxes and other charges of the depositary bank and/or service providers (which may be a division, branch or affiliate of
the depositary bank) in the conversion of foreign currency; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the reasonable and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">customary&nbsp;out-of-pocket&nbsp;expenses</FONT></FONT> incurred
by the depositary bank in connection with compliance with exchange control regulations and other regulatory requirements applicable to ordinary shares, ADSs and ADRs; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the fees, charges, costs and expenses incurred by the depositary bank, the custodian, or any nominee in connection with the ADR program.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">ADS fees and charges for
(i)&nbsp;the issuance of ADSs and (ii)&nbsp;the cancellation of ADSs are charged to the person for whom the ADSs are issued (in the case of ADS issuances) and to the person for whom ADSs are cancelled (in the case of ADS cancellations). In the case
of ADSs issued by the depositary bank into DTC, the ADS issuance and cancellation fees and charges may be deducted from distributions made through DTC, and may be charged to the DTC participant(s) receiving the ADSs being issued or the DTC
participant(s) holding the ADSs being cancelled, as the case may be, on behalf of the beneficial owner(s) and will be charged by the DTC participant(s) to the account of the applicable beneficial owner(s) in accordance with the procedures and
practices of the DTC participants as in effect at the time. ADS fees and charges in respect of distributions and the ADS service fee are charged to the holders as of the applicable ADS record date. In the case of distributions of cash, the amount of
the applicable ADS fees and charges is deducted from the funds being distributed. In the case of (i)&nbsp;distributions other than cash and (ii)&nbsp;the ADS service fee, holders as of the ADS record date will be invoiced for the amount of the ADS
fees and charges and such ADS fees and charges may be deducted from distributions made to holders of ADSs. For ADSs held through DTC, the ADS fees and charges for distributions other than cash and the ADS service fee may be deducted from
distributions made through DTC, and may be charged to the DTC participants in accordance with the procedures and practices prescribed by DTC and the DTC participants in turn charge the amount of such ADS fees and charges to the beneficial owners for
whom they hold ADSs. In the case of (i)&nbsp;registration of ADS transfers, the ADS transfer fee will be payable by the ADS Holder whose ADSs are being transferred or by the person to whom the ADSs are transferred and (ii)&nbsp;conversion of ADSs of
one series for ADSs of another series, the ADS conversion fee will be payable by the Holder whose ADSs are converted or by the person to whom the converted ADSs are delivered. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the event of refusal to pay the depositary bank fees, the
depositary bank may, under the terms of the deposit agreement, refuse the requested service until payment is received or may set off the amount of the depositary bank fees from any distribution to be made to the ADS holder. Certain depositary fees
and charges (such as the ADS services fee) may become payable shortly after the closing of the ADS offering.<B></B>&nbsp;Note that the fees and charges you may be required to pay may vary over time and may be changed by us and by the depositary
bank. You will receive prior notice of such changes. The depositary bank may reimburse us for certain expenses incurred by us in respect of the ADR program, by making available a portion of the ADS fees charged in respect of the ADR program or
otherwise, upon such terms and conditions as we and the depositary bank agree from time to time. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Amendments and Termination </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We may agree with the depositary bank to modify the deposit agreement at any time without your consent. We undertake to give holders 30 days&#146; prior notice of any modifications that would materially
prejudice any of their substantial rights under the deposit agreement. We will not consider to be materially prejudicial to your substantial rights any modifications or supplements that are reasonably necessary for the ADSs to be registered under
the Securities Act or to be eligible for book-entry settlement, in each case without imposing or increasing the fees and charges you are required to pay. In addition, we may not be able to provide you with prior notice of any modifications or
supplements that are required to accommodate compliance with applicable provisions of law. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">170
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You will be bound by the modifications to the deposit agreement if you continue to hold
your ADSs after the modifications to the deposit agreement become effective. The deposit agreement cannot be amended to prevent you from withdrawing the ordinary shares represented by your ADSs (except as permitted by law). </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have the right to direct the depositary bank to terminate
the deposit agreement. Similarly, the depositary bank may in certain circumstances on its own initiative terminate the deposit agreement. In either case, the depositary bank must give notice to the holders at least 30 days before termination. Until
termination, your rights under the deposit agreement will be unaffected. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">After termination, the depositary bank will continue to collect distributions received (but will not distribute any such property until you request the cancellation of your ADSs) and may sell the
securities held on deposit. After the sale, the depositary bank will hold the proceeds from such sale and any other funds then held for the holders of ADSs in <FONT STYLE="white-space:nowrap">a&nbsp;non-interest&nbsp;bearing</FONT> account. At that
point, the depositary bank will have no further obligations to holders other than to account for the funds then held for the holders of ADSs still outstanding (after deduction of applicable fees, taxes and expenses). </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with any termination of the deposit agreement,
the depositary bank may make available to owners of ADSs a means to withdraw the ordinary shares represented by ADSs and to direct the depositary of such ordinary shares into an unsponsored American depositary share program established by the
depositary bank. The ability to receive unsponsored American depositary shares upon termination of the deposit agreement would be subject to satisfaction of certain U.S. regulatory requirements applicable to the creation of unsponsored American
depositary shares and the payment of applicable depositary fees. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Books of Depositary </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The depositary bank will maintain ADS holder records at its depositary office. You may inspect such records at such office during regular
business hours but solely for the purpose of communicating with other holders in the interest of business matters relating to the ADSs and the deposit agreement. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The depositary bank will maintain in New York facilities to
record and process the issuance, cancellation, <FONT STYLE="white-space:nowrap">combination,&nbsp;split-up&nbsp;and</FONT> transfer of ADSs. These facilities may be closed from time to time, to the extent not prohibited by law. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Transmission of Notices, Reports and Proxy Soliciting Material
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The depositary will make available for your
inspection at its office all communications that it receives from us as a holder of ADSs that we make generally available to ADS holders. Subject to the terms of the deposit agreement, the depositary will send you copies of those communications or
otherwise make those communications available to you if we ask it to. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Limitations on Obligations and Liabilities </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The deposit agreement limits our obligations and the depositary bank&#146;s obligations to you. Please note the following: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We and the depositary bank are obligated only to take the actions specifically stated in the deposit agreement without negligence or bad faith.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The depositary bank disclaims any liability for any failure to carry out voting instructions, for any manner in which a vote is cast or for the effect
of any vote, provided it acts in good faith and in accordance with the terms of the deposit agreement. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The depositary bank disclaims any liability for any failure to determine the lawfulness or practicality of any action, for the content of any document
forwarded to you on our behalf or for the accuracy of any translation of such a document, for the investment risks associated with investing in ordinary shares, for </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">171
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the validity or worth of the ordinary shares, for any tax consequences that result from the ownership of ADSs, for the credit-worthiness of any third
party, for allowing any rights to lapse under the terms of the deposit agreement, for the timeliness of any of our notices or for our failure to give notice. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We and the depositary bank will not be obligated to perform any act that is inconsistent with the terms of the deposit agreement.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We and the depositary bank disclaim any liability if we or the depositary bank are prevented or forbidden from or subject to any civil or criminal
penalty or restraint on account of, or delayed in, doing or performing any act or thing required by the terms of the deposit agreement, by reason of any provision, present or future of any law or regulation, or by reason of present or future
provision of any provision of our Constitution, or any provision of or governing the securities on deposit, or by reason of any act of God or war or other circumstances beyond our control. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We and the depositary bank disclaim any liability by reason of any exercise of, or failure to exercise, any discretion provided for in the deposit
agreement or in our Articles of Incorporation<B></B>&nbsp;or in any provisions of or governing the securities on deposit. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We and the depositary bank further disclaim any liability for any action or inaction in reliance on the advice or information received from legal
counsel, accountants, any person presenting Shares for deposit, any holder of ADSs or authorized representatives thereof, or any other person believed by either of us in good faith to be competent to give such advice or information.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We and the depositary bank also disclaim liability for the inability by a holder to benefit from any distribution, offering, right or other benefit
that is made available to holders of ordinary shares but is not, under the terms of the deposit agreement, made available to you. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We and the depositary bank may rely without any liability upon any written notice, request or other document believed to be genuine and to have been
signed or presented by the proper parties. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We and the depositary bank also disclaim liability for any consequential or punitive damages for any breach of the terms of the deposit agreement.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">No disclaimer of any Securities Act liability is intended by any provision of the deposit agreement. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Nothing in the deposit agreement gives rise to a partnership or joint venture, or establishes a fiduciary relationship, among us, the depositary bank
and you as ADS holder. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Nothing in the deposit agreement precludes &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (or its
affiliates) from engaging in transactions in which parties adverse to us or the ADS owners have interests, and nothing in the deposit agreement obligates
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to disclose those transactions, or any information obtained in the course of those transactions, to us or to the ADS owners, or to account for any
payment received as part of those transactions. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Taxes </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You will be responsible for the taxes and other governmental charges payable on the ADSs and the securities represented by the ADSs. We,
the depositary bank and the custodian may deduct from any distribution the taxes and governmental charges payable by holders and may sell any and all property on deposit to pay the taxes and governmental charges payable by holders. You will be
liable for any deficiency if the sale proceeds do not cover the taxes that are due. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The depositary bank may refuse to issue ADSs, to deliver, transfer, split and combine ADRs or to release securities on deposit until all taxes and charges are paid by the applicable holder. The depositary
bank and the custodian may take reasonable administrative actions to obtain tax refunds and reduced tax withholding for any distributions on your behalf. However, you may be required to provide to the depositary bank and to the custodian proof of
taxpayer status and residence and such other information as the depositary bank and the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">172
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
custodian may require to fulfill legal obligations. You are required to indemnify us, the depositary bank and the custodian for any claims with respect to taxes based on any tax benefit obtained
for you. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Foreign Currency Conversion </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The depositary bank will arrange for the conversion of all
foreign currency received into U.S. dollars if such conversion is practical, and it will distribute the U.S. dollars in accordance with the terms of the deposit agreement. You may have to pay fees and expenses incurred in converting foreign
currency, such as fees and expenses incurred in complying with currency exchange controls and other governmental requirements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the conversion of foreign currency is not practical or lawful, or if any required approvals are denied or not obtainable at a
reasonable cost or within a reasonable period, the depositary bank may take the following actions in its discretion: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Convert the foreign currency to the extent practical and lawful and distribute the U.S. dollars to the holders for whom the conversion and distribution
is lawful and practical. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Distribute the foreign currency to holders for whom the distribution is lawful and practical. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Hold the foreign currency (without liability for interest) for the applicable holders. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Governing Law/Waiver of Jury Trial </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The deposit agreement, the ADRs and the ADSs will be
interpreted in accordance with the laws of the State of New York. The rights of holders of ordinary shares (including<B></B>&nbsp;ordinary shares represented by ADSs) is governed by the laws of Australia. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AS A PARTY TO THE DEPOSIT AGREEMENT, YOU IRREVOCABLY
WAIVE, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, YOUR RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF THE DEPOSIT AGREEMENT OR THE ADRS AGAINST US OR THE DEPOSITARY BANK. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The deposit agreement provides that, to the extent permitted
by law, ADS holders waive the right to a jury trial of any claim they may have against us or the depositary arising out of or relating to our ordinary shares, the ADSs or the deposit agreement, including any claim under U.S. federal securities
laws.&nbsp;If we or the depositary opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable in the facts and circumstances of that case in accordance with applicable case law. However, you will
not be deemed, by agreeing to the terms of the deposit agreement, to have waived our or the depositary&#146;s compliance with U.S. federal securities laws and the rules and regulations promulgated thereunder. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">173
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_19"></A>SHARES AND AMERICAN DEPOSITARY SHARES ELIGIBLE FOR FUTURE
SALE </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our ordinary shares have been trading on
the ASX since 1985. While we intend to apply to list our ADSs on Nasdaq, we cannot assure you that an active trading market for the ADSs will develop. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon completion of the offering, we will have
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADSs outstanding representing &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares, or
approximately &nbsp;&nbsp;&nbsp;&nbsp;% of our ordinary shares in issue and outstanding. In addition, we will have &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares not represented by
ADSs in issue and outstanding. If the underwriters exercise their option to purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional ADSs in full, we will have
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADSs outstanding, representing &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares, or
approximately &nbsp;&nbsp;&nbsp;&nbsp;% of our ordinary shares in issue and outstanding. All of the ADSs sold in this offering will be freely tradable without restrictions or further registration under the Securities Act, except for any ADSs sold to
our &#147;affiliates,&#148; as that term is defined under Rule 144 under the Securities Act. The ordinary shares held by existing shareholders are &#147;restricted securities,&#148; as that term is defined in Rule 144 under the Securities Act.
Restricted securities may be sold in the United States only if registered with the SEC or if their resale qualifies for exemption from registration described below under Rule 144 or Rule 701 promulgated under the Securities Act. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Future sales of ADSs in the U.S. public market after this
offering, and the availability of ADSs for future sale, could adversely affect the market price of the ADSs prevailing from time to time. As described below, a significant number of currently outstanding ordinary shares will not be available for
sale shortly after this offering due to contractual restrictions on transfers of ordinary shares and ADSs. However, sales of substantial amounts of ADSs or ordinary shares, or the perception that these sales could occur, could adversely affect
prevailing market prices for the ADSs and could impair our future ability to raise equity capital. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Rule 144 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In general, a person who has beneficially owned restricted ordinary shares for at least six months would be entitled to sell their securities pursuant to Rule 144 under the Securities Act provided that
(1)&nbsp;such person is not deemed to have been one of our affiliates at the time of, or at any time during the 90 days preceding, a sale and (2)&nbsp;we have been subject to the Exchange Act periodic reporting requirements for at least 90 days
before the sale. Persons who have beneficially owned restricted ordinary shares for at least six months, but who are our affiliates at the time of, or at any time during the 90 days preceding a sale, would be subject to additional restrictions, by
which such person would be entitled to sell within any three-month period only a number of securities that does not exceed the greater of either of the following: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.0% of the number of ordinary shares (including ordinary shares in the form of ADSs) then outstanding, which will equal approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares immediately after the closing of this offering; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the average weekly trading volume of the ADSs on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;during
the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">provided, in each case, that we have been subject to the Exchange Act periodic reporting requirements for at least 90 days before the sale. Such sales both by affiliates and
<FONT STYLE="white-space:nowrap">by&nbsp;non-affiliates&nbsp;must</FONT> also comply with the manner of sale, current public information and notice provisions of Rule <FONT STYLE="white-space:nowrap">144.&nbsp;Non-affiliate&nbsp;resales</FONT> of
restricted shares under Rule 144 also are subject to the availability of current public information about us until a period of one year has elapsed since the securities were acquired from the issuer or an affiliate of the issuer. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Rule 701 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rule 701 under the Securities Act permits resales of shares in reliance upon Rule 144 but without compliance
with certain restrictions of Rule 144, including the holding period requirement. Most of our employees, senior management or directors who purchased shares under a written compensatory plan or contract
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">174
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
may be entitled to rely on the resale provisions of Rule 701, but all holders of Rule 701 shares are required to wait until 90 days after the date of this prospectus before selling their shares
subject also to Australian law. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The SEC has
indicated that Rule 701 will apply to typical options granted by an issuer before it becomes subject to the reporting requirements of the Exchange Act, along with the shares acquired upon exercise of such options, including exercises after an issuer
becomes subject to the reporting requirements of the Exchange Act. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><FONT STYLE="white-space:nowrap">Lock-up&nbsp;Agreements</FONT> </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We and our officers and directors have agreed that, without
the prior written consent of Citigroup Global Markets Inc. and SVB Leerink LLC, or, collectively, the Representatives, on behalf of the underwriters, we and they will not, during the period ending 90 days after the date of this prospectus
(i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any
ordinary shares, ADSs or any securities convertible into or exercisable or exchangeable for our ordinary shares or ADSs or (ii)&nbsp;enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic
consequences of ownership of the ordinary shares or ADSs. In addition, we have agreed that, without the prior written consent of the Representatives on behalf of the underwriters, we will not, during the restricted period, file any registration
statement with the SEC relating to the offering of any ordinary shares or ADSs or any securities convertible into or exercisable or exchangeable for ordinary shares or ADSs. The restrictions described in this paragraph are subject to certain
exceptions. See&nbsp;&#147;Underwriting.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Representatives, in their sole discretion, may release the ordinary shares, ADSs and other securities subject to <FONT
STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;agreements</FONT> described above in whole or in part at any time. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We do not currently expect any release of ordinary shares or ADSs subject
<FONT STYLE="white-space:nowrap">to&nbsp;lock-up&nbsp;agreements</FONT> prior to the expiration of the <FONT STYLE="white-space:nowrap">applicable&nbsp;lock-up&nbsp;periods.</FONT> Upon the expiration of the
<FONT STYLE="white-space:nowrap">applicable&nbsp;lock-up&nbsp;periods,</FONT> substantially all of the ordinary shares and ADSs subject to <FONT STYLE="white-space:nowrap">such&nbsp;lock-up&nbsp;restrictions</FONT> will become eligible for sale,
subject to the limitations described above. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">175
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_20"></A>MATERIAL UNITED STATES FEDERAL INCOME AND AUSTRALIAN TAX
CONSIDERATIONS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>The following summary of
the material Australian and U.S. federal income tax consequences of an investment in our ADSs or ordinary shares is based upon laws and relevant interpretations thereof in effect as of the date of this prospectus, all of which are subject to change,
possibly with retroactive effect. This summary does not deal with all possible tax consequences relating to an investment in our ADSs or ordinary shares, such as the tax consequences under U.S. state, local and other tax laws other than U.S. federal
income tax laws and certain Australian tax laws. </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Material
United States Federal Income Tax Considerations </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following describes material United States federal income tax considerations relating to the acquisition, ownership and disposition of our ordinary shares or ADSs by a U.S. holder (as defined below).
This summary addresses these tax considerations only for U.S. holders that are initial purchasers of our ordinary shares or ADSs pursuant to this offering and that will hold such ordinary shares or ADSs as capital assets (generally, property held
for investment). This summary does not address all U.S. federal income tax matters that may be relevant to a particular U.S. holder. This summary does not address tax considerations applicable to a holder of our ordinary shares or ADSs that may be
subject to special tax rules including, without limitation, the following: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">banks, financial institutions or insurance companies; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">brokers, dealers or traders in securities, currencies, commodities, or notional principal contracts; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">tax-exempt&nbsp;entities</FONT> or organizations, including an &#147;individual retirement account&#148; or &#147;Roth
IRA&#148; as defined in Section&nbsp;408 or 408A of the Code (as defined below), respectively; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">real estate investment trusts, regulated investment companies or grantor trusts; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">persons that hold our ordinary shares or ADSs as part of a &#147;hedging,&#148; &#147;integrated,&#148; &#147;wash sale&#148; or &#147;conversion&#148;
transaction or as a position in a &#147;straddle&#148; for U.S. federal income tax purposes; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">S corporations, partnerships, or other entities or arrangements classified as partnerships for U.S. federal income tax purposes;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">certain former citizens or long-term residents of the United States; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">persons that received our ordinary shares or ADSs as compensation; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">persons subject to Section&nbsp;451(b) of the Code; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">persons acquiring our ordinary shares or ADSs in connection with a trade or business conducted outside of the United States, including a permanent
establishment or a fixed base in Australia; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">holders that own directly, indirectly, or through attribution 10% or more of the voting power or value of our ordinary shares or ADSs; and
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">holders that have a &#147;functional currency&#148; other than the U.S. dollar. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Holders of our ordinary shares or ADSs who fall within one of
the categories above are advised to consult their tax advisor regarding the specific tax consequences which may apply to their particular situation. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the purposes of this description, a &#147;U.S. holder&#148; is a beneficial owner of our ordinary shares or ADSs that is (or is
treated as), for U.S. federal income tax purposes: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an individual who is a citizen or resident of the United States; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the United States, any state therein or the
District of Columbia; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an estate, the income of which is subject to U.S. federal income taxation regardless of its source; or </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">176
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a trust, if a court within the United States is able to exercise primary supervision over its administration and one or more U.S. persons have the
authority to control all of the substantial decisions of such trust, or if such trust has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a U.S. person. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If a partnership (or any other entity treated as a
partnership for U.S. federal income tax purposes) holds our ordinary shares or ADSs, the tax consequences relating to an investment in our ordinary shares or ADSs will depend in part upon the status of the partner and the activities of the
partnership. Such a partner or partnership should consult its tax advisor regarding the specific tax considerations of acquiring, owning and disposing of our ordinary shares or ADSs in its particular circumstances. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Persons considering an investment in our ordinary shares
or ADSs should consult their own tax advisors as to the particular tax consequences applicable to them relating to the acquisition, ownership and disposition of our ordinary shares or ADSs, including the applicability of U.S. federal, state and
local tax laws, Australian tax laws and <FONT STYLE="white-space:nowrap">other&nbsp;non-U.S.&nbsp;tax</FONT> laws. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This description does not address the U.S. federal estate, gift, or alternative minimum tax considerations, or any U.S. state, local, <FONT
STYLE="white-space:nowrap">or&nbsp;non-U.S.&nbsp;tax</FONT> considerations of the acquisition, ownership and disposition of our ordinary shares or ADSs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This description is based on the U.S. Internal Revenue Code of 1986, as amended, or the Code, existing, proposed and temporary U.S.
Treasury Regulations promulgated thereunder and administrative and judicial interpretations thereof, in each case as in effect and available on the date hereof. All the foregoing is subject to change, which change could apply retroactively, and to
differing interpretations, all of which could affect the tax considerations described below. There can be no assurances that the U.S. Internal Revenue Service, or the IRS, will not take a position concerning the tax consequences of the acquisition,
ownership and disposition of our ordinary shares or ADSs or that such a position would not be sustained by a court. We have not obtained, nor do we intend to obtain, a ruling with respect to the U.S. federal income tax considerations in the
purchase, ownership or disposition of our ordinary shares or ADSs. Accordingly, holders should consult their own tax advisors concerning the U.S. federal, state, local <FONT STYLE="white-space:nowrap">and&nbsp;non-U.S.&nbsp;tax</FONT> consequences
of acquiring, owning and disposing of our ordinary shares or ADSs in their particular circumstances. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In general, and taking into account the earlier assumptions, for U.S. federal income tax purposes, a U.S. holder holding ADSs will be
treated as the owner of the ordinary shares represented by the ADSs. Exchanges of ordinary shares for ADSs, and ADSs for ordinary shares, generally will not be subject to U.S. federal income tax. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>United States Federal Income Tax Consequences If We Are
Not a PFIC</I></B>.&nbsp;&nbsp;&nbsp;&nbsp;The description of the U.S. federal income tax consequences of the receipt of distributions and the sale or other taxable exchange of our ordinary shares or ADSs, described in the following two sections
&#147;&#151;Distributions&#148; and &#147;&#151;Sale, Exchange or Other Taxable Disposition,&#148; apply only if we are not a PFIC in the relevant year and our stock is not subject to the rules described above under &#147;&#151;Passive Foreign
Investment Company Considerations.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Distributions</I></B>.&nbsp;&nbsp;&nbsp;&nbsp;As described above under the heading &#147;&#151;Dividend Policy,&#148; we do not
expect to make any distributions in respect of our ordinary shares or ADSs. Subject to the discussion under &#147;&#151;Passive Foreign Investment Company Considerations,&#148; below, the gross amount of any distribution (including any amounts
withheld in respect of foreign tax) actually or constructively received by a U.S. holder with respect to our ordinary shares or ADSs will generally be taxable to the U.S. holder as a dividend to the extent of the U.S. holder&#146;s pro rata share of
our current or accumulated earnings and profits as determined under U.S. federal income tax principles. Distributions in excess of earnings and profits will generally <FONT STYLE="white-space:nowrap">be&nbsp;non-taxable&nbsp;to</FONT> the U.S.
holder to the extent of, and will be applied against and reduce, the U.S. holder&#146;s adjusted tax basis in our ordinary shares or ADSs. Distributions in excess of earnings and profits and such adjusted tax basis will generally be taxable to the
U.S. holder as either long-term or short-term capital gain depending upon whether the U.S. holder </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">177
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
has held our ordinary shares or ADSs for more than one year as of the time such distribution is received. However, since we do not calculate our earnings and profits under U.S. federal income tax
principles, it is expected that any distribution will be reported as a dividend, even if that distribution would otherwise be treated as <FONT STYLE="white-space:nowrap">a&nbsp;non-taxable&nbsp;return</FONT> of capital or as capital gain under the
rules described <FONT STYLE="white-space:nowrap">above.&nbsp;Non-corporate&nbsp;U.S.</FONT> holders may qualify for the preferential rates of taxation with respect to dividends on our ordinary shares or ADSs applicable to long-term capital gains
(i.e., gains from the sale of capital assets held for more than one year) and qualified dividend income (as discussed below) if we are a &#147;qualified foreign corporation&#148; and certain other requirements (discussed below) are met. <FONT
STYLE="white-space:nowrap">A&nbsp;non-U.S.&nbsp;corporation</FONT> (other than a corporation that is classified as a PFIC for the taxable year in which the dividend is paid or the preceding taxable year) generally will be considered to be a
qualified foreign corporation (a)&nbsp;if it is eligible for the benefits of a comprehensive tax treaty with the United States which the Secretary of Treasury of the United States determines is satisfactory for purposes of this provision and which
includes an exchange of information provision, or (b)&nbsp;with respect to any dividend it pays on ADSs which are readily tradable on an established securities market in the United States. We have applied to list our ADSs on Nasdaq, which is an
established securities market in the United States, and we expect the ADSs to be readily tradable on Nasdaq. There can be no assurance that the ADSs will be considered readily tradable on an established securities market in the United States in
later years. In addition, the Company, which is incorporated under the laws of Australia, believes that it qualifies as a resident of Australia for purposes of, and is eligible for the benefits of, the Convention between the Government of the United
States of America and the Government of Australia for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Income, signed on August&nbsp;6, 1982, as amended and currently in force, or the U.S.-Australia Tax
Treaty, although there can be no assurance in this regard. Further, the IRS has determined that the U.S.-Australia Tax Treaty is satisfactory for purposes of the qualified dividend rules and that it includes an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">exchange-of-information</FONT></FONT> program. Therefore, subject to the discussion under &#147;&#151;Passive Foreign Investment Company Considerations,&#148; below, such dividends will generally be &#147;qualified
dividend income&#148; in the hands of individual U.S. holders, provided that a holding period requirement (more than 60 days of ownership, without protection from the risk of loss, during the <FONT STYLE="white-space:nowrap">121-day</FONT> period
beginning 60 days before the <FONT STYLE="white-space:nowrap">ex-dividend</FONT> date) and certain other requirements are met. The dividends will not be eligible for the dividends-received deduction generally allowed to corporate U.S. holders.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A U.S. holder generally may claim the amount of
any Australian withholding tax as either a deduction from gross income or a credit against its U.S. federal income tax liability. The foreign tax credit is subject to numerous complex limitations that must be determined and applied on an individual
basis. Generally, the credit cannot exceed the proportionate share of a U.S. holder&#146;s U.S. federal income tax liability that such U.S. holder&#146;s taxable income from foreign sources bears to such U.S. holder&#146;s worldwide taxable income.
In applying this limitation, a U.S. holder&#146;s various items of income and deduction must be classified, under complex rules, as either &#147;foreign source&#148; or &#147;U.S. source.&#148; This limitation is calculated separately with respect
to specific categories of income. The amount of a distribution with respect to the ADSs that is treated as a &#147;dividend&#148; may be lower for U.S. federal income tax purposes than it is for Australian income tax purposes, potentially resulting
in a reduced foreign tax credit for the U.S. holder. In addition, the creditability of foreign taxes could be affected by actions taken by intermediaries in the chain of ownership between the holders of our ordinary shares or ADSs and our company
if, as a result of such actions, the holders of our ordinary shares or ADSs are not properly treated as beneficial owners of the underlying ordinary shares. Each U.S. holder should consult its own tax advisors regarding the foreign tax credit rules.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In general, the amount of a distribution paid to
a U.S. holder in a foreign currency will be the U.S. dollar value of the foreign currency calculated by reference to the spot exchange rate on the day the depositary receives the distribution, in the case of the ADSs, or on the day the distribution
is received by the U.S. holder, in the case of ordinary shares, regardless of whether the foreign currency is converted into U.S. dollars at that time. Any foreign currency gain or loss a U.S. holder realizes on a subsequent conversion of foreign
currency into U.S. dollars will be U.S. source ordinary income or loss. If dividends received in a foreign currency are converted into U.S. dollars on the day they are received, a U.S. holder should not be required to recognize foreign currency gain
or loss in respect of the dividend. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">178
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Sale, Exchange or Other Taxable Disposition</I></B>.&nbsp;&nbsp;&nbsp;&nbsp;A
U.S. holder will generally recognize gain or loss for U.S. federal income tax purposes upon the sale, exchange or other taxable disposition of our ordinary shares or ADSs in an amount equal to the difference between the U.S. dollar value of the
amount realized from such sale or exchange and the U.S. holder&#146;s adjusted tax basis in those ordinary shares or ADSs, determined in U.S. dollars. Subject to the discussion under &#147;&#151;Passive Foreign Investment Company
Considerations&#148; below, this gain or loss will generally be a capital gain or loss. The adjusted tax basis in our ordinary shares or ADSs generally will be equal to the cost of such ordinary shares or ADSs. Capital gain from the sale, exchange
or other taxable disposition of our ordinary shares or ADSs by <FONT STYLE="white-space:nowrap">a&nbsp;non-corporate&nbsp;U.S.</FONT> holder is generally eligible for a preferential rate of taxation applicable to capital gains, if <FONT
STYLE="white-space:nowrap">the&nbsp;non-corporate&nbsp;U.S.</FONT> holder&#146;s holding period determined at the time of such sale, exchange or other taxable disposition for such ordinary shares or ADSs exceeds one year (i.e., such gain is
long-term taxable gain). The deductibility of capital losses for U.S. federal income tax purposes is subject to limitations. Any such gain or loss that a U.S. holder recognizes generally will be treated as U.S. source gain or loss for foreign tax
credit limitation purposes. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For a cash basis
taxpayer, units of foreign currency paid or received are translated into U.S. dollars at the spot rate on the settlement date of the purchase or sale. In that case, no foreign currency exchange gain or loss will result from currency fluctuations
between the trade date and the settlement date of such a purchase or sale. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">An accrual basis taxpayer, however, may elect the same treatment required of cash basis taxpayers with respect to purchases and sales of our ordinary shares or ADSs that are traded on an established
securities market, provided the election is applied consistently from year to year. Such election may not be changed without the consent of the IRS. For an accrual basis taxpayer who does not make such election, units of foreign currency paid or
received are translated into U.S. dollars at the spot rate on the trade date of the purchase or sale. Such an accrual basis taxpayer may recognize exchange gain or loss based on currency fluctuations between the trade date and the settlement date.
Any foreign currency gain or loss a U.S. holder realizes will be U.S. source ordinary income or loss. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Medicare Tax</I></B>.&nbsp;&nbsp;&nbsp;&nbsp;Certain U.S. holders that are individuals, estates or trusts are subject to a 3.8% tax
on all or a portion of their &#147;net investment income,&#148; which may include all or a portion of their dividend income and net gains from the disposition of our ordinary shares or ADSs. Each U.S. holder that is an individual, estate or trust is
urged to consult its tax advisors regarding the applicability of the Medicare tax to its income and gains in respect of its investment in our ordinary shares or ADSs. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Passive Foreign Investment Company
Considerations</I></B>.&nbsp;&nbsp;&nbsp;&nbsp;If we are classified as a PFIC in any taxable year, a U.S. holder will be subject to special rules generally intended to reduce or eliminate any benefits from the deferral of U.S. federal income tax
that a U.S. holder could derive from investing in <FONT STYLE="white-space:nowrap">a&nbsp;non-U.S.&nbsp;company</FONT> that does not distribute all of its earnings on a current basis. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will be classified as a PFIC for U.S. federal income tax purposes in any taxable year in which, after
applying certain look-through rules with respect to the income and assets of our subsidiaries, either: (1)&nbsp;at least 75% of the gross income is &#147;passive income&#148; or (2)&nbsp;at least 50% of the average quarterly value of our total gross
assets (which would generally be measured by fair market value of our assets, and for which purpose the total value of our assets may be determined in part by the market value of the ADSs and our ordinary shares, which are subject to change) is
attributable to assets that produce &#147;passive income&#148; or are held for the production of &#147;passive income.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Passive income for this purpose generally includes dividends, interest, royalties, rents, gains from commodities and securities
transactions, the excess of gains over losses from the disposition of assets which produce passive income, and includes amounts derived by reason of the temporary investment of funds raised in offerings of our ordinary shares or ADSs. If <FONT
STYLE="white-space:nowrap">a&nbsp;non-U.S.&nbsp;corporation</FONT> owns directly or indirectly at least 25% by value of the stock of another corporation or the partnership interests in a partnership,
<FONT STYLE="white-space:nowrap">the&nbsp;non-U.S.&nbsp;corporation</FONT> is treated for purposes of the PFIC tests as owning its proportionate share of the assets of the other corporation or
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">179
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
partnership and as receiving directly its proportionate share of the other corporation&#146;s or partnership&#146;s income. The determination of whether we are a PFIC is a fact-intensive
determination made on an annual basis and the applicable law is subject to varying interpretation. If we are classified as a PFIC in any taxable year during which a U.S. holder owns our ordinary shares or ADSs, such U.S. holder will be subject to
special tax rules discussed below and could suffer adverse tax consequences. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The market value of our assets may be determined in large part by reference to the market price of the ADSs and our ordinary shares, which is likely to fluctuate after this offering. Therefore,
fluctuations in the market price of our ordinary shares or ADSs may result in our being a PFIC for any taxable year. In addition, the composition of our income and assets will be affected by how, and how quickly, we use the cash proceeds from this
offering in our business. Whether we are a PFIC for any taxable year will depend on the nature and composition of our income, assets, activities and market capitalization in each year, and because this is a factual determination made annually after
the end of each taxable year, there can be no assurance that we will not be considered a PFIC in any taxable year. We believe that we were not characterized as a PFIC in our taxable year ended June&nbsp;30, 2019. Based on the expected nature and
composition of our income, assets, activities and market capitalization for our taxable year ended June&nbsp;30, 2020, we believe that we will not be classified as a PFIC for our taxable year ended June&nbsp;30, 2020; however, there can be no
assurance that we will not be considered a PFIC in the current year or for any future taxable year. As a result, our PFIC status may change from year to year. Our status as a PFIC will depend on the composition of our income (including whether we
receive certain grants or subsidies and whether such amounts will constitute gross income for purposes of the PFIC income test) and the composition and value of our assets, which may be determined in large part by reference to the market value of
the ADSs and our ordinary shares, which may be volatile, from time to time. Our status may also depend, in part, on how quickly we utilize the cash proceeds from this offering in our business. Our U.S. counsel expresses no opinion regarding our
conclusions or our expectations regarding our PFIC status. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If we are classified as a PFIC in any year with respect to which a U.S. holder owns our ordinary shares or ADSs, we will continue to be treated as a PFIC with respect to such U.S. holder in all succeeding
years during which the U.S. holder owns the ordinary shares or ADSs, regardless of whether we continue to meet the tests described above unless we cease to be a PFIC and the U.S. holder has made a &#147;deemed sale&#148; election under the PFIC
rules or is eligible to make and makes <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;mark-to-market&nbsp;election</FONT></FONT> (as described below), with respect to all taxable years during such U.S. holder&#146;s holding
period in which we are a PFIC. If the &#147;deemed sale&#148; election is made, a U.S. holder will be deemed to have sold the ordinary shares or ADSs the U.S. holder holds at their fair market value as of the date of such deemed sale and any gain
from such deemed sale would be subject to the rules described below. After the deemed sale election, so long as we do not become a PFIC in a subsequent taxable year, the U.S. holder&#146;s ordinary shares or ADSs with respect to which such election
was made will not be treated as shares in a PFIC and the U.S. holder will not be subject to the rules described below with respect to any &#147;excess distribution&#148; the U.S. holder receives from us or any gain from an actual sale or other
disposition of the ordinary shares or ADSs. U.S. holders should consult their tax advisors as to the possibility and consequences of making a deemed sale election if such election becomes available. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we are a PFIC, and you are a U.S. holder that does not
make one of the elections described above (and below in further detail), a special tax regime will apply to both (a)&nbsp;any &#147;excess distribution&#148; by us to you (generally, your ratable portion of distributions in any year, other than the
taxable year in which your holding period in the shares or ADSs begins, which are greater than 125% of the average annual distribution received by you in the shorter of the three preceding years or the portion of your holding period for our ordinary
shares or ADSs that preceded the year of the distribution) and (b)&nbsp;any gain realized on the sale or other disposition of our ordinary shares or ADSs. Under this regime, any excess distribution and realized gain will be treated as ordinary
income and will be subject to tax as if (a)&nbsp;the excess distribution or gain had been realized ratably over your holding period, (b)&nbsp;the amount deemed realized in each year had been subject to tax in each year of that holding period at the
highest marginal rate for such year (other than income allocated to the current period or any taxable period before we became a PFIC, which would be subject to tax at the U.S. holder&#146;s regular ordinary income rate for the current year and would
not be subject to the interest charge discussed below) and (c)&nbsp;the interest charge </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">180
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
generally applicable to underpayments of tax had been imposed on the taxes deemed to have been payable in those years. In addition, dividend distributions made to you will not qualify for the
lower rates of taxation applicable to qualified dividends discussed above under &#147;Distributions.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certain elections may alleviate some of the adverse consequences of PFIC status and would result in an alternative treatment of our
ordinary shares or ADSs. If a U.S. holder makes <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;mark-to-market&nbsp;election,</FONT></FONT> the U.S. holder generally will recognize as ordinary income any excess of the fair
market value of our ordinary shares or ADSs at the end of each taxable year over their adjusted tax basis, and will recognize an ordinary loss in respect of any excess of the adjusted tax basis of our ordinary shares or ADSs over their fair market
value at the end of the taxable year (but only to the extent of the net amount of income previously included as a result of the <FONT STYLE="white-space:nowrap">mark-to-market</FONT> election). If a U.S. holder makes the election, the U.S.
holder&#146;s tax basis in our ordinary shares or ADSs will be adjusted to reflect these income or loss amounts. Any gain recognized on the sale or other disposition of our ordinary shares or ADSs in a year in which we are a PFIC will be treated as
ordinary income and any loss will be treated as an ordinary loss (but only to the extent of the net amount of income previously included as a result of the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election). The <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election is available only if we are a PFIC
and our ordinary shares or ADSs are &#147;regularly traded&#148; on a &#147;qualified exchange.&#148; Our ordinary shares or ADSs will be treated as &#147;regularly traded&#148; in any calendar year in which more than a de minimis quantity of our
ordinary shares or ADSs are traded on a qualified exchange on at least 15 days during each calendar quarter (subject to the rule that trades that have as one of their principal purposes the meeting of the trading requirement are disregarded). Nasdaq
is a qualified exchange for this purpose and, consequently, if the ADSs are regularly traded, the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election will be available to a U.S. holder. It should
be noted that it is intended that only the ADSs and not our ordinary shares will be listed on Nasdaq. Consequently, our ordinary shares may not be marketable if the ASX (where our ordinary shares are currently listed) does not meet the applicable
requirements. U.S. holders should consult their tax advisors regarding the availability of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election for ordinary shares that are not represented by
ADSs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">However, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">a&nbsp;mark-to-market&nbsp;election</FONT></FONT> generally cannot be made for equity interests in any lower-tier PFICs that we own, unless shares of such lower-tier PFIC are themselves &#147;marketable.&#148; As a result,
even if a U.S. holder validly makes <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;mark-to-market&nbsp;election</FONT></FONT> with respect to our ordinary shares or ADSs, the U.S. holder may continue to be subject to the
PFIC rules (described above) with respect to its indirect interest in any of our investments that are treated as an equity interest in a PFIC for U.S. federal income tax purposes. U.S. holders should consult their tax advisors as to the availability
and desirability of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;mark-to-market&nbsp;election,</FONT></FONT> as well as the impact of such election on interests in any lower-tier PFICs. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We do not currently intend to provide the information
necessary for U.S. holders to make qualified electing fund elections if we were treated as a PFIC for any taxable year. U.S. holders should consult their tax advisors to determine whether any of the other elections described above would be available
and if so, what the consequences of the alternative treatments would be in their particular circumstances. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we are determined to be a PFIC, the general tax treatment for U.S. holders described in this section would apply to indirect
distributions and gains deemed to be realized by U.S. holders in respect of any of our subsidiaries that also may be determined to be PFICs. U.S. holders should consult their tax advisors regarding the application of the PFIC rules to our
subsidiaries. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If a U.S. holder owns our ordinary
shares or ADSs during any taxable year in which we are a PFIC, the U.S. holder generally will be required to file an IRS Form 8621 (Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund) with respect
to the company, generally with the U.S. holder&#146;s federal income tax return for that year. If our company were a PFIC for a given taxable year, then you should consult your tax advisor concerning your annual filing requirements. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>The U.S. federal income tax rules relating to PFICs are
complex. Prospective U.S. investors are urged to consult their own tax advisors with respect to the acquisition, ownership and disposition of our ordinary </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">181
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>
shares or ADSs, the consequences to them of an investment in a PFIC, any elections available with respect to our ordinary shares or ADSs and the IRS information reporting obligations with respect
to the acquisition, ownership and disposition of our ordinary shares or ADSs. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Backup Withholding and Information Reporting</I></B>.&nbsp;&nbsp;&nbsp;&nbsp;U.S. holders generally will be subject to information reporting requirements with respect to dividends on our ordinary
shares or ADSs and on the proceeds from the sale, exchange or disposition of our ordinary shares or ADSs that are paid within the United States or through U.S.-related financial intermediaries, unless the U.S. holder is an &#147;exempt
recipient.&#148; In addition, U.S. holders may be subject to backup withholding on such payments, unless the U.S. holder provides a taxpayer identification number and a duly executed IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-9&nbsp;or</FONT>
otherwise establishes an exemption. Backup withholding is not an additional tax, and the amount of any backup withholding will be allowed as a credit against a U.S. holder&#146;s U.S. federal income tax liability and may entitle such holder to a
refund, provided that the required information is timely furnished to the IRS. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Certain Reporting Requirements With Respect to Payments of Offer Price</I></B>.&nbsp;&nbsp;&nbsp;&nbsp;U.S. holders paying more than $100,000 for our ordinary shares or ADSs generally may be
required to file IRS Form 926 reporting the payment of the offer price for our ordinary shares or ADSs to us. Substantial penalties may be imposed upon a U.S. holder that fails to comply. Each U.S. holder should consult its own tax advisor as to the
possible obligation to file IRS Form 926. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Foreign Asset Reporting</I></B>.&nbsp;&nbsp;&nbsp;&nbsp;Certain individual U.S. holders are required to report information relating
to an interest in our ordinary shares or ADSs, subject to certain exceptions (including an exception for shares held in accounts maintained by U.S. financial institutions) by filing IRS Form 8938 (Statement of Specified Foreign Financial Assets)
with their federal income tax return. U.S. holders are urged to consult their tax advisors regarding their information reporting obligations, if any, with respect to their ownership and disposition of our ordinary shares or ADSs. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>THE DISCUSSION ABOVE IS A SUMMARY OF THE U.S. FEDERAL
INCOME TAX CONSEQUENCES OF AN INVESTMENT IN OUR ORDINARY SHARES OR ADSs AND IS BASED UPON LAWS AND RELEVANT INTERPRETATIONS THEREOF IN EFFECT AS OF THE DATE OF THIS PROSPECTUS, ALL OF WHICH ARE SUBJECT TO CHANGE, POSSIBLY WITH RETROACTIVE EFFECT.
EACH PROSPECTIVE INVESTOR IS URGED TO CONSULT ITS OWN TAX ADVISOR ABOUT THE TAX CONSEQUENCES TO IT OF AN INVESTMENT IN OUR ORDINARY SHARES OR ADSs IN LIGHT OF THE INVESTOR&#146;S OWN CIRCUMSTANCES. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Material Australian Tax Considerations </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In this section, we discuss the material Australian income
tax, stamp duty and goods and services tax considerations related to the acquisition, ownership and disposal by the absolute beneficial owners of the ADSs or ordinary shares. It is based upon existing Australian tax law as of the date of this
registration statement, which is subject to change, possibly retrospectively. This discussion does not address all aspects of Australian tax law which may be important to particular investors in light of their individual investment circumstances,
such as ADSs or shares held by investors subject to special tax rules (for example, financial institutions, insurance companies or tax exempt organizations). In addition, this summary does not discuss any
<FONT STYLE="white-space:nowrap">non-Australian</FONT> or state tax considerations, other than stamp duty and goods and services tax. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prospective investors are urged to consult their tax advisors regarding the Australian and
<FONT STYLE="white-space:nowrap">non-Australian</FONT> income and other tax considerations of the acquisition, ownership and disposition of the ADSs or shares. This summary is based upon the premise that the holder is not an Australian tax resident
and is not carrying on business in Australia through a permanent establishment (referred to as a <FONT STYLE="white-space:nowrap">&#147;Non-Australian</FONT> Holder&#148; in this summary). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">182
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Nature of ADSs for Australian Taxation Purposes </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Non-Australian</FONT>
Holders of ADSs should obtain specialist Australian tax advice regarding their rights and obligations under the deposit agreement with the depositary, including whether the deposit arrangement constitutes a &#145;bare trust&#146; for Australian
taxation purposes. Apart from certain aspects of the Australian tax legislation (for example, the Australian capital gains tax and withholding tax provisions, which are discussed below), there is no express legislative basis for disregarding
&#147;bare trusts&#148; for Australian tax purposes generally. This summary proceeds on the assumption that the deposit arrangement constitutes a bare trust. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Holders of ADSs can be treated as the owners of the underlying ordinary shares for Australian capital gains tax purposes on the basis that
they are &#145;absolutely entitled&#146; to those shares. Dividends paid on the underlying ordinary shares will also be treated as dividends derived by the holders of ADSs as the persons presently entitled to those dividends. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Taxation of Dividends </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Australia operates a dividend imputation system under which
dividends may be declared to be &#147;franked&#148; to the extent they are paid out of company profits that have been subject to income tax. Fully franked dividends are not subject to dividend withholding tax. To the extent that they are unfranked,
dividends payable to <FONT STYLE="white-space:nowrap">Non-Australian</FONT> Holders will be subject to dividend withholding tax except to the extent they are declared to be conduit foreign income, or CFI. Dividend withholding tax will be imposed at
30%, unless a shareholder is a resident of a country with which Australia has a double taxation treaty and qualifies for the benefits of the treaty. Under the provisions of the current Double Taxation Convention between Australia and the United
States, the Australian tax withheld on unfranked dividends that are not declared to be CFI paid by us to which a resident of the United States is beneficially entitled is limited to 15%. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Double Taxation Convention between Australia and the United States, if a company that is a <FONT
STYLE="white-space:nowrap">Non-Australian</FONT> Holder directly owns a 10% or more interest, the Australian tax withheld on unfranked dividends that are not declared to be CFI paid by us to which a resident of the United States is beneficially
entitled is limited to 5%. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Character of
ADSs for Australian Taxation Purposes </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Australian tax treatment of a sale or disposal of the ADSs will depend on whether they are held on revenue or capital account. ADSs
may be held on revenue rather than capital account, for example, where they are held by share traders or any profit arises from a profit-making undertaking or scheme entered into by the holder. <FONT STYLE="white-space:nowrap">Non-Australian</FONT>
Holders of ADSs should obtain specialist Australian tax advice regarding the characterization of any gain or loss on a sale or disposal of the ADSs as revenue or capital in nature. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Tax on Sales or other Dispositions of
Shares&#151;Capital Gains Tax </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT
STYLE="white-space:nowrap">Non-Australian</FONT> Holders who are treated as the owners of the underlying shares on the basis that they are absolutely entitled to those shares will not be subject to Australian capital gains tax on the gain made on a
sale or other disposal of ordinary shares unless: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">they, together with associates, hold 10% or more of our issued capital, at the time of disposal or for a 12 month period during the two years prior to
disposal; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">more than 50% of our assets held directly or indirectly, determined by reference to market value, consists of Australian real property (which includes
land and leasehold interests) or Australian mining, quarrying or prospecting rights at the time of disposal. Australian capital gains tax applies to net capital gains at a taxpayer&#146;s marginal tax rates. Net capital gains are calculated after
reduction for capital losses, which may only be offset against capital gains. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">183
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The 50% capital gains tax discount is not available to
<FONT STYLE="white-space:nowrap">Non-Australian</FONT> Holders on gains from assets acquired accrued after May&nbsp;8, 2012 where they were <FONT STYLE="white-space:nowrap">non-Australian</FONT> residents during the entire holding period. Companies
are not entitled to a capital gains tax discount. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Broadly, where there is a disposal of certain taxable Australian property, the purchaser will be required to withhold and remit to the
Australian Taxation Office, or the ATO, 12.5% of the proceeds from the sale. A transaction is excluded from the withholding requirements in certain circumstances, including where the transaction is an
<FONT STYLE="white-space:nowrap">on-market</FONT> transaction conducted on an approved stock exchange, a securities lending, or the transaction is conducted using a broker operated crossing system. There may also be an exception to the requirement
to withhold where a <FONT STYLE="white-space:nowrap">Non-Australian</FONT> Holder provides a declaration that their ordinary shares are not &#145;indirect Australian real property interests&#146;. The
<FONT STYLE="white-space:nowrap">Non-Australian</FONT> Holder may be entitled to receive a tax credit for the tax withheld by the purchaser which they may claim in their Australian income tax return. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Tax on Sales or other Dispositions of ADSs&#151;Revenue
Account </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Non-Australian</FONT> Holders who hold their ADSs on revenue account may have the gains made on the sale
or other disposal of the ADSs included in their assessable income under the ordinary income provisions of the income tax law, if the gains are sourced in Australia. There are no express provisions which treat holders of ADSs as the owners of the
underlying shares where there is a bare trust. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT
STYLE="white-space:nowrap">Non-Australian</FONT> Holders assessable under these ordinary income provisions in respect of gains made on ADSs held on revenue account would be assessed for such gains at the Australian tax rates for <FONT
STYLE="white-space:nowrap">non-Australian</FONT> residents, which start at a marginal rate of 32.5% for individuals and would be required to file an Australian tax return. Some relief from Australian income tax may be available to a <FONT
STYLE="white-space:nowrap">Non-Australian</FONT> Holder who is resident of a country with which Australia has a double taxation treaty, qualifies for the benefits of the treaty and does not, for example, derive the gain in carrying on business
through a permanent establishment in Australia. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To the extent an amount would be included in a <FONT STYLE="white-space:nowrap">Non-Australian</FONT> Holder&#146;s assessable income
under both the capital gains tax provisions and the ordinary income provisions, the capital gain amount may be reduced, so that the holder may not be subject to double Australian tax on any part of the gain. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The statements under &#147;&#151;Tax on Sales or Other
Dispositions of Shares&#151;Capital Gains Tax&#148; regarding a purchaser being required to withhold 12.5% tax on the acquisition of certain taxable Australian property should apply where the disposal of the ADSs by a
<FONT STYLE="white-space:nowrap">Non-Australian</FONT> Holder is likely to generate gains on revenue account, rather than a capital gain. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Dual Residency </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If a holder of ADSs is a resident of both Australia and the United States under those countries&#146; domestic taxation laws, that holder
may be subject to tax as an Australian resident. If, however, the holder is determined to be a U.S. resident for the purposes of the Double Taxation Convention between the United States and Australia, the Australian tax would be subject to
limitation by the Double Taxation Convention. Holders should obtain specialist taxation advice in these circumstances. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Stamp Duty </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">No Australian stamp duty is payable by Australian residents or <FONT STYLE="white-space:nowrap">non-Australian</FONT> residents on the
issue, transfer and/or surrender of our ADSs or ordinary shares, provided that the securities issued, transferred and/or surrendered do not represent 90% or more of our issued shares. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">184
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Australian Death Duty </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Australia does not have estate or death duties. As a general
rule, no capital gains tax liability is realized upon the inheritance of a deceased person&#146;s shares. The disposal of inherited shares by beneficiaries may, however, give rise to a capital gains tax liability if the gain falls within the scope
of Australia&#146;s jurisdiction to tax. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Goods and Services Tax </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">No Australian goods and services tax will be payable on the supply of our ADSs or ordinary shares. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>THE DISCUSSION ABOVE IS A SUMMARY OF THE AUSTRALIAN TAX
CONSEQUENCES OF AN INVESTMENT IN OUR ORDINARY SHARES OR ADSs AND IS BASED UPON LAWS AND RELEVANT INTERPRETATIONS THEREOF IN EFFECT AS OF THE DATE OF THIS PROSPECTUS, ALL OF WHICH ARE SUBJECT TO CHANGE, POSSIBLY WITH RETROACTIVE EFFECT. EACH
PROSPECTIVE INVESTOR IS URGED TO CONSULT ITS OWN TAX ADVISOR ABOUT THE TAX CONSEQUENCES TO IT OF AN INVESTMENT IN OUR ORDINARY SHARES OR ADSs IN LIGHT OF THE INVESTOR&#146;S OWN CIRCUMSTANCES. </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">185
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_21"></A>ENFORCEMENT OF CIVIL LIABILITIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a public limited company incorporated under the laws
of Australia. Certain of our directors are <FONT STYLE="white-space:nowrap">non-residents</FONT> of the United States and substantially all of their assets are located outside the United States. As a result, it may not be possible or practicable for
you to: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">effect service of process within the United States upon our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> resident directors or on us;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">enforce in U.S. courts judgments obtained against our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> resident directors or us in the United States
courts in any action, including actions under the civil liability provisions of U.S. securities laws; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">enforce in U.S. courts judgments obtained against our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> resident directors or us in courts of
jurisdictions outside the United States in any action, including actions under the civil liability provisions of U.S. securities laws; or </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">bring an original action in an Australian court to enforce liabilities against our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> resident directors
or us based solely upon U.S. securities laws. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">You may also have difficulties enforcing in courts outside the United States judgments that are obtained in U.S. courts against any of our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> resident
directors or us, including actions under the civil liability provisions of the U.S. securities laws. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">With that noted, there are no treaties between Australia and the United States that would affect the recognition or enforcement of foreign
judgments in Australia. We also note that investors may be able to bring an original action in an Australian court against us to enforce liabilities based in part upon U.S. federal securities laws. The disclosure in this section is not based on the
opinion of counsel. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have appointed Corporation
Service Company as our agent to receive service of process with respect to any action brought against us under the federal securities laws of the United States. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">186
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_22"></A>UNDERWRITING </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Citigroup Global Markets Inc. and SVB Leerink LLC are acting
as book-running managers of this offering and as representatives of the underwriters named below. Subject to the terms and conditions stated in the underwriting agreement dated the date of this prospectus, the underwriters named below have severally
agreed to purchase, and we have agreed to sell to them, the number of ADSs indicated below: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Underwriter</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of<BR>ADSs</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Citigroup Global Markets Inc.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">SVB Leerink LLC</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The underwriting agreement
provides that the obligations of the underwriters to purchase the ADSs included in this offering are subject to approval of legal matters by counsel and to other conditions. The underwriters are obligated to purchase all of the ADSs (other than
those covered by the over-allotment option described below) if they purchase any of the shares. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">ADSs sold by the underwriters to the public will initially be offered at the initial public offering price set forth on the cover of this prospectus. Any ADSs sold by the underwriters to securities
dealers may be sold at a discount from the initial public offering price not to exceed $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS. After the initial public offering of the ADSs, if all
the ADSs are not sold at the initial public offering price, the underwriters may change the offering price and the other selling terms. The representatives have advised us that the underwriters do not intend to make sales to discretionary accounts.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The address of Citigroup Global Markets Inc. is
390 Greenwich Street, New York, New York 10013, and the address of SVB Leerink LLC is One Federal Street, 37th Floor, Boston, Massachusetts 02110. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the underwriters sell more ADSs than the total number set forth in the table above, we have granted to the underwriters an option,
exercisable for 30 days from the date of this prospectus, to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional ADSs at the initial public offering price less the underwriting
discount. The underwriters may exercise the option solely for the purpose of covering over-allotments, if any, in connection with this offering. To the extent the option is exercised, each underwriter must purchase a number of additional ADSs
approximately proportionate to that underwriter&#146;s initial purchase commitment set forth in the table above. Any ADSs issued or sold under the option will be issued and sold on the same terms and conditions as the other ADSs that are the subject
of this offering. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We and our officers and
directors have agreed that, subject to specified limited exceptions, for a period of 90 days from the date of this prospectus, we and they will not, without the prior written consent of Citigroup Global Markets Inc. and SVB Leerink LLC, offer, sell,
contract to sell, pledge or otherwise dispose of, including the filing of a registration statement in respect of, or hedge any ordinary shares or ADSs or any securities convertible into, or exercisable or exchangeable for, our ordinary shares or
ADSs, collectively referred to as <FONT STYLE="white-space:nowrap">lock-up</FONT> securities. Citigroup Global Markets Inc. and SVB Leerink LLC in their sole discretion may release any of the securities subject to these <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements at any time, which, in the case of officers and directors, shall be with notice. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions relating to our officers and directors described in the immediately
preceding paragraph are subject to specified exceptions, including the following: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">transfers of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities (i)&nbsp;as a bona fide gift or gifts, (ii)&nbsp;by will, other testamentary document or
intestacy or (iii)&nbsp;to any immediate family member of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party or to any trust or other legal entity for the benefit of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party or immediate
family of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party, or if the <FONT STYLE="white-space:nowrap">lock-up</FONT> party is a trust, to a trustor or beneficiary of the trust or to the estate of a beneficiary of such trust,
</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">187
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">b.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">transfers of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities to a partnership, limited liability company or other entity of which <FONT
STYLE="white-space:nowrap">lock-up</FONT> party and the <FONT STYLE="white-space:nowrap">lock-up</FONT> party&#146;s immediate family are the legal and beneficial owner of all of the outstanding equity securities or similar interests;
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">c.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">transfers of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities to a corporation, member, partner, partnership, limited liability company, trust or other entity
that is an affiliate of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">d.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">transfers of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities to any investment fund or other entity controlled or managed by the <FONT
STYLE="white-space:nowrap">lock-up</FONT> party or its affiliates (including where the <FONT STYLE="white-space:nowrap">lock-up</FONT> party is a partnership, to a successor partnership or fund, or any other funds managed by such partnership);
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">e.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">transfers of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities to a nominee or custodian of a person or entity to whom a disposition or transfer would be
permissible above; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">f.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">transfers of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities by operation of law, pursuant to a qualified domestic order, divorce settlement, divorce decree
or separation agreement or other final court order; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">g.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">transfers of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities to us upon death, disability, termination of employment or cessation of services;
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">h.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">transfers of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities acquired in open market transactions after the closing of this offering;
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">i.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">transfers of ordinary shares or ADSs to us in connection with the vesting, settlement, or exercise of options and other equity awards to purchase ordinary shares or
ADSs (including, in each case, by way of &#147;net&#148; or &#147;cashless&#148; exercise), including for the payment of exercise price and tax withholdings or remittance payments due as a result of the vesting, settlement, or exercise of such
equity awards; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">j.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">transfers of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities pursuant to a bona fide third-party tender offer, merger, consolidation or other similar
transaction (including a takeover bid under Chapter 6 of the Corporations Act 2001 (Cth) and a scheme of arrangement implemented under Part 5.1 of the scheme of arrangement under the Corporations Act 2001 (Cth)) that is approved by our board of
directors and made to all holders of our share capital involving a change of control; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">k.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">the receipt from us of shares of common stock in connection with the exercise of options or other rights granted under an equity incentive plan or other equity award
plan or program or pursuant to an individual award agreement between us and the <FONT STYLE="white-space:nowrap">lock-up</FONT> party; or </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">l.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">the establishment of a trading plan pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act or to a similar effect permitted under the
rules and regulations of the Australian Securities Exchange for the transfer of shares of common stock, provided that such plan does not provide for the transfer of common stock, </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>provided</I> that: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">in the case of any transfer or distribution pursuant to clauses (a)&nbsp;through (f) above, each donee, trustee, distributee or transferee shall sign
and deliver a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">in the case of any transfer or distribution pursuant to clause (h)&nbsp;above, no filing under the Exchange Act or other public announcement would be
required or be voluntarily made; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">in the case of any transfer or distribution pursuant to clauses (a)&nbsp;through (k), any filing under the Exchange Act or other public report or
announcement would clearly indicate the nature and conditions of the transfer or distribution; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">in the case of any transfer or distribution pursuant to clauses (a)&nbsp;through (e) above, such transfer or distribution would not involve a
disposition for value. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior to
this offering, there has been no public market for our ADSs in the United States. Our ordinary shares have been trading on the Australian Securities Exchange, or the ASX, since April 1985 under the symbol
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">188
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
&#147;OPT.&#148; The initial public offering price for the ADSs will be determined by negotiations between us and the representatives. Among the factors considered in determining the initial
public offering price will be the price of our ordinary shares in connection with our existing listing on ASX, our stage of development, our current financial condition, our future prospects, our markets, the economic conditions in and future
prospects for the industry in which we compete, our management, and currently prevailing general conditions in the equity securities markets, including current market valuations of publicly traded companies considered comparable to our company. We
cannot assure you, however, that the price at which the ADSs will sell in the public market after this offering will not be lower than the initial public offering price or that an active trading market in our shares of ADSs will develop and continue
after this offering. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have applied for listing
of our ADSs listed on the Nasdaq Global Market under the symbol &#147;OPT.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table shows the per ADS and total underwriting discounts and commissions that we are to pay to the underwriters and proceeds to us, before estimated offering expenses, in connection with
this offering. These amounts are shown assuming both no exercise and full exercise of the underwriters&#146; over-allotment option: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Per ADS</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No<BR>exercise</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Full<BR>exercise</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Public offering price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Underwriting discounts paid by us</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds to us, before expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We estimate that expenses
payable by us in connection with this offering, exclusive of underwriting discounts, will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have also agreed to reimburse the underwriters for expenses in an amount up to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; relating to the clearance of this offering with the Financial Industry Regulatory Authority, Inc. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with this offering, the underwriters may purchase and sell ADSs in the open market. Purchases and sales in the open market
may include short sales, purchases to cover short positions, which may include purchases pursuant to the underwriters&#146; over-allotment option, and other transactions that would stabilize, maintain or otherwise affect the price of our ADSs.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Short sales involve secondary market sales by the underwriters of a greater number of ADSs than they are required to purchase in this offering:
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Covered&#148; short sales are sales of ADSs in an amount up to the number of ADSs represented by the underwriters&#146; over-allotment option.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Naked&#148; short sales are sales of ADSs in an amount in excess of the number of ADSs represented by the underwriters&#146; over-allotment
option. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The underwriters can close out a short position by purchasing additional ADSs, either pursuant to the underwriters&#146; over-allotment option or in
the open market. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">To close a naked short position, the underwriters must purchase ADSs in the open market. A naked short position is more likely to be created if the
underwriters are concerned that there may be downward pressure on the price of the ADSs in the open market after pricing that could adversely affect investors who purchase in this offering. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">To close a covered short position, the underwriters must purchase ADSs in the open market or exercise their over-allotment option. In determining the
source of ADSs to close the covered short position, the underwriters will consider, among other things, the price of ADSs available for purchase in the open market as compared to the price at which they may purchase ADSs through their over-allotment
option. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">189
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">As an additional means of facilitating this offering, the underwriters may bid for, and purchase, ADSs on the Nasdaq Global Market, as long as such
bids do not exceed a specified maximum, to stabilize the price of the ADSs. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Purchases to cover short positions and stabilizing purchases, as well as other purchases by the underwriters for their own accounts, may have the effect of preventing or retarding a decline in the market
price of the shares. They may also cause the price of the ADSs to be higher than the price that would otherwise prevail in the open market in the absence of these transactions. The underwriters may conduct these transactions on the Nasdaq Global
Market, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. The underwriters are not required to engage in any of these transactions and may discontinue them at any time.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have agreed to indemnify the underwriters
against certain liabilities, including liabilities under the Securities Act, or to contribute to payments the underwriters may be required to make because of any of those liabilities. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A prospectus in electronic format may be made available on websites maintained by one or more of the
underwriters or their respective affiliates. The representatives may agree with us to allocate a number of ADSs to underwriters for sale to their online brokerage account holders. Any such allocation for online distributions will be made by the
underwriters on the same basis as other allocations. Other than the prospectus in electronic format, the information on the underwriters&#146; or their respective affiliates&#146; websites and any information contained in any other website
maintained by any of the underwriters or their respective affiliates is not part of this prospectus, has not been approved and/or endorsed by us or the underwriters and should not be relied upon by investors in this offering. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Relationships </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The underwriters are full-service financial institutions
engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, principal investment, hedging, financing and brokerage activities. The underwriters and their
respective affiliates may, from time to time, engage in transactions with and perform services for us in the ordinary course of their business for which they may receive customary fees and reimbursement of expenses. In the ordinary course of their
various business activities, the underwriters and their respective affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (which may include
bank loans or credit default swaps) for their own account and for the accounts of their customers and may at any time hold long and short positions in such securities and instruments. Such investments and securities activities may involve securities
and/or instruments of ours or our affiliates. The underwriters and their affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or financial instruments and may hold, or
recommend to clients that they acquire, long or short positions in such securities and instruments. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in the European Economic Area </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In relation to each member state of the European Economic Area that has implemented the Prospectus Directive (each, a relevant member
state), with effect from and including the date on which the Prospectus Directive is implemented in that relevant member state (the relevant implementation date), an offer of ADSs described in this prospectus may not be made to the public in that
relevant member state other than: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to any legal entity which is a qualified investor as defined in the Prospectus Directive; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus
Directive, subject to obtaining the prior consent of the relevant Dealer or Dealers nominated by us for any such offer; or </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">190
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">in any other circumstances falling within Article 3(2) of the Prospectus Directive; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">provided that no such offer of ADSs shall require us or any underwriter to
publish a prospectus pursuant to Article 3 of the Prospectus Directive. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">For purposes of this provision, the expression an &#147;offer of securities to the public&#148; in any relevant member state means the communication in any form and by any means of sufficient information
on the terms of the offer and the ADSs to be offered so as to enable an investor to decide to purchase or subscribe for any ADSs, as the expression may be varied in that member state by any measure implementing the Prospectus Directive in that
member state, the expression &#147;Prospectus Directive&#148; means Directive 2003/71/EC (and amendments thereto, including the 2010 PD Amending Directive) and includes any relevant implementing measure in the relevant member state, and the
expression &#147;2010 PD Amending Directive&#148; means Directive 2010/73/EU. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The sellers of the ADSs have not authorized and do not authorize the making of any offer of ADSs through any financial intermediary on their behalf, other than offers made by the underwriters with a view
to the final placement of the ADSs as contemplated in this prospectus. Accordingly, no purchaser of the ADSs, other than the underwriters, is authorized to make any further offer of the ADSs on behalf of the sellers or the underwriters. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in the United Kingdom </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus is only being distributed to, and is only
directed at, persons in the United Kingdom that are qualified investors within the meaning of Article 2(1)(e) of the Prospectus Directive that are also (1)&nbsp;investment professionals falling within Article 19(5) of the Financial Services and
Markets Act 2000 (Financial Promotion) Order 2005, or the Order, or (2)&nbsp;high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d)&nbsp;of the Order (each such person being
referred to as a relevant person). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This
prospectus and its contents are confidential and should not be distributed, published or reproduced (in whole or in part) or disclosed by recipients to any other persons in the United Kingdom. Any person in the United Kingdom that is not a relevant
person should not act or rely on this document or any of its contents. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in Australia </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">No prospectus or other disclosure document (as defined in the Corporations Act 2001 (Cth) of Australia, or Corporations Act) in relation to our ADSs has been or will be lodged with the Australian
Securities&nbsp;&amp; Investments Commission, or ASIC. This document has not been lodged with ASIC and is only directed to certain categories of exempt persons. Accordingly, if you receive this document in Australia: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">you confirm and warrant that you are either: </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a &#147;sophisticated investor&#148; under Section&nbsp;708(8)(a) or (b)&nbsp;of the Corporations Act; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a &#147;sophisticated investor&#148; under Section&nbsp;708(8)(c) or (d)&nbsp;of the Corporations Act and that you have provided an accountant&#146;s
certificate to us which complies with the requirements of Section&nbsp;708(8)(c)(i) or (ii)&nbsp;of the Corporations Act and related regulations before the offer has been made; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a person associated with the company under Section&nbsp;708(12) of the Corporations Act; or </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a &#147;professional investor&#148; within the meaning of Section&nbsp;708(11)(a) or (b)&nbsp;of the Corporations Act, and to the extent that you are
unable to confirm or warrant that you are an exempt sophisticated investor, associated person or professional investor under the Corporations Act any offer made to you under this document is void and incapable of acceptance; and
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">191
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">you warrant and agree that you will not offer any of our ADSs for resale in Australia within 12 months of that ADSs being issued unless any such resale
offer is exempt from the requirement to issue a disclosure document under Section&nbsp;708 of the Corporations Act. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in Canada </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The securities may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as
defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument
<FONT STYLE="white-space:nowrap">31-103</FONT> Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the securities must be made in accordance with an exemption from, or in a transaction not subject to, the
prospectus requirements of applicable securities laws. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a
misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any
applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to Section&nbsp;3A.3 of National Instrument <FONT
STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (NI <FONT STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT>
regarding underwriter conflicts of interest in connection with this offering. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in France </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Neither this prospectus nor any other offering material relating to the ADSs described in this prospectus has been submitted to the clearance procedures of the<I> Autorit&eacute; des March&eacute;s
Financiers</I> or of the competent authority of another member state of the European Economic Area and notified to the<I> Autorit&eacute; des March&eacute;s Financiers</I>. The ADSs have not been offered or sold and will not be offered or sold,
directly or indirectly, to the public in France. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Neither this prospectus nor any other offering material relating to the ADSs has been or will be: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">released, issued, distributed or caused to be released, issued or distributed to the public in France; or </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">used in connection with any offer for subscription or sale of the ADSs to the public in France. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Such offers, sales and distributions will be made in France only: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to qualified investors (<I>investisseurs qualifi&eacute;s</I>) and/or to a restricted circle of investors (<I>cercle restreint
d&#146;investisseurs</I>), in each case investing for their own account, all as defined in and in accordance with articles <FONT STYLE="white-space:nowrap">L.411-2,</FONT> <FONT STYLE="white-space:nowrap">D.411-1,</FONT> <FONT
STYLE="white-space:nowrap">D.411-2,</FONT> <FONT STYLE="white-space:nowrap">D.734-1,</FONT> <FONT STYLE="white-space:nowrap">D.744-1,</FONT> <FONT STYLE="white-space:nowrap">D.754-1</FONT> and <FONT STYLE="white-space:nowrap">D.764-1</FONT> of the
French Code mon&eacute;taire et financier; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to investment services providers authorized to engage in portfolio management on behalf of third parties; or </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">in a transaction that, in accordance with article
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">L.411-2-II-1&deg;</FONT></FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">-or-2&deg;</FONT></FONT> <FONT
STYLE="white-space:nowrap">-or</FONT> 3&deg; of the French Code<I> mon&eacute;taire et financier</I> and article <FONT STYLE="white-space:nowrap">211-2</FONT> of the General Regulations (<I>R&egrave;glement G&eacute;n&eacute;ral</I>) of the<I>
Autorit&eacute; des March&eacute;s Financiers</I>, does not constitute a public offer (<I>appel public &agrave; l&#146;&eacute;pargne</I>). </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The ADSs may be resold directly or indirectly, only in compliance with articles <FONT STYLE="white-space:nowrap">L.411-1,</FONT> <FONT
STYLE="white-space:nowrap">L.411-2,</FONT> <FONT STYLE="white-space:nowrap">L.412-1</FONT> and <FONT STYLE="white-space:nowrap">L.621-8</FONT> through <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">L.621-8-3</FONT></FONT> of the
French Code<I> mon&eacute;taire et financier</I>. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">192
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in Hong Kong </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The ADSs may not be offered or sold in Hong Kong by means of
any document other than (1)&nbsp;in circumstances which do not constitute an offer to the public within the meaning of the Companies Ordinance (Cap. 32, Laws of Hong Kong), or (2)&nbsp;to &#147;professional investors&#148; within the meaning of the
Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong) and any rules made thereunder, or (3)&nbsp;in other circumstances which do not result in the document being a &#147;prospectus&#148; within the meaning of the Companies Ordinance (Cap.
32, Laws of Hong Kong) and no advertisement, invitation or document relating to the ADSs may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the
contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the laws of Hong Kong) other than with respect to ADSs which are or are intended to be disposed of only to persons outside Hong Kong
or only to &#147;professional investors&#148; within the meaning of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong) and any rules made thereunder. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in the State of Israel </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the State of Israel, this prospectus shall not be
regarded as an offer to the public to purchase shares of ADSs under the Israeli Securities Law, 5728 - 1968, which requires a prospectus to be published and authorized by the Israel Securities Authority, if it complies with certain provisions of
Section&nbsp;15 of the Israeli Securities Law, 5728 - 1968, including, inter alia, if: (1)&nbsp;the offer is made, distributed or directed to not more than 35 investors, subject to certain conditions, or the Addressed Investors; or (2)&nbsp;the
offer is made, distributed or directed to certain qualified investors defined in the First Addendum of the Israeli Securities Law, 5728 - 1968, subject to certain conditions, or Qualified Investors. The Qualified Investors shall not be taken into
account in the count of the Addressed Investors and may be offered to purchase securities in addition to the 35 Addressed Investors. We have not and will not take any action that would require us to publish a prospectus in accordance with and
subject to the Israeli Securities Law, 5728 - 1968. We have not and will not distribute this prospectus or make, distribute or direct an offer to subscribe for our ADSs to any person within the State of Israel, other than to Qualified Investors and
up to 35 Addressed Investors. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Qualified Investors
may have to submit written evidence that they meet the definitions set out in of the First Addendum to the Israeli Securities Law, 5728&#151;1968. In particular, we may request that Qualified Investors will each represent, warrant and certify to us
and/or to anyone acting on our behalf: (1)&nbsp;that it is an investor falling within one of the categories listed in the First Addendum to the Israeli Securities Law, 5728 - 1968; (2) which of the categories listed in the First Addendum to the
Israeli Securities Law, 5728 - 1968 regarding Qualified Investors is applicable to it; (3)&nbsp;that it will abide by all provisions set forth in the Israeli Securities Law, 5728 - 1968 and the regulations promulgated thereunder in connection with
this offering; (4)&nbsp;that the shares of ADSs that it will be issued are, subject to exemptions available under the Israeli Securities Law, 5728 -1968: (a) for its own account; (b)&nbsp;for investment purposes only; and (c)&nbsp;not issued with a
view to resale within the State of Israel, other than in accordance with the provisions of the Israeli Securities Law, 5728 -1968; and (5)&nbsp;that it is willing to provide further evidence of its Qualified Investor status. Addressed Investors may
have to submit written evidence in respect of their identity and may have to sign and submit a declaration containing, inter alia, the Addressed Investor&#146;s name, address and passport number or Israeli identification number. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in Japan </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The ADSs offered in this prospectus have not been and will
not be registered under the Financial Instruments and Exchange Law of Japan. The ADSs have not been offered or sold and will not be offered or sold, directly or indirectly, in Japan or to or for the account of any resident of Japan (including any
corporation or other entity organized under the laws of Japan), except (1)&nbsp;pursuant to an exemption from the registration requirements of the Financial Instruments and Exchange Law and (2)&nbsp;in compliance with any other applicable
requirements of Japanese law. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">193
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in Singapore </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus has not been registered as a prospectus with
the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the ADSs may not be circulated or distributed, nor may the ADSs
be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (1)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and Futures
Act, Chapter 289 of Singapore, or the SFA, (2)&nbsp;to a relevant person pursuant to Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions specified in Section&nbsp;275 of the SFA or
(3)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA, in each case subject to compliance with conditions set forth in the SFA. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Where the ADSs are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant party which is:
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and
the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual
who is an accredited investor, shares, debentures and units of ADSs and debentures of that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that
corporation or that trust has acquired the ADSs pursuant to an offer made under Section&nbsp;275 of the SFA except: </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to an institutional investor (for corporations, under Section&nbsp;274 of the SFA) or to a relevant person defined in Section&nbsp;275(2) of the SFA,
or to any person pursuant to an offer that is made on terms that such shares, debentures and units of ADSs and debentures of that corporation or such rights and interest in that trust are acquired at a consideration of not less than $200,000 (or its
equivalent in a foreign currency) for each transaction, whether such amount is to be paid for in cash or by exchange of securities or other assets, and further for corporations, in accordance with the conditions specified in Section&nbsp;275 of the
SFA; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">where no consideration is or will be given for the transfer; or </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">where the transfer is by operation of law. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">194
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_23"></A>EXPENSES RELATING TO THE OFFERING </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth the costs and expenses, other
than underwriting discounts and commissions, payable in connection with the sale of ADSs in the offering. All amounts are estimated except the SEC registration fee, the Financial Industry Regulatory Authority, Inc., or FINRA, filing fee and the
Nasdaq initial listing fee. Except as otherwise noted, all the expenses below will be paid by us. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Expense</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">SEC registration fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">FINRA filing fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Nasdaq initial listing fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Legal fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounting fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Printing expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Miscellaneous fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">*</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">To be completed by amendment. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_24"></A>LEGAL MATTERS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The validity of the ordinary shares represented by the ADSs and certain other matters of Australian law will be passed upon for us by
Gilbert + Tobin. Certain matters as to U.S. federal law and New York state law will be passed upon for us by Cooley LLP, New York, New York and Cooley LLP, Singapore. Legal counsel to the underwriters in connection with this offering are Goodwin
Procter LLP, Boston, Massachusetts, with respect to U.S. federal law, and Herbert Smith Freehills, Melbourne, Australia, with respect to Australian law. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_25"></A>EXPERTS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The financial statements included in this prospectus have been audited by Deloitte Touche Tohmatsu, an independent registered public
accounting firm, as stated in their report appearing herein. Such financial statements are included in reliance upon the report of such firm given upon their authority as experts in accounting and auditing. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The offices of Deloitte Touche Tohmatsu are located at Tower
2, Brookfield Place, 123 St. Georges Terrace, Perth, WA 6000, Australia. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_26"></A>WHERE YOU CAN FIND MORE INFORMATION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have filed with the SEC a Registration Statement on <FONT STYLE="white-space:nowrap">Form&nbsp;F-1&nbsp;under</FONT> the Securities Act
with respect to the ADSs offered in this prospectus. A related registration statement <FONT STYLE="white-space:nowrap">on&nbsp;Form&nbsp;F-6&nbsp;has</FONT> been filed with the SEC to register the ADSs. This prospectus, which forms a part of the
Registration Statement, does not contain all of the information included in the Registration Statement. Certain information is omitted and you should refer to the Registration Statement and its exhibits for that information. With respect to
references made in this prospectus to any contract or other document of Opthea, such references are not necessarily complete and you should refer to the exhibits attached to the Registration Statement for copies of the actual contract or document.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon the closing of this offering, we will become
subject to periodic reporting and other informational requirements of the Exchange Act as applicable to foreign private issuers. Accordingly, we will be required to file reports, including annual reports on
<FONT STYLE="white-space:nowrap">Form&nbsp;20-F,&nbsp;periodic</FONT> reports and other information, with the SEC. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">195
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are allowed four months after the end of our fiscal year to file our annual report
with the SEC, and we are not required to disclose certain detailed information regarding executive compensation that is required from U.S. domestic issuers. Also, as a foreign private issuer, we are exempt from the rules of the Exchange Act
prescribing the furnishing of proxy statements to shareholders, and the members of our board of directors, our senior management and our principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in
Section&nbsp;16 of the Exchange Act. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a foreign
private issuer, we are also exempt from the requirements of Regulation FD (Fair Disclosure) which, generally, are meant to ensure that select groups of investors are not privy to specific information about an issuer before other investors. We are,
however, still subject to the anti-fraud and anti-manipulation rules of the SEC, such as <FONT STYLE="white-space:nowrap">Rule&nbsp;10b-5.&nbsp;Since</FONT> many of the disclosure obligations required of us as a foreign private issuer are different
than those required of U.S. domestic reporting companies, our shareholders, potential shareholders and the investing public in general should not expect to receive information about us in the same amount, or at the same time, as information is
received from, or provided by, other U.S. domestic reporting companies. We are only liable for violations of the rules and regulations of the SEC that apply to us as a foreign private issuer. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The SEC maintains a website at www.sec.gov that contains reports, proxy and information statements and other
information regarding registrants that file electronically with the SEC. You also can inspect our registration statement, as well as any other information we file with or furnish to the SEC, on this website. This reference to the SEC&#146;s website
is an inactive textual reference only and is not a hyperlink. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We expect to make our annual reports and other information filed with or furnished to the SEC available, free of charge, through our website at www.opthea.com as soon as reasonably practicable after those
reports and other information are filed with or furnished to the SEC. The information contained on, or that can be accessed through, our website is not part of, and is not incorporated into, this prospectus. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">196
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom947560_27"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Page</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin947560_1">Report of Independent Registered Public Accounting Firm</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin947560_2">Consolidated Statement of Profit or Loss and Other Comprehensive Income</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin947560_3">Consolidated Statement of Financial Position</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin947560_4">Consolidated Statement of Changes in Equity</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin947560_5">Consolidated Statement of Cash Flows</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin947560_6">Notes to the Consolidated Financial Statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-1
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin947560_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To the Shareholders and the
Board of Directors of Opthea Limited </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Opinion on the Financial
Statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have audited the accompanying consolidated
statement of financial position of Opthea Limited and subsidiary (the &#147;Company&#148;) as of 30&nbsp;June 2019, the related consolidated statements of profit or loss and other comprehensive income, changes in equity, and cash flows for the year
then ended and the related notes (collectively referred to as the &#147;financial statements&#148;). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In our opinion, except for the omission of comparative financial information as discussed in the following paragraph, the financial statements present fairly, in all material respects, the financial
position of the Company as of 30&nbsp;June 2019, and the results of its operations and its cash flows for the year then ended, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company omitted financial information for a preceding
comparative period. In our opinion, disclosure of comparative financial information is required by International Financial Reporting Standards as issued by the International Accounting Standards Board. The omission of comparative financial
information results in an incomplete presentation of the Company&#146;s consolidated financial statements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Basis for Opinion </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial statements based on our audit. We are a
public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#147;PCAOB&#148;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the
applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are
free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an
understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our audit included performing procedures to assess the risks of material
misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial
statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable
basis for our opinion. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/
Deloitte Touche Tohmatsu </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Perth,
Western Australia </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 July 2020
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have served as the
Company&#146;s auditor since 2012. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-2
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin947560_2"></A>CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER
COMPREHENSIVE INCOME </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Note</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended<BR>June&nbsp;30, 2019<BR>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">159,064</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">836,821</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(31,347,891</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patent expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(161,148</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Intellectual property costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(112,795</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Administrative expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,174,755</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Occupancy expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(108,904</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net foreign exchange gain</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">362,574</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss before income tax</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(35,547,034</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income tax benefit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,636,973</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss for the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,910,061</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other Comprehensive income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Items that will not be reclassified subsequently to profit or loss:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value gains on investments in financial assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">259,864</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other comprehensive income for the period, net of tax</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">259,864</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total comprehensive loss for the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,650,197</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss for the year is attributable to:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Owners of the Company</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,910,061</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,910,061</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total comprehensive loss for the year is attributable to:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Owners of the Company</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,650,197</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,650,197</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss per share attributable to Owners of the Company&#151;basic and diluted (in cents)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8.98</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The above consolidated
statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-3
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin947560_3"></A>CONSOLIDATED STATEMENT OF FINANCIAL POSITION
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Note</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As
of<BR>June&nbsp;30,&nbsp;2019</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ASSETS</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Current Assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,534,919</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current tax receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,636,973</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Receivables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">295,786</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prepayments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">424,603</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total Current Assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36,892,281</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Non-current Assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investments in financial assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">714,118</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Plant and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54,063</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total Non-Current Assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">768,181</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TOTAL ASSETS</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37,660,462</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">LIABILITIES</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Current Liabilities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,951,942</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provisions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">538,547</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other financial liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,592</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total Current Liabilities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,516,081</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Non-Current Liabilities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provisions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24,844</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total Non-Current Liabilities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24,844</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TOTAL LIABILITIES</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,540,925</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">EQUITY</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contributed equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">113,021,993</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated losses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(86,060,060</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reserves</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,157,604</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TOTAL EQUITY</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31,119,537</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TOTAL LIABILITIES AND EQUITY</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37,660,462</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The above consolidated
statement of financial position should be read in conjunction with the accompanying notes. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-4
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin947560_4"></A>CONSOLIDATED STATEMENT OF CHANGES IN EQUITY </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Note</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Contributed<BR>equity</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>

<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Options<BR>reserve</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Share-<BR>based<BR>payments<BR>reserve</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$
</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fair
value<BR>of&nbsp;investments<BR>reserve</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Accumulated<BR>losses</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>

<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total equity</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Opening equity as of July&nbsp;1, 2018</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">98,403,149</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,989,067</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,452,838</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">477,391</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(65,149,999</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">38,172,446</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value gains on investments in financial assets(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">259,864</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">259,864</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss for the year(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,910,061</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,910,061</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total comprehensive income and expense for the period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">98,403,149</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,989,067</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,452,838</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">737,255</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(86,060,060</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,522,249</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Recognition of share-based payment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">967,511</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">967,511</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Transfer from option reserve on exercise of options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,989,067</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,989,067</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issue of ordinary shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,629,777</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,629,777</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Closing equity as of June&nbsp;30, 2019</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">113,021,993</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,420,349</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">737,255</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(86,060,060</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31,119,537</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">Amounts are after tax. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-5
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin947560_5"></A>CONSOLIDATED STATEMENT OF CASH FLOWS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Note</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended<BR>June,&nbsp;30,&nbsp;2019<BR>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CASH FLOWS FROM OPERATING ACTIVITIES</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest received</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">817,314</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Royalty and license income received</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">248,495</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payments to suppliers and employees and for research and development and intellectual property costs (inclusive of Goods and
Service Tax)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(37,268,212</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development tax incentive scheme credit received</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,017,247</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash flows used in operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(24,185,156</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CASH FLOWS FROM INVESTING ACTIVITIES</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash received on disposal of financial assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">339,046</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchase of plant and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(18,070</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash flows provided by investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">320,976</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CASH FLOWS FROM FINANCING ACTIVITIES</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash received for ordinary shares issued on exercise of options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,629,777</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash flows provided by financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,629,777</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net decrease in cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11,234,403</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents at beginning of year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32,510,230</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effects of exchange rate changes on cash held in foreign currencies</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">259,092</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents at the end of the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,534,919</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The above consolidated
statement of cash flows should be read in conjunction with the accompanying notes. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-6
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin947560_6"></A>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Reporting entity </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The significant accounting policies adopted in preparing the consolidated financial statements of Opthea Limited (&#147;Opthea&#148; or
the &#147;Company&#148;) and its subsidiary (the &#147;Consolidated Entity&#148; or &#147;Group&#148;) for the year ended June&nbsp;30, 2019, are stated to assist in a general understanding of the consolidated financial statements. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Opthea is a for profit company limited by shares,
incorporated and domiciled in Australia and has its registered office on Suite 403, Level 4, 650 Chapel Street, South Yarra, Victoria. The Company&#146;s ordinary shares are listed on the Australian Securities Exchange (the &#147;ASX&#148;) under
the symbol &#147;OPT.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group&#146;s
principal activity is the research and development of OPT-302 for the treatment of retinal diseases. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The financial statements for the year ended June&nbsp;30, 2019 were authorized for issue by the directors on July&nbsp;17, 2020.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Basis of accounting </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">These financial statements are general purpose financial statements which have been prepared in accordance with International Financial
Reporting Standards (&#147;IFRS&#148;) as issued by the International Accounting Standards Board (the &#147;IASB&#148;). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The financial statements comprise the consolidated financial statements of the Group. For the purposes of preparing the consolidated
financial statements, the Company is a for-profit entity. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Summary of accounting policies </B></FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The consolidated financial statements have been prepared
using the significant accounting policies and measurement bases summarized below. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Basis of measurement </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The consolidated financial statements have been prepared on a historical cost basis, except for investments classified as financial assets, which have been measured at fair value. All amounts are
presented in Australian dollars. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Basis of consolidation
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The consolidated financial statements
incorporate the financial statements of the Company and its subsidiary. Control is achieved when the Company: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">has power over the investee; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">is exposed, or has rights, to variable returns from its involvement with the investee; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">has the ability to use its power to affect its returns. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consolidation of a subsidiary begins when the Company obtains
control over the subsidiary and ceases when the Company loses control of the subsidiary. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">All intragroup assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-7
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Foreign currency translation </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Functional and presentation currency </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Both the functional and presentation currency of the Group is Australian dollars (A$). </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Transactions and balances </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Transactions in foreign currencies are initially recorded in
the functional currency by applying the exchange rates ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated at the rate of exchange ruling at the reporting date. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-monetary items that are measured in terms of historical
cost in a foreign currency are translated using the exchange rate as at the date of the initial transaction. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was
determined. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial assets and liabilities </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Recognition and derecognition of financial assets
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchases and sales of financial assets
that require delivery of assets within the time frame generally established by regulation or convention in the market place are recognized on the trade date, i.e., the date that the Group commits to purchase the asset. Financial assets are
derecognized when the right to receive cash flows from the financial assets has expired or when the entity transfers substantially all the risks and rewards of the financial assets. If the entity neither retains nor transfers substantially all of
the risks and rewards, it derecognizes the asset if it has transferred control of the assets. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">When financial assets are recognized initially, they are measured at fair value, plus directly attributable transaction costs. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Cash and cash equivalents </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents in the statement of financial
position comprise cash at bank and in hand and short-term deposits with an original maturity of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the purposes of the statement of cash flows,
cash and cash equivalents consist of cash and cash equivalents as defined above. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other receivables </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Other receivables generally comprise bank interest receivable, other receivable from external parties and Good and Services Tax (&#147;GST&#148;) credits receivable, and are recognized and carried at
original invoice amount less an allowance for any uncollectible amounts. The amounts are usually received within 30 to 60 days of recognition. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group measures the loss allowance for receivables at an amount equal to lifetime expected credit losses (&#147;ECL&#148;). The ECL on
receivables are estimated under the simplified approach as permitted under IFRS 9 &#147;Financial Instruments.&#148; This uses a provision matrix by reference to past experience of the debtor and an analysis of the debtor&#146;s current financial
position, adjusted for factors that are specific to the debtors and general economic conditions of the industry in which the debtors operate. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-8
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group writes off a receivable when there is information indicating that the debtor
is in severe financial difficulty and there is no realistic prospect of recovery. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Investments </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Investments in financial assets comprise of the Group&#146;s non-current investments in listed companies. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On initial recognition, the Group may make an irrevocable election (on an instrument-by-instrument basis) to designate investments in
equity instruments as fair value through other comprehensive income (&#147;FVTOCI&#148;). Designation at FVTOCI is not permitted if the equity instrument is held for trading. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investments in equity instruments at FVTOCI are initially
measured at fair value plus transaction costs. Subsequently, they are measured at fair value with gains or losses arising from changes in the fair value recognized in other comprehensive income and accumulated in the unrealized gains reserve. The
fair values of investments in financial assets that are actively traded in organized financial markets is determined by reference to quoted market bid prices at the close of business on the reporting date. The cumulative gain or loss is not
reclassified to profit or loss on disposal of the equity instruments. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Dividends on these investments in equity instruments are recognized in profit or loss in accordance with IFRS. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Finance income </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Almost all of the Group&#146;s finance income is earned on short-term bank deposits, and as such, finance revenue is recognized when the
Group&#146;s right to receive the payment is established. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Payables </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Payables are carried at amortized cost and due to their short-term nature, they are not discounted. They represent liabilities for goods and services provided to the Group prior to the end of the
financial year that are unpaid and arise when the Group becomes obliged to make future payments in respect of the purchase of these goods and services. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amounts are unsecured and are usually paid within 30 days of recognition. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Plant and equipment </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Plant and equipment is stated at historical cost less accumulated depreciation and any accumulated impairment losses. Depreciation on
plant and equipment is calculated on a straight-line basis over their useful economic lives as follows: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equipment and furniture&#151;3 to 10 years </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Leasehold improvements&#151;8 years or the term of the lease if shorter </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The assets&#146; residual values, useful lives and amortization methods are reviewed, and adjusted if
appropriate, at each financial year end. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">An item
of plant and equipment is derecognized upon disposal or when no further economic benefits are expected from its use or disposal. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-9
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Leases </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The determination of whether an arrangement is or contains a lease is based on the substance of the arrangement and requires an assessment
of whether the fulfilment of the arrangement is dependent on the use of a specific asset or assets and the arrangement conveys a right to use the asset, even if that right is not explicitly specified in an arrangement. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Leases are classified as finance leases whenever the terms of
the lease transfer substantially all the risks and rewards of ownership to the lessee. All other leases are classified as operating leases. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating lease payments are recognized as an expense in profit or loss on a straight-line basis over the lease term. Operating lease
incentives are recognised in the statement of comprehensive income as an integral part of the total lease expense. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group held no finance leases during the 2019 financial year. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Research and development costs </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research costs are expensed as incurred. An intangible asset
arising from the development expenditure on an internal project will only be recognized when the Group can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use or sale, its intention to
complete and its ability to use or sell the asset, how the asset will generate future economic benefits, the availability of resources to complete the development and the ability to measure reliably the expenditure attributable to the intangible
asset during its development. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of June&nbsp;30,
2019, the Group is in the research phase and has not capitalized any development costs to date. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Provisions and employee benefits </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Wages, salaries, annual leave and sick leave </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Liabilities for wages and salaries, including non-monetary benefits and annual leave expected to be settled within 12 months of the
reporting date, are recognized in current provisions in respect of employees&#146; services up to the reporting date. They are measured at the amounts expected to be paid when the liabilities are settled. Expenses for non-accumulating sick leave are
recognized when the leave is taken and are measured at the rate paid or payable. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Long service leave </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The liability for long service leave is recognized in the provision for employee benefits and measured as the present value of expected future payments to be made in respect of services provided by
employees up to the reporting date. Consideration is given to expected future wage and salary levels, experience of employee departures, and periods of service. Expected future payments are discounted using market yields at the reporting date on
bonds with terms to maturity that match, as closely as possible, the estimated future cash outflows. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Share-based payment transactions </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Group provides benefits to directors and employees (including key management personnel) of the Group in the form of share-based payments, whereby employees render services in exchange for shares or
rights over shares (equity-settled transactions). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-10
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The cost of these equity-settled transactions with employees is measured by reference to
the fair value at the date at which they are granted. Binomial models are used to value the options issued. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The cost of the equity-settled transactions is recognized, together with a corresponding increase in equity, over the period in which the
performance conditions are fulfilled (the vesting period), ending on the date on which the relevant employees become fully entitled to the award (the vesting date). </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The charge to profit or loss for the period is the cumulative
amount less the amounts already charged in previous periods. There is a corresponding credit to equity. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Until an award has vested, any amounts recorded are contingent and will be adjusted if more or fewer awards vest than were originally
anticipated to do so. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contributed equity </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ordinary shares are classified as equity. Incremental costs
directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Revenue recognition </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">License revenue in connection with licensing of the Group&#146;s intellectual property (including patents) to customers is recognized as a
right to use the Group&#146;s intellectual property as it exists at the point in time in which the license is granted. This is because the contracts for the license of intellectual property are distinct and do not require, nor does the customer
reasonably expect, that the Group will undertake further activities that significantly affect the intellectual property to which the customer has the rights. Although the Group is entitled to sales-based royalties from the eventual sales of goods
and services to third parties using the intellectual property licensed, these royalty arrangements do not in themselves indicate that the customer would reasonably expect the Group to undertake such activities, and no such activities are undertaken
or contracted in practice. Accordingly, the promise to provide rights to the Group&#146;s intellectual property is accounted for as a performance obligation satisfied at a point in time. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following consideration is received in exchange for licenses of intellectual property: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Up-front license fees&#151;these are fixed amounts and are recognized at the point in time when the Group transfers the intellectual property to the
customer. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sales-based royalties&#151;these are variable consideration amounts promised in exchange for the license of intellectual property and are recognized
when the sales to third parties occur given the performance obligation to transfer the intellectual property to the customer is already satisfied. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the year ended June&nbsp;30, 2019, the Group&#146;s
only revenue related to sales-based royalties. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Income tax
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Current tax </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current tax assets and liabilities for the current and prior
periods are measured at the amount expected to be recovered from or paid to the taxation authorities based on the current period&#146;s taxable income. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted by the reporting date.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-11
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and development tax incentive </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Research and Development (&#147;R&amp;D&#148;) Tax
Incentive Scheme is an Australian Federal Government program under which eligible companies with annual aggregated revenue of less than A$20 million can receive cash amounts equal to 43.5% of eligible research and development expenditures from the
Australian Taxation Office (&#147;ATO&#148;). The R&amp;D Tax Incentive Scheme incentive relates to eligible expenditure incurred in Australia and, under certain circumstances, overseas on the development of the Group&#146;s lead candidate, OPT-302.
The R&amp;D tax incentive is applied annually to eligible expenditure incurred during the Group&#146;s financial year following annual application to AusIndustry, an Australian governmental agency, and subsequent filing of its Income Tax Return with
the ATO after the financial year end. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group
estimates the amount of R&amp;D tax incentive after the completion of the financial year based on eligible Australia and overseas expenditures incurred during that year. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group has presented incentives in respect of the R&amp;D
Tax Incentive Scheme within income tax benefit in the Statement of Profit or Loss and Other Comprehensive Income by analogizing with International Accounting Standard (&#147;IAS&#148;) 12 &#147;Income Taxes&#148;. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Deferred tax </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred income tax is provided on all temporary differences
at the reporting date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred income tax liabilities are recognized for all taxable temporary differences except when the deferred income tax liability arises
from the initial recognition of goodwill or of an asset or liability in a transaction that is not a business combination and that, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred income tax assets are recognized for all deductible
temporary differences, carry forward of unused tax assets (or credits) and unused tax losses, to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused
tax credits and unused tax losses can be utilized, except when the deferred income tax asset relating to the deductible temporary differences arises from the initial recognition of an asset or liability in a transaction that is not a business
combination and, at the time of the transaction, affects neither the accounting profit or taxable profit or loss. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The carrying amount of deferred income tax assets is reviewed at each reporting date and reduced to the extent that it is no longer
probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to be utilized. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unrecognized deferred income tax assets are reassessed at each reporting date and are recognized to the extent that it has become probable
that future taxable profit will allow the deferred tax asset to be recovered. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Deferred income tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the asset is realized or the liability is settled, based on tax rates (and tax laws)
that have been enacted or substantively enacted at balance date. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Income taxes relating to items recognized directly in equity are recognized directly in equity and not in profit or loss. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Tax consolidation legislation </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tax consolidation is a system adopted by the ATO that treats
a group of entities as a single entity for tax purposes. Opthea Limited and its 100% owned subsidiary formed a tax consolidated group effective July&nbsp;1, 2003. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-12
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
The head entity, Opthea Limited, and its controlled entity, Vegenics Pty Ltd, are current members of the tax consolidated group account for their own current and deferred tax amounts. Members of
the tax consolidated group have adopted the &#147;separate taxpayer within group&#148; method to allocate the current and deferred tax amounts to each entity within the Group. This method requires adjustments for transactions and events occurring
within the tax consolidated group that do not give rise to a tax consequence for the Group or that have a different tax consequence at the level of the Group. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other taxes </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenues, expenses, assets and liabilities are recognized net of the amount of GST except: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">when the GST incurred on a purchase of goods and services is not recoverable from the taxation authority, in which case the GST is recognized as part
of the cost of acquisition of the asset or as part of the expense item as applicable; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">receivables and payables are stated with the amount of GST included. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The net amount of GST recoverable from, or payable to the taxation authority is included as part of receivables
or payables in the statement of financial position. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash flows are included in the statement of cash flows on a gross basis and the GST component of cash flows arising from investing and
financing activities, which is recoverable from, or payable to, the taxation authority is classified as part of operating cash flows. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the taxation authority. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Critical accounting judgments and key sources of estimation uncertainty </B></FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In applying the Group&#146;s accounting policies, management
continually evaluates judgments, estimates and assumptions based on experience and other factors, including expectations of future events that may have an impact on the Group. All judgments, estimates and assumptions made are believed to be
reasonable based on the most current set of circumstances available to management. Actual results may differ from the judgments, estimates and assumptions. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Significant judgments, estimates and assumptions made by management in the preparation of these financial statements are outlined below:
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.1</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Critical judgments in applying accounting policies Research and development costs </B></FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The majority of Opthea&#146;s expenditure is incurred as a
result of clinical trials for OPT-302. During the year ended June&nbsp;30, 2019, Opthea progressed Phase 2b wet age-related macular degeneration (&#147;wet AMD&#148;) and Phase 1b/2a diabetic macular edema (&#147;DME&#148;) trials. A key measure of
Opthea&#146;s performance is the level of expenditure incurred on the research of OPT-302. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Judgment is required in relation to: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the classification of expenses in the income statement between research and development costs and operating expenses; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether costs relate to R&amp;D, and consequently if they meet the capitalization criteria under International Accounting Standards 38 &#147;Intangible
Assets.&#148; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-13
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The directors have determined that the Group is still in a research phase and
accordingly, no development costs have been capitalized as of June&nbsp;30, 2019. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Taxation </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and development tax incentive </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Research and Development, or R&amp;D, Tax Incentive Scheme is an Australian Federal Government program under which eligible companies can receive cash refunds of 43.5% of eligible R&amp;D expenditure.
Judgments are required as to the R&amp;D tax incentive refundable offset eligibility in respect of: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the Group&#146;s ability to make claims and its continued compliance under the scheme; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">R&amp;D and other supporting costs previously approved by Australian tax authorities; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">estimated amounts, timing and geographical location of future costs related to the projects for which applications have been approved to date; and
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">assessment of whether expenditure on projects for which approval has been given by Australian tax authorities relate to Australian or overseas
expenditure. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the year ended
June&nbsp;30, 2019, the Group has recognized an R&amp;D tax incentive receivable of A$14.6&nbsp;million within the Consolidated Statement of Financial Position, with a corresponding amount recognized within income tax benefit within the Consolidated
Statement of Profit or Loss and Other Comprehensive Income. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Investment tax credits such as the R&amp;D tax incentive are outside of the scope of IAS 12 &#147;Income Taxes&#148; and IAS 20 &#147;Accounting for Government Grants and Disclosure of Government
Assistance.&#148; Based on the guidance in IAS 8 &#147;Accounting Policies, Changes in Accounting Estimates and Errors,&#148; companies need to make an accounting policy choice on how to present these incentives, which in practice is done by either
analogizing with IAS 12 or with IAS 20. In the Group&#146;s opinion, the R&amp;D tax incentive should be presented by analogizing to IAS 12 because the nature of the incentive is considered to be more closely aligned to income taxes, based on the
following considerations: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The R&amp;D tax incentive is considered an income tax offset which will be offset against the Group&#146;s tax obligation if and when the Group returns
to a net tax payable position. In addition, whilst the Group is currently eligible to receive cash payments under the scheme since its consolidated revenue is currently below A$20 million, if and when the Group generates revenue in excess of A$20
million the R&amp;D tax incentive will become non-refundable and can only be offset against any future income tax payable by the Group. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The ATO, which is the tax authority in Australia, manages the annual claims process as the R&amp;D tax incentive is included in the Group&#146;s annual
income tax return. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The ATO is also responsible for making the R&amp;D tax incentive cash payment if a company is eligible for a cash refund under the program, oversees
compliance with the requirements of the R&amp;D tax incentive scheme and performs pre-issuance reviews. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Income tax </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group&#146;s accounting policy for taxation requires judgments as to the differences between tax and accounting treatments of income
and costs recognized in the Consolidated Statement of Profit or Loss and Other Comprehensive Income. Judgment is also required in assessing whether deferred tax assets and liabilities are recognized in the statement of financial position and if
accumulated income tax losses can be used to offset potential future tax profits. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-14
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.2</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Key sources of estimation uncertainty Share-based payment transactions </B></FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group measures the cost of equity-settled transactions
with employees by reference to the fair value of the equity instruments at the date at which they are granted. Fair values are determined internally using Binomial models. The related assumptions are detailed in note 27. The accounting estimates and
assumptions relating to equity-settled share-based payments have no impact on the carrying amounts of assets and liabilities in future reporting periods but may impact expenses and equity. Should one or more of the assumptions and estimates used in
estimating the fair value of share-based payments change, this could have a material impact on the amounts recognized in equity and employee-related expenses. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Application of new and revised Accounting Standards </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Amendments to Accounting Standards that are mandatorily effective for the current year </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group has adopted all of the new and revised Standards
and Interpretations issued by the IASB that are relevant to its operations and effective for the current year. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">New and revised Standards and amendments thereof and Interpretations effective for the current year that are relevant to the Group
include: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">IFRS 9 &#147;Financial Instruments&#148; and related amending Standards; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">IFRS 15 &#147;Revenue from Contracts with Customers&#148; and related amending Standards; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendments to IFRS 2 &#147;Classification and Measurement of Share-based Payment Transactions;&#148; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Annual Improvements to IFRS 2014-2016 Cycle; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">IFRIC 22 &#147;Foreign Currency Transactions and Advance Consideration.&#148; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>IFRS 9 Financial Instruments and related amending Standards
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the year ended June&nbsp;30, 2019, the
Group has applied IFRS 9 &#147;Financial Instruments&#148; (as amended) and the related consequential amendments to other Accounting Standards that are effective for an annual period that begins on or after January&nbsp;1, 2018. The transition
provisions of IFRS 9 allow an entity to not restate comparatives. The Group has taken advantage of this exemption with respect to classification and measurement (including impairment) changes. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additionally, the Group adopted consequential amendments to IFRS 7 &#147;Financial Instruments&#148; that were
applied to the disclosures about the financial year ended June&nbsp;30, 2019 and to the comparative period. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IFRS 9 introduced new requirements for: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The classification and measurement of financial assets and financial liabilities; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Impairment of financial assets; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">General hedge accounting. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The expected credit loss model requires the Group to account for expected credit losses and changes in those expected credit losses at
each reporting date to reflect changes in credit risk since initial recognition of the financial assets. The Group has applied the simplified approach when calculating the expected credit loss as part of its accounting policy which has not
materially impacted the accounts. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The directors
of the Company reviewed and assessed the Group&#146;s existing financial assets as of July&nbsp;1, 2018 based on the facts and circumstances that existed as of that date. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-15
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group&#146;s investments in equity instruments (neither held for trading nor a
contingent consideration arising from a business combination) that were previously classified as available-for-sale financial assets and were measured at fair value at each reporting date under IAS 39 &#147;Financial Instruments: Recognition and
Measurement&#148; have been designated as at FVTOCI. The change in fair value on these equity instruments continues to be accumulated in the investment revaluation reserve (refer to Note 1 for further details). </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other receivables which were carried at amortized cost under
IAS 39 continue to be carried at amortized cost under IFRS 9. IFRS 9 has had no impact on the classification of financial liabilities. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, IFRS 9 requires an expected credit loss model as opposed to an incurred credit loss model under IAS 39 (refer to Note 1 for
further details). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There were no differences in
the carrying amounts of financial assets and financial liabilities resulting from the adoption of IFRS 9 recognized in retained earnings and reserves as at July&nbsp;1, 2018. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>IFRS 15 &#147;Revenue from Contracts with Customers&#148; and related
amending Standards </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the year ended
June&nbsp;30, 2019, the Group applied IFRS 15 &#147;Revenue from Contracts with Customers (as amended) which is effective for an annual period that begins on or after January&nbsp;1, 2018. IFRS 15 introduced a 5-step approach to revenue recognition.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The application of IFRS 15 has not had a
significant impact on the financial position and/or financial performance of the Group; however, the Group&#146;s accounting policies for revenue have changed and are disclosed in detail in Note 3. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other pronouncements adopted for the first time in the year ended
June&nbsp;30, 2019 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the year ended
June&nbsp;30, 2019, the Group applied a number of amendments to International Financial Reporting Standards and Interpretations issued by the IASB that are effective for an annual period that begins on or after January&nbsp;1, 2018. Their adoption
has not had any material impact on the disclosures or on the amounts reported in these financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-16
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>New and revised International Financial Reporting Standards and Interpretations on issue but not yet
effective </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At the date of authorization of
the financial statements, the Group has not applied the following new and revised International Financial Reporting Standards, Interpretations and amendments that have been issued but are not yet effective: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Standard/amendment</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Effective for<BR>annual reporting<BR>periods beginning<BR>on or after</B></FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">IFRS 16 &#147;Leases&#148;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">January&nbsp;1,&nbsp;2019</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">IFRS 17 &#147;Insurance Contracts&#148;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 1, 2021</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendments to IAS&#151;Sale or Contribution of Assets between an Investor and its Associate or Joint Venture (IFRS 10 and IAS 28)
Amendments to IFRS and IAS&#151;Effective Date of Amendments to IFRS 10 and IAS 28 Amendments to IFRS and IAS&#151;Effective Date of Amendments to IFRS 10 and IAS 28 and Editorial Corrections</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">January&nbsp;1,&nbsp;2022</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendments to IFRS 9 &#147;Financial Instruments&#151;Prepayment Features with Negative Compensation&#148;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 1, 2019</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendments to the Basis for Conclusions on IAS 28 &#147;Investments in Associates and Joint Ventures&#151;Long-term Interests in
Associates and Joint Ventures&#148;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 1, 2019</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Annual Improvements to IFRS 2015&#150;2017 Cycle</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 1, 2019</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendments to the Basis for Conclusions on IAS 19 &#147;Employee Benefits&#151;Plan Amendment, Curtailment or
Settlement&#148;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 1, 2019</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendments to IFRS 3 &#147;Business Combinations&#151;Definition of a Business&#148;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 1, 2020</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendments to IFRS 17, and amendments to the basis for conclusions on IAS 1, IAS 8 and Conceptual Framework&#151;Definition of
Material</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 1, 2020</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">IFRIC 23 &#147;Uncertainty over Income Tax Treatments&#148;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 1, 2019</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The new and revised
International Financial Reporting Standards, Interpretations and amendments listed above are not expected to have a material impact on the amounts recognized or disclosures included in the Group&#146;s financial statements, except as noted below.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>IFRS 16 Leases </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IFRS 16 &#147;Leases&#148; introduces a single, on-balance
lease sheet accounting model for lessees. A lessee recognizes a right-of-use asset representing its right to use the underlying asset and a lease liability representing its obligation to make lease payments. There are optional exemptions for
short-term leases and leases of low value items. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IFRS 16 is effective for annual periods beginning on or after January&nbsp;1, 2019. The Group will apply IFRS&nbsp;16 initially on
July&nbsp;1, 2019. The Group has assessed the potential impact on its consolidated financial statements and determined that there will not be a material impact on its consolidated financial statements. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IFRS 16 will change how the Group accounts for leases
previously classified as operating leases under IAS&nbsp;17 &#147;Leases&#148;, which were off-balance sheet. On initial application of IFRS 16, for all leases (except as noted below), the Group will: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Recognize right-of-use assets and lease liabilities in the consolidated statement of financial position, initially measured at the present value of the
future lease payments; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-17
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Recognize depreciation of right-of-use assets and interest on lease liabilities in the consolidated statement of profit or loss; and
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Separate the total amount of cash paid into a principal portion (presented within financing activities) and interest (presented within operating
activities) in the consolidated cash flow statement. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Lease incentives (e.g., rent-free period) will be recognized as part of the measurement of the right-of- use assets and lease liabilities whereas under IAS 17 they resulted in the recognition of a lease
liability incentive, amortized as a reduction of rental expenses on a straight-line basis. Under IFRS 16, right-of- use assets will be tested for impairment in accordance with IAS 36 &#147;Impairment of Assets.&#148; This will replace the previous
requirement to recognize a provision for onerous lease contracts. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">For short-term leases (lease term of 12 months or less) and leases of low-value assets (such as office equipment), the Group has elected to apply the recognition exemption as permitted by IFRS 16. The
lease payments associated with those leases will be recognized as an expense on a straight-line basis over the lease term. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Given the Group&#146;s current lease for Opthea&#146;s headquarters expired on July&nbsp;14, 2019, the adoption of IFRS&nbsp;16 was not
expected to have any material impact on the Group at transition date. The Group entered into a new lease agreement for its existing premises on July&nbsp;15, 2019 and a preliminary assessment indicates the Group will recognize a right-of-use asset
of A$365,264 and a corresponding lease liability of A$365,264 on this date. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Segment information </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group operates in one industry and one geographical area, those being the biotechnology and healthcare industry and Australia,
respectively. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group is focused primarily on
developing a novel therapy for the treatment of highly prevalent and progressive retinal diseases. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The chief executive officer regularly reviews entity wide information that is compliant with IFRS. There is only one segment for segment reporting purposes, and the information reviewed by the chief
executive officer for the purpose of resources allocation and performance assessment is the same as the information presented in the consolidated financial statements. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group&#146;s only revenue stream in the current financial
year is royalty income generated from licenses granted in respect of the Group&#146;s intellectual property that are unrelated to the Group&#146;s core business and the development of OPT-302 and that are not under development. These licenses are
primarily used by third-party licensees for research purposes. All of the royalty income of A$159,064 was generated from customers based outside Australia. The Group does not have any major customers. All property, plant and equipment is located in
Australia. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Revenue </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For the<BR>year&nbsp;ended<BR>June&nbsp;30,<BR>2019</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sales based royalties</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">159,064</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total revenue</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">159,064</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-18
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other income </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For the<BR>year&nbsp;ended<BR>June&nbsp;30,<BR>2019</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Finance income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">755,776</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Grant income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">77,745</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total other income</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">836,821</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Research and development expenses </B></FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For the<BR>year&nbsp;ended<BR>June&nbsp;30,<BR>2019</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research project costs(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31,347,891</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31,347,891</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">The research project costs relate to the development programs for the treatment of retinal diseases by <FONT STYLE="white-space:nowrap">OPT-302.</FONT>
</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-19
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10. Expenses </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For&nbsp;the&nbsp;year<BR>ended&nbsp;June&nbsp;30,<BR>2019</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(A) ADMINISTRATIVE EXPENSES</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employee benefits expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Salaries and fees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,020,795</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash bonuses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">414,423</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Superannuation/pensions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">217,592</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share-based payments expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">967,511</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total employee benefits expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,620,321</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Insurance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">377,181</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investor relations costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">411,181</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Audit and accounting</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">138,156</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Travel expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">84,103</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payroll tax</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">87,247</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Legal fees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,464</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">401,009</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total other expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,521,341</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation of:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equipment and furniture</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,898</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Leasehold improvements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,195</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total depreciation expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33,093</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total Administrative Expenses</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,174,755</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(B) OCCUPANCY EXPENSES</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating lease rentals</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">78,883</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating lease incidental costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total Occupancy Expenses</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">108,904</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-20
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>11. Income tax </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="90%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For the
year<BR>ended&nbsp;June&nbsp;30,</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2019</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a) Income tax benefit</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">The major components of income tax benefit are:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Statement of Comprehensive Income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CURRENT TAX</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current income tax incentive</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,636,973</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,636,973</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">DEFERRED TAX</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">In respect of the current year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total income tax benefit recognized in the Statement of Comprehensive Income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,636,973</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As&nbsp;of&nbsp;June&nbsp;
30,<BR>2019</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b) Current tax receivable</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and Development Tax Incentive receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,636,973</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c) Numerical
reconciliation between aggregate tax expense recognized in the statement of Profit or Loss and Other Comprehensive Income and Expense calculated per the statutory income tax rate </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A reconciliation between tax expense and the product of accounting loss before income tax multiplied by the
Group&#146;s applicable income tax rate is as follows: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="90%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For the
year<BR>ended&nbsp;June&nbsp;30,</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2019</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounting loss before tax</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(35,547,034</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">At the Company&#146;s statutory income tax rate of 27.5%</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,775,434</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">R&amp;D tax incentive on eligible expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,636,973</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Non-deductible</FONT> R&amp;D expenditure</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,261,833</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other <FONT STYLE="white-space:nowrap">non-deductible</FONT> expenses&#151;share-based payment expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(266,066</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amount of temporary differences and carried forward tax losses not recognized</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(247,535</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income tax benefit reported in the statement of comprehensive income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,636,973</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-21
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="90%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As&nbsp;of&nbsp;June&nbsp;
30,<BR>2019</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d) Recognized deferred tax assets and liabilities in statement of financial position</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred income tax relates to the following:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">DEFERRED TAX LIABILITIES:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest and royalty income receivable (future assessable income)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(56,114</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(56,114</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">DEFERRED TAX ASSETS:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other timing differences including income received in advance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">151,821</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employee provisions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">154,933</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Temporary differences:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Associated with other miscellaneous items</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">276,942</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">583,696</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Less: temporary differences not recognized</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(527,582</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net deferred tax recognized in the statement of financial position</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(e) Unrecognized temporary
differences </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Temporary differences with
respect to deferred tax assets associated with intellectual property and other miscellaneous items which have a low probability of realization are unrecognized. These amounted to A$527,582 as of June&nbsp;30, 2019. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(f) Carry forward unrecognized tax losses </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group had income tax losses of A$15,819,190 and capital
losses of A$877,704 at year end for which no deferred tax asset is recognized on the statement of financial position as they are currently not considered probable of realization. These tax losses are available indefinitely for offset against future
assessable income subject to continuing to meet relevant statutory tests. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(g) Franking credit balance </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Franking credits are a type of tax credit in Australia that is available to the Group&#146;s shareholders to reduce double taxation on any dividends paid by the Group. The franking credit balance at the
end of the financial year at 30% is A$330,630, which represents the amount of franking credits available for the subsequent financial year. Franking credits are not recognized in the Consolidated Statement of Financial Position. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-22
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>12. Earnings per share </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For the year<BR>ended<BR>June&nbsp;30,
2019</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following reflects the income used in the basic and diluted earnings per share computations:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(A) EARNINGS USED IN CALCULATING EARNINGS PER SHARE</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss attributable to Owners of the Company</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,910,061</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(B) WEIGHTED AVERAGE NUMBER OF SHARES</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted average number of ordinary shares on issue for basic earnings per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">232,795,371</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dilutive share options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted average number of ordinary shares adjusted for the effect of dilution</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">232,795,371</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss per share (basic and diluted, in cents)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.98</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Diluted earnings per share is
calculated as net loss divided by the weighted average number of ordinary shares and dilutive potential ordinary shares. Options granted under the Long Term Incentive (&#147;LTIP&#148;) and <FONT STYLE="white-space:nowrap">Non-Executive</FONT>
Director Share and Option (&#147;NED Plan&#148;) plans would generally be included in the calculation due to the conditions of the issuance being satisfied. As the Group is in a loss position, the options are anti-dilutive and, accordingly, the
basic loss per share is the same as the diluted loss per share. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A total number of 18,919,000 options outstanding as of June&nbsp;30, 2019 were anti-dilutive and were therefore excluded from the weighted average number of ordinary shares for the purpose of diluted
earnings per share. These options related to the following option plans: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">NED Plan: 6,000,000 options </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">LTIP: 12,919,000 options </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Out of the total of 18,919,000 outstanding options as of June&nbsp;30, 2019, 9,905,000 options were exercisable as of that date.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>13. Current assets&#151;cash and cash equivalents
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As&nbsp;of&nbsp;June&nbsp;
30,<BR>2019</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash at bank and in hand</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,034,919</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Short-term deposits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,534,919</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash at bank earns interest
at floating rates based on daily bank deposit rates. The carrying amounts of cash and cash equivalents represent fair value. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Short term-deposits are with a major bank and are made for varying periods of between 30 and 90 days, depending on the immediate cash
requirements of the Group, and earn interest at a fixed rate for the respective short-term deposit periods. At year end, the average rate was 2.36%. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-23
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>14. Current assets&#151;other receivables </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As&nbsp;of&nbsp;June&nbsp;
30,<BR>2019</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">102,162</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">GST receivable(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">91,736</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Royalties receivable(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">101,888</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total current receivables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">295,786</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The GST and Royalties receivables are <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing. There were no receivables with a material expected credit loss
recorded during the financial year. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>15. <FONT
STYLE="white-space:nowrap">Non-current</FONT> assets&#151;Investments in financial assets </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As&nbsp;of&nbsp;June&nbsp;
30,<BR>2019</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Listed Australian shares&#151;at fair value</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">714,118</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Details of listed
Australian shares </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Ownership<BR>Interest</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fair&nbsp;Value<BR>at&nbsp;June&nbsp;30,<BR>2019(1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Disposal&nbsp;in<BR>the year<BR>Financial<BR>Year (3)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fair Value<BR>Gain/(Loss)<BR>Recognized<BR>in OCI</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Opening<BR>Fair&nbsp;Value</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Listed investments</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>%</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Non-current</FONT> investments:(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Antisense Therapeutics Ltd.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">233,579</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(339,047</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">317,860</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">254,766</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Optiscan Imaging Limited</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.76</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">480,539</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(57,996</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">538,535</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total listed investments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">714,118</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(339,047</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">259,864</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">793,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The fair value represents the share (bid) price at year end and does not include any capital gains tax or selling costs that may be applicable on the disposal of these
investments. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">These <FONT
STYLE="white-space:nowrap">non-current</FONT> investments in listed shares consist of investments in ordinary shares, and therefore have no fixed maturity date or coupon rate. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">A fair value increase of A$259,864 in the carrying value of investments has been made through other comprehensive income in the year due to a net increase in their
market value in the year. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the year ended June&nbsp;30, 2019, 49% of the Group&#146;s investment in Antisense Therapeutics Ltd. was sold for net proceeds of A$339,047. As a result,
A$214,046 of the previously unrealized net fair value gains recorded in the fair value of investments reserve was realized at this date. In accordance with the Group&#146;s accounting policy, the realized gain remains within the fair value of
investments reserve. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>16. Current
liabilities&#151;payables and accrued expenses </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As&nbsp;of&nbsp;June&nbsp;
30,<BR>2019</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts payable (unsecured)(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,895,925</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payroll related tax liability</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">56,017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total current payables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,951,942</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-24
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Creditors are <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing and are normally settled on <FONT STYLE="white-space:nowrap">30-day</FONT> terms.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>17. Current liabilities&#151;provisions
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As&nbsp;of&nbsp;June&nbsp;
30,<BR>2019</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Annual leave</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">320,132</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Long service leave</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">218,415</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total current provisions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">538,547</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>18.
<FONT STYLE="white-space:nowrap">Non-current</FONT> liabilities&#151;provisions </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As&nbsp;of&nbsp;June&nbsp;
30,<BR>2019</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Long service leave</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24,844</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>19. Contributed equity </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For the year<BR>ended<BR>June&nbsp;30,
2019</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a) Ordinary shares</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issued and fully paid as of June&nbsp;30, 2019</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">113,021,993</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Movement in ordinary shares:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Opening balance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">98,403,149</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issue of shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,629,777</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Transfer from option reserve</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,989,067</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total issued and fully paid ordinary shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">113,021,993</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Ordinary shares on issue:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No. Of<BR>Shares:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Opening balance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">202,637,888</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issue of shares on exercise of options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46,776,951</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>249,414,839</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fully paid ordinary shares
carry one vote per share and carry the right to dividends. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Issued capital at June&nbsp;30, 2019 amounted to A$113,021,993 (249,414,839 fully paid ordinary shares) net of share issue costs and tax. During the year, the Company issued 46,776,951 ordinary shares on
the exercise of quoted options for A$12,629,777. At June&nbsp;30, 2019, the Company had no options outstanding, other than options granted to directors and employees and described below, as all options had been exercised or expired by
November&nbsp;25, 2018. The fair value of the options at their issue date of A$1,989,067, originally recognized in the options reserve (note 20) was transferred to contributed equity. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>(b) Options granted to directors and employees </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company has two share based-payment schemes, the Long
Term Incentive Plan and <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director Share and Option Plan. Options to subscribe for the Company&#146;s shares have been granted under these </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-25
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
plans to certain employees and directors. The Company granted 8,844,000 options over ordinary shares under these plans during the year ended June&nbsp;30, 2019 (note 27). These options had a
weighted average fair value at their grant date of A$0.22 per option. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>(c) Capital management </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Group is not subject to any externally imposed capital requirements. When managing share capital, management&#146;s objective is to ensure the entity continues as a going concern as well as to provide
benefits to shareholders and for other stakeholders. In order to maintain or achieve an appropriate capital structure, the Company may issue new shares or reduce its share capital, subject to the provisions of the Company&#146;s constitution. The
Group only commits to significant R&amp;D expenditure when this is fully funded either by existing funds or further equity raises. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>20. Accumulated Losses and reserves </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For the year<BR>ended<BR>June&nbsp;30,
2019</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a) Movements in accumulated losses were as follows:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at July&nbsp;1, 2018</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(65,149,999</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss for the period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,910,061</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at June&nbsp;30, 2019</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(86,060,060</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b) Reserves</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value of investments reserve (i)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">737,255</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share-based payments reserve (ii)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,420,349</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Option reserve (iii)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total reserves</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,157,604</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) Movement in fair value of investments reserve:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Opening balance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">477,391</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value gains on investments in financial assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">259,864</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Closing balance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">737,255</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) Movement in share-based payments reserve:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Opening balance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,452,838</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share based payments expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">967,511</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Closing balance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,420,349</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) Movement in option reserve:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Opening balance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,989,067</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Transferred to contributed equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,989,067</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Closing balance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>(c) Nature and purpose
of reserves Fair value of investments reserve </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This reserve records fair value changes on listed investments. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-26
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Share-based payment reserve </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This reserve is used to record the value of equity benefits
provided to executives and employees as part of their remuneration. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Option reserve </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On November&nbsp;25, 2014, the Company issued options to purchase 49,726,672 ordinary shares with an exercise price of A$0.27 expiring on November&nbsp;25, 2018. The fair value of the options at their
issue date of A$1,989,067 was recognized in the option reserve. The same amount, A$1,989,067, was transferred to contributed equity on November&nbsp;25, 2018 following the exercise of all quoted options. The balance on the option reserve at
June&nbsp;30, 2019 was nil. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>21. Financial risk management
objectives and policies </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group&#146;s
principal financial assets comprise cash, receivables, short-term deposits and financial investments. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group manages its exposure to key financial risks, including interest rate and currency risk in accordance with the Group&#146;s
financial risk management practices. The objective is to support the delivery of the Group&#146;s financial targets while protecting future financial security. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group&#146;s other various financial assets and liabilities, such as receivables and payables, arise directly from its operations. The
main risks arising from the Group&#146;s financial assets and liabilities are interest rate risk, foreign currency risk, equity securities price risk and liquidity risk. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group uses different methods to measure and manage
different types of risks to which it is exposed. These include monitoring levels of exposure to interest rate and foreign exchange risk and assessments of market forecasts for interest rates and foreign exchange rates. Liquidity risk is monitored
through future rolling cash flow forecasts. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
board reviews and agrees policies for managing each of these risks as summarized below. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Risk exposures and responses </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Group has investigated the main financial risk areas which could impact its financial assets and determined the impact on post tax (losses) or profits for a range of sensitivities. These can be seen
in the post-tax (loss)/profit impact for each risk area. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">For each risk area, the equity impact relates solely to reserve movements and excludes retained earnings movements as the impact of these can be seen within the
<FONT STYLE="white-space:nowrap">post-tax</FONT> (loss)/profit impact. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>(i) Interest rate risk </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Group&#146;s exposure to market interest rates relates primarily to the short-term deposits. The deposits are held with two of Australia&#146;s largest banks. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The objective of managing interest rate risk is to minimize
the Group&#146;s exposure to fluctuations in interest rates that might impact its interest revenue and cash flow. To manage interest rate risk, the Group invests the majority of its cash in short-term deposits for varying periods of between 30 days
and 90 days, depending on the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-27
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
short and long-term cash requirements of the Group which is determined based on the Group&#146;s cash flow forecast. This consideration also takes into account the costs associated with recalling
a term deposit should early access to cash and cash equivalents be required. Cash is not locked into long-term deposits at fixed rates so as to mitigate the risk of earning interest below the current floating rate. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group does not have any borrowings at June&nbsp;30, 2019.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following sensitivity analysis (an annual
effect) is based on the interest rate risk exposures at June&nbsp;30, 2019. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">At June&nbsp;30, 2019, if interest rates moved, with all variables held constant, post tax (loss)/profit and equity would have been affected as illustrated in the following table: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="80%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Post tax</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(loss)/profit</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>impact</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Cost of<BR>investment</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2019&nbsp;A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2019&nbsp;A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Judgments of reasonably possible movements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">+ 0.50% (50 basis points)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">71,903</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#150; 0.50% (50 basis points)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(71,903</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The <FONT
STYLE="white-space:nowrap">post-tax</FONT> figures include an offset for unrecognized tax losses (bringing the tax effect to nil) for the year ended June&nbsp;30, 2019. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Significant assumptions used in the interest rate sensitivity
analysis include: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The reasonably possible movement of 0.5% was calculated by taking the interest rates as at balance date, moving these by plus and minus 0.5% and then <FONT
STYLE="white-space:nowrap">re-calculating</FONT> the interest on term deposits with the <FONT STYLE="white-space:nowrap">&#145;new-interest-rate&#146;.</FONT> </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The net exposure at balance date is representative of what the Group was and is expecting to be exposed to in the next twelve months from balance date.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>(ii) Price risk
</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group&#146;s investment in listed shares
is exposed to equity securities price risk and as such their fair values are exposed to fluctuations as a result of changes in market prices. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equity price risk is the risk that the fair value of equities will decrease as a result of share price movements. The Group&#146;s equity
investments are publicly traded on the Australian Securities Exchange (ASX) and are designated and accounted for as investments in financial assets. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The investments in listed shares are not held for short-term trading. Their values are reviewed regularly by management and the board. The
strategy for realizing any part of these investments is determined based on the liquidity of the respective stocks, potential <FONT STYLE="white-space:nowrap">off-market</FONT> acquirers and likely developments in their values based on publicly
available information. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At June&nbsp;30, 2019, had
the share price moved with all other variables held constant, post tax (loss)/profit and equity would have been affected as illustrated in the table below: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="80%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Impact&nbsp;of&nbsp;loss<BR>after tax</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Impact&nbsp;on<BR>equity&nbsp;after&nbsp;tax</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2019&nbsp;A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2019&nbsp;A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Judgments of reasonably possible movements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Change in variables 10% increase in listed share price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49,988</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49,988</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">10% decrease in listed share price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(49,988</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(49,988</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-28
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>(iii) Foreign currency risk </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a result of services provided by <FONT
STYLE="white-space:nowrap">non-related</FONT> entities in the United States, Canada, United Kingdom and Europe, part of the Group&#146;s financial assets and liabilities are affected by movements in the exchange rate. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group does not enter into any hedging transactions.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At the reporting date, the Group has the
following exposure to foreign currencies: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="90%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2019</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>USD</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Consolidated<BR>as of<BR>June&nbsp;30,<BR>2019 EUR<BR>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>GBP A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>CAD<BR>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Financial assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">551,719</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Receivables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">101,888</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Financial liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,135,089</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(51,269</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,351</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net exposure</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,481,482</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(51,269</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,351</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following sensitivity is
based on the foreign currency risk exposures in existence at June&nbsp;30, 2019. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As of June&nbsp;30, 2019, had the Australian dollar moved with all other variables held constant, post tax (loss) profit and equity would have been affected as illustrated in the table below: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Post tax</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(loss)/profit</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>impact</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Cost of<BR>investment</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2019 A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2019&nbsp;A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Judgments of reasonably possible movements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CONSOLIDATED</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">AUD/USD +10%</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">285,185</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">AUD/USD &#150;10%</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(348,560</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There was minimum or
insignificant exposure to the GBP, EUR and CAD during the 2019. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Significant assumptions used in the foreign currency exposure sensitivity analysis include: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The reasonably possible movement of 10% was calculated by taking the currency spot rates as at balance date, moving these up and down by
10% and then <FONT STYLE="white-space:nowrap">re-converting</FONT> the currencies into AUD with the new spot rate. This methodology reflects the translation methodology undertaken by the Group. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The net exposure at balance date is representative of what
the Group was and is expecting to be exposed to in the next 12 months from the balance date. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Management believes the balance date risk exposures are representative of the risk exposure inherent in the financial instruments. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>(iv) Credit risk </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Credit risk is associated with those financial assets of the
Group which comprise cash and cash equivalents and listed investments. The Group&#146;s exposure to credit risk arises from default of the counterparty, with a maximum exposure equal to the carrying amount of these investments. Credit risk is
considered minimal as the Group transacts with reputable recognized Australian banks. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-29
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>(v) Liquidity risk </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Liquidity risk arises from the financial liabilities of the Group and the Group&#146;s subsequent ability to
meet their obligations to repay their financial liabilities as and when they fall due. The Group has minimal liquidity risk because of the high balances of cash and cash equivalents; however, the Group manages liquidity risk by maintaining reserves
and by regularly monitoring forecast and actual cash flows and by matching the maturity profiles of financial assets and liabilities. The financial liabilities of the Group relate to trade payables that are all expected to be paid within 12 months.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group&#146;s objective is to maintain an
appropriate cash asset balance to fund its operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>(vi) Fair value </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Group has investments in listed equities which are calculated using the quoted prices in an active market and are considered level 1 fair value measurements. The Group does not have any derivative
investments where the fair value is estimated using inputs other than quoted prices that are observable for the asset or liability, either directly (as prices) or indirectly (i.e. derived from prices). The Group also does not hold any financial
instruments where fair value measurement uses observable inputs that require significant adjustments based on observable inputs to estimate its value. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Details of the fair value of the investment in financial assets are disclosed in note 15 of the financial statements. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The fair value of financial assets and financial liabilities
in the consolidated statement of financial position at June&nbsp;30, 2019 is the same as their carrying amounts. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The methods for estimating fair value are also outlined in the relevant notes to the financial statements. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>22. Subsidiary </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The consolidated financial statements include the financial
statements of Opthea Limited and the subsidiary in the following table: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Company&nbsp;%<BR>equity<BR>interest</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name of company</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2019</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vegenics Pty Ltd(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Opthea Limited is the ultimate parent entity. Vegenics Pty Ltd. is incorporated in Australia and has the same financial year as Opthea Limited.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balances and transactions between
the Company and its subsidiary, which is a related party of the Company, have been eliminated on consolidation and are not disclosed in this note. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-30
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>23. Cash flow statement reconciliation </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>(a) Reconciliation to cash at the end of the year </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="80%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For the year<BR>ended<BR>June&nbsp;30,
2019</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash at bank and in hand (note 13)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,534,919</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,534,919</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b) Reconciliation of net loss after tax to net cash flows from operations</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss for the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,910,061</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Adjustments for:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income tax benefit recognized in profit or loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14,636,973</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation of <FONT STYLE="white-space:nowrap">non-current</FONT> assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33,093</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share-based payments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">967,511</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net exchange differences</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(259,092</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(13,895,461</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Changes in working capital:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Receivables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">97,946</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prepayments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(132,346</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,427,978</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provisions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">65,497</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash used in operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(36,202,403</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income tax refund</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,017,247</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash generated by operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(24,185,156</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>24. Commitments </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Operating lease commitments&#151;Group as lessee
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group has a commercial lease for its
office premises for a period of 6 years from July&nbsp;15, 2013. A new lease commenced on July&nbsp;15, 2019 for a period of three years for the same premises. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As&nbsp;of&nbsp;June&nbsp;
30,<BR>2019</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Within one year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,029</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">After one year but not more than five years</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,029</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-31
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research projects and license commitments </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group has entered into R&amp;D contracts and
intellectual property license agreements with various third parties in respect of services for the Phase 2b wet AMD and Phase 1b/2a DME clinical trials. Expenditure commitments relating to these and intellectual property license agreements are
payable as follows: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As&nbsp;of&nbsp;June&nbsp;
30,<BR>2019</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Within one year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,776,947</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">After one year but not more than five years</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">85,446</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">After more than five years</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">128,169</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,990,562</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>25. Contingencies </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group is party to various research agreements with
respect to which a commitment to pay is contingent on the achievement of research milestones. Assuming all milestones are achieved within the timeframes stipulated in the contracts, those which could become payable in more than one year total
A$16,728,122. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Also, under license/collaboration
agreements with three third parties, payments are to be made only if certain research and clinical development milestones are achieved and royalties may become payable on any eventual sales of products developed under these agreements. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Group had a bank guarantee outstanding at June&nbsp;30,
2019 in respect of a rental deposit for its office premises of A$43,841. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>26. Key management personnel </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>(a) Compensation of Key Management Personnel </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For&nbsp;the&nbsp;year<BR>ended&nbsp;June&nbsp;30,<BR>2019</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Short-term employee benefits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,002,359</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Post-employment benefits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">95,225</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share-based payments expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">752,306</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,849,890</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>(b) Other transactions
and balances with director and key management personnel and their related parties </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">There were no other director and key management personnel related party transactions during the year ended June&nbsp;30, 2019. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-32
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>27. Share-based payments </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Recognized share-based payment expenses
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The expense recognized for share-based
payments during the year is shown in the table below: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="80%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For&nbsp;the&nbsp;year<BR>ended&nbsp;June&nbsp;30,<BR>2019</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expense arising from equity-settled share-based payment transactions:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director and employee services received</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">967,511</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><FONT
STYLE="white-space:nowrap">Non-executive</FONT> director and employee share option plans </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">During the 2015 financial year, the Group introduced an ownership-based compensation scheme for <FONT STYLE="white-space:nowrap">non-executive</FONT> directors, executives and senior employees, the Long
Term Incentive Plan (LTIP) and <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors Share and Option Plan (NED Plan). In accordance with the terms of the plans, as approved by shareholders at the 2014 annual general meeting, eligible <FONT
STYLE="white-space:nowrap">non-executive</FONT> directors, executives and senior employees with the Group may be granted options to purchase ordinary shares. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each director and employee option converts into one ordinary share of Opthea on exercise. No amounts are paid or payable by the recipient
on receipt of the option. The options carry neither rights to dividends nor voting rights and are not transferable. Options may be exercised at any time from the date of vesting to the date of their expiration. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The number of options granted is subject to approval by the
board and rewards executives and senior employees to the extent of the Group&#146;s and the individual&#146;s achievement judged against both qualitative and quantitative criteria as determined by the board on a case by case basis. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The vesting condition of options granted under the LTIP and
NED Plan is continuous service. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Options/Rights series</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Grant date</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Grant&nbsp;date<BR>fair value<BR>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exercise<BR>price<BR>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Expiry date</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Vesting date</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">LTIP&#151;director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;7, 2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;7,&nbsp;2021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">June&nbsp;30, 2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">LTIP&#151;director FY2019</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">November&nbsp;29,&nbsp;2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.855</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">November&nbsp;29,&nbsp;2022</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">November&nbsp;29,&nbsp;2019</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">LTIP&#151;employees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;31, 2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">January&nbsp;1, 2022</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">January&nbsp;1, 2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">LTIP&#151;employees FY2018</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">August&nbsp;23, 2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.33</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">January&nbsp;1, 2023</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">June&nbsp;30, 2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">LTIP&#151;employees FY2019</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">April&nbsp;3, 2019</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.855</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">April&nbsp;3, 2023</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">April&nbsp;3, 2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">NED Plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;7, 2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;7, 2021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">June&nbsp;30, 2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">NED Plan FY2019</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">November&nbsp;29, 2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.855</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">November&nbsp;29, 2022</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">November&nbsp;29, 2019</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There has been no
modification of the terms and conditions of the above share-based payment arrangements since the grant date. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Fair value of options granted </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A binomial model has been used to determine the fair value of all options granted. Where relevant, the expected life used in the model has been adjusted based on management&#146;s best estimate for the
effects of <FONT STYLE="white-space:nowrap">non-transferability,</FONT> exercise restrictions (including the probability of meeting market conditions attached to the option), and behavioral considerations. Expected volatility is based on the
historical share price volatility over the past four or five years. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-33
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Grant&nbsp;date<BR>share&nbsp;
price</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exercise<BR>price<BR>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fair&nbsp;value<BR>per&nbsp;
option</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Expected<BR>volatility<BR>%</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>life<BR>years</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Dividend<BR>yield</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>%</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Risk&nbsp;free<BR>interest&nbsp;
rate</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>%</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">LTIP&#151;director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">65</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.09</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">LTIP&#151;director FY2019</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.57</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.855</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">58</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.04</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">LTIP&#151;employees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.70</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">65</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.09</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">LTIP&#151;employees FY2018</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.43</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.32</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">66</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.09</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">LTIP&#151;employees FY2019</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.67</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.855</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.04</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">NED Plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">65</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.09</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">NED Plan FY2019</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.57</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.855</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">58</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.04</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Movements in options
during the year </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following reconciles
the options outstanding at the beginning and end of the year: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="80%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For the year ended</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,
2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number of<BR>options</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Weighted<BR>average<BR>exercise&nbsp;
price</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>A$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at beginning of year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,075,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.46</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Granted during the year:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">To employees and directors under the LTIP and NED Plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,844,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.855</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercised during the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expired during the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at end of year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,919,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.67</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercisable at end of year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,905,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The options outstanding at
the end of the year had a weighted average exercise price of A$0.67 and a weighted average remaining contractual life of 716 days. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>28. Events after the balance sheet date </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On August&nbsp;7, 2019 the Company announced the results of its Phase 2b trial of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in wet
AMD patients. <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with standard of care <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapy, ranibizumab, met the <FONT STYLE="white-space:nowrap">pre-specified</FONT> primary
endpoint of superiority in mean visual acuity gain at week 24 compared to ranibizumab monotherapy. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On December, 6, 2019, the Company completed a private placement of new shares and raised A$50&nbsp;million in gross proceeds. The proceeds from the placement will be used to fund further activities to
support the late-stage clinical development of <FONT STYLE="white-space:nowrap">OPT-302</FONT> as a therapy for wet AMD, including the manufacture of sufficient quantities of <FONT STYLE="white-space:nowrap">OPT-302</FONT> for Phase 3 clinical
development and the commencement of two concurrent Phase 3 pivotal trials in wet AMD patients. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">COVID-19</FONT> restrictions put in place by Australian Federal and State governments since March&nbsp;16, 2020 have been adhered to by the Group. The Group&#146;s
clinical trial activity has been reduced to a minimum and to the extent required by jurisdictional <FONT STYLE="white-space:nowrap">COVID-19</FONT> restrictions and guidelines. The Company believes there have been no adverse effects of any <FONT
STYLE="white-space:nowrap">COVID-19</FONT> restrictions on patients, clinical personnel, employees or any third parties the Company has had dealings with in its ordinary course of business. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-34
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On June&nbsp;10, 2020, the Company announced the results of a Phase 2a trial of <FONT
STYLE="white-space:nowrap">OPT-302</FONT> in DME. <FONT STYLE="white-space:nowrap">OPT-302</FONT> in combination with standard of care <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapy, aflibercept, met the <FONT
STYLE="white-space:nowrap">pre-specified</FONT> primary efficacy endpoint of improvements in visual acuity at week 12. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Except for these events, no matters or circumstances have arisen since the end of the reporting period, not otherwise disclosed in this report, which
significantly affected, or may significantly affect, the operations of the Group, the results of those operations, or the state of affairs of the Group in future financial years. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-35
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2px;margin-top:0px;margin-bottom:0px;border-bottom:2pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g947560g04e62.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; American Depositary Shares
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Representing
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ordinary Shares </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P></center> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="2">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PRELIMINARY PROSPECTUS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>Citigroup</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>SVB Leerink</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Through and including
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020 (the 25th day after the date of this prospectus), all dealers effecting transactions in our ADSs, whether or not participating in this offering,
may be required to deliver a prospectus. This is in addition to a dealer&#146;s obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="2">&nbsp;</FONT></P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:4px;margin-top:0px;margin-bottom:2px;border-bottom:2pt solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PART II </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ITEM&nbsp;6.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Indemnification of Directors and Officers. </B></FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Australian law</I>. Australian law provides that a
company or a related body corporate of the company may provide for indemnification of officers and directors, except to the extent of any of the following liabilities incurred as an officer or director of the company: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a liability owed to the company or a related body corporate of the company; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a liability for a pecuniary penalty order made under section 1317G or a compensation order under section 961M, 1317H, 1317HA, 1317HB 1317HC or 1317HE
of the Corporations Act; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a liability that is owed to someone other than the company or a related body corporate of the company and did not arise out of conduct in good faith;
or </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">legal costs incurred in defending an action for a liability incurred as an officer or auditor of the company if the costs are incurred:
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">in defending or resisting proceedings in which the person is found to have a liability for which they cannot be indemnified as set out above;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">in defending or resisting criminal proceedings in which the person is found guilty; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">in defending or resisting proceedings brought by the Australian Securities&nbsp;&amp; Investments Commission or a liquidator for a court order if the
grounds for making the order are found by the court to have been established (except costs incurred in responding to actions taken by the Australian Securities&nbsp;&amp; Investments Commission or a liquidator as part of an investigation before
commencing proceedings for a court order); or </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">in connection with proceedings for relief to the person under the Corporations Act 2001 (Cth), or the Corporations Act, in which the court denies the
relief. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Constitution</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our Constitution provides, except to the extent prohibited by the law and the Corporations Act
and, to the extent that the officer is not otherwise indemnified by us pursuant to an indemnity, we indemnify every person who is or has been an officer of the company against any liability or claim (other than legal costs that are unreasonable)
incurred by that person as an officer. This includes any liability or claim incurred by that person in their capacity as an officer of a subsidiary of the company where the company requested that person to accept that appointment. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Indemnification
Agreements</I>.&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to Deeds of Access, Insurance and Indemnity, the form of which is filed as an exhibit to this registration statement, we have agreed to indemnify our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors against certain liabilities and expenses incurred by such persons in connection with claims made by reason of their being such a director or officer. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>SEC Position</I>.&nbsp;&nbsp;&nbsp;&nbsp;Insofar as
indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is
against public policy as expressed in the Securities Act and is therefore unenforceable. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ITEM&nbsp;7.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Recent Sales of Unregistered Securities. </B></FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Set forth below is information regarding share capital
issued and options granted by us since July&nbsp;1, 2017. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">From July&nbsp;1, 2017 through the date of this registration statement, we granted to certain of our directors, officers and employees options to
purchase 8,844,000 ordinary shares under our equity incentive plans at an exercise price per share of A$0.86; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-1
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">From July&nbsp;1, 2017 through the date of this registration statement, we issued an aggregate of 48,840,469 ordinary shares upon the exercise of
options previously granted in connection with capital raise transactions at a weighted-average exercise price per share of A$0.27, for an aggregate exercise price of approximately A$13.2&nbsp;million; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">From July&nbsp;1, 2017 through the date of this registration statement, we issued an aggregate of 875,000 ordinary shares upon the exercise of options
by certain of our officers and employees at an exercise price per share of A$0.48, for an aggregate exercise price of A$420,000; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">From July&nbsp;1, 2017 through the date of this registration statement, we issued and sold an aggregate of 18,867,930 shares of common stock to certain
institutional shareholders at a price per share of A$2.65, for an aggregate purchase price of approximately A$181.7&nbsp;million. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">None of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering. Unless
otherwise specified above, we believe these transactions were exempt from registration under the Securities Act in reliance on (i)&nbsp;Section&nbsp;4(a)(2) of the Securities Act (and Regulation&nbsp;D promulgated thereunder), (ii) Rule&nbsp;701
promulgated under Section&nbsp;3(b) of the Securities Act as transactions by an issuer not involving any public offering or under benefit plans and contracts relating to compensation as provided under Rule&nbsp;701 or (iii)&nbsp;Regulation S
promulgated under the Securities Act as transactions not made to persons in the United States with no directed selling efforts made in the United States. The recipients of the securities in each of these transactions represented their intentions to
acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed on the share certificates issued in these transactions. All recipients had adequate
access, through their relationships with us, to information about us. The sales of these securities were made without any general solicitation or advertising. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-2
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ITEM&nbsp;8.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibits and Financial Statement Schedules. </B></FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>(a) Exhibits </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description of Exhibit</B></FONT></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.1*</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Underwriting Agreement.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.1</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certificate of Registration of the Registrant.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Constitution of the Registrant.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1*</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Deposit Agreement.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.2*</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of American Depositary Receipt evidencing American Depositary Shares (included in Exhibit 4.1).</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.1*</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Opinion of Gilbert + Tobin.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1&#134;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Commercial License Agreement, dated as of October&nbsp;28, 2013, between the Registrant and Selexis SA.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2&#134;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Biopharmaceutical Manufacturing Agreement, dated as of October&nbsp;28, 2013, between the Registrant, Patheon Biologics Company Australia Pty Ltd. and Patheon Biologics Company
B.V.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3+</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Deed of Indemnity, Insurance and Access.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease Agreement, dated November&nbsp;12, 2019, between the Registrant and The Trust Company (Australia) Limited, as custodian for the Newmark Como Property
Trust.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.5+</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Long Term Incentive Plan Rules.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.6+</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors Share and Option Plan Rules.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.1</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">List of subsidiaries.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23.1*</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consent of Deloitte&nbsp;Touche Tohmatsu, independent registered public accounting firm.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23.2*</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consent of Gilbert + Tobin (included in Exhibit 5.1).</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24.1*</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Power of Attorney (included on signature page to this registration statement).</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To be filed or submitted by amendment. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">+</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicates management contract or compensatory plan. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#134;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Portions of this exhibit have been omitted as the Registrant has determined that the omitted information (i)&nbsp;is not material and (ii)&nbsp;would likely cause
competitive harm to the Registrant if publicly disclosed. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>(b) Financial Statement Schedules </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">All schedules have been omitted because the information required to be set forth therein is not applicable or has been included in the consolidated financial statements and notes thereto. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ITEM&nbsp;9.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Undertakings. </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The undersigned Registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement,
certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling
persons of the Registrant pursuant to the foregoing provisions, or otherwise, the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-3
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore,
unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of
any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The undersigned Registrant hereby undertakes that:
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1) For purposes of determining any liability
under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this Registration Statement in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or
(4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this Registration Statement as of the time it was declared effective. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2) For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of
prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-4
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Act of 1933,
as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing <FONT STYLE="white-space:nowrap">on&nbsp;Form&nbsp;F-1&nbsp;and</FONT> has duly caused this registration statement to be
signed on its behalf by the undersigned, thereunto duly authorized in Melbourne, Australia on this &nbsp;&nbsp;&nbsp;&nbsp;day of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="77%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>OPTHEA LIMITED</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Megan Baldwin, Ph.D.</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer and</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Managing Director</FONT></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">KNOW ALL PERSONS BY
THESE PRESENTS, that each individual whose signature appears below constitutes and appoints Megan Baldwin, Ph.D., and Michael Tonroe, and each of them, his or her true and lawful attorneys in fact and agents with full power of substitution, for him
or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to sign any registration statement for the same offering covered by
this registration statement that is to be effective on filing pursuant to Rule 462(b) promulgated under the Securities Act of 1933, as amended, and all post effective amendments thereto, and to file the same, with all exhibits thereto and all
documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys in fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be
done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys in fact and agents or any of them, or his, her or their substitute or substitutes,
may lawfully do or cause to be done by virtue hereof. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons on behalf of the registrant and in the capacities and on the
dates indicated: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="21%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Signature</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Title</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Date</B></FONT></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom">
<P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Megan Baldwin, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer and Managing Director</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>(Principal Executive Officer)</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="middle">
<P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael Tonroe</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer and Company Secretary</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>(Principal Financial and Accounting Officer)</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom">
<P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Geoffrey Kempler</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chairperson of the Board of Directors</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom">
<P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael Sistenich</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-5
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Signature of Authorized U.S. Representative of the Registrant </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Act of 1933,
as amended, the undersigned, the duly authorized representative in the United States of Opthea Limited, has signed this Registration Statement on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top">
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;
</FONT></P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-6
</FONT></P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>filename2.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CIRCADIAN TECHNOLOGIES LIMITED </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MIKE TONROE </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Level&nbsp;4 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">650 Chapel Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SOUTH YARRA VIC 3141 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certificate of the Registration</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>of
a Company</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g945701logo.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This is to certify that </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CIRCADIAN TECHNOLOGIES LIMITED</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Company
Number 006 340 567</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Did on the third day of December 2015 change its name to </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>OPTHEA LIMITED</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Company Number
00634056</B>7 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company is a public company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
company is limited by shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company is taken to be registered under the Corporations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Act 2001 in Victoria and the date of commencement of </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">registration is the seventeenth day of October 1984. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Issued by the</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Australian Securities and
Investments Commission</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">on this eighth day of December, 2008.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Greg Medcraft</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Greg Medcraft</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chairman</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CIRCADIAN TECHNOLOGIES LIMITED </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Level&nbsp;1 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10 Wallace Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TOORAK VIC 3142 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certificate of the Registration </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>of a Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Corporations Act 2001 Paragraph 1274 (2) (b)
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This is to certify that </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CIRCADIAN PHARMACEUTICALS
LIMITED</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Company Number 006 340 567</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">is taken to be registered as a company under the </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Corporations
Act 2001 in Victoria. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the eleventh day of March 1987 the company changed its name to </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CIRCADIAN TECHNOLOGIES LIMITED</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company is <B>limited
by shares</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company is a <B>public</B> company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The day of commencement of registration is </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>the seventeenth
day of October 1984.</B> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Issued by the</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Australian Securities and
Investments Commission</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">on this eighth day of December, 2008.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ E. Armistead</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">A delegate of the Australian Securities and Investments Commission</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CIRCADIAN TECHNOLOGIES LIMITED </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Level&nbsp;1 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10 Wallace Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TOORAK VIC 3142 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certificate of the Registration </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>of a Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Corporations Act 2001 Paragraph 1274 (2) (b)
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This is to certify that </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CIRCADIAN PHARMACEUTICALS
LIMITED</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Company Number 006 340 567</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">is taken to be registered as a company under the </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Corporations
Act 2001 in Victoria. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the eleventh day of March 1987 the company changed its name to </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CIRCADIAN TECHNOLOGIES LIMITED</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company is <B>limited
by shares</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company is a <B>public</B> company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The day of commencement of registration is </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>the seventeenth
day of October 1984.</B> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Issued by the</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Australian Securities and
Investments Commission</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">on this twenty-sixth day of October, 2004.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ W. Squires</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">A delegate of the Australian Securities and Investments Commission</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>3
<FILENAME>filename3.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.2 </B></P> <P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="57%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date: 23&nbsp;August 2007</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:24pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman"><B>Constitution</B></P> <P STYLE="margin-top:0pt;margin-bottom:1pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Circadian Technologies
Limited ACN 006 340 567</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:250pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Dominique Fisher </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Signed for the purposes of identification by the Chairman </P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="53%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g945701g86y61.jpg" ALT="LOGO">
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman">&nbsp;&nbsp;RIALTO TOWERS, 525 COLLINS STREET, MELBOURNE VIC 3000, DX 204 MELBOURNE</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman">&nbsp;&nbsp;TEL: +61 3 8608 2000 FAX: +61 3 8608 1000</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman">&nbsp;&nbsp;www.minterellison.com</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Constitution of Circadian Technologies Limited </B></P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Preliminary</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Defined terms</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Interpretation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Replaceable rules</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Issue of Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Commission and brokerage</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Trusts not recognised</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Joint holders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Share certificates</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Class&nbsp;meetings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Non&nbsp;&#151;marketable parcels</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Calls</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">General</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Instalments and amounts which become payable</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Interest and expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Recovery of amounts due</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Differentiation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Payment of calls in advance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Lien and forfeiture</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Lien</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">19.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Lien sale</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">20.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Forfeiture notice</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Forfeiture</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">22.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Liability of former Member</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">23.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Disposal of Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Transfer of Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>17</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">24.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">General</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">25.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Transfer procedure</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">26.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Right to refuse registration</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH 30-5499810</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Constitution | page 2</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Transmission of Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>19</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">27.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Title on death</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">28.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Entitlement to transmission</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Changes to Share capital</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>20</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">29.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Consolidation or division</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Powers of attorney</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>20</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">30.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Powers of attorney</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>General meetings</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>20</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">31.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Calling general meeting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">32.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Notice</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">33.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Business</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Proceedings at general meetings</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>22</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">34.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Member</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">35.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Quorum</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">36.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chairperson</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">37.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">General conduct</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">38.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Adjournment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">39.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Decisions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">40.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Taking a poll</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">41.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Casting vote of chairperson</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">42.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Admission to general meetings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">43.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Auditor&#146;s right to be heard</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Votes of Members</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>25</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">44.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Entitlement to vote</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">45.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Unpaid calls</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">46.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Joint holders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH 30-5499810</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Constitution | page 3</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">47.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Objections</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">48.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Votes by proxy</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">49.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Document appointing proxy</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">50.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Proxy in blank</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">51.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Lodgment of proxy</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">52.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Validity</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">53.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Representatives of bodies corporate</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Appointment and removal of Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>28</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">54.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Number of Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">55.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Qualification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">56.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Power to remove and appoint</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">57.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Additional and casual Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">58.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Retirement by rotation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">59.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Nomination of Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">60.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Vacation of office</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Remuneration of Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>31</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">61.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Remuneration of <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">62.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Remuneration of Executive Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">63.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Retirement benefits</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Powers and duties of Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>32</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">64.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Directors to manage Company</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Proceedings of Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>32</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">65.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Directors&#146; meetings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">66.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Decisions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">67.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Directors&#146; interests</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">68.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Alternate Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">69.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Remaining Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">70.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chairperson</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">71.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Delegation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH 30-5499810</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Constitution | page 4</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">72.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Written resolutions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">73.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Validity of acts of Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">74.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Minutes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Executive Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>37</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">75.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Appointment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">76.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Powers of Executive Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Local management</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>37</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">77.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">General</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">78.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Appointment of attorneys and agents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Secretary</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>38</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">79.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Secretary</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Seals</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>39</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">80.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Common Seal</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">81.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Duplicate Seal</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">82.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Share Seal</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Inspection of records</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>39</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">83.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Times for inspection</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Dividends and reserves</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>40</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">84.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Dividends</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">85.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Amend resolution to pay dividend</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">86.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">No interest</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">87.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Reserves</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">88.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Dividend entitlement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">89.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Restricted securities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">90.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Deductions from dividends</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">91.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Distribution of assets</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">92.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Payment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">93.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Election to reinvest dividend</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">94.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Election to accept Shares in lieu of dividend</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH 30-5499810</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Constitution | page 5</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">95.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Unclaimed dividends</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">96.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Capitalisation of profits</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Notices</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>43</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">97.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Service of notices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">98.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Persons entitled to notice</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Audit and financial records</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>45</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Company to keep financial records</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Winding up</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>45</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">100.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Winding up</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Indemnity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>45</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">101.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Indemnity</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">102.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Shareholder disclosure</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH 30-5499810</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Constitution | page 6</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preliminary </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Defined terms </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In this Constitution: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Alternate Director</B> means a person appointed as an alternate director under clause&nbsp;68. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Approving Resolution</B> means a resolution passed in accordance with clause<B>&nbsp;Error! Reference source not found.</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Approving Resolution Deadline</B> in relation to a proportional takeover bid means the day that is the 14th day before the last day of the
bid period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>ASTC</B> means ASX Settlement and Transfer Corporation Pty Limited ABN 49 008 504 532. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>ASTC</B> <B>Settlement Rules</B> means the operating rules of ASTC. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>ASX</B> means ASX Limited ABN 98 008 624 691. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>ASX Listing Rules</B> means the listing rules of ASX and any other rules of ASX applicable to the Company or the Shares while the Company is
admitted to the Official List, each as amended or replaced from time to time, except to the extent of any express written waiver by ASX. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Auditor</B> means the Company&#146;s auditor. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Business Day</B> has the same meaning as in the ASX Listing Rules. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>CHESS Holding</B> has the same meaning as in the ASTC Settlement Rules. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Claim</B> includes any allegation, cause of action, claim, proceeding (including civil, criminal, administrative or judicial), action, suit
or demand of any nature whatsoever, and whether present, unascertained, immediate, future or contingent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Company</B> means Circadian
Technologies Limited ACN 006 340 567. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Constitution</B> means the constitution of the Company as amended from time to time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Corporations Act</B> means the <I>Corporations Act 2001 </I>(Cth) as amended or replaced from time to time and includes any regulations made
under that Act and any exemption or modification to that Act applying to the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>CS Facility Rules</B> means the operating rules
of an applicable CS facility licensee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Director</B> means a person appointed to the position of a director of the Company and where
appropriate, includes an Alternate Director. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Directors</B> means all or some of the Directors acting as a board. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Dividend</B> includes bonus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Executive Director</B> has the meaning given by clause&nbsp;75.2. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Issuer Sponsored Holding</B> has the same meaning as in the ASTC Settlement Rules. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Liability</B> includes any Claim, liability, debt, obligation, cost, expense, loss, damage, compensation or charge of any nature whatsoever
and including those which are prospective or contingent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Managing Director</B> means a Director appointed as managing director under
clause&nbsp;75.1. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH
30-5499810</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Constitution | page
7</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Marketable Parcel</B> has the same meaning as in the business rules of ASX in force from
time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Member</B> means a person who is a member of the Company under the Corporations Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director</B> means a Director who is not an Executive Director. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Non</B><B><FONT STYLE="white-space:nowrap">-Marketable</FONT> Parcel</B> means a parcel of securities that is less than a Marketable Parcel.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Option</B> means an entitlement to a Share. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Register</B> means the register of Members of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Representative</B> means a person appointed by a Member to act as its representative under clause&nbsp;53.1. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Restricted Securities</B> has the same meaning as in the ASX Listing Rules. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Seal</B> means the Company&#146;s common seal. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Secretary</B> means any person appointed by the Directors to perform any of the duties of a secretary of the Company and if more than one
person is appointed, any one or more of such persons. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Shares</B> means shares in the share capital of the Company. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In this Constitution, except where the context otherwise requires, an expression in a clause of this
Constitution has the same meaning as in the Corporations Act. Where the expression has more than one meaning in the Corporations Act and a provision of the Corporations Act deals with the same matter as a clause of this Constitution, that expression
has the same meaning as in that provision. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Interpretation </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In this Constitution, except where the context otherwise requires: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the singular includes the plural and vice versa, and a gender includes other genders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">another grammatical form of a defined word or expression has a corresponding meaning; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a reference to a clause, paragraph, schedule or annexure is to a clause or paragraph of, or schedule or
annexure to, this Constitution, and a reference to this Constitution includes any schedule or annexure; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a reference to a document or instrument includes the document or instrument as novated, altered, supplemented
or replaced from time to time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a reference to <B>A$</B>, <B>$A</B>, <B>dollar</B> or <B>$</B> is to Australian currency; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the meaning of general words is not limited by specific examples introduced by <B>including</B>, <B>for
example</B> or similar expressions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Headings are for ease of reference only and do not affect interpretation. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Corporations Act prevails over any inconsistency with: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">this Constitution; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the ASX Listing Rules; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the CS Facility Rules. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH
30-5499810</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Constitution | page
8</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Replaceable rules </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The provisions of the Corporations Act that apply to certain companies as replaceable rules are displaced by this Constitution in their
entirety and do not apply to the Company. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shares</B> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Rights </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Subject to this Constitution and to the terms of issue of Shares, all Shares attract the following rights: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the right to receive notice of and to attend and vote at all general meetings of the Company;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the right to receive dividends; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in a winding up or a reduction of capital, the right to participate equally in the distribution of the assets
of the Company (both capital and surplus), subject to any amounts unpaid on the Share and, in the case of a reduction, to the terms of the reduction. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Issue of Shares </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the Corporations Act, the ASX Listing Rules and this Constitution, the Directors may issue and
allot, or dispose of, Shares: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on terms determined by the Directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the issue price that the Directors determine; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to Members whether in proportion to their existing shareholdings or otherwise, and to such other persons as the
Directors may determine. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors&#146; power under clause 5.1 includes the power to: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">grant options over unissued Shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">issue and allot Shares: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">with any preferential, deferred or special rights, privileges or conditions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">with any restrictions in regard to dividend, voting, return of capital or otherwise; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">which are liable to be redeemed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">which are bonus Shares for whose issue no consideration is payable to the Company; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">which have any combination of the characteristics described in clauses 5.2(b)(i) to 5.2(b)(iv) inclusive.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Commission and brokerage </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Any brokerage or commission which may be paid by the Company may be made in cash, by the issue and allotment of Shares, or the issue of
debentures, or by a combination of any of those methods. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH
30-5499810</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Constitution | page
9</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Trusts not recognised </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as required by law, the CS Facility Rules or as otherwise provided by this Constitution, the Company
will not recognise any person as holding a Share on trust and the Company will not be bound to recognise any equitable, contingent, future or partial interest or any other right in respect of a Share except the registered holder&#146;s absolute
right of ownership. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This clause 7 applies even if the Company has notice of the relevant trust, interest or right.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Joint holders </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If two or more persons are registered as the holders of a Share, they are taken to hold the Share as joint
tenants with benefit of survivorship and the person whose name appears first on the Register is the only joint holder entitled to receive notices from the Company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any one of the joint holders of a Share may give an effective receipt for any dividend or return of capital
payable to the joint holders. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company is entitled to and in respect of CHESS Holdings, must: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">record the names of only the first three joint holders of a Share on the Register; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">regard the three joint holders of a Share appearing first on the Register as the registered holders of that
Share to the exclusion of any other holders; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">disregard the entitlement of any person to be registered on the Register as a holder if the name of the person
would appear on the Register after the first three holders for that Share. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Share certificates </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors will not, unless they determine otherwise or the ASX Listing Rules require, issue a certificate
to a Member for any Shares registered in the Member&#146;s name or record any holding as held on a certificated subregister. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any certificate for Shares must be issued and despatched in accordance with the Corporations Act, the ASX
Listing Rules and the CS Facility Rules. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the ASX Listing Rules, the Directors may in their absolute discretion elect whether to maintain a
certificated subregister for any class of Shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the ASX Listing Rules and the CS Facility Rules, Shares may be held on any subregister maintained by
or on behalf of the Company or on any branch register kept by the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors may order worn out or defaced certificates to be cancelled and, if necessary, replaced by new
certificates. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Class&nbsp;meetings </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The rights attached to any class of Shares may be varied in accordance with the Corporations Act.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The provisions of this Constitution relating to general meetings apply, with necessary changes, to a meeting of
a class of Members holding Shares in that class as if it was a general meeting except that: </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH
30-5499810</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Constitution | page
10</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a quorum is two persons holding or representing by proxy, attorney or Representative not less than 5% of the
Shares of the class or, if there is one holder of Shares in the class, that holder or a proxy, attorney or representative of that holder; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any five holders, or holders of Shares of the class present in person or by proxy, attorney or Representative
who can vote not less than 5% of all votes held by Members of that class, may demand a poll. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Non-marketable</FONT> parcels </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If one or more Members hold less than a Marketable Parcel of Shares, the Directors may invoke the procedure for
the sale of Shares under this clause 11 (<B>Procedure</B>). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To invoke the Procedure, the Directors must give each Member (or each Member whose Shares are not held in a
CHESS Holding) who holds less than a Marketable Parcel of Shares (<B>Eligible Member</B>) written notice (<B>Notice of Divestiture</B>) that complies with this clause 11. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Notice of Divestiture given to a Member must: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">state that the Shares referred to in the Notice of Divestiture are liable to be sold in accordance with the
Procedure if the Member does not advise the Company before a specified date (<B>Relevant Date</B>) that the Member wishes to keep those Shares; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the Member holds Shares in a CHESS Holding, contain a statement to the effect that if those Shares remain in
a CHESS Holding after the Relevant Date, the Company may, without further notice, move those Shares from the CHESS Holding to an Issuer Sponsored Holding or a Certificated Holding for the purposes of divestment by the Company in accordance with the
Procedure. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Relevant Date must be six weeks or more after the date that the Notice of Divestiture is sent.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A copy of a Notice of Divestiture must be given to any other person required by the CS Facility Rules.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If an Eligible Member on whom a Notice of Divestiture has been served, wants to keep the Shares referred to in
the Notice of Divestiture, the Eligible Member must give the Company written notice before the Relevant Date, advising the Company that the Member wants to keep those Shares in which event the Company will not sell the Shares. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If an Eligible Member on whom a Notice of Divestiture has been served does not give the Company written notice
before the Relevant Date advising the Company that the Eligible Member wants to keep the Shares referred in the Notice of Divestiture, the Company may: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the Member holds those Shares in a CHESS Holding, move those Shares from the CHESS Holding to an Issuer
Sponsored Holding or a Certificated Holding; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any case, sell those Shares in accordance with the Procedure, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">but only if the Shares held by the Eligible Member on the Relevant Date is less than a Marketable Parcel. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any Shares which may be sold under this clause 11&nbsp;may be sold on the terms, in the manner (whether <FONT
STYLE="white-space:nowrap">on-market,</FONT> by private treaty, through a share sale facility established by, on behalf or, or at the request of the Company, or otherwise) and at the time or times determined by the Directors and, for the purposes of
a sale under this clause 11, each Eligible Member: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">appoints the Company as the Eligible Member&#146;s agent for sale; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH
30-5499810</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Constitution | page
11</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">authorises the Company to effect on the Eligible Member&#146;s behalf a transfer of the Shares sold and to deal
with the proceeds of the sale of the Shares in accordance with clause 11.10; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">appoints the Company, it&#146;s Directors and the Secretary jointly and severally as the Eligible Member&#146;s
attorneys to execute an instrument or take other steps, in the Eligible Member&#146;s name and on the Eligible Member&#146;s behalf, as they or any of them may consider appropriate to transfer the Shares sold; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">authorises each of the attorneys appointed under clause 11.8(c) to appoint an agent to do a thing referred to
in clause 11.8(c). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The title of the transferee to Shares acquired under this clause 11 is not affected by an irregularity or
invalidity in connection with the sale of Shares to the Transferee. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The proceeds of any sale of Shares under this clause 11 less any unpaid calls and interest (<B>Sale
Consideration</B>) will be paid to the relevant Member or as that Member may direct. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company will hold the Sale Consideration in trust for the Member whose Shares are sold under this clause
and will forthwith notify the Member in writing that the Sale Consideration in respect of the Member&#146;s Shares has been received by the Company and is being held by the Company pending instructions from the Member as to how it is to be dealt
with. If the Member has been issued with a share certificate or certificates, the Member&#146;s instructions, to be effective, must be accompanied by the share certificate or certificates to which the Sale Consideration relates or, if the
certificate or certificates has or have been lost or destroyed, by a statement and undertaking under subsection 1070D(5) of the Corporations Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the Corporations Act, the Company or the purchaser will bear all costs, including brokerage and
stamp duty, associated with the sale of any Shares under this clause. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Procedure may only be invoked once in any 12 month period after its adoption or renewal.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Procedure has been invoked and there is an announcement of a takeover bid for Shares, no more sales of
Shares may be made under this clause 11 until after the close of the offers made under the takeover. The Procedure may then be invoked again. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Calls</B> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">General </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the Corporations Act and the terms on which partly paid Shares are issued, the Directors may make
calls on the holders of the Shares for any money unpaid on them. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A call is made when the resolution of the Directors authorising it is passed. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors may revoke or postpone a call before its due date for payment. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors may require a call to be paid by instalments. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company must comply with the Corporations Act and the ASX Listing Rules in relation to the dispatch and
content of notices to Members on whom a call is made. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Member to whom notice of a call is given in accordance with this clause 12 must pay to the Company the amount
called in accordance with the notice. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Failure to send a notice of a call to any Member or the <FONT STYLE="white-space:nowrap">non-receipt</FONT> of
a notice by any Member does not invalidate the call. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH
30-5499810</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Constitution | page
12</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Joint holders of Shares are jointly and severally liable to pay all calls in respect of their Shares.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Instalments and amounts which become payable </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Directors require a call to be paid by instalments; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an amount becomes payable by the terms of issue of Shares on allotment, or at a time or in circumstances
specified in the terms of issue, </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">then: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">every instalment or the amount payable under the terms of issue is payable as if it were a call made by the
Directors and as if they had given notice of it; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the consequences of late payment or <FONT STYLE="white-space:nowrap">non-payment</FONT> of an instalment or the
amount payable under the terms of issue are the same as the consequences of late payment or <FONT STYLE="white-space:nowrap">non-payment</FONT> of a call. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Interest and expenses </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If an amount called is not paid on or before the due date, the person liable to pay the amount must also pay: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">interest on the amount from the due date to the time of actual payment at a rate determined by the Directors
(not exceeding 20% per annum); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all expenses incurred by the Company as a consequence of the
<FONT STYLE="white-space:nowrap">non-payment,</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">but the Directors may waive payment of the interest and expenses in
whole or in part. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Recovery of amounts due </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">On the hearing of any action for the recovery of money due for any call, proof that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the name of the person sued was, when the call was made, entered in the Register as a holder or the holder of
Shares in respect of which the call was made; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the resolution making the call is duly recorded in the Directors&#146; minute book; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">notice of the call was given to the person sued, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">will be conclusive evidence of the debt. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">16.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Differentiation </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Directors may, on the issue of Shares, differentiate between the holders as to the amount of calls to be paid and the times of payment.
</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Payment of calls in advance </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors may accept from a Member the whole or part of the amount unpaid on a Share before the amount
accepted has been called. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH
30-5499810</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Constitution | page
13</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company may: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">pay interest on any amount accepted, until the amount is payable under a call and at a rate (not exceeding 20%
per annum) agreed between the Member and the Directors; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">subject to any contract between the Company and the Member, repay all or any of the amount accepted in excess
of the amount called on the Share. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Payment of an amount in advance of a call does not entitle the paying Member to any: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">dividend, benefit or advantage, other than the payment of interest under this clause 17; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">voting right, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">to which the Member would not have been entitled if it had paid the amount when it became due. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Lien and forfeiture </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lien </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the extent permitted by the ASX Listing Rules, the Company has a first and paramount lien on every partly
paid Share and dividends payable in respect of the Share for all money: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">due and unpaid to the Company at a fixed time, in respect of the Share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">presently payable by a holder or the holder of the Share, or the holder&#146;s estate, to the Company in
respect of the Share; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">which the Company is required by law to pay (and has paid) in respect of the Share. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The lien extends to reasonable interest and expenses incurred because the amount is not paid.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If any law for the time being of any country, state or place imposes or purports to impose an immediate or
contingent liability on the Company to make any payment or authorises a taxing authority or Government official to require the Company to make payment in respect of Shares or dividends or other moneys accruing due to the Member who holds the Shares:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Member or, if the Member is deceased, the Member&#146;s legal personal representative, indemnifies the
Company in respect of any such payment or liability; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">subject to the Corporations Act and the ASX Listing Rules, the Company: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">has a lien on the Shares and dividends and other moneys payable in respect of the Shares, whether the Shares
are held by the Member solely or jointly with another person in respect of any payment made or liability incurred by the Company, together with reasonable expenses and interest on any payment made by the Company at a rate to be fixed by the
Directors not exceeding 20% per annum from the date of payment by the Company to the date of repayment by the Member; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">may set off amounts so paid by the Company against amounts payable by the Company to the Member as dividends or
otherwise; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">may recover as a debt due from the Member or its legal personal representative the amount of all payments made
by the Company together with reasonable expenses and interest at the rate and for the period referred to in clause 18.3(b)(i). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company may do all things which the Directors think necessary or appropriate to do under the ASX Listing
Rules and the CS Facility Rules to enforce or protect the Company&#146;s lien. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH
30-5499810</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Constitution | page
14</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless the Directors determine otherwise, the registration of a transfer of a Share operates as a waiver of the
Company&#146;s lien on the Share. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors may declare a Share to be wholly or partly exempt from a lien. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">19.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lien sale </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company has a lien on a Share for money presently payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company has given the Member or the Member&#146;s executors or administrators (as the case may be) holding
the Share written notice demanding payment of the money; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that Member fails to pay all of the money demanded, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">then 14 or more days after giving the notice, the Directors may, if the ASX Listing Rules permit, sell the Share in any manner determined by
them. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Forfeiture notice </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors may at any time after a call or instalment becomes payable and remains unpaid by a Member, serve
a notice on the Member requiring the Member to pay all or any of the following: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the unpaid amount; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any interest that has accrued; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all expenses incurred by the Company as a consequence of the
<FONT STYLE="white-space:nowrap">non-payment.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The notice under clause 20.1 must: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">specify a day (not earlier than 14 days after the date of the notice) on or before which the payment required
by the notice must be made; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">state that if a Member does not comply with the notice, the Shares in respect of which the call was made or
instalment is payable will be liable to be forfeited. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">21. Forfeiture </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">21.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If a Member does not comply with a notice served under clause 20, then any or all of the Shares in respect of
which the notice was given may be forfeited under a resolution of the Directors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">21.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unpaid dividends in respect of forfeited Shares will also be forfeited. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">21.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On forfeiture, Shares become the property of the Company and forfeited Shares must be: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the ASX Listing Rules permit, sold, disposed of, or cancelled on terms determined by the Directors; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">offered by public auction in accordance with any requirements of the ASX Listing Rules. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">21.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors may, at any time before a forfeited Share is sold, disposed of or cancelled, annul the forfeiture
of the Share on conditions determined by them. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">21.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Promptly after a Share has been forfeited: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">notice of the forfeiture must be given to the Member in whose name the Share was registered immediately before
its forfeiture; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH
30-5499810</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Constitution | page
15</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the forfeiture and its date must be noted in the Register. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">21.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Omission or neglect to give notice of or to note the forfeiture as specified in clause 21.5 will not invalidate
a forfeiture. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">22.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Liability of former Member </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">22.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The interest of a person who held Shares which are forfeited is extinguished but subject to the ASX Listing
Rules, the former Member remains liable to pay: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all money (including interest and expenses) that was payable by the Member to the Company at the date of
forfeiture in respect of the forfeited Shares; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">interest from the date of forfeiture until payment of the money referred to in clause 22.1(a), of this clause
at a rate determined by the Directors (not exceeding 20% per annum). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">22.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A former Member&#146;s liability to the Company ceases if and when the Company receives payment in full of all
money (including interest and expenses) payable by the former Member in respect of the Shares. The liability may only be released or waived in accordance with the ASX Listing Rules. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">23.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Disposal of Shares </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">23.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company may: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">receive the consideration (if any) given for a forfeited Share on any sale or disposition of the Share, or a
Share sold under a lien sale; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">effect a transfer of the Share in favour of a person to whom the Share is sold or disposed of.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">23.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The purchaser of the Share: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is not bound to check the regularity of the sale or the application of the purchase price;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">obtains title to the Share despite any irregularity in the sale; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">will not be subject to complaint or remedy by the former holder of the Share in respect of the purchase.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">23.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A statement signed by a Director and the Secretary that the Share has been regularly forfeited and sold or
reissued or regularly sold without forfeiture to enforce a lien, is conclusive evidence of the matters stated as against all persons claiming to be entitled to the Share. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">23.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the terms on which a Share is on issue, the net proceeds of any sale made to enforce a lien or on
forfeiture must be applied by the Company in the following order: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in payment of the costs of the sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in payment of all amounts (if any) secured by the lien or all money (if any) that was payable in respect of the
forfeited Share; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where the Share was forfeited under clause 21.1, in payment of any surplus to the former Member whose Share was
sold. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH
30-5499810</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Constitution | page
16</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer of Shares</B> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">24.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">General </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">24.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to this Constitution, a Member may transfer Shares held by that Member. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">24.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to clause 24.3, Shares may be transferred by: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a written transfer instrument in any usual or common form; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other form approved by the Directors. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">24.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company may participate in any computerised or electronic system for market settlement, securities transfer
and registration conducted in accordance with the Corporations Act, the ASX Listing Rules and the CS Facility Rules, or corresponding laws or securities exchange rules in any other country. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">24.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Company participates in a system of the kind described in clause 24.3, then despite any other provision
of this Constitution: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shares may be transferred, and transfers may be registered, in any manner required or permitted by the ASX
Listing Rules or the CS Facility Rules (or corresponding laws or securities exchange rules in any other country) applying in relation to the system; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company must comply with and give effect to those rules; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company may, in accordance with those rules, decline to issue certificates for holdings of Shares.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">24.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A written transfer instrument must be: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">executed by the transferor or (where the Corporations Act permits) stamped by the transferor&#146;s broker;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">unless the Directors decide otherwise in the case of a fully paid Share, executed by the transferee or (where
the Corporations Act permits) stamped by the transferee&#146;s broker; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of a transfer of partly paid Shares, endorsed or accompanied by an instrument executed by the
transferee or by the transferee&#146;s broker to the effect that the transferee agrees to accept the Shares subject to the terms and conditions on which the transferor held them, to become a Member and to be bound by the Constitution.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Subject to the Corporation Act, the written transfer instrument may comprise more than one document. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">24.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as required by the CS Facility Rules: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a transferor of Shares remains the holder of the Shares transferred until the transfer is registered and the
name of the transferee is entered in the Register in respect of the Shares; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a transfer of Shares does not pass the right to any dividends on the Shares until such registration.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH
30-5499810</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Constitution | page
17</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">25.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Transfer procedure </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">25.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except where the Directors determine (to comply with laws or securities exchange rules of a foreign country or
the CS Facility Rules), for a transfer of Shares that is not an <FONT STYLE="white-space:nowrap">ASTC-regulated</FONT> transfer: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the written transfer instrument must be left at the Company&#146;s registered office or another place
acceptable to the Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the instrument must be accompanied by a certificate for the Shares dealt with in the transfer where a
certificate has been issued, unless the Directors waive production of the certificate on receiving satisfactory evidence of the loss or destruction of the certificate; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Directors may, if the ASX Listing Rules permit, require other evidence of the transferor&#146;s right to
transfer the Shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">25.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For a transfer of Shares that is an ASTC-regulated transfer, a Share transfer must be effected in accordance
with the ASX Listing Rules and the ASTC Settlement Rules. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">26.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Right to refuse registration </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">26.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors may in their absolute discretion refuse to register any transfer of Shares or other securities
where the Shares or other securities are not quoted by ASX. Where the Shares or other securities are quoted by ASX, the Directors may in their absolute discretion refuse to register any transfer in any of the circumstances permitted by the ASX
Listing Rules. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">26.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors must: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">except as permitted by ASX, refuse to register any transfer of Shares or other securities which are Restricted
Securities if that transfer is or might be in breach of the ASX Listing Rules or any restriction agreement entered into by the Company under the ASX Listing Rules in relation to the Shares; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">refuse to register any transfer where the Company is, or the Directors are, required to do so by the ASX
Listing Rules. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">26.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Despite clauses 26.1 and 26.2, the Company must not refuse or fail to register or give effect to, or delay or
in any way interfere with, a proper ASTC transfer of Shares or other securities quoted by ASX. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">26.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If a person has lodged a transfer which the Directors have refused to register, the Company must, within five
Business Days after the date of lodgment, give to the lodging person written notice of the refusal and the reasons for it. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">26.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to clause 26.3, Restricted Securities cannot be disposed of during the escrow period except as
permitted by the ASX Listing Rules or ASX. The Company will refuse to acknowledge a disposal of Restricted Securities to the extent required under the ASX Listing Rules. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH
30-5499810</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Constitution | page
18</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transmission of Shares </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">27.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Title on death </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">27.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The legal personal representative of a deceased Member who was the sole holder of Shares is the only person
whom the Company will recognise as having any title to the deceased Member&#146;s Shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">27.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If a deceased Member was a joint holder of Shares, the other joint holder is the only person whom the Company
will recognise as having any title to the deceased Member&#146;s Shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">27.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The estate of the deceased Member will not be released from any liability to the Company in respect of the
Shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">27.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company may register or give effect to a transfer to a transferee who dies before the transfer is
registered. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">28.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Entitlement to transmission </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">28.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A person who becomes entitled to a Share in consequence of the death, mental incapacity or bankruptcy of a
Member may, subject to clause 26 and to producing to the Company evidence of its entitlement which is satisfactory to the Directors, elect to: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">be registered as the holder of the Share; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transfer the Share to some other person nominated by it. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">28.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the person who has become entitled to a Share: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">elects to be registered as the holder, then the person must deliver or send to the Company a written notice of
election signed by him or her; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">elects to transfer the Share, then the person must effect a transfer of the Share. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">28.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An election to be registered as a holder of a Share under clause 28.1(a) or a transfer of a Share from a Member
or deceased Member under this clause 28 is subject to the same limitations, restrictions and provisions of this Constitution as would apply if the election were a transfer or the transfer were made by the Member or deceased Member himself or
herself. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">28.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A person who: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">has become entitled to a Share by operation of law; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">has produced evidence of that person&#146;s entitlement which is satisfactory to the Directors,
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">is entitled to the dividends and other rights of the registered holder of the Share. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">28.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Where two or more persons are jointly entitled to any Share in consequence of the death of the registered
holder, they will be considered to be joint holders of the Share. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">28.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any person who is registered under this clause must indemnify the Company against all liabilities, costs,
losses and expenses incurred by the Company as a result of registering the person. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH
30-5499810</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Constitution | page
19</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Changes to Share capital </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">29.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consolidation or division </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">For the purpose of giving effect to any consolidation or division of Shares, the Directors may, subject to the CS Facility Rules, settle any
difficulty which arises with respect to fractions of Shares in any manner that they think expedient. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Powers of attorney </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">30.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Powers of attorney </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">30.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If a Member executes or proposes to execute any document or do any act by or through an attorney which is
relevant to the Company or the Member&#146;s shareholding in the Company, that Member must deliver the instrument appointing the attorney to the Company for notation. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">30.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company may require the Member to lodge a certified copy of the instrument for retention by the Company,
and ask for whatever evidence it thinks appropriate that the power of attorney is effective and continues to be in force. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">30.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any power of attorney granted by a Member will, as between the Company and the Member who granted the power of
attorney: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">continue in force; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">may be acted on, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">unless express notice in writing of its revocation or of the death of the Member who granted it is lodged with the Company. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">30.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Where a Member proposes that an attorney represent the Member at a general meeting or adjourned meeting, the
Member must comply with clause 51.1 of this Constitution. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General meetings </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">31.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Calling general meeting </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">31.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Director may call a meeting of Members. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">31.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors must call annual general meetings in accordance with the Corporations Act, to be held by the
Company at times to be determined by the Directors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">31.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Members may also request or call and arrange to hold general meetings in accordance with the procedures and
requirements set out in the Corporations Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">31.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A general meeting may be held at two or more venues simultaneously using any technology that gives the Members
as a whole a reasonable opportunity to participate. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">32.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notice </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">32.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notice of a general meeting must be given in accordance with the Corporations Act to the persons referred to in
clause 98.1. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH
30-5499810</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Constitution | page
20</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">32.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as permitted by the Corporations Act, general meetings must be called on at least the minimum number of
days notice required by the Corporations Act (which at the date of adoption of this Constitution is 28 days) and otherwise in accordance with the procedures set out in the Corporations Act. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">32.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the requirements of the Corporations Act, a notice calling a general meeting must:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">specify the place, date and time of the meeting (and if the meeting is to be held in two or more places, the
technology that will be used to facilitate this); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">state the general nature of the business to be transacted at the meeting; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if a special resolution is to be proposed at the meeting, set out an intention to propose the special
resolution and state the resolution; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">include such statements about the appointment of proxies as are required by the Corporations Act;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">specify a place and facsimile number and may specify an electronic address for the purposes of proxy
appointments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">subject to the CS Facility Rules, specify particulars of any determination made under regulation 7.11.37 of the
<I>Corporations Regulations 2001 </I>(Cth); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">comply with any other requirements of the Corporations Act. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">33.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Business </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">33.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The business of an annual general meeting may include: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any of the following matters, even if not referred to in the notice of meeting: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">consideration of the annual financial report, directors&#146; report and auditor&#146;s report;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">election of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">appointment of the auditor; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">fixing the auditor&#146;s remuneration; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any business which under this Constitution or the Corporations Act is required to be transacted at an annual
general meeting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other business which may lawfully be transacted at a general meeting. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">33.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The chairperson of an annual general meeting must allow a reasonable opportunity for the Members as a whole at
the meeting to: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ask questions about or make comments on the management of the Company; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ask the Auditor or their representative questions relevant to the conduct of the audit and the preparation and
content of the Auditor&#146;s report for the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">33.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors may postpone or cancel any general meeting (other than a meeting requested or called by Members
under clause 31.3) at any time before the day of the meeting. The Directors must give notice of the postponement or cancellation to all persons entitled to receive notices of a general meeting. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">33.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An accidental omission to send a notice of a general meeting (including a proxy appointment form) or the
postponement of a general meeting to any Member or the <FONT STYLE="white-space:nowrap">non-receipt</FONT> of a notice (or form) by any Member does not invalidate the proceedings at or any resolution passed at the general meeting.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH
30-5499810</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Constitution | page
21</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Proceedings at general meetings </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">34.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">In clauses&nbsp;35, 36, 39 and 44, Member includes a Member present in person or by proxy, attorney or Representative. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">35.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Quorum </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">35.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No business may be transacted at a general meeting unless a quorum of Members is present at the commencement of
business. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">35.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A quorum of Members is three Members unless there is only one Member, when a quorum is that Member.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">35.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If a quorum is not present within 30 minutes after the time appointed for a general meeting:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the general meeting is automatically dissolved if it was requested or called by Members under clause 31.3; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other case: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">it will stand adjourned to the same time and place seven days after the meeting, or to another day, time and
place determined by the Directors; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if at the adjourned general meeting a quorum is not present within 30 minutes after the time appointed for the
general meeting two Members will be a quorum. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">36.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Chairperson </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">36.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The chairperson, or in the chairperson&#146;s absence the deputy chairperson, of Directors&#146; meetings will
be the chairperson at every general meeting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">36.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">there is no chairperson or deputy chairperson; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">neither the chairperson nor deputy chairperson is present within 15 minutes after the time appointed for
holding the general meeting; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the chairperson and deputy chairperson are unwilling to act as chairperson of the general meeting,
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">the Directors present may elect a chairperson of the general meeting of the Members. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">36.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If no chairperson is elected in accordance with clause 36.2, then: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Members may elect one of the Directors present as chairperson; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if no Director is present or is willing to take the chair, the Members may elect one of the Members present as
chairperson. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">36.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At any time during a meeting and in respect of any specific item or items of business, the chairperson may
elect to vacate the chair in favour of another person nominated by the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH
30-5499810</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Constitution | page
22</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
chairperson (which person must be a Director unless no Director is present or is willing to act). That person is to be taken to be the chairperson and will have all the powers of the chairperson
(other than the power to adjourn the meeting), during the consideration of that item of business or those items of business. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">36.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If there is a dispute at a general meeting about a question of procedure, the chairperson may determine the
question. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">37.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">General conduct </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The general conduct of each general meeting of the Company and the procedures to be adopted at the meeting will be determined by the
chairperson, including the procedure for the conduct of the election of Directors. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">38.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Adjournment </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">38.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The chairperson of a general meeting at which a quorum is present: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in his or her discretion may adjourn the general meeting; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">must adjourn the general meeting if the meeting directs him or her to do so. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">38.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An adjourned general meeting may take place at a different venue from the initial general meeting.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">38.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The only business that can be transacted at an adjourned general meeting is the unfinished business of the
initial general meeting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">38.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If a general meeting has been adjourned for more than 30 days, notice of the adjourned general meeting must be
given to Members as if it were an original general meeting, but otherwise it is not necessary to give notice of an adjourned general meeting or the business of the adjourned general meeting. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">38.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A poll cannot be demanded on any resolution concerning the adjournment of a general meeting except by the
chairperson. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">39.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Decisions </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">39.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the Corporations Act in relation to special resolutions, a resolution is carried if a majority of
the votes cast on the resolution are in favour of the resolution. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">39.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A resolution put to the vote of a meeting is decided on a show of hands unless a poll is demanded by:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at least 5 Members entitled to vote on the resolution; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Members with at least 5% of the votes that may be cast on the resolution on a poll; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the chairperson. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">39.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A poll may be demanded: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">before a vote is taken; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of a vote taken on a show of hands, immediately before or immediately after, the results of the
vote are declared. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH
30-5499810</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Constitution | page
23</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">39.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless a poll is demanded: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a declaration by the chairperson that a resolution has been carried, carried by a specified majority, or lost;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an entry to that effect in the minutes of the meeting, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">are conclusive evidence of the fact without proof of the number or proportion of the votes in favour of or against the resolution. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">39.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The demand for a poll may be withdrawn. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">39.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A decision of a general meeting may not be impeached or invalidated on the ground that a person voting at the
meeting was not entitled to do so. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">40.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Taking a poll </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">40.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to clause 40.5, a poll will be taken when and in the manner that the chairperson directs. No notice
need be given of any poll. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">40.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The result of the poll will determine whether the resolution on which the poll was demanded is carried or lost.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">40.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The chairperson may determine any dispute about the admission or rejection of a vote, and such determination,
if made in good faith, will be final and conclusive. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">40.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A poll cannot be demanded on any resolution concerning the election of the chairperson of a general meeting.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">40.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A poll demanded by the chairperson on any resolution concerning the adjournment of a general meeting must be
taken immediately. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">40.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">After a poll has been demanded at a general meeting, the general meeting may continue for the transaction of
business other than the question on which the poll was demanded. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">41.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Casting vote of chairperson </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The chairperson does not have a casting vote (in addition to the chairperson&#146;s votes as a Member, proxy, attorney or Representative) on a
show of hands or on a poll. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">42.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Admission to general meetings </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The chairperson of a general meeting may refuse admission to a person, or require a person to leave and not return to, a meeting if the person:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">refuses to permit examination of any article in the person&#146;s possession; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is in possession of any: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">electronic or recording device; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">placard or banner; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">other article, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">which the chairperson considers to be dangerous, offensive or liable to cause disruption; or </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">causes any disruption to the meeting. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH
30-5499810</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Constitution | page
24</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">43.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Auditor&#146;s right to be heard </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Auditor is entitled to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">attend any general meeting of the Company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">be heard at any general meeting of the Company on any part of the business of the meeting that concerns the
Auditor in their capacity as auditor, even if: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Auditor retires at the general meeting; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Members pass a resolution to remove the Auditor from office; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">authorise a person in writing to attend and speak at any general meeting as the Auditor&#146;s representative.
</P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Votes of Members </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">44.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Entitlement to vote </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">44.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to this Constitution and to any rights or restrictions attaching to any class of Shares:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">every Member may vote; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">subject to clause&nbsp;48.4 and the Corporations Act, on a show of hands every Member has one vote; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on a poll every Member has: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for each fully paid Share held by the Member, one vote; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for each partly paid Share held by the Member, a fraction of a vote equivalent to the proportion which the
amount paid (not credited) is of the total amounts paid and payable, whether or not called (excluding amounts credited), on the Share. Without limiting the generality of clause 17.3, an amount paid on a Share in advance of a call is not to be taken
as paid for the purposes of this clause. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">44.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">During a breach of the ASX Listing Rules relating to Shares which are Restricted Securities, or a breach of a
restriction agreement, the holder of the relevant Restricted Securities is not entitled to any voting rights in respect of those Restricted Securities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">44.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If a Member: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">dies; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">through mental or physical infirmity, is incapable of managing the Member&#146;s affairs,
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">and a personal representative, trustee or other person is appointed under law to administer the Member&#146;s estate or
property, the personal representative, trustee or person so appointed may exercise any rights of the Member in relation to a general meeting as if the personal representative, trustee or person (as the case may be) was a Member. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">45.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unpaid calls </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">A Member is entitled to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">vote; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">be counted in a quorum, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH
30-5499810</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Constitution | page
25</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">only in respect of Shares on which all calls due and payable have been paid. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">46.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Joint holders </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">46.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If two or more joint holders purport to vote, the vote of the joint holder whose name appears first in the
Register will be accepted, to the exclusion of the other joint holder or holders. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">46.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purposes of this clause 46, several executors or administrators of a deceased Member in whose sole name
any Shares are registered will be taken to be joint holders of those Shares. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">47.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Objections </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">47.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An objection to the qualification of a voter may only be raised at the general meeting or adjourned general
meeting at which the voter tendered its vote. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">47.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An objection must be referred to the chairperson of the general meeting, whose decision made in good faith is
final. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">47.3 Subject to clause&nbsp;47.4, a vote which the chairperson does not disallow under an objection is valid for all purposes.
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">47.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A vote which the ASX Listing Rules require the Company to disregard is not valid. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">48.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Votes by proxy </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">48.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Member who is entitled to vote at a general meeting of the Company may appoint not more than two proxies to
attend and vote at the general meeting on that Member&#146;s behalf. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">48.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A proxy need not be a Member. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">48.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If a Member appoints one proxy, that proxy may, subject to the Corporations Act, vote on a show of hands.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">48.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If a Member appoints two proxies and the appointment does not specify the proportion or number of the
Member&#146;s votes each proxy may exercise, each proxy may exercise half the votes. However, neither proxy may vote on a show of hands. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">48.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A proxy may demand or join in demanding a poll. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">48.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A proxy may vote or abstain as he or she chooses except where the appointment of the proxy directs the way the
proxy is to vote on a particular resolution. If an appointment directs the way the proxy is to vote on a particular resolution: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the proxy need not vote on a show of hands, but if the proxy does so, the proxy must vote that way;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the proxy has two or more appointments that specify different ways to vote on the resolution&#151;the proxy
must not vote on a show of hands; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the proxy is the chair&#151;the proxy must vote on a poll and must vote that way; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the proxy is not the chair&#151;the proxy need not vote on a poll, but if the proxy does so, the proxy must
vote that way. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">48.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a Member nominates the chairperson of the meeting as the Member&#146;s proxy; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH
30-5499810</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Constitution | page
26</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the chairperson is to act as proxy under clause 50 or otherwise under a default appointment according to the
terms of the proxy form, </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">then the person acting as chairperson in respect of an item of business at the meeting must act
as proxy under the appointment in respect of that item of business. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">49.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Document appointing proxy </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">49.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An appointment of a proxy is valid if it is signed by the Member making the appointment and contains the
information required by subsection 250A(1) of the Corporations Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">49.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purposes of clause 49.1, an appointment received at an electronic address will be taken to be signed by
the Member if: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a personal identification code allocated by the Company to the Member has been input into the appointment; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the appointment has been verified in another manner approved by the Directors. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">49.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company may send a proxy appointment form to Members in a form which has been approved by the Directors or
by the chairperson and the Managing Director. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">49.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A proxy&#146;s appointment is valid at an adjourned general meeting. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">49.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A proxy or attorney may be appointed for all meetings or for any number of general meetings or for a particular
purpose. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">49.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless otherwise provided for in the proxy&#146;s appointment or in any instrument appointing an attorney, the
appointment of the proxy or the attorney will be taken to confer authority: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to vote on: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any amendment moved to the proposed resolutions and on any motion that the proposed resolutions not be put or
any similar motion; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any procedural motion, including any motion to elect the chairperson, to vacate the chair or to adjourn the
general meeting, </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">even though the appointment may specify the way the proxy or attorney is to vote on a particular
resolution; and </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to vote on any motion before the general meeting whether or not the motion is referred to in the appointment.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">50.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Proxy in blank </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If a proxy appointment is signed by the Member but does not name the proxy or proxies in whose favour it is given, the chairperson may either
act as proxy or complete the proxy appointment by inserting the name or names of one or more Directors or the Secretary. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">51.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lodgment of proxy </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">51.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to clause 51.3, the appointment of a proxy or attorney must be received by the Company, at least 48
hours (unless reduced in the notice of meeting to which the appointment relates) before the general meeting (or the resumption of an adjourned general meeting) at which the appointee is to attend and vote. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH
30-5499810</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Constitution | page
27</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">51.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the appointment purports to be executed under a power of attorney or other authority, the original document
or a certified copy of it must be received by the Company at least 48 hours (unless reduced in the notice of meeting to which the appointment relates) before the general meeting (or the resumption of an adjourned general meeting).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">51.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company receives an appointment of a proxy or attorney or other authority under which it was signed when
they are received at: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company&#146;s registered office; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a facsimile number at the Company&#146;s registered office; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a place, facsimile number or electronic address specified for that purpose in the notice of general meeting.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">52.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Validity </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">A vote cast in accordance with an appointment of proxy or power of attorney is valid even if before the vote was cast the appointor: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">died; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">became mentally incapacitated; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">revoked the proxy or power; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transferred the Shares in respect of which the vote was cast, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">unless the Company received written notification of the death, mental incapacity, revocation or transfer before the relevant general meeting or
adjourned general meeting. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">53.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Representatives of bodies corporate </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">53.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any Member that is a body corporate may appoint an individual as its representative as provided by the
Corporations Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">53.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The appointment of a Representative may set out restrictions on the Representative&#146;s powers.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">53.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The original form of appointment of a Representative, a certified copy of the appointment, or a certificate of
the body corporate evidencing the appointment of a Representative is prima facie evidence of a Representative having been appointed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">53.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The chairperson of a general meeting may permit a person claiming to be a Representative to exercise the
body&#146;s powers even if he or she has not produced a certificate or other satisfactory evidence of his or her appointment. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Appointment and removal of Directors </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">54.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Number of Directors </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">54.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the Corporations Act, the Company may by resolution passed at a general meeting increase the minimum
number of Directors or increase or reduce the maximum number of Directors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">54.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Until the Company resolves otherwise in accordance with clause 54.1 there will be: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a minimum of three Directors; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH
30-5499810</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Constitution | page
28</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a maximum of 10 Directors. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">54.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to any resolution of the Members determining the maximum and minimum numbers of Directors, the
Directors may from time to time determine the respective numbers of Executive and <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">54.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors and Secretary in office on the date this Constitution becomes effective, continue in office
subject to this Constitution. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">55.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Qualification </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">55.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Neither a Director nor an Alternate Director has to hold any Shares. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">55.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In addition to the circumstances which disqualify a person from managing a corporation according to the
Corporations Act, no person who has been an insolvent under administration within the previous five years is eligible to become a Director. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">55.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Director (and an Alternate Director when acting as a Director) is entitled to notice of all general meetings
and meetings of the holders of any class of Shares. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">56.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Power to remove and appoint </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">56.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company may, subject to the Corporations Act, by resolution passed in general meeting:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">remove any Director before the end of the Director&#146;s term of office; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the outgoing Director is a <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director, elect another
person to replace the Director. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">56.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A person appointed under clause 56.1 will hold office for the remainder of the term for which the Director
replaced would have held office if the Director had not been removed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">56.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the provisions of this Constitution, the Company may appoint a person as a Director by resolution
passed in general meeting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">56.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Director appointed or elected at a general meeting is taken to have been appointed or elected with effect
from immediately after the end of that general meeting unless the resolution by which the Director was appointed or elected specifies a different time. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">56.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the conduct or position of any Director is such that continuance in office appears to the majority of the
Directors to be prejudicial to the interests of the Company, a majority of Directors at a meeting of the Directors specifically called for that purpose may suspend that Director. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">56.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A suspended Director may not take any part in the business or affairs of the Company until the suspension has
been terminated. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">56.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Within 14 days of suspension of Director, the Directors must call a general meeting, at which the Members may
consider a motion to remove the Director from office in accordance with clause 56.1(a). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">56.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If a motion to remove a suspended Director from office is not carried at the general meeting called to consider
the matter, the suspension of the Director is terminated and the Director is reinstated in his or her office. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH
30-5499810</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Constitution | page
29</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">57.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Additional and casual Directors </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">57.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to clause 54, only the Directors may appoint any person as a Director to fill a casual vacancy or as an
addition to the existing Directors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">57.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless the Director is an Executive Director and the ASX Listing Rules do not require that Director to be
subject to retirement as set out in this clause, a Director appointed under clause 57.1 will hold office until the end of the next annual general meeting of the Company, at which the Director may be <FONT STYLE="white-space:nowrap">re-elected</FONT>
but he or she will not be taken into account in determining the number of Directors who must retire by rotation at the meeting in accordance with clause&nbsp;58.1. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">58.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Retirement by rotation </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">58.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At the close of each annual general meeting <FONT STYLE="white-space:nowrap">one-third</FONT> of the Directors
or, if their number is not a multiple of three, then the number nearest to but not more than <FONT STYLE="white-space:nowrap">one-third</FONT> of the Directors, must retire. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">58.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors to retire by rotation at an annual general meeting are those Directors who have been longest in
office since their last election. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">58.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Directors elected on the same day may agree among themselves or determine by lot which of them must retire.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">58.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to clause 75.8, a Director must retire from office at the conclusion of the third annual general
meeting after the Director was last elected, even if his or her retirement results in more than <FONT STYLE="white-space:nowrap">one-third</FONT> of all Directors retiring from office. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">58.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A retiring Director remains in office until the end of the meeting and will be eligible for <FONT
STYLE="white-space:nowrap">re-election</FONT> at the meeting. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">59.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Nomination of Director </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">59.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A person, other than a Director retiring under clause 57.2 or under clause 58.1 who seeks <FONT
STYLE="white-space:nowrap">re-election,</FONT> is not eligible for election as a Director at a general meeting unless: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the person is proposed as a candidate by at least 50 Members or Members holding between them at least 5% of the
votes that may be cast at a general meeting of the Company; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the proposing Member leaves a notice at the Company&#146;s registered office which nominates the candidate for
the office of Director and includes the signed consent of the candidate. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">59.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A notice given in accordance with clause 59.1 must be left at the Company&#146;s registered office not less
than 35 Business Days before the relevant general meeting. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">60.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Vacation of office </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The office of a Director immediately becomes vacant if the Director: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ceases to be a Director by virtue of the Corporations Act; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is prohibited by the Corporations Act from holding office or continuing as a Director; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is liable to pay a call but does not pay the call within 21days after the date on which it is payable;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH
30-5499810</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Constitution | page
30</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is prohibited from holding or is removed from the office of Director by an order made under the Corporations
Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">becomes bankrupt or makes any general arrangement or composition with his or her creditors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cannot fully participate in the management of the Company because of his or her mental incapacity or is a
person whose estate is liable to have a person appointed, under the law relating to the administration of estates of persons who through mental or physical infirmity are incapable of managing their affairs, to administer it, or becomes in the
opinion of the Directors incapable of performing his or her duties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">resigns from his or her office of Director by notice in writing to the Company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is removed by a resolution of the Company; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is resident in Australia and not being engaged abroad on the business of the Company, is absent from
Directors&#146; meetings for three consecutive months without leave of absence from the Directors. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Remuneration of Directors
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">61.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Remuneration of <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">61.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the ASX Listing Rules, the Directors as a whole (other than Executive Directors) may be paid or
provided remuneration for their services the total amount or value of which must not exceed an aggregate maximum of $500,000 per annum or such other maximum amount determined from time to time by the Company in general meeting.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">61.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The notice calling a general meeting at which it is proposed that Members approve an increase of the aggregate
maximum sum must state the amount of the increase and the aggregate maximum sum, and any other matters required by the ASX Listing Rules. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">61.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the ASX Listing Rules, the aggregate maximum sum will be divided among the <FONT
STYLE="white-space:nowrap">Non-Executive</FONT> Directors in such proportion and manner as the Directors agree and, in default of agreement, equally and shall be deemed to accrue from day to day. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">61.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors may not be paid a commission on or a percentage
of profits or operating revenue. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">61.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If a <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director is required to perform services for the
Company which in the opinion of the Directors, are outside the scope of the ordinary duties of a Director, the Company may pay or provide the Director remuneration determined by the Directors which may be either in addition to or instead of the
Director&#146;s remuneration under clause 61.1. No remuneration may be paid or provided under this clause 61.5 if the effect would be to exceed the aggregate maximum sum of Directors&#146; remuneration determined by the Company in general meeting.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">61.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors may also be paid all travelling, hotel and
other expenses properly incurred by them in attending and returning from meetings of the Directors or any committee of the Directors or general meetings of the Company or otherwise in connection with the Company&#146;s business.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">61.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company may also pay a premium for a contract insuring a person who is or has been a <FONT
STYLE="white-space:nowrap">Non-Executive</FONT> Director against liability incurred by the person as a Director, except in circumstances prohibited by the Corporations Act. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH
30-5499810</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Constitution | page
31</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">61.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shares and/or Options may be provided to <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors as
part of or in lieu of their remuneration under clauses 61.3 and 61.4 according to the rules of any share/option plan for the remuneration of <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors that may be introduced by the Company. For
the purposes of clause&nbsp;61.1, the value of any Shares or Options provided will be determined according to the rules of the share/option plan. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">62.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Remuneration of Executive Directors </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">62.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The remuneration of an Executive Director may from time to time be fixed by the Directors. The remuneration may
be by way of salary or commission or participation in profits or by all or any of these modes but may not be by commission on, or a percentage of, operating revenue. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">62.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company may reimburse an Executive Director for his or her expenses properly incurred as a Director or in
the course of his or her office. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">62.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except in circumstances prohibited by the Corporations Act, the Company may pay a premium for a contract
insuring a person who is or has been an Executive Director against liability incurred by the person as a Director. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">63.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Retirement benefits </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Subject to the Corporations Act<I>,</I> the Company may give a person a benefit in connection with a Director&#146;s retirement from a Board or
managerial office in the Company. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Powers and duties of Directors </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">64.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Directors to manage Company </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">64.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The business of the Company is managed by or under the direction of the Directors who may exercise all powers
of the Company that this Constitution, the Corporations Act or the ASX Listing Rules do not require to be exercised by the Company in general meeting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">64.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Without limiting the generality of clause 64.1, the Directors may exercise all the powers of the Company to:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">borrow money; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">charge any property or business of the Company or all or any of its uncalled capital; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">issue debentures or give any other security for a debt, liability or obligation of the Company or of any other
person; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">guarantee or to become liable for the payment of money or the performance of any obligation by or of any other
person. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Proceedings of Directors </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">65.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Directors&#146; meetings </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">65.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any Director may call a meeting of the Directors. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH
30-5499810</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Constitution | page
32</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">65.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Directors&#146; meeting must be called by not less than 48 hours notice of a meeting to each Director, unless
the Directors unanimously agree otherwise. The notice may be in writing or given using any technology consented to by all the Directors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">65.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An accidental omission to send a notice of a meeting of Directors to any Director or the <FONT
STYLE="white-space:nowrap">non-receipt</FONT> of such a notice by any Director does not invalidate the proceedings, or any resolution passed, at the meeting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">65.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the Corporations Act, a Directors&#146; meeting may be held by the Directors communicating with each
other by any technological means consented to by all the Directors. The consent may be a standing one. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">65.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors need not all be physically present in the same place for a Directors&#146; meeting to be held.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">65.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Director who participates in a meeting held in accordance with clause 65.4 is taken to be present and
entitled to vote at the meeting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">65.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Director can only withdraw his or her consent under clause 65.4 to the means of communication between
Directors proposed for a Directors&#146; meeting if the Director does so at least 48 hours before the meeting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">65.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Clause 65.4 applies to meetings of Directors&#146; committees as if all committee members were Directors.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">65.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors may meet together, adjourn and regulate their meetings as they think fit. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">65.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A quorum for meetings of Directors may be fixed by the Directors and unless so fixed, is three Directors
present. The quorum must be present at all times during the meeting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">65.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Where a quorum cannot be established for the consideration of a particular matter at a meeting of Directors,
one or more of the Directors may call a general meeting of Members to deal with the matter. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">66.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Decisions </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">66.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Questions arising at a meeting of Directors are to be decided by a majority of votes of the Directors present
and voting and, subject to the Corporations Act, each Director has one vote. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">66.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the case of an equality of votes, the chairperson does not have a second or casting vote in addition to his
or her deliberative vote. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">66.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An Alternate Director has one vote for each Director for whom he or she is an alternate. If an Alternate
Director is a Director, he or she also has a vote as a Director. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">67.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Directors&#146; interests </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">67.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As required by the Corporations Act, a Director must give the Directors notice of any material personal
interest in a matter that relates to the affairs of the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">67.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the provisions of this clause 67, a Director or a body or entity in which a Director has a direct or
indirect interest may: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">enter into any agreement or arrangement with the Company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">hold any office or place of profit other than as auditor in the Company; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">act in a professional capacity other than as auditor for the Company, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH
30-5499810</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Constitution | page
33</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">and the Director or the body or entity can receive and keep beneficially any remuneration,
profits or benefits under any agreement or arrangement with the Company or from holding an office or place of profit in or acting in a professional capacity with the Company. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">67.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The fact that a Director holds office as a director, and has fiduciary obligations arising out of that office:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">will not void or render voidable a contract made by a Director with the Company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">will not void or render voidable a contract or arrangement entered into by or on behalf of the Company and in
which the Director may have any interest; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">will not require the Director to account to the Company for any profit realised by or under any contract or
arrangement entered into by or on behalf of the Company and in which the Director may have any interest. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">67.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Director may be or become a director or other officer of, or otherwise be interested in:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any related body corporate of the company; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other body corporate promoted by the Company or in which the Company may be interested as a vendor,
shareholder or otherwise, </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">and is not accountable to the Company for any remuneration or other benefits received by the
Director as a director or officer of, or from having an interest in, that body corporate. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">67.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Director who has a material personal interest in a matter that is being considered at a Directors&#146;
meeting must not: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">be present while the matter is being considered at the meeting; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">vote on the matter, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">unless permitted to do so by the Corporations Act, in which case the Director may: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">be counted in determining whether or not a quorum is present at any meeting of Directors considering that
contract or arrangement or proposed contract or arrangement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">sign or countersign any document relating to that contract or arrangement or proposed contract or arrangement;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">vote in respect of, or in respect of any matter arising out of, the contract or arrangement or proposed
contract or arrangement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">67.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Director must give to the Company such information about the Shares or other securities in the Company in
which the Director has a relevant interest and at the times that the Secretary requires, to enable the Company to comply with any disclosure obligations it has under the Corporations Act<I> </I>or the ASX Listing Rules. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">68.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Alternate Directors </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">68.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Director may, with the approval of the Directors, appoint any person as his or her alternate.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">68.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An Alternate Director is entitled to notice of Directors&#146; meetings while he or she is acting in that
capacity and, if the appointor is not present at a meeting, is entitled to attend, be counted in a quorum and vote as a Director. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">68.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An Alternate Director is an officer of the Company and is not an agent of the appointor. </P></TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH
30-5499810</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Constitution | page
34</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">68.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The provisions of this Constitution which apply to Directors also apply to Alternate Directors, except that
Alternate Directors are not entitled in that capacity to any remuneration from the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">68.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The appointment of an Alternate Director may be revoked at any time by the appointor or by the other Directors.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">68.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An Alternate Director&#146;s appointment ends automatically when his or her appointor ceases to be a Director.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">68.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any appointment or revocation under this clause must be effected by written notice delivered to the Secretary.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">68.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An Alternate Director does not have an interest in a contract or arrangement or a material personal interest in
a matter by reason only of the fact that his or her appointor has such an interest. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">69.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Remaining Directors </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">69.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors may act even if there are vacancies on the board. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">69.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the number of Directors is not sufficient to constitute a quorum at a Directors&#146; meeting, the Director
or Directors may act only to: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">appoint a Director or Directors; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">call a general meeting. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">70.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Chairperson </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">70.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors may elect a Director as chairperson of Directors&#146; meetings and may determine the period for
which the chairperson will hold office. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">70.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If no chairperson is elected or if the chairperson is not present at any Directors&#146; meeting within 10
minutes after the time appointed for the meeting to begin, the Directors present must elect a Director to be chairperson of the meeting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">70.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors may elect a Director as deputy chairperson to act as chairperson in the chairperson&#146;s
absence. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">71.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Delegation </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">71.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors may delegate any of their powers, other than those which by law must be dealt with by the
Directors as a board, to a committee or committees. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">71.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors may at any time revoke any delegation of power under clause 71.1. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">71.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At least one member of each committee of Directors must be a Director. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">71.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A committee may be authorised by the Directors to <FONT STYLE="white-space:nowrap">sub-delegate</FONT> all or
any of the powers for the time being vested in it. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">71.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Meetings of any committee of Directors will be governed by the provisions of this Constitution which deal with
Directors&#146; meetings so far as they are applicable and are not inconsistent with any directions of the Directors, except that a quorum for committee meetings is two committee members. The provisions apply as if each member was a Director.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH
30-5499810</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Constitution | page
35</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">72.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written resolutions </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">72.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If all the Directors who are eligible to vote on a resolution have signed a document containing a statement
that they are in favour of a resolution set out in the document, then a resolution in those terms is taken to have been passed by the Directors without a meeting. The resolution is passed when the last Director signs. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">72.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purposes of clause 72.1, separate copies of a document may be used for signing by the Directors if the
wording of the resolution and statement is identical in each copy. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">72.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any document referred to in this clause may be in the form of a facsimile transmission or electronic
notification. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">72.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If a resolution is taken to have been passed in accordance with this clause 72, the minutes must record that
fact. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">72.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This clause 72 applies to meetings of Directors&#146; committees as if all members of the committee were
Directors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">72.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any document referred to in this clause 72 must be sent to every Director who is entitled to vote on the
resolution. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">73.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Validity of acts of Directors </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">73.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An act done by a Director is effective even if their appointment, or the continuance of their appointment, is
invalid because the Company or Director did not comply with this Constitution or any provision of the Corporations Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">73.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Clause 73.1 does not deal with the question whether an effective act by a director: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">binds the company in its dealings with other people; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">makes the company liable to another person. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">74.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Minutes </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">74.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors must cause minutes to be made of: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the names of the Directors present at all Directors&#146; meetings and meetings of Directors&#146; committees;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all proceedings and resolutions of general meetings, Directors&#146; meetings and meetings of Directors&#146;
committees; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all resolutions passed in accordance with clause 72; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">appointments of officers, but only if the Directors resolve that a minute of the appointment should be made;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all disclosures of interests made in accordance with the Corporations Act. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">74.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Minutes must be signed by the chairperson of the meeting or by the chairperson of the next meeting, and if so
signed will be conclusive evidence of the matters stated in such minutes. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH
30-5499810</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Constitution | page
36</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Directors </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">75.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Appointment </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">75.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors may appoint a Director to the office of Managing Director on such terms as they think fit.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">75.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors may appoint a Director to any other full-time or substantially full-time executive position in
the Company on such terms as they think fit. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">75.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Director appointed under clauses 75.1 or 75.2, and a Director (however appointed) occupying for the time
being a full-time or substantially full-time executive position in the Company or a related body corporate of the Company, is referred to in this Constitution as an Executive Director. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">75.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors may, subject to the terms of the Executive Director&#146;s employment contract, suspend, remove
or dismiss him or her from executive office and appoint another Director in that place. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">75.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If an Executive Director ceases to be a Director, his or her appointment as an Executive Director terminates
automatically. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">75.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If an Executive Director ceases to hold an executive office in the Company, then, unless the Directors resolve
otherwise, he or she also ceases to be a Director from the same date. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">75.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If an Executive Director is suspended from executive office of the Company or of a related body corporate of
the Company, his or her duties and obligations as Director are suspended for the same period. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">75.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Managing Director is not subject to retirement by rotation and is not to be taken into account in determining
the rotation of retirement of Directors. Any other Executive Directors are subject to retirement by rotation. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">76.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Powers of Executive Directors </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">76.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors may confer on an Executive Director any powers exercisable by the Directors, subject to any terms
and restrictions determined by the Directors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">76.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors may authorise an Executive Director to <FONT STYLE="white-space:nowrap">sub-delegate</FONT> all
or any of the powers vested in him or her. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">76.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any power conferred under this clause may be concurrent with but not to the exclusion of the Directors&#146;
powers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">76.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors may at any time withdraw or vary any of the powers conferred on an Executive Director.
</P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Local management </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">77.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">General </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">77.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors may provide for the management and transaction of the affairs of the Company in any place and in
such manner as they think fit. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH
30-5499810</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Constitution | page
37</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">77.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Without limiting clause 77.1, the Directors may: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">establish local boards or agencies for managing any of the affairs of the Company in a specified place and
appoint any persons to be members of those local boards or agencies; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">delegate to any person appointed under clause 77.2(a) any of the powers, authorities and discretions which may
be exercised by the Directors under this Constitution, </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">on any terms and subject to any conditions determined by the
Directors. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">77.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors may at any time revoke or vary any delegation under this clause 77. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">78.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Appointment of attorneys and agents </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">78.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors may from time to time by resolution or power of attorney appoint any person to be the attorney or
agent of the Company: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for the purposes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">with the powers, authorities and discretions (not exceeding those exercisable by the Directors under this
Constitution); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for the period; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">subject to the conditions, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">determined by the Directors. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">78.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An appointment by the Directors of an attorney or agent of the Company may be made in favour of:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any member of any local board established under this Constitution; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the members, directors, nominees or managers of any company or firm; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any fluctuating body of persons whether nominated directly or indirectly by the Directors.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">78.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A power of attorney may contain such provisions for the protection and convenience of persons dealing with an
attorney as the Directors think fit. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">78.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An attorney or agent appointed under this clause 78 may be authorised by the Directors to <FONT
STYLE="white-space:nowrap">sub-delegate</FONT> all or any of the powers authorities and discretions for the time being vested in it. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Secretary </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">79.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Secretary </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">79.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">There must be at least one Secretary of the Company appointed by the Directors on conditions determined by
them. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">79.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Secretary is entitled to attend all Directors&#146; and general meetings. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">79.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors may, subject to the terms of the Secretary&#146;s employment contract, suspend, remove or dismiss
the Secretary. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH
30-5499810</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Constitution | page
38</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Seals </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">80.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Common Seal </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If the Company has a Seal: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Directors must provide for the safe custody of the Seal; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">it must not be used except with the authority of the Directors or a Directors&#146; committee authorised to
permit use of the Seal; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">every document to which the Seal is affixed must be signed by a Director and be countersigned by another
Director, the Secretary or another person appointed by the Directors to countersign the document; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Directors may determine by resolution either generally or in any particular case that the signature of any
Director or the Secretary to a document to which the Seal or a duplicate seal or certificate seal is affixed may be a facsimile applied to the document by specified mechanical means. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">81.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Duplicate Seal </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If the Company has a Seal, the Company may have one or more duplicate seals of the Seal each of which: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">must be a facsimile of the Seal with the addition on its face of the words <B>Duplicate Seal</B>; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">must only be used with the authority of the Directors or a Directors&#146; committee. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">82.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Share Seal </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If the Company has a Seal, the Company may have a certificate seal which: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">may be affixed to Share, option or other certificates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">must be a facsimile of the Seal with the addition on its face of the words <B>Share Seal</B>; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">must only be used with the general or specific authority of the Directors or a Directors&#146; committee.
</P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Inspection of records </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">83.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Times for inspection </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">83.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as otherwise required by the Corporations Act, the Directors may determine whether and to what extent,
and at what times and places and under what conditions, the financial records and other documents of the Company or any of them will be open for inspection by Members other than Directors. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">83.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Member other than a Director does not have the right to inspect any financial records or other documents of
the Company unless the Member is authorised to do so by a court order or a resolution of the Directors. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH
30-5499810</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Constitution | page
39</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">83.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding clauses 83.1 and 83.2, the books of the Company containing the minutes of general meetings will
be kept at the Company&#146;s registered office and will be open to inspection of Members at all times when the office is required to be open to the public. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividends and reserves </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">84.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dividends </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Directors may by resolution either: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">declare a dividend and may fix the amount, the time for and method of payment; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">determine a dividend is payable and fix the amount and the time for and method of payment.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">85.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amend resolution to pay dividend </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If the Directors determine that a dividend is payable under clause&nbsp;84(b), they may, if permitted by the ASX Listing Rules, amend or revoke
the resolution to pay the dividend before the record date notified to ASX for determining entitlements to that dividend. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">86.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No interest </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Interest is not payable by the Company on a dividend. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">87.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reserves </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">87.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors may set aside out of profits such amounts by way of reserves as they think appropriate before
declaring a dividend or determining to pay a dividend. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">87.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors may apply the reserves for any purpose for which profits may be properly applied.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">87.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pending any application of the reserves, the Directors may invest or use the reserves in the business of the
Company or in other investments as they think fit. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">87.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors may carry forward any undistributed profits without transferring them to a reserve.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">88.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dividend entitlement </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">88.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the rights of persons (if any) entitled to Shares with special rights as to dividends:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all fully paid Shares on which any dividend is declared or paid, are entitled to participate in that dividend
equally; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">each partly paid Shares is entitled to a fraction of the dividend declared or paid on a fully paid Share of the
same class, equivalent to the proportion which the amount paid (not credited) on the Share bears to the total amounts paid and payable, whether or not called, (excluding amounts credited) on the Share. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">88.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An amount paid on a Share in advance of a call is not to be taken as paid for the purposes of clause 88.1.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">88.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless otherwise determined by the Directors, Shares rank for dividends from their date of allotment.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH
30-5499810</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Constitution | page
40</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">88.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the Corporations Act and the CS Facility Rules, a transfer of Shares registered after the record
date notified to ASX for determining entitlements to a dividend paid or payable in respect of the transferred Shares, does not pass the right to that dividend. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">89.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Restricted securities </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">During a breach of the ASX Listing Rules relating to Shares which are Restricted Securities, or a breach of a restriction agreement, the holder
of the relevant Restricted Securities is not entitled to any dividend in respect of those Restricted Securities. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">90.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Deductions from dividends </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Directors may deduct from a dividend payable to a Member all sums presently payable by the Member to the Company on account of calls or
otherwise in relation to Shares in the Company. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">91.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Distribution of assets </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">91.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors may resolve that a dividend (interim or final) will be paid wholly or partly by the transfer or
distribution of specific assets, including fully paid shares in, or debentures of, any other corporation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">91.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If a difficulty arises in making a transfer or distribution of specific assets, the Directors may:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">deal with the difficulty as they consider expedient; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">fix the value of all or any part of the specific assets for the purposes of the distribution;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">determine that cash will be paid to any Members on the basis of the fixed value in order to adjust the rights
of all the Members; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">vest any such specific assets in trustees as the Directors consider expedient. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">91.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If a transfer or distribution of specific assets to a particular Member or Members is illegal or, in the
Directors&#146; opinion, impracticable, the Directors may make a cash payment to the Member or Members on the basis of the cash amount of the dividend instead of the transfer or distribution of specific assets. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">92.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Payment </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">92.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any dividend or other money payable in respect of Shares may be paid: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by cheque sent through the mail directed to: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by the address of the Member shown in the Register or to the address of the joint holder of Shares shown first
in the Register; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by an address which the Member has, or joint holders have, in writing notified the Company as the address to
which dividends should be sent; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by electronic funds transfer to an account with a bank or other financial institution nominated by the Member
and acceptable to the Company; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by any other means determined by the Directors. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">92.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any joint holder may give an effectual receipt for any dividend or other money paid in respect of Shares held
by holders jointly. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH
30-5499810</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Constitution | page
41</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">93.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Election to reinvest dividend </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Directors may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">establish a plan under which Members or any class of Members may elect to reinvest cash dividends paid by the
Company by subscribing for Shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">vary, suspend or terminate the arrangements established under clause 93(a). </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">94.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Election to accept Shares in lieu of dividend </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">94.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors may resolve, in respect of any dividend which it is proposed to pay on any Shares, that holders
of those Shares may elect to: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">forego their right to share in the proposed dividend or part of the proposed dividend; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">instead receive an issue of Shares credited as fully paid. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">94.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Directors resolve to allow the election provided for in clause 94.1, each holder of Shares conferring a
right to share in the proposed dividend may, by notice in writing to the Company given in such form and within such period as the Directors may decide, elect to: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">forego the dividend which otherwise would have been paid to the holder on such of the holder&#146;s Shares
conferring a right to share in the proposed dividend as the holder specifies in the notice of election; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">receive instead Shares to be issued to the holder credited as fully paid, on and subject to such terms and
conditions as the Directors may determine. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">94.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Following the receipt of duly completed notices of election under clause 94.1(b), the Directors must:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">appropriate from the Company&#146;s profits or any reserve available for distribution to Members an amount
equal to the aggregate issue price (if any) of the Shares to be issued credited as fully paid to those holders of Shares who have given such notices of election; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">apply the amount (if any) in paying up in full the number of Shares required to be so issued.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">94.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors may rescind, vary or suspend a resolution of the Directors made under clause 94.1 and the
arrangements implemented under the resolution. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">94.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The powers given to the Directors by this clause 94 are additional to the provisions for capitalisation of
profits provided for by this Constitution. If the Directors exercise their power to capitalise profits under clause 96 then any Member who has elected to participate in arrangements established under this clause 94 is deemed, for the purpose of
determining the Member&#146;s entitlement to share in the capitalised sum, not to have so elected. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">95.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unclaimed dividends </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">All dividends unclaimed for one year after the time for payment has passed may be invested by the Directors as they think fit for the benefit
of the Company until claimed or until required to be dealt with in accordance with any law relating to unclaimed money. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH
30-5499810</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Constitution | page
42</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">96.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Capitalisation of profits </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">96.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors may resolve: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to capitalise any sum being the Company&#146;s profits or any reserve available for distribution to Members;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">no Shares be issued and no amounts unpaid on Shares be paid up on capitalisation of the sum; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the sum be applied in any of the ways mentioned in clause 96.2 for the benefit of Members in the proportions in
which the members would have been entitled if the sum had been distributed by way of Dividend. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">96.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The ways in which a sum may be applied for the benefit of Members under clause 96.1(b)(ii) are:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in paying up any amounts unpaid on Shares held or to be held by Members; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in paying up in full unissued Shares or debentures to be issued to Members as fully paid; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">partly as mentioned in clause 96.2(a) and partly as mentioned in clause 96.2(b). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">96.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the extent necessary to adjust the rights of the Members among themselves, the Directors may:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">make cash payments in cases where Shares or debentures become issuable in fractions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">authorise any person to make, on behalf of all the Members entitled to a benefit on the capitalisation, an
agreement with the Company providing for: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the issue to them, credited as fully paid up, of any such further Shares or debentures; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the payment by the Company on their behalf of the amount or any part of the amount remaining unpaid on their
existing Shares by the application of their respective proportions of the sum resolved to be capitalised, </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">and any
agreement made under the authority of clause&nbsp;96.3(b) is effective and binding on all the Members concerned. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notices </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">97.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Service of notices </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">97.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notice may be given by the Company to any person who is entitled to notice under this Constitution by:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">serving it on the person; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">sending it by post, courier, facsimile transmission or electronic notification to the person at the
person&#146;s address shown in the Register or the address supplied by the person to the Company for sending notices to the person; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(except in the case of a notice of meeting of Members which is required to be given individually to each Member
entitled to vote at the meeting and to each Director), advertising in one or more newspapers published in the city of Melbourne as determined by the Directors. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH
30-5499810</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Constitution | page
43</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">97.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A notice sent by post or courier is taken to be served: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by properly addressing, prepaying and posting or directing the delivery of the notice; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on the day after the day on which it was posted or given to the courier for delivery. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">97.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A notice sent by facsimile transmission or electronic notification is taken to be served:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by properly addressing the facsimile transmission or electronic notification and transmitting it; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on the day of its transmission except if transmitted after 5.00pm in which case is taken to be served on the
next day. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">97.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A notice given by advertisement is taken to be served on the date on which the advertisement first appears in a
newspaper. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">97.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A notice may be served by the Company on joint holders under clause 97.1(a) or 97.1(b) by giving the notice to
the joint holder whose name appears first in the Register. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">97.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Every person who is entitled to a Share by operation of law and who is not registered as the holder of the
Share is taken to receive any notice served in accordance with this clause by advertisement or on that person from whom the first person derives title. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">97.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Share certificate, cheque, warrant or other document may be delivered by the Company either personally or by
sending it: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">(a) in the case of a Member whose address recorded in the Register is not in Australia, by airmail post,
facsimile transmission, electronic notification or in another way that ensures that it will be received quickly, as appropriate; and </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other case by ordinary post, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">and is at the risk of the addressee as soon as it is given or posted. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">A Member whose address recorded in the Register is not in Australia may specify in writing an address in Australia for the purposes of
clause&nbsp;97. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">97.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A certificate in writing signed by a Director, Secretary or other officer of the Company, or by any person that
the Company has engaged to maintain the Register, that a document or its envelope or wrapper was addressed and stamped and was posted or given to a courier is conclusive evidence of posting or delivery by courier. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">97.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the Corporations Act the signature to a written notice given by the Company may be written or
printed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">97.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All notices sent by post outside Australia must be sent by prepaid airmail post. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">97.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A notice sent by post, courier, facsimile transmission or electronic notification to a Member&#146;s address
shown in the Register or the address supplied by the Member to the Company for the purpose of sending notices to the Member is deemed to have been served notwithstanding that the Member has died, whether or not the Company has notice of his or her
death. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">98.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Persons entitled to notice </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">98.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notice of every general meeting must be given to: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">every Member; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH
30-5499810</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Constitution | page
44</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">every Director and Alternate Director; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ASX; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Auditor. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">98.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No other person is entitled to receive notice of a general meeting. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Audit and financial records </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">99.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Company to keep financial records </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">99.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors must cause the Company to keep written financial records and to prepare financial documents and
reports in accordance with the requirements of the Corporations Act and the ASX Listing Rules. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">99.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors must cause the financial records and financial documents of the Company to be audited in
accordance with the requirements of the Corporations Act and the ASX Listing Rules. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Winding up </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">100.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Winding up </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">100.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Nothing in this clause prejudices the rights of the holders of Shares issued on special terms and conditions.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">100.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Company is wound up, the liquidator may, with the sanction of a special resolution of the Company:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">divide among the Members in kind all or any of the Company&#146;s assets; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for that purpose, determine how he or she will carry out the division between the different classes of Members,
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">but may not require a Member to accept any Shares or other securities in respect of which there is any liability. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">100.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The liquidator may, with the sanction of a special resolution of the Company, vest all or any of the
Company&#146;s assets in a trustee on trusts determined by the liquidator for the benefit of the contributories. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnity </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">101.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indemnity </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">101.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the extent: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">permitted by law and subject to the restrictions in section 199A of the Corporations Act; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the officer is not otherwise indemnified by thee Company pursuant to an indemnity contemplated under
clause 101.6, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH
30-5499810</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Constitution | page
45</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">the Company indemnifies every person who is or has been an officer of the Company against
any Liability (other than for legal costs) incurred by that person as an officer of the Company or on behalf of or bona fide in the interests of the Company (including Liabilities incurred by the officer as an officer of a subsidiary of the Company
where the Company requested the officer to accept that appointment). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">101.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the extent: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">permitted by law and subject to the restrictions in section 199A of the Corporations Act; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the officer is not otherwise indemnified by the Company pursuant to an indemnity contemplated under clause
101.6, </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">the Company indemnifies every person who is or has been an officer of the Company against reasonable legal costs
incurred in respect of any Claim or Liability incurred or allegedly incurred by that person as an officer of the Company or on behalf of or bona fide in the interests of the Company (including such legal costs incurred by the officer as an officer
of a subsidiary of the Company where the Company requested the officer to accept that appointment). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">101.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amount of any indemnity payable under clauses&nbsp;101.1 or 101.2 will include an additional amount (<B>GST
Amount</B>) equal to any GST payable by the officer being indemnified (<B>Indemnified Officer</B>) in connection with the indemnity (less the amount of any input tax credit claimable by the Indemnified Officer in connection with the indemnity).
Payment of any indemnity which includes a GST Amount is conditional upon the Indemnified Officer providing the Company with a GST tax invoice for the GST Amount. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">101.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors may agree to advance to an officer an amount which it might otherwise be liable to pay to the
officer under this clause 101 on such terms as the Directors&#146; think fit but which are consistent with this clause, pending the outcome of any findings of a relevant court or tribunal which would have a bearing on whether the Company is in fact
liable to indemnify the officer under this clause 101. If after the Company makes the advance, the Directors form the view that the Company is not liable to indemnify the officer, the Company may recover any advance from the officer as a debt due by
the officer to the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">101.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purposes of this clause 101, <B>officer</B> has the same meaning as in section 9 of the Corporations
Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">101.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Nothing in this clause 101 precludes the Company from executing an indemnity in any form in favour of an
officer of the Company or effecting insurance on behalf of or in respect of an officer of the Company against any Claim or Liability incurred or allegedly incurred by the officer and referred to in clauses 101.1 or 101.2 of this Constitution.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">102.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shareholder disclosure </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If a Member has entered into any arrangement restricting the transfer or other disposal of Shares and those arrangements are of the nature of
arrangements which the Company is required to disclose under the ASX Listing Rules, then the Member must provide to the Company such information that the Company requires and within the time that the Company requires, to comply with the
Company&#146;s disclosure obligations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Minter Ellison | Ref: JDH
30-5499810</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_72010793_1 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Constitution | page
46</P></TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>filename4.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is both (i) not material and (ii) would likely cause
competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g945701g75p65.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>AND </B></P>
<P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:36pt; font-family:Times New Roman" ALIGN="center"><B>OPTHEA </B></P> <P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Commercial
License Agreement </B></P> <P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Date: October&nbsp;28, 2013 </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Selexis 2013 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Commercial License Agreement (this &#147;<B>Agreement</B>&#148;) is made effective on October&nbsp;28,
2013 (the &#147;<B>Effective Date</B>&#148;) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">by and between </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Selexis SA</U></B>, a company incorporated under the laws of Switzerland, with its registered office at [***], Geneva, Switzerland
(&#147;<B>SELEXIS</B>&#148;) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>OPTHEA PTY LTD</U></B>, a company incorporated under the laws of Australia, with its registered office at Level&nbsp;4, 650 Chapel Street, South Yarra,
Victoria 3141, Australia (&#147;<B>COMPANY</B>&#148;) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(SELEXIS and COMPANY, collectively the &#147;<B>PARTIES</B>&#148; and, individually, a
&#147;<B>PARTY</B>&#148;) </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preamble </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">W<SMALL>HEREAS</SMALL>, COMPANY is a biopharmaceutical company engaged in the research, development,
manufacturing and sale of biopharmaceutical products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">W<SMALL>HEREAS</SMALL>, SELEXIS is a biotechnology company engaged in the development and sale of recombinant
cell lines based on the SELEXIS Technology; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">W<SMALL>HEREAS</SMALL>, SELEXIS is the owner of certain Confidential Information, the SELEXIS <FONT
STYLE="white-space:nowrap">Know-How</FONT> and the SELEXIS Patent Rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">D.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">W<SMALL>HEREAS</SMALL>, pursuant to a services agreement between the PARTIES dated November&nbsp;26, 2012 (the
&#147;<B>Services Agreement</B>&#148;) SELEXIS has developed certain recombinant cell line(s) for COMPANY using the SELEXIS Technology and COMPANY has evaluated such cell Line(s); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">E.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">W<SMALL>HEREAS</SMALL>, SELEXIS is willing to grant COMPANY, and COMPANY is willing to receive from SELEXIS, a
license to the SELEXIS <FONT STYLE="white-space:nowrap">Know-How</FONT> and the SELEXIS Patent Rights with respect to the recombinant cell lines, on the terms and conditions set forth in this Agreement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">N<SMALL>OW</SMALL>, <SMALL>THEREFORE</SMALL>, the PARTIES agree as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Definitions </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the terms defined above, the following terms, whether used in the singular or plural, shall have the following meanings as used in this
Agreement, unless otherwise specifically indicated: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Affiliate</U></B>&#148; shall mean any Person that, as of the Effective Date, directly or
indirectly, controls, is controlled by, or is under common control with the relevant Person. For the purposes of this definition only, &#147;<B><U>control</U></B>&#148; shall mean the possession, directly or indirectly, of the power to cause the
direction of the management and policies of a Person, whether through ownership of voting securities of such Person, by contract or otherwise. A Person shall only be considered an Affiliate for so long as such Control exists. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>BLA</U></B>&#148; shall mean a Biologic License Application for the Final Product filed with the
FDA or any comparable filing made with a Regulatory Authority in another country. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Calendar Quarter</U></B>&#148; shall mean, for each Calendar Year, each of the three month periods
ending March&nbsp;31, June&nbsp;30, September&nbsp;30 and December&nbsp;31 respectively. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Calendar Year</U></B>&#148; shall mean the period commencing on January&nbsp;1 and ending twelve
(12)&nbsp;consecutive calendar months later on December 31. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Cell Line</U></B>&#148; shall mean a mammalian cell line that is developed using the SELEXIS
Technology. Cell Line shall include, without limitation, any COMPANY Cell Line(s). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Clinical Trials</U></B>&#148; shall mean human studies designed to measure the safety and/or
efficacy of the Product. Clinical Studies include Phase I Clinical Trials, Phase II Clinical Trials, and Phase III Clinical Trials. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Collaboration Partner</U></B>&#148; shall mean a Third Party with which COMPANY collaborates on the
development of the production process and/or commercialization of a Licensed Product or Final Product or to which COMPANY has granted a license for the development of the production process and/or commercialization of a Product.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Combination Product Adjustment</U></B>&#148; shall mean the adjustment of: Net Sales for any
combination product done by multiplying actual Net Sales of such combination product by the fraction A/(A + B) where [***], if sold separately, and [***], if sold separately. If, on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, the other active ingredient, device or component in the combination is not sold separately, Net Sales shall be calculated by multiplying actual
Net Sales of the combination product in such country by the fraction A/C where [***], if sold separately, in such country and [***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Commercial License</U></B>&#148; shall have the meaning set out in Article 2.1.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Commercial License Option</U></B>&#148; shall mean the option granted to Company in the Services
Agreement to obtain a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> commercial license. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>COMPANY Technology</U></B>&#148; shall mean any Technology owned or controlled by COMPANY,
including, without limitation, any such Technology related to Licensed or Final Product, but excluding any SELEXIS Technology related thereto. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>COMPANY Cell Line</U></B>&#148; shall mean the mammalian cell line developed by SELEXIS and
provided to COMPANY pursuant to the Services Agreement and any progeny or derivatives thereof. A Cell Line which has been [***] shall be described as such in this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Confidential Information</U></B>&#148; shall mean any technical and business information pertaining
to materials and production techniques, products, processes and services, including without limitation physical working models and samples of the products, research, development, patentable and unpatentable inventions, manufacturing, purchasing and
product development plans, forecasts, strategies and information, engineering, marketing, merchandising, selling, customer lists, customer prospects, software codes, algorithms, names and expertise of employees and consultants, blueprints, technical
information, trade secrets or <FONT STYLE="white-space:nowrap">know-how</FONT> or other related proprietary business information and data, in any case whether such information is provided in tangible or intangible form, written, oral, graphic,
pictorial or recorded form or stored on computer discs, hard drives, magnetic tape or digital or any other electronic medium. Confidential Information disclosed in any tangible format will be labeled &#147;Confidential&#148; or words to similar
effect, and all <FONT STYLE="white-space:nowrap">non-tangible</FONT> disclosures will be declared to be &#147;Confidential&#148; or words to similar effect at the time of disclosure. Confidential Information shall include any and all material and
data created by the receiving party based on, containing or otherwise reflecting Confidential Information. Confidential Information shall also include any such information or documents which may be disclosed hereunder which the disclosing party
received in confidence from a Third Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Contract Manufacturing Organization</U></B>&#148; shall mean an entity of which at least fifty
percent (50%) of the business is directed toward the provision of services or products for <FONT STYLE="white-space:nowrap">non-affiliate</FONT> third parties. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.15.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Contractor</U></B>&#148; shall mean a Third Party contractor who: (i)&nbsp;develops the production
process for Licensed Products or Final Products by or on behalf of COMPANY or (ii)&nbsp;manufactures and supplies Licensed Products or Final Products by using such production process by or on behalf of Company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.16.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Default</U></B>&#148; shall have the meaning set out in Article 9.2. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.17.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Defaulting Party</U></B>&#148; shall have the meaning set out in Article 9.2.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.18.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;</B><B><U>Deliverables</U></B><B>&#148;</B> shall mean the reports and other data delivered to COMPANY
pursuant to the Services Agreement, excluding the COMPANY Cell Line. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.19.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>FDA</U></B>&#148; shall mean the United States Food and Drug Administration, or any successor
agency. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.20.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;</B><B><U>Final Product</U></B>&#148; shall mean any pharmaceutical preparation in final form
containing any Licensed Products for sale by prescription, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> or any other method, in any dosage form, formulation, presentation, line extension or package
configurations, including without limitation such Product in development where the context so requires in this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.21.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>First Commercial Sale</U></B>&#148; shall mean, with respect to any Final Product in any country,
the first sale of such Final Product for use or consumption by the general public in such country after Regulatory Approval as well as Pricing and Reimbursement Approval for such Final Product has been obtained in such country. For the avoidance of
doubt, sales prior to receipt of all Regulatory Approvals and Pricing and Reimbursement Approvals necessary to commence regular commercial sales, such as <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;treatment IND sales&#148;, &#147;named
patient sales&#148; and &#147;compassionate use sales&#148;, shall not be construed as a First Commercial Sale. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.22.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Force Majeure</U></B>&#148; shall mean conditions beyond the control of a PARTY, including without
limitation, an act of God, war, civil commotion, terrorist act, labor strike or <FONT STYLE="white-space:nowrap">lock-out,</FONT> epidemic, failure or default of public utilities or common carriers, destruction of facilities or materials by fire,
earthquake, storm or the like catastrophe, and failure of plant or machinery (provided that such failure could not have been prevented by the exercise of skill, diligence and prudence that would be reasonably and ordinarily expected from a skilled
and experienced person engaged in the same type of undertaking under the same or similar circumstances). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.23.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>IND</U></B>&#148; shall mean an Investigational New Drug Application for the Product filed with the
FDA or any comparable filing made with a Regulatory Authority in another country. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.24.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Insolvent Party</U></B>&#148; shall have the meaning set out in Article 9.3. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.25.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Invention</U></B>&#148; shall mean any invention, idea, innovation, enhancement, improvement or
feature, whether or not patentable or registrable, together with any intellectual property rights relating thereto (including without limitation the Patent Rights and rights to confidentiality and proprietary information). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.26.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U><FONT STYLE="white-space:nowrap">Know-How</FONT></U></B>&#148; shall mean information in whatever
form, tangible or intangible and on whatever medium, including without limitation, information and materials relating to Inventions and other <FONT STYLE="white-space:nowrap">know-how,</FONT> trade secrets, data (including without limitation all
data from <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical studies and other studies intended for regulatory submission), results, formulae, DNA and amino acid sequence information and developments. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.27.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Licensed Field of Use</U></B>&#148; shall mean all uses of a Licensed and/or Final Product.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.28.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Licensed Product</U></B>&#148; shall mean the recombinant protein listed in Exhibit 2.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.29.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Losses</U></B>&#148; shall mean all and any liability, damage, loss or expense.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.30.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Net Sales</U></B>&#148; shall mean the amount collected by COMPANY, its Affiliates and/or its
sublicensees on account of sales of Final Product to Third Parties in the Territory, less the following deductions: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***]; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***]; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***]; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***]; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***]; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the event that a Final Product is sold in any country in the form of a combination product containing one or
more other therapeutically active ingredients, the Net Sales for any such Final Product shall be computed using the Combination Product Adjustment for such country. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.31.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U><FONT STYLE="white-space:nowrap">Non-Defaulting</FONT> Party</U></B>&#148; shall have the meaning
set out in Article 9.2. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.32.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Notice of Default</U></B>&#148; shall have the meaning set out in Article 9.2.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.33.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Patent Rights</U></B>&#148; shall mean any and all of the following: (i)&nbsp;patent applications
(including without limitation provisional patent applications) and patents (including without limitation the inventor&#146;s certificates); (ii) any substitution, extension (including without limitation patent term extensions and supplementary
protection certificates), registration, confirmation, reissue, continuation, divisional, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuation-in-part,</FONT></FONT> <FONT STYLE="white-space:nowrap">re-examination,</FONT>
renewal, patent of addition or the like thereof or thereto; (iii)&nbsp;any foreign counterparts of any of the foregoing; and (iv)&nbsp;any utility model applications and utility models (whether or not corresponding to any of the foregoing).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.34.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Person</U></B>&#148; shall mean an individual, a partnership, a joint venture, a corporation, a
limited liability company, a trust, an estate, an unincorporated organization, or any other entity, or a government or any department or agency thereof, whether acting in an individual, fiduciary or other capacity. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.35.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Phase I Clinical Trial</U></B>&#148; shall mean a Clinical Trial conducted in humans which is
principally intended to obtain data on the safety, tolerability, pharmacokinetic or pharmacodynamic properties of a product. Phase I shall be deemed to have commenced when the first patient in the study has been treated. Phase I shall be deemed to
have completed when the last patient has completed his or her treatment being investigated by that Clinical Trial as described in its protocol, the database is locked, and data from all patients, according to protocol, has been analyzed for the
primary endpoint. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">6 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.36.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Phase</U></B><U> </U><B><U>II</U></B><U> </U><B><U>Clinical</U></B><U>
</U><B><U>Trial</U></B>&#148; shall mean a Clinical Trial conducted in humans in which the primary objective is a preliminary determination of therapeutic efficiency and/or to find an optimal dose range in patients with the disease target being
studied. Phase II shall be deemed to have commenced when the first patient in the study has been treated. Phase II shall be deemed to have completed when the last patient has completed his or her treatment being investigated by that Clinical Trial
as described in its protocol, the database is locked, and data from all patients, according to protocol, has been analyzed for the primary endpoint. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.37.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Phase III Clinical Trial</U></B>&#148; shall mean a Clinical Trial conducted in humans in which the
primary objective is a determination of therapeutic efficiency in patients with the disease target being studied. Phase III shall be deemed to have commenced when the first patient in the study has been treated. Phase III shall be deemed to have
completed when the last patient has completed his or her treatment being investigated by that Clinical Trial as described in its protocol, the database is locked, and data from all patients, according to protocol, has been analyzed for the primary
endpoint. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.38.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Price and Reimbursement Approval</U></B>&#148; shall mean any approvals, licenses, registrations or
authorizations of any supranational, national, regional, state or local Regulatory Authority or other regulatory agency, department, bureau or governmental entity, necessary to determine or set the pricing of a Product, and/or its reimbursement
level by the relevant health authorities, providers or other funding institutions, at supranational, national, regional, state or local level. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.39.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Regulatory Approval</U></B>&#148; shall mean any approvals, licenses, registrations or
authorizations of any supranational, national, regional, state or local Regulatory Authority or other regulatory agency, department, bureau or governmental entity, necessary for the manufacture, marketing or sale of a Product or conduct of Clinical
Trials in a regulatory jurisdiction, excluding Price and Reimbursement Approval. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.40.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Regulatory Authority</U></B>&#148; shall mean (i)&nbsp;the FDA or (ii)&nbsp;any and all
governmental or supranational agencies, ministries, authorities or other bodies with similar regulatory authority with respect to approval or registration of pharmaceutical or biologic products in any other jurisdiction anywhere in the world.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.41.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Royalty Term</U></B>&#148; shall mean with respect to each Final Product sold in a particular
country, the period beginning on the date of the First Commercial Sale in such country and terminating on the expiration of the last-to-expire or lapse of any Valid Claims in such country covering the Licensed Product, the Final Product, the Company
Cell Line, or any other Cell Line used to produce Licensed Product, or the development, use, or manufacture of any of the foregoing. In no event shall the Royalty Term exceed the 22<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP> of October
2024. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.42.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>SELEXIS <FONT STYLE="white-space:nowrap">Know-How</FONT></U></B>&#148; shall mean SELEXIS&#146;
Confidential Information and <FONT STYLE="white-space:nowrap">Know-How</FONT> owned, controlled by SELEXIS, or to which SELEXIS has received a license which includes a right to grant sublicenses consistent with the Commercial License relating to,
without limitation, the construction and development of recombinant cell lines for the manufacture of biopharmaceutical products and existing as of the Effective Date or obtained thereafter during the Term. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.43.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>SELEXIS Materials</U></B>&#148; shall mean the materials provided by SELEXIS to COMPANY under this
Agreement and all modifications and improvements thereof made by SELEXIS during the Term, if any. SELEXIS Materials excludes the Cell Lines. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">7 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.44.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>SELEXIS Patent Rights</U></B>&#148; shall mean Patent Rights which: (i)&nbsp;are owned or
controlled by SELEXIS, or to which SELEXIS has received a license which includes a right to grant sublicenses consistent with the Commercial License (ii)&nbsp;are necessary or useful for the use of SELEXIS Materials or the construction, development
and use of Cell Lines and (iii)&nbsp;are existing as of the Effective Date or obtained thereafter during the Term. Without limiting the generality this Article, the SELEXIS Patent Rights as of the Effective Date are listed in Exhibit 1 hereto.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.45.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>SELEXIS Technology</U></B>&#148; shall mean the SELEXIS Patent Rights, the SELEXIS <FONT
STYLE="white-space:nowrap">Know-How</FONT> and the SELEXIS Materials. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.46.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Tax Authority</U></B>&#148; shall mean the relevant governing tax authority as defined in Article
4.2. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.47.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Taxes</U></B>&#148; shall mean all excises, taxes and duties with the exception of VAT.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.48.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Technology</U></B>&#148; shall mean all inventions (whether or not patentable or patented) and
intellectual property rights therein, including without limitation, patents, patent applications, <FONT STYLE="white-space:nowrap">know-how,</FONT> trade secrets, copyrights, trademarks, designs, concepts, registered and unregistered design rights,
data, work product, results, reports, improvements, business and research plans, analytic methods and results, experimental methods and results, manufacturing processes, developments, technologies, technical information, composites of genes and gene
constructs, cell lines, manuals, standard operating procedures, instructions and specifications. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.49.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Term</U></B>&#148; shall have the meaning set out in Article 9.1. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.50.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Territory</U></B>&#148; shall mean the entire world. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.51.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Third Party</U></B>&#148; shall mean a Person other than SELEXIS, COMPANY or an Affiliate of
SELEXIS or COMPANY. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.52.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Transferee</U></B>&#148; shall have the meaning set out in Article 2.3. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.53.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Valid Claim</U></B>&#148; shall mean any issued or granted claim of the SELEXIS Patent Rights that
has not been revoked or held unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, that is unappealable or remains unappealed at the end of the time allowed for appeal, or that has not been
disclaimed, denied or admitted to be invalid or unenforceable through reissue, <FONT STYLE="white-space:nowrap">re-examination,</FONT> disclaimer or otherwise. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.54.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>VAT</U></B>&#148; shall mean value added tax and any other similar turnover, sales or purchase, tax
or duty levied by any other jurisdiction whether central, regional or local. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">8 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Commercial Licenses </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Commercial Licenses</U>. Subject to COMPANY&#146;s compliance with the other terms and conditions of this
Agreement (including, without limitation, payment by COMPANY of the amounts provided for below in accordance with the payment schedule and terms provided for below), SELEXIS hereby grants to COMPANY a
<FONT STYLE="white-space:nowrap">non-exclusive</FONT> worldwide license under the SELEXIS Patent Rights and SELEXIS <FONT STYLE="white-space:nowrap">Know-How,</FONT> in the Territory, with the limited right to sublicense in accordance with Article
2.2, to use Cell Lines, Deliverables and SELEXIS Materials for the manufacture of Licensed and/or Final Products, and to make, have made, use, offer for sale, sell, import and otherwise exploit Licensed and/or Final Products in the Licensed Field of
Use, including, without limitation, the use of Licensed and/or Final Products in Clinical Trials (the &#147;<B>Commercial License</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Sublicenses</U>. Subject to the provisions of this Article 2.2, COMPANY shall be entitled to grant
sublicenses to the rights granted under the Commercial License to any one or more third parties (the &#147;<B>Sublicensees</B>&#148;) provided always: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.2.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any sublicense granted under this Agreement shall be expressly subject and subordinate to the terms of this
Agreement and it shall be COMPANY&#146;s responsibility to ensure strict adherence by any Sublicensee to the terms and conditions of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.2.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any Sublicensee shall not, by virtue of this Agreement, be granted any right or licence, either express or
implied, under any SELEXIS <FONT STYLE="white-space:nowrap">Know-how</FONT> and/or SELEXIS Patent Rights to use COMPANY Cell Lines, SELEXIS Materials and/or SELEXIS Patent Rights other than for the purposes of the manufacture, use, offer for sale,
sale, import and other exploitation of Licensed and/or Final Products in the Field. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.2.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">COMPANY will notify SELEXIS in writing of any such sublicense within [***] following the grant thereof, and
[***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.2.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding the above, COMPANY is and remains fully liable and responsible for any breach of this Agreement
committed or any Losses caused by any Sublicensee, or any other Third Party or Affiliate to whom the Cell Lines, Deliverables, SELEXIS Materials and the SELEXIS <FONT STYLE="white-space:nowrap">Know-How</FONT> or parts thereof are made available
under any such sublicense<U>.</U> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Transfer of SELEXIS Materials</U>. COMPANY shall not transfer the Cell Lines, Deliverables, SELEXIS
Materials or SELEXIS <FONT STYLE="white-space:nowrap">Know-How</FONT> to any Third Party, except that during and for the Term only, COMPANY may transfer Cell Lines, Deliverables, SELEXIS Materials and SELEXIS
<FONT STYLE="white-space:nowrap">Know-How</FONT> to Contractors or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">9 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Collaboration Partners (the &#147;Transferees&#148;) solely for their use in connection with the development of a production process for Licensed and/or Final Product, the manufacturing of
Licensed and/or Final Product for sale or distribution of Final Product in the Licensed Field of Use, or, the commercialization of Licensed and/or Final Product in the Licensed Field of Use, with, for or on behalf of, COMPANY. If COMPANY makes any
such transfer, it shall notify SELEXIS within [***] of any such transfer and report the name and address of any Transferee together with confirmation that the Transferee has agreed in writing to adhere to the confidentiality obligations and use
restrictions set out in this Agreement. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, upon expiration of the last Royalty Term, the Commercial
License granted to COMPANY in Article 2.1 (and the sublicense and transfer rights as set forth in Articles 2.2 and 2.3) shall become perpetual and royalty-free. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Sale of Licensed Product</U>. If COMPANY (itself or in cooperation with one or more Third Parties) wishes to
sell or otherwise transfer Licensed Product to any Third Party in a form other than as a Final Product, it may do so subject to the following. (a)&nbsp;Such Licensed Product may only be sold or transferred to one or more Third Party(ies) for use in
Clinical Trials, for further research and/or development and/or for formulation for ultimate sale in the Licensed Field of Use as Final Product; (b)&nbsp;Any sale for financial consideration of Licensed Product in a form other than as a Final
Product will be deemed a &#147;Net Sale&#148; of Final Product and Royalty Payments will be due on such sale of Licensed Product in accordance with Article 3.1.3 as if the Licensed Product were Final Product; and (c)&nbsp;All sales of Final Product
incorporating such Licensed Product will be deemed &#147;Net Sales&#148; of a Sublicensee for purposes of this Agreement and will be subject to payment by COMPANY of the royalties set forth in Article 3.1.3, and will trigger payment of the
milestones set forth in Article 3.1.2 if a Final Product produced by such a Third Party is the first Final Product to reach the appropriate milestone trigger point. COMPANY will ensure that sufficient records are kept by COMPANY or available to it
to document the Net Sales of Licensed and/or Final Products to determine the amounts due to SELEXIS under Article 3. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Consideration </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Payments</U>. In consideration of the Commercial License granted to COMPANY pursuant to Article 2.1, and in
consideration of the right to sublicense the rights granted in Article 2.1 pursuant to Article 2.2, COMPANY shall pay SELEXIS as follows: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.1.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Commercial License Execution Payment</U>. COMPANY shall pay SELEXIS a
<FONT STYLE="white-space:nowrap">one-time</FONT> fee of thirty five thousand Swiss Francs (CHF 35,000), due upon execution of this Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.1.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Commercial License Milestone Payments</U>. COMPANY shall make the following milestone payments to SELEXIS
with respect to the first occurrence of each such milestone event for each Licensed Product: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.1.2.1&nbsp;&nbsp;&nbsp;&nbsp;[***];</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.1.2.2&nbsp;&nbsp;&nbsp;&nbsp;[***];</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.1.2.3&nbsp;&nbsp;&nbsp;&nbsp;[***];&nbsp;&nbsp;and</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.1.2.4&nbsp;&nbsp;&nbsp;&nbsp;[***].</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.1.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Commercial License Royalty Payments</U>: In addition to the milestone payments under Article 3.1.2, during
the Royalty Term COMPANY shall pay SELEXIS on a Final <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Final</FONT></FONT> Product (including Products deemed Final Products in accordance with Article 2.4, parts
(b)&nbsp;and (c)) and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis a royalty of [***] of Net Sales of all Final Products sold worldwide, where said Final Products have been produced from a
Cell Line [***]. If Final Products have been produced from a Cell Line [***], then the royalty rate shall be [***]. Where royalties are due for the sale of Final Products directly by COMPANY such royalties shall be paid for each Calendar Quarter
within [***] of the end of that Calendar Quarter. Where royalties are due for the sales of Final Product by a Sublicensee, payment shall be made within [***] of the end of that Calendar Quarter. For the avoidance of doubt, no royalty payments shall
be due for a Final Product in a specific country after the Royalty Term has expired for such Final Product in such country. Where royalties are no longer due in accordance with the foregoing, the Commercial License granted to COMPANY under this
Agreement shall become perpetual, irrevocable, fully paid up and royalty free with respect to such Licensed and Final Product in such country. At any time during the Term, SELEXIS and COMPANY may agree to remove the royalty in its entirety or in
part in exchange for payment(s) as negotiated. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Mechanism of Payment</U>. The payments due to SELEXIS under this Agreement shall be made by wire transfer or
electronic fund transfer to the credit and account of SELEXIS as follows: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">Bank Name :&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">Account:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">To:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Selexis S.A. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;[***] </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Payment Terms</U>. Except with respect to royalties due pursuant to Article 3.1.3, COMPANY shall make
payments due to SELEXIS under this Agreement at the latest [***] after receipt of invoice. All fees and payments, including without limitation under Article 3.1.3, do not include any applicable VAT or Taxes. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Records</U>. COMPANY and its Affiliates and Sublicensees shall keep true accounts of Net Sales of Final
Products and COMPANY shall deliver to SELEXIS at the same time as the payments due under Article 3.1.3. a written account, including quantities of Net Sales of each such Final Product, broken down on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis with respect to those payments. SELEXIS is entitled to have such accounts audited by an independent expert of its choice. Such independent expert shall be bound by confidentiality
terms at least as restrictive as the terms of Article 8 and shall be authorized to disclose to SELEXIS only the results of its audit. COMPANY shall provide access to all information reasonably requested by such expert. The cost of any audit shall be
borne by SELEXIS unless the audit shows that COMPANY underpaid SELEXIS by [***] of the amounts due in which case the cost of the audit shall be borne by COMPANY. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Single Royalty and Milestone.</U> For Final Products covered by more than one SELEXIS Patent Rights, COMPANY
will make one payment to SELEXIS for royalties on any unit of Final Product sold by COMPANY or Sublicensees, irrespective of how many SELEXIS Patent Rights may cover such Final Product. Each milestone described in Article 3 shall be payable only
once in relation to each Licensed Product, irrespective of the number of Final Products which incorporate that Licensed Product and undergo the events triggering the payment. All fees and payments, including without limitation under Article 3.1, do
not include any applicable VAT or Taxes. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Taxes </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>General</U>. All Taxes levied on account of any payment made by COMPANY to SELEXIS pursuant to this
Agreement (other than Taxes on income, gains or profits levied against SELEXIS by any competent Swiss tax authority) will be the responsibility of, and shall be paid by, COMPANY pursuant to Article 3. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Character of Payments</U>. The PARTIES agree that, for purposes of determining the applicability of any
Taxes, the payments to be made under this Agreement constitute payments for tangible property and license of intellectual property. However, in the event that the governing tax authority (the &#147;<B>Tax Authority</B>&#148;) qualifies differently
such payment, any additional taxes that may be applied (including without limitation any interest and penalties that may be unpaid) shall be paid by COMPANY. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Withholding by COMPANY</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.3.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All payments by COMPANY hereunder shall be made in full without any deduction or withholding whatsoever and
free and clear of and without any deduction or withholding for or on account of any Taxes, except to the extent that any such deduction or withholding is required by law in effect at the time of payment. If any such deductions or withholdings must
be made from any amounts payable or paid by COMPANY, COMPANY shall [***]. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">12 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.3.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each PARTY shall execute and deliver such documents, deeds and other papers and take such further actions as
may be reasonably required to lawfully enable SELEXIS and COMPANY or their respective Affiliates or Sublicensees to mitigate withholding taxes, such as take advantage of any applicable legal provision or any double taxation treaties, for the purpose
of assigning to SELEXIS full tax credit for amounts deducted or withheld by COMPANY pursuant to Article 4.3.1. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Intellectual Property </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Ownership</U>. Each PARTY shall retain all right, title and interest in and to its Inventions and <FONT
STYLE="white-space:nowrap">Know-How</FONT> which exist on the Effective Date or which are thereafter developed independently of the performance of this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>COMPANY and SELEXIS Inventions</U>. Any Invention developed hereunder by or for either Party, solely or
jointly with the other PARTY or any Affiliate or agent thereof, shall belong exclusively (i)&nbsp;to COMPANY, to the extent [***] (&#147;<B>COMPANY Invention</B>&#148;); or (ii)&nbsp;to SELEXIS, to the extent [***] (&#147;<B>SELEXIS
Invention</B>&#148;). Any SELEXIS Inventions shall be included within the scope of the SELEXIS Technology licensed to COMPANY under this Agreement as provided for in Article 5.5. Notwithstanding the foregoing, such ownership shall not be construed
to transfer to either PARTY ownership of or any license or other rights in or to any of such PARTY&#146;s underlying Technology which may be included or embodied therein, or useful or necessary to use in connection with exploiting such Invention.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Other Inventions</U>. Except as set forth in Article 5.2, any other Invention developed hereunder solely by
COMPANY shall be COMPANY&#146;s sole property and any other Invention developed hereunder solely by SELEXIS shall be SELEXIS&#146; sole property. The PARTIES do not anticipate that there will be any jointly developed Inventions hereunder, but if
there are any other such jointly developed Inventions which do not relate to either the SELEXIS Technology or the COMPANY Technology, such Inventions shall be owned jointly by COMPANY and SELEXIS (&#147;<B>Joint Inventions</B>&#148;). In the event
any such Joint Inventions arise, the PARTIES will use commercially reasonable efforts to cooperate to protect and/or exploit such Joint Inventions, including, without limitation, by sharing in costs incurred with protection of such Joint Inventions
and sharing in revenues generated by the use or sublicense of the Joint Inventions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Notification</U>. Each PARTY shall promptly notify the other PARTY of any Invention arising in connection
with this Agreement provided that COMPANY has no obligation to notify SELEXIS with respect to any COMPANY Inventions developed solely by COMPANY. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">13 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Improvements</U>. In the event SELEXIS possesses, acquires, creates or is licensed (with the right to grant
a sublicense consistent with the terms of the Commercial License) any improvements to the SELEXIS Technology which are necessary or useful for COMPANY to use in connection with the use of the Cell Lines as licensed hereunder, such improvements shall
automatically be included in the SELEXIS Patent Rights and/or the SELEXIS <FONT STYLE="white-space:nowrap">Know-How</FONT> and thereby disclosed and licensed at no extra cost to COMPANY in accordance with this Agreement; provided, however, that any
rights granted by the foregoing will be subject to COMPANY&#146;s compliance with any bona fide obligations owed to Third Parties (with respect to which SELEXIS has notified COMPANY), including, without limitation, and royalty obligations owed to
Third Parties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Third Party Patent Rights</U>. SELEXIS covenants that if SELEXIS becomes aware that COMPANY&#146;s use of
the SELEXIS Technology in accordance with the terms hereunder would or would likely infringe any Third Party proprietary rights, SELEXIS shall use its reasonable commercial efforts to resolve such potential infringement at SELEXIS&#146; cost to
ensure COMPANY&#146;s freedom to continue to exercise the licenses granted under this Agreement, including without limitation by using its reasonable commercial efforts to obtain a license from the Third Party owner of the proprietary rights which
entitles SELEXIS to continue to grant the rights to COMPANY as provided for herein. Should such efforts not be successful, SELEXIS shall inform COMPANY in writing and thereafter the Parties will discuss the matter in good faith for a period not to
exceed [***]. Thereafter [***], save that SELEXIS shall not have such right if COMPANY agrees to [***]. If COMPANY [***] and if COMPANY [***] relating to COMPANY&#146;s permitted use of the SELEXIS Technology hereunder, then COMPANY may [deduct any
royalties actually paid to such Third Party] to the extent related to the use of the SELEXIS Technology [***]; provided that in no event shall the [***] of the royalty amount that would have otherwise been payable for such Final Product]. The
obligations set forth in this Article relate solely to Third Party rights related specifically and solely to the SELEXIS Technology licensed hereunder, and do not apply with respect to any other technology or materials used by COMPANY at its
discretion in connection with its exercise of the license rights granted hereunder, and specifically exclude any such Third Party rights to the extent relating to the Licensed Product(s) produced by any Cell Lines hereunder. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Enforcement of SELEXIS Patent Rights</U>. If, during the Term, either PARTY becomes aware of any
infringement or potential infringement of the SELEXIS Technology it shall promptly notify the other PARTY in writing and the PARTIES shall consult with each other to decide the best way to respond to such infringement or misuse, provided that
SELEXIS shall remain free to take any action as it deems fit in its sole discretion. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>COMPANY Publications</U>. COMPANY shall have the unrestricted right to publish or otherwise disclose the
results and data obtained by the practice of the SELEXIS Technology in accordance with the terms hereof, provided such publication or disclosure does not include any Confidential Information of SELEXIS. The name of SELEXIS shall be given proper
recognition in such publication(s) as scientifically appropriate. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">14 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Further Assurance</U>. Each PARTY agrees to execute and do all things at the cost of the other PARTY (if not
specifically agreed otherwise) as the other PARTY may reasonably require to give that other PARTY the full benefit of the provisions of this Article 5. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Representations, Warranties, and Covenants </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>General</U>. Except for the representations, warranties and covenants contained in Article 5.6 or this
Article 6, the PARTIES do not make any other representations, nor give any other warranties, express or implied, nor undertake to any other covenants. The PARTIES expressly exclude any and all other representations, warranties and covenants.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Representations and Warranties by the PARTIES</U>. Each PARTY hereby represents and warrants to the other
PARTY that: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.2.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Corporate Power</U>. It is duly organized and validly existing under the laws of the state (or country or
other jurisdiction, as the case may be) of its incorporation and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.2.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Due Authorization</U>. It is duly authorized to execute and deliver this Agreement and to perform its
obligations hereunder and the persons executing this Agreement on its behalf have been duly authorized to do so by all requisite corporate actions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.2.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Binding Agreement</U>. This Agreement is a legal and valid obligation binding upon it and is enforceable in
accordance with its terms, except as enforceability may be limited by bankruptcy, fraudulent conveyance, insolvency, reorganization, moratorium and other laws relating to or affecting creditors&#146; rights generally and by general equitable
principles and public policy. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.2.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No Conflicts</U>. The execution, delivery and performance of this Agreement by it does not conflict with any
agreement, instrument or understanding, oral or written, to which it is a PARTY or by which it may be bound. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.2.5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Intellectual Property Rights</U>. Each PARTY represents that it has valid and sufficient arrangements and
agreements with its directors, officers and employees (which term shall include agents, consultants and subcontractors) such that ownership of intellectual property rights in and to any Inventions made by its directors, officers and employees vests
in such PARTY. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">15 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Additional Representations and Warranties by SELEXIS</U>. SELEXIS hereby represents and warrants that, to
the best of its knowledge, as of the Effective Date: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.3.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">There is no pending litigation asserting that the use of the SELEXIS Technology or the SELEXIS <FONT
STYLE="white-space:nowrap">Know-How</FONT> constitutes an infringement or misappropriation of any intellectual property rights of a Third Party; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.3.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">SELEXIS has the right in and to the SELEXIS Technology, SELEXIS
<FONT STYLE="white-space:nowrap">Know-How</FONT> and the SELEXIS Patents to grant COMPANY the rights which are granted to COMPANY under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Additional Warranties by COMPANY</U>. COMPANY hereby represents and warrants to SELEXIS that:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.4.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the best of its knowledge, there are no Third Party intellectual property rights or any other rights that
may be asserted against SELEXIS claiming that SELEXIS was or is directly infringing or is helping or assisting COMPANY in infringing such Third Party&#146;s rights in connection with COMPANY&#146;s exercise of the Commercial License granted by
SELEXIS hereunder (except to the extent that any such Third Party rights relate solely and specifically to the SELEXIS Technology and/or SELEXIS Materials), including, without limitation, the development, manufacture and commercialization of
Licensed Products and/or Final Products as permitted hereunder; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.4.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of the Effective Date, to the best of its knowledge, there is no litigation pending against COMPANY in
connection with the use or ownership of the Licensed Product, including, without limitation, the infringement or misappropriation of any intellectual property rights of a Third Party relating to the Licensed Product, and COMPANY has not received any
written claim that the use thereof infringes on any intellectual property rights of a Third Party or a request or demand from any Third Party for the licensing of any intellectual property rights to such Third Party in connection with the use of the
Licensed Product. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.4.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">COMPANY will use commercially reasonable endeavours to not knowingly misappropriate or infringe the
intellectual property or other rights of any Third Party in connection with its exercise of its licensed rights hereunder, including, without limitation, use of any SELEXIS Technology, Cell Line, or Deliverables, or development, manufacture or sale
of Licensed and/or Final Product hereunder. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Third Party Intellectual Property.</U> Without limiting the warranty set forth in Article 6.4.3, COMPANY
hereby acknowledges that in order to make, have made, use, offer for sale, sell, import and otherwise exploit Licensed and/or Final Products in the Field it may require licenses under Third Party patent or other intellectual property rights that may
be infringed by the manufacture, use, offer for sale, sale, importation and other exploitation of Licensed and/or Final Product and, other than in the case of Third Party patent rights provided for in Article 5.6, it is agreed that it shall be
COMPANY&#146;S responsibility to identify all such intellectual property and satisfy itself as to the need for such licences, and, if necessary, to obtain such licenses. COMPANY agrees that, with the sole exception of Third Party patent rights
provided for in Article 5.6 and for which SELEXIS provides indemnification in Article 7.1, SELEXIS will have no liability whatsoever for any infringement of Third Party patent rights. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">16 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Disclaimer of Warranties by SELEXIS</U>. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT AND WITHOUT
LIMITING THE GENERALITY OF ARTICLE 6.1, SELEXIS DOES NOT MAKE NOR GIVE ANY REPRESENTATION OR WARRANTY TO COMPANY OF ANY NATURE, EXPRESS OR IMPLIED, THAT THE SELEXIS TECHNOLOGY WILL BE USEFUL FOR, OR ACHIEVE ANY PARTICULAR RESULTS AS A RESULT OF ANY
USE THEREOF BY SELEXIS OR BY COMPANY PURSUANT TO ANY LICENSE GRANTED TO COMPANY UNDER THIS AGREEMENT. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, SELEXIS SPECIFICALLY DISCLAIMS ANY WARRANTY OF NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A
PARTICULAR PURPOSE. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Liability and Indemnification </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Indemnification by SELEXIS</U>. During the Term of this Agreement and thereafter, SELEXIS hereby agrees to
save, defend and hold COMPANY, its Affiliates, and their respective officers, directors, employees, consultants and agents harmless from and against any and all Losses resulting directly from (i)&nbsp;any Third Party claim alleging that [***]; or
(ii)&nbsp;any material breach of SELEXIS&#146; representations, warranties and covenants set forth in Article 6; except in each case to the extent that such Losses were caused by willful misconduct or gross negligence of COMPANY or any of its
Affiliates, Collaborators or Sublicensees. In the event COMPANY seeks indemnification under this Article 7.1, COMPANY shall notify SELEXIS of any claim as soon as reasonably practicable after it receives notice of the claim. COMPANY shall allow
SELEXIS to conduct and control the defense against the claim (including without limitation to settle the claim solely for monetary consideration), shall (at SELEXIS&#146; expense) execute and deliver such documents and other papers and take such
further actions as may be reasonably required to defend against the claim (including without limitation to settle the claim solely for monetary consideration) and shall (at SELEXIS&#146; expense) cooperate as requested by SELEXIS in the defense of
the claim, provided always that SELEXIS may not settle any such claim or otherwise consent to an adverse judgment or order in any relevant action or other proceeding which includes any admission as to liability or fault without the prior express
written consent of COMPANY, which consent will not be unreasonably withheld. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Indemnification by COMPANY</U>. During the Term of this Agreement and thereafter, COMPANY hereby agrees to
save, defend and hold SELEXIS and its officers, directors, employees, consultants and agents harmless from and against any and all Losses resulting from (i)&nbsp;Third Party claims in connection with [***]; (ii) Third Party claims relating to [***];
or (iii)&nbsp;any material breach of COMPANY&#146;s representations, warranties </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">17 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
and covenants set forth in Article 6; in each case, except to the extent that such Losses result from the willful misconduct or gross negligence of SELEXIS. In the event SELEXIS seeks
indemnification under this Article, SELEXIS shall notify COMPANY of any claim as soon as reasonably practicable after it receives notice of the claim. SELEXIS shall allow COMPANY to assume direction and control of the defense of the claim (including
without limitation the right to settle the claim solely for monetary consideration), and shall (at COMPANY&#146;s expense) execute and deliver such documents and other papers and take such further actions as may be reasonably required to defend
against the claim (including without limitation to settle the claim solely for monetary consideration). SELEXIS shall (at COMPANY&#146;s expense) cooperate as requested by COMPANY in the defense of the claim, provided always that COMPANY may not
settle any such claim or otherwise consent to an adverse judgment or order in any relevant action or other proceeding which includes any admission as to liability or fault without the prior express written consent of SELEXIS, which consent will not
be unreasonably withheld. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No Incidental or Consequential Damages</U>. In no event shall either PARTY be responsible for any incidental
or consequential damages, including without limitation, lost profits or opportunities; provided that the foregoing shall in no event limit a PARTY&#146;s indemnification obligation under Article 7.1 or Article 7.2. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Limitation of Liability</U>. SELEXIS&#146; cumulative liability under this Agreement, whether in contract,
in tort, or otherwise, shall in no event exceed the aggregate consideration paid by COMPANY to SELEXIS under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Confidentiality </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U><FONT STYLE="white-space:nowrap">Non-disclosure</FONT></U>. During the Term of this Agreement and for [***]
thereafter, each PARTY shall keep Confidential Information of the other PARTY confidential and shall not (i)&nbsp;use the other PARTY&#146;s Confidential Information for any purpose not expressly permitted under this Agreement, nor
(ii)&nbsp;disclose the other PARTY&#146;s Confidential Information to any Person other than those of its agents, employees, and consultants (collectively, &#147;Representatives&#148;) who need to know such Confidential Information for a use or
purpose expressly permitted under this Agreement. Any such Representative who receives Confidential Information pursuant to this Article 8.1 shall be bound by written obligations of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT>
with respect to the Confidential Information that are no less stringent than the obligations set forth in this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Exceptions</U>. The confidentiality obligations set forth in Article 8.1 shall not apply to Confidential
Information that (i)&nbsp;is, or becomes, public information other than as the result of the violation of this Agreement or other </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">18 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
act or omission by the receiving PARTY or its Representatives; (ii)&nbsp;was lawfully known to the receiving PARTY or its Representatives without restriction on use or disclosure at the time of
disclosure hereunder; (iii)&nbsp;is hereafter lawfully received by the receiving PARTY or its Representatives from a Third Party authorized to make such disclosure and without restriction on use or disclosure; or (iv)&nbsp;is approved for release by
prior written consent from the disclosing Party. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Authorized Disclosures</U>. Notwithstanding any provision of this Agreement to the contrary, each PARTY may
disclose Confidential Information of the other PARTY to the extent such disclosure is required by law, provided however that the receiving PARTY gives the disclosing PARTY reasonable prior written notice to enable the disclosing PARTY to take
appropriate measures to protect its Confidential Information and fully cooperates, subject to commercially reasonable efforts, with the disclosing PARTY to prevent or limit to the greatest extent possible the disclosure of Confidential Information.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Use of Name</U>. No right, express or implied, is granted to either PARTY by this Agreement to use in any
manner any trademark or trade name of the other PARTY including the names &#147;CIRCADIAN, VEGENICS or OPTHEA&#148; and &#147;SELEXIS&#148; without the prior written consent of the PARTY entitled to such trademark or trade name.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Term and Termination </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Term</U>. This Agreement is effective as of the Effective Date. Unless earlier terminated pursuant to
Articles 9.2, 9.3 or 9.4 of this Agreement shall remain in full force and effect until [***] (the &#147;<B>Term</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Termination for Default</U>. In addition to any other remedies which may be available at law or equity, in
the event of any material breach of this Agreement (the &#147;<B>Default</B>&#148;) by a PARTY (the &#147;<B>Defaulting Party</B>&#148;), the PARTY not in default (the &#147;<B><FONT STYLE="white-space:nowrap">Non-Defaulting</FONT> Party</B>&#148;)
shall have the right to give the Defaulting Party a written notice thereof (the &#147;<B>Notice of Default</B>&#148;), which must state the nature of the Default in reasonable details and request that the Defaulting Party cure such Default within
[***]. During such [***] period, the Parties will cooperate in good faith in order to resolve any issue(s) that may have given rise to the Notice of Default and/or cure such Default. If such Default is not cured or the issue(s) that may have given
rise to the Notice of Default not resolved within [***] after receipt of a Notice of Default by the Defaulting Party or if such Default cannot be cured, the <FONT STYLE="white-space:nowrap">Non-Defaulting</FONT> Party may, at its sole discretion,
terminate this Agreement by written notice effective upon receipt. For avoidance of doubt, if the Default is cured or the issue(s) that may have given rise to the Notice of Default resolved within [***] after receipt of a Notice of Default by the
Defaulting Party, the <FONT STYLE="white-space:nowrap">Non-Defaulting</FONT> Party may not terminate this Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">19 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Termination for Bankruptcy</U>. In the event that a PARTY shall become insolvent or make any arrangement
with its creditors or has a receiver or administrator appointed to the whole or any part of its assets or if an order shall be made or a resolution passed for its winding up unless such order or resolution is part of a scheme for its amalgamation or
reconstruction (the &#147;<B>Insolvent Party</B>&#148;), the other PARTY shall have the right, at its sole discretion, to serve immediate notice of termination (with the sole exception of the circumstances expounded in 9.5.2.2) of this Agreement,
effective upon receipt. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Termination by COMPANY</U>. COMPANY may terminate this Agreement at any time by giving [***] written notice
to SELEXIS. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Consequences of Expiration or Termination</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.5.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Termination of Licenses</U>. In the event of a termination of this Agreement by COMPANY pursuant to Article
9.2 or 9.4, all and any rights and licenses granted under this Agreement shall terminate upon termination of this Agreement except for the licenses which have become perpetual pursuant to Article 3.1.3. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">In the event of a termination of this Agreement by SELEXIS pursuant to Article 9.2 or 9.3, all and any rights and licenses granted under this
Agreement shall terminate upon termination of this Agreement except for the licenses which have become perpetual pursuant to Article 3.1.3. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.5.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>SELEXIS Technology and Confidential Information</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.5.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the provisions of Article 9.5.2.2, upon termination of this Agreement under Article 9.2 or Article
9.3 where COMPANY is the Insolvent Party, or Article 9.4, COMPANY shall dispose of all tangible embodiments of the SELEXIS Technology and SELEXIS Confidential Information, including without limitation the SELEXIS Materials and Cell Lines, and render
inaccessible or useless all electronic embodiments, of SELEXIS Confidential Information provided to COMPANY by SELEXIS hereunder, except that COMPANY may retain one copy of the SELEXIS Confidential Information delivered hereunder in its secured
legal files only for ensuring compliance with the terms of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.5.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Where the COMPANY is the Insolvent Party, SELEXIS acknowledges that this Agreement and the Commercial License
may constitute a material asset of the COMPANY and as such the continuation of this Agreement (and the exercise of the Commercial License) may be of benefit to both Parties, in particular where the Commercial License has been sublicensed. As such,
SELEXIS agrees to provide COMPANY or the COMPANY&#146;S receiver or administrator the opportunity to make submissions for maintenance or restructure of the Agreement. Any submissions must be received by SELEXIS within [***] of the COMPANY
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">20 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
entering into insolvency, receivership or administration. SELEXIS agrees to take into consideration any such submissions received within the [***] period before making any decision to terminate
the Agreement under Article 9.3. If no submissions are received within the [***] period or alternatively after due consideration of any submissions, SELEXIS shall have the right, at its sole discretion, to serve immediate notice of termination of
this Agreement under 9.3 and the COMPANY shall dispose of all tangible embodiments in accordance with 9.5.2.1. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.5.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>COMPANY Confidential Information</U>. Upon any expiration or termination of this Agreement, SELEXIS shall
dispose of all tangible embodiments, and render inaccessible or useless all electronic embodiments, of COMPANY Confidential Information provided to SELEXIS by COMPANY hereunder, except that SELEXIS may retain one copy of the COMPANY Confidential
Information delivered hereunder in its secured legal files only for ensuring compliance with the terms of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.5.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Accrued Obligations</U>. Expiration or termination of this Agreement shall not relieve the PARTIES of any
obligation or liability accruing prior to such expiration or termination. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Miscellaneous </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Assignment</U>. Neither this Agreement nor any interest hereunder shall be assignable by either PARTY
without the prior written consent of the other PARTY; provided, that either PARTY may assign this Agreement and all of its rights and obligations hereunder, without such prior written consent, to an entity which acquires all or substantially all of
the business or assets of such PARTY (or the business or assets to which this Agreement pertains) whether by merger, consolidation, reorganization, acquisition, sale or otherwise; and COMPANY may assign this Agreement and all of its rights and
obligations hereunder, without such consent, to an Affiliate if COMPANY remains liable and responsible for the performance and observance of all of the Affiliate&#146;s duties and obligations hereunder, and provided that [***]. This Agreement shall
be binding upon the successors and permitted assigns of the PARTIES and the name of a PARTY appearing herein shall be deemed to include the names of such PARTY&#146;s successors and permitted assigns to the extent necessary to carry out the intent
of this Agreement. Any assignment not in accordance with this Article 10.1 shall be null and void. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Compliance with Governmental Obligations</U>. Each PARTY shall comply, upon reasonable notice from the other
PARTY, with all governmental requests directed to either PARTY relating to this Agreement and provide all information and assistance necessary to comply with the governmental requests. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">21 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Counterparts</U>. This Agreement may be executed in any number of counterparts, each of which need not
contain the signature of more than one PARTY but all such counterparts taken together shall constitute one and the same agreement, and may be executed through the use of facsimiles. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Dispute Resolution</U>. The PARTIES agree that in the event of a dispute between them arising from,
concerning or in any way relating to this Agreement, the PARTIES shall undertake good faith efforts to resolve any such dispute, with the matter being referred at the request of either PARTY to the General Counsel (or chief legal officer) of each
PARTY and, if remaining unresolved after [***], then to the Chief Executive Officers of each PARTY (or their designees). If after [***] of the matter first being referred to the General Counsel the PARTIES are unable to resolve such dispute, either
PARTY may seek any remedy available pursuant to Article 10.16. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Entire Agreement</U>. This Agreement sets forth all of the covenants, promises, agreements, representations,
warranties, conditions and understandings between the PARTIES with respect to the subject matter hereof, and constitutes and contains the complete, final, and exclusive understanding and agreement of the PARTIES with respect to the subject matter
hereof, and cancels, supersedes and terminates all prior agreements and understanding between the PARTIES with respect to the subject matter hereof. There are no covenants, promises, agreements, representations, warranties, conditions or
understandings, whether oral or written, between the PARTIES other than as set forth herein. No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the PARTIES hereto unless reduced to writing and signed by
the respective authorized officers of the PARTIES. For the avoidance of doubt, to the extent of any inconsistency between this Agreement and the Services Agreement, the terms of this Agreement shall govern and prevail. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Force Majeure</U>. Neither PARTY shall be liable to the other for loss, damages, default or delay due to
Force Majeure, provided that the PARTY affected by a case of Force Majeure gives prompt notice of such case to the other PARTY. The PARTY giving such notice shall thereupon be excused from its obligations hereunder as it is thereby disabled from
performing for so long as it is so disabled, provided, however, that such affected PARTY commences and continues to take reasonable and diligent actions to cure such cause; and provided further that if any Force Majeure delays or prevents the
performance of the obligations of either PARTY for a continuous period in excess of [***], the PARTY not affected shall then be [***] written notice to the affected PARTY. [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Further Actions</U>. Each PARTY agrees to execute, acknowledge and deliver such further instruments, and to
do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of the Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">22 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Independent Contractors</U>. The relationship between SELEXIS and COMPANY created by this Agreement is one
of independent contractors and neither PARTY shall have the power or authority to bind or obligate the other PARTY except as expressly set forth in this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Interpretation of Agreement</U>. Articles and other descriptive headings used in this Agreement are for
reference purposes only and shall not constitute a part hereof or affect the meaning or interpretation of this Agreement. Whenever the context so requires, the use of the singular shall be deemed to include the plural and vice versa.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>License Obligations</U>. Nothing in this Agreement imposes any obligation upon a PARTY to enter into any
other license or agreement with the other PARTY. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.11.<U></U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Notices</U>. All notices and other communications required by this Agreement shall be in writing in the
English language and shall be deemed given if delivered personally or by facsimile transmission (receipt verified), mailed by registered or certified mail (return receipt requested), postage prepaid, or sent by express courier service, to the
PARTIES at the following addresses (or at such other addresses that a PARTY specifies by like notice, provided, however, that notices of a change of address shall be effective only upon written receipt thereof): </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="70%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">If to COMPANY, addressed to:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">OPTHEA PTY LTD</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Level&nbsp;4, 650 Chapel Street</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">South Yarra</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">VIC 3141</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Australia</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Attention:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">CEO</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Facsimile:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="64%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">If to SELEXIS, addressed to:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Selexis S.A.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>[***]</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Attention:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">With a copy to:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Facsimile:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">23 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Binding Effect</U>. This Agreement shall be binding upon and inure solely to the benefit of COMPANY and
SELEXIS (and their permitted successors and assigns) and nothing in this Agreement (express or implied) is intended to or shall confer upon any Third Party any rights, benefits or remedies of any nature whatsoever under or by reason of this
Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Severability</U>. If any term, covenant or condition of this Agreement or the application thereof to any
PARTY or circumstance shall, to any extent, be held to be invalid or unenforceable, then the remainder of this Agreement, or the application of such term, covenant or condition to PARTIES or circumstances other than those as to which it is held
invalid or unenforceable, shall not be affected thereby and each term, covenant or condition of this Agreement shall be valid and be enforced to the fullest extent permitted by applicable law. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Waiver</U>. The failure on the part of a PARTY to exercise or enforce any rights conferred upon it hereunder
shall not be deemed to be a waiver of any such rights nor operate to bar the exercise or enforcement thereof at any time or times hereafter. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.15.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Survival</U>. Articles 1, 3.4, 4, 5, 6, 7, 8, 9.5 and 10 shall survive any termination or expiration of this
Agreement in accordance with their terms. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.16.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Governing Law and Jurisdiction</U>. This Agreement shall be governed by and construed in accordance with the
substantive laws of [***], without regard to principles of conflict of laws. Any dispute arising out of or in connection with this Agreement shall be subject to the exclusive jurisdiction of the courts of [***]. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">24 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, the PARTIES, having read the terms of this
Agreement and intending to be legally bound hereby, do hereby execute this Agreement: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SELEXIS SA</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>OPTHEA PTY LTD</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Girod PA</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Megan Baldwin</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Place, Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Plan-les-Ouates, Nov&nbsp;15, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Place, Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Melbourne, 7&nbsp;Nov 2013</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Girod PA</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name: Megan Baldwin</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Chief Scientific Officier</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Title: CEO, Opthea P/L</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Regine Brokamp</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Robert Klupacs</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Place, Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">PLO, Nov 15th 2013</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Place, Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Melbourne, 7&nbsp;Nov 2013</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Regine Brokamp</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name: Robert Klupacs</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: COO</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Title: Director, Opthea Pty Limited</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">25 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EXHIBIT 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SELEXIS PATENT RIGHTS </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patent 1. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Filing date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Application Number</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant Patent Number</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Geographies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Status</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patent 2. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Filing date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Application Number</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Publication Number</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Geographies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">26 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B><I></I></B><I>CONFIDENTIAL</I><B><I> </I></B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT 2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LICENSED PRODUCTS </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vascular Endothelial Growth Factor Receptor 3
soluble proteins </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October 28, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">27 of 27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Opthea</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#3366ff">Selexis SA</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>5
<FILENAME>filename5.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g945701g99j46.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">BIOPHARMACEUTICAL MANUFACTURING AGREEMENT </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Dated <U>October</U><U></U><U>&nbsp;28, 2013</U> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">By and between </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">DSM Biologics
Company Australia Pty Ltd </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Brisbane, Australia </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">DSM Biologics Company B.V.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Groningen, The Netherlands </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">OPTHEA Pty Ltd </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">South Yarra, Victoria, Australia </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 1 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">TABLE OF CONTENTS </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SECTION 1: PREAMBLE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SECTION 2: DEFINITIONS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SECTION 3: OBJECTIVES AND OBLIGATIONS OF THE PARTIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SECTION 4: EXECUTION OF THE SERVICES &#150; DEVELOPMENT WORK</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SECTION 5: EXECUTION OF THE SERVICES &#150; MANUFACTURING WORK</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SECTION 6: PRICE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SECTION 7: MANAGEMENT OF THE SERVICES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SECTION 8: RECORDS AND REPORTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SECTION 9: QUALITY AUDITS AND REGULATORY APPROVALS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SECTION 10: SUBCONTRACTING</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SECTION 11: INTELLECTUAL PROPERTY RIGHTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SECTION 12: REPRESENTATIONS AND WARRANTIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SECTION 13: LIABILITY AND INDEMNIFICATION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SECTION 14: CONFIDENTIALITY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 2 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SECTION 15: TERM AND TERMINATION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SECTION 16: NOTICES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SECTION 17: ASSIGNMENT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SECTION 18: DISPUTES AND APPLICABLE LAW</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SECTION 19: FORCE MAJEURE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SECTION 20: MISCELLANEOUS PROVISIONS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 3 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>LIST OF EXHIBITS: </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Exhibit&nbsp;1:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Services Schedule</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Exhibit&nbsp;2:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Invoicing schedule</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Exhibit&nbsp;3:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Quality Agreement</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Exhibit&nbsp;4:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CCN Format</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Exhibit&nbsp;5:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cancellation Scheme</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Exhibit&nbsp;6:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Draft Product Specifications</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Exhibit&nbsp;7:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Designated Vendors</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 4 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIOPHARMACEUTICAL MANUFACTURING AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This <B>Biopharmaceutical Manufacturing Agreement</B> is made and entered into on this 28th day of October, <B>2013 (the &#147;Effective Date&#148;):</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BY AND BETWEEN: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>OPTHEA Pty Ltd.</B>, a company
incorporated under the laws of Australia having its registered address at Level&nbsp;4, 650 Chapel Street, South Yarra, Victoria 3141, Australia; (hereinafter referred to as &#147;OPTHEA&#148;), of the one part; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AND: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DSM Biologics Company Australia Pty, Ltd.
</B>(A.B.N. 33 141 099 041)<B>, </B>having its registered address at 37 Kent Street, Woolloongabba, QLD, 4102, Australia (&#147;<B>DSM Australia</B>&#148;) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DSM Biologics Company B.V., </B>a company incorporated
under Dutch law, having its registered address at Zuiderweg 72/2, Groningen, The Netherlands (hereinafter referred to as &#147;<B>DSM Netherlands</B>&#148;), of the other part; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DSM Australia and DSM Netherlands are hereinafter referred to collectively as &#147;<B>DSM</B>&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OPTHEA and DSM hereinafter sometimes individually referred to as &#147;<B>Party</B>&#148; and collectively as &#147;<B>Parties</B>&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>SECTION 1: PREAMBLE </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WHEREAS </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">OPTHEA is the proprietor of a <FONT STYLE="white-space:nowrap">VEGFR-3</FONT> protein known as <FONT
STYLE="white-space:nowrap">OPT-302;</FONT> and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">DSM has expertise and <FONT STYLE="white-space:nowrap">know-how</FONT> in the area of development and cGMP
production of biopharmaceutical products; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">OPTHEA wishes to contract DSM to perform manufacturing and development work as specified in this Agreement in
connection with such protein; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">D.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">DSM is willing to perform such Services for OPTHEA; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 5 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOW THEREFORE, </B>in consideration of the promises and the mutual covenants and agreements hereinafter
contained, the Parties agree as follows: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>SECTION 2: DEFINITIONS </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this Agreement the following terms, whether used in the singular or plural form, shall, as used herein, have the following respective meanings: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Acceptance</B>&#148; has the meaning ascribed thereto in Section&nbsp;5.8. &#147;Accept&#148; and &#147;Accepted&#148; have the correlative meaning;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Affiliates</B>&#148; means any individual, company, partnership or other entity which directly or indirectly, at present or in the future,
controls, is controlled by or is under common control with a Party. For this purpose &#147;control&#148; shall mean direct or indirect beneficial ownership of at least fifty per cent (50%) of the voting share capital in such company or other
business entity; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Agreement</B>&#148; means this Biopharmaceutical Manufacturing Agreement (including any amendment signed by the Parties
hereto), including all schedules and Exhibits attached hereto, and CCN&#146;s entered into hereunder; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Batch</B>&#148; shall mean a specific
quantity of Product that is intended to be of uniform character and quality and is produced during the same cycle of manufacture; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;Batch
Records</B>&#148; means in relation to a Batch of Product, the production records showing how the Batch was manufactured; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Bill of
Testing</B>&#148; means the agreed upon written list of testing, methods, limits and specifications applicable to <FONT STYLE="white-space:nowrap">in-process</FONT> bulk harvest and Product, applying to the manufacture and disposition of Product by
DSM, as defined in the Quality Agreement attached hereto as <B>Exhibit 1, Annex 4,</B> that may be amended by written agreement between the Parties; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>CCN</B>&#148; means a contemplated change notification initiated by DSM in writing and provided to OPTHEA upon request of either Party, and
describing any material deviation from the Services, and which must be approved by OPTHEA in writing before entering into force. The standard format of a CCN is attached hereto as <B>Exhibit 4</B>; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Certificate of Analysis</B>&#148; or &#147;CoA&#148; means the certificate containing the outcome of the disposition tests on the Product as
performed by DSM or on behalf of DSM according to the Bill of Testing; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>cGMP</B>&#148; means current good manufacturing practices and general
biological products standards as promulgated under the United States Federal Food Drug and Cosmetic Act at 21 CFR (Chapters 210, 211, 600 and 610), the EEC Guide to Good Manufacturing Practices for Medicinal Products as promulgated under European
Directive 2003/94/EC (replacing 91/356/EEC) and PIC/S Guide to Good Manufacturing Practice for Medicinal Products <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PE-009-08</FONT></FONT> Part 2, including any amendments to such
regulations, to the extent these regulations relate to guidelines applicable for biopharmaceuticals and active pharmaceutical ingredients; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 6 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Claims</B>&#148; means any legal claim, demand, action, suit or proceedings made or brought by any
third party (other than an Affiliate of either Party); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#148;<B>Close Out Costs</B>&#148; shall have the meaning set forth in Section&nbsp;15.5; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Confidential Information</B>&#148; means any scientific, technical or business information furnished by the disclosing Party to the receiving Party
in connection with the Services and this Agreement, whether orally, in writing or as a tangible sample of material; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Cost</B>&#148; shall mean
the actual invoiced price paid by DSM to a third party in connection with the acquisition of materials and services in connection with the Services, including without limitation shipping and handling costs and customs duties. Costs for third party
service providers and vendors, and for media, feed, or any individual item having an invoice price [***] shall also be invoiced at Cost [***] to cover DSM&#146;s procurement and inventory costs in connection therewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Defaulting Party</B>&#148; has the meaning ascribed thereto in Section&nbsp;15.1.4; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;Deliverable&#148;</B> means any deliverable to be provided to OPTHEA, by DSM, as further specified in <B>Exhibit 1</B>, any amendment thereto, or in
a CCN; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#148;<B>Designated Vendor</B>&#148; shall have the meaning set forth in Section&nbsp;4.7 below and shall include those entities specified in
<B>Exhibit 7</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;Development Work&#148;</B> means the activities as undertaken by DSM which relate to
<FONT STYLE="white-space:nowrap">non-cGMP</FONT> manufacturing of the Product which are performed in the laboratory facilities and include technology transfer and any kind of development, <FONT STYLE="white-space:nowrap">scaling-up,</FONT>
validation and testing activities including toxicology batches and engineering batches; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Documents</B>&#148; means the documents on the basis of
which a Batch of Product is released by DSM which include but may not be limited to: the Certificate of Analysis, Statement of Compliance, production and testing records, analytical test data for release tests of the Bulk Harvest Product, Batch
dossier summary and deviation reports as agreed upon in the Quality Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>DSM Facilities</B>&#148; means the development and production
facilities of DSM located at [***] and [***]; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>EMA</B>&#148; means the European Medicines Agency; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;EFFECTIVE DATE&#148;</B> means the date indicated on the first page of this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>FDA</B>&#148; means the U.S. Food and Drug Administration; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>For Cause Audit</B>&#148; shall mean an audit to address a Major cGMP Deviation resulting in a failure of Product to meet Specification due to
DSM&#146;s material breach of its obligations under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Force Majeure</B>&#148; has the meaning ascribed thereto in
Section&nbsp;19.1; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;Intellectual Property Right&#148;</B> shall mean inventions, Patents, and/or Know How, and all intellectual property rights
related thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 7 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">&#147;Know-How&#148;</FONT></B> shall mean any and all information not
covered by a Patent, including but not limited to materials, trade secrets, information, experience and data, formulae, procedures, results and specifications, regulatory filings and clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT>
data, in written or electronic form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Latent Defects</B>&#148; shall have the meaning set forth in Section&nbsp;5.8.3; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Losses</B>&#148; means, in relation to a Claim, any and all losses, obligations, liabilities, damages, deficiencies, costs and expenses which a Party
incurs or suffers (including reasonable attorneys&#146; fees and legal fees incident thereto or in seeking indemnification from the other Party therefore) as a result of such Claim; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Manufacturing Work</B>&#148; means the activities as undertaken by DSM for manufacturing the Batch of Product, including all manufacturing activities
in compliance with cGMP (which for the purpose hereof shall include all operations of receipt of materials and products, production, quality control, release, storage); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Material Change</B>&#148; means any change in assumptions or scope that results in the necessity to modify the Manufacturing or Development Work
previously agreed to by the Parties in order to achieve a desired result; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>New General Application Intellectual Property</B>&#148; has the
meaning ascribed thereto in Section&nbsp;11.2; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>New OPTHEA Intellectual Property</B>&#148; has the meaning ascribed thereto in Section&nbsp;11.2;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">&#147;Non-Defaulting</FONT> Party&#148;</B> has the meaning ascribed thereto in Section&nbsp;15.1.4; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;Patent&#148;</B> means any and all granted patents, including without limitation utility models and certificates of invention, and reissues,
renewals, reexaminations, supplementary protection certificates, extensions, and term restorations thereof, and patent applications therefore, including any continuations,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-parts,</FONT></FONT> divisionals thereof, and the like, and foreign equivalents thereof; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Price</B>&#148; means, depending on the context, the total price for the Services or the price for any element of work in the Services as specified
in the <B>Exhibit 2</B>; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Process</B>&#148; means the process for the development and manufacture of the Product as used in the Services,
including any improvements thereto; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Product</B>&#148; means bulk purified <FONT STYLE="white-space:nowrap">OPT-302</FONT> drug substance
manufactured in accordance with the Process; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Project Manager</B>&#148; means the individual assigned by a Party who will be responsible on
behalf of the respective Party for the scientific and technical components of the Services; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Quality Agreement</B>&#148; means the agreement
jointly developed by the Parties during the Development Work, attached hereto as <B>Exhibit 3</B>, incorporating all relevant Quality Assurance and Quality Control obligations and aspects for the Parties; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 8 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Schedule</B>&#148; shall mean the description of the Services, as set forth in <B>Exhibit 1</B>,
incorporating the specific details of each Services phase and a time schedule mutually agreed upon by the Parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Services</B>&#148; means all
the activities performed by DSM, as further described in <B>Exhibit 1</B>, and all amendments thereto, or in any CCNs entered hereunder; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Service
Activity</B>&#148; means the [***] activities performed by DSM, as further described and identified in Annex 1 of <B>Exhibit 1</B>, and includes any CCNs or amendments entered hereunder; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Specifications</B>&#148; means the specifications, technical data and/or formulae of the Product manufactured during Manufacturing Work, and all
amendments thereto, to be agreed upon in writing between the Parties. The Specifications are set out in <B>Exhibit 6</B>. Any amendment to the Specifications must be in writing, signed by both Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Statement of</B> <B>Compliance</B>&#148; or &#147;<B>SoC</B>&#148; means the confirmation to be issued by DSM contained in the Certificate of
Analysis stating that the Product meets the Specifications and was manufactured in accordance with cGMP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Steering Committee</B>&#148; has the
meaning as set forth in Section&nbsp;7.6. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Term</B>&#148; is defined in Section&nbsp;15.1. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>SECTION 3: OBJECTIVES AND OBLIGATIONS OF THE PARTIES </U></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Services for Payment:</B> Subject to the terms and conditions of this Agreement, OPTHEA hereby engages DSM
to carry out the Services; and DSM, subject to the terms and conditions of this Agreement, hereby undertakes to use commercially reasonable efforts to carry out the Services in accordance with this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CCN:</B> Any Material Change to the scope of the Services shall not take effect unless approved in writing
through a CCN signed by both Parties. Subject to provisions under Section&nbsp;4.4, DSM shall submit a CCN to OPTHEA in a timely manner. DSM shall not be responsible for any delay resulting from OPTHEA&#146;s failure to timely execute a CCN
necessary for the completion of the Services or any portion of such Services. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>SECTION 4: EXECUTION OF THE SERVICES &#150;
DEVELOPMENT WORK </U></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Commencement:</B> DSM shall begin the Services on or about
28<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> October 2013subject to DSM having timely received the appropriate payments in accordance with Section&nbsp;6 and the necessary OPTHEA approvals, consents, information and materials necessary
for the commencement of the Services (or any part of the Services), as specified in this Agreement, and specifically without limitation in <B>Exhibit 1</B>, any amendment thereto, or in a CCN. The different stages of the Development Work are
estimated to require the periods of time identified in the Schedule to this Agreement. Any estimated timelines are dependent on OPTHEA&#146;s timely provision of necessary approvals, consents, information and/or materials specified in <B>Exhibit
1</B>, any amendment thereto, in any CCN or other writing agreed to by the Parties. DSM shall timely notify OPTHEA if it expects execution of a part of the Services not to be possible within the timeframe as described in the Schedule, and, subject
to Section&nbsp;4.5, shall take commercially reasonable efforts to perform that part of the Services as soon as possible thereafter.<B> </B> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 9 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.2<B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>In accordance with [***] set forth in the Schedule as described in Exhibit 1, the second Service
Activity being part of the Development Work will not commence unless the Parties have agreed in writing to [***] in respect thereof. DSM shall keep OPTHEA informed of the impact of any delays in commencing each Service Activity, and shall use
commercially reasonable efforts to minimize any such delays. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Incremental Work: </B>Within [***] after performance by DSM of each individual stage of the Development
Work, as described in the Schedule, DSM shall notify (electronically, in writing) OPTHEA (i)&nbsp;about the results of the stage and (ii)&nbsp;to what extent, in DSM&#146;s opinion, the stage has been completed. Based on this information Parties
shall discuss in good faith whether to (i)&nbsp;proceed with the Services according to the Schedule, (ii)&nbsp;perform incremental work with regard to the stage (and agree on the consequences, e.g. in relation to previously agreed Manufacturing
Work) or (iii)&nbsp;terminate the Services. DSM shall employ its best efforts to incorporate incremental work into the existing Services as outlined in <B>Exhibit 1</B>. Any resulting agreement with respect to how to proceed shall be set forth in
writing. In the event that the incremental work leads to a change in the Schedule for the Manufacturing Work the consequences with respect to the change in the Schedule shall be negotiated, and the Parties shall set forth in the CCN the impact of
those consequences. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CCN Discussion:</B> In the event that the Parties agree that incremental work is necessary they shall
negotiate a CCN in good faith. If the Parties fail to reach agreement on the CCN within a [***] period after having started discussions on the CCN, the Services and this Agreement shall terminate automatically, unless the Parties agree to extend the
time for such negotiations, in writing. Any agreed CCN implemented for the Services shall include a discount in the amount of [***] to DSM&#146;s standard rates. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.5<B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>OPTHEA Responsibilities: </B>In connection with any Development Work related to the Services, and subject to
Section&nbsp;4.2, OPTHEA shall provide DSM with all required approvals, consents, information and other materials specified in <B>Exhibit 1</B>, on a timely basis, and no later than the time period specified in <B>Exhibit 1</B> or such other time as
specifically agreed to by the project teams and set forth in approved meeting minutes. In the event that any delay of the Development Work results from OPTHEA&#146;s failure to provide necessary consent, information and/or materials within the time
frame specified in <B>Exhibit 1</B>, subject to Section&nbsp;4.2, or the time frame agreed upon by the project teams in writing, any other part of this Agreement, any amendment to this Agreement, any CCN, or as otherwise set forth in any writing
between the Parties, when required thereby, OPTHEA shall be solely responsible for such delay. Any unreasonable delay resulting from OPTHEA&#146;s failure in accordance with this section 4.5 shall be considered a Postponement within the meaning of
Section&nbsp;15.2. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 10 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DSM Responsibilites: </B>In connection with any Development Work related to the Services, DSM shall use
reasonable efforts consistent with industry practice to execute all activities according to and in line with the timelines as specified in <B>Exhibit 1</B> according to applicable guidelines and laws and to supply OPTHEA with all required materials
and information, subject to Sections 4.1 and 4.2. DSM will provide all required documentation requiring approval or action by OPTHEA in time to allow suitable time for approval. Each Party will take all reasonable efforts to prevent the loss of any
scheduled manufacturing slots. Nothing contained herein shall limit or otherwise modify Section&nbsp;12.4 of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Vendor</B><B>&#146;</B><B>s Designated or Contracted by OPTHEA:</B> If, in connection with the Development
Work performed pursuant to this Article 4, or the Manufacturing Work performed pursuant to Article 5, OPTHEA elects, at its sole discretion, to require DSM to procure raw materials, media, feed or other supplies (&#147;raw materials&#148;) from
vendors designated by OPTHEA which are not approved vendors under contract with DSM (hereinafter, &#147;Designated Vendors&#148;), then OPTHEA shall so advise DSM in writing, and DSM will establish supply arrangements with such Designated Vendors in
accordance with this Section&nbsp;4.7. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Cooperation on Supply Problems.</B> DSM shall promptly advise OPTHEA if it encounters supply problems,
including delays and/or delivery of <FONT STYLE="white-space:nowrap">non-conforming</FONT> products from Designated Vendors; and (ii)&nbsp;DSM and OPTHEA shall cooperate to reduce or eliminate any supply problems from such Designated Vendors.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Annual Certification.</B> OPTHEA shall be obligated to certify its own Designated Vendors, as specified in
the Quality Agreement, on an annual basis, at its expense, and shall annually supply certification to DSM for such Designated Vendors. If DSM is required to certify such Designated Vendors, DSM&#146;s certification expenses including, but not
limited to, quality audit visits to the Designated Vendors [***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.7.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Cancelled Manufacturing Runs.</B> If scheduled manufacturing runs are required to be cancelled because a
Designated Vendor failed to supply acceptable materials on a timely basis, OPTHEA may be obligated to pay DSM a cancelled production fee as outlined in Section&nbsp;15.2 and where appropriate, the cancellation scheme set forth in <B>Exhibit 5.</B>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.7.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Batch Failure Resulting from Designated Vendor Failure.</B> If any Batch of Product fails because of defects
or other <FONT STYLE="white-space:nowrap">non-conformities</FONT> in raw materials supplied by a Designated Vendor that could not have been discovered by DSM as a result of DSM&#146;s obligations under this Agreement and the Quality Agreement, then
OPTHEA shall be obligated to pay DSM a failed Batch fee computed as [***] of the Batch Price including [***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.7.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Rescheduled Runs. At the request of OPTHEA, DSM shall use reasonable efforts to
<FONT STYLE="white-space:nowrap">re-schedule</FONT> any production run which is cancelled due to Designated Vendor problems, subject to its then existing production schedule. Upon the rescheduled production of the cancelled production, [***] Price
shall be charged for such rescheduled quantities upon completion, notwithstanding and in accordance with Section&nbsp;15.2, OPTHEA&#146;s prior payment of [***]. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 11 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.7.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Quality Issues.</B> OPTHEA shall be responsible for compensating DSM for [***] to investigate and resolve
quality issues arising with the Designated Vendor. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.7.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Direct Contracts with Vendor.</B> If OPTHEA requires DSM to procure raw material from any Designated Vendor,
then DSM shall require that such Designated Vendor enter into a supply contract directly with DSM; otherwise, and until execution of such supply contract, OPTHEA shall be solely responsible for the supply of raw materials, and for any liability
arising as a result thereof. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.7.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For avoidance of doubt, the provisions of this Section&nbsp;4.7 shall equally apply to Article 5 of the
Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Engineering Batch Failure due to not Using Diligent and Commercially Reasonable Efforts: </B>If any <FONT
STYLE="white-space:nowrap">non-cGMP</FONT> manufacturing of an engineering batch fails because DSM has not used diligent and commercially reasonable efforts to perform such manufacturing, OPTHEA and DSM shall agree on one of the following as the
[***] for OPTHEA and the [***] for DSM: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.8.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to [***] for such batch; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.8.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to obtain, at [***] and [***] as soon as reasonably possible; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.8.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to [***] in such a way that it can be deemed to have been manufactured diligently and using commercially
reasonable efforts. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>SECTION 5: EXECUTION OF THE SERVICES &#150; MANUFACTURING WORK </U></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Performance</B>: It is understood by the Parties that the [***] Service Activities are optional to OPTHEA
and may be requested by OPTHEA at its discretion, no time slot being reserved by DSM for any part of the [***] Service Activities including the Manufacturing Work. The [***] Service Activities including the Manufacturing Work will thus not commence
unless they are authorized by OPTHEA in writing. If and when OPTHEA provides such written approval, DSM shall reserve<I> </I>a time slot for OPTHEA for performing the [***] Service Activities including the Manufacturing Work. DSM shall perform the
Manufacturing Work under the Services in the DSM Facilities, subject to DSM having received in due time the appropriate payment(s) in accordance with Section&nbsp;6 and the necessary OPTHEA approvals, consent, information and materials necessary for
the commencement of the Services (or any part of the Services), as specified in <B>Exhibit 1</B>, any amendment thereto, or in a CCN. The different parts of the Manufacturing Work are estimated to require the periods of time identified in the
Schedule to this Agreement. DSM shall timely notify OPTHEA if it expects execution of a part of the Manufacturing Work not to be possible within the timeframe as described in the Schedule, and subject to Section&nbsp;5.2 shall take commercially
reasonable efforts to perform that part of such Manufacturing Work as soon as possible thereafter. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 12 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>OPTHEA Responsibilities</B>: In connection with any Manufacturing Work in connection with the Services,
OPTHEA shall provide DSM with all required approvals, consents, information and other materials specified in <B>Exhibit 1</B> or the Quality Agreement, on a timely basis, and no later than the time period specified therein once the Manufacturing
Work is approved to commence by OPTHEA. OPTHEA&#146;s responsibility to provide consents, information and other materials includes the requirement to approve Documents, supply or order OPTHEA supplied materials, or provide information in accordance
with the schedule set forth in <B>Exhibit 1</B> or in the Quality Agreement or such other time as specifically agreed to by the project teams and set forth in approved meeting minutes. In the event that any delay of the Manufacturing Work results
from OPTHEA&#146;s failure to provide necessary approvals, consent, information and/or materials within the time frame specified in <B>Exhibit 1</B>, any other part of this Agreement, any amendment to this Agreement, any CCN, or as otherwise set
forth in any writing between the Parties, when required thereby, OPTHEA shall be solely responsible for such delay. Any such unreasonable delay shall be [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.3</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Quality Agreement</B>:<B> </B>In relation to the Manufacturing Work, each Party shall perform their
respective obligations and responsibilities set forth in the Quality Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Manufacture in accordance with cGMP: </B>The Product to be manufactured during the Manufacturing Work (as
described in the Schedule) shall be manufactured in accordance with all applicable cGMP requirements. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Testing: </B>Each Batch of Product will be sampled and tested by or on behalf of DSM against the
Specifications according to the Bill of Testing. The Bill of Testing shall be approved, in writing, by the Parties, and signed by each Party. Any modifications to the Bill of Testing shall only be effective when approved in writing by the Parties.
In connection with Manufacturing Work, the quality assurance department of DSM will review the Documentation and will assess if the manufacture has taken place in compliance with cGMP regulations. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Statement of Compliance: </B>If, based upon such tests, the Batch conforms to the Specifications and was
manufactured according to cGMP, a Statement of Compliance will be completed and approved by the Quality Assurance Department of DSM in connection with Manufacturing Work. The Certificate of Analysis including the Statement of Compliance and all
other Documents will be delivered to OPTHEA for each Batch. In the event OPTHEA has not received all Documents at the time of delivery of the Certificate of Analysis it will promptly notify DSM in writing and DSM shall, within [***], send such
Documents to OPTHEA. In the event that OPTHEA requires additional copies of the Documents, or copies of any other documents concerning the Manufacturing Work, these will be provided by DSM at Cost. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Shipment:</B> When OPTHEA requests DSM to ship Product to OPTHEA or a third party, DSM shall do so in
accordance with OPTHEA&#146;s instructions but at [***] of OPTHEA. Product shall be shipped, [***] from the DSM Facilities (in accordance with Incoterms 2000) with responsibility for and title to the Product passing to OPTHEA in accordance with the
applicable Incoterms. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 13 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Acceptance:</B> OPTHEA will notify DSM in writing of its acceptance or rejection of the Batch of Product
within [***] of delivery of all Documents; and such acceptance or rejection shall be based solely on OPTHEA&#146;s review of the Documents (&#147;<B>Acceptance</B>&#148;). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.8.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">OPTHEA shall be obligated to accept the Batch in all instances other than where the Batch fails to meet the
Specifications and/or was not manufactured in compliance with cGMP. OPTHEA shall notify DSM of any rejection of the Batch of Product pursuant to this Section&nbsp;5.8.1 within the [***] period set forth in Section&nbsp;5.8. In the absence of any
such written confirmation to DSM of rejection of the Batch or any material substantiation of the underlying reasons for such rejection, the Batch of Product shall be deemed to comply with the Specifications and manufactured in compliance with cGMP
and shall be deemed Accepted by OPTHEA. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.8.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">During the aforementioned [***] and thereafter, OPTHEA shall have and retain full control and title to the
Product, but unless otherwise requested by OPTHEA, DSM shall store the Batch until delivery pursuant to Section&nbsp;5.7 or shipment pursuant to the Section&nbsp;5.8.4 under controlled conditions compliant with cGMP requirements and according to the
agreed upon storage instructions. Any other use or processing of the Product by or on behalf of OPTHEA prior to Acceptance shall be [***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.8.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon Acceptance by OPTHEA of the Batch of Product, OPTHEA shall [***] in respect of the Batch <FONT
STYLE="white-space:nowrap">vis-&agrave;</FONT> <FONT STYLE="white-space:nowrap">-vis</FONT> DSM save for [***]. Latent Defects (as defined hereafter) shall be reported in writing promptly after discovery but in no event more than [***] after
delivery of the respective Batch of Product. &#147;<B>Latent Defects</B>&#148; shall mean a <FONT STYLE="white-space:nowrap">non-compliance</FONT> of the Product with the Specifications caused by a provable failure by DSM to comply with cGMP, which
defect was already present at the time of delivery and which could not have been identified by or on behalf of OPTHEA prior to Acceptance by review of the Certificate of Analysis and other Documents supplied to OPTHEA on delivery of the
Batch.</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Without limitation of anything to the contrary set forth in this Agreement, including but not limited to
Section&nbsp;4.7, OPTHEA&#146;s sole and exclusive remedy for Latent Defects for which DSM is responsible under the terms of this Agreement shall be the remedies set forth in Section&nbsp;5.12<B> </B>and DSM shall only be liable upon OPTHEA&#146;s
proof that DSM failed to comply with cGMP. In the event of any attempted rejection of Product by OPTHEA due to an alleged Latent Defect, OPTHEA shall either dispose of the Product or return the Product to DSM, in accordance with DSM&#146;s
instructions and applicable laws. Where it is established that a Latent Defect exists, all Costs of disposal or return shall be borne by DSM. Otherwise, OPTHEA shall bear the Costs of return or disposal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 14 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.8.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Shipment to Third Party: </B>When OPTHEA requests DSM to ship Product to a third party, DSM shall do so in
accordance with OPTHEA&#146;s instructions but at the sole risk, responsibility and expense of OPTHEA. In such event and subject to the other terms of this Agreement, responsibility for and title to the Product shall pass to OPTHEA along with the
risk when the Product is placed [***]. Following such shipment, if OPTHEA claims that such Product does not comply with Specifications, then it must demonstrate by clear evidence that such <FONT STYLE="white-space:nowrap">non-compliance</FONT> is
caused solely by the failure by DSM to comply with cGMP and that such defect was already present prior to shipment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Dispute on Specifications: </B>If during the aforementioned [***] period (or, in the case of Latent Defects,
the aforementioned [***] period), there is any dispute concerning whether Product complies with the Specifications or whether such failure is due (in whole or in part) to acts or omissions of OPTHEA (or a third party to whom OPTHEA has requested
that DSM ship Product) after delivery of Product, a sample of the Product received by OPTHEA and a sample retained by DSM shall be exchanged between OPTHEA and DSM for a counter-check. If such counter-check does not resolve the dispute, the Parties
agree to act in good faith to arrive at a solution and, in doing so, may mutually agree to submit a sample of the Product received by OPTHEA and a sample retained by DSM to an independent, qualified third-party laboratory that is mutually acceptable
and selected by the Parties promptly in good faith. Such laboratory shall provide the Parties with a recommendation regarding whether the rejected Product met the Specifications at the time of delivery by DSM to the carrier; and the Parties shall,
based on such recommendations, negotiate an appropriate resolution of their dispute. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Dispute on cGMP: </B>If during the aforementioned [***] period (or, in the case of Latent Defects, the
aforementioned [***] period), there is any dispute concerning whether Product was manufactured in compliance with cGMP, the <FONT STYLE="white-space:nowrap">QA-managers</FONT> of the Parties shall discuss in good faith to attempt to resolve such
dispute. If the <FONT STYLE="white-space:nowrap">QA-managers</FONT> of the Parties fail to reach agreement in due time, such dispute shall be submitted to the Steering Committee. If the Steering Committee fails to reach agreement in due time, such
dispute shall be submitted to an independent, qualified third-party expert that is mutually acceptable and selected by the Parties promptly in good faith. Such expert shall determine whether the Product was manufactured in compliance with cGMP; and
such expert&#146;s determinations shall be final and determinative for purposes of this Agreement save for manifest error on the face of decision. [***] shall bear all fees and costs of the expert&#146;s activities. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Remedy on Failed Specification:</B> If the Batch of Product does not conform to the Specifications, provided
the nonconformity is not due to DSM&#146;s failure to comply with cGMP, and OPTHEA subsequently does not Accept the Batch, OPTHEA shall have to pay the Price for this failed Batch of Product. DSM shall at OPTHEA&#146;s request either obtain new raw
materials and produce a new Batch of Product as soon as reasonably possible or investigate and rework the Batch with the Price of any replacement Batch to be paid by OPTHEA. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 15 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Remedy on Failed cGMP:</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.12.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Regardless of whether the Batch of Product conforms to the Specifications or not, if this Batch was not
manufactured according to cGMP (if applicable) and the Batch is subsequently not Accepted by OPTHEA, OPTHEA and DSM shall agree on one of the following [***] for OPTHEA and the [***] for DSM: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.12.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to refund the Price and Costs paid for this Batch of Product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.12.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to obtain, at DSM&#146;s cost and expense, new raw materials and Manufacture a new Batch of Product as soon as
reasonably possible; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.12.1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to rework, at DSM&#146;s cost and expense, the Product in such a way that the Batch can be deemed to have been
manufactured according to cGMP. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.12.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Regardless of the decision made pursuant to Section&nbsp;5.12.1, the Parties shall meet to discuss, evaluate
and analyze the reasons for and implications of the failure to comply with cGMP and shall discuss in good faith whether to proceed with or to amend the Services, or to terminate the Services. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***]<B>: </B>Subject to the indemnification obligations under this Agreement, [***] under this Agreement with
respect to Product (i)&nbsp;not complying with the Specifications shall be limited to the remedy as provided for in Section&nbsp;5.11 and (ii)&nbsp;not being manufactured in compliance with cGMP shall be limited to the remedy and liability as
provided for in Section&nbsp;5.12. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Indemnity for subsequent Purchasers</B>: OPTHEA shall indemnify, defend and hold DSM and its Affiliates
harmless from and against any and all Losses resulting from claims made by any subsequent purchasers of the Product against DSM for loss or damage arising out of the performance or <FONT STYLE="white-space:nowrap">non-performance</FONT> of Product
provided under this Agreement, if OPTHEA cannot obtain for DSM from the subsequent purchasers the limitation of liability protections in this Agreement. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>SECTION 6: PRICE </U></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Price Assumptions:</B> It is understood between the Parties that the Prices for the Services shall be based
upon [***] hereto. If, during the execution of the Services, it becomes clear that [***] and have consequences for the Services, which cannot be addressed by a CCN, the Parties shall adjust the Price for those parts of the Services so effected
accordingly. In addition, OPTHEA agrees that it shall bear any adjustment to the Price due to subsequent regulatory changes relevant to the Services, Product, and/or the Process, or any delay by OPTHEA in providing required consents, information and
other materials specified in <B>Exhibit 1</B>, on a timely basis. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Invoicing Schedule: </B>The invoicing schedule for the Services undertaken under this Agreement is set out
in <B>Exhibit 2</B>. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 16 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Invoices:</B> All invoices shall be payable by OPTHEA within [***] of receipt of the invoice with payment
being made as specified on the invoice. Any delay in the payment by OPTHEA of the Price shall carry an interest rate as of the first day of such delayed payment, which interest rate shall be based on an annual interest rate of [***] above the base
lending rate at the time as set by the Reserve Bank of Australia. In the event of a failure to pay within the required time frame, DSM shall notify OPTHEA of such failure, and OPTHEA shall advise of the reasons for the failure to pay. If the failure
to pay has not been resolved within not less than [***] of such notice by DSM, DSM shall have the right, in its sole discretion, to suspend or discontinue any scheduled commencement of or continuation of work to be performed, or being performed,
even if such discontinuance or suspension results in the loss of a time slot that was reserved for OPTHEA. DSM shall notify OPTHEA of any such decision in writing. DSM shall not be held responsible or liable for any
<FONT STYLE="white-space:nowrap">non-commencement</FONT> or discontinuation of the Services or missed time slot as a result of any suspension or discontinuance of work pursuant to this Section&nbsp;6.3. Any loss of timeslot hereunder shall be
considered a Postponement pursuant to Section&nbsp;15.2. DSM may also, in its sole discretion, treat the failure to pay the invoice as a cancellation by OPTHEA, and OPTHEA shall be responsible for payment for such cancellation in accordance with the
terms of the cancellation scheme of <B>Exhibit 5</B>. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>SECTION 7: MANAGEMENT OF THE SERVICES </U></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Parties hereby agree that the Services shall be under the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">day-to-day</FONT></FONT> supervision of the DSM Project Manager. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Parties shall work together through the respective Project Managers to ensure the satisfactory execution of
the Services. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Project Manager shall be entitled to propose recommendations to the Parties to ensure that the Services
meet their objectives. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Project Manager shall be in charge of all scientific and technical components of the Services within its
own organization and shall maintain communication with the other Party in connection therewith. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Party intends and shall use reasonable efforts not to replace its Project Manager and, in case of
replacement, to timely notify the other Party of such replacement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Parties shall also nominate a Steering Committee (<B>&#147;Steering Committee&#148;</B>), which Steering
Committee shall be in charge of (i)&nbsp;monitoring the overall progress, timelines, results and Price of the Services; (ii)&nbsp;taking the relevant decisions as described in Sections 5.10 and 5.12; (iii) discussing the forward planning of the
Services for the upcoming 12 months insofar as this is not yet firmly agreed upon between the Parties, and (iv)&nbsp;attempt to settle any disputes according to Section&nbsp;18. Unless otherwise provided for or agreed upon in writing, all decisions
of the Steering Committee shall be taken on the basis of unanimity. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 17 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">DSM shall permit a reasonable number of persons authorized by OPTHEA, including but not limited to OPTHEA
employees, representatives, contractors or employees, representatives or contractors of an Affiliate of OPTHEA, licensees or potential licensees of OPTHEA, under appropriate confidentiality provisions acceptable to DSM, to visit the DSM Facilities
during regular business hours where the Services are being conducted to evaluate the progress of the Services, unless such visit would conflict with a prearranged visit by another client or an inspection by or for another client or by a regulatory
authority. Unless otherwise agreed, such visits shall only be made subject to [***] prior written notice of the request for such visit, such notice to be given to DSM by OPTHEA and such notice to identify the persons who will be visiting and the
nature of their association with OPTHEA. Nothing contained in this Section&nbsp;7.7 shall be construed to permit OPTHEA employees, representatives, contractors or employees, representatives or contactors of an Affiliate of OPTHEA, licensees or
potential licensees of OPTHEA to be present in restricted cGMP suites or locations of the facility. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Parties may use electronic mail to communicate during the execution of the Services. The Parties shall use
all reasonable measures to ensure the confidentiality of information so communicated. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">DSM shall, throughout the Services, use its commercially reasonable efforts to maintain adequate resources
(including suitable equipment and facilities and qualified, trained and experienced staff) to perform the Services as currently planned and as may be modified by agreement between the Parties. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>SECTION 8: RECORDS AND REPORTS </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DSM hereby
undertakes that it shall submit to OPTHEA, at the times identified in the Schedule, a report detailing the progress and results of (the relevant part of) the Services and highlighting any major issues encountered during the previous period. If no
times are identified in the Schedule, then reports shall be issued [***] and final reports shall be issued promptly after completion of the relevant part of the Services. In any event, as soon as DSM becomes aware of any major issues that may impact
on the time for completion of the Services or any part thereof, or that may have an effect on a deliverable or impact the Product, such major issues shall be reported promptly to OPTHEA, as well as being highlighted in the next report that is due on
that part of the Services. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>SECTION 9: QUALITY AUDITS AND REGULATORY APPROVALS </U></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All audits shall be governed by the Quality Agreement attached as <B>Exhibit 3</B> to this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The &#147;Annual Audit&#148; as set forth in the Quality Agreement and &#147;For Cause Audits&#148; will be
[***] to OPTHEA. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 18 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For any other Audits other than those outlined under <B>Section</B><B></B><B>&nbsp;9.2</B> of this Agreement
during the same calendar year or twelve month period (as applicable), DSM&#146;s expenses (including DSM&#146;s internal costs, such as, without limitation, labor which for the purpose hereof shall be charged at [***] in accordance with the terms of
<B>Exhibit 1</B>) associated with such audits or inspections shall be borne by OPTHEA. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">DSM shall permit inspections of DSM&#146;s facilities by governmental authorities (such as the FDA and
equivalent EMA regulatory authorities) in connection with any registration or pending registration for manufacturing of Product. All DSM&#146;s and such subcontractors&#146; expenses (including internal costs, such as, without limitation, labor
costs) associated with such audits or inspections shall be borne by [***] and shall be in accordance with [***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">DSM and OPTHEA agree to promptly inform each other on the outcome of other inspections by governmental
regulatory authorities potentially connected with the Product(s). </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>SECTION 10: SUBCONTRACTING </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Unless to an Affiliate in relation to an activity which is not covered by cGMP, DSM shall not be entitled to subcontract portions of the
Services to any third party without OPTHEA&#146;s prior written permission thereto, which permission shall not be unreasonably or untimely withheld. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>SECTION 11: INTELLECTUAL PROPERTY RIGHTS </U></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Neither Party will, as a result of this Agreement, acquire any right, title or interest in any Intellectual
Property Rights that the other party owns or controls as of the Effective Date, or that the other Party obtains ownership or control of separate and apart from the performance of the Services under this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">OPTHEA shall exclusively own all right, title and interest in the Intellectual Property Rights that DSM and/or
its Affiliates, contractors or agents develop, conceive, invent, reduce to practice or make, solely or jointly with OPTHEA, in the course of performance of the Services or as a result of receipt of OPTHEA Intellectual Property Rights and that [***]
(&#147;<B>New OPTHEA Intellectual Property</B>&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">DSM shall exclusively own all right, title and interest in the
Intellectual Property Rights that DSM and/or its Affiliates, contractors or agents develop, conceive, invent, reduce to practice or make, solely or jointly with OPTHEA in the course of performance of the Services or as a result of receipt of OPTHEA
Intellectual Property Rights and that [***] (&#147;<B>New General Application Intellectual Property</B>&#148;). By way of example, process changes to DSM&#146;s standard platform process based on and/or in connection with the Product and/or the
Process, shall be deemed to be New General Application Intellectual Property. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 19 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, the Parties agree that New OPTHEA Intellectual Property shall not
under any circumstances be interpreted or defined to include any New General Application Intellectual Property, and that New General Application Intellectual Property shall not under any circumstances be interpreted or defined to include any New
OPTHEA Intellectual Property. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">DSM hereby assigns to OPTHEA and shall continue to assign to OPTHEA all of its right, title and interest in any
New OPTHEA Intellectual Property. DSM shall promptly disclose to OPTHEA in writing all New OPTHEA Intellectual Property. DSM shall execute, and shall require DSM&#146;s personnel involved in the performance of the Services to execute, any documents
required to confirm OPTHEA&#146;s ownership of the New OPTHEA Intellectual Property, and any documents required to apply for, maintain and enforce any patent or other right in the New OPTHEA Intellectual Property. Upon OPTHEA&#146;s request and at
OPTHEA&#146;s reasonable expense, and at no cost to DSM, DSM shall assist OPTHEA as may be necessary to apply for, maintain and enforce any patent or other right in the New OPTHEA Intellectual Property. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">OPTHEA hereby assigns to DSM and shall continue to assign to DSM all of its right, title and interest in any New General Application
Intellectual Property. OPTHEA shall execute, and shall require OPTHEA&#146;s personnel involved in the performance of the Services to execute, any documents required to confirm DSM&#146;s ownership of the New General Application Intellectual
Property, and any documents required to apply for, maintain and enforce any patent or other right in the New General Application Intellectual Property. Upon DSM&#146;s request and at DSM&#146;s reasonable expense, and at no cost to OPTHEA, OPTHEA
shall assist DSM as may be necessary to apply for, maintain and enforce any patent or other right in the New General Application Intellectual Property. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">DSM hereby grants to OPTHEA a perpetual, royalty-free, fully <FONT STYLE="white-space:nowrap">paid-up,</FONT> <FONT
STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide, transferable license, with the right to grant and authorize sublicenses, to use any and all Intellectual Property Rights proprietary to DSM, including New General Application Intellectual
Property, embedded in the Process, solely for the purpose of and to the extent necessary for developing, conducting clinical trials for, formulating, making, testing, seeking regulatory approval for, marketing, commercializing, using, selling,
importing and distributing the Product. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">It is agreed between the Parties that such license to OPTHEA shall not include a
license to [***], it being understood by the Parties that the technology embedded in these DSM Intellectual Property Rights shall not be used by DSM to perform the Services. If, due to an amendment of the Services, such DSM Intellectual Property
Rights will be used to perform the Services, DSM may require a separate license, including provisions for payment of royalties under certain circumstances as set forth in such license. Any amendment of the Services which may lead to the use of such
DSM Intellectual Property Rights will be discussed between the Parties. In the event that OPTHEA does not enter into a license agreement on terms acceptable to DSM, DSM shall not (and shall have no obligation to) include the use of such Intellectual
Property Rights in the performance of the Services. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 20 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">OPTHEA hereby grants to DSM, for the Term of this Agreement only, a
<FONT STYLE="white-space:nowrap">non-exclusive,</FONT> royalty-free license, without the right to sublicense, to use any and all Intellectual Property Rights proprietary to OPTHEA, including New OPTHEA Intellectual Property, solely for the purpose
of performing the Services and to the extent necessary to perform the Services. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The rights and obligations set forth in this Section&nbsp;11 shall survive any termination of this Agreement
for any reason. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>SECTION 12: REPRESENTATIONS AND WARRANTIES </U></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">DSM hereby represents and warrants to OPTHEA that on the Effective Date of this Agreement:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">it is a corporation duly organized, validly existing and in good standing under the laws of<B> </B>The
Netherlands, and has full corporate power to conduct the business in which it is presently engaged and to enter into and perform its obligations under this Agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">it has taken all necessary corporate action under the applicable laws and its articles of incorporation and
bylaws to authorize the execution by its undersigned officers and consummation of this Agreement. This Agreement shall constitute a valid and legally binding agreement, enforceable against it in accordance with its terms, subject to bankruptcy,
insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability relating to or affecting creditors&#146; rights and to general equity principles; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the best of its knowledge, the execution by it of the activities contemplated by the Services in accordance
with this Agreement will not infringe upon the rights of any third party, nor conflict with any law or regulation applicable to DSM; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">it has the capabilities to perform the Services. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">OPTHEA hereby represents and warrants to DSM that on the Effective Date of this Agreement:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">it is a corporation duly organized, validly existing and in good standing under the laws of Australia, and has
full corporate power to conduct the business in which it is presently engaged and to enter into and perform its obligations under this Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">it has taken all necessary corporate action under the applicable laws and its articles of incorporation and
bylaws to authorize the execution by its undersigned officers and consummation of this Agreement. This Agreement shall constitute a valid and legally binding agreement, enforceable against it in accordance with its terms, subject to bankruptcy,
insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability relating to or affecting creditors&#146; rights and to general equity principles; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 21 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">it has sufficient right to the Product for the execution of the Services; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the best of its knowledge, as known to OPTHEA on the Effective Date, the Product does not infringe upon the
rights of any third party, nor conflict with any law or regulation applicable to OPTHEA and there are no third party rights to a process which is exclusive and specific to the manufacture of the Product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.2.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">non-cGMP</FONT> Product will not be for human use. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Disclaimer of Warranties</U>. Subject to 12.1.3, DSM EXPRESSLY DISCLAIMS (i)&nbsp;all implied warranties
[***]; (ii) any warranties that the Product will not [***]; (iii) any warranties in respect of [***] of the Product or in respect of the [***] the Product to third parties, and (iv)&nbsp;any warranty, either express or implied, legal or
conventional, with regard to the Services or Product other than [***] in this Agreement<B>.</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With respect to DEVELOPMENT WORK performed under Section&nbsp;4, DSM shall use diligent and commercially
reasonable efforts to perform its obligations as set forth in the Agreement. It is recognized and agreed by and between DSM and OPTHEA, however, that since the services being performed by DSM as part of the DEVELOPMENT WORK are of a developmental or
research nature, there can be no guarantee that the DEVELOPMENT WORK will be successfully completed or successfully completed with the contemplated time period, despite DSM&#146;s diligent and commercially reasonable efforts to do so.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Parties hereby acknowledge and agree that there is no representation nor guarantee: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the Product or the Process [***] of OPTHEA, commercially exploitable, profitable or approved by any
regulatory authority; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the results identified in <B>Exhibit 1</B> can be achieved or can be achieved within the set time limit;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that, unless otherwise agreed upon in writing, any Product resulting from the Services will [***] or will be
delivered [***] for any further use or clinical programs intended therefore by OPTHEA. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>SECTION 13: LIABILITY AND INDEMNIFICATION
</U></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Limitation of Liability</U>. Notwithstanding anything herein to the contrary, except for [***] the total
aggregate liability of either Party to the other Party, on all claims of any kind, whether in contract, tort or strict liability, arising out of the performance or breach of this Agreement shall not exceed the sum which is equal to [***] under this
Agreement at the time a claim is made, provided that in any event each Party&#146;s aggregate liability under this Agreement ([***]) shall not exceed the amount of [***]. Without limiting the foregoing, and except as set forth in [***], in no event
shall a Party&#146;s liability for any particular Development Work stage or Batch of Product exceed [***]. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 22 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Advice / Assistance</U>. If DSM furnishes OPTHEA with advice or assistance concerning any products, systems
or work which is not required pursuant to this Agreement, the furnishing of such advice or assistance will not subject DSM to any liability, whether in contract, tort or strict liability. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purposes of this Section&nbsp;13, the term &#147;DSM&#148; shall mean DSM, its affiliates,
subcontractors and suppliers of any tier, and its and their respective directors, officers, employees, agents and/or representatives, whether individually or collectively. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The provisions of this Article 13 shall prevail over any conflicting or inconsistent provisions contained in
any of the documents comprising this Agreement. For the avoidance of doubt however, the limitation of liability set forth in Section&nbsp;13.1 shall not in any way [***] if and when applicable. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U><FONT STYLE="white-space:nowrap">Non-Direct</FONT> Damages</U>. In no event, whether as a result of breach
of contract, warranty, indemnity, tort (including negligence), strict liability, or otherwise, shall either Party or its subcontractors or suppliers be liable to the other Party for loss of profit or revenues, lost business opportunity, loss of use
of the Product or any equipment, claims of the other Party&#146;s customers for such damages, or for any special, consequential, incidental, punitive, indirect or exemplary damages. In no event shall DSM be liable to OPTHEA, or any direct or
indirect third party customers of OPTHEA, for [***] of Product. For the avoidance of doubt however, the limitation of liability set forth in this Section&nbsp;13.5 shall not in any way [***] if and when applicable. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Indemnity</U>. DSM hereby agrees to indemnify and hold harmless OPTHEA from any Losses resulting from Claims
arising from [***], to the extent arising from [***] and resulting directly from DSM&#146;s or its officers, servants, agents, employees, and/or assigns breach while engaged in activities under this Agreement, except to the extent in each case
caused by the negligence or misconduct of OPTHEA. OPTHEA shall likewise indemnify and hold harmless DSM from any Losses resulting from Claims arising from [***] (except to the extent caused by DSM&#146;s breach while engaged in activities under this
Agreement and for which DSM has an indemnification obligation pursuant to this Article 13.6), or to the extent resulting from the breach of obligations or warranties hereunder or the negligence of OPTHEA, its officers, servants, agents, employees,
and/or assigns, while engaged in activities relating to this Agreement, except to the extent caused by the negligence or misconduct of DSM. In the event such damage or injury is caused by joint or concurrent negligence of DSM and OPTHEA, the loss
shall be borne [***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In addition to 13.6 OPTHEA shall assume full responsibility and liability for, and shall indemnify and hold DSM
harmless against, any and all Losses resulting from Claims caused by or relating to [***], or [***] in the performance of the Services and in accordance with the terms of this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The indemnities contained in this Agreement are subject to the following conditions. The indemnified party
shall promptly notify the indemnifying party in writing of any Claim with respect to which indemnification is sought (which notice shall include copies of any pleadings or other documents served on the indemnified party in relation to
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 23 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
such Claim) and will permit the indemnifying party, at the indemnifying party&#146;s cost, to handle and control the investigation, conduct and defense of such Claim and select counsel of the
indemnifying party&#146;s choice. Neither Party shall settle any such Claim without the prior written approval of the other party (such approval not to be unreasonably withheld or delayed). The indemnified party shall neither accept nor make any
admission in respect of any such Claim or take any action relating to any such Claim which is prejudicial to the defense of any such Claim without the prior written approval of the indemnifying party (such approval not to be unreasonably withheld).
The indemnified party shall keep the indemnifying party fully informed of any developments of which it becomes aware that may give rise to such a Claim and fully cooperate with the indemnifying party in the investigation, conduct and defense of such
Claim. However, the failure of the indemnified party to adhere to any of the above conditions will not relieve the indemnifying party from its indemnification obligations, except to the extent that (i)&nbsp;such
<FONT STYLE="white-space:nowrap">non-adherence</FONT> has given rise to such Claim or increase of Losses resulting from such Claim; or (ii)&nbsp;the indemnifying has been prejudiced by such <FONT STYLE="white-space:nowrap">non-adherence.</FONT>
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Party shall at all times maintain all necessary insurance coverage with sound and reputable independent
insurers at commercially reasonable levels of coverage or shall be self-insured having regard to the nature, type, scope and size of the business it conducts and all its respective activities and obligations under this Agreement. General liability
coverage in the amount of at least [***] shall be maintained by each Party. Each Party shall, upon reasonable request of the other Party, produce satisfactory evidence that all insurance premiums have been paid and kept up to date and are kept in
accordance with local insurance laws or regulations from time to time in force, or shall furnish appropriate certificates of insurance showing proof of coverage. The insurance coverage may be provided through a combination of primary,
excess/umbrella or self-insured retention, and shall not serve to operate as a limitation on the recovery of any claim. Each Party shall include the other Party as a named insured on its policies of insurance, as the other Party&#146;s interests may
be affected pursuant to this Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>SECTION 14: CONFIDENTIALITY </U></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Party shall maintain all Confidential Information it has received in strict confidence, except that the
receiving Party may disclose or permit the disclosure of any Confidential Information to its Affiliates and its Affiliates directors, officers, employees, consultants, advisors who are obligated to maintain the confidential nature of such
Confidential Information and who need to know such Confidential Information for the execution of the Services. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Party shall use the Confidential Information it has received solely for the purpose of executing the
Services. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Party shall be responsible for any breaches of this Section&nbsp;14 by any of its Affiliates, directors,
officers, employees, consultants, advisors and Third Party contractors. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 24 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The obligations contained in Section&nbsp;14.1 shall not apply to Confidential Information which:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">14.4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the time of disclosure either is or was part of the public knowledge or literature; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">14.4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">after disclosure becomes part of the public knowledge or literature through no fault or action of the receiving
Party; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">14.4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the receiving Party can establish by competent proof either is or was at the time of disclosure in its lawful
possession from a source other than the disclosing Party; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">14.4.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">after disclosure is acquired by receiving Party from a third party who was not known to have obtained such
Confidential Information, directly or indirectly, from the disclosing Party; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">14.4.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is or has been independently developed by the receiving Party without the use of disclosing Party&#146;s
Confidential Information. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The obligations set forth in this Section&nbsp;14 shall also not apply to Confidential Information which is
required to disclose in prosecuting or defending litigation or in complying with applicable governmental regulations, provided that such disclosure is subject to all applicable governmental or judicial protection available for like material and that
reasonable advance notice is given to the other Party. In addition, the obligations set forth under Section&nbsp;14.1 shall not apply to Confidential Information that is reasonably required to be disclosed in connection with any regulatory
submission relating to the Product. For the sake of clarity it is understood between the Parties that the obligations set forth in this Section&nbsp;14 shall otherwise remain applicable. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The obligations as set forth in this Section&nbsp;14 shall expire [***] from the date this Agreement
terminates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Press Releases</U>. After signing of this Agreement, neither Party shall issue a press release or use any
other form of publication regarding the entering into this Agreement or its content without the written consent of the other Party, not to be unreasonably withheld. Any such press release or other form of publication shall be in a form mutually
agreed upon by the Parties. Notwithstanding the foregoing, however, if in the reasonable opinion of a Party&#146;s legal counsel a public announcement concerning its entry into this Agreement or its content is legally required by applicable laws,
regulations or judicial order, or the rules or regulations of any stock or securities exchange to which that Party or its Affiliates is subject, then the Party shall be entitled to make such announcement provided that (i)&nbsp;it provides the other
Party notice reasonable under the circumstances of such intended announcement, and to the extent feasible under the circumstances consults with the other Party relative to the nature and scope of such intended announcement, and (ii)&nbsp;shall not
mention the name or identity of the other Party in such announcement, unless in the reasonable opinion of the first mentioned Party&#146;s legal counsel inclusion of the other Party&#146;s name or identity is legally required by applicable laws,
regulations or judicial order, or required under the rules or regulations of any stock or securities exchange to which that Party or its Affiliates is subject, in which case such Party shall be entitled to include the other Party&#146;s name or
identity in the announcement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 25 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the extent they relate to the same subject matter, the provisions of this Section&nbsp;14 replace in their
entirety, as of the Effective Date, the terms and conditions of any mutual confidential disclosure agreement previously entered into by the Parties, which agreement(s) shall be of no further force or effect, provided, however, that information
previously disclosed under the terms of such prior agreement shall be deemed to have been disclosed pursuant to the terms of this Section&nbsp;14. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>SECTION 15: TERM AND TERMINATION </U></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement shall become effective as of the Effective Date and shall remain in force and effect until the
earlier date of (i)&nbsp;the Services being completed or (ii)&nbsp;the Agreement being terminated by either Party as provided herein. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">15.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Mutual Agreement.</U> This Agreement may be terminated at any time upon mutual written agreement of both
Parties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">15.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>OPTHEA right to terminate.</U> OPTHEA shall have the right to terminate this Agreement upon [***] prior
written notice of termination to DSM if OPTHEA, at its sole discretion, elects not to proceed with the Services. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">15.1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>DSM Right to Terminate</U>. DSM has the right to terminate this Agreement upon [***] prior written notice of
termination to OPTHEA if, at OPTHEA&#146;s request or solely due to OPTHEA&#146;s fault or negligence, DSM has not, at the time of providing such notice, performed any activities under this Agreement in the previous [***]. This Agreement may also be
terminated by DSM upon [***] written notice to OPTHEA in the event that, despite the commercially reasonable best efforts of DSM, DSM determines that the Services cannot be completed according to the Specifications approved by OPTHEA, or cannot be
completed within a reasonable time after the conclusion of the period originally planned in the Program. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">15.1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Material Breach</U>. Either Party (the &#147;<B><FONT STYLE="white-space:nowrap">Non-Defaulting</FONT>
Party</B>&#148;) may terminate this Agreement if the other Party (the &#147;<B>Defaulting Party</B>&#148;) fails to perform any material obligation, warranty, duty or responsibility and such failure or default continues for a period of [***] after
written notice thereof by the <FONT STYLE="white-space:nowrap">Non-Defaulting</FONT> Party to the Defaulting Party; provided that where such breach is curable but cannot be reasonably cured within [***], such breach shall be deemed cured if the
Defaulting Party provides the <FONT STYLE="white-space:nowrap">Non-Defaulting</FONT> Party with a plan to cure such breach and commences to cure such breach in accordance with the plan within such [***] period and diligently continues such cure.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">15.1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Insolvency, Bankruptcy</U>. Either Party may terminate this Agreement upon the occurrence of either of the
following: (i)&nbsp;The entry of a decree or order for </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 26 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
relief by a court having jurisdiction in respect of the other Party in an involuntary case under the applicable bankruptcy code, as now constituted or hereafter amended, or under any other
applicable insolvency or other similar law and the continuance of any such decree or order unstayed and in effect for a period of sixty (60)&nbsp;consecutive days; or (ii)&nbsp;the filing by the other Party of a petition for relief under the
applicable bankruptcy code, as now constituted or hereafter amended, or any other applicable federal or state insolvency or other similar law. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">15.1.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Other Grounds</U>. This Agreement may be terminated pursuant to Sections 4.3, 4.4 or 5.12.2
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event of any cancellation or postponement of Development Work or Manufacturing Work by OPTHEA. including
any deemed postponement pursuant to Section&nbsp;4.5 or 5.2 (&#147;<B>Postponement</B>&#148;), DSM shall use commercially reasonable efforts to fill the capacity which becomes available as a result of such Postponement. Where DSM is capable of
filling the capacity which has become available as a result of the Postponement of certain Development Work or Manufacturing Work by OPTHEA and there is no negative revenue recognition impact for DSM in the current European financial year (running
from each January&nbsp;1 through December 31), no Close Out Costs for this Postponed Development Work or Manufacturing Work will apply. Where there is a negative revenue recognition impact for DSM caused by Postponement of Development Work or
Manufacturing Work then Close Out Costs shall apply up to the amount of [***]. For the avoidance of doubt, Close Out Costs shall be applicable to the [***] Services Activities but shall not be applicable to the [***] Services Activities unless and
until the [***] Services Activities have been authorized by OPTHEA in accordance with Section&nbsp;5.1. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event of any form of termination OPTHEA shall compensate and/or pay to DSM for the following (to the
extent not already paid to DSM): </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">15.3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Price for all work properly performed pursuant to the terms of this Agreement in connection with the
Services up to the date of termination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">15.3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Costs incurred in performing the Services up to the date of termination (including without limitation the Costs
of raw materials and supplies already ordered on a <FONT STYLE="white-space:nowrap">non-cancellable</FONT> basis by DSM) other than those Costs that have arisen with respect to that part of the Services in which DSM has committed a material breach
of its obligations under this Agreement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">15.3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">non-cancellable</FONT> Costs in respect of third party commitments, such as in
respect of external testing, already entered into by DSM, other than those Costs that have arisen with respect to that part of the Services in which DSM has committed a material breach of its obligations under this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event of any form of termination except termination by OPTHEA as per Section&nbsp;15.1.4, and subject to
Section&nbsp;15.2 last sentence, Close Out Costs as defined in Section&nbsp;15.5 shall also be payable under Section&nbsp;15.3, but only to the extent that DSM cannot recoup its lost revenue as outlined in 15.2. In no event shall the aggregate
amount paid by OPTHEA to DSM as outlined in 15.2, 15.3 and 15.5, exceed the total amount for each stage which is being terminated. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 27 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Close Out Costs</B>&#148; shall mean: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">15.5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">with respect to Development Work: the Price and Costs as defined in <B>Exhibit 5</B>, under the heading
&#147;Development Work&#148;. and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">15.5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">with respect to Manufacturing Work, the Price and Costs as defined in <B>Exhibit 5</B> for each cancelled
Batch, under the heading &#147;Manufacturing Work&#148;. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The effective date of termination will be the date stated in any termination notice given hereunder, which date
will not be before the expiration of any applicable cure period provided for in this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Termination of this Agreement will not affect the rights and obligations of the Parties accrued under this
Agreement prior to termination nor the provisions contained in this Agreement, which by their purpose have a term beyond the termination of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon any termination of this Agreement: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">15.8.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at OPTHEA&#146;s first request, any and all Confidential Information disclosed by OPTHEA which is in DSM&#146;s
possession and all documents containing such Confidential Information or any part thereof, and all copies and extracts made thereof shall be returned to OPTHEA, provided however that DSM may keep one (1)&nbsp;copy of all Confidential Information
received by it for its legal files to enable it to determine its obligations hereunder and for regulatory compliance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">15.8.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">OPTHEA shall return to DSM or destroy, immediately upon DSM&#146;s first request, any and all Confidential
Information disclosed by DSM which is in OPTHEA&#146;s possession and all documents containing such Confidential Information or any part thereof, and all copies and extracts made thereof, provided however that OPTHEA may keep one (1)&nbsp;copy of
all Confidential Information received by it for its legal files to enable it to determine its obligations hereunder and for regulatory compliance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">15.8.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">DSM shall at OPTHEA&#146;s request, risk and expense (in so far as it has not resulted directly from a material
breach of the obligations of DSM), transport to OPTHEA or OPTHEA&#146;s designee any and all capital investment equipment or other assets and raw materials purchased prior to or in the course of and for the Services and paid for or whose Costs have
been reimbursed by OPTHEA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">15.8.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">DSM shall at OPTHEA&#146;s request, risk and expense (in so far as it has not resulted directly from a material
breach of the obligations of DSM), transport to OPTHEA or OPTHEA&#146;s designee any and all <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">work-in-progress</FONT></FONT> and samples arising from the Services and all materials
being held by DSM on OPTHEA&#146;s behalf. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 28 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>SECTION 16: NOTICES </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All notices, requests, demands and other communications to be given in accordance with this Agreement shall be given in writing and shall be given by prepaid
registered mail, receipt return requested, to the other Party at the following addresses: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="82%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">if to OPTHEA:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>OPTHEA Pty. Ltd.</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Level&nbsp;4,</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">650 Chapel Street,</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">South Yarra,</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Victoria 3141,</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Australia</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">Attention: CEO </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="82%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">if to DSM:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>DSM Biologics Company B.V.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.30em; font-size:10pt; font-family:Times New Roman">Attention: [***]</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.30em; font-size:10pt; font-family:Times New Roman">With a copy to: [***]</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.30em; font-size:10pt; font-family:Times New Roman">Attention: [***]</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or at such other address as a Party may have previously indicated to the other Party in writing in conformity with the
foregoing. Any such notice, request, demand or other communication shall be deemed to have been received on the [***] following the date of its mailing if sent by registered mail. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 29 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>SECTION 17: ASSIGNMENT </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Agreement will be to the benefit of the permitted successors and assigns of the Parties hereto. Except to Affiliates, neither Party will be entitled to
assign its rights under this Agreement to any individual, partnership or other entity without the prior written consent of the other Party hereto; and any attempted assignments without such written consent shall be of no effect. In addition, either
Party shall be entitled, without the prior written consent of the other Party, to assign all or part of its rights under this Agreement to a purchaser of all or substantially all of its assets, or an entity with which it may merge. Notwithstanding
the foregoing, any such assignment shall be under the conditions that (i)&nbsp;the assignee agrees in writing to assume all obligations undertaken by its assignor in this Agreement; and (ii)&nbsp;the assignor guarantees unconditionally and in
writing the proper compliance by the assignee of all obligations under this Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>SECTION 18: DISPUTES AND APPLICABLE LAW </U></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event of a dispute between the Parties, the Parties shall first make every effort to find an amicable
settlement to such dispute. If the Parties cannot so settle such dispute, the Steering Committee shall, within [***] (which time may be extended by mutual agreement) from a request by either Party, meet and use its best efforts to resolve any
disputes. Failing such settlement, the Chief Executive Officers of the Parties, or their nominees, shall within [***] (which time may be extended by mutual agreement) from the date of expiration of the [***] (or extended) period provided for in the
previous sentence, meet and use their best efforts to resolve any disputes. In the event that the Chief Executive Officers of the Parties or their nominees fail to reach a settlement, the provisions of Section&nbsp;18.2 shall apply. Notwithstanding
the foregoing, any dispute with respect to Quality Assurance issues shall be settled according to the relevant provisions of Sections 5.9 and 5.10. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement shall be governed by and interpreted in accordance with the laws of the Australia without regard
to conflicts of laws principles. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>SECTION 19: FORCE MAJEURE </U></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">19.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The obligations of either Party (other than the obligation of payment) hereunder shall be suspended during the
time and circumstance beyond the reasonable control and without the fault of that Party so affected, which prevents or hinders the execution of the relevant Party&#146;s obligations under this Agreement (&#147;Force Majeure&#148;) including but not
limited to: inevitable accidents, perils of navigation, floods, fire, storms, epidemics, acts of God, earthquakes, explosions, hostilities, civil commotion, war (declared or undeclared), orders, requisitions, regulations or acts of any government or
governmental authority, whether de jure or de facto or any official purporting to act under the authority of any such government, illegality arising from domestic or foreign laws or regulations, insurrections, failure or slowdown of public utilities
or common carriers, inability to procure raw materials or other circumstances or conditions of a </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 30 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
similar nature, quarantine or custom restrictions, damage in factories or warehouses, strikes, lockouts or any other labor difficulty at the Parties and/or suppliers of goods, raw materials
and/or excipients, lack of conveyance, breakdown of machinery or instruments or other disturbances at the Parties or their suppliers. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">19.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As soon as possible after being affected by a Force Majeure, the Party so affected shall furnish to the other
Party all particulars of the Force Majeure and the manner in which its execution is thereby prevented or delayed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">19.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that any Force Majeure cannot be removed, overcome or abated within [***] (or such other period as
the Parties jointly shall determine) from the date the Party affected first became affected, then either Party may, at the expiration of such period, by written notice to the other Party [***]. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>SECTION 20: MISCELLANEOUS PROVISIONS </U></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Laws</U>: DSM shall comply with all applicable laws and regulations in performing its activities under this
Agreement, including without limitation Dutch, EU and Australian Health and Safety and Environmental laws and regulations in so far as they pertain to the development and/or manufacture of Product. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Permits</U>: DSM warrants that it has obtained all permits and governmental or other licenses required in
connection with its activities under this Agreement and shall maintain all such permits and governmental or other licenses until completion of the Services. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Cumulative /Indivisible Rights</U>: All rights and recourses of a Party under this Agreement are cumulative;
and the exercise by a Party of any of its rights or recourses will not prevent it from exercising any other right or recourse available under this Agreement or at law. All obligations of the Parties under this Agreement are indivisible.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Severability</U>: If any covenant, obligation or term hereunder or the application of any part of this
Agreement to any person, party or circumstance shall, to any extent, be illegal, invalid or unenforceable, the remainder of this Agreement or the application of such covenants, agreements or obligations other than those which are held to be invalid
or unenforceable shall not be affected thereby; and each covenant, obligation and agreement contained herein shall be separately valid and enforceable to the full extent permitted by law. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No partnership</U>: This is an agreement between separate entities; and neither entity is the agent,
representative, master or servant of or possesses the power to obligate the other or to make any warranties or representations on behalf of the other. Nothing in this Agreement will be interpreted so as to create a relationship of partners, joint
ventures, agents, mandate, fiduciaries or any other similar relationship between the Parties. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 31 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No Waiver</U>: Failure by either Party to take action against the other Party shall not affect its right to
require full performance of this Agreement at any time thereafter. The waiver by either Party of the breach of any term of this Agreement by the other Party will not operate or be interpreted as a waiver of any subsequent breach by such Party. No
term of this Agreement will be deemed to have been waived by either Party unless such waiver is in writing. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Entire Agreement</U>: This Agreement and the documents referred to in it or attached to this Agreement
constitute the entire agreement between the Parties with respect to the subject matter hereof and supersede all prior discussions, negotiations and agreements with respect thereto. No amendment of, change to or variance from this Agreement will be
binding on either Party unless in writing and signed by the Parties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Agreement Prevails</U>: In case of any discrepancy between this Agreement and any of the Exhibits hereto,
this Agreement will prevail. In the event that a discrepancy between this Agreement and any Quality Agreement subsequently entered into between the Parties, the terms of the Quality Agreement shall prevail as to matters that are primarily quality
related and the terms of this Agreement shall prevail as to all other matters. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Validity and Effect</U>: Each of the Parties agrees to perform such acts, sign and deliver such other
agreements, cause such meetings to be held, resolutions passed and <FONT STYLE="white-space:nowrap">by-laws</FONT> enacted, exercise their vote and influence as may be necessary or desirable from time to time in order to give full effect to this
Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Counterparts</U>: This Agreement may be executed in two (2)&nbsp;counterparts, each of which shall be an
original and all of which shall constitute together but one and the same document. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Headings for Convenience</U>: The headings and subheadings of the sections of this Agreement have been
included solely for ease of reference and do not form part of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Number/Gender</U>: All words and personal pronouns relating thereto shall be read and construed as the
number and gender of the Party or Parties referred to in each case require and the verb shall be construed as agreeing with the required word and/or pronoun. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Writing Necessary</U>: This Agreement will not be binding upon the Parties until it has been signed below on
behalf of each Party, in which event it shall be effective as of the date of signing. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No Employee Solicitation</U>: During the Term of this Agreement and for [***] thereafter, neither Party
will, without the prior written consent of the other Party, directly solicit [***]. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 32 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Documentation Control:</U> OPTHEA shall not make any changes to
<FONT STYLE="white-space:nowrap">DSM-owned</FONT> or <FONT STYLE="white-space:nowrap">DSM-controlled</FONT> cGMP Documentation without prior consent of DSM, in order to ensure that all cGMP Documentation, which is maintained at DSM and subject to
regulatory review, matches or is consistent with information filed with regulatory authorities. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 33 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Parties have signed this Agreement by and through their respective and duly
authorized officers: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>OPTHEA Pty Ltd </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Megan Baldwin</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Robert Klupacs</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Megan Baldwin</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name: Robert Klupacs</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: CEO</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Title: Director</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DSM Biologics Company Australia Pty Ltd </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">/s/ Scott Lorimer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">/s/ Amgad Hanna</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Scott Lorimer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name: Amgad Hanna</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Director: </TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Director/Secretary: Director, Quality Affairs</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DSM Biologics Company B.V. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">/s/ Scott Lorimer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Marc Gurman</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Scott Lorimer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name: Marc Gurman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Title: VP</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 34 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT 1: SERVICES SCHEDULE </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Annex 1: Timing of the Project </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following Gantt chart outlines the
initial estimated timeline for the program. Agreement on the timing of key activities will be dependent on development and manufacturing slot availability within DSM Biologics planning schedules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To meet the timelines outlined below, it is assumed that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">-</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>[***]</U> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">[***]</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 35 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Annex 2: Description of the Different Activities within the Project </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B><U>Module 1 </U></B>[***] </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Project <FONT STYLE="white-space:nowrap">Kick-off</FONT> meeting </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Cell culturing - development and implementation of a CHO cell culture fed batch process
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.2.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Transfer of a qualified Research Cell Bank for a CHO cell line </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.2.2</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>[***] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Purification Implementation </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.3.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>[***] </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Analytics &#150; Implementation Product Specific Assays </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt" BGCOLOR="#99ccff">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000" BGCOLOR="#99ccff">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000" BGCOLOR="#99ccff">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000" BGCOLOR="#99ccff">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt" BGCOLOR="#99ccff"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#99ccff" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#99ccff"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#99ccff" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#99ccff"><B>[***]</B></TD>
<TD VALIGN="bottom" BGCOLOR="#99ccff" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt" BGCOLOR="#99ccff"><B>[***]</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><B>[***]</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>[***]</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>[***]</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>[***]</B></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><U><B>Assumptions</B></U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 36 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">Pre-Production</FONT> Reference Standard </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Evaluation of Formulations for Drug Substance </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="90%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="14%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B><U>Module 2</U> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.7</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>[***]<B> Confirmation</B><B></B><B>&nbsp;&amp; Material Supply Batch </B>[***] </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.8</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Analytics Verification </B>[***] </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="90%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="22%"></TD></TR>


<TR STYLE="font-size:1pt" BGCOLOR="#99ccff">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#99ccff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 37 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="90%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="22%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.9</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Production of a Manufacturing Cell Bank (MCB)</B><B> </B>[***] </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.10</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Production of an Engineering Batch using Fed Batch</B><B><SUP STYLE="font-size:85%; vertical-align:top">
</SUP></B><B>at 250L Scale</B><B> </B>[***] </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">[***] </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.11</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Drug Substance Real-Time Stability Study on Engineering Batch </B>[***] </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.12</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Virus Clearance Validation </B>[***] </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.13</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Master Reference Standard </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B><U>Module 3
</U></B><U>[<B>***]</B></U><B> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.14</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Production of a cGMP Batch using <FONT STYLE="white-space:nowrap">Fed-Batch</FONT> at [***]
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.15</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Drug Substance Stability Study on cGMP Batch </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.15.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Real-Time Drug Substance Stability Study </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.15.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Accelerated Drug Substance Stability Study </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.16</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Drug Product Testing </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.17</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Drug Product Stability Study </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.17.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Drug Product Real-Time Stability Study </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 38 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.17.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Drug Product Accelerated Stability Study </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.17.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Freeze/Thaw Study (as part of the Drug Product Stability Study) </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.18</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Regulatory Dossier [***] </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">[***]. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="90%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">Title</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">[***]</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 39 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Annex 3: Assumptions for the </B><B>Program</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Financial Assumptions</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">[***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Technical
assumptions:</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">[***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Service assumptions:</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">[***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Safety, Health and Environment (SHE)
</U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">[***]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 40 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Annex 4: Bill of Testing</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bill of Testing for MCB </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt" BGCOLOR="#99ccff">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000" BGCOLOR="#99ccff">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000" BGCOLOR="#99ccff">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt" BGCOLOR="#99ccff"><B>Test</B></TD>
<TD VALIGN="bottom" BGCOLOR="#99ccff" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#99ccff"><B>Method</B></TD>
<TD VALIGN="bottom" BGCOLOR="#99ccff" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt" BGCOLOR="#99ccff"><B>Performed by</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safety
Testing on Crude Harvest </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt" BGCOLOR="#99ccff">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000" BGCOLOR="#99ccff">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000" BGCOLOR="#99ccff">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt" BGCOLOR="#99ccff"><B>Test</B></TD>
<TD VALIGN="bottom" BGCOLOR="#99ccff" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#99ccff"><B>Method</B></TD>
<TD VALIGN="bottom" BGCOLOR="#99ccff" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt" BGCOLOR="#99ccff"><B>Performed by</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bill of Testing for Drug Substance </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt" BGCOLOR="#99ccff">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000" BGCOLOR="#99ccff">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000" BGCOLOR="#99ccff">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt" BGCOLOR="#99ccff"><B>Test</B></TD>
<TD VALIGN="bottom" BGCOLOR="#99ccff" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#99ccff"><B>Method</B></TD>
<TD VALIGN="bottom" BGCOLOR="#99ccff" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt" BGCOLOR="#99ccff"><B>Performed by</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 41 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">[***]</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 42 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT 2: INVOICING SCHEDULE </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Annex 1: Pricing Overview </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="18%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="9" STYLE="BORDER:1px solid #000000; padding-left:8pt; padding-right:2pt"><B>Circadian</B></TD></TR>
<TR STYLE="font-size:1pt" BGCOLOR="#99ccff">
<TD HEIGHT="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#99ccff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt"><B>Description</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Stage</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Price</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Estimated Raw<BR>Materials&nbsp;&amp; External<BR>Testing Costs</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"><B>Comments</B></TD></TR>
<TR STYLE="font-size:1pt" BGCOLOR="#d8d8d8">
<TD HEIGHT="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#d8d8d8" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt"><FONT STYLE="font-size:8pt">[***]</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Price in</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>AUD</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR BGCOLOR="#d8d8d8" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR BGCOLOR="#d8d8d8" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">[***]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes: [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Annex 2:
Invoicing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 43 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All invoices are payable [***]. All prices or other sums payable or consideration to be provided under this
Agreement are also [***]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 44 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT 3: QUALITY AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Left intentionally blank. Execution version of the Quality Agreement appended below. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">45 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g945701g91n35.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" COLSPAN="5" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>Quality Agreement</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Quality Agreement No.: [***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Version: 1.0</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Date Issued: 25/Oct/2013</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">Review Period: [***]</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>CONTRACT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt; padding-right:2pt"><B>QUALITY AGREEMENT</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>By and Between </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR BGCOLOR="#d8d8d8" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER:1px solid #000000; padding-left:8pt"><B>DSM DETAILS</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>CUSTOMER DETAILS</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>DSM
Biologics Company Australia Pty Ltd</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>OPTHEA Pty. Ltd.</B></P></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Referred
to below as &#147;<B>DSM</B>&#148;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">Referred to below as &#147;OPTHEA&#148;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"><B>Registered Address:</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Suite 0403, Level&nbsp;4, 650 Chapel St, South Yarra, VIC 3141</P></TD></TR>
<TR BGCOLOR="#d8d8d8" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="BORDER:1px solid #000000; padding-left:8pt; padding-right:2pt"><FONT STYLE="font-size:11pt"><B>APPROVED BY</B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><BR><BR>Approved By:</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DSM Biologics</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><BR>By:<U> /s/ Amgad
Hanna&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> Date: <U>30 Oct 2013&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amgad Hanna</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Director, Quality Affairs</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><BR>Approved By:</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opthea Pty. Ltd.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><BR>By: <U>/s/ Michael Gerometta
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> Date: <U>30 Oct 13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael Gerometta</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Head of CMC Development</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><BR>By:<U> /s/ Scott
Lorimer&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> Date: <U>30 Oct 2013&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scott Lorimer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Vice President for Global Affairs</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>This Quality Agreement shall be incorporated within and constitute a part of the Biologics Manufacturing
Agreement (BMA) between the Parties and becomes effective upon signature by all Parties. In the event of inconsistencies between this Quality </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">Attachment 2 to PRC-BRN-00238</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Page 46 of 63</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>
Agreement and other sections of the BMA, this Quality Agreement shall prevail with regard to quality compliance and related regulatory matters, and the other sections of the BMA shall prevail
with respect to all other matters. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Unless separately defined in the </I><B></B><B><I>Glossary</I></B><B></B><I> at the end of this
Quality Agreement, the definition and interpretation of terms, acronyms and abbreviations used in the Quality Agreement shall have the same meaning as the BMA. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>This Quality Agreement may be amended from time to time by mutual agreement in writing and signed between the Parties. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">Attachment 2 to PRC-BRN-00238</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">47 of 63</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Purpose </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The purpose of this Quality Agreement is to define and formalize quality responsibilities and obligations between the Parties in relation to
quality-related services and the manufacture, supply and testing of cGMP Batches of Product by DSM to OPTHEA. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Scope </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">This Quality Agreement is applicable to the manufacture, supply and testing of cGMP Batches of Product and quality-related services as defined
in the Biopharmaceutical Manufacturing Agreement (&#147;<B>BMA</B>&#148;) between the Parties. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Responsibilities </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">DSM is responsible for ensuring that Product is manufactured, tested and stored in compliance with cGMP requirements in accordance with the
United States Federal Food Drug and Cosmetic Act at 21 CFR (Chapters 210, 211, 600 and 610), the EEC Guide to Good Manufacturing Practices for Medicinal Products as promulgated under European Directive 2003/94/EC (replacing 91/356/EEC) and PIC/S
Guide to Good Manufacturing Practice for Medicinal Products <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PE-009-08</FONT></FONT> Part 2, including any amendments to such regulations, to the extent these regulations relate to
guidelines applicable for biopharmaceuticals and active pharmaceutical ingredients and as applicable to the manufacture of Product (Bulk Drug Substance) which will be further processed by OPTHEA at a third party Drug Product contractor. Detailed
responsibilities are defined below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Procedure </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="36%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>DSM Responsibilities</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>OPTHEA Responsibilities</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><B>Basic cGMP Contract Responsibilities</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP
STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;Shall maintain a Quality Department, Quality System, and manufacturing operations to be in compliance with cGMP requirements;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;Shall manufacture, test and supply cGMP Batches of Product and cGMP Services to be in compliance with cGMP requirements</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;Shall test Drug Product as defined in the BMA Exhibit 1, Annex 2.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP
STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;Shall be responsible for taking delivery of Product and any subsequent processing thereafter, including but not limited to storage,
testing not assigned to DSM (as defined in the BMA Exhibit 1, Annex 2), further processing into Drug Product, use and distribution.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;Responsibility for communication and implementation of this Quality Agreement between OPTHEA and DSM rests with the management of DSM&#146;s Quality Department and OPTHEA&#146;s nominated representative for quality
related matters.</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="36%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt"><B>Personnel, Premises and equipment</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;Ensure that there are adequate numbers and suitably trained and skilled personnel to manufacture and test Product.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;DSM shall perform required operations for manufacturing cGMP Batches of </P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;Evaluate DSM by audit according to the allowances outlined below</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 48 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="39%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>DSM Responsibilities</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>OPTHEA Responsibilities</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">the Product and performing cGMP Services at either or both its Groningen or Brisbane facilities.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;The premises, utilities and equipment used to perform cGMP Batches and Services shall be designed, validated and maintained as applicable to cGMP requirements and in accordance with DSM controlled documentation.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;The performance of cGMP Batch and Services shall be conducted in a suitably controlled environment; and such facilities shall be regularly monitored for parameters critical to the process in order to demonstrate and
maintain compliance with applicable cGMP guidelines.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP
STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;Ensure appropriate separation and controls between products to prevent cross contamination, including use of disposables, cleaning
procedures and labeling of any product dedicated equipment.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP
STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;DSM shall maintain controlled access to the premises.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;All visitors shall comply with applicable facility control procedures.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="2" STYLE="BORDER:1px solid #000000; padding-left:8pt"><B>Audits</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;DSM shall permit OPTHEA or authorized quality representatives of OPTHEA, to perform one (1)&nbsp;standard annual cGMP compliance audit for the services contracted, upon minimum [***] written notification from
OPTHEA, with actual audit dates subject to mutual agreement between the Parties and based upon the availability of DSM&#146;s personnel.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;Notify DSM in writing at least [***] prior to intended standard annual cGMP compliance audit.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;Such audit shall not exceed [***] and the auditing party shall have no more than [***] auditors.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;In the event that OPTHEA is accompanied by a third party, a total of three auditors can join such an audit for no more than [***] so long as no more than [***] audit items are addressed during such audit at any one
time.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;OPTHEA shall provide an audit agenda at least [***] prior to the agreed audit date.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;OPTHEA representatives will be escorted by DSM personnel at all times and will only have access to the facility and records relating to the services and Products under contract with OPTHEA.</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">Attachment 2 to PRC-BRN-00238</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">49 of 63</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="36%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>DSM Responsibilities</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>OPTHEA Responsibilities</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;Notwithstanding the foregoing, DSM shall permit OPTHEA or OPTHEA&#146;s authorized quality representatives to conduct additional audits pursuant to the terms of the BMA, including For Cause Audits.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT
STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;DSM shall formally respond to observations made by OPTHEA&#146;s quality representatives requiring corrective action.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;DSM&#146;s response shall include corrective actions, preventative actions, and remedial actions, where appropriate, and shall include a timeline for completion of each action.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;The response shall be sent to OPTHEA&#146;s auditor within [***] of the receipt of the audit report.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP
STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;OPTHEA shall report audit findings verbally at the close of the audit and will provide a written report within [***] of the
audit.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;In no event shall photos or videography be permitted within DSM&#146;s facility without prior written authorization of DSM.</P></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt"><B>Person in Plant</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;DSM shall allow OPTHEA reasonable access, by means of &#145;Person in Plant&#146; (PiP) to observe and review operations related to the manufacturing and testing of Product, subject to reasonable restriction to
preserve the confidentiality of DSM and its clients.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP
STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;The PiP will be supervised by DSM personnel at all times during the stay.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;Visits to the cGMP production area and laboratories will be restricted to areas where a PiP can view the operation of a Product being processed or tested without disturbing the operation, under supervision and
limited to [***] in the cleanrooms a day as <FONT STYLE="white-space:nowrap">pre-scheduled</FONT> during the PiP&#146;s stay on site.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;To limit the disturbance of production activities, the PiP will have one point of DSM contact and is not permitted to disturb the operators in the clean room.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;The PiP is not permitted to perform any operations within the cGMP facility nor review documentation during operation.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;OPTHEA will provide a minimum [***] prior written notice of intention for PiP attendance at DSM.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;OPTHEA shall comply with the terms of PiP access and behavior and with the instructions of DSM.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;OPTHEA will undertake relevant cGMP facility training and safety/security training before being allowed PiP access.</P></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER:1px solid #000000; padding-left:8pt"><B>Regulatory Agency Inspections</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;DSM shall promptly inform OPTHEA of any regulatory agency action involving DSM that may materially affect Product.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;OPTHEA shall promptly inform DSM of any regulatory agency action that may materially affect the contracted services for Product.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;OPTHEA shall notify DSM of any regulatory agency inspection </P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">Attachment 2 to PRC-BRN-00238</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">50 of 63</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="36%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>DSM Responsibilities</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>OPTHEA Responsibilities</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT
STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;DSM shall notify OPTHEA of any regulatory agency inspection concerning the Product within [***] of the initiation, or notification, of the audit by the regulatory agency,
whichever occurs first.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT
STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;In circumstances where the inspection pertains to OPTHEA&#146;s Product, DSM shall be responsible for responding to the regulatory agency and DSM shall provide OPTHEA with an
opportunity to review and provide advice on such responses to the extent they pertain to OPTHEA&#146;s Product and DSM will incorporate reasonable changes where possible prior to DSM submitting or disclosing the responses to the regulatory
agency.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;DSM reserves the right to present site data and/or procedures during such an inspection</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">specifically impacting Product within [***] of the initiation,
or notification, of the audit by the regulatory agency, whichever occurs first.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP
STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;OPTHEA reserves the right to be available on site during an agency inspection when the inspection pertains to Product.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;Review and provide advice on the responses drafted by DSM pertaining to OPTHEA&#146;s Product.</P></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"><B>Change Management</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT
STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;All changes to Product and related documents shall be managed by DSM in accordance with DSM&#146;s Change Control procedures.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;Major Changes that do not directly impact Product and related processes will be communicated to OPTHEA according to DSM&#146;s change control procedures.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;Minor Changes that do not directly impact Product and related processes will not be communicated.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;Rework or reprocessing will be agreed with OPTHEA and governed through DSM&#146;s Change Control procedures.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;Major Changes impacting Product and related processes and documentation shall be reviewed and approved by OPTHEA prior to implementation of the change.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP
STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;Major Changes impacting Product and related processes and documentation shall be reviewed and approved by OPTHEA prior to
implementation of the change. This should occur within [***] of receipt of a Change notice or a mutually acceptable time frame.</P></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><B>Documentation</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP
STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;Prepare, approve and maintain documents relating to general and Product specific processing and testing, including the Bill of
Testing.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;OPTHEA shall supply the most recent&nbsp;batch records and/or process development specifications for
development or manufacture of Product which shall be translated into </P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">Attachment 2 to PRC-BRN-00238</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">51 of 63</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="36%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom" STYLE="BORDER:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>DSM Responsibilities</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>OPTHEA Responsibilities</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;In the event that there is an inconsistency between the DSM generated and&nbsp;OPTHEA approved Master Documents (Tech Transfer Reports, Production Protocols, Buffer Protocols and Bill of Testing) and OPTHEA batch
records and specifications, the DSM generated and OPTHEA approved Master Documents shall prevail.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;DSM will address each comment and return one consolidated reply to OPTHEA for
consideration.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">the relevant DSM documents including but not limited to:</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Technology Transfer Reports, Production Protocols, Buffer Protocols and Bill of Testing (&#147;DSM Documents&#148;).</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;DSM Documents shall be signed off by&nbsp;OPTHEA in order to document that all information required for manufacturing Product is present, correct, and cross checked against the original&nbsp;OPTHEA or DSM
development documentation, at which time the translated DSM documents will be considered the Master Documents.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;Documents shall be reviewed by OPTHEA within [***], or a mutually acceptable time frame, of receipt
from DSM providing one consolidated set of comments.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP
STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;OPTHEA will review and return one consolidated reply for each subsequent revision of the documents within [***] of receipt from
DSM, or a mutually acceptable time frame.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;A joint final check and approval on content will be performed within [***] of the review reply of the final revised version of the document.</P></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER:1px solid #000000; padding-left:8pt"><B>Raw Material /Packaging Components</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;DSM shall use raw material and packaging components from approved vendors.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;Prior to use, all raw material and packaging components must be found to be acceptable against <FONT
STYLE="white-space:nowrap">pre-established</FONT> standards and appropriate for Product processing.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;Changes to test methods or deviations from existing raw materials, packaging components, packaging
component specifications or vendors shall follow DSM Change Control procedures in accordance with the requirements of <B><I>Documentation</I></B><B><I></I></B><B><I>&nbsp;&amp; Change Management.</I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;Any animal derived components should be avoided where possible or otherwise tested and sourced in line with current regulatory guidances.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;Evaluate DSM by audit according to the allowances outlined above</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;Provide DSM with applicable information regarding any required animal derived
components</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">Attachment 2 to PRC-BRN-00238</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Page 52 of 63</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="36%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>DSM Responsibilities</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>OPTHEA Responsibilities</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER:1px solid #000000; padding-left:8pt"><B>Retention of Samples</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;DSM shall retain samples of Product and any applicable precursors according to cGMP requirements</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;DSM shall notify OPTHEA prior to destruction of any Product Samples at the completion of the retention period and upon written request shall provide such samples to OPTHEA.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;Evaluate DSM by audit according to the allowances outlined above</P></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="3" STYLE="BORDER:1px solid #000000; padding-left:8pt"><B>Validation</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;Where applicable, DSM shall be responsible for ensuring that the equipment used for manufacture of the Product will be validated to support the operational ranges of the Process.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;Evaluate DSM by audit according to the allowances outlined above</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;DSM shall be responsible for ensuring that adequate cleaning is performed to prevent contamination of Product.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;Data shall be available to support the effectiveness of cleaning performed between manufacturing of batches of both the same Product and different products.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;OPTHEA will provide information required by DSM to establish adequate cleaning procedures for their Product where this information is known to OPTHEA.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;DSM shall be responsible for ensuring that all laboratories are in compliance with applicable cGMP guidelines.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;If DSM subcontracts work to a third party vendor, DSM shall be responsible for ensuring any such vendor is sufficiently qualified to perform such work and will audit such vendors in accordance with the supplier
qualification procedure</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT
STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;For vendors selected solely by DSM or recommended to OPTHEA by DSM, DSM shall be responsible for the vendor satisfying cGMP requirements where applicable.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;If analytical work is performed by DSM, OPTHEA shall supply any available analytical documentation to assist in methods transfer and/or methods validation.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;For vendors selected solely by OPTHEA, OPTHEA shall qualify the vendor and OPTHEA shall be responsible for the vendor satisfying cGMP requirements where
applicable.</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="36%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt"><B>Deviations</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;DSM shall inform OPTHEA of any Major deviation relating to Product and corresponding manufacturing Process within [***] after recognizing such deviation, and shall provide to OPTHEA the details of the deviation
available at that time.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;When a deviation may potentially impact purity, safety or potency of an already distributed Product, OPTHEA shall be responsible for reporting such deviations to the relevant regulatory bodies.</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">Attachment 2 to PRC-BRN-00238</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Page 53 of 63</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="36%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom" STYLE="BORDER:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>DSM Responsibilities</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>OPTHEA Responsibilities</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;If any problems are discovered that may impact Batches previously shipped, DSM shall notify OPTHEA within [***] of becoming aware in order to assure regulatory reporting guidelines are met.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;OPTHEA shall inform DSM of any deviation reported to regulatory authorities when such deviation is in any form related to the activities performed by or under responsibility of DSM.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;Additional investigations and/or testing requirements shall be agreed by DSM&#146;s Quality Department.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;OPTHEA reserves the right to provide input into any Major deviation report pertaining to Product prepared by DSM and further reserves the right to request DSM to perform any additional investigations or tests to
finalize an investigation relating to such deviation.</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="36%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="2" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Product Release</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;DSM shall release Product to OPTHEA.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;Product released by DSM is for shipment and further processing which shall become the responsibility of OPTHEA upon delivery of Product for shipping Ex Works.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;DSM shall provide a documentation package with each Batch of released Product to OPTHEA.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;The package shall include, as a minimum, the following documents:</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#10147;<I>
Copies of all Production Protocols;</I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#10147;<I> Certificate of Analysis indicating the test results and
including a Statement of Compliance;</I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#10147;<I> Copies of all Batch related deviations; and</I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#10147;<I> Copies of all Analytical Protocols for release tests mentioned on CoA</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;DSM shall release Product only if all release criteria are satisfied as <FONT STYLE="white-space:nowrap">pre-defined</FONT> in the Bill of Testing for such Product and cGMP compliance for Batch manufacture has been
met.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;Evaluate DSM by audit according to the allowances outlined above</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;Executed Production Protocols shall be reviewed by OPTHEA for cGMP compliance within [***] of
receipt or a mutually acceptable time frame.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP
STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;OPTHEA will review and return one consolidated reply for each subsequent revision of the documents within [***] of receipt from
DSM, or a mutually acceptable time frame.</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="36%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Quality
Control</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;Perform release testing against Product Bill of Testing.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;Notify OPTHEA of confirmed Out of Specification (OOS) results within [***] of confirmation of the OOS.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;Resolve OOS within a [***] target or as mutually agreed.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;Review and resolve any questions with a target approval time of [***] upon issue of a draft OOS
report or as mutually agreed.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">Attachment 2 to PRC-BRN-00238</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Page 54 of 63</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="36%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom" STYLE="BORDER:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>DSM Responsibilities</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>OPTHEA Responsibilities</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;Use only approved vendors for any contract testing of Product.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;Notify OPTHEA of any contract testing laboratories used for testing of Product.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;OPTHEA to approve vendors used for contract testing of Product.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;OPTHEA to request use of alternative contract testing laboratories if required.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;Agree with OPTHEA on Product testing strategy <FONT STYLE="white-space:nowrap">(in-process</FONT>
and release), as well as method transfer and qualification requirements.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP
STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;Agree with OPTHEA on Product-specific raw materials intake strategy for materials which impact or may reasonably impact Product
Specification.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT
STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;Prepare and characterise reference standard, or accept OPTHEA reference standard as appropriate.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;Agree with DSM on Product testing strategy <FONT STYLE="white-space:nowrap">(in-process</FONT> and
release), as well as method transfer and qualification requirements.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP
STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;Agree with DSM on Product-specific raw materials intake strategy for materials which impact or may reasonably impact Product
Specification.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT
STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;Agree with DSM on preparation and characterisation of reference standard, or supply DSM with information on OPTHEA reference standard.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;Perform stability testing as agreed with OPTHEA.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;Notify OPTHEA of any OOS as defined above.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;Review and agree with DSM <FONT STYLE="white-space:nowrap">pre-defined</FONT> stability protocol and
specifications.</P></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="3" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><B>Storage and Shipment</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;DSM shall label and store Product under conditions specified by product label requirements as
supplied by OPTHEA.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT
STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;Ensure that during storage of Product before shipment from DSM&#146;s site, appropriate controls are in place to ensure that there is no interference, theft, contamination, or
mixture with any other products or materials.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP
STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;Ship Product to locations nominated in writing by OPTHEA.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;OPTHEA shall provide details of any container sealing and integrity requirements, and storage and
shipping conditions for the Product.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;The Product shall be labelled and packaged for transit in accordance with instructions and destination as defined by OPTHEA in writing and complying with cGMP and other applicable regulations.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;A shelf life for Product will not be defined by DSM until sufficient data is available from stability studies to support such storage.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;DSM shall not ship any Product that is under Quarantine unless in accordance with applicable regulatory guidelines, and then, only according to controlled procedures which fully comply with such regulatory
requirements and where such shipment is mutually agreed between the Parties.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">Attachment 2 to PRC-BRN-00238</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Page 55 of 63</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="36%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom" STYLE="BORDER:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>DSM Responsibilities</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>OPTHEA Responsibilities</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;In the event that OPTHEA requests DSM to ship Product under Quarantine, DSM shall only ship Product
after written approval of OPTHEA.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;OPTHEA is responsible for ensuring that the third party can accept shipment of
Product.</P></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><B>Document Retention</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;DSM shall retain, at a minimum, Batch production and test records for Product and materials in
accordance with regulatory requirements in the region within which the Product will enter clinical trials.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;DSM shall notify OPTHEA prior to destruction of any Batch, Product related documentation or
materials at the completion of the retention period and, if requested in writing, DSM shall provide such records or materials to OPTHEA.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;Evaluate DSM by audit according to the allowances outlined above</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;OPTHEA will approve destruction of records of request receipt following the storage period.</P></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><B>Regulatory</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP
STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;DSM shall be responsible for registering and maintaining DSM&#146;s facilities with the proper regulatory agencies and to update
the registration according to the requirements of those agencies.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP
STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;If requested by OPTHEA under the Services, DSM will draft and review the relevant C&amp;MC sections of a regulatory dossier.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;Following submission of a regulatory data pack dossier by OPTHEA to a regulatory authority, DSM will support update and review of relevant C&amp;MC sections as required.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;DSM shall forward all appropriately redacted regulatory agency documentation (e.g. <I><FONT STYLE="white-space:nowrap">FDA-483</FONT></I>) and responses that have specific impact on Product to OPTHEA within [***] of
receipt, or earlier in accordance with Regulatory Agency Inspections section above.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;OPTHEA shall review and approve the C&amp;MC sections of a regulatory dossier as drafted by DSM
including any updates as required.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT
STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;OPTHEA shall be responsible for ensuring all appropriate regulatory filings and import/export documentation are filed with regulatory agencies and other applicable government
agencies prior to shipment of Product.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP
STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;OPTHEA shall also be responsible for filing and obtaining approvals from all relevant regulatory agencies and other applicable
government agencies prior to administration of Product to humans.</P></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><B>Complaints</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;Upon receipt of such written notification from OPTHEA, DSM shall promptly perform appropriate
</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;OPTHEA shall be responsible for receiving and initially investigating any Product
complaints.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">Attachment 2 to PRC-BRN-00238</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Page 56 of 63</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="36%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom" STYLE="BORDER:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>DSM Responsibilities</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>OPTHEA Responsibilities</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">investigations that may be due to manufacture of
Product to identify and confirm cause of such problem.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP
STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;Investigation report(s) shall be forwarded to OPTHEA within [***] following the date of receipt of notification by DSM.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;Any Product Quality related complaint received by DSM shall be immediately forwarded to OPTHEA within [***] of receiving such information.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;OPTHEA shall notify DSM in writing of any problems that may be due to manufacture of Product, which
are found during the distribution of Product within [***] of receiving such information.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;OPTHEA shall review and agree with DSM on investigation reports provided by DSM.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;OPTHEA shall be responsible for reporting the results of any Product complaint investigation to the relevant authority.</P></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><B>Recalls</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;In the event that DSM has reason to believe that Product should be recalled or withdrawn from
distribution, DSM shall inform OPTHEA in writing within [***] of receiving such information.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;OPTHEA shall inform DSM in writing of any intention to recall Product within [***] of agreeing such
action.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;OPTHEA, with data and assistance provided by DSM, shall be responsible for filing documentation that may be required by regulatory authorities and initiating Product recalls due to any Product defect considered
sufficiently serious.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT
STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP></FONT>&#8194;&#8201;&#8201;OPTHEA shall provide DSM with a copy of any regulatory correspondence related to recalls.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;OPTHEA shall notify the appropriate regulatory agencies of any recall, and OPTHEA shall be responsible for coordinating all necessary activities regarding the action taken.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;DSM and OPTHEA agree to cooperate fully regarding any proposed recall or Product withdrawal; and the Parties further agree to keep each other advised, and to exchange copies of such documentation as may be required,
to ensure regulatory compliance.</P></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><B>Periodic Review of Quality Agreement</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT>
</SUP></FONT>&#8194;&#8201;&#8201;DSM and OPTHEA to jointly review Quality Agreement and revise, as necessary, every [***] if there are ongoing Product manufacture or cGMP Service Activities or otherwise within an agreed timeframe.</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">Attachment 2 to PRC-BRN-00238</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Page 57 of 63</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Glossary </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="75%"></TD></TR>
<TR BGCOLOR="#bfbfbf" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="BORDER:1px solid #000000; padding-left:8pt; padding-right:2pt"><B>Glossary</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER:1px solid #000000; padding-left:8pt">Change:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">Any prospective addition, modification or deletion with respect to Product, material, method, equipment
(including computerised systems), specification, labelling, packaging, responsibility, facility or license involved with GMP manufacturing.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER:1px solid #000000; padding-left:8pt">Batch:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">A specific quantity of Product that is intended to be of uniform character and quality and is produced
during the same cycle of manufacture.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER:1px solid #000000; padding-left:8pt">Batch Records or Production Protocols</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">Means in relation to a Batch of Product, the production records showing how the Batch was
manufactured.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER:1px solid #000000; padding-left:8pt">Bill of Testing:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">The agreed upon written list of testing, methods, limits and specifications applicable to <FONT
STYLE="white-space:nowrap">in-process</FONT> bulk harvest and Product, applying to the manufacture and disposition of Product by DSM, that may be amended by written agreement between the Parties</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER:1px solid #000000; padding-left:8pt">C&amp;MC</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">Chemistry and manufacturing controls.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER:1px solid #000000; padding-left:8pt">Certificate of Analysis (CoA)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">The certificate containing the outcome of the disposition tests on the Product as performed by DSM or on
behalf of DSM according to the Bill of Testing</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER:1px solid #000000; padding-left:8pt">cGMP:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">Current good manufacturing practices and general biological products standards as promulgated under the
United States Federal Food Drug and Cosmetic Act at 21 CFR (Chapters 210, 211, 600 and 610), the EEC Guide to Good Manufacturing Practices for Medicinal Products as promulgated under European Directive 2003/94/EC (replacing 91/356/EEC) and PIC/S
Guide to Good Manufacturing Practice for Medicinal Products <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PE-009-08</FONT></FONT> Part 2, including any amendments to such regulations, to the extent these regulations relate to
guidelines applicable for biopharmaceuticals and active pharmaceutical ingredients.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER:1px solid #000000; padding-left:8pt">cGMP Services:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">Any cGMP activity performed by DSM under this Agreement other than the manufacture of a cGMP Batch of
Product (e.g. creation of a MCB)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER:1px solid #000000; padding-left:8pt">Deviation:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">An excursion from cGMP principles. Excursions may be defined as either a Major Excursion or a Minor
Excursion.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER:1px solid #000000; padding-left:8pt">FDA</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">The U.S. Food and Drug Administration.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER:1px solid #000000; padding-left:8pt">For Cause Audit</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">An audit to address a Major cGMP Deviation resulting in a failure of Product to meet Specification due to
DSM&#146;s material breach of its obligations under this Agreement.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER:1px solid #000000; padding-left:8pt">Quarantine</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">The status assigned to Product prior to final release under conditions established by the
manufacturer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER:1px solid #000000; padding-left:8pt">Major Change:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Change that may
affect:</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;the production, control and/or quality of the BDS (including corresponding
intermediate products or raw&nbsp;materials)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;the validation status of related
systems/activities</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;the content of any of the licenses of DSM Australia or DSM Groningen
depending on the site that has manufactured or is planning to manufacture Product</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Regulatory filings of OPTHEAs</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;business critical processes/applications</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER:1px solid #000000; padding-left:8pt">Minor Change:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Change that has
no potential impact on the quality of a material, system or activity, or on the content of any of the licenses of DSM Australia or DSM Groningen depending on the site that has manufactured or is planning to manufacture Product. Examples of minor
changes are:</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Like for like replacement of equipment parts to repair initial validated
state</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Adaptation of procedures without modification of critical steps in the work
process described</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Organisational changes not affecting names or responsibilities of the key personnel mentioned in a
license.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">Attachment 2 to PRC-BRN-00238</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Page 58 of 63</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="75%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER:1px solid #000000; padding-left:8pt">Major Deviation:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">Any excursion that is not a Minor Excursion. A deficiency of the material, documentation, Process, facility,
validation status and/or equipment which questions the quality and / or efficacy of the Batch, Lot and / or an item which may result in batch reworking, reprocessing or rejection.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER:1px solid #000000; padding-left:8pt">Minor Deviation:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">An excursion considered to be an incident with no (potential) impact on Product, Process, and facility,
utilities, equipment and/or validation status.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER:1px solid #000000; padding-left:8pt">Process</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">Means the process for the development and manufacture of the Product as used in the Services, including any
improvements thereto.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER:1px solid #000000; padding-left:8pt">Product or Bulk Drug Substance (BDS)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">Bulk purified <FONT STYLE="white-space:nowrap">OPT-302</FONT> drug substance manufactured in accordance with
the Process which is supplied to OPTHEA for further processing to Drug Product.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER:1px solid #000000; padding-left:8pt">Product Quality:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">Product which conforms with the Specification as <FONT STYLE="white-space:nowrap">pre-defined</FONT> between
both Parties</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER:1px solid #000000; padding-left:8pt">Qualification:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">An action proving that any equipment, Process, facility, utility, vendors, performs according to <FONT
STYLE="white-space:nowrap">pre-defined</FONT> specifications and meets the user requirements.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER:1px solid #000000; padding-left:8pt">Quality Department:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">The authorised quality representatives within DSM that are responsible for maintaining, improving and
implementing the organisation&#146;s Quality System and Quarantine, release or rejection of Product.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER:1px solid #000000; padding-left:8pt">Quality System:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">The management system administered by DSM to control, maintain and comply with <FONT
STYLE="white-space:nowrap">pre-defined</FONT> specifications and standards.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER:1px solid #000000; padding-left:8pt">Specification</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">Means the specifications, technical data and/or formulae of the Product manufactured during a Batch, and all
amendments thereto.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER:1px solid #000000; padding-left:8pt">Statement of Compliance (SoC)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">Means the confirmation to be issued by DSM contained in the Certificate of Analysis stating that the Product
meets the Specifications and was manufactured in accordance with cGMP.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER:1px solid #000000; padding-left:8pt">Validation</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">An action proving, in accordance with the principles of current Good Manufacturing Practice (cGMP), that any
procedure, process, equipment, material, activity or system actually consistently leads to the expected results.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Note: Definitions not included in this Glossary are defined in the BMA.</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">Attachment 2 to PRC-BRN-00238</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Page 59 of 63</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT 4: CCN FORMAT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONTEMPLATED CHANGE NOTIFICATION/REQUEST </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(EXAMPLE - FOR ADDITIONAL ACTIVITIES) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Drug Substance name&nbsp;&nbsp;&nbsp;&nbsp;: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Client name&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; : </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Services number&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; : </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Form number&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; : </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Date of issue&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; : </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Change requested by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Contract&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>TITLE: </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>With reference to: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Content: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>The following
is included in CCN</B>: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Price:</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">[***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Effects of change:</U> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="16%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">1.&#8195;&#8194;&#8201;Payment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">[***].</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">2.&#8195;&#8194;&#8201;Schedule</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">3.&#8195;&#8194;&#8201;Other</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><U>Signatures:</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">(name)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">(signature)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">(date)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PM</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Site Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Client approval</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 60 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT 5: CANCELLATION SCHEME </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of Termination, cancellation or Postponement by OPTHEA of one or more of the stages of the Services, the following amounts (&#147;Close Out
Costs&#148;) shall be due by OPTHEA in accordance with Section&nbsp;15: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Termination, cancellation or Postponement of a stage of the Development Work:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For Development Work scheduled to be performed [***] the date of Termination, cancellation or Postponement: [***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For Development Work scheduled to be performed [***] the date of Termination, cancellation or Postponement and [***] the date of Termination,
cancellation or Postponement: [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Termination, cancellation or Postponement of engineering batches included in the Development Work and each Batch
being part of the Manufacturing Work: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If Termination, cancellation or Postponement occurs [***] the Scheduled Starting Date(s): [***].
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If Termination, cancellation or Postponement occurs [***] the Scheduled Starting Date(s): [***].
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If Termination, cancellation or Postponement occurs [***] the Scheduled Starting Date(s): [***];
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If Termination, cancellation or Postponement occurs [***] the Scheduled Starting Date(s) or [***] the scheduled
starting date: [***] </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 61 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT 6: DRAFT PRODUCT SPECIFICATIONS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Product Specifications for Batch release will be proposed and mutually agreed once sufficient data is available following Development Work. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tests are anticipated: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional tests may be required following process development and/or regulatory agency discussions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 62 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain information contained in this document, identified by [***], has been redacted because it is
both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Strictly Confidential </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT 7: DESIGNATED VENDORS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 63 of 63</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>6
<FILENAME>filename6.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.3 </B></P> <P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="57%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:24pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman"><B>Deed of Indemnity,<BR>Access and Insurance</B></P>
<P STYLE="margin-top:0pt;margin-bottom:1pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Opthea Limited (<B>Company</B>)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (<B>Director</B>)</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:200pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:230pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="53%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g945701g86y61.jpg" ALT="LOGO">
</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman">&nbsp;&nbsp;www.minterellison.com</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Deed of Indemnity </B></P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Details</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>3</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Agreed terms</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>4</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Defined terms&nbsp;&amp; interpretation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Indemnity</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Obligations in relation to events and Claims</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Conduct of events and Claims</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Failure to comply</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Other indemnity or insurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Insurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Access to Board Documents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Confidentiality</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Expert determination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">General provisions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Signing page</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>18</B></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_85539103_3 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Deed of Indemnity, Access and Insurance | page 2</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Details </B></P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Date </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Parties </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Opthea Limited</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ABN</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short&nbsp;form&nbsp;name</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Company</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notice details</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Suite 0403 Level&nbsp;4 650
Chapel St</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">South Yarra, Victoria, 3141</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AUSTRALIA</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facsimile:</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Email:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short&nbsp;form&nbsp;name</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Director</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notice details</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Email:</P></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Background </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To ensure
that the Director agrees to act or continues to act (as the case may be) as an officer of a Group Company, the Company considers it reasonable and in the best interests of the Company to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">indemnify the Director to the extent permitted by law and the Constitution against certain liabilities and
legal costs incurred by the Director as an officer of any Group Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">maintain, and pay the premium for, a D&amp;O Policy in respect of the Director; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">provide the Director with access to particular papers and documents requested by the Director for a Permitted
Purpose, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">both during the time that the Director holds office and for a seven year period after the Director ceases to be an officer of
any Group Company, on the terms and conditions contained in this Deed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_85539103_3 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Deed of Indemnity, Access and Insurance | page 3</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Agreed terms </B></P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Defined terms&nbsp;&amp; interpretation </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Defined terms </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">In this Deed, except where the context otherwise requires: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Authorised Person</B> means any person authorised in writing by the Director and approved by the Company, which approval cannot be
unreasonably withheld. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Authority </B>means: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a Royal Commission, Board of Inquiry, Parliamentary Committee or similar body; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Australian Securities and Investments Commission, the Australian Prudential Regulation Authority, the
Australian Competition and Consumer Commission, the Australian Securities Exchange and any other regulatory authority or investigative body, whether in Australia or elsewhere; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a department of any Australian government or of any other jurisdiction; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a public authority; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an instrumentality agent or appointee of the Crown in right of the Commonwealth, in right of a State or in
right of a Territory or the equivalent of any of them in any other jurisdiction; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other body exercising statutory or prerogative power. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Board</B>, in relation to a Group Company, means: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the board of directors of the Group Company; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any committee of the board of directors of the Group Company. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Board Documents</B> means the Books of a Group Company to which the Director did, or was entitled to, have access (or receive a copy) during
the Director&#146;s term of office as an officer of the Group Company and <B>Board</B> <B>Document </B>means any of those Books. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Board
Papers</B> means: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">originals or copies of all documents (including, without limitation, board papers, committee papers,
correspondence, legal advice, memoranda, submissions, reports and minutes of meetings) provided to, or tabled at any meeting of, the Board of a Group Company during the Director&#146;s term of office as an officer of that Group Company;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">copies of resolutions and minutes of meetings of the Board of a Group Company held during the Director&#146;s
term of office as an officer of that Group Company; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">copies of resolutions and minutes of meeting of members of a Group Company held during the Director&#146;s term
of office as an officer of that Group Company. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Books</B> has the meaning given to that word in section 9 of the
Corporations Act and includes, without limitation, Board Papers. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Business Day</B> means a day that is not a Saturday, Sunday, bank
holiday or public holiday in Victoria, Australia. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Business Hours</B> means from 9.00am to 5.00pm on a Business Day. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_85539103_3 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Deed of Indemnity, Access and Insurance | page 4</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Claim </B>means: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any writ, summons, cross-claim, counterclaim, application or other originating legal or arbitral process to
which the Director is or might be a party; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any hearing, complaint, inquiry, investigation, proceeding or application however commenced or originating
which does or might involve the Director, including any investigation or inquiry by any Authority or External Administrator; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any written or oral demand or threat that might result in any such process, hearing, complaint, inquiry,
investigation, proceeding or application referred to in (a)&nbsp;or (b) above, </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">arising out of, or in connection with, or
resulting from any act, omission or conduct of the Director in the capacity of an officer of a Group Company or in connection with the affairs of a Group Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Constitution</B> means the constitution of the Company as it existed on the date of this Deed as modified or replaced from time to time
thereafter but excluding any modification or replacement to the extent that it limits the scope of the indemnity available under this Deed. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Corporations Act</B> means the <I>Corporations Act 2001</I> (Cth). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>D&amp;O Policy</B> means a contract or contracts: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">insuring the Director against liabilities incurred by the Director as an officer of a Group Company; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">allowing the Company to obtain reimbursement for certain claims paid by it to the Director under this Deed.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Deed</B> means this deed of indemnity, access and insurance. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Expenses </B>means all costs and expenses and includes, without limitation, legal costs and disbursements (on a full indemnity basis)
relating to a Claim or Notified Event. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>External Administrator</B> means a liquidator, provisional liquidator, controller or an
administrator. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Group Company</B> means: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any Subsidiary of the Company. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Information</B>, in clause&nbsp;9, means all or any part of information contained in or related to the affairs or a transaction of a Group
Company, a Board Document or a discussion at a meeting of a Group Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Independent Expert </B>means an expert appointed under
clause 10. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Notified Event </B>means an event or circumstance that may give rise to a Claim that is notified in writing by the Director
to the Company<B> </B>in the Relevant Period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Permitted Purpose</B> has the meaning given to that term in clause&nbsp;8.1. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Privileged Document</B> means any document in respect of which any form of legal privilege applies solely in favour of a Group Company,
jointly in favour of a Group Company and the Director, or jointly in favour of the Director and one or more directors of a Group Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Relevant Period</B> means the period: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">beginning on the date of this Deed; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_85539103_3 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Deed of Indemnity, Access and Insurance | page 5</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ending on the seventh anniversary of the date on which Director ceases to be an officer of any Group Company.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Requested Documents</B> has the meaning given to that term in clause&nbsp;8.1. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Subsidiary </B>has the meaning given to that term in the Corporations Act. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Interpretation </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">In this Deed, except where the context otherwise requires, references to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a title or expression defined in the Corporations Act is to that title or expression as defined and without
limitation, &#145;officer&#146; has the meaning given to it in section 9 of the Corporations Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">one gender includes each other gender; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the singular includes the plural and the plural includes the singular; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a person includes a natural person, partnership, body corporate, association, governmental or local authority
or agency or other entity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a party are to a party to this Deed, and includes the party&#146;s executors, administrators, successors and
permitted assigns and substitutes; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a statute, regulation or provision of a statute or regulation (<B>Statutory Provision</B>) include:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that Statutory Provision as amended or <FONT STYLE="white-space:nowrap">re-enacted</FONT> from time to time;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a statute, regulation or provision enacted in replacement of that Statutory Provision. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Headings </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Headings are for convenience only and do not form part of this Deed or affect its&nbsp;interpretation. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Indemnity </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Company indemnity </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Subject to this clause 2, the Company indemnifies the Director to the maximum extent permitted by law and the Constitution against: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all liability in respect of a Claim in the Relevant Period or any Claim later arising out of a Notified Event;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all Expenses relating to such a Claim or to any Notified Event, including costs and expenses reasonably and
necessarily incurred to mitigate any liability for such a Claim or any Claim which may arise from such a Notified Event. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Indemnity extends to certain proceedings </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Without limiting clause 2.1 and subject to clauses 2.5 and 6.3, the indemnity provided applies to the maximum extent permitted by law and the
Constitution to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the defence of a criminal proceeding (whether or not the Director is convicted), but not to any criminal
penalty imposed; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the defence of a civil proceeding (whether or not any pecuniary or civil penalty or disqualification order is
made or any relief or remedy is granted), but not to any pecuniary penalty imposed. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_85539103_3 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Deed of Indemnity, Access and Insurance | page 6</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Conduct not in good faith </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Company is not liable to indemnify the Director against any amount, including any amount of Expenses, in the event that, and to the extent
that, the liability of the Director for that amount: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is found by a court or other judicial body; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is agreed by the Director, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">to arise from conduct of the Director that was not in good faith. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Claim by the Company or related body corporate </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Notwithstanding any other clause of this Deed, the Company is not liable to indemnify the Director against, or advance to or on behalf of the
Director, any amount, including any amount of Expenses, in respect of any Claim by the Company or a related body corporate of the Company. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>When Expenses are to be paid or advanced </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Expenses are to be paid under clause 2.1 as and when they are incurred by or on behalf of the Director. Expenses are to be advanced by the
Company to or on behalf of the Director (in advance of payment under clause 2.1) on terms, including as to security, as the Company reasonably requires, where: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">clause 2.3 may apply&#151;and will continue to be advanced until any conduct of the Director referred to in
clause 2.3 is established in accordance with that clause; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company may not be permitted by law or the Constitution to indemnify the Director for those Expenses by
reason of an adverse outcome of a proceeding (including where the Director is convicted of a criminal offence) but the Company is permitted by law or the Constitution to advance payment of those Expenses &#150; and will continue to be advanced until
the final outcome of the proceeding, including any appeal, is determined. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Nature and scope of indemnity </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Subject to the other provisions of this Deed, the indemnity provided by clause 2.1: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">has effect in respect of any act, omission or conduct occurring or arising prior to, on or after the date of
this Deed and in respect of liabilities incurred prior to, on or after the date of this Deed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is irrevocable except on 20 Business Days notice in writing to the Director, and then only in respect of
conduct of the Director after expiry of the 20 Business Days; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">continues irrespective of one or more previous applications of clause 2.1; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">continues in full force and effect without limitation in relation to any Claim, even if the Director has ceased
to be a director, officer or employee of the relevant Group Company before such Claim is made against the Director and/or before a claim is made under this Deed; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is separate and independent from any indemnity in favour of any other director, officer or employee of any
Group Company. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Obligations in relation to events and Claims </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Director&#146;s obligations </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Director must: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">give notice in writing to the Company promptly upon becoming aware of any Claim or any event or circumstance
that may give rise to a Claim; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_85539103_3 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Deed of Indemnity, Access and Insurance | page 7</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">take such action as the Company reasonably requests to avoid, dispute, resist, appeal against, compromise or
defend any Claim or any adjudication of a Claim; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">not make any admission of liability in respect of, or settle, any Claim without the prior written consent of
the Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where the Company assumes the conduct, negotiation or defence of any Claim, render all reasonable assistance
and cooperation to the Company in the conduct, negotiation or defence of the Claim including, without limitation, providing the Company with any documents, authorities and directions that the Company may reasonably require for the prosecution or
advancement of any counterclaim or cross claim; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">upon request by the Company, do everything necessary or desirable which the Company reasonably requests to
enable the Company (so far as it is possible) to be subrogated to and enjoy the benefits of the Director&#146;s right in relation to any counterclaims or cross-claims or any claims against any person and render such assistance as may be reasonably
requested by the Company for that purpose; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the Company has not assumed conduct of a Claim, keep the Company fully informed in relation to the status
and conduct of that Claim; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">notify any Claim to an insurer or any other person who may be liable to indemnify the Director in respect of
that Claim, promptly take all reasonable steps to enforce all the Director&#146;s rights against the insurer or other person and comply with all obligations under the terms of the insurance or other indemnity. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Company&#146;s obligations </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Company must immediately notify the Director if any investigation or proceeding is anticipated, threatened or commenced against it that may
involve or result in a Claim against the Director. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Costs </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Director is entitled to be reimbursed by the Company for all costs and expenses including, without limitation, legal costs and
disbursements (on a full indemnity basis) in taking any action pursuant to clause 3.1. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Conduct of events and Claims </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Request or election </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Where the Director is or may be entitled to be indemnified by the Company under this Deed in respect of a Claim
(including a Claim which may arise from a Notified Event), the Director may request the Company, or the Company may elect, to do one or more of the following: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">assume the conduct, negotiation or defence of the Claim or Notified Event; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">institute a cross-claim or a counterclaim; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">subject to clause 4.2, retain lawyers in relation to the Claim or Notified Event to act on behalf of both the
Director and a Group Company (and/or another officer or other officers of a Group Company) to the extent that the Company reasonably considers their interests to be in common. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Director makes a request under paragraph (a), the Company must, within 20 Business Days of the request,
notify the Director in writing whether the Company accepts the Director&#146;s request. The Company is under no obligation to accept any such request. If the Company refuses the Director&#146;s request, the Company may, at its discretion,
nevertheless later make an election to do one or more of the things set out in paragraph (a). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_85539103_3 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Deed of Indemnity, Access and Insurance | page 8</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Company accepts the Director&#146;s request under paragraph (b)&nbsp;or the Company makes the election
under paragraph (a), the conduct of the Claim or Notified Event will be under the management and control of the Company, unless and until the Company elects to pass conduct of the Claim or Notified Event back to the Director. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Disputes </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Director disputes the Company&#146;s decision to retain lawyers in relation to a Claim or Notified Event
under clause 4.1(a)(iii), because the Director does not consider their interests to be in common with others for whom the lawyers are retained, the Director must notify the Company of that dispute in writing. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">During the period of 5 Business Days after notice is given under paragraph (a), the Director and the Company
must use reasonable efforts to resolve the dispute. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the dispute is not resolved in accordance with paragraph (b), the Company must refer the matter to an
Independent Expert (in accordance with clause 10) who must decide whether, in relation to the Claim or Notified Event, the interests of the Director and others for whom the lawyers are retained are sufficiently in common for common legal
representation to be appropriate in all the circumstances. If the Independent Expert decides that their interests are not sufficiently in common, the Director may engage separate legal or other representation in relation to the Claim or Notified
Event and reasonable Expenses incurred by the Director in relation to such legal or other representation shall be borne by the Company under clause 2.1. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Own representation </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If the Company elects not to retain lawyers in relation to a Claim or Notified Event under clause 4.1(a)(iii), the Director may engage separate
legal or other representation and participate in the Claim or Notified Event as the Director sees fit and reasonable Expenses incurred by the Director in relation to such legal or other representation or participation shall be borne by the Company
under clause 2.1. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Reasonableness of Expenses </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Director may instruct a &#145;top tier&#146; law firm and/or senior counsel and the Company agrees that the
normal charges by any such firm or counsel are reasonable for the Director to incur. Where legal costs are advanced or paid pursuant to a D&amp;O Policy or other insurance and there is a shortfall between the costs incurred by the Director and the
amount that the relevant insurer advances or pays, the Company will meet that shortfall amount. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that the Company considers that any amount of Expenses borne by the Company under clause 4.2(c) or
4.3 is unreasonable (other than by reason of the rates charged per clause (a)), the Company may refer the matter for determination by an Independent Expert, in accordance with clause 10. If the Independent Expert finds that any such amount was
unreasonable (other than by reason of the rates charged per clause (a)), the Company is only liable for the amount which the Independent Expert finds to be reasonable and the Director will refund the difference between that amount and the amount
paid by the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Consultation </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Where a Claim is under the management and control of the Company, the Company must: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_85539103_3 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Deed of Indemnity, Access and Insurance | page 9</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">consult with the Director about material decisions regarding the Claim; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">take into account the Director&#146;s interests (including the Director&#146;s reputation) in making material
decisions about the Claim, including in relation to settlement or compromise of the Claim; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">keep the Director reasonably informed of developments regarding the Claim. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Settlement of a Claim </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Company proposes that a Claim be settled or compromised, the Company must: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">provide to the Director details of the proposed offer of settlement or compromise; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">allow the Director a reasonable period (to be specified in the notice) in which the Director may object to the
offer. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Director does not object to the offer within the period allowed under paragraph (a)(ii), the offer of
settlement or compromise may be made or accepted, as the case may be. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If, within the period allowed under paragraph (a)(ii), the Director gives notice that the Director objects to
the offer, the Company may (at its sole discretion, acting reasonably): </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the Claim is under the management and control of the Company: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">relinquish to the Director the control of the conduct of the Claim (to the extent that it relates to the
Director); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">continue the conduct of the Claim without making or accepting the offer, or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">permit the Director to continue the conduct of the Claim without making or accepting the offer, and
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">in any case, the liability of the Company under this Deed in respect of that Claim (to the extent that it relates to
the Director) will not exceed the amount of the offer specified in the notice given to the Director under clause 4.6(a) together with Expenses reasonably and properly incurred by or on behalf of the Director up to that time. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Role of the insurer under the D&amp;O Policy </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The obligations of the Company under this clause 4 are subject to the rights and obligations of the Company and the insurer under the D&amp;O
Policy relating to the management, control and settlement of any Claim. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Failure to comply </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If the Director fails to comply with any obligation referred to in clause 3.1 or another provision of this Deed to the material prejudice of
the Company, the Director is liable to reimburse the Company to the extent of such prejudice. The Company may set off any such liability against the liability of the Company to the Director under this Deed. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other indemnity or insurance </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Precedence </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Company is not liable under clause 2.1 for any amount (including any amount of Expenses) to the extent that the Director is also entitled
to be indemnified in respect of that amount under an insurance policy (including a D&amp;O Policy) or other indemnity. However, if the insurer or other indemnifying party fails to pay any such amount within 20 Business Days, the Company will advance
that amount to or on behalf of the Director. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_85539103_3 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Deed of Indemnity, Access and Insurance | page 10</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Director must claim </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If the Director is insured or entitled to any other indemnity for any Claim, the Director must claim under the applicable insurance policy or
other indemnity. The Director is not required to await the outcome of a claim under the insurance policy or other indemnity before being indemnified under this Deed. However, if indemnification under this Deed may enable an insurer or other person
to deny insurance cover or other indemnity to the Director for any Claim, any payment made by the Company under this Deed is to be taken to be an advance. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Reimbursement of the Company </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Director must account to the Company for any amount: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">which the Director receives under an insurance policy or other indemnity available to the Director in respect
of a payment which has already been made by the Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">advanced under clause 6.1 or taken to have been advanced under clause 6.2 if and when and to the extent that
the amount is received by the Director from the relevant insurer or other person; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">of Expenses that were advanced to the Director under clause 2.5 and for which the Company is not:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">liable to indemnify the Director by reason of conduct referred to in clause 2.3 being established in accordance
with that clause; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">permitted by law or the Constitution to indemnify the Director by reason of an adverse determination of a
proceeding (including where the Director is convicted of a criminal offence), </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">such amount to be reimbursed within 20
Business Days of the Company providing to the Director details of each such amount. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Insurance </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Obligation to insure </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">To the extent permitted by law and the Constitution, the Company must at all times during the Relevant Period, maintain and pay the premium on
a D&amp;O Policy that complies with clause&nbsp;7.2. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Terms and conditions of D&amp;O Policy </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The D&amp;O Policy must: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cover (but only to the extent required by paragraph (b)) liabilities incurred by the Director (or the Company
under the indemnities granted to the Director under clause 2.1) in respect of, or arising out of any Claim; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">be for an amount and on terms and conditions (including premium, insuring clauses, exclusions, excess amounts
and extended reporting provisions) as are appropriate for a reasonably prudent company in the Company&#146;s circumstances acting reasonably and fairly; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">be on terms and conditions that, taken as a whole, are not materially less favourable to the D&amp;O Policy
taken out at the same time by the Company in respect of any other director or officer of the Company. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_85539103_3 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Deed of Indemnity, Access and Insurance | page 11</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Notice to Director </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Company must notify the Director immediately on the Company becoming aware that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the D&amp;O Policy required to be maintained under clause 7.1 has been cancelled or not renewed; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">there is a material diminution in the terms of the D&amp;O Policy maintained under clause 7.1 for the Director.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Company to take reasonable steps </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Company must take all steps and provide all notices reasonably required under the terms of the D&amp;O policy (including without limitation
any extended reporting provisions), to avail the Director of the full benefit of the D&amp;O policy. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Parties&#146; obligations </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Company and the Director must: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">not do or permit to be done anything which prejudices or renders any part of the D&amp;O Policy void, voidable
or unenforceable, and immediately rectify anything reasonably within the control of the Company or the Director (as the case may be) which might prejudice or render any part of the D&amp;O Policy void, voidable or unenforceable; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">immediately notify the other in writing on becoming aware of anything done or omitted to be done which could
prejudice the D&amp;O Policy. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Access to Board Documents </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Request for access to Board Documents </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Director (or any Authorised Person) may make a request to the Company for access to Board Documents, which must: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">be in writing addressed and given to the Company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">include particulars of the Board Documents to which access is sought by the Director (<B>Requested
Documents</B>); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">state the purpose for which access to the Requested Documents is sought, which must be for one of the following
purposes: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to discharge the Director&#146;s duties as an officer of a Group Company; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the investigation or defence of any Claim or any other investigation or proceeding that is anticipated,
threatened or commenced that may involve or result in a Claim against the Director; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other purpose in respect of which the Company gives its written consent, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">(<B>Permitted Purpose</B>). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Inspection of Board Documents </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Company must permit, and must procure that each other Group Company permits, the Director to inspect at the offices of the Company or
relevant Group Company and copy each Requested Document during Business Hours subject to such conditions as the Group Company reasonably requires, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company considers that access to the Requested Document is not for a Permitted Purpose, in which case:
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_85539103_3 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Deed of Indemnity, Access and Insurance | page 12</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company must notify the Director that it will not permit the Director to have access to the Requested
Document on the basis that it is not for a Permitted Purpose; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the Director disputes the Company&#146;s decision to refuse access to the Requested Document, the Director
must notify the Company of that dispute in writing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">during the period of 5 Business Days after notice is given under paragraph (ii), the Director and the Company
must use reasonable efforts to resolve the dispute; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the dispute is not resolved in accordance with paragraph (iii), the Company must refer the matter to an
Independent Expert (in accordance with clause 10) who must decide whether access to the Requested Document is for a Permitted Purpose and, if the Independent Expert so decides, the Company must permit the Director to inspect the Requested Document
during Business Hours; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Requested Document is or refers to a Privileged Document, in which case clauses 8.4 to 8.5 will apply.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Return of Board Documents </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Director: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">subject to paragraph (b), must deliver any Board Documents that the Director holds to the company secretary of
the relevant Group Company at the conclusion or as soon as possible following the conclusion of each board meeting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of any Board Documents copied and provided to the Director for a Permitted Purpose, must return
those Board Documents to the company secretary of the relevant Group Company as soon as possible after they are no longer required for the Permitted Purpose. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Privileged Documents </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If a Director requests access to any Board Document under clause 8.1 or 8.2 which in the Company&#146;s opinion is or refers to a Privileged
Document, the Company must notify the Director that privilege exists and: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the Company believes it reasonably practicable, provide access in such a way that privilege is not lost or
waived; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">subject to paragraph (c), waive, and procure that each other Group Company which is entitled to claim privilege
in respect of that Privileged Document waives, such privilege; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if access to that Board Document would, in the reasonable opinion of the Company, jeopardise the ability of a
Group Company to claim legal privilege in respect of a Privileged Document resulting in material prejudice to the Group Company: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">impose such conditions on the Director&#146;s access to that Board Document as it determines, in good faith,
are appropriate to ensure that the ability of a Group Company to claim privilege in respect of that Board Document is not jeopardised by such access; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">refuse to permit the Director to have access to that Board Document if the Company determines in good faith and
acting reasonably that it is not possible to ensure, by the imposition of conditions, that the Group Company&#146;s claim to privilege in respect of that Board Document would not be jeopardised by such access. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_85539103_3 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Deed of Indemnity, Access and Insurance | page 13</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Disputes in relation to Privileged Documents </B></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Director disputes the Company&#146;s decision to refuse access to a Board Document, or to impose
conditions on access to a Board Document in accordance with clause 8.4, the Director must notify the Company of that dispute in writing. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">During the period of 5 Business Days after notice is given under paragraph (a), the Director and the Company
must use reasonable efforts to resolve the dispute. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the dispute is not resolved in accordance with paragraph (b), the Company must refer the matter to an
Independent Expert (in accordance with clause 10) who must weigh up the interests of the Director in having access to the document against the risks to the Company of waiving privilege to determine whether and, if so, on what terms, access should be
granted to the Director. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.6 Director&#146;s obligations </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Director must not waive any privilege of a Group Company nor do or omit to do anything that will cause that
privilege to be waived or lost, without the prior written consent of the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Where the Director obtains access to Documents subject to conditions imposed by the Company under clause 8.4,
the Director must comply with those conditions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Access permitted under Corporations Act </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Despite any other provision of this Deed, if and to the extent that the Corporations Act gives the Director the right to inspect a Board
Document that is, or refers to, a Privileged Document, the Company must allow, and must procure that each Group Company allows, the Director to inspect that Board Document in accordance with the Corporations Act. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Confidentiality </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Obligations of confidentiality </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Without limiting the Director&#146;s duties as an officer of any Group Company, the Director (both during the period in which the Director is
an officer of a Group Company and after the Director ceases to be an officer of a Group Company) must: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">keep all Information confidential (except to the extent that disclosure is permitted under clause 9.2);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">not disclose Information to any person unless and to the extent permitted to do so under clause 9.2; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">not use Information for any purpose other than a Permitted Purpose. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exceptions </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The obligations in clause&nbsp;9.1 do not apply to Information if and to the extent that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Information is or comes into the public domain (other than as a result of a contravention by the Director
of this Deed or any other obligation of confidence); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">disclosure of the Information is required by law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">disclosure of the Information is either: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reasonably necessary for a Permitted Purpose; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">made in confidence to the legal, financial or taxation advisers of the Director, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_85539103_3 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Deed of Indemnity, Access and Insurance | page 14</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">and either: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">no Group Company has a right to claim legal privilege in respect of some or all of that Information or the
proposed disclosure of the Information could not reasonably be expected to jeopardise a Group Company&#146;s ability to claim such privilege; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">each Group Company that has the right to claim privilege in respect of all or any of that Information has
waived, in writing, its right to claim legal privilege in respect of all or any of that; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">disclosure of the Information is reasonably necessary for the purposes of the discharge of the duties of the
Director as an officer of a Group Company; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company has given its prior written consent to the disclosure of the Information. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Limitation </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If the Director is permitted to disclose Information under clause&nbsp;9.2, the Director must: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">disclose only the minimum Information reasonably necessary in the circumstances; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">disclose the Information only to persons who have a need to know and only to the extent that they have a need
to know; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">comply with any conditions imposed by the Company under clause 8.4(c)(i). </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Expert determination </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Referral to expert </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Any matter which is expressly required in this Deed to be referred to an Independent Expert must be dealt with in accordance with this clause
10. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Independent Expert </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Company must refer the matter for determination by a lawyer mutually acceptable to the Director and the Company or, in default of
agreement, a lawyer nominated by the President for the time being of the Law Institute of Victoria. The seniority of the lawyer should reflect the complexity and significance of the issues which the lawyer is to be asked to determine. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Determination by Expert </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Independent Expert appointed under clause 10.2 will: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">make a determination based on the information made available by the parties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">make a determination having regard to the obligations of the parties under this Deed; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">notify the parties in writing of his or her determination within 10 Business Days of his or her appointment.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Independent Expert not arbitrator </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Independent Expert must act as an expert not as an arbitrator and his or her decision will be final and binding on the parties. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Cost of Independent Expert </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The cost of the Independent Expert&#146;s determination must be borne by the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_85539103_3 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Deed of Indemnity, Access and Insurance | page 15</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>General provisions </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Service of notices </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">A notice, demand, consent, approval or communication under this Deed (<B>Notice</B>) must be: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in writing, in English and signed by a person duly authorised by the sender; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">hand delivered or sent by prepaid post or facsimile to the recipient&#146;s address for Notices specified in
the Details, as varied by any Notice given by the recipient to the sender. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Notices sent by email </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">A Notice may also be sent by email if the Notice is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">authorised by the sender in accordance with a procedure agreed between the parties; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">sent to the email address specified in the Details or the email address last notified by the intended recipient
to the sender. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Notices effective on receipt </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">A Notice given in accordance with clause 11.1 or 11.2 takes effect when taken to be received (or at a later time specified in it), and is taken
to be received: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if hand delivered, on delivery; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if sent by prepaid post, on the second Business Day after the date of posting (or on the seventh Business Day
after the date of posting if posted to or from a place outside Australia); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if sent by facsimile, when the sender&#146;s facsimile system generates a message confirming successful
transmission of the entire Notice unless, within eight Business Hours after the transmission, the recipient informs the sender that it has not received the entire Notice; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of delivery by email, the first to occur of: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">receipt by the sender of an email acknowledgment from the intended recipient&#146;s information system showing
that the Notice has been delivered to the email address of that recipient; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the time that the Notice enters an information system which is under the control of the intended recipient; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the time that the Notice is first opened or read by an employee or officer of the intended recipient,
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">but if the delivery, receipt or transmission is not on a Business Day or is after 5.00pm on a Business Day, the Notice
is taken to be received at 9.00am on the next Business Day. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Severability </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If anything in this Deed is unenforceable, illegal or void then it is severed and the rest of this Deed remains in force. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Governing law and jurisdiction </B></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The law of Victoria governs this Deed. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The parties submit to the exclusive jurisdiction of the courts of Victoria and the Commonwealth of Australia
and agree that any law suit may be heard in those courts. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Amendment </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">This Deed may only be amended by a further deed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_85539103_3 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Deed of Indemnity, Access and Insurance | page 16</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Waiver and exercise of rights </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A waiver by a party of a provision of or a right under this Deed is binding on the party granting the waiver
only if it is in writing signed by the party or an authorised officer of the party granting the waiver. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A waiver is effective only in a specific instance and for the specific purpose for which it is given.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A single or partial exercise of a right by a party does not preclude another exercise of that right or the
exercise of another right. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Failure by a party to exercise or delay in exercising a right does not prevent its exercise or operate as a
wavier. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.8</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Counterparts </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">This Deed may be executed in counterparts and both counterparts taken together constitute one document. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.9</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Assignment </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Neither party can assign, novate or otherwise transfer any of their rights or obligations under this Deed without the prior written consent of
the other party. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.10</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Further action </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Each party must promptly do all things necessary or desirable to give full effect to this Deed. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.11</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>GST </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The intention of this Deed is that, to the maximum extent possible, as between the Director and the Company, neither is to be adversely
affected or advantaged by the operation of tax payable under <I>A New Tax System (Goods and Services Tax) Act 1999</I> (Cth). If either party requires a tax invoice or the assistance of the other party to obtain an input tax credit, the other party
will provide such invoice or assistance promptly upon being requested to do so. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.12</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Costs and stamp duty </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Company must pay the costs of negotiating, preparing and executing this Deed and any stamp duty on this Deed. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.13</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Survival </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Each indemnity in this Deed is independent and survives termination of this Deed. Any other provision by its nature intended to survive
termination of this Deed survives termination of this Deed. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.14</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Entire agreement </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">This Deed constitutes the entire agreement between the parties in connection with its subject matter and supersedes all previous agreements or
understandings between the parties in connection with its subject matter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_85539103_3 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Deed of Indemnity, Access and Insurance | page 17</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Signing page </B></P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EXECUTED</B> as a deed. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Executed</B> by <B>Opthea Limited</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="FONT-FAMILY:'WINGDINGS 3'">&#102;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="FONT-FAMILY:'WINGDINGS 3'">&#102;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="font-size:8pt">Signature of director</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Signature of director/company secretary</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">(Please
delete as applicable)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="font-size:8pt">Name of director (print)</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:8pt">Name of director/company secretary (print)</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Signed sealed and delivered</B></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">in the presence of</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="FONT-FAMILY:'WINGDINGS 3'">&#102;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="FONT-FAMILY:'WINGDINGS 3'">&#102;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="font-size:8pt">Signature of witness</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:8pt">Signature of Director</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="font-size:8pt">Name of witness (print)</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">ME_85539103_3 (W2003)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Deed of Indemnity, Access and Insurance | page 18</TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>7
<FILENAME>filename7.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.4 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman"><B>Lease </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">Building: &nbsp;&nbsp;&nbsp;&nbsp;Como Centre, 650
Chapel Street South Yarra </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">Premises: &nbsp;&nbsp;&nbsp;&nbsp;Suite 0403 Level&nbsp;4 </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">The Trust Company (Australia) Limited </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">ACN 000 000 993 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">in its capacity as custodian for the Newmark Como Property Trust </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>(Landlord) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">Opthea Limited </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">ACN 006 340 567 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>(Tenant) </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><SMALL>GADENS</SMALL> <SMALL>LAWYERS</SMALL>
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Level&nbsp;25, Bourke Place </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">600 Bourke Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MELBOURNE 3000 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">T&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;+61 3 9252 2555 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">F&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;+61 3 9252 2500 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ref:&nbsp;&nbsp;&nbsp;&nbsp;RSS:21904819 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="4" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Contents</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>COMMERCIAL TERMS SCHEDULE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>1</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>1.&#8195;&#8201;TERM</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>5</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term of lease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Monthly tenancy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>2.&#8195;&#8201;BASE RENT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>5</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First instalment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>3.&#8195;&#8201;REVIEW OF BASE RENT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>5</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Market Review of Base Rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dispute as to Base Rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Base Rent criteria</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Minimum Base Rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consumer Price Index Adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fixed Percentage Increase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>4.&#8195;&#8201;OUTGOINGS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>8</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outgoings Contribution</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of contributions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tenant to pay charges</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>5.&#8195;&#8201;USE OBLIGATIONS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>10</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Positive use obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Negative use obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No warranty as to use</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laws and Requirements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tenant&#146;s Fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Essential Services Certification</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cleaning</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>6.&#8195;&#8201;REPAIRS AND ALTERATIONS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>13</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repair and maintenance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Landlord&#146;s right of inspection</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tenant to carry out obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Landlord&#146;s right of entry</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alterations to the Building</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>7.&#8195;&#8201;ASSIGNMENT AND SUB-LETTING</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>15</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dealings not permitted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subleases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assignment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Control of Tenant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mortgage of Tenant&#146;s equipment etc</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>8.&#8195;&#8201;INSURANCE AND DAMAGE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>16</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tenant&#146;s insurances</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Insurance terms</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Not affect insurances</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property of Tenant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Releases of Landlord</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indemnities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Damage to Building</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>9.&#8195;&#8201;LANDLORD&#146;S OBLIGATIONS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#8194;&#8201;&#8201;&nbsp;</B></TD>
<TD VALIGN="bottom"><B>19&#8194;&#8201;&#8201;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&#8194;&#8201;&#8201;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Quiet enjoyment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outgoings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common Areas</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Directory board and door signage</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Minimise disturbance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carpet</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>10.&#8194;&#8201;DEFAULT, TERMINATION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#8194;&#8201;&#8201;&nbsp;</B></TD>
<TD VALIGN="bottom"><B>20&#8194;&#8201;&#8201;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&#8194;&#8201;&#8201;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Essential terms</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Default</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Avoid default</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Termination of lease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Landlord may rectify</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tender after termination</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Damages</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Landlord may institute proceedings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Landlord to mitigate damages</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest on overdue money</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>11.&#8194;&#8201;END DATE OBLIGATIONS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#8194;&#8201;&#8201;&nbsp;</B></TD>
<TD VALIGN="bottom"><B>22&#8194;&#8201;&#8201;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&#8194;&#8201;&#8201;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reinstatement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Abandoned Tenant&#146;s Fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>12.&#8194;&#8201;LANDLORD&#146;S RIGHTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#8194;&#8201;&#8201;&nbsp;</B></TD>
<TD VALIGN="bottom"><B>23&#8194;&#8201;&#8201;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&#8194;&#8201;&#8201;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Roof</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Building name</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change of Landlord</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Landlord&#146;s agents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Close Building</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Premises security</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rules</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in PCA Method</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Emergency</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Landlord access</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Structural works</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prospective tenants or purchasers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Environmental Initiatives</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subdivision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>13.&#8194;&#8201;NOTICES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#8194;&#8201;&#8201;&nbsp;</B></TD>
<TD VALIGN="bottom"><B>25&#8194;&#8201;&#8201;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&#8194;&#8201;&#8201;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>14.&#8194;&#8201;BANK GUARANTEE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#8194;&#8201;&#8201;&nbsp;</B></TD>
<TD VALIGN="bottom"><B>25&#8194;&#8201;&#8201;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&#8194;&#8201;&#8201;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>15.&#8194;&#8201;PAYMENTS AND COSTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#8194;&#8201;&#8201;&nbsp;</B></TD>
<TD VALIGN="bottom"><B>26&#8194;&#8201;&#8201;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&#8194;&#8201;&#8201;</B></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>16.&#8194;&#8201;GOVERNING LAW</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>27</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>17.&#8194;&#8201;GENERAL</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>27</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Waiver</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legislation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Approval and consent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discretion and opinion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Set-off</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indemnities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Further assurances</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exclusion of statutory provisions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Antecedent rights and obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Severability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">If document not a lease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Relationship of parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Counterparts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No caveat</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entire agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attorneys</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tenant&#146;s representations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-merger</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>18.&#8194;&#8201;GST</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>30</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>19.&#8194;&#8201;LANDLORD LIMITATION OF LIABILITY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>31</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>20.&#8194;&#8201;NEWMARK LIMITATION OF LIABILITY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>31</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>21.&#8194;&#8201;APPLICABILITY OF THE RETAIL LEASES ACT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>32</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>22.&#8194;&#8201;COMPLETION OF BLANKS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>32</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>23.&#8194;&#8201;ESD REQUIREMENTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>32</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>24.&#8194;&#8201;PREMISES CONDITION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>33</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>25.&#8194;&#8201;BUILDING WORKS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>33</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>26.&#8194;&#8201;LANDLORD&#146;S CONTRIBUTION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>33</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SCHEDULE 1&#151;DEFINITIONS AND INTERPRETATION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>35</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SCHEDULE 2&#151;OUTGOINGS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>45</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Executed as a deed on 12 November 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>48</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman"><B>COMMERCIAL TERMS SCHEDULE </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="72%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;1</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Landlord</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>The Trust Company (Australia) Limited ACN 000 000 993</B> in its capacity as custodian for the Newmark Como Property Trust</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="72%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;2</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Tenant</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>Opthea Limited </B><B><BR></B>ACN 006 340 567</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="72%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"><B>Item&nbsp;3 <BR>Premises</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">Suite 0403, Level&nbsp;4 of the Building as shown hatched on the plans attached as annexure A to this lease</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="72%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"><B>Item&nbsp;4 <BR>Area of Premises</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">180 square metres (subject to survey)</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="72%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"><B>Item&nbsp;5 <BR>Land <BR></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">The land located at the corner of Toorak Road, Chapel Street and River Street South Yarra Victoria but limited to 650 Chapel Street South
Yarra</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="72%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"><B>Item&nbsp;6 <BR>Commencement Date <BR></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">15&nbsp;July 2019</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="72%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"><B>Item&nbsp;7 <BR>Expiry Date <BR></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">14&nbsp;July 2022</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="72%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"><B>Item&nbsp;8 <BR>Base Rent <BR></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">$460.00 per square metre per annum multiplied by the net lettable area of the Premises, being $82,800 per annum (subject to
survey)</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="72%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"><B>Item&nbsp;9 <BR>Market Review Dates <BR></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Not
applicable</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 1 of 53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="72%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;10</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>CPI Adjustment
Dates</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">Not applicable</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="72%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"><B>Item&nbsp;11 <BR>Consumer Price Index <BR></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">Not applicable</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="34%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"><B>Item&nbsp;12 <BR>Fixed Increase Date and Fixed Percentage Increase</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fixed Increase Date</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Each anniversary of the Commencement Date</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">Fixed Percentage Increase</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">4%</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="72%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"><B>Item&nbsp;13 <BR>Tenant&#146;s Proportion</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.96% (subject to survey)</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="72%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"><B>Item&nbsp;14 <BR>Exclusion of Statutory Provisions</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">The covenants, powers and provisions implied in leases by virtue of the Transfer of Land Act 1958 do not apply to this lease.</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="72%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"><B>Item&nbsp;15 <BR>Permitted Use</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">Commercial offices</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="72%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"><B>Item&nbsp;16 <BR>Redecoration Date</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Not
applicable</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="72%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"><B>Item&nbsp;17 <BR>Facilities Hours</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>Lifts and Escalators</B>: all lifts and escalators to be operating daily between 8.00 a.m. and 6.00 p.m., Saturdays, Sundays and public
holidays excepted. Outside those hours, at least one lift in each rise to operate on call and subject to conformity with the Landlord&#146;s access control system for the Building.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="72%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Air-conditioning</FONT></B>: to operate daily between 8.00 a.m. and 6.00 p.m., Saturdays, Sundays and public holidays
excepted. Outside those hours, <FONT STYLE="white-space:nowrap">air-conditioning</FONT> to be provided to the Premises at the request and at the cost of the Tenant which at the Commencement Date of the initial term is $60.00 per hour per zone
(minimum charge for 2 hours to apply) but subject to change during the Term as determined by the Landlord (acting reasonably) and notified to the Tenant.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Access to the Building</B>: public entry doors to the Building to be open daily between 8.00 a.m. and 6.00 p.m., Saturdays, Sundays and public holidays
excepted. Outside those hours, access to be available through a nominated entry and exit point for the Tenant and the Tenant&#146;s nominated staff and in accordance with the operations of the Landlord&#146;s access control system for the
Building.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Other Facilities</B>: to be available at all times when the Building
is open.</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="72%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"><B>Item&nbsp;18 <BR>Public risk insurance</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">$20,000,000</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"><B>Item&nbsp;19 <BR>Notices</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Landlord:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Newmark Capital Limited <BR>Como Centre</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Level&nbsp;18, 644 Chapel Street <BR>SOUTH YARRA VIC 3141</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attention: Asset Manager</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Tenant:</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Opthea Limited <BR>Suite 0403 <BR>650 Chapel
Street <BR>SOUTH YARRA VIC 3141</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attention: Company Secretary</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="72%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"><B>Item&nbsp;20 <BR>Bank Guarantee amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">An amount equal to the Base Rent plus GST and Outgoings Contribution plus GST for 6 months being $57,281.40 as at the Commencement Date
subject to clause 14.6</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="72%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"><B>Item&nbsp;21 <BR>Trust</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Newmark Como Property Trust</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="72%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"><B>Item&nbsp;22<BR>Further Term</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">Not applicable</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="72%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"><B>Item&nbsp;23 <BR>Retail Leases Act</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Act does not apply.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Reason: The Premises are not used for the retail sale of goods or the provision of
services by retail.</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Landlord is the registered proprietor of the Land and the Building. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Landlord leases to the Tenant the Premises for the Term on the terms and conditions contained in this lease. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TERM </B></P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Term of lease </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the provisions of this lease, this lease commences on the Commencement Date and ends on the Expiry
Date. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Monthly tenancy </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Landlord in its discretion allows the Tenant to occupy the Premises after the Expiry Date (other than
under a grant of a further lease), the Tenant does so as a monthly tenant on the terms and conditions of this lease with necessary changes applicable to a monthly tenancy except that: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Base Rent will be an amount equal to <FONT STYLE="white-space:nowrap">one-twelfth</FONT> of the Base Rent
payable immediately before the Expiry Date increased by the Fixed Percentage Amount. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the first payment of rent is to be made on the next day after the Expiry Date; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the monthly tenancy may be terminated at any time by either party giving one month&#146;s notice to the other
party and the tenancy will end one month after service of that notice; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the Tenant defaults in performing its obligations, then the Landlord may terminate the tenancy by giving
notice to the Tenant and the monthly tenancy will end seven days after service of that notice. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>BASE RENT </B></P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Payment </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant must pay the Base Rent by equal monthly instalments (and proportionately for any part of a month) in
advance on the first day of each month during the Term. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>First instalment </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant must pay the first instalment of Base Rent on the Commencement Date. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>REVIEW OF BASE RENT </B></P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Market Review of Base Rent </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Landlord chooses to review the Base Rent at any Market Review Date then clauses 3.2 to 3.16 inclusive
apply. The Landlord is not obliged to give a notice under clause 3.2. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">During each Review Period the Landlord may give a Rent Review Notice to the Tenant in respect of the Market
Review Date to which that Review Period relates. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amount in the Rent Review Notice is the Base Rent reserved by this lease from that Market Review Date
unless a Dispute Notice is given by the Tenant within the Dispute Period. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Landlord does not give the Tenant a Rent Review Notice in respect of a Market Review Date, then as from
that Market Review Date until the next Review Date (or if there is no further Review Date, the Expiry Date) the Tenant must continue to pay Base Rent at the rate payable before that Market Review Date; and </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dispute as to Base Rent </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Tenant wants to dispute a Rent Review Notice, then during the Dispute Period the Tenant must give notice
to the Landlord: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">stating that the Tenant disputes the Base Rent assessed by the Landlord; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">nominating the figure which is the Tenant&#146;s assessment of the Base Rent to apply from the relevant Market
Review Date. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Within 21 days after delivery of the Dispute Notice, the Landlord and the Tenant must agree on an Umpire who
will determine the Base Rent. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Landlord and the Tenant do not appoint the Umpire under clause 3.6, then either party may ask the
president of the Institute to appoint the Umpire. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An Umpire appointed under this lease: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">must be a full member of not less than five years&#146; standing of the Institute; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">must hold a licence or be registered to practise as a valuer of the kind of premises demised by this lease;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">must have at least three years&#146; experience in valuing such premises and be active in that market at the
time of his or her appointment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">must have due regard to any evidence submitted by the parties (and, in the case of the Umpire, by the Valuers)
as to their assessments of the Base Rent; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as a condition of the appointment agree to make his or her determination of the Base Rent within 30 days of his
or her appointment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">must give his or her determination and the reasons for that determination (including setting out what was taken
into account, what was disregarded, their respective weightings and any other adjustments) in writing; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">acts as an expert and not as an arbitrator. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The determination of the Umpire is final and binding and is the Base Rent as at that Market Review Date. The
Umpire&#146;s determination must be a speaking valuation which complies with clause 3.8 (f). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Umpire does not make his or her determination of the Base Rent within the required period, then either
party may ask the president of the Institute to appoint a substitute Umpire. On that appointment, the appointment of the previous Umpire ends. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Base Rent criteria </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In determining the Base Rent, the parties and any Umpire must determine the current market rent on a face rent
basis for the Premises as at the particular Market Review Date having regard to the provisions of this lease and must: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">disregard the value of any goodwill attributable to the Tenant&#146;s Business and the value of the
Tenant&#146;s Fixtures or fitout or any other interest in the Premises created by this lease; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">disregard any deleterious condition of the Premises resulting from any work carried out by the Tenant or from
any breach of this lease by the Tenant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">disregard any rent or other money payable under any sublease or licence where the rent or other money payable
under the sublease or licence is less than the Base Rent; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">have regard to the Term and, if part of the Term has elapsed at the Review Date, disregard that fact;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">have regard to the rental value of comparable premises but in doing so must make no reduction on account of any
Incentive; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">consider the Premises as used for the Permitted Use but must have regard also to any other use to which the
Premises may be lawfully put; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">regard the Premises on a floor by floor basis without a discount where the Base Rent is to be determined for
more than one floor; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">assume that all obligations of the Tenant and the Landlord in this lease have been performed and observed;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">make no reduction on account of any Incentive paid, provided or allowed to the Tenant or which would be likely
to be paid, provided or allowed to a tenant in relation to a new tenancy in respect of the Premises were they vacant; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">assume that the Building has been reinstated in accordance with clause 8 if the Building has been damaged or
destroyed. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Costs </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The costs of the Umpire in determining the Base Rent must be paid by the parties equally.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Minimum Base Rent </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If a Rent Review Notice is given under clause 3.2, then despite any other provision of this lease, the Base
Rent from and including any Market Review Date until the next Review Date or the Expiry Date as appropriate is the greater of: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Base Rent determined under this clause 3; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Base Rent payable for the 12 months immediately before that Market Review Date. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Adjustments </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If a Rent Review Notice is given under clause 3.2, the Base Rent specified in that notice is payable from the
particular Market Review Date, whether or not a Dispute Notice is given by the Tenant. Any receipt for the payment of Base Rent at a lesser amount due to the Landlord&#146;s delay in issuing the Rent Review Notice does not prejudice the
Landlord&#146;s right to demand payment of any additional rent payable by the Tenant as a result of that review. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If a Rent Review Notice is given after the Market Review Date to which it relates, then any shortfall in the
payment of Base Rent as from the Market Review Date must be paid by the Tenant on the first day of the month next following the date of service of the Rent Review Notice. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If a Dispute Notice is given by the Tenant, any variation in the Base Rent arising from a determination under
this clause 3 takes effect from the relevant Market Review Date. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.17</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">After the determination of the Base Rent: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the Base Rent payable is less than that specified in the Rent Review Notice, then the Landlord must credit
to the Tenant any excess rent paid by the Tenant in one of the next two rental statements; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the Base Rent payable is greater than that specified in the Rent Review Notice, then the Tenant must pay any
deficiency to the Landlord within seven days after the date of the determination. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consumer Price Index Adjustment </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.18</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Base Rent from and including each CPI Adjustment Date until the next Review Date (or if there is no further
Review Date, the Expiry Date) is the greater of: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Base Rent payable immediately before that CPI Adjustment Date multiplied by the Current CPI and divided by
the Previous CPI; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Base Rent payable immediately before that CPI Adjustment Date. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.19</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On the first day of the month after the information is available to make the calculation in clause 3.18, the
Tenant must pay the difference between what the Tenant has paid on account of Base Rent and the Base Rent as adjusted pursuant to clause 3.18 for the period from and including the relevant CPI Adjustment Date to but excluding the first day of that
month. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fixed Percentage Increase </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.20</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Base Rent from and including each Fixed Increase Date until the next Review Date (or if there is no further
Review Date, the Expiry Date) is increased by the Fixed Percentage Increase. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>OUTGOINGS </B></P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outgoings Contribution </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant must pay the Outgoings Contribution for each Outgoings Year calculated as follows:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">OC = LP x I x <U>N </U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Y </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">where: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">OC = the Outgoings
Contribution </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">LP = the Tenant&#146;s Proportion </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">I = the amount of the Outgoings for the relevant Outgoings Year </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">N = is the number of days of the Term falling within the relevant Outgoings Year </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Y = 365 (or 366 in the case of a leap year). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord may allocate to specific tenants (including the Tenant) Outgoings costs which in the
Landlord&#146;s reasonable opinion have been incurred in respect of those tenants or in respect of a particular part of the Building occupied by those tenants. The Landlord must exclude those costs from the Outgoings for which other tenants are
liable. The Tenant must pay any cost allocated to it under this clause. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Outgoings for any particular Outgoings Year will be calculated on an accrual basis, unless the Landlord in
its discretion decides to calculate the Outgoings on a cash basis. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Not used. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Not used.. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Not used. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Payment of contributions </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord may notify the Tenant of the Landlord&#146;s reasonable estimate of the Outgoings Contribution for
each Outgoings Year, and may adjust the reasonable estimate from time to time. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant must pay, on account of the Tenant&#146;s Proportion of the Outgoings Contribution, the estimate
notified under clause 4.7, by equal monthly instalments in advance on the days for payment of Base Rent. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As soon as practicable after each Outgoings Year the Landlord must give the Tenant a statement for that
Outgoings Year with reasonable details of the Outgoings and the Tenant&#146;s Proportion of the Outgoings Contribution payable by the Tenant. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Within 14 days after receipt of the statement, the Tenant must pay or the Landlord must credit, the difference
between the amount paid on account of the Tenant&#146;s Proportion in the Outgoings Contribution for that Outgoings Year and the amount actually payable by the Tenant. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">By notice to the Tenant the Landlord may recover any Tenant&#146;s Proportion of the Outgoings Contribution by
payment of a lump sum, even if the Landlord has not notified the Tenant of an estimate under clause 4.7 or gives notice after the End Date. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant&#146;s Proportion of the Outgoings Contribution is payable even if the End Date occurs before the
relevant amount for any particular Outgoings Year can be calculated. In that case the Landlord&#146;s reasonable estimate at the End Date is taken to be the actual Outgoings Contribution to the End Date without any further adjustment.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant acknowledges that details of the Tenant&#146;s Proportion of any increase in the Outgoings
Contribution and Outgoings provided to it at the Commencement Date may have been based on estimates and that the estimates may require revision when the actual amount of the expense is determined. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tenant to pay charges </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant must pay on time all: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">waste costs, water costs and other costs which the Landlord reasonably determines to have been incurred in
respect of the Premises as a result of the Tenant&#146;s use and occupation of the Premises; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">costs of services separately connected and supplied to the Premises or connected to the Building and separately
metered to the Premises including water, electricity, gas and telephone; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the connection and usage costs of all services not connected and supplied to the Premises but required by the
Tenant; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">after hours trading costs including but not limited to cleaning electricity gas insurance and security costs
and air conditioning . </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>USE OBLIGATIONS </B></P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Positive use obligations </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant must: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">use the Premises only for the Permitted Use; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">lock all exterior doors and windows in the Premises when the Premises are not occupied; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">keep the Premises clean and tidy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">notify the Landlord and the proper Authority promptly of any infectious illness in the Premises which must be
notified to an Authority and, if that infectious illness is confined to the Premises, the Tenant must disinfect the Premises to the satisfaction of the Landlord and that Authority; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">notify the Landlord of any damage or accident to or defects in the Building including the failure of any exit
lights or other equipment or any circumstances likely to cause any damage or injury within the Building promptly after the Tenant becomes aware of the damage, accident, defect or circumstances; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">comply with all reasonable directions of the Landlord relating to the receipt, delivery or other movement of
any goods or articles of bulk or quantity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">pay all reasonable and proper costs of the Landlord in providing, at the request of the Tenant, access to the
Building outside the Public Access Hours or Facilities and Services outside the Facilities Hours; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">comply with all Laws and Requirements and the directions of the Landlord in relation to smoking and place in
the Premises signs as the Landlord reasonably requires to notify persons of the prohibitions contained in this lease in relation to smoking; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">comply with the Rules; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">participate in emergency procedures as required by the Landlord; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">provide Keys only to employees and invitees of the Tenant, keep a list of the recipients of Keys and their
status and on request provide the Landlord with an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">up-to-date</FONT></FONT> copy of that list; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(l)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">pay all costs arising from the issue to the Tenant of any Keys and the upgrading or reprogramming of the Keys
and the costs incurred as a result of the loss of or damage to any Key including the cost of replacement keys; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(m)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ensure that any Key system installed in the Premises is compatible with the system for the Building;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(n)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">obtain all consents or approvals of any Authority or under any Laws or Requirements necessary in relation to
the Tenant&#146;s Business and not allow them to lapse or be revoked; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(o)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">use the cleaning service for the Building provided by the Landlord and comply with any recycling program
operating in the Building; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(p)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">fully satisfy any Requirement in respect of Contamination which exists by reason of any Tenant Cause;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(q)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">nominate to the Landlord a representative of the Tenant who can be contacted by the Landlord on a 24 hour basis
in relation to the Premises or any emergency in them; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(r)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">comply with any Environmental Initiatives implemented by the Landlord in the Building. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Negative use obligations </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant must not: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">without the Landlord&#146;s consent, bring, place or store Heavy Items in the Building; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">install any equipment in the Premises that overloads the Services; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">obstruct access to or impede the Services or the Facilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">affix any telecommunications device to the<B> </B>Building or install any communications cabling in the
Building without the Landlord&#146;s consent (and any consent so given may be withdrawn at any time without consultation if the Landlord reasonably considers it to be in the interests of the Landlord or the other tenants or licensees of the Building
to do so); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">use any sound, picture or image producing equipment in the Premises which is audible or visible from outside
the Premises; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">install Coverings on the exterior of the Building or the internal face of perimeter glass without the
Landlord&#146;s consent; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">deface or mark or drive any nails, screws or hooks into the Building; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cover or obstruct the <FONT STYLE="white-space:nowrap">air-conditioning</FONT> ducts and outlets or the
skylights and windows which reflect or admit air or light into the Building or cover or obstruct any lights or other means of illumination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">throw anything out of the windows or doors of the Building or down the elevator shafts or into the light areas
of the Building; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">deposit rubbish anywhere except in proper receptacles; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">place any article or thing on any sill, ledge or other like part of the Building; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(l)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">obstruct the Common Areas nor place items in any part of the Building other than the Premises;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(m)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">without the Landlord&#146;s consent, store or use Inflammable Substances in the Premises;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(n)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">smoke cigarettes, pipes, cigars or any other form of tobacco or similar substance in or around the Building or
the Land; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(o)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">without the Landlord&#146;s consent, remove any ceiling tiles, carpet or other floor coverings or other items
in the Premises at the Commencement Date from where they were originally installed in the Building; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(p)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">do anything to the carpet or other floor coverings in the Premises which contravenes any guarantee relating to
them notified to the Tenant by the Landlord; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(q)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">keep animals or birds in the Premises; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(r)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">carry on any noxious, noisome, or offensive business or do any act or thing which may cause nuisance, damage or
disturbance to any person including the Landlord and any other occupier of the Building; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(s)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">hold any auction, bankruptcy or fire sale in the Premises; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(t)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">prepare or cook food in the Premises except in areas approved by the Landlord; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(u)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">open external windows of the Building; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">without the Landlord&#146;s consent, display or affix any Sign on any part of the Premises or the Building that
is visible from outside the Premises; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(w)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">use the Premises as a residence; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(x)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cause damage to the Building; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(y)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">make any duplicate of the Keys provided by the Landlord; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(z)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Contaminate the Premises. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No warranty as to use </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant acknowledges that the Landlord gives no warranty as to the use to which the Premises may be put. The
Tenant acknowledges that it has satisfied itself and is taken to have accepted this lease with full knowledge of and subject to any prohibitions or restrictions on the use of the Premises under any Laws or Requirements. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Laws and Requirements </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to clause 5.5 and any obligations of the Landlord under this lease, the Tenant must comply with and
observe all Laws and Requirements affecting: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Premises; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Tenant&#146;s Fixtures; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Tenant&#146;s Business; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Tenant&#146;s use or occupation of the Premises, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">whether addressed to or required to be effected by the Landlord, the Tenant or both or by any other person. The Tenant must promptly give the
Landlord a copy of any Laws or Requirements notified to the Tenant. In complying with those Laws or Requirements the Tenant must obtain the Landlord&#146;s consent and must observe the provisions of this lease. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant is not required under clause 5.4 to effect structural works unless rendered necessary by any Tenant
Cause. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tenant&#146;s Fixtures </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord agrees that the installation by the Tenant of the Tenant&#146;s Fixtures in accordance with the
terms of this lease does not constitute a breach of clause 5.2(g) or clause 5.2(x) by the Tenant. This clause 5.6 does not derogate from the Tenant&#146;s obligations under clause 11. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Essential Services Certification </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If due to a Tenant Cause the Landlord is prevented from or delayed in obtaining a statement in relation to each
essential fire or other safety measure implemented in the Building as required by any Law, then within a reasonable time (having regard to the Law and any Requirements) the Tenant, on being required by the Landlord to do so, must at the cost of the
Tenant carry out such works and do such things as are necessary to enable the Landlord to obtain the statement and to comply with the Landlord&#146;s obligations under the Law. This clause operates subject to clause 12.13. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If required by the Landlord at any time, the Tenant must, within the period nominated by the Landlord in its
notice to the Tenant, obtain and provide to the Landlord an essential services certificate in respect of the Premises. This clause does not limit the obligations of the Tenant under clause 5.7. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cleaning </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant is responsible for the Premises cleaning costs and may at its discretion use a third party cleaner
to clean the Premises provided such cleaner has been approved by the Landlord. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>REPAIRS AND ALTERATIONS </B></P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Not used. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Repair and maintenance </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant must keep the Premises, the Tenant&#146;s Fixtures and any Landlord&#146;s Fixtures located in or
exclusively servicing the Premises in good and substantial repair, maintenance and condition including: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">replacing all damaged or faulty light bulbs, light globes and tubes (including exit lights) in the Premises;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">keeping current during the Term such Maintenance Contracts as the Landlord reasonably requires in relation to
the Tenant&#146;s obligations under this clause 6.2. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Tenant must give the Landlord such evidence as to the existence of and performance of
the Maintenance Contracts as the Landlord requires including copies of reports, certificates and other statements issued in connection with those Maintenance Contracts. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Clause 6.2 does not impose any obligation on the Tenant for: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">structural works unless rendered necessary by any Tenant Cause; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">fair wear and tear (apart from replacing all damaged or faulty light bulbs, light globes and tubes (including
exit lights) in the Premises). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to clause 12.13, the Tenant must promptly make good damage (including of a structural nature) to the
Building due to a Tenant Cause. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Landlord&#146;s right of inspection </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On giving the Tenant not less than two days&#146; notice (except in an emergency when no notice is required),
the Landlord may enter the Premises to: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">inspect the state of repair of the Premises; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">review the Tenant&#146;s observance and performance of the Tenant&#146;s Covenants. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tenant to carry out obligations </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord may give the Tenant a notice of any failure by the Tenant to carry out any obligation of the
Tenant under clause 5 or clause 6. The notice may require the Tenant to carry out that obligation within a reasonable time. If the Tenant fails to do so, the Landlord may carry out that obligation at the Tenant&#146;s cost. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Landlord&#146;s right of entry </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Landlord wishes to do works to the Premises which the Landlord acting reasonably considers necessary or
desirable (including Environmental Initiatives) or which the Landlord is obliged to do under this lease or under any Law or Requirement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an Authority requires work to be done at the Building which the Landlord decides to do and which is not the
Tenant&#146;s obligation under this lease; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Landlord decides to carry out any obligation which the Tenant is required to carry out under this lease,
but fails to do, </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">then the Landlord, on giving to the Tenant not less than two days&#146; notice (except in an emergency
when no notice is required), may enter the Premises and do those works (provided that such works do not adversely affect the Tenant&#146;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operations). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Alterations to the Building </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant must not: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">make any alterations or additions to the Building including the inter-tenancy partitions or floor coverings;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">interfere with, alter or make any connections to the Services or the Landlord&#146;s Fixtures; or
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">use, install or alter internal partitions in the Premises, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">unless</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Tenant: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">obtains the Landlord&#146;s consent (which consent must not be unreasonably withheld); and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Tenant complies with the Works Conditions. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant must issue drawing to the Landlord for approval prior to submitting them to any required Authority
for approval. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant must complete the works to fit out the Premises to a standard commensurate with a <FONT
STYLE="white-space:nowrap">high-end</FONT> shopping centre precinct and to the reasonable satisfaction of the Landlord. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant must provide to the Landlord a copy of all endorsed planning and building permits and approvals and
plans within five (5)&nbsp;business days of being issued to the Tenant by the relevant Authority or issuer. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Where the Landlord imposes a condition on the Tenant pursuant to clause 6.8 requiring the works or any part
thereof to remain in or on the Premises when the Tenant vacates the Premises, the parties agree that part of the works are deemed to be a Fixture for the purpose of the PPS Act. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ASSIGNMENT AND <FONT STYLE="white-space:nowrap">SUB-LETTING</FONT> </B></P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dealings not permitted </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as otherwise stated in this clause 7, during the Term the Tenant must not assign, sublease, mortgage,
charge or otherwise deal with or part with possession of the Premises or this lease or any estate or interest in this lease or agree to do any of those things and Section&nbsp;144 of the Property Law Act shall not apply. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Subleases </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant must not grant any sublease of the Premises without the Landlord&#146;s consent which shall not be
unreasonably withheld. Subject to clauses 7.5 and 7.6 , the Landlord will consent to a sublease if the Tenant complies with the Dealing Conditions (other than Dealing Condition (i)). </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Assignment </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant must not assign this lease without the Landlord&#146;s consent. Subject to clauses 7.5 and 7.6, the
Landlord will consent to an assignment if: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Assignment relates to the whole of the Premises and the whole of the Tenant&#146;s interest in this lease;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">before the Tenant assigns, the Tenant and, where applicable, the assignee, comply with the Dealing Conditions;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">before the Tenant assigns, the assignee covenants with the Landlord to perform and observe the Tenant&#146;s
Covenants after the Assignment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An Assignment under clause 7.3 does not release the Tenant from the Tenant&#146;s Covenants.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Despite any other provision of this lease, consent to assignment or sublease by the Tenant may be withheld by
the Landlord in the Landlord&#146;s absolute discretion to: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a government department or instrumentality (unless that government department or instrumentality is already a
tenant in the Building); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a trustee or a legal entity constituting or representing a political party; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an embassy, consulate or trade commission office of a foreign country. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Control of Tenant </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant must not allow a Control Event to occur without the Landlord&#146;s consent. The Landlord must
consent to a Control Event occurring if: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Tenant notifies the Landlord of the Control Event; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Tenant satisfies the Landlord that the Control Event will not materially or adversely affect the
Tenant&#146;s respectability, responsibility or solvency or its ability to observe and perform the Tenant&#146;s Covenants; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Tenant complies with the Dealing Conditions applicable to the Control Event. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Clause 7.6 does not apply to a Tenant which is a corporation whose shares are listed on the Australian Stock
Exchange. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mortgage of Tenant&#146;s equipment etc </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant must not mortgage, charge, lease or otherwise deal with any Tenant&#146;s Fixtures which requires
the Landlord to sign a waiver or similar document without the Landlord&#146;s consent. The Landlord must consent if: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Tenant is entering into a genuine mortgage, charge or lease as a means of financing that equipment,
fixtures or fittings; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Tenant and all other relevant parties execute the Landlord&#146;s standard form of waiver document; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Tenant pays the Landlord&#146;s reasonable costs (including legal costs). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant must notify the Landlord on or before the Commencement Date if the Tenant&#146;s Fixtures or any
other Personal Property of the Tenant relevant to this lease is subject to a Security Interest. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Without limiting clause 7.8, the Tenant agrees not to create a Security Interest in favour of any third party
in respect of the Tenant&#146;s Fixtures or any other Personal Property of the Tenant relevant to the lease except with the prior written consent (not to be unreasonably withheld) of the Landlord. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Despite anything in this lease the Tenant must if directed to do so by the Landlord reinstate and make good to
the Landlord&#146;s satisfaction any <FONT STYLE="white-space:nowrap">sub-divisional</FONT> works undertaken as a result of this clause 7 on or before the End Date. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INSURANCE AND DAMAGE </B></P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tenant&#146;s insurances </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant must keep current during the Term: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a public risk insurance policy endorsed to include the risks referred to in clause 8.7 and all other claims
arising in connection with this lease, such policy to be for not less than the amount specified in item 18 or such other reasonable amount as the Landlord may notify the Tenant from time to time in respect of any single occurrence;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a policy against glass breakage covering all plate and other glass in the doors, offices and staircases on, in
or about the Premises and covering frames, surrounds and temporary shutters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a policy insuring all additions to the Premises carried out by the Tenant and all the Tenant&#146;s Fixtures
and the Landlord&#146;s Fixtures against loss or damage by events for which a Tenant can and does ordinarily insure, for their full replacement value; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other insurance (including business losses) that in the Landlord&#146;s reasonable opinion a prudent Tenant
would maintain. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">each anniversary of the Commencement Date, the Tenant must give the Landlord a Certificate of Currency; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on request, the Tenant must give the Landlord copies of the policy, the receipt for the last premium and a
Certificate of Currency, </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">in respect of any insurance referred to in clause 8.1. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Insurance terms </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All policies of insurance under this clause 8 must: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">be with a reputable insurer with a Standard&nbsp;&amp; Poors rating of A or better; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">be for such amounts and cover such risks and contain such conditions as are acceptable to, or are as required
by, the Landlord acting reasonably; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">be taken out in the name of the Tenant and, in respect of the policy referred to in clause 8.1(a), must note
the interest of the Landlord as principal under the policy. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Not affect insurances </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant must not do any act or thing which may increase the cost of insurances in connection with the
Building or property in the Building or affect or make void or voidable that insurance or which may conflict with Laws or Requirements. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Property of Tenant </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All property of the Tenant or of the Tenant&#146;s Agents in the Building is at the sole risk of the Tenant.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Releases of Landlord </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant releases the Landlord from liability in respect of: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">loss of or damage to any property of the Tenant or any other person; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">injury to or the death of any person, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">in the Building or in places adjacent to the Building except as a result of the negligence of the Landlord or of any servant or agent of the
Landlord if that person is acting for the Landlord. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnities </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant is liable for and must indemnify the Landlord against all Claims for which the Landlord becomes
liable in connection with (except to the extent that the relevant loss or damage is caused or contributed to by the default, or negligent act or omission of the Landlord or any servant or agent of the Landlord): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">loss of or damage to the Building or to any property or injury to or the death of any person to the extent
caused or contributed to by a Tenant Cause; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the negligent or careless use of the Building by the Tenant or the Tenant&#146;s Agents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any defect in the Building due to a Tenant Cause; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Tenant&#146;s failure to perform or observe the Tenant&#146;s Covenants; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any act of the Landlord in connection with clause 5.1(j) or clause 12.13. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Clause 8.7 applies even if a Claim results from any act or thing which the Tenant may be authorised or obliged
to do under this lease and even if at any time waiver or other indulgence has been given to the Tenant in respect of that act or thing. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Damage to Building </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Building is damaged so that a substantial part of the Premises cannot be used or are inaccessible, the
Tenant&#146;s liability to pay Base Rent is reduced in proportion to the nature and extent of the damage for the period the Premises cannot be used or are inaccessible. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Building is damaged so that a substantial part of the Premises cannot be used or are inaccessible, the
Landlord may, within three months after the damage occurs, give the Tenant notice that it: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">intends to reinstate the Building and make the Premises fit for use or access by the Tenant; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">terminates the Lease on 7 days&#146; notice as it is impractical or undesirable to reinstate the Building.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Landlord does not give the Tenant a notice under clause 8.10 within three months after the damage
occurs, then the Tenant may terminate this lease by written notice to the Landlord. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Landlord serves a notice under clause 8.10 of its intention to reinstate the Building and make the
Premises fit for use or access by the Tenant and does not carry out the necessary works within a reasonable time (having regard to the nature and extent of the damage and the time expected to commence and to carry out the necessary works), the
Tenant may serve a notice requiring the Landlord to carry out the necessary works. If the Landlord does not comply with that notice within a reasonable time, the Tenant may terminate this lease by written notice to the Landlord.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant may not terminate this lease, nor may the Tenant&#146;s liability to pay Base Rent be reduced under
this clause if the Tenant or the Tenant Agents: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">caused or contributed to the damage; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">prejudiced the Landlord&#146;s rights under an insurance policy in connection with the Building; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">caused or contributed to a claim being refused by the insurer. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Clauses&nbsp;8.13(a) to 8.13(c) do not affect any other rights the Landlord may have in connection with the events specified in this clause 8.
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If at any time, the Landlord considers it is impractical or undesirable to reinstate the Building and make the
Premises fit for use or access by the Tenant (including if it has already given a notice that it intends to reinstate the Building), the Landlord may terminate this Lease by giving one month&#146;s written notice to the Tenant.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Nothing in this clause 8 obliges the Landlord to restore or reinstate the Building or the Premises.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Termination of this lease under this clause 8 does not affect the rights of either party in connection with a
breach of any covenant of this lease before termination. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>OHS Indemnity </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.17</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to any matters and works which under this Lease are the responsibility of the Landlord, the Tenant
indemnifies the Landlord from and against any liability under the <I>Occupational Health and Safety Act 2004</I> (Vic) and the Tenant acknowledges that, to that extent, the Premises are under its control. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>LANDLORD&#146;S OBLIGATIONS </B></P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quiet enjoyment </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the Landlord&#146;s rights reserved by this lease, while the Tenant complies with its obligations
under this lease the Tenant may use and occupy the Premises during the Term without interference by or through the Landlord. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outgoings </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord must pay the Outgoings not payable by any other person. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord must use reasonable endeavours to ensure the Facilities are functional during the Facilities
Hours. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Landlord has complied with clause 9.3 and, despite that, at any time: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any Facilities or Services do not function or are not available; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Landlord because of the need to repair, maintain or replace Facilities or Services or because of the
operation of any Laws or Requirements is compelled to shut off or remove any Facilities or Services; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Landlord exercises its rights under clause 12.6 to close the Building, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">then the Tenant is not entitled to terminate or rescind this lease nor to make any Claim for compensation or damages or abatement of rent
against the Landlord. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Areas </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to this lease, the Tenant and the Tenant&#146;s Agents (in common with other persons authorised by the
Landlord) may use the Common Areas for their intended purposes as determined by and subject to the Landlord&#146;s directions. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directory board and door signage </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant shall be entitled to place its name on the entrance door of the Premises at no charge. Signage is
subject to Landlord approval (which must not be unreasonably withheld or delayed) as well as relevant Authority approvals. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Minimise
disturbance </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord must use reasonable endeavours to minimise any disturbance to the Tenant&#146;s use of the
Premises in carrying out works under clause 6.7(a) and 6.7(b) and clause 12.15. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Carpet </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord must keep the carpets and floor coverings in the Common Areas clean and in good repair.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant must keep all the carpets and floor coverings within the Premises (whether installed by the Landlord
or the Tenant and irrespective of the ownership of them) in good and tenantable repair and condition subject to fair wear and tear. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Clauses 9.9 and 9.10 do not impose on the Landlord any obligation to replace any carpets or floor coverings.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DEFAULT, TERMINATION </B></P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Essential terms </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each obligation of the Tenant to pay money and its obligations under clauses 3, 4, 5, 6, 7, 8, 11, 14 and 27
and are essential terms of this lease. This clause does not prevent any other obligation under this lease from being an essential term. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Default </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">It is a default under this lease if: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Base Rent, or any GST or any part of them is not paid within 7 days of the date on which they are due; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other money payable by the Tenant under this lease are not paid within 14 days after the Landlord asks the
Tenant to pay it (and the Tenant has been given a reasonable period of time to rectify such default); or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Tenant does not comply with any other obligation under this lease and, if the failure to comply can be
remedied, it is not remedied within a reasonable time after the Landlord asks the Tenant to remedy it; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Tenant is a corporation and an Insolvency Event occurs in respect of it; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Tenant repudiates this lease. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Avoid default </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant must ensure that no Default occurs. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Termination of lease </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Tenant Defaults, the Landlord may: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(unless prior demand or notice is required by Law or under this lease) without any prior demand or notice, <FONT
STYLE="white-space:nowrap">re-enter</FONT> and take possession of the Premises (by force if necessary) and eject the Tenant and all other persons and repossess the Premises and terminate this lease; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by notice to the Tenant, terminate this lease as from the date of giving that notice; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by notice to the Tenant, convert the unexpired portion of the Term into a monthly tenancy (as to which clause
1.2 applies) and this lease is terminated from the date of giving that notice. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;146(1) of the
Property Law Act 1958, fourteen days is fixed by this lease as the time within which the Tenant is to remedy the breach or <FONT STYLE="white-space:nowrap">non-compliance,</FONT> if it is capable of remedy, and to make reasonable compensation in
money to the satisfaction of the Landlord for the breach or <FONT STYLE="white-space:nowrap">non-compliance.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Landlord may rectify </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord may, any time and without notice, remedy a Default by the Tenant. The Tenant must pay all
reasonable costs incurred by the Landlord (including legal costs) in remedying a Default. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tender after termination </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Money tendered by the Tenant after this lease is terminated and accepted by the Landlord without prejudice to
the Landlord&#146;s rights in relation to the termination may be applied in the manner the Landlord decides. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Damages </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If this lease is lawfully terminated by the Landlord: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Tenant indemnifies the Landlord for any Claim in connection with any Default giving rise to the termination
or the termination of the lease; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Landlord may recover damages from the Tenant for the damage suffered by the Landlord for the Term including
the difference between: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the aggregate of the Base Rent and other money payable by the Tenant for the unexpired residue of the Term; and
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any amount which the Landlord is able or could, in the Landlord&#146;s opinion, reasonably be expected to
obtain by observing clause 10.10. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord&#146;s right to recover damages from the Tenant or any other person is not affected or limited if:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Tenant abandons or vacates the Premises; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Landlord acting lawfully <FONT STYLE="white-space:nowrap">re-enters</FONT> the Premises or terminates the
lease; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Landlord acting lawfully accepts the Tenant&#146;s repudiation; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the parties&#146; conduct (or that of any person on their behalf) constitutes a surrender by operation of law.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Landlord may institute proceedings </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord may institute legal proceedings claiming damages against the Tenant in respect of the Term
including the period before and after any repudiation, abandonment, termination, acceptance of repudiation or surrender by operation of law whether the proceedings are instituted before or after that conduct. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Landlord to mitigate damages </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Landlord terminates this lease, the Landlord must take reasonable steps to mitigate its loss and to <FONT
STYLE="white-space:nowrap">re-lease</FONT> the Premises at a reasonable rent and on reasonable terms. The Landlord&#146;s entitlement to damages is to be assessed on the basis that the Landlord has observed this obligation to mitigate damages. The
Landlord&#146;s conduct under this duty to mitigate damages does not constitute acceptance of the Tenant&#146;s breach or repudiation or a surrender by operation of law. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Interest on overdue money </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant must pay on demand interest on any money due but unpaid by the Tenant under this lease. Interest is
payable at the Default Interest Rate and is to be computed on daily balances from the due date for payment of the money until payment of that money in full. Interest not paid when due is to be capitalised at monthly intervals. Interest is payable on
capitalised interest at the rate and in the manner referred to in this clause. Interest is recoverable in the same way as rent in arrears. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>END DATE OBLIGATIONS </B></P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reinstatement </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant must, unless agreed in writing by the Landlord, on or before the End Date: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">remove any Tenant&#146;s Fixtures, fittings and equipment as directed by the Landlord from the Premises;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">return the Premises to the Landlord in a clean, tidy and safe condition and hand over all Keys to the Premises
and any licensed areas; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">remove all the Tenant&#146;s Fixtures and fittings from the Premises and make good any damage to the Premises
or the Common Areas of the Building caused by such removal; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reinstate the Premises and its Services to a standard base building open plan configuration.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Abandoned Tenant&#146;s Fixtures </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any Tenant&#146;s Fixtures remaining on the Premises after the End Date will become the property of the
Landlord and the Landlord may deal with those Tenant&#146;s Fixtures as it sees fit and recover costs of dealing with the Tenant&#146;s Fixtures on demand from the Tenant. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>LANDLORD&#146;S RIGHTS </B></P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Roof </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord reserves the exclusive right to use the roof and the external walls of the Building including the
right to erect and display Signs or to grant leases or licences or otherwise authorise any person to use those areas for such purposes as the Landlord in its discretion thinks fit. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Building name </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord reserves the right at any time to name or create a logo or to change the name or logo of the
Building. The Tenant must not make any Claim in relation to any exercise by the Landlord of its rights under this clause. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Change of
Landlord </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If another person becomes entitled to receive the rent payable by the Tenant under this lease, the Landlord is
released from any obligation under this lease arising after that other person acquires the Landlord&#146;s interest in this lease (and in respect of obligations prior to that date, once it has complied with those obligations) and the Tenant at the
Landlord&#146;s cost must enter into such covenants with the other person as the Landlord reasonably requires. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An obligation owed by the Tenant to the Landlord which is due for performance before an event in clause 12.3
(including the payment of amounts owing for Base Rent in respect of a period or date or because of an event or Review Date occurring before that event) remains owing to the Landlord and not to the other person and may be recovered by the Landlord in
its own name. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Landlord&#146;s agents </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord may appoint persons to exercise any of its rights or perform any of its duties under this lease.
The Tenant must treat those persons when they are exercising those rights or performing those duties as if they were the Landlord. Communications from the Landlord override those from the persons appointed if they are inconsistent.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Close Building </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord may close the Building in an emergency or if the Landlord otherwise deems that action reasonably
necessary but not limited to the Landlord&#146;s right to close off the Building or any means of access to or egress from for one (1)&nbsp;period of twenty-four (24)&nbsp;hours continuously during each calendar year for the purpose of preventing any
prescriptive public or private right of way to or across any part of the Building or the Land or any access to or egress from arising. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Premises security </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord may enter the Premises to lock any door or window left unlocked. The Landlord is not responsible
or liable for security in the Premises or in respect of any unauthorised entry to the Premises. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rules </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At any time the Landlord may make Rules or vary existing Rules if that Rule or variation does not materially
derogate from the express rights of the Tenant under this lease. If there is any inconsistency between this lease and the Rules, this lease prevails. The Landlord must give the Tenant copies of all Rules made and notice of any variations to those
Rules. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Changes in PCA Method </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the PCA Method changes and the Landlord subsequently surveys the Building, then the Landlord may notify the
Tenant that the: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">lettable areas of the Building and the Premises are to be changed; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Tenant&#146;s Proportion is to be <FONT STYLE="white-space:nowrap">re-calculated</FONT> and item 13 amended,
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">in accordance with the altered PCA Method. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Base Rent is determined by reference to the lettable area of the Premises, the Base Rent may not be
amended until the next Review Date after a Landlord&#146;s notice under clause 12.9. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Emergency </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Where in this lease there is reference to an emergency the reasonable determination of the Landlord as to the
existence of an emergency is conclusive. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Landlord access </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To allow the Landlord to perform its obligations under this lease or under any Laws or Requirements, the Tenant
must give the Landlord access to the Premises during the hours notified by the Landlord to the Tenant from time to time. The Landlord must give the Tenant not less than two days&#146; notice of its access requirements, except in an emergency when no
notice is required. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Structural works </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Where in this lease the Tenant is obliged to do any work of a structural nature or which affects the
Facilities, the Services or the Landlord&#146;s Fixtures, the Landlord may elect that that work will be carried out only by the Landlord at the Tenant&#146;s reasonable cost (and in determining reasonable cost the Tenant accepts the need of the
Landlord to have regard to factors such as the urgency of the work, the nature of the work and the need to preserve any warranty or guarantee rights or to comply with service contracts). </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prospective tenants or purchasers </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">After giving reasonable notice, the Landlord may: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">enter the Premises to show prospective agents, purchasers, investors, analysts or tenants through the Premises;
and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">display for a reasonable time from the Building a sign indicating that the Building is or the Premises are
available for purchase or lease. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Environmental Initiatives </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord may, at any time, implement Environmental Initiatives in the Building. If access to the Premises
is required to implement the Environmental Initiatives then the Landlord, on giving the Tenant not less than two days&#146; notice, may enter the Premises and implement the Environmental Initiatives. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Subdivision </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord may subdivide (including by strata or stratum) the Land or the Building or grant easements or
other rights over it or the Premises unless this would have a substantial adverse effect on the Tenant&#146;s ability to use the Premises in accordance with the Permitted Use. The Tenant must promptly sign all plans and other documents reasonably
required by the Landlord to enable the Landlord to do those things and if the Tenant fails to do so within a reasonable time then the Tenant is deemed to have appointed the Landlord as its agent to sign the plans and documents on the Tenant&#146;s
behalf. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NOTICES </B></P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A notice: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">must be in writing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">may be left at the address of the party in item 19, as varied by notice; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">may be sent by prepaid post to the address of the party in item 19, as varied by notice. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If more than one address appears in item 19 for any party then notices must be left at or sent to all addresses
for that party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A notice sent by prepaid post and correctly addressed is taken to be received on the fifth (ninth, if posted to
or from a place outside Australia) day after posting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A notice by a party under this lease may be given by an Authorised Officer of the party or an attorney or
solicitor for the party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless a later time is specified in it, a notice takes effect from the time it is received or taken under this
lease to be received. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A certificate signed by an Authorised Officer of the Landlord or an attorney or solicitor for the Landlord
about a matter or about a sum payable to the Landlord in connection with this lease is sufficient evidence of the matter or sum stated in the certificate unless the matter or sum is proved to be false. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>BANK GUARANTEE </B></P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On or before signing this lease, the Tenant must deliver to the Landlord a Bank Guarantee.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord may at any time after Default occurs call on the Bank Guarantee and apply any money received
towards money (including damages) payable by the Tenant in connection with this lease or any Related Agreement as the Landlord determines. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord may call and the bank is entitled to pay under the Bank Guarantee without reference to the Tenant
and despite any contrary objection, claim or direction by the Tenant or any other party to a Related Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord&#146;s rights under this clause 14 are in addition to the other rights and remedies of the
Landlord in relation to any default of the Tenant in connection with this lease. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each time the Landlord claims on a Bank Guarantee, the Landlord may notify the Tenant to top up the Bank
Guarantee in relation to the claim (and any previous claims) made by the Landlord. Within seven days of receipt of each notice the Tenant must: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reinstate the Bank Guarantee to the full amount before the claim; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">give the Landlord a supplemental Bank Guarantee equal to the amount of the claim. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">After each increase in the Base Rent under clause 3, the Tenant if requested by the Landlord must give the
Landlord within 7 days of that request a supplemental Bank Guarantee for the amount required to bring the amount of the Bank Guarantees up to the increased amount then required by item 20. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord may call on the Bank Guarantee after the End Date and notwithstanding that this lease has been
terminated. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">After the Tenant has complied with its obligations under this lease, the Landlord must return the Bank
Guarantee to the Tenant. The Tenant acknowledges that the Landlord may have called on the Bank Guarantee. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Despite any other provision in this lease, if the Landlord sells the Land or otherwise disposes of its interest
in the reversion of this lease, the Tenant must deliver a replacement Bank Guarantee in favour of the purchaser or disponee within 14 days after the Landlord asks for it. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PAYMENTS AND COSTS </B></P></TD></TR></TABLE>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant must make payments under this lease without <FONT STYLE="white-space:nowrap">set-off</FONT> or
counterclaim and free and clear of any withholding or deduction. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All payments by the Tenant under this lease must be paid: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the Landlord or to a person nominated by the Landlord in a notice given to the Tenant; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in Australian dollars. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Tenant pays an amount and it is found later that the amount payable should have been higher, then the
Landlord may demand payment of the difference even though the Landlord has given the Tenant a receipt for payment of the lower amount. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord need not make demand for any amount payable by the Tenant under this lease unless this lease
expressly states that demand must be made. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Tenant must pay to or reimburse the Landlord any cost, charge or other money under this lease, that
amount is payable on demand unless otherwise provided in this lease. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant must make: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all payments under this lease on account of Base Rent and GST by direct credit to the Landlord&#146;s nominated
bank account; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all other payments under this lease to the Landlord by such method as the Landlord reasonably requires
including by direct credit to the Landlord&#146;s nominated bank account. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant must pay all stamp duty (including penalties and fines other than penalties and fines due to the
delay of the Landlord) in connection with this lease. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant must pay the Landlord&#146;s reasonable legal and other costs (including the costs of any
consultants of the Landlord) and expenses relating to: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the stamping of this lease; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any consent or approval of the Landlord required under this lease even if the consent or approval is not given.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Tenant defaults under this lease, the Tenant must pay all costs and expenses (including legal costs)
which the Landlord suffers or incurs in connection with that default. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Where the Tenant is obliged under this lease to do some act or thing, it must be done at the cost of the Tenant
unless otherwise provided in this lease. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Party must pay its own costs in relation to the negotiation, preparation and completion of this lease.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant shall not be responsible for mortgagees consent costs which the Landlord must procure if required.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>GOVERNING LAW </B></P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">16.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This lease is governed by the law in force in the State. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">16.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each party submits to the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> jurisdiction of the courts of
the State. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">16.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Without preventing any other mode of service, any document in an action (including any writ of summons or other
originating process or any third or other party notice) may be served on any party by being left for that party at its address for service of notices set out in item 19, as varied by notice. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>GENERAL </B></P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exercise of rights </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord may exercise a right, power or remedy at its discretion, and separately or concurrently with
another right, power or remedy. A single or partial exercise of a right, power or remedy by the Landlord does not prevent a further exercise of that or of any other right, power or remedy. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Failure by the Landlord to exercise or delay in exercising a right, power or remedy does not prevent its
exercise. The Landlord is not liable for any loss caused by the exercise or attempted exercise of, failure to exercise, or delay in exercising a right, power or remedy whether or not caused by the Landlord&#146;s negligence. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The rights, powers and remedies provided in this lease are cumulative with and not exclusive of the rights,
powers or remedies provided by law independently of this lease. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Waiver </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A provision of or a right created under this lease may not be waived or varied except in writing signed by the
party or parties to be bound. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A custom or practice which may grow up between the parties in the course of administering this lease is not to
be construed to waive or to lessen: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the right of the Landlord to insist on the performance by the Tenant of any provision of this lease; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Landlord&#146;s rights, powers or remedies in respect of any default of the Tenant. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A waiver by the Landlord of a particular breach or default is not to be deemed to be a waiver of the same or
any other subsequent breach or default. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The demand of or subsequent acceptance of any money under this lease by the Landlord is not to be deemed a
waiver of any preceding breach of this lease by the Tenant, other than the relevant Tenant&#146;s breach to which the payment relates. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legislation </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any present or future Law which operates to vary the obligations of the Tenant in connection with this lease
with the result that the Landlord&#146;s rights, powers or remedies are adversely affected (including by way of delay or postponement) is excluded except to the extent that its exclusion is prohibited or rendered ineffective by Law.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Approval and consent </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If this lease states that approval or consent must be obtained, then: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">consent or approval must be obtained before the act or thing is done; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Landlord must not unreasonably withhold its consent or approval unless this lease expressly states
otherwise. However, an approval or consent may be given conditionally or unconditionally; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Tenant must address its request for consent or approval to the Landlord&#146;s employee holding the
position of property manager for the Building. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Discretion and opinion </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord may form an opinion, exercise a discretion or be satisfied as to any matter or thing in its
absolute discretion unless this lease expressly states otherwise. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Set-off</FONT> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At its discretion the Landlord may apply (without notice) any credit balance in any currency in any account of
the Tenant with the Landlord towards satisfaction of any amount then payable by the Tenant to the Landlord under this lease. At its discretion the Landlord by notice to the Tenant may reduce the amount payable at any time by the Landlord to the
Tenant by the amount payable at that time by the Tenant to the Landlord under this lease. The Tenant is taken to have paid the Landlord that part of the amount then payable by the Tenant equal to the amount of the reduction. The Tenant authorises
the Landlord in the name of the Tenant or the Landlord to do anything (including execute any document) that is required for the purpose of this clause. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnities </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each indemnity in this lease is a continuing obligation, separate and independent from the other obligations of
the Tenant and survives the End Date. It is not necessary for the Landlord to incur expense or make payment before enforcing a right of indemnity conferred by this lease. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Further assurances </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If asked by the Landlord, the Tenant must: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">execute and cause its successors to execute documents and do everything else necessary or appropriate to bind
the Tenant and its successors under this lease; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">use its best endeavours to cause relevant third parties to do likewise to bind every person intended to be
bound under this lease. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exclusion of statutory provisions </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The statutory provisions referred to in item 14 do not apply to this lease or have the effect described in item
14. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Antecedent rights and obligations </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The End Date does not affect: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Landlord&#146;s rights in connection with a breach of this lease by the Tenant before the End Date; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Tenant&#146;s obligations under this lease in respect of periods before the End Date.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Severability </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If a provision of this lease is void, unenforceable or illegal in a jurisdiction it is severed for that
jurisdiction. The remainder of this lease has full force and effect and the validity or enforceability of that provision in any other jurisdiction is not affected. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If document not a lease </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.17</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If this document is found not to be a lease or to be a lease for a period less than the Term, the parties are
bound in contract to carry out their obligations under this document for the Term, as if this were deemed to be a lease, unless expressly released under this document from those obligations. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Relationship of parties </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.18</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This lease does not create any relationship between the parties other than the relationship of landlord and
tenant on the terms of this lease. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Counterparts </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.19</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This lease may consist of a number of counterparts. The counterparts taken together constitute one instrument.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No caveat </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.20</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant must not lodge or allow to be lodged for it a caveat against the Land in relation to this lease.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Entire agreement </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.21</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This lease constitutes the entire agreement of the parties in relation to the matters in this lease and
supersedes all prior agreements, understandings and negotiations between the parties in relation to those matters. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Attorneys
</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.22</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If this lease is executed by an attorney the attorney states by such execution that as at the time of such
execution the attorney has received no notice of the revocation of the power of attorney under which the attorney executed this lease. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tenant&#146;s representations </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.23</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant represents to the Landlord that: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Tenant has full power to enter into and to perform its obligations under this lease; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">this lease constitutes valid and binding obligations of the Tenant enforceable in accordance with its terms;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in entering into this lease the Tenant has not relied on any representation, warranty or undertaking given or
made by or for the Landlord prior to the execution of this lease, and the Tenant has satisfied itself as to all relevant matters in connection with the grant of this lease. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-merger</FONT> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.24</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each representation and covenant under this lease continues until satisfied or completed.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>18.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>GST </B></P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In this lease: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">words or expressions which are defined in the GST Law have the same meaning, except where the context suggests
otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any part of a supply which is treated as a separate supply for GST purposes (including attributing GST payable
to tax periods) is treated as a separate supply; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">references to GST payable and to input tax credit entitlement include GST payable by, and input tax credit
entitlement of, the representative member for a GST group of which the entity is a member; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">references to something done (including a supply made) by a party includes something done by any entity through
which that party acts. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All consideration for a supply made under or in connection with this lease is exclusive of GST, unless
specified to be GST inclusive. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Where a party (<B>Supplier</B>) makes a taxable supply under or in connection with this lease, the recipient
will pay to the Supplier an amount equal to the amount of GST payable on the supply (<B>GST Amount</B>) at the same time as the recipient first provides consideration for that supply, unless the consideration is specified to be GST inclusive.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Where clause 18.3 applies, the Supplier must deliver a tax invoice to the recipient of the supply no later than
the time at which the GST Amount for that supply is to be paid. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If an adjustment event occurs in relation a taxable supply for which a GST Amount was paid under clause 18.3:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">and the GST Amount properly payable varies from that paid, the Supplier will provide a corresponding refund or
credit to, or will be entitled to receive the amount of that variation from, the recipient. The amount paid, refunded or credited is taken to form part of the GST Amount should a subsequent adjustment event occur; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Supplier must deliver an adjustment note to the recipient as soon as reasonably practicable after the
Supplier becomes aware of the adjustment event. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Where a party is required to reimburse or indemnify another party under this lease, the reimbursement or
indemnity payment will be reduced by an amount equal to the amount of the payee&#146;s input tax credits entitlement on the outgoing, expense or loss which is to be reimbursed or indemnified. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This clause 18 does not merge on termination of this lease. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>19.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>LANDLORD LIMITATION OF LIABILITY </B></P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">19.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Custodian enters into this lease only as agent of Newmark Capital Limited
(<B>&#147;</B><B>Client</B><B>&#148;</B>). The Custodian can only act in accordance with the terms of the agreement under which it is appointed as the Client&#146;s agent and is not liable under any circumstances to any party under this lease. This
limitation of the Custodian&#146;s liability applies despite any other provision of this lease and extends to all liabilities and obligations of the Custodian in any way connected with any representation, warranty, conduct, omission, agreement or
transaction related to this lease. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">19.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Custodian is not obliged to do or refrain from doing anything under this lease (including, without
limitation, incur any liability) unless the Custodian&#146;s liability is limited in the same manner as set out in clause 19.1 to 19.4. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">19.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No attorney, agent, receiver or receiver and manager appointed in accordance with this lease has authority to
act on behalf of the Custodian in a way which exposes the Custodian to any liability. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">19.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If, whether by the express provisions of this lease or by implication of law, the Custodian makes or is taken
to have made any representation or warranty then, except for the representations and warranties that can only be within the Custodian&#146;s actual corporate knowledge, those representations and warranties are taken to have been made by the Client.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>20.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NEWMARK LIMITATION OF LIABILITY </B></P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord enters into this lease only in its capacity as agent for Newmark Capital Limited
(&#147;<B>Trustee</B>&#148;) as the trustee of the Trust and in no other capacity. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The parties acknowledge that the Trustee incurs any liability through the Landlord as its agent solely in its
capacity as trustee of the Trust and agree that (to the maximum extent permitted by law, but subject to clause 20.5), that the Trustee will cease to have any liability as trustee of the Trust if the Trustee ceases for any reason to be the trustee of
the Trust. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A liability incurred by the Trustee arising under or in connection with this lease is limited to and can be
enforced against the Trustee only to the extent to which it can be satisfied out of the assets of the Trust and out of which the Trustee is actually indemnified for the liability. The Trustee will exercise its rights of indemnification in order to
satisfy its obligations this lease. This limitation of the Trustee&#146;s liability applies despite any other provision of any other lease (other than clause 20.3) and extends to all liabilities and obligations of the Trustee in any way connected
with any representation, warranty, conduct, omission, agreement or transaction related to any agreement between the parties. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No party is entitled to sue the Trustee in any capacity other than as trustee of the Trust, including seeking
the appointment of a receiver, a liquidator, an administrator or any similar person to the Trustee or prove in any liquidation, administration or arrangement of or affecting the Trustee (except in relation to the assets of the Trust).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The provisions of this clause 20 do not apply to any obligation or liability of the Trustee to the extent that
it is not satisfied because under the Trust&#146;s constituent documents or by operation of law the Trustee is not indemnified or there is an elimination of or a reduction in the extent of the Trustee&#146;s indemnification out of the assets of the
Trust as a result of the Trustee&#146;s fraud, negligence, wilful misconduct or breach of trust. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No act or omission of the Trustee (including any related failure to satisfy its obligations or breach of
representation or warranty under this lease will be considered fraud, negligence, wilful misconduct of the Trustee for the purpose of clause 20.5 to the extent to which the act or omission was caused or contributed to by any failure by another
person (other than a person whose acts or omissions the Trustee is liable for, as agent, officer, employee, contractor or otherwise) to fulfil its obligations relating to the Trust or by any other act or omission of another person (other than a
person whose acts or omissions the Trustee is liable for, as agent, officer, employee, contractor or otherwise). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No receiver or receiver and manager appointed has authority to act on behalf of the Trustee in any way which
exposes the Trustee to any personal liability and no act or omission of any such person will be considered fraud, negligence, wilful misconduct or a breach of a representation and warranty as to authority for the purpose of clause 20.5.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Trustee is not obliged to enter into any commitment or obligation under any agreement unless the
Trustee&#146;s liability is limited in accordance with this clause 20. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>21.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>APPLICABILITY OF THE RETAIL LEASES ACT </B></P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Tenant represents and warrants to the Landlord that the Retail Leases Act does or does not apply to the Tenant or this lease as stipulated
and for the reason set out in item 23. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>22.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>COMPLETION OF BLANKS </B></P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Tenant hereby authorises the Landlord or the Landlord&#146;s solicitors to complete any blanks in this lease. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>23.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ESD REQUIREMENTS </B></P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">23.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant acknowledges that the Landlord intends to obtain or retain certificates that the base Building
achieves the ESD Requirements. The Tenant agrees with the Landlord that: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Tenant will not decrease or adversely change any of the ESD Requirements at any time, and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Tenant will do anything reasonably required by the Landlord, including adopting any procedure or practice,
which maintains or increases the ESD Requirements. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">23.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant acknowledges that the design of the fitout of the Premises can have a significant impact on the
NABERS Rating and the Tenant agrees that it must comply with any </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
requirement in relation to the NABERS Rating when designing the fitout of the Premises. Without limitation, the Tenant must ensure the design of the fitout of the Premises is based on the
internal load estimations in the current NABERS Energy Guide to Tenancy Energy Estimation Version and for areas served by supplementary air conditioning plant being part of the fitout of the Premises, the supplementary air conditioning plant must be
separately metered by the Tenant to the reasonable satisfaction of the Landlord. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">23.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant agrees that it will design the fitout of the Premises so as to maintain the NABERS Rating during the
Term. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">23.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant acknowledges that it is reasonable for the Landlord to refuse approval to the Tenant&#146;s detailed
plans and specifications for the fitout of the Premises if, in the Landlord&#146;s opinion the NABERS Rating will be decreased or adversely changed at any time or the Tenant otherwise fails to comply with the requirements of this clause 23.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>24.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PREMISES CONDITION </B></P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">24.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Premises will be provided to the Tenant in &#147;as is&#148; condition&#148;. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">24.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant accepts the condition of the Premises as suitable for the Tenant&#146;s business purposes and agrees
that the Landlord makes no representation or warranty in relation to this issue or the proposed use by the Tenant. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>25.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>BUILDING WORKS </B></P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">25.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant acknowledges that, subject to clause 25.3, the Landlord may carry out works to any part of the
Building (other than the Premises) during the Term. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">25.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Despite any other provision of this lease, the Tenant: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">consents to the Landlord carrying out works to any part of the Building (other than the Premises) and assumes
the risk of any impact those works may have on its use and occupation of the Premises; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">releases the Landlord from, and must not make, any claim against the Landlord in respect of any loss which the
Tenant may incur or may become liable for in respect of or arising directly or indirectly from the Landlord carrying out works to any part of the Building (other than the Premises) (including any claim for breach of the quiet enjoyment covenant of
this lease or a breach of the implied covenant not to derogate from grant); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">must not seek to terminate this lease because of or in connection with the Landlord carrying out works to any
part of the Building (other than the Premises). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">25.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Landlord carries out works to any part of the Building (other than the Premises), the Landlord must
ensure that the Tenant is able to access the Premises at all times. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>26.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>LANDLORD&#146;S CONTRIBUTION </B></P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">26.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord will provide the Landlord&#146;s Contribution to the Tenant. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">26.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Lessee shall be provided with a Lessor&#146;s Contribution amount of $20,000 + GST. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">26.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord&#146;s Contribution must be given to the Tenant taken as a contribution to the Tenant&#146;s <FONT
STYLE="white-space:nowrap">fit-out</FONT> of the Premises. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">26.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord&#146;s Contribution is to be used only for fixed and identifiable items of a tangible and real
nature. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">26.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord will at its sole discretion determine which items of the fitout are to be deemed to have been paid
for by the Landlord by way of the Contribution. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">26.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord will own and will be entitled to depreciate those items of fitout which has determined that it has
paid for under clause 26.5. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">26.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Payment of the Landlord&#146;s Contribution to the Tenant will be made within 30 days of receipt of the
Tenant&#146;s proper tax invoices and evidence to the reasonable satisfaction of the Landlord that the whole of the fitout works have been properly carried out. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">26.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant will be responsible for maintaining and insuring that part of the fitout paid for by the
Landlord&#146;s Contribution throughout the Term. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">26.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If this lease ends for any reason (other than the Landlord&#146;s default), or the Tenant assigns this lease,
sublets the Premises or ceases to occupy or use the Premises prior to the Expiry Date, the Tenant must repay to the Landlord the equivalent amount of the Landlord&#146;s Contribution, calculated by the unexpired period of the Term as a proportion of
the Term </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">26.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In this clause 26 &#147;<B>Landlord&#146;s Contribution </B>&#147; means the amount of $20,000 plus GST.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman"><B>SCHEDULE 1 - DEFINITIONS AND INTERPRETATION </B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Definitions </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless the context otherwise requires: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>APRA </B>means the Australian Prudential Regulation Authority. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Authorised Officer </B>means: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for the Landlord, a director or secretary or an officer of the Landlord or a Related Body Corporate of the
Landlord whose title contains the word &#147;manager&#148; or a person performing the functions of any of them or any other person appointed by the Landlord to act as an Authorised Officer for the purpose of this lease; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for the Tenant a person appointed by the Tenant to act as an Authorised Officer for the purpose of this lease.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Authority </B>means any government, statutory, public or other authority or body having jurisdiction over the
Building or any matter or thing relating to the Building. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Bank </B>means an authorised deposit taking institution as listed on the APRA
website which is acceptable to the Landlord. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Bank Guarantee</B> means an irrevocable and unconditional undertaking in favour of the
Landlord issued by a Bank or other person approved by the Landlord containing such terms and conditions as are acceptable to the Landlord in its discretion for the amount specified in or determined by item 20. A bank guarantee that specifies an
expiry date that is earlier than 6 months after the Expiry Date is unacceptable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Base Rent </B>means the annual rent payable by the
Tenant under this lease in respect of the Premises as specified in item 8 and varied in accordance with this lease. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Building </B>means
650 Chapel Street South Yarra Victoria including the Facilities, the Services, the Common Areas and the Premises, and where appropriate includes the Land. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Certificate of Currency</B> means a certificate from an insurer permitted under this lease which contains: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the name of the insurer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the policy number; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the policy period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">details of any policy conditions or exclusions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the policy type; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the name of the insured; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the interest insured; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the sum insured; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the territorial limits (if any); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">confirmation that the cover includes the interest of the Landlord or that the policy contains a Tenant&#146;s
liability endorsement. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Claim </B>means claim, demand, liability, loss, damages, proceedings, costs, charges and
expenses. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Commencement Date </B>means the date in item 6. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Common Areas </B>means those parts of the Building designated by the Landlord from time to time for use by the tenants or other occupiers of
the Building and their respective employees, invitees and licensees and any other persons authorised by the Landlord (including members of the public) in common with each other. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Consumer Price Index </B>means the Consumer Price Index in item 11 or the index officially substituted for it. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Contaminate </B>means to cause Contamination. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Contamination </B>means the presence in or on the Building or in, on or under the Land of a substance at a concentration above the
concentration at which the substance is normally present in or on buildings or in, on or under (respectively) land in the same locality, being a presence that presents a risk of harm to human health or any other aspect of the environment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Control Event </B>means that a person becomes or ceases to be a Parent of the Tenant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Corporations Act </B>means the Corporations Act 2001 (Clth). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Coverings </B>means blinds, screens, awnings or other window coverings. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>CPI Adjustment Date </B>means each date in item 10. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Current CPI </B>means the Consumer Price Index number last published before the relevant CPI Adjustment Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Custodian</B> means the Landlord. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Dealing </B>means a proposed sublease under clause 7.2 or a proposed assignment under clause 7.3, and <B>Deal</B> has a corresponding
meaning. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Dealing Conditions </B>means in relation to a Dealing that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the time of applying for consent and up to the date of the proposed Dealing, the Tenant is not in Default;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Tenant pays the Landlord&#146;s reasonable costs (whether or not the proposed Dealing proceeds to
completion) including the Landlord&#146;s administrative and other expenses and legal costs of giving its consent; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Tenant satisfies the Landlord that the Subtenant or Assignee is a reputable, respectable, responsible and
solvent person; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Tenant satisfies the Landlord acting reasonably that the Assignee is a person financially substantial (at
least equal to the Tenant) and capable of observing and performing the Tenant&#146;s Covenants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Tenant and either the Subtenant or the Assignee execute a deed with the Landlord in a form approved by the
Landlord acting reasonably; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Subtenant or Assignee covenants with the Landlord not to cause or contribute to a breach of this lease by
the Tenant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Tenant covenants with the Landlord that if the Tenant sublets the Premises or part thereof at a passing
rent that is greater than the Base Rent payable by the Tenant under this lease (<B>Profit Rent</B>) the Tenant will pay any Profit Rent to the Landlord together with all payments of Base Rent under this lease; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Tenant and either the Subtenant or the Assignee comply with the Landlord&#146;s reasonable requirements in
relation to documenting and, if applicable, stamping and registering the proposed Dealing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Tenant procures in favour of the Landlord any guarantee or security the Landlord reasonably requires in a
form acceptable to the Landlord of the obligations and covenants of the Assignee in connection with the Dealing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Tenant will be responsible for any subdivisional works and costs if applicable; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Dealing will not result in the Landlord being in breach of an existing lease for another tenant at the
Building. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Default </B>means a breach of this lease by the Tenant and includes the defaults listed in clause 10.2.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Default Interest Rate </B>means the rate calculated on daily balances and compounded quarterly at the rate of 4% per annum higher than
the rate for the time being fixed under Section&nbsp;2 of the <I>Penalty Interest Rates Act</I> (Vic) 1983. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Dispute Notice </B>means a
notice given under and which complies strictly with clause&nbsp;3.5. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Dispute Period </B>means the period commencing on the date of
delivery of a Rent Review Notice and ending at 5.00 pm on the date 14 days after that date, time being of the essence. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>ESD
Requirements</B> means the environmental rating for the base Building as advised by the Landlord from time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>End Date </B>means
the earlier of the Expiry Date or the date of termination of this lease. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Environmental Initiatives </B>means activities, programs or
works (including the installation and operation of plant and equipment) which are aimed at environmental awareness or at reducing damage to the environment. Examples of such activities, programs and works include Earth Hour, the introduction of
recycling programs for waste, the installation of energy efficient lighting and the reduction of water usage by the installation of dual flush toilets and waterless urinals. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Expiry Date </B>means the date in item 7. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Facilities </B>means all facilities to the Building including lifts, escalators, <FONT STYLE="white-space:nowrap">air-conditioning,</FONT>
toilets, loading docks, access control systems and Keys. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Facilities Hours </B>means the times for the provision of relevant Facilities
as specified in item 17. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Fitout Guide </B>means the fitout guide for the Building from time to time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Fixed Increase Date </B>means each date in item 12. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Fixed Percentage Increase </B>means the percentage specified in item 12 by which the Base
Rent is to increase on the relevant Fixed Increase Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>GST </B>has the same meaning as in the GST Law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>GST Law</B> has the same meaning as in the A New Tax System (Goods and Services) Tax Act 1999 (Clth). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Heavy Item </B>means any thing which the Tenant proposes to bring in the Building which in the Landlord&#146;s opinion might cause damage to
the Building. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Incentive </B>means any inducement, incentive or concession of any kind however named or structured in connection with a
tenancy and includes any premium or capital payment and any period of abatement or reduction of rent or other money. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Inflammable
Substance </B>means any substance or thing of an inflammable nature including acetylene gas, volatile or explosive oils and alcohol which in the Landlord&#146;s reasonable opinion might cause damage to the Building. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Insolvency Event </B>means the happening of any of these events: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an order is made that a body corporate be wound up; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an order appointing a liquidator or provisional liquidator in respect of a body corporate is made;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">except to reconstruct or amalgamate while solvent on terms consented to by the Landlord acting reasonably, a
body corporate enters into, or resolves to enter into, a scheme of arrangement or composition with, or assignment for the benefit of, all or any class of its creditors, or it proposes a reorganisation, moratorium or other administration involving
any of them; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a body corporate resolves to wind itself up, or otherwise dissolve itself, or gives notice of intention to do
so, except to reconstruct or amalgamate while solvent on terms approved by the Landlord acting reasonably or is otherwise wound up or dissolved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a body corporate is or states that it is insolvent; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as a result of the operation of section 459F(1) of the Corporations Act, a body corporate is taken to have
failed to comply with a statutory demand; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a body corporate is, or makes a statement from which it may be reasonably deduced by the Landlord that the body
corporate is, the subject of an event described in section 459C(2)(b) or section 585 of the Corporations Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a body corporate takes any step to obtain protection or is granted protection from its creditors, under any
applicable legislation or an administrator is appointed to a body corporate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a person becomes an insolvent under administration as defined in section 9 of the Corporations Act or action is
taken which could result in that event; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">anything analogous or having a substantially similar effect to any of the events specified above happens under
the law of any applicable jurisdiction. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Institute </B>means the Division of Australian Property Institute
Incorporated in the State. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Keys </B>means keys, access cards and other access or security devices relating to the Building. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Land </B>has the meaning given to it in item 5. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Landlord </B>means the Landlord specified in item 1 and its successors and assignors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Landlord&#146;s Fixtures </B>means the plant, equipment, fixtures, furniture, furnishings, Coverings, and light fittings in or on the
Premises from time to time supplied by the Landlord. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Landlord&#146;s Valuer </B>means a valuer nominated under clause 3.6. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Laws </B>means statutes, rules, regulations, proclamations, ordinances or <FONT STYLE="white-space:nowrap">by-laws</FONT> present or future
and includes applicable Australian Standards and Codes of Practice. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Maintenance Contracts </B>means contracts for the maintenance,
repair and service of the Tenant&#146;s Fixtures and any Landlord&#146;s Fixtures located in or exclusively servicing the Premises including contracts for the maintenance of air conditioning equipment and pest control. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Market Review Date </B>means each of the dates in item 9. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>NABERS</B> means National Australian Built Environment Rating System or, if the National Australian Built Environment Rating System is
discontinued or suspended, whatever national or international system used to rate buildings on the basis of their operational impacts on the environment is substituted for it. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>NABERS Rating</B> means the NABERS Rating of the Building from time to time, as advised by the Landlord to the Tenant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>notice </B>means a notice, approval, consent, certificate, nomination, offer or other communication in connection with this lease. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Outgoings </B>means the total of all amounts: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">paid by the Landlord; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for which the Landlord is or may become liable, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">in any Outgoings Year in respect of the Building or the Land, and includes the items listed in schedule 2. The Outgoings exclude capital
expenditure. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Outgoings Contribution</B> means the amounts payable by the Tenant under clause&nbsp;4.1. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Outgoings Year</B> means each 12 month period ending on a date that the Landlord chooses and notifies to the Tenant, even if part of that 12
month period does not fall within the Term. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Parent </B>of a person means the person directly or indirectly exercising the decision
making power of the first mentioned person including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the first mentioned person is a corporation, a person who: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">controls the composition of the board of directors of the first mentioned person; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is in a position to cast, or control the casting of, more than one half of the maximum number of votes that
might be cast at a general meeting of the first mentioned person; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">holds or has a Relevant Interest in more than <FONT STYLE="white-space:nowrap">one-half</FONT> of the issued
share capital of the first mentioned person (excluding any part of that issued share capital that carries no right to participate beyond a specified amount in a distribution of either profits or capital); or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the first mentioned person is a trustee of a unit trust and, in the case of the Tenant, its interest in this
lease is property subject to that trust, a person who: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is in a position to cast, or control the casting of, more than one half of the maximum number of votes that
might be cast at a meeting of holders of units at that meeting; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">holds or has a Relevant Interest in more than one half of the issued units of that trust (excluding any of the
issued units that carry no right to participate beyond a specified amount in a distribution of either profits or capital); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the first mentioned person is a trustee of a trust and, in the case of the Tenant, its interest in this
lease is property subject to that trust, a person who: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is a beneficiary of that trust entitled directly or indirectly to more than one half of the corpus or profits
of the trust; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is entitled to or whose consent is required to: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">appoint or change the trustee; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">give directions to the trustee; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">vary the constituent document of the trust; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">appoint or remove beneficiaries; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(E)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">decide to whom any distribution is made or the amount of any distribution. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">A person is a Parent of another person if the first mentioned person is a Parent of a Parent of the other person (including a person that is
the other person&#146;s Parent by another or other applications of this definition). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>PCA Method </B>means the method of measurement
from time to time adopted by the Property Council of Australia Limited for buildings such as the Building. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Permitted Use </B>means the
use in item 15. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Personal Property </B>means personal property as defined under the PPS Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>PPS Act </B>means the Personal Property Securities Act 2009 (Cth) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Premises </B>means that part of the Building demised by this lease as described in Item 3 of the Commercial Terms Schedule which: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">extends up to and including: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the internal face of external walls and of any internal structural walls of the Building;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the false ceiling below the internal face of the concrete ceiling; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the internal face of the concrete floor; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the centre line of any partitions which separate the Premises from other parts of the Building; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">includes the Landlord&#146;s Fixtures in that part of the Building; but </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">excludes the tea rooms, stairs, water closets, toilets and lift lobbies which are intended or are physically
available for use jointly with any other tenant of the Building. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Previous CPI </B>means the Consumer Price Index
Number last published before the immediately preceding Review Date or if there has not been one, the Commencement Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Public Access
Hours </B>means the hours for access to the Building specified in item 17. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Related Agreement </B>means any document entered into by the
Landlord and the Tenant (or parties related to the Tenant) in connection with this lease. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Related Body Corporate</B> has the meaning
given to that expression in the Corporations Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Relevant Interest </B>means the power: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to exercise, or to control the exercise of, the right to vote attached to a share or unit; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to dispose of, or to exercise control over the disposal of, a share or unit. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Rent Review Notice </B>means a notice given by the Landlord to the Tenant under clause&nbsp;3.2 specifying the Landlord&#146;s assessment of
the Base Rent of a face rent basis to apply from the relevant Market Review Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Requirements </B>means requirements, notices, orders
or directions of any Authority. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Review Date </B>means any of the following days: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a CPI Adjustment Date; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a Market Review Date; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a Fixed Increase Date. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Review Period </B>in respect of a Market Review Date means the period: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">commencing three months before that Market Review Date; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ending on the day prior to the next Review Date, or if there is no further Review Date ending on the day before
the Expiry Date. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Rules</B> means rules relating to the management and care of the Building or the conduct of tenants,
occupants and other persons in the Building or the use or occupation of the Building. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Security Interest </B>means a security interest
as defined under the PPS Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Services</B> means all services supplied to or in the Premises such as gas, water, drainage, fresh air,
exhaust systems, electricity, sprinkler heads, heating and lighting and includes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Facilities to the extent that those Facilities are in, connected to or exclusively service the Premises;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Landlord&#146;s Fixtures. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Sign</B> means a sign, advertisement, notice or similar thing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Subtenant</B> means a subtenant proposed under clause&nbsp;7.2. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>State</B> means the state or territory in which the Land is situated. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Tenant</B> means the Tenant specified in item 2. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Tenant&#146;s Agents</B> means the Tenant&#146;s employees, agents, contractors, consultants, invitees, Subtenants, licensees,
concessionaires and others who at any time are in the Building with the consent of the Tenant express or implied. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Tenant&#146;s
Business</B> means that business of the Tenant carried on in the Premises in compliance with the Permitted Use. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Tenant Cause </B>means:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any act, omission, neglect, default or misconduct of the Tenant or of the Tenant&#146;s Agents;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the use or occupancy of the Premises by the Tenant or the Tenant&#146;s Agents; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Tenant&#146;s Fixtures. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Tenant&#146;s Covenants</B> means the covenants, obligations and agreements on the part of the Tenant contained or implied in this lease.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Tenant&#146;s Fixtures</B> means: all fixtures, fittings, plant, equipment, furniture, internal partitions, fitout (including ceilings,
kitchens and kitchen fittings and showers and shower fittings, tiles and flooring) and other articles in the Premises in the nature of trade or Tenant&#146;s fixtures (including any riser duct cables) in each case which are owned or leased by the
Tenant or by any Subtenant of the Tenant or otherwise brought onto or installed in the Premises by or on behalf of the Tenant or any Subtenant of the Tenant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Tenant&#146;s Proportion </B>means that proportion (expressed as a percentage) which the lettable area of the Premises bears to the lettable
area of the office space which forms part of the Building known as 650 Chapel Street both measurements to be calculated in accordance with the PCA Method and which at the Commencement Date is the percentage in item 13, as varied under clause 12.9.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Term </B>means the term of this lease being the period from the Commencement Date to and including the Expiry Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Trust</B> means the trust described in item 21. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Umpire </B>means a person appointed under clause&nbsp;3.6 or 3.8. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Works Conditions </B>means that relevant works consented to by the Landlord under this lease must be carried out: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the Tenant&#146;s cost; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in a proper and workmanlike manner and to the satisfaction of the Landlord, acting reasonably;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by a contractor (who has a public liability policy of not less than $20,000,000 and appropriate contract
construction risk, workers&#146; compensation and other usual insurances all of which must note the rights and interest of the Landlord and evidence of which must be given to the Landlord) and under the supervision of persons both approved by the
Landlord; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in accordance with all Laws and Requirements (including the <I>Occupational Health and Safety Act, 2004</I>);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in accordance with plans and specifications approved by the Landlord; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in accordance with and only after obtaining the approvals of all relevant Authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">only after providing copies to the Landlord of all approvals from relevant Authorities in relation to the works
prior to carrying out the works; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">so long as the Tenant provides <FONT STYLE="white-space:nowrap">as-built</FONT> drawings for the Premises
layout and services on completion of the works; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">so long as the Tenant provides copies to the Landlord of all certificates of compliance from relevant
Authorities in relation to the works within a reasonable period as nominated by the Landlord (but in any event within 30 days) after the completion of the works; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">so long as the Tenant pays the reasonable costs of the Landlord in connection with the works including the
Landlord&#146;s administrative and other reasonable costs of giving consent and the fees of any architect or other consultant used by the Landlord in connection with the works; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in accordance with clause 23; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(l)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">subject to the conditions of the Landlord&#146;s consent in relation to those works; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(m)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in accordance with the then current Fitout Guide. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Interpretation </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless the context otherwise requires: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a reference to this lease or another instrument includes any variation or replacement of any of them;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a reference to a statute, ordinance, code or other law includes regulations and other instruments under it and
consolidations, amendments, <FONT STYLE="white-space:nowrap">re-enactments</FONT> or replacements of any of them; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the singular includes the plural and vice versa; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the word &#147;<B>person</B>&#148; includes a firm, a body corporate, an unincorporated association or an
Authority; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a reference to a person includes a reference to the person&#146;s executors, administrators, successors,
permitted substitutes (including persons taking by novation) and permitted assigns; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an agreement, representation or warranty in favour of two or more persons is for the benefit of them jointly
and severally; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an agreement, representation or warranty on the part of two or more persons binds them jointly and severally;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a reference to an accounting term is to be interpreted in accordance with approved accounting standards under
the Corporations Act and, if not inconsistent with those accounting standards, generally accepted principles and practices in Australia consistently applied by a body corporate or as between bodies corporate and over time; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a reference to any thing (including any amount) is a reference to the whole and each part of it and a reference
to a group of persons is a reference to all of them collectively, to any two or more of them collectively and to each of them individually; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a reference to the president of a body or authority is a reference, if there is no such person, to the senior
officer of the body or authority or to the person who fulfils the duties of president; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a reference to a clause is a reference to a clause in this lease; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(l)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the words &#147;<B>include</B>&#148;, &#147;<B>including</B>&#148;, &#147;<B>for example</B>&#148; or
&#147;<B>such as</B>&#148; when introducing an example, do not limit the meaning of the words to which the example relates to that example or examples of a similar kind; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(m)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a reference to this lease includes the cover sheet, all schedules and annexures to this lease and the Rules;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(n)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a reference to &#147;<B>month</B>&#148; or &#147;<B>monthly</B>&#148; means respectively calendar month and
calendar monthly; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(o)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a reference to &#147;<B>day</B>&#148; means any day of the week including Saturday, Sunday and public holidays;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(p)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a reference to an &#147;<B>item</B>&#148; followed by a number is a reference to the item with the
corresponding number in the Commercial Terms Schedule. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If this lease prohibits the Tenant from doing a thing then: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Tenant must do everything necessary to ensure that the Tenant&#146;s Agents do not do that thing; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Tenant may not allow or cause any person to do that thing. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If this lease requires the Tenant to do a thing then the Tenant must do everything necessary to ensure that the
Tenant&#146;s Agents also do that thing. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Headings are inserted for convenience and do not affect the interpretation of this lease.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the interpretation of this lease no rule of construction applies to the disadvantage of one party on the
basis that that party put forward the lease. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman"><B>SCHEDULE 2 - OUTGOINGS </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Statutory or regulatory </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Rates, taxes (excluding income tax, capital gains tax and other taxes of a like nature) charges, assessments
duties impositions levies surcharges and fees (including council rates) payable to any Authority in respect of the Building or the Land or the Landlord&#146;s ownership and operation of them or in respect of receipts of rent and other money under
this lease (including any bank debits tax and financial institutions duty). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Rates, charges and costs (including water rates) payable to any Authority for the provision, reticulation or
discharge of water or sewerage or drainage, including excess water charges and meter rents. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Land taxes or taxes of the nature of a tax on land computed on the taxable value of the Land at the rate for
the time being payable by the Landlord in respect of all land owned by the Landlord in the State in which the Building is situated. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Insurances </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Insurance premiums and amounts payable (including policy excesses and deductible amounts) in respect of
insurances: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on the Building for its full insurable value; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for loss of rents resulting from damage or destruction of the Building or other like causes (including Base
Rent) but excluding loss of rents arising from normal vacancies during letting up periods; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for public liability insurance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for workers&#146; compensation insurance for all employees of the Landlord engaged in employment in connection
with the Building. If any employee is engaged on less than a full time basis in connection with the Building, the cost of workers&#146; compensation insurance is to be equitably apportioned by the Landlord; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for other insurable risks (including machinery breakdown and boiler explosion) as the Landlord reasonably deems
appropriate from time to time. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Head lease </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any money (excluding rental) payable by the Landlord to any head lessor under a head lease on account of
operating expenses excepting any amount already included by any other item of this schedule. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Water, sewerage and drainage </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Costs in relation to supply of water, sewerage and drainage services to and the removal of all waste, sullage
and other general garbage from the Building, including the cost of operating and maintaining any plant and equipment provided for that purpose, whether or not such plant or equipment is located in the Building and the costs of operating and
maintaining recycling programs in the Building. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pest control </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Costs in relation to the control of pests or vermin. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gardening and landscaping </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Costs of purchasing, hiring, maintaining and servicing all outdoor gardens, lawns, potted shrubs, planted
areas, fountains and any artificial water courses and associated plants. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Security and caretaking </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Costs of providing security and caretaking services including the cost of policing and regulating traffic in
the Building and the Land and roads giving access to the Building. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Miscellaneous operational costs </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reasonable costs of providing general amenities for the Building (including art works in the foyer, Christmas
decorations, newsletters) and rental and hiring charges (or where appropriate replacement costs) for the provision of indoor plants, music amplification systems, telephones, and similar equipment servicing the Building. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Air conditioning </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The cost of the repair, maintenance, servicing and all other running costs of the <FONT
STYLE="white-space:nowrap">air-conditioning</FONT> equipment in the Building including any reasonable fees or premiums payable to specialist contractors. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Repairs and maintenance </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The cost of repairs or maintenance of the Building, (excluding repairs and maintenance of a structural nature),
including the cost of operating, supplying, maintaining and repairing all Facilities and Services and the cost of complying with essential services, Laws and Requirements in relation to the Building. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Light fuel and power </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Costs incurred in providing lighting, fuel, heating, security lighting and power to the Building and other
services and systems in and for the operation of the Building. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Operating costs (labour) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All reasonable costs in the form of salary, wages, leave entitlements, superannuation and other employment
overheads, (equitably apportioned by the Landlord where any employee is engaged on less than a full time basis) for the operation maintenance and supply of any Facilities and Services. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Management </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A management fee to cover the Landlord&#146;s reasonable cost of managing the Building and, if applicable, fees
payable by the Landlord to any managing agents for the general management of the Building and any other money relating to the management and promotion of the Building including that part of the Landlord&#146;s expenditure which the Landlord
reasonably apportions to the Building of operating a central tenant&#146;s service centre in another building for the Building and other Landlord&#146;s buildings. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Computer Services </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">16.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All fees and charges relating to any computer service in respect of the Building or the services to the
Building. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General expenditure </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any other expenditure properly incurred by the Landlord in the management, operation or maintenance of the
Building or the Land generally including Common Area cleaning, excluding expenditure of a capital nature. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman"><B>Executed as a deed on _<U>12</U><U></U><U>&nbsp;November</U>______________2019 </B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Executed by <B>THE TRUST COMPANY (AUSTRALIA) LIMITED ACN 000 000</B> 993 as custodian for the Newmark Como Property Trust by Power of Attorney dated</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><U>/s/ Shane Johstone</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><U>/s/ Trent Franklin</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Witness Signature</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attorney Signature</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shane Johnstone Custody Administrator</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trent Franklin Manager Custody</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Print Name</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Print Name</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>EXECUTED</B> by <BR><B>OPTEA LIMITED ACN 006 340 567 </B><BR>in accordance with s127 of the Corporations Act 2001 by:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>/s/ Megan Baldwin</U></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><U>/s/ Mike Tonroe</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director / Secretary</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Megan Baldwin</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Mike Tonroe</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name of Director (Block Letters)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name of Director / Secretary (Block Letters)</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman"><B>Annexure A &#150; Plan(s) </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g945701g11h62.jpg" ALT="LOGO">
</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 49 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>8
<FILENAME>filename8.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.5 </B></P> <P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="57%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:24pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman">Opthea Limited</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACN 006 340 567</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Long term incentive plan rules</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Long term incentive plan rules</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>1.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Introduction</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name of Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Objects of Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commencement of Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Defined terms and interpretation</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Defined terms</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interpretation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Headings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Primary instruments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>3.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Principal conditions</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>11</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options or Rights issued only to Employees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compliance with laws</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No prohibited financial assistance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Plan limit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director participation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operation of the Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>4.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Offers</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>13</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Board may make Offer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of Offer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Information provided with Offer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of Options or Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issue Price and Exercise Price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Terms</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise Price and Issue Price in Australian dollars</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offer personal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Application for Options and Rights</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acceptance of Offer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Application for all or some of the Options or Rights the subject of an Offer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lapse of Offer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Withdrawal of Offer prior to acceptance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>6.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Issue of Options or Rights</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>15</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acceptance by Eligible Employee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acceptance by Company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notification of issue of Options or Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consideration for Options and Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entitlement to Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest in Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>7.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Vesting of Options or Rights</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>16</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Requirements for vesting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting Notice</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Variation or waiver of Vesting Conditions and other terms</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notice of variation or waiver</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>8.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Exercise of Options</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>17</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise during Exercise Period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="99%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Long term incentive plan rules | page 2</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise Conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of Options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clearance of Exercise Price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise or conversion of all or some Options or Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Replacement Certificate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>9.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Allocation of Shares to satisfy Vested Options or Rights</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>18</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Requirement to allocate Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Method of allocation of Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Timing of allocation of Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares rank equally</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discretion to settle Vested Plan Securities in cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Calculation of amount payable for any Cash-Settled Plan Securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax withholding and superannuation contributions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>10.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Lapse of Options and Rights</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>20</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lapse of Plan Securities where Vesting Conditions not satisfied</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lapse of Plan Securities on cessation of employment in certain circumstances</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lapse of Plan Securities to prevent inappropriate benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lapse of Plan Securities where a Corporate Control Event occurs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lapse of Options on Last Exercise Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Timing of lapse</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entitlements and rights cease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>11.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Dealings with Options and Rights</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>23</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options and Rights personal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No unauthorised disposal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Permitted transfer of Options and Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>12.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Participation rights, bonus issues, rights issues, reorganisations of capital and winding up</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>24</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Application of this Rule</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New issues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bonus issues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Pro-rata</FONT> issues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reorganisation of capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Winding up</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rounding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Calculations and adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notice of change</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>13.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Corporate Control Events</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>26</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Treatment of Plan Securities on a Corporate Control Event</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Board determinations under Rule 13.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Board determination as to pro rata vesting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Terms of Offer prevail</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>14.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Restriction on disposal of Shares acquired pursuant to exercise of Options or conversion of Rights</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>27</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No disposal during Restriction Period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Refusal to register transfer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Release of Holding Lock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notification upon request by Participant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="99%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Long term incentive plan rules | page 3</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>15.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Quotation of Options or Rights</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>28</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No Quotation of Options or Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Quotation of Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>16.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Power of Attorney</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>28</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Appointment of Attorney</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ratification of Actions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indemnity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>17.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Administration</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>28</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Powers of the Board</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Delegation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of powers or discretion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Determinations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expenses and costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Board members not liable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Participants responsible for Tax in respect of Options, Rights and Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>18.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Amendment to Rules</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>30</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Board may amend Rules</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Waiver or amendment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consent of Participants required</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exceptions to requirements of Rule 18.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of discretions under Rules</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eligible Employees outside Australia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>19.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Rights of Participants</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>31</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>20.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>No representation as to Tax consequences</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>32</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>21.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Notices</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>32</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service of notices</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective on receipt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Address</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>22.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Governing law</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>33</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>23.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Advice</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>33</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="99%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Long term incentive plan rules | page 4</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Long term incentive plan rules </B></P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Introduction </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Name of Plan </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Plan is the long term incentive plan (<B>Plan</B>) of Opthea Limited ACN 006 340 567 (<B>Company</B>). </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Objects of Plan </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The objects of the Plan are to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">provide Eligible Employees with an additional incentive to work to improve the performance of the Company;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">attract, retain and motivate Eligible Employees essential for the continued growth and development of the
Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">promote and foster the loyalty and support of Eligible Employees for the benefit of the Company;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">enhance the relationship between the Company and Eligible Employees for the long term mutual benefit of all
parties; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">provide Eligible Employees with the opportunity to acquire Options or Rights in the Company, in accordance with
these Rules, as part of the remuneration for their services as Eligible Employees. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Commencement of Plan </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Plan commences on the date determined by the Board. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Defined terms and interpretation </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Defined terms </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">In these Rules, unless the context otherwise requires: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Allocated </B>means allocated by any means permitted under Rule 9.2. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Applicable Law</B> means any one or more, as the context requires of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Corporations Act; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Corporations Regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other applicable securities or financial services laws; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any class order, declaration, exemption or modification made or granted by ASIC pursuant to any of the
abovementioned statutes, regulations or laws, or any waiver from the Listing Rules granted by ASX, on which the Company seeks to rely or that binds the Company in making any Offer or otherwise in connection with the operation of the Plan;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Listing Rules or the rules of any other applicable securities exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other legislation regulating or applying to the activities of the Company; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Constitution. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Application</B> means a duly completed application for the issue of Options or Rights made by an Eligible Employee in respect of an Offer,
in the form approved by the Board from time to time (which may, without limitation, be an electronic form that is accessible and submitted via a website managed by the Company, its share registry or any other third party service provider). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="99%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Long term incentive plan rules | page 5</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>ASIC</B> means the Australian Securities and Investments Commission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Associated Body Corporate </B>means: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a body corporate that is a related body corporate of the Company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a body corporate that has Voting Power in the Company of not less than 20% and that has been approved for
participation in the Plan by the Company; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a body corporate in which the Company has Voting Power of not less than 20% and that has been approved for
participation in the Plan by the Company, </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">and <B>Associated Bodies Corporate</B> means all such bodies corporate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>ASX </B>means ASX Limited ACN 008 624 691. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Board</B> means: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all or some of the Directors, acting as a board; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any committee, person or persons to whom power or authority to exercise or perform the relevant power, function
or discretion, or to administer the Plan generally, has been delegated under Rule 17.2 (including any <FONT STYLE="white-space:nowrap">sub-delegate).</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Business Day</B> means a day on which banks are open for general banking business in Melbourne, Victoria excluding Saturdays or Sundays.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Business Hours</B> means from 9.00am to 5.00pm on a Business Day. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Cash-Settled Plan Securities </B>means Plan Securities that are the subject of a determination made by the Board under Rule 9.5. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Cessation Date</B> means the date on which the relevant Participant ceases to be employed within the Group. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Clawback Policy</B> means the policy, if any, adopted by the Board in relation to any circumstances in which the Company may claw back
performance-based remuneration from key management personnel (or other senior executives) of the Company (or any other Group Company). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Company </B>means Opthea Limited ACN 006 340 567. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Constitution </B>means the constitution of the Company (as amended from time to time). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Corporate Control Event </B>means any one or more of the following events or circumstances: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an offer is made for Shares (or shares in a subsidiary) pursuant to a takeover bid under Chapter 6 of the
Corporations Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Court orders a meeting of members (or a class of members) or creditors (or a class of creditors) under Part
5.1 of the Corporations Act for the purpose of considering a proposed compromise or arrangement relating to the Company (or a subsidiary) or a compromise or arrangement proposed for the purposes of, or in connection with, a scheme for the
reconstruction of the Company (or a subsidiary) or its amalgamation with any other body corporate or bodies corporate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">approval is given by a resolution duly passed at a general meeting, or by circular resolution, of members of
the Company (or a subsidiary) for an acquisition that would result in a person having Voting Power in the Company (or a subsidiary) of more than 50%; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a person acquires Voting Power of more than 50% in the Company: </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="99%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Long term incentive plan rules | page 6</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as a result of a takeover bid for all of the issued shares in the Company; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">through a scheme of arrangement relating to the acquisition of all of the issued shares of the Company;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Board determines that a change of control of the Company has occurred within the meaning of section 50AA of
the Corporations Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other event or transaction (including any other merger, consolidation or amalgamation involving the Company
(or a subsidiary)) occurs or is proposed where either or both of the following applies: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of a merger, consolidation or arrangement, the transaction results in the holders of Shares (or
shares in a subsidiary) immediately prior to the merger, consolidation or amalgamation having relevant interests, in aggregate, in 50% or less of the voting shares in the body corporate resulting from the merger consolidation or amalgamation; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Board determines, in its discretion, that the relevant transaction constitutes a Corporate Control Event
for the purposes of the Rules; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company (or a Subsidiary) enters into an agreement or agreements to sell, in aggregate, a majority in value
of the business or assets of all Group Companies (whether or not in the form of shares in a Group Company) to a person or persons that are not Group Companies; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an administrator, liquidator, provisional liquidator, receiver or receiver and manager is appointed in respect
of the Company or substantially all of the assets of the Company. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Corporations Act</B> means the <I>Corporations Act
2001 </I>(Cth)<I>.</I> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Date of Grant</B>, in respect of an Option or Right, means the date on which the Company issues the Option or
Right (as the context requires) to an Eligible Employee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Deal</B> or <B>Dealing</B> means sale, transfer, assignment, mortgage, pledge,
grant of a lien or other alienation or encumbrance over or attempted sale, transfer, assignment, mortgage, pledge, grant of a lien or other alienation or encumbrance over, or creation in favour of any third party of any interest whatsoever. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Director</B> means a director of the Company (including a <FONT STYLE="white-space:nowrap">non-executive</FONT> director). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Eligible Employee</B> means: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an Employee to whom, or who falls within a class of Employees to whom, the Board determines that an Offer is to
be made under the Plan; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an Employee who satisfies the eligibility criteria (if any) determined by the Board for a proposed Offer.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Employee</B> means: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a full-time or part-time employee of a Group Company (including any employee on parental leave, long service
leave or other special leave as approved by the relevant Group Company); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a director of a Group Company who holds a salaried employment or other salaried office in a Group Company
(excluding, for the avoidance of doubt, a <FONT STYLE="white-space:nowrap">non-executive</FONT> director). </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Exercise
Period</B> means the period commencing on the First Exercise Date and ending on the Last Exercise Date, subject to any variation to those dates determined by the Board under Rule 7.3. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Exercise Price</B> means the amount (if any) payable by the holder of an Option on the exercise of the Option, being (subject to Rules 12
and 18) the amount fixed (or the amount calculated in the manner determined) at the time of the Offer of the Option and determined by the Board under Rule&nbsp;4.5. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="99%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Long term incentive plan rules | page 7</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Final Acceptance Date</B> has the meaning given to this term in Rule 4.3(b). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>First Exercise Date</B>, in respect of an Option, means: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the Offer Document for the Option specified a fixed date as the first day on which the holder may exercise
the Option, that date; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the Offer Document for the Option did not specify a fixed date as the first day on which the holder may
exercise the Option, the date (if any) on which the Company issues a Vesting Notice in respect of the Option, </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">and, in
each case, any different applicable date determined by the Board under Rule 7.3 or 18. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Grant Conditions</B>, in respect of an Offer of
an Option or Right, means any conditions that must be satisfied, or circumstances that must exist, before the Option or Right will be issued, as determined by the Board under Rule 4.6. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Group</B> means the Company and its Associated Bodies Corporate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Group Company</B> means any body corporate within the Group. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Holding Lock</B> means a mechanism arranged or approved by the Board and administered by the Company (including through its share registry)
that prevents Shares being disposed of by or on behalf of a Participant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Issue Price</B> means the amount (if any) payable per Option
or Right by an Eligible Employee on application for Options or Rights offered under an Offer. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Last Exercise Date</B>, in respect of an
Option, means: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the Offer Document for the Option specified a fixed date as the last day on which the holder may exercise
the Option, that date: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the Offer Document for the Option did not specify a fixed date as the last day on which the holder may
exercise the Option, the date that is five years after the Date of Grant; or </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">and, in each case, any different applicable
date determined by the Board under any of Rules 7.3, 12, 13 or 18. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Legal Personal Representative</B> means the executor of the will or
an administrator of the estate of a deceased person, the trustee of the estate of a person under a legal disability or a person who holds an enduring power of attorney granted by another person. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Listing Rules</B> means the listing rules of ASX Limited and any other rules of ASX (or the applicable securities exchange) that are
applicable to the Company or the Shares while the Company is listed on that exchange, each as amended or replaced from time to time, and except to the extent of any express written waiver by ASX. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Notice of Exercise</B> means a notice of exercise of an Option by a Participant, in the form approved by the Board from time to time (which
may be in electronic form and, without limitation, accessed and submitted via a website managed by the Company, its share registry or another third party service provider). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Offer</B> means an invitation to an Eligible Employee to apply for the issue of Plan Securities and, if the Eligible Employee is not already
a Participant, to participate in the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Offer Document</B>, in respect of Plan Securities,<B> </B>means a document (or documents)
setting out the Offer of the relevant Plan Securities and given to an Eligible Employee under Rule 4.2. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="99%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Long term incentive plan rules | page 8</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Option</B> means an option issued, or to be issued (as the context requires), under the
Plan to acquire a Share, subject to these Rules and the terms and conditions set out in the relevant Offer Document. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Participant</B>
means a person who holds Options or Rights issued under the Plan, or Restricted Shares, and includes, if a Participant dies or becomes subject to a legal disability or has granted an enduring power of attorney, the Legal Personal Representative of
the Participant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Performance Period</B>, in respect of Plan Securities,<B> </B>means any period or periods (if any, and however
described) determined by the Board and specified in the relevant Offer Document as the period during, or by reference to, which the satisfaction of any performance-based Vesting Conditions applicable to those Plan Securities is to be measured or
assessed (and, where Plan Securities the subject of an Offer are divided into tranches to which different performance-based Vesting Conditions apply, means any such period applicable in respect of the relevant tranche of Plan Securities and, where
any such period may be or is extended by the Board, excludes any such extension of the period unless otherwise determined by the Board). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Plan</B> means the long term incentive plan of the Company governed by these Rules. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Plan Security </B>means an Option or Right and <B>Plan Securities </B>means Options or Rights, or both (as the context requires). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Resignation </B>means<B> </B>the resignation of a<B> </B>Participant<B> </B>from<B> </B>their employment with a Group Company other than:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Retirement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Total and Permanent Disablement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where the Participant has accepted an offer of employment received from any other Group Company or from the
purchaser (or a related body corporate of the purchaser) of all or part of the assets or business of any Group Company, or from any person to whom any Group Company has outsourced, or agreed to outsource, any part of its functions or business; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for any other reason, or in any other circumstances, that the Offer Document for the Offer of the relevant Plan
Securities held by the Participant specified would not constitute resignation for the purposes of these Rules. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Restriction Period</B> has the meaning given to this term in Rule&nbsp;14.1. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Restricted Shares</B> has the meaning given to this term in Rule 14.1. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Retirement </B>means the resignation of the Participant from their employment with a Group Company in circumstances where the Board is
satisfied that the Participant intends to leave the workforce permanently in the sense that the person intends to no longer be employed on a full-time or permanent part-time basis. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Right</B> means a right issued, or to be issued (as the context requires), under the Plan to acquire a Share, subject to these Rules and the
terms and conditions set out in the relevant Offer Document. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Rules</B> means the rules governing the operation of the Plan set out in
this document, as amended from time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Security Interest</B> means a mortgage, charge, pledge, lien, encumbrance or other third
party interest of any nature (including the registration and/or perfection of that security interest under the <I>Personal Property Securities Act 2009 </I>(Cth)). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Share Allocation Date</B> or <B>Share Allocation Period</B> means the date on which, or the period during which, the Company expects to
Allocate a Share to a Participant in respect of a Vested Right. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="99%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Long term incentive plan rules | page 9</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Shares</B> means fully paid ordinary shares in the capital of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Tax</B> includes any tax, levy, impost, GST, deduction, charge, rate, contribution, duty or withholding which is assessed (or deemed to be
assessed), levied, imposed or made by or under any law or by any government or any governmental, semi-governmental or judicial entity or authority together with any interest, penalty, fine, charge, fee or other amount assessed (or deemed to be
assessed), levied, imposed or made on or in respect of any or all of the foregoing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Tax Act </B>means the <I>Income Tax Assessment Act
1997 </I>(Cth). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Termination for Cause</B> means the termination by any Group Company of the Participant&#146;s employment with that
Group Company: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)<B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>where neither<B> </B>notice nor payment in lieu of notice is required to be given by the Group Company;
or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in circumstances involving the Participant&#146;s actual or alleged serious misconduct, whether or not notice
or any payment in lieu of notice is required to be given by the Group Company. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Total and Permanent Disablement</B>
means the resignation of the Participant from his or her employment with any Group Company as a result of his or her total and permanent disablement, as determined by the Board. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Trading Policy </B>means any policy adopted by the Company in relation to trading or dealing in Shares or other securities by the
Company&#146;s key management personnel (or any other persons), as amended from time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Unvested Plan Securities </B>means Plan
Securities that have not become Vested Plan Securities and the terms <B>Unvested Options</B> and <B>Unvested Rights</B> have corresponding meanings. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Vested Plan Securities</B> means Plan Securities: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that have become vested Plan Securities under Rule 7.1; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that are taken to be vested Plan Securities by virtue of a determination of the Board under Rule 13.1; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the Board has determined and notified the relevant Participant have otherwise become vested Plan
Securities (including by reason of the waiver of any Vesting Conditions under Rule 7.3), </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">and the terms <B>Vested
Option</B> and <B>Vested Right</B> have corresponding meanings. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Vesting Conditions</B>, in relation to an Option or Right, means any
performance, service or other conditions that must be satisfied, or circumstances that must exist, before: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of an Option, the Option may (during the Exercise Period) vest and be exercised; <B></B>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of a Right, the Right may vest and be converted into a Share, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">as determined by the Board under Rule 4.6. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Vesting Notice</B>, in respect of Plan Securities held by a Participant,<B> </B>means notice to the Participant that, to the extent
specified in the notice (or in information accompanying the notice or that the Participant may access using electronic means specified in the notice), the Plan Securities have become Vested Plan Securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Voting Power </B>means voting power as determined in accordance with section 610 of the Corporations Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="99%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Long term incentive plan rules | page 10</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Interpretation </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">In these Rules (and any Offer Document), unless the context otherwise requires: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a reference to any legislation or to any provision of any legislation includes any modification, amendment or <FONT
STYLE="white-space:nowrap">re-enactment</FONT> of it, any legislation or legislative provision substituted for it, and all legislation, statutory instruments and regulations made under it; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">words denoting the singular include the plural and vice versa; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">words denoting a gender include the other genders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a reference to any document or agreement includes a reference to that document or agreement as amended,
novated, supplemented, varied or replaced from time to time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where any word or phrase is given a defined meaning in these Rules or an Offer Document, any part of speech or
other grammatical form of that word or phrase has a corresponding meaning; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a reference to a document or record includes a document or record in electronic form; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a reference to a person includes a natural person, partnership, body corporate, association, governmental or
local authority or agency or other entity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a word or expression defined in the Corporations Act<I> </I>has the meaning given to it in the Corporations
Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a reference to a Rule is a reference to a rule of these Rules, or the corresponding rule of the Plan as amended
from time to time; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the meaning of general words is not limited by specific examples introduced by <B>including</B>, <B>for
example</B> or similar expressions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where these Rules provide (or an Offer Document provides) for an act or thing to be done, occur or take effect
on a particular day or within a particular period, that act or thing must be done before, or occurs or takes effect, or that period ends, at 5.00pm Melbourne, Australia time on the relevant day or the last day of the relevant period (as the context
requires); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(l)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a reference to Plan Securities (or Rights or Options) <B>held by a Participant</B> does not include any Rights
or Options that have lapsed under Rule 10. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Headings </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Headings are for convenience only and do not affect the interpretation of these Rules. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Primary instruments </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">These Rules are to be interpreted subject to the Applicable Laws. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Principal conditions </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Options or Rights issued only to Employees </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">No Options or Rights may be issued to a person under the Plan unless, as at the Date of Grant of the Options or Rights, the person is or
remains an Employee, or the Board determines otherwise. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Compliance with laws </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No Option or Right (or Share issued on exercise of an Option or conversion of a Right) may be issued or
otherwise Allocated to, or (in the case of an Option) exercised by, an Eligible Employee or Participant if to do so would contravene an Applicable Law. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="99%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Long term incentive plan rules | page 11</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Nothing in these Rules requires or permits any act to be done, determination to be made or thing to occur where
that act, determination or thing would, in the opinion of the Board: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cause any Group Company or Participant to contravene, or be involved in a contravention of, any provision of
any Applicable Law; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">require approval by resolution of the Company&#146;s shareholders under a provision of Applicable Law
(including section 200B of the Corporations Act and the Listing Rules applying to options) where no such approval has been given. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No prohibited financial assistance </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">No person may, whether directly or indirectly, provide financial assistance that is prohibited by the Corporations Act for the purposes of, or
in connection with, the acquisition by an Eligible Employee of Options or Rights under the Plan, or of Shares on exercise of Options or conversion of Rights. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Plan limit </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to Rule 3.4(b), the Company will not make an Offer of Plan Securities if the total number of Shares the
subject of those Plan Securities plus: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the total number of Shares that would be issued were each outstanding: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">offer with respect to Shares, units of Shares or rights or options to acquire unissued Shares (including an
Offer); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">right or option to acquire unissued Shares (including a Plan Security), being a right or option that has been
granted but has not been exercised or converted (as the context requires), lapsed or otherwise expired; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">unit of a Share, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:16%; font-size:10pt; font-family:Times New Roman">issued under an employee share scheme of the Company (including the Plan) to be accepted or exercised; and </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the number of Shares issued during the previous five years pursuant to the Plan or any other employee share
scheme of the Company; </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">but disregarding and excluding any offer made or option or right acquired (whether under the
Plan or any other employee share scheme), or any Share or unit of a Share issued, by way of, or as a result of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an offer to a person situated, at the time of receipt of the offer, outside Australia; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an offer that was an excluded offer or invitation within the meaning of the Corporations Act as it stood prior
to the commencement of Schedule 1 to the <I>Corporate Law Economic Reform Program Act 1999</I> (Cth); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an offer that does not need disclosure to investors because of section 708 of the Corporations Act;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an offer that did not require the giving of a product disclosure statement (as defined in the Corporations Act)
because of section 1012D of the Corporations Act; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an offer made under a disclosure document or product disclosure statement (as defined in the Corporations Act),
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">would exceed 5% of the total number of issued Shares as at the time of the Offer.&nbsp;&nbsp;&nbsp;&nbsp; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="99%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Long term incentive plan rules | page 12</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If ASIC replaces ASIC Class&nbsp;Order [CO 03/184] with a new class order in relation to employee incentive
schemes (or substantially modifies ASIC Class&nbsp;Order [CO 03/184]) Rule 3.4(a) will no longer apply and Rule 3.4(c) will apply instead. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Where this Rule 3.4(c) applies instead of Rule 3.4(a), the Company will not make an Offer of Options or Rights
if the issue of the Options or Rights the subject of the Offer to the Eligible Employee to whom the Offer is made would cause the Company to exceed any limit that applies under the ASIC class order that replaces or modifies Class&nbsp;Order [CO
03/184] (when aggregated with the total number of Shares and other financial products required by the replacement or modified class order to be counted towards the limit, and disregarding and excluding all offers, Shares and other financial products
that may be disregarded when applying that limit). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Director participation </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Neither Options nor Rights may be issued to Directors or their associates pursuant to the Plan unless prior approval of the Company&#146;s
shareholders is obtained in accordance with the Listing Rules or such approval is not required by the Listing Rules. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Operation of the Plan </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Plan must be operated in accordance with these Rules which bind the Company, any Associated Body Corporate and each Participant. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Offers </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Board may make Offer </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Subject to these Rules, the Board may from time to time make an Offer (on behalf of the Company) to an Eligible Employee. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Form of Offer </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An Offer must be set out in a document (or documents) given to the Eligible Employee to whom the Offer is made.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to Rule 4.3, the form of the Offer Document and the form of the Application accepting the invitation
constituted by the Offer will be as approved by the Board from time to time. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Information provided with Offer </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Offer Document provided to an Eligible Employee must include the following information: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the date of the Offer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the final date by which the Eligible Employee may accept the invitation constituted by the Offer (<B>Final
Acceptance Date</B>); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the number of Options or Rights the subject of the Offer, or the manner in which that number will be
determined; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Grant Conditions (if any) for the Offer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Vesting Conditions (if any) that will apply to Options or Rights (or, if the Options or Rights will be
divided into tranches, the Vesting Conditions (if any) that will apply to the different tranches) issued the subject of the Offer; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in respect of an Offer of Options: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the first day on which the holder may (subject to these Rules) exercise the Options the subject of the Offer
is fixed at the time of the Offer, that date; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="99%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Long term incentive plan rules | page 13</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the last day on which the holder may (subject to these Rules) exercise the Options the subject of the Offer
is fixed at the time of the Offer, that date; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Exercise Price (if any) of each Option the subject of the Offer, or the manner in which any such Exercise
Price will be determined; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in respect of an Offer of Rights, the Share Allocation Date or Share Allocation Period; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the Board has made a determination under Rule 9.2(b), details of that determination; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if any Shares Allocated pursuant to exercise of any Options, or conversion of any Rights, the subject of the
Offer will be subject to restrictions on disposal under Rule 13, that fact and the applicable Restriction Period; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other specific terms and conditions applicable to the Offer or that will apply to any Options or Rights
issued under the Offer. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Number of Options or Rights </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Subject to Rule&nbsp;3, the number of Options or Rights the subject of an Offer to an Eligible Employee, or the method for determining that
number, will be determined by the Board. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Issue Price and Exercise Price </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless otherwise determined by the Board and specified in the Offer Document for the Option or Right, no amount
will be payable by a Participant to acquire an Option or Right. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Exercise Price (if any) in respect of an Option will be determined by the Board (subject to any adjustment
under Rule 12). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Terms </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The terms and conditions applicable to an Offer, including the Final Acceptance Date, any First Exercise Date, any Last Exercise Date, any
Share Allocation Date or Share Allocation Period, any Grant Conditions, any Vesting Conditions and any Restriction Period, will be determined by the Board. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exercise Price and Issue Price in Australian dollars </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Exercise Price (if any) and Issue Price (if any) in respect of an Option must be denominated and payable in Australian dollars, unless
otherwise determined by the Board. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.8</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Offer personal </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">An Offer under the Plan is personal to the Eligible Employee to whom it is made and, accordingly, the invitation constituted by an Offer may
only be accepted by, and Options or Rights may only be issued to, the Eligible Employee to whom the Offer is made. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Application for Options and Rights </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Acceptance of Offer </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">An Eligible Employee may accept the invitation constituted by an Offer by giving to the Company a duly completed Application (and, in the case
of any Offer of Options or Rights that have an Issue Price, payment of the relevant amount) by the Final Acceptance Date. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Application for all or some of the Options or Rights the subject of an Offer </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Unless otherwise determined by the Board and specified in the Offer Document for the Offer, an Eligible Employee may, in his or her discretion,
accept the invitation constituted by the Offer, in whole or in part, in multiples of 100 Options or Rights or another multiple of Options or Rights as the Board may allow for the Eligible Employee. An Eligible Employee cannot accept less than the
number of Options or Rights that would constitute the minimum parcel determined by the Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="99%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Long term incentive plan rules | page 14</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Lapse of Offer </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">An Offer not accepted in accordance with Rule&nbsp;5.1 will lapse at 5:00pm Melbourne time on the Final Acceptance Date. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Withdrawal of Offer prior to acceptance </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Board reserves the right (subject to any Applicable Law) to withdraw an Offer made to an Eligible Employee. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Issue of Options or Rights </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Acceptance by Eligible Employee </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">By accepting an Offer in respect of Options or Rights in accordance with Rule 5.2, an Eligible Employee: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">agrees to become a Participant and be bound by these Rules; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">offers to acquire those Options or Rights, and Shares following exercise of those Options or on conversion of
those Rights (as the context requires): </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">under, and subject to, these Rules; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on and subject to the terms and conditions of the Offer; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">agrees to become a member of the Company following exercise of any Options or on conversion of any Rights, and
to be bound by the Constitution (as amended from time to time). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Acceptance by Company </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Unless otherwise provided in the Offer Document for the Offer, the Company may accept an Eligible Employee&#146;s Application in respect of an
Offer of Plan Securities by issuing to the Eligible Employee the Plan Securities the subject of the Application. Unless otherwise determined by the Board, the issue of Plan Securities to an Eligible Employee will be constituted by the registration
of the Eligible Employee as the holder of the relevant number and type of Plan Securities in a register of holders of Plan Securities maintained by or on behalf of the Company (which may, without limitation, be in electronic form and maintained by
the Company&#146;s share registrar or other third party service provider). Nothing in any Offer Document or Application, or in these Rules, will be taken to confer on any Eligible Employee any right or title to, or interest in, any Plan Securities
until the Plan Securities are issued to the Eligible Employee. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Notification of issue of Options or Rights </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Within a reasonable period after the issue of Options or Rights to a Participant, the Company must give the Participant notice in writing of:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the number of Options or Rights issued to the Participant; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Issue Price (if any) of those Options or Rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of Options, the Exercise Price (if any); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Date of Grant of those Options or Rights. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Consideration for Options and Rights </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Any Options or Rights issued to a Participant will be issued for consideration comprising the services that are expected to be provided by the
Participant to or for the benefit of the Group and, unless the Board determines otherwise, no monetary or other consideration will be payable in respect of the issue of an Option or Right. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="99%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Long term incentive plan rules | page 15</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Entitlement to Shares </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to these Rules, each Option confers on its holder the entitlement to be Allocated one Share following
exercise of the Option and payment of the Exercise Price (if any). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to these Rules, each Right confers on its holder the entitlement to be Allocated one Share.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Interest in Shares </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">A Participant: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">has no right or interest in a Share the subject of an Option or Right held by the Participant unless and until
the Share the subject of that Option or Right, as applicable, is Allocated to that Participant following the exercise of the Option or on conversion of the Right under these Rules; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">does not have any rights to dividends, rights to vote or rights to participate in any new issue of capital of
the Company as a result of holding an Option or Right. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Subject to the Corporations Act and the Constitution,
Participants will not, as holders of Options or Rights, have any right to attend or vote at general meetings of holders of Shares. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Vesting of Options or Rights </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Requirements for vesting </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Subject to these Rules: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the Offer Document for Plan Securities held by a Participant specified any Vesting Conditions and each of
the following occurs: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Board determines that the applicable Vesting Conditions have been satisfied in respect of all, or a
specified percentage or number of, those Plan Securities; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if any additional terms were specified in the Offer Document and required to be satisfied before vesting, the
Board determines that those additional terms have been satisfied or, in the Board&#146;s discretion, are not required to be satisfied, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">then all, or any specified percentage or number determined by the Board, of those Plan Securities will become vested Plan Securities on and
from the date of the Board&#146;s determination (or any later date determined by the Board); and </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the Offer Document for Plan Securities held by a Participant did not specify any Vesting Conditions, the
Plan Securities will become vested Plan Securities on and from the vesting date specified in the Offer Document (or any earlier date determined by the Board). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Vesting Notice </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If, and within a reasonable period after: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any Options held by a Participant become Vested Options; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any Rights held by a Participant become Vested Rights, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">the Company must give the Participant a Vesting Notice. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Variation or waiver of Vesting Conditions and other terms </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Subject to Applicable Law, and without limiting Rules 12, 13 and 18.1, the Board may, in its discretion and at any time and in any particular
case or cases: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="99%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Long term incentive plan rules | page 16</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reduce or waive the Vesting Conditions (if any) that apply to a Plan Security held by the Participant (in whole
or in part); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reduce the Performance Period (if any) that applies to any Plan Security held by the Participant;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of an Option, determine that a new First Exercise Date or Last Exercise Date (or both) will apply
to the Option (whether earlier or later than the original date); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of a Right, determine that a new Share Allocation Date or Share Allocation Period will apply to the
Right (whether earlier or late than the original date or period); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">do any combination of the things referred to in paragraphs (a)&nbsp;to (d) above. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Notice of variation or waiver </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If the Board exercises its discretion to alter any terms of a Plan Security under Rule 7.3 or in reliance on Rule 18.4, the Company: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">must within a reasonable period of the alteration give notice to each Participant affected by the alteration in
respect of any Options or Rights held by the Participant; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the Company issued a certificate for the Plan Security, may have to issue a replacement certificate.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Exercise of Options </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exercise during Exercise Period </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Subject to Rules&nbsp;3.2 and 8.2 and the Trading Policy, an Option held by a Participant may be exercised at any time during (and only during)
the Exercise Period for that Option. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exercise Conditions </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">An Option may not be exercised unless and until it has become a Vested Option. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exercise of Options </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Subject to these Rules, Vested Options held by a Participant may be exercised by the Participant giving to the Company: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a Notice of Exercise duly completed by the Participant; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if there is an Exercise Price for the Options: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">payment (in cleared funds) of the amount calculated by multiplying the number of Options being exercised by the
Exercise Price; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">payment, or the Participant&#146;s agreement to pay, the relevant amount under any &#145;cashless
exercise&#146; arrangement that is acceptable to, and approved by, the Board; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if a certificate was issued by the Company in respect of those Options, the relevant certificate.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Clearance of Exercise Price </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Unless the Board determines otherwise, the Company is not obliged to Allocate Shares on exercise of Options until payment of the Exercise Price
(if any) has been received by the Company in cleared funds from the Participant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="99%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Long term incentive plan rules | page 17</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exercise or conversion of all or some Options or Rights </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Participant may only exercise Options and convert Rights in multiples of 100 or another multiple that the
Board determines, unless the Participant exercises all Options or converts Rights with the same Date of Grant able to be exercised by him or her at that time or under a cashless exercise arrangement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The exercise or conversion by a Participant of only some of the Options or Rights held by the Participant does
not affect the Participant&#146;s right to exercise or convert at a later date other Options or Rights held by the Participant (whether those other Options or Rights have the same First Exercise Date or otherwise). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Replacement Certificate </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If a Participant submits a Notice of Exercise in respect of only part of the Options or Rights for which a certificate has been issued by the
Company, the Company must issue a certificate stating the remaining number of Options or Rights held by the Participant. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Allocation of Shares to satisfy Vested Options or Rights </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Requirement to allocate Shares </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to these Rules (including Rule 9.5), where any Options held by a Participant become Vested Options and
are validly exercised by the Participant in accordance with Rule 8, the Company must Allocate to the Participant the number of Shares that are the subject of the Vested Options that have been exercised, as determined in accordance with these Rules
and the Offer Document for those Options. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to these Rules (including Rule 9.5), where any Rights held by a Participant become Vested Rights, the
Company must (without the need for any action by the Participant) Allocate to the Participant the number of Shares that are the subject of those Vested Rights, as determined in accordance with these Rules and the Offer Document for those Rights. For
the purposes of these Rules, the Allocation of Shares in respect of Vested Rights constitutes the conversion of Vested Rights. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Method of allocation of Shares </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to Rule 9.2(b) and Applicable Law, any Shares to be allocated to a Participant under Rule 9.1 may, in
the Board&#146;s discretion, be allocated by the Company by any one or more of the following means: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">issuing Shares to the Participant; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">procuring the transfer to the Participant of Shares purchased <FONT STYLE="white-space:nowrap">on-market</FONT>
(within the meaning given to that term by the Corporations Act); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">procuring the transfer to the Participant of Shares acquired through an
<FONT STYLE="white-space:nowrap">off-market</FONT> transaction (including from any &#145;employee share trust&#146; within the meaning of the Tax Act that may be established by the Company for the purposes of the Plan); or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">procuring the holding of Shares by a person as bare nominee for and on behalf of the Participant.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board may determine and the Offer Document for Options or Rights may specify that any Shares to be
allocated to a Participant to satisfy those Options or Rights may: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">only be allocated by a specified method or methods under Rule 9.2(a); or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">not be allocated by a specified method or methods under Rule 9.2(a), </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">and, where so determined and specified, those Shares may (where paragraph (i)&nbsp;of this Rule applies) only be allocated to the Participant
by the specified method or methods or (where paragraph (ii)&nbsp;of this Rule applies) may not be allocated to the Participant by the specified method or methods. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="99%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Long term incentive plan rules | page 18</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Timing of allocation of Shares </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Subject to Applicable Law and the Trading Policy, any Shares to be Allocated to a Participant under Rule 9.1 must: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of Shares to be Allocated to satisfy Vested Options that have been exercised by the relevant
Participant, be Allocated within a reasonable period after the Participant exercises the Vested Options in accordance with these Rules; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of Shares to be Allocated to satisfy Vested Rights, be Allocated on (or before) any applicable
Share Allocation Date or before the end of any applicable Share Allocation Period (in each case, subject to any variation determined by the Board under Rule 7.3). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Shares rank equally </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Unless otherwise determined by the Board and specified in the Offer Document for the relevant Plan Securities, Shares Allocated to a
Participant to satisfy Plan Securities will rank equally with all existing Shares on and from the date of Allocation, including in respect of all rights issues, bonus issues and dividends that have a record date for determining entitlements on or
after the date of registration of those Shares in the name of, or on behalf of, the Participant. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Discretion to settle Vested Plan Securities in cash </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding any other provision of these Rules, and unless the Offer Document for the relevant Plan
Securities specifies that this Rule 9.5 does not apply, the Board may, in its discretion (and at any time), determine that, in lieu and satisfaction of a Participant&#146;s right to be Allocated Shares in respect of: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any or all Vested Options exercised by the Participant; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any or all Vested Rights held by the Participant, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">the Company will make, or cause to be made, a payment (in Australian dollars) to or for the benefit of the Participant of a cash equivalent
amount in respect of the Vested Options or Vested Rights the subject of the Board&#146;s determination, as calculated in accordance with Rule 9.6 or in any other manner determined by the Board and specified in the relevant Offer Document (and
subject to Rule 9.7). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Where the Board has made a determination under this Rule 9.5, the Company must make, or cause to be made, the
relevant payment to or for the benefit of the Participant by the time that Shares would otherwise have been required to be Allocated to the Participant under Rule 9.3. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any payment made to or for the benefit of a Participant in respect of any Cash-Settled Plan Securities in
accordance with the relevant determination of the Board under this Rule 9.5 constitutes full and final satisfaction of the Participant&#146;s right to otherwise be Allocated Shares in respect of those Cash-Settled Plan Securities.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Calculation of amount payable for any Cash-Settled Plan Securities </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">For the purposes of Rule 9.5(a), and subject to the Offer Document for the Cash-Settled Plan Securities, the cash equivalent amount in respect
of any Cash-Settled Plan Securities will be calculated by multiplying the number of Shares that would (but for payment in accordance with Rule 9.5) be Allocated to the Participant in respect of those Cash-Settled Plan Securities by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if Shares are quoted on ASX or another securities exchange at the time, the volume weighted average price of
Shares traded on ASX (or on the securities exchange or exchanges determined by the Board) over the 5 trading days preceding, where the Cash-Settled Plan Securities are Options, the date of exercise of the Options or, where the Cash- Settled Plan
Securities are Rights, the date on which the Rights became Vested Rights (<B>Valuation Time</B>); or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="99%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Long term incentive plan rules | page 19</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if Shares are not quoted on ASX at the time, an amount reasonably determined by the Board to be equivalent to
the value of a Share at the Valuation Time, </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">and, where the Cash-Settled Plan Securities are Options, reducing the
resulting amount by the aggregate Exercise Price (if any) for the number of Vested Options in respect of which the cash equivalent amount is to be paid. If the resulting number is a fractional number, it will be rounded down to the next lower whole
cent. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Tax withholding and superannuation contributions </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company will deduct or withhold, or cause to be deducted or withheld, from any amount paid or payable to a
Participant in respect of any Cash-Settled Plan Securities any Tax and other amounts required by law to be deducted or withheld from the payment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any amount payable to or for the benefit of a Participant in respect of any Cash-Settled Plan Securities in
accordance with the relevant determination of the Board under Rule 9.5 will be payable such that the total of: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the amount payable to the Participant (before any applicable deduction or withholding for Tax or other amounts
under 9.7(a) above); plus </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the amount of any contribution that any Group Company makes, will make or is required or has agreed to make, to
an Australian superannuation fund for the benefit of the Participant that is or will be attributable or referable to any amount paid or payable to the Participant in accordance with the Board&#146;s determination under Rule 9.5,
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">is equal to the cash equivalent amount in respect of those Cash-Settled Plan Securities determined in accordance with
Rule 9.5 (and, if applicable, Rule 9.6). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purposes of Rule 9.7(b) (and without limitation), a Group Company will be taken to be required to make
a contribution if it is required to make the contribution in order to ensure that it will have no liability or potential liability to pay any superannuation guarantee charge (as defined in the <I>Superannuation Guarantee (Administration) Act
1992</I> (Cth)) in respect of the amount paid or payable to the relevant Participant in respect of the relevant Cash-Settled Plan Securities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the maximum extent permitted by law, in no event will the amount payable to a Participant under Rule 9.5 be
included in any definition of pensionable or other earnings or salary (however defined) for the purpose of calculating any contributions payable to any Australian superannuation fund for the benefit of the Participant. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lapse of Options and Rights </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Lapse of Plan Securities where Vesting Conditions not satisfied </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Board determines that the Vesting Conditions (if any) applicable to all or a specified number or
percentage of the Plan Securities held by a Participant have not been satisfied and should therefore lapse, all or the relevant percentage or number (as the context requires) of those Plan Securities will lapse with effect from the date on which the
Board makes this determination (or, if the Board specifies a later lapse date when making this determination, on that later date). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Board determines that the Vesting Conditions (if any) applicable to all or a specified number or
percentage of the Plan Securities held by a Participant are not capable of being satisfied in accordance with their terms and should therefore lapse, all or the relevant number or percentage (as the context requires) of those Plan Securities will
lapse with effect from the date on which the Board makes this determination (or, if the Board specifies a later lapse date when making this determination, on that later date). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="99%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Long term incentive plan rules | page 20</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Lapse of Plan Securities on cessation of employment in certain circumstances </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the terms specified in the Offer Document for the relevant Plan Securities and unless otherwise
determined by the Board (at any time and whether before of after cessation of employment), all Unvested Plan Securities held by a Participant will lapse: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the Participant ceases to be employed within the Group due to his or her Termination for Cause, with effect
from the Cessation Date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the Participant ceases to be employed within the Group due to his or her Resignation, with effect from the
Cessation Date; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the Participant ceases, or will cease, to be employed within the Group in any circumstances not covered by
paragraphs (i)&nbsp;or (ii) above and the Board determines that, in those particular circumstances, all of the Participant&#146;s Unvested Plan Securities should lapse (for example, because the circumstances involve the Participant&#146;s poor or
inadequate performance), with effect from the Cessation Date or any earlier or later lapse date determined by the Board. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless otherwise determined by the Board, if: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a Participant ceases to be employed within the Group for any reason or in any circumstances;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Participant holds Unvested Plan Securities that have not lapsed under Rule 10.2(a)(i) or (ii)&nbsp;and the
Board has not determined that all of those Unvested Plan Securities should lapse under Rule 10.2(a)(iii); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Offer Document for those Unvested Plan Securities specified that this Rule 10.2(b) applies or the Board
otherwise determines that this Rule 10.2(b) applies, </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">then a proportion of the Participant&#146;s Unvested Plan
Securities will lapse with effect from the Cessation Date, being the proportion determined in accordance with Rule 10.2(c) (and rounded to the next higher whole number). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Where Rule 10.2(b) applies, unless otherwise determined by the Board, the proportion of Unvested Plan
Securities held by a Participant that will lapse under that Rule will be: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">subject to paragraph (ii), equal to the proportion that the number of days in the period starting on the day
after the Participant&#146;s Cessation Date and ending on the last day of the Performance Period applicable to those Plan Securities (or, if no Performance Period applies to those Plan Securities, ending on the date specified in Rule 7.1(b)) bears
to the total number of days in the Performance Period (or, if no Performance Period applies to those Plan Securities, to the total number of days between the Date of Grant and the date specified in Rule 7.1(b)); or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the Offer Document for those Plan Securities specified that the proportion was to be determined on a
different basis to that set out in Rule 10.2(c)(i), the proportion determined in the manner specified in the relevant Offer Document. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any Plan Securities held by a Participant that do not lapse by operation of this Rule 10.2 or determination of
the Board as a result of the Participant ceasing to be employed within the Group will continue to be held by the Participant subject to these Rules and the terms and conditions set out in the Offer for those Plan Securities. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="99%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Long term incentive plan rules | page 21</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purposes of these Rules (and any Offer Document), a Participant <B>ceases to be employed within the
Group</B> if and when<B> </B>the Participant is no longer employed by, and no longer holds any other office with, any body corporate within the Group. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Lapse of Plan Securities to prevent inappropriate benefits </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Subject to the terms specified in the Offer Document for the relevant Plan Securities and unless otherwise determined by the Board (at any
time), some or all of any Unvested Plan Securities that have not otherwise lapsed under this Rule 10, or Vested Plan Securities (or both), held by a Participant will lapse: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if, and with effect from the date on which, the Board determines that the relevant Plan Securities should lapse
because, in the Board&#146;s opinion, the Participant: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">has been, or could be, dismissed or removed from his or her employment in the Group for a reason that entitles
a Group Company to dismiss the Participant without notice; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">has committed an act of fraud, misappropriation or serious misconduct in relation to the affairs of the Group
or any Group Company (whether or not charged with an offence); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">has done an act which brings the Group or any Group Company into disrepute or causes material damage to any
Group Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">has been convicted on indictment of an offence against the Corporations Act in connection with the affairs of
the Company or any Group Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">has had a judgement entered against him or her in civil proceedings in respect of the contravention by the
Participant of his or her duties at law, in equity or under statute in his or her capacity as an executive or Director of the Company or any other Group Company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">has materially breached his or her obligations to any Group Company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">has performed below expectations or requirements (whether or not any performance-based Vesting Conditions have
been or are likely to be met); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">has materially breached any policy of the Company (including, without limitation, the Trading Policy or the
Company&#146;s policy (if any) on the hedging of long term incentives) or of any Group Company; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ix)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">has dealt with the Options or Rights in breach of the Rules; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of Unvested Plan Securities, on the happening of any other circumstance determined by the Board and
specified in the Offer Document for those Plan Securities as a circumstance that will cause an Unvested Plan Security to lapse; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of Vested Plan Securities, on the happening of any other circumstance determined by the Board and
specified in the Offer Document for those Plan Securities as a circumstance that will cause an Vested Plan Security to lapse; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if, in the opinion of the Board, the Plan Securities are liable to clawback under any Clawback Policy.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Lapse of Plan Securities where a Corporate Control Event occurs </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If the Board makes a determination under Rule 13.1(c) that any Plan Securities held by a Participant will lapse, those Plan Securities will
lapse on the date determined by the Board under that Rule 13.1(c). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="99%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Long term incentive plan rules | page 22</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Lapse of Options on Last Exercise Date </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If a Participant fails to exercise any Vested Options by the Last Exercise Date, those Options will lapse on the Last Exercise Date. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Timing of lapse </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">A Plan Security held by a Participant will lapse upon the earliest to occur of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Plan Security lapsing under any of Rules 10.1, 10.2, 10.3, 10.4 or 10.5; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the date that is seven years after the Date of Grant for the Plan Security or any other date nominated as the
expiry date in the Offer Document. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Entitlements and rights cease </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">On the lapse of a Plan Security under this Rule&nbsp;10, all rights of a Participant in respect of the Plan Security under the Plan cease and
no compensation will be payable to the Participant for the lapse of the Plan Security. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dealings with Options and Rights </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Options and Rights personal </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Except where Options or Rights have been transferred under Rule&nbsp;11.3, Options and Rights held by a Participant are personal to the
Participant and, in the case of Options, may not be exercised by another person. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No unauthorised disposal </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Except as permitted under Rule&nbsp;11.3, a Participant must not dispose of or grant a Security Interest over, or otherwise engage in any
Dealing with, an Option or Right or any interest in an Option or Right, and any Security Interest or disposal or dealing granted or undertaken contrary to this Rule is not recognised in any manner by the Company. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Permitted transfer of Options and Rights </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Board may determine that Options or Rights may be transferred, by an instrument of transfer, where the transfer would be: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a transfer constituting the necessary transfer documents following an acceptance of an offer made under an <FONT
STYLE="white-space:nowrap">off-market</FONT> bid made under Chapter 6 of the Corporations Act relating to Options or Rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a transfer to a bidder on the sale of the Options or Rights under Division 3 of Part 6A.1 of the Corporations
Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a transfer to a 100% holder on the sale of the Options or Rights under Division 2 of Part 6A.2 of the
Corporations Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a transfer under Part 6A.3 of the Corporations Act to a person entitled to acquire the Options or Rights under
section 661A or 664A of the Corporations Act; or<I> </I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a transfer approved by the Board in any other circumstances as may be determined by the Board.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Board must notify Participants if a circumstance set out in this Rule 11.3 occurs and the Board authorises transfer
of Options or Rights pursuant to this Rule. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="99%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Long term incentive plan rules | page 23</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Participation rights, bonus issues, rights issues, reorganisations of capital and winding up
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>12.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Application of this Rule </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">This Rule 12 only applies to Participants who hold Options or Rights that have not lapsed in accordance with the Rules. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>12.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>New issues </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">A Participant is not entitled to participate in any new issue to existing holders of securities in the Company by virtue of holding an Option
or Right unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of an Option, the Option has become a Vested Option and been validly exercised by the Participant;
or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of a Right, the Right has become a Vested Right and been converted, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">and a Share has been issued or transferred to, and registered in the name of, the Participant (in satisfaction of the Option or Right) before
the record date for the determination of entitlements to the new issue of securities (in which case, the Participant will participate in the new issue as a result of being the holder of the Share). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Company will give Participants, in accordance with the Listing Rules, notice of any new issue of securities before the record date for
determining entitlements to the new issue. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>12.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Bonus issues </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If the Company makes a bonus issue of Shares or other securities to existing holders of Shares (other than an issue in lieu or in satisfaction
of dividends or by way of dividend reinvestment) and no Share has been Allocated in respect of an Option or Right held by a Participant before the record date for determining entitlements to the bonus issue, then: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the number of Shares to which the Participant is entitled on exercise of the Option or conversion of the Right
(as applicable) will be increased by the number of Shares that the Participant would have received if the Participant had exercised the Option or the Right had converted (as applicable) and acquired the underlying Share prior to such record date;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of an Option, no change will be made to the Exercise Price (if any). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>12.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">Pro-rata</FONT> issues </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If the Company makes a <FONT STYLE="white-space:nowrap">pro-rata</FONT> issue of Shares to existing holders of Shares (other than a bonus
issue, or an issue in lieu or in satisfaction of dividends or by way of dividend reinvestment) and no Share has been Allocated in respect of an Option or Right before the record date for determining entitlements to the issue, then: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of an Option, the Exercise Price (if any) of the Option will be reduced in accordance with the
relevant formula set out in the Listing Rules applying to options at the time of the <FONT STYLE="white-space:nowrap">pro-rata</FONT> issue, and there will be no change to the number of Shares to which the relevant Participant is entitled on
exercise of the Option; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of a Right, but subject to Rule 18.3, the Board may determine, in its discretion, whether any
adjustment will be made to the terms of the Right (including, without limitation, whether or not there will be any resulting increase in the number of Shares to which the relevant Participant will be entitled on conversion of the Right and the
manner in which any such increase will be calculated). </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><I>Note: At the time of adoption of these Rules, the relevant
formula for reduction of the Exercise Price (if any) of Options in the event of a <FONT STYLE="white-space:nowrap">pro-rata</FONT> issue is set out in rule 6.22.2 of the Listing Rules. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="99%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Long term incentive plan rules | page 24</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>12.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Reorganisation of capital </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If, prior to the Allocation of Shares to a Participant in respect of Options or Rights held by the Participant, there is a reorganisation of
capital of the Company (including a consolidation, subdivision, reduction or return of capital), then the rights of each Participant (including, where applicable, the number of Options or Rights (or both), and the Exercise Price (if any) of any
Options, held by the Participant) will be amended to the extent necessary to comply with the ASX Listing Rules applying to a reorganisation of capital at the time of the reorganisation (whether or not the ASX Listing Rules apply to the Company at
the time and, in the case of Rights, on the same basis as required by the ASX Listing Rules applying to Options). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>12.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Winding up </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If, while a Participant holds Options or Rights, a resolution for a members&#146; voluntary winding up of the Company is proposed (other than
for the purpose of a reconstruction or amalgamation) the Board may, in its discretion: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of Options, give written notice to the Participant of the proposed resolution, in which case,
subject to the applicable Vesting Conditions (if any) being satisfied (or waived by the Board), the Participant may, during the period referred to in the notice, exercise the Option provided that no Option will be capable of exercise later than the
Last Exercise Date; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of Rights, determine that the Rights are Vested Rights and that on conversion, Shares will be
Allocated in respect of the Rights on a date specified by the Board and notified to the Participant. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>12.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Rounding </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">For the purposes of this Rule&nbsp;12, if Options are exercised simultaneously or Rights are converted simultaneously, then the number of
Shares or fractions of Shares that the Participant is entitled to be Allocated in respect of those Options or Rights may be aggregated and, in the case of Options with an Exercise Price, the Exercise Price payable by the Participant in respect of
those Options may be aggregated. Fractions in the aggregate number or amount will be dealt with as follows (unless otherwise required by the Listing Rules): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">fractions in the aggregate number of Shares that the Participant is entitled to be Allocated on such exercise
or conversion will be rounded down to the next lower whole number; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">fractions in the aggregate Exercise Price of Options payable by the Participant on exercise of those Options
will be rounded up to the next higher whole cent. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>12.8</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Calculations and adjustments </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Any calculations or adjustments which are required to be made under this Rule&nbsp;12 will be made by the Board and, in the absence of manifest
error, are final and conclusive and binding on the Company and each Participant. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>12.9</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Notice of change </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Company must, within a reasonable period, give to each Participant notice of any change under Rule&nbsp;12 to the Exercise Price (if any)
of any Options held by a Participant or to the number of Shares that the Participant is entitled to be Allocated following exercise of an Option or conversion of a Right. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="99%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Long term incentive plan rules | page 25</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Corporate Control Events </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>13.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Treatment of Plan Securities on a Corporate Control Event </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Subject to Rule 13.4 and Applicable Law, and without limiting Rule 7.3, the Board may, in its discretion, determine that, where a Corporate
Control Event has occurred or occurs in the future, any one or more of the following things will occur: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all or a specified proportion of any Unvested Rights then held by a Participant will be taken to have become
vested Plan Rights (and that any Vesting Conditions applicable to those Unvested Rights that have not been, or are not then capable of being, satisfied will be waived), on a date determined by the Board, and that the Share Allocation Date or Share
Allocation Period for those Rights will be brought forward to an earlier date or period determined by the Board; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all or a specified proportion of any Unvested Options then held by a Participant will be taken to have become
vested Options (and that any Vesting Conditions applicable to those Unvested Rights that have not been, or are not then capable of being, satisfied will be waived), on a date determined by the Board, and that the First Exercise Date or Last Exercise
Date (or both) for those Options will be brought forward to an earlier date or dates determined by the Board; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the Board has determined under paragraph (a)&nbsp;or (b) above that a specified proportion of any Unvested
Rights or Unvested Options then held by a Participant will be taken to have become vested Rights or Options (as the context requires), the balance of those Unvested Rights or Options will lapse on a date determined by the Board (or otherwise remain
on foot); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the First Exercise Date or Last Exercise Date (or both) for any Vested Options then held by a Participant will
be brought forward to an earlier date determined by the Board; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Share Allocation Date or Share Allocation Period for any Vested Rights held by a Participant will be
brought forward to an earlier date or period determined by the Board. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>13.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Board determinations under Rule 13.1 </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Without limiting Rule 13.1, the Board may make a determination under Rule 13.1: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at any time (including before an Offer is made and Plan Securities are issued to an Eligible Employee, or at
any other time before (or at any time after) a Corporate Control Event occurs); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in respect of any one or more particular Eligible Employees or Participants, or class of Eligible Employees or
Participants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in respect of any particular type or types of Plan Securities; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in respect of any particular Corporate Control Event, or any specified class or classes of Corporate Control
Event (including any Corporate Control Events that satisfy any requirements or conditions determined by the Board). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>13.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Board determination as to pro rata vesting </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">In making any determination under Rule 13.1 as to a specified proportion of any Unvested Plan Securities that will be taken to become Vested
Plan Securities, the Board may (without limitation) have regard to either or both of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the proportion of the Performance Period applicable to those Unvested Plan Securities (or, if no Performance
Period applies to the Unvested Plan Securities, the proportion of the period from the Date of Grant of those Plan Securities to the date specified in Rule 7.1(b)) that has, or will have, elapsed when the relevant Corporate Control Event occurs (or
by any later date determined by the Board); and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="99%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Long term incentive plan rules | page 26</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the extent to which any performance-based Vesting Conditions would be satisfied if they were measured and
applied by reference to performance against those performance conditions up to, or at the time of, the relevant Corporate Control Event or Board determination, and expectations of future performance against those conditions. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>13.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Terms of Offer prevail </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If the Board makes a determination under Rule 13.1 before an Offer of Plan Securities is made to an Eligible Employee, details of that
determination must be included in the Offer Document for that Offer and the treatment of those Plan Securities where a Corporate Control Event occurs will be determined in accordance with that determination to the extent that it is applicable in
relation to the particular Corporate Control Event, but that determination will not otherwise be taken to limit the Board&#146;s powers under Rule 13.1. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Restriction on disposal of Shares acquired pursuant to exercise of Options or conversion of Rights
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>14.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Restricted Shares </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">This Rule&nbsp;14 applies to Shares Allocated to a Participant pursuant to exercise of Options or conversion of Rights (as applicable) if the
Offer Document for those Options or Rights specified that any Shares so Allocated would be subject to restrictions on disposal under this Rule 13 and the period for which these restrictions would apply (<B>Restriction Period</B>). Any Shares to
which this Rule&nbsp;13 applies are <B>Restricted Shares</B> for the purposes of this Rule. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>14.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No disposal during Restriction Period </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">A holder of Restricted Shares must not dispose of or engage in any other Dealing with any of those Restricted Shares, or any interest in those
Restricted Shares, for the duration of the Restriction Period. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>14.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Refusal to register transfer </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the Listing Rules, the Company must refuse to register a paper-based transfer, and must apply or
cause to be applied a Holding Lock to prevent a transfer, of any Restricted Shares, and the Company may take any other steps that it considers necessary or appropriate to enforce and give effect to the disposal restrictions under this Rule 13.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Participant: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">irrevocably authorises the Company to apply a Holding Lock to any Restricted Shares held by that Participant;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">undertakes not to request the removal of the Holding Lock (or permit or authorise another person to do so),
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">while those Restricted Shares are subject to restriction on disposal under this Rule&nbsp;13. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>14.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Release of Holding Lock </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">On the expiry of any applicable Restriction Period, the Company must, as soon as reasonably practicable, lift the Holding Lock in respect of
the relevant Shares and must notify the holder of the Shares that the Holding Lock has been lifted. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>14.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Notification upon request by Participant </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Company must, if requested, notify the holder of the Shares of the particular date on which when the Holding Lock was lifted under
Rule&nbsp;14.4. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="99%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Long term incentive plan rules | page 27</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Quotation of Options or Rights </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>15.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No Quotation of Options or Rights </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Company will not seek official quotation of any Options or Rights. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>15.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Quotation of Shares </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Company must, to the extent required by Listing Rule 2.4, apply to ASX for quotation of any Shares issued: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">following exercise of Options; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on conversion of Rights, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">if Shares are officially quoted by ASX at that time. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">16.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Power of Attorney </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>16.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Appointment of Attorney </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">By accepting an Offer for Plan Securities and agreeing to become a Participant and be bound by the Plan Rules, the relevant Participant
irrevocably appoints the Company, each company secretary of the Company from time to time and any other person nominated from time to time by the Company (each an <B>Attorney</B>), severally, as the Participant&#146;s attorney, to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">do all acts, matters and things (including executing any instrument of transfer or other document) that the
Attorney considers necessary or desirable to Allocate Shares to the Participant in respect of any Vested Options that have been exercised by the Participant or any Vested Rights held by the Participant, including all acts, matters and things to be
done in order that Shares may be acquired by and registered in the name of the Participant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">do all acts, matters and things (including executing any instrument of transfer or other document) to exercise
and give effect to the power of sale referred to in Rule 17.7(b); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">appoint an agent to do any of the things referred to in paragraphs (a)&nbsp;and (b) above.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">This power of attorney is given by each Participant for valuable consideration. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>16.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Ratification of Actions </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Participant will confirm and ratify everything which an Attorney may do pursuant to any power set out in Rule 16.1 and no person dealing
with the Attorney shall be bound or concerned to enquire as to the occasion for or the regularity of the exercise of any such power. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>16.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Indemnity </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Participant will indemnify and keep indemnified the Attorney against all losses, liabilities, costs, expenses, proceedings, claims,
actions, demands, and damages in consequence of or arising out of the exercise by the Attorney of any of the powers granted under this<B> </B>Rule 16. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Administration </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Plan is administered by the Board. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>17.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Powers of the Board </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Board has power to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">exercise all powers and discretions vested in it under these Rules; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">determine appropriate procedures and make regulations and guidelines for the administration and operation of
the Plan that are not inconsistent with these Rules; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="99%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Long term incentive plan rules | page 28</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">resolve conclusively all questions of fact or interpretation arising in connection with the Plan;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">terminate or suspend the operation of the Plan at any time, provided that the termination or suspension does
not adversely affect or prejudice the rights of Participants holding Options, Rights or Restricted Shares at that time or contravene any Applicable Law; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">take and rely on independent professional or expert advice in or in relation to the exercise of any of their
powers or discretions under these Rules; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">appoint a trustee to acquire and hold Shares on behalf of Participants or otherwise for the purposes of the
Plan; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">administer the Plan in accordance with these Rules as and to the extent provided in these Rules.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>17.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Delegation </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Board and the Company may each delegate any functions, powers and discretions conferred on it under these Rules or under any Offer Document
(including this power to delegate) to any committee, person or persons it considers appropriate, for such period and on such conditions as it thinks fit. Without limiting the generality of this Rule, the Board or the Company (as the case may be) may
appoint, and delegate some or all of the responsibilities of administration of the Plan, to a third party provider of employee share plan administration services. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>17.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exercise of powers or discretion </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Any power or discretion which is conferred on the Board by these Rules may be exercised by the Board in the interests or for the benefit of the
Company, and the Board is not, in exercising that power or discretion, under any fiduciary or other obligation to another person, including a Participant. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>17.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Determinations </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Where these Rules provide for a determination, decision, approval or opinion of the Board, that determination,
decision, approval or opinion may be made or given by the Board in its absolute discretion. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Where these Rules refer to an opinion or state of mind (however described) of a group of persons (including the
Board), the group of persons will be taken to have that opinion or state of mind if persons constituting a majority of the group each have that opinion or state of mind. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the absence of manifest error, any determination, decision, approval or opinion of the Board as to the
interpretation, effect or application of the Rules will be final. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any calculations that are required to be made under these Rules or the terms and conditions applicable to any
Plan Security will be made by the Board and, in the absence of manifest error, will be final. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>17.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Expenses and costs </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Subject to these Rules, the Group must pay all expenses, costs and charges incurred in the administration of the Plan (excluding any costs
incurred by a Participant&#146;s disposal of Shares). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>17.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Board members not liable </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">To the extent permitted by law, no member of the Board (including delegates and <FONT STYLE="white-space:nowrap">sub-delegates</FONT> of the
Board) shall be liable for anything done, or omitted to be done by him or her or by any other member of the Board in connection with the Plan, except for his or her own wilful misconduct or as expressly provided by law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="99%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Long term incentive plan rules | page 29</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>17.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Participants responsible for Tax in respect of Options, Rights and Shares </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No Group Company is responsible for any Tax which may become payable by a Participant in connection with the
issue, acquisition or disposal of Options, Rights, or Shares Allocated to the Participant pursuant to the exercise of Options or conversion of Rights, or any other dealing by a Participant with Options, Rights or Shares. For the avoidance of doubt,
this does not prevent a Group Company from complying with any obligation to deduct or withhold Tax and any other amounts required by law to be deducted or withheld from any payments made to a Participant in respect of any Cash-Settled Plan
Securities in accordance with a determination of the Board under Rule 9.5. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Company or any other Group Company becomes liable to pay any &#145;TFN withholding tax (ESS)&#146;
pursuant to <FONT STYLE="white-space:nowrap">Section&nbsp;14-155</FONT> of Schedule 1 to the <I>Taxation Administration Act 1953</I> (Cth), or any other Taxes in respect of a Participant&#146;s Options, Rights or Shares Allocated to the Participant
pursuant to the exercise of Options or conversion of Rights, the Company will, in addition to any rights afforded to it or any other Group Company by the <I>Taxation Administration Act 1953</I> (Cth) or any other legislation or by law and failing
any arrangement satisfactory to the Company being entered into with the Participant to meet or reimburse the Company or any Group Company for any such Tax liability, be entitled to sell all or any of the Shares acquired by the Participant under this
Plan for and on behalf of, and as attorney for, the Participant and to apply the proceeds firstly in and towards meeting or reimbursing the Company or any Group Company for such Tax liability and to pay any balance to the Participant. This Rule
17.7(b) does not apply to any obligations to deduct or withhold Tax and any other amounts required by law to be deducted or withheld from any payments made to a Participant in respect of any Cash-Settled Plan Securities in accordance with a
determination of the Board under Rule 9.5. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amendment to Rules </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>18.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Board may amend Rules </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Subject to the Listing Rules and Rule 18.3, the Board may, in its discretion, at any time: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">amend or add to any of these Rules (or the terms and conditions of any Plan Security issued under the Plan); or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">waive or modify the application of any of these Rules (or the terms and conditions of any Plan Security issued
under the Plan) in relation to any Participant or class of Participants. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Any amendment may be given such retrospective
effect as the Board may determine from time to time. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>18.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Waiver or amendment </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Neither the Board nor the Company will be taken to have waived any provision of, or any right or entitlement under, these Rules, or agreed to
any amendment of or addition to the Rules, unless it does so expressly in writing and provided further that any waiver or amendment of, or addition to, these Rules (or of any right or other entitlement under these Rules) is permitted by the Listing
Rules. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>18.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Consent of Participants required </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Subject to Rule 18.4, if an amendment or addition proposed to be made under Rule&nbsp;18.1 would in the opinion of the Board materially
adversely affect the existing rights of Participants in respect of any Plan Securities then held by them, the Board must obtain the consent of Participants who between them hold not less than 75% of the total number of the particular Plan Securities
in respect of which Participants&#146; rights would be adversely affected by the proposed amendment, before making the amendment or addition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="99%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Long term incentive plan rules | page 30</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>18.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exceptions to requirements of Rule 18.4 </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Rule 18.3 does not apply to any amendment or addition proposed under Rule&nbsp;18.1 that the Board considers necessary or desirable: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to correct a manifest error or mistake; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for the primary purpose of ensuring that the maintenance, administration and operation of the Plan (including
the making of Offers, issue and vesting of Plan Securities, exercise of Options, conversion of Rights and Allocation and release of Shares) complies with present and future Applicable Law (having regard to any changes or proposed changes in
Applicable Law); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">having regard to any possible adverse taxation implications, or the conditions for maintaining or obtaining any
concessional taxation treatment, for any Group Company or Participants in connection with the administration or operation of, or participation in, the Plan, including as a result of: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any changes to the Tax Act<I> </I>or any other applicable taxation legislation (including an official
announcement by the Commonwealth of Australia); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the issue of any public or private rulings, determinations, interpretative decisions, circulars, decision
impact statements, or other statements by the Commissioner of Taxation or any other person or authority administering applicable taxation legislation; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">changes in the interpretation of any applicable taxation legislation by a court of competent jurisdiction.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>18.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exercise of discretions under Rules </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">To avoid doubt, the exercise by the Board of a discretion or power conferred or specifically contemplated by any other provision of these Rules
or the terms of an Offer will not constitute an amendment under Rule&nbsp;18.1. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>18.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Eligible Employees outside Australia </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Board may make any additions, variations or modifications to the Rules it thinks necessary or desirable in relation to the implementation
of the Plan, and the specific application of the Rules, to Eligible Employees residing outside Australia. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">19.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Rights of Participants </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">These Rules: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">do not confer on any Participant any right or entitlement if that right or entitlement could only be provided
with approval of the Company&#146;s shareholders and that approval has not been obtained; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">do not confer on any Employee the right to receive any Offer, Options or Rights, nor any basis for expecting
that the Eligible Employee will receive any of those things; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">do not confer on any Eligible Employee the right to continue as an Employee; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">do not form part of or constitute any variation to, and are not incorporated into, any contract with any
Participant (whether or not they are an Employee); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">do not affect any rights which the Company or an Associated Body Corporate may have to terminate the employment
of an Eligible Employee; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">may not be used to increase damages in an action brought against the Company or an Associated Body Corporate in
any circumstances, including in respect of the termination of employment of an Eligible Employee. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="99%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Long term incentive plan rules | page 31</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No representation as to Tax consequences </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">None of the Company, any other Group Company, any representative of or adviser to a Group Company, or the Board: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">represents or warrants that the Plan will have any particular taxation or financial consequences or that any
Eligible Employee or Participant will gain any taxation or financial advantage by participating in the Plan; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">are liable for any Taxes imposed upon or duties assessed against a Participant as a consequence of the
Participant&#146;s participation in the Plan, the receipt by the Participant of Options, Rights or Shares under the Plan or other Dealing in Options, Rights or Shares by the Participant. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">21.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notices </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>21.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Service of notices </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">A notice, document, consent, approval or communication under the Rules (<B>Notice</B>) is validly given if it is: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">hand delivered to the intended recipient; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">sent by prepaid post or facsimile to the intended recipient&#146;s address for Notices specified in Rule
21.3&cedil;as varied by any Notice given by the recipient to the sender; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of a Notice to be given to an Eligible Employee or a Participant, sent or notified by electronic
means (including, without limitation, by electronic notification that the Notice may be accessed using electronic means specified in the notification) to the person&#146;s last known electronic address shown in the records of any Group Company, as
varied by any Notice received by the Company (or, in the case of an Eligible Employee, any other Group Company that employs the Eligible Employee) from that person; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">given in any other manner that the Board from time to time determines. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>21.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Effective on receipt </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">A Notice given in accordance with Rule 21.1<B> </B>takes effect when taken to be received (or at a later time specified in it), and is taken to
be received: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if hand delivered, on delivery; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if sent by prepaid post, two Business Days after the date of posting (or seven Business Days after the date of
posting if posted to or from a place outside Australia); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if sent by facsimile, when the sender&#146;s facsimile system generates a message confirming successful
transmission of the entire Notice unless, within eight Business Hours after the transmission, the recipient informs the sender that it has not received the entire Notice; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if sent or notified by electronic means, on the day on which it is sent or notified, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">but if the delivery, receipt or transmission is not on a Business Day or is after 5.00pm on a Business Day, the Notice is taken to be received
at 9.00am (addressee&#146;s time) on the next Business Day. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="99%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Long term incentive plan rules | page 32</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>21.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Address </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The address of an Eligible Employee and the Company for the purposes of giving a Notice is: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of the Company, at the address of its registered office from time to time, which at the date of
adoption of this Plan is Level&nbsp;0403, 650 Chapel Street, South Yarra, Victoria, 3141; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of the Eligible Employee, the address of the Eligible Employee as specified in the employment
records of the Group Company that employs the Eligible Employee. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">22.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Governing law </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">These Rules and the rights and obligations of Participants under the Plan are governed by the laws of Victoria, Australia, and each Participant
irrevocably and unconditionally submits to the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> jurisdiction of the courts of Victoria, Australia. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">23.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Advice </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Eligible Employees and Participants should obtain their own independent advice at their own expense on the financial, taxation and other
consequences to them of, or relating to, participation in the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="99%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Long term incentive plan rules | page 33</TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>9
<FILENAME>filename9.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.6</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.6 </B></P> <P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="57%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:24pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Opthea Limited</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2" STYLE="BORDER-LEFT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">ACN 006 340 567</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2" STYLE="BORDER-LEFT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors Share and Option Plan Rules</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors Share and Option Plan Rules</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>1.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Introduction</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name of Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Objects of Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commencement of Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Defined terms and interpretation</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Defined terms</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interpretation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Primary instruments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>3.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Principal conditions</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares or Options issued only to Eligible Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compliance with laws</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No prohibited financial assistance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eligible Director participation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>4.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Operation of the Plan</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Offers</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Board may make Offer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of Offer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Information contained in Offer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of Shares or Options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issue Price and Exercise Price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Terms</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise Price and Issue Price in Australian dollars</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offer personal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">In lieu of cash remuneration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>6.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Application for Shares and Options</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>11</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acceptance of Offer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Application for all or some of Shares or Options the subject of an Offer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lapse of Offer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Withdrawal of Offer prior to acceptance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>7.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Issue of Shares</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acceptance by Eligible Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acceptance by Company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares to rank equally</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ASX Quotation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>8.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Vesting conditions</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compliance by Participant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Refusal to register transfer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retention of Holding Statements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting Conditions to apply to Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Waiver</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Permitted transfer of Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate Control Event</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">1</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Non-Executive Directors share and option plan rules</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares cease to be subject to Vesting Conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notification upon request by Participant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>9.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Forfeiture of Shares</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeiture of Shares to which Vesting Conditions attach</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Treatment of Forfeited Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of forfeiture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conditions on forfeiture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>10.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Power of Attorney</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>15</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Appointment of Attorney</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ratification of Actions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indemnity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>11.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Voting rights</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>16</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>12.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Bonus issues</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>16</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>13.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Capital reconstructions</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>16</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>14.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Issue of Options</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>16</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acceptance by Eligible Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acceptance by Company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Certificates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consideration for Options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entitlement to underlying Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest in Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>15.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Exercise of Options</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>17</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise during Exercise Period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise before Exercise Period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Exercise Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise Conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Waiver of Exercise Conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of Options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Participant agrees to be bound</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issue of Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clearance of Exercise Price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise all or some Options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.11</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Replacement Certificate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.12</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares rank equally</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>16.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Lapse of Options</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>19</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lapse of Options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rights cease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>17.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Dealings with Options</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>19</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options personal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No unauthorised disposal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Permitted transfer of Options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate Control Event</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Exercise Date brought forward</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notice to Participants of change</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">2</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Non-Executive Directors share and option plan rules</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>18.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Participation&nbsp;rights,&nbsp;bonus&nbsp;issues,&nbsp;rights&nbsp;issues,&nbsp;reorganisations&nbsp;of&nbsp;capital&nbsp;and&nbsp;winding&nbsp;up&nbsp;in&nbsp;respect&nbsp;of&nbsp;Options</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>21</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Application of this Rule</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New issues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bonus issues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Pro-rata</FONT> issues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reorganisation of capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Winding up</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fractions of Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Calculations and adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notice of change</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>19.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Restriction on disposal of Shares acquired pursuant to exercise of Options</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>22</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">19.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">19.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No disposal whilst Shares in Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">19.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Waiver</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">19.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Refusal to register transfer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">19.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Withdrawal of Restricted Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">19.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cease to be in Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">19.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notification upon request by Participant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>20.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Shareholder approval may be required</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>23</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>21.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Quotation of Shares</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>23</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No Quotation of Options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Quotation of Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>22.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Administration</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>23</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">22.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Powers of the Board</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">22.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of powers or discretion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">22.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Determinations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">22.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expenses and costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">22.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Board not liable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>23.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Amendment to Rules</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>24</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">23.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Board or Board may amend Rules</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">23.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Waiver or amendment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">23.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consent of Participants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">23.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eligible Directors outside Australia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>24.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Rights of Participants</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>25</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">24.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No conferred rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">25.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No representation as to Tax consequences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>26.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Notices</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>25</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">26.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service of notices</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">26.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective on receipt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">26.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Address</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>27.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Governing law</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>26</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>28.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Advice</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>26</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">3</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Non-Executive Directors share and option plan rules</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opthea Limited </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors Share and Option Plan Rules </P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Introduction </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Name of Plan </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Plan is called the Opthea <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors Share and Option Plan. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Objects of Plan </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The objects of the Plan are to enable present and future <FONT STYLE="white-space:nowrap">non-executive</FONT> Directors to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">elect to receive newly issued Shares or Options in lieu of receiving some or all of their entitlement to their
Director&#146;s existing cash remuneration (in accordance with article 61.8 of the Constitution); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">be awarded newly issued Shares or Options in lieu of additional cash remuneration in respect of services
provided to the Company which in the opinion of the Board are outside the scope of ordinary duties of the relevant Director (in accordance with article 61.5 of the Constitution); and/or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">otherwise be awarded newly issued Shares or Options as part of the Directors&#146; remuneration in addition to
any existing cash remuneration paid to Directors (if any). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Commencement of Plan </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Plan commences on the date determined by the Board. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Defined terms and interpretation </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Defined terms </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">In these Rules, unless the context otherwise requires: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Accelerated Vesting Event</B> means: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the occurrence of a Special Circumstance in respect of a Participant; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Board determines under Rule 8.7 or Rule 17.4 that a Corporate Control Event constitutes an Accelerated
Vesting Event. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Applicable Law</B> means one or more, as the context requires of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Corporations Act; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Corporations Regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other applicable securities or financial services laws; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any class order, declaration, exemption or modification made by ASIC pursuant to any of the abovementioned
statutes, regulations or laws, or any waiver from the Listing Rules granted by ASX, on which the Company seeks to rely or that binds the Company in making any Offer or otherwise in connection with the operation of the Plan; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Listing Rules; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other legislation regulating or applying to the activities of the Company; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">4</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Non-Executive Directors share and option plan rules</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Constitution. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Application </B>means a duly completed and executed application for the issue of Shares or Options made by an Eligible Director in respect
of an Offer, in the form approved by the Board from time to time (which may, without limitation, be an electronic form that is accessible and submitted via a website managed by the Company, its share registry or any other third party service
provider). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>ASIC</B> means the Australian Securities and Investments Commission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>ASX </B>means ASX Limited ACN 008 624 691. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Board</B> means all or some of the directors of the Company acting as a board or its delegate under section 198D of the Corporations Act.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Business Day</B> means a day on which banks are open for general banking business in Melbourne, Victoria, excluding Saturdays or
Sundays. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Business Hours</B> means from 9.00am to 5.00pm on a Business Day. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Capital Reconstruction</B> means any of the following events: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company issues Shares by way of capitalisation of profits or reserves; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company gives shareholders the right <FONT STYLE="white-space:nowrap">(pro-rata</FONT> with existing
shareholding and on terms including the payment of some consideration by the shareholders on exercising the right) to subscribe for additional Shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company subdivides or consolidates the Shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company returns issued share capital to holders of Shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company issues or cancels Shares on a <FONT STYLE="white-space:nowrap">pro-rata</FONT> basis; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company reorganises its issued capital in any other manner that is not referred to above (other than in
lieu of dividends or by way of a dividend reinvestment). </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Certificate</B> means a certificate issued under Rule 7.4 or
14.3 in the form approved by the Board from time to time or if the Board determines that Options are uncertificated, then a statement to the Participant disclosing the information in Rule 14.3. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Company </B>means Opthea Limited ACN 006 340 567. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Constitution </B>means the constitution of the Company (as amended from time to time). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Corporate Control Event </B>means the occurrence of one or more of the following events: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an offer is made for Shares (or shares in a Subsidiary) pursuant to a takeover bid under Chapter 6 of the
<I>Corporations Act 2001</I>(Cth); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Court orders a meeting of members (or a class of members) or creditors (or a class of creditors) under Part
5.1 of the Corporations Act 2001 for the purpose of considering a proposed compromise or arrangement relating to the Company (or a Subsidiary) or a compromise or arrangement proposed for the purposes of or in connection with a scheme for the
reconstruction of the Company (or a Subsidiary) or its amalgamation with any other body corporate or bodies corporate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">approval is given by a resolution duly passed at a general meeting, or by circular resolution, of members of
the Company (or a Subsidiary) for an acquisition that would result in a person having voting power in the Company (or a Subsidiary) of more than 50%; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a person acquires voting power of more than 50% in the Company: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as a result of a takeover bid for all of the issued shares in the Company; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">5</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Non-Executive Directors share and option plan rules</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">through a scheme of arrangement relating to the acquisition of all of the issued shares of the Company;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Board determines that a change of control of the Company has occurred within the meaning of section 50AA of
the Corporations Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other event or transaction (including any other merger, consolidation or amalgamation involving the Company
(or a Subsidiary)) occurs or is proposed where either or both of the following applies: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of a merger, consolidation or arrangement, the transaction results in the holders of Shares (or
shares in a Subsidiary) immediately prior to the merger, consolidation or amalgamation having relevant interests, in aggregate, in 50% or less of the voting shares in the body corporate resulting from the merger consolidation or amalgamation; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Board determines, in its discretion, that the relevant transaction constitutes a Corporate Control Event
for the purposes of the Rules; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company (or a Subsidiary) enters into an agreement or agreements to sell, in aggregate, a majority in value
of the business or assets of all bodies corporate in the Group (whether or not in the form of shares in a body corporate in the Group) to a person or persons that are not bodies corporate in the Group; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an administrator, liquidator, provisional liquidator, receiver or receiver and manager is appointed in respect
of the Company or substantially all of the assets of the Company. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Corporations Act</B> means the <I>Corporations Act
2001 (Cth).</I> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Date of Grant</B> means, with respect to a Share or an Option, the date on which the Board grants or issues the Share
or Option to an Eligible Director. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Deal</B> or <B>Dealing</B> means sale, transfer, assignment, mortgage, pledge, grant a lien over or
otherwise alienate or encumber or attempted sale, transfer, assignment, mortgage, pledge, grant a lien over or other alienation or encumbrance or creation in favour of any third party any interest whatsoever. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Director</B> means a director of the Company (including a <FONT STYLE="white-space:nowrap">non-executive</FONT> director). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Eligible Director</B> means a Director of a body corporate in the Group (excluding a Director who holds a salaried employment or office in a
body corporate in the Group) whom the Board determines is to be issued Shares or Options under the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Exercise Conditions</B> means
the performance, vesting or other conditions (if any) determined by the Board and specified in a Certificate or Offer which are, subject to these Rules, required to be satisfied, reached or met before an Option can, during the Exercise Period, be
exercised. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Exercise Period</B> means the period commencing on the First Exercise Date and ending on the Last Exercise Date, subject to
any variation to those dates determined by the Board. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Exercise Price</B> means the amount (if any) payable by the holder of an Option
on the exercise of the Option, being the amount (or manner of determining the amount) fixed at the time of the issue of the Option and as determined under Rule&nbsp;5.5. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Final Acceptance Date </B>has the meaning given to this term under Rule 5.3(c). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>First Exercise Date</B> with respect to an Option means the date specified in an Offer (or determined under Rule 17.5(a)). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Forfeited Shares </B>means Shares the ownership of which has been or is required to be (as the case may be) forfeited under the Rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">6</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Non-Executive Directors share and option plan rules</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Grant Conditions</B> means the conditions (if any) determined by the Board and specified
in (or attached to) an Offer which are, subject to these Rules, required to be satisfied, reached or met before a Share or an Option will be granted. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Group</B> means the Company and its Subsidiaries. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Holding Lock</B> means a mechanism arranged or approved by the Board and administered by the Company (including through its share registry)
that prevents Shares being disposed of by a Participant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Holding Statement</B> means a statement issued by the share registry of the
Company detailing a Participant&#146;s holding of Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Issue Price</B> means the amount (if any) payable per Share or Option by an
Eligible Director on application for Shares or Options offered under an Offer. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Last Exercise Date</B> with respect to an Option means,
unless otherwise specified in a Certificate or Offer in respect of that Option: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the date five years after the First Exercise Date; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if a Special Circumstance arises in respect of a Participant during the period starting on the First Exercise
Date and ending on the date five years after the First Exercise Date, then the date 12 months (or longer period as may be determined by the Board) after the Special Circumstance arises. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Legal Personal Representative</B> means the executor of the will or an administrator of the estate of a deceased person, the trustee of the
estate of a person under a legal disability or a person who holds an enduring power of attorney granted by another person. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Listing
Rules</B> means the listing rules of ASX Limited and any other rules of ASX (or the applicable securities exchange) that are applicable to the Company or the Shares while the Company is listed on that exchange, each as amended or replaced from time
to time, and except to the extent of any express written waiver by ASX. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Notice of Exercise</B> means a duly completed and executed
notice of exercise of an Option by a Participant, in the form approved by the Board from time to time (which may be in electronic form and, without limitation, accessed and submitted via a website managed by the Company, its share registry or
another third party service provider). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Offer</B> means an invitation to an Eligible Director to apply for the issue of Shares or
Options pursuant to the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Option</B> means an option issued to a Participant under the Plan to subscribe for a newly issued Share.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Participant</B> means a person who accepts an Offer and holds Shares or Options issued under the Plan and includes, if a Participant
dies or becomes subject to a legal disability, the Legal Personal Representative of the Participant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Plan</B> means the Opthea Limited <FONT
STYLE="white-space:nowrap">Non-Executive</FONT> Directors Share and Option Plan governed by these Rules. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Restriction Period</B> means
the period (if any) determined by the Board and specified in an Offer as the period during which Shares acquired (either directly or upon the exercise of an Option) will be Restricted Shares and held in the Plan and subject to the restrictions on
disposal under Rule&nbsp;19.1. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Rules</B> means the rules governing the operation of the Plan set out in this document as amended from
time to time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">7</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Non-Executive Directors share and option plan rules</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Security Interest </B>means a mortgage, charge, pledge, lien, encumbrance or other third
party interest of any nature (including the registration and/or perfection of that security interest under the <I>Personal Property Securities Act 2009 </I>(Cth)). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Shares</B> means fully paid ordinary shares in the capital of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Special Circumstances</B> means with respect to a Participant: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Total and Permanent Disablement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the death of the Participant; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">retirement at 65 years of age or older; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other circumstances as the Board may at any time determine (whether in relation to the Participant, a class
of Participants, particular circumstances or a class of circumstances) and whether before or after the Date of Grant. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Subsidiary </B>means: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a body corporate of which the Company is a holding company in terms of Division 6 of Part 1.2 of the
Corporations Act) that the Board has approved for participation in the Plan; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a body corporate in which the Company has voting power of not less than 20% (determined under section 610 of
the Corporations Act 2001 ) that the Board has approved for participation in the Plan. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Tax </B>includes any tax,
levy, impost, GST, deduction, charge, rate, contribution, duty or withholding which is assessed (or deemed to be assessed), levied, imposed or made by or under any law or by any government or any governmental, semi-governmental or judicial entity or
authority together with any interest, penalty, fine, charge, fee or other amount assessed (or deemed to be assessed), levied, imposed or made on or in respect of any or all of the foregoing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Total and Permanent Disablement</B> means the termination or cessation of a Participant&#146;s office with the Company or a Subsidiary as a
result of total and permanent disablement, as determined by the Board. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Vesting Conditions</B> means, in relation to a Share, the
conditions (if any) included in the terms of the Offer under which the Share was offered, limiting the rights of the Participant holding the Share to Deal in the Share or which might result in forfeiture of the Share. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Interpretation </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">In these Rules, unless the context otherwise requires: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">headings are for convenience only and do not affect the interpretation of these Rules; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reference to any legislation or a provision of any legislation includes a modification or <FONT
STYLE="white-space:nowrap">re-enactment</FONT> of the legislation or a legislative provision substituted for, and all legislation and statutory instruments and regulations issued under, the legislation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">words denoting the singular include the plural and vice versa; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">words denoting a gender include the other genders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reference to any document or agreement includes reference to that document or agreement as amended, novated,
supplemented, varied or replaced from time to time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where any word or phrase is given a defined meaning in these Rules, any part of speech or other grammatical
form of that word or phrase has a corresponding meaning; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">8</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Non-Executive Directors share and option plan rules</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reference to a rule or paragraph is a reference to a rule or paragraph of these Rules, or the corresponding
Rule or Rules of the Plan as amended from time to time; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where an act or thing must be done on a particular day or within a particular period, that act or thing must be
done before, and that period ends at, 5.00pm Melbourne, Australia time on the relevant day. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Primary instruments </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">These Rules are to be interpreted subject to the Applicable Laws. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Principal conditions </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Shares or Options issued only to Eligible Directors </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">No Shares or Options may be issued to a person under the Plan unless the person remains an Eligible Director as at the Date of Grant, or the
Board determines otherwise. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Compliance with laws </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">No Share or Option may be issued to, or exercised by, an Eligible Director or Participant if to do so would contravene an Applicable Law (or in
the case of an Eligible Director resident outside of Australia, would contravene the local laws or customs of that Director&#146;s country of residence or in the opinion of the Board would require actions to comply with those local laws or customs
which are impracticable or unreasonable). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No prohibited financial assistance </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">No person may, whether directly or indirectly, provide financial assistance which is prohibited by the Corporations Act to an Eligible Director
for the purposes of, or in connection with, the acquisition of Shares or Options under the Plan. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Eligible Director participation </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Neither Shares nor Options may be issued to Eligible Directors pursuant to the Plan unless prior approval of the Company&#146;s shareholders is
obtained in accordance with the Listing Rules. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Operation of the Plan </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Plan operates according to these Rules which bind the Company, any Subsidiary and each Participant. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Offers </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Board may make Offer </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to these Rules the Board may from time to time make an Offer to an Eligible Director.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Offers will be in such form and content and with such terms and conditions as the Board determines from
time to time. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Where an Offer is made which will involve fee, bonus or other monetary sacrifice by a Participant, the Offer
may be made conditional on the Company and the Participant entering into an agreement (which may be constituted by the acceptance of the Offer) setting out the terms and conditions of the fee, bonus or other monetary sacrifice arrangement.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">9</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Non-Executive Directors share and option plan rules</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Form of Offer </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">An Offer must be in writing and subject to Rule&nbsp;5.3, the form of the Offer and the form of the Application accepting the invitation
constituted by the Offer must be as approved by the Board from time to time. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Information contained in Offer </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">An Offer must state: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the name and address of the Eligible Director to whom the Offer is made; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the date of the Offer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the final date that a Participant may accept the invitation constituted by the Offer (<B>Final Acceptance
Date</B>); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the maximum number of Shares or Options for which the Eligible Director may make an Application;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Grant Conditions (if any) attaching to the Shares or Options the subject of the Offer;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in respect of an Offer of Shares: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Vesting Conditions (if any) attaching to the Shares the subject of the Offer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Issue Price (if any) or the manner of determining the Issue Price (if any) of the Shares the subject of the
Offer; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in respect of an Offer of Options: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the First Exercise Date of the Options the subject of the Offer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Last Exercise Date of the Options the subject of the Offer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Exercise Price (if any) or the manner of determining the Exercise Price (if any) of the Options the subject
of the Offer; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Exercise Conditions (if any) attaching to the Options the subject of the Offer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Vesting Conditions (if any) attaching to the Shares issued upon exercise of the Options; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other specific terms and conditions applicable to the Offer. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Number of Shares or Options </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The number of Shares or Options the subject of an Offer to an Eligible Director is as determined by the Board. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Issue Price and Exercise Price </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Issue Price (if any) in respect of a Share and the Exercise Price (if any) in respect of an Option (subject to any adjustment under
Rule&nbsp;18) is as determined by the Board. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Terms </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The terms and conditions applicable to an Offer, including the Final Acceptance Date, the First Exercise Date, the Last Exercise Date, any
Grant Conditions, any Vesting Conditions, any Exercise Conditions, are as determined by the Board (in its absolute discretion). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exercise Price and Issue Price in Australian dollars </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Issue Price (if any) in respect of a Share and the Exercise Price (if any) in respect of an Option must be denominated and payable in
Australian dollars. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">10</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Non-Executive Directors share and option plan rules</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.8</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Offer personal </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">An Offer under the Plan is personal to the Eligible Director to whom it is made and, accordingly, the invitation constituted by an Offer may
only be accepted by, and Shares or Options may only be issued to, the Eligible Director to whom the Offer is made. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.9</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>In lieu of cash remuneration </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Where an Eligible Director: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">elects to receive newly issued Shares or Options in lieu of receiving some or all of his/her entitlement to
his/her Director&#146;s existing cash remuneration (<B>Election</B>) and the Board agrees with the Election; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is to awarded newly issued Shares or Options in lieu of additional cash remuneration in respect of services
provided to the Company which in the opinion of the Board are outside the scope of ordinary duties of the relevant Director, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">the Eligible Director will as a Participant be issued the number of Shares or Options that is derived by the following formula: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="57%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of Shares or Options to be issued =<U></U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>A</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">B</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">where </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of an Election, A is equal to the dollar value nominated by the Participant; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in all other cases, A is equal to the dollar value of the award to be granted to the Participant (such dollar
value to be determined by the Board in its absolute discretion); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">B is the by reference to the volume weighted average price of ordinary shares quoted on the ASX on the 5
trading days preceding the date of determination of the award by the Board. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Application for Shares and Options </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Acceptance of Offer </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">An Eligible Director may accept the invitation constituted by an Offer by giving to the Company an Application (and in the case of an Offer for
Shares or Options that have an Issue Price, a cheque for the relevant amount) by the Final Acceptance Date. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Application for all or some of Shares or Options the subject of an Offer </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">An Eligible Director may in his or her discretion accept the invitation constituted by an Offer, in whole or in part, in multiples of 100
Shares or Options or another multiple of Shares or Options as the Board may allow for the Eligible Director. An Eligible Director cannot accept less than the number of Shares or Options that would constitute the minimum parcel determined by the
Board. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Lapse of Offer </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">An Offer not accepted in accordance with Rule&nbsp;6.1 will lapse at 5:00pm Melbourne time on the Final Acceptance Date. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Withdrawal of Offer prior to acceptance </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Board reserves the right (subject to any Applicable Law) to withdraw an Offer made to an Eligible Director, provided that Offer has not yet
been accepted in accordance with Rule 6.1. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">11</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Non-Executive Directors share and option plan rules</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Issue of Shares </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Acceptance by Eligible Director </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">By accepting an Offer for Shares in accordance with Rule 6.1, the Eligible Director will be taken to have: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">agreed to become a Shareholder and be bound by the Constitution; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">agreed to become a Participant bound by these Rules; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">irrevocably offered to acquire Shares: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">under, and subject to, these Rules; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on and subject to the terms and conditions of the Offer. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Acceptance by Company </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the terms and conditions included in an Offer, the Company will register that number of Shares set
out in the duly completed Application in the name of the relevant Eligible Director. Nothing in any Offer or Application, or in these Rules, will be taken to confer on any Eligible Director any right or title to or interest in, any Shares until the
Shares are so registered. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company will give notice, or cause notice to be given, to a Participant (or any person authorised to
receive such notice on the Participant&#146;s behalf), in accordance with the Listing Rules, of the registration in the Participant&#146;s name of Shares issued under the Plan, including information on the following: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the number of Shares issued to the Participant; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Date of Grant of those Shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Vesting Conditions (if any) attaching to the Shares; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other specific terms and conditions applicable. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Shares to rank equally </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Unless otherwise determined by the Board at the time of an Offer, all Shares issued pursuant to the Offer will rank equally with existing
Shares on and from their Date of Grant, including in respect of all rights issues, bonus share issues and dividends which have a record date for determining entitlements on or after the Date of Grant, unless otherwise specified in a particular
Offer. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ASX Quotation </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Company will apply (at its expense) to the ASX for the official quotation of any Shares issued to Participants for the purposes of the Plan
in accordance with Listing Rule 2.4. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Vesting conditions </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Conditions </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Board may offer Shares with such conditions relating to the Dealing or forfeiture of the Shares as determined by the Board from time to
time. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Compliance by Participant </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Each Participant undertakes to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">only Deal in the Shares as permitted by the Vesting Conditions (if any); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">observe all Vesting Conditions attached to the Shares issued to them. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">12</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Non-Executive Directors share and option plan rules</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Refusal to register transfer </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the Listing Rules, the Company must refuse to register a paper-based transfer, and must apply or
cause to be applied a Holding Lock to prevent a transfer, of any Shares to which Vesting Conditions attach, and the Board on behalf of the Company may take any other steps that it considers necessary or appropriate, to enforce and give effect to the
disposal restrictions under the Vesting Conditions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Participant irrevocably authorises the Board on behalf of the Company to apply a Holding Lock to any
Shares to which Vesting Conditions attach held by that Participant. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Retention of Holding Statements </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Until any Vesting Conditions for a Share are satisfied and any restriction on Dealing in the Share imposed by Rule 8.1 expires, if required by
the Company, the Company may retain the Holding Statements in relation to the Share and any subsequent shares issued with respect to the Share under a bonus issue. The Company will promptly deliver any Holding Statements in relation to a Share which
it holds to the Participant on the satisfaction of all Vesting Conditions for the Share and expiry of any restriction on sale of the Share imposed under Rule 8.1. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Vesting Conditions to apply to Shares </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Any Shares that a Participant acquires in respect of Shares to which Vesting Conditions attach pursuant to a rights issue or bonus share issues
by the Company will also be deemed to have the same Vesting Conditions attached. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Waiver </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Board may, at its discretion, by notice to the Participant reduce or waive the Vesting Conditions attaching to Shares in whole or in part
at any time and in any particular case including due to Special Circumstance or another Accelerated Vesting Event, subject to Rule 20. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Permitted transfer of Shares </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Board may determine that Shares to which Vesting Conditions attach may be transferred by an instrument of transfer, in the following
circumstances: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a transfer constituting the necessary transfer documents following an acceptance of an offer made under an <FONT
STYLE="white-space:nowrap">off-market</FONT> bid relating to Shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a transfer to a bidder on the sale of the Shares under Division 3 of Part 6A.1 of the Corporations Act;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a transfer to a 100% holder on the sale of the Shares under Division 2 of Part 6A.2 of the Corporations Act;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a transfer under Part 6A.3 of the Corporations Act to a person entitled to acquire the Shares under section
661A or 664A of the Corporations Act;<I> </I>or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a transfer approved by the Board in those circumstances as may be determined by the Board.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Board must notify Participants if a circumstance set out in this Rule 8.7 occurs and the Board authorises transfer
of Shares pursuant to this Rule. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.8</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Corporate Control Event </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If a Corporate Control Event occurs, the Board may determine that this constitutes an Accelerated Vesting Event. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">13</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Non-Executive Directors share and option plan rules</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.9</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Shares cease to be subject to Vesting Conditions </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">On the earliest of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a determination by the Board that any Vesting Conditions have been satisfied, reached or met; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Board making a determination under Rule 8.7 or to waive any applicable Vesting Conditions under Rule 8.6;
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">then: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the relevant Shares cease to be subject to the restrictions under this Rule 8 and the forfeiture provisions
under Rule 9; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Board must, as soon as reasonably practicable, lift the Holding Lock in respect of the relevant Shares and
must notify the holder of the Shares that the Holding Lock has been lifted. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.10</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Notification upon request by Participant </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Company must, if requested, notify the holder of the Shares of the particular time when the Holding Lock was lifted under Rule&nbsp;8.9.
</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Forfeiture of Shares </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Forfeiture of Shares to which Vesting Conditions attach </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If a Participant holds any Shares to which Vesting Conditions attach under this Plan, the Participant&#146;s ownership of those Shares will be
forfeited by the Participant (or any person claiming through the Participant) to the Company (or otherwise as directed by the Board) if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Vesting Conditions applicable to the Shares have not been satisfied, reached or met in accordance with
their terms or are not capable of being satisfied, reached or met (except for reason of Special Circumstances and the Board determining that in such Special Circumstances the Vesting Conditions are to be waived or modified); or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Board determines that a Participant: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">has been convicted on indictment of an offence against the Corporations Act in connection with the affairs of
the Company or any body corporate in the Group; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">has had a judgement entered against him or her in civil proceedings in respect of the contravention by the
Participant of his or her duties at law, in equity or under statute in his or her capacity as a Director of the Company or any body corporate in the Group; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">has committed an act of fraud, defalcation or gross misconduct in relation to the affairs of that body
corporate (whether or not charged with an offence); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">has breached the Company&#146;s policy (if any) on hedging of long term incentives; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">has done an act which brings the Group or any body corporate in the Group into disrepute; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Participant&#146;s office of a body corporate in the Group is terminated or ceases, other than:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where the termination or cessation of office is due to the occurrence of a Special Circumstance; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where the Board determines otherwise, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">subject</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to Rule 20. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">14</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Non-Executive Directors share and option plan rules</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Treatment of Forfeited Shares </B></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As soon as reasonably practicable after Forfeited Shares are transferred to the Company, the Company must:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">sell those Forfeited Shares in the ordinary course of trading on the stock market of the ASX;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cancel the Forfeited Shares; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">deal with the Forfeited Shares in any other manner determined by the Board from time to time.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the avoidance of doubt, the Company will hold full legal and beneficial title to any Forfeited Shares which
are transferred to the Company pursuant to any power of attorney granted by a Participant under Rule 10 at all times until those Forfeited Shares are disposed of by the Company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Effect of forfeiture </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, no consideration or compensation will be payable to a Participant for or in relation to the forfeiture by the
Participant of ownership of Shares held under the Plan. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Conditions on forfeiture </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">In making any determination as to the forfeiture or otherwise of the ownership of Shares or other entitlements under Rule 9 the Board may: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">impose any conditions that it thinks fit; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">determine that a Participant will be required to forfeit all or a specified number of the Shares held by the
Participant or other entitlements arising from those Shares under the Plan. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Power of Attorney </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Appointment of Attorney </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">At all times while a Participant holds Shares in respect of which a Vesting Condition has not been satisfied, reached or met, the relevant
Participant irrevocably appoints the Company and any person nominated from time to time by the Company (each an <B>Attorney</B>) severally, as the Participant&#146;s attorney, to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">do all acts, matters and things which the Attorney considers necessary or desirable to be done in order that
any Shares may be registered in the name of the Participant or to give effect to the powers of sale or forfeiture referred to in these Rules including acquiring or disposing of the Shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">execute in the name of the Participant an instrument or instruments of transfers of the Shares or make any
alteration or addition whatsoever which the Attorney may think fit; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">exercise all of the powers of the Participant in relation to acquisition, sale or disposal (including
forfeiture under Rule 9) of the Participant&#146;s Shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Ratification of Actions </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Participant will confirm and ratify everything which an Attorney may do pursuant to any power set out in Rule 10.1 and no person dealing
with the Attorney shall be bound or concerned to enquire as to the occasion for or the regularity of the exercise of any such power. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">15</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Non-Executive Directors share and option plan rules</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Indemnity </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Participant will indemnify and keep indemnified the Attorney against all losses, liabilities, costs, expenses, proceedings, claims,
actions, demands, and damages in consequence of or arising out of the exercise by the Attorney of any of the powers granted under this<B> </B>Rule 10. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Voting rights </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Unless otherwise resolved by the Board when it makes an Offer, and subject to the terms of issue of the relevant Shares, a Participant may
exercise (whether in person or by proxy) any voting rights attaching to the Shares registered in the Participant&#146;s name which were the subject of the Offer. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Bonus issues </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Unless otherwise resolved by the Board when it makes an Offer, a Participant who holds the Shares issued pursuant to the Offer has the same
entitlement as any other shareholder in the Company to participate in any bonus issue, provided however, if the Shares held by the Participant are subject to any Vesting Conditions or any restrictions on sale imposed under Rule 8.1, any shares
issued to a Participant under the bonus issue will be subject to these Rules as if those shares were Shares issued under the Offer made to the Participant. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Capital reconstructions </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">In the event of a Capital Reconstruction, subject to any provision in the Listing Rules, the Board may adjust any or all of the number of
Shares issued pursuant to the Offer to a Participant as the Board deems appropriate. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Issue of Options </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>14.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Acceptance by Eligible Director </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">By accepting an Offer for Options in accordance with Rule 6.1, the Eligible Director will be taken to have: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">agreed to become a Participant bound by these Rules; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">irrevocably offered to acquire Options (and Shares upon the exercise of Options): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">under, and subject to, these Rules; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on and subject to the terms and conditions of the Offer. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>14.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Acceptance by Company </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Unless provided for otherwise in an Offer, the Company will be deemed to have accepted an Eligible Director&#146;s Application in respect of an
Offer for Options on the issue to the Eligible Director of the Options the subject of the Application, and the notification to the Eligible Director of the Date of Grant of those Options. Nothing in any Offer or Application, or in these Rules, will
be taken to confer on any Eligible Director any right or title to or interest in, any Options until such issue occurs and notice is provided. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>14.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Certificates </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Company must give a Participant one or more Certificates stating (or which, if applicable, attach a separate document stating): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the number of Options issued to the Participant; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">16</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Non-Executive Directors share and option plan rules</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Issue Price (if any) of those Options; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Exercise Price (if any) of those Options; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Date of Grant of those Options; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the First Exercise Date of the Options; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Last Exercise Date of the Options; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Exercise Conditions (if any) attaching to the Options; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the underlying Shares over which the Option is exercisable are to be Restricted Shares under Rule 19.1,
details of the restriction; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other specific terms and conditions applicable. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>14.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Consideration for Options </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If Options are issued with a zero Issue Price, the Options will be issued for consideration comprising: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the services that are expected to be provided by an Eligible Director to or for the benefit of the Group,
either as payment in lieu of the relevant Director&#146;s existing cash remuneration or in addition to any existing cash remuneration payable to the relevant Director; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the services that have already been provided by an Eligible Director for the benefit of the Group which in the
opinion of the Board are outside of the scope of ordinary duties of the relevant Director, </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">and no further monetary or
other consideration will be payable in respect of the issue of an Option. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>14.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Entitlement to underlying Shares </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Subject to these Rules, each Option confers on its holder the entitlement to subscribe for and be issued one Share at the Exercise Price (if
any). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>14.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Interest in Shares </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">A Participant has no interest in a Share the subject of an Option held by the Participant unless and until the Share is issued to that
Participant pursuant to the exercise of an Option under these Rules and does not have any rights to dividends, rights to vote or rights to the capital of the Company as a result of holding an Option. Subject to the Corporations Act and the
Constitution, Participants will not, as holders of Options, have any right to attend or vote at general meetings of holders of Shares. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Exercise of Options </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>15.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exercise during Exercise Period </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Subject to Rules&nbsp;3.2, 15.2, 15.3, 15.4 and 20, an Option may be exercised at any time during the Exercise Period for that Option. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>15.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exercise before Exercise Period </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">An Option may be exercised before the Exercise Period if permitted under Rule 17.5 or&nbsp;18.6. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>15.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>First Exercise Date </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Certificate or Offer will specify the First Exercise Date in respect of an Option. The exercise of an Option after the First Exercise Date
is subject to any Exercise Conditions under Rule 15.4. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">17</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Non-Executive Directors share and option plan rules</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>15.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exercise Conditions </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Subject to Rule&nbsp;15.5, if the Certificate or Offer in respect of an Option specifies any Exercise Conditions, the Option may not be
exercised unless and until those Exercise Conditions have been satisfied, reached or met. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>15.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Waiver of Exercise Conditions </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Board may, at its discretion, by notice to the Participant reduce or waive the Exercise Conditions attaching to Options in whole or in part
at any time and in any particular case including due to Special Circumstance or another Accelerated Vesting Event. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>15.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exercise of Options </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Subject to these Rules, Options which have not lapsed may be exercised by the Participant giving to the Company: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a Notice of Exercise signed by the Participant; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Certificate for those Options; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if there is an Exercise Price for the Options:, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">payment (in cleared funds) of the amount calculated by multiplying the number of Options being exercised by the
Exercise Price; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">payment, or the Participant&#146;s agreement to pay, the relevant amount under any &#145;cashless
exercise&#146; arrangement that is acceptable to, and approved by, the Board, </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">but no Participant shall be able to
exercise an Option that remains subject to Exercise Conditions that have not been satisfied, reached or met, or else waived under Rule 15.5. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>15.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Participant agrees to be bound </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">By exercising an Option, a Participant will be taken to have agreed to become a Shareholder and be bound by the Constitution. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>15.8</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Issue of Shares </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Subject to these Rules, on the exercise of an Option the Company must issue and allot a Share, as soon as reasonably practicable (subject to
Rule 15.9) to the Participant. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>15.9</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Clearance of Exercise Price </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Company is not obliged to issue Shares on exercise of Options until any cheque received in payment of the Exercise Price has been honoured
on presentation (if there is an Exercise Price for the Options). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>15.10</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exercise all or some Options </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Participant may only exercise Options in multiples of 100 or another multiple as the Board determines unless
the Participant exercises all Options covered by a Certificate able to be exercised by him or her at that time or under a cashless exercise arrangement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The exercise by a Participant of only some of the Options held by the Participant does not affect the
Participant&#146;s right to exercise at a later date other Options held by the Participant that have not lapsed (whether those other Options have the same First Exercise Date or otherwise). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>15.11</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Replacement Certificate </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If a Participant submits a Notice of Exercise in respect of only part of the Options covered by a Certificate, the Company must issue a
Certificate stating the remaining number of Options held by the Participant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">18</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Non-Executive Directors share and option plan rules</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>15.12</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Shares rank equally </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Shares issued on the exercise of Options rank equally with all existing Shares on and from the date of issue in respect of all rights issues,
bonus share issues and dividends which have a record date for determining entitlements on or after the date of issue of those Shares. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">16.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lapse of Options </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>16.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Lapse of Options </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Unless otherwise specified in the Exercise Conditions or determined otherwise by the Board an Option lapses on the earlier of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Last Exercise Date; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a determination of the Board that the Option should lapse because the Participant, in the Board&#146;s opinion:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">has committed an act of fraud, defalcation or gross misconduct in relation to the affairs of that body
corporate (whether or not charged with an offence); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">has done an act which brings the Group or any body corporate in the Group into disrepute;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">has been convicted on indictment of an offence against the Corporations Act in connection with the affairs of
the Company or any body corporate in the Group; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">has had a judgement entered against him or her in civil proceedings in respect of the contravention by the
Participant of his or her duties at law, in equity or under statute in his or her capacity as a Director of the Company or any body corporate in the Group; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">has breached the Company&#146;s policy (if any) on hedging of long term incentives; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Participant&#146;s office of a body corporate of the Group is terminated or ceases, other than:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where the termination or cessation of office is due to the occurrence of a Special Circumstance; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where the Board determines otherwise, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">subject to Rule 20. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>16.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Rights cease </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If a Participant fails for any reason to exercise all the Options registered in the Participant&#146;s name before the occurrence of a
circumstance set out in Rule&nbsp;16.1, those Options that the Participant: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">would have been entitled to exercise and that have not been exercised; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">may have had a right or entitlement to have vested in the Participant, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">lapse and all rights of a Participant under the Plan in respect of those Options cease. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dealings with Options </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>17.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Options personal </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Except where Options have been transferred under Rule&nbsp;17.3, Options held by a Participant are personal to the Participant and may not be
exercised by another person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">19</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Non-Executive Directors share and option plan rules</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>17.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No unauthorised disposal </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Except as permitted under Rule&nbsp;17.3, a Participant must not dispose of or grant a Security Interest over or otherwise engage in any
Dealing with an Option or an interest in an Option, and the Security Interest or disposal or dealing is not recognised in any manner by the Company. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>17.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Permitted transfer of Options </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Board may determine that Options may be transferred by an instrument of transfer, in the following circumstances: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a transfer constituting the necessary transfer documents following an acceptance of an offer made under an <FONT
STYLE="white-space:nowrap">off-market</FONT> bid relating to Options; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a transfer to a bidder on the sale of the Options under Division 3 of Part 6A.1 of the Corporations Act;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a transfer to a 100% holder on the sale of the Options under Division 2 of Part 6A.2 of the Corporations Act;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a transfer under Part 6A.3 of the Corporations Act to a person entitled to acquire the Options under section
661A or 664A of the Corporations Act;<I> </I>or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a transfer approved by the Board in those circumstances as may be determined by the Board.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Board must notify Participants if a circumstance set out in this Rule 17.3 occurs and the Board authorises transfer
of Options pursuant to this Rule. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>17.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Corporate Control Event </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If a Corporate Control Event occurs the Board may determine that this constitutes an Accelerated Vesting Event. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>17.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>First Exercise Date brought forward </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If an Accelerated Vesting Event occurs or is expected to occur while a Participant is employed with the Group, the Board may, at its
discretion: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">bring forward the First Exercise Date of all Options held by the Participant to a date determined by the Board;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">waive or vary any Exercise Conditions in regard to an Option held by the Participant in accordance with Rule
15.5, </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">subject to Rule 20. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>17.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Notice to Participants of change </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If the Board determines to alter the First Exercise Date and Exercise Conditions under Rule&nbsp;17.5, the Company: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">must within 14 days of the alteration give notice to each Participant affected by the Accelerated Vesting Event
in respect of any Options held by the Participant; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">may have to issue a replacement Certificate for the Options. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">20</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Non-Executive Directors share and option plan rules</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Participation rights, bonus issues, rights issues, reorganisations of capital and winding up in respect of
Options </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>18.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Application of this Rule </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">This Rule 18 applies to Participants who holds Options that they have not yet exercised, provided the Options have not lapsed in accordance
with the Rules. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>18.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>New issues </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Participants holding Options are not entitled to participate in any new issue to existing holders of securities in the Company unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">they have become entitled to exercise their Options under the Plan; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">they do so before the record date for the determination of entitlements to the new issue of securities and
participate as a result of being holders of Shares. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Company shall give Participants, in accordance with the Listing
Rules, notice of any new issue of securities before the record date for determining entitlements to the new issue. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>18.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Bonus issues </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If the Company makes (whether before or during the Exercise Period) a bonus issue of Shares or other securities to existing holders of Shares
(other than an issue in lieu or in satisfaction of dividends or by way of dividend reinvestment) and no Share has been issued in respect of an Option before the record date for determining entitlements to the bonus issue, then the number of
underlying Shares over which the Option is exercisable is increased by the number of Shares which the Participant would have received if the Participant had exercised the Option prior to such record date. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>18.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">Pro-rata</FONT> issues </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If the Company makes (whether before or during the Exercise Period) a <FONT STYLE="white-space:nowrap">pro-rata</FONT> issue of Shares (except
a bonus issue) to existing holders of Shares (other than an issue in lieu or in satisfaction of dividends or by way of dividend reinvestment) and no Share has been issued in respect of an Option before the record date for determining entitlements to
the issue, the Exercise Price (if any) of the Option is reduced in accordance with the Listing Rules. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>18.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Reorganisation of capital </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If there is a reorganisation of capital of the Company (whether before or during the Exercise Period) then the rights of a Participant
(including the number of Options to which each Participant is entitled and the Exercise Price, if any) are amended in accordance with the Listing Rules or as would be required by the Listing Rules if the Company was subject to the Listing Rules at
the time of the reorganisation. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>18.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Winding up </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If (whether before or during the Exercise Period) a resolution for a members&#146; voluntary winding up of the Company is proposed (other than
for the purpose of a reconstruction or amalgamation) the Board may, in its absolute discretion, give written notice to Participants of the proposed resolution. Subject to the Exercise Conditions, the Participants may, during the period referred to
in the notice, exercise their Options if the Last Exercise Date for the Options has not expired. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>18.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Fractions of Shares </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">For the purposes of this Rule&nbsp;18, if Options are exercised simultaneously, then the Participant may aggregate the number of Shares or
fractions of Shares for which the Participant is entitled to subscribe. Fractions in the aggregate number only will be disregarded in determining the total entitlement of a Participant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">21</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Non-Executive Directors share and option plan rules</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>18.8</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Calculations and adjustments </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Any calculations or adjustments which are required to be made under this Rule&nbsp;18 will be made by the Board and, in the absence of manifest
error, are final and conclusive and binding on the Company and the Participant. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>18.9</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Notice of change </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Company must within a reasonable period give to each Participant notice of any change under Rule&nbsp;18 to the Exercise Price (if any) of
any Options held by the Participant or to the number of Shares which the Participant is entitled to subscribe for on exercise of an Option. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">19.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Restriction on disposal of Shares acquired pursuant to exercise of Options </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>19.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Restricted Shares </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Shares acquired under this Plan pursuant to exercise of Options may be subject to restriction on disposal under this Rule&nbsp;19.1
(<B>Restricted Shares</B>). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>19.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No disposal whilst Shares in Plan </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Certificate may specify any period during which Shares will be Restricted Shares (<B>Restriction Period</B>). A holder of Restricted Shares
must not dispose of or engage in any Dealing with any of those Restricted Shares or any interest in those Restricted Shares while those Restricted Shares are held in the Plan and subject to these Rules. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>19.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Waiver </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Board may, at its discretion, by notice to the Participant reduce or waive the period in which Restricted Shares are subject to restriction
on disposal under this Rule 19.3. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>19.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Refusal to register transfer </B></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the Listing Rules, the Company must refuse to register a paper-based transfer, and must apply or
cause to be applied a Holding Lock to prevent a transfer, of any Restricted Shares, and the Board on behalf of the Company may take any other steps that it considers necessary or appropriate, to enforce and give effect to the disposal restrictions
under this Rule 19.4. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Participant irrevocably authorises the Board on behalf of the Company to apply a Holding Lock to any
Restricted Shares held by that Participant. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>19.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Withdrawal of Restricted Shares </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">A holder of Restricted Shares may at any time, by serving on the Company a written withdrawal notice in a form approved by the Board, apply to
withdraw from the Plan a portion of or all Restricted Shares held by the holder. The Board may determine in its discretion whether to grant a request made under this Rule 19.5. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>19.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Cease to be in Plan </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">On the earliest of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the expiry of any applicable Restriction Period; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the acceptance by the Board of a request under Rule 19.5; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Board making a determination to release some or all of the Restricted Shares under Rule 19.3,
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">then: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">22</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Non-Executive Directors share and option plan rules</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the relevant Restricted Shares cease to be held in the Plan and subject to these Rules; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the relevant Restricted Shares cease to be subject to the restrictions under this Rule 19.6;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Board must, as soon as reasonably practicable, lift the Holding Lock in respect of the relevant Shares and
must notify the holder of the Shares that the Holding Lock has been lifted. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>19.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Notification upon request by Participant </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Company must, if requested, notify the holder of the Shares of the particular time when the Holding Lock was lifted under Rule&nbsp;19.6.
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shareholder approval may be required </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">To the extent that the exercise of the Board&#146;s discretion under Rules 8.6, 9.1(c), 15.5, 17.5 or any other amendment to the terms of a
Participant&#146;s Offer under the Rules would trigger the requirement for shareholder approval under section 200B of the Corporations Act, the Company agrees to use reasonable endeavours to seek shareholder approval for the benefit under section
200E of the Corporations Act<I> </I>at the next Annual General Meeting of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><I>Explanatory note: Section&nbsp;200B of the
Corporations Act deals with retirement benefits given to a person who holds (or has held any time in the last 3 years before his or her retirement) the office or position of a managerial or executive office in the Company or a related body
corporate. </I></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">21.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Quotation of Shares </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>21.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No Quotation of Options </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Company will not seek official quotation of any Options. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>21.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Quotation of Shares </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Company must apply to ASX for quotation of Shares issued following the acceptance of an Offer or Shares issued on exercise of Options, if
other Shares of the Company are officially quoted by ASX at that time. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">22.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Administration </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Plan is administered by the Board. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>22.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Powers of the Board </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Board has power to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">exercise all powers and discretions vested in it under these Rules; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">determine appropriate procedures and make regulations and guidelines for the administration and operation of
the Plan which are not inconsistent with these Rules; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">resolve conclusively all questions of fact or interpretation arising in connection with the Plan;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">terminate or suspend the operation of the Plan at any time, provided that the termination or suspension does
not adversely affect or prejudice the rights of Participants holding Shares or Options at that time or contravene any Applicable Law; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">delegate those functions and powers it considers appropriate, for the efficient administration of the Plan, to
any person or persons whom the Board reasonably believes to be capable of performing those functions and exercising those powers; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">23</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Non-Executive Directors share and option plan rules</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">take and rely on independent professional or expert advice in or in relation to the exercise of any of their
powers or discretions under these Rules; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">administer the Plan in accordance with these Rules as and to the extent provided in these Rules; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">make regulations for the operation of the Plan consistent with these Rules. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>22.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exercise of powers or discretion </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Any power or discretion which is conferred on the Board or Board by these Rules may be exercised by the Board or Board in the interests or for
the benefit of the Company, and the Board or Board is not, in exercising that power or discretion, under any fiduciary or other obligation to another person, including a Participant. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>22.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Determinations </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Where these Rules provide for a determination, decision, approval or opinion of the Board or Board, that determination, decision, approval or
opinion may be made or given by the Board or Board (as applicable) in its absolute discretion. In the absence of manifest error, any determination, decision, approval or opinion of the Board or Board as to the interpretation, effect or application
of the Rules will be final. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>22.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Expenses and costs </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Subject to these Rules, the Company and its Subsidiaries must pay all expenses, costs and charges incurred in the administration of the Plan in
the amounts and proportions as they shall agree. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>22.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Board not liable </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">No member of the Board shall be liable for anything done, or omitted to be done by him or by any other member of the Committee in connection
with the Plan, except for his own wilful misconduct or as expressly provided by law. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">23.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amendment to Rules </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>23.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Board or Board may amend Rules </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Subject to the Listing Rules, the Board or Board may, in its absolute discretion, at any time amend any of these Rules, or waive or modify the
application of any of these Rules in relation to any Participant. In particular, amendments, waivers or modifications may be made in order to enable Shares or Options issued to Participants to be assessed at the &#145;ESS deferred taxing point&#146;
as defined in section 83A-120 of the <I>Income Tax Assessment Act (</I><I>Cth</I><I>)</I> 1997. Any amendment may be given such retrospective effect as the Board or Board may determine from time to time. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>23.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Waiver or amendment </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Company will not be taken to have waived any provision of, or any right, or entitlement under these Rules, or agreed to any amendment of
the Rules, unless it does so expressly in writing and provided further that any waiver or amendments of these Rules is carried out in accordance with the Listing Rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">24</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Non-Executive Directors share and option plan rules</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>23.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Consent of Participants </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If an amendment to be made under Rule&nbsp;23.1 would adversely affect the rights of Participants in respect of any Shares or Options then held
by them, the Board or Board must obtain the consent of Participants who between them hold not less than 75% of the total number of those Shares or Options held by all those Participants before making the amendment. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>23.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Eligible Directors outside Australia </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Board or Board may make any additions, variations or modifications to the Rules, in relation to the implementation of the Plan and the
specific application of the Rules, to Eligible Directors residing outside Australia. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">24.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Rights of Participants </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>24.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No conferred rights </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">These Rules: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">do not confer on any Participant any right or entitlement if that right or entitlement could only be provided
with approval of the Company&#146;s shareholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">do not confer on an Eligible Director the right to receive and Offer, Shares or Options; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">do not confer on a Participant the right to continue as a Director (or as a director or officer of any body
corporate in the Group); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">do not affect any rights which the Company or a Subsidiary may have to dismiss or remove the Participant as a
Director (or as a director or officer of any body corporate in the Group); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">may not be used to increase damages in an action brought against the Company or a Subsidiary in respect of that
termination or removal. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">25.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No representation as to Tax consequences </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Neither the Company nor any adviser to the Company, Board or the Board: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">represents or warrants that the Plan will have any particular taxation or financial consequences or that any
Eligible Director or Participant will gain any taxation or financial advantage by participating in the Plan; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">are liable for any Taxes imposed upon or duties assessed against a Participant as a consequence of the
Participant&#146;s participation in the Plan, the receipt by the Participant of Shares or Options offered under the Plan or other Dealing in the Shares or Options by the Participant. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">26.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notices </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>26.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Service of notices </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">A notice, demand, consent, approval or communication under the Rules (<B>Notice</B>) must be: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in writing, in English and signed by a person duly authorised by the sender; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">hand delivered or sent by prepaid post or facsimile to the recipient&#146;s address for Notices specified in
Rule 26.3, as varied by any Notice given by the recipient to the sender. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">25</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Non-Executive Directors share and option plan rules</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>26.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Effective on receipt </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">A Notice given in accordance with Rule 26.1<B> </B>takes effect when taken to be received (or at a later time specified in it), and is taken to
be received: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if hand delivered, on delivery; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if sent by prepaid post, two Business Days after the date of posting (or seven Business Days after the date of
posting if posted to or from a place outside Australia); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if sent by facsimile, when the sender&#146;s facsimile system generates a message confirming successful
transmission of the entire Notice unless, within eight Business Hours after the transmission, the recipient informs the sender that it has not received the entire Notice, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">but if the delivery, receipt or transmission is not on a Business Day or is after 5.00pm on a Business Day, the Notice is taken to be received
at 9.00am on the next Business Day. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>26.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Address </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The address of the Eligible Director and the Company for the purposes of giving a Notice is: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of the Company, at the address of its registered office from time to time, which at the date of
this Plan is situated at Suite 0403, Level&nbsp;4, 650 Chapel Street, South Yarra, Victoria 3141; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of the Eligible Director, the address of the Eligible Director as specified in the records of the
Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">27.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Governing law </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">These Rules and the rights and obligations of Participants under the Plan are governed by the law of Victoria, and each Participant irrevocably
and unconditionally submits to the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> jurisdiction of the courts of Victoria. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">28.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Advice </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Eligible Directors and Participants should obtain their own independent advice at their own expense on the financial, taxation and other
consequences to them of or relating to participation in the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">26</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Non-Executive Directors share and option plan rules</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>OPTHEA LIMITED - ESOP PLAN OPTION CERTIFICATE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This certificate is provided under Rule 14.3 of the Opthea <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors Share and Option Plan (<B>Plan</B>).
The terms used in this certificate have the same meaning as in the Plan. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">Participant</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Name]</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">Number of Options issued</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Insert number of Options issued to the
Participant named above.]</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">Issue Price for the Options</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Insert issue price (if any) for the Options
issued to the Participant.]</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">Exercise Price for the Options</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Insert exercise price (if any) for the Options
issued to the Participant.]</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">Date of Grant for the Options</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Insert date the Options issued to the Participant
were granted.]</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">First Exercise Date</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Insert expected First Exercise Date (typically 2
or 3 years after the Date of Grant) for the Options issued to the Participant.]</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">Last Exercise Date</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Insert expected Last Exercise Date (typically 5
years after the First Exercise Date) for the Options issued to the Participant.]</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">Exercise Conditions</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Insert any conditions to be satisfied before the
Participant can exercise their Options (e.g. Participant&#146;s KPIs, etc).]</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">Restricted Shares</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Insert period of disposal restriction, if
any.]</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">Other terms and conditions</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Insert any other terms and conditions to be
satisfied by the Participant.]</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">27</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Non-Executive Directors share and option plan rules</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>OPTHEA LIMITED - NOTICE OF ALTERATION TO OPTION CONDITIONS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="76%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date of Notice:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">[Note<B> -</B> this notice must be given within 14 days of the alteration.]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Participant:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">[Name]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Number of Options affected:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">[Insert number of Options held by the Participant that have not been exercised as at the date of this notice.]</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">This notice is provided under Rule 17.6 of the Opthea <FONT STYLE="white-space:nowrap">Non-Executive</FONT>
Directors Share and Option Plan (<B>Plan</B>). The terms used in this notice have the same meaning as in the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As a result of an
Accelerated Vesting Event the following alterations are made to the Participant&#146;s Options: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt" BGCOLOR="#bfbfbf">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000" BGCOLOR="#bfbfbf">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000" BGCOLOR="#bfbfbf">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt" BGCOLOR="#bfbfbf"><B>Condition Affected</B></TD>
<TD VALIGN="bottom" BGCOLOR="#bfbfbf" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#bfbfbf"><B>Previous Condition</B></TD>
<TD VALIGN="bottom" BGCOLOR="#bfbfbf" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt" BGCOLOR="#bfbfbf"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Revised Condition</B></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">First Exercise Date</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[Insert the First Exercise Date included in Participant&#146;s Option Certificate.]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Insert revised First Exercise Date determined by
the Board under Rule 17.5(a) of the Plan.]</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">Exercise Conditions</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">[Insert conditions outlined in Participant&#146;s Option Certificate.]</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Insert revised exercise conditions determined by
the Board under Rule 17.5(b) of the Plan.]</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">28</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Non-Executive Directors share and option plan rules</P></TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>10
<FILENAME>filename10.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-21.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 21.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Subsidiary of Opthea Limited </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:10pt; font-family:Times New Roman; "><B>Name of Subsidiary</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:10pt; font-family:Times New Roman; "><B>Jurisdiction of Organization</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vegenics Pty Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Australia</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g945701g11h62.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945701g11h62.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#^17AI9@  34T *@    @ ! $[  (
M   1   (2H=I  0    !   (7)R=  $    B   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $%B:7)A;6D@
M1&5V861A<W,    %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,R
M,   DI(  @    ,R,   ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MQ6TGKCR[CO\ ],TKM,"@#EO^$@\5_P#0F?\ E5B_PH_X2#Q7_P!"9_Y58O\
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M(/EANV<<X^E ' CXI:T1QX&O^G_/1_\ XU4=Q\6=5M(7FNO!=Y#$@RTCS,%
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M#583-I=[;WL2MM9[>99%!]"03S5N@#F=9\6_V7K$ME_9\\PC2-MZQRG?O)&
M5C*\8_B8=?QKIJ\]\623MXNEA@MHVB\BV,TIN)0NUGD1E<)*H7(;@LN,;C\Q
M^6O0J .9^(G_ "(&J_\ 7(?^A+3_  &P'@32,G_EW'\Z9\0QGP!JN/\ GB#_
M ./"N!>_U*TT'PV-.O9(5%@9)(S,(4*JQW?,SJ"3D# R0!G(H ZS0>?B[XFQ
M_P \8/\ T!*A^)UA]O&E1^1I<V)7(6\\LS9Q_P LED94;WR>.,#-0>"9?/\
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M'/4_AR:XEANA<I>(%D&P7+[\ H#A6*J2 20<YY!Y-0>!?^19'_7U<?\ HYZ
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MAQG_ (5]I>?[C_\ H;44 4;W_DK6F?\ 7*?_ -%)7;5Q-XP_X6WIP_Z93_\
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MM5<R1R[M-M#YD4?EJ_[F/D+_  CV[=*]*QFN$\.QI%\7O$R1($1;>W5548
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MV?9WM3*HW_*(6&5*Y/S?Q9'IQ6TG5I+BUN+^2"]\R" 1%HH"Q"^9@F(+"#(
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MZC6:SFCDC\U'C960'&X$=,]J8C!B,.AZ//\ V5<K=BW_ 'IMMT*A%9]S8QL
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MKG?B+[OX]*XW4='ALO"&O7]GX7FT(7>E,)E2Y0P\ L (@?E(+L> .IS7:>)
MQ\0:.$9T8I= -'RX/E<$#U]*\M,\,NB:Q:P:=/8W-KI$WVV<6LB?:VP #*6)
MPW!(!+,?7U /<Y?]0W3[O?I7FNBZ#:1>#]22[T^TLYM0TF02RV*PJLRA<,5V
M*C8!8'#,,9'0\UZ5(I:$J,9*D#<..E<9X9^'UMH\,\-U:67EW=F;:\6!%43$
M]3\L:;1][Y<GMZ9H S].N3?^!_$*W$-Q+#Y!!\R^9F<%3N \R678,8YS@Y/'
M%7/[*T_2O!FMPV<<;JSEYEMI5<@[N1A8^%7ILVG"C %;^JZ-96_A_5 H=O.M
M61VN;AI,@*< M(_ &2?O <DY'6N4T(2W/@W6"T4=^7PL6R7F=NH3>LC*3N/W
M@_4MNYY(!C"VTG4_A_<O%#J%FL]^DCI#%*TBS"'!<?N,[N-Q<*?F&[=Q7HO@
MY@_A.P9(FB4Q957<,Q&XX8D <GKSSSSSFLS^Q]&_LV5?$<44;7,GF3E[Z23<
MWDD,'?Y<#RPP(^Z1FNEL+.UL;80V*!(<LP ;/+,68Y]R2?QH YS7_!LVL>(!
MJ$-S:)&\<:2QSVQD8["^"K;AM($C@>A.>H!J]<Z?J5SX@6;(%M;E6@VS!,$C
M#Y&QL\<=1QZ=:WZYW5/%D6EZI]A:SGEEW1#*;<;7)&[D@X!P"?5@/6@!_C<8
M\"ZS_P!>DG\J\PN="M?$7@KPW;7D=LJ0VDDIEN@BK(/,(\M9#&S9[E5*Y]Z]
M.\<'/@76>1_QZ2?RKS[3[-'\+:%<75YH,-N+*1!'JB%F9O-)RH#*2,<8R>>V
M: -?P"ZOX]U-DMGM%;3+0K;R1A&B'DQ?*5' QTP/2O2J\\\'Q)%\3-:2)8T1
M+"V54B0JJ@1Q] >0/8UZ'0!A^-X_.\ :_&(TEWZ;<+LDD\M6S&W!;(VCWSQ7
M.:SX)N?%?AW05MKRUL6M;9"9&@:9AE ,*1(%*\?Q!P>"*Z3QH W@/7@1 P.G
M3\7#;8S^[;[Q[+ZU5MM7&FZ/I-NLFGJ7LD;]]=^4N JCY?E;(Y_E0!QEI;-:
M?'FS@=P[16:H65=H)%OC(';Z5U_CS1Y=:T%+> :;N68/YFHE@D8VL-RD#[W/
M?C&:Y2.0R_'^VD;;E[;)VMN'^H/0]Q[UWWB#PWIOB;3ULM6A\V)7\Q,.5*O@
MC<,>Q/YT >:?#W2H-&\9+;/>:3J-RR.3+:/+(T7?&0H0?SKT7QAY!\(:E]LA
M\Z'R#N3SEAS_ ,#;A?J:Y71?#Q\$>-K*PLM4FEM-560F"2 'F-<\OGCKV%=1
MXST@Z[X-U'3%N8[4W$.WSY?NI@@Y/MQ0!P%GIWBB^N=/M=;L-3N],MYT:.)Y
M84"X. 68#+ #GWKL_B2/^+<ZI_N)_P"C%KCFTKP99:Y8+;ZUK.H7T<Z$16-Z
M\B@@CEMO&WID9KL?B2?^+<ZIC^XG_HQ: '_#C_DGND_]<C_Z&U2>)Y6MYH)H
ME=IU!\O;"'&>/?@U%\.#GX=Z1_UR/_H;5'XM"FXAWR%?W3;OW8;"Y&2,GK]*
MBH[1,JOP,V]*EFGM-]P)-V3Q+%Y9Q],FN5T\@?%*XD_MR2Z22.5%L'64+ R"
M+=MRQ4\,,\#V[UTNA33SV&;EBYW':60*<8&,@$U3CLM6/C?[5+;V2:8+<HLD
M3,9Y'X^_T&!@XX/UJEL7'X4.\5?>T7_L*P_^S5IWT%W.NRWFBC0C#;XBQ/ZB
MLSQ3UT7_ +"L/_LU7[_5X[%RKQR2,J;R$QTW =S[_I38-I+4KZY"8/!.I0EM
MQCT^5=WKB,U3U;6+S2=-TI;"&W=KIDA9KB98PF4X;D@D9QD#)QT%7M?E$W@[
M4Y%SM>PE(R/6,UF>(=)M]3T33C/>M9-$HVRK&S$Y7!'RD<=/RH**E_JU[8W]
MA->0B.YE@EC>WAMI9'<JXVL#''* ,?-M]2.3TK3ENKBW\$)<WM[%:3I"K2W,
MA^S*G(SG>AV_BGX"HH?#]EXCT""#6WFOX%WHR2DJ)2'.'.?F!X!'S<5J7=C;
MP:']ABNGL(%18DF60;HQD <MG/ISG.: (_#MXNH:8+F.]CO(Y3NCD24.-I P
M/NC'Y55\"\^#K3_?F_\ 1KUJZ?80:?:K!:E_)4816;(08P /0>U97@7_ )$Z
MSQ_>E_\ 1KT 8/B7PQ?7FN7>HP64,T_F0/:7;W10P*A4LN,=R&_[ZKK=(U"7
M4;:5IHH(FCDV;8+D3#H#R0!@Y)XKC_&VB6>I7\SS^+4LFV -I]Y<*8%^4_,$
MRI!.0<\]*Z+PA)"VA+#;R:;(ENWE;]-G$D;84')P!AN>1SV/>@#G=9'AK4/$
MFH0Z\U\DUI-&%$4TY5CY2,& 3A<;L?AGO74^&AIPTMO[(EN)(/,/-P9"V?\
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M8FRN_L]M#<(RR0,CF8F(DJ0RD<;O0_=XXKH]-ACMK&.&"?STCRN\[<DYYX4
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M57P$NH_V5>/JS%I9+MG1WMO*D=-BX+YBBW'.?FV#C YQFK/@/_D3K7_?F_\
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MI#\1]'_Y]M2_\ VKK-HH"@=* .2_X6/HW_/OJ7_@&U'_  L?1O\ GWU+_P
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M3%<?^BDKLZXO4"?^%KZ1_P!<[C_T4E=I0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 56U'_D%W7_ %Q?_P!!
M-6:K:E_R"[K_ *XO_P"@F@#"^'/_ "3[2O\ KFW_ *&U%,^&K%_AYIA/]V0?
ME(PHH JW_P#R5?2?^N=Q_P"BDKLZXK4/^2L:1_URN/\ T4E=K0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MGIMKJVFS6-_%YMO,NUTSC(Z]17#>&OA;IMDVH+K=E'=(UR3:,9&+"+MG!'-
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M^Y<_^BEKM:XO4QCXK:(?^F=S_P"BEKM* "BBB@ HHHH **** "BBB@ HHHH
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M<4 /.3QSTZCM31@ LQX4]2,8IR$$?+T!QTIC+N;+_=#?*!W^M  TGR'<F1V
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M/2N<^(BX^'VK<\"$#'_ A0!I>%=G_"':+Y6=GV"#;GKCRQ6M6-X0X\%:(/\
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M N!WQ2X).3GC@#/ZT (@7S&*CYB/F;'7TY[]Z<#M0 <XXYXIL:E0<8Y.0,8
MI0<\?>^M  7^8A02<<GT]JYKXA,/^%?ZL'QGR <'O\PKI@?G(X]:YOX@_P#)
M/=6W<'R?_9A0!H>%&#^#M%95V@V$!"^G[M:UZQO!YSX)T,^NG0?^BUK9H **
M** "BBB@ HHHH *AO#BSF/I&Q_2IJ@OO^/&?_KFW\J .:^&"[?AQI8!SQ(?_
M "*U%+\,?^2<Z7_NR?\ HQJ* (]5/_%SM '^S<_^BEKKZX[5?^2H:#_NW/\
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M,#/OS_Q,M,'K._\ Z*>M"LZ_&[5=,/I,_P#Z*:M&@ HHS10!@^*@OV2W+H6
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M3VH 11AR< $\>YI1M4[1U//UH*A5Z[5'4T%LG ZXH :T<;2#*#<HX..:\_\
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MS/\ *IJBNO\ CTF_W#_*@#E_A=_R3?2_^VO_ *->BCX7\?#?2_I+_P"C7HH
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MKVK8% !1110 4444 8]TC'QMIC@?*-.NP3[F2VQ_(UL=JSI_^1GL?^O.X_\
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M/;YH_P#XJ@"#P]_R+&E_]><7_H K1K+TG[39:+96LUE,9(+>.-B&CQE5 /\
M%[5;^TS?\^4__?4?_P 50!9HJFUY<*V!IMTWN&B_J])]NN?^@7=_]]Q?_%T
M7:SM,_Y"&K_]?B_^B(JD^VW'_0+N_P#ON+_XNF:7%.LU_-/"T/VBX$B(Y4D
M1(O."1U4T :%%%% !1110 4444 %%%% !1110 5R'BB_\66K7']BZ;"]LD1:
M.=,2RE@.GEDKCGC(W'VKKZX^XN_$&G:MJ(M].NKZ*?4(I(V+H42W\J)7509
M0=RN<8QD^] %GP#/#/X:,D.IZGJ;&=S+-JD)BF#\97857:!Q@ 8KIZQ?#7V]
MK:]DU..:%I;R1X8YG5F2,@;1P2!WXS6U0 4444 %177_ !YS?[A_E4M0W?\
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MM$,8_>OG &X<<<\]/QKH=V...GK6'XQTR76O"MY8PS6\3S;1NN.$&&!Y_ 4
M>5Z;<^&GTR#[1X.U*XD"!7ECED(<XZ]17K/A86O_  C=@;&Q>PMA$!';/G,8
MR>#FN(TW3?&ZV\=IIWC#298XE"*JLDA50.!_JR>.G/2O0=(COX-(@36)4FO0
MO[Z2,8#-D\@8%3$"\1@]?>F\CH?\_P"?RHSS[$?Y-*.1_GK5".&U7_DMWA\]
MC;2_^@2UZ&.E>>:L<_&[P\!R!:2D?]\2UZ&*2!A1113$%%%% !1110 4444
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M,BDM &^#M0&IZ?=3QW/VF'[01$RRF554QHVT.0"V"QZ\]NU=!@J3Z>P_S_\
M6K!\)12VVD.DOF\S'!D>1\C:!D%P&QD'.1UR>];V1@YZU0'"ZH,?&[P\/6SD
M/_CDM>BCI7GFJ?-\;?#^#TLY./\ @,M>A#I4H3%HHHJA!1110 4444 %%%%
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MHH *AO/^/*;']P_RJ:HKK_CTE_W#_*@#FOAJ,?#W3?H__H;44OPV;=\/].X
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M10 4444 %%%% %:Z_P"/FS_Z['_T6]6:K77_ !\V?_78_P#HMZLT <O\2/\
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M_0%T_P#\!4_PH A_X2[P^.NL6?\ W]%-/C#P]_T&+0_2458_X1K0CUT73O\
MP$3_  H_X1G0O^@)IW_@)'_A0!!_PE_A\]-8L_QF%*/%F@'KK-C_ -_U_P :
MF_X1G0?^@)IW_@)'_A1_PC.@_P#0$T[_ ,!(_P#"@!H\4^'S_P QO3A];I/\
M:/\ A*- _P"@YIO_ (%Q_P"-+_PB^@?] /3?_ 2/_"C_ (1?0/\ H!Z;_P"
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g945701g75p65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945701g75p65.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#^17AI9@  34T *@    @ ! $[  (
M   1   (2H=I  0    !   (7)R=  $    B   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $%B:7)A;6D@
M1&5V861A<W,    %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,T
M,   DI(  @    ,T,   ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MYZ/_ -]&OJKXC?\ ).=<_P"O1J^4J]C+TN21P8I^\A_GR_\ /1_^^C1YTO\
MST?_ +Z->K? O2--U:?6QJFGVMZ(U@V?:(5DVY+YQD''05[!_P (=X9_Z%[2
MO_ */_XFM*N,C2FX..Q%.A*<>:Y\D^=+_P ]'_[Z-'G2_P#/1_\ OHU];?\
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M,G'EV*CAY22=SY)\Z7_GH_\ WT:/.E_YZ/\ ]]&OK;_A#O#/_0O:5_X!1_\
MQ-'_  AWAG_H7M*_\ H__B:G^T(?RE?59=SY)\Z7_GH__?1KZ(^![%OA\Q9B
MQ^V2=3[+77?\(=X9_P"A>TK_ , H_P#XFM"RTZRTV#R--M(+2'<6\N",(N3W
MP.*Y\1BHU8<JC8TI490E=LM#I7"?$31);Z/[4BEHO*\J3 ^YR2&^G-=W364,
MI##(/4'O7+2JNE-31=>BJ]-PEU/ER[LYK*8QSK@]CV8>U=#X<\?ZSX=VQ)+]
MJM!_R[S$D ?[)ZC^7M7I_B/X?VNI1NUBJH3SY+?=S_LGL:\GUGPC?Z5.R&%S
MC^!AAL>W8_A7TE/$4,7'EG]Q\96P>*P,^>G>W='KOA[XCZ)KFR)YOL-TW'E7
M! !/LW0_S]JZ]6!4$$5\JLI5BK @CJ".E=#H/CC7/#Y5+6Z,UNO_ "PGRZ?A
MW'X&N.OE76B_D_\ ,[\+GK7NXA?-?Y'T5FBN"T#XK:1J>R'4@=-N#QF0YC)_
MWNWXXKNHI8YHEDB=71AE64Y!%>/4HU*3M-6/I*.(I5X\U.5Q]%&:*R-PHHHH
M *,T9'K4%W=V]E;M/=SQP1+RSR.% _$T;Z";25V3YIK,J@EB  ,DDUY[KOQ;
MTRSWPZ/"U_-T\PG9&/ZG\OQKS77?&>M^(69;Z[*P'_EWA^1/R[_CFO1HY?6J
MZO1>9X^)SC#T=(OF?E_F>K^(OB?H^C;X;)O[1NAQMB;Y%/N_3\LUY1XA\8ZO
MXED/VZ?;;YRMO%\J#\._XUAQQO*X2)&=CT4#)-=-H/@J]U2=0T3-ZHG;_>;H
M*]FGA</A%S/?NSYVMC,7CY<D=NR,+3]/EU"<)&"$!^=^P'^->\^!]*GT_39)
M;A#'YY!1".0H''\Z;X>\$6>D1I)<*DLJ\J@'R(?;U/N:ZH<"O)QN-5;W(;'O
MY9EKPW[R>XAKY&\532#QCK($C ?;Y^-W_31J^N:^0_%?_(Y:U_U_S_\ HQJG
M+]9R/0Q6R-;X:2R-\2M%#2,1YYX)_P!DU]3#I7RO\,O^2E:+_P!=S_Z":^J1
M4YA;VJ]!X7X6%1SS1V\#RS2+''&"SNYP% [DU(:\*^-_C*>74_\ A&;&4I;P
MJKW>T_ZQB,A3[ 8/U/M7+1I.M/E1O4FH1NS0\8?'%())++PE"D[#Y3>S#Y?^
M +W^I_(UY-K'BC6]?D+ZOJES<@G.QGP@^BC@?E69%%)/,D4*,\DC!451DL2<
M "OH'P5\&]+TNUAN_$<*ZA?L-S1/S%$?3'\1]SQ[5Z\E0PD5=:G O:5V?/JH
MSGY%+?09IQ@E7EHG ]U-?9%M96UG$([2VB@C' 2) H'X"I2H(P1Q7/\ VCVC
M_7W&OU1]SXQ21XI \3LCKT93@BO0_AIXI\6WGB[3])MM7N)K:1\S)<'S0L:\
MMC=DC@8&#U(KW;4O"NA:PC+J6D6EQG^)H1N'T;&1^=9?AKX=:)X3UVYU+1TE
M1KB/RQ'(^]8QG)VD\\X'4GI2GC:=2#3CJ..'E&2:>AU8Z4M%%>6=H5X-\?R?
M^$@TD<[?LK8^NZO>:\W^,/@ZX\1^'HK[3HC+>Z<681J.9(S]X#U(P"!]?6NG
M"SC"LG(QKQ<J;2/G2OK/P++%-X#T1X""GV&)>/4* ?U!KY,/!P>M=]\//BA=
M>#?]!OHFO-*9MVQ3\\)/4KGJ/;]17JXRC*K!<O0XJ%10EJ?2M%87A_QCH7B:
M(-I&HQ3/C)A)VR+]5//X]*W<UX3BXNS1Z2::N@HHHI#"BBB@#F?B-_R3G7/^
MO1J^4J^K?B-_R3G7/^O1J^4J]G+O@D>?BOB1[-^SW_Q\:]_NP?SDKVVO$?V>
M_P#CXU[_ '8/YR5[=FN#&?QY'3A_X:"BC-&:Y3<**,T9% !6%XV_Y$/7O^P?
M/_Z+-;M87C;_ )$/7O\ L'S_ /HLU4/B1,MF?)->N?L_?\AW6/\ KV3_ -"K
MR.O7/V?O^0[K'_7LG_H5>_C/X$CRZ'\1'N]%%%?/'K!1110 4444 >7_ !Z_
MY$:T_P"P@G_H#U\^5]!_'K_D1K3_ +""?^@/7SY7O8'^">9B?XA]-_!__DEN
ME_6;_P!&O7<5P_P?_P"27:7]9O\ T<]=QFO&K?Q9>IWT_@0449HS61H%%&11
M0 4444 %5KRPMK^$Q7<*RH>S#I]/2K-%--IW0FDU9GG^O_#2WO59['!/9)."
M/HW^->::QX-U'2YBIB;CHKC#'Z=C7T74-S:07<1CN8DE0]5=<UZ-#,:M+26J
M/(Q64T*^L=&?+<D;Q.4E1D8=0PP:V-!\6:OX=D!TVZ819RT$GS1M^';ZC!KU
MW7/AU8Z@C&SPA[1R9(_ ]1^M>9:YX&OM*E($;+SPK]&^C=#7L4\7A\2N67W,
M^<K9?BL'+GA]Z/2O"WQ,TW76CMK[%A>MP%=OD<^S?T/ZUVX(]17RO+%)!(4E
M0HPZAABO3/AOX\N/MD.AZQ*98Y/EMIG.65NR$]P>WY5Y^,RY0BZE+;L>KE^<
M.<E2Q&_?_,]=S37=44LQ  &22>E)G KQ7XB>.I]4OYM)TV5H["%BDK(<&=AU
MS_LY[=Z\[#X>>(GRQ/9QF,AA*?/+Y+N=1XI^*MEIS26FA*M[<C@S$_ND/X?>
M_#CWKRG5]>U/7;GSM4NY)SG*J3A5^BC@53M[:6ZD\N"-G;V'2NQ\._#N\U1E
MDE7,?=B=J#\>I_"OHH4<-@XW>_=[GR%2OC,QG9;=EL<=!;2W,FR"-I&]ATKI
M-&\"W^J2#]V[#N(QP/JQX%>M:/X$TS38U\Y!.P_AV[4'X=_QKIHXDB0+$@11
MT51@"N&MFO2DCU,-D2WK/Y'$:#\-[2P56O<$]XX\\_5NIKL[:TAM(1%;1+$@
MZ*HQ4]%>/4K3JN\V?0T</2HJU-6 4445D;B'K7R'XK_Y'+6O^O\ G_\ 1C5]
M>'K7R'XK_P"1RUK_ *_Y_P#T8U>EEWQR./%;(U/AE_R4K1?^NY_]!-?5(KY6
M^&7_ "4K1?\ KN?_ $$U]4BEF'\5>@\+\+$-?*OQ+)/Q*UO.<_:._P#NBOJO
M%>"?&[P?/:ZT?$EG&7M;H*MR5'^KD P"?8@#\?K48&2C5UZE8F+<-#@_!5Q!
M:^.M%FNL")+V(L6Z+\PY_#K7ULOW17Q;7M/@/XT0PV<.F^+2ZM& B7Z@MN';
M>!SGW&<]_6NO'4)SM*.MC##U%&\6>U454TW5;#5K5;C3+R"[B;^.&0,/TJWD
M5XST=F>AOL%%%% !1110 4A&12T4 >:^.?A!I_B.674-&9=/U%B2PV_NICZL
M!]T^X_(UX?X@\(ZYX8G,>LV$L*YPLP&Z-OHPX_#K7UU44L$<\;QSHLD;C#(Z
MY!'TKMHXRI2T>J.:IAXSU6C/C))&BD5XW9&4Y#*<$'ZUVF@_%GQ5H>U#>_VA
M O\ RRO!OX_WOO?K7K/B#X+>&]8DDGLA+I<[G/\ H^#'G_</3\"*\S\0_!CQ
M)HRM-8"/5;=><VXQ(!_N'^0)KO6(P]?2?XG*Z56GK$]"\._''0]2*0ZU#)I<
MQXWD^9$3_O#D?B,>]>DVUW;WELEQ:3QSPR#*21N&5A[$5\:2Q202M%.C1R(<
M,C@J5/H172^"_'FI^"[_ 'VA\^SD(\ZT=OE<>H_NM[_G657 1:YJ1I#$M.TS
MZLHK*\/>(+'Q+HL&IZ7)O@E'(/#(PZJ1V(K5KR6FG9G<FFKHYGXC?\DYUS_K
MT:OE*OJWXC?\DYUS_KT:OE*O8R[X)'!BOB1>TS7-4T4RG2-0N;(RX$A@E*;L
M=,XZ]3^=:'_"=>*O^ABU/_P*?_&NG^$G@K2/&,NJKK22N+58C'Y<A3&XOG/K
M]T5Z7_PI+P?_ ,\;S_P)-:5L11A-QFM2(4JDHWBSPW_A.O%7_0Q:G_X%/_C1
M_P )UXJ_Z&+4_P#P*?\ QKW/_A27@_\ YXWG_@2:/^%)>#_^>-Y_X$FLOK>'
M_E_ T]A5[GAG_"=>*O\ H8M3_P# I_\ &O??A)J-YJO@"WNM2NIKJX,T@,LS
MEF(#<<FJO_"DO!__ #QO/_ DUUOA[P[8>%](33=*61;9&9P)'W').3S7-B*]
M*I"T%J:TJ4XRO)FK6%XV_P"1#U[_ +!\_P#Z+-;M87C;_D0]>_[!\_\ Z+-<
M4/B1T2V9\DUZY^S]_P AW6/^O9/_ $*O(Z]<_9^_Y#NL?]>R?^A5[^,_@2/+
MH?Q$>[T445\\>L%%%% !1110!Y?\>O\ D1K3_L()_P"@/7SY7T'\>O\ D1K3
M_L()_P"@/7SY7O8'^">9B?XAK6/BO7],LTM=.UF^MK=,[(HIV55R<G !]35C
M_A.O%7_0Q:G_ .!3_P"->F?#WX7^'/$G@>QU34XKAKF8R;RDQ4?+(RCCZ 5T
MW_"DO!__ #QO/_ DUG/%4(R:<=?0J-&HU=,\-_X3KQ5_T,6I_P#@4_\ C1_P
MG7BK_H8M3_\  I_\:]S_ .%)>#_^>-Y_X$FC_A27@_\ YXWG_@2:GZWA_P"7
M\"O85>YX9_PG7BK_ *&+4_\ P*?_ !KZMTYB^F6KLQ9FA4DDYR<"N$/P2\'_
M //&\_\  DUZ!#$L,"1)]U%"C/H*X\36IU;<BL;T:<X7YF/HHHKC.@**** "
MBBB@ J*:WBN8VCN(UDC;JK#(-2T4":ON<%XF^'EO>0M)IZ9QSY+'D?[I_I7F
M5GI,VE>+M+#@F/[;$ Q&"#O'!]#7T%>7<%E;O/=2+'&HY)->5ZG>Q:EXFBND
M3RTDO8"H/M(HS^.,U[."Q%6490EJK'SV8X.@I1G'25SU@]#]*^;M,T6;5+DL
MP81ER!@99SGH*^DCPOX5Y%X3U"'2;BTN)XO,C$8!P.5R.H]ZSP%25.-1QWT_
M4US2C"M4I*;TU_0ZGPQX#MK&!);^)<]1 .@_WCW-=HD:QJ%10H P !@"F6MS
M#=VR36\BR1N,JRGK4U>?5JSJ2O-GK4:-.E!*FM HHHK(W"BBB@ HHHH 0]:^
M0_%?_(Y:U_U_S_\ HQJ^O#UKY#\5_P#(Y:U_U_S_ /HQJ]++OCD<>*V1J?#+
M_DI6B_\ 7<_^@FOJD5\K?#+_ )*5HO\ UW/_ *":^J12S#^*O0>%^%A45Q;0
MW=O)!=1+-#*I5XW4%6!Z@BI:*\XZSQ#QG\$)5DDO?![;T)R;&5L$?[C'K]#^
M=>27^FWNE7;6NI6DUI.O6.9"I_6OLJJ.IZ/I^L6K6VJ6<-W"PQME0''T]#[B
MO0HXZ<%:>J.2>&C+6.A\@V=_=Z=<"?3[J:UF'22&0HWYBN[T+XT>)])94OGB
MU2 <%9UVOCV=?Z@UW.N_ C2+K=)H5]/82'D1RCS8_IV8?F:\O\2_#;Q+X85Y
M;NR^T6J];FUS(@'J>Z_B!7<JN'Q&CW\SG<*M+8]L\,?%SPYXB9()I3IEXW B
MNB K'_9?H?QP?:N[!!'!KXMKTOX<_%:X\.O#I6NNUQI9.U)227MO\5]NW;TK
MEKX&RYJ?W&U/$WTF?1%%,AFCN($FA=9(Y%#*ZG(8'H0:?7EG:%%%% !1110
M4444 <!\3?A];^*])DN[&-(]7MU+1R 8\X#^!OZ'L?:OFNOLZ:1(H7DE8*B
MLS,<  =37QM=-&UY,T/^K,C%/IGBO8R^I*47%[(\_%12::/4/@1KDMMXDN]&
M=B8+R$RHOI(G?\5)_(5[\.@KYR^!UC)<_$ W*C]W:6LCL>V3A0/U/Y5]&UR8
MY)5G8Z,,W[/4YGXC?\DYUS_KT:OE*OJWXC?\DYUS_KT:OE*NS+O@D<^*^)'L
MW[/?_'QKW^[!_.2O;:\2_9[_ ./C7O\ =@_G)7MM<&,_CR.G#_PT%%%%<IN%
M%%% !6%XV_Y$/7O^P?/_ .BS6[6%XV_Y$/7O^P?/_P"BS50^)$RV9\DUZY^S
M]_R'=8_Z]D_]"KR.O7/V?_\ D.ZQ_P!>R?\ H5>_C/X$CRZ'\1'N]%%%?/'K
M!1110 4444 >7_'K_D1K3_L()_Z ]?/E?0?QZ_Y$:T_[""?^@/7SY7O8'^">
M9B?XA]-_!_\ Y);I?UF_]&O7<5P_P?\ ^26Z7]9O_1KUW%>-6_BR]3OI_ @H
MHHK(T"BBB@ HHHH **** "BH9[B*VC,MQ(L:#JS-@"N8U/QU:P9CTZ,W#_WV
M^51_4UI"G.H[11E4K4Z2O-G5.ZQJ6=@JCDDG&*YK5O&MG:!H[ ?:I?[P/R#\
M>_X5Q>HZW?ZHQ^USDIVC7A1^%9TLT<$9>9U11U+'%>C2P*3O/4\FMF+:M3T\
MR_J.JWFJS>9>2E\?=4<*OT%95B9=6\8:9IU@-_E7*33L.BJI!/\ GUQ3;"TU
M;Q5.;?08&2WSB2\D&U5^A_PYKU/PIX0L?"UD5M\S7,@_?7#CYG]AZ#VKIK5J
M>'ARK?L<-"C5Q=12^SU??T-_'R5X7$LFE:K<Z+? K/;2,(R?^6B9R"/PKW<=
M*Y7QGX+MO%%N)8W^S:C"/W-P!_XZWJ/Y?GGSL'7C2DU/9GKYAAIUHJ5/>/3N
M<?I6MWFCS;K63*$_-$W*M_\ 7KNM*\7Z?J 6.9OLLQ_AD/!^AKR6>6_T*\^P
M>([9H)!]R<#*./7/?\/QQ5Y761 R,&4]"#D&O1K86%5<WXH\G#XVI3?+^#/:
MU(*Y%+7E&F^(-1TO"V\Q:,?\LI/F7_ZWX5U^F>-K*ZVQWP-K)_>/*'\>WXUY
ME3"5(:K5'M4<;2J:/1G444R.1)8U>-E96&05.0:?7(=P4444 (>M?(?BO_D<
MM:_Z_P"?_P!&-7UX>M?(?BO_ )'+6O\ K_G_ /1C5Z67?'(X\5LC4^&7_)2M
M%_Z[G_T$U]4BOE;X9?\ )2M%_P"NY_\ 037U2*68?Q5Z#POPL****\XZPHHH
MH *1AD$'H:6B@#Q'XQ_#^PL+!O$>CPK;;9%6ZA080[C@.!V.2 ?7->-5]*?&
MBZBA^&EY%(P#3RQ1QC^\0X;'Y*:^:Z][ RE*E[QYF(BE/0]]^"7B]=0T@>'+
MEG>ZLD>6-CT\D,H S[%R/I7JU>%_ 31+Q=9N]<* 636TEJ&SR7WQM_(5[I7E
MXN,8UGRG90;<%<*\U^)GQ(N?!>J:;:Z=#!</(C2W$<N?N9PN".A)#?E7I5>%
M^//AEXSUG5&U5[NVU=_+5 D?[IE4=@IXQDD]<\FIPT:;G^\>@ZSDH^[N=3HO
MQQ\-7Z*NII<:9+WWIYB9]F7G\P*ZZS\:>&KY0;77=/<G^$W*JWY$YKY4U'2-
M1TB;RM4L;BS?/2>(KGZ9ZU7BGE@;=#*\;>J,0?TKT98"G+6#.58F:^)'V VO
M:2B;GU.R5?4W" ?SK#U3XF>$M)1C-K-O.P_Y9VK><3[?+D#\:^8VU;4G7:^H
M73+Z&9B/YU4+%B2Q))ZDGK4K+U?WF-XIVT1Z3X\^+MUXFM9=-T:%['3Y.)7<
M_O9AZ''"CU SGUKSB.-YI5CB1GD<A551DL3V K=T/P-XC\0NO]FZ5.T;?\MY
M%\N,>^XX!_#->Q^"/@W9:%/%J&O2)J%]&0R1*/W,1]>?O'Z\>U;NK1PT>6)F
MH5*TKLV/A;X+;PCX;)O% U&](DN/]@ ?*GX9.?<FNYH'045X<YN<G)]3T8Q4
M59',_$;_ ))SKG_7HU?*5?5OQ&_Y)QKG_7HU?*->ME[7)(X<5\2/4O@MXET?
MPY-K!UJ^CLQ.L(B,F?FP7ST';(KU;_A9O@[_ *#]M_X]_A7RO1FM:N#IU9N;
M9$*\H1Y4CZH_X6;X._Z#]K_X]_A1_P +-\'?]!^U_P#'O\*^5\T9K+^SZ?\
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M_:_^/?X5\KYHS1_9]/\ F?X!]:EV/JVU^(GA2]O(;6UUJWEGF<1QH-V68G
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M>-QD$?RKQJU"5)ZGOT,3"LM-R<]:^0_%?_(Y:U_U_P __HQJ^O.U?(?BL_\
M%9:S_P!?\_\ Z,:NO+])R(Q6R-3X9?\ )2M%_P"NY_\ 037U2*^5?AG_ ,E+
MT7_KN?\ T$U]4CI4YA_$7H/"_"P)KQK6OC?<:1XROK.'3[>\TVWE\I2'*2$K
MPQW<C&<XXKV&X$C6\@@95E*G8S#(#8X)KYI\1?"KQ?IMQ-<269U-'8NT]HWF
M%B3DDK][]*SPD*4I/VA=>4TERGKNC_&/PGJD:BXNI-.E/6.Z0@?]]#(_,BNH
MMO%.@7:@VNM:?*#_ '+I"?YU\C3VT]K,8KJ&2&1>J2(5(_ TZ"\NK;_CVN9H
M?^N<A7^5=DL!!_ SG6*DMT?7<NOZ1"I>;5;&-?5KE!_6N9USXM^%-'B?R[\:
MA./NQ68WY_X%]T?G7S=)JFH3*5FOKF13V:9B/U-5TC>60)$C.[' 51DG\*(Y
M?!.\F-XF3V1TOC?QUJ'C74EEN@(+2'(M[5&R$SW)[L?6L?1-$OO$.KPZ=I<)
MEGE.!CHH[L3V ]:Z3P]\*?%&ONC-9'3[8]9KP;./9?O'\L>]>X^"OAUI/@R'
MS+<&ZOW7$EW*OS?11_"/U]36E3$4J$.6GN1&E.I+FD:_A3P_!X8\-6FE6QW"
M!/G?&-[GEF_$UL4"BO$;;=V>BDDK(****0QDL,<T926-70]5900:QKCP9X:N
MV+7&@::['JQM4S^>,UN44TVMA-)[G-#X?>$@?^1>T_\ [\"M&R\-:)IS!K#1
M["V8?Q16R*?S K4HI\\GNQ<L>P 4445)04444 (RJZE74,IZ@C.:B^QVW_/O
M%_WP*FHIW: A^QVW_/O%_P!\"C[';?\ /O%_WP*FHHNQ61#]CMO^?>+_ +X%
M'V.V_P"?>+_O@5-11=A9$/V.V_Y]XO\ O@4HM;=6!6"($'((0<5+11=A9!2,
MH92K $$8((ZTM%(9#]CMO^?>+_O@4?8[;_GWB_[X%344[L5D0_8[;_GWB_[X
M%'V.V_Y]XO\ O@5-11=A9$/V.V_Y]XO^^!1]CMO^?>+_ +X%3447861$+6W5
M@5@B!!R"$'%2T44KC&R11RKB5%<9SAAFH_L=M_S[Q?\ ? J:BG=A8A^QVW_/
MO%_WP*/L=M_S[Q?]\"IJ*+L5D0_8[;_GWB_[X%'V.V_Y]XO^^!4U%%V%D0_8
M[;_GWB_[X%.C@AB;,42(<8RJ@5)11=A9!7!?$"5CJ-K%GY%B+8]R<?TKO:\S
M^*J227^DV\,OE&\?R&<#) R/_BJZL';VRN<68-K#MHY/[9/>7HL-%MFO;MNR
M?=7W)KK]%^& F=+KQ7<FZDZBUB)6-/J1U_#'XUU_AWPU8>&].6VL(QN(!DE8
M?-(?4G^G:MD=*VK8Z4O=I:+\3DP^6Q5I5]7VZ+_,@L[*VL+5(+.".")1@)&H
M4#\!5BBBO.WU9["22L@HHHH&%%%% !1110 4444 %%%% %34-.M-3M6MK^WC
MN(6ZI(N17G.M_#2ZT]GN_"5P2OWFL9FR#_NL?Z_G7J-%;T<14HOW7IVZ'+B,
M)2Q"]]:]^IX1;:@7N7L[V%[6\C.'AD&#GVS7HOP^8FWO$S\H=2![D'_ 5-XW
M\'V7B&Q>Z+?9KVV0M'<(N3@<[2.,C^59?PGN)+O0[B>8Y=I IX],\_K7H5JT
M*V';6C['E8>A4P^+4):K6S_S/0*B-I;LQ+01$DY)*#FI117D7/?(EM8$8,D$
M:L.A" 8J6BB@ HHHH KW5E:WL9CO+:&=/[LL88?D:QYO OA6=B9/#VFY]5M4
M7^0KH**:E);,7*GNCG(_ /A2-LKX>TX_[UNK?SK8LM*T_3EQI]C;6H](853^
60JW13<I/=B44M@Q1114E!1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g945701g86y61.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945701g86y61.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !2 5H# 2(  A$! Q$!_\0
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MOP%X9U[3=%\21P:;;:KH]O<QV49ENLI"LB$1K@*,+@84>@H@G*37DW]SBO\
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M^3I_V+_^QS;_ -+M*H ^_P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *^9?&'P;L_V@?"O[3/P_O9!"FM:];1PS%F BN$T?2I8)#CG"RQQL1W
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M&S_7L/+VX;[O7=ST%?IO8WB:A96]U&LJ1SQK*JSQ-%( 1D!D8!E//*L 0>"
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M/Q _\#O#W_RUKU6B@#RK_A<GB[_HA/Q _P# [P]_\M:/^%R>+O\ HA/Q _\
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M5%;*J,S/$N9%^;&XK^FE? '_  4=_P"3I_V+_P#L<V_]+M*H ^JO^%R>+O\
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MG\>_'^K_  Q^%^H>(-"T\ZIJL-U8VT-J+*>]+">\A@=A!!^]DVI*S[4!8[>
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M52) ;2XG3:2Q&"X;*G*@8)Z"BB@04444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
C!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g945701g91n35.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945701g91n35.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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9+P!@4(!:8!0 4 % !0 4 % !0 4 % '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g945701g99j46.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945701g99j46.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#^17AI9@  34T *@    @ ! $[  (
M   1   (2H=I  0    !   (7)R=  $    B   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $%B:7)A;6D@
M1&5V861A<W,    %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,T
M.0  DI(  @    ,T.0  ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MGK_@VXNM9O)+R=;YXUDDQD*$0X_,FO0JPJ4W3FX/H:0ESQ4D%%%%9EA1110
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M&5"VJ8I1Q?,[25K_ (?<5)O&$%I$K7L4,;EI%98[D/L9$W;3@<$],4R;Q?+
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M_&GU7LK*.PA,4+2%,@@.Y;: H4 9Z# Z>N3WJQ7,[7T.^-[:A1112&%!HHI
M)2T44( HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
#?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g945701logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945701logo.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /;-][<:E=0Q72PQP[, Q!LY&?6@"3[-J/\ T$5_[\#_ !H
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MI?V0T2WVM10F5MJ@P#_&@#06WOV4,NI(0>A$ _QH /LVH_\ 017_ +\#_&@
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M*PR".] #J (+S_CQN/\ KFW\J &:;_R"K/\ ZXI_Z"* (;/_ )#&I?\ ;/\
M]!H T* (I[B&V56FD"!G"*3W8G 'YT 2T % 'CGQ=U2"ZU2QL8GR]J',F/\
M:VX_D: .C\-W?AS0O#XL)M8EECFPQ5@Y$9/88R!S0!J#2/":$I\N2.A=LXH
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MNBQ6XBCN3=:O<?Z^Z!XC']Q#VZ#I[T <5RQ[DF@#N-.%M;>'!8^)+@HER?\
M14*[G@Z_/Z@<].^1Q0!R^K:-=:/<>7.H:-AE)4.4<>H- #M%UF;2+L,,O;2$
M+/">5D3N,?0G\Z /1O#_ (C30D$\-TUWH4Q^X 2]JQY.1UVYW=,]10!Z1--'
M<:9-+"ZO&T3$,IR#Q0 :;_R"K/\ ZXI_Z"* (;/_ )#&I?\ ;/\ ]!H T* .
M0U/PFNI:P]]:ZLZ7:M\V&!,8SP!CIWZT <UIP>RU^.>&$%1O57'F,'<-CD#G
M)P3SQ^E 'G?B'4+K4]<N;F[W"5F^Z?X?:@#H/AQ%;QZQ=:E=(6AL8&E/H,#.
M?TH 75]4C34;EIK60Z?=8E14 ZC S[=#0!?;5[=]%%TM\[ZA<X66 !0$ P>-
MW3J>G)H J:#<6U]JIMX8&421L)Q*!AAD>G>@";4/AX;B[O/[&N%D2W;YD=N@
MV@Y!Z=Z .)-C<K!'-Y1\N1BB$$$DC';KW% '5^#--UC^UELI+6ZAM+@;79XF
M"KR/F&1C- 'J6G>&)K*_:XGOB4,A;:GR[QC 4XQP#SQ0!TU !0!1UE[Z/2+E
M]-56NPA,8;UH \?O+B^CT.:XTU)&U"1F&I2,,S1GG@>B_>^[Z"@#@SG)SU[Y
MH ZGP9'I,EQ/]J*G40N;19?]6SX./;.<=>* ,/6);Z75)SJ);[2&PP88QZ8]
MO3% &AH^MIY7]F:MF?37XY^]$>Q4]>N./K0!4UK2'TF[VJWFVLGS03#I(G8_
M7&./>@"WX3;4AJX33E1@RD3++CR]F1G=GC&<4 >F^&7G%UJ<6EF1O#RHWEF7
M/WMI^YGG'W>OO0!VVF_\@JS_ .N*?^@B@"&S_P"0QJ7_ &S_ /0: *EUKB3&
M>TLMPN0/D8J0I/4\GCIF@#@;35-0M;S4;AY6^U_*KK"5<CEL'C(R.>.OK0 Z
M_P#$LFBVJ0#4D>\/SR;8T& >?FXZ\C@4 <;X:T4Z[=W5S>%S:V\;22N.YVG:
M,_7% &UX=TNZ;PO<W&FRX>\<QO&67 09'.>>A_&@#4UNQMBBR)&L5_M5?)+;
MXY.!]W' /M]: *=W::6KS&XTX+?I($:52VQ7SC:0#UYZ].10!:T>&T<&\>WE
MN;N-VC\BVC.4VG&7*CVX]?>@!S1M<)%;:=J4YU2X)B\M(C& G+'<& ],9^E
M#;WPI_9T-C:I(D-T]R@C'F!V7YADX)(H Z-[OQ%IDGV*ZO\ ]\Z'[.Q1,2$$
M8 P.#['T- &)/>ZI:06=YYMTQ\PHK/A0<#)?#<9.<8/IP,T =?8^)T'V2&5)
MIA,(@UP0 JO)]U>!SSGIT[T =-0 4 <UKOA?[7.=0TJ7[)J ')'W)?9E/!H
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M;0Z% 07DQM:\8=\G^'CM_>H ],@ACMH$AA0)&@PJCL* &7G_ !XW'_7-OY4
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MQXW'_7-OY4 ,TW_D%6?_ %Q3_P!!% $-G_R&-2_[9_\ H- &A0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0!YGXK\4_8O&%I+#<#RK)Q'+!NY<D$Y^GS#\
MJ .\U.2>;0KF33F!F>%C$<]\<8H X?PU>06^M6-M>VMW::FRL&+C*S$L.<T
M3:[$K_%K1;4C]Q-;EY$[,P$F"?R'Y4 7O$EQ+J/BO3M :=H+20&24J<&3&/E
M_G^= &[8^'[;3=5-Y:NT<9A\IH?X2<CYOKQ^M &A>?\ 'C<?]<V_E0 S3?\
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MH ?)I.FRRM+)I]L\C')9HE))QC.<>E #SIMB8S&;. QE A7RQ@J!@#'H!VH
MA&AZ2H8#2[0!QA@(%Y'OQ0 #1-)4DC3+0$KM)$"]/3ITH 1=!T=%V+I5F%Y&
M! N.>O:@"2/2--BN%N(]/MDF3[LBPJ&'T.* &OHVER7#7$FFVKS-G,C0J6.>
MO..] "#0]) 0#2[0"/[G[A?E^G'% "+H.CIMVZ59C:<C$"\'&,]* %31-)C^
MYIEHO7I HZ]>W>@!&T'1W4JVE69!Z@P+S^E $T>F6$-S]HCLK=)]Q;S%B4-D
,C!.<=<<4 6J /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g947560g01q44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g01q44.jpg
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M1WZM_6W.?\45+X-V?+6Z7HLN^P8& , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P",?;/Q,^N/1COO[*I7@L<5O7$CSX/?R6_!?HQU;^[R
M;!9\N72EQ99%@R, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M+F:E3ED&.#AM$F1(]K5HP;4JMI$:1-L\PS9"8@KUA0!DYV , 8 P!@# & ,
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M!VS\3/KCT8[[^RJ5X+'%;UQ(\^#W\EOP7Z,=6_N\FP6?+ETI<6618,C & ,
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M[7#V7YM_N^R?TOKO78+U+'G[,<//SD_,$& , @!:'>\;+G#[1W*5?O?8?0[
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M[4] ULB5JY=R@<I9G2NYYT,_21W?$39TTX* L);;;D<-1F,X'EX5F('PH+,
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MTF,+14_6K$TSTHAR=S4+P>-))Q3;5%RO*=4FVM%+"CQNO=:51MED;.$22)0
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M8;$@7&C;VEW?4B4#RN'&Z:O.J>MF5L BQ8O9%&UCU!SUQY(7U>HO;I9!8#U
M8NS(2G MKCM<0V235WD<U5;6$"CC,[(HD_-46/$G5GR!];'%&B3;3-3PM;Q5
M%M.6I4J][HBNCU1K\COU;^MN<_XHJ7P:L^6MTO19=]@P, 8 P!@%:W,XM;\1
MOQ/0_P#'35P\+?\ ^@JAG>M?_P =X+J6]\(EE."# & , BWW)\2GL'T6^@?L
MFEN"QQ6]<3Y(S;^CD']R2_Y!>?>F8_D7,_V7F_\ *6)ZS:?"6G3EZ3.;GE#
MP!@# -VWU);_ &+]K?XTUI]G!F?'WNL_/K._U6;/TS)#S^1_%;'=/\6T-N//
MS@[(P!@# & , J^\6KM"H^0N2[&!.I-3":?VI!)I'ZIK^]F)=*X#92A 4RHI
MHVO,11IC2Y@WLT=DH7%7$%*A)J5&#21\H8QN6PZ&HJK6-SU.CYKWAACJ(K^$
M?-Z=L*Z^BIS!>O.*>G[ G46B#_9*KF7C\[G">^SI' ]"V2"QY2LE\D<)@B&
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MA.#)%ON3XE/8/HM] _9-+<%CBMZXGR1FW]'(/[DE_P @O/O3,?R+F?[+S?\
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MIDP7&3S&62-P>)9,9&L*(3ISGV4/;NZB2)4B/SO25(G)*!MO$D'@@P!@# &
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MK;6E<:5OIM)>8(, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P#C+42-R1JVYQ2)7!O7ICT2Y M3E*D:U&J*&0I2*TIX#"%*9228,D\@X R
MCBAC+, ( MZV!7K>/AC\]WG<L/OA7+.@ZDL.OZ_65C"EO.]YS:B6^,P]U?7"
M22!O9FZNU3,4@,E#PX#52A2G$6=(/-&PIS$H);$0"1I3:5+G?6]5OI3@6#G-
MS>H,V:H0HSS=ZUK9AR8@TS>@Z\FM;&, A;UK7YM:WO\ -K\VL&3DEEEE "64
M !98 Z" LL(0  '7YM!" .M!"'6OZM:UK6O^& ?[P!@# & , 8 P!@# & ,
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M^^< >_Y1?STU-]8T/^^< >_Y1?STU-]8T/\ OG 'O^47\]-3?6-#_OG 'O\
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MA",YJ34I:*44FZTK5UDBGK^4S7W]!?B?_P!JF?\ _8SW_P#N.S__ .[YG_\
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M2WHLZ-LOY*FJ&5*([6 [ ?HW8:!A=KTCCQ =6S XS''A)74S9G62UPJ?SBY
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22JJ7OU$R,$& , 8 P!@# /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g947560g01v78.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g01v78.jpg
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M%A<B6'&2F-/8\",D,CAX@;&X&"4S-T)U=\$90[*W"B8U8K2U\33_Q  = 0$
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MYW8GV6+8<;BH63TE+50X!C649ID^X> XS/C>-718]1>Y3"!&UL8A3X%2[23
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M:R$*,<VTH733$BQAN.J8I:X<"GKY<]V8UM6I(-F])NT;=@D%3H45%11^T0B
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M(%K.-&PRJUVCQ#:P\&_J[!N-MP[)]G=\,^GIQFC>*5,N*#V<)=62R-%5-@!
M.96 .7AYDXY@B/.>F;INXR^.7:_AWM\YR3,-_P!^=;J;E<)^P6VN5<7?"GL-
MM!MAMCD'$CN6'A=MN_6LV4S0VSW IL$JRIC":?+#<?K$L#<2692H#[(1JH
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MC@M%C,\F?P81A.SVZ8UE#N-F&^..LP\:RR^OR::VI;H4;-NX8]0QT(\LBHJ
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MM+5V7U.G<VXGO$]Z3O S]D@IC!)R,F"(%:[IO9^_N=-UBTO0#I^M6%Y:+LE
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M0GSC@16V>T3_ !E]M>TVGL6'931+?L*VXD"\N_>D:QJ+L$2=-=92A.G[H_\
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M@.%K):P_8.S.CC6M1;963W#:@IY&1N3,;"I,%(5U"@KD".6.U2]-E;+=1&\
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MK(:VR)MS>*$(0;99$?9@5U9'#65U?V_0- M-&LPEESO+X#Q.8+CJAC:I0\4
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MWO1W&MB= ML\<5S"1MZ]G^I6.G:NI-ZIM"KEA3#+SB02%K<:(0%$R K:28Z
MR*T;M[87M[I(5:HN'D6[J7GF&%*&Y"6W05J2F)"9 S/VIXG&OQFXEY8%,QK&
MZV_R:RC!$+4+$J6PMV1#V$I,-<\JSCB2BKF'O"*<*^QM F2002$JY(&.>G8-
M0U;0=*<6J\N$EQ202KB2GB 5%0D>6>))@5R+3-!UK56T^YV=RTC<H;7)VA7[
M12(\/""0>F>,V/SW=27'9%QNNQRY.W,L6R1Q8A; % FT4\CEA0C+HY%:\0)T
MB]H(P5Y,]_%'VU%-/6236T%VSK5I>LH.F.]^XXD%#8. GF4B83M$G&!B>54G
M-#NK%YP:FU[LT@D.*VP5+Y)4-HW21'F! /$BX?#:NYW"[=B;D0A26UQ=PSLS
MNA/>T*3-1##YK>4B(J&6 6NR6OL2[,VC>5U4S4N+BKG960V;;:IUCM/V4MM=
ML%*M' G4$.&X<VP)7'V"KBH8 DDS SUV/LWVGN=)OT-7()L%(#34R0&Y^TD'
MP@C),8@]3CT+[6;S8#NUCE+D&(Y "='< *=&"Z=L%L-V<SQBQCJ@M8;4$P R
M*< \,P.$H$X8D(R* H>6%G"+FW=M7W;=].QUI12M.,'!'#&00?QKN;#[-RTV
M^PLK9=3O;61Q!)$')R% CK6*V]W!;4[M<=7"'Q<DL!7_ *.^';T4]F.2J*1:
M6.5 4H6WCH(^A'*F/$VN<VJO<Y4C)F$5KHW)REH54C(/(3RB.'GF<_'/45L
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M)2EH[H_82  00>!SYJ..E=D.V*W+EG2M5?<*'# N5J*W$%!B-RB3M,C@3R@
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M'G$QST_]!W:'E[B/=E**AM.02?(\L_/SJ\F7\ 6[@FU^39/CVY1,N:P8M>6
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M:+:ZAJ6HI-G:*<NU%:K1AD.WD@N+9=4TCO'2Z4AU87)4IM)4H*2!4EQ3-3:
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M7=M"- [LZ&AS4<Y"8.AS%C)J,F)"$B88V6/=]'UN_.G+M/&\$N(0VI(G8WM
MSQ..D]#SBO3G^%;V%:+[2.V]YVI[365\KL[V%81JC-HVPI5GKNN+7L1I3ZB
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M:JBKB;.PG5/)4C%$CFE5$Y_IN1O2Q%5SG-;YZE>O+=MM)2$K1X825AH!6X0
M-O$85.)Q^'8NTWM$[)=A;=J\[2:OI^B6*AO2]>O,MAP$PEIMIP_K5.$I0 D&
M-X->B+T:GHEZ_/L=O,KXI=LB8#K(J%,9HKJQL!)P*5HJ]N897U!HO<CR2".S
M8/83/-A9 V9L0<BJK]=U+4'TKFW>1!)W%)W@RK<4YS$B1' #I%?+S_$)_B:[
M0]INU2['V9]JKO2.S;:5K>N["S]V=5<I62EZTN=PW#(0E*2D%"G%9"9.#GI
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M(R5TI\&<VCLZQ^Y)?(1WZDLHH:Y]3(5(Z5\4^(&A.QT4-%Z1,>9C2P,BBF=
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M4!PW'C%=]"4)PB=H "21!V@ #^7^]5;J6HU;7=_"UW!VOW!PR'NK"LHPO)J
M28QCY!AR[:F- %(G9&K9'1#3D,F=V;FRM1G5$YDB-<E:W=##[+RIV-.H<5'1
M"@HD#K"9'F!5)YI3K;C:%%*W6UM @Q.])2 ?(DP9D03(/"M*>&WPHVWLX-D'
MW&Z$-M*VW!)=#//76],>556];,3 KX2GU]B$4"I0SWBE+!VPLCQI(GN](VSH
MO_<KUE<M/6S*FP 8.Y"03P(&9D8/'G%>:;]MRP?O;1Y$$7;J5G&()@GAF1$Y
M',<JKK@F"O+'B(M<@QYD\-)28R_&,MG8V6,6SN;(JJOZ(":-J+&3+C-/,<=W
MF5O(5F7L&"(ZBK:!.?>T^YM5WMM:IW>\L-)4O[.V%Y(!!*@8,Y2!!&,B>D^S
M2WOA8OW3NSW9UQ:6C*BHJ20)(*$IP005!2L\.8&[S7*:ZE32E-*4TI32E-*4
MTI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E:)_290Y
MS8[[8=#1'IB\%?M:-/4%I5!$PY9*1EEJ[) 3YS@YWDCX]&+C"L$K2*\VI7(2
MR2"%;=@]UZ9[/6$._I ]YM="0$)B21LF>.)/AX&9Q!%:WKRTA")3)*"H<> /
MRY@F#$\<36$6U65;A[<[J[>YOG5G4D8=C&4.L<AL*ZHG'L*RK.J;*DG/)<RP
M*@GI:I+-AUJR.J?8QUX\Q3#97AR13['VLTS4+S24(:4E\M)"W&$H 4E($@[B
M>D\!U&36.TU]M+Z3,*4@)*.<$D3/V8/2.6>=>IZBL1K2J -$ECG')%AFCFBD
M;(R1KXVN1S7-56N1W/GS:Y4]CE3ESX@2@**4G )2)!'V3$9YCA6YH^R)XQUF
M/(^?QS4WTJ:K>[G[EXCM/AEYFN:VHE32T]::4YY)@HDU@5 ).0-352%30M-N
MK-T*BU=?$Y2#2Y(H(&/>]$U488=NWDVS+9<<<*4 #CXR$S@' F2> YU(XXEI
M"G%& D%4GR$Q\3&!SKRVY3M/6;AY+=9YE%1)%+DF19)E$M%WDL^AQF?*[P^_
M+HJ$<J24, $)]@@?( 81IL8L)4[.N61%]":/IPLM(L[99'?-A!+1X%4@0K,Y
MR3)('(UH-[=..O/+CPF8F23)Y& !QX@&<^59\>C>IJS$]],RJ:MB 1G81BT@
MPP[N41@M=;9*TZ4EB.5>T$FL 8A.IK8VQ&$]@CG*3T:![1047EJAM#*6BV2O
MNVX4%;1M.^>9&<9'SK/Z#WA8<6<"1 CJ8\L\(SQ,<ZM'Z5+.=\^%7B2O"]DI
MLK/G]*;P[@<%N BUQ5J16;>\9-3G5/B&V&Y?5VKA,79+LQN[G]L2:&T=DY.S
MX99RO>.Q).;5LR(($_LF3P^SS\SF('F>N->F4X[L-M'Z2+BPV7W9WHX4*+#-
MD#>!; L&%XO^)_B*VPSZ?$\>X/MD!;JSVVI]M<WI,=R.QN"A9+?(['*X3)#\
MP.9.;/*PXY\JH^+:D@*R%$D)!!.Y7$\08C/2(X5W<1^^>#[9V_$SN/OF+GVX
M7I(\'X\LZ'V_VL'XOMXN'3?&FV J<ZKY^&8#@^VXH=OMU<1W0V[S3!6U ]U5
M0[>.K<H&O<UL,OR"2_B%C@?W_?Q_O- )@" F "=H(!B#)/,$R.@(@ 5GSPB<
M.^<;R^D4XV]ZKC#=L<SP;9STA^24D&99EO=Q&4>ZN#OQC9S9S+Z6DV]VQQ*9
M-EKW&0;V]!M&Q9C/!*23:Y(.:&0$+60D*@H@)2!(E(.(CB>/.M8GHS(=W=K[
MST5^[>641V#5V\.V>]V587N;A^_6\.9G<;VY];AN>5>/\(N\=/NID^/;);-9
MUE!#1,TP.Q-K[['\@+Q(,+'<GJLB@LD!5,OBOG!B(^R)'BD9(&1'*>=;H^-F
MYW^SHOT8^]V=)O+PNS%^D.X<]O\ )^$HC,]J[^F-GM\YS9OY6[@YKM4=E$.8
MNL,=HZF3'<5K\X7%*@6V,)R"B.R=!GT;Z?WY5((\0$'PD@YGA\8^D^=;W-*D
MII2FE*:4II2FE*:4II2L6^,K;S+-T>'K/,.PAC",D-BHSPZYQ,87C4%!DU+D
M!U$PV=\0XTMP'5S@P/*F@!>1-%#93PUTI4L=[I;S-IJ-I=/MJ=2RXF4I7L.2
M!NG:LX,*(VDF(&<TF".G'T'3G_[K0%B>& Y5A#<F%*D28B)I(\$K7-E;!*QL
MD230<TZ']+D21CU58W]3%_T477=5:BG>R&D]XEYOO$*"C&1P&".!P>0$P:N4
M[%A1VQ /.>7^X_E\)OIP4;O[C;;[UXYM_CAT9V%9M:WA^88J:*(^"O:)0S1R
M9-2F1-@L1+!US!CU>2/,3859##R)%JQB2);:'3.V>DV"&T732=ERY"U%(F05
M *"N0)3N(C.,XP*2@G:2" 1!'',D><\,_"<9KT4Q/26*.1$5$D8UZ(OKY.1%
M3GZ_@5-<PZ^1(^1@U3&0#UJV.]N1Y1B&TFY&4X2&+8Y=CV#Y3<XV":QTHI5U
M6TQ9M;'/"V<5\[%+@A11V$COG54A;-$K^MM1E <?8;482XZE"L22%$#'PF3Q
MQB,T&2!U(_G_ 'Y]*\Z-:'=;P'Y1NKN%DYV17^1RC&%VYD%>"I:AU8=:%&-7
MU8=9758(=:&**."'7#,18YC"&SG&%F$]TL&6-&89M+!K:'$(6\LDDE:A!XRH
MXC!/ 8P*NFVP!),\\CACSQ &>''\:IW:O#KK+][=O,<Q<;O1]/F%-EY!CI'#
MQ5^/XM?5,EO)V[&+(^>T&.6B@"C<U#V6A32Y(:Z(Z5MGVLNVV=)-JI)"[TF%
M%7V-H*C(CQ!1!($@IB3/ T;@[0D ?:'#C$XG@>$_'F.%>H^FB?!4UT,B<I(A
M(&/1$Y?IM8B.\O+EY\_7Y^WSUQ11DD^<?+$_C$BJ0&W$@QS'.O,QA06[DG'Q
M7>B9(L,[7;3:7C+RKTD3LR\5N^ZE<&9-0'N3MCLU)9SD]XM<?@XOLZ,P2QJR
M2Y(2,9PJ4"6"8")\9T*JF(WP,C;B!XN!,3PVY^)&*P']&KF(9>V).2[9;J\(
M.4<<OYH^-6;9/#UXC=_\DXR[7>H+%]](=NZ^VV3R/,2]E3)FBC!RM _)J2&+
M"H@KF*..VC<9&J*@9X';X?V?#!C]J?[X5=?8'>WAWQK=/A1I>&^3/]S-X-TN
M%/=H7BPSP?C)WKO=Y<?W9CX?LXR'=,GC)X8<SP++JJO9BNXV/5XV(Y(9N'MR
M?59YD#1J&HDQVDKX+%2%9!$ $$"!!R!X3B>/F(R<Q5&4NP6YVW/H,]P.)>VQ
MC;G',IW9X3N%Q,8W3PCB!XF\DW4S&'.=Y]C[F^(W-I,W(CP?";*]:-6SV9NV
M;S"!2);.NKYVU,\D9:HDCO(S 4J1 Y3P^O&LX>">WWWX5>*?C;V]K.'R^.W:
MQ7"]B4Q;@%VFXBKW*,"SW;HZWRV0_C1VOWAXPL_QBOL@"S;(/:_,\:I:W$2\
M=L\>  OZHZ[+%F14I$A)Y$F51&8'A(',1(,YG' U&[;[R</NX_II*G$=J-_\
MFQ/=+;?--SK#B2"W0XAK2[N]W<^R79^QH!."K939BON/R,-VPX>#*R?/LPRM
M^/R046;XG)48S<75M)<W82A"@C($$""!Y\28P>74@Y%>F#2J=-*4TI32E-*4
MTI32E<.7DG/Z/VJJ(G^[FJ<]#P/.H$P/D.D3SK0%Q44E/F'$AO.$ZO=:"RW&
M*A'0GPH0DMR#M_B8YJ"0.8UK*M@+:J.%DZ=<MA':F->X0H5&]Z]F[91H3MP\
MEG]:_*0M()0D)((*CQDF< <0(G-<1[>N-_IQE#:G@&K<A>U9 6M2@H*  ,1$
M1DDYJQ.U^,XQL7O#@6X3!$J,=I+_ +ME%?,00+5UE9DBLJBLG&":[PT4JGF4
M,NSM>ZQSKC\=S"XSIG>Q][VYTC])Z(\]8M)6];_K TR/_- !4F9A"N$PD\<)
MQ-678G6AI^M(1=N%#5T2TI3RLM \%G'B!X?LQD[N5>EK';RJR2DK;ND/"LZN
MR$@+!/KC!SPBAYF(^*<8P2688B"5BI)%-#+)'(QS7,<K51=>>UH6VHH<24K$
M;DGBE1 )!\Q,5WEM:7$A2#*3(2>H!(D?*IUJ2IZH;<//\9VUPW(,URX]E=04
M%;*:<0C'DSR*]S1Q @0X&23V%E9F3#5]77"LE*LK$H8$6*0B>-CIF6EW;Z+-
M@;[AY26T-Q/_ )#M"C_E$DF8$ R15-YY%LRY=.D)8927%K)C"1N@8R3$#S/"
MO+I-9;ZNG(<)#BHT5A+869#+:MLK2UGL[8PJR,)LS:_(*VN)LB"BWN-DKPX@
M"CGD$Q=C#.R ;U%I-C>VNEZ=;J>8:++33#@#"BH!($E/B!'"8.>5>;M5O-.N
M]0OW@T\[N=<?0X7P$C<3X5 ),G)R"$DQRP-G_HLIL@C9NZ#E$@EM:IFL1T^0
M!B0APS%$XI003TJP0HL+2*$0*N'5XO9L[J2+"8D]O!:&E\5]H3:&>T5P%7 N
M'5M-D*""@)2.6W<O.#F8,&.0KL/8=P+[/6@0CN4!U8*"=Q69D*F$C C !\X/
M#<+Z_7K1:W2O+SL<'N[8<:V,>BNMK'/%VYX%N)W?'CBLLQ(M;OIRKAHNZ6KS
M3@VV[,RR8I9\G\+WAWWRFIOZ$N4@5:O8D47L.[CI!6JJ& G= \20F/\ ,#XC
MY<!$?>\C6O#T;.:SD<(Q>4;%;J\)V8<=Q'!9Q '[3XQA_$7Q!YSQKG;NC;>9
M:4"ZTV9RW+[3::;*P:D0^PB K\;E[$H6FF$@1SB7Z5,L'=D$)W#]D  3R(\O
MQZU>S"=[N&?&LTH<3X.YLVS^UW+]'IQ1E;][K4'&;O/G&>TF=4'#+E&;WE[Q
MD<.N;8)DE?A^>@[FT$.-X/E$NZ.#9&%EN37(<=&^K$J:.9_?/_>H0?V@ )$2
M!PG@#T@YY5]W?#EN;MEZ%PC>6SP[:W&,NWUVZ]&;%C&;8'Q$<4F09CN&!N1O
M_P /=EE#MXF9O(VHV]L,JCMJEU]/M&RP6%]ME( ,CJR"NA-5$&5@=-Q@@1(2
M8C'\ZS"X#LJW]X7]Z^/+;^CX=,KRS>#%LIV%J ^ ';+B&*NL,H-LGXYG93>,
M7:G>+C W%QT7+L0W6L":K$<DIL<#Q*VQF\QNNJLIQE]O&D@<,Y^D?U_&I#!"
M<XSF,SB4P.G'CF9GE5?;>9[M>/Z:/"*_8[=?.LV/S8/B]Q3B?VYGS_>"PW#P
M+<C&1,7R&F/WIVRW!2+#<5X9L7&I0L-X:+[",=HAKG)LK@+QK*LVQ.WE>/'^
MO]_W^$T,[<P!B,#/4 QQYG->B;2I*:4II2FE*:4II2FE*:4II2FE*:4II2FE
M*:4II2FE*:4II2FE*U5>D4VVNTM,-WI%EC,QJGKZW ,I EDG0JG3(,M$%Q^[
MJ8FP3030G7-U%69+&^4.5H\5)8,EGBK)H4W?L1JK=AJ/NZTI)NU!M*E$^&1R
M B3($3@B1'7!:Y;%U@.)!44^ I Q"C.['.8_#/$5A1DV)5$=$+9U;XY.<;4(
M9R:])/T$5[7-55\N?4U4>U4YIR<UR?HKU2T?=6Z^RZF4[BC/%2!&WR@21^!S
M6LK2EK:MI2MP1!7S''$8B#\ZRT]&_F!\=]N+M^3DA<E14-QZ?&\2LK,TY]8!
M(!*\VWIFV<\\T%&87-'3L KW)65Y]&0K((23IG$<I[=6%M97X4Q;AE!(.Y((
M!4I"5'=PR5%1R8@P.$UL^B/%ZWA;A6XF9!,S*E1S/*/D),XK;NB<D1.?/DB)
MS]OSZTKC6<K5WZ2E]#*/LB(XV5<L9E.2$AU:1LF$3$WT"#9#<&+(YC0B!;Q<
M1KZXN%9CY&V5B)"))7S6YM;N_8%IY6KNK0TVXA#)*BY/A,C:4Q$J W0.HF>1
MP^M$>Z;-Y05JC<GC!\R(@F,2"8Z21A'DMO5BXR%5"11.E[%B/Z4:G-ZL3J5?
M+U+S57*JJO+X%Y(FNK6K5PJ^=6ZM123,$ A Y$0<Q$08GRFM244I9"0=Q0!!
M."KEGD,R8&8,]9RV]&]@E>:W--S)V]M:6&2V5+ 2KWN0>JQ2=U$/5C>?1$,/
M:BVQ<D;$:KSRBI)>J1W)G(NV5V]<:FXVI:5H:)22"9)R1CAP _#E6Y:2WW5H
MF 2'0%$G!3!!@",C$&>N,5MI<QCE:KFM<K'=35<U%5KD141S>:+TN1%5.:<E
MY*J<_/6GUDZZGC#2.5\@\#WKRYO?%&YR\D1$YN<U57DB(B<U\D1$^#2E</#$
MD)A,D%'D+&9)&.4^")Q,$<W+MF0SN:LL3)>EO:-8YK7]*=2+R32E=S6M:KE:
MUK5>[J<K41%<[DB=3N2>;N2(G->:\D1/@TI7SV42-8Q(X^F-R.C;T-Z6.;SZ
M7,3ER:Y.:\E:B*G->7KTI7TYK7<NIK7=+D<WJ1%Z7)ZG)S1>3D^!4\T^!=*5
M]:4II2FE*:4II2FE*:4II2OEZ(K7(J=2*U45.2+S3EZN2HJ+S]BHO[-/A2O,
M5O=BV0<*^Y.48;DTK:C$C[:P.P6]LY8P:3(,9L2B2ZP,(\GNX3KVC&:^LO:E
MDG?1GB1V\@\-9;5<A?8NS6KV.H65O;N;&;BV;#22,SM@;E;B2),$&8X@Y$54
M;7&(^U()Y_+F1, \(Y\S:3 <HBGW*VNR'&;D%;&3<W$DJ[*OL85C<R:\@BOA
MHB!)7H4TJ@;="%!]3XS!UF$D8U'R.UD.TZ;5W1[F%LK=0ED)*3+J1WJ)X\B,
M'\<DU.O9L\*I.('6"/Y?$UZNZ">0BFK9I4Y/D$A<Y.2MY+T(G+I5$5O+ER5K
MN;FKS:YSE17+PY0A1'0G_P!?APJW'GY_*?\ >!6'OI#BK,/A.W,GK+)]6USL
M.%N)VDL$;/C!VX&)@Y57SRO?&BBV>/$65<8/VB*8(5.&UDKR&QNR.C)97JMB
MEX$I[T*@3G;! _$P/(2K@#4Z1)^&1\>G\Z\^$^Z-+CE:N/F9-0TBL8LBPGVX
M $[().IR3=B01$_H5$562(C8U:Q/-7=;U[R5V96IXJ*0$@D;<8'49@B!PZ\0
M *N"M(3D<(D2. R.O3A\8K95Z-W:3(++,+K=^WKBP*,JOBHL9B.'E@*-"'-E
M*M+QT<O2Z$*S*:%%5))%',2)7+8)U#'"HWEW;#56K^Y0AE8+=L $;2<J4F%;
MAF"#Q@\_(U:K7WVU4Q!G&08Y"1PG_>:W>HG)$3V:T02!GSYSSZTKCH9U]?2W
MKZ>CKZ4Z^A%54;U<N?2BJJ]//ES55Y<]1I74T89CD>P>!CTYJCVQ1M<BJBHJ
MHY&HJ<T547S\T54TI7S&&)#,21"*-$08L:ESQP1,F*6)G9Q*3*UJ/G6./]"-
M97.Z&?HMY)Y:4KN[.-6)$L;%C1$1(^AO0B-Y*B(SET\D5$5$Y<DY)R]6E*YZ
M&=?:=#>T1O0C^E.M&*O-6]7+JZ>?GT\^7/SY<]*5UH..C^U2"%)>:N[1(F(_
MJ=SZG=:-ZN:\UYKSYKS7GZ]*5W:4II2FE*:4II2FE*:4KY>WK14YJG[/VHO_
M +<M 8,CC4")$?#^=:C^,FGJL$XCMOLK$ CC;GV#9%+E)#8UC98V.%VN)5M*
M7,UG*"4Z"KOYPB"9(W%35PM4-+(X:L"CAZE[.'+E]%_8%\EIILOM() 4MQ6"
MB.@$JE(F3G%<O]H[+#+=G>H8/?+<##JP"4I:&=Y('V@3!"L$<!X<8V;ES5Y9
MH]C7O8U9/)R-<U/-S4<U/T?5YKR5R)Y=7E\&NLZ6'PWL<3XBTHJ;424%S@9Y
MD"/E7(+DM]X3O("7T!#J<*#8/A(C$J)//E'&MD7H^B8I.'/$QF$R2%ANM([X
M&5(HUJ<IEN;$G*Z^*"%$CC"&R&>P96]DCH):SN<PTY$#V32>:M;9>9U.]2^E
M*'?>7=Z$R4IR"@ D D;"GB!SQ7J'2UL.:?9.6ZE*:5;-;5+ "E0D!9($C*]Q
MQ,XR>-9QZQ-7]:7.*>S/S_B6N,$FS$RZQ+%Z7!36X]7W!K<8QF_D==%EUEU2
M"&I3%9@(P>HR9I-J+/;55=D&-RP-$8T64CK?LYLK<Z?=:I<V:%727"FTN%@[
MG6XXIF1*%#]G$ \ZY)[1M0N+>YM=/9O%BV<0/>;=! 2VLG$QGQ)()GARQ$V+
MW2"QG$Q93!YXX ZT2<NQG5>:QBA#/(*(?ZN:11Q.?_X>?ES<WR>G4K2[=+#K
MUT/ VDKSP2!)P1PF!G\1QKECEJEU]ME@G>XI*(F222!DQ(Q/Q@=*V">C[V_R
M;%L,R+)<CKGT\F<9!-D@=+,YCYZ8,JJK 8@IWP/D$0XF2MDNK6$1\@PUI;&#
M1SFNADM+'SMVIU%C5-5?O6P-SBE-P)*4I:.""9)*I@SRKT;V<TQS3-/M[19_
M\" Y/[2BZ (5F !RB9C\:V)ZUNMAKYZ&(Y7HUO6Y$:YW2G4YJ<^35=RYJB<U
MY(J\DYKR]>E*ZV##1N1\8\$;TY\G,BC:Y.:<EY.:U%3FGDOGYII2OB((."0F
M6$0:&4UZ2&21011R%R-8D;7DO8Q'3O;&B,1TJO<C$1J+T^6E*[ECC5B1JQBL
M;T\F*UJL3H5%9R;RY)TJB*WDGZ*HG+ER32E<]#.OM.AO:=/1U]*=?1SZNCJY
M=73U>?3SY<_/ESTI76T8=D\I3!X6$SLBBG);%&V>:.!7K#'+,C4DD9"LLBQ,
M>Y6QK(]6(G6[FI7=I2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE
M*:4II2K8;R[;@[M[9YCMY8$D 19+33!C68K87E5-I"^,VFN!8IV/@E*I[84*
MS&B(9(-),*QD\<D3GM=7M+A=G=6]VV 5L.H< 4)!"5!1!&,$ CB.)YQ4JD)<
M!;7]E22"8X&#!DXXGZ9D5YS-RL@O]B;TK;K=JNM*?(!E>^!U?36UO37=4TB8
M,?(:(T&$URU1SAY',%.>VT E_P F;!VC&OF[MH^N66JMH?"2+@#:ZVD@92/M
M;8YR.! _G6D7^GW%FXL.N-EE:RI"@!P5T)4>0C^R3</@JW0Q6ZXJ,/&H+<B:
M5^WN:),KZRUK6)WS(-N)H@Y9+(0)ZD20"E$>'L1[D8/(21%&X>-6Z]V[<1=V
MS.QDGNU>):@#PGF,& 0 ?YQC)=GVPV\^E3B0=LM@XXI21N!(.3QP28SCCZ/(
MG-?'&]KD<U[&.:Y/4YKFHJ.3YE1>::Y'$8X1B.E;/D8/'G'">=:@_2CWM503
M;)6X@4UYDD<V<!$4U837LM5Q$@2E,-MFC&3#*1"'D-;CXD,CR(AX/$"W)VA"
MPL7>^P+[[.INE""II36Q1"5*A2L08(P1)/D,U@=?:0JW:45D*2XDP% 2@$%1
M'.0)'E/")K4UAN6;H;HYWBV!5>'"XU%EU@;7#WA5D3>6U17AU1]B5;2440 (
M;9H>[C!(OBY8(M@:(KY2TEA'(Z!KVMO:9I[EPTE(==<4TE2V_!' 1*Y/R$\2
M!DUK^G6J+NXV*W=T%<0HDP/,",'\ ( XUZ9^'39ZJV:VYHL7K870M&"B1Z/>
MLLTDK^J4@DJ=W^(4:81)(8:7-_CEESS$S_XLK]<,NGE/W#SRE*4IYPN+DR-Q
M^Z.*0)X$GC6]MH#3:6D3L0,3D_B>?_N9J_NK>IZ:4II2FE*:4II2FE*:4II2
MFE*:4II2FE*:4IJ!P#\#2M77I4X,.-V7Q&GOZ<NQR"ZW!J4PXR!8(Q*@ZL#L
M3+XBTEF:]LPQN)+>U8X#(Y9R33("(G!('+9A;-V/MW7M:9"%([I*>]N&UB2M
M*2)C*><?(\>%1&2!YCX?W_*M#X6WE)57M=E%(QE-D=/9U]W4W PXTI(=M53Q
M% $N:1!-$0V.>%K9828YH9QU?#/&Z"18T[%>Z:Q>6SML&D-]X  I$I5((4!)
M) D@!1F8F(P*JI;22 9Y\QR!_GR^L5Z2.#7BI#W^QB:@M:=<=S["*N@'R8"-
M[)JFP6PA+A%O,>G;))(M38DU-HR( Y![.L<*Z F&8=P=@;P_6M(N-)N%MNP
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MC'#4J^YSS>[)3\WSDZ6VS.T#'#N4F"AJQL;CJ9BXW8;74T#6>$@XS9DVM<X
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M).Q4<.4 9D"N1'SCU%[XS).R'J:!+>0.FZ'64"OYUV[3<'4&WE(/=N-=TWC
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M:4II2FE*:4II2K.[^;50[U[29KMI-9S4SLFK1XA+6"-9W5]G6V8-W4F2#)+
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M*;M3D]6F0YL#2U-CC$U77%05-Y4VXTT->9:2=O8^$J%85MJ'8QD'.*)&K_$
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M4; GC*1^UCB1-9C1].N ZF[ 4IM8[Q)+:A*5@*!F3 @\8)Z"!66O&+L>7?Y
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MU*]]0RW:UJK+8. AZ9745ZI9HV_K4G=TY?&>O+K54=EM<42!8KQPR(5'$)/
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M2M*BF?M 2#G;B83 !XP"3,R,)B:ZX+BKKLI=*6>V"26Q#D@?')"K&,%S/"[
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MLM8LZK:K0D 3A(]ZS0G$8\<#% Z+HZFRS%9&J=$J,DE8 >R-\SQ'/AARXGA
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MG&-K"R;1(Q)D#A#LNZE/?*.> 0/_ ("-(@/ GA=)&<,K[E-PRI(4'40H2)4
M?E/'-63VGWUNI27K5YLI$D%"CM'/= ($&1QX@CE57B9#0GI,H-U4F=W,=73]
MUL1".PL&*UKP)EBF>D1C7/8UPTG3,U7M16(KDYS]XW]]'[P^7'CY5;*:>2,M
M. D2)0H8ZY Q4Q2>-51.TCYNYJGZ3?-&_P"DJ?I_^'U.]?)?)?/RU-(ZCYU3
MS(R,\HR>L9KL22->7)[5ZN7+DY%Y\T14Y<E7UHJ*GS+SU&D@&.?3Y^E?>E1I
MI2FE*:4II2I ;E&/5;"WV=W6@,KQ$L#Y32X1(P@%<YB'%NG?&T<-SV2,:3*K
M85>Q[$>KV.:E,N(0"5N($"22H#'SX]?E44A2U)2A#BU*4$I"6UF23  Q'&K:
M9!Q![14$$TA.;5LJ,KY;"(FOA+L:R9L32WH%'=BCR4*6I/<"H1:F:TAL2)FL
MBA'=)-"CZ"K^T0DJ+R# F H$GERQ]:R3.BZI<$!NS?RO8241M./M Y R,D1F
M9BK,Y)QL;98ZEEWB.TCEHX16WH9+*V(ZHL[6:>"FJYA8[*=;"8V6*!92:>4X
M,$8T:>:=SVEPB6R]7M$IW!1)Z0>/2/PX^=9QCL/KCH"BA"4E4">8$;E Q&U,
MYF#(( QFT5]Z00.N+-A$Q^KGDI.[(:&"1:W\&02%BSV$\>.WH=># ._'JH.P
ML[E+.K<XCPVV!!:CJHXN#%/=HT)5M0CGS$G$XS'(2?IBLTS[/;@@&YNT,B<*
MB?WDY(!.$D<929S!L]=\>6XYTL,8 $(SPPN]"/%K*D0>\R XBJA$Q>U#L2[\
MYE8.7,H26%"<!8VC;FL8'*U$2TDM'=?><*=D)V@S*8W$QC:2>!!R(P1GG6<M
M_9YIJ0I2K@W)D ^(I#0\0*P0D25)\4*!2-AD$$"K-&\5F[EL2 "R]+A6P2F'
MCDDR:VY"YGD*8+"S)625C*^>.C %W&HSEPY\TN/HZOL!X$C+1ID=JO5KM9$.
M<"!PZQ'#B "( QRSQK,(['Z*R0IRS;6X$&(PGNTE>% S+A4A:=^%&0KA5K['
M>O.K>&,^TMXBX# 3[7(!^Z]X8:I>,?E#->%0%$FALRE +F_IZPZ()@8$E*.^
M<"2NEDIH[==Y<.*)4ZJ203! !@8\AS'#EBLHWH6E-(2$VC,)2$I)3, *$I)X
MD$I2HDJE0)W&0#5)V.89MU"+-FUO86]*W*)J6U@):(DEC=3[J.N2R[8!62FO
M6]Q;'9 Y;$R>4D.X,@=+*PJ>-:!<=422ZN3))WF"3))P0>(C!S(Z$U>)L[-L
M -VC*$@(3M2B2E(V  2"!(6=QB04SC J!)FFD@?6#2E]PC,O0L:CD+L9B@21
M:N^CK"!FK,D8]K9$7F!O(-%9$2VSQ@ Q[W3M69)2I1_:4<$03_(]3],$&JH2
ME+14$-H45P=B!D2 )CE 4>84%*!G<:XK8()+F%K>YQ1-NA\EA&[O"R!"3,NP
M<$02.%G3$V",+-FL'C7KZV#P11-5)%5D)' GCRSG('*>9$]1CRJH1#:TR2%)
M4DF2%)&Q1PJ1!.TP>1@S-20>:6,<.4=[1(Z^IIY)W(KYN]*+4TV36Y$Z23,<
MUQMUM]/:2QO?+%"2V6*-7QCQ,;3*$J3!$S&0/@>F,IG,<@.%3$;2D!:SW<P"
MJ3S3GJ$I<VCC R0"9KMEGDAK;R!\D,CPW)',Q5CY*S%Z;<^LK8IE1[^3&'4^
M-A]DYK'/*) BC1)2AD2I"0G:0-H(/+B 0!,#Y\)SG%0W*61!49$Q,[I*)CJ0
M"8X<Q/&N\TV" Z8-EA!.Z:7+18HNTAG*D/@3>Z@'@='$Z29UH6/X;V0[%B5R
M7(!$<4LA0JLEVI/E$\,2?$/C&#Y=1B A< G<<)P)$"6R28(D@<3G@K\()+,
M*T1QTQSXIK8(4B1H93N85;F.)7Q934FAA"DG)%$R8N<2";O321E'FBBFLZ2
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MUC;EO*$0=EI;V4Q8Z22]!K;W<(V'L27S.5G_ '6!%MZDD63O<;V=M#_B.E4
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MAQK<A(DJG=VG%#KLI>DLCPX!"RC28Z>A= 352.26%A3)(VCRCDL_3,9_'@.
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M O;$ 80>64D+N%8=+#-W:1+&D;VW22E)&T'B)R(/'/GR/^]05IU["I8D$3Q
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MEL[,A'W\-<#: S.9!20U,@,*FAR"@11PE>8B.DC>U)IT?'-!37?(4!"(B=W
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MO+9>[*QG=TBZ?/6%NN;2KO'("2J=RYP)D<@<<0?@1)K;4VEH -MK;I/("W9
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M(/Q03_M4-S@X+.>/CX_Q4Y)[$^CV(J)]"*J?L54^'3:C[@_<_I4=[GWU?_\
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M-0T?3+&_[\H:*[BV$(>:(!* I)R4I$*!,#(X36X]D+>V;UC3-1O;NQMV&G'
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MZ51W#,9Y0]I_9FR[/=H39V# M[)^U8>80$A*0XM;X6V#]DD!*"8@00. )KZ
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M4/),%!,^()ZB3^T>-6NJ=D,V'6VO"]QK47++,Y"Y):U8GT2PQ#H(.$E!8LL
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M2M0W8*H'V3@\LFN6:5[(.W3^MMV%WICMM:)N&N_OMP7L;[Q(<<0U"-Q2G<H
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MB_K6E6JFD7%\RTIU"'$!94#W;L!MQSPPTA9,)6[L23(!P8[]Q^+3ABVBS ;
MMR-Z\'Q++)Q:HZ>JL[1RI3@7DC8Z4_)SQ6D5F) 6SGL=7'9.;4"FPO9./-)
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M62U1>.AVHI-225!+!$4V9&ND9T_"WG,W87CN_8PL]VLMK"BE!2L"2DA:DD$
MS$53>US2;?N>]O6A[PR+ADI"W XRHE(=06T+!02")GC585W$5L/;+DC -S<=
MFGP_:VHWLR41TQ<!]1M1>U$M]69R2 3#":M'/4PN+EEA@DF#1\$)L(Y!0T,L
MAM;A.R6E +=4P@X(4\E6TM@@QN"L9.>(D":K)U.P7W@3<MDM6J+UP>(*1:.(
M+B'RDI"MA0))B4R H D V^R3C=X2\2R%<4R#>K'0<A;5XS=/JV Y(=/'5YE1
M@9+BYLKJ^H+ABBNJ&T LPNTE:]PQ+'/:QR/:VHC3[Q:-Z6%%$K3.Y RVHI6
M"H$[5 @P.(Q5NYKVD-.=TY>MI<V-+*=CJB$/-I=:4=K9 "VUI6F2,$$U5S^*
M3AQCW7;L>_=[$F;HNO&XLW%G&SHY<L>$EBS$4N%B\ _*YP:I,W%O%?R@5')&
ME=VJHQ9!9W)9[\,K[H)W[X'V 8W[9W;)_;C;YU6_2^FB[]Q]\9]ZW]UW4F>]
MV[NYWQW??;<]UN[SEMG%4]DG&?PI8CC^+93D.]V(U]%FD>3D8V8C[0N2P PN
M_*Q;++=X((1-A7T6/9"$746M_9BATHAL$D<AZ<D59DV-VM2TI865(V!0P "X
MG>@22 5*00I*022#PJFYKFDLMM.N7S*6WN]+:O&K<EAPM/+A*2I+;;B2A;B@
ME 4"-V*R9J9ZV^JZV\I#Q+BEN:\.UJ+:L+A.K;2KL1XS +&O-&(E&,!-$FB)
M$*'DD@(@ECFB>^-[7+:J24J*5 I4DE*DD0008((.00<$'@:R27$+2E:%!:%I
M"D+3XDJ2H I4E0D*2H$$$$@@@@Q4?W%?BO\ K_F:A4TCS^1]*=Q7XK_K_F:4
MD>?R/I3N*_%?]?\ ,TI(\_D?2G<5^*_Z_P"9I21Y_(^E.XK\5_U_S-*2//Y'
MTIW%?BO^O^9I21Y_(^E.XK\5_P!?\S2DCS^1]*=Q7XK_ *_YFE)'G\CZ4[BO
MQ7_7_,TI(\_D?2G<5^*_Z_YFE)'G\CZ4[BOQ7_7_ #-*2//Y'TIW%?BO^O\
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MTE757[@]:UL[VXIOMA7&J/OEM]PUY/O]A%IPB&[+SCX[FFT6*#B9F9NS+E[
M\@AW*SG&"_ I*<:)IY]757G0TYK(@RY(R(&9!D,KLRRX^&%BZ#TK;>42@-;#
MM[I"QNG@"4\.(K7KQ%^UK'OK&GNWS*]*-F0ART: =-TI[:X+AYLE!0!)2E?V
MH )D5@)A?!)Q3;$Y;LZU<+XC\NK,8X,-N=J+_)>%3>78[;X@3<*NW;W:SNZP
M^S=O#F&.'W&,XO4YC3UU,?7UR"D]C#)#(G1,./D%W5L^AXA5N@KO'74INV7W
M);4TRV%CND*"5*+9)!,^69.#8TC5+%RT'=:BZEK2+>U6YIMW9L$/HNKIY;2S
M=.MJ6VTEY*4$"#@\H&5Q^WW$MM=N3Q-Y)C/"=+Q!@\76)[*FT<6=9OM/'5;?
M7F*[4UFW61;<<1(]UDT;KC&:@H4O(YS=MA,YJ[U;2ZK &(69&;/:3;NMVR57
M/<>Z+>"MC;VYP+=+@=MR$D!1PD!PH( 23P K**:U.VN=1<;TPWZ=5:LRGOG;
M7:PXU:IMUV]^E:_&TA04Z56P>2O>M*1N5)I[,-E>)7;63CAVXQ;AA$WNKN,5
M/$<.W#Q_-=N<>P_"R,BV<H=J[+"=S*O-KRARP/#=MS*<NXQ)V*T65>*T!ZUX
MHM3;2RC0S(<MW/<G57"F39X6VIMQ2UA+RW4N-%"5)*W-P"]Y1"A.1%4W;74K
M<ZS;M::F\1JT*:?0[;MLM;[1NU4S<(>4AT,VY05M!I#NY"MJ0E9(%96O ";'
MO;Z/JY/H",UQ_9O:>'"N(O*8+V"NH<SR/9'!\>7A[OLOQ<RS#/S*>GW&FRJ_
MQV=E79S594L"W;H081(]2"\'<WZ02A3SI7;I[LE2$OK4+A*% 0@*:"4JRD$<
M)-55Z(KWS0EJ0MY%G:AF_="@EM]=DRW[@MYI2@IXHN"ZXV2E122-^  -L7<&
M_$^[7WZQ>W_5^[_6MHE757[@]:=P;\3[M??IM_U?N_UI*NJOW!ZT[@WXGW:^
M_3;_ *OW?ZTE757[@]:=P;\3[M??IM_U?N_UI*NJOW!ZT[@WXGW:^_3;_J_=
M_K25=5?N#UIW!OQ/NU]^FW_5^[_6DJZJ_<'K3N#?B?=K[]-O^K]W^M)5U5^X
M/6G<&_$^[7WZ;?\ 5^[_ %I*NJOW!ZT[@WXGW:^_3;_J_=_K25=5?N#UIW!O
MQ/NU]^FW_5^[_6DJZJ_<'K3N#?B?=K[]-O\ J_=_K25=5?N#UIW!OQ/NU]^F
MW_5^[_6DJZJ_<'K4IOT.JZ*ZLZFC)R.UKJFR.K,>"F!!,OK 0.8@*F$-M"1*
MP,FT)CC!@*L2A@1Y9V2ED0CLDD;%* 5)!)2"0"HI)"03!40"3 XF 3T!-2N*
M<2A:D)6XM*%*2V E)<4 2E 4HA*2HPD*40D3)(%:(MGN"OC>VDS##]Z[^EVW
MS/)]\L2WKQ;B8Q;"F-H<YJ2M]H;[<ZMN,TR?*-Q3,(S=NT&Y;:C!*AV!5]:0
M%B5B=#5CY!7K-8Q9QZYLGD+93WR$L*95;*<E39#!2T4MI0V%H[YO<M6\F5 3
M! !TFTTG6K5]J]6W;NNWK5XUJ+;*>[>2;[?=!3SCMPIEX6ER$,([@(4EI1".
M\22H41MGZ-'B<PQ_#QMW60KCFT5QPI;L YZA&0T9MEPZ\36[G###M-N$T!1+
MXHN_QC,,UAJ\Q@7#O'0*W+DS YDM?6V8)!L[M_;K-PXH%3HNF2B$KVW%LU<E
MYN1MA*D(E!*]I*"@02DBJ-MV?U)GW"W2"W:+TR[#\K0I5AJ-YIHM']A2LJ6V
MZZ$/?JN\"7N^5A*A-ZL?VDXXK^PX<\"39*RVMPG8[9'(MKMQ@;HOA=R;;&^-
M!V@RG"*N\V+R,$6\WWIK7<"Z(QKQ%I9^ T]7CM<E5=B]XGLIS:"E621<.%T/
M+?>2ZT4BZ0ZF7D+*7TDI8*6P%1A94HRDD 1>M6^M+.GL>YJM6;*S<M7TK_1C
MELLBT<82NR<2A=\A5PHM[I4PA#:=BQN*B>_AYV0XHN$5:/)I>%VUW^(W&X-^
M%_:.YQS'L^VGJKS:;<C9+#KS'K_ \BGS7+:NB-V[RTN_CM+#)<.M,EA'LJTO
MO%)80O *(C<.6UWN3[Q[OW=Y=/!2FGE)>;?6E06G8@J#B0F E03@B#QI86NJ
M:5L<_1J[TW&DZ9:K0V]:I7:OV33C:V%]\XE!8=+FY3C2G %).Y)&TFE=I^$;
MBPX0*K&SL?PC)MW;G+.$S$=E;2^V:O\ 9Y,\V&SO&]Q<YSY:C%J_B +KL'O]
MM+"'.X:)QBLN)1B\7B/,QB45P,S)G;FVO"H+4&4HNW'PEY+_ ';Z%-MH!4;<
M;TN#NYCPR%$!<R*I6FF:KI*6U-,NW2W=*:LU.6B[3O[)YI]]_8TF_(9<MU=_
MLW'>4EL*+9&TBF:[A=XTL<S'8#-\YVXWMM;NBX3KG;'.3N#_ '$X8=G+"FS
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MLZJ=Q-PZJVLG5N3 '4XDX$+ BPX[*80H@4L,N0IZV=8;0'+4%+ET3[PQ<+4
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M[]4MO^K]W^M74JZJ_<'K3N#?B?=K[]-O^K]W^M)5U5^X/6G<&_$^[7WZ;?\
M5^[_ %I*NJOW!ZT[@WXGW:^_3;_J_=_K25=5?N#UIW!OQ/NU]^FW_5^[_6DJ
MZJ_<'K3N#?B?=K[]-O\ J_=_K25=5?N#UIW!OQ/NU]^FW_5^[_6DJZJ_<'K3
MN#?B?=K[]-O^K]W^M)5U5^X/6G<&_$^[7WZ;?]7[O]:2KJK]P>M.X-^)]VOO
MTV_ZOW?ZTE757[@]:=P;\3[M??IM_P!7[O\ 6DJZJ_<'K6/_ !4 ;PR</NZ=
M;P_T#KW>+(<9GQ7!8VV=31LI;7*R!\=FS&:RN["M"BBP>OLS,O="V>4TU:1H
M->&<:3 )-7M4L^\-%\J#*5!3G@4=R4>+9"9/C(".&-TR.-6.IF]-A<IL$*7=
MN-EIC["-BG2&RZ5+4E(#*5%WF3LA*5$A)TU$^CZXKMJ-I>)/AUQS#MO-S=L]
M[MF=FG4;ML(1-O<?I=TMG;_;_";(2XQS<G<>ULB+[=#:^DBR7+<M%-6HM\@Q
M-_>1JRSM&^)9@7MJZ];7"E/-N,//;N]E:E-/!Q8*5MM@0TZHI2@P0E>"0,:C
M^@]5M;34=/;98N+>]M+/9[L!;MHN;-;#*@MNXN%*+ES;(#CKH5M6XT20E2O'
MWY+Z.;BA RO?K#\<!JLSVGP? .'JKX6WY5DU9 /G>"[0<15QOW%P]YY(2>?<
MBNQX6[LMOJ+(;NI9CY=)5X7*68UL5HT*";ZV*&%JWH=<<N3=;4&4./VR;<W#
M8 B%;0XI*3N"E.1RW1<T'4TN7K+:4O6C#%@C3>]6D=\Q::@N_%@^25+!;[Q;
M#;BTELH2SN4(5MK#>K93CFXCV\35K-L_EF,8;FVV.V>.8+MUN>1PIP[@,S2@
MX@-NLUL*G&<VVOF(N9MLL7Q"HRXT2'<C<HF:QNK*<JNJYRB1FBTV5V5M[LD.
M)4MMQQ:W&A=ELH5;N(E2'82'%+*1^J:$) !, U7O+76]1_2*C:.MLO6ULVRQ
M<#2P_P!\W>V[RD-OVTK-LVTEU0%Q<J*G%$I1)$5)N'PZ\3E=MKQK<*6.\.;=
MQ >+#>W=+<##N(-^;[>5VW^-X]O+:55E)8;E4]U?#;D#9-M!'!W:E&QS#LCB
MNFT=$E*0*@Z]$&WK<NV5TI\MFT9:0JW+;I<4IE)3^K*4EO:]Q5N6F-RMP.:F
MN+'4DV^LZ8WIY?3JM[=7#=]WMNEA#=XI*BJX0M?O <M -J$MM.!>Q&Q28J4[
M@<.W&=M7BW$[LSL_MWDNX=EOEO%-N[A&_-85PVW6-7 MUM_CV*D[;\0>'\0<
M=R=#C>*W5%%;1$XCC&1&W-2/7@4EC3%268I,S;MFZJV>>6&PPR&5VY3<I6DI
M<4OO&%VY3XUI5'B4 E1)4" ")7K+6;5O4K2TMW7U7MV;MJ]!TYQM:5L-M&WO
MFM0#B@VRML+EIM96D)2VI*BL&9#;"<46#<56^VXAVV7%5D=!GMYP^7-7=<.>
M\W#A@FWN5E8+L;MSB&9/S#$MP,TQ?))AFY91W-=$,)25,4]+',T$=D! CW0[
MVV7:,-!=JDMIN$D7+%RXZ@./N+2$+;0I,[5 R5$[N)F:G%IJC.J7UPJVU-Q%
MPNP6E>GW5@Q;N%BRMV7>]:?=:61WB%)@(0"@': "*M=EWH^.)NMSC*MS-M\9
M[)V[/I R,PWKP,S)<98)E&Q>+\3-/O/M-O;3.DR*&N#R;$Z\+(*<ZE(G7)K+
M%LM<"ZA99TXT*U47ML4(;=4K]58;&7 A<H>7;*8>85"2=JCM4#&T+3(40HU:
M.Z%J:7G;BW;/_=ZZIZ\84MN';-O4DWEI>H_6;$NM)#B%-D]XII[:6]R,7IX4
M]C.(_:+<[(A,KVIXK!:>XX@]^,L")KMZ.'F;AC=B^XF>9A:X[?Y#MW%GLNZ!
M(BU=T%;VX 50^Y;;M;+%7.?$\9:%TXPZTG:Y:DBW8098N/>MS;:$J2ESNPV#
MN20"5!.WB:O=,M-2M+EQ+EKJ80J^OG4E-W8G3N[N'WEMK<8[\W!&U:5J 1OW
M\$XBL>Z[@^XMVXGG6W.$[&[D;?X@_A@XJ]N[?;C<G=W9_=;:6LS7/MN[6CVU
MQS@\R2RNK'=K Z#),HG"(OX\YM,2QT7&VQU5Y"TX*"35=5Q;;D.+>;<<]ZM7
M ZVR\T\4-N!3BKQ(2&G%(2/"4!:MY)28)JQ3IFK=T_;LV5RPS^C-4MU6]Q=6
MMU:H=?MUMV[>DN*4JZ90ZX07.^6TVEJ$K (%5SNKPK<5(V3SR[3;*9_C^?9%
MC'#6#%FF.[K;477#5G1.WN*8519#_P!*[97<VTLIR[C;YE&=64%KM;C=N5=U
M==CYE1:16X\[5D:?MB@AYU"FTJN3L4RZFY1WBUJ3[J\V$P')E0=4-JBJ1!JM
M=:=J@=)M;.X;N'&].3WS=Q:N:<^;=IE"_P!*6=RI4KM]A2VJV;67$);*%[P1
M6_'N#?A9]VOOU@]ODK]W^M;O*O\ -^Z*=P;\3[M??IM_U?N_UI*NJOW!ZT[@
MWXGW:^_3;_J_=_K25=5?N#UIW!OQ/NU]^FW_ %?N_P!:2KJK]P>M.X-^)]VO
MOTV_ZOW?ZTE757[@]:=P;\3[M??IM_U?N_UI*NJOW!ZT[@WXGW:^_3;_ *OW
M?ZTE757[@]:=P;\3[M??IM_U?N_UI*NJOW!ZT[@WXGW:^_3;_J_=_K25=5?N
M#UIW!OQ/NU]^FW_5^[_6DJZJ_<'K566L/_6=BO-$7Q U%Y,1W-$)D5/7RY<D
M5$]7GY\_GK.IFY<&"<G^8C/F#]/B,=;*/NC0DX*!G\#RS$=,U ]DWXWW4>I=
MB>GU/K5WX_\ +]:=DWXWW4>FQ/3ZGUIX_P#+]:=DWXWW4>FQ/3ZGUIX_\OUI
MV3?C?=1Z;$]/J?6GC_R_6G9-^-]U'IL3T^I]:>/_ "_6G9-^-]U'IL3T^I]:
M>/\ R_6G9-^-]U'IL3T^I]:>/_+]:=DWXWW4>FQ/3ZGUIX_\OUIV3?C?=1Z;
M$]/J?6GC_P OUIV3?C?=1Z;$]/J?6GC_ ,OUIV3?C?=1Z;$]/J?6GC_R_6G9
M-^-]U'IL3T^I]:>/_+]:=DWXWW4>FQ/3ZGUIX_\ +]:T=[(>DRWDW0W=VXP9
MM/L5F,F;;\9IM?D.TNWU7NO#O1MUMYBN9YCB)6\V1V-A'=8"_$Z2+'*V[O7N
M(KXY![H:M$(@M)&CLR[VF,-M.+)>3L90XEU9;[IQ:T)4&DB0O<=Q @'[))Q6
MH6?:&\N;IE@(LG2[>NVR[5A-U[VPPVZZT;MQ1WL=TC8A2S*00L)!"L5-N&7T
MDNY&Z]?-GNXMKL=5X=C^*[T9OE^WV'[8<0+-QQ<?VGK<V+<VJSF^CFV?*/)3
M&!+.>-+N9DP))%8-V=RU(H87&FM-'8A+Q4I32$.*<9[LJ<*/M(2>] &XC[(@
MP3CC-I_:"ZNDE]]5DEI#5V\ZPU;WXN BU2\80\L&U4H]V%$!9E)*1"Q O;0<
M27&I!L;<\2N:[6[ KM7=\,&X/$%BH&*9+ELF6[<6-5MX_<7;S$]Q&W2#!9_#
MDM>^&MO;/"(,8\%LH#>B*4-1"R*1M;(O"W0M_O!<H845)3M6DN=VM2()*"DY
M 652"/,5>(U#6!9KU!ZVL?=EZ<_?-I;==[VW4ACOV6GRJ ^'$D)4ME+>Q05B
M-I..('I*M[6<,^Z^_P#/9\..2'X/M1@><AX=2[:<1F)>"W6;9Q@6/.ARC(<^
M2KQZ[I:>MR2Y84N(6Q!1%F+7G"D2TZ$.FKG3&/>&F=KZ0MQ:-Y<85(0A:O"E
M!4H%12(W 0"1$\+!/:"]_1US?%6GN*9MF'@TBWU!K:IYYE$.+?V(<0A+B@2T
MHDJ"5 [>-7XIQX\2NX>VO%7E6VS>%;/XN%['ZK<"7=O$X]U;79;<S&7[>9SE
M^48-BLLI8%A#N3B9V+T\-C/#?W>/1@9&,TYE<:D+9Y5:?:H<MDK%PV;A1;[I
M9;#K:MZ$I6J)'=JW'$!4IQ(JJUK6I7#&I.6XTQ_]'-I?-TW[TJTN&RP\ZXRT
M92H7#2FTA1#BT;7!NVF)N1C_ !2\7N3+PX[7U./<.$F]_$7MWD._L&03C[D#
M[7;<[)TN.[>3BC7%"MK)E>5[A6V5YPM1'#4Y!448=>,PZ=[U1[9*9L[-/O#A
M+_<L+2S$M]XX\I3@P?LI;"43)!43('E7;U+57/<+=*-/]\OV%WH61<BW8LT-
ML$!:-_>./K<>*(2M*$I 49JR.>^D[W7Q&7!,-OP>'W:C.J_>[B-V*WPR_<!V
MX>1[2TM[L3AN"YU6Y-ALV,25F5,Q_.*'.JJ6&"]"(,I#"5!L)>D @R>JC3&5
M!:T]\X@M,/,I1L2XI+RUH*5[B4RA2#D$ C(XQ5F]VCNVBRTXFPMGA>7]E>.O
MFX<M4+LF6G@XT6RESNWD.I("TDH)A7V23L>X--[LUXB]BJ7=#/,0K\1MK+(<
MPJJTFB&OH,4SK&:'(CZO&MS,+%RZOK,I&P[/:@<:_P =CO@HCI:\F(I'3"D#
M326-U;-,/%M!*@$H)"B"I"E)!4VLI)25()*51B1'$&L_I5X_?V:+EUI#2E+=
M2DI[P-O-H<4ENX9#B4N!EY "V]XDI,Y!!K*CLF_&^ZCU;;$]/J?6LCX_\OUI
MV3?C?=1Z;$]/J?6GC_R_6G9-^-]U'IL3T^I]:>/_ "_6G9-^-]U'IL3T^I]:
M>/\ R_6G9-^-]U'IL3T^I]:>/_+]:=DWXWW4>FQ/3ZGUIX_\OUIV3?C?=1Z;
M$]/J?6GC_P OUK6%O/QRYWL[D'%AML;AF*66Z^WIFP__ $7,?1+06#><#B,M
M!,!PMMF*X^0P@K&=U!LCI<MEHYP87U%;"0+"',]\BY!JP:=%LX%*#3@>]X42
M):+ WKCR4V4E,SDP9K7[O6;BU7J5N6F57+!LOT>WXP+L7Z@PR%#=)+=R'$.E
M!2-B00 :C,EX[+O%>-;$N'([&<8+VF:;@.T&Y.[4$I0Q=%Q-[IX9E>?X)A%3
M62'$POQVSH,<J0"I26$G!9#G.-5Q!L3NI"R;!"K1=P"H.0MUMHYW6[:DH6LF
M/M!141P!2A1HYK+K6K-6"FVC;;F+6XNAN!1J%RTZ\RRE.XCNU(;0DDRH./-I
M)'.B N/'=D?B_GV'S;']I=ML?FWJN-M<>PO<,#<[#-R\TV^%#)6AWEV]W+MZ
MO\R^?1Y,3#"97;7T3TRQ0R4KDL)+:%[73_H]DVH>07'%=T'%*04*;0Y/B:<;
M"N];V\W%2G$Q!Q23K=T-4-D\BUMT^]KMT-/BY:?=9 /=W;-PI)M'@Z1N3;H(
M=VG;)6"*N)P\\1W%EOU2;>;^UFV>RK>&3=2?+C*BH'R/)1=Z\&PFM3(8<0SC
M)R;!GY%Y-)D!=&&EQAN/!U]E0P7X;H+>W>!9-BD>M+1E2V"MWWAO8"2 6EK.
MW<A,'<D)W&%J)!VG D37L=0U2];8O4V]G[A<ETI2''!=LLI*PT\X5?JG-Y0-
MS382I 6#N44J%4GB''=N'D6UO /G96'X5!8\6>-[M769!CQ7/<L:(V^V.SS=
M*LBQCM+1\_8FV^)AUQWBLI[_  XDGN[HB>RGCF58-)=O6]RXMBV$F1*M[J&S
MN^ 62(C(JDUK5RY;:*\6F K4V[E;H <ALL6;URD(E9,%302K<5':3$&*R7VH
MXG KO@DPOB]W5AJ\9",V#"WLS<*DCE2LK8FXFN36M?2ML22#)>?1()5CD%3E
M$SO''226:5O5;NV@3=KM6P5$/%I!)R?%M!,8\SR&3BLA;:B5Z0UJEP&VTFR%
MV\$;H2 UWBP@$DG@0@$DDD"236!XWI+-VX>#/=G=[,-O=N, XC-G=R]E\/S+
M;VYDR&TPJBQ??B\VX-P?+SVUEBW(I1OR&W!E<;$(>Z5<HQ6^'B@2")@>KPZ8
MQ[VTTA:UL.MO*0X("RIA+@6G(V_;;Q(PE22>IPH[0W?Z*N;IUBW8O[2XM&GF
M%]XII#=ZMA3+JMJ]\=R\=T*GO&U@"(%91\#W%;GW$O=[T562";:Y3B>VQ>%B
M8OO;LO7YZ!MEG-KD =W-E6'A#[C P63LFV](JZYN0R55C;5\;<BKAR5KC8UA
M(M[RS:MTLE/>)4X%%3+Q07$ 1M7^K,;5@F 0#X3Q!FLEI&IW&H+NTK3;.-6Y
M:#=Y:BX%L\M8676DA](5WC!2G>4J6G]8 =JA!PXV;]*%NON#NEBF'$5O#]E[
M,IW(WVP2ZVUVXGSUV]&TM'M2[/VTVY.X@1T]QB[,0MDPVMDL'.+HRG09362U
M7>)&S#MNG=+90VI7Z].UME:7%[ TZISNY:0<*WC>8,*'A,UBK7M'=/7+;138
MN]Y<7C*K>W+_ +W;-VQ?VW#Z5%;?=*[I.XR@PZDIDR*@]HO28[X9_L!N#OD<
M7P[FGX?PS;A;Z,VSHML^(NFN0K?%<;6TKJBSS3*4AV^M:R*SD%$MDQZ^(,-&
MF?-3$*R&:>([IC"'D,@/@+N$,]XIQD@A2MI(0DEP&)(W) '.H6O:&^>LG[Q1
ML"6M/?O!;HM]00L*;;W)2IUR&%)W$!7=N$D&4'!J&JO2C[V2X!OMEM?1[![N
M";5<."[QOS/:NKW:KL*P?<%V1XS5UVT&YS,Q;"DU_>TU[87U:S&LC:?&)CA\
MT]>X*>(R(=+8"V4DO-%Q_NMCA;*UHVJ)=;V$^%)2$G<(.X09Q4$]H[TL7KJ4
M6-T+73S=EZV3=I99>WMI3:W >B7%H6I:0VYN 092$D*JI<=]*7N+EFZ?#[M[
M3;=8.D.6[#Y[EF^YD[KN0C ]\L*P#B!O"=ML>1EI''W 3)^'^^BM$M(SK&*A
MLZ_D3";,V=(*TME#;ZRM?@=;#(Q"V5N,)#BCU*7TD1B0?A4Z.TER[<V3"+=B
M';-]V\)[PEF\98OG%6Z"% $)<L7$KG<=JA"IS5T^"WCQSC?NGBSO=7+]A:?#
MPMC#-Y\PH<-VUX@,=R/":\("DLK)]AF6X J[<W5?CT-E/!:+CMG8SV"QLL*:
M0FL@*(;3N]/;85L;0\5%[ND*6XR4K,D"$(47 20(W 1S@XJYTG6KB]2'KAVQ
M2T+,W;J&K>_;6T$A"E;GGQ[NI+>XA7=J450"B4R1;G'?2?[F6G"5Q3;SY#M?
MAV';O[)4^VVY^$X%8SVAU'D.R&^4..6NT^4WJBV<=JMT^OL,AJ<M"K"AXJS(
MZ'NZQ#+.H;)U:6T+FV92M2VWBMM:Q@I>9W!U(D1$A)03.Y*IX9J@WVCNE:9J
M5VY;,M75FABY:845E+EI>!M5LXN%;MT*6AT)4 EQ$8G;4!7^DYW.BPOB+L'!
M;%[A6^RXO#79T^2X17;IXAC]G'O?O96;67M%;X'NA#0Y\IN.593[T'**64O$
MYBS0*PHGO\!@"Q.F,[V!^M0'>_!2M3:U#N62X%!;14B%$;2D^( $\"#4J>T5
MSW5^J+)]=H+!27&4W32%"\NTVZT*9N=C\H2=X=1+1)"2=P4FL\MFN(_*-R=K
M^*7.K6CQ\"PV(WRXG-K<=#KXCNY7%1L==6=9C]C==Y,FG\2MX@8Y+CN,HHO:
M/?W* 5O2B6;UHVVY;(!40^S;NJ).07@"H#R'*9/6LU::@]<6^HO*0TE5E>:A
M;( WPM-FM24*5*IW*"0500)X 5B)5<6_&SF=AP4,Q"GX5P*_C2VG_+_'/RDI
M]UYS,-LL=V4Q7<S,@KMU7D\<!8)=Q;V8&,]P;*1!6Q@):RRE(1.^Y-E9(%WN
M-P3:.]VK:6X6%.J;04R,$  JGG,8K%IU3675:0&D:8$ZO;%]OO$W1+2F[1NX
M="]KL%)4I26]LD)V[I,DW0K^+W?\CB+CX/2=JL:CWN$W(ERBWS&.JR5-I4X-
MFCM.%WI"E?:.L/RVL[25FU@^'.N)PQ]Q8#2ISG48SX]4_<K;N#==XKN>[VA$
MCO3=3!9X1M '>;X_\9&-V*N1JM^;_P#17NS7O@?+JW=KONPTGBF[!W[N]4K_
M +8-;B!<!1)V"MG'9-^-]U'K'[$]/J?6M@\?^7ZT[)OQONH]-B>GU/K3Q_Y?
MK3LF_&^ZCTV)Z?4^M/'_ )?K3LF_&^ZCTV)Z?4^M/'_E^M.R;\;[J/38GI]3
MZT\?^7ZT[)OQONH]-B>GU/K3Q_Y?K6+.QF]F4;N9_P 66$FUV/T[-AMY!=L,
M2L10SB7V@1FUV#YO':9&--9,0@J&TRLD9\-9-5Q35XL$;5A(=(2MR];MM(ME
MC<>^:[Q0)X$.+1"3&)")R#!/.,XZSO'KI_4F2EI'N5V+=M0"SN!MV7MRP59(
M4X1"2D%(' R:PUQOCNX@,DMMP-MY-F\:QS='A?P7>/+^+D^W!R63;VDGQBCM
M;'8X#:@U+ (V^BWS$&&S4$BU+<N.X4#<QD1G6J!N==*T^W2EMP.*4W<+91:@
M$;U;R ]W@SM[D^$P/$HB,36*;UJ_<6_;^ZM-W.G,W;NIE8=[A!;0I5FFV.X%
M8O$@/ J)[MI*P=RBDU8_;?TL>Y^?+P2XZW;3 !L\WMW3,POB*KHG7SJS;3'S
M]Q,+Q7 ;3#EDMN]2V&=8WF]?E%6R\>;$T<0YZ#R01<]57-*91[VK>LH9;WL'
M$N*"%J6%XB$*04G;D$@>=6=OVFNG_P!$-^[L!Z[N%,WR?UFVW07VFF%->.27
MVW4N)WE0@*@$"I9L]Z5W=_/C*%)Z?AWS:;(L5XD[J\P;;&?<!^XNQZ[)8UG%
MYC60;NB6)-MC\6*YF7B5=5-2.VQ^P?)E53)5O+G1P;YG=*80#_YT0JW"5N%'
M=O=\I"2EN %;DA1,P1X3('&I;3M-=OJ0"C3WBXWJ"ULVZKCWBS%FV\MM=TE1
M6@-O*:2B=Z#+J"G<3!R=V*])'0[XY_P>8+0?D\\O>783.MS]]WD8QG6.0[<Y
M9B>";<Y+#48G:Y4)64UQC[[;),K$-L("\DCCKZ:N)2SB87$4=;O:;W+=TM05
M^J>0VS"T*[Q*UK3*@@DA4)20/#))$8K(6?:!-X_I;+?=3=63UQ>$MOMAAQIE
MAP);6Z$H6C<XZ%*!< 2E)W@&54-MMZ33+<\VJXQ\Z.V_Q?'+C:?9+..)[AGK
M3);&2'=C8"NDW"J,-RK*A&G-,#L2+[ X)<E%K":]H]7E^.H+'#-*\A\[FF-H
M<M4!2B'746]P?_QOG85)28@@)7"9F2A62.%&W[1//6^JO%AIM5K:/:CIZ5%?
M_<V(+Z&77$[@I*BMD%P IA+J !,DT^-Z6YL>'IF-IMJ) ?B/"YNCN/NSMJX@
M@',<4XA-O=T]G=K0]K_$)Y"00<1R*PW4!O <A*K#RI,4L\?R&#M8Y" 9IOT0
M-Y0%F%7+;;3G[*F'&W7"[&"5)#>TI! WA:>(%2?]4$-%Y5N@%K3KE^YMR5!U
MJ^8N+2W3;E4E*6G%7*5I<*22TMMT8E)K3-.-_?\ V3'XAL?W:LN#;)-S]J.'
M#+MZ:W ]K<\R9N8XQEF.40.3"X7G>WV2V'Y37V.65!:"6\6=T!&/1]W9$V6B
M&9:B%02(L+=[N%-"Z2V[<)9*W$#:I*E%.]"T^%*@H$;%3\<0:SVL7]I[\W<G
M27+BVT]V[2S;/NEUMUM <#+S#BN\6VI"DK#R"WB 4#>DB>V?&)Q0YN-Q!YOL
M3M]L>5MQPKUE;#GH>Y%KF8>8[HYA7[6T&[6>4& D4+%I\'"IZ7(0Z2BM\I%R
M>.XNE[8B "N[2:&465JCN$/*>[RY)V%L)V-H+BFD%<Y424R0G; YDXJ=6JZD
M\+YZR8LRQIJ4AY+ZG@[<NIMF[IY#!;.QD)0X$(4X'-Z\D)3,4E>^D3W(SVHW
M W(V.9PY;>;-[385LA>Y#E/%+E608M-FN9;Z;:X]NOCF X]84,X-'A2!X]E>
M/TD^4Y--<CEY58.&$I75H<YZS)TYI!;;>#ZW75O)";8!6Q#+BFE+4#)7XDJ.
MU,$)&3)BJ:M>N7T/W%I[@Q:6S-FM;NHN.-%YV]MV[EMAM2"$LPVZA!<<W@NJ
MA*"D%52;<?TCNY(6]!N X==</&(XE'LIL;NQ4WV5XAOIO-'DDN[]+=VY(M#D
M.Q(EA3E4=,RJ&6MO3 *T?(0[& VK4B-A#1YD::T6MZDOJ7WSS12E3312&B!)
M2\003.4@D@B#4EQK]RF[4PRNP;;]TL[E"W&KZ[#GO25J(0Y9!2"A&T;5E*0L
M*!3(!CHW+]*/F&U^8<8NW&28%B063;(E4XFQ>0$174>([LVE14[66NZV)V"O
MLXBX\JP^LW1I,H !K21GGXP5,7(.U:&QF+-Z6VXBU<2M12\"7DR-S0)<#:A_
ME46RDDC"H'[0J%QVB?MWM4MW&&4N6A0+-P]X&KE24VRKEH^.>]:3<H<2E)&Y
MLDD#8HFKL-X[]W<VXH-PMF(KC87%:#!^)P[9 .BN-L^(2_SO)L<JR\;=+<BY
MCBD!^UU+<V@ET4" E^;7AU]B$TVW$@J9X))I5Z>RBW0]M>45VX>)#C*4)40K
MPE*E!P@0"=H)(,"351K6KQ[47[0*L6T,Z@;,(7;WZWG$)+<K#S05;(4H+(3W
MBDA*AN6 D@F58GZ0W>4S>_+=M,\Q?9[;XVL)WWB!V>S,'=+"-Y0*C;*IR>UP
M?,:7),HK1ML-\*G.1* &U.J=LBPC:3'[I+B ^SAK"FR17IS 92X@NN AF74*
M;6T5.%(6@I22XR4%6T*<!!4(C(J#6NWBKURV>;M&%)5>!-H\FZ9NPBW2XIEY
M#CB1;WB7@V%*3;E)0VO>"K:0:'S/TF>^F.8QL-F)^';,[:XQNCPV[,;RQ9=N
MQ4;NC;:[BY[N*(\W*MK\6W5Q4&XPS9Z7$AD#<RXW7*LT(\:K9I1& (IL\Z=,
MMRIY 4ZXMM]UK8V6RXA"/LN*;4H+=WDQ#8$$$3-47NT-ZVW9NJ:M+=NXL+2Z
M#MTB[%N^]<"7+=NY:"VK4M"/%<E4[TR ,G9AM-N;O?F>[NZN+YOL_3X=M1C0
ME&7MIN2!DYEW^<!MI!#/*@8[L<!KR(AHI)7VI33:^&K.8*!0+GE29+E(&/=8
M80TVI#A6XJ0XV1&R)_S$](P9R5;#X3G[:YO7KJY;=M6VK9L(+%P'%+#^X ^$
M; D@#[1D!*H2CODGO!DUV3?C?=1ZM]B>GU/K60\?^7ZT[)OQONH]-B>GU/K3
MQ_Y?K3LF_&^ZCTV)Z?4^M/'_ )?K3LF_&^ZCTV)Z?4^M/'_E^M.R;\;[J/38
MGI]3ZT\?^7ZT[)OQONH]-B>GU/K3Q_Y?K3LF_&^ZCTV)Z?4^M/'_ )?K4TM?
M_P!2L?\ S W_ /D/U57_ /=+^!_FJK*V_P#M6_BC^2:E^I*OZ:4II2FE*:4I
MI2FE*:4II2FE*:4II2FE*PIJ. W9C'Z?9D&AMMP*>]V&W>SW>+;W/*^[I(<U
M$LMT<LR3+=Q,,LK'\F75UEMUF,V4'4U[C,M2QYE(+5QNL$L@66;KPWKRBZ2$
M%+S2&EMD*V$-H2A"P-TAQ(2"%3@SB#%8A&BVC:;0(4^A=E=/W;#R5H#P5<N.
M./LJ5W>U5N[WA0MO:"4!/BW#=4NV:X$,4V3 K,4H=]>(G)=IZZ#,@I-D<UR7
M;FVVMM:O.TR&2_J+>L VLJ,A*K93\FLK2&!F2P/:<D';RD",E%F.WJGB5*8M
MTN':>^0E8<!1M@@EPI!A('V>'0YJ6TT5JS2EI%[?N6J0\#9O.6Z[927N\*T*
M2+9+A25.*4!W@S$DC!I_'O1P;1TE6=CMANCQ#9CB(NT&X>QFW.'9EN0#;X[L
MUMWN9CR8GD-;MV-%BP1<YHV-1C4=%9[A&YZ53U@0(8SNP&8S4RK]U2@H-,(7
MWK;RUH;(4ZMM6Y)7XB "K*@V$ G)S4C>@6J$J;5<WSK0M7[)AIVX"V[1BX1W
M;B6!W8)(;A"%/E\H2E(& !7=_P##WQ,[:F^V0ROB(XG\\VMNL+QK!1<0RW+]
MM":_&ZK$,DQ#(\=,QU]3M+3E#VM:N&@4L4]A/9C.H["V'D#<;.+8!/?E!Q+R
M6+9#@4I14E#DJ*TJ2K=+ID'<3B#,9B08_H-M5LNS=O\ 47K9;+;(:==MREM+
M3C3C9;*+5!"D]TE *BH;%*!$D*&9FX^!TNZ&W6>;89#(>-CNXF%Y3@EY-430
M"V<%+EU&?C]I+6$$BFC#GQA6$[PYB RX(B4CDE&GC:Z)]HVM3;B'4P5-K2L3
M)!4E04)@@D2,Y!\ZRMPRBX8>MUE0;?9<964$!00ZA2%%)(4 H)4=I*2 8D$8
MK'?/.#';S,Z+8X.HS;=;;',N';%TPK:_=C;3)J:FW$KL5GQZHQJYH;B:XQC(
M,1R*JR(&@IB+>ON<1+$2RKQSZN&LF1RNKHNW$%Z4-.(?5O<:<22@J"BH*3"@
MI)25&"% P8)(JQ>TEAU%FE#UU;.V#7<V]S;N(0^EHH0VM"RMMQIQ*TMH*DK:
M(W)"DA)J4X#P&;'[>7.U61UI.=7F0;89'O9F9=UE^0!9)9;IYGQ!8^)C.Y>5
M[LE'TKI,EM[2J #@%;6+05P<8PXB 2UT$(3(KO7EI<2=@2XEE "4[0VAA14V
MEH ^$ DS.XF9F<U*SHMFPNV<27EN6SEX\5NK#BKEZ^;#=P[=%2/UBE)  V[$
MB -NT!-7DX?]@\/X;,!DVOV]M,J)P07)LDOL4Q_)[46W'P*KR2SEMUP7$"(:
MT P;":,T@MV.UMN3<V5:.7(&MN0'"' -2??7<+[QP)WE*4J4D$%92(WJR960
M!N(@&)B9J[LK)JP8]W84X60XXMI#B@H,)<5N[EHA*2&4*)[M*RM202G>4A(%
M[]4:NZ:4II2FE*:4II2FE*Q?W/X0]GMW-_MD.)'+Q+Q^X>PD=U%BD5?8BC8[
M>,LVNFJDS&MEKB2;C\C;>4G(L/[I8U:5=\60:2A[',@CN&[IUIAZW3M[MZ-T
MB5",':9$;AX52#(QBL=<Z7:75]9Z@Z%]_9!8:VJ 0L*RGO4E)*NZ7+C4*3M6
M23NX597(O1B<*.5UV>DWN+'G[H9_N98[M%<0DL>*+OUC68F9D%FM?-A>?KBB
MKCM5C9M<#48]2CUDM:'CL#JHD<QI)DQ%9.HW*2@)4 VAL-A@;NY4G84'>C=X
MBH$DF?M9$0(LW.SNF.I?*VU&Y?N%71OOU?OK;I>#R2R_W?ZM+:DA*$!)2&P4
MD*E1-1R< FV).Y%=G%AN5OI:8K3[UP\155LA99Q4E[/5V\@UA+=C9@%6OQ3\
MM18A<CGFR03%8,Y9A8EO(YXV.Q!*@*2^_.;%(#;(4IKN"\$$.EJ(VSNV93"2
MK9N( \4YJH=$MS<)>5<7JFD78OTV:GD&U%V%;PZ$]UWT!PEP-=]W(7P;"?#7
MUM]P!;3;;9KB&046=[UE8)MME&39IM?L);9X*3LCMQDV60W<%C88WC@V/A9&
M2.''DE^VAI<ER[(*#'O%S?!ZL-'QI&7>NK0M)0R%N)2AQX(_7.)3$!2B2D$[
M4[E)2E2H$DT8T2UMWFEH>O"Q;N..VUBIX&SMW' L*+;8;2X0.\7L0XZXA&XA
M"0,5(=N?1Q;-[;7^(6(.X&^.2XQM?4;CTFS&VF7YM2VN!;-![ITUGC>4+@HH
MN(UV1$3,QRXLZ&D=FN29>REK#)8 HV.2.1DR[]UQ*P6V4J<+9=<0A06[W9"D
M[SO*8*@%*VI3)XU(QH%HPXTH/WCC=LFX1:6[KR%,6@N4*;<[D!I+AAM2D([Y
MQW8DPF,5)JGT:NWP>U0.Q%UQ <3^:;' 5&'8XS:7+,QVV)PZ?&<(RC&LHJL<
M);4[2TUW)4%/Q<2CMH&74<UACI]O6OG8XU"8HG4'"X7@Q;(>)4KO4H<W[EI4
MDJ!+I$C=(,84 >45*GL^P+862[W47K-*6D>ZNNVY:+;+K;J4'9:H64DMA"AO
M\3:EID$R)O=>C*X5B;?(C\*QFPV:I\NK-K0<IP?9R+$\(P6^L=G=UZ[=[!\I
ML,=AQ,R%^5!7@$M"7;Q30N,Q*SL*I\+2^XV0,!J-S"0M0=*"X4K=W+6D.M%I
M:0=P\.T[@(PL \)!F7V>TTK<4RVJT0ZFV#C-KW;+*U6MRFZ9<4WW2AW@6"@J
M!$M*4F 84,C]ON'G!=KMV-W]V<)+R.F,WQ)H[G/\)A/ 7;TK,Z01]?)N#5T/
MA:&4^9Y!7=@'EE@%;L!R3N01]I6SVP[;!;=Q];C332PDAG<$+@[PA1G853!0
MDY2(E,D QBK]BP9MKJZNF2X@WA0M]D*3W!>0-I?2C;*'G$P'5)6$N0%*25#=
M7;M!P_X1LGM6?M!B)>0DXO8W6Y-\05>&@%W??=TLOR3-<B8PP*KKA4'&MLIL
M8:AC@'R"@1B0DRFS12DSG7UO.!U6T*2&T@ $"&TI0G!)R0D3G)F(&!&UL6;2
MV5:M%9;4NX62LI*YN77'G,I2D0%.J"/#(3 ))!)QCQ7T=.&XMM);["_](GBC
MR'9JUVIR79QFW619AMF3C]5B&2X^7C;G52U^T=9916M,$6^>D**L"QQS612&
MAGPM<.^X5?K4Z'O=[9+H=2]WB4.!16E05F72()$$0,<"*QS>@M-VJK+W_4EV
MBK9RU[AQVW*$M.(+?AVVJ5;D R@E1 ,$A0Q52[E^CXV/W-GRN<NXW%Q1VX.Q
M-5P][CQX9>T58-N%A>.3 38E<98'8XM<"&YSB" N$Q[*Q80C!:HTZE)C+IY(
M08)6[UYL) 2VH(>+[>]*B6UJG<$$*!"%3*DF02 >.:J7&AV=P72I=PV7[)-A
M<=TM"0^RC;W:W4EM0+S6V&W0$D)*D$%!"1*JCT;?#K0Y_E&Y-1)G8&1Y?NOO
M%O!<)!=TB .R7>[;/(MK<MKAQW8RZ6''0:G+<CO,>K^\/)K\GMRS2C["O<VJ
M;$W[Y0EL["E+;30\)G:TZEU))W?:*DI"C&4@  '-2I[/V"'W;A/?!QZYNKI<
M+1M[R\MG+5U('=R&PAUQ:!)*7%$E13"!*:[T<F)![0&;!&<2W%A>;-E[?5^U
MK=O[;.-LTIPL&KGT\,=&#/5[0UEM#!/25'Y,%2.L9)9:"SM!FO87/ :-$WZB
MZ'A;VR70X7.\2AS<5F3)ETC[1W</M <I!E3H+0M56)U#4UVA83;=PIZWVI93
MM&Q)3:I6 4)[L^(^!2AQ((XSGT6_"1E,>6C8AB!>Q=;GVV1NU.;TNQ0N'X%2
M97CQ&7XQFX%E=53L0M@B<HH+S%0O!+YL49,%>;:5Y;31B8V#Q1J5TG9O4'BA
MP.(4]O6I*@E2" =X\*DJ.X'B8/$5!_LYI;O>AII5FE^W5;/(L@TPAULNMO!2
MT]TH%Q"VT[%X(25),@XC;7T<6U.6QYV5N7NKQ ;KY5GV.[=X:9G6?9IBIF3T
M.';:;JTF\M+B^,1TF!4.-5U78YUC]<=>O*QT^R-';*.-8 ND[9LHOW$[ VTP
MTE"EK"&T*"2MQHM%2I6I1(02$^( ',&IE:#;.]\;BYO;EUYMAHO/NM%Q#5O<
MHNT-M[&$-I2IYM)7+94H2 H8(J''N!/&,4R3<JVQS?OB/J,7W9W!W1W+S7:P
M7*MO%VYL,BW?,M3LPCC FVNER*&ND(MI' #KDTA R"!),63V<JSP5>J4EM*F
M;<J:;;;0Z4+[P): ",]YMD1GPYDXJHWHS;3EPIN]OTMW3]S</6P<8]W4Y=%1
M=@&V+@3*I2.\D0))S-Q,6X2-LL0?PHOJ[+,9%X.L*N\#VL0VTJI4LZ6_V_K-
MMC9LU[*B@6VL&4%2-.//4+00,M'3$2"RCN8''(JZ<7[S(1_W2TK<@'!2LN#9
MXC W$S.['/G59O2[=HZ84J=/Z*:6S;2I)W(<83;J+T(&Y6Q((*-@W28(Q5PV
M;*8DS?PCB,0J]_+LG: /920%3 OR93$@<S.SJ$IE?X<E@EZMS83PR&+;."=7
MMCA;7-G:XE]/O5=SW$#9WI=F#NW% 1$S$0.$3/.KCW1KWTW\K[XVJ;0ID=WW
M27E/ [=N[?O403OC; VSFKOZI5=4TI32E-*4TI32E8:@<&5-0[RYQO+A^_'$
M/A!6Y6XE'N9G>W^,Y/@$.W&2WU'48[0(*?5V>V=ID*5%K28S75=L,-E$!4PK
MB>Z&ARR1RQ79NR6D-+987W;:FT.*2LN)22I6"' F05$@E,3$@UB4Z2A%V]=M
M7M\R;A]%P\PVXQW#BT)0B%)5;J<VJ0VE*@' 2)@@\+B2<,^W\N1\2V4./RGQ
M'BIQG&L4W(C2QK4$KJW%<$L]O*V3$8_!UEK"Y*.U)G+EM)[N*6R;#/%! .UP
MCZ?O#FVW3"8ME*4W@R2I86=V<C<!$1CYU<?H]CO-0=W.;M2;;;N/$F$I:84P
MGNALE)V*))45@J@@ 8K'/$_1B<->%YH)GU'/N#%D8=]PQ9%&1->T3X''\*6+
MQXG@370,Q6+H'R8$<$S<1D#X9,@M:\0VNFHNF6*6NK4;A:"V=FTIN$QM/"Y5
MN7^UQ29".@)G=QJP:[.Z>R\'T%\.!>GN25HRK36NZ9QW6 XF%/@1O6D*249!
MR*VYX9=O=K^'@GAFQTW*)]ORJ'</'9K"UL*TC*E!W,M\GNL@D2R%I@J[O0Y6
M66;*J1U.Z,8>(-A,1CXI9)Z"[A;CXN%!.\*0H  [9;"0D023'A$YR9X5?V^G
ML6UB=/;+A8*'T%2E)+D7"W%K.X("9!=4$G9@ 3N()-KLQX#MI<RPG9O!ILKW
M2H0=C.'W/>&O"K?',@QX+('[?;D8+A>W>2F6QQ>)6 \V4NQO!JN.OMZX*K'"
M-,LS(ZYSY F@U$7KJ%NK"6U=\^BX6E224]XVM2T@#<#MW+,@DR !/&;9W1;5
MUJT9+MR@6=B_I[*VW$)<[BX998<*E%I0+O=LIVK2E(!4H[?L[:*NO1=\(9$$
M<&"X*[97O.T6Z6R&43[-C8OAQ.X&!;M8B+B=Z+G\\F,6C\HLZCN(.28S:FJA
M5=E(J6):V(I)H!4XU&Z_;7WL.MO)#NY00MI14G9XAM!DI4.:<8(!%%?9S2R(
M99-I-K<V;AM VT7V;EH-K#Y+:N\4C:'&U*REP;CN!(-37?HZ>&')=RLWW/OL
M8MK.VW,X=6\,VXE-)9CCX]F6#QD8O*-D-M #7"VL6X(0V&8U6A935W%<H@5/
M7NA!8<$&:/*F_N$MH;2I(#;_ 'Z#$J0OQ>$$F-A*U$I(.2<P8JHO0=.<N'KA
M;:E*N+#]'W"-P"'F06X<7M2%A](:;2EU*TP$)A(4D*%)%^C5VJR,?)H]RMX^
M)+=XR[V?S?8RAMMR-P\>M+';[;_<,$"NRH?$75&"T895W8A559!-D6;AYC;S
MI7AO,**EA;)J<:@ZG;W;5NT ZAXAM"@%K;)*=TK40 2?"@I&35,]G[98<%Q=
MZA=%=J]9H5</MJ4PP^$I<#6QE"2LA"?UCR75G:-Q5%3O.O1W[49E;9F96;F;
M^[:T6ZN/XYC6].#;9[@5F.X=O'7XUC@V'03YH$7BEO:5]G;8D&+C>1V>!6^%
MEW]1$D%E),][Y72HOG4A +;#BFE*4RMQLJ6T5*W^ A0! 5XDA86 3(J=_0K9
MY3Q3<7MNBY;0W=LV[Z6V;M+;89'?)+2U)4MH!MQ3*FBXD0LFHS/O1\[299;W
MUGA6=[S["!YK@V*;;[BXWL?F%)C6,;B8?@V/KB.)5V25628EEZ"&4.(=&* W
MV*S8WD#<>A@K9+22."%T<$7SJ0D+0T]L6IQ"GDE2D*6=RBDI4F05>(I5N3NS
M%1?T.U<6XIEZ[L@\RTQ<-V;J&V[AIE'=-)<2XT[!0U^K"VBVYLA)48%0<7H]
M\ QW)X<FVFWJXB]BWQ;6;4;./I]KLRPJ.I*PC96GL*+;X0U^<;<9O<EG55=:
M'QS'S6[I39"'S3HZ1>K4WO[BDE+K+#TN..RZA<A;I!60$.(2 2! C'*H#0V&
MW Y:W=_9Q;6UKLMW6=I9M$J0P"7K=Y94E*E2HKDS)KC=#T;_  \[QX7N1AFX
M!&>77YS-Y<:WYL<H6ZHH<LQ_<7&L-Q' 6V&*V+,7[E7A76,8A"!?@GUEHP[Q
MJ\?"\19:U*N#>H/M*;4@-I[MI3(3M.U3:EJ7"ANDE*E2D@B($SF87.@6-VT^
MT^7EFXNV[U3N]L.MOM--,!3:NZVI"VV@%@I5NWK,CP[:FQ_@HJ,.W*S7<7!^
M(3B2PL;<3=T[>K,MN\?RG;IFW=WE]L^F;<P$UMCM;8Y VEMP*&MJ3A(LFC+=
M70JR"P@)=WE)57A6VAM;%NLMM!E#BD+[Q*1,$$.!.X%1()3$\01BJC>D(:N'
MGV;[4&1<72KMYA#C'<+=5L"P4JME.!"TMI2H!P':,*!S5*#^CGVD;D-4=9[E
M[]Y'A.*9%GV7[>;/Y'GE/:;:[;95N-5Y/475YB<$F(LS*6:N$S'(EQH#*,RR
M2FHI;*9PE;T(R-L_O[NT@-L)6I*$+=2@AQ:6RD@*\>S)0G<0@*,<:IC0;4.)
M4JXO7&FG'W6+5QY"K:W=?2XE:VAW7>RD.N=VEQUQ""HPG@*E5UZ-+:.PQ&JP
M&EW:XB\'PK\R>#\/N>8QA^X&/!T^[NVVWU(1CE$#N"):X/<1PV\M 8;3VMY@
M?Y#V%A6FE"22-B>U&1&H.[RXIMA:^]6\A2D*):<60HELA8P" 0E>\ B>M2+[
M/VJFD,(NK]EGW1FQ>;:?;"+JW824(2^%,K\105(4MCN5*2HB<UL!HZ6KQNEI
M\=I!(Z^EH*NOI:@")TCX@JNK$A! $C=*^25T8PD$4+'2R/D5K$5[W.57+8DE
M1*B9*B23U),D_B:SB$);0AM VH0E*$)$PE*0$I&9.  ,F:FFH5-32E-*4TI3
M2E-*4TI4PM?_ -2L?_,#?_Y#]3K_ /NE_ _S55A;?_:M_%'\DU+]25?TTI32
ME-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4
MTI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32
ME-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4
MTI32E-*4TI32E3FT#(=8GN2/FCCS7-7KC\T4A_G_ *7E^Q?/518(N%N1X((G
MSE7+CS'*L;;.H]U;&[@4\CR"9Y5 =R)^2^W'^/4NQ73ZCUJ\]X9^_P#PJ_+3
MN1/R7VX_QZ;%=/J/6GO#/W_X5?EIW(GY+[<?X]-BNGU'K3WAG[_\*ORT[D3\
ME]N/\>FQ73ZCUI[PS]_^%7Y:=R)^2^W'^/38KI]1ZT]X9^__  J_+3N1/R7V
MX_QZ;%=/J/6GO#/W_P"%7Y:=R)^2^W'^/38KI]1ZT]X9^_\ PJ_+3N1/R7VX
M_P >FQ73ZCUI[PS]_P#A5^6G<B?DOMQ_CTV*Z?4>M/>&?O\ \*ORT[D3\E]N
M/\>FQ73ZCUI[PS]_^%7Y:=R)^2^W'^/38KI]1ZT]X9^__"K\M.Y$_)?;C_'I
ML5T^H]:>\,_?_A5^6G<B?DOMQ_CTV*Z?4>M/>&?O_P *ORT[D3\E]N/\>FQ7
M3ZCUI[PS]_\ A5^6G<B?DOMQ_CTV*Z?4>M/>&?O_ ,*ORT[D3\E]N/\ 'IL5
MT^H]:>\,_?\ X5?EIW(GY+[<?X]-BNGU'K3WAG[_ /"K\M.Y$_)?;C_'IL5T
M^H]:>\,_?_A5^6G<B?DOMQ_CTV*Z?4>M/>&?O_PJ_+3N1/R7VX_QZ;%=/J/6
MGO#/W_X5?EIW(GY+[<?X]-BNGU'K3WAG[_\ "K\M.Y$_)?;C_'IL5T^H]:>\
M,_?_ (5?EIW(GY+[<?X]-BNGU'K3WAG[_P#"K\M.Y$_)?;C_ !Z;%=/J/6GO
M#/W_ .%7Y:=R)^2^W'^/38KI]1ZT]X9^_P#PJ_+3N1/R7VX_QZ;%=/J/6GO#
M/W_X5?EIW(GY+[<?X]-BNGU'K3WAG[_\*ORT[D3\E]N/\>FQ73ZCUI[PS]_^
M%7Y:=R)^2^W'^/38KI]1ZT]X9^__  J_+3N1/R7VX_QZ;%=/J/6GO#/W_P"%
M7Y:=R)^2^W'^/38KI]1ZT]X9^_\ PJ_+3N1/R7VX_P >FQ73ZCUI[PS]_P#A
M5^6G<B?DOMQ_CTV*Z?4>M/>&?O\ \*ORT[D3\E]N/\>FQ73ZCUI[PS]_^%7Y
M:=R)^2^W'^/38KI]1ZT]X9^__"K\M.Y$_)?;C_'IL5T^H]:>\,_?_A5^6G<B
M?DOMQ_CTV*Z?4>M/>&?O_P *ORT[D3\E]N/\>FQ73ZCUI[PS]_\ A5^6G<B?
MDOMQ_CTV*Z?4>M/>&?O_ ,*ORT[D3\E]N/\ 'IL5T^H]:>\,_?\ X5?EIW(G
MY+[<?X]-BNGU'K3WAG[_ /"K\M.Y$_)?;C_'IL5T^H]:>\,_?_A5^6G<B?DO
MMQ_CTV*Z?4>M/>&?O_PJ_+3N1/R7VX_QZ;%=/J/6GO#/W_X5?EIW(GY+[<?X
M]-BNGU'K3WAG[_\ "K\M.Y$_)?;C_'IL5T^H]:>\,_?_ (5?EIW(GY+[<?X]
M-BNGU'K3WAG[_P#"K\M.Y$_)?;C_ !Z;%=/J/6GO#/W_ .%7Y:=R)^2^W'^/
M38KI]1ZT]X9^_P#PJ_+3N1/R7VX_QZ;%=/J/6GO#/W_X5?EIW(GY+[<?X]-B
MNGU'K3WAG[_\*ORT[D3\E]N/\>FQ73ZCUI[PS]_^%7Y:=R)^2^W'^/38KI]1
MZT]X9^__  J_+3N1/R7VX_QZ;%=/J/6GO#/W_P"%7Y:=R)^2^W'^/38KI]1Z
MT]X9^_\ PJ_+3N1/R7VX_P >FQ73ZCUI[PS]_P#A5^6G<B?DOMQ_CTV*Z?4>
MM/>&?O\ \*ORT[D3\E]N/\>FQ73ZCUI[PS]_^%7Y:=R)^2^W'^/38KI]1ZT]
MX9^__"K\M.Y$_)?;C_'IL5T^H]:>\,_?_A5^6G<B?DOMQ_CTV*Z?4>M/>&?O
M_P *ORT[D3\E]N/\>FQ73ZCUI[PS]_\ A5^6G<B?DOMQ_CTV*Z?4>M/>&?O_
M ,*ORT[D3\E]N/\ 'IL5T^H]:>\,_?\ X5?EIW(GY+[<?X]-BNGU'K3WAG[_
M /"K\M.Y$_)?;C_'IL5T^H]:>\,_?_A5^6G<B?DOMQ_CTV*Z?4>M/>&?O_PJ
M_+3N1/R7VX_QZ;%=/J/6GO#/W_X5?EIW(GY+[<?X]-BNGU'K3WAG[_\ "K\M
M.Y$_)?;C_'IL5T^H]:>\,_?_ (5?EIW(GY+[<?X]-BNGU'K3WAG[_P#"K\M.
MY$_)?;C_ !Z;%=/J/6GO#/W_ .%7Y:=R)^2^W'^/38KI]1ZT]X9^_P#PJ_+3
LN1/R7VX_QZ;%=/J/6GO#/W_X5?EIW(GY+[<?X]-BNGU'K3WAG[_\*ORU_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g947560g02a85.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g02a85.jpg
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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MFZ4IT5I[JU9++!!@# & , HX\IWRYO"3]<FP?U4J8.D.;:>S\R\?!S& , 8
MP!@# & , 8 P!@$;>Y?R0.UGU;;S_5A*,%CFN*[R0P[_ #>Q_P!3:_\  TP0
MYF , 8 P!@# & , 8 P!@'F9J/4+0V6BD=PZ2I.,GAZ2DB:-G\?34>BG;;3<
MXQ>(N6;P/ILIQL3:.F[ALX9<+HKHJI;[I[ :9]==\/(;5=NPKK3*NWD2N]JW
M/#(MPQ\6O7'JMV\A@$7N_P!$-6$KA 8744OJX/JTY5;E.-0Q7<0DDY71256X
M19[#JXQ:;46L/TFUU;GC73*F9N:1:(1.#!DX["8O'8='T7I4BB"BP0;'@R1
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MLM[\8?C\_)/M+^E.ON?;?T+_ )X6O[FOO\Q<CP^4/R5_MK/X+4U#<_5I\&,
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M-7@DPQ9$F;EJD,M4P9DW (;RZZ>ST>M2,UF.H6BBO,Y:V$8B)I[V>GPGA4#
M',<T7<2(<AU.+^\I8DUE0I=(6-?2-FV<:$&VYE9-NV=O1:*E:O=NUKT]!+<.
MJ77$"EY Q'##RPUBJ;&ARCDX)'EU&J6Y)B+-O0\>>&!S1YRLW9%'8 &Y(-DT
MG:X<8JMNR0$.QP!@# & ><F+61/HC*6,0(-A,L>1PXUBY1YIZUH-D3@8Z1"D
M'2?JE_6-F9+=LX7T]2MZ:2>VOJE/;]#D#3U%=(>]\SKB G)Q1G9D%=].M.N/
M73J8Z,]FVLF(PKLP_L2:7SWA[YV1)A=L/V+NMSDI;%HN#2)?"HV>B[L)"1,%
M"C4V'O/._IW>>W4Z[44W1IIU;PS6"C&E$JJE:Y5QK7/<MRG(8 P!@# & 4:^
MQQ_FDNO_ .7'8[]HJT,&[3GOA'X47E8,# & , 8 P!@# & , TH?9;WXP_'Y
M^2?:7]*=?<^V_H7_ #PM?W-??YBY'A\H?DK_ &UG\%J:AN?JT^#& , 8!\;?
MS<_U<_W9)9/@^XDLGP?<?J1^&WYK'H=]6^O?T;SG\^#VN?/E[4N]EEV#(P!@
M# *'IC7/9SK;V$[WD WCF']_X'WJEP*0<6&/N"F(@]^ :%016L$^M5WQFYG3
M)5.N(>^#2PC'"()*51MR!GA/1\);E]G3!0;P:7UMEI4R>M:JF]UW[UG1X6*>
M/*A)YU?Z7=?J'LT@,?SBO(8N/.-P9,B: 1ODI(#,@'0./&"WM$2D=KD2780$
M 0=:I[NP\;9+ZI(I[Z):#,G5MZOSUDS<$& , 8 P"CCRG?+F\)/UR;!_52I@
MZ0YMI[/S+QN>.-N.==N..=>>.>.>.>..>.>.>/:YXYXY_BYXYX_BYXY_BYXP
M<RF]QJIXHK>4?I<;H>,[L!._3)H:\;<B.AU]SPSQQ[Z-]>./5Q[JI=4G(<<$
MD/\ %1ZF+0)ZO4>0T.F+A,=,NA=QKG+_ %)?Q4KGTI+C+CG9I=-$4MV3K\C6
M=YUK#;8K\SPFNM'I@':&6*;K33;AF8$.%-?=@0XQX5V6$R$&[8&A:_.KH80:
MN-=%>*93IBBOS\!/>#I7_EG4Z?N^X_7\?_*VZG]F9RHUNF&BD_Y.HV@.U)E-
MZX-M62/*: B!=AT#;9-DS38L[6!Z*:\:.[SOKV&JIYX/5+#/>EIT4X-DD^M_
M?"A>R9\I6PM[)JH[!1=KPZF_62\X^M6=\Q)+C7;91_M"RZVZ4OC'H:\*MYU7
M1.805X@J@HVD:FRO&G C3SS6JRQ[GT/$F9MKKMQSKMQQMKS_ !<\;<<<\<\?
M_P <\<_Q<X(1@H1%'BU>Z_/"27'.O9R*>CSPGKQSK_\ DTZD<_R>>./;X_CY
MYY_B_P#'GGG_ ,<%>4>'S9BSM7W.=55+ ?7'KO"D+_[I6*(W*PFGVY)0?%J[
MBNZW#)>Z^Q4L:).>*TIT"YWX]!59/:5V"533B5?"B99PY=BA4JXO"*S>O0EO
M?8M]#G]4.F+:CSDFO.Y)JOV [C6F.;,K4OT\.38)CP:*_+YE4M+1?E1RUJFD
MHT\WVW$Q .KR]/OM/A+-B9^0*)N6@.5<$J162S][>]]/N6!.3!D8 P"$7D"+
M6PQZK=C&< @,(E8!]UPO1.5%Y19I>$$P"&U<R%+98*#'5C.&\E4U9;NG7"#L
MY&M=G""+/U^NCG=VV%CFN*[R0U3%K9*!UN+3@,'@JS5L)3":0NS3%DIE$-FJ
MG#U8BH6K"M=@RC?;1KPW102,\.]5UME%FG+;35R(97P!@# *J[DZV6YU6LR6
M]N>A<>3D*4S)J2;M3TGT?-@D.[ K<:::E+8I95ULD&K7M W9(\;/5O1:0^ZT
MF[<;--&<H382C=2GOQ-*CPEAH]..J[N!-SKCV3J/M95XRV:;D*I@ Z>OP1T,
M68.0,T@$T"*\-9/7ECQ CJD9A<]BC_G9A((T9;HNVJO"3I#ET,>,'[H1IIT9
MYRP?E4]:_P#9YV/_ -^F<#<^*[I$F\$& , 8 P#STN'&3$4DXF.&.8](2D>-
M#@)_A+U_(,R^&N6PLQPC_P"=R,?*H/?5?^9ZCT/_ !P#5M9U?V$D?3'KIXVP
M_CO[55SVBHRQ*PF8_ML8F,75ZX0.[X].^9!:O;P!>[2U7DME[Z<\'[+FG,&Y
MA6YLFO/RL/4$I*;^WL\U.CI5RVDXM8+&M,E&FZE%C7!*N.1M9X.8P!@# & ,
M HU]CC_-)=?_ ,N.QW[15H8-VG/?"/PHO*P8& , 8 P!@# & , 8!I0^RWOQ
MA^/S\D^TOZ4Z^Y]M_0O^>%K^YK[_ #%R/#Y0_)7^VL_@M34-S]6GP8P!@# /
MC;^;G^KG^[)+)\'W$ED^#[C]2/PV_-8]#OJWU[^C><_GP>USY\O:EWLLNP9&
M , 8!3+Y1^]$^ZHVAUKKH%V2ZU=2H=<$3NV2';C["UM-;>T=R2M"%3LX[ ([
M$(9,(<H)U.#I[(SA&5F73H4EM&V8;58<3)#6QP;C&J;I*5*81Z:YX/30G_U1
MM?2R^L5;VU(+MK.[4#,;,&RMWUQ&G]=5C*F@PV:;.3H6.R(Z>>QP2+;#]F#_
M -\CSS7AR,>OMETD%=4TAEX-JC70\UQP7<1]7\O7C*;2[:%J]UJ)X):$_>=0
MQI*_6P%(GZWU'+1:T4FN]:)*:K?XK?926:)Z;^WKMOQSQS@NQ+[+ZL=^[/<6
M'C"8TV-8& Q!B7$%6;8B+*C';=^-)#WJ.CEF_8/FJBK5XS=MU$UVSINJH@NB
MIHJEOOIMKMR,G.P!@# *./*=\N;PD_7)L']5*F#I#FVGL_,O'P<SSDQA\5L&
M)R6"3F/")9#)B#*1F51@^Q0)A)!'S;)8<6#EA[K11N\'D&+A9JZ;K:;)JHJ[
MZ[<?QX!5CUYF$JZ!W%$NB=X2$O(>N]CO7 OQ_P!^2E\N0<L^&K=9[STPMF1O
M=]U>;"A0M!92AY(7<;;VC7@_X,:NE9K$E6!(:?UJR5$]Z7>NC71O3*W'!DC;
MV0ZB]?.V( 6%N^O&$C(1EUR3@D[%/"42M*LSVO.NZ$BK.SXL[$3B"&VZZ:*_
M#R.'&.KO9%-$BB]:>L;;BIM9>];GT-9-%:MY6MWK\7-<D9H4."/(;UR1,1*"
M0O:R)"-JCMW")I9,K#5U5<=E$S%1YW7=]1(G-Y#&@9J6K1R"V6&:%G4B)I3=
M,6\4V>?/#S4J2EJGB\%588ZU6%=2*\[["^47K8UDLQ.R'ICRAV^[ 4Y$9C-8
MK7]M:<]2YW;;>F^L\9L,4+DDZ.,[QAD;'QB+-G <NQ@3]W."C>0NT]XBH2C3
M'4HR2KANU\]I(RA-T2DFDVJM?62JZ=#I5[\B[WJIU&K3J=$SH^+.C\XLFPR^
MDLNV]K">Z'K;NZ=[(\HK2F>239)/91%HGNHSC$5%IL8G"PW.@:,"!S3A;U^0
MVW[E1+0E/@@P!@# (V]R_D@=K/JVWG^K"48+'-<5WDAAW^;V/^IM?^!I@AS,
M 8 P!@%:O8_J7940M GW.Z*N ,4[*JLF"%QT\?>[ Z:[H1 &ESHTBUD;()[M
MX?<05CZUK5=\-&BA,&MNG%YNF=@;Q5N(&DU2CRW/>GX:K?Q(/;>7FO[%L"J.
MP8#J;W1>U'3$8N:(7M-AM5Q4D*K*9%W<)&S &V8:6$A*[-:U0:@DD&6"?JN,
M3 0VW9\[Q]<^HD];LE'G1LM$OJN44WLM)O-.N_)9[Z=J+X8+.(C9L*B5C0"0
MC)9!IY&PLOA\H#+\.A,AC,C'-RP0R.<<<:^M9D1SMN[;[;:Z;^K5UXWTTWXV
MUX&,LSU6 , 8 P!@%$5S^2:\X_W"NZ@8W?'BJZ^Q:G+ KN#LHQW NF91Z]['
M92ZLZ[L-U,8R#CTC!1M 2_<SEW%8T+VY(&N"T>=J&FS1%V/X=#:C@G23P;P6
M"HVJ-XZ5]Y=O,9K#:[C1:9V!+8S!8> ;<O3LKF)X7&8T%9\;:Z<NRQTTZ9"Q
MS;C??33E=XZ12XVVUU]+V]N..1@CI3W?+I1V#E2L%H_MCUYM>;)^OYTB$$MR
M#R.3/$FVNV[AT,!CC2Y,LQ0TTVW6?C&SMDGI[6VZ_&NVO/(KC)9Q:XIHEC@@
MP!@# *-?8X_S277_ /+CL=^T5:&#=ISWPC\*+RL&!@# & , 8 P!@# & :4/
MLM[\8?C\_)/M+^E.ON?;?T+_ )X6O[FOO\Q<CP^4/R5_MK/X+4U#<_5I\&,
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M6G1AX;^PVXI)8+FUJYI/CLNCX*CJM[J;&\7BL7@\?%1*%QP#$(J!::L <9C
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MP<Q@# & 4:^QQ_FDNO\ ^7'8[]HJT,&[3GOA'X47E8,# & , 8 P!@# & ,
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M P!@# *-?8X_S277_P#+CL=^T5:&#=ISWPC\*+RL&!@# & , 8 P!@# & ,
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M$IL2BT>C^XEX='N@&SPZVV8D@[DF.BC]5/9FZUJUDL6M'7+'%&P#@YC & ,
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M+S?RJEU/'SDLB:>"# & , 8!1QY3OES>$GZY-@_JI4P=(<VT]GYEX^#F, 8
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M & , 8 P!@# & , 8 P!@# & , C)8/RJ>M?^SSL?_OTS@NY\5W2)-X(, 8
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M# & 4<>4[Y<WA)^N38/ZJ5,'2'-M/9^9>/@YC & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & 4:^QQ_FDNO_Y<=COVBK0P;M.>
M^$?A1>5@P, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P"C
MCRG?+F\)/UR;!_52I@Z0YMI[/S+Q\',8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P"C7V./\TEU__+CL=^T5:&#=ISWPC\*+
MRL&!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & 4<>4[Y<
MWA)^N38/ZJ5,'2'-M/9^9>/@YC & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M5[OZ*81)ZS]V,G&J;A9BNBNIJ@EISOZ/'/&";>#2C%55'1/Q+O<&!@# & ,
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MM(5'N,55WF+%VQ=LW1G5;5J[170:\^I45##<WU4^;))8(, 8 P!@# & , 8
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MZHD+[-.6#GUP8V/<;^H7W]2HKNW5]%9)334:4&U7:C_^O^)<K@P, 8 P!@#
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MPLQ[D5LYH/))1*+R8?,ZS%HM=RKV=;Q>'1CC6N1XS9?>TF:A\A,Q8.-C1J6
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MB =#1^BY!R.;/1:.E?/5F=EM<M0:RGX#;6M6VLU]]&X/X'[3F,<2GWZ=\/\
MEJ(^#_)3WV]]'/ LGRW'^Y/=:W Y_P"K1V]QN/5B'V#+7J4E&#LU#6573^&1
MUVZ1DTM&3&-.HP"?-^$%'R1T\U(J"ACM#5RVW=:$':"R7"Z&RW&O"J?.P&)4
M>X/7!Y:>M3B+"%R"=*BX _XXC+ A(A&S&S'HY""Z<RH,S>@N>#B9T279:>^7
M*7O,5:F?2X8K<K\"T>FO9GU'LX3V0H6PX3"+$B5O5Z2B-C.@@R&E5)6&'\FI
M!(1;(R+B2+,B\:OD9HL/(LUEH:Y;(R=GNOJ@\%(+\;)\ TUFCN4KII,HLF.0
MMFK"+ATB><),$IY$G:SEO$D%'LG73:Z%5-UD8RV;JNSRNJ>V@9!%1P0V;)I[
M;ZA1Z,Z\KV'H8*'X/$+EK%,4I#Y#8#5RWF\<?[DH1%&)HE))2&:L"#EX;"!&
M,</N2#\0W>H-] I3C?;TV+G5,2E>[K.T)715@="-/2LYCHX3+8>0L$(?($FS
M".+P@8O%&KF4.) ]4;AV(G9Y.8@R:+O'J&SYS(&";)-?CU^R >?/4=83["4>
M*;[+;VM!23K:*KS=@#C<B'2R5GXLB!<2?4O%(?%UR\JER+V/M%RHI&,!RSHP
MSTX4%(//33XV%H_=KNZSPJ?;VD%N!O"9&<\J$WI0/ZK:I+52V&247(9A$MHB
M?55AVC:/RLC*8%*8^! &%V1"0DV+)(*D^TD,;4,!1]'6O'KTWG 2-B)+VKJ:
M1Q\DS, 3_52TC80N.7T=#RH@K8]#/QI)BY2YV3<,WS-=%TV73VVT615T4TYY
MUVXYP0E7@# & , 8 P!@# & , 8!&GNA\COMC]6F]OU72K!8YKBN\H&\WG<&
MB^N':ZJP$YZASB\9\7Z]-##>QX/WV['=.W8R(.K(F3)&$O@U$L%FTM;H&@[P
MZF3..?7H*DN6J"&B;?513W?T*^C_ ):]/;>_W?D:WY-L)\FV5A;6[Y1O%ZN\
M91O$[2$%9.[7.]N4D[*6TIJ"2:HY5:7QG*7*UUY)L[*TO,;:4;:<H1]39V=H
MTX14GM;=I9T33PI7+'<5T=7_ "']8K:[3]6:Y)>/ZWA3B5]EZ''QJ1RORZ=W
M;L!0V;IVA&'L'G#RJK"8:PR<[0N6-1$G:@)#OH-?.Q:":^^NO/I<>P>E7T-^
ME/H?R+>.7N5+WR';7.ZVEWL[2%QOE_MKPY7FWA=[-PL[?DV[6;2G:1<ZVL6H
MU:4FDGXO)_I'<.4KS&ZW>%YC:RA:23M;&QA#9A%RE64;:<E5*BI%XO&BQ-WC
MF=0/X::U]S,8C^$3@-L>UA',A#?#3B/;+:I;F=8U[L]_. W*^NB6Q'AE[AY6
MUUTY6]/CCC/J@^</M!36$RLG(!$:EL6DAF&$>!4J& CPDP3BA93W0GP-D#(>
M[<N@1'?W,[TX9DDFKG;W.XUX3Y]4KQJ!ZG /$SNRZXJT2W/6=8$)KD&\?:"V
MAF=RL%$!+HFHW<NTQS<C('X]FN^4:,W;K1HDMLXV;M7*VJ?*:"NVH'EB/8.@
MP\C)P\O=]0"Y<%#.)&9BQ&RH8QD8F/,XW\,G9TF$<FDB; ,UB'_XK<%'35)B
MA&__ *ZJOJ+_ ,JP6CT?4<N+7C2,SB)V=PJWZKE<#B7NK233*+6!$3L1C/ ]
MIH]>Z'9")+.@P;W"QW3=NM2#QM[F:;Z.%>-$=M=^1*-9JAXN:/NLMHNX;I,)
MI6LC<IQYU8<29\60/;)GX(FJV,D3^XX5(VC>:5JHXBS(N63+-S4'=.(TS(D&
MZJH5!9J+1[D]-^>AF6*RR(SL(RE<(DT<F4<(^ZTATDBID9(0C[ED\68/DV1@
M0Y>,'/N0@T<,W>B#G?U#QLLW6XT714TU$.+*)Y!(8N!93291**.9:51 1AI*
M)$&!+R8XZ421;A +<L\:J&2KA5P@DB-'Z.7:RBZ6FB.VRFG&P'V+36$M9@T@
M;B6Q9O/B0;8\QABQX2C,"$?;KN4-S+2.[N]33H,@Y0>([$46:C)-=%RGRMJH
MFKQJ!Z;E-/GTO;3TY]/;7??V]->?2WT]#T-]O;X_E;:>AIZ.W/M\Z^AI[7/'
MH\>T!TP.- 8TB0;@1306B6-%Y$23:I^CJ\-GR+@L8)+^ESMSLY($G3EXOM[?
M&O*RV^VNNO'/M8!X9>:4L%L<ZR=3:NA5J+QV',)&'=2Z/LYES&/A$^8P34J"
M6))DTACB4SIZ-C;APRT3>F91P.8*K.B2*"@N--].SS@9(&DAQD<P,!W[(J)*
MLFI(64&ND'PXD.?()NF3]@]:J*MGC)XV52<-73=51!P@HFLBINGOKMR(<4\
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M]^8 -F1QQ[X:?F<]S^?GSP1U,0ZVLXS;:]LD)U(9&]75*'_@^\&@!XA*P)+
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MEG7F-I$EFVJBVK=5\F-U=*(:K*ZH[J\I\**<:\;<@W5MZNI-W!!@# & , 8
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M7X(2.ZJ4ZS*4Q8D5M"6R'WG+G)W%J5VFTI_"&)&V.8>RJ.RNH44$G;I@>3F
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/EM_4MD$4$_122TTU%/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g947560g02f26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g02f26.jpg
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MKX[GV-'F\M?X$SQ;/<V-N>&*]F&O&3)*N=^'$[I"M_VY87_@$JFHLN72<RV
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M3_-(LZK&+I0MO;WB'97ZO'EY?<M;C@]_\_L/WXV9Y[0(UO2ZOM,_JF><Q7O
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M 4!_+KK;;;KKKN+;;>.;KKKN>.+;;>./5YNNYY]3CCCCCCGGGGGGU../\>:
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M'/"+W5A_,,(=#A>]J'B/KR-G2N'+XH!0"@% * 4 H!0"@% * 4 H!0"@% *
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M_P!$GPYX1>ZL/YAA#H<+WM0\1]>1LZ5PY?% * 4 H!0"@% * 4 H!0"@% *
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M>?MM2'Y"M<J\7^B3X<\(O=6'\PPAT.%[VH>(^O(V=*X<OB@% * 4 H!0"@%
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M^0K7*O&/HD^'/"+W5A_,,(=#A>]J'B/KR-G2N'+XH!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H"+KQT?TLD1SFGO(&H.KKZ>;D67$7$[GC $3N=SGB%]EF.]
M>:/FVDN*E%E^/'CLN5+E>?/=9CLMYOYMMMXX$E*25E*27(FTB1P,&%;(40VV
MV(%M]NM\6/!@  ,>D$A0842DPH!8@0+084Z$:+&H4^!$/'HL&!(C28<*9-AQ
MX<=EEHB<I0"@% 4N.CXP9$WW34F^=4TZ$_4WXZZLBZ.A 4!4HR.^4;__ %3:
M-?V78*MSLG2OTT_HF8&/TH]-7Z*9,NMN:X4 H!0$"^IK\"N5/ZD@[R_Q=6)C
MN]*W1'KQ,C"]\4_U^I(N4KFC<"@*3NR)N\_;6_2>NGG2PI6YX.>$.P??G9?G
MU A4]*J^U5?JY'FP5[O.:+M^GMU0(^U:@]I1'*&'8-/9#VT=VTS#P06=;@P#
M+2E:PDK.-0E-Z<^8$7)X[**12 CE,C4CO57)29P=F:V;_P""IL^;\+.!>+VW
MM*OC\$]DO\(;$6P\4]ITJTZN C'%2Q-/:6S94J=2^+@JDH*G.5".]3I359=T
MGE4:\:<%&6_W-3LJW&K3>ZHN$[_FNRS2>K5M&?.[JYLUU:BSMK<^M18<%$W5
MKY'\#Q"3CU-(@QOC$;9E##(2X\]Q*J7L(9 8&G5)>3@9%DM1+[/RQW#G?" N
MU+U@FY_P%7H;?V7MC#;>VC4A0VKB]J;0ABY8.=:<J^">$A2PU2.S^R2ISI*G
M@JL,37EV+ [RPLJ>(4:@[878ITW2@KPC"&ZI))*>\VUOVNFW)-+.?Y5TVCJN
MI&YFHFK;W)+&^YNH4$8C$V"C>>8I!,V2&4+'2>G90%)C*1U/T>HG$!8R&PX?
M3YD620FUP["U[%7JFTI;.3U><M][;W!W;^V\-"-6CP3JXK%;*QFR\=5Q&#Q,
MYX)XFK)PQFRL9*C5Q4G2I24EA*W8*?;48UHUEH4IU:=.5TZ]HU(SBHR24E'6
M-2&]NJ[_ #EO2W6U;DJHD]Z<23)4AR):#&MCA_/EVO3AMAK?6B&]PZ3Y YP#
M%6]KQ>M&B>%_<"&WM6/U$J?%QVNSU/6\=S@L-VG@\)A.RSK]JX:AANS5,ZE;
ML%*%+LM1W=YU-W?GF^Z;S9CR>]*4K)7;=EHKN]ES+1&]'V*1WO\ GG[;4A^0
MK7*O''HD^'/"+W5A_,,(=!A>]J'B/KR-G2N'+XH!0"@% * 4 H!0"@% * 4
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M * WW.Q2.]_SS]MJ0_(5KE7B_P!$GPYX1>ZL/YAA#H<+WM0\1]>1LZ5PY?%
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MI#\A6N5>+_1)\.>$7NK#^880Z'"][4/$?7D;.E<.7Q0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H"EQT?&#(F^Z:DWSJFG0GZF_'75D71T("@/.
M:[)3[ZH\OJ$@W_;NZO17H$][\)?;ME=3:!J]I>H_VG^F4*5]^-6* 4 H#O\
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M%:Y5XO\ 1)\.>$7NK#^880Z'"][4/$?7D;.E<.7Q0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * I9ZQL(F9<;\$F@T=;(2$7C:^<CC#3P+&$%S2 '3&
M;C&X!%_$PQI-[3? XDS#!!65$6.! V_8QM\JB&9R.%K8EHLOB$X:ZI:7NVLK
MYV:^_(0JAG5K:Q-O3$+ADW7E>WY:3[7Q1LP_MC6@VPB>'&]K^,Z9B. 7S [9
M?2!;>H2)A\]<KF<#B9%AYP\BK$SP3H[F[QP9H5NMU\?<M6>N]O[R;^#C^ RX
M8Z=_5Y);9#=QL6]6IF&6 ,*G]? >6_61S7@T\8GWVCD!0B5A;7I;A5&[38])
MS:9[HLOX36Y$_"?UN3U_ *4-W=W'JG^5JTK<F6K,^^X3UT_#XTM\4=Q>GM"E
MX>L?Q_Z1[A/73\/C2WQ1W%Z>T%X>L?Q_Z2IO;WL>7??=Z;"$_P Z;Q:\+)")
MMAMM%5G:\#NQNB.0[5L76";+!F)V*;+%%MI%3W1GXR\\Y^>;/5MM]9QZO6<&
M>&FV^"<<9#9$\-&..E0E7[8PZKMO#JJJ>XW*.[E6GO:WRY"Q6HT*^[OPGW-[
M6J6_*M>_<\R(Q_REVS'AL0S^4;P]):ZC\<?#/V79O[!'[0L]HX3UE3Y7^@?R
MEVS'AL0S^4;P]):?CCX9^R[-_8(_:#M'">LJ?*_T#^4NV8\-B&?RC>'I+3\<
M?#/V79O[!'[0=HX3UE3Y7^@?REVS'AL0S^4;P]):?CCX9^R[-_8(_:#M'">L
MJ?*_T'* NQ1MI&Z> N,;NS"MI)MG@KC&79H?=^7#:2 %$A<?=GQ<N;CC+AM6
M(\'.;%S=;QEQ\78^>>.+O5XUNU_1.X4;;V;BME8ZI@7A,9"-.LJ6#C3J.,:D
M*JW9[[W7O0C=V>5UQDZ>%PU*<9QA/>C>UZEUFFM-WG+[/<)ZZ?A\:6^*.XO3
MVOGIE7AZQ_'_ *1[A/73\/C2WQ1W%Z>T%X>L?Q_Z2.VUW3GZOVYL"O?6^:][
M]2E<:2#F:>=Q)VUK Y@!K)D9;T;K^"=R%L3W47I>+' UQ5ZGBW#=W0DMSIN?
M6\9N;[<C"8FK@L7AL90W56PF(HXFBYK>BJM"I&K3WHW6]'?@KJZNKJY1]CDI
M1<':491?=\4DT_S>1E1'\I=LQX;$,_E&\/26OIGXX^&?LNS?V"/VAA]HX3UE
M3Y7^@?REVS'AL0S^4;P]):?CCX9^R[-_8(_:#M'">LJ?*_T#^4NV8\-B&?RC
M>'I+3\<?#/V79O[!'[0=HX3UE3Y7^@?REVS'AL0S^4;P]):?CCX9^R[-_8(_
M:#M'">LJ?*_T#^4NV8\-B&?RC>'I+3\<?#/V79O[!'[0=HX3UE3Y7^@LYTCZ
M3_58Z?D7.:']>-[-5T+-=LBE91,8G=K6YW.1N=9EM-)IK<B=?F>:6[ @N$,H
M';C1\8[K<:BQ3GXOYY4<VV_/=L;5Q>W-I8O:N.=-XO&3A4KNE#L=-RA2IT5N
MPN]U;E.-U?6[XS+A&G3A&$82W8JRO.[M=O7=Y63']PGKI^'QI;XH[B]/:UI*
M\/6/X_\ 2/<)ZZ?A\:6^*.XO3V@O#UC^/_264ZV-W8=JQ.&#;220PI7F+ 0-
MY3;TC5E*H^::\:H)J,H%*C;"PD6SI% \5<G2+L]RV_A8IQY%%MF/B_BS@1=K
MY*RY+W^?(SS0H* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% 5=V
M[[3B.W#>^KCOU*"-=M1S&J.?7A,=VQP8JB%Z[E7W(#($2/8R4D8V$U9W/DCD
MX57L!.9N(CDUV##P55Y;K;KQ+=5DT[MNUK<>65_A^;BR,AC.J9H07',LP@V$
M$9 \@9;N6P7SLJ3D0K.']D6T&Q/,L26LE.B;$:JS;O;P(=*+HSAHY)G5]X4>
MZ%)1"02) W9<C^_[^;7F."GCJKZ<0*W9^(%WT<=3KUY9D@.]S,%M,=ZXRSHY
MC(\":+R!Q^Y#S?#,)ZDVN\'2W&Z\;FXZR:1C*2G"QX9PHY$O5)@46VN=I)O3
M/2_3G;EME<Y@EU3=%@1@<V7!-W(=U$.64DX;6>-I>SE4KAD>,A4OL%F+,"6/
M\W*5]OA@F$A9E,93QA=[O68R#?;H0BY1)4.B#=ER<O)Q:^3C?PZ':4G4?TD7
MYHCPHM@&PK]W$*VG#'BE,'>.8?G"O)XJ8Z:)!X$\;;N'1A@<\A(E[" >Z>J9
MV0L]AY%IH;,Y\>L'X!3=>>6FNB\G+EGE?+,QJ_\ JTZ.,EF3$ZA\JJWV0AF-
MY@DHPT&FS'KP;<R&##O#3D<"RB+@;X-IN%RMEV9AP,^.3./CALXRPYQN?,&:
M.?V?M%=V5TK:M+RYJ_)EGGQ$Z8KD4#+L:L.4FO:NL;T@M,$[PUA(>1%$,0\\
M.3D4^)8.+(AQ)(HQ69^,>7$L0ILO%UG-W.*VVZWU1$[]0%7^\O43.ZARS'<3
M-N'F#(A%[0Q+\W+SLD[(MC71OAF]#YAC""@0<7=C(=(DZYS5SX2J!(W.2!8[
ML0Y==D4<8L>3-A$HQNFV[)-+2^;O;Z#]<>]7+2=XL%LO%QR&9C@P2@N,I]=[
M,<D?2.1(1JTY::85V,E [G VF>8:&(ZZ<9Q&'9 A&<4%)#/W6A&.@.F+^!W
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M"@% * 4 H!0"@% * 4 H!0$/7EJ WWCL!,<_*'D81%9AU"#ZB$&]A&HLH\*
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MFS8,"R,E"CA"V,?:\V WAQ692W&"[CUE!ON]\K]SR_FVMQ\V99Q$C-.1W&#
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M+:S*<7,QJ>1Q@@L>SB01^X$K\X%1FC3EF:M0*Q%I)*W(N37C7WTX]2^BA$4
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M=2IE:KO[:PX_0S&.8F>4;3%NB]7D94?*2R,;?)3T)-^5VT<NPM#D@(%7K1X
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&@% * __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g947560g02q76.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g02q76.jpg
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M67&5F+0:(B5!4F&4V"114Y;1UB<H,C9#>8&1DY>X_\0 '0$!  (# 0$! 0
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M*4'HBG *8TXLL!9IA8C  "$6@Z%"N\ 8 P!@# & , 8 P!@# & , 8 P!@#
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M&?2ON?E^"T/'CUH\47NY(^2ES)[/=+^[>-8*DA, 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & 0-\4S
MYM'Q ?8SZ5]S\OP6AX\>M'BB]W)'R4N9/9[I?W;QK!4D)@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP"!OBF?-H^(#[&?2ON?E^"T/'CUH\47NY(^2ES)[/=+^[>-8*DA, 8 P!@#
M& , 8 P!@&(_L3H"=Q6\5LZ@]CKHW6/!D;@%G="0U$\$I6JUVVX9*2EL>/O[
M;Z31[LMH'F-CEUT,[+LH1*R4SVMUA0O6D0#D0LEAUG1894RQYV\:;$]Z)/=T
MVK?M5T.GF?,+ NF%@GS".(2T+)13]T>:;&7%(ZG."TJ Q:WJ57B3!&0@W]\0
M9J-*WZ- 6-I7^O%FI1$4F\<NFG;1\"B.0KIZZL7E^P;!MZK37&_&.13%)!*X
ME53/_'*>7)VN,1YPB[6L;Y99G2*UF;WI^6.3<;87PHM1!#HTH$0"-D..= :5
M:++#;K=J2KZC&S%^_O$G;>0[WEMH<O3%-93KU+;%"5!/ZS8GWH9[K1 NNVQ8
MP?)Y+1U1TBP21\KKFFOHX,46GQ:1Z'?3PVP_3L0Q_?JH<"!9QC54:I1/%TQH
ML*MT3;K7'#%;"K?#F[E4POPAXM8;CJ[.C^AX#&>B5D;K"5MDS<^C>A7.%7'(
M$B!QB\>?D*B?3Z-MHYI!F&932*,DB:(49IV9SB].4;/9"PE']MK!+#:J+#?6
MGK94_@6WE:5N17NUHNR:7/85FQ7M-W?'B1VK6%I5>SM*2>TC3;@97\!C5F-#
M6IA3##I<SS,;?4P"TS]!8@]PE]DK0BU/F=P>A-HDM6B2K'8T]KQ=&^;';LR,
M[>#&, 8 P!@# & , 8 P!@# & , 8 P!@# & , U->Q^YXTA[$MRE[CD'BDQ
M]VC$\<F&O$,&ZFYSX!HUQ92=EF,XJJ=I'8='2*W$JDHW0]OTNF$Y6/"P1GJ:
M-M0>J-*89$L*IPQ6-4Y-98ND7J\V7I-A;C"*S2.TE%W256O<MEM\V9(Y-(PV
M7Z\53-+/K5N?V)&N50-\M"GV]%&+,*:UIQFTLG.6RE>=YQP-363-_J"HH4EG
MDELPK1TVT>*K\)$M,$# & , @;XIGS:/B ^QGTK[GY?@M#QX]:/%%[N2/DI<
MR>SW2_NWC6"I(3 & , 8 P!@# & , 8!8Z9<Q\V6+(E\PL'GNCIW+7720+I*
M)E4T"D\B<@H$2=M0A7O;VP+G-9I$W)$B!)I0J,TF1)4Z4GS""2RPB:O>_67K
M3)DR),G1HTY"1(D(*3)4J8HLA,F3$%A*(3IR"@@*)()* $LHHL(2RRPA  .@
MZUK0@YL 8!1++6E<1M2Q+(]7\)85<70/K7&53+%&)K4QULE#D4\29N8CT* @
MUH02)W((=7U(WB3IW=R)*7.!:A46 W0'VV>-1R.FOA\?8&1B/DSV?)9(<SM2
M%L-D,C4HD#:I?WPQ$00-V>U#<U-B ]U7B4+C43:@2F'B(1IRRP/MX P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P#5(Z=YAG?9O45GL<P\19#-:TE/05S5?6
M_(EQT1T0YU'%Y1S["&FRIK&3VBG^EJ=@D])BD67IG5!)++:5B=[5&&I&T*A>
M$1(AD4DE11::6,E))XTQ3<6UG3!K-UYM@WAAXB<AXQY6?8&9'C84[T!5#C$S
M8E!5%81@R/*X6SG- X_7*M^E"J#- T(R1-\54R1^/8TVRVXUW<#"!*C11UJZ
MUK5UJZNM=KVOGVDJL$# & , @;XIGS:/B ^QGTK[GY?@M#QX]:/%%[N2/DI<
MR>SW2_NWC6"I(3 & , 8 P!@# & , 8 P"T$IK"52)]7/#;?=P0I$KTFT3&H
MLCIDUB;O5TA"8S:(R65!*7\6UAI(URGU]]7>16I/TE]61Z3I" +#2N#6DT6Q
M4D/1]3WQIFF+=9"EZ 8T<[&*!FQAM8%35M,?N@M;3A":XJ=GZ"$7I@[ '?D\
MS7E NT"EYP$81;ZBOX>@B"+8!H.>?-'K6];V$7F4$$7FB_,+S1!%Y-[\@M;\
MF] 7^P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & :>O4,=96_JBS)%S
MI<GB&O5M+>UK[CU2U+3<,Y21QJ174_4/MZZ^=ZMD%O,RE<NB595@QMD/F3C,
MS@>L2UQ;V:%(%9ABI^)&5-46M&/BIMMRR3PJEO=,JX9Y&R-X>A-8)N$N/DM*
MO<FD=2)>;J=2UR]S5$@;IDX1!-!60AD.EK>U;$UH9,%$644_)&T9C>G=2U92
M,TY, LT8I*NM*N>LZ]-28F"HP"GY:Z/3'%9,]1R,JYK(6B/O+HPPU Y-3,NE
MKTWMRE6UQE&\/RI$QM*M^7$D-2=R>5J1J0G*@*G%4G1E'&@ P1D^(5W_ "/C
M^:6)$*&C+QTPT>(S9G(SE"JUJZR.B8E5E>5W+9"W2.3/;3$)37[W-/O7;8TJ
M91S96_UU&7Z2.3(::DCY;LE;="^K'6HVZ:J>:3;<4\\4L7SX<Y:/L;Q3:DF?
MA:73#YDXV-9UIWSQ#>Y94^J#DN_(Y2I<C?V*T:Y/:7Y8\ G22JU\-E,><HW/
MFF9SQ8=%7%F<7!R6DM9J8S0M&#UDU1)36#:K@T^:OJQ,X/)#LEUROS&5Z)S\
M[=#4RB\OP*\;+],"NHR#8]G:0>ATDWL6MA7['I",.A# I$ (A:&(D"!Z1CT7
MO1+MKT@3QA\]@?2]ZTG!L9FC-#;@[*$(.MZ( ;H U0_(6F"<9O0=@/AI'YNA
M>A=O)L@2GR? #[YWHPF"+V'8/@[S]'[$'>PI=A]:$7L)H2=E""/8 3TC!H>]
MDNV_1ED&B\U@?1[V%0$L9>@: W"V88'1@='DEZ$<F%HP"D!0RC0@ _0GA($0
MP[)=/*6H+3"V%C>Q!V89H>PB (+?L)J?6BQ>D5%[&E*WL&C3@;,+T( %X2"$
M .B776S#S$X?.8WL(=&%! (0AB$WZ"41O0P^C4F; F.%H8231B+,T$#\A>D8
M] WHEVUH91QVO.8'T&] (T8(81Z&W!V6:+10O0D#T$]3O984Y9HC2M# ?#2/
M0=B]"[>31 5.]? #[L7HQF +T'0--OG;/T(>MB2ZUM4 O0S1DA* ,80 WI&#
M1F]DNV]%:($+S6%\'O>E //+]'H#<+9NPZ_(>$K0Q)1_R:G1(_\ -P#][=TF
MA[+]$Z>=I5I'O>F1ZV#TNQ;#H>C-(-EB2^76][7:'M$$/D%M1H(@[V!\.0SR
M)Q&//4NECN&+Q6-M#U()))9&C<&-@CC!'&\QV?7V0.[HD2M[(RM382>O6.SF
MH2MY*5,I/$H]&F/$6!#37BJ^&?L(1:[ZY!\@R#5&M;Z#J\(M%DB- ,(@[DNA
M /WLD>RDP]!4GAV4,@HP!Y(C!;4G]V7X7W 7BJ>&>'0M[[ZY!\@""U&_-Z#J
M\6]EFB+"$(=!DN]C/ULT.S$P-"4DAT8,XH "3A #4G]V7X7W%DIMXG/AS*[N
MI-Z2]T\FJ6F/-=J$O3DGORLCD3<:]M$7*:@*%)<D$5K:TQ.H+*\T0M:&2: >
MP"+%K0:D_NR]3+X:\5'PT=F!*_'[X^\X:KU/6]]#U7HO1WEUKSQ&[D^B@)?*
M+7_3AC"B\GEWZQY BWH-2?W9?A?<?@'BJ>&>/1>P]]\@Z])H[8?/Z$J\O>M$
M V,?I-&24.RMB#KR$Z-T#:D?D+3Z-,WH.PU)_=E^%]Q)&H>C:)Z"BRF<4/:\
M(NF&(W-8R+)75+XEL&.HWUO3H5BY@5O,3$[-Z9_2(G-L7*&,]06[%(')N7#1
MZ2KDIQHAIK--=*IQ+IB>D8=#WLEVWHLH@X7FL#Z/>P*- $6$&@MV]FFAT8'T
MY!>AGI=Z&%264(HS0!!^A/"0.QZV2Z^4L\I,+R,;V+6S#M&; ( @M^PFD:]$
M+TJHO8TI&]EZ/.+V<5YX'T@BT,(1ZT+6A!T+6AA$ 6M"UK>M" /01@%Y-_E"
M,(1!WY="UK>MZP#]8 P!@# & , 8 P!@# & , 8 P!@# & :^5]\IJH=T9?U
MHI_#QZ?L5UN5'83!&+BY"[(A:8B-)[921=JL.:1RK[EL&F?Q>[ALMBAT:8K/
MEU>MTN1/"1GV:5+_ "NB\DP73JDG**IL<7S[4G6FQ/+H,KO&K7/8S2L7@LFY
MP8^5X373%&8!3]0I+6;[:E3%7D38$3.U!G3Q'VS[U&M]+ E D VQ^9V4 ].F
MT[.<R5.;BH1(Q5XMNM:YNE*LEA@@8 P"##UX?%'.4#E,&9)!<E?&R;IJ>]<E
M3BMK2?X78$:NJRGAY=Y:[1V0M.BR@QYPW(7INW$7MO>X]MN7>:<@/5HV]8D$
MZSYLDLMBHEP6*HRRO:%%5MS/X.?95'5$SJ6.OX#Q'U B94:]T<'QU4J76M9]
M(9 ^/;V[*%3D\R"2R1W=Y'('9:>8H<GIU7K3-A$?Y@1:+;G%O[T>*HES)8$S
M>2/DI<R>SW2_NWC6"A(3 & , 8 P!@# & , AQXBGS??=7L<=.>Y.;X+0\>/
M6CQ1Y@Z(@G:)'Y22OT5/_P##!_V0/]V>H5QLK+^A7/\ JK/Z+=_[$?W4.8X;
M;VEI\M;?MS^=M/[4OORYR8_$=#U'T->+?6EL2V411M=([+EL?1PIC;USW)Y(
MRQ9Y?4+08\.NQM45:2 -9SDZO*IM?%)R5'MG;FG:QS XMOY[EEI2_: T+/2.
MB]'7&]6EE>+I"WG?)N%C=KM;7JQL+2U5E915K>;5_*JSLK&-I8Q4I_*VEKJ6
M;L[3;T;96=[O*L;>\6UFG"T<(V=7*TG&$I*.LWJV<4HZTI-2;2U4JNJN@JY=
MHU3PP3>D1?GN87TPL2":6Y%TD^96UDJF'/\ >3C4L4<EM>K:?$ODZ5[*!&@G
M.#-=!;DT/,P:U"R)B94RH[?S(Z>TI'EL]"7NY72Z:#M[>=ST5>9Z,G:6VE+Y
M8:$L]*WJSAI"&E59W:5BW>:6=MH=V=K8W.UC"]?+3BEL.ZV7Z+5ZL[>VM+U&
M$;6WLU>%&-A93O+L(2=D["LU+]E5C>$XRFFX4314-H<851#>06^W69WFIMLL
M==\UVU,5#FX1T^NGV/=+O=MM+7%(M'$T81R)D?H(57[$H7OCC,I$DDQKG)""
MF&.A9D9BS!HWE3?;WRLGHFVN>CEHJWTARCT5=%97>U6D+"\<G+'15K:7J]7B
M5O.[VUA?G?K>-G86=SN\[LK.[R=O>/E9J-K>Y0L]'J\1MKQ_2(V-RO%HY6B^
M2G"^RO$5"$%%3C*S^2@W)VDE.LOV8T5<:/H"/^Q*_P#Q@_\ #.B_(V7[JS_!
M'N/B_*6G[R?XI=YNZ_<P6M!X5O70=:UK7:=B:UK6M:UK7X$>=_R:UK\FL\_?
M# E'PD<J%%**5YN=$DDE_P"5W%Y+#/$Z[H!MZ&T>VVV[&56\6_ZZUVFR!G-3
M[ P!@# & , 8 P!@# & , 8 P!@# & , 8 P#6G\1GQA>FJ+M>P:!KJNJ\Y3
M*CTUKV%16_>KF2RG;=V-L\G46A;Q-.:(PU11BIJ1I*Z02%=,WP^>W<2:)BCS
MMLZ'!&C5!)&2,$]M6T\(TPPJJUQ]"3Z:X&PM4K>^--7UZVR:ROPR2)##8XF?
M+:TU1]B#93J4U)0KYR6RQ308PT%2A3HQX*;8_KX&1%JP)V[8DA90MC&\WA3F
MW<Q<+ & , 8! WQ3/FT?$!]C/I7W/R_!:'CQZT>*+W<D?)2YD]GNE_=O&L%2
M0F , 8 P!@# & , 8!#CQ%/F^^ZO8XZ<]R<WP6AX\>M'BCS#$/Z$C_94_P#!
M!GJ-<?H5S\UN_N8'"K?Y^V\K:>W(K:#SJ75K*&R:P1^71F5,X5X6Q[;A%A6H
M@NC:L9W#1(C2S2]>M-C@M1F^<6+^14&:#Y!>06E]N5UTC=K2YWVPA>;M;.S=
MI8VE=2;LK2%M9UHT_P!FTLX36.<57# BRM;2QG&TLIN%I&NK)9K6BXO/?%M/
MF9=MBZRZ.C,'B%;,=NRU!!H%(&231.. 4)#D+0YQN3*)I'R@"4I#E*MD9I@K
M5RIMC#@>KC2.1JE+V2T@<CS5(_E6_);D]>;[>](VVB;I:7V_6%M=KW>'&2G;
M6=YNT;G;MZLE&%M;72$;K:7FSC&\SN\8V+M79Q45L1TA?(65G8QO%HK*RE&=
MG"J:BX3=I!8IMQC:-SC!MP4WK*-<2GI'T-=DOK!BIB2V3)GBKHTY =F6&K%1
M8FI&M(4R!8A\H@$@5JDC2KEDI4L;<L4J&YA/DC\8S)4(W=?M1L7?0&AKKI*W
MTQ=]'7:RTG>;-V5M?(0?RLX2C=X3S;C&=K"ZW6-M:0C&TMXW>P5M*:LH:M+2
M^7JUL8W>TMYRL8/6C9MK533DUDDVHN<W&+;C%SDXI5=;,Y]<UC=Q^Y@_D+7M
M[:=B>Y'G?//KPP_:3RH\YN7Y5<3L')_ZET?Y&7OK4V/\YH?8& , 8 P!@# &
M , 8 P!@# & , 8 P!@# & :T_:W7%I0"]+?I:A+B@7B<.#U)#BYOX9LPY%D
M%O*:Y1+1DFKXP9T%432=#8&W(SM[T!MZ(8Y/\"%&F 4GZ3)MB1#)%*B;3BOO
M*26&3_9=6WOU=^1GMYM;SVKGVE&U33#?SFI15=!TZB@FEV9GYKI@\N.M^CJP
M;GJ.ITC"Z(H29YT>2KF=(E;5!* !B),G3B+) */-XUQ>._GQWEZ\$# & , @
M;XIGS:/B ^QGTK[GY?@M#QX]:/%%[N2/DI<R>SW2_NWC6"I(3 & , 8 P!@#
M & , AQXBGS??=7L<=.>Y.;X+0\>/6CQ1YAB']"1_LJ?^"#/4:X_0KGYK=_<
MP.%6_P _;>5M/;D=K-HQ# & , W<?N8/Y"U[>VG8GN1YWSSZ\,/VD\J/.;E^
M57$[!R?^I='^1E[ZU-C_ #FA]@8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M!KH3KK^%4/,O$CIKJZ^^D^=[=MZV78'+L?INE):N'NJD\+9C:RGG,SM!ZGE,
M=FUFV-(E[P1:JV2/[B\G2YN PNB:,)&D#@=%?CXV<^1=*M&DFDOVFWAG3'%4
M2PRIA0S2\AN]V2#E?G-\Z2;MM%_N]*5HY7*VF(4S8I1V0LB+2HEQ*]K1%E(F
MIT"\F*]NK6A*+0MKEM4A1%@2D%!U)5TJZ95=.C82*P0, 8 P"!OBF?-H^(#[
M&?2ON?E^"T/'CUH\47NY(^2ES)[/=+^[>-8*DA, 8 P!@# & , 8 P"''B*?
M-]]U>QQTY[DYO@M#QX]:/%'F&(?T)'^RI_X(,]1KC]"N?FMW]S X5;_/VWE;
M3VY':S:,0P!@# -W'[F#^0M>WMIV)[D>=\\^O##]I/*CSFY?E5Q.P<G_ *ET
M?Y&7OK4V/\YH?8& , 8 P!@# & , 8 P!@# & , 8 P!@# & :?'5?15N.G8
MULP6V.D_$SK2L3ND[RATRB7-59W(UPN*4?7M--9_,LBJN<U=3;L_)WF479I?
MJPUD8F;GN5M1H$\L;DS*G+4B/X^/CU&5)45%#)8N2JVWC5-[.CUU-E/@J6V9
M/.(^1YG<YCX=;DGYQIMZLT^3-QS1)%,Z7P%B/E*N0-9Z9&<WOBIY$L4.R0Q&
MD$0O-4%[3$>3T0!CE36E3*KIT5P($]>]E=34%*)0KEW17AR<FPUATA>X[#;7
MC/0/1]L2>$/LS6P:$RJ1I*YD]-!BQ<V>&]9H#!&(Q/=LHD3R ,N=DT:?5Y E
M)/"DFWE1I8TRQ3KZUT&3/G*5W+,ZS;WV\&FH$DI5J"SV:0T1-G^;UC84-<&E
MI=X[/XX?*(Y'7R/$OI3BH)'&%IDD W[0:5(I=(&]P2*\$.FROI^,>G"NY%]\
M$# (&^*9\VCX@/L9]*^Y^7X+0\>/6CQ1>[DCY*7,GL]TO[MXU@J2$P!@# +$
M*Y#TX!4I AJ&B%*("@X*-0KZ,L%$J/2A,%I.<I1D\M+R4B@TG0!G)BERTL@P
M0B@*U(0:.&)PWOU+O*"06UTPOL64UP72%%@<XI"H#-U:\?2T_P#45*&P'VR6
M%N1IM!Y2VHTK0J*S=#ENS2@$[)<$'H##!Z4!*"BI6KV[%LIS\Y<^.OG0BEZ;
MR)96%-,D=,.$%U=8[>\WE#TB3^B,V$UO8'+G.((7,[9VBBQ$*9(T@"4,P[2@
M0RPDFAAO?J_U+RX(& , AQXBGS??=7L<=.>Y.;X+0\>/6CQ1YAB']"1_LJ?^
M"#/4:X_0KGYK=_<P.%6_S]MY6T]N1VLVC$, 8 P#=Q^Y@_D+7M[:=B>Y'G?/
M/KPP_:3RH\YN7Y5<3L')_P"I='^1E[ZU-C_.:'V!@# & , 8 P!@# & , 8
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M4N9/9[I?W;QK!4D)@&-/Q1?U2<^>W!R9[ST63'-=*XC9+JR]EG'F<UQ@# &
M, JSPJ/FZ^1OW0L_^-<<US9EF^E\3()@@AQXBGS??=7L<=.>Y.;X+0\>/6CQ
M1YAB']"1_LJ?^"#/4:X_0KGYK=_<P.%6_P _;>5M/;D=K-HQ# & , W<?N8/
MY"U[>VG8GN1YWSSZ\,/VD\J/.;E^57$[!R?^I='^1E[ZU-C_ #FA]@8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8!KR^()<]]S+I)-#-5AXL-><VUQ +';9
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MYWSSZ\,/VD\J/.;E^57$[!R?^I='^1E[ZU-C_.:'V!@# & , 8 P!@# & ,
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MHL!/^;_[>B0EZ-W_ )QOGB_+FN;,LWTOB9 _@=#Y^S/(J\[:K2W?D<7'0?6
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M'[F#^0M>WMIV)[D>=\\^O##]I/*CSFY?E5Q.P<G_ *ET?Y&7OK4V/\YH?8&
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M\,/VD\J/.;E^57$[!R?^I='^1E[ZU-C_ #FA]@8 P!@# & , 8 P!@# & ,
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MFR3QZ 8 7D%H->F4(>J7\Q T'W*ORX (0 Z]Z_"  0@"'2^F_($(=:T'6O\
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ME2BJJF*VMK&[V;M;>UL[&S32=I:SC9P3EA%.4VE5O)5Q()_')^%S_/VZY_\
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M7=*[&BA6@)#6YM5IEJO1F]:)3'%FBWH._+@%DHG-ZSEE<V3:.N@>JXS&ZGB
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MV0JBM)MLJD$B4L#NK43IR02V?+$;A'&(J<*69LCB=)$$2E36[BH=7CUH&_\
M6N+KTTKZ"E(CPH0Q5%TE6CC-(4A7]$TBAHE8NJBE6:GX+&F%EKZ90)FEP*L9
M)6[LKC/E!$V7&R=X;W2-M+RS,$*BC0P1AEBC> 0ERQ3QP=55U^$4G>_"0Y*3
M/IM"'K2N6*[:+O:,PY(QLC4C4R=EJR@*\8(RK5N+NE:7EH)6T R2%P9W@Y@:
MIBC=#X"YO<2;1[F*417X]>STY["KJ@YFGC[1Z-ANQ4RQ^;.G6ZCJAU;F:--
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7YBEP6&^F,)$>+TWF"-$664  E)+(_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g947560g02v46.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g02v46.jpg
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M 0$! 0$           H%!P@)"P0& @,!_\0 01   0,%  $ ! L$" <! 0
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M=G5>R&1[5PJHN'-:J+A45%PNQ45-Z!51%PJX7H78O3Y"G_\ %P\8O^/#E_\
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MJH]^D\]2A5U!CB@)?7HDOV\[Y_"/+_YST)47^'#NEM?Q'%Z_7F_M?)G>_O\
M1PDU:O%S8B@.33Y!O7_[R]MKK7]06Q*F/P5]P5AZKG]<7 YNX<LG^:]!$8BU
MZ"88H"2YZ*U]X7N+V,]A>^_GBH]<.^_1;JO?EM!N;3NJ>N'R3$_2H^&W% *
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MZ_7F_M?)G>_O]'"35J\7-B* Y-/D&]?_ +R]MKK7]06Q*F/P5]P5AZKG]<7
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M^=.8/+AS3#)3!X7MWQRF!DMW#N?=+]S*-/=,NWZ$DWALN2;1DXYFH*W.%;X
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M2"O(0$ASR4S<VT(N,',1&$QA,<T%-5=NU-B9W[T[QLMH6B@% * 4 H!0"@%
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5L-FM"@H!0"@% * 4 H!0"@% ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g947560g03q94.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g03q94.jpg
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
M0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M_\  $0@ V0&0 P$1  (1 0,1 ?_$ !\  0 !! (# 0             )!@<(
M"@0% 0(#"__$ $00   & @(! P(#! <' P('  $" P0%!@ '"!$2"1,A%#$5
M(D$6(U&X"A<R-F%Y@20E.'%XD:%"4O 8,S1#1'*2L<'_Q  > 0$   <! 0$
M             0($!08'" ,)"O_$ $(1  (! P,"! ,$"0(& 00#  $" P $
M$042(08Q!Q-!410B83)Q@? (%2-"<I&AL<%2T0D6)#.RX?$E0U.28J+2_]H
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M*8I3%*8I3%*8I3%*8I3%*XCM\S8)&7>.VS1(H#^\<KI()]@ CUYJF*7OX'X
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MK99M,8Q1BXD"Q&28^6F[>^$7-2:<%.54H]XM\G=32FT:84U%@'CJGN-J7IK
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M9Q HE3$"? @'?8%'L?GY[')Z5<!^6+<M5VCE9N4CE,Y#AV4HB!BB B(=]=
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M**OY:X3=N6,$_*]4D&#IPW1!-8FWL5N[N]M(WG;;%8+(&N!M179Y,9"9W^6
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M/)(+AQ@#T4^GW5KG5OTF_#G1;:.2ZNI[N>X7_H8M-L[ZX%\SKA!&R6K1@R9
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M!R01@CD^IIJ9V56:K*'4<R*8).HP[@6:0_4.'+TBR94"()H@8YUU1,8H%*(
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MLK@.LR[<HI&WE?>A5F-9<V@[6VSCF0*@JD9DP=.E%8Q8ZH=)^X()D!10AB]
MFKWU\? _(C>[B/4;.Q/ZLL8[< $2R?L?.4@?/@E@2.." <]AR*UU8WWA]U5U
MW=:=XD]8ZGKUJD]L^F:*+BZDT9@7_9S/)"#$7D.[?$[ED  =!D"LBE8"*D&#
M8\6S1]QFF0$D2HD$$R@ "!DA H 0H? ^)>@_PZ >M7_K6\M[N1;R9P)209 Q
M"DCC##)].,Y('?C-?067H+I/4M#TZ30M'T>)K."'X)(H(F2)$0>5C>BD-A<D
M@DD\$DU3\W:7U3AW G17555\46K<B1C'.Y5_(F0AA ?9\S"!A$![$ 'Q#X[R
MXVFE6NJW<4@DCVJ&>9RPPL:MR2"06(&.%R3NQ[BL-ZG\0-6\.NE[DWEJ)+KS
MEM+,6]K.8_/N&,<2J8T=8P R[F=@HD#$,N21RF3.RN6;*5ESJ>VFV)[C=$3^
MT!_#H0.83"8?#L ,'0)^0&Z#KX'SGDTNVN+BQMO)D=CA)MI3D@.2NY5.1G!&
M,\<<$&KCI-IUQJ-CIG4.OWLEK;+!\5<:7$Z.[Q@NJ^88'DSF,!PO[I;!"MD#
ML6ECI4T\*S48(+NFPE%0AA-^4R?8&[24 H>11*(F#X$.NNOX4DFEZU96S3K<
M-Y4I;RVX]03C(W$YR?8=QR*]K+KWPXZLUH:884N-1TT!I$N+5U-H0^P/,D\4
M+.-Z$';YIVC<<@Y.;_#_ '-&\?>2&F-QEA8N?95"UH)*1SXA *6.L39>M2SB
M.-[R8-YAG$RSQ>+7,)B)/")&4*9/R /7H[6+S2.I[24JUQ<22""X 5B7CGPI
MVG;^ZK94]O\ -A_2:\/=.\1O!;JG1+F\73HK*Q.M6-U&1Y27&FHUU#&RJNTQ
M3E/+<  KDGY""1^A(S4]YHV5 ADP5024 ANA,0#D*8"CT(AV4!Z^!$/CX'.N
M 00". 1D<;3@\\CT/N/2OSJ$$,P;&X,P.#D9!(.",@]N]<G(U"HT?5B_X5:I
M_P!97I\_SQZ Q4R]S_"__@U278J6F*4Q2H7O5XV+O^KV/@;KS0=CW/%R&Z>1
M5TIUNK>AMAZYU5L*[P$+HS85S;PL7>]KL)"B0)6,K7VDVY6G402=-(YRP:F^
MO=M,5.H!#$^@&#SQD@=@15F-P\]]]>G#J#BO#;!UM8KW8N2]TNNJH5MRJY1:
MFF=KZ]W#)7:+8T*8V;?M70*>NY'CN2M2)I:VW"K,UI36HNJQ"3Q'$C8VY6Z@
M4,6P?LC/ /(]<9/?V![^XKKY'U$.<FM=Q\KJC)4S16U#-O46XX<)=!5UY<+-
M1X2GJ;LTM7+>TE[-)QFN9277KC9Q,1-JGWBW[4V5.5F;76H9)W#5ZL.9)0A<
M+W&5)/W@M_?&,<>ASWJJ)[U@]C:TY%+ZMV'J/6MQU]#%Y*U*U6S2,UNV;7A=
MI\4>,UCY ;+K3"U7W3%(U?;I)S)4JRT@U'IMLG[+1G#F#<W%\G(JNH4BFT8X
MSDX/..Q.!V)/J.<>_%?>R^JYR&UUI#65\OVE>/K^_P#).>XJ-M!5+46W]D[A
M?04#RF@+M:HZ1W'KBDZAD]RB2GPM$DF<3):XI5ECMM6ES^SU3+%*QCYR+W_/
MY]:;021DX&<G &<8[9..<_>/8UA3R6]2;E5<JCLC8=>=; XTS4=Z<5XO2^NT
MDYR.:P>WZ)ZA>O-%J[,K:-ZJ%4MQ&%KHYI-:O%M%7@YMC6K.$3/0K2;9O 35
M.J+V//SJ,Y]"I.,C^X[_ '5*4X]2^P)W(U/'6M<(J?U9''INI*?M.^!V-82T
M$.YAVH5L,=V,Z5T*<0->[_#09G(\&3]TQ415Y[>"<_N[O_[A<?RY_I4<.J_6
M'WGI_AQPPM4_"U3D59)'CKH7:7(V8G)7;;C:WL;FW>]U%'3$G(4O3\[IW7*"
M_P!.J^K<OM'8L&\O\NU>5NN58#1II1[ G\\_X!J<HNY@,CD@>W SW)R3],<=
MR>:F5X2\H-V\I;!R0F[=K?6E#U!J+D/O3CIK^0@;K9;'L2Z3FC-KV>A3-JL\
M$]JD17:O!2L;&1:D<QC[#/R9I=*9.Y*UCC1ON1J1@!CG)(!/X@$#N??UQ]U0
MR:[WUR9IU3U1RM#E[NJ[6V_^KE;^'\GQENDKK^P:FN>EYCE;=]-G@:76#4AK
M>:];J11X]K;HBRQER728EK3XTO'NH=RY215/@=L#_MAL\YSC/OCDG';':K]#
MZU.V8[5K+?,]QXULEJS=W';G#O;B_'P6V)Z8V2T/PK@)BPR->Y$5Y>BQD14R
M; CHDXE?TJ;L@T:>.A3YQ!])NTGI%2A!G&><J.W'S>H.><>QQG^==\P]6+E7
M$;$DJYL'C9H>/JE)W-P-H^Q92J[JO<S/HU7U!!@6FN_V/C)34\-'RUGU@\DW
M3B^.IB2A(>P(),V5;:-C+N9%HIM'H3V8C([[1D^OK@_=[U8?>7K)[0FZ9RFK
M3"EQ435HKC;MO>VE-TZ"NVTZ](R$9J#DCK?24@PA;[N#C_!U"X'F$KRA)*7[
M6,'<Z/%R$?,5)NZG%1+.-E1"=C[$ @@8S@GT;Z=LCT/K@9I(>IONI/D(%1DM
M':S3T*GZC%L].I6W-]F6$NTU[LPTN^W% ; )5'5+2I[*IIM(_P#!9I)U<SR2
M[Q\*K5LQ:1@N9-4NT8SGG;G&/_Y;<=^YX/TJL/3L]1W9'+W95ZU?NC4=:T)>
MH?74=M6O:T<J[<3OO[)N;:[JKZ20DK=JROZLVM1F3E6!3:[:U!L6?@9*2EDV
M7[.LFJS.3<J,H'(.><9X_P!\@_0C/KGFNK/OCD3JSU/]Y0&Z-@JV[CW7> =H
MW_K[2NFM<V>;E(..KN]F-7;23N'8K6*W[2W'-PC&2(JC6HN.8%3?L:O6JXY<
MMW,S-*8&T>^[&2?I_3Z\U8WFARHOH.]%<M]&\D=MT#6];V/Q:BMR<?9ZNTK7
MS[4&I]F\@7.NK5L;D'Q[V%71Y%W1SNM!P77VLH.,;4M2KE@76P:XX? E*.L5
M%0.5(!//(.22 3@'[(]R><]JGY51273.DL0JJ2A3$.F</(AR' 2F*8H_!@,4
M1 0$!^!$/L(XJ2HX>6'I,\&.8POI7:.FXV$O3MD#-/9>MW!Z-=D?:3.1JL[=
MQ!2Q4^9KY![25EB9E$"%!(2>V %!4,<_GO\ V'^?[ZHW*CTV-X^GHI<C2%2E
M]H:%CP=/*ONB$A%9)G&0#EV*4>VV&UCB'4K$^P!5NT?NUT"0<@N)'48Z*54S
M5NI_3\_G_/M6&FO[[8=K4J7UA6TW,++':*(2%E<(KLDX:/>G,4KY!/Q27<2#
MI,YOH"%%-,I?-PHJ $(FJJ-=_:R+:>H"%5EG"$A"M&1&B;P0*4P(I%*7]Z'0
ME >R@ &$/@1\0'KQQ4/7\_R_SS^'TP!9\@[L2Q*1%!11?-VZ@*($<$=M%A2\
M@%,A%"])F*<HE%,XICY ("(B'SBHU5-MW9R!V%(P%'=BG2&4P[;1/XBJHH)!
M6<&,4!<2!$!1;IF\1*'DDH83F(3L/+R!3\_G\_A[77@> 6X+9I/D#O.5L);?
M"\7G6J7MHI!WDF_=SE?V;-3<0I/L'::"35)I5EX=)[+HNDSE,P=*NBK(),51
M5@?Y?GG^GK4/I[@_X_WJW5AV_#0\.PKPQ#V(EUFR;6(9(( 4I3*I>*)@4(;V
MDDP$X#Y>)?[)@*43%Z"-1KXTV4W8:";:ZU["NXM!X#F3L]M=-Q!5^JKY+N3F
M<E3]XRBXA].BF(&$B I%*5,B90(I^?S^?OJM$Y^G0K<&6T2/XEZB HG>D07,
M*RA"^!CM5"%.)SF5+WX&\3& W1>AZ#%0.>,#///T'//Y]ZN[QMU-1YZ&L=P?
MJ218QU9QEX->4*V83!RQJ**3-Z[=*H ^*BD?WPCFRBWMH^^HLD0%W*@C<;?4
M]0L%9M*O4LIY$:":5XFD#VSE6DA"JIP7=(F)X&$(]15/);(+EIR/BD>)HC"^
M $+,K;QOP-RA-HP#]H_6MC;T\/3COVUKU4=Y[WJCJFZ0JKJ.M5%I%A12_:+:
M4T@)7D)+3$6H95:*H[8Q6TH0DD"4A9C%;H@U)#G5<NJ&24N?VK>9,[9,H!"O
MP20$].3G)  ' />JFW/PR21VZ"..12KA<#Y202!@_P"H#U[^G>ME]6Z4UG,M
MZTXLT TL*X #: <2K!O,KE OD MXI5<CU4OB'9?:0, E#LO89X--"KB-I8ED
M(R$,B!CZ<+NR3] ,XYJI2RO9+8W:65X;16*&Y%K/\.&')!E\ORQZ\EO0YKNW
M!VZP$ P@<"]J!\]  E#L#=]E$/$0^>NQZ$0^,F+$$C![?,2, +WSD\'\#D=R
M,52[0Z@@;AN!4J23D'C&W)_/UK2*]>S6VPH/EM9MJ7:/<.]4;&J51@];VI,I
M7T-'C6X$$9>F.72(&3C9=&?3F+(2,=G3.[;2@R*'NB+KVM0=<6.I3ZO!>6LJ
MRV:1;"(KA&*D*I<-"KF0?0[!O(;!R"%^E7Z('6WAS8^&?4W2&O0VMEU/=ZBU
MRSZA93,T]NXE%C+%<- 8"0^Y&19=T9"EU4.A: V[L&YZQ6'TDS.NP(X_VIXD
MD8Y&[5RP52!4_ME,<"")D@\@+V3L1'H!S$-(O)UU*X6"53=#8B1R-MW?,=P#
M,0H.,'D\D?2NG?$G2].MNB>@M7UK24N=,CO[OXN]A6.1+&RGM9(5OO)0M)<;
M#)'M6!)) 6+$592N#?)]\>BUFSG)4R>Y[\D5%5,R3,1,)FR:XE*JH)B&]LI"
MF( C_:$"]CF7Z@F@Z?"=6U"P676"08X-ZO$S8Y=]I9#A@.S>_ -<S]%:AXM=
M3ZL?"3H#KN5^@+=_^MU2."2SNH+.XEEDDMEEN!#,KI$Q"JHRW<=@*O5"ZH:#
M?M55./$B$A<+I5:>>VRB:LFG$&G9J/B E5&27DX738"[!U]*BH!U"$]E+KL3
M90:->W'4\\MC-J$=C;RN";:*%E)7&-JE(R "..6]SQZ9SXR=&V?@5I6E=3:'
MH-WKG45A$/+ZEU6\BNK>+#N[!X9IE?<7#/A8R%#8#]Q6^!QC]"OB/H]^2R;-
M2FN2UH;D0,R_K1:Q1*+'+) F<5H_7\9X1#Q4Z@"<JEG7G_9Z*+<$%"B8VR-/
MZ-Z?TX(8K/S95.6EN")"S<?,!CY?NYQR!GN>%/$7]);Q9\2[=M.UK7Y+71MB
M1-I6EYLXY&C9F$CRQ%78$,J%"X'R G-9LWOA]P7I\U)\C+MQ\TM#3&O(5Q;7
MUX=4Z(;(03.JQBCM2==,DD@AC.H>/CP.VD%F"SUL5N44%RF(F.7\P6L69C!$
MOE(<L$4 (O.  !VR?8^W%:8_6^MW<%OI/ZQO9K<W :VM3.['XF8+'D.S%LN$
M0'+!>,GW.@-S%VW5.5/,/:VT(JMH5"GW.S#,5.)2CVT:="G5]HTKU4!=DT3*
MW9OI./C49B401\O!T[72!502B<=/]6:P[I+=Z< T&XP%%P"'3(8E2 1WX;;C
MMC-?1[]'[PFT>>^Z8Z8ZNT^;3=2EMY.H9;J:ZBEDGBG\MHU\V&610@\MB(]V
M]?51G!HB+=K5V64(N<5(U=LBDV\>P*02CV?HP=!V80 2^8C^H /8=9JR[B75
M+17BV"YC=VD5B 01QC./4<\=\\U]']#+]&:S-9W#RG0KF&UCT^1MTJ(JIC<<
M%RH;.[:Y7M[U<%S^#3C8Q%BHKE,F!P\RI^XF(=^)B^0'\1(?]X/7QV7S$0Z\
M@L$8N;%XQ$SJSN5*@$ G)RKL1MP><9(X/'<UL^[L],UJT$%W':ZA:/\ MEC<
MK(O[,@B4 X*,K!5W,,!L*0<8KKXBSQ2\6FHEY)L$'+F,6=E;KF8$DF8].V0N
M1**1UR%4(JHEV*I4UDSB )F*(U]SH6K13I<R6LKPS -"^#F3([@X(.&RN,\$
M8 X!K ]*\5O#:]DN=-AZHT.VOM,EEL[W3);^WBDLGMW:/RW$C* 651*N"R&-
MAEF8G.=>A_21WQR>TA?^2^I4&#9]'6)LRIVO)V.<P3W:3%DQ4<V27K,_(.FL
M>@HV<JM&4(W=-TXZ9<MI9N,FQ.DT!;;73O3.M:GTU*+ES$P.ZU@E&YW5<YR1
M]CG &['N>1\WSU\9?'GP[\/O'9)-#BMM4L-0L8X>I-2T^9F@M+UG0IL6--LX
M$>'D>%F7<2,L=P&-U4X8<P=BWQEJVK<?=RLKH2;;M' 25.GJY'5QTW<)*&?3
M-CE6K.$BF#8Q"+FDE7WTZJ7@=J+@5$BGH]'Z5UF+589UA7?!*K>:^W VGO@@
M$CGC@]^YK.?%7])+PSU3P]O+2WZH5AJ6E-%!9V\5[++*9(V'E.(H6,;DG!$H
M3 !SM&<?HPU!G+1]3K#"?=)O9UC7H9G-/$BB1)W*MHYLC(N4RB(B5-=V194@
M"(B!3@'8_?-]IO"()"#)M7>5^R7P-V/IG./\5\<)VC>:9X@1$\LCQ@Y!$;.S
M("#SD*1G/.>]5%D]>51M^K0:MAPCNI)UML1U,K;1XV-]5DU9(TB)N26^''(W
M5B.A7;:0V5'3%#:PS/;QZ:ZM9[3$2D8-62F2&8.7!D$Q5,O?T[-G.<8VG/;G
MMG_<5BII>O\ ](G:,$C[-V#Z7[ALJ8QD6]RK&]K+?&S43#[*,Z[U035E"5E2
M)^)7:\&R-&K+@=1J@W1,1$JHGR_9OYC'\N3_ %_VJ7?2:6\T=>Q2?(U_J>2V
ML#J3&;=Z3B;A":].S%\L,,6*CKU-6"R).B1GTY),[N4625? LHU(BW,FD54I
MQGC('U.3_/ _M5V,5"L1N5.O.&.X7>F=2<O:)J792]_O<M&:2IFUJLSM2$SL
M",I\Y8)=*M-7[!ZU;3#:F14Z]7<*F:@,<V=)E5,8Q4CJB"PR5)&.Y!(]<<X^
MM6ST_P 4O38MM?V'3M.<?..<M5]?26T.,VPJW":V@OP6LR,B^KU@VUJ]Y&O(
ME-HW"4D?V8E+0@P2%O)NFL0NLY<*,&PH*B2W<D\X/<^G /W^QJ]R/#3BFA>5
M=FI<?]6!L%Q-:SLCBY&J48I87%CTU&?@NJ["XDU$3.5YVAQ $C:Y,*G/(L&2
M2#<CD4D$2IJAD^YXS_7O_/\ W]Z^33A;Q)8;8?[V9<<=.-=R2=BF;:]V4A0X
M!.X+6:R5Z0J=HFPFBL@=HR-KKDI(1-L<('3-:&KI0)_\1.!3E4R<8R<>V>./
M?WJE83T\^#%:H5[U?7^)>@H;7VS9:%G;Y4HW6579P]DEZPY5>U5\^;H1Y!(M
M47CAP[J -3MR51RY<KUXD:JX6,HIN;@Y/&<9)/?O_/U]_6J=D-$^GW7[;2.+
MLAI[0T-:+9HRTU>A:H4H,0Q1G]$5&^UV[7*MPK0D4G$/J[%[&?5RYV"%(X4>
M*V)TVM#YJLX45D!5'+=\GN.<GOS@_?C/-8I7;?OHGU?=R.\+B_XT);[G+++V
M9GL\FLY"8O,E9]0V.7U'-VF.LL/3W[I=[6+) 2=(?V-DY$CQW"(L57SXD8P%
M!4<.1CG QQGCGD>N.>]=?NJ4]#36L3HE[NRM\2(5C)Z1KLCH]E-:U;R4E$\?
ME'ZMBJDXC7XZL/YFFZWC9:6D)&OV"SQT)#5^7>SOX>^CWZDR3% '.<;CSSSZ
M_P ^3Q624SS>]-[B=*%H2FX-2ZT>[/8J\DB1%.B)>58W5CNN;F)Y;;Q'E(@I
MF*ET]CSB$Q,GL17:IIUS[[_W5BK$545#:QYP3Z<_3''/L,?=6.]=V'Z'>E>5
M4R]@&?$+6_+%+9DC59NY&UK'5^ZQNV+P[+^*L'&QG]50CX:V6=U8@1>N2V)F
M\DOQPS55PHG(G265'Y]O[VW';)Q@?3V&/;'%7\W7J[TNN(4?LK;^Z]8\9-,-
M^1Z-BUALFT2]"KS&0VTTO3*2FKM37K2+AW,I/LK4PCY:QWN-CV2C66;QSZRV
MHJQ&"T@BJ W' &3CD 9XQV/W\X'KS@5D="Z%XK;#AVU^K^LM17& V2GI#83.
MVQ$) S,5=$=0-6,OQ^M[28:$7:S*%#9?ATCKB70772BFPM7,0L1,4S"J'(XY
M&,C'MG@C_>J'9>GAP6C5+8K'<2]",%+U&V:$MYV>MJTV&PP-RGXJUV:NR7LL
M2>_7)>SP<78G%>^(4DVT+*-V*+U5=953)]S_ #/H,#^0X^ZKP#QRT,+P) =1
M:_%\&Y5N1 .AK,8*_P#7HXKJE17VR)Q0[&^*UA96!4L8]R)HI0[(5A1,),5"
MNCTWQ,XR<>)RRV71>AM5ZFG[>@1E89:ATR$K;U_&)R#J63A2+1K1 6, E*O7
M<HE7X[Z2%3D7*SXC KI0RHJB23P22*NC_5S0_P"L0-N?LC ?UGA2QUR%\_#6
MW[4A0QG LPU'\8\/K/P ;" 3(QON?3?B( Z\/=_-BH5;387%/C3MG9]%W3L[
M0^J;[MK67T?[!;$ME(@)NVU;\,D59B("+F7[)9VF6#FEUYN *HHJ6!FEUY>'
M!E)+*NCJCDCC/!J_^*A3%*LAR5U:YW;Q^W3J-BX;M)'8VL+M3HIV\*)VC26G
MZ^^CXMVZ#Y$4&SY9NJJ)0%0J93B3\_6*AQWQ^/X=S7YU&Y=?;VXL[1D*]=:3
ML.AVH&S:'E8TM5D7I':T=YMVC^'6,D#.>C7A#>XRDXIP]:N$S$+[A?DI51K$
MZT62_P"Q+0YJUAD+(T/&+^#QC:6 ,9)LXZ(MX.ZZ*:!VBQ3&*)$WP',41 XI
M  %.:'Y]OO\ K^>/>E<:IT:7J$VI9Q[E1AG!D9:,%M[;YQ$*@59O((-B )E0
M2(81  *('*4Q2G\BB&1_(_EC_>E9,6CDIIU]4&L%'L&CR:]]#]RDW3]]LHET
M(G4$Y?>24*) \P. " @(&#H!Z9]/\'^_:E;4W]'<5UKL7C9R.7=1*,E9YO;:
M<#>XB=1;R3-]2 IS,E0CCL7*!TEH%?ZVWD,T=E717=+2)# *8D1(J'MQQZ_W
M_OZ__(QQ]?/AAH_6U!X_VW27'_6FME'&T+(:X7ZI4UC$*$D%(!)>O5R:=QR"
M2:43.+?BKTA%?%,KV(1(VZ.8Z2BHUKE.N1]FHD[&U)M2G2KI$ON*E2,W50>)
M'(=,%63E,0371[*/RH!!*(AY$*(E$5/\U<1[R(H4K75CV/6Z[N=1!,I$5(HA
MDDWBGB8GO/!2.W;E%7_\P5OD.^@#KK%/S[?Y_K5Y."T=([2YB\:ZA;T*P]JT
M_N"EGDM>&<)A&R]<;32#VP(32[ITT0<M6\.DX4",*1-*17238>R]^J(U65 G
M'8<GV&><<9QZ<8SV%?H8/95@!WE3AUT&\ZU@DWK5@1$Z:3-DX%XPCEP$B8-R
M-P=,ED2I$,)DRH#VD1,4Q-(S$AE4,&VG!((&<<')XX.,_P!JF 'R\C 92R@Y
M(4,,E@.0,>I[YQR36@WN.3VO1-RWYEN9:VM=Q5ZU2+FP/I!>27G5)7W_ *ME
M)LI#R!Q].\14;O(-RV7^G-'+-%6:A4?; .9^JK748.I',E^L3!S(A-W$A4CD
M+EW&W"C(((S@8[8'W1\!+[H36/!S1K/3=%@U.Q72UM]3@334D^*G "W,,D;1
M;G!;(+D%2<!221NYMZ]0/EK;ZY!:SLFYMB#6G8*'30<3(LU'#-B"*0-IB6CD
M&$W-@8JR @UD915$OY16!50H9ZW/5/4;:=<J=;>6"W1%$81MY'(P;A5RRX4?
M-DY!/.#D46A> _@Y8]=Z7=P^&6BZ7>:@LUZEIJ<EV\VPGBXBL)))+: L^0J,
MF RX7&TK6*.R36JXU:8K4K;Y;\$FO97>Q*+UZ@QDWS5P#EJ[?-E7JJ3UVU6'
MWFZB_F)% *<HE4_-F/Z1U;<V%S!<LC2AG83ABSJXSP2I&<#+ MV&1CDUM[Q#
M\">C>M]*E@FMX-.DM(F72GL+6VM#92RHJ$>; L;3+*T4("R8VE6(PI-8D.[;
M8:-%'K4S75I9FU3\&<BB!/IG#<@>) 6]\O[I3VRAYE'LH"4P!T _.71:!9Z[
M>C4[/4DM9)R9)(,.K*[?, NT?-R6P0!Z=Q@G0\WC/U3X+Z))X<]9]#ZIU!9:
M79K!8ZS;Q13V9L\.8Q--+N@:1E90 K,R;'5]I(KLJ//PDNU.[:1A8A=9007;
MF2(D/F4?S 7P "G*7X#LOY1$.^Q[^+=K5A=VDIBDNOB0@PK$L2?3LYSSCODC
MD@\5L3P<ZZZ2ZILWU6RT;]0W5U(IN(IX+>"5\YVM&8559$4'![D'MV!K*_4K
M.K+;*T[(S+):281&T==RCIHP4]J3<IL;;$.E6S0Y2J&!TL1,Z2'1!'W3@8 -
MUUF/]-75];=1VRB.7:TZAMH8Y4N!D$ C !] >_/UV?X_=/Z'U1X,=6VUU+:(
ML/3][=V=S(8QMGMK>5U )9"6<_+C<3P .2*_2;CU!4;%,(F$>^OS@(&_LE^!
M[^>_X_<0_7.N!R%)X)52?O(!K\WZ#"XR3@L,G@G:S+DC\/OQS6/7+_1C[DMQ
MEWAHB-GCUB2VCKFPU.,G@%7VH^3?M#FCE'A4!!96,4>I((2J"?9G$:LZ1 IQ
M,!1\IXO/AEA/ DC9<CW((_V]*N.EWOZMU*PU#8)/@[N"X*,,@B)U<_>>#@?T
M-?G?<D.*'(KC-:3UC=^I+A2YMHD\:P-I0C'<I3;,E%**(%>P%I8(K13^/5*4
MJH)BX0>-T%T_JVC41*7-.7?3>I:7+=;81<VLV]CEUPH<L2W)(W+CL.?IS7T_
MZ4\<^@NL[+2[Q)UT_J?1]+^"MT\N6WDFFC15BA+%5PC$XW@[.V3R<T&@2R6"
ML-$T*PHF].C^=5ZLW332[*(BH8I%#JJ"<.CHI%+YB'7D"8]B&M#;66GZL\DM
MXR0,T:R((Y259S@C:!P .,]N""37<EKU)U)U;X>6IM.F&DU-; 1CS;JW2,31
MQ%5,4S-M;>3NRG ) ^7BICN-/H,<FM]::UCMX=_:SI\'LN$;6$L&XBYV7FH"
M%D%5 :BJNR(1D]E!9 559BF\:)M%SBT.\]Q(Z@;DM^A-/O$L[^-PR2K%,4_=
M*G# YYR3@$C@@Y'!%?,O6OTO>M^C]4ZBZ8GTZZBO=/FU#29%GD,<MM,))$D&
M&!;"L<JPX92K(2I!K;1XR\/M2\9./>O>/-;KT+8J]1XP"OY:P046Z>VVSO%3
M/;!;IE!5!PD>5G)19P[4,8ZQVZ MF)'"B#1$0V6D$*0Q6XC0PP*$C0JI  Y)
M P0"6).>^>:X,NM0O+K4=0U1YY?C-2N[F[NIC*_FR/<2,QW2 AFVJ1&,_N*H
MQP:R@08-VS=!JW:MV[9 A4DFZ"1$FZ*28>*::*1/$J292=%*1,H%*   = '6
M>H^7(4;01C P,CVQP/[<Y[>M&PW\R$NW?+$L<^^22?QS_BOLFV(43") [^>N
MQ$P_/?ZF./\ 'Y 0 /\ 0 Q@#L%'U"@'W[@9]34 H';=G'<L3SSZ$_7VKDE#
MHH!_  #_ ,8J8?7FO.*5&CZL7_"K5/\ K*]/G^>/0&*F7N?X7_\ !JDNQ4M,
M4IBE17>HSQ9VIR;VWZ?!=?2NRJ96M7\BKW<=H[4U)::M4KYK"K2&@=EUF,GH
M20L[663.I+6>5B*PY1CZ[8'0L9ET)V;=O[D@U5.I 5P>Y P.><$'T_WJ.O37
M%+FYQ.VM7;Q#ZUW[O:EP/J&>H#;K"T2VAJ=79FU-:[[T)KZD:0W#=S35XUM2
MIU@I?*T\<6)Q(C%3E6]Q6>1JB7Y$E%1RI'< [1C.>XSD#@_^_>L>C>GOZAUD
MX]HDM$)R :[KH/!'@K5-8KPG)21KTG$<E*9R=OLQO.50=UW;+"(>WN!T_+LA
M4N<ZH\16B)1Q'5^7=R)W#5-42R\[<8+,?L^FT;1V[$YXJYV]^%_-6(K^V]&Z
MVT=MBZZ.E^:'(2V:@>DWG9[3.:_UY8>,6H&&JW\!!3G+73*+NM3^\U=JJFL6
MSK/<OZH9MH^ML=K&5=6AM(8J&5R#D9P,Y!Y.XGG"GMQZ<CUSW\0W"/G_ #]#
MFMF76'WTKR+HU/\ 1G5U$Z<\@W;<6UYUDVUO \\95Q$16TB4N<ES0S*V-[O*
MVYI)'N37ZT]87F5YAV,A#_8>I_MG^O?GO3*@\8QAQG'N#M],CT^[UJ3[U7-)
M<D;51](<D^%-/;W?EYQ0V9*6#6M76EX.#-;J)MZFS.H]M5(9*RR$5 HMQC+!
M 7Q4DE(()J+Z]:D:E7D!9H*1J"$9(;@$8)P3C!!';GTQ^-1IW+T_M]<8]T<1
MFVI:#S3MNM=/>G0UX^7'8O![9W'B@["G-XR.ZD]EWIW;E>0=QK:$C5[E,*V*
M\RIXQLN\5LDI#'!?P1?ID5'<&#9(&7W8.[@8(Q\H],X]/NJ[FP=5\U]4[#Y-
M[5UCH#DG?5><'&GB55:O=H"3X<77D1QYOVB:Q)UFUZGWO6=\VISI2P5O:;*3
M=/[I<Z>G?ZK'S<_<G+6'%\K7Y9LH"" "1\I;ON .<<@@9!]ACT_"OOQ@]/[F
M5*<E*'LOD#LK:_'J1K7I[\4]9W*R\7)G0%(I5XV_1-D;>G;GJ^2J<7K>PP+*
MKU2%GZ\"+:B52FUCPDW+> EWB20?3*@2NW &?F8C.<@$ #^>.>_:K-;:].KF
M+,2/+W82+#:%^U+=_5.;;LN7!%M=M75FC\K.-#6-T(Z;[ JUK3",M57V5"W&
MI#-(P-MV;7ZY9X76:,&[K,8]?HO[ J.X84# (3&[!.#SQ^/ R.V<CUJ1KDS1
M^8;75=ZA]@U>9YDPFR[9<(*L2'%""USQJY*\6M;VRG6F/8/:7(;>V%9*YL>P
M2KAW$Z[O%DC;=K.8B:K-S<VSKMA:F>Q#94HP?IC_ %<@GU[#(^[G/;.>^8?!
M'7FSM2<,.+FK=S0=2K&T-=:,UO2;E6Z,#4*O7Y6L5B/A@A8PT>JO&*FBVK-L
MRD'$2NO#N9-!XO$+*QJC50RH,06)&<$D\]ZRPQ4*8I3%*8I3%*8I3%*8I7#<
MQ[!X)#.V31T9,WFD+ELBN*9P^QB"J4PE$.@Z\1+_ ,PQ2HI^6?HU</\ EEL6
M:W/-1MLUMN*?0;DEKQKJ9;L$IITT02:M9&P5F6CY6 DGI6R"*+AT@S8/GI$R
M"N]%4/>Q3\_G^M83Q_\ 1S-/.IV-D;KR0V7.QC!= %F%<JE;ITK(1B2Q5%(M
MS8/K9Y0J+A/W$U%$8XBB?N&,T%J8"&*J'/M_7^?YS6+//+^CB$6G(?8/ 52-
M:BN"S:YZJV5;G(C[I@*+:<IEPE&KM<PF_>I2<'8WP%[%%Y'2H 4\:>!&>*B/
MS^<#^U2U>CYZ>5PX"Z1N$?M.9A);;.U;*PL%H:UITM(059AX-@JPK59:R:S5
MD>6>- >RSZ4D2-DVYG<B+1J9R@T3=K1_//Y_/W5#\_GC\X%9H<Q=M:&T[I.:
ML'(FN-+G0)N2C:D%(=5Z-M)[E-S)E#1L$TA)<Q(URJH5HY>'7>JMFS)LR=/%
M7"0(]F5'\^OI^?QK4;]1J5T+R!IM'H?%_BAK?CHM"V(]CDMGDB8)K='[4C1V
MV"I,TZZW*DG&OE7"4A)N)%^_.95FU;,T6Y0<.'2E1NUZ$)5H&1H<]2"S3IV0
M2#)II 8CQ02&2*L<XD,)! _2GAV'?Z!^N*?G\_TJZFM-1ZVUDT3?HQIRVF5(
MW37E'[]RN_:C]0#DB3 RJP@P(DMXF*9H5(W[LGST4 !@>OIR/O[?Y-1#M'DJ
M =P*D'MM/)/]!WX^M2=ZDYX;3XZS;.]K[3LMMJZ2,?&V^N7:P+3R,M!1C9Z2
M.8,I:;1F9.'68JN/<8&CCI@)Q%%8ITU#",ES<R) SE8TBME,K,OVBH4J<#'S
M$$@X)'N,FJC1],AN;\VJ137=[JIBLK.,S^1#!<27,+B>5SN'EB-98R-N?V@P
M01S$#=-L[$M[ZT;,MCP;#:K9-O[%-2<NHZ=/'SV6=G<&,H<IT_%%JD<B+9 A
M 2:M$$FB)"()ID+RSKALM5ZCN9IIV>V8MDG*R(WV<A=V<9X W8QR?8??'PPT
MR]\-/"'IVUMK#32]OI:"46TH++<RQAA))-Y0,BK(VYB0"2"<#.30[R)&3_W\
M_FTG$HDS,FF@D)$&3=$1%95)LV(/D0PG^!44,JHIX)]J 4H%+9VU#X?;H\,+
MM;B1F:>1&W2(V%16;!&$P3CC&>.2<Y_IW1Z79L.L=<U8W>O)IWE1W&Y(;:&,
MN\R00JK -AI""2NYCW%4PUMA';D\.L#OW&_YDE'"2@(K%#L#&:KF#HWS]R?J
M!?OWUE7<:&8[=+B-[?RVW,523,B<+@,@4!<^OU!X!&*M6@^+4&I:K<=-:AI^
MHPSPW#K'<W=E\/'((2V)(IS)^V1@#M;';'!S76[5<E<:\D5VL>9)P*!&QG8I
M =,R*RJ:*QP$2CV8J1C"!O@"B #^F.E'DBUR*&2Y CW\*'R1@$[2,@#DCZD=
M_3-'^D@[W?A'KLT%OONG-LJ2&W4R1QDL)71QEBNT#@C@C' &#CQ4GY8N7CXA
M<OUC:1;G51^G*)U6XD)YG6.D3L_M@ ]G,4/RE#OKH![V3KVG/<0WE[$5C%HZ
MH'D.U75P6P#A@3Q@#N?<8XY!\(.L],T#7NF^E=2@.HP:W"8H+RU4R26-P&"E
M)T4J4C8G>S\X*\XJ3/T]S,:SS?XO7-S'M[G#LMKU^(<TMZR2FF[Q2RKC M9=
MHR4 XFE:RZD4K#%.2^X5F_C$5A*4"J&+8^C]7^&URWM)M.$K3. )A$&*YXRI
MQQM."<X[$C%;A_29\.%Z@\*-9UC2/$.?2X=$L;F]ETH78CM[[R [&TGPX<EP
M/+1,D$XX/:OT6FQBF3$Q2>'D;L0[ >Q$I>C?'\2^/?Z]]]_/R/1)&">3[\^F
M0..YKXA+R,X W$GCUYQG\<5R,5-742D+'33=9G*1[&1:+$\#MW[5!X@?LIBF
M Z+@BA! 2F,4P"7\Q3F ?N/<"%<%'4,A'(/(.<CL>./>IHY)87$T$CPS)@I)
M&Q1@0=PP5(/<9[_TK48YX^DYNW6.\IRS<9-9RFQ]-[+E5YJ*KE229J26M)R1
M6%>2KCABLNV%*MF>JJN:]() +&/CE!C'@LRQB"CS2/6OAY=:A?\ Q>F*OERM
M$/+\QD"L@YR%5NYR5)!SV[9 ^IOZ,OZ8_3FA='GICQ-O+N.\T@L]IJ**LOQ=
ML<[(F0M'^TC4*IP<NQ)-;(7 S4EVT9Q(TKJ[8R:+>Z5FM.OQY@W=)ODXIU+3
M<I-DA_JT1%!=6);R*,>NHW,=L*[=4&ZBB($.;:^@6,VF:/8V-P0TUO#L<AMP
MR69\!B!D*&"@X':OG_XS]8:5U[XG]8]6Z) ]MI6LZJ]Q91R*$D:&.** 2R*"
M=KSF(RL,G!<C)K+S+Q6L*8I3%*8I3%*C1]6+_A5JG_65Z?/\\>@,5,O<_P +
M_P#@U278J6F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2
MF*4Q2F*4Q2F*4Q2@!U\!BE04^N^-@3TKQ]>(-G9Z7&;X2>VV0;)G.A&2"E)L
MT;5SR"A.RMFKIQ(231-14 3.\5:MP,"RZ)5%0]?O_/M_GTX]:@9=!"3L:F11
MRDI[9/<1,17HX'  $.A*/?8" C\? A]\5&NBA92+%LX!9J1RY:F4('[D#&$4
MQZ OET;]0#K[!]A[^ Q2L3Y?7&X]G6^6L,"\B*W78]V5LQ3ECNSKN!2, K'1
M:MTSB4/_ &'.)2B/?B'CWVI^?S_ZJI0TJ\?N61=A6P[V*C%R.UXV/;2  Y41
M-^0''MI@8J28CY#T0WQV80+UWGG+$DT;PR9V2*5;'?!^^JBSN9;&[MKZ!ML]
MG-'/"/W69"#M<]PI&>V>P'KQ2]WU3/1K \O3'+*YULIS^31LY\95JT AB'$S
M7Y3=F;!Y%4(D8'/0 (-_(3E+J75?#>,W5QJ%K)&5 +E'+>8W)8A0$8$CT&?J
M3Z5]%NB_TX9)-$TSH[J'0+:WMOAX;&744E#,6 $894<*#GN264@ \$G%8X-%
MW#&0;H/Q4<M'ICI-D16\Q25* F!!8H?G*/1#] (!T<HE,  (".*ZAI__ -/N
MS'9-#+;JI:::,ID9*YC(SN(([<<'/)[="=(=57+]4Z/87VO2:MT]K*B>T6PF
M6XCT[R )XUO 9$$0E#+&JQ^;ED((P.:^MY4E(!!ZP9 V.Q$.O$H%4 J8![@=
M= 8P D*AA'L._P#U?IF$Z%)(UX(KEBT<[^6P1B1A,C)#8 )WX.3S@C@]^C/%
M.VCDZ._YFTJWC-]I4L4ENT"#>\;2('!=44D;(3A2/E)SN]:ZX++&*U5PTE 2
M4:E:&#S.':)4P#S JH"/R(?F#["(]_ ?.>S:)>1Z\PLAM4RJR&4LF,<Y!56X
M((SG SZ^WO<=<]-7O0,UWU)Y,=JVC%I[>0PF262.!MRK%(_+(VW]\$\9'.3C
MY4#5JN3BU\?D;M$P*Y0@H=L115PY!;W$BJ+>7N 'FB<WBF7Q*0@_(B(_&U-3
MCO\ 5[&UT.W1<F,S7\[,RP*\>U0#* 6Y&XX*@G';N3\\^@M8Z Z$ZFD\8->U
M#;:":^L>E^F8XS-<:B9V8"7R  B3QR!(XPCR?*Y;/&VMX3T.N)6FZ[QEKG(.
M1B];7K<5_LTQ;_VG8Q3"1G-6(/H^/8-M>)2;IK^(Q,Q%LT/K9M%(&H$?R[@&
MP*-3IN7&>]-:18V&G6HB6WGN84,;W"$.V[)R-^"0<'UY_"N/_%_Q,ZPZOZGU
MU]0?4]"TW4KR:X7I]GNH($M996>W+02K%N+1;2QV%"V0"1R9ZDR^!?'Q H!T
M   B/P!2A\]_;[==?P !_7,F!)[XSD]JTL   !V' ^ZO?(TIBE?$Z)5#=G*!
M@#H0$?N'\?T__P!ZQ_(XY&1QG\<_SQ4I4$Y('W^OYX%?0H>)0#H  .P  ^P!
MV/7Z!^G^&.?7DU$ #@  ?2O;%1IBE,4IBE,4J-'U8O\ A5JG_65Z?/\ /'H#
M%3+W/\+_ /@U278J6F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4
MQ2F*4Q2F*4Q2F*4Q2F*4Q2F*5%CZS.U:YJOT]]XGFXAO,R6P&,;K*FLG3))Z
MD%PMCPI8V4*0_D*+BO-&4A8FKHH%50<Q21TCD/T8%*T^XA5&#I*<J29^J?-X
MTZA&RJ_BHNY30 ?9/Y"41-Y (#\!V81'Q 1'%/R?Y>O]/Z5=76=ZI\S7V3E%
MXU!T[;%4<D,8@'(Z42\E4A\AZ$Q5!-XAY"(B7XQ4#G/<=NQXY]\_R'XU1\9L
M>=:IV-XQ"/-%1EED&8 LLD@N=-$$@*<$C='$#&\RD$H&,8XB %^>\5&NZHMF
ML%F?S\Y8H=XR:'=>U$-P3 "?AS=($P<&*( J8[I4JJO1DP,!?$HE#H Q2NP?
MO:4]@IQXR!&*FVPO/]L2*#%^@[;$$Z1U"&]LYTA$"BHFJ44'*?9# 8IQ$&4!
M!=6=1DE5 )/!_P!1 _KGV&:%MB.YA6XP47RQDW!WN%#VR\*SH<,V]T 0,P)8
M 5@99ZLR6BC[*9>V6:3>)2L@W:=_3+E<NA2=$(D'Y ,F#DJY! "&$Z2A!.8I
MA'-$:SU)+=]17FC2(+6UEQ'$9458U(+;B[(68Y&/LHWOQFOJWX>^#$/2_A#T
M]XF:3J]_KFOZ6GZUN+&WNB]K=PW"PJFGS1SF':UOAV?;CEL*6&#7LV6>/6@@
M[;F037(8# NJ!@,"P !B&^Q@\R&,!0\#&,/?8@'WPV[MK:UN)&M)EFN%D*I'
M KL9&!&3&-B[@#@DL5], \"NHM(ZKU#J/2K1>I+3]1:9?6$!6SR1&\LL;!]K
ML(XLQ#8909/E#+L9QG%E+L@HDI^S\4JN^67[-].D F^E)V<P?5B40ZZ(/QYF
M ! 0$P!T(!L;IV&>1(;C58XK5U!\M+C<D\P/VC&@4CY0%SO*$[AC()-<4>.N
MKPZ%+-TGT]J,^OW]S(["&SD6XM;2"0H1%++&PV,P8[E* -L)4G!K,+CKP7Y6
M[PK=;N%!T!=+]0SR2S&/GH* _P!R2S^/>"V=IFGY-=LS*W9OVYV[YPFJDDB<
MBR*BY0 <OE]I%Y<+<1:<T]N+M"OFE0$S]GYF!+  9R5!^[N*USTCXE]-=-7N
MB6W6HTAX.F+F.^&FQ6\=[>B\7YU^6Z^'A7!'($Q.<'![UNS^EEQ+V+Q/T3.1
M.U7+)M=;_:26Q_48I\G)1M-:I1+.,91:CYN4&CR;630.YF5V F8%.+5FV5<
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MJK:(*ZUR%MM8E&4W7;%'-9:%EHY8'#*0CGJ15FKINJ !Y$52,4W0@!B&[(<
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M)J:&[@G4*C_M3\Q0]@!D$\X/<C/W\X];?1)G5H?+OI9^Z=2:_F"?X<!@73;
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M[)&0> ?F-0$U34MBG9!V:&E9VKP+E<HI,T%#)D42,  X,0!\U&X.%##X)$,
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M;)Z1$Z8LR&(02 ==4 9M#I.5DU4,<ZMMFU+2+[2[9+226[MIH9)KJ"&ZMK+
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M,X)Y';OV[]C4=O&#>O(_B+M>2#<UC?L]=;+]4CU((CD?:*%HNQDI-]N <?\
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M+FY$=CNX)?7E5VA$TBDR2*K6&(I$L-<7:0V=9;%%0:NRF]U;,EW#-\J1@.<
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M"R"7 ;:<-NR,##;NQ%4_@)%-#=:S<E4MK:4K&%F)!DN%8+*8N5RN]"%!!(
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=IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4K_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g947560g04e62.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g04e62.jpg
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M'P3BC?/U5V7R5[X \*<')+-8F]EJY>]3DO9.],QZ$&)P4:N$=G',)NBW+*C
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M=JM9BGFRV*F5NO+)*MUD!50514(JBLD)B+)*I'*<BB1R"4Y#D. &(<I@,0P
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M5+MT0PJ\C=**S,0IZ5!8\ $ZYRRQ0(9)I(XHUXZI)'5$') '+,0!R2 .3W)
M'?56OC+NG3^?AL]_:1Q!^]^GWZR]X?O5W%_$N1_J^DGPKC/[X4O\JA_U]23C
M/>7M#S1.)U?$&Z;;ME*S+"((UO'V:<<W"P+<%$PBC"P%C?R:H 4!'N3:F+P
M^WV#I%=VYN'&Q&?(X+,48!ZS7,;<K0C\,LT*(/P%M=8KU*=NB&Y5E<^B1SQ.
MY_ JL6_S:LGIFTJU'V3LLXLPI4W5]S'DBB8IH[%TS8O+AD>VP-*K#9[(K>7C
MV:\[9'\;&)NWRX^"S;&<@LY4Y(B0Y@$-*Z./O9.PM3'4K5^TRLRUZ=>6S.RH
M.7810H[E5'=B%X ]3KE+-# ADGECAC! +RNL: D\ =3$#DGT'/?59/C+NG3^
M?AL]_:1Q!^]^GOZR]X?O5W%_$N1_J^DOPKC/[X4O\JA_U]'QEW3I_/PV>_M(
MX@_>_1]9>\/WJ[B_B7(_U?1\*XS^^%+_ "J'_7U9O&.6<69KJ;6^X<R11,K4
M=\Z>,6=PQQ;8&ZUAR]CEA;R#-"=K;^2C%';%</!>-BN16;*>XL0AA -,E['W
ML98:ID:5JA:559J]RO+6G57'*,8ID1PK#NI*\$>ATJBFAG0202QS1DD!XG61
M"0>".I21R#ZCGMKR<H9UPSA-:CM\NY1HN-5\E6UA0Z C=++%U]2WW&3X!C7H
M$LBY0&0D7!C)D!)$#%(HLW34.0[E JG2CB\EDQ:./HVKHI5WMVS6ADF%>LGR
MYI>A3T(/G/J 2 0IX_);$$'EB::.(RN(X_,=5ZW/HJ\D<G\'SCYQJ5](-=M&
MC1HT:-&C1J*,HYUPSA$U*)E_*-&QH?(]NCZ%0RW6R1=>&V7&5Y!A7H,))P@+
M^1<#V@"2/)4Q42!4Z8K) =?1Q>2R?M/P=1M7?8Z[V[7LT,DWL]:/Y<TO0IZ$
M'SGUX/ /!XXS6((/+\Z:.+S7$<?F.%ZW;T5>2.2=2OI!KMJM&4=Z&T#!]K5H
MF9MTVWC$]W;LF<DXI^1LS8\I=H;Q\B0RL>^<0-BL,=*(-'R13*LW"K4B3E(/
M$1,<GO:>J.V]PY.N+6-P68OU2S(+%/&W+,!=#PZB6&%XRR$\, W*GL>#I+->
MI5W,<]NM#( "4EGB1P#W!*LP(!'<=N^HZ^,NZ=/Y^&SW]I'$'[WZ6?67O#]Z
MNXOXER/]7UR^%<9_?"E_E4/^OKUH'J([!+1-Q%:K>]K:=/6&?DF4-!P<1N%Q
M/(RTQ+R3A-G'1<9'M;8JZ?2#]VLDU9LVR2KATY53003.JH4H\Y=H;L@BDFFV
MSGXH8D:2663$7TCCC12SN[M7"JBJ"S,Q  !)/&OU<GCF956_39F(55%F$EF)
MX  #\DDG@ =R=7&U'=+M&C1H^3Y=&C54L%[Y=HFYF]WC&6 ]P..,J7S'2;AQ
M;:U4YD7CYBP:2"42[EX\RB"#:Q0323<-6#J>K;B7AFSMZP06?$4?LRKOV4VO
MN#"5:MW+8B[0JW"HKS6(NA7=D,BQOP2T,K(K.(9A'*55R$X5N$=?(4K<DD5:
MS%-)$"75&Y( (4L.P#*&(!9"R\D=^XYM;IATLT:-&EJ.O/N;?K*47:'4Y!5)
MF[;,<F9:\JL8H/4P=+HT*JN_#$.Y%%PS?6R18K\D.L6H/B 4R =VNOJ9]G1C
MX2WU>B#/&\F'P?6H^QMT(V3NIU#LQ22*C#(O<*;T9Y#<:PO]5[XA2QG$^&^-
MF*K-'%G=Q"-B/,0R.F'Q\G21RH>*;(3Q/V++C9AQT]\F-H.PC.&[":\OCRNE
MCZE'NDV]AR+8RN(^G0ANTAU6X/2H*KS,N1$Y#DA(1!\_*"[=9\5@Q5%\2\M]
M^)NV]CURV5MF6]*C-4Q53IER%@'D*_E]2K7@+=C9LM'&>AUC,LJ^4<S^&O@_
MN_Q*N%,+2$.-AD"7L[>$D.*J'A2R++T.UNT%(*U*B32KU(TWDPN9@T/MHZ4N
MV/ ;2/D[-!IYJOS<J2B]COK!NO7FCHH )O4-%$[J#:(%.4BB"LV-BE4%2BHW
MDT"G\(N-=W^-N\=SO+#3LMM[%L2%J8N5TM.AY ]JR7"69&()5EK^R0,IX:%B
M.H_0+87U.>P-F1PV+]-=UYE K27\S#&]*.0>OL>(YDJ1H" R&V;UA''4EA >
MD:8-FK9DW09LVZ#1HU230;-6R2:#=N@D4")(H()%(DDDF0 (FFF4I"% "E
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M@<;!_<]'2&_-/6_^^-R/_M_5>?LN^(7]_P ?Q5A?_+M/7UM8;_DA_P HL_\
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M\DCL>2SN[%F8]R23J7(B1HL:*$1%"(J@!551PJ@#L    !Z#7O:Y:]:-&C4
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M[][0??P[\+ /[3N+>I/_ ,L]>G-#_BNOLN/D'S25[V1/[GM"_MWN']U1Q?\
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M/?IC75.ZD^OD@F@D@BDU(DFV323(W30*0B!$2E $B(D3 $RI%(!03*0 (!0
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MQ5W2@)E3.'B&5.5,"B<P /S;W. -T;C$ (1<[F#&$[],:W[)!!7GLJ#DD=@
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MF2/B&K692(&[<'VN=HJY7D-Y<DCK_:SIGSE_X/Q\LBD":7[#!W[B1P>7'XM
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MM8I&K+R+%!A ZMV;RAR(B0?0ITM$1[O+!/=M6"ZAF(W$59XG,,4U,>+LJ+6
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M ^8 <:PC])?^:UNGTPX=^T#G5I>"WW=5?S?D?U U']U?:E_Q\'\XZUIV7_\
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M!%=&0;?R^Y/!;;>/PM3VVXF6MV6A\^M7XACRF<1W\RW-!$>EI8QTARYZN0I
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MI02R2/+(\LKM))([222.Q=W=R6=W9B69F8EF8DDDDDDG715"J%4!54!54#@
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MD[5=FB;<J#@H2L0\;7JY$1L# PS-"/B8:'9-HV+C&+8@)MV;!@S31;-&R)
MJ:*"1$R ' %#5)3SS69I+%B62>>9S)+-,[22R.QY9W=R69B?4DDG7THQV-Q^
M'H5,7B:-3&8VA!'5HX^A7BJ4ZE:)0L4%:M B0PQ1J %CC15 ]!KU=<M+=&C1
MHT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-
E&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1K__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g947560g12q20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g12q20.jpg
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M_6>J>B'.7(<ZWKN)!LK886QR!]="7A7R\9;D,&UJQ6U.3?MI3D654,10"@%
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M][6$!'!SS"%PO>U[6SPSRQO>U^O2@.30"@% * 4 H!0"@% * 4 H!0"@% *
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M44--=<"R<Q+! %\32HK'S9XQ8  $&PH^=@@@\/!PL,'@WQ9*&A!0"@% * 4
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M[5-C7@-B26G</V?I<+[!ID_NYS3K&TERXD;"/!29#K9KT>DKK;VLHJC1D8J
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M*YE7TNQ:>"1UU<YK"@% * 4!E'"G\GOK%_4M7_75T5KFR\_9'DBPBA!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4!$S?CWBNZ?=,V-]#SRH6.:XKF=3PZ/)\:)]
MS;6'T),>@EF^+YDR:$% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!&W<
MOWH&UG=MG/T8.BA8YKBN9JGA?^38X?W<MU@]"S+H)9OB^9.BA"N#BJ>]4;_?
M#X>?[>>N56.:XKF5?2[%IX)'75SFL* 4 H!0&4<*?R>^L7]2U?\ 75T5KFR\
M_9'DBPBA!0"@% * 4 H!0"@% * 4 H!0"@% * 4!$S?CWBNZ?=,V-]#SRH6.
M:XKF=3PZ/)\:)]S;6'T),>@EF^+YDR:$% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4!&W<OWH&UG=MG/T8.BA8YKBN9JGA?^38X?W<MU@]"S+H)9OB^9
M.BA"N#BJ>]4;_?#X>?[>>N56.:XKF5?2[%IX)'75SFL* 4 H!0&4<*?R>^L7
M]2U?]=716N;+S]D>2+"*$% * 4 H!0"@% * 4 H!0"@% * 4 H!0$3-^/>*[
MI]TS8WT//*A8YKBN9U/#H\GQHGW-M8?0DQZ"6;XOF3)H0@UQ"I?E:%X#0E^%
MW(C,]^N^?=;XC).A=:Y9YD$)+E^:V5'2\IV;9P\FEE,V31W$<') C'B^'JK
M++(3&UN=5*K2WNA53%M5HI.F62;7O(B>K.(3\MYC_P#*,SO_ %(K/S?7[OYG
M'YQ?47>_Q-,OO939J,GTSHS?_$LAMJ/Q_B)P32;"OJPS %)5R65G!N(F>6-I
M&S"3@5YQB8-U ,*HI$!=<&7K(D"'%2UREHXI9RSZOYE4FTVK.J6;J_Q,L:4M
M;DOQ;?;<9G$,BMSK<8N$!I/\@BZJ,H\(U'.922*[@@JX@,D9  *N"6I$C)DG
MB+F,3N/8N;Q -!B@X-1.JULL\/YASHDW!)/%8O%95S,9BO8O:&;S+M)Q)Q*(
M<D RQ5 LFNL)MZL,L]=)'.BJ0">8SRQD;' VE*8Z,LETI;(9&D95,(ZL GGS
M(J:=P *"=:2RZOYAS:I6S2KEB^KKZT;@]6<0GY;S'_Y1F=_ZD5?-]?N_F3SB
M^HN]_B3GT)F!\3_IKKA-$EFDP\_I(BUO.=VG$9,P1DLTMG@Q/5@Y%*"&'#3R
MXN8?AX%<!A<0;7\&V>5K<ZXSD>#?%DN:$% * 4 H!0"@% * 4 H!0&%R.HOE
M'C][JL8MI(>4CIS47SC"::^NW;""Y'@72S0K;1%MQXE%#-"2%)7Q*%5-6#('
MA4\D*.:"*&1 L <P**VYQ-]Q'*I@P6WVIJL[YP=>XI35B/9X; $JB:IJIQOZ
MZ.*>IIP#21',8>CG<,.+#6.1$L#-Y\A(2LZ5'%1P$3!F\KMH49ZJQ>-%&K6"
M?I:M-M,T\5ELRKS)@XONNSQX<*2[)9*/U@R;MEI"_GDCLQHQ#,LGM=)7'(U'
MLPCZ8._F2PUUL(Z<7>Z,KEBAATJJ.;!0L":TJ@E"1BQBXJ@];"C499U2Z]KW
M<2Q+A@96]K9X?UN67O+M8;?>9\N=H697X?!Y<NO3+[V_7E?I>AA+-\7S)T>'
M:_+IEUOR^\SM\';SQZ6Z]M^5NWKTOR$*X.*GE:^JC>Y6RZ[A\/.W7#.W9OGK
MC?KSQMR\U[\K7OTMSO:]6.:XKF5?2[%IX)' KG-84 H!0"@,FX5&5K</C6*W
M++JS%>WWN5[<_MU<_P"&UN5K=>V]^7;UZ7Y:YLO/V1Y(L(\.U^73+K?E]YG;
MX.WGCTMU[;\K=O7I?D(/#M?ETRZWY?>9V^#MYX]+=>V_*W;UZ7Y /#M?ETRZ
MWY?>9V^#MYX]+=>V_*W;UZ7Y /#M?ETRZWY?>9V^#MYX]+=>V_*W;UZ7Y /#
MM?ETRZWY?>9V^#MYX]+=>V_*W;UZ7Y /#M?ETRZWY?>9V^#MYX]+=>V_*W;U
MZ7Y /#M?ETRZWY?>9V^#MYX]+=>V_*W;UZ7Y /#M?ETRZWY?>9V^#MYX]+=>
MV_*W;UZ7Y /#M?ETRZWY?>9V^#MYX]+=>V_*W;UZ7Y /#M?ETRZWY?>9V^#M
MYX]+=>V_*W;UZ7Y ?JU^=N?P]>MKVO\ [[7ZV_V7ZT H!0"@% * U]+"I(Z)
M&;[5H?:J"^)4(-99,QZTG2X,VJV5]WX$A?6%.<#B"*'QDA&&4+@>N9P H.8#
M)XC6+X6&RPRQ!9XX+:\Z%%B+Q1=OG4*E0VRFIJT]9F=VT\O0/'<_HA:5,=47
MZW($UA4-A);66TB"N@1]K"JU'4DJ,&"*28]3;5..XBJKI,X8+HIQ!S&=(YU?
MHU:V^E3!Y98^[;AV&T/%MUM=G#9.GY%"D)DR=M_P[';)K99C<A^9)(;",>E:
M+WPUP$50DIF,%79B26(/1-64S(XYE="'+(Q8FXU@HEI9\ ?(50>M3#X,L<4M
MN>++.>'1E;VOG1*W++WF^L-OO,^7.T),?\/@\N77[[[V_7E?I>AA+-\7S)D^
M':_+IEUOR^\SM\';SQZ6Z]M^5NWKTOR$*VN*7E:^OT4\K9==V=%K=<,[=FU<
M5WZ\\;<O->_*U[]+<[U8YKBN8V2[,O"SC5SFN5\[10?L1+\\0B:;+=A%=UK9
MBHRWC)R YI$=C D9\OADOT)U,G!5S0H8D$JYX\BTX2+/]ML$1UM(H[Y(S*9N
M91(H2+XE9PDI-JB5,*]?'J[SE@X1C*K:DTU&BK2JHZ?"5&\F]U3)XJUQ=D(2
M'LNKQRW(J26%/$Q1>X4AO(JFILT1HL-*A=BQ[(BP$FHS'.)=WX,Z6ZMN%$20
M1K);ANHX*2XZ4=2-&P<&JU6E*.B]E&G[2.2:C5MN*??6J]FS#+8C5G#HU%FW
M4I&<30DEX(JJS$R/HGCAD(:%(TBR(355&-AGZ76I8%*2&D)>$5FWXWEYDHPT
M3,D=89S;NRO5)%7-Y'L? 0BU6O\ _>O\/>6UG&=*+&K;P2SI\%4>-*/%XLLR
MK,XC)N%#E:W#ATWMRR_[$&K;IAG>WW@_X;8WMRZ]O/EV]>EZUS9EF^+YEA'A
MV^#+MY?>9_1[//V>>A!X=O@R[>7WF?T>SS]GGH!X=O@R[>7WF?T>SS]GGH!X
M=O@S[>7\'G]'L\_90#P[?!EV\OO,_H]GG[//0#P[?!EV\OO,_H]GG[//0#P[
M?!EV\OO,_H]GG[//0#P[?!ETOR^\S^CUMY[=//0#P[=>F72_+[S/S]GN>MNG
M;;G;LZ];<P'AVMSZ9=+\OO,[_#V<L>MNG;;G;LZ];<P/U0"@->RU'1*7HP?\
M6*3D>#03)$:*\S%-S1^LAMQ[HJ:XTTPE*!YJN 0DH>LBX&3-#63U8(H*93C&
M6!LI<(T$",&!70U.$1!3+A%CP4A3;M:60HA>K;?L#.S&4VV ^8"7&\V'8S!@
MHG424>E$-'27.V'NYTIWIBRW7 67KJ>2F/;!9+E5$$9:SJW18UKUU=<?;1]3
MR-Z2W#,?:[<.&8X+BI'R0(YBC3R5V.STH4T,?,ET5!B-R$BPA]0,Y9&5%3-^
M+S.*BD9RR,J"B8,G!\KBCYWN";<DWFY5?%L_'"_\FQP_NY;K!Z%F70DLWQ?,
MG10A7!Q5/>J-_OA\//\ ;SURJQS7%<RKZ78M/!(ZZN<UA0"@% * RCA3^3WU
MB_J6K_KJZ*US9>?LCR1810@H!0"@% * 4 H!0"@% * 4 H!0"@-6S=%"5.L1
M2+#:\Y7JST*36FKLM<<4=+@3:>R<BKQ;,@K?:ZOBD%.R0?-IXIDCZO#)"F"X
M!D;,KD 9L$8"%3HT]SJ5\)/"(@I%A:/83(3;M8"FPTY?MA@Y[A2FVRT@PF4-
M1XX(I7VA&JH2CTJ@HS+=;#=*\B.1".MM4Q.Y*%U0N8**Y4B?+"ZSJWACFL:/
M&N5?Y=1N/9V+&/!W#$V/AJ-$;%O1[%FC$T,!EHN(XYO)-;+3@ASHB.6&.&LQ
M39XU@2)@W-GS@HQP^:N,<-C"F1A1,A$ZR3>;:;[S+>'1Y/C1/N;:P^A)CT$L
MWQ?,F30A6UQ3/>_13WV=%?VK(KJQS7%<QLEV9>%G$KG-<4 H!0"@,HX4/DX-
M-_[#VK^@8K7-F6;XOF6$4(* 4 H!0"@% * 4 H!0%*?$P$VR?$W0O#6M,OFF
MDU7C'[CO-*/'L_Q[#<LM!D(,PP@Z7L_F^67U%.>IY?<+$1E2%(]=+/'\3'[F
ME0RHN*Z:062RP3&4:4;:VX5K3)[MSHWG5*BVUL&T>6WDY=.]8UZ0WTCR:^E:
M#XX.NU_(3F27JF.I>&:Z=DI*P3S0<<$1W&!C/AXJ#H2,,$UP*&!I6)88%C8>
M-A'@WLQVDIJ$(V[E^] VL[MLY^C!T4+'-<5S-4\+_P FQP_NY;K!Z%F702S?
M%\R=%"%<'%4]ZHW^^'P\_P!O/7*K'-<5S*OI=BT\$CKJYS6% * 4 H#*.%/Y
M/?6+^I:O^NKHK7-EY^R/)%A%"$;=RI#=D1Z@[5RNPE(-'?48ZVSG(;+5Q2)!
M3"2G8RXP=#D;BD(FJA8XF*(9%8329K,BHE#1 WB%<N;+#EQ! LA5BUQ1X,B_
M',XLHQ< ;+;G&V0H(0E[6@+6WE:^>&.5[6YQ->_*U[\K<^O*O["N_P#R<^C%
MK86-K+3FGE*ULK.T:3T?1.<(R:5;FW1-X5;=#KRTZ97R%I:05SNC4)RBFW;U
M:C)JK_XG4;9B#BM\;N?'9FR(?V"67VY@$98<1T@DZ_ZRA@): @$!E)76EE54
M(M)I"(E$BH&5LSZL?)%A38I5/ %%/G298?1TMY".@>@KJK[I;I5IFXW9VUC=
MX6EK*X.5K;WBTC9V-C8V5G<9VMM:SG)4A90G)14K225G"<H\EWZ5Z4O<W9W?
M1MVM9J,IM1=LE&,4W*4I.U48Q26<FE6B6+2,B6.)CQT4&&T>?5;87U+%:[ZV
MB$%W[DFH)A6P3UM8<3?0EU29)5AC/I$:Z^NM)RHS?=BTVD]M+JHBGR"0JG#0
M-PKZ]CY$O)];Z7MM!672G3\])V'G%:6/F+"-D[2QLKO;V]A9WV6BXW&VO5A8
M7N[6UXNEC>;2\V%E;0M+6RA%U,Y=)]+0NT;W+1UT5A.CC/SDW*DI3A&3LU;N
MUC"4X3C&<H*$I1:C)L_@X^)[QPFE$;1G)Q[+I23&S\PP&:*D9CC3#[8%LF(K
MKZ"&IEF $S!)!"1A%=KKQ$-:--8!)$$3\\L#N00Q80;*[^0_H#>]*WO0EWZ3
M=([72-Q;5[LXW.'F+&:LK"W=G*_/1*N#ME97FPF[&-YE:I6B3@FI))]*-*V=
MWL[U/1]RC8VJ3LV[9Z\HN4H*2L5>//:KE"2UG9J-5GBJZ1]O(XLGRNK?F"UM
M_P#2:OL_[M_1;^W=/]^CO]$:OZ:7W_N5T[[?_,/6-P--KI^W$TU<DI;(/L*1
M9!2)]D1AEW&&U6@SO";2 ALDZEDQ$AD(3>1+B%S"RH9Y&[)UC8UAL<1QA,0@
MK8?R_P!,]!W?HUTHTUH*ZVUM;W?1M[=WLK:\:GGK2/F[.>M:>;A"&M6;7P81
M5$L#]SH^\ROEQNM[G&,)V]DK24(5U8MN2I'6;=,-K9<G7Y@W!0"@% * 4 H#
MS]\3]0W(>,^++"UZG$\SHA;6NS;E"3"4:;01?!DC,P>/C>S3D52!D)<4DY[H
MQR?'FW8'8;6D; X$PFRVX_F=*>/J4HJCYF1G'52JUM>QXY;<L$VVL\O9=K"*
M@NJT,1$JNAT(;X<JG&#!4'$]6R.7,MMWKIUJ))E7=#?,% P2IA#<"@(85DD<
ML$$7%(&RX@(> >6.-A@\W_'/VFSZ B9OQ[Q7=/NF;&^AYY4+'-<5S.IX='D^
M-$^YMK#Z$F/02S?%\R9-"%;7%,][]%/?9T5_:LBNK'-<5S&R79EX6<2N<UQ0
M"@% * RCA0^3@TW_ +#VK^@8K7-F6;XOF6$4(* 4 H!0"@% * 4 H!0'F$XR
M;"U);6WL+.>2V%P\H_=\O0[)2@ZI[W,A^79D"=AN/UV*6^VV479,5/UB)0*V
M705 0PGR"];*RB71$(=H-TZF%13Y)5C:6;2XG)%RU7C.B:HHRIG6NQ^U);:L
MOUU)S;N>K^O^;0/18IM:\1,+[7E&#FDH,.'3R/9ND+)YJ,F6K'U54:S('+6#
M$;J&HJ:@>3DS(N6-'# P>8N=,'F\\WGB_:]^\D-0A&W<OWH&UG=MG/T8.BA8
MYKBN9JGA?^38X?W<MU@]"S+H)9OB^9.BA"N#BJ>]4;_?#X>?[>>N56.:XKF5
M?2[%IX)'75SFL* 4 H!0&4<*?R>^L7]2U?\ 75T5KFR\_9'DBPBA"''$4\GW
MO5W.-G/0F]Z%CFN*YGS#"/\ $B?]%+_W.%>H]R_4[IZM8?=0.B[?X^V_:VGC
MD2@U*GO'7*;&Y)"CBXU!L$B3G(N1N-U0L3$< "NT7 B)8)PN.:+)YX!-650B
MKXA'[B8 YDO5!?&QL,&]?%Z5:#_2'0UXT=9_T>SO,YW:=WO%XL]=7>5C>[O;
M6LH2C&5I"5I8V4[)NSHVIZLGJMFQ<+U_0[S"V>N[-*:G"#IKZUG.,:IM1:C*
M2ECE2JQ):F]UX4=6G\:ZM/)H2F73T,"+D!T8-O-CY$$,LQI-DA\N:1V2X5+#
M%UKCN>:1(B@WB\?O$2T>-,T.HKB2**9'* D_RT.ANF;KTLTETFNE[T9*TMWI
M*WNKO"OJM+:=]T;HZY7;1U]N]F_Z+872YVNC[.WE?[FO]H7N,;.QM4HQFY_0
M>D[K::/L;C:6=X48JPA:*'FJ1\U;6UK.VLIOX<YVBM7!65K_ ,&S;E.-94IK
MV0]NF.[M.6[KU<A*+K=R:%&!!+%D8PP5!DQ 6CHP^15@_#IYOH*2Z@LY)"=)
M HN(Z\#CZU$R!D$\O/(QDEG4K?N'12^W7I=>-/\ G-&W6Z6CTE.U6CXWZSOF
MEI7^-R5C#2\+>WM;K+_9TKK:3L;:P;\[.TB[.PN<5:PM>*VTC96FCH72EO.T
MBK",?/>:=E=U8NTUI7>4(QM*VRFE.,E\%+&5I@XU[5^]/CGN6^QG/)\/GO72
M[^K$:5YX>57YP^E?VF_N+ [CT'\CZ.]6CXIGH:KKX^J* 4 H!0"@% >3WBJ,
M+39D\0$^&]F5PR(><LD:]L657+*>X\%3/-2O++I-R-)[2/%$EK1C([(9C3/-
MI+:R,:67@OIPKKD3U_*IN"@II[$, I<JEFTO:<L6]3.;H\%&5*9=3=.I8+:E
M4]0<49D!8MC41*&:QE+$8#.S33#&1QF\R1R&;=3LB8S.0# Q@PAM84O</-OH
MXY@<9,2<BA(487,#+/*G$9_0$3-^/>*[I]TS8WT//*A8YKBN9U/#H\GQHGW-
MM8?0DQZ"6;XOF3)H0K:XIGO?HI[[.BO[5D5U8YKBN8V2[,O"SB5SFN* 4 H!
M0&4<*'R<&F_]A[5_0,5KFS+-\7S+"*$.F<;C;S/;ZX['<O(S6:K925%?<CF<
M:H11&^WD)(*"GU9:7%E3'*IR2DI9$N.=45(^9+DR10$4R9&"!#SSQ BS[83H
M+\N'4#_F6ACZZT+1[GW,>V$Z"_+AU _YEH8^NM!1[GW,>V$Z"_+AU _YEH8^
MNM!1[GW,>V$Z"_+AU _YEH8^NM!1[GW,>V$Z"_+AU _YEH8^NM!1[GW,D''$
MIQC,39">D1R,PY39PYPVG .R.'>WWNV1E AGB&?(A+S9451+$.$A,\<#9; U
M<8MGECB-AAE>UKB&>4 H!0%!W%KF*;FW(FORK!4O#F60RW<$4DN,8FW"@/6I
M\#OEORK!KF<!.0AI:>30P=K7'@@Q(37+M(LNV ;;N?;1=+U:JX@&"!E-&<$L
M:[L&XMK%-;$]M&L-C55MMDT_$DD75;7828WJ@R-*N<-1YE(+[;*XDN="=CLN
MV$ZZTMI[G002R$Y0SQWQHHKB12I1)73%Q55.*%29L$ ,8O-TWLD;0A&W<OWH
M&UG=MG/T8.BA8YKBN9JGA?\ DV.']W+=8/0LRZ"6;XOF3HH0K@XJGO5&_P!\
M/AY_MYZY58YKBN95]+L6G@D==7.:PH!0"@% 91PI_)[ZQ?U+5_UU=%:YLO/V
M1Y(L(H0AQQ%/)][U=SC9ST)O>A8YKBN9\PPC_$B?]%+_ -SA7J/<OU.Z>K6'
MW4#HNW^/MOVMIXY'*K9.(4 H!0'N6^QG/)\/GO72[^K$:5YX>57YP^E?VF_N
M+ [CT'\CZ.]6CXIGH:KKX^J* 4 H!0"@% >;_BNS)L@F;$1^:U^G(0>-L8T<
MK*#:$4[N:ZZY'&A+1H+8&.)!<\K(\HN]NGG: CKBC$MV2I%\G00B]VQ-(P:@
MRA74?2;W&<4J/?GBF\,&DJ)YXUK2N&)Z HHS<^<6QKF]G"B.UYYL!G9NYUMK
M(#-N.9SY-U.NON%OY%@P2V2(M*MS:DE9%P@@,B!D"X0> =\<;#!YNF6PSZ@(
MF;\>\5W3[IFQOH>>5"QS7%<SJ>'1Y/C1/N;:P^A)CT$LWQ?,F30A6UQ3/>_1
M3WV=%?VK(KJQS7%<QLEV9>%G$KG-<4 H!0"@,HX4/DX--_[#VK^@8K7-F6;X
MOF6$4(02XHWDU.(%W+MG/0P\Z&4/3CVH\T?,N#($?%X?]"*?>8__  P/P6__
M *5ZA6=PN/FX?\RNGH1_ZM8[E_X#HR=O;:TO^-:^D_\ I)[WUDO=,M>X@V#D
MY;8LENU::5P(UE1U-%):3<)'E9W.5B1>]G^533*VH@CH[70B>#4R-K)\R155
M!1 N&B)!  PHB+J)^8Z7WNTT#HVQONCM"Z+O6MI'1=UO5K>H6<+*Z7>_:3N5
MPE:1L;.,;:]6\OZ5JV-G&TLK.SE6VM;1QLU86^]HZ"O=M*RM[W>+.EC;3LXV
M<I.5I.RL;2UU7.3<;.*5G63:DWZ,4F]:.\9GT:CJ,=/HZFI(/+KFDU<9$-RD
M^@R;A89AIM5FS<??Q%L$SS"]9R3V1_4X[724T!X!NIS%U=PF%=,4&>TD_!OK
MB[\70_2*.DNEFD-#VNC-%W;1MA?=+Z,N3GHVWC>KS?-#6=QM+S.%^UIW*UUH
MWFUM)71W6[2L;"-E:6=\O=I_2+"PVKS<Y6&CK&]1O-XG;RLKM;VJ5XB[.SL[
MS*UC9IV6%I'&"CKZ\TYZRE9V:U92_6P^D<2Q/I_$\ZM=7<RI(R]A!!F16^IJ
M;342*&3G6+WM(J684V4EME.=,6%@<VJ3)L0Z['&Z )?0% V[T/!NE$ZR<:F@
M.D$]*=+-*Z$O.BM$66C[!Z<CH^WLKA.SG;ST)I.Y:/M8V=]M;6TNNDY-7J4[
M]"ZW>[2T3>+.%TMW>)6GG(KW=/Z/HZPO4+S>96T_Z*[:$K9.,%>K"TMHULXI
M6EBEJ)6;M)S\_%N<5!*A6EZ@(_\ \(I_PP/T*[%_H%Q_[E=/_36/_L/B^?M_
M^VM?\2?XGO&^QML, ^&V#@'CCAACL-.5L<,,;8XXV]?$[ICC:UK6MYK6KSR\
MI<(6?3[I9"$8PA'3-Z48PBHQBE)448I))+<E0[BT.W+16CG)MMW.Q;;;;;U<
MVWBR_6OPY]$4 H#S&\5(52A;;=HK#B<6A7W,)5:#M6FC%,D<,F2]OY7-2$>5
MX;:2_(+K&B4F;43IU:42:.U$1X'W.R['@3R&QAF1(2FED'2U1R02<7A*JVJ:
MBJ8X8X=>WV;;I=0P%L_H1 (<;2 @.!PJ>M#+$CZ3UJ&L8V:2FK*;"*C-!YGX
M';YMI7:S5%-&$Y7SCE+46X9+(G)% 4$LSE8V",'Z3PIB\*U]^->)2,$]MO'=
MINJQSGNLF(\QX\7K9N$%Z;)=G=5UA./N.(A=<P>,8##=K7:LAYL09:&:2.81
M(_:Z"82$5KE%E-2;!E$_"^0S^"G75P<$Z4KCO=:?GC4V^Z-M-NY!X739>, :
M>JDVQ))^DTHG))E::MRD!.DIBJ023(C4=9@7UWBPXHS:2*I*3]N39>941I_;
MPB**4$$EI(PM\\9NI[\/X?@1):V+I\+)+\TW4V%GO# OG[6SP_O<X\O87:P_
M]Z_/P?N+,KE?EX';V\[<^5NGNK\^E,99OB^9.CGGTYXX]O7W=[\K=.MO<6YW
M[>G3LMUZ]!"N#BIWR]BHWN=L;?Z8?#SY\LKW_P#WYZX\N7/&W/G?GS[.73MY
M\K6.:XKF5?2[%IX)' KG-84 H!0"@,FX5%\O:^-8N5L>7VF*_._A7M?E]NKG
MZ\O!OSOV].=K=+=>O37-EY^R/)%A'//ISQQ[>ON[WY6Z=;>XMSOV].G9;KUZ
M"$..(I?/VOO>GGCC[SG9SG[N]^5ON)O;K;W%N=^WIT[+=>O06.:XKF?,.(_Q
M(G_12_\ <X5ZCW+]3NGJUA]U Z+M_C[;]K:>.1RJV3B% * 4![E?L9WPO:^7
MQRM:]O97R[SO?*]KVM]K$:=;6\&_._;TYV[+=>O3SP\JOSA]*_M-_<6!W'H/
MY'T=ZM'Q3/0SSSZ<\<>WK[N]^5NG6WN+<[]O3IV6Z]>G7Q]4<\^G/''MZ^[O
M?E;IUM[BW._;TZ=ENO7H!^K<^77M_#ROSMS_ -O*W/\ V\K?[* 4 H!0"@/)
MGQ,S@\(;@/Y#?K[X?Z:S9%BC!TQDTEOA22/M/+,>@N=SSH]G:_7*M1\F**26
M=;B5$62GA9SN)V&4AY78CN<QZ)T 5O/9W/$<L:-92JL_AQBGDDL=F66..;P/
M2DQDYW&=8F6DQR\4DH^1X+;">R7^[HWN01"[F$89$L@.]QQ$B*[4]0)X:C<J
ML*D=)2XW<"8-AFV34TO (,R ./;797?CWNO?1GGD ?NVSZT6B1F![IIK?EPY
MQ)-RF6]Y@E_8U5UA<<J1["#VV9*!L!IOEMLU_P#VIAF1D!KJY1H-]O70F\UV
MODB))<BC% Q"0SPUG2/T8M)+6HVHMMY;WCO:-R3+MEMS(O"K3G= ^FRK+4%2
M_P .!VN20IBFW;M 0Y9CTRMQJ_49X9*Z"K1>=59G-H;9(D7NGO0J>:EI'#60
M00$I"'OF)4==E/;^<?<1)*5&Z-2I1+#![,?<^K'=;-PZ+Y^U\Z)>YQY>PWUA
M_P"]?GX/W$F/ROR\#M[>=N?*W3W5^?2F,LWQ?,F3SSZ<\<>WK[N]^5NG6WN+
M<[]O3IV6Z]>@A6UQ2[Y^Q^BGGCC;_39T6Y\LKWY6]E7%?+ESPMSYW[;=.5NO
M._95CFN*YC9+LR\+.-7.:XH!0"@% 9-PH;Y>UPZ;\K8\ON(-7MRO:_+P#'7E
MX-^OFY_[ZUS9EF^+YEA'//\ U<>W_7OV?#]YV^;_ ,Z$()<4:^?M:G$"]SC[
MR_9SG[N_9]QEY=?O.M_-TMYZ&4/3CVH\T?,[#_@P_P"9C^C:O4VS^+L^Q'PH
MZ'GZ<NU+FS,F*_G?&;D+N]B+IIN.4JF.-&+JQ+ L(8"3':VU9HN,ICB; , >
M+56VNJR4/E<*XF!<Z+F!F$/B&+AKWZXW325WE=+[8QO%WE:7>VE93<E%VMTO
M%E>[O.L)1E6RO%A96L:.FM!)IQJGE96MI835I92<)I3BI))X6D)6<U1IKX4)
M2B\,GAB;@2-N]CT)EL:/$V5%L)F1NKI*VST,<B@GP$TT@**VKM\H:,'TDT>7
M$%OJSE<"F@MA?-*C;15!943B6DE3!L83+Y-KT4Z/6]\OND+31=B[YI&RM;&]
MV\9V]G*TC;V=A96\X1L[6,+"WO%E=KO96]ZL(V5YMK.QLX6MK.,4C9CI"^0L
M[*QC;R\W8RC*SBXP:BX.4H)MQ;G&$IRE&$W*$7)N,4V= \MDIRD&-&O#SRD9
M:7HX9OK!9!;1H),###P::2?0&@$IJ94@76G" SD%44D-G@.%15 6HC'SB4WL
M$T@8%+Y\]TZ.Z%N&DKSI>Z:/L;#2-\\_Y^\Q=HV_Z7:V=XO;L[.4Y6-WE?+>
MRL[>]RN]G92O5M9PM;P[2TBI+"TOMZMK"%WM+:<[&SU-6#U?^CBX6>M))2FK
M.+<;-3<E"+:C1,T?7VC5/=W]C<WR]K=#Y6QO;V1$X]N5[=/7Q.Y]/!OUY]EN
M?7MYV[*\Z?*;\X'2W[:O?B1W-H;Y)T;ZG8^$OSYY]?<X]O3W=^SX;^XZ7[.G
M7_;TZ_A3Z0YY]>6./;T]W>W.W7K?W%^5^SIU[;]>G4#]4!YSMCY@:VR.\I>-
M95A8-IPLCSHJ</1N[*L#9QTQQL(VIH!C./=YT1\%(\0DDFA%V8U'W$K+P8CP
M/.0ZX&P]$H1;)@X$5E3;QV8?GO\ 9_$S2HJIXTUJ:J:HG2E7M2;;5&GQ+XH4
MB]BPG$4;1'&6!K"/XX9C?9[0N>633B/C(2&G $2)I07SPYDXM*!P(*QL^JF1
MQ1CYL88UGES%Y6I@W5M[\3^+A@F$'<TUUA.N&XJ<[&=#E4'HYF6X8\:*TTW$
M\592$655V+K=4D@RCJ[E4U<4554%U0)F%0ZI"B'C)H0UGD+<6KP=759.N7 U
MIMNEIB)I=LVBHJ<12$=(U?FA,2DE+*%T]-3$TA%+E*D4]/(% P2I(B2*A!%B
MA0L$$7+@!A@@AX!X8XV!9KBN9K?A?^38X?W<MU@]"S+H)9OB^9.BA"N#BJ>]
M4;_?#X>?[>>N56.:XKF5?2[%IX)'75SFL* 4 H!0&4<*?R>^L7]2U?\ 75T5
MKFR\_9'DBPBA"''$4\GWO5W.-G/0F]Z%CFN*YGS#"/\ $B?]%+_W.%>H]R_4
M[IZM8?=0.B[?X^V_:VGCD<JMDXA0"@% >Y;[&<\GP^>]=+OZL1I7GAY5?G#Z
M5_:;^XL#N/0?R/H[U:/BF>AJNOCZHH!0"@% * 4!YIGB^H_WBW>7V'.$/&(C
MC^1W;L3J-%&Q<1;5NUF3ABY- WV]AU94>K'3$I);;31W$9=$Z(<>.,@JJ[D!
M:;S>K66PA$MYAB MOYY=_<9XQ2QRI)II4^$E2CK5[*X*C6&29Z,F2U6XQ68T
M60SBF">T6:V$!JM8@&9'.ADFXWDHHD(90,X:&,&3>!9,)E0<#)@P../CA844
M843/+/(89F&N&!(+=S.-QV[(6B9SQ^?<9UX'F,X8Y9ZTSCKN4E,XM*+I-ME2
M1C**8<:@LJ!]6.K8Q'-3-*9XX?'-"&C(PN8M7O9IO>HB23-"-QTU-)E4].3]
M0MA2) @1+A%"1$D4AEWERI,F5+X!@%BI8 ,,$N7!#P"!"PP##PQPQQQL$<UQ
M7,X?#H\GQHGW-M8?0DQZ"6;XOF3)H0K:XIGO?HI[[.BO[5D5U8YKBN8V2[,O
M"SB5SFN* 4 H!0&4<*'R<&F_]A[5_0,5KFS+-\7S+"*$()<4;R:G$"[EVSGH
M8>=#*'IQ[4>:/F<A_P &'_,Q_1M7J;9_%V?8CX4=#S].7:ES9^ZS,10"@% >
M[W[&Y\FZ'WAYR_QQ.KSI\IOS@=+?MJ]^)'<VAODG1OJ=CX2_.OPI](4 H"J/
M;?4+A4$A'9LILAJ?%$H.UXO9);2VN(D-K4PR<^Y$4Q@&\FMXBV6(D.)U.!R?
M]!Q+&2I9,$R3"*<:.*F9(B0-F01G&4\HMI*KS22VO,GCK>IPVKP/$YS7E-)H
MD(V9"(2C%"(MU6:!=OM),*XIB8WOM37B"4N-@=!P)Y)!MOK":04T8V2'3CQ,
MN9+"A8C%UJZYUQXFZZ$(V[E^] VL[MLY^C!T4+'-<5S-4\+_ ,FQP_NY;K!Z
M%F702S?%\R=%"%<'%4]ZHW^^'P\_V\]<JL<UQ7,J^EV+3P2.NKG-84 H!0"@
M,HX4_D]]8OZEJ_ZZNBM<V7G[(\D6$4(0XXBGD^]ZNYQLYZ$WO0L<UQ7,^881
M_B1/^BE_[G"O4>Y?J=T]6L/NH'1=O\?;?M;3QR.56R<0H!0"@/<M]C.>3X?/
M>NEW]6(TKSP\JOSA]*_M-_<6!W'H/Y'T=ZM'Q3/0U77Q]44 H!0"@% * IUV
MHT^X0+ %,SA.>G,62*ZIJE1QE!#[$@-T3=(DCRDL O%^O8UBW8S0'4XE-1+E
M&N^'.[%,0A@43L4=4N?, G+@%AQFISI12=$MZ5%EMXY%IL5*[!<$7QNO12*G
MC1<ML)GJ\;#))4P12A6"I-Y..,X5,)&P"QHFGB-T9.S)%3)8N8+EKA@C !"8
M9!XC#B9[0$3-^/>*[I]TS8WT//*A8YKBN9U/#H\GQHGW-M8?0DQZ"6;XOF3)
MH0K:XIGO?HI[[.BO[5D5U8YKBN8V2[,O"SB5SFN* 4 H!0&4<*'R<&F_]A[5
M_0,5KFS+-\7S+"*$()<4;R:G$"[EVSGH8>=#*'IQ[4>:/F<A_P &'_,Q_1M7
MJ;9_%V?8CX4=#S].7:ES9^ZS,10"@% >[W[&Y\FZ'WAYR_QQ.KSI\IOS@=+?
MMJ]^)'<VAODG1OJ=CX2_.OPI](4 H"AF3],INV5W,F]OOV#VA%&O3H)'CPDI
MMR/8K7V;+II *LTS'2A-+(>LZ2>R-FE]350ET@O(TJZ41TYXP26^G91M/90X
M F*CE&=4HJC^%[UB\G14PZY)MXHN>A]FJ4>1<Q&&K Q\7/,YM)K;R BECYQI
M' )='!L0(ALR/<UQRV92%@0 +8DVR$X%@NC8VN1*J)HL"$+D,'^:XFR* C;N
M7[T#:SNVSGZ,'10L<UQ7,U3PO_)L</[N6ZP>A9ET$LWQ?,G10A7!Q5/>J-_O
MA\//]O/7*K'-<5S*OI=BT\$CKJYS6% * 4 H#*.%/Y/?6+^I:O\ KJZ*US9>
M?LCR1810A#CB*>3[WJ[G&SGH3>]"QS7%<SYAA'^)$_Z*7_N<*]1[E^IW3U:P
M^Z@=%V_Q]M^UM/'(Y5;)Q"@% * ]RWV,YY/A\]ZZ7?U8C2O/#RJ_.'TK^TW]
MQ8'<>@_D?1WJT?%,]#5=?'U10"@% * 4 H#S[7T5F[9'8[8Q/E^#(S@^(AG>
M\WNT%"\/1/(4$2R\TN0LB47N61X/=FP,SLV?%U\1H<4W9),K&H&TZG-C.C/%
MGMR0%T@KGC:4,ZI)4;;RS=4J<%2CR56NHOD9:6I(;.::*LAMH)71VTA):J$R
MT8=NLX-23TLJ4/!M-OFCZJ90FU@:!%Q0D8PIJ(Z6EV*DACYP0#(P(,#): B9
MOQ[Q7=/NF;&^AYY4+'-<5S.IX='D^-$^YMK#Z$F/02S?%\R9-"%;7%,][]%/
M?9T5_:LBNK'-<5S&R79EX6<2N<UQ0"@% * RCA0^3@TW_L/:OZ!BM<V99OB^
M9810A!+BC>34X@7<NV<]##SH90]./:CS1\SD/^##_F8_HVKU-L_B[/L1\*.A
MY^G+M2YL_=9F(H!0"@/=[]C<^3=#[P\Y?XXG5YT^4WYP.EOVU>_$CN;0WR3H
MWU.Q\)?G7X4^D* 4 H!0&!*<JQ>BMY<=RS)#"26FV%HXVG*YU-X-X@WF\XTY
M0Q25! 7%HTHA)J2M$57/!,.)1\R7/%E#/$D.!@9RL'<#4FX1@N<TXVE-E!P3
M14UK/-Q@L9+BX#ES!<>+7.*". ,%ED&,",'EB($*'EE@)AECGAE?&]KW%CFN
M*YFK^%_Y-CA_=RW6#T+,N@EF^+YDZ*$*X.*I[U1O]\/AY_MYZY58YKBN95]+
ML6G@D==7.:PH!0"@% 91PI_)[ZQ?U+5_UU=%:YLO/V1Y(L(H0AQQ%/)][U=S
MC9ST)O>A8YKBN9\PPC_$B?\ 12_]SA7J/<OU.Z>K6'W4#HNW^/MOVMIXY'*K
M9.(4 H!0'N6^QG/)\/GO72[^K$:5YX>57YP^E?VF_N+ [CT'\CZ.]6CXIGH:
MKKX^J* 4 H!0"@% * 4!K]3EF*T5M'WFLR7'Z2STI=.M=4=:F\FX0;2:Y4U7
M&;ZBW3ZZ:4@DLFND%XN81#J08-!J!57 &31RX9P+,'$#1.^@H8VB.YXP(F H
M(NI.Q0H0H6>(@8H8D./'/ 0//&]\<\,\;VRPSQO?'+&]KVO>U[7H6.:XKF=9
MPZ/)\:)]S;6'T),>@EF^+YDR:$*VN*9[WZ*>^SHK^U9%=6.:XKF-DNS+PLXE
M<YKB@% * 4!E'"A\G!IO_8>U?T#%:YLRS?%\RPBA""7%&\FIQ NY=LYZ&'G0
MRAZ<>U'FCYG(?\&'_,Q_1M7J;9_%V?8CX4=#S].7:ES9^ZS,10"@% >[W[&Y
M\FZ'WAYR_P <3J\Z?*;\X'2W[:O?B1W-H;Y)T;ZG8^$OSK\*?2% * 4!C[M;
M@#P:KF:1I37T4JZ6\M-PRLM1;/MITI("VFF4P93;;C2A0%1OKY ,UD:1UM-'
M!/I2B$6/DQ0S  >=@/+DFZMN2&(9BI.=NLDR/W62"N,UNL_7U"0,42',KN<L
M!+R?L$RH,DLO':DF.1[S S@%EQLU3).8,FZAU0LK%'L(</E"IY:+#D<J[<7"
M*3JDDZIOW?AF;B!U,X@C=X1<3H(>XBQK&#%'#V<Z),>OJSKQ&<M*[B&3&6]%
MJ[:5W^\E(%S,A1)1^;0HU.IR*&/BW#"$(=*7R/8YX6"L7-X5K+!U:V[O?CCO
MJ6P\,"V7M;/#^]WT]A=K#?EX-NMON+,KECS\W7KVWY^:AA+-\7S)SVQSZ<\^
M?*_._N;=;=.GF_#U\_FH0KAXJ=LK:J-[GGX7^F'P].?N;6Y_Z>>N/+L^#K_M
MY^:K'-<5S*OI=BT\$C@5SFL* 4 H!0&3<*BV7M?&L5[9<K?:8KWO;P;7YV^W
M5S].?^Z_7S^:M<V7G[(\D6#VQSZ<\^?*_._N;=;=.GF_#U\_FH0AQQ%,<_:^
M]Z>>?/EISL[>_N;=;?<3>W3S=E^OG\U"QS7%<SYAY'^)$_Z*7_N<*]1[E^IW
M3U:P^Z@=%V_Q]M^UM/'(Y5;)Q"@% * ]RGV,[;*_#Y?'++E:VU\N\[<K7YV^
MUB-.G/\ !^'KY_-7GAY5?G#Z5_:;^XL#N/0?R/H[U:/BF>AFV.?3GGSY7YW]
MS;K;IT\WX>OG\U=?'U1;'/ISSY\K\[^YMUMTZ>;\/7S^:@/W;GRMSOSORZW[
M.=_AY4 H!0"@% * Q9\-(F_68[&.HJCE1$]X-Q:;)Y99KB56@[4LFN)YA-,G
MVRZT(R36VTO% 3.8Z2O(YLJJ))[  ^0,@&P A< 6#KNWY>T\KI75UVQ'KCJB
MG/G5F9) UR@KB"<3,^_(%(0\_P"7'<:8TCINU+)UC?UXM,)#@>;Y;&"LYVN.
MB/;-.6L2Q5U)+U%5,B @RT&.1RJY4>+C!5JDJTC55R674L'U)R%DO53B -_A
M&LI-$W.4M?4V(.%V;:DZZZJ.O47RLH.]P-*&G<==:(IRJZ5/!TM)0-M 9)C$
M]@W\3A=!,ML5?23!H\<%RR"J<VZ5K-M.K6#>&!;WPZ+9>U\Z)>[Z>PWUBOR\
M&W6WW$F/RQY^;KU[;\_-0PEF^+YDR+8Y].>?/E?G?W-NMNG3S?AZ^?S4(5M\
M4JV5M?HIYY\_]-G1;G[FUN?/:N*N5O\ =UOY^?FJQS7%<QLEV9>%G&KG-<4
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M>A9ET$LWQ?,G10A7!Q5/>J-_OA\//]O/7*K'-<5S*OI=BT\$CKJYS6% * 4
MH#*.%/Y/?6+^I:O^NKHK7-EY^R/)%A%"$..(IY/O>KN<;.>A-[T+'-<5S/F&
M$?XD3_HI?^YPKU'N7ZG=/5K#[J!T7;_'VW[6T\<CE5LG$* 4 H#W+?8SGD^'
MSWKI=_5B-*\\/*K\X?2O[3?W%@=QZ#^1]'>K1\4ST-5U\?5% * 4 H!0"@%
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MN6^QG/)\/GO72[^K$:5YX>57YP^E?VF_N+ [CT'\CZ.]6CXIGH:KKX^J* 4
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M"CW/N8]E)KK\<K ^<!3Z5!1[GW,>RDUU^.5@?. I]*@H]S[F/92:Z_'*P/G
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M^7K2G%RI,MXPP/GE%:SI6F%2-J*JTWBEG3--[GN-._=+W^^/;4__ )/95_\
M>Y67F^OW?S,?.+ZK_>7_ +3H5?8C=R/5N+%%WR=K,\FHYYW@2,',@-_6B2F2
MO&$&7)B949*IM%=!_;%\$4E52B3K&5" QUJ+940R3# ,$\@A<L\)*.JJUKC3
M+^9E&2DVJ-8-UUD\NK57,EAMT_)@;1N*6S#JNJ *CI4'FIN%OQ^-"]YN7V^T
MT(L/XV-$S8=41(E64U&5U9+-R"045@@Z;MT4,9IC!C!*!@# R5,:T]M:;=V-
M7LV9D38^XB;V)(RB_7NCLA\PRH9MXNBRF16%**CY)4+\.=+W0< IF,%IL.G)
M+9:N,UWKE986)//KS5$=2$BXI+F3T,XLYJT_/M_@75QHOS\)Q_#9OX'8#<35
M\99.E.3=;DHTX8Z-2CG(B>L2G(+$!3DB,TW3Y8$$;9"0];6H_E!PK:=N$V<B
MZ ]X^C<J5,,U>_Z^-IJF@JAT51KM_..YM;-^[#.DN2&R+U/:XR7,0,+J*Y(4
M:+\RL]3BF/G@WW,&H.&(7XZ&*=.(+N?MX<)*K>-6;MG,/F?(-Y>P2A32<F(B
MLN $B2D,:*M*X;V=$[IKDQQQ5K.H$D1PZ_NG8B2VLQG(8<Q9@N-S1<FJ#+?C
MV%/D@4U<D&/1U1WF&.FM1H9JYU>"(BOU&$7$'!QEQVV &&.VF77BN#WFDW7L
M7/SIUBUB?<=JS0)2$_RYISR>935V,&T=76*TXDD%SK2Y%J)+*D?2A[NI?1VB
MZ$HIXI?!2F0?.BJ:TFI&([P("T56GOHN^F-.JN6TV%-NZRE%47QW(S&C*\II
M3IUFE7:-4N[7CE%*X4C>'6A'3Q700DHLQ7J 9?J^E2 7P2VT;NW$8LME,T]2
M7TLB*(HD1*8TZZ>UUI[,#7ZYQ"'FWE5^-E4@QE@.B&UDB0ETL)/!PJA )[@D
M)H,1K&HH6E&&B)R2U,Q9X$%%R(RRA1S9N'!4E"+**^<<:*,:"BW[]F.&...'
MLK_ V_.>W#FB.2GJQDF+VZY$ADQ] 3G'<"L_WDF+2\[MBI9DF+66R&O'[ A2
M672XLD^\7+R\N'D<$ZNY8'DA.0&<NY9JAU)"F"QS;7=3&K:6TCH3XE[B<+4'
M=J=!Q)-:B:ALXN\5V\I'\'(WWA(4ASG$B&49[07(<)6=*,EO6%Q#2DJ/,W':
MN W7*1.B,H=735)L7!JF_.E&J;L\>LQ]O\0.3R;>.''BTD@VBNB3LF9'CK;3
MV1C#W)#)Z?#2^HI;T80L<XH:2C8([]5@LGB"MJ!LTJ9HA#)KM\)SH"L +J[J
MY5>&&5<_<2*:6Z;M45),&>,2LQ%8+IE9YQ<PY,:4R*CM;#UO'4)R_+SV=R1]
ML<01T8R:J2>BD=B$%<.QA-<*H(Y'"B'SC5;B2J/ 2F[=BJ8UK2AH8/B=OT\S
ME.1DG6IM#LE*BB3Y=,CJ$^'R#ES;\+Q3$,MR$3+H1:#U-.S4LT66BJ.R\!7&
M""X%Y#-X+HK.2C@"L&R%,NOJZZ;_ .!S9$XB;V&>"E'$91XUL%W[J3+0&,Z%
MMWO1.:CW04S=B(-6Y!3EI9<L'I3=2;+/W11,4EP1.MSH72C8"JG&/$.I*(HZ
MF*EM>Y\<FUMZMM/:6(P7*><RQLGODP@AME1^V20V8NHA98LXDPHYHND5UQ@Z
M,V^X_6Q$R<;6.N)G*9]J.(5$1!UUM&DI6,(J0.<$3BPQ>'N]ZJ;=H!0'B>V#
M^R&N(#&FPNPL8-)IZEW:D63]-T6M<1P1/+*HO#MV-I2=C(0S*XHI^PJ(0/+!
MI,02IE3-$4=*)C'A1\RJ>4 N&!A_0_0SR%V'2SHSHKI#/I+:W&6DK.\6CNL=
M%0O$;'S-[O%U25L](6+GK*P4ZNSA1RU:.E7^1TGTI>CK];W-7%6WF?-KSCO.
MIK><LK.U]#S$Z4UZ>DZTKMH:C_\ U)W$A_DGII^9B9/_ ',U^H_W:;M_?"W_
M /L=G_\ *FA^FS_LU?\ K'_IB_\ X*?$7V"XA30V#6)_1HD25.*G:Q45N91,
MU':TR1H@Z$)94CUUDJ[)"D(<R;!,)H6)88F=3PL0<Q,!2PN?@B6Z+\HG0R'0
M3I!'0EGI"6DXRT?=K[_29W971IWBTMX.S\U&WO"I'S-=?SF.M355,?U6B-(_
M[4N2O?F?,-VMI9>;\YYWXO5^%K:EGGK9:N%,R;4)2K**^_9L-G7L0EZ+&DGG
M2*>X4UII3.0<IC3'8[2BS%L/FRPHZN]FVTD$DWVR\'*OCN/"THXJ2(@.H^HD
M7@S&%^$/J.E%O_A1?SIU>RN :Z[-R.H,&1W9(:ZD2D$W=18 VW***&F)C6)E
MU696A+CC<D3)8Z4 :+V;S=^Y>E*K245D)6=Q=O/M/Q<RDXQBY14/BM*J2SJU
M^#]_NP,%4N)"_&BFK2W(&NS81D9,=.<=@&&Y.YUR&A9 4M6T/;)KEU,)4A9I
MD$9BYL%>+H[V>XRJ8&9CB** Q1M.EM%;N#,-7\TZ]797:;:=NV$@XZ_S0] F
MTQ8]?\7SZR]>5I5 =YF5HX9WVV/Z(6<Y9@4%<1NQF:4&S%K?E)0?+F1U=/;7
MJ0NR%8BNJ20!8Z9(A3%9XIOKPKQSI[]I'>7I^V0CB:6_K2V9.?<J^K)+AP(Y
M([#8,$F9HQ2Y*@#>"1ER+1TIQD6O".:XV5?6>/7Y95$0VVN!1G(@1 RGG5#)
M$<3D!)4KU/#'&C2KOQKWK=@MDME9W#&D/6! E*7W)'1^2DR=5=[L!.8<(*1S
M!#B=QI0\=9*IU.17X637B]X^6D0W*Z8T'BO-U)>)E7(QZIE$DJ1%$$=,:)>_
MW8Y;JX[S))CVB=26X(N?\8.-=$8AM]0@R7Q$;MB8Y'+V0D^8Y97HH(/*2&G+
M6#4GP@G2 Y 4ME01FRXW3DC!Y(KL=#W5'1'09\PSA4LZ[GM6Q5PV<<>&-*QY
M1-KIU6&.D8'9K(9N=\0;J[.S+"8<7M)??CUDC91DSTIE];HM1%(7[5<6ZW%N
M*&\]3;I?!<ZMMZ'U)S*3\?3>2R&4I(047O:IN2IBWCGC[<JY$])IF^7(3B2,
M71C!Z],3_<3K@UF/M'BI58I9OMQ4D*1([8CM.$!Y)D)AGC2?85UK%F6,!DI%
MPSI-.,/@VVFU937R@B5=J6#>-=B;V(U%N#L%*D77Q-L=0 9.;/U7V!VB.MI>
M14!<4Y"<<*J,0ETB&3AG$VJDB24M?;^HH;H-LL^(X_7]599AK.3$F =(.,%3
M;O2[ZX^PY>R$Z2='DV,#%O+A8O";<PBW*6"C25(H67Z<5I=G,E$+5 .L]U&3
M#Q#:>*L3.I)DZV"J6J*HIER%VH?7'>T@VL:!4H]^S###%_FCI[UW4P[8R.PY
MR"AIB0LTGL#D-#*2,Z73,:HP/%N.;[S*&VBH2(EQ!(60R(C"0Z<R<RQFJ 'R
MY=?(B(K?71RAHK<$E2K?NKNZUO,#A/B 'YI<\'E2,1HS?9LR.=HQ^(JJ,L8#
M/MMOISZ4![L"A@1]A'X!-P,I-:9HBR;.G!ZI*P=<(IA5Q9I=O!DCRB*XTKO2
MKEAZ6KGQZC')FXBKGB%'EEQBPBW5E'CMP3D302@,FR"==;O:NN1 ,Q*CQ4&V
MQ==) Q8J004%=HI28L.%5R8I<PO9Y/E],3+[6@7:&KECNV+;EF\=O=D<Q5WU
M= [B1$;[E9=N-EVRT=8C*>"9(Q=:<2L#'F[.NVJ[WNYF<J1F"DMH@O!S@ M)
M626Z7.I")Z4MIUC#<4LT5PW"G7LJ^YM>Y8[NLUI%/$)D=48FN.,HMV.6^]'I
M$T/RTXW=A+9(E%2ZU)+U7VUED):D1?$B<P9BG(JZ-75X^Z$9L);J(-A/5$(V
ME/)V$2+D;@@:N>>#:RW-+VY]1O)!WG=9=& -RG!0$;KBB1@9=1T"\DGE$P>;
M6P.S FO#.4S@3CC-BKJ$I9E<TJ0LVJMMTBY2A5=3&<XTYM.K!2*IX46QUSV;
ME7>^_J-9-GB4NTRE-%Y/V!6<QXY<<;0A+BDY09],+*DW6-L*RY5=,?&CJ2I0
MRUD:ZDE'(B<!*1"YIV)R2V$=11EY%77</DJHB4&KNJVJX4W4KMZ\,*O<8?CQ
M)956'&=R2(=:"/A&3?G)<E!E.V0WRPPU9"CZ&X+FQ)7&^O2EKTQ'PGKY9 D=
M93L6JMQFB(:OCB Y<GJ&V [*@ :N&UY4PZVM^]9U+ ]@58!>UU7ETJ";+%EI
M-9"L6+J!?(H?  47,V3@()TIG>^98V$&-C@9+YWOD"-CF'E>]\;T(L_9+DR1
MU""@% * 4 H!0"@-"3#_ -H>JG]O;B_9>V1H"(NV_ORM4>[5NKZ3M%*SAF^'
M\48S]#_S1Y2/ZURG":,GG^(0KWO]*?VL(>K">2X_P9R67I/LRY%C>PIZ C)!
MGLR?V0R) ;CF5U]7+)$@-5JNYK-PG'[,<+T<LB. D[@3*<D(+41$L8H;<6!8
M8<FJ+Z(F!XXYK.&5N(Y579L_CL77_,P0:>]%3K;LHG9&URR:I]>4T6PJH?8X
M"4<<"=':(W5 KXE0P"!,&[Q"]&VDAB^*SL>B]VH0!00PSU]/L;"DJY.N:SKG
MGW^\Z]ON[59LNJ9(I:4' HX<+1VT'T[,6AKP-BVW(@R\:4RI5'C9,;;6$592
M4#PL,H8;@ 8[?7$<T?1V>A!JBFY&T?1VR&.#KF]^.%.XZ5J;Q04<6X+:+.:+
MF 5MCH]C*<T9$+81:VU1#1=A!EE5;2DZ&NI2&DN9SN)0/ICD4W]:*D*3AV<
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MKFDQ/,JJ2&>!2E,<D6&4$P%3Q P4@D\Z('D9)!J&!4KB>#+"AXF\2P&(]A+
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LYEYMX,N23DTBNCG#IL<2]L 2Q8$487.]L<,,LKVM0JS]DN3)PT(* 4!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g947560g12r10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g12r10.jpg
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M 0$! 0'_P  1" $= 5,# 1$  A$! Q$!_\0 'P !  (!!0$! 0
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MXZX8<]#D235*9E/J5NIU,VV+S$3.R">93$3-547O;V$;OI]KE?KP>FD_%8X
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M_/\ )_\ K#-?Y>?QMT+\?-_T:/\ &/[J'YJ?BB<;/Z1;'_W(/Y/7+S^?Y/\
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MXF?)7R/R\%4=.GBI[X>9Z3]Z*_)Z?JX'U-P_:\/@I\V'0]?3JXJN^6H+2
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M]VMR+\5MO\K,>'C_ -4E[_\ )SYGS'WVMV/R+]PYSY73]C2S?!YO<Q
M                          4Z1+P]US_%74S]*"S07\'''/FTKBP0 *4E
M'A&N=/Z/.''[IVP-F'O\7I3B]'#^EWP[]&QI    1/YZ>X9YG^*?R*\D$Q$U
M]"KAJ[I51TZ>*GOA=16/X-J]_,>)_L%O&EN<X 0-Z4SP:/2 ^)GR5\C\O!5'
M3IXJ>^'F>D_>BOR>GZN!]3</VO#X*?-AT/7TZN*KOEJ"T@   ,C3S,9[M;D7
MXK;?Y68\/'_JDO?_ ).?,^8^^UNQ^1?N'.?*Z?L:6;X/-[F(
M                   "G2)>'NN?XJZF?I06:"_@XXY\VE<6" !2DH\(USI_
M1YPX_=.V!LP]_B]*<7HX?TN^'?HV-(   ")_/3W#/,_Q3^17D@F(FOH5<-7=
M*J.G3Q4]\+J*Q_!M7OYCQ/\ 8+>-+<YP @;TIG@T>D!\3/DKY'Y>"J.G3Q4]
M\/,])^]%?D]/U<#ZFX?M>'P4^;#H>OIU<57?+4%I    9&GF8SW:W(OQ6V_R
MLQX>/_5)>_\ R<^9\Q]]K=C\B_<.<^5T_8TLWP>;W,0
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M*"S07\'''/FTKBP0 *4E'A&N=/Z/.''[IVP-F'O\7I3B]'#^EWP[]&QI
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M&>[6Y%^*VW^5F/#Q_P"J2]_^3GS/F/OM;L?D7[ASGRNG[&EF^#S>YB
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M,QGNUN1?BMM_E9CP\?\ JDO?_DY\SYC[[6['Y%^X<Y\KI^QI9O@\WN8@
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MQYO<Q.O?_LZ?YO;Y_P#;[/ZP']QU_P >,8_[LYSV?^.,?Z/ZP']
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MQX>/_5)>_P#R<^9\Q]]K=C\B_<.<^5T_8TLWP>;W,0
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M\/'_ *I+W_Y.?,^8^^UNQ^1?N'.?*Z?L:6;X/-[F(
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M7XK;?Y68\/'_ *I+W_Y.?,^8^^UNQ^1?N'.?*Z?L:6;X/-[F(
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MS&>[6Y%^*VW^5F/#Q_ZI+W_Y.?,^8^^UNQ^1?N'.?*Z?L:6;X/-[F(
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M@/B9\E?(_+P51TZ>*GOAYGI/WHK\GI^K@?4W#]KP^"GS8=#U].KBJ[Y:@M(
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M[M;D7XK;?Y68\/'_ *I+W_Y.?,^8^^UNQ^1?N'.?*Z?L:6;X/-[F(
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M8^^UNQ^1?N'.?*Z?L:6;WU[]O5KK_F]OG'^GVF>K^L>;W,3KW_[.G^;V^?\
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M?BMM_E9CP\?^J2]_^3GS/F/OM;L?D7[ASGRNG[&EF^#S>YB
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MKV[+:OC15Y8F;>"]]^]<P"0   %.D2\/=<_Q5U,_2@LT%_!QQSYM*XL$
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M\3,4XE$4XN%BWIC#BF9OA5UQ&N+6FTLS$=*.1@
M         *=(EX>ZY_BKJ9^E!9H+^#CCGS:5Q8(                1YNW^
M'_$_QAG;Z,_(P&8V5>#TPD,#
M"G2)>'NN?XJZF?I06:"_@XXY\VE<6"                $>;M_A_P 3_&&=
MOHS\C 9C95X/3"0P,                                    *=(EX>Z
MY_BKJ9^E!9H+^#CCGS:5Q8(                1YNW^'_$_QAG;Z,_(P&8V
M5>#TPD,#                                    "G2)>'NN?XJZF?I0
M6:"_@XXY\VE<6"                $>;M_A_P 3_&&=OHS\C 9C95X/3"0P
M,                                    *=(EX>ZY_BKJ9^E!9H+^#CC
MGS:5Q8(              !U-++\HN!/2B-3FZ:FA<B2E)SU3!++&A\=>DQ*L
MG50D.4-3P\HUQ)2I/OH>G,,(UT.)WU-+SMIMC;(1?N7E!QH5SKBX<EY$46I)
M;K]=%K@:GMN '%($>W'+D$@U5K3"Y!MJE2[+ER)%JH/R65E6L2IL;Y.4%:;F
M8_XO!Z8=^>NMXN?C)T%_3%7?_P C!AW6SO+1(FEM?H^ZMKZQO*),YM#RSKDK
MFTNK:M)T4(W!M<41IZ-<B5D&:'IE:4XT@\G?0PHS?3;&V0W(
M                      4Z1+P]US_%74S]*"S07\'''/FTKBP0
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MFRH-&S$_HDN1.:0PU&ZJ\=TF0Z:("\;GJ )FGFQ33SNE,ZXB-L1&Z9ZEPX(
M
M                                   17@-I\C[$@L+L!FI>DDC/.HE'
M)BU)7/D;.RG),VR=G1O:%.X%)>+JQ*4N)2KBBU9:96J3Z*-3-25)Y>-3=@Y;
MZHN4/O/4)\I&P_JJ 'JBY0^\]0GRD;#^JH _F9'R@QC.<T_0>,8QG.<YY(V%
MC&,8[<YSG/%3JQC&._D!\:.:<D'$A.I;ZNX[KTRO0TQ*H1\FYXJ(4ED[X*.,
M3FD<6-RSM"C=L%F[E[;:E[YQIOG&V<8 ?;ZHN4/O/4)\I&P_JJ 'JBY0^\]0
MGRD;#^JH >J+E#[SU"?*1L/ZJ@#0+EG)@TC"HJIN/IB7;3)FJDODM/\ <C;3
M'7U[X.UXK9+SICJSU[8VZL=6>WL :A<FY.FZ:F%5%0)A>W7G7<ODG8.^FV,9
MSC.==M>*N=<]6<9QGJSW\9P _?JBY0^\]0GRD;#^JH >J+E#[SU"?*1L/ZJ@
M!ZHN4/O/4)\I&P_JJ /GUEW);<DQ1I5''S8@G7NS3]>2\^V)*TR3HHQN89CB
MOG337*<PL_NMML8\Y,T-Z^XVUVR'T>J+E#[SU"?*1L/ZJ@!ZHN4/O/4)\I&P
M_JJ /QO)N3I6,;&5%0)>N=RR\;;\D[!TQDPTS4HK3&=N*N,9W--WT++UQ[;<
MS;737&=ML8R'[]47*'WGJ$^4C8?U5 #U1<H?>>H3Y2-A_54 /5%RA]YZA/E(
MV']50 ]47*'WGJ$^4C8?U5 #U1<H?>>H3Y2-A_54 /5%RA]YZA/E(V']50!H
MDRKDRITR8GJ7C\>7J8:5L83R5L W34T@S8D\K.VG%;;7!A)NFY1NF<]T69IM
MIOC&VN<8#^DRGDVI*+4)ZDX_J"#M-3"CB>2E@&E&E[8Z]=RS"^*VVF^FV.W7
M;7;.N<=N,@-7U1<H?>>H3Y2-A_54 ?*ME_)1M2G+G&JN/2!$FT\\4+%O)B>I
M4I&G7C7NSE!_%<LHK3NML:]UOOKCKSC'7UYP TS)KR/)/3I3:NX[%*5FNNR1
M,9R;G>AZK7;.<:[)R=N+&##]=LXSC7)6NV,YQG&,Y ::>=\B5BG9&DK3CDJ5
MZ=WW:5/R?G)ZG3SK/<F=T05Q9V-U\[V[-^O7'<9[-NK(#Z=I=R5TPJVWJGCW
MIJAU[I=MMR8GVN$>OG.%'=*LYXKXPGU\XVU/ZSNXQYSM@W_\,XV ?OU5\F//
MBT_W)N/WH@TG=041ZY:?^?&)R]B]-SRRO6K=WN3IN:5KN;KKG378PO7.V,[Z
MXR&MZHN4/O/4)\I&P_JJ -+64\F]S32-*DX_['DZE[G$Z\E+ V-*T.[OSG8T
MO'%;.Y>IOG9GG>V^,8W\[W[G.>YVZ@:2GDT;N8654G'\S<K/<FZ:<E; WW+V
MZ\X[DS77BMG.F>O7;'5MC&>O&<=_&0&KZHN4/O/4)\I&P_JJ 'JBY0^\]0GR
MD;#^JH >J+E#[SU"?*1L/ZJ@#2]57)KSWT/]R7C]Y_U=?G/KE; \]ZNKNNOS
MOUJW=]7<^VZ^Y[W;W@'ZTDW)TS&<EU%0)F-=]R]LZ<D[!VQJ87MG0S3.=>*N
M<8W+WUVTWUS[;7;&==L8SC. '[]47*'WGJ$^4C8?U5 #U1<H?>>H3Y2-A_54
M ?@N3<G32]#2JBH$THS34PLPODG8.Y9FF^,;:;Z;Z\5<Z[:;:YQMKMKG.-L9
MQG&<XR KHOGI6)?QZM>54_,>-L;=9'$/2/TQ7QJ^714R'^G\;9Y0D]!'NE%-
M"\SSI ])25/G[<G[E66?H5YZ3J6>:9U=<_5^]VU=BA0EZ'2?J4BA0D4D='@X
M&D*DAYJ54G-TX^XSH<G4D;EGD'%[=6Q9I)FAA>V,;:;:[8QG C;'ACO1W]9[
MQD]YF'?S97_O@W<RGJ\L_BT<^KK\D?@>L]XR>\S#OYLK_P!\#F4]7EG\3GU=
M?DC\$B:$B3G9G1*U5!R8\\S]=-.(<8C9T9;Y@UQ6129*[PI,WKVUJE<M;GV-
MIWU4WFJ"VK6:(541=7'T,US PB.+G143I;YU53V3-O%.I%IIXJ<J$R6:2&N(
M)+:?=XO7?+!UIIQ9S^/M/V+*[:E%:\9TE3:6I$Z<F\@H[;1]GE9N9!ZN*HX5
M$)&W0EM^ZE$VI"Y*5$W*O&S;LOMU1$SLF=?^^KL[><H1T@DGNF9$E;6I#:GD
MD_5)'56GL2N,Y(@[1S#IK9F70=Y)LE<X,Z9_XFZ6ZH-1Q>I*LDD>;E2>/R!]
MLJXTK1,-C&K\-79/IMMU>*Z3/%&O^3$-.EJ&YY?.7A([T]4_I2[S:4129J6N
MW4LQO]LGVS<G9CS-4Q*:O": .5$^<$QUZ7:'.91SA+EL_7J#&JW;K]'[VW**
M$Y(D\1>3E42VW][?M.R&KDP573@;J1'-4""QY-9CK7\7S(=B42EK[J.R2-L)
MN,X]*:\V3[,D45*HXPM2LX7UQ/5;R6NZJ549+'FB.1-:%\>;"A%>7);[58D/
MJ&$NG&IH<8%7<8QQH99; \L+[(YK3A;S;$AB]P6FEAVB"05_)61SDS+8$H@T
MNEJ).K,WUQ.^-M[]NO5KU:O]G8$)J.^$W'6B*Q*)?*Q,;[RDVLY1P(ZJ*RE3
M-QS,EELKXBC?-*E)::\:)LY1-76Y=BYII*EUUF2Y_<XCNDP7Z9IS$VU^#5MV
MZK^G:@Y:+US#X\U'$W.ZK'N+9*^4U$7.0G-5LTZS6&IY9;T%*E<G;([(7A_C
M\2,AS#9#,A<,U5&EIZ&;/QK.5 (;/XSI-6!89BTS;=NU3KB_9KO;?:^V\IRW
M#%^5;\Q5W(H$KL@UPCG$ZSC76,1B<PV!*I)R-?$U2M<(U?=I,G-+5NS0RJ;9
M<V9.Z$IX0GD!1&\C5-SEK&G!"8U6GKO&OLUW]';U;W0-;5GTA!AIRZ7R"TFU
M-#)M!%U>M"J<0-&1(8PHY',3G-B9HWFVM;CT]I$5"JY4T%-LTL>3+]T9NOH%
M0HFS9$S6<S/-W:]7;JFT]D?[]4.F([QWYT1V 69'6."SEIG%@5WKI)"E,TH1
M11\FU3=&+#:6(B26$E2U4E26/Z[*&P]-AW6Q5NAI<-BZS9/+2X4Y.#3(C-XO
MKUQ?5JGXU]?7J[]FV4HXN7S 9;(>+'/JODH5%R;\\]-J!RMNAIBV.]%H(5<L
M4;G"*+'B^5V,2R4V%)J_LR5L;NLK]@B,+8(W$8ND>Y%%9&ZSLG5UQ.KMVZM7
M?'5Y'3J6F.DA=:U7/3[.[@;+9S4BY(B8FJV*R3,FMAL?"*BS(B5DI&XY8S%*
MKFJV6H>\NYJG1._:F+T<F6JZ:=V]$M,^QOX^W9>;^2V[ROFMJL.=UA3NP"'.
M&W"X5.=9D?E6L=8K*J-,[+D53\]>-L\KAUK!_=[A:T#&XJ^-T7M:0(T"*OJ9
M7,.-4,7ETPLFV2F>8A^?W[?SY"\>3OIF_EZY\%H6E\=$-G-U0QQ);VSOZLRW
M6<;E)Y&XLKS+&Z$'SV3J*L9IJ\QQ6X,+S.V.KC8<SSIW:'1W0.DN0O2].\O!
M:C#FK,3;=V?O\KNX& !Y24OG$Z/F,R.-GDZW,WF,LSMMF9R;'7GU0N6,=F'7
M&,8QC&,8QC&,8QC&,8QC&,#WAR%Y!<B\_P C>2^=SG)C0N:S>:T'H['S.8QL
MA@8F-CXV)EL.K$Q<2NJB:JZZZIFJJJ9O,S>75FE]+:2P=*9_"PL[F,/#P\SB
MTT44XDQ333%4VIIC=$;H<?\ 5G-O_P"YG/\ KG)_^*CE?_1QR"_\HZ _JW+_
M -Q_._AO2W_B&:_YM3-\\STNST_=&O81KSZIYXJ)O6YT*9IS(3,R!W2ZQ"#F
M%1UG?'U[;"6Q2O-/.2MRE6_,Z%"L685'.3<7@U65XC_2EH_(Z*Y>\HM'Z-RN
M!DLEELQE*<#*Y;#IPL#!IKT=D\2J,/#IB*:8JQ*ZZYB(UU53.]VAH3%Q<?16
M1QL:NK$Q<3"JFO$KGG553&-B1>J=^J(CP19)2NZ.MG7BKR/A2'BY(*+L"^FE
MXQM4;,\<?V>JHBA9ZM9(FQ5W'W.O[BDWIL7*(Y'$\ D%I/:!KD,IEKLH?W>.
M0B (6%LCG ']:9UQKO$;]=Y[=T^"-5OK=SQRI+E;*,L=AK:*R"B-K"Y8UK+8
MC74>>*]C\CJR@G"VJ117@F0GQM[?H%'5LIAS'=5E&-L4>G)T)Q.C2&PO6>J,
MMA(O%^O5,3,[YUV]%K^1&>5I^4E"-S"]W%9-M&T\Y2F.-MB*EEU55'YBJ0-K
M_P M4,;:H?84HEL,C$"5J6 KBB[RQS>YK"T\U:V1X:3'F0VU)Y$PRPQ&O]WB
MW:^W9'DV=R(8?:EGT!T=]FVQ54CY%&Q:GH;);YIV1D5V3,W2TIE1\<3I[.=H
MS8SG J\>Y7 I29*4#O'URQA/;CIPZR"-MV[O'$#.>)M>==M<S%O#V>2?S$>8
MWT;L[M&02YML^.1*J*KD]1O$5BK2IAE8V7/J>C,MY*<G+!9*PJ.5^G[LAIJ:
M5565A0$A!)(8TRB%Q%Y-:F"M'AU::X9UP,S.RW7K[=41KZ[Z^W7KVILQ#C"M
MK^[.3UH5+65'5M+9VMJ_>M[">ZW8WE(I2IXPG367JJ;8/((;,4VSJYZJ<+,J
M'UEPZ.^Y#PH+>$Y1FIQ/C\74BS8/&:SWB[I=.(YQJ5D5TLD49=;=@:ASH[=!
M>:F)<H6*Q$CW!%"65-3I-RIA'UTOM28LW)0U ?$W=IBE;UHM2M[Y-D2LJ)U;
M?';9JM/X:NV9B]GWT1QYLMANNBLS#BH^P>/U<:Y3)%<K*^T/('<D]^:[7:*^
MHMT<ONQ9GL(I[C[65@I($LC-;0N2-4^L(K"IJ5-E?,3L[6B)G5MO?Q>.>N9Z
MYW;=>R?I=9W9KR=4VEO=!F]'F5\FCY--^DZ;N"Y*4I6[FK_1/H?N-=,F')W7
M#_JJR^&F%YCAJ?#(449DG=Z=Z+U5T[:$ Y*O5BK*:=SSDCSRJ43"UF9VJ_T;
M=D>O"[JPDM',:?T=.&V3KB*7K)G,CSMB>(8_F*(*ZV8Z]*DB62MY*\S?5;P:
MNJU[_7MU-?B)1%C5!8=^N&M?OT/C\\2/TD=7R>(^-RF8S&Y9#:%FRQT>(M.:
M086"6RN *4,E(=$Y][%XE#<<[,R1J2-:LF:(]!,ZHU]^RT=?C_VLCVOK?I :
MTJH^:[VC:9DN8:\PXRI9,K!@,G9&=<=P1LM;8S[Z2)2G9"J6(>8+;7!S(2WL
M[X@CQNANT+8BZM7RY*XF=4S&KR3\;?;;['Q]MW;5.OMS79Q_N[6K9-;R9 X\
MM:GC]7261657$MG+5Q^1K.,>MV*HS:T=D\V@LI1-*+:^L('5KF4U=LK4R^/%
MN#I,46S9J8G;&S5MU:IF.S5X]FN[A!U>]($Z6O*6E"JM^,U0Z2TIC6/"JS*\
M<7'>#L',OC^2SOD6DAMDKW)&HD7#]+=[BXE,=0UE)F8A=HP2616I<A;)+-GY
M_/E9U6_/5/IMMGP6AUU)J$YN9F2:6.L8N&2K8AI;#! Y975E44QV*<7A#9T:
MII]E\AD,Q8#Y"WZMNE8.,CU>#G%:O5_PL9'5I/F[(M$6MKF-O5/9LMLV3W>#
MM9G@/-G2;11E>XC:["2A?+JEDFLRJ[)J%HJ^42&7V79?W-61YKE9:3&\I8FV
M-KLUV5/90774DGSN@WA$12$K'4F<)&\Q%K3?;N],]O9$SUMC>8ITC=DLLP7$
MI[EJ-<S<=YV97[7]T:B4KL\\DH_3=/)ZYW=/4_,9DQ'Q]ZN1'92_9*^KRXJZ
M$)]]9N21%'PML<#/L>S;'7JB\WZMUHW[.MNTZ@W2 ,DXC##7_P!U9[A,/N)(
M\1^5KK*K]^].ZR57?#7*0LLX3N]FP![6><51I+DC2Y2]-;QA[8M,8&V Q:4M
MS/+#GY_/Y^MC5Y.WJGLW:NK7MO&MW1T>U;7]54,;(1:C'8L4B42H;CY#$$;L
MF9U[-3B;?BB&<M=K.-?*H#)Y64SU@9']:M9XXU.2]N[HUD5K"(ZWNQTD>9,9
MJF)G5;;.SJU6\>V_X64;=)W[N.[_ /RU\D, !*Z*\_ W6)\7:Y?1\P#-.V/#
M'>W ?H?F 'S<=[$>:GZ)ZF+"C9*0Z1QOBO!CX[EQ)W4-*20+8VW-;(Y/9)9I
M!AC TNBY(YOVI9Y!GI.D79T.*WQ@S7\[],]*?#/>Y"=S)L]JELKAZ:F6B4(F
M$RZ8[#7TN=SQZETVD%"RNJ8L_K)-!:NXYS-W8DLH360K>$F8*QSH]M51O<A2
MQI6=X,<XX9MV]75%KQ,[YCQ=?7&_DI%[7I(I/PR=5#)&:QBELW995=6G!%L<
MM-;*G-*S<>N05A1'=D>K=KBB9-&6TA\K%J=G;9=4GHQ[VW2(V9\*8B5ZB0F+
M1K[(B8V=<=5^OK1IMKDURBBYLR@^97%4$@*Y56) ")S&4D&@3)%8#$>'<5Y&
M,L/2NEOE3N/&/JA>Z.7IA(']J=%<M3,+^G;T%9-+N5(:V%MG@UWOUS%]7Y\.
M^;_&6YGZUS[&2O9ZAP2LVU4RJ*N:N.:11RUBMLTY"; )89"PEJU^&F1,,A<I
M(68UF+5JQLC2R+(G1S>G8E>]N0F+6_=USU;OWI5 P              #R:Y3
M_"R8?GA+/WB<A]'?T=?]@^2'_P >T5]TPG3FG/?C27RO&\Z6QCF;^4SC/,[3
M\7%NC0LJ3FHU3B5'+\NM^,;T.N-UJXMHA<#<-T:/3/7C=4JU3Y(3ZY[-CM],
M?QCY]?IA_P"\GE1\IR7_ .5D7<')_P!Y='_^S5]MBIQQ/FO;B0J"-3Q6<3G.
MKHPULCD,S;IS(T3FYV/:/&Z8\A6Y#%JYB%.3!:HA"!?%RX.D,;G:23<]J=T+
MNB89:_-AS7(^M']FU[[O+OB-NJ-_^T.5O_(_D&_U7$9\@B$9II2FY4\9ZTF+
M2_1J\'EQDE;V?>M0US(4T8Q=E*<:')C=W!+/EZ?>2%PR;,J!"WJ4[6HQ)%N%
ML4,VB]MNJ9W;HF=TSU-HNJ[.0<.GW(*,$R^.((['M^&KC#S(@R0ULF\2@]TW
M!:\ G1;&LME\4PV?6T\(H0W;QE$ZHDK1JJ<$K#&8%,).B)33D1:T:OC=>Z+Q
ML<LX<<B;*MU>V-]A%^?$R.F6^PV!3LBCZ=?IZ1W!:=6J'QQ4112LC9[?9L5C
M-?V%'\L2]V9-G)QFID<>%<3VCR5O$QO[;6O^,1.K\]<V @D
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?_FA7G?GOG7]\\[\]WB:[3,6V=O[EQ1>(F^WL_>__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g947560g17z07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g17z07.jpg
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MS*E3-U1'M<\%=/'-XA!_$,W &_V=03R89_A(X^"7V&SOA#][/W,>T_VZ:O\
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MV=*MM+$LK;?$PW3=S=078W.#CM(J-YSHJ6X4%3"G#68$)11EHB I)9X,(R_
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M!0&:1CW6H8\=T+^E)I5K?X7OR<:T]3NWUC<SN]7.[5Q\>U]GM3U?*_/<VZ*
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M&:1CW6H8\=T+^E)I5K?X7OR<:T]3NWUC<SN]7.[5Q\>U]GM3U?*_/<VZ* 4
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M$QS6]<2&,,=QZ*/%JQ?-=*K/');EP./+-[WQ-E5) H!0"@-3Z^^$Z6O(/O\
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M/=A!5NK>%/!2GHV;MA,*A H#2<HZTZY3@IIJU-4 0G+ZRBD,TM'5I1BIB/\
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MA0"@% * PGA_]]CQ&_K)JSZ#\ZPSYS\G!&:'-7EXLMFJI84!YR7&W\+=NO\
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M!0&:1CW6H8\=T+^E)I5K?X7OR<:T]3NWUC<SN]7.[5Q\>U]GM3U?*_/<VZ*
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M&9<'(3,(#,:V]-A,@0LQ1<PPLLKX89""98XVOGE>[EOH7F_['(L^B?TX_P#
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M78H!0"@.$<WZ..#Z$5?Z Q72:S=[FL'S)I7V"\'+N';URZW=O70/54U=]O\
MFS:Z]./<)B3GT7Z_R ;_ "^7JZN?\:_,HW:;U^/^O'JOSZ+]?3R^7JZN?\:
M6]OSMSOCR^7E:_/GT\N73_PZ_P#VT!U_.+I(7O0[)ZRR''LQ2/'DW#Q?(,=
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MIPGNO3G8U=T-;.IZ)]??CXO77M31_6+QZNR.OM7K0UV6)Z=3;"L2N5IJR";
MA>8[1Y,S1=DT3-@XYAA-7S?;>6F^C)12+HO:"/(T=XFV\IB-U1>)=7ES$L9,
M&#PC&'3SPH29\!K=H;3&E;M>K*W@],:(=_T/>KKH?1#N^B=,V2N-O8V]M:ST
MGI.]VVCM(.-XLU>;.YRL=%<J,8P5]C."=KW.CKU=;O.SE#_XUY_ WB%I>;QR
M[Q=I?A(2C&*L;"$;:RK%\EVB=O3'^KI+#?*;+FIZ7LYLT]F)-)%CLO8F)YXA
M-I+RHUYI,8Q8XEQDQW=.D]5,6;CI>8$:R<[@'VWFTDH&#I?[*:0P8#K;:<5R
M+!#]'::)UIM=6]7+E?M#SOM\U?TIH/3-[L+.\Z&C^-+O8WS2"M-&V<?Y1=;D
M](Z-NDKC>+Q:V[NMPOE[3=UO%I)2DN4KQ<(WZ_6ME>E96=[N]YNUG.5G>?ZB
M<K.QY-NVHSFK&VM(VL81AR[6SLW24%\4A!O'+#+G+;&;Y4CPR:4&8[';@,A+
M)X@82SCC+I2,EH0[K,)QS$,^2%=AU+,N3,NHAA*8=U7VJD"$?[(#Q^SU*T5?
M-"ZK:%T9I",;.^76ZM6]C"TC:PN\K6VM;>-UC:0_JYJZPM8W92LV[)_@OZMN
M');ZO2EXL[U?[U;V+;L[2TK"33BYJ,8Q=HTZ-.T<7.C2E\;XRK4ANYOT<<'T
M(J_T!BN;K-WN:P?,FE?8+P8[AV]<NMW;UT#U5M7>]FUU\141^8#?K\RC=IO6
M@% =?+C2M"2WB_(7NA0K##DCEE1NZGR]I;DW05"WI6&^E@S-!K2?C?;R2L%S
M.;/R:$3NYZSI=OIV.*W*X4:'VLWKV4B=S)07A3:W5M)).G2\<*4;HJUPK4LP
MX;AA=-Z+ZS&G*T2#%6C$;$ASC828I2H-1B.(JBI9E#*'$2,E(9&/D%7)7++2
M&V[I">?))*@3[;%L%7,[S%99O?3.N7AJ^)-VA H!0%:/&2\%COCY-\A?=MJ%
MH<^/C1XHFK ?<+A;Q31SYGHU")9O>^)MFA H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% 43<3+2#B6;B2@8;<4SGK^F:8F6DB%3\&/HTI-)SN%YX6.
MX.)27WN@Z^R4[ 4,V ,7 ($VP]FX9PMB()EF7$MS%%XN"6/*Y5<&MB\ZQSSJ
MB;'#/U)4M)]74B"55@0W'!E*=SG7K($&OF8Y#99C!<R("761W'.5_P M<G I
MC%QA58B$&7;Y.^!?%'+ !9"AXB)OE2;JWEBTDWY%@6 T*B@% 8'*?<PD?ZAN
M_P WE&A,<UO7$KSX)W@H]%O$2@_>*K0M:<^6\M(H4% * 4 H!0"@% * 4!7[
MM?PN-'-W9"0I4V8AQ2D!^-MFDX_1UU/EF:(^N6:*>MKKC)I J=&LAM!*.V 6
M7*MG,3IXB94+W.W R-Y%@"P(/8:/TOI71,K66B])Z0T;*V48VTM'WV\W.5K&
M#;A&U=WM;-VB@Y2<5-M1<FU2K,=K8V-LHQMK&RME%MQ5K90M%%M)-Q4XRHVD
MDZ4K1$8O[/EPE?V9W+_F9VO]>%=G_/'6[\Z=8_\ ?-)_Q1A_D-Q_P5S_ &6P
M_=C^SY<)7]F=R_YF=K_7A3^>.MWYTZQ_[YI/^*'\AN/^"N?[+8?NS3D'\!SA
M:/!K.E2<6NKE4#B;,D[-0D-^<AM&4]Q069,;W:K;(^YDIH+!"=KD%'3B/90N
M&9PWV/V2>,&38HPXC^>&MWYTZQ_[YI/^*'\AN/\ @KG^RV'[LW'_ &?+A*_L
MSN7_ #,[7^O"G\\=;OSIUC_WS2?\4/Y#<?\ !7/]EL/W9_ GL>[A)"AYA"ZR
M.(4(7#(,0,39?:W,,0//&^.>&>&4WWQSPSQO?'+'*U\<L;WM>U[7JEIK;K5:
MV<[*UUFU@M;*UA*SM+.TTSI*=G:6<XN,X3A*\N,X3BW&49)QE%M--,E7*Y1:
ME&YW2,HM.,E=K!--.J::LZIIXIK%,N%:S91&6V&XSFT2[7-QIH*0V4!/[(-'
M.P$1!3RZ6E$NRSPYDZ:[%(E0 .R#ADP:']S]U,#BC99B9?/G).=H!0'6%XR.
MS# %G>";L'9O75W*.N3Z;AV0M9G%OBCZH.-IR8TYT@^3KO)QE!%,!%?5U2*6
M-)$-B-Y[6R&8-Y-L^FPBK:H"8*AC)!-I_%ECDU'E*E&GCLHZ-4VK'8U=9P[@
M%PMI%K07<DL-V<5D&+T<,U)[2>QN2FVX@\1C=B8"/(JC:RD_23<(]C-;!YJ>
M.*FY\D7);4<,#IX?&PH\WA3')JGHV;B9U"!0"@*T>,EX+'?'R;Y"^[;4+0Y\
M?&CQ1-6 ^X7"WBFCGS/1J$2S>]\3;-"!0"@% * 4 H!0"@% * 4 H!0"@% *
M 4 H!0"@% * 4 H!0"@% 8'*?<PD?ZAN_P WE&A,<UO7$KSX)W@H]%O$2@_>
M*K0M:<^6\M(H4% * 4 H!0"@% * 4 H#A7$XD-I(BBXW*J%$5"2"_92FJ'Q/
M<2A(O;/ .XPXG*_M,/;B88\^5^G*U :4_.QUN_WRL;_]VQ__ ,Z T;K]LM J
M"T'>46I2:B4:-SEL.M%2Z@=$*#&$A?G%_+2&I@AC X9"$59(/DE-.,XVN";(
MFBYD#/,(7#*X$HF3.$1R0KC(+$D%MNI9+D!E09.2#UC)H)/+CEBPQS,.V./(
M (P<*A9Y\^C,<.W_ &J VK0"@% * Z;O$&A'8F0MS)L5(+X<^Q&O!G-[6#-[
MO:SI[ZEE[S< 7+$\AW:+$5]D=985.8G[XV)V"?Q&1LL\"^>8HE\L_BC(G%12
M;Y73%K!=%)4;5:UPIT9G:&TQ(NM,U8@Y.?(TFF'<18B:5<!B96,RHTE$=1 %
M,!C#/5AQTK+S);"T);'',5-;ZVJD\ ;@BB'S1H4P-D*.E72E/!6GIQ).4(%
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MN%O%-'/F>C4(EF][XFV:$"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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MCTO[2GX6U_OR\Y]4%05"L,[YZY&(CB>.XQ'<41;-EE\5A,Y!:@BT73O>:&(
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MI)CQMLAK2,MRLT7,UU:9$!.?R)F[HU)IQ9<4EMM9(+S1C;?"74O)L''@<9.
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M\PY[_E>//6E0#X9S5[YASW_*\>>M*@'PSFKWS#GO^5X\]:5 /AG-7OF'/?\
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# __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g947560g20b36.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g20b36.jpg
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M:?:F\6Z(<N5)VH05 R$KB=I,X! CWF>LTCP'JMPZA_4'DV3*5;DL AQU29!
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M/&0U;&+)B.3]X28[\2G1IJ\H'LAQPHCB,,C=@R=M@I8!'I=DF1R2D1WDF/\
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MN[N/?A5YY\_;[_W_ &^VN&XYQ71CF(@?.!$ 3R09X^^<@C:8D='*GA../O\
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M:B-]RA24)D^E 6E2]PYW$H"4F1Z>F0:K+U,8GCF6[C]+V,9=C]/DV.Y)O-:
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M",&3]3 6 C7,431]:G6.B(*]CEC37$:N_"M/(CC,]U+*D-+)QR0@I>/EK)0
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M[_?_ &KV"#UAQS1T/8=-5K'29C#93A4^Z./F= ;7D;F98['WN3,;,+:((V,
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MI4^T$NVL*&DGWU.S'KV;45LNZH!V0;AE';28836-.RWC!CQ[5E9,>:$VR!'
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M?C/%K[()*=/8;MH!G.7%D#YK /&$@GW^@/ -H&- 9<*0%73BGN,E.$IDS)
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MUQGK7O:1!P"))B>A/6#T)(4#UG$]<R!BJJ\MY1/*<*G\7"?G_;_GQ[><)U1
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M-B-AEORHZ'95A2!,,XXLR'ZJBENU'A?4;ZW7;Z<L*#3S3A9E.4N%+IZX"IX
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MTI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E?"JB>57CW_R]_\
MG\O/MJDC[=\?7Y>_%/YXXFH"W,ZA,4V\A,GQX4W,(@K>106\C&CU\N+0W(6Q
M%'57!G2VNB6$I9@DBQ4&][U0G>H^Q$=J+[5V+-KSD@7*$N!IPL+0H-KQZ29(
M"LX!B>/GL+33W;I>PGR24;T>8A7K&8*8&03@G@1\R.>T;?"UW_L<]I\A("!4
MV,NCLL8A7L>JMX&-B$?YBH2KI$<A#6-K423EFWIY;"!*K6#B-:K6-YO3[I[Q
M&+Y+@"&@N&_-3N9MP#M"6T2-[BH,N*B"82)K=75FWI!LU!"5O(]2W6BX@NR-
MQW**2!L'  ()',$Q!]Q#S'%+0]]@$"5E=CA-S/Q+, D@2)YHK31X=U2SZ5];
M!^;@U@8,Z?7*U(=F2%+).9)D'0[I.N4;NT>&M=NT.M6]RG:%)<V[2@[-R2 ,
M[HP J!R,&*WBK<:M8- *-N52X-JI4H3RLI&8!'I  @R2(%9L]IC.[&.Y9>Y
M6:*CE1\6A@@5LBOCW%3G-$*_%D4@AY<<\20XM=80ZIT>1',EA&:K?1$L=KV4
MU]U&J:A97%GM1OLV7EJR@;W-Z2%;,^E20D8R3)$#$^B6+J656JUY#RH4O_)
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M&%A8CY'RYVN>)ZE(YXW+KRFQ\1MOBZ\U)'D>:XVI:T-PR%83M4=Z^J@I*3/
MFO3KW17$+MRV4 O!E)"=RI4I)28Z2%8C=P(/-="MM-W\$W7HX]YB%[ LQO%&
M2='C2&F+5SC102BULSA$[9<;UD&5O''<U>/;6_LKUB_92_;K2XA0$J292%$
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MY+MR7:VRD6,QSBFM,!AS'"QXM$:$"'#6U8,95B2G2D!)+/1K7&D"F>@ 0"#
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M8V*SU@JY$?W/0;1^$1WID5'*]/;Z.WAONCO*M2SYS/\ 7]3GY5,0E4$J2G$
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M7D<1 QSF3WZ)R_N;.Q;9#JC?7(#SBB0K\(V20A&02'%I3O)!"@E:2-M;3<W
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M=M:+)?9M$)0&P!#;I!+;:B,D-I.]>1*@,Q*:QO(M0^MP$!3B@H@<R@"0)X!
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M.QS\3BS1DA'MFR 5MJ\0Y<APE.]-<8WJ.M:47;%MQUC\*=CB$@@#8LJ!]1)
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MO#DN'"JV6P^]?H4T>YKRHJ(CE:Q[>]$<O"W6S89NGV3 0"M$Y]:73O0H&3M
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M=H)4ZRD^H\2$G!(X ,X%5_W,W=)T>Y,>YM:>5=PLZG3L;RK;Y@@2SW4HL<I
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MD5",:K7(G#W-E<,*5YS:VB/W7&ELGM^5:4R)Q*=R>FXD$#8"XVDB%I@P1M4
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MT;V6UI "RG@U\EIIX9$1AI$8[C,%YWXCUERXLXM%!5F?*<_\,\5J2T[#BE7
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MU458VO%OAIQ)6-8M_3$ N*3(.!'I^4#$$"/;87'P=^)MNK8YX.OEB)"VTM.
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M$-M9*W09C>X<CA0!@@9JA-),%O)U 6F9=WSVV/3<^108Q)[E6MO]T+!A%O\
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M;@838'Z>]PQ1S18LB.#',ABQY5GBXI@G!FUU<:6$EK1&]%Q!0#-?*AP2(Q\
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MV+'U_KMCPD66P@A,.0!Q,Q6_%*;E\6UM:*#Z7/+=#[R&FD*Q.UP(7YA2#.T
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M>(;-SS2O<VEG+SD!QMJ2  I:3^](((3 '.<5KEZ-=I*!^S)<_P ,!>5 S'0
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MI!4#*2E0(.Z!CF(KP,ZZA3*BZOJ[&Z1T6NG1"0*F5?3$O+2A&YS;:6UD>E-
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M&M-&B11QY149)E2P.,]8RJT+GR10ZVWB078<4TPAM ;662\^E)=>;!*T!0]
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M%O;,-..I"%O/(9EQ14VCT@J<24F%(*CM"C@Q(P:B4N^>2SLKMPY=;LS*# I
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M.>==7+EZ%A#UW= BWPE32W'?+(&T8#9A9CYD0:RDVP8L@LK2XVPD)'4N)X)
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M8=/$G19M?)*LR8\A_E)$!@G'.4*,EM;IA@/H?2P\G;Y3*U[AZPI0+B$\^6L
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MU? ^LW"G75(GTI! ' P,' $GJ#R#)YXO4E?$1O8@&(WCCM1$XX_+^6MM '
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M+MA6L+5:MA0;L_PMR^0/+2^'E*@QRLIV@J@J.!7H&@6UT+!"EA>PNE;9DX1
M)2F8@'. 8SUG-2,;Q_)\JV^RX0%%,^0I*:CJY_?$C3,J9&NL5NAU%<,B\S;B
MKQR+=5<IP>ULAUQ'!&5I+,\<&LU35$735@E+$/V@>\Y<>@-);2TV7!@E0*=P
M)_>S&9K8V=DZTZ^M.[RG1O:3T94J275#(VJ),<"#TS6'V_HLBS&@S6'!?!($
M6,2H]'<&="AE/-LY<>5&Q4:S$:.3=Q0 DMBJK4;'ASX0I+0O/W'K>:FE^QL6
M/(:5<VMR%J<2A.;0-*+9<,2I(\Q/I)B #&*M9L7$7+RT!Q;;B2I8W$[70#M
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M&XQBM'N1+LPUMG6XW5R<F4"F87&+8Y+4E(Y92L0-M2O2=#Q:<+M[?GV!"HI
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M*=KA-_><-7+1XML#^;S /_0/M[_/ ^F1"O07A(2II4$\N'/0$C$>\<< \BI
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M[SF09BF].99$/J@PG'<8BG;2[/7UHRJ;>%>U<NR5\ZEF7)[ P6C;Z4CDT.K
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MU:V8WI<L'EJO$E!"4E*UD*2Z.H0 3S!..]1L7S[]@ZT1M<02,XW$<$2).(F
M3@1%>?<.PR_/^F/&JD8X#[%V<5])DMT,4F+.OH.-T\2]P^%=,+WAC2FV<6:V
MQ9Z 7RI%'"G'9Z[3*^.[%O8ZTVMBX#ULE"+ME,#:E2EKW)^0$B)P(&*M;>N+
MFP4VZI04A7D)3F2G@J Y($C(^L\UL>2X9FVZ/3/&Q1I+^>#;G-:"3/C%B+,L
M*F ^DFNKX<UT9"%LX-!*'!FPV(:2V+5707,>&(,+8\=]=65KK-O?::2V'F=Q
M:D$!?_FI5G&_CI\Y$58PBX7;+M[DY3+4@$$I(_9E,Q.WJ9/TFMI@].60[E[
MX793(L62S;[*,IA8U')92 1;C%\B#C;[-U)(.B)&?'R6D_W ,@X&!*DU8\MJ
M- \N%=W[:M15=VS190\!@80T\A(7YB3!!6"02D$>P,U(VUL9\A:O,4!(2>B8
M.5 00%"2)B<5/NW>RN-9UT^W%C:VDTU=#S!+#'"C+%9;X_+I:P-1(99ND1B
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M5NNH&BS*^Z<\%S2S?@+*^L(.3/@,/EV*QKV&5TJ@;;N1?DIS8!0L$4,<<J-
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M" ,C!G*M)(M1M5%([UO38UXSH-KLAJX*'$D$9C.('W(^QGVYQ%;NK;N&U%9
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M!ID/(RI\[FD.K05H=0HIP%)2P5^61SP.8ZD'@"KKG:T@J4@%;92L P2A;B@
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M$%XE1I'J+$G":KQ1S(Q!/2+,J_F;+AQXK:WF6D)"&ED'S%%)*I<,25IR K,
MI@YJ:R2RA"VD!2?,)*PHRG<1^X.A'()B!(!Q4);2VN1[.;J9#$P\SNZJF-..
MG(94B9!BT]C+"NA%<Y'#;+C0I:1HTP@G-9*"5AFDC%,U<U#K@2EUI6US'J(D
M8Q!P9!S/(B>2,:YYMOS%,+ +6_@2)$DPDB""#$9DX$P3/02QK\?W)QMFX>!\
M@07=^-52#0<_'[!KG_.,+%<[O'$0RD!+BD>\<,_K=Q$AR)%H2RXMT/-FZM&U
M) /_ #END9#A_,XR9]+"B"0)!2=Q( @F2VN"RK\+<D.E:CY+JI*5-\!*N@=
M@1@'!!F0* [I[Q[D=/&34VW^U)(,5=RH$^SL,,LX3K.LQ4Z2@)#R;&H?K";
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M9?6]$S' 5.SER)Z;D>-51ZZJ(',B8Z$1'OVDQ]N:R[2X\J0M *DX&])*!'/
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M)Q_=QOK4R-L_NS[F.>W7^/$ 5W=TG:VS'5+?7N!Q$=#[_:9[@:RJPZ_)G_\
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M1S2TCRHS1Q3.=*:R9U*+>V*$J#CERTIH%!!2EQ;B51)C  ]1@XD15BH6\AQ
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MDY& -HY.[(-1[N/U&87_ +=-L8?X=E$^NP?>*189;D$^I%!0M<RDL\;D%DL
M2/)0A;F;%?\ ,#@N&"LBF(3O>YJZI:MI0RIYQ0A*4%"$F2H[PLIB!"HR<\ 9
M,U=<*#@;#>/,;V)"LH05(W I29D0=RIB%J( .*F7?SJ,V_J-ZJBNG+:V4B!N
M?B,N_B1(W>RCKXD2S98-FS0@C,:D,M@%IUB2K0[?6*YKT:+L2D+>7=7*4CRP
MYY_J(!*$.MD@#B2!A,CM,BJ)"4VUNPIP;DMK0H@0DJ4 ,9X)@Q'3$Q4>=:F_
M.+GR2WQBK_$;2_'GNW4ZSK(T-93J:KH;2)>W8"'$*& TD,<:!$./.L"K)DHB
M*UHG#9.PVFY??N)\IIU3[C94208:4$A4 E.X@!/7J35A<;:MK9I"PIQ&U"B
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MVDVBT$X;NG$>\DE4_(B ,YC'05 ^27@<MZ@>F: -&.BR,KQK)BL ]%&XE@6
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MY3VRG,DM5_"]YGKWJJKW$CO,21)/^Y'0_P @>L*W]H*4-E2T]4C=/'7/>.!
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M:BV0II+;:AP4VR,=#TR""1!'\<?=(Z"4#''%C"@A$)C1B8QLV.J-8U$:G(I
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M>TC6GC2&$"5K2,81J$8Y$>QKD1'-144KV:4II2FE*:4II2OY<G+5_E_S]_\
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MYK:=E\9QVKR7>J764%1#DGV^P=Q5BP*4+'+8W^519[/3<84)HYL:#%%-&UZ
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MN@TG5;AM]MM3A+;JDI,CF4@_O@[=I)$ YZG@CK1M-/QFRQJ-+QP$8 2#8Y6
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MG"*B9-V0K4+R<I#K))QA0)1 ]O1C'))QS45N@(TRWP KRP3VDN!23[R"9GH
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M:V.UB*UG8TSD];CN<KG)PK415O2F9R)C@Y[1_OTZ9R!F)LU/H<6IV$22(@=
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M8^3XZ"S4@! 82XH)<:UB*%I.Z,5CB.:_Z4R6;%A3BPZZI]QLI\P*43M*D[D
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M8ZWE-O*:#B86M>Z2 3M$ $D3B (D#J>:Z0=->"NV\I=U*J2K&%D8=BLPB.?
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M4Z^%(KD5G$CH'X"S!R/Q5P!P8R%=?<GDCIP*MM0?QUW&!^&9GD3)5W[DD\P
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M$LSY54'^%_A1Y#G#4+40R]BZF]:>4_:M!A]3PMTLOA+"]OF,*4VV 01D(@3
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M_J-=&EQE8Q8XF,4N7O4H05%2<  Y VX$3,''(R>M<]YSRRI06H-H.029B/\
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M:+M/CV]LK-\UR?*JF@EW-U97%A=S)-0 84MWVA9DZ3'CHQ@"NC!(HPB,U1(
M3&J,9E^9UT%JQ;VUL+4-(<:2G:J4@^8H ["J!!,D;3F"?G6IO?$+ZEAU*@EQ
M1/I' *HD@3R9YP9B>*N#59[O]M-;6MOB55@=[&RJMCU=WCUS43@UA2P\KS2%
M4]DFHL*^Q<>-+K Q1D>485A%"^1$DS1*0NIU/0[._(4"JR(2 H6Z4CS4).XI
M6F E0ZG<"!$CBI-.\87=O =2ET()4@J)*DSU229ZYC@34"8-U+]8V/;CYCDL
M?#MO[.KRZDQ^-*Q"=3W+,>BU81OL<>C5TJ+;BN6G')MIAC.E6<QI'37(59*
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MHCD&CCJ(@%<8(V#3@/:H3*JC.JL5O#8<*$]",]?:#&.I,=:R'5.MRM;1]2R
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M@<GF#!YY'UG.!VJ&XT4L*2NT="@@ J22#/<<@R8R#'>,5,6TN:[3W-JDZAW
M@39[1O"REG(E39!4OAZ284QXSN>Q$5J(@FM[_J7VU$H&"""?D)S].L_(=.]8
M=^[<!(;=MU)P/4I*DI)R)!( (]Y,Q(]YFQ.WC66Z>0W$60"4+$*>%CP% 5IF
MBLKEZ6]FQZM54&8<6+4*WQWJ.4O*HBHBQ02>".!G[<D?UTK6M*6TK=M7QR ?
MN,3B01&.]8#/L_O*S(G@!%C()&L,P\D+B/D>JG+_ $WHK58QB_NW(Q557(JJ
MOE$2_:-I!S]N2!QQSC'6MG;V;=R@K4X=RU$D1$ "9/88$>\@S63;,996VUUH
M6*D19-X^7*"K?/;"J+8XFI]**X7S'!1]WE4?W*OE>8RB(.#S'\9^O]'-:]4-
MNE(45H;4($$D&3$P,1D_*O;N)NE6'R<\,E?*EB@$?')(%)=&09'"< WHL8J/
M(K&$>QKW$&J.17#<BJUR5B9)$#GY\=3B>LQF2>PK9FW>?"G$K*04))XDB3T^
MA^0&36/SYL,^%DN8L?U%BDJKJ.X36B/VQ[.!9*J$5.6O>X(RE15^IPT5ZK[J
M(C&>!/S_ -I'W]ZU"O,;5LW%6TS,=(Q]CB?I\I)W M[6UHW%I>YUD.((8>U4
M:1&<L:3TN5[?407=Z:^%[N.$\)HF J3C '2.N?KU/!!F:RP^AQ]D/+(2$@$?
MZS$8_K-05C"66.EFWV86:4U&&(=T\EY/:()^4^HA4DF[&-$B*\A7\(B(K>5Y
M7FY4=3@_(F.<8G)$<Q_+(OE6ZVVVV$DJW 8$F.A[]\XYCY<Z<V^(Y58?E><;
M1;+8"7=W\,D(?%,NA6<=F'0I=@I#6-7-7Y<YI$>GE*XH9$#U0%:98C7 0"DU
M<VTXZH)0"M4X1&5#G@23,GH<]:R[;0WW&T7+CIM$*E3O*=J4Y),\& 8!B3$3
M5>:#IXW]ZO,NBYIO[DLVX@!DH>IP^#ZL3$:(2K]+(M:URQW/1B-:Z6=32RIR
MU\A&<#3K=,\-*=V.W8*42"&B" 0)PJ1/U/OP<BU_6;'3$J:TU"5/D0Y=$!9<
M,@3 ),G/'>9,2>O^SW3-@>V%9"8R!!:6,-C6J@!HP:L3C@;..%1.$5%7^?8J
M^==Q;VK5JA*&&PF$Y(SCY@=>>9)]P(Y)^\?NW%/.NK)DD%9W%),P1T2!)PK&
M>*UOJZW2K<;VVD;88LUBYAN>H<5JHH7JV8VOFR ALYI6C5"!AI&4D57O5K>T
MQ2HQ11I"MY/QC?[+(:6V4O7NJ*%LVP""4MJ*?.<6@'<E"4YW$ 28)KV'X,>'
MR]K-SXOOFT,^'?"%G<:I=WMTB&G[NT;4Y9VZ2H +6[<;-H020I(XP:Q>S$/T
M9<2O"0AXE)60:H!.Y[VJ.OBBB,5JN<JM:K!-X153A%X5?===#IC";:VMK=N2
MEAEMD$",-H2D 8,@1 /7WS/F.OW[FI:AJ&HNJ"G;Z\N;IR!G<^\IQ0@Y*05>
MF( $"8BK-SK>/!;V-<AC*G@3%\HOV[U7PWE4Y[?*\<K]_&XXB<3Q/4]AW-<X
M42)$C$D'IC,GI[DX^51CD>;5M:(DB[MXT$+.7- XS6\<?F+GN<Y.U>5<BJJ^
MWVTWH&.5=1.?] 9CZ<U($$@ )D&)B8[X(_UP!Q5/MRNMK:S!2&ABLXDZ>QKD
M2.PCI,E7(JHBI!A,/*5%5/#GC:GE>Y??46]QR PA3X) "MN))@#=!2#)CI!(
M)J\MH;(\YU#)Y("A@1), E7$3$S'&15*LK^(1FEZ8L3#<9LR]ZJP2E>*N81%
M3Z7"'&%:3RIRJ<(:+&<Y/'#?&K7T.,(+M]>V=DU&%7-PI"1P#(W)03'<\^U6
M(O;5U91:,7-ZZDY\A"E D8@DI)$^P_0U'1=X.K7+7>K6XS8L&9ZJSOK;@R(B
MIW>#R;&O&O"+RKO08G/LU/*:YB[\7^";%2D7GBVSW)D*1:N)=,YZ-A:LR<9S
M )F*WEOHGBN\ 79^%[C8<!RX!2".D I1F8,SD3C@C^6V?6:UR2'4TY6(B+V+
M7,5JIX\?3<H7VY]B_?Q[>-9_]H_PUF!XI4.@3Y*NO?\ 98 (F>QR>:V1\'^/
M )'AQ,#(B,YX_P 3^'6OOC]174Q@1&OR/%K#TAJBD*@[FL&C&N555#%2\CJJ
MHBJB*UB*J<]W'OOM/\0>%]6(&F>*].?42=K#SJ4.D]IE('0$1,S6EO+#7+ '
M^\?#-XR!(+C5NZ4E.?5*4GWX4(Q,8)L!M[\1"$YX(V8Q9-:Y'(,BVH.0JY>$
M5&64%906HG*_7.;7HGNJM36]+-\TG>IDNLGAQAWSFE#@%*020GYC)X ZZUNX
MT^X4$AXVCJ>C[:@5J!R L[HCW XR,5<>@WAVWW$@J^LF50%MU<\KE2&:+.*5
MB,>]TD*.%*>YC6L<KWO=VHC7>.-8:D6SVY(98!68<2MJ7 2<E25 D2>N1T,B
M*VJ;G464H6W>77E-A'X9UFZ?"&5^8H$L>6M*=\<X ZQ%1_GO3M19;%+*CU-:
MPBKZH9M2"/&(CVIR,B_+C^7,]OT]JE 5S4:G8]CFHJ<_JOA+2]122+5##X!F
MXLYMK@&,$EL)02.1((F9$5Z)X7^,'C/PTZWLU>YO+#TMNZ?K#KNH6C[!*8:#
M5PXX %#"RC(!)BHFH=V]\>F^P9!N"V&X&WX2L&V%;RBOLZZ+X:@ZRYFD*6.\
M+4X9!MSR*TK6-9%M(/*1V<G^/\2^#WXN"_K&DK*4APC=<,M2$[5*C.T*@'GB
M"20*]@1HGPR^-%D5Z2+/P1XT2F5V>X-:5J*QZE*2W*6DN+4)"FBA:5$%QM9!
M-6NK>O39<U4V9/#FT.=VIWU'[(6LF6CUX549(AM/6$8U>>",L%&J<\+QK?-_
M$?PTM!*WGVUI]*6U,J2ZG!)202DE,^\\8ZUP;_\ 9H^)J;M=NFTM+AO<2BY1
MJ+1MR)])2%J3N!2J=P3(B)]5:[+^(AM8,Y!1,'W.L0-7A)#*O&8;7IQ[H&PR
MJ+);YY1$(%BJJ*O"IJ!7Q+T3<=K-ZI/ +5N2#[JG=&9B(GG-;=K^RSX\VH6_
M?>'VE*&U3;EX-X)X]>\I!!QCB<BJD=3>[NS.^M537%-^*8YE37DQRPH<JK&5
MTNVHKUS8Z+"FQI$ZIL'UEI\E-:.-8%,,2R7-9PY4UQ/C76=#\2Z>F[LUEK4+
M%8VAX);?6TI0E"(B0%$*@ J$DGO7M7P0\#^/OA9XC?TW5[9N[\/ZRPM:+JP=
M%U;LWMJDK2EU8)+1>9*VL0E14$JZ3)O0)N;,+3BQ&WDO?-HI<FB,A7_5W5Q/
M1 YR*ON2+Z)%5/=7KX]M=WX!U8WVD6_F%2WF5.,+).Y1( !)(YR#'TC-?.O]
MH#PFCPQX^U5NV0&K+45)U*T1MVI2U>H4LC$I 0N4J*24@S)FNM;5:]B*GEKD
M1?[%UZ%T_K^(KP'@]H/VJ'=Y=L*K<G"KNCE@$DJ3",L"4HVN)$L L4D"6Q51
M?KCRFB)PB_4U%8JJCE36IUG3&-4T^ZM'&TP^S!.W(=0D[% 03A4&1C!KL/!G
MB>]\*^)M'URS>4P[8W;+BU(,./,$H1<MK(,>4ZP%)*#).Z,DQ7YZI1+$\RDP
M*YF$6HCY#;0 PE<1&UF.U<\=C?5K$)VKS+N&BHD=V)Z42(,2(C6N1?G33$7F
MK:GIVCWCA<MM)=6K:9GRV72IP&8@J4D!(/3OT_2#Q=<Z+X(\(>)_'FD6S=IK
M/BVVLRAY)0%)N[ZU0TPH#J6FG%W3@$RZH*/-==NE#"F?O\C)&:SYE6N$K6HG
M:Q5_=M;PWPU&HG"<>WA$3C7T)IEN-B5[0G*ML=&P1Y8*>A QF"(Q/7\U=8NE
M+<62X7%J6I2U*B5K65;U>H?O+25$D2,3R*M#OMPFVE\B(C>(JIPGG_A=_P".
MMR]_AJ^:?OG_ 'K16\EP3U!/Z*Z?2?UJ6.A'_P"=H/\ ]SC_ /Q2:\Q'^(]_
MZG/_ .+7JKWY6?\ ^FU__"KHUJZH:Y?;D_"@Z>LBVCZ@ML]K\HWNVFD;\X-O
M_C!AOZB.I3<#:#%\@ZBX68_MUF$;IMR7>P6S-A(/D6<7V7-JA8[4 %D$LEG6
M2JBS0-@!5P69!P8(Z"?3$"8GI'-2CC?PU^D+'PA)*V^R#++Q;W*LEM,KSG=?
M=_-\KO;;,]B;CIGNQW62Y?GMYD%K1 V.O[7;W&L9LK2918?4R&2\:A5EV$=L
MBJ%1,9X$" !&9Z1US/-9;$?AW])F%UM95U>WU]8BJLCV%RP$K*MT=U,QLSWW
M3) /5;)2K"SRC,[:;8QL*JY#ZT=5,,:HN*]D>%?0+.+%C!$IN/?OT'7)_K[5
M].#_  Z>DW;RIQR@QS",Q)0X7G&"Y]@='D.].]674^W]KMC5Y72[?4^!U>5;
M@W$+#\(Q*KS?)X51@./@@8:P%B)DBE.VKITKU"2>?]_J>OUK 4OPP.BS'+O:
M^\H=LLEJ"[/5W3]7814U^\N]<7%V.Z6)I)NP-MD^(AW"9C.>9%MLIY4.GR+.
M*K(;J35S)=9;3;""=X%57<K.>9G _>YZ=?\ M6PUWPYNCRJQ^DQ:!M0<%'CN
M"["[;4\-<_W)*L3#.F7>BRZA-E*A9)<O?*D.P_=NWL,I)823FL\C8=*+*)EU
MC@@U(U4W'O\ YNW[P@_<?;I5WM*I32E-*4TI15X157V3RNE*BD>^&U)MV)VQ
MH,WI2[L5F*CS:PPAI#_B\3%RR!1F6QNX"1$$I#@<H$E++: X)3HZ1BC*YTF1
M]Q/SB9CWB.E;-6BZNC1T>(%:==)T5R\5I[>IELBT5>H1YJ[<.\>8EOUD'$$9
M]29Y"2>N/'\SZJKWI]P>E;:8#'/N;:YEO3+O8]=CL6X@6A#5M!AD5H#NR=Y2
M648EC=NDU]7%&2/^&DM4D,*W47+)\Q;IF),0)QG,CZ_+B)KCKIAQ'GND*(6^
M%H2,RG GL)Y'^]2-0@Q>KO8]E(W Q58T0Z&&H+<"29''<B,*Q[VL&CN>"KWE
M141S4\.1R8)5D2([]QD?6<=8[0.31ZY\RV+(MES$2&U>H1!,P1GGG_;Z<5W8
MV[RV%O!0XWN5BKYL7.S0K!HKR&CHQG4..E0)589"( [1D#\P)'#4@SB5_JB*
M-M !,SQT$]^![_U(S&.PA]AQLN-%39 2?2HDCM $@F>>!-:_(W"Q_:#%LMSF
MSR.CN%J*8_X;B]3>PC3LDO)!0QJ*FA]Q6B9.N+<T.J@N)X;(GL<;L$URZD3!
M5!20#[2,# ./D8^>:R+K;<E"&V5ID$E7EK](1*IDI$F$D0)GCM6T;=;WX3(S
M[,**TSO!1YU%PS;R9E%149!'+$C3Y$>Y99)5OEE')E0 3W/8)Y&+('%+#)+8
M-TEG=&I)"HVF/D1P!W'S^?O6 6+EI(<2VYY:B4[MB@#()C(!).,CI !B*_K)
M@XM<WIK&-N!BK(\IPWE23; ]>.K>U%02,>YI&)PKV(KA<+]/M]2WF(YY&#Q/
M,=?<$XCDGVS[:Y4TP6U6ZB9,C803(P>(QTD\D_.O4+>';"HW9QG%_P#:+B[;
MT^WMV^'&/=P&RI(H-A2H<R(IT:I>QRF:)7>H9K#D$U[ G5ED03R1'2,\&>O3
M.,@<XFL+RKH++Z;=PI\S*=L0F!R,=^<CI)FL/!)6Q\E%8GS[&?09.282?^/Q
ME.=B%]5S5&I%=WF;]#V.?Z:=SD[E:G&KYA/Y>^"1 SGF.# ,QF,FMDM]M5OM
M-NH+VF92H$F8(@@YC'RSS%9C.MY]KZ3/-G(<[<#%(<VVRRYB5PCW<!BGD+B=
MYZ;$5QD8-"/XCC>]6C?)+' CO5.)C[%&8Q\IYC[QWZ#$1BM0TP^K<MMAP);5
MO4=BI2"21,\X[3/V%9G<"VQ3+71)4;.L9":,I4<&5;Q6QRM*K%[T(PCE81G8
MB)^[<CF+[IPBK>DB(R8$\@<'GH>>\=.*S+-UQM:E.6SBE*G/EGL.X@?PZ36A
MY3N)MGMSAV--R'<C% C+GV(,22:ZB,CCD3LA@B&(3G%[D$Q50A3/:T8AM))*
MH@C>YMJAQ'?_ 'X)..9GN9C%6OH>?>6XTPXD!(_=(S(,"0,_S,=*S^=V53D-
M\MI%SC&#QR" -C37\0?R:":UCD9VE>QPWJU2H\2N5[G.3A>&N601 $_0_KU/
M;]/:LNWN AG8^RL+GDH)R)S*1G/OUSB8_K<O=';K%-G\FE7V?8VV/58P=LR<
M2WAN1[V"1JJB*97$>]W Q,1%*9RM:B.>Y&K$>2(YC'\,?Z??F=:IAU^X)98<
M)).TA"@"."9Q'_>*W2[SO!<SQ./'AY_C*Q9L"!(@S@7=?(C'CO8"4!Z/%(5"
M1SC4:\M<YSF/541?9:I(',&><<=?E&..3TX$W,FX:>05L.$()"@4*Z=\?PZ'
M$D0- Q[(-O<.6TFW.Y>&#4E>82QV7T$;$'V^HIB^N8;G*U&*J-:SA/*JY5\:
M*$Y$'&,]?E^L#)S)&!65>/.702TW;K2HJ$0(Q,GD#)Z?6HPI>I#IYS/:?'6-
MWTP.$*F)/BJV=D$&,9"U,N57D;+KY!X\QBN&)IX9O11L@#F28OK!*QRA &29
MP<1[D?7'7B>.HK;M7]NZ$JM7% PI,-J." >@R",3/,16LUG6ITJ;<1YJ$W7C
M9-82?258^+U%M=L5C%>UC _AD28QSW=ZJ1Q"-<C5X5B(BJMX!5!'Z"8)[_0=
M8@]ZR;BPU*^4C;:K2D$&%(V?+\Q!ZDC,'[U ]#\16<;/-Q8V [#YWEN,7$NM
MM,8MS/'2%EVJ5PX5NRPKY('GB5Y4BPG1)+'$D]S)#SPT:]B-)942,P3/T^9Z
M?4#^=2CPT\MI"WG/*7/[0&)"?W9Y!YP9)^]:IGW5SUAVK),FMP[;79.E*UR?
MC^73FS)\8:_4KOG[4M'7->@T[E:2/(1%551%1$XRF=.N7U -,N.S'^&DK','
M* 1@])!^8K(&D:=;)2;N^VH(G:MT)!P"(2HI'>.IB>F*'YGE=-E^6P\RWJW\
MS+=+)*R!,KXD7;N(0$*'!F$:2= ASV.QS'$B3'M8R0L6?+]5C H7O:-K6=%:
M>#M3>*5+:2RCE2GU^60.X1S&,E40>#!D8CWB+PSI8+;1#RIP  O<1B050 8Z
M#=/O-8^IECN)O&T&P C/54:EUE"6&5S2N<[Z9+VQ1TM1"*Y>%4<F5;#1>>XC
MTU-=L>#O#Z?/U[Q+8,E*03;L7#9=4> DH07'"J<8"3CF>(F=7\5:VH,Z#X=N
MW KA]ZW6AD)/5)4&VCU,@F0034[4&PG5CF@F#FY&3"ZZ0C>8-,85(@QN3GL^
M4Q:+!:1K45/I//>Y?'>]RHJKQVH?&/X>Z2HMZ1I=YJSZ?2E:T*#!.,J4Z5%4
MXB1DQC;706?PW\?:M"]2U&UTEA8W*&XEP@XV@H"4IQS*HGV-3=B7PQ<@R$C)
M=_;99?R2*U32(L%S&O>OCE\N:RP(J\\IRZ1RJ?DBHNN7N/CIXPO-Z- \*LVK
M)_*I5N\_.9!"E;68!()3( B.#6W9^#_ARV_::YXDNKM<^I/G-M&9$Q&YPI/(
MF)%6*I?A78Q&$Q;"BE.\-57VN0M!_P /:[E@IK'>?NG9S[\HGNNFN/B'\7;P
M*6J]8T] $E.RUM0)[B2>>V>QK=L^!?AI;)V?A[B_/&Y1N'IZY4$B,XG:3V%;
M4[X;6V4<?8^DQQ53GG_ITA")^BJI5\JGCQQSX3[^=(]XT^*!RKQ2$$9AN[MS
M)[1!$>\3SFMFUX0^'I&U/AQO(RM;#VZ3P=V\?_MS&:U"Z^&WML\97AIV,<Y%
M5%@7AOI]O+&K+1JKX\?2OC[+QXN;^)OQ0L0#_?C=UM)E*UVKD@9RD  YD<_3
MI5KGPY^'ER-J=*7;*7@J;0ZCN<R5XG^9XJ \I^&Y61GND45U?TQQKWB5ZAEC
M$Y..U6N0;#>%\^)37<^4<B)XW=G_ &@/&-HI*-6TO3]29D;TED,+@9/K;W)4
M9$DJ BM/=_!/PP^DG3;^^LEF2G:X22KD8.U6W@0%?2<UHP]L.M39<3V[>[K7
M=[2A152DL+ EK7.8WPH_P/*67-.C'I]+FA(!5^SFJGCN--^-O@;62EK7]$?T
MMTG:'VD(6VCB"%-A)!^848YD@URM[\*_&^CCS-&U5J^:$[VGUJ05)3TA96E2
MCS(.?;%:I8=25_"D,@]1G3K73B->UA<JPT4S"+YKT7A\QK2-M<?LI")R]!0I
M%$%7>Q!M\:[BSM_!_B5M+N@>([%]2@"+5RY0AX$SZ%-K*72H3D%!F3).#7-7
M&J>)=%7Y'B'0+I#4P7VVRI@C_-N 4V>XA201 C-3GLON;T\B+<R-I.HF^V9R
M+(YD>;98YNJ%*JOL;(05!'))M[!UKB9I#!JD5"COQRBB0;%;]#49#>>$M1M4
MDBU+J!)"D$N0!F1M)/N,3[34K>M^'M5VI64M.<!*R6(Z#E*1C RH]9R:M&[*
M^L.OCAG0:7:W=VC1&$BVM<TK72@?Q^H&?7S+&!W$:K7(04=S4]^Q47SS[EBX
MT=BTJ0H@':04J'S!)C'.Z/?I6<G2+%Y.ZVNUI!.=CH(Z]4SC',D=@:T2YW\Z
MNSYCA$_^CQ5AJ<9L+$]W %>V)9%P";72JYHJ^6ZJ$*M?&^8;(0A8TYIG!078
M)CWJL)ME0#)QCY1[\3QP??.:M_X?9V*)N@7%?E4#"2.<DP"J>._3-?9DW4[N
M>&S=)G=(]M,FJK7$</*BC&16_P *E1M/Z9'>.U5<-5\+W(Y/IU:6'!!,@&,D
MX)'/)$F(R,=9ZB5O2+D(2E-ZDHV@ )!)Q!@G;!Z#MS' K3\_ZI>JO/,3NL1P
MOIO'BDB[JY%4"XLKN5:K6..-!ME@@1Z6$(SH[%5XADDL8A&#[NYC7,?<+52B
M.3]CUZQ\_F<QQ5B- 2%E3UR%#Y$&3]([P)K.IF'Q'LCQ>I@0<>P;')XZ^)"F
M7$;'[*3-E'"%@WST!-LWQ(YS\=Y!)'(!I%51-8SAB7BU,1!) Y(,=@3CI\_;
M ,5*G0M.0YN6XI29D(493)Y@@A6>0*TZ!\.[JEW^L S-]]S\KO8)2H4E.Z62
MOI1\N1SD'3US(L#A$3AJD"]R(GO[\R)M!()2HCY1R?:) _2.9,C8LHL+/#++
M87^ZH@N$1/\ F $]XX!CY6&RWHDP+IMJ]L<;KH(0&S+(#1[>U4;$>V%510R'
M1$+PWL648K2$1%17,$K7*K'.1>HT"R95<*4H#<D>D1)@YGK$03]"<<UI/$.H
M/FV"4RA*HWE @3F$J@9!B(XC%7.H:6JQ^OCP:>*&-#")B#0+4^M../4<]$12
M*Y/J5RJJ^5XX3A-=V @)VY"4\\C"<Q/7CI/49XKSV5E1,$*/6),P8["9CM''
M2J(=0753DS<L-M+LHD:5DL9) LARB5Z:P:) .8.6\)RCDQ8T>O<[T)UB6),*
M2:JUM7$++88P/.=>\3:@_J"]"\.)2JZ;)3>7Q2I3-N-P!X/_ )?& 4F3!,&O
MI3P-\+_#VD>&&_B'\3W'[72'8=T31FUEN]U5S:'$J63M5Y3O,(5^0^H@G->L
M0H&0\@/E60Y/)S;.)C"!E9/;&>.'7".U62 TT63(DF%Z@T4+YDJ1(E*#D ?E
M8[G1M3:1H";.[7?7K[NI:@Z2K\2])0VDIREH?N@$]#)Q('%:/QS\3GO$-DWX
M?T73+3PWX4MEAQK2+$%*KM0PVN^=0272?S>7!05$23%6%7?K;/:&@(6YR:NC
MF5O)7K+ #O>B?P*<SF*]SE7M:P3>]ZKPBJOC79LDI"4I2%*).T)!SD](/4Q/
MM,]O%[D%2U*6-B4 #,  #A49/'YL$3/ %4TW+^(E/LGGJ=LL?EV1C.4(9A1E
MKHI'/3A'#<4);.4Y%5JM0,!@3)PC)3>Y':S'4.MM>;=O,V-N$G>[=.-MH2$@
MR05+ !C.?IFL%-Q;K<;M[9#M]<*5^S:MFUJ*B2(E: =WJ)!!R.(P*A"'@/5;
MU!24-?3K/'J:6Y5>-ZRJ6*HW^55D8;RW,GEJ\*R7+" G'A&-5->8^(?B[X%\
M.;FF;AWQ)> %'DVA\QA"TX4E;Y ;1!$#<#CK.:[C1OAWXTU\I6XPC0K(P0NY
M);=((E(!"0X,1T&9D# JY.S_ ,,.%(^7G9"*QOG.5"&-*5*FF1Z^7.5R/80R
M)RJN5TF0JM17*U>7)KRG4OC#X^\0E3&@65MH%@4E/FA"0H)(@DW%Q 3T,(2!
M@P#&?1]/^%O@[1H>UF[>UB[!"BV5%;:E#U%(:3S)@#<N3(@9%7SQCI:V*VVC
MC#8VN,P3 1$=7XU7#LIG<U/8DM@T:UWE$Y*Q5\_Q)[:\XU)3K[A=\3^,7[AY
M1*BS;K=N!)_=,*\M/_R)@<\21W5@VVPE+&@^&F&FT^EMUZW;MPCNI14E2C@$
M^HR#&2<'>VCV1JFH&NQJ_M7-1$0LHL2"-W_WD=>Y$7W3EG*)X7SSQH%WGA-D
MPW;:A=KZK=<\IM0ZJ&TJ45$\ @8)ZC.\1:>(W0"Z_96PYVMH"R!VF   .1W
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MYK!R'C<G< AD5$;-AG8&=!<Y>>&2P![T1%8Q[5:Y9[A"/4S>-*;(3Z@M,".
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M("CPC *3', IHY/2*"IQZM$P2(UZZC'A&[>"$%ZV!<:#PDQ"5&!.1"@" 0!
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MLH87UQDX3E&S8<>2]4X+)Y^K7O6@^+O"7BIOS-#UMM%PX0!:7H\IY!&5( 4
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MUVBD7392#'F-J9*Y2KE(66U#J 9%>@:9\3_!NK;4L:Q;H4L2$W.^V6!V4'$
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M0)?B-T&1W.7(O"QBAB]!6)5\<"L:R;)RFVD8JKO6B?O%2!8C@SM*9]ML#_\
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M_P!OW_7WUG>_\?Y]*Y6, >W3'RZS^O>:\1L/QP__ %E7&5?_ ';?_!4T@3)
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M2"(W?;&8^=:&^^"OQ/TY*BYX8OU) )*K4H?$#K*%*[]>?F*LWA.<],.Z*#7
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MO'NJJJ>?'ZJO'\UYA7=/#"&TSVP8'M(C](X%2V_A+0RL&XU DD"2M2U))ZB
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MBN1&^%[4<OW3CCA=:188"O0I?/0$CIQQ' Q, $'/%>JI=NG[<HU&VLD%2?\
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M]L=S[J38C>QO+5[^QI7*B<D1%5%Q3XIU94E#+*!TEL*,XC$8XYQU/6*WMO\
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M<]!UJZ#V]Z*B<>41%7POZI_<BK_8OC2J'KC]8^=4!N,LP3I1ZHL*QDM1"QC
M^LFUE4-0:AQEH((.HNF_$[PILBMJV"T8';EXH<XH<JXD\.O,2%$B-0]L]'5)
MXD_*>O7KS_I6;>ZE?ZBBV1?WEU=BRMTVMH'WBXFVM$*4I+#"58;;2224R>9)
M$Q70!/9/*+XXY3V\>%U2L*>)P3T_KFOG2JU])Q#D"( G"M*QPW)XY[7(J+QS
M^7.E 2,@P>XJK>4]+F)Y1<'M9@A.>9[GJCFHO"N5%_1/YKX74:FT*.?M_O\
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M[#(P*C/)=_\ L:\,0C0B3GAHE08T]TX1$1J>$3AJ<+X7W\:O)>< 2B0)D@"
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MN!*2![3["9]N*B+'X@'UWZ0H_E;<\M(B8]*4!4?6.?>LI+P'+)3"_B>["/\
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M$""$Y4,@Y]B>M8.3L;M_*Y1;EKQISVM*0KFM1WNG8Y7(G'V3PGV3A.=72?\
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M 3/) J?NYJIRBIY]O/\ SQK2'^,])G!Y_P!JVO\ 7]?U\JK17]07SVZR[/\
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M1.?OJGX58GUJ^TCO\AGM4IUO1B$J3IQ]2BD':F"0.AVC '*N!WKRDW)S*6G
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M82"1@Q'ZU-M9,WSN!LC *.F$_ACSC$\\AB.7RYCC+Z3%1..%4;N/T\:JEU8
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MPZW=V@GS[#]J[K=0FW]$RB/MY@]^>O@GI572F1/01P(/J)X@]#$0,SGOV/\
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MM.-'\'R7Y)I)DGEK_EJ^(]A+"QF%5&]D6O!(DE5$1K%^GBZZ9LK9M2[OR$M
M DE($@&0.9Y^D]1%8^@.^+=8OT6WAT:J_=J4E*$6(?24J/YEO;2$I1!DK68"
M9,YSRPSG#MJ7WJ2]F:>[VXP."4OS646LR973\F$B/'VU6,FDG#50GL5A&2C.
M98$56J\$)4>U_F.M7NGW3ROP#*6FTDA3P)258(V[")@F#,Q,#Y_<OPZ\/>+=
M)LMGBS4DZY>7*6RWHS*6W_PJ@ 0;F]V!2'&TA1+>[\I,G JOFX&\%)BM)*H\
M+9^'502C!9W;FD(0TJ21!C)*E(CG//(*J]C'.^MRKY_B<FJ9M'WR%!"U-C)7
MD8/.<\1.<],37H5]J>FZ(II6H7+%UJ2MWX:S.W:RD04I;;$;W$X2=N21).!.
MH])&YEG3]1-929G6Q1XQG4J'35V0&$CYM?/.9RQ'FG/14^4M3$9&,(2C&%ZQ
MG*XB-,\G6Z"[;VEP&E)1*SA1()$XGCH1QC(,0:^>OB[8ZUXQT!>KV+UZMO3R
M7'[($I"@A9*_-2(*DLH.] $#=*8K]N/3YM)B5%C5?91H\>09X O<_L8J][F(
MJ\JGE//O_)/OSSZ4VVE !&21R3/.>.,SS[8BOBMUY:EE))!!!)40I1D'@]!G
M'8$1&";$Y1?0</QB^R2:-4K<=IK&XEL"B(_Y:MAFEE:-B)Y>Y@5:W]51?9%T
M?=#++CQ]0;0I1$\[1Q/Z>U7V=LN\N[:T;_Q+I]MA$Y]3B@D'W.9]S[FOQP;U
M]5L7K1W9=:;BY3E]1CL"R/'P?&9D>&/ :2+Z[Q (L*)(67%L90N/F+JS2RDE
M<]6$+!AHR.'R;6KF\U):E./K0U(VL))+8[Q!'3K&<3Q7W)\-T:-\/+)QFTTE
MA[4+EIHW>KN*4;PN*&4)*DK"&IDI;00.\S6L9MF]5MT&300([8!H:J$K%1B'
M>K4147O3EJL>U4>Q6.4;V.:]KU8Y%7FUKV*+;393) @"5DB).8(!&< ]I,BO
M>-*TPZZA.IW-TVJW<;#X>=(2TEODH"I5D$!($$F.!Q51K++LMW N%J,<BS;6
M;)>Y@X\1A"-;RO\ Z5[.41$1%<[RB(GE>/*I/;6#MPH';O4K 0D3DGK'')'^
MXFLK6/%6C>';1WRWK9AEAN7KIU:$M-I R9.%*G*=I42.!R*M5M1T(Y;FBAG9
M?(D'EFX>*D@(K@B5R-<GS1_J8Y45RHYC$(CO"(5J\IKM=/\ "Y.QRYA @'R@
M/40>LX@3&8ZY,YKY1\:_V@$K6[;Z"E5ZM.\)U"\+C-K(4)+3 /J[H4I6WILR
M:PF_GP[MR]H*6?N#=6 ;O;KYD#95#=G#7V, DTS11HE 5HQ1K,A'D1@8+V,F
MN:WAKY3NY6W:KHS=BP[<,E(: 'F(7Z5K@F-ADS$\  CIC-1> /B3<^--5MM&
MU-F[&HN&;6ZTYI:[<1&Y5VT $MM 3O>*M@! (!JOE-LSA&U59(S+(*V.*\L^
M#4U$Y6E6O K50+CHY.'27M^IR]B(CG?2B-[6)Q:KIU4I1@'&T*.!F)$@&1SV
MS'2OI%CP^Q<!7F*0W;VY_P"=ODMA =VF%,-'(4%8&W(623@YJ,,2W1VOA;O0
M$W4Q^XL,?:0?IRHD=)%-5S'':@B64%$21/!';P\J 5S!O\.$=6N1-UI*+=MU
M#E^00.!^4Y,\G! G]/>*\]^(3VM7FDNZ=X(0AA"-[+RTC<M30!&T*3*D.+)P
MO)1,1 D?K:Z.MA]I]Q<3I<ZQRWH,FHIP!.B2Z<L:5&8C$:BQW-%YC&"J(PD8
MC!F J*QXF.16Z]-LQ;OL@L%"FAD)2,I'N?KVZSTS\):Y;ZIIMX];ZM;OV]\I
M:O.3<H6%*4,;MZY"PK!2M!)/4<QU8H<"Q?'HPX]?4Q!H-J-1WHL^WLJ?2GM]
MORUL$@)$ 0/Z_6M!R9)ZSC ^TG_?K-;8V-'8B-: +6IX1$$Q$1/RX1NJR>]
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M=$9R8!<$<' R.HFOJ_I"QN51&B5.?=1,XY_/RS^_C[^--UQ'Y#_^F?X15_\
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MK(L)9%7'KH0F#5(XH[1L1K43W1&IW.7V[W\J[W5?*Z[6VL6F4)2VVEL)2.
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M+6ZWCGAU\6X=5 4V"HI@DJ"<]Q''(F.3!Y\CLOC5HSFNVFG-I4JR?N2TJ_\
M++*&7U*"&UH;"E++9)VK*P@%/3))R.S>9R:NR'"E.>,PC>B4;E[7#,-ZM>U4
M545.%15:OLJ<<<JJ:XBX3Y3J%C$DF(. #!,?/Y3,=(KZN86WKVC)"R%W+3>U
M9P9 C;DP ".%$D*B8&*E7J&PYE]0,R6K1!G>)3(4**U12&-Y[D>U.?I?P[C_
M (D\*B)J0'8ZEZ/0HP1,#(@Y@\<XY'/MI=)_YBVN])=2%.LJ6Y:!9"B%(G:
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MIV&W#W7W/WOR6V9@TN!6QMH<ZVOR#:*=2PRV<7(K'(]M<H%D%/79L*!7*%,
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M=$?N E)MU>7SO=_*.DXCB>8Q/6M/X@^+-IIUV]=)U)AFX45J1;:>4J6B0HI
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M]E\/CJ'KW+\K:5,E&>WK,L8[N?/V2$Y/O]UX7W7QQQB+\(W)_*&%G$#?L_\
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M4JDD\D_>LY%Z<>GF#?[?Y7!V&V8AY1M/2"QG:S)(NUV#Q[_;3&PL.,./[?W
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M+J:T3DXXX>R$D-'-5?*^W\^/&LMGPKIS)W;'5J X4D!) S!@X]XSV[5S=_\
MV@_'=V@MHN;:T200?*;*EP09*5**I4 8$X,9%7$VL^''5XVHDJ\:JZ1CNQ"F
MC0&)*(SE55#3"H^49%\HJO*J^Z_JNXM=*M[<#RF6T'&2D$C G*N\?RP:\RUO
MQOX@UXJ7J6K7ETE6%,J=4&U#W:00D@&#G ,'!F>B>VO2MB.'L :7&">2-6N5
M',1WU)[\\^.57^7O]U36S2TE.>IB0,)QCCZ#^B:Y-;KB\3"1,#L3U Z>_4Q!
M[FTD"IKZN.V/"C" -K43AC6MYX^RKQQQ^GM_;YU)[# [#CK_ *]:C[D_H/X
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MD&1GYU6S+^F#!\J,:0>,'U3*Y7J\?/*N]^5\\^.$3GG[^W*\QK:0X(4)XC<
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M1D_-5 Q57^WE%U:66R02D8_J*JE:DSP=P((C$'VF.N.W2MSQS#J3%V.9516
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M2U_5K,_Q$W2_UKI23W/W-/Z"G2U_5K,_Q$W2_P!:Z4D]S]S3^@ITM?U:S/\
M$3=+_6NE)/<_<T_H*=+7]6LS_$3=+_6NE)/<_<T_H*=+7]6LS_$3=+_6NE)/
M<_<T_H*=+7]6LS_$3=+_ %KI23W/W-/Z"G2U_5K,_P 1-TO]:Z4D]S]S3^@I
MTM?U:S/\1-TO]:Z4D]S]S3^@ITM?U:S/\1-TO]:Z4D]S]S3^@ITM?U:S/\1-
MTO\ 6NE)/<_<T_H*=+7]6LS_ !$W2_UKI23W/W-/Z"G2U_5K,_Q$W2_UKI23
MW/W-/Z"G2U_5K,_Q$W2_UKI23W/W-/Z"G2U_5K,_Q$W2_P!:Z4D]S]S3^@IT
MM?U:S/\ $3=+_6NE)/<_<T_H*=+7]6LS_$3=+_6NE)/<_<T_H*=+7]6LS_$3
M=+_6NE)/<_<T_H*=+7]6LS_$3=+_ %KI23W/W-/Z"G2U_5K,_P 1-TO]:Z4D
M]S]S3^@ITM?U:S/\1-TO]:Z4D]S]S3^@ITM?U:S/\1-TO]:Z4D]S]S3^@ITM
M?U:S/\1-TO\ 6NE)/<_<UQVZ]O\ ZG>VDZY>IO:#/R;D66RVPNW^W!<=S'$L
M/->Y9N;G.1GRNTM7LJ<ASVQO:'":H=3*B"2V6#E!BRQR ?LR%%99JJ]+A2"!
MDD\G,?U_4UVMZ3NDC8OHFV:H=ANGC%Y^)[=T!I,X,&TR7(LKL9MM/0;K2XG6
MF265E)^;LSC^:D1H*P:F.5[V5U;!C=@&*L)*C)YJRFE4II2FE*:4II2FE*:4
MII2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*_+EUP]-O6U_2<ZXMW=DL)W
M*S?:[?+?+H6VPSW;:-6VQH=U@&#8YTX9C3]0NU( 17$N)NT^>XKG&W>Y8*M\
MF*?%<VN+.Q;%)@!"Z5(DI@ QB3_&0?GB.T1^]4AY[O-\7>*O4(_ HG4)(W(@
M8OU>EML1M>G/;\^RNU\W&MW*2KZ,IW2?F(]N16N^ESG>UY95IGM1>99NRU$-
M=3,CKMOKBIJ:J0H0G&1!V]<Y_-N$F(_TB<U-N:8Q\2V#U#+M]CG4OU3RMG:K
MJ1Z?-I!YV+93IGEGO-D,ZZ9,RRO>K=N;D#.F[\&_&\6WCJL9Q^LR:N@0L.P^
MWL34UKC=P^PB1(E,Y_VP(Y^^/ZS3TQ,"8.).#NQUSCISUFJYXCOW\6/*,KZ0
MJ?-L)ZE:O\2V_P!AJ/J2J[+9&CC[<9D+.,(W)@;O9;9 I.F\I<$RG'<K'@8\
M@&7J$P>THK8@CX[LF[ #WF2/K52$PHXY,"<\@=^,DY!P/S5V?^'5B>7X%T!]
M%&$;@4-YBV=8ATI[ XSF6,Y-"E5N18_E%'M=B];>TM[7SF#FP;>LLXTF'8Q)
M8V28\L)1&:TC7(BK505*CC<8^4U<K2K::4II2FE*:4II2FE*:4II2FE*:4II
M2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*
M:4II2FE*:4II2L'D^.5&8XUD.(W\5)M%E-';8Y=PW.5K9=1>0)%9915<GEJ2
M(<HPE<GE$?RFE*_&MAG1+\0>\J]M39]MSNHIMS,IV[^$KNW73(UZ6-0]#FQM
MITWV ^IBSA.$Q U&9FVDZBQQLG[00+*'O#0L);3?Q"*Z53_7L?K]\Y^U2RG,
M&"/4.AW$&0#/21@]OG-G]S+_ .+1NSMWU046X<CJ9Q"/BFXVVN0EQW:/::.:
M[J8N+=?&#1@5?3S/!TRU*;DX0WI3BW^;Y#04&;]34G+96,8R[)KZNC9-G^TE
M_6K?2(X/(@S!QUS(S\OL)J[/Q;=G.K/J[?L9TV=-^"Y--H*+&,ZZC,PW2O<W
MM=D*&JW5QC'2X5TRUJYK"P3)XUSE>)[FY7)WQR#:Y*>G'8AVRHHUK/I8%F%7
MJ)(3).9Q$3CKU'R'S)Z5RQZ@=GNOCJ2WDS'>NEZ<]\L#3K.V Z7^D[J/QB;B
MV64H\#QO(Z2BW#W\OJ^&6,U'BP67LOGVU-7?1R1XQR;T8VX\HOX[4QY"JC:)
M!(.TJ(SDP, >Q)GZ5YL?Z5-W1X9=4;ND;J$;UH673-\*3'>DW?2-M1FE-"V0
MW*VQZ>MJ*'=B9D6]IV5-#MW P7):VP!N;CMQ=,/=,JK?')-+:S3+7DH.@,S
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+-*4TI32E-*5__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g947560g29f80.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g29f80.jpg
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M*$48K:*.QUD>3D!S>XO('HF/J4KJZ!(BZ0TU,:D"*5DDE-)Y^/2V3(8(C &
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MVC/'T*;3DX:(2J"BM+E>@]^8*SO\ 8 P!@# & , XGCZ#Q[R7XZD\I^*>/\
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M!L<LC-*I0Q-K[-81V>1U1$IHR0L?<=ZQM<HC2H]E?$*,9:=Q0#T2I+,T O8
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M3OM9EN$(0A"$(=!"'6@A"'6M!"'6O!H(=:\&M:UK6M:UK7@UK\FL&#]P!@#
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M="7=36*/%$@F 6G;6:L>QC&@$M\H!"ITD(!J!*%RB^DI[I66\@RR^+AUBO\
M$UXY_P#;^1_[A,$9P?5B^TOP'2R2B.L3'HZ_/^^I;QT5Z8V5T>-I=< D9&U.
MFQ">MVGT=OD";HG9VB.[T;LHSN^UV^['X.SL)P?5B^TOP&'-*V#U?[CINI;=
M*YY<>X^5:E90.QRV$SA,WN9C(7.(LU2<#0-R#<R$+@-M"Z:1"7!0HPJQ$[/T
ME3Z,[D$U VD[+=?P(N.C3:R8[&UNH<SY)<WN>L'_ (A/'C_(PA_KAC(>E>?X
M&.Z4?U8_M0_A'<]8/_$)X\?Y&$/]<,9#TKS_  '=*/ZL?VH?PCN>L'_B$\>/
M\C"'^N&,AZ5Y_@.Z4?U8_M0_A'<]8/\ Q">/'^1A#_7#&0]*\_P'=*/ZL?VH
M?PGUXRI>L'R/BL_DY'4*X\1$,$NJTJ=&B.X+H7O;F;6<B,8#) !0"\6K20MY
MV#QH#9LE0)!K?<B7*]Z[W<'8VM!.<%ED5J3W2SJ?U3([XN'6*_Q->.?_ &_D
M?^X3 G!]6+[2_ 4A8-.=8>!P*;SD?4GXZN@(9$)++!M@> R-&)Q#'69:\"0A
M5[OY3I*)7I'M/I1M,HT1LSO=D&Z#W8@60VEDQ6_]E^ U86SX07U:'%M;W#5N
MT83I>A2+=%;X_,P]E:5$%GZ+V/\ "(';V#O.SVNR'M>#P]G7A\&O2N#.UUI\
M(X-P?A!8VT-"J_4:I751/ L<;HE6J"CIU1N/_E(,MP=TR<K)ARI3R5.2Z93X
MXU>@IZ:A>#Z:+N-+2465^50+*[G'%!E2[@Y3E.4W*Z;.=\O]U:?[X:,_R]LW
MWDSF_HT5C]\:'^11_P!V*OSVJ_[-IOXJ#^G'R_W5I_OAHS_+VS?>3'Z-%8_?
M&A_D4?\ =A^>U7_9M-_%0?TX^7^ZM/\ ?#1G^7MF^\F/T:*Q^^-#_(H_[L/S
MVJ_[-IOXJ#^G'R_W5I_OAHS_ "]LWWDQ^C16/WQH?Y%'_=A^>U7_ &;3?Q4'
M].3Q]/2?=7_GQQBC?)%'SSX]U<1(I;8L6#$%7"5OF!R05?S5ZAHUVWPJYHT
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MD8 P!@%KZ4])?%_87N/W_<?\II-VN2]J+J/</E+8R8#(DA@'G!=:+TL?./\
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MV3WZQ9\%USK<!L7$OO.N<YA]5";NV>:SN8P!@# & 6AY!G)$]"7>H<+#W4:
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M.[.DY':%LT10=D!UM5KPGE=YL1H-[T$(2S=A&+80Z%$D?HW08>\_Y4ZC[L1
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MY,7IQ&0.6%(P!@# +7TIZ2^+^PO<?O\ N/\ E-)NUR7M1=1[A\I;&3 9$D,
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M5"X)K<1ZX/O$M>" P"$Z+>>OU)/7K1'V)^->64>?H]Y&ENH^3%Z<1D#EA2,
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M34U"Y7SDY&<2):C<D:1Q;E:5P;UZ8A:A7HE!2I&M1JB@'IE:140,PA2F4DF
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M3@>[R" 0E]=56BM*7-XBK$YN"C1!):<C1ZU:@/4FZ)(**(*T8:+19)990.R
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M@XQL=?!B_//Y&^S"V>]9ASR'VR>_6+/@NN=;@-BXE]YUSG,/JH3=VSS6=S&
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M)Q>79A6HF]'I8Y4:C;TVU"DXLK1ZU6F3%=KMG'%EZ$+0S)\7E7Q+[?&XJO\
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MG*_TM/2*]7G4C]V5"X)K<1ZX/O$M>" P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@$2'3D\ZKK >W+&/LQTG@LCW-'R?>2WX*Q@# & , 8
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M-*!VM>$"*7IR>=5U@/;EC'V8Z3P61[FCY/O);\%8P!@# & , 8 P!@# & ,
MQDL/SI^-/[!<C/\ X5!@SF>M;(C)O!@8 P!@# & , 8 P"UETK[H;*W?UO'R
M,5Q,;:)&T:C$>MJ82*!P%>68]-Y3Z)[E,4B$\?FT:2/#=5C6%%%G+2UW3H4"
MH2)(J/7I1E2G;.6>5_GD:YL#J;DTQ=6Q98UF4DIE5IR_E1#93^$Y-"2*3UA
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MO/O%@%UHE,X?/F4F20661J:QU2<I3)W^)/K7(V4]0B.&F6$$NK.J6(33DB@
MR%)0#Q#(. ,HT(!AV'0%2X P!@# & 4;-;%KZM6]([V-.X; &EP7A:D#G-9.
MR15O6N8TRE:!M2+7U<@3*5XD:)8K"C)-&H$F2*3]%[*(-& "VWQJ^+WTD:$^
MN&O/O%@#XU?%[Z2-"?7#7GWBP!\:OB]])&A/KAKS[Q8 ^-7Q>^DC0GUPUY]X
ML ?&KXO?21H3ZX:\^\6 /C5\7OI(T)]<->?>+ 'QJ^+WTD:$^N&O/O%@#XU?
M%[Z2-"?7#7GWBP!\:OB]])&A/KAKS[Q8 ^-7Q>^DC0GUPUY]XL ?&KXO?21H
M3ZX:\^\6 /C5\7OI(T)]<->?>+ 'QJ^+WTD:$^N&O/O%@#XU?%[Z2-"?7#7G
MWBP!\:OB]])&A/KAKS[Q8 ^-7Q>^DC0GUPUY]XL ?&KXO?21H3ZX:\^\6 /C
M5\7OI(T)]<->?>+ 'QJ^+WTD:$^N&O/O%@#XU?%[Z2-"?7#7GWBP!\:OB]])
M&A/KAKS[Q8!QCN7'%),/0%')SCV0/8=#T ZZ*W*'L&][UH6@CDH=[#O81:T+
M6O!O8=Z\/AUO!F3=R;Z#(3!@8!&_RWL*:52DYGV%73Z*,3>,\4^.2R-2$#:S
MO!C,Y'VIR;0%N)+9(&]V8UIR4M68:20ZMB]"(T(/&$AY>A%B M%XARE^G;??
MU8<-O]KV6=SX_-_DAW1?47E?Q+P\?>5#M%>'S9;%_2=\LF3I>0?(.CT\@"@K
M2'O4Q50KEO<%(UR!T.V95E11IQ51R'L*5P=G)9"8XL<RA: 8%W=42%;!J3:T
M.19?+--)YW*:3>EE_H_S#H-V<W5@?YHCK*3L<;;96\1:USV^ R!N9E\34S10
MI/;WI>6(13.PM[PM<EA SFT:1B>W5J7.;&W'NH<!I^6Z6>V5ASW'F%Q59RTA
MKMR)IMK"N0*G--IQL*,HC!HT"^4-:XT9*EQ+.(&B<8-.42M.> I0F4PB9E'E
M '$Y!IN"3T/R%X7.>PQFD,8BCI)F=%(YF6M-BS0>L+"L?"VXDM0K,0 UO83
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M5JR K#I,R*"U7DQR2KS!F6FS6<@SE/QG)3NJM5R"IA$D8W9.PNZMPLN'MZ1
M\JAO929L4*5KP00%8>?&9,D*(T9L9BV,R-"'6U;"[$HQB3T%(S#E]5T747.D
M:D,KGYU 1&#SJT3(8GC?DUABT\03QV0.J=_ELGB<>=BV=IKUW<I$4UNRH]M(
M7LQ19:I8I5I4 RE.6:=T\Y>.N;,9++0O1[8W2!A=(RYMC+*8Q*VT#3(XT\/$
M.BT]0MCNB)5+DQ:P<7F<>7G%IEJH*0Y8:VJQDN:!>C3#!<7 & , 8!86B/\
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MN2AA2FVVVDDE-NQ"Q6N[/FL(WOCR0+Z=72L^OZ;?=S/T?^-PK^S:]_!UG_\
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M::/+<1&X;'''RC+#ZTCKDO1+'19&FE::Z B;!'&]66A3A.R7S\VZRP<FX%0
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MC'D*-O2.PW A<K4$J] W.?'[M<V988,# & , UF.LYYT,#]0D7]X=I8!LSX
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M(U"KM-L9W68)P2VMTI*!49%QFDO:Q1%7]OC4:4JIZ:N;!)E!$<!7Z==D]O\
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M *O_ .0W_P#M'GTCQ!X#8G>+& O9E6-,89WVPESZM>NC-MGX-Z\ACO&CJ#2
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MI:T"I:&SM*5")M4O#NH0)3C1D(SW5R-3EEF+E0C0.;\LYRA_0.A/W7L/^J6
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-@C&8)PPIJ;G?\#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g947560g29k54.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g29k54.jpg
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M,E%T1$935&-DDM+4_\0 ' $!  (# 0$!              $" P<(!@4$_\0
M5Q$  @$! P4)" P*"@(" P    $1 @4A,0,$$D%1!F%Q<H&1L='P!S(U-G1U
MH<$3%R)#4E2#E+*TPM04%D)359*3L[7A(U9B@I6BTM7B\3.C%24T1-/_V@ ,
M P$  A$#$0 _ -_@
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M9*VNB(TI#,8*PO;(]IGR.+2E1[-NN4R4:AW.;NRN;Z28P$
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MMPND;_LE;UNK#HRJ-F.0$9=BUK=[$-!T-4Z4TM3%S>,3K2+6 *
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M^L&I3_E8-"K9Z5UB<C^=_P#74/?._+K_ #-$3_U@U*?\K!H5;/2NL3D?SO\
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M7$2XV3=S%4_F9^$3P[_*[\Q?JB> 6HPKXCZ:2\,"@ &KYZ)B_BOP?^6^V/\
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MTPDG+G2I>S8F;$@H            *.EWWR(R?(L+OIM'@9/>OE/LEXH&,
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M:C30_1,I,,)U.UU-UTQOKC; 2WBV^4RT!
M       4>>9GX1/#O\KOS%^J)X!>C"OB/II+PP*  :OGHF+^*_!_Y;[8_P %
MWL>JW%>,F8<7//J6<'A.Z9XDVQQ[-_B>:&L$-['*0      &Z_Z'U^Y2<_\
MX]]2_2ONP<V6EX1S_P MSK]_E#M:Q? UC^:;,^HY NA'XCZ0    !&/MG^1G
MUQ_5COO_  JE8$TXKA722< @                "CI=]\B,GR+"[Z;1X&3W
MKY3[)>*!C       C'R'\#:[\NG5OTI[E $G
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M6%WTVCP,GO7RGV2\4#&      !&/D/X&UWY=.K?I3W* ).
M                      "CSS,_")X=_E=^8OU1/ +T85\1]-)>&!0 #5\]
M$Q?Q7X/_ "WVQ_@N]CU6XKQDS#BYY]2S@\)W3/$FV./9O\3S0U@AO8Y2
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M[?=TT!I+">!J+K]]^HL) J     4>>9GX1/#O\KOS%^J)X!>C"OB/II+PP*
M :OGHF+^*_!_Y;[8_P %WL>JW%>,F8<7//J6<'A.Z9XDVQQ[-_B>:&L$-['*
M0      &Z_Z'U^Y2<_\ X]]2_2ONP<V6EX1S_P MSK]_E#M:Q? UC^:;,^HY
M NA'XCZ0   8UL2OW>=ZM&K3:ME5CEKRNR?M79L'*V>L+<(\%:N_NT@TTUVP
MW>Q3,H?:[5MSC*U9[+RKQE-A,!@^9<G+;!B$K@4PZ;Z3>8E-XV^Q"4LYCE2Z
M0MVCDE:U3,]MNZIOI-(O3:+FQ:J2[*$2I,K)U-R8F4$G:Z&:A@=D^Q]F'^5=
MTM_G5&?46 ,Q0.).,+9#&ASGLTL51NO/6X?YYO%S'LHHXI.7JW%[1&+1%K]@
M)]B-SB,;M>ZS!JE1ZZL.+]9+) [H      -3V]>.*<ZR[OFTGD'5G1Z>63?M
M6><I0NMK4H?FKI2E(!8U5\Q-O1[N?!HQ?Z.RV:+UZ; BU)#4L115(\GS+90E
M4L*5O-+><Q/H<>B3+35%/>JY2VFZ6TZHAQ#=^J]07T^.69MM@\44#*VAV>WU
MM71AW1HW:10BM:W>%I3%+Y&P>N*X-3S8S5I&M==FO8I*W1%J0MN$9:<[=/JL
M-4^G)C>+X7OZ]KOYR;($   !1TN^^1&3Y%A=]-H\#)[U\I]DO% Q@      1
MCY#^!M=^73JWZ4]R@"3@                          U;_/Y#:,EMM445
M*.).A[]NDNN'<J&WG7:.5.]25A'S),N])BG\<;^?.L(Y)'#VWRH?-6A?1#PN
M4-YQ1>KN02<7JG&7)IM.*H4J5,-[Z<J(WFIPOP)A>!V+O\2YULULE1%=%2']
MT9"8OVKSAIVXB3;%XC:+1(6\M;G2W/Y5M.9!.OK6T]0UBP%%Z:^UII6IVF2B
M1&4Q4SAKJTO6X6\VR\X#&     4>>9GX1/#O\KOS%^J)X!>C"OB/II+PP*
M:OGHF+^*_!_Y;[8_P7>QZK<5XR9AQ<\^I9P>$[IGB3;''LW^)YH:P0WL<I
M     ;K_ *'U^Y2<_P#X]]2_2ONP<V6EX1S_ ,MSK]_E#M:Q? UC^:;,^HY
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M;1X&3WKY3[)>*!C       C'R'\#:[\NG5OTI[E $G
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MVK-TQ*L5<3C,WN%"G>PZ$3@ @   *.EWWR(R?(L+OIM'@9/>OE/LEXH&,
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MW.9YG&2S7-;<LS.,YR]:R>1R.2SO)5Y3*Y2KO:**4YJJ>I*]FP=]L?*/N
M                   04Z+H7BCJ>XX[4%TQPAVZ%C57.%E0]YB3Y9-7V[&:
MLVEB:,N#@PW'5[G$)$W1\R8*4I*J)Z3/"=:OVT<%,?4D:;J<"4VKUAAA*X+[
MCG*"\?G*G-LMQ8M>5\\/%HZ-ZQI3VM;=D69>=F-K6XZ8*<FV/S:XY=-WV*-K
MF1KHG<VZ*JV1"YDEZ:+TZG&/X0=3?!L227,DD3/ @XUY<=FAH=7;5O<G?9K;
M5SCJU,R<M6[N>R)*:IPWM24TY,4I<EN2O8R%.8H(+.5&E%[G%:[9WU UK?)7
M>]F7]&:*L2./\UXSC-7U_P!=6[87-G3?0=H<,7W>B*L(Y7!S)O#5%!/DF->V
M5I*5R+V'NXS,E.2\O;4J6L2E$2I+.&1*)P=]*E)5)3QHOU8;;UKC7%^H+)F_
M5M76LR6G>D)FYG;'BYI&K.;Y5<LV6)TG&_1/(L9L&UV^;U2K?=8]8CZX;R*4
M3696O)HR[RIOET%3J$DB:=6HQ'EV_P"R826IK1JEW3*J:3F^%A@[YC6C.?E%
MGO:#WVWXUXA;="5E">7&'RS\Y&TQ<$>L\N1SR>N17M^0VI9- M2M=XP0J9E,
M@7GG[&;>L*6Q&F_^V>G@13$5WN=!W1=BM<^I;TFT*!C  U?/1,7\5^#_ ,M]
ML?X+O8]5N*\9,PXN>?4LX/"=TSQ)MCCV;_$\T-8(;V.4@      -U_T/K]RD
MY_\ Q[ZE^E?=@YLM+PCG_EN=?O\ *':UB^!K'\TV9]1R!="/Q'T@
M        -<;R<]5O?.LNF\1Z"?O'9W50LS>B%L;X:L]M<HYV&R%KD*=,D8*\
M8HXP7BT6.I+4['+65\DM;P1T]?6)TVDH2;$Z+<.W;TF2A3>M.E_"6&]LC9BR
MX?A76"Z\C41M6=%6#S-!#H24JC5"VHC>&Z>5>@6.;BJS&7U _N;N[HL$*3CU
M+4E6+?5)V52W%$HVU/J4VI!2K%WS>[UKW^4ED!!CM;4M;N5G-MS+X<S*[19X
M$^U<VS101N8\)*^D[VRR201,O;8S*?9H=GR.LCDL(,(WV,4-J?.#,:8VTV$R
MXC5,QO\ 9F-^?^1N:.5M9CISM2T%J+%@."%RE^8<TX0;O)C3JNU94)FYAI^Z
M1B8-7-SUCT;0;)(]']7-QPS-:'"]7@X&V\6WV_E?M*QEWWR(R?(L+OIM'@7]
MZ^4^R7B@8P -$WSC_=4;3_JX\W?IUO#9_<WQMG@L_ISTT;W:>\W-<:V>BRBK
M$;1-$@    &*KQ^"&Q/Q6<_[H?#W2^ +5\CROJ/5;A_&_<[YTS;Z9]537[6/
MZ,?V#GLZ^/(                     H)\D-9\5N_;L,LGL2UYU'H[$^&;=
M>LPZJ9;?D!E$=BU93LB>R>TYM,J2=F M'"SDF^\'BT;D+J8LFEA.#:U1=F='
M=/C"87I;B$DYJ6.B[W<DE4O2N4E7XK'CD)VK&T2^3VWI")ZM<_;$EIUWU6_7
M>OMR'21?#6*11<Y8R7G*)4_,<=ED&?&&41M0Q+_<^^-SAJM+SLX%KBB!%4W3
M&$J%2DU_=N?JP+2P*@ 8SLJEJ<N=,QHKAJ:L[81QEUT?8VDLJ!Q:=IH\]EXU
MU+>6,B4-3J4TNNFNFF-'%!HG5ZXTUQJ=C&N/2"7M/T5TY4*^QVBXUU5UNMMV
M/LQT=8;45P>,*;'9(^HT4EGL31.#FO>3MK,>6L6%G-B)T)1&:*E.NY&VIYN-
MPEX3=L*A/,S\(GAW^5WYB_5$\ O1A7Q'TTEX8%  -7ST3%_%?@_\M]L?X+O8
M]5N*\9,PXN>?4LX/"=TSQ)MCCV;_ !/-#6"&]CE(      #=?]#Z_<I.?_Q[
MZE^E?=@YLM+PCG_EN=?O\H=K6+X&L?S39GU'(%T(_$?2
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M& !HF^<?[JC:?]7'F[].MX;/[F^-L\%G].>FC>[3WFYKC6ST6458C:)HD
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M /CWU+]*^[!S9:7A'/\ RW.OW^4.UK%\#6/YILSZCD"Z$?B/I
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M?/1,7\5^#_RWVQ_@N]CU6XKQDS#BYY]2S@\)W3/$FV./9O\ $\T-8(;V.4@
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MAL3\5G/^Z'P]TO@"U?(\KZCU6X?QOW.^=,V^F?54U^UC^C']@Y[.OCR
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M5[8^O^N8]7ZYZK^$!+B)<;)<&> (  HZ7??(C)\BPN^FT>!D]Z^4^R7B@8P
M-$WSC_=4;3_JX\W?IUO#9_<WQMG@L_ISTT;W:>\W-<:V>BRBK$;1-$@    &
M*KQ^"&Q/Q6<_[H?#W2^ +5\CROJ/5;A_&_<[YTS;Z9]537[6/Z,?V#GLZ^/(
M    ,#S#HZNH/(W*+/;+=ZMT:=DVBM1$^8NE)]'S,JD:=<5ENET$J61Q1XUU
M(5%:*-VAZ7:)%>JAO5[$KTBI,2)C@YUUG1UO:M&-JYG;'%'?Z!RD2M2@8&]9
MR!UPE6OBY$W+'A8C:$I]'Z'N2I(TMZ]T4IT99QI#<B5K3=-4R8XS0(>]SKK.
M3^RZJ7XN=(_F9=A?44 A[W.NLDFA6$N")&X)]5.B=<E3K"-%J)8VK-"5)6AQ
M6JMN<4Z5P0*==-]<'HEZ5,L2FXW(5)R3R]R]1![0         (.^0B*WQ-.?
MDL<H*=S&MG9RMJGT]DS2N9;$H)8L?I(^>-">TW>$2Z;Z^YYE>F6.'&/:@Q08
M4N7,3:\-3/D]W7H4:D33"=\8/%2IAQZ?3C<1.\-Z#IQOKF[$W2THNJ7NR*:P
M-G9GR\KQA5UOJQ]8ZLC+;:ZJ#K($\.C,T5 YV>3)'JL#G-.U2UZC3H0;)46Z
ME 0J/$UQ-VCAA3-W#*QVWLN3 J     4>>9GX1/#O\KOS%^J)X!>C"OB/II+
MPP*       1CA'\KKHG\B/+G^U73P DX                       HV\JK
M3!WBZ:3;8] .Q[$Z6<J3M-3!$7)D)IN9;Q")P*ZN;+49+2F15X2"+QLE37%^
MP>FGN,(69WV/D&QCQ'I2A/8G1/G46IURTE*F9W[E">*G_N"PG@6"JZUX_HR%
M.#1;3$YL\77[NS3>;9"V.TDCPZ25\>7?63Q^N71Y@D<U-<G!4>Q1N)NBQCCL
M;-9V5 ;@E!KIH(>/_?HF^-DDP (   "CI=]\B,GR+"[Z;1X&3WKY3[)>*!C
M T3?./\ =4;3_JX\W?IUO#9_<WQMG@L_ISTT;W:>\W-<:V>BRBK$;1-$@
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MP_C?N=\Z9M],^JIK]K']&/[!SV=?'D      1CNGX;^//RK67]'2W@!)P
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M$;/CL2G6M=0.;S('"")%)!)9I30L>%BC?&WLXW).ZO*8D5>+X7KGTZ^'62V
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M,S\(GAW^5WYB_5$\ O1A7Q'TTEX8%       (QPC^5UT3^1'ES_:KIX 2<
M                     4$>8NP*;C%O<R1":0E+I+[&C3Y%EUPNG1[MSAB
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MJN++MEM<F5CAT71H7^8O,U=Y#))&8L/7*/8Y"-.F"MR]2Q=S;Q;;EO7R(NT
MH     4>>9GX1/#O\KOS%^J)X!>C"OB/II+PP*   !_.^-\Z;X+VUT,SKM@O
M;?3)FFN^<9]3MN7KN7MOKC;TL[:8,+SMC&<8WTSGU6 (R^Y3LS\/?,?YH]J?
MML 3=L?.NHZ$U4EUJT63-;/3]#<Z&/<ZBD B#HB.Y+LO+4E;ZZ<)ZY,ZA 5I
MV?HKT6+#K#=]'+=0L4D&%)&W"4A+N6JW5!=L?.NHRQ&XWU0E?FI1+[EY^?(P
M2L*W>VB-\SV-%7YP;\9SZ\F:I&Z=9S)O9EAF/2P4N5Q9]))SC.=VX_T_2P%V
MQ\_\B0($                    &G+Y;;@Z=8>E9Y +"Z.Y3Z*HG:8HGRJ>
M18+3W)G3O6%6::M3>5OHY<\771,A<7EX-/.4JFMYTL-&O-1*=2<;>M[ZEDQ_
M+AUKMRF2E)I7-/!U-M4\K4QALQ6S#9NX=>I)(>2:%=Y:DLIO?U<"086-MOTS
M%>>;(;"4RE6D;FN44I!S3HC7*IM;"$:%)'8^9LVDMB="H)QI[(SIK)1W-QMU
M.5R/6MA*P"    HZ7??(C)\BPN^FT>!D]Z^4^R7B@8P -$WSC_=4;3_JX\W?
MIUO#9_<WQMG@L_ISTT;W:>\W-<:V>BRBK$;1-$@    &*KQ^"&Q/Q6<_[H?#
MW2^ +5\CROJ/5;A_&_<[YTS;Z9]537[6/Z,?V#GLZ^/(      C'=/PW\>?E
M6LOZ.EO "3@            "G?R?<N>2#J-VAL+Y1O&C:\YU4Q1:CN> 6/H6
MVRN>2;=U4F(?:V5F\^W@>R1TIHRF(4^TV\?>#5/LG!2DK78M1@7I=*F4YU/9
MR73_ #.W^)G@^1<"T_8E=22N*'K]PF$\3RXTZB[0O.ST<K4>T:1M5/LM5W8U
M,>S&^Y,3ZIB6J$,S9&LH2RC\I"UNYN=A%53J<MSR)=!:R!4     H\\S/PB>
M'?Y7?F+]43P"]&%?$?327A@4                                K7L;
MQ#>/BU[6L&[YI1KV?:-J.Q3[8,JCM[=%04V3NI"0A"2K7-4%MJ-L162DJ8DH
MLE&UID^GJ=M]2L&&&;[BVDX2FY8*%"]!.6IZJ@U(5U%:IK1J7,D%A3=LU1MJ
M<I')I<N1(=U:A;L4IDDR>)!)W;?*E6?OA2\/*]3C7?4G!V"2RB]!4R&    "
MCI=]\B,GR+"[Z;1X&3WKY3[)>*!C  T3?./]U1M/^KCS=^G6\-G]S?&V>"S^
MG/31O=I[S<UQK9Z+**L1M$T2     8JO'X(;$_%9S_NA\/=+X M7R/*^H]5N
M'\;]SOG3-OIGU5-?M8_HQ_8.>SKX\@"&7D/OF=<P<1]+= UEHQ&3^J*P>);%
M-).W*':/[.Z(Y(6G]MFU*O:U"U'C!^^3""7!)OOZ6/2.T]("5>TGK:(#8D?E
M=SC&?LP^2?X<>G_(?FO[7(OH/:O3U%?9,G\&O]:G_2/=%Y7?\L/DG\Q^:_M<
MAH/:O3U#V3)_!K_6I_TG2I(R>4"4R:O98Y]B\KX=*S?7F11O";B>8E)=G!]B
M$@A"[#D3MUF9LJ3X9I*X[$%EFI]BUN$Q^QF^A6Q)C0>U>GJ'LF3^#7^LO])W
M7W1>5W_+#Y)_,?FO[7(:#VKT]0]DR?P:_P!:G_2/=%Y7?\L/DG\Q^:_M<AH/
M:O3U#V3)_!K_ %J?])FKQ^="=46%T!U_0O3DZJBQU%%17F250Z5U=5#Q4A1Y
M=U)[L-?D#RR.]DV7LLW09KIFP@5$NJ7&,'+?7$^WKNGK=6H<%O<NE54IJ74H
M;3PC8EM+7!!                 %'GF9^$3P[_*[\Q?JB> 7HPKXCZ:2\,"
M@   4O>5_JFP(;SKU7649K7I:H#([&*?UCO6S<?$X92+TY3ZXZ4BJB&MUI1^
MT4EHP)&N2SURCECS_P!Q\>.@,0:K!E,;=7!Z8XVD?A:E7IRGC=$NY.^&H>%R
MF6XVR4=OM_38VH8Y6MF]0677M5UW+?,9LDFL ZMM95"]+GH" 5O->5Z\K+JE
M=,&:T;Z@%=H)P_O$ 3V(X)UTVFC"]Q9]A*]'!$S1K'\^VOM@C(DI<)-^XN="
MF',^YO2>&&K#&2_FQ.UK0Y]Y3\7MG6:KA4?DO2-I\@5)T@]V>G-9T<8+MVF9
M%)K%="3RWB.-T7DB29,*=.2N>,*V1KT/7DJV@STRC$LE%2FZX_)3:WTFELV2
M]17B[>7/L.>PJ32RE7'E](U1BAO*;T:3)'FMYY/&>80S@^^4<,K!FCF6*ZXL
MG)VLZ$*$A$AE>ZYU0DK'$R3L3-HG3)F!1#N3>Q$Z%*5\XT+%7:5,O5J>JZZZ
M=99;X^.LN@[ZM'H>L;^S4RY77M7\?7;#G6JHA*H:E0L75M>369*8"]I91/)X
M<_JZ_70W+:DF:91'_=20MW<%$78=LEMJ:2M222:G%ISMIB]7*$YPOX2TT"H
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MZ,?V#GLZ^/( K*\S'W+7N#\A4B_2FX":<5PKI/TU^UC^C']@_0?F/(
MPUP-]T-\E'Y)/']^A=5C#7WSY.A'Z*?_ !4<:O[)<J*@
M"CSS,_")X=_E=^8OU1/ +T85\1]-)>&!0
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M7[6/Z,?V#GLZ^/( K*\S'W+7N#\A4B_2FX":<5PKI/TU^UC^C']@_0?F/(
M    PUP-]T-\E'Y)/']^A=5C#7WSY.A'Z*?_ !4<:O[)<J*@           !
MG.,8SG.?2QC^'.<_:QC_ .>0!^):@@THL\H\DPD[77<HXLS3<HW3;'JM=RS-
M=LZ;Z[8SC.NVN<XSC/IXSZ0 _KUXG!NI&32\';E[&Z$^KU]=W*TVTUW,U+]/
MU>Q>FQFFNV^,9UUVWTQG.,[8],"D#S,_")X=_E=^8OU1/ +T85\1]-)>&!0
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MW_WB!&E1HZ,5Q.EC3,Q&PE1[']$D_P#B'A9_S;M?_<!']'LKYZ>H>Q_1)/\
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MCOL$WVVQ,,6]_P"\,O.7+UG+?[3_ /4L(O7/9'_3^I J]'\F>6'T03* @
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MV&?$^;RM95KF290B.V/:[_O$0M'&5%4QAI:3T6]]W8ZL-^VCJ'B;R2=2=?\
M.DPF-K<A(^0.9.T:QZ>KZ)M#-:;=>ZABKY4>1EED+N8SN<-<WE0S.SX662F-
M;4!B_=O,,<B"2CL;R53I2=U4NEINZ,4\,=6TO0 H
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MUSMKC;TO58UVSKKG;7&?2SG77.<>GC'I ?T
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M:1X=SS"4Z0G<YR<2E*PS<I*F+VW.VVT3DZYP7K)B.V
M                                                  'V_M@#U42)
M$W)243>D2H$2?7.A"1$G*2I2-,[;;YU)3D:%E%:YWVVVSKIIKC.VVVV<>GG.
M0![0 ]5$A1-J8I$W(TJ!&1C;!*1$G*2IB<;[[&;X*((T+*+QN9OOOMC33'JM
M]MML^GMMG.0/:           'JK$*)Q(RE<$:5<FR82;E.L3E*2,FIS=#R#,
MDGZ;EY,(/++.)WSKZHHTO0S3.N^NN< >T
M
M
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MBH8MM\/),2SB3&H-63_KX"+IT:HVS_Q,V,!71DJ8F641B_N:9%&I(TMS]'I
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M\_?FSV-^UF NV/G74/<WU3^&7G[\V>QOVLP%VQ\ZZA[F^J?PR\_?FSV-^UF
MNV/G74<*CD5[1&UJSB4^F52S&-6 3-TYQ</J*8U^^-:Z,L1+VB5%NKU>5D(%
M20_TCTJI#LQ$';>N%'E.!/K.Y)X7:D^>?4B38$     '$2#_ +!>_P#RAR_0
MC@!BWFW^3M0?Y%JL_P!AF(":L7POI-"3R&::;=_=HYSIKG/V04I_ASKC.?\
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M2QNDL1?+%:'M!M&8JZ+FQO<%C4C9%E:V03N(279Q-VJ[5CCL6LO6^W]H"
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M$H0E:BF[+EM7S-,C71U1N"5/@0[M^5S3>N6(YVBQ@"       (^V1\.G-_\
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MFOMVXM38O=?9BMO1G$B9>UF2/?G.H?B'0GS7L/ZT@('OSG4/Q#H3YKV']:0
M>_.=0_$.A/FO8?UI ![\YU#\0Z$^:]A_6D .&9?+UT''"G E@JOG)E*=GEUD
M3F4V0N=HM'!^?%>Z]Y>%FJ>SR\*')T6F&*UZPW&QZM1ON<=OOOMG;(',^_.=
M0_$.A/FO8?UI ![\YU#\0Z$^:]A_6D 'OSG4/Q#H3YKV']:0 >_.=0_$.A/F
MO8?UI ![\YU#\0Z$^:]A_6D 'OSG4/Q#H3YKV']:0 >_.=0_$.A/FO8?UI !
M[\YU#\0Z$^:]A_6D 'OSG4/Q#H3YKV']:0 >_.=0_$.A/FO8?UI ![\YU#\0
MZ$^:]A_6D 'OSG4/Q#H3YKV']:0 >_.=0_$.A/FO8?UI ![\YU#\0Z$^:]A_
M6D 'OSG4/Q#H3YKV']:0 >_.=0_$.A/FO8?UI ![\YU#\0Z$^:]A_6D 'OSG
M4/Q#H3YKV']:0 >_.=0_$.A/FO8?UI #@]/+M?Y;X[R?2J.<-)$_L;)&7Q\U
MA,[U=7:.QM9(W"/LCBOQ9V%*MK9%TPE2QK0GF;IT*F1O1R<LLQR5;&@?A$?+
M9>\ C;1#H147-D4BK"E]ALT?8(/.FMI;4V33#]RTJ))9Q1)>3E!QRI29C7)J
ME4>>J4;FJ#C3-P.Q^_.=0_$.A/FO8?UI ![\YU#\0Z$^:]A_6D 'OSG4/Q#H
M3YKV']:0 >_.=0_$.A/FO8?UI ![\YU#\0Z$^:]A_6D ,\\?]Z6_UAU]4D.L
M6.5LRMD;B-MR9"?"F>3MR\U?AB9VOUE6:^S&1IS$GL=>=OZV2E(.]>U*V]D>
1HUV+W$ZF]]>F>HON @ #_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g947560g37q51.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g37q51.jpg
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M87%R>8$H0G21H28G,S9(4H:BL=-#8FB"P</A_\0 ' $!  $% 0$
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M0\/=;+Q[X7TG<.LKL>L;(K<!>ZB^KLQ?6+MM6+1'BF(6>BG9'N<X.EDV:J%
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MSO+-6%KK=ADLJQ(S< M4-)NW4:K+;+3)]S\]8G/"WB,\NVK-D.^-.D7-^TC
M5FJZBMY];50L_KJN4H/MZ5#5.27&*<Q#"F"[_D@!LM*:N19#07L#$(133)YY
M//?D\_?[ZDWTU31TTT=--'331TTT=--'331TTT=--'331TTTBWNN*#)7V!VG
M(4ZMO=DU:NSU0K=Z<Q#(UJ@JM:'D3(6.O14VL*G[&(G'T%"NY1@W.AL]<1;
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MJ[J&,>9D1O*8R:C28ZVV6SMUE0LEP):&LD:J[$$>A/!/N/<GWU<QX5/^;,X
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M=E=Z5=[.%V+4QO(7=560@1;0C;2Z^(PC9T)5FD5Z9K"K,6QM60D+%(^2CA
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M9SVZS15E).S+#4P2LK,C*DJ,RLA =64,64H3M8$ JW!P=624\\0!EAEC#*K
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M954!4,CY<*R QJK%R6 4 G)7#&R6RW&+.85;&.$EC+<OX:X0LKG>_E3"Y8D
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MZ;)"$>>3?X4HDE-.&?\ 5*NL,E,RJS;I8\B0EE;(8RJ#,_9U#2!(%RZG;XF
M=YQK8''7 .4R]8=OG#]PHKYLYJTTF!L#-PX9AFE1[%ZW,-N4,,WE*94\B&8
MPO9*5=G;)=HP?&;\XO$%-/45%,RH%7<SOM5$(79+&R3(6,]953*@$7B2P)L;
M9N7 :9'+"HABE4L2S(JA68L 6>%PT/.R""/&US&DC;L$AL^+KN:;=":2$KL6
M54APH#.2GI!J #<!XVK(:/';M^X,$@ YM87[@OHNBKCVTB0C8RC.UYRF\UCD
M235\DQB*NL8$KY,;RY5FE/&Z*$H<D$Q5/G(=CMM_-]$ Z1TP4.",A(T'F0,,
MA-W/B-P%'>$*O "MB&SGWC^)S/3M:JV91\VPF-D#/)9;!G9:A8(=Y$R:RGCP
MJ3"7RN.V+B-3@H$)PS7'N$9]4)=8U011'MF<)'!!O:H='*4E>SPR!0&VM%3E
M0@)(C:3> 01C,L);<5CA&&ED*^'NR9J5$*$L?,KN7E)VKN(*L1@G7*;P<UZ(
MG$?8:M:,QK"%>"$EU(1[EV:NZO!/%SAR ST"S/[39*P-R-7R>!4W2[;O2.6Z
MFEC5CR8!::/)D.#(LX7QZHU,S*)0H#+'#&&8$R2U$;#Q%C9XM7"#''A1';M'
MD#QLRQIX$8(4L/,7+ %2JJQ"CN=9YAGM1D=O%^YN2&4>Y($F$W9F\B\MVKB[
ML'I58<N5GR#TZ>:0(W'@H#9PX$H2DX!D]7N-4T1BDJ*AE*, H\52!NRP&#L7
MC>@QP-@X 122TM)O#BG 8[.ZQ$C*X!#%0V 2C;CD^<D$G..T> DI(PV%JL8H
M=S*#>Q3ME7LEF) #&U9#5R>\G7B7!#+J=ZR#"%,6+EN2,L$8^R_#ZJ,]:TDV
M]@S*K$NDKM*3([NN8YG\,':#/"L)89\VS.2O&KU0H,(%C78ZH%51PP$BJ"06
M 3!56\NQF\P&#G@OHZN/&CQTEQL%))6#GGF2)>/$F4YF]9U3.61&H8_YH1)A
M>(:C&!*PE*?">SQ>2EQ+(ZC#%3@J#OC0@[ V6!SD;BJK(PP'C&&)5<G8,<K
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M4$ISQGD1,966T?#'55IV)^'M*:^S\.D,2(W"*I4[!86[7#?,D^,;U[#9ZJV
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ML8P20S!G  8X"+G+'8X W ;E*,5<@&.UKYSSJEYQ"5Z%K4>HO]5)3DBER?T
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MJ&F,C=I2#)4V=\INI.<+(7!BDR@RTN.FURK%O*"T0#'D%F>E1P3DX7*Y('<
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M2REXMC9+!MQ5NT:11^0,3A^CE0JQF5%*LN S$;3$(QY7+KQXBH,@X+R.V&)
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M,R1G(YMKIBQ/V61M(1M5'C*3 ,@:N-E26&2.&5)(I'1&8.I62,NQD;"M]4)
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M8;E090  2-+"PP^$"F1AP]<.8ME<0,6[N2E'K=S+@H]$F8EKZ1Y!T'/K2=*
M06%)2C&&Q,H-G.2I7JB,MM3+#(B1@Q !,D#QKP>^&W< \G"C@*!MG8N]QC<#
M(Z>H(CJ%8]\#A#@YY!)/<G221>X&NUQM8Y5XTK2Y61L_P0?M?:DD5_$'>Q*9
MB#:B IV9A'2!7\4\4Q$4N4V K425D=>8DM2V&\U4HIX[=5^*PW%?H[H-LF$5
MPSE5&R:(2E2V\PDLJD<&/GN]KIHO&>LA6(9&7D5CNC).'5<L1+!*T0893<JY
M/!QNU:.MDY V157KEI3$3<M(#KZ).JGC,P<$Z;1RFRFJ9I[$N)$(,L6#%OVR
M$A&T<W,HB%D6-/?4/PKN=1%#/--'22,=\T!"N-ZON_5L",H0 "Q3.Y1D*.3Q
M%7\2+73RRP1K)5H R1SKD$QE"F'7S<@9(PV!G:3@9TMF=)M5<B(Z&AH:=L9,
MQM@^*.Y"*Q#'1(3L;B+,T;@-).6"FH@X2I#K$DDA4HP(N$D[.^ME_A'6^*?#
MK8XX<QD IDGRLLHW"1#APS%3L\I/(8 ZUU^)UO$0\2"5Y0K@L,@MED*-@J2"
MH4*P).0 <@DXU7-.FJUBU7RVNH6CFE$UQFTG;';HJ&B8<<3'0;//FAL1UB9O
M)66+7VQLC3,C*IUC'M\&4D:.I9?AG9Z"C1[S<885C=0U4\@IT?<I1("7949L
MD&,(!*TJJ5R3M&O3=;7R^W(T?35DKKG63K)***CIGK)0J$/+4>%#%)(L48"F
M:5SX446YI'5%W:\\_C[?D@WX>:R;UF_T^Y.'?*&$E)1,%9V<G(X=*U)L%AER
MJ)%%LRB8!:,X]IEX%QEJ$JFP%@R9PE:,U+8>G+7(U39KA!53RQB"6!)A(ZP@
MAS,%:1Y=I=45V.5!,8!7(!W*INLS$HZCZ<N5JH_$+15M11314LE40R+3&I,8
MA-08DFECA,@E:*.218VC&\6G>']6'KOAAQ%$[GZG$-93COII:?<B>/'V1.HV
M%@,>J([ABV$Y(.W1@QX]4J<N ,\CR% VZ\^-WN9%O-R!$G%?4$EJ@1K@U"@<
M*O 0T[X!(*IX<O=79NTH584-(=D>131#)0L2#$SJ<,Y7C>I^J06W >@$M6#2
M$2U92CJQV.RN%,&TNN.KK,;!I@V8.H[!;@4X8-UB5EW)P5T9)PJ0%ZRW9?0P
MEJ5R+,.7] B1@>5]J98#9M(+2 \B-B<*N \ 8855SO[)3DAFR20 N!D[V(.U
M "?UB)@'_3(R2==036!@#LXII5HB,.IZFK)D)MSA^Z(A9)K70.ZL+D3$0B)D
MZ)+>3$@V2D0@*6(>66,=6OOE8!V+.VX>8X!<F0N0@(0>'(TC$ 85R64%&P+H
MX H,@!"(0_&/J@PE>%4DAX]JKG)95Y8,!K%<KA*PD))6>7DW+GV+@5A(T8C'
M%1[%^Y5'W2.2)?\ RE\M2[57;?"B;I>X"Y5-F1D),X0/%/K[=H)+."JKA2N6
M#C: /023(,8V["00>-9?#2,/O(0(CYR,Y:-&CPQ))!W0T[$XPQ(_XB.5?#1=
M0@Y=TR,V5)M8P@8LCQR@[Z09QJ#UERU9DD2K=GD9.IS]<=!&E9C_ /(,&POR
M"R46Q#2S54O@P))([.L8V@,-K/)'DY&%5OU;;F8*J[FW #C')/!3(TTS1QH$
M9SO<*22(Y@=S<DJ&D4CS$LB@@DYUQ[EL!FVC4,ECEGUHF(#WB?:1S@T:PDGH
MH>9$=+U641J@L+E"2X#Y;.5DPUDB%:H,%!LBFUZ8N<LLB211P1[R'EDE4KM,
MD3%D6,N[E6>H*D ;MN-W(U!S]662DB1S6*[A!M2-=S!E1XMKG/\ I0T^[.2#
MDD'!SQ56Z4'78""CFK27<BKL5"/W+Q<BU(8YZ[,P*V^(MN%04C*QPQ](JI-)
M$YB!.A#<MG!QLI<=(P;V+U[&/!"HE.%DP50<LTKJ.%4<*WF57R&W \Q)\0Z=
M(5$-$[NK$'>P"D[GPRD ,02[@@[2H<+A@ =?<.WNJH6L5F&!/A2$;>%&Y&!+
M\LK8V4F[F7#_ -8[ IG8%H'8#$"/&5NUN_269V(B&ZY,V"REV(II&W* (S/+
ML7ZRD@(RGD2-D%B%.UE"@ :@CUY=RK+$D2 ,760@.WG>-@&)\IR8PO!X&[=G
MS'7:!KW8,=!Q@$0)8J)KIG 5Q_NOAKIP([]L\?R$HP:2#8KURDS-BMJ%?MWQ
MG3-H;"0%"VP+?^BV\N&^@49(5$7=31MY5!"_64DD XW'!(QG)56$3^DE^(.*
MN5(WW2%<E4 (8L1R,C R2,A#D<9<%6N]#;,PRBX*:#%1;$"2R#Z/(E"B,CR6
M"E5ENMDVRDI76"O?>&(Z4HAC^51$Y6O),Y=/(/#3]6H2,>%'^K1<;43RY55V
MC"C@$ ]]:9N%V9W+ULZF1B<"0*201DNO<E@<YYW(6()\PULJT7M&2J\0\DI"
M$8L9QFFSPC$><H:M9&1RAT]S\-CVBF@ K4[4U%@)$),A LKRA"/:%O,S=LX]
M H4<>I&!P 2 <# /&.1QB-57L?$%7,@=LEFD*AUPP+8QQ@J20>1R%!]?@.D=
MM25?DAXD(<<-%2S%@ :5X T>3WM6KMT\P@#=9R)29R (73D:G?<7I]\-<"\M
M3,77:RAE (VE%*\YW$*00-P8AL9RI.>#Q<*RX*0Z5DPV>1Y/$8%BN'"]\%@!
MWXVD!2 5UH,M2[@"*<@X5O%/8X#6#?3+]JSC&#H#%(WS=J4<FZRF02J*-#,,
MA;C*CRB*L3=>"!-Y\3&&6/PI(8'C#E]DD$3*'8'+;2I7?YCEP-W)YQG69+I=
MHWW1UD_B ;=P?)6-FV[7;'U#MQ@D8VYQAO*F,TC:-<=NF^*>UF)69 FJ,)8:
MW4K+IBQAD'RR-73);A49D#4TJ-PU-E30I'Z\"QCU$G'KO16V6)HI*&EV,0Y"
M1"$[L+C#1>$RJ40)M!"LJX8$<'=BZGOT120UDKLL;8,H\3)+;CM5BP;)+$DY
M(R3D'&N ;\JXB;:6"V4^<D7,9F6BX5T58HP#&7L\Z=UEYENH./B*CSSX7L3X
MRG %D$!NX"H.,!TFL5G=)46"2$R1[5DCGD+H K*642%T9FRV[Q%=BS,XPV-2
M<77%W62)JA()#$WBE#&4! V\M@ X 1,*&7"KV\P)X9;6*:D*F6Q(>Q=:;3*9
MH;5G'G5B?RV;U "*\OW+H&6 4-:OB/<Y]1T0H7!60FV0H+ZT>>EJ<%FAK9,J
M':)985(\4A^'D0Y /ZH K$2NPMYL@"9C^(4;_JYZ(H 5$K0R!MZ X7:I SG#
MM@,%;?YL+WZTQ?,6(#2+K#\;"1E'3>/>S+UR-O', ,(";;.94;QP</JE';;'
M,'"U4@)RX&)*PH/@H0Q+=*W $@/3RQQ@-F.5U9PA4*BI)&A\210Y(^KY]FXG
MD]%%UK99,8F:&5CC;.H4+XI9MV_)!"DQ;3QG:6X! *SN%PJC"-=2K1+"7(R=
MQD>UBAH"\4]#,6=<@-L!!5H6ISBN:\K@#YQC"%@.+"%C;J;E'#R6^OC<AZ2H
MC<N#B2&4 @,[$Y .51&1&8'&UBN<LQUT,=;02H'CJ(9T4 AHI$9C_1(!P>"V
MV25._.UL #&E(9,E 0Z"*D7T-*Q\09R]:B=X=,4SK6-+#K(V#)#>H)C-[OUD
M=C0% E&<10,D7G(<9QI'"AB.0HQMX);:50'G)&?U_ SM4G8 Q##8$8?!.!O.
M>"-H)#3A3D$@@&F7O]8Y(/(.XWD SS)L^,P@;#!3+S#X;:6:X9.<U<ZU/EX:
MND8D@92K6>OHYHS,C##"FU@.H9 B<Y">H)C8XW*4+LP#,K_5W[20RD,$# %2
M0OC;0#DL,34X=< HRL-N[.5/F6,-C!!!=F<DD9$19CD :XF6%>=M2O&D;8(.
M4*S&0:X%V5\U-,N&8GAA>T:Y?(]N38>S1_J&8!&,4"4B< "DKQ5PF?RAF24
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M/.R>(2N9F9^(85BO#?*3""BOAPT,FC@;8 ,.,LSC=8<B<'D,>NX)G/(VV_\
M3%PCDK+Q<=M7/+(Z1U7TR%*6!I&--%0L8UC3PXA&&DI7WR2HTS$L^YO8^IOA
MK\6.GZF&S]&]-YLMNIJ:DFGLTECKI+M7T])$MUJ[\(ZB:IJ?I%;+42Q4MWC:
M"DI9H:6&)%B8!P:OMR5M\W(M-$5&U[0A -PQQ[KL^TRX:>IN)2%X2PCY,#AV
M_P *#WQ[UR9@[.0BG)@NE#(@LU07&KJY7>Q4-3/2;0@N-ZKJ[PYE5EPU+22B
M6=X^?Z65Z4R9#CQ 23P5]Z>LMD@BI^O;_1Q7@22U$O3/0MDZ?DEH9I,JT5WO
ME$U';*>J0C!H:."\)2JK1$4C-M$B:@\DZB 1%M:>"R/Y5B)>KH=R&RUBW9.^
M0D<8WK\D-PXBI5VMPL29&#4T<(-E+DRE@PL&9BIMT-512FZ1T8J#'(9)8%9(
MRH!P&25I6=-IP0Q;<20,9QKSQ+FM/<56Q-<10%H@D-PFBJ*D-V<^+3P4T2[F
M&]-D"L@PK-*5+M)'DOI'6]/I$?)U6@P\:-_:RAMMC0Q++&KD--QLGF3EL!=>
M^;M,/9!O'1+J8(T/B,:O2$%@*U#< Y*TVNTR506:DI$'AX0>%'&K.A!C0L%!
MVJ26 !&"/+SQKJ;K<[G%2;H:BI;]8/$*LSR)&V=\B*Q^OVY/[^!J#C6;<LVV
M<0.IX.U69DT5%QD^/:4;-OPMU8]!!8N>F89W*QHA-\^J!JE@% 2)&WR%(D^K
MCJ=URAA:"FLM"K89%>"Z^&O(*[TD-M+JV#N!,1*L.Y'(C(X.DI:N.IJ^K+[X
M6])G2JZ2@J7)0^)X,U.G4\,4JEP(I M1&)(BSX!?P])N37L2.:B?S&F]HLPM
M,+,YL=%VV.<M T8-EP0JXQ#:*=SPD>NZ5[0[UX=22%"$)?<*QU&31W*&,236
M&I*Q99YK9?ZB6X;<L2Q\6&B>IQN=MDE0Q.2%5B<'K:&?IJLG>&D^(%)%-5%$
MAH^K/AY;:7ID.5$:*?HEQO\ !:>4BC$]/:X8UPLDT\2HT@V('<L77_;6BH;+
MDMK0&&KA=XU]/2C/&Q:V!IE9BSD)"R602ACPPQNQ3L%A>4';"&Z8K]46/<XX
M+[2T[?2;=<9+I"L+FXVBJJ?_ )K2I$"S5-/353+4F2!0ZU=*Y42J%DB.^(";
M?K.@[U71&V=2]-4_3-9-701]-]96NTQKTA=):PK3Q6NXW6RQ-:S27*4P26J[
MPK*]-4%X:M#2U#RV]EMM\GM87[<M(8QT';MFTF@Q\K*2,=5:Y(RZ9&RR:6B&
M3G+48,)4RBVHO34=^L"R^^<X9-CLG"73F+J^IZ6XWNEFHK;<KY;[7#.JR4-.
MCPO7SF-7EA:>2%9/H]/&85="Q/TB<*NW#MTUK^%MRZ=Z'K[=U%U9TKT%U'U7
M7VV>6@Z@N4L-R3IRAAJI(*>J@H*>MGIH[C<9XZR:GF1(]UKH6GD$\?@PTX_X
M01O#3>S^'VI86E5][4KI&<CZX_D:].U5%<G00:-8[4:G,O 4D1AG[]RQ'@!S
M <+7D9<-/(C*T;=5U%;KO$*6&DK:"NAD$LE)7T,E+,(%5D9PV'AD4221KY9=
MY)!VXR1R51\->H>CPEYJ;IT_U!T]6?Y!37OIN^TMWH7KG J8Z9T4Q5<4WT>"
M=R9*81+L*&4N54V7^'[)N6'%'C4T:1[=<-%<2-6662FT-6Z6D?*9UWK*6BV9
MY! EC&\=OZR^243A8RI<J;YRI1W0T]>"W.V7&>XWBH@HYYHUN=0$=(F<;FJ6
M<^ARN J$@%5W'<54G/=TM=114EMAFF@B<T<+/ND5>#3K$,\C:WUG.2&;' .,
MZE ZN$5+WVH1]7GF[F.C)^819W)\.FC)]$@DI8S!"7[ENW9I<_!;8XAD**4:
MA.AK0[4S E)<J'IBX5!/BH*11"X7QVP7<M*@0HF70M'L(+J BMD'D*=.MZJM
M-(J@5<,LAFC++"59ERL; @@X.)2W"L2W!Q@@Z1D_:I&[N(:%'5I-C$,YZ&E$
MR))5J*4DWL0S9LI+#=LU9O6Y$2:HRO2!"G<HPT<B<=T.AJR;,O1=+1QNDEQJ
M%D50P:"F# ,7B1&)G)C=275B<)D[CM()XYJY?$"D"/'00RL^0%EDV@;4D<JO
MAD$E?#*+@G *G()"Z4[FH;,V<Z5(C<2.:=+32747&8BXV$B\P@I9U8V[UVY>
M+<.)%;=\3)6S1H[.4.9!P$(FHCE'B6IK1;*%TFCA,DJ-O26=RY5P9-K!5VQ*
M0)6 PF%.".06/-5W65[KQ)#&%AB93&1&@R0?#!WL[,X):-&+,W#AAZMIRX[C
M#)6H<E=[.:&9N 2WP-VZ ,)G9 1C=J,2QHPI+1B-TU;,7#EPA>?;X,9.6^2!
M4[+)!@ ?#14W DJBK&#N.2V  "2V6;(RS')Y)USD]375(!J:F9@NV/#,S,9-
MJX4*2IY4 #'<C& 3C3L06DM;1K6SR<^Z(^#&QD3)0N5NO79$6X,5@8./8*RM
MVU;.F+=26>5E2%U(.EJSG+@*T5\Y\I!W9&,CL>,'/;MQV^S[-8(XDDD,>'8J
M5 1\H[Y8[\;BA3"8922"?+NP!M+D4^OT*,F(.PM8:+<L9:/L+!N0\>()$R10
M#,-QG!!H6M8@Q+P/G)C.1I\Z@X2$R_+0J0,$DY(!^P#OSVQ]_P!^L;2>#*\;
MQ!-BOPIR,D!D8D%B"&PP\V1NP3D<IEULRM4^:$\LDG5(%Q#6&$^%-OCK5U*N
MVSF2#'%S\*:G<N\IPQ=X)@@F(>P<9$K^H252,@B_T-Q)SNP">3SZ>N?F/3UU
ML!)7$!IO&J7R)9$$3;595R3NP3N)#<98L2Q[L<\YQLS$FWNQ,,)VU.787RH<
M53U];9')'"PN%MQJD%088W""$PT&@CM]D EI\YW(0H]3K**:1MH2%CGC)!'[
MP>3D'TSQ^[6>:W5,HB,4$T6>9&GD6- 6Y&49U(P2Q. ?*0"!VUTK'LEU(6&,
MEW,?=(W+8#=;R'=.*C$M3+2GSJ&Z++6]@C"_)G 7"5"<=L#_ *M0\Y\V=F.V
MUK*0M,[9/!".>_\ RJ?NS^_UQJOT68+*L[4.]R5$KU40(PH0$ ;CP%R""#R,
M\@YX0M@OQ#IQW91,D0L.TCUP(=F:DR#(VF2B1APO-^&C*R"]+UTJ"8B>R4HR
M%>,^7*+/<0"/H<H).>8GSSQZK_+MJSZ.%A>!JFW2''AQS-4$,JX!PHVY!##[
MCQ_HZ[9+XZDX"68JRWBTR$ZXD6*H?8NK7[S#; 681E*%M> D1EQ@*\9"@WGS
MVPK!LHSZ?0V>X@Y-'*<=LQ2$'OCG9_CVU;%3&)DS56Z=%!)B>HPH9EV\$H58
M@>I7U( X!&TUM=B)&S#2'9V,97#&O1N9/ J[8CR6&"Y8[H>64%-S;U259<C]
M0R&;C*\*0A"BJR5:<#6ZK0Y>F<+W(*E2/O!  X''; XSK+%23+(\F*>2*4DM
M#!51D)M.5VDE!P22 ISP2<8QI50UL^#S44\D(>S,CL*Q+ID9B2HMFB6(7CL\
M(T$0S@\.-LW45.79!X5E&$C056,B3YDYUVIIEY\)E SGC=Z>H7[^_I\]:YHZ
M^)WEC@D*;B$7>LK(&5AD*I;) .,CMG'.=)F'M,)*RL8WL$A3GYG-I:'9-8^2
M:&*\%&(?SYO4:F=J7GLJ-2ENOR8)YE]BH2).5IQ&)1^RP]\CU/KD_+/![_NI
M,#&8E5:HQ#:TRS1NJKAD]=H!!VJ#@[20#@-DG8FF4+=HNQRCJJ?"%X==F+5S
M' 3CW1\";-,LS8& J3>OD>,$:K 0;I:%^N9*1I1;LVGZV<X)QVX'8\^I&?OR
M?75D[K"55?H\H=6"L@'D\QVY[]LKW;:54  >8LD[GHO2QY%G5H@/M'C0(7(T
MJ>.UNSG])1G64NSH< \CA*<KRU(O'_T?<. K4DR05\;_ $XSDX'KR<8X^SGN
M<^NJLJX,H20Q !6E0H1DE0Q*Y8E=W&54<'OQ@M&]XE.(J'AIR%M. R,RN0E6
MC=(7>,1K)ZI2892W:3/'C=XS:%;I]5MC&'11^1;;""$RBHD9>V<>XX]N.WH0
M!W/'OSJJM(FUTF,>Z-&5?$*MM4L/,5&!NP".RJ"<L,#+33&F=OX;3;<_Q:PU
M=O,!CG#_  MPL,B4+B/GT)&(!W+QRA<A(O0O B6W<+?M%8R%*5K];3DH+=*0
M\M%3%EYSX83=E2GF$97< .%#;BI&X$$YU-4_4E]IHMB5DLJX96$A$@&TAMNY
M@6'D57R&(*Y!(VMA.2]XOK9C(UR5JK:#.YBW4#'";@RG, F1@V,1%.!$0X,/
MX:.(KSYI%I*8.'!W+T)SC7Z8\0\_2]#,S/#45%.7;S JDZ*N066,?JF4X1$4
MEW\BD-N+[M=-2]?U,4>RKHDDV*5WP.\))19$W%'# E6E:0J"/,01@ @JRM;/
MI\:S9PHG<J9U ';/'\D]:B;.LS@9"RVJ5&X!A9,-S.;0\AF*8X2%I:,FP B0
M0#-:5Q-3TM7J[&E>GJ$4$0C>890B!]F]9=J%R9=S;9",1$[BS!==+1=:V>=%
M^DR2T\CY:7QD)0EVCWLKH6X"(5 V@@R ;0J@GIUB1(ZI3G-E>QC>7E(V9<1\
M:219/E!C20D%4V; SC"2-ER"U3%HD$,?-@X0%,)?F0VRZS&5-CNE+^K-)+,Z
MCB2&/Z0A\0H%4/$' \*,/R2"A4%L9&9REOELK@9$JZ7&<",RJK 1I(Q.URI+
M22R*6 7EG(P02 _WA<O&;_DUXE3I@A*&I=B<?\"\@DA&O ];3PU$'A*4I6E:
MT*5DF,K]1>5*RM6<YSUZATA%)#98EDC>(F>H=4D1D8(\A9#M8 A2I\O&-N,<
M:X?J5XY+FYB9'58H4+(592R1JK<KP3D>;UW9SJZ?KI]<_KR?0&PGD18N5M>N
M>FQ7VB@YY<UGE=L]6GU1EXK\B7D1L!3SRB9(D)$/J.O52AXE<"#+/*0J3)>?
M.599*BN$$=/4],F\VL.9*:KHJF%*VFF\PDW12O&ZG<65)8I8P8VV/NSANQZ>
MM_3K*:ZV_%,]#=6F$T]TM=YM=9+8KC1>)NIRE;215$,J>"(FDHJZCJB:I?%C
M,2H'7O4K?&W:#*DL=/UM=W&JV83%L%:NEZ<V(V6HU84J3@2259C9"NNVH4E(
MX:)(_B7*>V7'M$!4^QJ07/J*U2-7T_3UQ@LL22/6T-7=HZZ3PE!9JBCB9'EI
M7A +R1+*\$T8/ZM7Q,.NK.F_AEU?##TY<OB98[AUS65,-/8NH;7T346&A-9*
M67\V7FN@DAI[Q2ULGAQ4]=+01UU'.R.*JH@=Z(\2I<IL6]O<&&FM;"LMBL>R
M;Q*OK5--84[*J1+JRR;]BR<!G7S=BWFE@-Z[P;QVL,:\-EO\,>96C#;);[U=
M:^EFCZ?M63-<+A4RW&JV11+!4U]541+2I*LADG:&16ED=&@IV9E\.8C"Q_4?
M1'1_3=\@?XD=6HTU!T[TW:X>F+()JZL%?:NF;1;:L7JII'I4HK=3UU//%34E
M-4I<+A!$)TJJ02+-,YU9V+L_MAC8C7KWP4%(K-0@]12;W!DESZ39M(5X$0Y;
MA<@QG!'00M'@,J6,:38['S*0O?8U*5RW?)#$M#5=/A<@G:BRQTU!(B-CAU5)
M5XP/4\?7KT%+,)['5=%QJ"GAI6V+XAIX:E 6EDI:JY]24\DL3DH()'J:9P-S
M>B++EI)5=K3@,'[6WV:2?A*[CY2Z1CR.>A>/"%2DZ+-8LL@,Q,I!!,J<ADU@
MC2!R "P""$*.E2MM=%2^')7"3AF/TBH:JG)<DL&:2261NY 3.Q!A%"J% \EN
M!N%?7M524]+2L_AI']"HJ:V4BQQ*(HVBIJ:&GA1=B EQ%XLC9EG>25GD:1<I
MM'C#^;VI1.RXNO[=O3:&A8RR.HF$0Y+(3D+'L2OG4A+.1L3.V@')O,J2,DJ'
MKD93Y"DWF0CSVLFMSSO*L<;A99&A!C4M&&)/E)&%.TX.TY].==9%=A2TZ)])
MD=MB)+X+-M=@JYW<@$9P02#R#ZYU'"Y;0U=>9%*:1I6782CP;'X,(=ELH&Q&
ML,[61;AG 5]RS0!XRE3L31V&PG6?,MT[]'*/5(&#FIK3([2"UTC2LY<NT,1)
M)4HS'"]RI(&<]W.,ZR?I5<5B,=/-4!4VA=TKD8.YCD C&"JD9...<@ %!!I^
MPY6'!5V5+K#**FIM),-EL(O#P<M(._=B?O9 YG,H9](2:6B'A<OG:6K9P5!,
MN2$,U/02HJ(D<42)"A6)5C0")2 I6/ \@P #C[22=:$MUN\SR/)42(TP!;'E
M=V+X7()W,X))!;&.26&<Z4KC0=RK@9)0[*6.D(ED=1F\0!T9HM\T25T!.'"3
M,S9 C"PIR9#99O13G(Q@)A8NAG<MG+X'8@GUP0.X./\ '!R-1SO+NS/4'<I)
MV[VWD[NV,%1YE;DGG&> 1I;27'>H5U]"-I.U+?NBLL$!A3H+(+]Y(Y;D*X6+
M""G=.0+$#V2U. @0K)!HP%:T%Q9F0Y(P ><\_N R.!P"#^[C0PKYCB24 ;G*
M %0& 8 L0<$#<#M&3MSRH"G9:Z6U1$0=9CW3I;V;G6OM)$<F]>9]4C)][1&1
MI:)"-)G#UEA92F2)+LZED[>HE/D;9#DCG'<\>H[#/W?OP?718U:/Q@C.H5F?
M8$"HP)&W)(8*8R3]4X\N 5XUL)TOJF-@+:_EVADN&%LCFK7L\D%A;L01-=.+
M Q#7EPM17!%K[K6I6'13+P<0R9REAB=H^SG  X'?M]W\1SC5(3'.4"IN<NP6
M/(!(\/<68EAG$A)'_!@;3PHY[/16IWYI2=<O%1D8PAXR5CD@,)J!])2BI6+0
MEP-Z'N/!&[0@S-1+&C.<8SE*%)\^1#[L?M<\<XP/4X]_?_VQ41F1I(F0JT0&
M8UR[,V[+*I4MQM.=V">!@'.=)?/&!O(RT0QJ=CDHHDNYDY9W)N9/+P2(EK%.
M"X6S.T(!/I#E#P:A(6U] P4%&I25N$=P=T))XQV ]3Z@]^V,_?WQQJU0I<QH
MQW!65MX\/9MRS,X  Y"[2%8XW'G R4R]UMN&DR4?(UZP!L!!20&(XJ2CV\RA
MV[<.EQC:3"VFD%9A3A"_Z]H-!DE8Y(I!%FRMOC*E3(#C)(Y&&&5.1M(8'(.!
MW^SVULPU-3",PU38.TC$K-R0I5=C=FW,@] "">5 )2\V>T1*7[?:VG%3+"0:
MRT795PDQ/U)+,,@Y:R$L!?L'2H=,;,.@8<94UBC(6M)5+2%&/.O5-+;)'#RV
MVC9@5Y6%8^8PQ3*IA6522=K*5R<X!Y$O!U3>H0R-42NA!4!RP9@RA6 )X!("
MJQ49' &G0B=@<3IO#(<NG;6HHE)HB.8M6RXV6A1O8*=?2K%0W^6!YH+\LFIZ
M5N00UE<I(8@5Y!G'5QL_3TTGBO1&-MX<!9)5C!"% 0B2!5 5CA54+N.X#=DF
M5AZPK0I@:9U55*^:*&1@K,&8%@C/DE5))R?+C/&E=?Z'QE=5^'9:WEXRZPEB
MG9J5V6S^-);WN4R\91V85K@9UP\H>%8F$<,I Q:O=E*M@E;-PW Z2/L.GJ;I
MZC*T\T5,L,2J*;Q<,L;*SG)>0E_$\YV2,21EQD9XAK[=[E7)XM+7%YI&S/L=
M4>164 8!V@Y. R@ L<<<$:;!XN>K.7-<UM :KK]%D(\@D1UEUE>HN1&=PE24
MXDP)?-F<V!6?*0Q%H:+=8\^/U<]B*ZR=ZJ4O%15M@%%(I4)44LL[J"N LBK<
MHHIE! R0D>0<;!C6I;9^G*9*:JN5IZU>[T\B2FIMO4=OH(G*OO,M,S]+UE31
ML.0F)JED8!Q(<[0U\_J^UV)I(XF]GZ@@%/T+],336:0I:XRI91Y#+/W 9ML5
MOG]1N[%*X<-Q@"1!?=B*Z-&U%BK*V&6.:\T($B[0D%JH1 A&<;=_C52E>"CB
MK61,!A() )-=7;/B#9++6TE50]%W63Z.ZN\UPZOOTU=.$78R2FF6CM3I(,F>
M&>RU%+,'ECEII*>3P0R=FY1[KJ[2+X[-I>H.]A2,L*LQ^U_C(3Q[^N/V+HT?
M)!,7*<!EQ 9.@2;]R'!Q+;D0$(7V,RH.?EO/4PG@Z/$L,=U*2>)?MC.LML$:
MK!50Q;O+62.6BF\1B$=&*G+HZ^E4W1WPN6V5_P ;'I*ZLZ12JI8*+X>B=:6>
MGZO>=I:^RUU>()1)8Z2F5+A1O#$)*FDJ8HYHU2GEIIU52]4;UH<$WBZ]R.T6
M%KGS$=0SJJPTBW,4@?(K+B3DRO)!XM.<X4@IU9SE>/.M.<+4G,I2=-]26^GA
MIJ+JJ..*)-BP26>WR1X50JC=L64GOEF<D]V9F))Y*Z_$[X9=07&NN=Z^#DM3
M5UU2]3+64W7?45+5-(\@D=F!26F[ *(X:>GBC0*D2QHJ*'AX"-;^R\262;7^
MT:YM+Q'"*^+8/->LXID(0";\U/DPY@$2PCP8<J6E&6N5A43(4KQDBLXSG."H
MIKO3%%N]?2W"1@QADIJ2.D")GS*ZQ,5<DE<'"[0,>^(6XW3HRZ,DO1O3-RZ8
MIT&VMIKC?)[YX\I \*2GEG@B>!$175T+/O8@^7: ?0IUK:C=>;7D70]8W?Q!
M^:([VPQB3CZ]Q7-!30)YS#R,=A>MYQ!L-1(CY)H\[F4#&,.6Q%C*4> )\Q,Y
MQ9)3=/5*;;U"[3*V:6H@:6.HA4CSA)871@"0,JQ9<\[21D25MZ\ZPZ+E?]&K
MQ'14M<A6XV^KIJ6NM]?L($9GI*R">$N@)595"2A255L$C23'QQT -ZX/874E
M:W1"N6_NW5ZS@*TASE!,I<1-8 -P).49PEPLJQF\N<Y4M*%X3B%KZ%W.9X*J
ML=]RM)5U%9,X#$DA79R5.2<,N#G!R=2\GQR^+ \.*BZEH+3!3N&CI;39[50T
MV]?].*"WJLT948\.7?&06&S:2-1<T?K:'NFQ-R0FPK3+RM$H=O@XFOQ(K4^B
MW,F,44+(<.GX(TQ_A3, 4-&#)O[= &*E@;@;@$-"8/I^"RSBL_/-365D$%?4
M0TD$KRO$\=,X@@FE (+RK!'$L3.&\)% CV'<6]&^+'Q#O=CJ>F_T4ALW3-7>
M^C[+?*^XV^ABBKO%OT3W2NHZ6H,4GT6WSUU145<\5.L35M1/-+6/.&2..Q2H
M.FFOC-_R=V#*NJ/Z#EAFBS5KQ8&X@E4D(U1DDYKF++%H:D7E#-3>02V4E1$^
MF=(FZ@=S27.ST#$07&Z_0RK)]!F=ZB!0W&Z*697K(0@.(TBJ%B4,?+D($^>[
MQ?:J^PK+<+;TO^=1/%.+]0VP6RX2F'*NE52VYJ6S5@G)1IYJRUS5+F,,)QOE
M$NA)APZ 9$)N2\P;?)AI$VQLYU)K2ET$Y$!;+EH8[LK9N(><D7@Z\->X?<$Q
M@F,+Q/76=MW@W>_0 X&%K:F; X 5?I+2LH[X;.\9^MQK;I^J*I&$E5T_T%<&
M 4,9NF+=2[GW B5H[=3T8=B1M;RF,AB&0E@1"#D$E[I^G,6FOMJV?,/L2SQU
M7N<%,V/$C!GC;-,1PWSP#,T #$:X*XD<&?.D8<O#>Y2V+E+9ZZ"ZY*ZO;Z;Z
M)16RYW44-UJ9::[TTT\TL4L$I-3(\23,XAEE:.1)&@V-(M0^YL<Z]KZ$ZPJ.
MH:7JOJ&^V3I.JO\ T'8*._\ 2=TI;/26ZJH:RE>*R4RU#T<-/^<:.DAJJ2:F
MIJX3I#-04K1H"N-2<IVF-+P#)L%O(3+>U" D:[FUV;,U^:5Z> MS*&^CHII@
M3(R@)'A!EY#D:4I2KRX1G/10P]&Q*HCAJ(YT'_BX7JH*P\8.:N&1)V5NS*TK
M!@<-G(UY14_$[XB5TL@J>HZ>JHY" +374-OK;#&0Q*&.R5E!+9X&B))C>&B1
MHR2RE2QRZ<>NGU^'(PJ]ADH%\!XX=NK VN[\KV35D&%NAO4XA,-9#&1^B9)3
MM\N4D&/TCXP58R2*7+IZ.)(*:>NI KM(7IWJ(WD=QM=IF!Q.[8!W3;WR 0W?
M/,R7R\5-;-77%[3=I9(HH?#NENIJR*GA@9C%%1)) 10119D404G@TY#D-$V$
M96LM6J:7/8)E_LJ[9L;5^-Z*Q?G(D)7*94"RX;/!MWT,]:F.T+A:VIL9_P"1
M?XK13<6?3ZBJJ'I:J7$M7>?&#B1:@5]Q,OBH2T<F7J&!>-R&1L,8R $(4;==
M=;/BAUC9Y66F3I 4CP24CVYND>G4HFI)@J3TJK!:X95AJ8AX52(I$-4I/CLY
M.X1QT[7"[N<62^;FV+:929K%@<TRN&87 D8Z S@$,% D5K!"/2I*J2/ETV;I
M*I"G9,O$C4<N?+!646BY4Z7*_P!==:JXN)(8YQ55430T\4S)$L34SHJ86-'8
MXR\F7;<Q UZ;\3NMKKT'U'6]%]%V[I2P]-T8MU?-:QT_;+C!7UUSM%-75-16
M?G6CKVF<?3I:2% Z1PT(2GC10"6DN37D&=#?$WN78,[%-5(R"*7LA8C82U&-
M*$.#,*\%X<21K3GNY4H9L^92LE6C.4]$#T^0JS76_P!3%G(BGN->T8QD;6"S
M)O3G_.;SG!8L>=>4O\0K['OFH;3T%:ZJ5762MH.C[ M4Q9@SR(TMNF%/(S#*
MO2B!D (0H"5*[AVE9K+AF^K^P;VW91[D)_R?SMN;D8]ZZ(OS]EL'T053CS+9
MJPZ995EKW]9+EMCW!O5W8*WIZFDCDIZR[QI&X<4XK[BU.6!W8,#S&(JQQNCV
MB-_-N0DDB$K^J;[<Z6>&O@Z4JY)H33/7OTOT^MT$3AE 6X16M*I)5#.$J1(*
MF)MC13IX<6W3M2]7V^1>/IN&<20#/#D-$OKY,$K_ ,0=D]-[[2,3#NF@3NUO
M3%<"9H%APLCCRI(0GE52IK^E*EVEJ*>:I+,[^'(KRQ!I#ERL$KF)"Y+%MB(#
MEL\,1K!0]5]76VGCI[??3;A%%%"L] B45>T-.%2GBDN%)#%6SK %C$0EG8QQ
MQJJG"C$'.4%1IM>H,M9*/!O(&3;$]&12.RV"6;JKSF,<NRMW+:9:QH_:DRAF
MY:X25!!.$H.!:!**OKA^I?T=,-+);;=+3/\ G&D6I8/X:U%&TGZRFD4.VZ)F
M2(A,;$(+ 9U[_P#!7XA=;7>\=06VZ7^>ZM%T1U-7V)*N%9Y*2_6ZB,M!7TCN
M \5:L4E3$9LB2=)/ =V4H%E36HAN.DUF(;T*%)68FN,I,2XNFP@#C:(;C,59
MI*1CK-E$BY1Z[A).ZUD(H?E&I:EI%T[]3((XX8;91HD2JL8E3Q2,=F4>0J01
MW],\'7S1XE2U543-5USR322>.PJ'5Y 23('8G.T_6)DR#C+' R';9ZOV-@;=
MDJ/+#13AEAPAJ]>9;,V82(%ENEO#H.V9.G3ESE:2+%'8;"PC.4E6%?ES'R]2
MW1P46H\%#QL@C2, 'C(."V,CN6)&.3P=8UIBS>)X09CQXCC<<@9W$R,< #G=
MC@=^#I:1.GMF.(R-M!)=I7LS:"NV0Z^(+-;>00Y*0ZE-(8+-F!HW4MPS;^@K
M(C# ,BQ 2H;14;-75<S$R3S29Y.9';D]^Y(&>XP..WVZV"D@;<)4B5@Q7'ZL
M8#;&Q@8'F]R/K$@;!QV&ND=@O8Z5DW>PY8C>(D6E=;MC/Y53ERA;5E)O2Y%A
MVA37!GL@9:DB<F$,"<E]11C$ZP&>4@'<W''+$D8_D>3^_GVU4^(RAA.2BEDW
M&0J"2I<!1N)90"<$Y.YL8[:1^-,;9<23R/BY@$VR8-ERLBXEFC9\1LQ'EXVB
M@&;2H%I]<YR&+CV>/3< :JSG"O.E&-B&XUL(S'4U"^^V1QR,Y/!SV)R"0#QQ
MQQ=M9E8960@*^?+(BJ&(9BS!@!YF!!P"0>-RXTD/6VQ17+7#J"<.4R#C#)F*
M EW[(WJ-F+A^\4T;M2.*RC! LGJVN746[\I,A:G#@^/:XEZ;JFZPD!J@3*!R
MLR Y ]"PVM]Y# \=\=]=J.'!\6F0;1DLGD8'(')1]A)!'!4C ) P-1TY"V6I
MRM#M<W8ZZYA[?'A:/(FRAK49F?09N]"EVVD+=%N*VD"C1X7@7C9Q /299J44
M&$N_8FQI=37VDK[/5-/0)'7HJ-25U.52>*H,D:*5DP'VN"8W'BY=69<9VD>R
M_ .JN,/Q%L%JI:ZH:SU[UT5YL];(:BTUEMAMU765'TBE+^$TE/\ 1_I-+(82
M(ZJ*)B=GB N9PKL<)0M)U1!$TES:;0S5:K&[S,S#&2*[F".7N1N5OJ@!ND;,
M*5H(@+TS<)$KQA?F*/S]/T]=[/:+51T.)(WAB59&$>0SGEV+ GZS98G'+L3Z
M\>==?W2KZQZOOW4$U9&_YPN53-#&[2GP*8NPI:=-R *E/3B*")6P1'&JX& -
M5'?X2!=X.V\1]1#:P\,UE6O)&ND5),GH7SH[%>L-K)6!)D1[4OM%F] J\++C
M&5C O EX4DB=FYWB@N421TQ9IED$A+1E2(]KJ1N(&<LR\ X.,^G$=TW32T]7
M.&F5HS3M^K1FQN$L0#E2 ,@!E![^8C5E7 '1\S(\&N)\XJQGBVL[QVT:;.&@
M28]K&2-,KPG^3*0O/N"+C3$PC*T82G!?31E2A*QUP51)()Y0"V/$D&2W \Q&
M,#G!' Q[X/'>E:Y6JJ"9V.V:7;'N8_6;;CD@!5 8%5!)"[< '=J?[KCG28V4
MEZZB61)R(XK+$24/6[5+0:@K4MTV8-,8>8=K,X$;+MT5PO\ 4\R3#2M(^M?S
MD@D9'&"/N/ R3[^_/IC6O)&D(+.)'PQ7>%8QE^,,&8<J ,>8DEN,%>=.$[@Z
MC6XRIR-2IA'.9&%CAO\ V24H6$F&J<E&]<+;E],*/6.)#=20-QXQW\P<@'C%
M0F[(+ $#MGOS]N/M_@,^NKX3$Q8I)##MC1]SC<XDSEA&=V_&54C);;CL0S:2
M<_N:KQS1E48BTUYW)4R>D6LG$13-U;;"-#P@)6-2."K3*6?Y6AC)X$M6&PU9
M6C'IG%D9<#R)&7/]&6R.,#"^G8G"G.0!@?9SC6:F@EGB :EJ2A5_">-6CB?<
M^3NE=E& V2<L>%&0>,I)[NB3F7EHAH6@N%UZ3#&F2JW3OP"0<S2$N&;KR4Z#
M866[M6V&;2+6ER[A6"E%25!&R/+@A9.EL=RJBIAIG"\^8KM4]L8+;5//L3JP
M4J4@1JJY4M,ZON,:DU+C X)$>Y0QR5VGC&"6/8<N+B]QRYFOF<+K<.UC)./#
M#UB%B(9FZ3)N6;K)I"?OR;?-O<MBM/4!D-)A59]PY2<94+&@,_3]'5+D-4S(
M@(Y"G<WW8&T#TY#$>YX&<,MRM".\A6KK9BP(E9_HRC"A?*L9!VX&.23@ #'.
MM1SKRMHD6:=A7JL/GD683MM'W>TO;02.?+ 8 7+>$F)J&IK4Z0."C:D%1@J2
M@I$#SZ1<BQ(K8^GZ*3965\"S* 6CFJJ>!@#R#L<[P#W7D^N!ZG<I?TDKH?'L
MO2U;/3R;E6KH[37UX?8<./I$<4BMM(\X)V@@94'.M"(6Q<2+QEJ:*>SV&9$^
MM9X62C-=P+EQE?F(IDN@PD0J29J[+%A\5TW0YSG#B/Q*,OZ\FS!#2S,XM-LI
M*B%" E=52L()F!&XTZK%*TT(QCQRT*.2'@,T>7UNU5/):UB3JF]U]#7R#?-8
M[71PR5U#&R$QI<Y9ZFCAH*TG8YMZ)55$*$Q5PH:G=$KHN&M*BVK$NP*NX+-F
M$(SE:X6WWYHDY'*FZ/+,8C9A'J$-G&<!<%&Z&DHR%$A!AK)+M4TM$D2U4'@2
ME S?1J.KGIPQ.,+-%3N@.[.$9ED(()7': AL]?>YJB2T5$512QSR)"+I>;/;
M:]D50X>2EK;E!(P$9W/+$KP AP) 8W"I*:VE1HV=BZCKFC0]UM;WW9'\*U"U
MK9:^!FM _P#GP;N&<24:[=J44C!L[C (<-FKITIR(*09<:DE\CFJ(Z.UP)7U
M 5GJEDE>B%$@(1%J5>FEJ$GE8GP86IUWQ1R.TD:A-\RG0U1;[;)>NJZNHL5M
MDDCI[5+24<-[DO<S1M+*]LDBN5';:BAH4$:5U7'<W\"HJ*>F2&65I1#V<3^U
MI%(F4=J&NUEXLJ\%D9B8#/1H&Z5D2)26<>R@"N5&1@9%X^(-U-E>821.NWJ8
MS^->I/(M'0TG.3-)4RUJA>>$@2&B+,>.6J(MO/#:C_HO1%-^N>[=0WA=B[**
M&V4-BD9SM+;Z^2X7]853SJJK;YC+PQ:$>5E0:1?5B%0XN];86*3(HJ1#HE7.
M03G*<>I@2FLH^>"8$P//E05]-# Z(A21*&58P9V&GJZ6!6J8C6S$MQ;Z;P@<
M8(4K454BH=I^M+5!6((7:V%:/6BMETK91;:B.Q6]5C!/4%S%;+&2,,WC6ZT4
MLU4A89\.EM+R1*5W;E#NK2.WFUK+DKZ$X_Z[;1"/,L;*Z206\Z_&A6,X0G#.
M(4T8N3C\R4H)ETV O*5>[<H3G&8]Y^HI 9*>W6V%!DK3U=3,T\HSP&EAC$=/
M(P!7"I4QJV#XDBYUT,5%\.J9TIJZ^]45TKE4FN5KME#!14K-D,\-'75AK+A#
M$0&!DEM<LJY!AA8C2\U,^HNPJVN<@JX[I,O'R#V!L<"P?/8.6KE@BRY!)Q+H
ML,Y8=UMG"<Y&9*!I,/(R>FC.<H3MVZII+O1I4FE5&5Y8:BFG5'>FJH7:*>G<
M@ ,\4BLI*^5@ X\K#41U/9:[I.]3VPW 5L BI:VVW.E,J4USM=QI8JZVW&G5
MV+(E71SQ2^&Y,D+L\,A\2-].06JGSYU!MEKRM:"#S\:D6]R#A!,92L?MKNRL
M8,CRG.4^GE&4^7NG./+WQUDEM5NDR&I8AGOM 7W.<KCTY[X]A@@:B8KQ<HQA
M:N5ASP[!QCGC# @X^[/'?OI.KHK\"@9;9J[\0'35VL)HJ8JY#.&;D;MN7*J#
M8*S%#,)R(9T*)!N!((GS);]\X[1L_2ULD)**\1/.00R__J1FP.W?TQQK96_3
MG^GI:.HR"I9J=%<@\'S+CD8.#COSR=:SYG;A>J94=)Y=K;G:#E&3FKW,[0#A
M!!94R!,Q](F!J",BO20:PO\ .5_,RCI41"X6HZ,SGP*H$9)"ON4']XW=_M7@
M=S[["72W2+LEIZJG4D,RT\Y:,D$$^23<3R.^0>V=V-8L6-I&V(,V]RX"8#1+
M 3227)U >&P6V6C=!L6)F6L)\@DI\H@W@X<N4I-A7GPK"H6IZ:NE."%A\9!S
ME,,<=O0EB>_)4<=LZVA+1SP?1H*^#!(VK5H8I1YL@;P60D<C.,X\H.,:53JU
MRN*=%M&F&S))'SB7?'?"Q,5PA99R>0<"39H5<I7BY;G-@.,JD4J2$/E3Z6$I
M1U"244\#L)H)%P",;&R,#GRD C'?) Y^SOGCI94.)%DF@3<T<E'()!N.//\
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MYFJF#8?G]5TILH[DQRRD?2=!-"LT=541JZD@S120L5&2=T<RQ21GOY753QV
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MPL"3A5WBRA1@MZC )XYQ@\Y].3[#&.=7>9E)27RHP4N7PF7&Y0OG;C((8MV
MQ@'(U"^]:@N\AS(TC7'%ZE'4N"C2DXB6>OWK(^(]EBXLPL$J6HZEH]<A' FR
M.S0A,J6I"L*7E<69G_/2N6<.MNPARP(_RDL=I!''(!^[)!/&O9Z=I_\ X U_
MA395OBHOC,K$_JDZ5A90Q[Y1R749X8X[ZF.SU;NI,A"Q+#8,BL]CD',:7UY&
M3:" R%'R-@ '"R9+DF$O(]H)P49<G2 1UM3B5D'J2XJZ@$CQI1_U/QW[\\\G
M'I^[@:\9!FW%4G#LX\-0DK$%OK9W,%"J-G#$ \@8'F"G%*L6JL>)JMO;+":P
M/3<'=C8$4CARY&!#;D%J4)O16YPG*4&/YU>4:$#\J$J3CY]2MOEDE20R,S$.
M "Y).,=N2?W@>NIBV;_!EWOO)D4@Y)P"I('H ?7 [9P3G@7C=2&I+5#]FK5+
MLOB.\U069H!W)AK_ !=#!X.E[E*,/M73F7B<*;E&!&3$9,E(6<95(6#"AY'^
MM@L1<U8M$0< *V?^Y>WVX^[^.-1-T0[8Y#'O1 ^\[PI"Y3.!D,3@GZO<' P<
M$.@RU)IH;"@LT,FY[#(56*?O$/'$IE"GCQ@)2.P&A11V%Y2DZU#*E&2$5ZGE
MRHF?-&;7(RIX]<\<_8",XY_]^-1/A+X'C[&=557D*L@"DYW*!NW%5( !"-@%
M\<9&H>\5];ZPCI3DN2:8J]6 W 6JQQ2N)!UC$,RC5,&[4XP$0I\3(1K\SAPC
MUBX2H:SH$4@U1=J#&*H"G.*VKSZ\B=E/IGMSG')X^W7M'QF/TFZ=$2A%>:?X
M<='2LBD1HJFV*Y*C/E\S%0HW +]7) U,%AJ;3<:SL$R]:( $$;!-ZV)+J7]D
ME4S[QX8JP(6I^4ILLFZB*(190##GV^6V<+SF3 <\?M<X] .<\\8SP?7U[8.O
M&(XDE=X_#;<C#,2LN6RWZP[R=O *^'AN">21QKJ0>B-4N9J(46.$&''6IN68
M CWCX>'3Y+VO$:'69R8CO*1H5Y<(2<0U(<N F;J216,L,/*3SS[Y&!ZG[#C\
M2.-6!HB\J.A0J&+98DLZ_44$,?*<ONQ];.[O@K!SE5K34LDG1S%C&MS1+[<5
M6@9WU%2J2$8.)"+<E0LKTZLD20D:$H' \",W4#"4X&- D#C:\.M3:\G.:ICP
M<?YB0_SP!G(X]N->S?#* I8/BR7B\#_^!4[-N!1NH+4, %FPP&%R<Y)!);DB
M9#S5&IY:/>N:ZP L48X"R;O$N9=4@T;N7ZL"5YY$A$%4A#IR4*B"*'!596K"
MUA2K$GM<8R>/OY_?\^>?NSC7C<RB A7B9&<94DJP;'?.#W)X8=QD8 Y&NU8=
M/Z8CI]E6H^-2LT<V(N&$[++'PE18X8"9R9#C#;NY&Q$I7N$GPO.%Y4GS92DU
M-CD%@2!P,'ZW^.>W'?Y7M$I625(C)"KD,_B#GD9(&=Q(9CN[?9NR6&$FG=,-
M<5&O@:B>3.85L\<I?NY5:RR#P"7"B9RT(W9*(1/K$](GDQA7IY$%*5>55<,1
MN'E &.1G[N/W^@SZ<\8M,*B+Z1X;NA",SJR@*X)#J 6!"@E1ZD<\\ ZASPRH
M&L'&E[=9;&S-F6SN&\1B#Y<R"Q)9>X]-L+#-H9."*]%/FR0F,97[="5F\F<C
M5&6A2;? JD<^,<9'K-+G//L?;C ]<Z]A^.D?B?$Z\A4\60T=@)4,%PHZ;LW(
M.006Y&<'@D  @'4OV>I=-1<?-3S]L)OD1(M%<$AS+8:"5+L?>'+ENW7AZ4;@
M018P(ZB>V0):09 O'GS)8<@KZ^_ICU&1^' ]<$:\>CA65I$$;;HV ,88*3@L
M)&+%@,C]G!./V=P\NNG :,U4N:9$+%"%'!K$U+1HV#Q\D1GAG$<,3A:CD6X(
MI 7QU-_ZQ&!^LO'HY5Z?IT"L/4_9@X'KWX[_ 'X^_MK&&B+2HR&,J'R&;S,Z
M,-HR#WR6W!3R,<Y"L-:K4#4TG.0KE$0$\>"PJ5*"(*0"MPX_)^<6$N5E<%R[
M1DHLD2(O_P!&K"EJ"DGMTHJ4=?VLY]">W_M\\Y/!QQEDC6!XUFB$:RD'*R;\
MH <@$YV'++EE)!7A<$,78CE/4:?;..&X#UF(S&.HT#0XEIB(R/61.)IH+&%.
MBB,X/AO'D6,J<N!.E)3Z?I)4Y\I(R\1,+=4-DDHJ2(,\#9(I[@9SM!Y&,9XQ
MP1[!\"Z@6_XK])PS1P&GN3W&V3@AY=\5=:ZN H5P 0[L@8.K1\@G.Q0%OKK:
MU6=ZPU;+3LK1J[7[!K^"S(/)FQ1T0Z&X'$)9&0W:&D6Q\D[A$A24M#9<)]/*
MECPE/DDH0LD22#)+*CC&<<@'M[??Z^IUYI>*%Z6Y7B@_7M4T-PK*(0QQ^*@,
M$[Q."RHRD;U8;U*J,$KC<=W;?<FZDY/6+"J>E).(7 LFN6D?0[,L[YRT:*;E
M].4?0<?'C0ITE>1N/B;9HI&/,-! KR16W'15$N!'!+(>0-JL?? ( )_<?3C6
MH])4-"5J(#!*JHHDFJ8H8@JD8)\24#( .05.6P"0<Z21=Y2=OKJ8AMJO8;H+
M.P3#B*4A]&M4.(]Q*/'C(I5Q0[+@ \@>)&IL822C(!*T=N_9,I!T]=G(84C)
MN YD*I@<\D.RMC'8A>W?'&M>-H:1@7N5 2J;< 2U&PMABJE$ )!'!#\[B.!S
MKIJN^P91J\%+:UL$>TQ.ADXT,;,3ZG/MQ0D-%J]\M=.7A3GUF+HPS#PI6$%'
MVRDF28)MCI6[ ;O"BR>X,D1)]/\ 3_M^\8U9'4T$)?9<(I/$5MXDHY0@<LQR
M@W [<'D;?8=ARKP;M<!_*5,Q!6*H)DVD9'-7JVIW'H)9H>E4Y<XDVL0A2$.G
M2\8]#UED'Y592@F/+UIR].7:'+-1NX')\,A^#WX1F[@^@Y[\DC6.'Z.&7PJZ
MEG5LF2$L]/D*> #,L:G(],C&,9.1I15#:$*(1)1E)-+-*1$(5NW<R#4L*U>R
M$V]]L(('+\ 6SY]&Q[$N,X"LI\I="&G]9RC.8N:EFA?$T,D/;(D1@<?\6X#'
M'//OG' UM+&XF$IC\.G;>JR!A411,5&Z0"-G5<Y.,G R2>Y&HB\\$QTGJ&CQ
M)V"6LML;8%?@W[,N N'JH0Q7#.5RW<)&DPP)Q(,4Y&E.$#$<(\C'Y59S W1=
MQI(%Y\:N@##<.4C#2L<#@?5 Q]HY&O8O@N5I+CUW?GV-'TW\/^H9:6J1-H2X
M7*."VT2[P"=[^/4!6##<5DR'7*Z?V*T[J'(@PD1'H;OJ[',66%J5)9*Q PR-
M@;TLN,DCRC$1V42D$:KQCSY<B4LREFZE2C9#,1@Y[>@[]R<$<_+&<C(UXS.A
M5?&: *DTA*.'#9WGC<N>X R /*/,,+D T&?X2Y3-8U+B3J..H8AC)"<EZW#8
MP1S*N70FN=5[74^'DSPA&Y1J>,6F5K0HAT%1Y<DP+*$)D;:K^.[-V,7 YR/,
MF?[.W&?34S:8?#J9'57V21,5D)4AP'C(^J>&R6[JHP!@=]61<!)V6;\%>*@H
M-A"(DG_%34,,&0D+)9IQ+9:];P#83LE>J5(F70E"6)!_ASF2&H&4^W202_*1
M,F+!<JHM)'#F.1RZ,=H!5CN4@LPSW'[\\ZU*UZ/Q98ZBXP1JL[LT<4#O,OZQ
MSL9\@!QO920"-V"<@8U+ZPR&P6F)2X$EV\ !G&&D9^R15&'" 2V;-O6D' Y"
M^V>5?,TI0)><8%17CDWZJ/ZQ:\H)N'I>6"GDJ*ZHBI::"-YIG+%MD<8+,2$!
M/"@X5"2QX&20#CHVI;E5T=GM\=?=ZRLJH:2BI%\. 3U$TGAPH&.W&78#=(RQ
MIDLS*@9Q'QO*R5AB?*6B;+FX91S/&<WL6UDDJY+O)=V9X=1TO+#%P,2QPZ=K
M$WC2:U<-VB<B8MF"0#P@5U/;($3Q#:ZYE8 I/7ST-OI7SMV^(5J:JKB)Y\K4
MY<' 9%.1KJ/S5;(:A8(^H>GGJ(_$6>BZ>M5]Z@NT?@@B04AGM5LM-:R[=YFA
MNXII$5I4J9!MW/UKVBV 49Z#X=%D8D82/"4V!=.(V/SATP]>,$6.@GZ:H,SD
MF$Y5(%@3)=,R#R@2/1R0O4V^B:)2\:6F5D4N8J:-_$\\>Z!#4O4S!0S=Y6AV
MNI\L: 9;E;S54,DT<)BZHM\4LL< K;E4P/&%BJ?#KIUMT-JH"YC4X%(E>6IY
M4:-ZF;.%5RWFW0(2"E:^H=9:!4/'H2KMVY0X$G*O4&A46B"]H9:<I0E>&TB
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M1G8Q!(W*3@J$ !XSC(/(-<J$2F.:C"M#*X%102D([*QQ)&) =R-A60D D8(
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M=7FY,8R#$@27"G$GKG#8C@"L(;^Z:^[<-^_HH.A.?+SU=9[;258H#?;=%4L
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M.O:/AK++</AY\8:-HH3=([;TXU3"BIXDE);K^)+A*)(E;='#&4>4K)L "L&
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M>\<T4$=7254L3/3RQ2PA!(CM"ZE9%5!N"\,^\>D?#BE^'OQ%N4T]/T5!\/\
MJ#HZF7J<5-ON%RJ;)>;-0U,4-SI;A27":H-+)3Q54<B5-'(9I=S,X,4'@MV8
M+&\]K.JY=[)K:O$I$#7H=C4Z%:7%PCW1V:&GG)*"''0+EJPF'V5"4Y?$\GN
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M798TSM169B% !9CEC 7GW)-+O(<?J%'.)%FBU7>1:OI4<?,M'K!DAY5&SSV
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M=77?#NJD\:#HCJJVR<_Y/0]9TS4/",$V1W'I6X5X/B['EW7)]Z!TC\ L)$D
MRN5%$R")V_A4.%A'[Q#.,=(:+/E"?5R)"V>5^CE??T\$[KPG&,*SG.._4^DL
M(4 R0AL8;;M SZCELCD'C)." 2>->?O#*6)6.7;DA=^68+V + *"0.#@ >P
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M 6?E^=:P8[_+_HTV!C_X_D_\NGZ)WT=Z2+]U73$_(29.GZ9]/_ZW+_Y2J_\
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MQMQJ1O\ 0J[Q_?\ +[_N[;_Q7ZZ;]+Z/_8=/_P!T/]UUY9^A5=_O!4?U4_\
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M=9/#/V$]Y743CB'E]8IFSQ]/E]ER&R40TZXE:VG*"Q3:EN&F;^:0:9,W,"?
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MVOUUWZ747^PJ;_N@_NFO%/T*KO\ >"H_JI_[]K]_H5=XX_9S\ON/_P .V_\
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M65G&,=L9^>>L3=7S*"6ZA4 =R;A$,9[?YS4I%\'K_,P2+X;7^1FS@+TM=3G
M)/\ ]CQV!.DW>J%X1=5I%HM *_PS?FAZ[*RC%C&3>MI&2D7C=@8S!C'1[:4=
MN7CUZZP!LU;B:G64Y1H])7?..L4_6<\,$TPO^_PXGD"I7([L54E55%<LS,<
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MK$$_6YP/3SUU.O!->9/E5QOU'N?Q!.9UIV3R1A= R%7K7%R)@L35ZJE2%/\
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M.%C4GBO.8IS>*M:XVS:HAW$W&ESE=AUM-5BWUC*_+CNIQV/+UKMCOYLMI)N
M@\X_6"E2<>7DYHY[?,5\:FD9"&'AR0U*'O@,OZV/VX;:>V![?1M%<+;U;:M_
M_P \HH*A-HI[]07.Q5XRVX"GK:7\UW1\D ":'=&QR!(P9B)!TKE97]*9 B>J
M6C9N':_)UBRQ*(:V93C.,8P)>NIDE>QYN^$Y2YAV.5=D95D6<*PN9HNIZN'
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MJKLZ\<QR4TJ+WQCQ&39R<X)!'OSKRCJ6[?$"WO-^B'PWM<Y!;97P=3TE7.X
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M,S-'UC NU+A0O3L>#+3X>,GCG8Y4KGCRK)*>#WY&O,>HOR8[IB:IZ.ZCI;G
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M+7H.O1@@I#C& ''&H(X1^N4I5?K==Y8)ZVIMJ2W#=]):68'?&D1V!_)Y$1%
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M&>IFE?=-4S.>V7D:9N_IXK@\<\!3Z\>WH%/9+5:J=HXK2;>@7<D-/0T]DI&
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M68LH>&'G&8X(T-2>WPA+8:1CB&NEVKGQ+<IAN)X:I:! #@'RQB&(#OD'' /
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M?,G&<X<L1!7C*L$QA.<H5%MTG<Z-S)05\38[)-'YL>P!$R#D#G8.1R==W_\
MO"]"]34ZT?6/2=U@1_Z1[;6I5Q%CY26D,ELN04J2"HJW([!@"6UCBC<W-08]
MO+<=V]F$WSG"3R-8HEE:XQZ2$)2E%=E=?2Q4C4A14K*/)2%*OU"%1D8AY@_5
M]*,/34M4HY!VQ'/KG;$]/\]O?[@1$RT7Y--_)ECOEZL$SC+0N;S!@[AR9:V#
MJ& Y!P LN%4#" CQ#.KPD[U:=B;LY]6.YT,&N)]4WQECWE9;0#VM!'\/U7.-
MTOTQ+^7G#A^(9PIQY\2)A$PK&18PG&._5VF>KJ:)):ZE6DJ"[JT*J5&%.%?!
M=SYQYN6/RUX'\0+3TW9>HIJ'I.\M?;**>GF@KWF2H8R3)OFA,L=)0JQA?R?^
M'4C]HL<ZN_ZD]<3KRL:XYHYTQ>N6%"B^-;;8DO'<\>:#Q=P-%7B<S( DN0^P
M7WLTL(&J+8C*QR83=!T6-QC" +2=J,J_*#E;K>J^CK7IJ6S25@18F%0-^UMZ
MJQ4!8CDJ?*0'YP./37O?0OPMZ0ZCZ;IK]?\ XCV_IV6=ZJ-K5/):H9H/H]0\
M,<CR55T6?;.B>( U#'D,"CLH#,\.?$.Y@3^/;ZTXUP]>2I1,#6/5+]B]0-9Q
M*:X2]NM]:LT$"@9 G*2$(DR2J,ALU4E&,1WYWZIJ.(+1#3YSS*C!L'M_23;<
M\'.5QCD^FNQ_^'GY/]H.^[?$>INQ4+E+?7BIC)56+8CM]BE=U8D8$=8,' $C
M9(.B6[^*]MQ"FR)2>JT>[^7HCE(6G%9H7E6<(:N-74^/E/,)),H3Y[,K.?2&
MI;E1.[A5OT7K&KXEKHZ1/58@BD#)S@T\1?MC'ZWT))!/-WZ0_DU]/<V[IBY=
M0SQ?4FJ*6H>*9@#CQ$OMTJ*;8Q"YQ;%(W-Y",(O['^&IRUVL\%*[5VB^,Y(M
M"B.G8G<_,"3Y!(QZ=BO4E9Y+*D)$(:5X"%2!A%A*4X2A*+ATA/4,'N%TJJD_
MM LS>O[+2N[+]F!P1W';6.7\HZVVF,T_1O0%FM$04K&\LBQH<%N7HK12VZE/
M?)#M)DLP.<DF4-(\''7(\@<;&L<Y;SH4E2TS4Y)/PJ[=NZ<QH"LX7R_M[I^'
M>7OV[)SCMA,O3=*VBGVDT_C%<$&=VE.<8/UB%P?;;C[->?W?X_?$FZ!HX;RE
MG@=65H+)1TEN&&SSX\<;UA)!QGZ3D8!!W$DR!/X2W"^2CQL)W5L',H%C/IX>
M1[0@1+SCME80*'D8E9QW[Y'A.<XS\\_//4K^;*'PQ']'B"CL!&@'; P O'''
M'\,G/G1ZQZH-2U8;]=VJGQOJ'N-7),^.P=VF)91Z*V5'H!IF++X(G$5YZA*E
M"R-,.KOZ:X.:FV"19SV[90W%(+98[>7&,)]IE/S5GMYL]\1U1TU:JC.Z$J><
M%7<=_L+%1]^W]W.NZM'QU^)EFVK!U T\2=HJJEI)%.,X#.D,<[ Y.29MW  8
M#C3(S/@@,0+SFJ;MV%&#QE7D$N88.483G'ZJ$8<P^282C]G=92*S^W.?]/48
M_15M)RDDZ#.< H?4<9V \<\^OKV UW-+^5-U]&I6LH.G:[@ &6V%6)'[3,:B
M3.[)RJJBC@J%.<H-[X+FT FPEGOBX';?/Y*<1>%X^?R_6]AA.?E\L_J8SG/S
MQVQ\NL1Z(H^2*F;^W'MG(!^_:/W:D!^55U0!YNF^FBWHPH1]QR-C$>X\Q'N-
M;33P4+@X(G,MNF[&'G_&0B7C ?\ 5_CHB%9Q_P"[]G[,X_TWKT3;P06FG8 Y
M(W(<_O,9(YY['[.=:\OY5'6Q1A3VGIJF?]EQ;6DXSV*^+'QC.,,,9.,=].)"
M>"!1,*2JR72S37?_ !\/K+*8QG.<_/.<1BX_&<_Z\82E.<?M3G/;K:BZ/M,?
M>-G[_7<@^N.8PG;)'R].-0%;^4M\4*E2L%SI+<#W^@4*(.V",5$E3Y3WR?/G
M&& X+[U7P;>,<&L99"$:2JT93G/Q(3B8\V<=L9SWF'+S_5WQ\OEWSVQCOGJ0
MBZ?M46-M)%QZ,&<'[P['/OSV/;GG7%W#XQ?$FY[A5=674AL9\"9*0Y&<8:DB
M@?G)SECGC.<#$H:IX??&NIC0-C18G"$XQC(PQ[-H+/;.<_\ T;<*$XQG.<YS
MCM_\?GU(1T-+$ (X8TQ_H1H@^2J![_OUQ5;U!>[D2UPNE?7,>[5E;553'(Q@
MF>5R1@ #^ 'JM)'A5QGE&JVKS559*DB,H6M3 "U*QG&<9\WG0I*N_?/RSC..
M_P#HZRM3PNI5XU=3W#C<#]ZME3\O[=:=/<*VEE6>FJIZ>9""LL,LD4BD=MLD
M;*XQ]_<9U$+8_@\<4KDL[J"K:J:_)E2D.*V[?P6!DSC_ !_1B739H16%?K=S
M-2XSG]N,XSG'434].VFIR6I(T8YYCS&.>_E0A.?7R\^N=>DV/XV?$VP;%H^J
M:^:-3S%7,E:K*.=IDJ5>H"G &U)T&#WX!U#RR^"G;(HQ":[WG<F(,9[B:R+J
M/E!(QCYIQCSLV9\XQWQC'G,O/9/;.<YSYL0LW1-"V?"FF3U'U6P1]^SOZ9''
M/;.O3:'\J?J]4"7:Q]/7,\9<TC0.>V=SDU!).#DC')R!Q@M/(>$SRW99RF/W
M&%ZG"LXPIU60KSVQGOC.<HF<]^_^G/EQ^S]F._6D_1!XVUS]A]:(X] <8F//
MV#'V ZZ"#\JBF.?I7P^MA_XH+C.&8YY)'T:(#//;G/\ HC@\A'A4\P7*U!>;
M0;#'\TY4WJH^ZL9S\^V"2^$X_P!?R[_L_P!'^BB]#MD%JU@![1Y)X]<S#CWY
M!^WOK)/^5-;MOZCX?V]LX_I[E-MQZ\"GDP?;((]\Z^L>!YLZWD2NY;-E_/G.
M,J-&@BX@F,]_GE*LC?D3CRXSC_&SG/[._;Y9WX>CXXSAZR:0>O 4=^^&>0=L
M@CD'.N9KORF+E(6-MZ2L-LD.=DJ"6:1>,9,B1TS$[B"#GC;VY)T[L5X(MU@(
MOV<#O6= G"<X]K-J8SC8N,__ ,,[-PQ0P*/Y8[X2 :U8^62?/K)+T;;G7"&:
M)_21'7!('&4V!3D]^!]Y&HNB_*8ZZ@J5EK::RW* $9@J**:.0)VQ#6QU0K82
M.X)E=5QPF<:92S>$_P E]<R1)RHQ>K+DZ$K"\/FC!_3I,N$=\YSENQ;6"#=&
MSG]GN8\0EXSGSXQV\N8P])7*D??05Z,1C:)H^1SV7RRQXY. 4'KGOKO!^4/T
M1U)2BCZPZ3NE.K\2/;+@M7&S$@%FDD>VW,+MY\E;(V0 !QN&O%(YNZ>5AO*\
M>06@+?.<)-(5NAV5IC&!81C"1P,EKZ7*@:DY/YRIR51E>52UHS@.,JMU?284
MT])5*.Y*P@DXP!^J:%^_N V>.!VBIJ3\FKJ ^)'>;W8)G[Q'\\0;?-N&9:Z/
MJ.$C&$P), =BI\QDGX?VV+YM/Q'71;]J=GJJ1KW!N[QX6K.HRU11.^OO?4I'
M3]364L=CPX](PL(1EHY$)N@N!J];*DDZZ2R55QJHIC<*)*-T=!&$#@2 J2SG
M>[GN!CGL>>^=>-_$SI_HJP5=M3HGJ5NHZ2KAJ):MWJ8JEJ*1)5$,+-';K=M+
MQLS$-$Q)7.5Y77H8ZF]>8:\X&^]5<L-E>(GS2'QUO,S48)O5N+;6W!C+9>J\
M-X]/K>=(P*5M4)R'"[()L,Z4%>*486%*0(B!J7C//WJW7*N>#Z#<9:&-4=9A
M$TJER64JWZIUY4 CGG!(!UZ]\-.M>BNDZ6YKU1T;3=45=14P34$U13VB<4L<
M43H\0-RH*UE621E9O"VJ<<J6QK57X:_,F_%R78&WB2*C*#DI)9C*V5TK !9
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M!..V/]&?U/G_ .?60 #MK 23W).>^3KGR=$ITRG*).MQ#O"L=L^HR#C.<?\
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M)4V'7->>>MW\_KQK-RG/?]OZC@)$Y_9C]N,_XJ?]76"2DI9N)8(I!Z[T5O\
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MF#['Y'1].CA+^^)Q8^\'J3^;NFF#['Y'6L7FYP:/CL?EWQ0-C_47?NH5X_\
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ME \:%,U.$RVJ9;W/S.NY^8/1?U+:F^SFG_W-TTR?<_,Z/S!Z+^I;4WV<T_\
MN;IID^Y^9UP+7JWC31JM9;M;M6Z:K]3I\!,VFSSTCKVGACX2NU^.<RTU+ORX
MA59$SC8UHY>NB82K* !6KMGMVZ:98^I^9UW4Z&T2M*5HTQJ52%IPI*L:YI_9
M258QE.<?\S?LSC.,XZ:9/N?F=<"Q:OXSU(,4XLNKM,PP9RPPE4B"/M>T\29"
MQV1\.,@H=OG$*KSO91^831H/Y8(9:4Y5COWZ:9/N?F=*'\P>B_J6U-]G-/\
M[FZ:9/N?F='Y@]%_4MJ;[.:?_<W33)]S\SIK-HQ_#S3 *X?95 U!7/ROF'$!
M5VV-314U(STPTB)"?=L(R+K]4E9)T9K"Q4C*.<C:9&W9,G!RK0@><]-,M[GY
MG33R^Y?#9@V,'*23GCF*+L$!+VEC*-]>P+^,:UZO6"5J=CEYZ0CZLZ9U9E6K
M/ SM>LA;.>(_)Z9A)F-F<,7<4_$W:KYLXR<\^I].=*AC;^!DKL(NK(BN:7F;
MP":CZZXBH743.89MYN5B(R?CX]Q88VFNJV SF$FHF40HLN@264BS.0B$''G+
M5,M[GYG4@_S!Z+^I;4WV<T_^YNFF3[GYG1^8/1?U+:F^SFG_ -S=-,GW/S.C
M\P>B_J6U-]G-/_N;IID^Y^9T?F#T7]2VIOLYI_\ <W33)]S\SH_,'HOZEM3?
M9S3_ .YNFF3[GYG1^8/1?U+:F^SFG_W-TTR?<_,ZAC&4>ETGQ1Z@WIE0J]1;
MO^ FTC/@5B B8 +TP>1&FT"*[%%-&B'!1(6I R&2M2$J4E.<8SG&6JY)7DY\
MW]FK)^FK=5FZAUWK^[<^/$)<7.BTZW'8,.(@6)[/682?,R";5-G6830LJQ=K
M;C*M"%D&%2$K4E*E8SE.,X:NR0!@D<G^0U-G\P>B_J6U-]G-/_N;IJF3[GYG
M7P31&AA83DNFM1CPI:!)R37E-1A1"KP@0TY5#XQE9%J2A",=U+7G"4XSG.,=
M-,GW/S.FLO[3AEJVP4^IWZG:.K=EO_Q+-.@G>N:T>4GQP[V!C95PR9L:ZZ-A
MG'R%HKS-X].D+0#B88"(9*CIQTTRWN?F?\>FDH:W\ Q(NZL1_'UTO7<DRA[8
MVCM?UJ4?,I21MKJ@LV4='QM;=/K&<U\8R%'\M:;R_IW*-E*L7(YV-?,&[5<M
M[G]YQ_/3JU77_%F\IDB4[76D+."(7##D'D)0Z9(L $L-;AKC"CQ(-H<C$ZY*
MJ6*OV-LANX*I<-.1$AG&&TDS(9JF6]S\SI6?F#T7]2VIOLYI_P#<W33)]S\S
MH_,'HOZEM3?9S3_[FZ:9/N?F='Y@]%_4MJ;[.:?_ '-TTR?<_,Z3U8U?QGN<
M:YF*KJ_3,[&,[#;JFZ>L->T\H 62A6N:HUQAR*S"I[/:[;J[.5^2'V[!D8QT
M'"E81A66F6]S\SKJ2>E>/D-&R$O*:@U QC(IB[DI%ZXUW3T 9L&(".GCHZ_@
MV?*%NW$0Q%=L^5"%9[?+IID^Y^9UAA-.\=K)#1%B@M2Z>E(2>C&$U#2;37=/
M6UD8J4:"?1[YLO,+C*V[MH<+@*^V/,,B<]L=^W33+>Y^9UT_S!Z+^I;4WV<T
M_P#N;IID^Y^9TD[WKWB[K*GV*_WW6>F:Q3:E%N)JQS\CKJJ89146T3A3AVX]
M"",92$8SC&$!$4JU*2@:%+5A.6F6]S\SIB2[7\.MO#R,TY9Z+:AB)RMUN3C'
M>IFC6TLIFXM9Y]4FAZ6XI@[>E%F:56T'@7F(/+&616K!EBY/F&DL-FJY;W/O
MW/\ C_'VZUW6XO#B;-J^Z0+0TDBT,YY]#AK^J65E>D!5IY=7LR7\=7J9)R$*
MZK]D&2!F6$TVCWT;,"+'.VX70B"2U3+>Y^9U*!CI'0,DR9R++36IS,W[5N]:
M%SK6IBR5LZ"@X"9$:#&865B(A61E&,J._E(A*\93AID^Y^9UM?F#T7]2VIOL
MYI_]S=-,GW/S.C\P>B_J6U-]G-/_ +FZ:9/N?F='Y@]%_4MJ;[.:?_<W33)]
MS\SH_,'HOZEM3?9S3_[FZ:9/N?F='Y@]%_4MJ;[.:?\ W-TTR?<_,Z\M_P#A
M9>L]<4O@-H>2IVOZ14Y%SR_J;%P_K-4@8%Z=DO3&\'"V9G46P:G*U6=NW,IN
MLBA** ),HRL2%):S0DECDD^4]S]HU?=X5/\ FS. '^QYQV_LKJ_36)_KM_S-
M_,Z=CC)QZNV@5;N5<^2&W^1&-L[ON6V:VG;,@!_C4=;L_L_A^J*-Z2R^SIM;
M]L3X:R;?#H@&#9^&0$1E3O+QJA.<< 8 ''KCU/VGUTU')_B#)[JM.PYNEHHM
M3=;*X<<GM V*QNF*V\O+WW;;G10-?2]I3%12G5DK$+"ZPE8F<*\DERC2(S&P
M\2T<-G!%,6@./F#\LZCQ>.(W)RWWC=VZ&U>TXRM_('77(/34GKB1V38WM;H$
M!N;4/$G6\1?#VL.L!DN<A$R_&1](6:LMZS7U2M7M5=CV4YB1JC@<JU7(P!SQ
M@^W8G[?MX.E=M;A?LZN6=%YXNN6%0M-8@(=45,2-IR_E+1L"<3LAM:+BTB]A
M0FR-?:^7 FN$A)F3!4](;JG<F_7TI%9N;RI61+5 >.?\=OM'L/NP/<Z<WE]Q
MMO\ O"1TC.-=?ZEVX77]0W%"62N[!N=CU_"IMFQJG6(6NW"OFB*;>C$S6IZ(
M<RHTN@M9.O"RUL=:=GMT)"IZ:#CU(^[_ .HU"DOAO\JCOKVF?W2\NMEL$%:X
MQYN!YLF-JTGL.%GZ=7JW"4RVP\%H9>U&L75W[)Q+1S8G("9KL'*UR MU;B 3
M-IL$1 M7!A[=NPY//..[?QQ[Z4.Y?#EW?/V:R,]96:'K.H\SNWU:CUY4KS7Z
M TTJ]V)!:2) ;(J*+1Q\W0PJMBKMNJ6SI9D\URQJ=SI3BPC?4>T)S=K@T8M4
M##U )X[^N,GG!&<\9S[:3]P\//DC<]G6^\6.%TA8H>2M$M;)6K25K'\#VE)0
M'.?C?R*UNJ>&;2#ZW)<MM)ZLV+K\LGLC8&U&]+L-]?4_6==IVJ#.0/&F1C'/
MV?O4@_QP?MYSDXU,[BOP_G^/5]K]K"&H1;>5H&\XS;:JW)RY7MZO=RWY&[%U
M?/RR748T'/*J%(>7&O-I&3,-Y6@S":U! +7\IRU:H<?OX_@,'^S&F"7X>6U(
MR/A9=E=DVZ5SN7FS;IK5UUVCL$^GX&,Y*W+D#+:ZV=KV" P)&P^U]?0>SXB-
MDHF2K[^INF%KV7\/6.UMJI;@M5R,YY[+]_ &1W[9''KV^T:[5X\.RPXX[4>%
M@+5;MF<@*HUXGPV9K8&\;;3F$-3-*;QT_MV_TK6ETI-2P_UX.PEUPM<3:(RG
MFL[J1BZFB3D@-8MMEBTR,D]@<_;W! ."<9Y_=Z:GWQXK5WJ5 +"7V!>UZ6!/
MR)6C62WY?.1S]S%N&[ HGCG86QJY6;&-2GBGS85>RS=,8UNU"X:OEY?E:M&K
M?\=L:?7IIHZ::.FFCIIHZ::.FFCIIHZ::.FFJ_\ CO\ Y=OB+?\ =XB?V/SW
M35Q^JO\ U?SU8!TU;JO[PZO^CKD?_P"(#SX_XIME]-5/?]R_R&G>U]QZNU*Y
M0[[Y!2O)#;UXI6XZ[KR#J_'2ROP&U+IEW28@49*SFOX_"UY92%Q.%4G,K;MH
M\CAZ^DB2QYQ68A4,T)X P!C.3ZG/O]WIK+R8XTM.1L;5&SJ]3U;S37LK("J+
MYDSN.E=BJDP,@XA=ZZ@E",HS:E39+8C=1\.N;KDC'.R.7$9/,%N3Y(T!Q_CG
M]Q]#J"VSN"V\K78;RBA8H.MV<Y,V2YV&9A]R[M-0MZN@U&JMM?:_M7'V?#:Z
M7J:(9W*HUTLU:*?)61Y6*I4F4=48N3!?KA!Q35<C.>?X9'VY]3]XY]>VG/E^
M%D[L\&P+=LFNP$!LC<?((%Y>?DIL>YG8ZCU<JF:%ID['L7\4WI;.]W288\;:
MK;*XYEZT:/UKN"QQ=WKA'CNB!F9AIG[\ ?9R><>_'."/4:=G4ND]Y63BY?M(
M\DK>Q;V.TUUQ2*[8*!BO1KRCQ!=75&MGE:T2GU6C0\=F%VFSNUQU@)K#@DJ_
M2G%$BYIS\?BI(0&J'&1@=O?U_C\]0BOW ?EIL85-MUSV5$/MF6:'V'+[(71]
M@QE7@]7;FN=RKKJM;$U1)[!X][>D^VN]6UFK:ZKUCJL?J[8,>F@QI(Z10VV#
M;30S5P*CT)&1P><@>XR._?N1K2F/#]Y%.W.VVR!4EW5;ALR.OJ8YWL.I3%CM
M<BULNWY)#JP$M'&&7H&P*RUC+]!*'6N0E&VQ?VS]N84-N6-?:ZUM:EM4!'R^
M_P"S/[7'[L?=SPF;CX<'+6ZM+VFR;#J\A;+GH]Y1VUDA=BIC:C7UR'!M/'F6
MU(F/M&A+INB;U7([MS)['S'.MWQ]>>-[$O9,O52[9KV$V9H"!Z=C[<D Y]\9
MQQV/WX.IN\=>-&W]4<I=O[.FUU/&M[^WV@Z,9=E!9[O+SUHV77[10LM)!AK.
M@S6*M7JH*TQK^O[8L^WI.A/WL%4-*VBLZO:/Z^=JA.0/LQ]WVGN>?NP#C)&=
M0I>>'IR=E[E)VJTUO1UKAIBU5"V; UXXV*_BZCM29IG(V$V@EU)+;://;99L
M_H6+!#,#[GNFWIP[R0=TN1?1%#>'RY:J2/M]L^N,8[9QW/88P.W?ASZEP2W_
M !DQ7ORC3K260K86L;75[?G8]S>37%W557Y)7/;-VXT:KC75&!^5%%L6FI^-
MT F8!*4-M<*VITQO-9Q4ZE5*^^:9'IGM[#DXP#]^?O\ ?OG*=MOA[<F9VMU\
M%CV-&;(S4+5(4B-J#F[QT:TL>A=>:X<:\XY2]LE]G:1W96I+:,#*OKCL>]."
MZ](]9VG:T[.5.Y.9S7U5Q.M,C/;C'V]SWP 1@>GW :F/L?B===CP_"NO2VSK
MHU+Q](^)L?8D'L>=@=J3[XG'FX:L38(JX0\'&$G)R5MTZSE[ >2CX!C+,R2+
MMQ%]R8A2-4SWX[^GIW!^7&H]:E\.N],)M$9L_8D["4]EJ"]:FLDOJ#9]LB[=
MOAQ;-[[-V--;"VI)3T*\LT?:=FP=X_*38.:[=!N(K9,W;$526%7QP)FS5=WL
M/4D9].!C'W?V#C2\U'Q9VMIOD+L*Q5^FA5J6R[DAK54E0/+K<50@*U0&>I]9
MZV'&RO'%C1'>N+++0B:9($;AD+&M$RVQ#J=2C-RV0ILU3C [Y ]N.Y/?/V^V
MK/>FJ:.FFCIIHZ::.FFCIIJ $I_G3:-_L ;6_P"(K3735W['_5_9J?\ TU;J
MO[CS_EY>(I_[)P__ +)[3TU7T'WG^2Z=[6O'N[4/DKR%WS,\C]O;!IVZXW73
M&I\?K4_ ?5FD#4F$S%2S[7;!*UX8N+BX_P"=)A31K%J<NRN23))]U[%Y'M,\
M 8''KSD_?SC^&E/R9K3:YZ<LM1>0T-.-K$Y@F1V=ATR\WY$C"WFV,F9Z36K.
M5A?B,BR$P6XKDP[?*85>SHAK&[CIH49F&?M!W_\ ?'\=5]RG$38,S!T=&F)O
M;4E8ZM6']&KO(/?N\M[:YW7K"4>;'B;\^FUZ^A8-C0]NZ_:1V1LZ[2)B$@XD
MWY-L=;RKIW19R6=5IJN1Z@?<,$'C&,]Q]^3SSW&EA1^%U[P*#AML5JHV&JZ)
MTSLO66K1TW:5VK5KVU.V/<]$V]3KM/62#A:A-ZCFX/&HJ2 KF#LEE=8L]POR
M</35UBU<VMH3GWYP3GW ]_WGT&G6XG:$WWH*Y3=1GK/5Y'1+>N+<Q$9#,X1B
M,UXEH'4I"NX",;UAK:8*+B+=';R:_"++<[1%1FO9C254IB(V/IDE&1S5"0?O
M]?Q_?QS[YXYU'+:/ [D%;'%Z;,]D1LI0(#:4,\U!KU=C;@)/Z0L=UN>X-M4.
M\+OFM-G4$)U[#N5/K].K4Y0[[4I#7O''6L'+.Z^JWS[FO-5# >GIS]_ ]QG@
M=\C&X_O0(_#[Y,L)BENXVPPC]VRU!8M>S$_;]V.)&6KT5.TO<\&*G4FX4_CE
M0MDTPT ZV!5H&O3M%L5>UKFOPR;1*Z/->:= .[&TW#G/J?0?=[Y'VX]_7DZ1
MLKX<G*Z8JT5 +L]8B:]$*W''TFH5&\Z\HLC0I2^P6D@5#;CJ4C.)<YK&,V/5
M['2MEN&EGT1I[3-EJD58H6:JKM5TM>T7TLU7</;DXSG)[9X'.2.W!)SCT[:?
M"O<'N0%6WQKK94>_HC]M7]R[2N$I+S%L1(-65%V#S/Y);WEPQ585J4%QKFP)
MO5>Y(6$-)Z[V[4*?:+2@M>V[4+W2J%4R2S5,@CU]/F ![_V=NV,G7<Y2</>1
M6Y>1"]D4\^N8ROQSZB@KEB/:5Q=G%1V]4L$!L*IS"9#5MVM3<LQ*6*0.*%UW
ML/6U L-=/@EVA;#96Q%R+0$8(([_ .!GGTQ]O?YM=1^ V[JJWHRY#5FAY36]
M5IVM:E9N)N-O7(NJM@; IVL[]4ISDC*V9[J58W5\G9RS55JN,G*1)/W,33&&
MS7]C+LZ/AHL#521]OK@X /)SC&?XY]2-=M[X?O*DM F->DY!BEFC#1=/7 3A
M;9:F,_9.2TQ3-3ZYWK)3$I*5ZVX@:1<:EJ:VFAK(\C;W+YL?*?<,S/TJ1578
M1M-M4R,]O7TX('./WCC[@ .QT\T?P[V>O@UO[CBJ5!$V;;#ZYFI4-(W.!=U[
M7<-8!U]LS@(61UEIG45<J$9ES$REIS!4W7.(Z L-CDTQ\C+(5A[TU0GG./Y\
M_?DG^>D;9_#\V4YV^:6A=I6>2J4CMW1FRQ;@L^T[;,<C*E5M:4K>U:D=/0LE
M982UUP],@+%LU5UU^[&B.?$=[)VHPLPG+EA S<JU7/';T(QZ=QS[^G[L#'V9
MKYP8N=.W#6KKI.+LENKJ]=WR+O$C)<QMT:%V59-DWG9$=>9:WV6UZ^J%G<7-
MH_"U4S%%/"Q$17!MHZ.KT.SBF;1LU:IG/<GTQP#VS]W^,ZM5AO?8B(K$FV&R
MDOAK'X@S#)'FA-'WM1>[;"F'+1@YEA@<>H)$DX8LSODHPZ*T;D*H*&J:Z733
M1TTT=--'331TTUY3/\+Q_P WQH'_ &R:A_8EO;IK-!]<_P#*?YC5W'A4_P";
M,X ?['G';^RNK]-8W^NW_,W\SIV.,G+W4_+-6[T:K:7MKG0&[[EH&]?EO2Y2
MH8/>*/[3XP>NYD>^)>"7[T7M7>?:R".W>0BV&#-,N&J$$8SZC(Y!X_=IKJ'R
M^>IM_B2.-KMX2)UAP=OL0TCI2MQ,J2PN=>-^)NIN0ENDK"-Q+OP34\SD[G9F
M\8F&8P8%Q#2)8+9.) ;F2>-5(^KCNPS^_<1_9J**_&JU*G2$CN3\PNWF[F.L
M#./31)2U:,B9R:K\AJ>0W(VLM.D'FU41%_,&LQ4C"352H3BS6ZM7)@]8V*(C
M*P#%O(]_L_QQIL.<9'W\^^/;(]\D 8]=</</C646HQ.\&5 T5L1[<M?\7K;R
M.UR/:$SKG647LZ,@=#1&_ .JW V.]QUVNE195:8<#L,OK2'N$DP?U&Z-%10&
ML8TEWK50AR!D<D#/?N2/YCMQW&<9U-S:O,>6T_JKBQ;)?0NP[ML[E-<J;K&L
M:?I,WK5O-PNP[1I^^;=<L9NQVF]P]&;0D+&ZZGV,E+M+9)A&138[)4F'S$RU
M:!G/(P!G//;(''&?7V&HE,?&GTM-5O;]LK6B.0]G@-9I6^A9BOURLSD;=:XR
MW6#1,_:W!H.SR;K7L+6;*Z:V^9%?F4)-#U<YQ<6L0Z.RF(2+:KM(]1_'OC..
MW)].,\ZZH?&.U$[:P<_&Z5VM/4-.L]#;9V5L2IVW0=QJ.JJCO[>&P./5=-+/
MJMN"7)<)""V+KZ3Q98K7@;3)1$'[TDBU966&D*JAJNP^X[D#ODD 'MC/8\?;
M\]8'_C+ZAC*ZJX/="[[15;;!FMN@I42=4F+R#J,7R4U?Q:L$O48Y.S,/*<ZC
MK_N"C3+*'VFBDO)>F2Z98.6\BVD(9BU38?L[@'["02/3V![9U]V3QC=7TK-)
M;W70FYJ<\G=P[7TC=GEJF-/UNBZUO6G]B5_7ECAIO;<]LF-U4[E)0MD:VFL1
MZ+BRS-5>/F7 W 91JTB9!_C_ !_CGTSIM^T'MVSZC/M]WS'VX^JOXL5,B HK
MVQJ;<9R^6[96Y*-I=K4ZG"U1KN":U]SPE^&'YMZ?&2^S[>9S=J.\E-;6F\3+
M^9C(F4I=B/L5O#U-HWF:=5VA7UX[ D9R>5#9[#@^GV\<]R_/"SQ'-5\X+!;X
M?7%#V56HN$KS:ZU*V6QG7"5W8%)=VN?J I6.=5JPSY:W.(?00I9Q2[B&#LP*
MU9*S+>R61U+,H5H5(]NY'K_:!Q]HSJ+-,\7Z3-5;D\NO%+:4C>*A;^<4_*TS
M6]BU*]5!<:^$>WF^J[]MN4EK;L^ C)&<!,RD=6TTB$=GG;#:XZPN*\PS3TP=
MBF6J[?M]%]#W89 ]?GQ_9J27*3G8TXW(XF;XDG-9SPPW/BX1VU=@2<3,"M5,
M=3VG9/;.AK1&G7+L&,;7;*>GS])L$?-P#QX6PV^D":R$.03MM)M4 SD>H[?/
M!'W\@_N/V:KZUIX@?B-;&W#3=7RM1UQ1G[GCYQ8WC>HJF<,MV\@W%6=<G+#M
MA\"HV^PP?*S6C'6/Y#TVFUZ(>S<O#VH,S9@W2:"S81<2&%RU=M4+G.3S^T!V
MQV&#G)SZC3P47Q%=XV/8NG-@6NT:(HG'S>G,3;O$ZDZADM#<G;#M-IC6.X+'
MH..F;;R1UZ>[Z=U_MF[;#B8N7K>I]H:XH%9DZ?,. L=H'?P$Q+A:H5&,<Y"A
MB<C'(!QCOP#W!.3Z<ZT.!'B7[,V/HQER<YO7:@:KU59*U6%0B8_B+O+3=:!<
M+;-R;:*9UC==QW?MBO[CC,,(.0$X_)>B5K('+ID^/( !C#)TU0@9PH)([\Y_
M@ ,<_:=*G4GBRPNR?%*V-PBS-Z4)K!J\V1J;6+B%M87.\7?('1%6H-SVJUN]
M4S8CXB]<S+.U7VK:^EDUQB9];-%7YN9\]$_BQB:J5(4-@\\]L#!SCTY/&>_8
MC5U735FCIIHZ::.FFJ_^._\ EV^(M_W>(G]C\]TU<?JK_P!7\]6 =-6ZK^\.
MK_HZY'_^(#SX_P"*;9?353W_ '+_ "&G>U]R%NUUY0;[X^RW&_;]&I6G*[KR
M;JW(NRQX0ZEW.\NL0&3EX/7\A@:,O9"G'/\ #)A#9S(D ]920Y8$%E,0F9:$
M< Y!SG(]1CW^_P!-5[>+'S0W3PRVEPKNM&MKF)TDUG=I7WE93V55KEC>W?25
M&G]%P%I,Q=RD+(3T.]H%;V39]@MU5:2A'<IFOJCGIW0"""EJY%#;AZXX[]^<
M=O?&/7OJ"G&KQ<^6M(T7(*Y",M6;"W428Y9;@FY;=%\@N.5'JVL] :^X\WQY
MQYHTG3M730+AML3G=IH:MCF(L#G,37)BQV27D1""V0U5E&>,@>7T)/.>3D\=
MN?;.G%VYXS^T 7V@W2IT*&INGJ)M;?3+8&F7-QC7G*;:==TUX=NRN4KF&L>K
M9;7SQ.N*Q+VUQ3!0-KKUQ-,">5R-Q*!=P=T/%,V@3OGO@8/H#O"]\_?P?YC4
M@-(^+!NG=ULTSKJ&T'IZ/LNP]A7^&M-L<[QL)M>5_7^O-,ZIWM-V6)PUU8>Z
MFM2*OL*1K8*?:*S5@/)6-K]N:SY*7:VKMFU0J!ZGMQQZY(P>1CMGUQVQGC3
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MYFJ6F>QK&POU[.OC2QM348!V9A3+!I>K4]<,XJIMH-XU7:..3R%..,DGCC[
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MW&<>V,Y[88'';UY 'H(Z:QZ.FFCIIKRF?X7C_F^- _[9-0_L2WMTUF@^N?\
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M #V,'? W3%9U\N"U_=2V-#:&IV[)N"=-K;&.V621E)E9>/SF<>2Y$,6F[_\
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M;(_?G[A[:M/ZKJW1TTT=--'331TTT=--'331TTT=--'331TTT=--'331TTU
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4Z@0C <-7)&J'()[8YQ]GL![:_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g947560g38g34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g38g34.jpg
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M3VWUPHZ>ND$-,[:XVWQG./2!C<9MZIIJ<TC$-M"NY;)5(B'GZ<>C,UC1XXI
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M%7BB*>FRZN=PBX<TGXU++.#(X X X X X X X X X X X X X X X X X X
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M-%1XXV3TURKOG81WHZ)57#JRR3@@X X X X X X X X X X X X X X X X
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M@[V=/8M,G\#D/8JKQ4A#EUX\=W<R)'$<C<B:NMF+J.2B:IZ;PR,2)J^URQ=
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MLW162SJESSZT/2)P8' ' *Z.@W\HODO_ *Q>9?W6>IG!J+^W]J^Y8OP9' '
M' ((L4]:@:;0,)%I76XT38$@?QYDUD=>2,\8%J"8-)I<\?;/QUKQ=L8T<*QO
M9HFT2#C=F2)#195V[V:YU=![9D-JWE45'C!Y2U[!C<+T-.=Q\<&DGOM9)+RV
MFGM/@<(B+#1Y*9O(5=/\YO'HD'-&W/\  W8*Y_=P5)O+WUT-8IM-^R?9:&2Z
M#4E51*AH9-XP>BW[?>Q."D6F UC(A3L7B4UIUVCCQK93LH/3=[.&;>Y)3UY-
MB2:"#O 0JWTUT7!46=^2]6FO)GGG\9G@<MBK>W9:6=ILT;,Z7H%>1P=Q#A2Q
M&:B+J-22NPSZ/-#<.D<6%BFD"%B)H!FQ ;(U":VLWCP$6B(),QZI]/V'M_\
MB?@NV?9GL]L'#=GY>RYNQXY$V;B%,EQRY?P,%'@_Z39\$$J"*5@YV_#.F01M
M.%R,/!NQ_#^(?/[*V+,V;C<;BXL;'/AQ2C2@<,2B^::IGQ)T3C:BFPTW4TG5
M1QNL.]NGKZ$!Q$?%L @$6."!135)B,$"&+8:+&LF^N-$&; >R21:,VJ.F,:)
M-VZ2:2>N,:Z::XQZ.>/'?G52V+-9@'4"/"D@$MEE/66<1LT\!$%4\HK(*-=W
MS';1?+5;1?;*J.-L:[[Z);^G&R>N< ?' X0,KR.,HJ%(2$@*&IMVX[YD./I
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M[V +'8:I#H)(+>%F:W,W94-$2N?&)97.S,&[C4DN4S%(O+1,.',9,3D5=[3
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M)IPLMEVN3:X)QEF2E4/4F(6*)SN+BR!Z%[GAJ&%]U'H-;IM9I7IU+%. . .
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M8O..L4?"-,YQ_LI+6*XQZW[LK8Q_G\@MJ_!>IH-<?9SL=,K1GFFSR%]05.I
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MJS0?.<,<.1:N&2N^CEK[%R@@JF%?=%U]^&1*O ' ' ' ' *Z?*Q&TI;TCLD
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MQLMD?NDVDI\4*-U;=*+@O>I+I)-MTXWIW5O;5],D6C<@' ' ' ' ' ' ' '
M(]FU6PJQ%&:DN8%".!^[%9HBUE,L"-$W(PD@8&/-F0$V,9K/QI5JU(CWZZ"C
MUD\:MEVRZ2C=';0#-1H]J)'L1;+"^&8YJ@R:X=/'A!SA!LEJBE[P_(+NG[Q;
MU--?:.GCEPY7W]*BZRBFVV^0/MX X X X X!YE^^;Z8UEY'L7E!*0DMFR2MQ
M,=F NKFSB]DM+C4#54M)WUA",07KW8<;WTCA"M(;6HM%*U 2&T['BT3=>D%7
MZ>TW&T_EHW2^=J7X/K?/KP.W\OHFNY%V:I$S$:TZWRJVXW&)/%[!)V]USB%C
M&!CJ1AQI"DB,IDL[Z\VZB<K>"GWSZ3D1%92(!83!QEP+&NUV1XJV;"P5H\Z5
MK^9K+/)JCIDVFCTH\'&. 5U>/C_?'?\ _K%;U_L)3O!7E#T^[+%>"%4_E'<#
MA(2C#]J!SLTZR(2Z5@;>KN.CR<F7D,LD %IFK#,GK<'A<W:\ C*0N>XD4&'!
MY5AJ6,QBP247<B($_.QVJE57+BO;%Z/=:45J-VX\+6?.JR?%DP^.FK)#4U(R
MT.0@A:KH=)+HL*=5-7$F11;S&)5]*O@SW=*6M]7#UXP(22=:S>;A@!A\N<B$
M.E$8AI=L%>QY6.AY:KIE5T[_ .?07M5U=%5^Z99>9E3+_ME[FE"&?]9@W3N(
MZQQCC_;9NNQ]X1]@:D#C;7;_ +DU5= NHRS'.TMO47&=E).Q6TRJRURF+PZ\
M>2T[\^B,[L6="A%Q5FBX"6*]3CZ$TT+D0-2VG)P;/8T!$9&XS(8W#2H);WC;
M.4MO=R*WN[A-9LZ]BX0623"G2_->UWFR7!#";+K^.VS7%@57+TG2\2LN$RNO
MY0BQ<Y9O5H[,@3^.&TF;S77?9JZ4&$G.C=SKIOE!7.BN-=LZ^C(9% _C%\)\
M<Z:]L+$O4[?1.VGE.$S=:U8$2@*$&PUUG%;0TZ0E<R?I2V2Z2 RVB\[=Q-LP
M%#XZ']ZP1DF[;*CT6(C_ *3VS_%'M#VYV7LK9.UI.SY4C9DR'$13,')F2YN,
MQ<$B/#PXB>YDZ;! U*F3/]J1!*EN9-F1;N[\*"5U&SMB8/9D_$3\,YSCQ"<-
M)D:BAERW$HW! E!"W\Z344;BB4*2K^9Q>B[GFQVY'MN?R4V=_1[-/[-DN 9+
M%_XLQW_[$(_^/;\ [W@#@#@#@&L=06K5\GL^ZQ,;LB!2$J6G(!V+&@YA'BQ
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M=F9W-%V+9))LS=2J1&'+9LDDW15T1233UZ<YVV\_1=R5EW$HR-Q)VHS96(B
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MSC&Z>^N^F?\ .TVUVQC. ([B515]!B[X]%PC@:5*;;*$W>Y^1D/B"^S-@/\
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M:J*H.@TX/+65>PS;7?VS="YOASO5)=AL@C"NJHM/J[^.2?3.E#=K@@X X X
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M5\^ PL6"P6&PL<USXI$M0.:TUO.KBHDVVH8*[D";JH(84Z,LZY\T?L' ' '
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MFUHM\KN$75\6)<$A164^8-]]AF)U?O/B_3E0L#X(. . . . . . . . . .
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M>:Z+Z)*9QZR*FVOJJZ9QOKZ<9X!WG ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M' ' .@^;(M\PNHC\RQ_YK8A4Y(]C'QD=\PLXZLY49)'W07WGXDW"JO$E6B91
M5MHQW<IJ(:KY5TVTP!Y>*G3"][_(#:_7"+2 5)^M\&[Y6-Y KE.AWS8E%;<C
M$<Z_];J3Z_PN-EVBCD7-8;++.:V@^F_N>Q*..PE>K#'+G5Z3&;X'([)/6%0I
MZ-7?1Y+@Z-GJFX.,< < < < < < < < < < < < < < < < < < < < < <
M< Z.22>-PX,]D<ND(.*QX=A#) ])"S &&88<N46;;+TH3<-6+7#AVX0:H977
M3]JY7103]957378"GGRO]FZVZ]6)T(FATP,-R.J>P5B7,\KD868?-Q*,?Y&G
M;* 19[NPRKNJ%!3&TI1$JU$2PRFSC6LKDH]@X))[86]D-PJJBYJBZ[T+^B;Z
M(L*ZCTD4H>D0,9EY%E(+8EA206M>LN8Z[X:RZ[[/+.)?91AALKG9?6/-#Y):
M.PEBOOOD' P47CR&=6@ANGH,O.V7#++A6E+ZOB[FS'!!P!P!P!P!P!P!P!P!
MP!P!P!P!P!P!P!P!P!P!P!P!P!P!P#'<R^)X.$HQF41W$E#!T9$7CV38W!P5
M'W*BR+<Z2$Y<^_L0ZZS=PDB3=-TF2JB"VFB^VR6^-0/,Q078W6S^WMV59U_1
M V_* W<'L-V<JQHD]6=UJ?D-F0B%4O5]Y2>3A]E&I*@:DB+.]9'+"@9RZVD<
MW/4K'(0Z4F<BCBFCW[]_8W3Y:M<*7ZMM9.[M3E7/AZ'*)I /248),OC1&;S^
M:&5)C;=JR%%LG*K0G[UHU9OI(8T:XPU&#F;%DQ 0Z)#,)Q^"PT2"B$=;-Q =
MMID9;K]N2)MX(. . . . . . . . . . . . . . . . . . . 5)W9XUI+=
M'8'L59"UMMH5#[TJ6SX<U*Q<<11M:-'[-HZFZ+7"Y*>\H#'=: F50:3_ $$)
MND79J52LDQ50%MV7Q8F-5RSL];9MY4SOF87&>CO8NYI]"REZOVO5@%1@661>
M*R/J'=IUM/[+=28?%62^X<WM7L75K>D]&8?5PO 2FIN1'I2, 9>)AA<&%EYI
M8G6EJ4T]Y:(S"E!6CWJO*)67G^;FN'6AL5]'4S^VWY%OO6G?\/<AK>_3#X$8
M7=X[K'2I>W5:,[J=_7-V)5A/E*=;2/M<6UCSBT](H6VKY ]LZ"-VVH966X$)
ME,N7""&&.R^5EDD_6WU%42JJPPTJJVX<3-(UXZR&T<C^TG[L^0W22[!!69#H
MS[6FLM-#F6"&2VK7.@#?3+;5_P"\80SIOMK[+&OJ[;8]&<B;VD,/@=W]'4S^
MVWY%OO6G?\/<#>_3#X$*S_QWW'I;%")U[W2[ZJU&L:L''8!P4[7D\&V@32OR
MV]=[1C58,DXV<+6'@0D4]T0<[8%[+Y6U21]97#VR[RH_EAKPMXDU?1U,_MM^
M1;[UIW_#W!-[],/@/HZF?VV_(M]ZT[_A[@;WZ8? A6MO'?<:ED]A4[,[I=]4
M:S1G\1TZZK".UY/)=W7NU05ZK,%95A ,JOJ43N/>Q6[##Q)JMD"B*V32W;91
M75%WE:D,.5[<:O[4)J^CJ9_;;\BWWK3O^'N";WZ8? Q*?^.R1Z02:[U[W7\A
M"T^TB4DV@Z)3M<9P,5E^H9[F-)D<K DDL,=S6&6KO*JJ:>&^5,[J::^G; ;W
MZ8? ^"J_';,U*PKA2V.ZWD#0M-2!0_>RD O:XOL&1G^T>';3)(3EN#60R,3D
M62.C#*"RJ.6N$LIJ*:>KMD-[2&'P,\^CJ9_;;\BWWK3O^'N!O?IA\"%;8\=]
MQIRN@=:C[I=]7$26N%9+L&H<[7D]7K2FOV46@JBYC&' 9%38_P#M:3JMOMJS
MT<N?@BYG;*'N^JZZ(N\KUAARM;C59]U2:OHZF?VV_(M]ZT[_ (>X)O?IA\!]
M'4S^VWY%OO6G?\/<#>_3#X&6]3:&NJA[4[*BIK;=NVY2QU>H'E$E;IM'>S9>
M-59Q0TE:37+AP@U=AV2LF7&[-4%VR>KM)+15'931'.W ;3I9)WK14Z5Y^67&
MIO3P9' ' ' ' ' ' ' -.^\'7"2]GJ=&0>(%HB.D,=L",SP>QL <_*0619"M
MRXQR$E+49JJ^RSPT.KF1RJ#5Y[&0APRBC?"6NZZ(J=*\TT^\T1/]%>R53/C\
M7III6=^Q:YZYJFN)=,;SFQ:-$ZS>UG28NGEWA:,MH?,LV+3YH9%D)2S@ <V&
M.,;!F<Q8KJ; 9B3F,5THJ)JB=?=]5_)F);S3JU3*FK;=5=4?.^2T)VA7C(90
M^&Q*):]XO(:ZUB\9 QW#EGV=-"6CC 04T&87:BTPKE,:V5PU]H@/3<N-&:6V
MK?1=75/"FV3>]^F'P,F^CJ9_;;\BWWK3O^'N!O?IA\"%8'X[[CWMR^$I_P!T
MN^J5/HOZYQ03@9VO)Y.NV"D)0WLK,EU1#*N=549Q[PD)][0;9R.]7*&%4O0I
MP-[],/.Q-7T=3/[;?D6^]:=_P]P-[],/@=2>\=;O ,UD!W9\A^Q[ DCD)JY[
M6F\-MB^&:V1NKC.X#73V&7GL<*^OMKK[/.WK;8QZ<\#>_3#X& T5X[K,6I&G
M%;Z[J=_&MYJU57JET-8UVN*[1QM;&\1$;6*@ V:!'+78(C,,F$Q6S9PNWRQU
M0RBLJGZN^PKB572&&E72JO3AQ)4^CJ9_;;\BWWK3O^'N";WZ8? A6X_'?<:3
MZF<4QW2[ZN6*MU1E*ZLG^UY/51M2.T>EN90YC_O(9#.TA3D6L0T9ZML+NLM%
M'^4V^^F%-M WL_EAY6YK[5)J^CJ9_;;\BWWK3O\ A[@;WZ8? ?1U,_MM^1;[
MUIW_  ]P-[],/@0K%/'?<FU[W(C+>Z7?1.@TH536]+NF/:\GF3.9NJXL[]M*
M4@U3#;N]1S9NG5N8_ERV02VW7,>[*+YPOA$7>5%\L-:NMN%J?<FKZ.IG]MOR
M+?>M._X>X)O?IA\!]'4S^VWY%OO6G?\ #W WOTP^!"O7/QWW&O1]:J]DNZ7?
M5G>JD;0VLUK$^UY/:.(R7WAQA?01LR#.FN6GN^&V=<H.%4_7SOZ-_3Z<8#>T
MAA\":OHZF?VV_(M]ZT[_ (>X&]^F'P(\GG1:Y8*9I>8T/VS[FS,U&NQ-%F;"
MB]L]EGY^$&J1'6*$=W$P)@B IB@:W<P5(LBW%:K^V?J;^[(IJ**8TR&\KUA6
M3R5ZT=..M"UG@R. . . . . . . . 5"W-XS91<-Z=JK!5MH;$8KV&JVW8H+
M? A)+-B!#MN4OU.IIS'9 [][:CC52@$>JR$K7C"#QLYE;RS9&%<9 (BL%CXU
MO6A_2T_!MUZWIW+NZ",='^P]V61&)9?)57JH/IV+3:#Q8GU&O8[B?V2O+W4'
M5?O-9;M7<24AE,HMX>U<M("19%)'(I'H'(&$HNW@X[:7V)[U+4IIZ:+AF9A6
M[6C<576D2MQOFZN^=N.MM@_HZF?VV_(M]ZT[_A[D-;WZ8? B#L#X[[71HNX5
MNO'=/OP[OE*M)JI3364]KBFL:<V=I'B&T(0/[/ K5IJ'5D>!^A'+ER@AAKE7
M*JR>GK;X%42JJPPTJJT5Z<>)*C#QU>E@RR0[M>1/#_+1ME]A+M:<]GAY['3W
MG"?JQ_.OJ86]?&GHSG'J^CT9SC@F]^F'P/K^CJ9_;;\BWWK3O^'N!O?IA\"%
M9QX[[CTN.C$H)W2[Z*TPMK9W[>')+M>3P?:[)QAEM5WRUJJ&3<[87E.7R9GW
M5!SZ&6$\K^Q3]&^0WL_EAY6]^Z$U?1U,_MM^1;[UIW_#W WOTP^ ^CJ9_;;\
MBWWK3O\ A[@;WZ8? A6J?'?<:DNO_6VNZ7?5O#T;>:I=>U G:\GL^=T[^R>L
M%'3F48;AEE=3V+<4M-OIJ\T;.?@: ;;"&6^4%UA7$K4AARO;C5Y=U":OHZF?
MVV_(M]ZT[_A[@F]^F'P,$M+QVS).LK%4JKNMY U[0T@DNWK= UVN+X#K3[6/
MD-H>D6RN#10P,4D.!VC_ "LLDEAKE7*BFFGK;8!17588:<;?R?97WCLDN\"A
M&]B=U_(.C8&\0C6TZ2%]KC.1B4QV#,LR9,=E$$JCEAH:R^U9Y2543RWPGG13
M?7T;9#>_3#X&7_1U,_MM^1;[UIW_  ]P-[],/@0K97CON-.Q^O2=9=TN^JU:
MKV%+=.Q:Q?M>3P69UUK3]BJQ%:*X7#(K[%5+ETK=N^PS2=+8 K%ME$M&V%ET
MA5$KUAARM;C59]U>\FKZ.IG]MOR+?>M._P"'N";WZ8? ?1U,_MM^1;[UIW_#
MW WOTP^!F?4BB[IHFPNS 2=VM;%M5"8E%9D*!-7-9V]F3-D(1K@<A8K-P]71
M:NA37-@;$]F;1PU1]NUU072RHEZN^0;3I9)WK2RY&\?!D< < < < < K:Z)=
M7[IZ_6)V=DMI$8\N)M"2M78+8%)R<A=S<ZUN'L;/"ERREL_#B] ,HEM?6O4=
M<$!'O!AR/;4RQ%I%74<&1C;CW[]]"MITIP]%]ZOO99+P0@OLK [/M"DYS7U/
MSL76LWEK,>%1F!5B:?)CXZ[,#]9HS8J1TU'SH<T=AV#H %* Y9J4B9<FSDH[
M.[X4WTV%6>ITO3RMY_3?4_K745J/ 1"QJLHNK*YF+V-+OW81R=A,*#1IXHQ?
M%-LOB.N=AF,+$U]&^23G"S]-FQ2<:,T ;3;:R;;72IL=P0K/[;]7+PN+MOTX
MN6OGD90@]'&L/I5@K)%A;]IJ[LBN3\G7T&9C!HD[P5KN+R6.@MX%)J]*/9(4
M9A+.>S2I")^)J#2:2:?'T=/!TX.O)I5LPX,G7&!B1H05#+NB3)$L-?#%GH<B
M\#EVB3]JJU4="BX]5N_%DF^BN56)%BNB\8NM$G+95-9+3?4"FJF.DMYUU=72
MQZ9@T0>0KKQ&K(Q*;;;W+*#%J/2LADU[HPZ#>PE(HLN1K5A%+03D%@>YE!LL
MMBP-X*M-#[@'38L?)QJJHZYOE9*WGP5J)5IG:Z;@R:I]N:,D%Z0^K&,3)OQ\
MAKGLWU8N-%).92.*@W\=JKL56$ZL-J?8@G";*884K4#,$@$9D[,D"7E"P9][
M!B69"S0L^7+ZW\BIT\&O%$ ^.OK'??6E._&5VG8U),3JPLR<-(AI :4D<Q,K
M&9BYD<\DKL5"85MII)A!*%I,!\JWF<]%D1$@8&)X<C:$-9B0;KX>[<./NI95
MP0I*[3]*NP%S=G;3LJ-596^E?.!-&M6F5K;*#R?9 !$[DZX6+<U:W6(?Q8XB
MPADE@%-%*IK2##W6*X$+'[&ELT$G7UT']HT^EO?T\S2:2I?B]*.C2HZZM-NE
M;45*7LZZKUS-Z@ZS]?JILN0I2NPJWIFMH--I&@1(F&YB4Q>(" IQZV,%T6Y<
MPV4(,W&&Q<LW0*%$,)OR*"+QPNGJ([MM63;I[5B5YDT=/XA*F+ 7@X^>QLXT
M9A<GGL5P8=.1;I%N+S)QNBA&.8(+;Z-,GF">[T/[;X@UTV7;IZY$]ZE'-']"
M^Z46,]-CY,Q457P^ENPTOM^SJ BA^6EX$S<SR/3&/FR58N!JP-GB/1J*F1T1
MKZ%2D63?-9$3G-K2^0R222]TU8#3:>]G?)VK;7KQNZ62LB^K@R. . . . .
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MI&7/:,WJ.I<I(#;\AAP[*OU7 5>K)6X(. . . . . . . . . . . . . .
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MFV59$A90:]279D!Q!FNLT?,7:*S9VV65072424WTR!'Q2C:3-B)%'S-/5:7
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M!!9PR%^$P4'(TSV.OZYE=+:,AGLS2'(H29BF#GB^T<!!:NMN*I>EN+5*Z]Y
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M?$@MES5^5ZY.FGJ6A<$' ' ' (=[$?S?[S_H=LW^Q1O@&9U]_$&$?^D(U_\
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M>%883#K;O"L<0>*%V#9-&11Y999TT2T11D )57.B9D;LZ\K.YH\Z6U.6%6+
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M>$9,P-L3!*0HN^KUI3RX(!D"8T)ZZJI3"2SG8+.G!?55XE&Q:V@_=X^-KJL
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4CC=MM[?VFZ.RJ2.Z8JA2R7U/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g947560g42j16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g42j16.jpg
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M(B,S-G-UF+*TN!DD,5ET=[;5US)"1TA1=H?')B<H041A9&?_Q  = 0$! 0$
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MC%1,CD*#<Z?%1AJ''&B[9J1)MG3ML@JF%6]>SLPZJOK>TDQ@P8 P!@# & ,
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MYCKW_:O!E8>K+[R_H'UN?/Y^,IXS_P QU[_M7@5AZLOO+^@?6Y\_GXRGC/\
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MB/[C]X_TAWEY_P!U]1?]MT!_X\QH2V=J]XK9?XC^X_>/](=Y>?\ =?47_;=
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M1JVD0Q-0)JC37)E>O%=#N+@<$# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MYGEP!@# & 4K]?\ Y]+R%^Y[T^_6,WP7]FN>_9B748(& 4Q=</O'US_47/\
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M=#WJ;=ZU43<MTE-0P*5.G%FS/K1V!.5Q<!=1TC8EHCNN/8$JYUX:M&7<..1
M7OU\[(:->.4T!\:\A'79E#MY0\123#CNR\.;0UINZE,O/*8+=^&I57#6M^BZ
MW^K>[D7TX(& , 8 P!@# & 00J7YQ7NQ[MG0_P#ZL[K8*?(CSI=T"=^"1@#
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MY*9K"6S,4M+$8^DP2D:PMHV&JF-'BC!!)ILCIP.<JZ4JXU=:85K>2IP8, 8
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M]LDT8!\;1?\ EUOZ53^_MGW=Y-_5W,'[ES5^!L#^<M_S]M^UM/;D>+/='(8
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M<-W"2:Z"Z"FBJ*Z*NG"B2R*J?.VBB2FFVNZ:FFVVF^FW&VO//'/'.08>7 &
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M*-;(=K19@*C"SF<H;)R==6."QH%14IMN(8,Q_+=NF.;Q=U+W=LW7WW&Q\&#
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M>*-SQ08S#BR^@M==V? INY^CJ4<4]%)U>"5[:;KA>T=&&"!@# & , I7Z_\
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MW&PF#CI*J>DY*C3HE>J77Z^)8YXMOFTO'[[F/6?Z'(?@F?+ESI=[)X8)& ,
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MGHQ HSC@4UJ_6UK7OXKI2)\X,((]@?PV/'S_ ,5VH^AMG@U82X>*)W8,& ,
M8 P!@&CNRU#17M!0EK=?IJ0,!XW:T.)Q1\;CRR"!X NZUT7%2$-N[0=,N2@
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MS\(3!QTDJ-O26BZTI>J74>!8_P"+;YM+Q^^YCUG^AR'X)GRY<Z7>R>&"1@#
M& , 8 P!@# & , @A4OSBO=CW;.A_P#U9W6P4^1'G2[H$[%$TUDU$E4]%4E=
M-DU4E-==TU$]]>==TU--N.==]-]>>==M=N.==M>>>.>.>.>>,$E8H113QSV"
M.AI#??3H-;<L0&5Z86VVY8],[:F!7A)E69I;?GG47UEM&1/]6]9E5MM!E+6
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MNP>%U+E5XW4Z>,$# & , 8!2OU_^?2\A?N>]/OUC-\%_9KGOV8EU&"!@# &
M, 8 P!@# & ?&T7_ )=;^E4_O[9]W>3?U=S!^Y<U?@; _G+?\_;?M;3VY%D?
M3KJM$FTUIR[^XP,7IT\E\>N8\X=BY:\E!<Z\@5;SYZ#82*%4,</7K!0/R[!B
M?CF0EHU&6" 1!TZY*ILW399QZCRASY;RR;..;/)ZUF_*')[7-UDHSR>-C9V4
M<KRS)8VDK+*<Z6=EFO*;7\EM;3S5E"VMINU<8^;<HR2VSA&L)VM/-2T[ZU=8
MQE2L8-SBE)*K:2I6^],L!C?4_J0$O&XD+<ZOQ)CUD95_3][%^PL;OF]A58TQ
MUNM*DTI+ 7]9"YD0&V+)NRMP3(B,5BE<6?S-4%"R)2,#8'S'V#R5-OY6US[G
MZUS9F]Y!GO*)9ZEE><,UPS3;9KS7/+LX9XR+.3L<JAEL\GA/([#,V;LFA:?E
M&69$LF:LW"VGE:MIQL)=E9V:G+3@O-I0M':1G::,+.4*QT4Z2=I.35(STJNJ
M4:)R(!>-.L*;M6R)@$N2@V=M0T.VBDEG-D3>UYA4U1]=:4%'5>+@LZ;DX,0
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MSZF&^;6(^\C:OZAK_/C_ .E+Z^9^YV;OY1D![[(_T6QX3_BVAT2Y^?GDC &
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M,(7_ -\YI/>N4/"B+1TKBWK#C-KVD=IDDC-&XE<).R,MCCEM+)I=$!EU3O\
M9X#<N'XZR;<95::NHZ16DU2J5(U=+L'<DZUU=46#D, 8 P!@%*_7_P"?2\A?
MN>]/OUC-\%_9KGOV8EU&"!@# & , 8 P!@# & ?-)7^I^?+GRNMSIU-UWTY5
M4YUWUOCK1QKOKSOM\'?7C>Y--^.-N/1SQQOIKMQQS_"UUY]/''TWF?Z7_)7(
M<TYKR&VL<\.VR/-V19+;.SR3)Y0=KD^365C:.$GEL7*&G!Z+<8MJC:6!ZFUR
M"VG:6DU*RI*<Y*KG6DI-JOH8T9L"J?"IYOZ.G FR:DZ_&X#.0:;] =(H_P!@
M^LK9XFT+,'(HN.<I[W&JU("BXMX[&EA)%NZ&E![EPR?M7#991+;MEWTM>0F<
M\FM,CR_(,ZY5DUJX.=C:Y!DTHN5G-6EG-/\ +E*%I9SC&=G:0<9PG%2A)229
M,<@RB#4HVEDFJT:E/6J/[/!IM-8-.C-YI=7_ *H^JB6:#$4;,!RGLC8;A977
MZ_/6(JI-YS%ZS?D4^'SE6RB#04WC]9URY9 VKA46!$B0;4$#0;J+-&*_I+;R
MW^BC*(Y-"V\G\NG#([&5ADT?R"QBK*RG:SMYQCHYQC65I;6MI:VLY5M+6TG*
M=I*4G4Z+)<L6DU;0O=9/3G>Z**K6SU*B2U*Y7'[:W\?7U2!4+=9K6L,G$0;N
M(?":_<)"K\ZG\:+PNMU3R\%C:_M-I+\K#(NO*) L*14YVY16*NU>=M]]]=M>
MV6>7_P!%^<&I9;F/.&4-91E.5IVF0V-5E.6*R656RT<XJD[96%BIM8JSBDD9
M'),KA=&V@KE&Z4\(UT4_[N^E72NTBG(_ UYCY=(3TLDG5M8O(I.:*2$^5<WS
MUBX<DS1I\N2*D''"5QII>O>OG*[E7U:>B?K%=O@::Z^C7CWEC],GD9D]E96%
MCDV>;.QL;.%E96<<BR?1A9V<5"$%7+FZ1C%)5;=%B0\WV[;;G9-MMMZ4\7C^
MH=A'@FZG7]TSZ0.Z@[(P36NK%7NNP)AI'=93#9?Z(\;%1%H+?;%H+(9,"XV=
M+"GW'LG!/EXCPEQLX02X43^'^ ^6V><D\H?*?.F>,@C;1R3+'DCLEE$(V=LO
M,9!DN33TX0G:1C_>6,W&DY5CHMT;:7LLGLY65C9V<FG*"E5QJU?.4E2J3PDM
M2OJ7-9_*G88 P"JOOGWQL'K)<%34[!"?2B!JV%74ZL5Y8W>'LR0Z\0!;6'2.
M)1S6%1!<'!YL0-2YS\J.#BB1!,6SW#L'FP[=^LQ)\,148UKCPC'2>O>MF\L2
MJ.4D9S5%8S8P2KTR7F%>PN4E3%1RA>;U25(R".#2SXE64T=,!3F7UZ^<NU74
M,E#@6-7/QQ4:568,U'>S=,8[FU?<]:H^E:GN-A8,& ?S;;737;??;7737CG;
M;;;GC7777CCT\[;;<^CCCCCC[O////''''W>< _/L]9ZIZ*[.VVJ2BR;9-39
M=+A/=PMMQHDAIOSOQKLLKOMKHFEKSSOOMMQKKKSSSQQ@$3_(#^ ;W:]T;LC]
M#<SP5#EQYT>]&$>+;YM+Q^^YCUG^AR'X$^7+G2[V3PP2, 8 P!@# & , 8 P
M!@# & , 8!'GLIUWC_8R"L@:YPI K#A1YK/:6N&,)-MYE3UHAV[I '-([[5Q
M[,0;;-WCT%+XF2YW 3R$EY#"I(W<A#CQ+D:G3?J:VKYO6QI/489U<[$'[.YE
MU/W4#%P#M32G MC;\%%JN=HW(Q17ETE$KNJ1R0Y]N.4U:*8Y\\CSI;98I$C[
M*15Q+-])5$B6S@&M:P>&U;GO[\40>[1=08))>\_3T@\M+M6P5LJ0=H#)9"/]
MM^Q<<8QUPVJY KHUKI@%L=DTK44JLMLT<B(,B"'.A7"8A=LH-3T;:BE)T=T;
MEZL=JQNOQUUU%P4="-XU'P4<9O#!!I'PXP(U?R(T4DL@?-Q3)!@@\.R(XZ?&
MCYARDAJL3-&'SPH5>[KOB#IP[766W$'N, 8 P!@# & 5@]<.^=P]A[F3BK7J
MS$X13CB>V]!M[,-]K:N(6HSYJ<E.8]PZ+]<1,?6F X@8D\/]@<QU>2[$(R-*
M[G"6RC<>Y;JC6DM=]$\-N^O@6?8,& , 8 P"E?K_ //I>0OW/>GWZQF^"_LU
MSW[,2ZC! P!@# & , 8 P!@# & , BE?7W\NC_\ SWLC_*?V&P:L)</%$K<&
M# & , 8 P"BORZQ_M*2F=4FZD6?A*IC,()D)04A=#]5+SLB52AY:]8QXK!XR
M'[,B#6RDB'UB>EECPB)0Q$<I/'4+E(@D42?MXZBH+BTD]K>MM:G3"FO&NK#6
MU:?U';V(TZI]:&=NAW,?M9G0-/L[*!O6T99/!,\:U]'F\M'NV,+'"(>P=-3R
M;]%PPBHH;'&2VF[4(P:#46R&@F5*NF%73A7?>2%P8, JE\DC:_K*HCME2A:L
MG,;ZQRNC.1#F^ZB?E[ROY50\7BHZ< !G4L=&X<X.B$(L0E_!$J)N1R7U"CUR
M ^+%GBJ0505&B:=;U)77)<=)U6.U'.C/:?=;TPT!G^L)N0]3H\T\H,)ZOE:L
MZA6)7?%M=@Y?35#,NI]]':%CT7=D8-9A65-;4K>H[/<QV+C$2$,2DPU:-JF4
M2+]\X>&OQ+3UU>EZ+;<D[JM-5NJG5.E-Q;YWCJ7RG+]*+,+B>T=)PZKP70$@
MVNVKYM2[F;68?D@'KR_3O!%O9B,C;MD",K(-SB0DE[ XT%NW.COGVK73^$,A
MHZ2NE726C1JBO5*U3Z2QSQ;?-I>/WW,>L_T.0_!,^7+G2[V3PP2, 8 P!@#
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MX!O=KW1NR/T-S/!4.7'G1[T81XMOFTO'[[F/6?Z'(?@3Y<N=+O9/#!(P!@#
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M)7.NFM&C26*I54;^!8_XMOFTO'[[F/6?Z'(?@F?+ESI=[)X8)& , 8 P!@#
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M & , 8 P!@# *5^O_P ^EY"_<]Z??K&;X+^S7/?LQ+J,$# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@$1O(#^ ;W:]T;LC]#<SP5#EQYT>]&$>
M+;YM+Q^^YCUG^AR'X$^7+G2[V3PP2, 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & 4K]?_GTO(7[GO3[]8S?!?V:Y[]F)=1@@8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# /SNG;5BANZ>N6[-LE\'UCATL
MFW03^'OJGI\-97;1/3X>^VNFOPMN/A;[:Z\>GGGCCD#\'!\#LW3=\&Q'+59Z
MB-1<\$F?+=4BXYTU;L$UN%O5[O5]E$^$6NNW*ZO.^G&B>W.VOI B[Y ?P#>[
M7NC=D?H;F>"H<N/.CWHPCQ;?-I>/WW,>L_T.0_ GRY<Z7>R>&"1@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , ]:F9$*I$5DBHU1$.JX
M0+JIOFNZ0M=JGPLZ1(J:J\ZL56R//"KA-SRENBGSQNIQKKSQS@'[6[A!V@BZ
M:KHN6SE)-=NX;J:+(+H+:<*)+(K)[;)JI*I[:[IJ:;;:;Z;<;:[<Z\\<X!2Y
MU_\ GTO(7[GO3[]8S?!?V:Y[]F)=1@@8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# (!]K.;!D\?[$16YNIE0WWTVC5%G[)1$O927L"R+8L*MV ^P0E
M=*]?%:M=AG:3F2Q_GF-E&4Y-%UCHT#NRCFSQYIHT%+51M.M-B2=U:U\%Q.>#
ML-T+%]?.K/4Z*G>MIZ<QF=]3._,XGD,J.BI/,0\>\EW96J:M?TX3:UW HT9Y
M@!*-OF4@J:AY6N*#CZO8180SV.1UXI[:Y?/S@7I5;;='6*57^HFZU>O4WK;O
MVELEV]/O*7?5,!ZOC_>"JZBK^>=5X94-P5[,NNPZT9@ZEINJ&\.N4BI9?RL&
MO55Y$5>F5VSELCSN/54]>V75V^"IR)3BG6C=)55'17.JJG%]ZN+-^I]*.^MO
M5[KKUZ?R!O+'U&TC5U2/)0T'JB6LB<UY"@L37-MA:SI\L.0**"MGJ3%5Z[4:
MZ+:H;N5]M.5-A,G5M[6WULD!@P8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@&AKCDO8J/R"KT*1JBN+)BA:0KM[C)36URM<2"%Q/1T$U3
M*0 .QKZ8L9T?78N)"KH&,'(.R3=C1:&YO5(FNZ&C;KZUW75Z[U3M.-*A^O-O
MA*;M-BO0=N$Z]< ?'N6[?1%MUHLFMR[*/5MW>EDP[!4+8<>>1- MW@ML;5<A
M5D=H7Y&AY!>;5X)1!N0'L9A% BP.KI6E4UZ6BJIXQ:37JU=&HXI\"ZKJE17?
MDCTXAHKJ+=$7Z;1+CLGW(EM?0Z[>N3Z7DTNLLUON5&^N<=%0.4OHD:J\:(B2
MSHJ&CQ <U<MXO((^P^+1B ]%KJ(DU6]5NC>I:U%5OI)._6N-=LE.CO17M#1_
M:;L)VQ[6]F*_[!V%>58UA67&T"J#:I608;61 TZ'++,$I$:8NMEVY?EOSRBB
MW5YW2Y5544^%QKJ#DG%12:HVZMU;;Z$6T8(& , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M!SL@%98U?7P]Z):?84]//Q6>O?YGH#_V'!E7M?6Q]A3T\_%9Z]_F>@/_ &'
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M8NF#'<DE=D3"C@8%98U?7P]Z,-'L?&[/&I-C274?KM9\R;PH#80L&ZZO"(.
M(0X_I&'VDE5F9RFUQ_Q:,CLJ92<D- LI+-' UJ^81Z('Y(FD"6#TM;:U7MTK
MQP-!AK;\>!-/XP==$NL0L8G7K2P7(]>N:37G:(D?2\2[ 3@MK!T(!RYVA\=K
MLY)Q8:4*DT%I):-=2ZN70.-NVR!50;?ZSK6F+VTU-T=V&S"I9Q]A)TQ_%%ZP
M_F#JG]D\$U>U];'V$G3'\47K#^8.J?V3P*O:^MC["3IC^*+UA_,'5/[)X%7M
M?6Q]A)TQ_%%ZP_F#JG]D\"KVOK8^PDZ8_BB]8?S!U3^R>!5[7ULY^O.K0%#U
M7]BU];"DZCKCX]^O=\>?(.MX;$/CGXK^M%\6?&OR>##OC'XN^,2'L/MGKO9/
M;GGL_J_:5_ACI!MUJV\,>DZH\'(8 P!@# (GW?LCI?'6;=RX1:-]&M^[+NG&
MWP&[9'6L=>57"^__ *B*.G&RBNW_ *NFNW/_ .V#5A+AXHYRZ*[9@Z1I&G:8
M']Z?$1(6%1U;7]8L3[KLY:3)R<9P*)B8LV+N&:%3.$6BY)$5H\6;(KK)(*+;
M))JJ::\;\^5&PRMQBXY-;2BTG%JQM&FFJIII4::O35S.<HQ<I-NCJZIM53K@
M[M1:SXUQ$0O&-=RIL?MGJ[V'C-^SF,QN8">M\XD-BP$,.!TM&8&3B,E,2"/Q
M=_J6-A=4BB[-)IZ$1Y5#9-QQMMKMQPM(SA-QM(2A-4K&47&2JDU6,J-55&JX
MIU+5T8I8*M'7&K\&6!#.J-#C/:5-H>3.$'W)'DB>F4^L:>2HM\:D:O*.]3,M
MFTMD$G,:<.J6J[1EH4+.]!C&'#18W5H,5?,W<&U?^UW<>GB/3'K7!F_LT;KC
M=!'6,-X6EJ3F=@2+=K$F:L&691UDK(Y6658B&'-:P5(>R9[H(,&D;8LF>J#/
M9R@N,-XB:_A80'M&A\;&< =I64G7Q6\0Y*--9>8G;RSGLATT*;/.4R>M@/G$
ML8+I\Z\B#/#9R)X9>Q,M6X&%2.@ZUE5F-K@)MYHUL%K$4H)H9C=KVO#62T31
M>F":0A]&XA-0<6))Z$3I!_JZ(A73[A[PP=>U>O#B-V(VMU/GKQU'\%=?:C#&
M)<=8Q5;DC.0Y\!(-GTEEA9GR*ERS9W,VX065.O1<34G))DR-SMY%&05[-Y$S
M:2.5N#!UJ@03&5IW]1KRQNH54346MP!9NH!+]';%Z(G4>?&.#P9=IS3R"_Q>
MYX+MGPO<D(H:KP;DG'B0&1M1\;UY$'1CHD8<D0K\]?OQ/*SZ<T;\@*0KX^$.
MREC0-;":K@QA_,)4%-N(J-0@7#AM)U8<7C3&2ZF2-9PHZ59%F#@4H9!,WC4<
MU^!\#!K=:[W7O]YYW/3;K>XX'<I5XJ+<A]6W <G'IK8,9."-F?%:<-5A1Z.R
ML6:&ND.*?K?A-VR?H.M>(NWX]=_KI7V\*OY\=I[,+U.H".KLU0D#4&M1RT#=
MCP3:6SC6),259OJ\(PDXSAG,EVB;:1!W545]ZV2(A=#Q=M&VS$V1),79)L]"
MK^4EC7LOPP/RZ=1* 1(I%FT0.,B#?=\BT<C[+M(=LR $R7!@E &";&:MTF%3
MD"FJ3][3S--"K'3INU67A^^[1MRD%6_GOV])^6K.HM-52I%2HD=(C,OB+O1Z
M-FD@FDR)'/2D/G ML*X36/[#&T/8M+(FR@ZOV;%"!C2DA?'V$;;'MDR285^>
MKW(D]@P8 P!@# & , 8!&.A/OJ]V/><BG^3/J/@UX1X>+).8,& , 8 P!@#
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M:1TC [\<<L[1F<YM*"Q^?* Y*UB,TB-^H1"KX!,W=K-):7"5C:!*H73,F6E
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MVW]2[W95UG&6*%IJ.";8(2TK/AYF>MC9.;NP;^0/TM+!E/(5UN\CB:0AP*6
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M'F]_9\1]L>_D;?I#?N-P/-[^SXC[8]_(V_2&_<;@>;W]GQ'VQ[^1M^D-^XW
M\WO[/B/MCW\C;](;]QN!YO?V?$JS\EOE8^S/^LK_ /D-];;ZVWUQ_P#VH_+'
FXZ^6/R#_ /\ G46^+OB[Y+?_ ._VOV[_ /B^R_ZP*C'1K?6I_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g947560g42m12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g42m12.jpg
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M-W*7M+76V"(Q25&(,E6YR-4C05-6=I2S)$-QD=3_Q  < 0$  @(# 0
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M#9AH;&;C$2^SZ>EME3X4[TEZ&<"K9=23%4#/ 1XGFDDR@;+,5-DY_O521#6
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M4TM*M%K6G @BJ[Q;"S#J:DZW:EO?:Y;F9\[,3X3:<K-=[,K9>3DO7V &.QI
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M,.IFM<IJ@CY'4Y @^,G6HFY-249#D!0/++023AI4>"6W"28WBJ\JCBB*)_M
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M=<?V'UC\)7X8/_F>9_V1*G_4J?(]NT_D^3_T^7]T?&5EUQ_8?67EQX^4"4&
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M^[4_^FT&9%JXUUCY1_1OZRL<_P#NU/\ Z;09D6KC76/E']&_K*QS_P"[4_\
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M@% * 4 H!0%9>Q/C1>&AY%>(?_"]5Z$Z'OKDB+-*$"@% * 4 H!0"@% * 4
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M*Q^+]X#JYUDM#/;OUNH7E^&MZ+FLLXH4% * 4 H!0"@% * 4 H!0"@% * 4
MH"LO8GQHO#0\BO$/_A>J]"=#WUR1%FE"!0"@% * 4 H!0"@% * 4 H!0"@%
M* XE?_(2U]DJ/[F-0$&N%3XLS0#J>:[>JMKT+1^'%YT7*R?="I6MJ1^2-ANN
M?MOZ[G70EX^R'D1C&<M'E29-GX\V'*[#3"QR3+BV6H_'8;=7BP*'D9D,S$@Q
M41&!NFWR3VX?M'!D>14,0R,9=QW-M#D%1OV1#&*@)3HFJ)U:O>BB>C"M]ST7
MZR/?#VU"V7UF8IB')D1V$\HK<#+BJ&5].^/%\OX=(;T70LZF8ZY';-G;'1-1
M ;DPN3!EHR+K\36V^U8?;=UY<;ZP,:%';*H$3A=6JJ]O!:6J+'1??>W==I)C
MZ1Z]J.L,++D4G4QI(:>'/FSSZ9Z$Q\,0&T@1W*6PTE21'*$0(A)J462<D9D.
MA!332*1)XIR,;+#)B>,:)E0#(HB)U==D*OUJ%)\:,@:8?I8XC?769O\ P\]"
MZ$Q80>:^?$3TH5*NF,C)"EMKOH*HI2:?%#E*$0\!#I$J:$P#[UN'<N9AF.$)
MECASLLLN;:]L>=E>_)RWO6<R6DY,RJ3_ '5Z/_"$Q]N;44JC:^8]/_DSB]K]
MB($TZC&THRL@A9))A>0VZF)J T.VRDIJ*RK$4[+$+L1-&*$PDXJ;&5C(RD8)
MA#%B(Q4EF94QR9(QSITR7)@SXU=5))*K;?%A??3#6<63+F3H\V%Z&VW%1)+2
M].R[7J(\H.XR<Z=P&?!:7#;01H/?*0@BL:<'NW9@:P\J.9PPZM3"7:\5AF8!
M&B986$Q"3PAUE =4R,YW IZ<[3!!MJ!]N9I9KYJ<G.4M0)01).&9$HUGN*!Q
MI0?N>8VEBG&HKG1-JA]')<,J*-QQ..&N= HH'F)1J"L?S\Y)Z*0M5<-]&>C'
M>[K>=V\:_J O0]'S>P[:3"@-4V7<02A*)<Y#2/':^*YI#C4RRDTHU8_EA%?*
MFIQ$Y4]UKO;XHS%',8M80\."A1#/44]R7!"KYD*O^?66H76*'-5(8U$W ZNJ
MAVW3%(:D*<HXG= W=\VD;:I#%6^*%I*)4NJ31UU3R"=OOMF GDBA '/4+0P7
M($D6!*A9"Y3/Q&,,A,@P, \,A+X!X8WSO:^5\<,,;WY,;6MC,J)*T045/W&'
MGS#EV-MV=U=?W:9S)18Y6-.4* 4 H!0%=VS'AY<,[[;VZ]GT:A*PBWNE%B-"
M"#6X&R,MPFZX*8D.LN.G6Y)A/2+B9-R6XW,WD1$3V WTM:$S S:R"OGS9U0S
M4\0, Q"X( 6(66>0E[Y6M07:>2O2B*KWW>V\C-MGGE(R%HXPVDF9E U%SO&9
MI1;2 1%/FP2! (TKK$?DR  IX\9+DB80@^(AHV."6 Q$&%#PR$T6M\'^YP+;
MX@VRSR=)AC-$;A_NEZ%&ZG.XTTF[/LA+;D+M58*)1]*<HR(FL@RI!H*D07D(
M\15LBUB!HDN(QH$?,NJD!# FBI7YU->;=ITUV/@9[;'WXVCDX=S%HV"T'D$R
MREH5N/$NR9WD9U#M-PE\QPAT)RA(;&/9H:P"(6,ABIBGB5.AYEQ\,P;9!9VQ
M!I*E<Y5O58<5K5Y,K3?8N4IV,3PWI=9S!:3KA626\R+YQPX'$X6\N$''%K&D
MDJHV'<Z(@J14V7Q>-TPP6[$S!O<E88,;*PM\<1#6&U5U:6MNHFQ0@T OA3GC
M#HLZH$=>M^>JVG[B7DG;?7]K]PR68'*GC$'H8>?,-:RO83&B@% ?6UTH\#34
MGJR0+ZJVI6B.Z3RBR_ZZRK[]/.UR/H)/HI?,A)-UA3ZB@% * 4!6/Q?O =7.
MLEH9[=^MU"\OPUO1<UEG%"@H!0"@% * 4 H!0"@% * 4 H!0'Y$QRRPSQQSR
M#RRPRQQ$QMCED'E>U[6SQQSQRPOEA>]LK6SQRQO>W)EC>W+:X%"#IA7>M"+P
M23).?::4%=C[@;(K!ZZI(B@WT*3& O[,1\8C1?G)VQ'/<!FVXSTJ$@Y!<;+:
M:5&K^B, +IVPK18FV!:#%=3MV[;Y=N'0DJI5N=S5:TJG>W15K[4KUS S VO9
MO%RTO4=B]AF'-3/<D8\0,W#3:9\* 16HQDA!6U]'.I#C707>YLGZ:-)9]K$
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M@% * 4 H!0"@% * 4 H!0"@% 5E[$^-%X:'D5XA_\+U7H3H>^N2(LTH0* 4
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MB35SZ.#FDWNJFSZ.5/V%X(FXFM#SF[E7!O&E>,V9*'R% * 4 H!0"@% * 4
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MX-8T?C'1#.2VGYEQL'4RG&G7+Y@WRY2&0MKW#$#OEZ9N/W$9;W09+F90R?\
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MM=?VFP74E2L?B_> ZN=9+0SV[];J%Y?AK>BYK+.*%!0"@% * 4 H!0"@% *
M4 H#&\RIP*Q$$JI!A#6W.758V?*<.VVT&G#.-P@GFPJ%A4- !6"IY)%6U; 7
M(@E!JA(XG9GC &)TJ8+7%!S!8K]A5KP95YU+$-201<21*1(JVG>G-E(/2*TF
M,UR8H+> 54&Z.W1VKIWIHM.'-+()24I*RPZV0Z#X@3@2 Q5]*7L',T6^+1)*
ME*8:*U]M\1<E0J* K+V)\:+PT/(KQ#_X7JO0G0]]<D19I0@4 H!0"@% * 4
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M^+,T ZGFNWJK:]"T?AQ>=%RLGW0J4>PW^=&TG7&V/].S-"7A#O=+,Y4(% *
M[/P[/SFX@775;OL$Z-4+180>:^?$64T*GSV_A/OC(T+JSQ?Z6296UO<7\CYO
MKFV^[V(Z_E/QG\W!RQ&OZRWT]HW<9!XQV\74PG<E=D=JW2RW"KM9QIO99<4H
M:[ 7$,X14R?9)0<8J8['-!],7&% $YP0F>-_5+39;-;),=GM=GD6JSS*9\BT
MRI<^3'FM1+/E388H(J1)-5A=&DU>C@0Q10M10MPM8.%M-;S5Z.SE9PFHBC!M
MTC+\HDV^"] 9(!0BL@.PNC!2(6.8*)=^AI8*M@2P>@"@&&>!=.(%EP(X'@:P
M/8CXXYV^,63<G13'.BR?8HIKLSL;FQ660YCLCA<#LKC<O.^#.!N%R*]Z<+<.
M;1T)SXTJ*.)*N=3.=,['.QQKIQ.EC.ESF$M50QW&O#HJZO$G2MHXRNH"):PY
MTTNL$TYQJJ?F8R**"\0*.%?*DE<V",H%2ZXL  & PE,[B/R%(DJ.":I,I3)4
MJ*1+F*7 HY<F-RXHY,$:6=!*CBDRHHI<+4$3E2VTW!#2*N^]WNKOQ:K1O6U5
MW[7K-X#X*'X,VTOEU;OH G5K;W<OPSD3U9.]ZC,UDKZ.;Y\/--K.O#C*B@(Y
M;;MB8WGKI*#5@%3,I$LKJ0G)[8/$7>)'REB7%<*/W3%TA]@)BP99BT?:6*Z0
M1G233#9Y 5#)14(AXFRH(F E8KIO,-Z LW8>/8K4&9L=%[99[M0%$0DD/U-E
MHE+SMDUI@K+C 8X<A.,)@LE3/.6.(X 8S#&<:X.NJ3NR3!U@45/ROF6S$Q4K
M<ZW:J;]/;5D\:%2N[9CP\N&=]M[=>SZ-0E81;W2BQ&A!5_O5X1FDGZVR/H&T
MZ X^@% * YWA^_I1WR\O<7>RQ!U"7A#O=++,Z$&@%\*<\8=%G5 CKUOSU6T_
M<2\D[;Z_M?N&2S Y4\8@]##SYAK65["8T4 H#ZVNE'@::D]62!?56U*T1W2>
M467_ %UE7WZ>=KD?02?12^9"2;K"GU% /[O[Z J#T2U-;FA<G_$.E[AM!X&'
M/'[-/F(%M$L<1VZ'%=A,%)C=N20:.MQ9&55!S*+98 QQU*@Y$94?)U(6'$I#
MC63#HX M%%G7TOQ;K73UOH+?*%2L?B_> ZN=9+0SV[];J%Y?AK>BYK+.*%!0
M"@% * 4 H!0"@% * 4 H"*FZK'FR2-=78SM?%$VG20J.B)A^1-E)?A%65V&C
MRXQER6FJCR\U45PN:.%=Y14FO-IIKO;Z0:644VM!'$S,H=#!.EQ*I55PWJ\3
MN>\[F=5T0:NQC$A%)9&S+#93:D%JE4=%'>K5E<665>6 DM*!2@'B^EHS&4;G
M<78 DIR.BGCJC9QJ*Y8A93.*H8N?8^(.E;N2E^R]W?LVN:M"!0%9>Q/C1>&A
MY%>(?_"]5Z$Z'OKDB+-*$"@% * 4 H!0"@% * 4 H!0"@-;26I<"=/&5A\BZ
MTW9V"CA1=*0ZUR<AH\=M&/9D(-)[DG65<D$2$OS@W3"NRGD9;Q )X,QJQH_W
MHY6\IKR4:(H9E;+]K';MVZ2Z3S'>GA%=5M:+[GRK?Q1=M)FL:%)+L'> 4N['
MQT>4@B1=P)473H^6FUUXN0+!$B^.37N?441M',B@6 )M:8A)I+ZA>V Z@JFC
M0)<<$5KL7 MO7IU(A7Q*5W9^$X=@M&U* F8TBI;B=Z>^#\<EG;+,O* #8A9_
M+44-8RXEJ.=A73GG(<II;8;BA(;R:[@2PW2>;HDD+)IK*KB3%X2J.M<;J:%C
M?JPU7;-F'8<DGB8N1W[;E"#<Q5%Q,$=^24U=K$9UQ3"#,.%]H]AV\R$6(Y#C
MZ)E=2?B>K:A(T+NY7.-\604*[K.I9U87&TMN5=(Y"?FW7ZL+W@JW.FFN/LJJ
M-30X5/BS- .IYKMZJVO0B/PXO.BY63[H5*/8;_.C:3KC;'^G9FA+PAWNEF<J
M$"@% =GX=GYS<0+KJMWV"=&J%HL(/-?/B+*:%3Y[?PGWQD:%U9XO]+),K:WN
M+^1\WUS;?=[$=?RGXS^;@Y8C73KULQXH!0&\[\%#\&;:7RZMWT 3JUH[N7X9
MR)ZLG>]1F;R5]'-\^'FFUG7AQE10&#]DUA^($'R&LQ@EN]9?J>DE1VR18AA'
M+.BY^RNG8Y&R&:XQ90(BEDTMD.I+!(.-WXJJ"*442"$T'$N&4Y*-"5CU]ERK
M;<1ET.A>86!:4I7FL50[M-AP(^D=73#3D%S!:RVHEW6ON!E91X.URYAG*+/4
M77D@&%D](LB&G0E$D)*(E(T:S+;4=H8-JY+171CA?Q:EMJ[RPJA!7=LQX>7#
M.^V]NO9]&H2L(M[I18C0@J_WJ\(S23];9'T#:= <?0"@% <[P_?TH[Y>7N+O
M98@ZA+PAWNEEF="#0"^%.>,.BSJ@1UZWYZK:?N)>2=M]?VOW#)9@<J>,0>AA
MY\PUK*]A,:* 4!];72CP--2>K) OJK:E:([I/*++_KK*OOT\[7(^@D^BE\R$
MDW6%/J* _ N'2!B!\F%^?AGAR"X=*'?G8WQY! ^=ATF%^7^WASL>?CRX\ZW+
MRV K8T]T67(0<:?*\IK;$59;(%E]J%P6.U&P<9Z1'AP $1(;K%4UU@H;PBM'
M3%P9?4TR/HO.,^,DI$7LT!9;+W=1=0DU=%F]"K3EVN_'JT8%E5"I6/Q?O =7
M.LEH9[=^MU"\OPUO1<UEG%"@H!0"@% * 4!6KQ#N*=KQPT/B@^/IJS YOCJ[
MO^Y3XJ&ZSU_L+XN.XGM[V_[K'ZQ^Q.R>[Q'[5]@=M.G['4>RNPNA+=E]QW)[
MB,K;L?C#XKGY/D_%WP7O_P .G6B5G?#/A/>N]=XLMISJ?!9F?G9E*P9N=5YO
M&M%JEV;,[Y#&\_.IF*%TS<VM<Z*'ZRI2NDKG2OA0FA"Z<NGH<+;I+)^Q-24+
MD4J+8H43EB".G&EA7/7+$YV&&L32DDB>5%(SS.A(IQ,T=-9A%BXPN';9G<6W
M4RH<^;E'<[+@SH(,Z9;K=!#GS(X9<N'.BR8EG1S(H8((:UBCBAAA3B:3XRRG
M(=RESV[[E# \+W__ $T*]G+*WPF729 )ME07=>]Z$4@]27;%FGE:&XT3B;M3
M^FP+]GMDR<G $%>)=.(&#V4E9FP.F$P#Z3GYXXWI+[C>Z2;%.@E95W-3([/%
MF6B&7E"V1Q2(Z-YDZ&')K<J*B;S8U"Z)NEQ+RG)5*RYZSKU6"!56M?NE_L/3
M<OPG71=F+9]LO""=W&HY$K,,)4;[EB2+D);31!@ C0(9]*5)S*GR>8I8< P'
M@8+AY" #!#8VN&)AE>9/<8W36B5!.L^4]S<^3,3<$V3;[;-E1I-PMP3(,FQ0
MQ)1)IM-T::Q3#RG(A;44N>FL4X($UOIS*EX.LFPK)VN@:--B(Y3G,DLB54'-
MQ-U.>1%,37.4(X*1Y+N&L$499<"66-=D)XV=@R:RH!=#D%E<:V>60>'FV6<D
MVG(>5+9DFUQR9EIL,WO,Z.SQ1QR8HLR&.LN*9+E1N&D2OBEP.M;M+YLJ9#-E
MPS(:J&-52B23Q:OHVM&ALSO6,/H1QVS5960X%>BM"+<=[JDXD.UA&RD,9RM]
MJ.+G".Y" 5%(!4=# E1%')(B**HK"LBF8Z=XSA3")M#(I&9X^6,%Q*I6_#MJ
M,+:*Z[OR$$N3G7)9-* ?$Z+R-*3J$3%L>XQ9S.0)7<3D;:VT@B!M(35UH+CC
M/(!IZ%Y!D90?I,JGVR4FVUVTSV@B@]F"P[;<::*D]Z$"@*R]B?&B\-#R*\0_
M^%ZKT)T/?7)$6:4(% * 4 H!0"@% * 4 H!0"@% 06:O#>U)8^PSFVG9S0D9
MLS8]'LH2$[W$B;$[%IR Z7.J&!#)X1PQV6E4..%E&&$%RPLUE%IF&N"6Q")@
MHX90$$' 3G.E-&\NHG30@4!Q*_\ D):^R5']S&H"#7"I\69H!U/-=O56UZ%H
M_#B\Z+E9/NA4H]AO\Z-I.N-L?Z=F:$O"'>Z69RH0* 4!V?AV?G-Q NNJW?8)
MT:H6BP@\U\^(LIH5/GM_"??&1H75GB_TLDRMK>XOY'S?7-M]WL1U_*?C/YN#
MEB-=.O6S'B@% ;SOP4/P9MI?+JW?0!.K6CNY?AG(GJR=[U&9O)7T<WSX>:;6
M=>'&5% * 4!4N]N*ZV6005SRG $ED!6U+\O,AU(K@66NBN!#C2#42)EU^RL*
MG@F%8 4[D2F5GF6W'&1X!>42@QJRRH-Q6*&D<N+9OMKJUWW8['?@=2DC:B"Y
MEXGVD$/QT[U)<D*&'=N0CR.B&V)(;;*H2@FPPI-TX 4<3H:B*V7)@$KIYLMB
M9:RRME1PP\3@ PI$8$R(%'1O8M*TM-%RM"I5_O5X1FDGZVR/H&TZ X^@% *
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M[9"B""999Y"TOP_9%S66PT*"@% * 4 H!0&FO\+<_P /[_59_P MM;"=P?\
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M8?(4([CA80 0/,*][\MK TDJIU5:84)P4*FFO\+<_P /[_59_P MM;"=P?\
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MD1T](Q9[VD,\TPS4H%!EIN,Q=3D!2?2==FXK. XM#2M]-]M*EZOO3K=6[I,
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M;[\17$G*RT\E1Y*+*5#D<JC90T@F,I+:$PC:6IR7(I)'.%%,.,&:^S8)=3.
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M)%+FTZI.F&]MV_L+4:%10"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@/'F"$+D%F($&)F )<4#//#'/($7((0#(0++*U[AB9 ## WSPOCE<(
M40.]^8)E:X'X#*E0BV!,(L $4#"Q #*A@AX%@P,,;88 X 8XV"Q"QQM;'$/'
M&V&.-K8VM:UN2@/+S<>=?/FX\^^-L;Y\EN=?&U[WMC?+DY;XVOEE>UN7DM>]
M[VMRWO0'ZH##TPP!#D_)B6C3$PTA^)2.,H9DT]7%40B@A=8)]KEQ(4@4\Z2P
M6FXX$_D(.)KK%C[<<!/$,JLI9X / /$35K S#0@_.6..>.6&>..>&>-\<\,K
M6RQRQRM>V6.6-[7MECE:][7M>U[7M>]KVY* _5 >/H@N7EZ,/EOGTM[\S'EZ
M3F\WI/[O]OF_V>?_ +7-_%R\GXJ _N 08=^7 /#"_,P#Y<,,<;]&'SNCP_%:
MW]@/G9<S'_9QYV7-M;EOR@?W'##&^>6.&..0F5LA+XXVM?/*V..%LL[VM:^6
M5L,<<;7ORWMCCCCR\EK6L!^J 4 H!0"@% * 4 H!0"@,;RE#L53>VPF?+\>M
M&26P752JX51'DA$%T@36B9<V3+*Q$(^"-V$I!$E!1(6.E+@F;IZBH$,A,B9X
MV ,!WA(2$I 2DQ"0DQ/14-%3R20C(R23+IR4DI2:6")IR8F)Y,,$H13R!0$$
MJ3)E00BY4L$&  '@%ACC8#D* 4 H!0"@% * 4 H!0"@% >,4((;&V P08N&(
M@0ML!<,1,;"EQ<!P!;8YVO:P@(X88P6=K<X,4/ 3"^.>.-[ >D91TDX5%(G$
MM.-DAQ\C(Y,R2+#E1C.8MQ\S I<4+,(0?,:]QLA<\,A,A;W$OE?._+0'C!0D
M,N(&*71DH 4)/S20A 4XH$($E""].(F!YX XY8)^8UK#9DL;V+9"_P#:9!WS
M_'0'\+H"$4#+ E$5)*A$@02Y,(NG$P0RA<OB9Q  +8!@XX@ @8G3F((05L,
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MK'?;PG\[DWS?M@/=A04>SA76.^WA/YW)OF_; >["@H]G"NL=]O"?SN3?-^V
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MU7,HH2N1;KG,(X+A+MQ=-IY@ND+PZ 8-D"ZX"CJ A=0%1QSQ,%3P+Y$A39?
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M.YKY8WL&[5Y?!#'.AAX'S0CMV[=2EZT/S2:__IU$_AA6@.Q4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@-6B=>*QL-JAL_M1#4=LV&%
MEL)$Z+*N6/O1O/A17LS*\T68HG,!S2'(C<3\@ QQ,L2V(:6$)@%:V(HHV?+G
M<?10II-U[-F//EZ=O_HXUM^Y\G^^&A.8M;XNH?+T[?\ T<:V_<^3_?#09BUO
MBZA\O3M_]'&MOW/D_P!\-!F+6^+J'R].W_T<:V_<^3_?#09BUOBZA\O3M_\
M1QK;]SY/]\-!F+6^+J'R].W_ -'&MOW/D_WPT&8M;XNH?+T[?_1QK;]SY/\
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(0"@% * __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g947560g44c18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g44c18.jpg
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M 0$! 0$! 0$! 0'_P  1" "  >8# 1$  A$! Q$!_\0 '@ !  (# 0$! 0$
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ML03:/'C71ZBCHYT;.W*&JG"2ZNN^DX5@@L7K"3PQ3J*C,%FC210W30CF <,
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MUC0)&V0'\+)J>C::DZ[;;1133LC>J8 ;,;!OT>_Z1/<#^2W7G^N;USFG=/\
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MR*Y:5#W?ZZ2>WH_UZGO9NK:TC]97-,-I&QAC)>OK0&S67UC+Y)$ YT_%@%J
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M29(BS;MG4LY9#]&;W9R95;,$W"NF^Z8&CT\RQ3!H [K">>&4.O4L9EY04?<
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MO*:%&*Y5OZ/9U6;:9)7GB%&26ZYI232(R/+%#ROS;QY-[JA7\&"=2*<K87(
M-MP-&K!D<7/_  9HM%)R->,56YK9N$))*I?JP25</VK,,^2632#;(CW&JVFF
M_MME0AB33ZT"NEB(5U0OR@QRJ5V?9#N.C8E@$(("[*<BVOV[4G$&HW7AET^V
M;SS"+I"+%5U8&/>5"#TZ!49I$()EW<;'R8P$L*IY7,*D9N.O<F&Q2*RHY#>O
M]S&8[6WZF#I$'!2".KLH.B.FI"S(<*.@H\;"!"A>"QN/R%HR9M='6R1*,\E/
MA)H)):X[S=8XY'CJ662#H@X1T(B E,\:NB,BLT*(X  /7'S9$M34(*VH.-8@
M>>Q!'9U?38YKG?+PRRQ3![1>LE*S)'+-')*D=J::%F9BNZS<D ?']^AQ6OUF
M(;_:VY<TW%_K;!^O1?1[.2KN4>R*[Z%L_3M.RO2E_P#P[4_\M()_2PK.N:!Z
MQ:+Z)T[Z'#GFGCCV:<7_ -J.(/WM;S9>;;(OFPJLJJ>W5-Q5<UF"XDDQ--S#
ML<)V*A0FBS4 &(2$PX5*2(D)#M$6 86_?JJ/"#?7E-MMHGSNMLFGOBW;M73J
MSV[DO0UXS&KR<DDA#2R+%& D2/(Q:1U4!5/6>O8;G-EI&D:CKM^'3-*K]]7I
MUG>*'IH( R5H)+,[&6S+#"BQP122$O(HV4@;L0#[=M41:]&NH^UL^*;1[65C
M7!>,$FAF/28#(![-YNP>KAY)$RQV/D=F#S3WL_0:DU7+%7='5VBC[NCRI:HZ
MG1U)96I3B7H'$<R-'+#+$[+S*)(9XXI4YEZT+(%8 \I.QVR-9X>UCA]ZR:M3
M-87(FFJ2I/6M5[,<;F.1H+5.:Q6E,<@Y)%24O&2H=5YEWP:21([$M@6IUNT;
M\R2-B):(]Z%PY?A8$<345&N'/(=^_P"!KM71)3E<03Y9F&//'&K]@UWWTUVR
M89XI^EZ(L>AF>"3FCDCVECVYP.D5>=1N-I$YHV_Z6;KS7VJ5BD:XL*B]]58;
ML/)/!/S5[ )B9N@DDZ)R >:"7DGC/5)&A(&8WE[,7)15]TT[$6E!4K+A$0C9
M6$[ZZ[JFGEL5!'_@_A4F]#M^#(Z23P06!;O20YXV'IF6##<C[C[JQU<(*)*[
MZ:UQ!I5*R:=FQ*ED=0B6C?EY]D60]&T-:1)>5'4L8V8+OLVQW ENF\#\3:OI
MZZKI]&M-0(W-A]7T6L(P99(%Z>.UJ$,U<O+$Z1B>.,R<NZ!E()B]SQSQSSQS
M_P!^.>>.?W\<_OX_=S^_CV>.?_[Q^[-SD2\F?YC&9')(A)X>H&1E((F 6D,=
M#RX*B4:J-%B49D+?EX".-D5>-5-AIAE[5Z-<\ZZZ/62J#QORHV7154LPV(;
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MVOH?Q*W]H8\$U.V?X1/JL?-*XWY]\A^[J*]<F/';QA[7T/XE;^T,>":G;/\
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M<\L* 1 \?WZ'%:_68AO]K;ES5\7^ML'Z]%]'LYONY1[(KOH6S].T[*]*7_\
M#M3_ ,M()_2PK.N:!ZQ:+Z)T[Z'#GFGCCV:<7_VHX@_>UO-EYMLB^2PZ36W#
M*.[#1RR)]MIQ&1$/ML8Y26&D"[9X0E-2S:+ QSU@+VT?K,"1LR/8/MD%4.4&
MCA9?=PW33W6TT?$="QJ6DS4ZO_&DL474AT0JL-ZM-(ZLX*!DCC=E!!W8 ;$G
M8S'@/6:.@<2UM4U$CO6&CK,3!HI)D>6WH]^I7BDCAVD:.6Q/''(5*\J.S%E
M+"059]]2K!C8G)1C!ZGUB_6^<0#KK&*P@RZ$=B]B3&U:WFQ(TTT+.92_:'B*
M4=)$MI(8*+:LG@UA[R4:.MDN5=5<X81FJ!&LWNFUBM:U::[9!FFJ5Z5NLD;%
M! K1(9400QH.97?F#+OM)-*[HDT::F9H]/T85.%]0TWAFII.GLM6IJ=[6-+U
M"6=!,UR1+$HJRRFU/,PC>*+HRC[;[BC?;JFU@@]F'MA]3-JJ4;U?C3R\N*R(
M2]RW)5PM,U[AK]1JU'KF$OUM=G(^2V+#F:X.6[@^0T@?MAFVBNV!-H.H"1VD
MHKJ%(:EK,RZ;WXD 9+8K"A:YF<1GH!%*O1NPD@$G21*S[C-W4XTT(UXD@UB3
M0M8.@<*59.(!I,EUUETMKS:UII1(VG'?KSUI3-$A@N&#H+,BQ;', NCN529F
M(:16MH4OQ6TH[&WI.K$IA--Q =9%6<A6KXC70AS+8\T7<@FBTA $I$YCL8([
MM!;IHS8+:+,D66W.3IW#^HQS]/<LCOR'2=-K5-1)%HQ7(A:2W(()6 E812I"
M)ITYI%+,-F+#-=KO'&@STA3TN@W@NWQ/Q!J&IZ& VG=]:59;39=,A>[6C9ZZ
M/9K2VGJU)"D3HD3 QK&<C;&KAK!A1O<B$CA"T%=7&?H\A64'1<FI0U'"X3-Y
M$;-BUY2^0Y65^"1A%I[@\,;HN26W.VJ?"BVN^O&XEH76U+0+#R"RM"+4DN62
ML<)=[%>&.-Q IV'2.C;K&"J>?8;9%JNMZ3'H'&]"*!M/?7+&@2:5IZO/;2*&
MA?LV+$36Y%YCT,4B<KSE7E)V )! FY#.\54H3\",*RET(A<=Z@UU6]=R7B-'
MF+2M;S8Q*N!M@2136*#.)JB].-XL9B.\]CS<J<;,%6: [50,Y=;)1RSPW>-6
M5XX1)8FUZW<MP]-$S7--:>V]2(&=^]RL1FCG[VE*1LP8O^$5=Y[1X_TA=1K0
MRW&@HUN"M,TO3;8JV8TTOB".GI<6I66%2+O\/86I/2.H5EFG2(HL0,#N1G4#
M[B]4Q$BM\T\F>XP+8U@6)S)X2E64E"0Z8 35-BH8!EHV+1Y(WL_6-3E,M(9*
M,LV7$F87WS\.16$,3[]WNCC6M UR2+3XUK\\E.K4,%@W(9+%>6/4'L2UWGE,
M041UC'#"].NC2!>BGLM$J[[#3^-^#X+&MSM>,,&J:EJ??=!=*MP4;M>QH<5&
MO=BJ5A.9&GOB:S:BU6Y*E?GZ>G0CL2.0BO>2D73J.F)-:C]O,UNKW7ZO!\N*
MP^<[+UA,:Y<C/VP1Y4A&!VQQTVM)1NB43?Q?A\(*HA= 4E7'L"[K5.D_#6HJ
M)HX:2FN-:U6VT$<]8"[6MJ_@^0),XB4TMS'RS\KQF3I80[1C=4X_T!VJS6M7
MD6\W"?#FFQ7)J6H<VD7M,>(:U6,M2(V'35^59EDI])#*M<5[+11S.,^.K.Z_
M72.%Q)H5.%*>C@BU^SDDG=;1JH"*8RY&EJ#7K6K9,W2'/)$VC#2%Z.M6*4>*
MG7KV)MD=$(YN_1<+JI_=WAW5I8WC>L-0FDHZ-#6N3:@I?3VHNK78276)IFLE
M>8RI&JSD[S<A4 _&D\><,59H9X=0;1*T.L<5VM1TNKHLJQ:XFKQ2II%M%BDM
M)42@'$8K36'>H@"UND#,V499TG//^,8RRWP;OXDM2?RBOG_XJ)YR[NH?\CI7
MZW/_ )(ST=]SGZ\<2^C:7TJ3.UO.,9ZRR%=D_3_ZC_5E[O\ ]>](\IYQ^@_X
MKE?,?TC_  ;)J97*8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&
M,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,9PN^*1_$Q[I?\PI+_$W
MK]G<NYEZQ7/2TWT.CGCO[HCV8:1_9FM^]=8R0,ED<QZAP709(*\J&S)3UXMV
MW^NU,6^L7L45*H08=#$9[)B.\)8OV4+E0=N\LA^6B+J2[O'XLX[?)NQKD>V9
M\*9D,5?7K1DAMWZ<.JT:&JZCIXCJ/#9C20U85[Y96L0N5IK'.L/*KQJI5PQ;
M;3VK5W@O3A%9TW1=5M\,ZUK7#.A:TT^IPW*$\D2ZE:F-".1*%N!7U.2:D]DO
M+#8>0/$T:H3!VC(G&9L NV/%2U?!)2[KP$K7A&PY1'H<P1D#6U:]<E]11Z2O
M6 ]J55A:4G2Y3U<Z+N1^[YNGKOPIMKS)-3GFK2Z=,D=N6!;4HMI4@FL,8FI6
MA'TD4*N[(+!A.Y797Y2?)D!X>I5-0K:_5FGTRO<?3:QTR74[=:C&ME-8TUYQ
M#9M/'&DS41:78,&>,R* =R,V[V>A%60L38',%-U 8;R#LO-R]=IUW,XK,BHV
MFMFA/]663W<&1)% @G354?J@++*HJ\.=/942Y<)[[<8.C6;MF2KWS%?C,6CU
MH[9MUIZZ/J.Z=,R]*B)(^X?=XP1L>H[$9NN+:&CT(-1\'V-$G6SQ7J$^F#2[
MU.]-%H9CE[TCD->666O"-X^6&8J>;K(+!MI\_H]_TB>X'\ENO/\ 7-ZYS;NG
M^NVG^CA])GSO_P!SM[%M;]/O^[J.6(>(3],WJ=]6+N+_ '5Z4YH.#_7"S^IM
M_GP9,>ZQZP4?3$/T*_E._;JBC,E:2J97!:E^6E3!B65S$1?5NF]V%: -@DWE
M42@A;:=R.(M%+%L$.P=EWLP/<.)(#',P;=VUU8:HL^'6TKU"JT@DDLSVYZK/
M#&M"MM"A662.%NE>,=-,H+F1_P (BA01R[#?.9\/:I%"T%;3J&DT=2BKW+,F
MN:ESW9C+6@L68Q5AL,*E25UC2O%RPR.TI#<^[<N2ODE3;1?KV6IRA$$(#P&@
M:\4KMB/-E@:8=NV:^XM!;.4H\%#T>6=M^%1Z,K:ZD#0%PZU/--'3]DEIOGO7
MY*C5J@$/+"8X0&90H V"AQS.FXZND&[H3SC=@,T$-\6-7CU'5B;72VA/<=HH
MY3(6;=I&@/1Q3!6V<P,4CE"F)B%8YI1K45V1*:TBC""IUS3.LV8S6>Q.:6>?
ME4UJUVE7,W$DHR+EA]\7)V77QN0'@JZ@(R?=.8E(0VI"._"48*M1D*QQ7LQR
MU>B9S6Z7I)HY)W>2 ]!,I19'+-/"SNAY'<F-UYDYD8+%LSJ.F6*VJ&TD2ZD:
MKU:EBM1B@K7U-RK(D[P1+&E*W%##(HECA5;$,G)-R31L]F#'C^_0XK7ZS$-_
MM;<N:?B_UM@_7HOH]G)-W*/9%=]"V?IVG97I2_\ X=J?^6D$_I85G7- ]8M%
M]$Z=]#ASS3QQ[-.+_P"U'$'[VMYLO-MD7R3G3^H85>=\1^N[#<RAK$'46L^2
ME]X81$B9(IK ZQE\Y:-1Q$V#D8QKR\?1ULT<*.0SWCWJLOPEJDMRFLGIM?OV
M-,TR6W46%IUFIPQBPDDD([YN05F9TCEA=N592P"R+ZH#?<;@RO@K1:'$'$-?
M3=3>VE)J>K6YC1EAAM'P=I5R^B12V*]J).DDK*C%X)/4,VVS;,)N4=TMZMWD
M\JZR&$ENV'T9*AM^LYV(/R"!O+!B4DI&(!ION_%2UG!V\<-1DR!-I++Z.(6.
M?#G+!RUV<K<.$ET([J7$.M::MZHT.FV-2@?2VJR116EJSQ:E8DK<DD#63-'-
M'+&0-K#JZL&V&Q4S[0.!.$>('TG5([>O4N'[D7$2:A!9LZ<^I4[6@TX+YDAN
M)IZU9ZD]>P&;FHQR1O&R%CS!ESN+>&%6[ '2(FTI/9 ZT)WVFUIZ=!09&-#Q
M8:N7K^^@@0T(;D8F6>MY*:?TFN79O7S\B)V E4-M0^^[A%REBS<97&DU*2E#
M3>E5T3PA6DD29WDMJNF22QR%)XU,,::B(V555^E0_A-@5.PJ=R?2XZ^@0ZO;
MU2+5M1XM\"ZA!7EJQPP:8[\10UYX%EI3.MJ>303,CR22P][S+^ W97$$^UU-
MUO46D/0A$8E@!V:>2+1ZM(.R?7J_V[QJ(X%:)\(M:,"#'$1<:*D/;\\RI7;@
MMIOLF+1]N+);:2;0]0MW^^#9F@E6-8N41:1JNEE6DYR=VU*5Q.-D_P#('X,[
M%SLZ;\]XPT/2]%%):%2[6>P]GG:UQ1PUQ&LB0="!RIP_!$U)@90=[A/3 [0K
MO%*1+NY>A-*0"HY3+&SNUH85"TS5%B16P;"L:IGU<V3-9X/ACTE6X*&L(M&9
MX,?I;20IJ/)J$RS%DW!.GI=7WMPGNXT.G\3ZC:OP0%:-A)-0O5)ZM6I>6Y4K
M5GLJER6PT\U9T/0ISH(T9FE54&_4)IKO<ZT+3=&N7$?6*,T&AZ/J5/4=2U/1
MI-+U2_J,=&272ZU%*E34(I!WU*(YC--'&L#/.>78MKF)>&?*]Y1%VM@VS7H6
M$RV'76?$3$(VL;WHL;IR&HR@B%U3E5;QUV_%K)/FQ/:81L?)(J^C8J1N8Z6-
M%V@\21RY^,8.AF:K0MR68+&G1/7D-3F$>H6#"DGX"Y*JN"C1BO,\,ZS/")DB
MC9W364^Y5<-RI'J6LZ;!0N4M=L0W:ZZGR-8T2BMN2 "YIE9WB82I*;M:.U4D
MJPVFK333I%#+C0SP])]8&L/=5Z1 "0;ZG*CG4@D\J.RF2!WLFMH], D:'@VD
M*J=:0B&QK>)O76C,F$*BXJ/9N"<IGB#5RCJWO/Q75J]\+:6625-0OU8H8(H(
M9%AHQ5Y)FD-F^(I&CZ=5YDD1YW8)!5+*=\6+N::CJ7>+Z;+7AKR:)HVH6;ER
MQ;M026]9LW:]6*NM#1VLP).:;N$F@FAJ1HTMO4%1U"X6VZ!7%L!6(E)15T>D
MW(^]GHRMC$@D/$[...N!0V+M86-0'1(C&4GX;8 _=L=RLG&#C#7C3@>06=Z.
MFK;(/%&G]*$2"[+#S:8KW(XHN]HQJZ1O1=R\Z3%9.E56"0N\;?UT"E6; 7N<
M:V:[2S6](K6^BXADBTN>S9&H6'X7FL0ZQ#$L5.6J)8#6D>,S6XHIDVZ.4N'1
M-H&?#8E!.;*12KK6@DM8@Z:J"TI<;6&V:_6&+VL)9O&+5M&836DLE:P51=SN
M_:G= BXD1%]F1B;%(NZ=*#&V%'Q?"E83W:-F!I-0OTH(U>FH<4G968S6+D$
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EFNZ7J-.)M(L1K+:I6:\;2&Y081J\L2*7*H[!0>8JK$#921__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g947560g54a02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g54a02.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #L E # 1$
M A$! Q$!_\0 'P !  (#  ,! 0$           <)!@@*! 4+ P(!_\0 4!
M  8" 0$!!Q '!08' 0$   ,$!08' @@!"3@1$EAW>)>W"A,4%188&38Y5W:6
MM;C6UQHS-7F8MM@7(599M"(C,3=SU20E5)*5TM0F)__$ !P! 0 " @,!
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MG J
M                                       !B<[EQ$"ADHFBAAE<I)B[
M(X/64;@L>72R9/\ R@3YGX,\8CC;CDL>'MQ,QQ2-Z/#DHO-0;ADI4)4V)RDH
M#1*%]4/6F=2.FXPTI+-3KKC4HVXI8NB2'EFKQY?+7LNC(6U6"\MT@<6\OFPK
M;J"Q(5!7N%'S:*R!5'^'HJ0%1=W8WUS%G"U/D[D^I-3P+"R71L4'\IB'%">I
MXYSXY3DJTYI_')?=[_CDK S(SNX=SGO^.]_V>YSW>YW *GG
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M2^SB22U!.9IR+G+##A847CGSF8EYS,+P]D88\D]\9ACW_=RQXY \H
M                                                  !AU@Q)1.X1
M*8<DETL@"N2,JYI23:"+&U!,8JJ5%<X)GZ-JGEJ?6;!V;3N\5)2WAD>&A1F7
M['<VMP0FJ$AH%<T$Z3M'P2<UI/DME7 YN<)E""<2YI5'5FVQ>V9=&[JM38:
MN,E8([6K*CAS77=M7-/)'%HQ4?%>1WE.L;VI^;WM(@SX5/'CQ[B<Y\F&JQ*S
M6D:X3O4?6?6_JS].27T12< JJ3VVS[]N=EOD-9"6IPFK@CK&!NB56_GEY<\K
M3R'"0O:PO//CCG$]S5Y_\3>0+YS<$4VW)P)<E_<7L@8P
M        "O/:72EYV-DEMR?F51AK7NM%5_7-+8.;(K6EP^8M%MJ;5M!WE&28
MP@YQC]K8PFAX6Z%(#.7-NC<'>\">3L7?A)F\>/&@E.73/NPNMTKJ-*MN=6K<
MULZ;EK6/%-O-@JLM36VBMG;E(:J#E4?B=22.P9+*;(OO)*\1^4PB3R1TCL:?
M9.9$&/),_P <6*8BU(L32&]:9EZP+0M110II.;2=\]"O36$]>)=U"5BEPAD1
M7K3LU*Q=&&!8K4&<\<F'J5+4D./.,YXXXXYS--SSSSYXXXXYRRY_NX H9.
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M7)M)5IS7!O3N7*KAN4+D>!F2A(2OY1+>$1IY99:KE(J]8R,]CF]X!YP
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MIKF)U @XYO5;W["T"^D^R'V#4(^H[S_'6K>@90]2C5KO!:3:H_M'&0/6YP(
M  =W?J3SL3;,>6/(?091@\9;YG'G=!]?5?9]4.PU7@M7V(O6TAU*CHAG
M    "LV%?+#;%?NY]1_O';B@6?F0[479 69 5          /CI33X\S_ ,8,
M\_F]Z'M'>WXD;GO1*7[W6#@:[PJFVE]F$QP=W-4 ">=4>UEJ;Y4^N/IGA(^=
M[ZW$/+>UDSVO4#<J'"J/9IO44A]=<>.SG         @C:7LQ[&>(BWO1](0!
M'?3[[!>D?DB:V>AJ%B(;EJ783%>];[3;L20
M !5CM1\J'TG_ *,]03T156!=>9'K@^(M. H5;=4N%Q&Q8YIU")]&&&9PV1;H
M1U*_Q64-2)\C[TF2ZZ;*N:9.ZM#B2H0+R"'%"B7$E*B#<"U:1.HQQX-)+SQE
M6M:T2G*&-J]033P\J$UC]X1I!X(FMWF8K[_L RYD.'6^\P_A(_I,>\(T@\$3
M6[S,5]_V ,R'#K?>/PD?TF/>$:0>")K=YF*^_P"P!F0X=;[Q^$C^DST45UJU
MYI3<CI^R2GZ/JBKI"Z["VM'G-[@$!C,2=7%A/T<VZ=#F9:O8VU"I5-AKFTM;
M@8A.,S39K&Y$IR+Y.2DYX5BA25BT]Y>".*+.3B;6;=__ %"= 0QE@
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M[T?2$ 1WT^^P7I'Y(FMGH:A8B&Y:EV$Q7O6^TV[$D
M    !BDZG4.K&'2:PK!DK/#H1#69=(91*']:4WL[&S-I&2A:X+U9V6.!1))6
M'/<XX[XPTSG DG PXPLO($IV(@6-[M:GRY\K2,QV^( Y2*WSWQ)7K'@Y&IW9
M\<8V]OD9>6A2@5IDZJ/OB23QF2QG%CDI3.[JY)'GU@1(E#NT."-.)DY3E8O>
M:K;4?*A])_Z,]03T156!9>9'K@^(M. H5N=1G];I#Y:[)]V;9\3#>M:[2?F4
MFQ\4)X0SFL   $-27M7=.WRG;1^X;N4*1W+7[F9*.^+9^*$N5&(R
M       &G]S:,T#L!,'29VLBL"4+%[&K;&]C-M6PTL0B+RK92([S/8'$TLB*
M8X582=D3$(DDICB-O5IC,3G,LOAX7.#BK$IRPZ$^W4:;=275'7JONE7MLRM=
M4PY[551J/L4K@TMFS&VSB?,KRZQJ8S5[DB:<RA*YR8F1/DT=G67.KLG<2%"B
M1.*MRPY*-SQXP%H&\^&V^*'DTK M9KSX@0;Z'QG[%1 4-4^I+V#=K/$W*_\
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M;'Q0GA#.:P   0U)>U=T[?*=M'[ANY0I'<M?N9DH[XMGXH2Y48C(
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M!\@$<6G($4%(=9ECE9(LI2OMMLG?9AFO5:[=!?4!4 ""-I>S'L9XB+>]'TA
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M;J,9<XYO5;W["T"^D^R'V#4(^H[S_'6K>@90]2C5KO!:3:H_M'&0/6YP(
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M4G-*^%\M2*R\XLX3M@>R3IDQ>QE4?2"9>4DYRFD]>$Y2Y^>TN] J
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MU@   -F=(^W#I!Y9NJWIV@8^:[[?$;*?I&3?O]7-W)_"H-BF]5&?6W'D$YL
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M^YPXRRQQYR[G>\99<<<\]WGC@ 5H0KY8;8K]W/J/]X[<4"S\R':B[("S("H
M        !\=*:?'F?^,&>?S>]#VCO;\2-SWHE+][K!P-=X53;2^S"8X.[FJ
M!/.J/:RU-\J?7'TSPD?.]];B'EO:R9[7J!N5#A5'LTWJ*0^NN/'9S@
M  01M+V8]C/$1;WH^D( COI]]@O2/R1-;/0U"Q$-RU+L)BO>M]IMV)(
M   #DH]5H?\ (?3+Q[SST8. ^B[U''O(NQE/V5736KG!:;5!ZVC.(8>PS@
M  [DO4FG9BVZ\I9E]#\''CC?4X^Y>UY,]CY/.?J7!*#52_>*8ZOA\^-D
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M3'8FV4LSOC@<W(*ZMI1(<GV4&K9%'+#RA/L80LVV=EG*W.3[7+2I=)?L!4
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M3-+*K=OQDMBC+RYF-"O42;*^QK36J&36*,D3G-FI9$T6$M05_;":#I)+"6^
MDS!TC[N_R%L:EKBYI6/B5B"S;)O0YJ3OFY77Z-*P-73Z ZLQLYA%A*[&N)ZE
M9#G0\A7$&3'7:-5@0H8J2VL@;NUSZNVN0NG"A.R63,Z-E]SL\(<'J.2QO/F$
MIJ[VVFL>A+5&&'7T/WR)G#AC??>FFGHL4E=?)V-LE"OZ]ZO[E7RLR=W+/8[*
MV>F=@%D:(]RNH)TE=KE<4=5,U/M<V;FEUD,-DC>T+%-URZ+F,,XK)E6%%P)I
ML1P:,V]2E7 \W0L)VOEGAR+3CJLUU"+O\G7J D;/D+";L3YRPB5\N3I"G9T4
MH2IK(\(>M=#JZ2$0M$XK(5Q'E*ME9%TFP8C3.6=?-9PZHE\M>15RG9=X\:-2
M-E0(          -&]TM<IA=F-5RZLY//XY9U</3PS1=5%97'HS'F-KLI1&6V
M:6#(?;IL<'!2^P2,Q]:?!N8OWKLM<W9?$'A.K@\QEWK E.6A.YV\F'2:UV-5
M.UULZ>ZPM$XHAG12&M[6Q<+TU+@<X86QLL6F(O$[=K^NX:@='2WN88_EL+ZZ
M4O<3G!)7=Z&.3 J"K(X]2QL5+>&LD2FINV^YVV-M-NZ=TU-+3.1J$NIOJ]I:
MGA=3Q&*I(=&"=;]@8-)(*SS*H9;6*MXF,%W$05&TJ3KEL&S+AC$VC<D<]3,'
MAI3V?<%0%I.9$R1F3QB$1-T8ILPZ_%O;SD^3UKW3L2DU?*Q/$V/<:FZFSG,6
MDQYE:B30,Z\&R3&Q5X,U_P &6#0:N]XJQD-?&13)LCC;)#3UVJQ,]7//+T[R
M)\Y=6YH2$FMLM);"#1$UJLY;;'.=N-W)>:B;!SOJZZYT"T+938]R2VPI%59:
MIJ-K> 4'-YSELVHU%9UIL.R*C--/<#XJ!GV602E+[GSD26PYH8X,"2OI#*&L
MARPQ$K-;L2E/3.2AGR.;<K]$IV63+Q-@&Z[G%I@F%/<R9IDI2M28^3".N,/<
M.8ZDX2H<STKA6,\D,6A=ADR$S YNP,6OS6X1'O37=C6<*#LTRH57CQ)F&;%4
MS9DXNC2JS8*\28TNF[BGCK8[*1-<HU!S(9)M5]B84ED#U#O96:&5O)-K2.KV
M]JR.1R1PC2%>YKVI"2@RD*LT$[&L5[T^8KNJ#5;;.K=$)Q5B" 6"Y39BVJU'
MM2 1:6V=3ZN]YY!*ELS4V:7@9-K%B\L9*?<W>3*ZVN!/"SUK[''"3P3.+D6&
MG02YY>TP%IK.FY*R)63E-IR=MM[70>PVAB?5?OE\NM-5V-@454TYUHG[/ :Z
M(>M:DTE:+!,J^P6QJ9'FS&&R7Z3Q.TI#;V$'=6>4Q)=(ZY;ZL5FMRV20N:&.
MBQK>-'CILZR%FJ4[;;;^3JE/1.>*L/#A58]5Z)W%&<&6:VMA3KOL_8$YF2BS
M5^K5@/"FM9/8=0O;2RR;)LE3*Z,<$;*;PLJ#M3769;C)HM:N+DL;XVYP(FOW
MY,\=EW]>PF<,KIN2TM6RU2OOQE8YS)3H^%]4F*6QID?:]A3*QZ_547"CMND;
MW[V%E88]=[E$K%767B0]PIF0S!_;6B8+X"R0V*P6!^U1J./(791<2=(IF+;)
M \F45DG/R;[IK%Z[YW]%Q0%              K"W.UEMF6VPR7M19<ND\QYK
M(N!R^$.4NB[95SO"X)-4UEM$5PCZ]WA\B=I;9,S4-+4^MBF=1VN)%6,=FD:D
M[["Y ]1>29"4U<[I\]MCZ+\9R,AE7.U#=?.H=\JZ D\YQ3ZFW)7%]U_5MC54
MA05W<MJ2_4N8HC\2[-LN#MTMC<9_LRM)E2OL?62%W((,3\)DII#X8:8)LE$N
M5-3P2BLLTVKD-*Y7&NM5G YME'97+2IB1)X.I*1D\:?+U$E>R,=A2[!*IUP7
M'QQJ@^O"TEPUO41-=;N$IO!H=XU)_;R 2ME6OR"5O'BWQRDS@G=-2QBY.N_!
M6WK1GK/675,89O)'YEE">'Q,JXDLR;H.B.I!_ADE89KM79BZRCY:>3#,;%=4
M[/KF[1)T;"XZIBLB='I,3D0V*IB6J;.!$UAHY<$EIQGS&<],JV]I+CJN]G2^
M<KCE2QG25NQPS"U&&*50^O4T,I-@<K>115W@L!K0UJCBVU'!U+CBUS;.)3!T
M*E&S/V$=D[&[QAB")2E==HGBY3FW>O\ C2]W*6A]L+*LFD5MV56*W.TA,>FE
MB5''0YKE< C;JQ$H$2.)32*S"PW:1.$;./4F-E@3EWSF3F[)L75Q:T^/!.!H
MB=L_'1RX&EB*DMFZRU&T)C37 YI9=EZ[73#);:\)9[0AILQ?X8SQ>WF->5G-
MK'L"/1J7+>%<JBZM9@]S4U0Y98&*S352Q+GW!-C<5RG.5G+.Y7>XA:Y(+U8+
M6G%QN*%TLZ 5(N?J)G%:UA"7?5YDDJ&.1RW=4YE(X*QV#E/7%PQL]KAS%LLS
MV"U3<Q534Z<'-D:&Z=R"&*T;.GCQX]^NQDK-4IVNU:=*B2YIR=EN%J,(B]5]
M9F#Y81>+S^<*(ZS5_L'@T.,X6ZQSK.268[R':QVBCO+I,OD2&8(BGHU\UD<J
MG.;V%X;6/EJD;-9S!$F4AV;GU;)RL=LA.&5JMLNG@OZSF[>LO2JMAE,8KF&,
M4XEK_.IB@84.,HEDGPBY3X\OQY?LIT.6E0MAC,6+Q(6'FHTA;*QH$>"%.FQX
MP.,X,4G24,_
M
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MF=X:5B9Q:W9K<4Q:QO<FUP1F')%[>O2'$JD:Q*<:F5)C2SR#,RL\<N1![
M                                               %:EG["GZNH-V[
M@104^RG1)L[JY7[)"4\B21+)[D-U0W4ZEX]B=(US<[)6E&A>[ 0.:]4:W*NX
MA1J"\"^#,\<\1:4Y+_\ +?1G/W&+^_FVX\ QB_BUB7Y5BV9%AUKO*9T'TG^K
M_4W2U7O?#9J@:XO+&)J8+E/FUT5GQ%6\)Y >PJV>0O$<6H<GI(C;TSECBK9S
MS"E9*)-@849ASZUCSQSW:EFI/&[K4S(7?8*C&"4R&$/ENUTT2^)-#@^R>..,
MN9$;NPM32P$RQU5.J,]9@:B]JXHH32EQ(/QP4H8TK2/ZHDII5)UA@B3P\>&B
M8   'IGN11^-,;S)I$^-##'(X@<'60/[RY(VQE8VMI(-5.KB\.BTXE$VH6U,
M2<H7JUAY)",@HPU087AAEEP!@BB\Z81P$FU%=JU\EK8]<<UE3I3+6,B*YNJ5
MT5,BMJ]NS5N"#AU1/*!>TKFW([A<A<T"Y"K()5(U)10$F)%:5>E3+D*E.M1+
M4Y*M&L2'%J4JM*I+Q.3J4R@G+,D].>3G@:2<5GF6:7GCGAEECEQSR!Y  P6P
M;/KNJ&9/(K,FT9@C$K7\M:5VE+NB9D*APP;')Z-2$J%II6!IR=D97E[5XX<\
M^Q&9H=795R2WMRQ22$F[E,]LQ3&*2=6](([(F9[71M;DVR!&V."98I95^"A8
MDR1N9!!F9B)1PI;UQ/!2C'#+DQ(?CQQSZUEW ,D   >C42:-I"Y :JD#(F+B
M2;V9*LSW5"5A&DGM?[;>RG_+,_'AG3^U7_F?KSCRG+]K_P#QG?>Q_P#> #VJ
M922L3)U:;/@U.J(*4IS>,<L>#"3R\32L^,<\<<\>,R\L<N]SQQRX[O<RQXY[
MO  PR36A6T+4N2*7SZ'1A8SQ@Z;.R1^DC0U*FR'D.1#,9)UZ=:K).2,/MPI(
M:BW4_ M$<Y&8H23LU7=*X \N)V!!IX1BJA4OC<L39M32^X*(\\('<DQD?3'(
MAF=RS4)YV!C8Z*&5Y2(5V&6292L9W9&4;DI;5I1 &7@  -;]P-B$FI6L-X[*
MKXJIG".E:]?)\IB*-V*854A*9"<3<FPAY/0.A3:8H[[O<51C<LQ*[G=Y(S_X
M!>3"LYI8N1R\_I;L>\ 65?Q&1_\ *4?4?D?W:_W:H?ZA0]QJ?CM5_21?LXCH
M<Z:V];?U%M7VG95MK-=4J=SFLVAF4-<92FF*E,HA;KPU'K>7Q(QQXDXM<9W3
M2R<6W#DC'CO>33>[WP^<U^I4^3:]7,GUI0PUFHUFGJE8A@B4<"IJO2145(H8
MU9%"HX'*)6-6FTFG##%"YPQPPQPN35D2FIIW,V^DMI5K#)#&(E+I]#HQ*)JH
MP21&//TC:6EYDBDU>A:2265N7*R%;AF>[NC6T)^$Q1GLAW=&UJ(]<<'!&F.U
M ?LGLJO%<Z6U@EG,24V.VM?+VX00B0-1LM1-..+:9FXJH_@JR="4I13TRGG&
MF)L<2$[TS'F\X$NK?FH S8 8Q,IK$*\CJZ73N3L4/C#9FC*7/TC=$;.U)SW)
M<F:VQ+FL7&DDY+'1T6(VMK1899*G)S6)&]"2>L5$$& 1,JVMUF0EQ@Y=?M1H
MB)F0J4Q=0KGT:3)WDE ^FQ9PR2J#G' GC)ODY"B-.!9QA1B&0IU#(KP)<R#D
MN F3P?09) +\I2U9!(HI6UI0B<26(99EREBC,@;W9TCIA>*#/,IY1I#C#FX[
M$MU;#O6E6)1GK#BB/XQY)5$9YB#UJ/9;7=P;6IX07G4JUI?),5#&9R2V#%5"
M%TE9Z1K<$[ @5%.F1*IT5-SZPN21*3GF8J;7YC<$_!J)X;3U0F3P>-VC$S.(
M6C6U@N,F9X+/H?,76&+<6V6ML9D;2]KHVNS6NK9@F>DK<K4'-V>;HPO[7C[)
MP+QR=&%\;<<N5S.Y$)1$G@>QEDYAD#CJB73651^*Q=,:@3G2!_=D36TXJ79<
MF:VE)BN5G%)S%CJYK$;:UI"L\U+BX*TR%&4<J4$E9@8\ZW-4+&TPE_>+0K]M
M8K+R:\:[>ELP8$[3.?;PE(H9C(DXF+^$<@)=2'!O.;U#4<J(5EKT.1!F?"Q-
MZZ!)8  # I=:5<0%VBS#-IQ&(J]397D@B+4^O")M7R)7@Z,+'D2TI5)I9JSG
M%\E479.<RL<B^'B2Q]K[_P!GO3:G4@>[C$NB\U;.7F(R!HDK3PI/19.+*O3.
M*/%8F[SV0ER/2F&%XJ"/7,.#B<LN#"N<N.,\<>>>X ,B   8Z?+XJF;5;P=(
MV3%J0O'$=6.&+FC,2II#D\DQS%@-.*.SPQ?,Y"H(8<&CGGVPS>3R6O%-RN-P
M(R R( 0LOV/U^:C)42XW95B(Z#.:=EF!"B=QHL^-O"MS<F1.UNY&3CZZC<#7
MMF>F3%&;AP?[<LKPU<E\.#4X)TPF3P9EV,NBTSB$B<XC(F63-Q38M(,7L3FC
M=4>)JI@3O*/CE2B-.)YQ6LKLU/*$SC/DM<T.C:Z),CD"](H.$$>ZH]ES6SQ!
M4[Z.XX!,5[UOM)] @
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MCN. (KWK?:3Z!
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MB^KN'P].W_S<:V_4^S_SA 9BQ?5W#X>G;_YN-;?J?9_YP@,Q8OJ[A\/3M_\
M-QK;]3[/_.$!F+%]7</AZ=O_ )N-;?J?9_YP@,Q8OJ[A\/3M_P#-QK;]3[/_
M #A 9BQ?5W#X>G;_ .;C6WZGV?\ G" S%B^KN'P].W_S<:V_4^S_ ,X0&8L7
MU=P^'IV_^;C6WZGV?^<(#,6+ZNX?#T[?_-QK;]3[/_.$!F+%]7</AZ=O_FXU
MM^I]G_G" S%B^KN'P].W_P W&MOU/L_\X0&8L7U=P^'IV_\ FXUM^I]G_G"
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MSW.[QSQ_< S%B^KN.FO5'LN:V>(*G?1W' ,<5[UOM)] @
'      #_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>g947560g58w10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g58w10.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X<V(:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC
M871I;VXO<&]S='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET
M;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/F<U.'<Q,#PO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @
M(" @(#QD8SID97-C<FEP=&EO;CX*(" @(" @(" @(" @/')D9CI!;'0^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M<F5P86ER(CY&:6QE
M($YA;64Z(" @(" @(" @(" @(" @9S4X=S$P+F%I)B-X03M5<V5R;F%M93H@
M(" @(" @(" @(" @(')R,CDT,38U)B-X03M,;V-A;"!4:6UE.B @(" @(" @
M(" @(" Q-BU*=6PM,C R," Q-#HP-SHT-B8C>$$[15-4(%1I;64Z(" @(" @
M(" @(" @(" Q-BU*=6PM,C R," P-#HS-SHT-B8C>$$[4V-R:7!T(%9E<G-I
M;VXZ(" @(" @(" @,BXV)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" Q
M-BXP+C,F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @1FQO=R!#:&%R="8C
M>$$[)B-X03LJ*BI4:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0
M;&5A<V4@96YS=7)E(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@
M<')O8V5S<RXJ*BHF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@
M<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @5&EM97,M
M0F]L9"8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&-O;&]R<R!A<F4@<')E<V5N
M="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @0FQA8VLF(WA!.R @
M(" @(" @("!#35E+)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[1FEL92!.86UE.B @(" @
M(" @(" @(" @(&<U.'<Q,"YA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @
M("!R<C(P-C S-"8C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @,3<M2G5L
M+3(P,C @,34Z,#$Z,S,F(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,3<M
M2G5L+3(P,C @,#4Z,S$Z,S,F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @
M(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X03M'
M<F%P:&EC('1Y<&4Z(" @(" @(" @($%R='=O<FLF(WA!.R8C>$$[*BHJ5&AE
M('!R969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N<W5R92!M
M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R('!R;V-E<W,N*BHJ)B-X
M03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE
M(&1O8W5M96YT.B8C>$$[(" @(" @(" @($%R:6%L350M0F]L9"8C>$$[)B-X
M03M4:&4@9F]L;&]W:6YG(&-O;&]R<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C
M=6UE;G0Z)B-X03L@(" @(" @(" @0FQA8VLF(WA!.R @(" @(" @("!#35E+
M)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+28C>$$[/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F
M.D%L=#X*(" @(" @(" @/"]D8SID97-C<FEP=&EO;CX*(" @(" @/"]R9&8Z
M1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T
M/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @(#QX;7 Z
M365T861A=&%$871E/C(P,C M,#<M,3=4,34Z,#$Z,SDK,#4Z,S \+WAM<#I-
M971A9&%T841A=&4^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(P+3 W
M+3$W5#$U.C Q.C,Y*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @
M/'AM<#I#<F5A=&5$871E/C(P,C M,#<M,3=4,34Z,#$Z,SDK,#4Z,S \+WAM
M<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/D%D;V)E
M($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+WAM<#I#<F5A=&]R5&]O;#X*
M(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \<F1F.D%L
M=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U-CPO
M>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z:&5I
M9VAT/C<V/"]X;7!'26UG.FAE:6=H=#X*(" @(" @(" @(" @(" @(" @/'AM
M<$=);6<Z9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T/@H@(" @(" @(" @
M(" @(" @(" \>&UP1TEM9SII;6%G93XO.6HO-$%!45-K6DI29T%"06=%05-!
M0DE!040O-U%!<U5':'9D1SEZ84<Y=TE$375-04$T46ML3D$K,$%!04%!04)!
M05-!04%!045!)B-X03M!44))04%!04%104(O*S1!1&M&:V(R2FQ!1U1!04%!
M04%F+V)!25%!0F=114)!545"9U5&0F=K1T)164I#=V='0F=G3$1!;TM#=V]+
M)B-X03M$0D%-1$%W341!=U%$031014$X3T1"351&0E%417AW8D=X<V-(>#AF
M2'@X9DAX.&9(=T5(0G=C3D1!,%E%0D%91VA54D92;V9(>#AF)B-X03M(>#AF
M2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&8O.$%!15%G051!14%!=T52)B-X03M!04E205%-4D%F+T5!
M84E!04%!2$%114)!445!04%!04%!04%!05%&07=)1T%104A#06M+0W=%04%G
M241!445"05%%04%!04%!04%!)B-X03M!44%#07=11D)G8TE#46],14%!0T%1
M341!9U%#0F=C1$)!24=!;DU"06=-4D)!049)4DEX459%1T4R16EC645537!'
M:$)X5WA1:5!")B-X03M5=$AH37A::3A#4GEG=D5L47I25&MQ2WE9,U!#3E51
M;FLV3WI.:&156DA41#!U24E*;TU*0VAG6FA*4D92<5,P5G1.5DM"<GDT+U!%
M)B-X03LQ3U0P6EA71FQA5S%X9%AL.5=:,FAP86UT<V)7-799,U(Q9&YD-&58
M<#=F2#$K9C-/16A984AI26U+:31Y3FIO*T-K-5-6;'!E66U:)B-X03MQ8FY*
M,F5N-4MJ<$M7;7 V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%914-!341B
M445!06A%1$)#15--545&55).:$EG6GAG6D5Y)B-X03MO8DAW1DU(4C133D-&
M5DII8W9%>DI$4D1G:&%357E7:5DW3$-",U!33F5*16=X9%5K=V=*0VAG6DIJ
M6D9':61K9$95,SAQ3WIW>6=P)B-X03LP*U!Z:$I3:W1-5%4U4%)L9%E75G!B
M6$8Q95@Q4FQ:;61O85=P<F)',75B,E(Q9&YD-&58<#=F2#$K9C-/16A984AI
M26U+:31Y3FIO)B-X03LK1&Q*5U=L-6E:;7!U8VY:-F9K<4]K<&%A;G%+;7%Q
M-GET<G$K=B]A04%W1$%104-%44U2040X03E5-'$W1EA9<3=&6%EQ-T9867$W
M)B-X03M&6%EQ:'14+T%/3V)D+SA!1T=4+T%):6-69D,R:C949&%N8U%75FQ#
M2F)M5E-656Q%04-)6&1M9'EQ<7%Q<%IM66=!0W!Z<T1'15DR)B-X03M14&LV
M*S5%,$4Y4#5B*V$Q:&5:-T=*26\U0D4P:C-.<6DW*VQ2=U=L2$M,+T%%;4PY
M-E!G*TYF:3-Y<GAS4#1(=CAV23=C,EA$3D1,)B-X03LU23$Y.69M.'9P87A3
M879"55,R>50R-U5D9&I'2%=1>&U113AE06)L>3)P6&)*8V5,:#0V.5!U+UEI
M<%A3<'%8:T1Z4G!L<&-85CEP)B-X03LT:&=T44=N4'%1<WEQ6$524$983$AH
M27=2-D0T1RM&<4AB1T=41$DP2S,X:VU-=V@S.&]A-&UK='%Z,EE&:6EP27HX
M-'594U5Q168P)B-X03MU6'%C4UI%,S0P*TIF-6A5.%=,:31D<CEY2VQ6<C=R
M>5(U;G1T4F)4;C!M85,K5T@V=SA&=6XQ:&QI1"MM>G0V4'%50WE$9S%F<W0X
M)B-X03M*;V1S4E!#4F9P<%-*9S%U-5!)+VUT>DHO=45V145*6EIN:W0S:E)'
M54%L5UHQ5E9B-&=!<$Y34T%.>4UE4$0S>"MX86XU<%5B1UE7)B-X03LX9'@V
M0CE#6C-I:6PT+T,P:UE5=6EN=59%:3%(=4US-$E85D)J>%-462M24$])6FM0
M;#-547E6-7(Y5&YQ2T%%,4A$=V1F=D=694IH)B-X03LW-"]9>7%F;7)**UAN
M;3$T-T=23DMD;V13:VAH=$IG67I',&QX2$9,0W)/1S1X.#!U14DU:V1X,59Q
M1'AC3R],8GDW=C=&-%IO969Y)B-X03M4-7-T-45J;C!#+VAK;"]U:VMT2FQ,
M5F1)+VA"5&8T-558-7-",T=313A*-4=0,DQ5+TY:4#50.'I7-E-04&]L-T-K
M56)44W1*87EQ)B-X03M&:5$P95)I5C)65'-4,$=%4W=N;'<O66HQ*V%R2C5'
M.'IX-C=*;TUM;'E*<3!7-U=R0E%33U%51E=*-'-'66=+5DI$16EL835%5'<X
M)B-X03M01G1W<'%D,'1(:S-7+S!N9&%A,71&2&1754EU8FMY>C(X8U-W='<T
M>65U-W)#5F(Q531K4#A64E1$>%EQ0G)9*U@V2U=P6%-J0C55)B-X03LX>%0R
M4S,P1VHS8W1K-FPP=6MT<%=I2W$S17-(0SAA0G1U=EA#5&E";SA.+T)(<3@Q
M3R\X=39T<#!::W8W0U,P-'E#1C!N47AY2S51)B-X03M32T=J86IR>5)Q<5-.
M*S)'4&AY-5564$5%0C9A9GEJ-W-N-&-E-$DT:C-Q;'9*3F)4>%A.<DDQ=F-W
M3W-K1GA%4VMK8F]A<7E-3G=1)B-X03MC17-%2D-I06]M4C%F568U3V9N2$(U
M=&=84F1A6DE033A#5D)&16IV63!'.'-1-D-11&53368V>2]$54QZ5W,P6G=N
M*VDU=5!)2D)/)B-X03MV>G-65R],6%9!=T)";'-A9SE0.3=O36\P-#E9861A
M4TU-<69/9C%A,B\S,&XO06I.='=2-VYM4$=N,VXU<59Z8E<O,658.3!N,D<O
M)B-X03M:2&AK6G=&2%IN:7EZ-'AU95DV=G-N3DLY8S=&6%EQ-T9867$W1EA9
M<3=&6%EQ>&%X,$A1<%!+1G902G Q<3AZ-F5J=DLP35I9<UE1)B-X03M3>%ER
M5W1E*T98>#4U93%E-#!E-FAV3&1)-4M24$1,0DM#67!)6C1J1DQ'-%5O,T8T
M,TDR24DW14A/>&QJ16\P6%A#5D9/=%HO341Z)B-X03M"<6QJ1' W<VQT<#A%
M;VQ3>G1Z26M20U)1=W=X=6I/=V19571L0V-Q='534U-C<G@V84549E@K,S<W
M4V-H2W)B+VU0<FM/=G1R9W0W)B-X03M-,VYR6$YZ06910V5L3F1Y*W,W<DI'
M56UF:3)Y:58R2$=Q:T9345%D3$5X-&0V,BMZ-U!K:UI$9'%M=F9M6'%U=#9D
M9#)6-UE746$X)B-X03M+=$ID>$Q/:W<T>71/44-*=4)6<'!:2D-R2U)Y8EE#
M:3A2:C!K645%13=E-S-D,V-S<W!)6%@S;CE*9$]A>6HP<3%K3GAB5VM6>F-4
M)B-X03ME=6MQ>3)6<6QR1UEZ0E!':%)21TI&5C!O2$HR3D)J2%158G,X>C-D
M5&9C:S5&4TPX,2]-8V9M138W-D9O,3)95F<Y3FMK.4MI,W$S)B-X03LW3E%3
M0G54,T-L;2M+;GA%041A9T]I:'=C3SEF<S1F=5AX5&1P.6\O-7<R8V1H0RMQ
M,DIK,6%Z:71B3S!L=#!O;C%7>6QH=4EK671.)B-X03M495<S4% X061K;FY5
M34%O43!4,$IV,&XP;7HX5%DW=E X8S)9>D1Q=T9V33)V4'!&<&\X;#=+*VPR
M57I81G1:<WA-87E.4W9W,39$)B-X03MJ<T\Q5W Y;S%Z=D)J>$=696]T4$=A
M<&PQ=CA!;F(U;V=H=4EO-TQ4=V)M.5A52G!04VU$1U9,=S-Y<6%406-223-(
M8V-U1S%D9V-X)B-X03M4,F9!.51S2RMY=35S.%EO83 O3B]W07E7<5<T:G1B
M3#%,6F]$2$MY4VQU3G5T<6]J4#<S:GAF.4AW<S(S2W1A14$P>55T1$$S=68W
M)B-X03MB+S1O;SA9<7-F-7EA-T-):&)A6' Q=6M,471#:4QD1E4Y0U,S8TMO
M931C0E<K;W=Q=TA98E5*2DE/9VEE6FPY;FXU95I8>&ES2#5W)B-X03LK679Q
M53%O,6Q936MS5'=I47AY.#!$,F-D:7A2:$M0.3%1:EDQ2$QE;C)A2#AJ0S=S
M+V<S,THX671$.#%T5FTQ-C0Q<31G:&=U5W1J)B-X03M&87)B27AJ:FU&-G5O
M<3575C-9.')L9FDK3&]4461S9GE54DAH2$LO,&-0,TE'53-A1'1V>DTQ;3(Q
M5V)626)/,%,V;6A&<5%0<D%1)B-X03M7-DI#:U5(2#%Q4$A'3&1A2R],;%9U
M9DU';5-/:VE9.$I*<FXP-3<W.'90.59).%4S84LX<R]M=G)U:69O=4-/2T0V
M<G S0D9C27AL)B-X03LT3#EA0DDU4'<U,#%#4VQ6<%5,561A>'IA2TTW4%4O
M<R]W0TI42$M1<&5D9D\R;6$Q8C-.<G Y<SA-33 Y:3!99%%G5TQ4-TTR<55(
M)B-X03MQ5$U/6FM9.%,W54%(>$UA-&10<'I!9VLY+S)M,6YK0D1$37I'<'!M
M5E9,35%&07%39&=!34-V9'9Y3B]*<31A-',O3U!M3THT1FA9)B-X03M4-DQP
M>E92>3,W3GI/3FE0*TLP*VQU=WIN*S!.9'@K:5!*>DU72W1Z>F5L9FY6+S5,
M8E4O*TUT:B]W0E(P1V$O5"]71W989C--;FIV)B-X03MK0T-X;3%A-%,V5TEN
M-G-X9V5D8F%216LY4U T=E1U-4EO;5!$:TM62C-Q0G158DQ/4T)T*U!K-DA1
M>$)M8C=V3'DW,',X-U<K;#(K)B-X03MS86Q$<'EY>%%X=D]S;'9-:4E96D$W
M9WA*-F-K=UI504%$8W0X66MM1R]C:5EI33%2+VYF<&96=6%D-G R2W5X5C)+
M=7A6,DMU>%8R)B-X03M+=7A63%!,,&%395=.3FIC8VME>6=6:#1G>$M$:7)%
M:"M1;C549T%$47E!3VXK;#-V+U9B37(X-VTO;D9H-&-E-78X03553"M62"]6
M)B-X03MK4#A!,&PS=B]68D@X.6TO;D9F1&HS3R\U54PK5D@O5FM0.$$P;#-V
M+U9B2#@Y;2]N1F9$:C-/+S553"M62"]6:U X03!L,W8O5F)()B-X03LX.6TO
M;D9F1&HS3R\U54PK5D@O5FM0.$$P;#-V+U9B2#@Y;2]N1F9$:C-/+S553"M6
M2"]6:U X03!L,W8O5F)(.#EM+VY&9D1J,T\O)B-X03LU54PK5D@O5FM0.$$P
M;#-V+U9B2#@Y;2]N1F9$:C-/+S553"M62"]6:U X03!L,W8O5F)(.#EM+VY&
M9D1J,T\O-55,*U9(+U9K4#A!)B-X03LP;#-V+U9B2#@Y;2]N1F9$:C-/+S55
M3"M62"]6:U X03!L,W8O5F)(.#EM+VY&9D1J,T\O-55,*U9(+U9K4#A!,&PS
M=B]68D@X.6TO)B-X03MN1F9$:C-/+S553"M62"]6:U X03!L,W8O5F)(.#EM
M+VY&9D1J,T\O-55,*U9(+U9K4#A!,&PS=B]68D@X.6TO;D9F1&HS3R\U54PK
M)B-X03M62"]6:U X03!L,W8O5F)(.#EM+VY&9D1J,T\O-55,*U9(+U9K4#A!
M,&PS=B]68D@X.6TO;D9F1&HS3R\U54PK5D@O5FM0.$$P;#-V)B-X03LO5F)(
M.#EM+VY&9D1J,T\O-55,*U9(+U9K4#A!,&PS=B]68D@X.6TO;D9F1&HS2S%L
M*U-(-5A75C5"9'=A1W!N=#-75TPQ6C=M6D$V)B-X03M'<6MX>7EU:E5/+WA$
M0DQ6-5I#:DDP:U%I3VI/8WAM5$(O>G$O=T1*8F%N+T%-6F)(+W%/9WDW5"]7
M2$4Q,SEZ2C58*U5L<&,S4&UW)B-X03M#,W5:<E=32T5Y.#1I+T9U16E(:$UQ
M03@T,B]A5FU59%!I-TA986\Q0C!N6G-38W5X<EII3W9W;4<X,4M%>71C1TM3
M6D1/-4):*TQ-)B-X03M/6DMS-$IB<G-X*UIY,C=H.$A(07),6% Q9G!58E=3
M95-+165O4WIQ=3=.5&-G9%-4*W9)>'AX;V)";&MZ-4]-9U-04'94=34X<"MA
M)B-X03MO2FI$.51L=4I&5TYN1F]Y,UE55&)X8S)T,FQ#;'=A<40Q2%1)9S1Z
M,TYK;S9G1W)K9F-B*S54="],4&UQ-&EA5TA4<G0P5E!52#=T)B-X03MW5U@Q
M1FDO9&=I<B]!0G5"4F$T5#19-VM!86=I+U@Y<7@O3#-M:$-1*VTS>6M),&A"
M9VU"0TEA33,R9G-G-T4T+W4O-E R22]W:BMN)B-X03LY<39F>3<U;70W95,T
M=6)'-70T;UAJ:6Q->4Y'5F%A=G Q5C9.4G5*,W!4-WAI4$108VLO;4%,4$@Y
M<7)E955V3G1M6D)065A!.48U)B-X03M%;4MF=D%H:4---6-O5S1Q0DMP-4@T
M5%A9-$%C4C=K>6IQ63@K3#5Q3GHU93AY,C$Q3F%Z5T8P2C=D;E=:5E(S04U9
M-4UE4S%59TPX)B-X03M646%5,S994C1:1C=-5"M90G(Q-V4Y05%4>G!01WEY
M37)+=TMS0U%1465O=S5-8V5%-T1K=410:T]324UJ>DA6.61:<&YQ:W4X=&8X
M)B-X03MO-7!8+TU(8B]W1$IP8U99=D(K6B]R=WAZ4C922UDU5D1O5$Y'1'A9
M5D92;5=.2$EU361614PO*U9K>68Y5V54+VMD2&HK5&MJ.#-&)B-X03LS+TMY
M6E X07%Z>68X:F\X9GEC;"].>&0O=T%R2FLO-G,X;B]!0T]J>"]*>5@X,T8S
M+TMY6E X07%Z>68X:F\X9GEC;"].>&0O=T%R)B-X03M*:R\V<SAN+T%#3VIX
M+TIY6#@S1C,O2WE:4#A!<7IY9CAJ;SAF>6-L+TYX9"]W07)*:R\V<SAN+T%#
M3VIX+TIY6#@S1C,O2WE:4#A!)B-X03MQ>GEF.&IO.&9Y8VPO3GAD+W=!<DIK
M+S9S.&XO04-/:G@O2GE8.#-&,R]+>5I0.$%Q>GEF.&IO.&9Y8VPO3GAD+W=!
M<DIK+S9S.&XO)B-X03M!0T]J>"]*>5@X,T8S+TMY6E X07%Z>68X:F\X9GEC
M;"].>&0O=T%R2FLO-G,X;B]!0T]J>"]*>5@X,T8S+TMY6E X07%Z>68X:F\X
M)B-X03MF>6-L+TYX9"]W07)*:R\V<SAN+T%#3VIX+TIY6#@S1C,O2WE:4#A!
M<7IY9CAJ;SAF>6-L+TYX8E@X>3%69UIT2FY7145E;S932DEY)B-X03MR,UE)
M2T9Q9&%$9G<S>$]J:VMA<4Q,<D<K<S<K,&EV3$]:8FDQ;E501$Y'87%Y;G5$
M;4E1-4Q$=GIQ+SAL='%F+T=7>"]W0V\V1$QT)B-X03M0.5EC5%AF,TUN;&XU
M66%C3#(K=F]W9E5D-%9I3FY322MT1U@Y5G1N=6)35#1':%9Q>&LK*S-866%M
M5D%F:CE"9$XR9$,U2#-C=G=2)B-X03LS358X,'E34V%R<3AK<VYQ>5!08TTX
M=$5(2FDW17133FY49B]!0U=).$-C<T@P9D)X:68S,RMD*VQ:;T]J-FQQ;VIT
M.5!H.65D63!9)B-X03MX:&Q5,%IK:D9/4D9F:6M(5#4Y2S1I66I%17%C57 U
M2D-)<S,K;&TY=F5F;4)A86UK43!E2U=E-&QT-&UI95 Q25,P145U;DQ&2W=F
M)B-X03MG=G%*>C5";49E;V]U56M9>4]F-#5U64IA:4UQ-&5D93=L=SDV2W1F
M3C-N-U5U13!/:C)S9U,K4S-E<5!&5SEA84MD039M6D],8S=:)B-X03MA.48O
M;3-/4D],2$AQ95@R36\V;E!0;$5C+W0R4&8U274S,6HX>F)E3&=D1W-#<2MJ
M3D5K+W X:$HV470T1VE6-7=X:W!:='A686UT)B-X03MD=G,U17=X2'%F>#A0
M3G-'6%5J*T=0-#(W+TI+0G)V;FY73$)T4W0Y3G1R:44S0F50,#0Q;6M%<7I3
M<WA3,F0U1V-"=%(T12MM=T96)B-X03LV3G9L;D)#2G$O>"M!,&5.;FY(:451
M9"\Q.4PO04M88VHU4$Y(-6QN5"]7=4Y':FQI=7!R:$QD,VEK339Y6&I3;S!5
M84Q)2D1X.4XQ)B-X03M65U4P049F,F-J-&5/*V):*UDQ4$1::GIV,S<O04)5
M8F9Z4BM:8C-"=D8P64YW:75,:TI,87EC5U,T=4DU:DEG9'%U63,Y4&AX<E)1
M)B-X03M/=$LT5&IX.')9>#%';TIV:#<K;F5F>%1Z*V$R=7)3-TU&>D)*1&-2
M34)*0DEP4G=E=$-R56]F;FU236=W3F1Z9S19;4]724EO.%%F)B-X03M64#96
M=G8X07%Z6&XO0C)F+UI2;6ME=5,W>3=Q9#9V;"]404Y)=3)!=$E!1T17;$0K
M-UAC5FY">%8T.7%L>'%T=C5/9VPP=U-F5U)()B-X03MA0C-H:D4P>5%S.%EN
M:VEI2W5*2%-)<WER43%)-DAO9#%V=S=/<#(T=#)/-E!,*UI/;S9I-&QU-3=0
M5$E,6FE*6F)E2TME65!*9'!#)B-X03LT:F4S64-C<$A!-W%754HP369X9D1%
M8U):2&A#<DYQ,VYE3'E48D])9%%/=D=+,6PK=$<S='!$3%!01C9K<TIG:E1L
M16MB+W5Y6&E7)B-X03MM,5='-VA*;'<K84%).%AK:&9+5W4K9DQJ5W1/=#E:
M1C5&1R].<F]386559TDY049K37E204MY,TI:639S;SE.2VMU6%4T25-L939:
M)B-X03MX:E=Y<C50.'HK8V)V57AC-G)$3RMK>C)Y4TM%='%O:VLS,68P=VIX
M25=:;&QL;E-116YI<4)M<#%9=VQ).#%N161&3TAZ3"M9;'0U)B-X03M6=#=K
M869.96%U8FED8G!B;3)D9U5I=$=N2&]X=W@R8F]R>6]);$QQ9FE/>&-C4U53
M;%AM=D1',$4S-6IE8S!U9%-S-S)Z:71:-T,S)B-X03MV2F]Y:T5Q3DUB2U=%
M4G-P;&52071W2E-/1S=+0W)C<4UU4CA34V9$:7I,5G14.#,R<W5U4U<R;E%3
M,E9P<'AN,&PQ95-786$W5EI4)B-X03LV5%%Q:6LQ2W%/26)W;U=,14IA4V0R
M<T%B35DQ,WIN*UI6:G$O=T)1<V1&1C5&2&)T3$QD:7=U:D<P:U9R-C573FMM
M6F8S<VXW=%)Y)B-X03LU2U(K,71L6FY+*U1-46I83D(S6&UJ.#!9-VI6-&]B
M2S5D1$9E1W=R6DU41UDU8C!W=DA+145B;FI(8F]),U9I-%E-4#)U5'A3,U1W
M)B-X03MX,E95."MF;5)X=4]/:6TU25=:-UIV,%AF,C,Y,41D37%Y2DDW+T5Z
M>%<Y2TYV>DMI<D1:-#5D>3A%93E7:#@W+VU/;"]B45A':$8T)B-X03M:8FE.
M2&QJ<V)P5CE%,U5L=DI6=E5F9S-P>&EC37<T.%11.6U:-#5D>4]#4&4Q0C5Q
M+TU%*U-B85=A,6506'!:+W$P56MT<UE(;%IB)B-X03M&<F=C;TIA8U,Q=VYO
M16=!3C%7;%)J>%,T9DY01$AI.&M48V$Y-3!(;'%W36-.."MP0S=9,TQP86U/
M95=X36QW<T=Z5S!S36-R:4]-)B-X03MU1U)E3F9I.4U.545Y;%-"1TYT95IV
M3U U9S9:<4=P1W@P94\U,#9Z8RMG5W0U=UI),$9S0U10-F=J04IU;F)L>&]"
M13-U5EI4:T]I)B-X03MX:$4Y568U3#@S87AR3CE!;#1Q:4]A0RM,2VM,=T)7
M<W(P5S9-6353.'%.26HO17).<U8K94=%>5-I8T%!>EA,5W R2V]R>7IQ.3EO
M)B-X03LR=E<Q<EEQ,7IB87).>'5.35AQ1TI(3S9I-TIW1SAT84MW+WDV8W-,
M5C1O,7AD6$TP,E$S6%)0+T%--G8O2F)A;B]X;'-F.$%Q3V=Z)B-X03M%,"\Q
M:&YR=C=M5'E0>49C-DI!,2]W1'!#-5-'831264E92EDW:5-/6E=6,T-N-G-P
M:T)7-6IT,C)99D1Y1V)(3TI'<2](-$9U:3!5)B-X03MO06UZ=61U=C903VU-
M-B]C>5A6-7%6>DI-='A*4$I.2SEX1W!22D=D;5EU<7-&64)Q,4%)1U=654LX
M;6M3=DQF3S5F<%8O2RMV6"MH)B-X03LS14XO66Q23TE':4A-16EK:V9%;EER
M=4LQ2'9K94%3:4%747I3>#542U!M>55F;7(U;35&;6IT6&-Y=U1C,VI9<T1"
M-EAW:'5694UH)B-X03MT,%HO9G!4269L;RMB9"]+5U1Y+T@Y:44P8CAW9%DP
M:3-I=&)+,W1"85)31UE14$=Z07E'5EI1>&-T-FYW*VUI:6I5;T)7<#-Y53A!
M)B-X03ML=6)9671D3T%O055I-2]Z53AW,T5G;'5,93%M;E0P5$9+>7IC:VMT
M,FQA3U%5;$%,2UHR*S!#=E1B26I44DAE>E!A5U$X=U!T+U=L)B-X03M/;&5C
M9%<P,C%T8E-$9SEP87EZ5&TR9C%05&QA9$91*W%Q=79,:'=Q:$9#<#-R;&MS
M44I*86-E<FY!041K3"LS=B]1;3,O2S Y93E8)B-X03LQ1&%75$U:6&QC3DA)
M>75*1VY:;S)5>45C4#A!5$I"-#E..'(O3%(W>BM0-T<W*U5:.3!F>&9N-713
M+VUN-6EL=4AU2DEB5G!(4$EK)B-X03M*279X1#9V4FAX:T9#1%IO9FY8,F\O
M;&\K9C1V.6%N=$A*9#!0>%AN-4UE,6)6-3E8,6@Y46YJ:FEL;5I/56-+;%5(
M14)24W!:=3(U)B-X03M*2D]434]'0DAK5W%/535-,%I(*V-(,6AM;65R4S=Y
M,2]W06\U<%@O041",B]W1'EA6$98;&UN-EIQ,$9H8E%Y-F1E:5-+2D5C0S%N
M)B-X03M.1U911'5%24]B84]O:%A.,6MS13<U26HV;G%8+U9V=F8K:U,T+S5O
M=R]M660V4'DX*S4S,5!5=BMR9F4O=T132F-F.#!9+VU99#8O)B-X03ML-3EZ
M=G%E<&8Y5RLY+S923&HO;6I(.'I$=E@X=E!U531D379)53E/2%,W=4]/<&)G
M;&Y/;W%X3$UA0U!U5%4T+VU-9F5V9U0W;%0V)B-X03MN<5@O049B-S,O<$5U
M4#A!;6I(.'I$=E@X=E!U46HK6%5E-6MU;C!+6G)Q6E575V,R17!K9%DR1$E'
M67A6259H558V2$(T*U!V5#1/)B-X03M4=5)F,5!5=BMR9F4O=T132F-F.#!9
M9GI-3SE(-65F8S<V;G%8+U9V=F8X07!%=5 K84UF>DU/.69Y."LU,S%0578X
M07$S,W8O4TIC)B-X03MF.#!9+VU99#8O;#4Y>G9Q97!F.5<K.2\V4DQJ+VUJ
M2#AZ1'98.'90=60Y5#%,+W$S,W8O045I6$@O3D=0-6U(978U969C<'DV6F53
M)B-X03MH4DQP9#-)1EI854Y:>G12;$Y6659J-F<W9S0O;4UF979G5#=L5#9N
M<5@O5G9V9BMK4S0O-6]X+TUW-S$O3'HW;'-M;C,P:V)2>6%:)B-X03ME4$<T
M2W5J5V1W45%D:4-$2'5$:BM9>#DV*T)0=55,4%%$6DEQ5V5I5#)Y26=I4EEB
M0V%-3$=#5T-!3$=+2T-X3E!F04TK3615;D1K)B-X03M04D4O53E3+S9T.3<O
M=T));'@O>E)H+TUW-S!F;#4Y>E)S3F%F-$QB4S=U5V1Y1FI2-$I957%45#1P
M2D965E5D4U0R.&5M039M04A.)B-X03M),#@K-6YV;$QY;$1O8TQZ>G5,;E8W
M:T0V-655;TM$8U)202]::5AS3R]5-S5R8W55>DYL>CAE35)&0DHO=T$V=B]*
M8F%N+WAL<V8K)B-X03MO-D1*868V=S!A-RLU:SAL+TPW5V)N4TIB>39G,6E0
M5%=R0VXQ95I056EN2EIQ1U%":UE):#)*4W)$;# T.',R3V5(1E%Q,U(V2$E9
M)B-X03M794E2-6,K<D=V37%"3E(Q5D)D9EAG<S%W0F4Q1&5V4FTO93%"8790
M-UA82B]W04AD<S O-6)N9G$U.2LW,U)F>4HX:'%O5E)E0E%+)B-X03M!9E=7
M-D0V33%G,4TK.39%-D1#5%I$9B]!0V]V>4PO>2MF.$%34S,Y35 U<69E:BM4
M<U!C-R]L4F9K6"]!2F90*VML=C99+VUP.38O)B-X03MY9&@W;F8X04MI+TEV
M+TPU+W="2DQF,'@O3E0W,2]K-T0S3R\U55@U1B\U9E K:VQV-EDO;7 Y-B]W
M06Y9934S+TMI+TEV.$%Y*V8Y)B-X03M*3&8P>"].5#<Q+VLW1#-/+W=#5D8K
M4F8K6'HO04M35R]P:BMA;C-R+THR2'584B]K9#5&4U)8-#-B8U-'-'1C3E$P
M3F%(061436ER)B-X03M42%%99V)!-5!136]C>$QV3%@O2T]A5B]Z0C(O+TIP
M8U942$9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M)B-X03M867$W1E=$+T%*,68K4S(Q4"]J3%DO.$%59$)L,FXK<T]*<G8W;51Y
M8CAT0C59:S%M8418-&\U25IO=TEN;FMJ:FI6=6$Q+W9"5&PP)B-X03MA=DYF
M:$1$-'5813=(56-696PP96<X37I);4(X5TTK6E1B2%5T5DYQ>79B1V$T341)
M1D-&3U1C4V]663%P5'!245!96E K1&9U861V)B-X03M',C5C6#98,79M;&5T
M9&ER<U9D:7)S5F1I<G-69&ER<U93-WDQ+WEJ;6QF.'=D=B]!36UL>%8U;50U
M6C!V>7IB-G!Q;'9"2&)X=U%')B-X03MA67=#4FDP9U9&*T9&6C-:,UE!04%K
M:S1526)4+TUV-6%8-C-:9W5.4%$R2W)*97!C4G)B4$5J2W)",U-D63)69C-I
M:7!&069H-C=9)B-X03MQ:DQ,55!Y+W9R<&)/>75D2G5R=&EW5S-H93)K:TI1
M175!:6MT.$E'+VAG5EAU,CAM,F-&>E!E9F\K,F=S-49H=35P=E)J4TM2,5(Q
M)B-X03M34FUO1DQ,2VA!4&E02$95375Q9FPT>GAO;#%P3'E44U!$0VEV8DUZ
M>7@P-7AO;TI,3W9)5E5B:75+<&)A9610>6]U.4UG,5-+.# T)B-X03M713EX
M.557-&QJ5TE,3G=D=VMO:U)$1E99;4E-;D5(=#%'2W!M,G!F;#9S6'%T9&%1
M275)9C%$2F)"94Q#36<Q<E-H1GA&+W=A+WI$)B-X03M&5D\V,6XX=7)7>DXU
M3&-A65E046MU:TUF;WES.$5&9E9K:E--33AG5&EA.$%C5F1Q3W)E4610<W)E
M.750<6)7=#)#8E=70T5806Q!)B-X03M:5B]D*VEK:&%R3W%I;E5K06)N0W%R
M1&0K5' W,GIS<F4R:6YM=G)D8GDR84LP85-)=T]#56ME5EEZ2$='-&YJ>EE6
M-D1F07%Y1%8O)B-X03MY-'5)-5I)3#-2-5DT53E76C!L=%=622M16&UX0C)8
M:W=&5#-X5D8V66YL5%991W5.3VAT3'%"5S1'5T]*0W!.07=O94\T2W-'56I9
M)B-X03MG9VI9-'%J4#!,;S,O3$)B+W=$27!0-EEQ-SE#-DXO>7=7+R]!0TM4
M*VU+=2]1=6IF.'-&=B]Y2U0K;4MU+U%U:F8X04Q"8B]!4$EP)B-X03M0-EEQ
M-SE#-DXO>7=7+SA!>4M4*VU+=4]I-E8Q:G19;UI"=6LP2TQ(26I$8TUJ<4%Y
M<T0P27A6:S-L-WI$2DY)=6UA;7=&*T%F<3EX)B-X03M12W1Y<6EP24$R5U92
M.710.6MU,5%Q;$HO=T$V=B]*8F%N+WAL<V8K;S9$3'10.$%72$4Q,SEZ2C5V
M.$%K.6$K<'$Q-V-X4W)(9#(X)B-X03M3*VEP3E=:4U-Z0DEL-%!)87AR.6U2
M9'%G,415>D\Q6C)!9%0R6$<U13E1=VYZ4C9N-E4Q8C%A*W(V.7AZ-5)I13AU
M8E9R1T,S1&8Y)B-X03MM=3-43'8T4&<T6B]V=CA!3R]3*W1S,'(Q<G-69&ER
M<U9D:7)S5F1I<G-69&EQ5U(K5SE-:6I73TIR<4].04921G9,=%9644M!04-7
M)B-X03MG07A6-30R:3(K<RM53&943&E34TM'93)G1%!%5DQF0T998E-,26I!
M.&%-<G%666)%15EO63-B+T%*2V573&4S94='.3%"3V9Q2#%&)B-X03ML:%5G
M>6TR3&-1<TE13"]O2T%*>#0P3$-L2T%+550U9"]+3'DQ;TUU;E,R;'AE4TYP
M8DDQ=C8P:U1!;$1D:V,K36%F.5A#5'!4;W9V)B-X03M65DYP9DE0;&1N=5I)
M3$Y,4V$X=G)B57)U5S-616%793!K4U9!>$MN-$,P5E=8=5=9+V%9;D95:G,O
M>5DX<S(Q>#E9*W4S.#!V<7).)B-X03MY;&MH2DI35S%L545I2E-D-T=-5D\U
M0F%P<6%H5D,R,S5&958W8E-"<&M/<&%M<4EY;4]C4U<O<7%I<F-R-E$O8V-/
M1&98<%-A<EAF)B-X03MR455X5D5A="M3+VQV5E5U,74W-BM0,3)-4GIE;3%T
M2#A1*W$X<$9#=T)66G9Q16110GA'+T926$96,3<K5%!L;3AL6C5,,U5&5FAE
M)B-X03M!>$Q,1G=R9D<T.5)G1VEA:$@Q>'=T4$)E6$MM2W$Y-RM73FI-;6U7
M>5A5,S%A>E,V171W>G(Y6CEA-74T8CA80V9U>D0V9W5B8T5J)B-X03MG1F]3
M2U5!1TMO,G<O3'92<DQ7=% Q5TME-&%84S=D3$]X:6(P94M7.%5*:%-,;7-3
M>DUG1',S17E53$=P<E)E2W%1-F@K5%=N439A)B-X03M";S%Z3V11=#%H5S%A
M-FQ654)H1FUQ='E31C9-0G!S6D)+3713,59);T%Q>4@X=B]!0VYD95=T264P
M=7!K;G5*1&)H;6DU8T].=%IW)B-X03M786M"<55,3&)C:C@V8C!X5FLK2TA9
M<3=&6%EQ-T97=6U+<75I85,K=%1W6#AO2V%48GE*3F$P,F4U;&IB:VMG4%99
M5EE656ID>B]K)B-X03MF8E5R4'IQ+SAL='%F+T=7>"\V:F]-=3 O=T)98U18
M9C--;GHY8C,Y+V)24WA7.7I,1$9.>#EA3TXR4E@T,30X9T-!86-J4W9J;3--
M)B-X03M196)Y.&-K;SAI46A,<B]E95@O56(Y5T-F,&QL:"MS93A0<U1.1SEI
M-T9867$W1EA9<3=&6%EQ-T9867$W1E="5R\X07ER;C!)+U$O)B-X03M36&]C
M5CE,:"MM3U!#;G<X861Q67%Q9C@V0B\R<R\X075C67$W+VY14"LQ;B]W0GIJ
M1EAF.#9"+S)S+RLU>&ER=BMD02]W0S%N+S-/)B-X03M-5F0O>F](+T%'<R\K
M-7AI<G8X06Y14"LQ;B\S3TU69"]W039"+S)S+W=$=6-9<3<O;E%0*S%N+T%.
M>FI&6&8X-D(O,G,O.$%U8UEQ)B-X03LW+VY14"LQ;B]W0GIJ1EAF.#9"+S)S
M+RLU>&ER=BMD02]W0S%N+S-/359D+WIO2"]!1W,O*S5X:7)V.$%N45 K,6XO
M,T]-5F0O=T$V)B-X03M"+S)S+W=$=6-9<3<O;E%0*S%N+T%.>FI&5VHO04UQ
M-3(Y9C8W-E92>BMS+W!4,$M6+S-B-C,W<F@O3GHK1VY88D979$-L0G@V9'%D
M)B-X03M+67%K2&YV+T%!="]H83@O>%9Y+U%82T0V,7<Y9FQY.650,&%F5G8S
M,SDY=RMZ.4\Q8VY#-S(U=%=B:#14>"]3.'4O-GAT+S5E=CA!)B-X03MU935L
M9G8X07ID9"]G9FPY<E0O.4,Q8T<U+U=U1D1Y<BMN854W-$0T,6)S;R]L3$96
M9GAF+SEK/3PO>&UP1TEM9SII;6%G93X*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]X;7 Z5&AU
M;6)N86EL<SX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM
M<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @
M(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+W-4>7!E+U)E<V]U<F-E4F5F(R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V
M96YT(R(^"B @(" @(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z0T0W
M0T8P0S0P1D,X14$Q,4)$.35&0T$X0D%!-C@Q0C,\+WAM<$U-.DEN<W1A;F-E
M240^"B @(" @(" @(#QX;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z0T0W0T8P
M0S0P1D,X14$Q,4)$.35&0T$X0D%!-C@Q0C,\+WAM<$U-.D1O8W5M96YT240^
M"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^=75I9#HU1#(P
M.#DR-#DS0D9$0C$Q.3$T03@U.3!$,S$U,#A#.#PO>&UP34TZ3W)I9VEN86Q$
M;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ4F5N9&ET:6]N0VQA<W,^9&5F
M875L=#PO>&UP34TZ4F5N9&ET:6]N0VQA<W,^"B @(" @(" @(#QX;7!-33I$
M97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z0T,W0T8P0S0P1D,X14$Q
M,4)$.35&0T$X0D%!-C@Q0C,\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @
M(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z0T,W0T8P0S0P1D,X14$Q
M,4)$.35&0T$X0D%!-C@Q0C,\+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @
M(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^=75I9#HU1#(P.#DR-#DS
M0D9$0C$Q.3$T03@U.3!$,S$U,#A#.#PO<W12968Z;W)I9VEN86Q$;V-U;65N
M=$E$/@H@(" @(" @(" @(" \<W12968Z<F5N9&ET:6]N0VQA<W,^9&5F875L
M=#PO<W12968Z<F5N9&ET:6]N0VQA<W,^"B @(" @(" @(#PO>&UP34TZ1&5R
M:79E9$9R;VT^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @
M(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I
M;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.FEN<W1A;F-E240^>&UP+FEI9#HR145#-#4Y13-&0S=%03$Q.#DV,#A&
M0SDT-$4Q,3!!1#PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @
M(" @/'-T179T.G=H96X^,C R,"TP-RTQ-E0Q-#HP-SHT-"LP-3HS,#PO<W1%
M=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E
M;G0^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F
M='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^
M+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$
M/GAM<"YI:60Z0T0W0T8P0S0P1D,X14$Q,4)$.35&0T$X0D%!-C@Q0C,\+W-T
M179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N
M/C(P,C M,#<M,3=4,34Z,#$Z,SDK,#4Z,S \+W-T179T.G=H96X^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S
M=')A=&]R($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG
M960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D
M9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @/"]R9&8Z
M1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T
M/2(B"B @(" @(" @(" @('AM;&YS.FEL;'5S=')A=&]R/2)H='1P.B\O;G,N
M861O8F4N8V]M+VEL;'5S=')A=&]R+S$N,"\B/@H@(" @(" @(" \:6QL=7-T
M<F%T;W(Z4W1A<G1U<%!R;V9I;&4^4')I;G0\+VEL;'5S=')A=&]R.E-T87)T
M=7!0<F]F:6QE/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D
M9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z
M>&UP5%!G/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O="]P9R\B"B @
M(" @(" @(" @('AM;&YS.G-T1&EM/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O<U1Y<&4O1&EM96YS:6]N<R,B"B @(" @(" @(" @('AM;&YS.G-T
M1FYT/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1F]N=",B
M"B @(" @(" @(" @('AM;&YS.GAM<$<](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]G+R(^"B @(" @(" @(#QX;7!44&<Z2&%S5FES:6)L94]V97)P
M<FEN=#Y4<G5E/"]X;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#X*(" @(" @
M(" @/'AM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/D9A;'-E/"]X;7!4
M4&<Z2&%S5FES:6)L951R86YS<&%R96YC>3X*(" @(" @(" @/'AM<%109SI.
M4&%G97,^,3PO>&UP5%!G.DY086=E<SX*(" @(" @(" @/'AM<%109SI-87A0
M86=E4VEZ92!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(#QS=$1I;3IW/C4Y-2XR.# R-S,\+W-T1&EM.G<^"B @(" @(" @(" @(#QS
M=$1I;3IH/C@T,2XX.#DV-#@\+W-T1&EM.F@^"B @(" @(" @(" @(#QS=$1I
M;3IU;FET/E!O:6YT<SPO<W1$:6TZ=6YI=#X*(" @(" @(" @/"]X;7!44&<Z
M36%X4&%G95-I>F4^"B @(" @(" @(#QX;7!44&<Z1F]N=',^"B @(" @(" @
M(" @(#QR9&8Z0F%G/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O
M;G1.86UE/D%R:6%L350M0F]L9#PO<W1&;G0Z9F]N=$YA;64^"B @(" @(" @
M(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/D%R:6%L($U4/"]S=$9N=#IF
M;VYT1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A8V4^
M0F]L9#PO<W1&;G0Z9F]N=$9A8V4^"B @(" @(" @(" @(" @(" @(#QS=$9N
M=#IF;VYT5'EP93Y4>7!E(#$\+W-T1FYT.F9O;G14>7!E/@H@(" @(" @(" @
M(" @(" @(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SXP,#$N,# S/"]S=$9N=#IV
M97)S:6]N4W1R:6YG/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z8V]M<&]S
M:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^"B @(" @(" @(" @(" @(" @
M(#QS=$9N=#IF;VYT1FEL94YA;64^87)I86)?7RY01D([(&%R:6%B7U\N4$9-
M/"]S=$9N=#IF;VYT1FEL94YA;64^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" \+W)D9CI"86<^"B @(" @(" @(#PO>&UP5%!G.D9O
M;G1S/@H@(" @(" @(" \>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(" @
M(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI/D-Y86X\+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y-86=E;G1A/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D^665L;&]W/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D^0FQA8VL\+W)D9CIL:3X*(" @(" @(" @(" @/"]R
M9&8Z4V5Q/@H@(" @(" @(" \+WAM<%109SI0;&%T94YA;65S/@H@(" @(" @
M(" \>&UP5%!G.E-W871C:$=R;W5P<SX*(" @(" @(" @(" @/')D9CI397$^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U<$YA;64^1&5F875L
M="!3=V%T8V@@1W)O=7 \+WAM<$<Z9W)O=7!.86UE/@H@(" @(" @(" @(" @
M(" @(" \>&UP1SIG<F]U<%1Y<&4^,#PO>&UP1SIG<F]U<%1Y<&4^"B @(" @
M(" @(" @(" @(" @(#QX;7!'.D-O;&]R86YT<SX*(" @(" @(" @(" @(" @
M(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/E=H:71E/"]X;7!'.G-W871C
M:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^
M0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P
M,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'
M.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W
M871C:$YA;64^0FQA8VL\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO
M>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC
M>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P
M,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8FQA8VL^,3 P+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D--64L@4F5D
M/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO
M>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM
M86=E;G1A/C$P,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C$P,"XP,# P,# \+WAM<$<Z
M>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C
M:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D--64L@665L;&]W/"]X;7!'.G-W
M871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO
M9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N
M,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.GEE;&QO=SXQ,# N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \
M+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z<W=A=&-H3F%M93Y#35E+($=R965N/"]X;7!'.G-W871C:$YA;64^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP
M1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E
M/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8WEA;CXQ,# N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM
M<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M>65L;&]W/C$P,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C
M:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.
M86UE/D--64L@0WEA;CPO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X
M;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y
M86X^,3 P+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P
M,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0TU92R!";'5E
M/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXQ,# N,# P,# P
M/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.FUA9V5N=&$^,3 P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z
M>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C
M:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D--64L@36%G96YT83PO>&UP1SIS
M=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM
M;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA
M;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XQ
M,# N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P
M/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.G-W871C:$YA;64^0STQ-2!-/3$P,"!9/3DP($L],3 \+WAM<$<Z<W=A
M=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D
M93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIC>6%N/C$T+CDY.3DY.#PO>&UP1SIC>6%N
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C$P
M,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z>65L;&]W/CDP+C P,# P,#PO>&UP1SIY96QL;W<^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C$P+C P,# P
M,CPO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIS=V%T8VA.86UE/D,],"!-/3DP(%D].#4@2STP/"]X;7!'.G-W871C
M:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^
M0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/CDP+C P
M,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIY96QL;W<^.#4N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM
M<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M<W=A=&-H3F%M93Y#/3 @33TX,"!9/3DU($L],#PO>&UP1SIS=V%T8VA.86UE
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\
M+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XX,"XP,# P,# \
M+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z>65L;&]W/CDU+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L
M86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C
M:$YA;64^0STP($T]-3 @63TQ,# @2STP/"]X;7!'.G-W871C:$YA;64^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP
M1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E
M/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C4P+C P,# P,#PO>&UP
M1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY
M96QL;W<^,3 P+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA
M;64^0STP($T],S4@63TX-2!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO
M9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/
M0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,S4N,# P,# T/"]X;7!'.FUA
M9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO
M=SXX-2XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @
M(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]
M-2!-/3 @63TY,"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO
M>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC
M>6%N/C4N,# P,# Q/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/CDP+C P
M,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STR,"!-/3 @
M63TQ,# @2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z
M='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXQ
M.2XY.3DY.3@\+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,3 P+C P,# P
M,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STU,"!-/3 @63TQ
M,# @2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXU,"XP
M,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,3 P+C P,# P,#PO
M>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STW-2!-/3 @63TQ,# @
M2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXW-2XP,# P
M,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,3 P+C P,# P,#PO>&UP
M1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L
M86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STX-2!-/3$P(%D],3 P($L]
M,3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C@U+C P,# P
M,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIM86=E;G1A/C$P+C P,# P,CPO>&UP1SIM86=E;G1A/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,3 P+C P,# P,#PO>&UP
M1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L
M86-K/C$P+C P,# P,CPO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @
M(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,].3 @33TS,"!9/3DU($L]
M,S \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/CDP+C P,# P
M,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIM86=E;G1A/C,P+C P,# P,CPO>&UP1SIM86=E;G1A/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^.34N,# P,# P/"]X;7!'
M.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA
M8VL^,S N,# P,# R/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STW-2!-/3 @63TW-2!+/3 \
M+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C<U+C P,# P,#PO
M>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM
M86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXW-2XP,# P,# \+WAM<$<Z>65L
M;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP
M+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIS=V%T8VA.86UE/D,].# @33TQ,"!9/30U($L],#PO>&UP
M1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^.# N,# P,# P/"]X;7!'
M.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N
M=&$^,3 N,# P,# R/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.GEE;&QO=SXT-2XP,# P,# \+WAM<$<Z>65L;&]W
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P
M,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIS=V%T8VA.86UE/D,]-S @33TQ-2!9/3 @2STP/"]X;7!'.G-W
M871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO
M9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXW,"XP,# P,# \+WAM<$<Z8WEA
M;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XQ
M-"XY.3DY.3@\+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \
M+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z<W=A=&-H3F%M93Y#/3@U($T]-3 @63TP($L],#PO>&UP1SIS=V%T8VA.
M86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--
M64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F-Y86X^.#4N,# P,# P/"]X;7!'.F-Y86X^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^-3 N,# P
M,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'
M.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W
M871C:$YA;64^0STQ,# @33TY-2!9/34@2STP/"]X;7!'.G-W871C:$YA;64^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO
M>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT
M>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8WEA;CXQ,# N,# P,# P/"]X;7!'.F-Y86X^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^.34N,# P,# P
M/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.GEE;&QO=SXU+C P,# P,3PO>&UP1SIY96QL;W<^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L
M86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C
M:$YA;64^0STQ,# @33TQ,# @63TR-2!+/3(U/"]X;7!'.G-W871C:$YA;64^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO
M>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT
M>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8WEA;CXQ,# N,# P,# P/"]X;7!'.F-Y86X^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,3 P+C P,# P
M,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIY96QL;W<^,C4N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,C4N,# P,# P/"]X;7!'
M.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W
M871C:$YA;64^0STW-2!-/3$P,"!9/3 @2STP/"]X;7!'.G-W871C:$YA;64^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO
M>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT
M>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8WEA;CXW-2XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XQ,# N,# P,# P
M/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L
M86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C
M:$YA;64^0STU,"!-/3$P,"!9/3 @2STP/"]X;7!'.G-W871C:$YA;64^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP
M1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E
M/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8WEA;CXU,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XQ,# N,# P,# P/"]X
M;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA
M;64^0STS-2!-/3$P,"!9/3,U($L],3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'
M.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^
M4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIC>6%N/C,U+C P,# P-#PO>&UP1SIC>6%N/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C$P,"XP,# P,# \+WAM
M<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M>65L;&]W/C,U+C P,# P-#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F)L86-K/C$P+C P,# P,CPO>&UP1SIB;&%C
M:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.
M86UE/D,],3 @33TQ,# @63TU,"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'
M.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^
M4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIC>6%N/C$P+C P,# P,CPO>&UP1SIC>6%N/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C$P,"XP,# P,# \+WAM
M<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M>65L;&]W/C4P+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA
M;64^0STP($T].34@63TR,"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO
M9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/
M0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^.34N,# P,# P/"]X;7!'.FUA
M9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO
M=SXQ.2XY.3DY.3@\+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @
M(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]
M,C4@33TR-2!9/30P($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3
M/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.F-Y86X^,C4N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,C4N,# P,# P/"]X;7!'.FUA9V5N
M=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXS
M.2XY.3DY.38\+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @
M(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]-# @
M33TT-2!9/34P($L]-3PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X
M;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y
M86X^,SDN.3DY.3DV/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUA9V5N=&$^-#4N,# P,# P/"]X;7!'.FUA9V5N=&$^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXU,"XP
M,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIB;&%C:SXU+C P,# P,3PO>&UP1SIB;&%C:SX*(" @(" @(" @
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]-3 @33TU
M,"!9/38P($L],C4\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP
M1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N
M/C4P+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM86=E;G1A/C4P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^-C N,# P
M,# T/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8FQA8VL^,C4N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STU-2!-/38P
M(%D]-C4@2STT,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'
M.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^
M-34N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.FUA9V5N=&$^-C N,# P,# T/"]X;7!'.FUA9V5N=&$^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXV-2XP,# P
M,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIB;&%C:SXS.2XY.3DY.38\+WAM<$<Z8FQA8VL^"B @(" @(" @(" @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3(U($T]-# @
M63TV-2!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT
M>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C(U
M+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIM86=E;G1A/C,Y+CDY.3DY-CPO>&UP1SIM86=E;G1A/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^-C4N,# P,# P
M/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3,P($T]-3 @63TW
M-2!+/3$P/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXS,"XP
M,# P,#(\+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6%G96YT83XU,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C<U+C P,# P,#PO
M>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.F)L86-K/C$P+C P,# P,CPO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,],S4@33TV,"!9/3@P
M($L],C4\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C,U+C P
M,# P-#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIM86=E;G1A/C8P+C P,# P-#PO>&UP1SIM86=E;G1A/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^.# N,# P,# P/"]X
M;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M8FQA8VL^,C4N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STT,"!-/38U(%D].3 @
M2STS-3PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,SDN.3DY
M.3DV/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.FUA9V5N=&$^-C4N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXY,"XP,# P,# \+WAM
M<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB
M;&%C:SXS-2XP,# P,#0\+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/30P($T]-S @63TQ,# @
M2STU,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,SDN.3DY
M.3DV/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.FUA9V5N=&$^-S N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXQ,# N,# P,# P/"]X
M;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M8FQA8VL^-3 N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STU,"!-/3<P(%D].# @
M2STW,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^-3 N,# P
M,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.FUA9V5N=&$^-S N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXX,"XP,# P,# \+WAM
M<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB
M;&%C:SXW,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" \+W)D9CI3
M97$^"B @(" @(" @(" @(" @(" @(#PO>&UP1SI#;VQO<F%N=',^"B @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM
M<$<Z9W)O=7!.86UE/D=R87ES/"]X;7!'.F=R;W5P3F%M93X*(" @(" @(" @
M(" @(" @(" @/'AM<$<Z9W)O=7!4>7!E/C$\+WAM<$<Z9W)O=7!4>7!E/@H@
M(" @(" @(" @(" @(" @(" \>&UP1SI#;VQO<F%N=',^"B @(" @(" @(" @
M(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TP(%D],"!+
M/3$P,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P
M,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z
M>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C
M:SXQ,# N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP($T],"!9/3 @2STY,#PO
M>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM
M<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G
M96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXX.2XY
M.3DT,#4\+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TP(%D],"!+/3@P/"]X;7!'.G-W
M871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO
M9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N
M,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C<Y+CDY.#<Y-3PO
M>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIS=V%T8VA.86UE/D,],"!-/3 @63TP($L]-S \+WAM<$<Z<W=A=&-H3F%M
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+
M/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \
M+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^-CDN.3DY-S R/"]X;7!'.F)L
M86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C
M:$YA;64^0STP($T],"!9/3 @2STV,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z
M;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y0
M4D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM
M86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL
M;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIB;&%C:SXU.2XY.3DQ,#0\+WAM<$<Z8FQA8VL^"B @
M(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#
M/3 @33TP(%D],"!+/34P/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\
M+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P
M,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F)L86-K/C4P+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,],"!-/3 @
M63TP($L]-# \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT
M>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N
M,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X
M;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M8FQA8VL^,SDN.3DY-# Q/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP($T],"!9/3 @2STS
M,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \
M+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L
M;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXR
M.2XY.3@X,#(\+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TP(%D],"!+/3(P/"]X;7!'
M.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC
M>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A
M/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C$Y+CDY.3<P
M,3PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIS=V%T8VA.86UE/D,],"!-/3 @63TP($L],3 \+WAM<$<Z<W=A=&-H
M3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#
M35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P
M,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^.2XY.3DQ,#,\+WAM<$<Z
M8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A
M=&-H3F%M93Y#/3 @33TP(%D],"!+/34\+WAM<$<Z<W=A=&-H3F%M93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'
M.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^
M4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z
M;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L
M;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z8FQA8VL^-"XY.3@X,#,\+WAM<$<Z8FQA8VL^"B @
M(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" @(" @(" \+W)D9CI397$^"B @(" @(" @(" @(" @(" @(#PO>&UP1SI#
M;VQO<F%N=',^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'AM<$<Z9W)O=7!.86UE/D)R:6=H=',\+WAM<$<Z9W)O
M=7!.86UE/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U<%1Y<&4^,3PO
M>&UP1SIG<F]U<%1Y<&4^"B @(" @(" @(" @(" @(" @(#QX;7!'.D-O;&]R
M86YT<SX*(" @(" @(" @(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @
M(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.
M86UE/D,],"!-/3$P,"!9/3$P,"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'
M.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^
M4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,3 P+C P,# P,#PO>&UP
M1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY
M96QL;W<^,3 P+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA
M;64^0STP($T]-S4@63TQ,# @2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM
M;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!2
M3T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C<U+C P,# P,#PO>&UP1SIM
M86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL
M;W<^,3 P+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@
M(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^
M0STP($T],3 @63TY-2!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T53
M4SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,3 N,# P,# R/"]X;7!'.FUA9V5N
M=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXY
M-2XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @
M(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,].#4@
M33TQ,"!9/3$P,"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO
M>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC
M>6%N/C@U+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM86=E;G1A/C$P+C P,# P,CPO>&UP1SIM86=E;G1A
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,3 P
M+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @
M(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STQ,# @
M33TY,"!9/3 @2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM
M<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA
M;CXQ,# N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUA9V5N=&$^.3 N,# P,# P/"]X;7!'.FUA9V5N=&$^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P
M,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STV,"!-/3DP
M(%D],"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT
M>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C8P
M+C P,# P-#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIM86=E;G1A/CDP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,#,P.3D\
M+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIB;&%C:SXP+C P,S Y.3PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(#PO<F1F
M.E-E<3X*(" @(" @(" @(" @(" @(" @/"]X;7!'.D-O;&]R86YT<SX*(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*
M(" @(" @(" @/"]X;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" \+W)D9CI$
M97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70]
M(B(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M
M+W!D9B\Q+C,O(CX*(" @(" @(" @/'!D9CI0<F]D=6-E<CY!9&]B92!01$8@
M;&EB<F%R>2 Q,"XP,3PO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$97-C
M<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ H@(P
M P$1  (1 0,1 ?_$ !\  0 " @(# 0$            '" 8)!0L"! H# ?_$
M $X0  $#! $! 0L("0,"! 0'  4#! 8  0('" E8$1,4%A<8&5:7F-82%7>4
MTM/4V"$T-WB6M;:WUR(U. I7(R0QU24Y8;-!47&9L=GP_\0 '0$!   ' 0$
M              (#! 4&!P@!"?_$ %$1  (" 0(" @P)!@T#! ,!  $" P0
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M0PRM\UFGM[]RK;1XCT;4KL>GT[G37)=(J:]' :]J)CI5YN2K:+301HO2MU=
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M+9D1DK]--#TI&X[TALHT2'/@Y%^)*-5F)(6]=#B+)QA=-PS?,EU&SMJNG?\
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M9CJ\9?.7VX]+%TU.V_QO]IL?_$TY'\5O-/LQU>,OG+[<>EBZ:G;?XW^TV/\
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M 8X7@E660-^24C*AW#;';E4[[=617L[E%JW7>MB^UQT@ ;#B$4?05><.X)*
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M5$41<V=S*.MHB25<*JHH),)(L1P#/%%UD%TD<&[U3)15%5/"V6:>=K1M=II
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MD8[L\DC%W=C\[,Q))^<G(9WW^Q+;7T=R_P#D3VK/Q)\G]:_LN]]FDS+.Q_\
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M'7\V1/&.K;LF3:VC3\+H> R?:I?G=&^$/S6'V9+ VM#I&80$G,X[L8')I7K
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MSLR(,#OS$C=N;J4'K/SC<C8_Y_LZLGW0'!K8FNY=P %S@G'R,*X,<<9D,;&
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M$_UZ/['6SEJR;-?XIC%,9$N^_P!B6VOH[E_\B>U9>)/D_K7]EWOLTF9?V/\
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M '.V%_&DD_\ <J?#6L^5M3]/M?>X^*'"?T7X=]2:;^&QY7-K?]SMA?QI)/\
MW*GPUK/E;4_3[7WN/BAPG]%^'?4FF_AL]9[L_91%HZ'D-ASE^P>H*M7C)[+3
M[IH[:KX9)+MG39<@HBX063RR3515PS34PRRPSQRQO>UX)-7U65'BEU/4)(Y%
M9)(Y+MET=&!#(Z-*596!(96!!!((VR;!PMPS6FBL5N'="KV()$EAG@TC3XIH
798V#1R12QUU>.1& 9'1@RL 001OG_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>g947560g59e21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g59e21.jpg
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M 0$!              $" P0%!@<("?_$ %H1  $$  ,$ @H,"P0* @(!!0$
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M*)K?\)WTCUIY*+AD^H%J%S?XS^'*)K?\)WTCUIY*+AD^H%J%S?XS^'*)K?\
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M+HY>T2ZW'6C(HY*26F;99J9)4=+JDAX*2@ZNX61$!98S%.-9EKALOBJ#7 4
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MG1&GK$<0'^\"VVZ5J)F?!XAU)Y.B-/6(X@/]X%MMTK43,^#Q#J3R=$:>L1Q
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M%7%I(2%LX6':2ZDLE9,D2*:HJ(2.^TPP&2R R#OD50?DV)QX[MQ! Y\]0_\
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MDKXKS?6.#_\ D4[8<%[X1>3L>I3\:%TM]6O=KZ':[_>7I[C7LE?%>;ZQP?\
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M5YOK'!__ "*I[8<%[X1>3L>I3\:%TM]6O=KZ':[_ 'EZ>XU[)7Q7F^L<'_\
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MFSTY.YFKC>B H0+.$KKA8.2!FN7DH%60'N5:<"MI72T=I".-+';AEIG6@J*
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M&EA- RQ2SU67'S&&1DK&=D6-Y&S>,+FDZ!J(!X9CIS.SI@;7L)HI\/QN0D&
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MC/F!P^=9''$@)<G-,D\$=#?3<('QSQ<)*D=@N^,W8#D0-BDQ1#K0?2.A.,B
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MGFW&NWETRHL]S(":J'(_L<2CZ,>4R:&X$4+*R(74T^!_$_:<DS/'(@'WO',
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M2<5,^?42XN Y(L":/"CA8 "C8;-T<T^Q^&QQB9\LE# =0A,F^(WE RN!C_"
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M7&OH5&)EI94,C:[;I9+V4*HA;'IUCL<O%?\  "8LU:]&1TZ-8#LU>20=M55
M*;8-]CRNS2*"P-.M*E77].0S3*$*H4TY@ZB-R2'5&]P0A<_#(00'9,9-R.5$
M$$?"*5++=C1PD&TR]D?B<.V5CG.RT]W"[CY[^UVV46/23LN!T^# [66,.K8C
MF0/:A\]7"'5Z\P%*9SH=+'FV[?;2:^YGM@V*>(,BP_#34#=V0VP109,^'+G.
M&26 ]S<Y&@.S(#/>_KLD0RXLYN<>NDKQ@R=G7PV.'H['+))V28PB[-T-@YJ,
M2.;'(*#)CM6FZSTMW'9U.(K@F9H!KZ4Y'8*F+&*@050&Z[4_%4P]M<8+6VAP
MO$KNS5.SM]5K8<S#L2Q,5;3-JWMV>GGPZK#8MRU&8(V:#![9@EKU1)%NY(C8
MJ/-4LI?V2^G/!%=D9A,CYC+##KC-$=EM;-(YL;9.R-+[$8<)'Z79AVEX4822
M9;3:XT46GW@HL%-:R-L5J H/%9*A(S<C0JFE$B&C;H5\0A@$M!16ACCBH'Q;
M&2R>G$4N^=S()8$,3##9X<VS9]A[$XZD=Z2U-L_M:RI"XS6<1?(^;&&U8LVN
MEGFMG..,:722/DRTN<X@G%G+&;20%YB:QMO#S(X:60AH97+W<0UK8^9.8 #<
M\\@L[UOFMZ/%KR',"].RE=]93<W&NIMID3/ 6KSA;D3M)O#CME;<DBO]L.=6
M6(#)9JJDW2,1,!G'4*QA$S#5<+&#S3)#8&T.#4Z=K#\)@P2/L'VEL68[%[!\
M>VE@L8K:L-%F&MA]&S6AAQZ3=16'XK>MLFTS Q>]CM/&13M22,GL/LN,O9;6
M%D5BI3>R"-OX-SY96/<ZH-3FB"&,C-O'FP*0'QL U8>E5K(L&R/&C69+HXN.
MV9QXX,Q38@J.H:ZJZ_K#@U"2R:*7,@806XT0R[<04DP*&P' 71C5ABQN[9Q[
MG8-+ ;.+X9:FQO#L2M7:OL4[*LJ&Y'>$T>T,-?:3LI\+7:7'&Z\S:N<K0;\#
MIF9.;V3^$NS6V5IXV59H6128]=WHC,1:ZHYU/2UQ&?\ JSP9,FY[IVD\#HX?
MK$>S6;J MH<$29#+*?\ XIFX;.8!DZ_([;)4HY%'B)(2TQ4--6G JDTA(>"C
M'I/NO&)P\=)&B80*,Z$8\2))X"N57J5JQ/!/CF'8Q<H]M.R-N^UE'$++WUX_
M8_GAO3R0UXGS2U([[]UB3&,>UY=-6F8]\CHG4Q2-8US*LU>*7L'$HX2Z6)@#
MSBS'1-#GN#6R&(9PDD$9->TY %8BYUQ.=3?<;6O+,/D-N5.&M,V]($G&9*8!
M)-&V!3]K'$J!.8_)A)2,("TY6#$!F+L)8>Z,J+-R2@W%D==/'%-.4QQLNM!)
M6GKVO:K%Y-E(\8VPL4,-9AU]\HP&39>"(UH\-?&VQ#7O8LW$SA5.:*'7'8A$
M#&Q21 4O<)&21[^N,0-;#633F6(-[+;?<X/,H)8Y\4!AW\C2[(M=K)()4CO-
MU/0S(B##3RE:+GE$";"6V,2,667ML5KT[EZ8=BY7UEE-M-Y^.BR))KD/Q6R%
MAT63&K%)!T=PVXR4\PD&70JEGX[5LR9UM2I3;A\^+T\+Q.GBTF,[+8M>PJGL
M_C]6#"=GL+VCPRQ8HUM_AE9F*7(:QDM8H^MO[%Q[9FUHG4JL+&WI))3,VO)/
M#)7%:[7BL26ZCW6+D]29C)7ADSS!&YWO(0_2R,$&1PD>XJ*6TY$?7&!4Y)#D
M"'B,WLK0J=TW&[9?,:OE4;$HN'>F-7&VTM/6D%474D63TIA&3+C1>X2@><#;
MP(&3Q <DH-T]=.VMFO-M#CKY30Q>3!;NW.!R'LFEB-**UAD&Q.)5[$LD,\4$
MHPV2\UE>;?QL@L%[&2->RPS>8S'-IU&MWM=MJ+"[8S9)#*YDSL3@>QH<USF[
MYL9<YFDES""6Y%ARZ^3=D[2*ARPRW9)K.76FZ>&M#KO5D<0^T,"3KVD+DH14
MUEV*W:N(62[/P:@$NE599,YF']VF344@\+<B6-%<;F&[.^UT^%W*F&W(+5;V
M1<6J13".V7U=F7/QF.&K%JSW&!%CH'11-#:.M\<K!K<QQB6Z9FV(I9HWQOP6
M&5S28P'WM-=SI'99:K.K4''_ .3(%IX A2U,:JR$_6G9F.U.6T>0FRGP+"@\
M%'S<[Z^!QFXW,W)/@<0ZL:]:M,5$$=\7JZ>S+/4LZ7"KO:[H5BHSB(.UNG5Q
M36\T7581%=DVCV<Q"/"I:%F3'<9;C;&X'CSL3KU[.&XX&0X_M-=F%3$H9+AI
MNJUX:78T3A7DJ6&010B;)L.C%.["9VS,%6N:Q[)J"![V35B75*43=["6Q[S6
MY\FMV;P]CG%VG#^(#(:FYL-_SLJRU$<FQX\YR3%'2A.9$C1J_14U2"EPZ?<#
MD9B&RE=5662B8Q)WS(\J*2H20B#O?ZTBG5$9PN#(%0PR]@Z$58[",PO"L6PW
M$*>"RQ[927</Q&B)(SA3(X*UR:Y%%#<F.*]C389'&^:2I0AF9&*\&J,VL6E<
M]N+&>>O-#+:8[#1'+#*01.2]T;8G.=&W<:VSEP:'RN!.IY#E09D27BQ-("QI
MKNU-1I0:>]<=R4V$\NJ$<70GXMB(W4(G.THCW&[HY)J8X<$\#NI8M<B$H9%R
MN8UAQ, \NZNX=V=MH]MFI)-AEK8B_AUF1T3S6D[)Q:L)*CYLMWO)*YD=NM6L
MQZG :02M1%-N<,#HWALT>*13,&H:QHKO(>&YYZ0X 9Y99\,\U,FX[UB-M1BO
M8PBXFN=&W@DU$V8?C=:RL24!XI9"4URZFWH170"HY@9$.H\W/Z8\%!OG>P#B
MH\;QDX;V,E3Z>+AJ-D:>+6<2@.-5[+!L7ALVSE&Q9A?&W%+LEIT5C&H'.:UL
MS)L%HX08YV:FB7$<2K@M='(#E8E+79 _L9[#[:3MNRL8X.W$36!S*S@"2TML
MRV,VG(Z8H79<0J^SZXF^JZLZ&H:6NHRDM-=@3R5<R.04R1Q4;II4V)?:NF%E
MU/+CB&T@=12C193( J )<0XGF #I?$0L*&+EOL"KV(MI]N9Y8)HX;5[ G5II
M(GLBL-BV?I12N@D<T,E;'*UT<AC+@R1KF.(<"%AVWL=0PIK7-+F1V];0X%S-
M5IY;J .;=0XC,#,<1P5,J[!:U>Q+\%P\RNY/S_,O_")LU\&^SI_:1C'[+A'_
M &RJO6=E_P AT_\ ':_>)%N=XBWF2:WSIHGV2>]>0KHF<S\G\0K50CYF(B^;
M!@_91)HJ%)]$2B)1$HB41*(E$2B)1%J/WR_AI:"?-[NG^[]=Z*H?BN_X?M60
M45*41*(E$2B*ODIZL07-#@%<\BLX^K+!YME66OYI+WD!G)[U9A$ZIJ))FR*B
MLMTMY$DIHE#JVMCEFP_D]QH0%UI8P"(8AJI_ P4@D<OE[F8/2#S'S>#H"EMS
M.5H1JSEMV.I61F<QF0@'%E<65$8!+0FXW$(CF9.&S(M^QER:>G$2^676XVQQ
M#"#L&'A>_6X7*%79C;F1$]W8T6@,D2W'QR2!# ,6*TM0](,9-R3C!9.,+.1!
MH+;M0TTIDN&$4H:6D]L+MT-T*J25-J"6BG"I(X(7*2,N@_(05G[PV,B9D2>1
MAA8<(H\GJ,8/*82[.1TT\KJ]F"QQBA555S 1($7 J(?.&\B3>(F! S;@-D50
M%+",73#EP2C+AGW.2QD_MY Z=CK6(9=HUPMM0$XW"(X",J& '$15D5!6TX^H
MB@EL\&\2-ANIL)H)I9N4"R77$C(W7=OGP <BG2>/]WGX\OZ^0J5V?)[1?;ED
MYJ-DV:/*D0NQ-8[W$R(&@$XDZ5-F-A_AI)%1%PQ*J@Y1LO%NFE*Y',8-/,J&
M) SE@<!, A%&7+P\?21_!2#1%6J8-LX;@]=/MYZG'@:/MYH@R&^A69'KU?9"
M,X\,'%$@7?4D*#31%8HSVV8'15W,L85!0S9HBWW$JE20R4@+!TD4@$\NZ<AQ
M'$\. Z>8\:L<5-%CI8N<)F 390V $:*FBPN Q<R6'#Q% , #!Y9!B@C!9XB!
M"AY98"898YXY7QO:]%"^]$2B)1$HB41*(N^X5/F#F/\ 3>W<_P R+_J!R^=W
MVE2>?S-^P*#N*YYX>'Y\Y,_?X$+E=M['WYSU/\BY^[2+DMM_S;N?YU/]X8JU
M5]!KPM*(E$2B)1%#$DZ^Q/+:J76WPWE(XK!(1AK&#Z$\WPR3"TU#1G,X8:;H
MR9#D;MG<U!30HYC)LNBRNA]E-',[$+7.&KC8%O"Z5YXDLQ/<\1F$NCL6:YDA
M<2XP3=CRQ;^ DD[F;>1YN=[WWSL\^IB=VDPQUY6-89!,&R05[ CF: T3P]D1
M2[B8- &^AT29!HU>]&4BG#C68#4,GCHZ,T66RV^*9,F!<BJ0WVTV6\GW$%$S
MR_Y)),2$=+*7ROU.Q%B9,OU+6P"#M:V4YT-6!SG&."O7B+G$Z8XH88F9DGDU
MD<;&^!K6CN +%:V:S,&M$D]BQ*&M U/EFFE=D .;GOD>[PESCW25 K3VUBIU
MKS41,B$EM$M(1O$A&[HD*+7PQ6?()X4H,HDB#:<+D1B!.RDKIQ<<^@):WW&4
MW$4"S&0B:C;'*UM9!CE*>2"/3<@%IVFI-:I6:T%IQ:7M;%+-&UH>]@+XF2;M
M\K03$UX!6RFP2[#'/)JJ3FJW7:BJW*]B>LT.#7.EBBD<[0QS@V1\>MD1X2.:
MI*<$S1XVI,:,.J2YUTD/ANN9UMYK$BI@\?';[3!P%5%(W<N'F"F@#9Y"%4FY
M\0O=9-E3Y=-L9S3C_:^9+?JPW(*#Y/\ 6[,4TT4+6ESC% ,WO=D"& \0S41O
M'-<&9ECLL2*A:FJ37F1_ZK7EAADF<0UHEG)#&-S(+R.;](.[:6E^6IN>"FMK
M82)-:"7D8<QH-"V.66J@1</W%5;CJ"B\@RO<;!:*V+7&;8/;Q].13YA9Q* I
MRZI)Z0;S".&P@LL8XUAXAPVP9CNL6DABI'=OS>^P!N]XW3G$-3F1N,FD-E>R
M-V3G +(&#7S-B, B:9,*CFEN#>,R8R G>&-V>4ITM<]H9F71M<]N;02I60)"
M;#F=[^8Z.:,&5Z-##;).["Y,P$2('W4AA.5*( GA,,2YLYW#,D%$X 7SSS)E
MU)/R'ZVYH.U9L5J&:>U6C<72TS"V<:7!K'3QB9C0XC2YVZ+7N#2=(>S/\8+#
MEK30P5K$C0([;970'4"YS89#$]Q;S#=X'-:3P<6NR_%*S:LA8Z@R4]BHUB!4
MQ1'3F[%%7!;!U\K"<RF,[7V;;#%3C(A0Z]'2"U$A5R0F\&9!- EC!VV!I5$3
MU7%')J%TA4[3UUW%:E!^[FW[WB%UB1E>M/9=#682UUB80L?NH@0X NR<\M?N
MVOW;].QIX7;O,WD(A:PRMKQNL6(*PFL.&IL$)G>P22D$$AO!FIFMS=;-4R)2
MHG+B6FK:.=+*20L$":HEJ),7$<H?3E N&;(G2HV%[X#%C188(< 7"]\1 A,<
M\;WM>U9['LD8R2-P>Q[6O8]I!:YC@'-<TC@0X$$$<"#FL!['QO?'(TL?&YS'
ML<,G->TEKFN'<+2"".X0N?52I2B)1$HB41*(KG<'SS-[+_IN3K^Z8_KYIVM_
M.3&/VQ__ "M7T'LS^0,*_9&?:Y51_"8/XOIC?I71%]F)+K?^Q5_:'LI_O,?]
M"=9.-_D?$?V5_P!K5X;Z_0]>-I1$HB41*(ICBJ?)1A8LXT]A+*($BNX5$,N1
MM.YAL"3&DKJ#9S4LVTL&FC)C7=S9[OMVZRL607 $DAK:-@K*@2<?+!J!S ;4
M8I@6&8RZO)?AF,U03MK6*EZ_AMJ&.R(Q9A;;PZS4L[BP(8=_ 93#,8HC)&XQ
ML(R(+<]8/;$YH;)IULDBBFC<69Z'&.9DC-;-3M#PW4W4[21F<\%=[O=TE/!>
M>KS6U5VO1XK)M97EQ4&$/*RVM*9BXI@R/GU+Y"##C"=8$"%AB$%A8,N6"#!#
M#"QS:E2IAM2"G3ABJ4Z<+88((@&10PQ-R:T#N!H&9<223FYQ)))MR223R/DD
M<Z261Q<YQXN>YQXD^$GN#Y K4*NA.P"046R8N,:')(:[>/NMTP0E2RP%2>6V
M@I*9FMK(RI%Q)<&7^[*$BAB*[A9I+ X^6ZG@&S*ZV4[ @H=J\Q%MU@,KX7CV
MR9AUFPRK5QR7"K\6!V9Y91!"V+$WP"#<SSN$->V\LI6)"UL%F37'JSCA-L!P
M_ F9C#(^JV>)UIC&M+G%T =JU,:"Y\8SE8 =3!D<H*CN#)/E1I2T^V4VAE-H
M0>T2CUDMP"F"Q)-;R.H*Y5#2P;CFQ0L3BPJGC(F2:BDNSJ9PFG+!\$MD225
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M+P1D%>44W8=ZR >NZDL9?'#;&+=L7+!#FKF\BHBL73C)<H<[,Y@NY99DC/T
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M-#DS80 XY +$00L-CCU;AY6MX3M'9@N8YB=JK()J\]ISXI&AP#V%K0' .#7
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MMXUA>T&W.)XI@UQEZA/7PUD5F-DK&/=#0KQ2@-F9')[R1CFG-@!(.1(XKT7
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M>I.]@0=T.436>@>GK5%N)>F/P+1C8<0[-$AJY7%K(W9DX^BP\"4-8W>;9M;
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M;VIM6:6!7+%2>6M.U]4-EA>8Y&AUF-K@'-((#FD@Y'B"0J5^(MIOZLL+?0%
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MB79F-C\YV#U[,4=N3)D-?#,$88HK%*BZ>Q<K2R%[K%QS(&Z6UY'O][)+*XM
M;EK>S^Q=N)8(O-(F)VM\XTHZ9NG6QTH/V(%%(>J$N+#@B61T1N=VD$JZR#</
M%0W0*12%%AJ3K:I0Z28SD5+*!  ^I]D*R[&[K+$=^>)T%2O@.+7+-!\=B*62
M6E;CBWD8F;$YHF+8W5GS0!S:\S]30Y_"!@M)T#Z,$K9K,^.855K76OKR1LBN
MU9)=W*Z%TK280Z1MEL,SFFQ$S2XM80<G*[O2B@(;K/.V,+KYH*/DQRM=228S
MGJ*&>DOU<?+*CU(B]W.&8&2F@J=SBP_TE3)/)M8XY'4) =QL=G)69!/P4;PV
MAN113.GIF5PJLFA>RGB5*NRS)9KU8Z<\M^NP/U26F/;8AXNBBG<:["U@?:.
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M/HAGB+35<]L=YMJ>^V2NZM!)J,9B?%7CA-/\*QFH.AC!W)U"-[9"6^^:[,/
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M!<3QH15<)V@K2X7%2PR;%JT-S%;]"/";PN5X75^R:<D,4=U\+(&W()1.VN7
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MN:;ZB=7GDUB"#@MG%NP3C#S,MXT4ZN.?= R' >'[,^@K8L"""7!"+EP@P
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ME>Q:U\\^KM';/X8Y\CS"_5)@HV?>=]+QPP%Y$(&K(/SD=^&'X7C^-P"QQ<G
M #FY"UV8/>CA/P]]_AX#WO)6@+[_ +R;T0QHWVLD-<S+;8G"?)O6WR\XOCMU
M!M]X2F-&1UKNR+#RV353S7="&I-5QG3N(":GI )L9KJ !9344-*-(7-'8.G/
MBV)3VI;+<)M8+@6"PTJ>)XA5=8IX6W$H[-3%&0OB99K31VJ[&$R22N8+,9=%
M'-*V?/\ ;>1E:!D;(S8CLV[+Y98(I R2=T+HY("[46/:6/)]Z&@EA&HM!;![
M9W G%L@-Q.[MH+D;[?C=RQ(::SV:3>>#:=S =LIK\U+2(^$I>(' G./G)SC/
M.].73^5W"B*Y=+-HRJ0'2R0@6ZL[)8)9-A^YGK3SXC6Q5MJE:L5+-2_4PRO@
M\,U*6![#6:,-K1U)((QV/-"Z5DT4C97@XC,1M,T#4Q[60OKF.6-DC)(I)GV'
MME:X'63,\R!Q]^UV1:X9!?53W#FE8%DG!0,LD5%E"-F_$RLT@HZ9A1H-UDLX
MP <8Y)A-XFCER+(464H%[*C<76_@36BZP.=6CIX\K'SITQ$>R.#0C#C&VXV;
M#<1L8K%;.(7'V[%RXUS+K[UA\SGW8[L;MU8@G+X70M9"QC(F,8V78E9<9L]U
MIFAC@=&(8Q&R.(YQ")@:!&8W#4QS<G!V;LR22NV=^\.P3R*FLC*TTV^YUIS-
M!YO.1F7'[.9TF2$[6"HA+31<3Y?+?1R*ZN*J2O  .48QVR6[N.HN5=3DQ6'&
M4+*@-JIL7@--S-,-J>M#6MTZ>'W+]NWAN'U;\9AMUZ5*>9\$,4T!-<-TNW%9
MSJM<PUWOB=5)BEN0'-T;'N?%)+-%#''--)"=4;Y9&-#G%K@']S4\![M3AFNC
MEG;F6ID8QV.',5C=%:*M(9"6UY-8$6,2/\G#)I-&<:"*]%DRTT-+,FU-1374
MK!'2EA D3#+,#-/2B%PNIE>PK93"L(NLQ"L_$9K45"3"H)+^)WKXKX:^:O.*
M<+;4TK61QR58BQ^1F/OA)+)F,J+&(3V8G0O; R-TPL/$,$<6N8->S>.+&@DD
M2.S'+,C(#)<B-]OY7C=C(L;V1XDD1G--455MAI4R0U&\L91ZJKI@,ZMCLH\]
MFZK'T8@KJ((*JIMSMDPU3ZMADJ&D,4^8-&!Z<1V2PO$;TV([[%</MVXHH;TN
M$8OB&%C$(H&ED+;K*=B)DSX8R8H[&EMED1W39A&UK6S#B,\,38=%>:.-SGQ-
MLUXI]RYQS<8C(TEH<[WSF9EA=[XMS))Y*3NUL<DC*"E9[$U-S'9V3]E2SS7&
MLV%EWH<SD1T\4=VM]</I(QA*#60DA)3UY  Q[VU5)32J282.Y^(A82F78W9Z
M41Q]A/CK,P.39QU."S9AJ3X.\/#:L\$<K6RF$RRR06'?ZQ%+*^5LN\(<);B=
MQI<X2@O-H7!(YC'2,L#3G(QQ:2W4&M:]OXCFC26Y9@]L>WJGL0TQ!&\)&S!2
MXV=KP>K4:L>Q)';29X"S(;:*,^0 UELIK>Q2G4E/=L%+-]SI#I+K*>J((XK?
M% L@AE4PM:9L1@0;>%@8C>EQ&I4I6K5_%<0M6W0X?9?;H&&S).9:LM*R_?UI
M:SH9(IVB<.WY=(Z3BMK.+1N(6PR221QPP11QZI6".74P-TO;*P:9&O#@YI+?
MQ<@,VCK<D56E_7MW369,M".M8'.=D"+F9KK%L=MG(NO9.-O.\RU0B_=-HD$U
M(>2TW@L%YWJHCR54BYXZ?Q;;EL8&3L\+$-D!#A./U,&:VYB&TM9E#$[FT.)X
MA9#H.Q[%1MHNW5N226I#8)@J1"G%-NV1]D5M(D%V'$M5BI):)CAHO=+!'3@B
M8=9>R0QY:F!K9"S)TAUN;F3I?GDJ@2C(CAER27[*3L%#%<DAN]PO);N!C? J
M$H.)5-*I@J2!ZO4+IY/,SVHGE [8A%"0(!8'# (+##'K<,P^OA.'4<,J@BOA
M]2O3AU<7&.O$V)KGG_:D?IUR//%[W.<2225KIYGV)I9Y/QYI'R.Z 7.)R'0!
MGD!W  %@=9RM)1$HB]9OX-'YH=O?GU9O^$[;KX-]G3^TC&/V7"/^V55ZILU^
M1*?^*S^\RK;SQ!?,RV?G.1OLJ]*\A6_9S/R?Q"M!#'F>BCYM6+]ETJBI=S/R
MG[5)5%"41*(E$2B)1$HB41*(M9&WG\-;17YNMRO_ &.OU%>B_%D_X?M*E^BJ
M2B)1$HBH1MELO-,4SGJ; ,'LJ-G0Z]H!9U(A+$G+3E16^T18D8Z(] E4SFV"
M2DH'R>1$XJY&4L$GB95#!4@FEE%&L<'52A5  @DGEE\IS.7]>/N+7ZY^+#,!
M" X3DDP/J+$3X=CUV$CF0T68S6R:PVE!QP<]D5H9J,7&X=C-]J.*.:L?$/*Q
M=[V3397(^DEDD=7Q!4S !5!HS(]\1DTC++/WPSR.9'H74;+;$[3[$<+Z49WC
MV?(08I9HD)-'DES:YH\S74'(G-SO7#:K/83DEA'CEU,@T<,J"N(_W%WNFS61
M -)3FF;"[=5C8)&AH>!D2"0/?9#+,CF!F#\F?RJ2N)VK;*(^F45R)'DUYQS'
MJ"!K8(^TYNE%@*4I'<SLDJ-V\"GF'^$LE,FVS2A)6&6%<%-*CK;G50@TQ2.8
M((QXL;(T#601G^-ET#('N=WP<LO#W($XA,MS*X-PI_:A4;8H.(]3]4V?- @>
MOL^EH'46?V^K**^]YE'+&BYLM+;J0D0@$BMEA+A85KC)R6X>S&$Y2-865"E@
M&0_%S<[3D6Y]P9=! X\2./$>'+8KO5.JXB</_!YQ([5HLO3P1@V-6+(>8(*6
MX$XGL(Y6>TA'QE@0!)A([B+-1SJ:R1$3RY3%,</:>90,M8 .P94-'ON/<S)'
M/\4$Y?/EDM4/$.=VQNLKRV3E FK[<H8L'^*H:TE5V,IOD]JV#&29=I-J5D*:
M!"!G-EJ;A<RX.L(RR3DNYAUN=3.M<LWL#B.+8.BK8&G2,AQS#L\L\^.67,\L
MN7#I4M[1*4_QWMM)NSTV!;%)VGS>E_6ID-06&=T>\9/91,^FLY 65EQZ]-D-
M>!?*:MR8L8A.E$7U1BKV:,+_ ,M*6B9P0T$4-R+=(RU9.SS:#TG@[F.'+GQZ
M%?/B4$9640]:RR(%L":UY$EE8#V>):MY/+PU&FR(R5C&/[)8,;Y8R":: 3X[
M5$>I=K6$-9$K$Q# 60(5LL"AF7'EGE[T.Y9Y\<\^'+/+/@M6L3)V\.UNJ,8.
M] E%[%"\$/C9R+#;UD:8%R-'BT5!I2A'2E&<Z2N?1S%B\G&8J8;?D-DNE'5!
MU+,V.;%&$++ R@LJ $#N<^7=_CX54<FD\N(:>'+(M]\T=&K,$'+@MBVK>U\6
M23*S[ DMT/(O(6V*TD!1HQ5!!?(#.8L+Y,)TN""& 9<>)'%JM64):BM#>>PB
MJC=U2C@,@.\!+&$[*B(!7*5000.7 <^7/, GF> )#<QP.6?,E3?PT9%=+XUD
MLV7NMJ3I=<#2U,FN"H[5@R*=5'45AB0%EIMI<4SP^69@^J&6B WP5=2,BC&5
M-6+GE P+D,:$ZA'C(^ @.'S@'E\JV T5*41*(E$6#\-+S.37^FUNI_F*?E0.
M7SN^TJW+^,/\+?L41<2WSP:!_.W-O^75^UVOL?\ YSTO\FY^ZRKD]L_S<O?Y
ME/\ >HE%E?0B\/2B)1$HBISM%/\ )<1O;7./(L:3+<[CGU\NID!#OE7649'0
M,T9G'7&761C"(34#@Y<H(6R,'B(9,0=0*%Q$\H.1,F@SY;0XSB=NC8PJK2@K
MS2XG9FK@V9)(XXMW Z42$QM>XANDES0TES1I:6DZAO,(PVI=KXI:N3V(8L-K
MPV"*[(WR2[R=L1C D<UH+L\FN+LFN(<0X-+74D<7$>EI&BI)<"N+K#&K_1)O
MG*#7Z#(YB>5)FKBY#JDWR BM'6<:,1Y+A<D9LM=>>+N[$IGC:Y7,B.9OF:!*
M<]-M7=CI,E><&IV8\1Q'#K(N.Q)]>22@^-A?4-.M/(&G>9N$X:?Q2TGWP'01
M;+4I+CXV#%K=:3#\.Q"L:HPYD\<=]DK@RT+5B&,N&[R:821^-J X$_"4IXV*
MV"X?LSRLR)GA9HBLPC*N;T=,%(\M&#2B@-5D)*TEM1I*LHH[!7FJX54^H&@7
M.Y@4<]9/1!B'>N:P6,SHQ*+F)XKBFS&(7:V(8?":[;IL3X:R\2Z*"NR1D$$E
MR.M+#*]SR)IA&[1&6[EV\U%LT\.PO#-I:%*Q0OSBPZF*\.(R4PUDDUB2.2:=
ME1]B.:)C6@Q0E[=4@=O@6:0[G[Y*^P!3AQ-:0([ET5@(C?A.+UZ0SR: K"R>
M]E=8'C5*1TY*>P2L4$:Z4(*KJZNZE0 (XOK0Q8@DA&"Z<?6,AZMI7XHW92&U
M5O&K'%AU26VYH>;EA[S49&QE@/:86$O>^9X#I9"&L!#'29V]G68:[:>:M:I"
MS)+?MQUFO+!4KQL%M[WOKECA,\:&,A82(F N>07M9EF/$631BN2,JD)LG8.5
MGHQ#L>ZO:Y0@[%IF*2]-XID0^!*ZP8;:L1,K2(UBY@A9TCNO'%IMYN$S&>(P
M:HJ88F;^U32W=O;B.)"]8K.JX-A6'3R0/EQ$DN%V0PO:9(X06;YT^4$433QU
MR#.ULN\'>-=0PXTX++;.+XIB$,=AL>'@!IIQB5CA'),X.W(A_#RRN _$9FV<
M=M9"EB$M!W MFG %G-]H_C*.%%X)EK A%I&D17:$9KKQ2[@X 8%LDY7<BBXD
MO+ ,' (<L5M@%CU,0ZV6-VKN';,RR.E!Q'L6G4?89P MVI(*<MAF6619),^9
MF0&1:WAW%K\%K4L0VDCC$1&']DV[;('\2:M5D]N.N_,G/4R)L3^>8)^5:YMY
MAYM@I:F=?*.#:1(08;B" Q]/G1&RH[C<3I@K4RQ(2V/.QI/'$:IY;5S1<($Q
MX3.V!W&BF,2*9B?-&"947E=I'8CATE^5LN,QQT*.&.P*>HZ=U)A@.F^<2<PF
M!\DA ![,!,L9TL#G%K3U&SPP_$8J$3HL(?)>O8BW&X;3(&W'B;C2&'!XWS6,
M#LP:F0BD&IY: XBTLVN/8 3:O0AU*\DAH,42,_ R2=$#4(JB,(,;&A(^XG&I
M24M"*F??..$XQ#)%O-_ B C)"45+G1\3:V9'' W.(RXG[=;-3/MB.E:M!K:,
M#7QDN.'OEE?;D+SOB)26Q1!HCC8T..J1Q(TU"+#?:;:.%E3>W*M;6Z],YDF0
M&(,BB948&?@FF+)TLA<9'O<6C3& #*G$D<;L3H[A-I,=9>??!(NQL>M4S'D=
M.T['KWF!KYD7"<<C 1)$)#$L6*&,7+EEU4<!Y514[N>BC)1E6*=U,+"YFUDL
M[*N'05I+&]M8M5A-6I.ZK9O0Z97358[32WL8$!LKY7/C;IC+#(TO&>)LK% ^
MU?FL1P;JKA=F86;4#;5>C,'1-BLR57!W9&1)C;$UDCM4@>UAT<*,-!E;4S]K
M&WTUCR*\!'1$<M[61N\FT[9G=+9><-/$(T$2A^SUDPKD&/*><!8"=TU4UD94
M"2Z572?<L!4P20< ^<@KXSB>$1LK6YS-1O8W4GAGOS16*%@.#: LVP?]<.&#
MW\AS<V02MW8?H70SSX/AN+2OLU8!#>I8/;@DAHPS5[\!:3=['JG,4QB1&A@R
M8Z(QNUEFLYW U\VCC]SRXO+3_>;A,N*<33*:$/HW>^Z!62CQ8$6?(,6*:PH%
M2(K2;#NV/5&K)\G(1<^:*JBNS[LY(%ZEDQ*#,[W"\9JS7I9+5B4RXDZO!0CW
M4W8\=("R*+Y'AFXAGQ9\-RY$'.#Y(#7C.6B,.TF)X19AI11UJ\0BP\6)[TF\
MAW\EPNKFXR-I=OIH,+9-4J2%@<QDPGD_VGD2_H6\%U9C.4([<*LHN$WKOL9,
M^OZ<XEDZ845=::['<(2@S#"F?-B"F#AT@T7$B(8QD<44P-=*L(:&&-9##"9V
MS4\LE2Y5F>^5V%XKB&&,ED<7R20UY0ZN7N<27.;!+'&222= +B3F3@[1P1QV
MJ=J-C8FXIA=#$G1,:&,CFGB++ 8T9!K73Q22  !HUY- : %=^NB7/I1$HB41
M6!X5'FCV%_3/V#_>#>KYGVK_ #CQG]NF^T+Z V>_(6$_L,/V%5._",OX"#&_
M2DBG[,R/70^Q5_:'LI_O,?\ 0G5[&?R3B/[+)_!>+^OT/7D*41*(E$5UM'=:
M6#LV\YI29*>KH8;2B#6>7=@E%<:"*F.)9S!BPNBJ!LB$C*IU,+*.(Z<>/"X$
M[*J4(:-%RQ:RF1#%$,A\;MKM'?V;IX/+AM.K>MXMM'A6 QP6YI:\.K$W31L>
M9HF2.C+9&1@OW4H:USG;IY :=EA=*&[+9;/))%'7I6+9=&UKW?@-)(TN(!!:
M3PS:20.(5\FCPU8#?DDP6.P1ML9*B&?M5E^>D!NLTGK\FS6T5]KR>CQTL$W(
M8D1\L>-U!H8#'1A S",J9..QXZEA!)IL@$I* '#V_9%QVCAV-MOC9;#L6P+:
M>O@<]BX_'I,&M06L-FQ"%]=M"E<Q&.V0QH+9HQ7T,E)D;(8XW;:/!:DLM4Q&
M_-!:HNM,9'V(VPQ[)FQ.#S-)'$6>^)S:2_/+(%N;ATTIZL:P:9;+:_%Y&@K:
MQVLYZ J Q./)U=.OS< =3U*NQHI+>NI*<&O"4;BQTGEE54-.U('$0U]:.!HR
M8G&0TLRKF ;N&;3[2[7[.8\[#L;V7JVZ9C#\0P2MCUAU6DZK;EL;J/&JN&@8
MC(Z*)M25HF@A89I)&F5L+31-1HX==J;ZK>DCDU:8K,E1H?*)(FLU&L^7\" Y
MQD:=+G'2UITERE)QHJ^B<4W=F&];]7(,?\A.-[#)4>N"2V>UU&(]9&:@'TE6
MD"1#[(6T$]'J>AX(%[)IM>529;-NAC7"005)46<$93UM>:";V,=C<7VAVFQJ
MAA]>DV7$*^'6[,>*[26YXY8J&'QW89V7WSF?\(V")[A8(SG,<4)FCR'A[,=Q
M*O3I5I9GR 1/FC8:]*-NETLKHW-,0;I]Z7.RT?[(<YP:9C4E+5!I&-Y-K-98
M<@F1T]-V8U,@5HE5Z+F\ZHG(I3C2@,9T7XSCUPE5)%;[?E1WI:TE(!\J7$%)
M-X; 5JF4LLH]BQT\<>U%INQ6R^TF+XYA\DFSFU..VC!B<]7%7RUY7'!(,2Q"
MNZ.:>QA=22&6=CB ^PTBTV5\>I9)-&,XG?I5ZLN5VA49JA:^ -?I%I\,3]36
M,G>'-:0,PW\0@.*U\3?J9&YGC"+.HK.+AMZ*G/M6SF2"FI@^083;:#W66\I+
MR(C"7SSS!Q;Y!;4TE&!R$R$ [2*%\Q.OPRSKOL%VJQ%OL2P[5VW&QBE;9>W=
M,DC038MTH;$4$TPX [^2&.69P&3M;W!O'):>S0A.T+J$8T0/O1QZ6\F1R%CG
MM;T:0YS6Y\LAF>96QK6MP:]2'*$KE$!FZ8IDENCB1E(^D*/-A&Y'X.>>C6 !
M)@-)A0&BNLCD7-NH,V1-IAQ/CLOG("NX0V\=/ &2 @->>;15]H*&&84^>YMA
M+AU7V.W7Z&(8!8ON';L727K5['9JC]3*I8]LC),0<*,5<V&,>V0.SW5.2I--
M.&1X<V9^+[F:*VV($X:W**.*JUXR+\Q[YL0WA?I)!&2CZ&7&P]<)5XA356->
M]59$U4T2=\T'0E"1X&8[^E1X.=S2>LQ_ L.#2<Y2JJK@E3CJ$ +GE(4J>,)[
M9::]@7##-#!#@;#&*]W:+"]@;46/;3T-J-MZF#L,>'8Y=HX94JUL-AOX[B[<
M-K.BB<YE4.='&',:^S;@+W%H+76:SXJ=C%XW5*,M##)++LY:L<L\CWS.CK5]
M\\$Y:R 3EP8QV66>8H=PM8TCW9#?-+O+;<8QQL$V_,DQ&6.I(78HT/KK9::^
MYT1$4&FE!"7%8R,M9E54RU$\N. ;0D3)$R)FB HQ47N/9-Q'$-GMAI!A5B\V
MR^QA&$-NQ3YXDR"S:@K331VI",KTT(=$VU(YI;//OM;7AKAJ<#AAN8J.R&1E
M@98L;HMRA+V,<]K2QHXQM<=1C (+6Z<B.!O@Y9!@&,G]!VR\E$=>E&.-@M<7
MVVHAGR+-2B#5+CR)&L^-$H_S\EZRJQQ;:2>Y2;-3'9%22[FRG9"J"6Z4T\:#
M["$(:2N'KX?CN)4,:V<PY^/QXC@.T-&SBV!8GM4^TX8?B.!6WT68=M)$R"U)
M6?<DJXI+4LR ,EJR1L(<0V7;/GIPRU;DXJ&*U4E9!;AH!@,L-J,2F:FXN8'"
M,/A:]@.8>#W,Q!.QFISB=,7.Y/UMB)MH24XY+D#::1$E85&.VGTTFXY6B\99
M@?6-DHJDIE5Y66XFU7 4YHD-E-4-0N5'?)!/.8FE!JHH&>\V?VJKU<3J/VBQ
M:S/+7PZALSA\L,5VS2MV*UNIA6.;2W98XWP10XKM.Z/!J%RUN]3:+Y&%D=J8
MC%N8?))!(VG!&P232WI@YT;)&,?&^>M2C:XAQ=!3!L2Q,!#3( 22QH53=VF2
MWS$2:)[$H:0F(!^>]<1D=\D$HB532ZH_=?WLM0VJO,0F2" *A'G>@H+8/K H
M0&%U%=!55DQF*<4S.=^IV,N6&XKMOL_/-+/'@>T(FI22R/E=%1QZE#B\5,/D
M+G%E2>>RR)I<=U Z*%H:R-H6OQ2-A@PNXUK6.M4\I0T!H=+5D= 9,@ ,WL:P
MN/\ M.!<<R23KRKOUITHB41*(O6;^#1^:';WY]6;_A.VZ^#?9T_M(QC]EPC_
M +957JFS7Y$I_P"*S^\RK;SQ!?,RV?G.1OLJ]*\A6_9S/R?Q"M!#'F>BCYM6
M+]ETJBI=S/RG[5)5%"41*(E$2B)1$HB41*(M9&WG\-;17YNMRO\ V.OU%>B_
M%D_X?M*E^BJ2B)1$HBB)YP;'3^E6&9G<J4<-O^ \Y"$C-3!55 F52,I0;(+1
M>-SJ66'#(*]CZ&7"+%[*0!CM 6US)/L0^5\[OX*<SQ'3S^9?D)P9'.O;//,6
M+THXCMQ1>#P?9LJ=5E%9&$<CZ73;D<AO$VICF3& )M6.F!P2F F)8IAG8 L&
M&%ACA8A.?B \0 'H"[.8XC8\\Q>]H=DI.,JS#D)#,-UT)I-1.I!HXE&<PQ!@
M %--&+GB6>606%[#E1@Q<;6O;'*W5O1 <B".8(/B6,2SKI%4VQ"!!DAHIY4C
MDN,QAPDHHM*B4<Q$CI;17"U<KJR>9 4,K$E1OI8P]KCWL=P!S!-6%"&%QR("
M0<^[Q]((/VJ*=A]"];-H7@FON5FRYA7,6:F<?+A]G2"]H_L_(V%5N[HL<2&$
MSEQ&#>+*$5[YJ'<97L-B$.*-< 8+ 83#(I#B.67//D#QZ1F#D?D7?;::UE-A
M=7GU ;6,I;*4QT-OF8M4\2O8$=F/>.5='=<8G.UB0 @A5#27(VD0NH%T\MF+
M9![=*%@,^OQ"R* <B#W.1^0\#Z%@+MT U[F"3$B>9=8YP6450O&JS)K9;4C/
ML&(GX](R*@9LU1>;)"/(S>D3%A'L<RS34'0W0Q!DTN4"5$[,'KB6!2'$#('A
MQRX#/CSR/,9]W(KDN_AW:K/F:C$ZN%F. =S*CO;$B.9JE7\]4^*7G(K* "+M
M)^O*+"2X"R7$Z4$(N!VL?/I @9D0/(=3+GAS!L0P34[++/AD1R&>1Y@'+,#P
M9KL7[H5KW([?64)PE)#!-*4YN/8Q,=R%*K_07VRI5=9'%+6U5@.],7BZTST8
MTEV$3PVHCF0&R6+CBY%DH(QB ."0.(Z.67(99>$99$Y@'/GGS6: :BPDEZU"
MZE-="4V="9I$&;:@A-M</@*JJAJBS=;=A!6<:CFI+*E=^##JI1ZJ!PT,JKA)
M>6L,SX!@Y8R$4:CGJ[N>?+N_)RX=SN+'EW3.'1YP+[)I*(JWDI"LE+J&U<G6
MHH\7'GZT8[<D7LEVJS:)DCQ<LMH;$<ZHS22D4*CE$]',AF\4(XJ)Y$P&34<L
MNY\G<SS^T _,NTTRU]4M9]?6G&SE5TYQR";4G7($JN9(Q,XI;@E*2G.JO=\G
MDJYP$L<$1BRVMF$A!&.%"AP9"3$T0X5+FLA@L2$YDGN< /D R'H"M/10E$2B
M)1%@_#2\SDU_IM;J?YBGY4#E\[OM*MR_C#_"W[%$7$M\\&@?SMS;_EU?M=K[
M'_YSTO\ )N?NLJY/;/\ -R]_F4_WJ)197T(O#THB41*(HQ>\/L60W?%SY=*:
M:...'' K.=A&P%(\2!3%A;0S3<41S10J,&64PQ4HX.!@ ?#'!"SRL.'AB+CC
ME;$L4:UJ>G9F872T)9)JS@]S0R22)T+R6M(#P6.( <" >(&:RZ]ZQ6@N5H7A
ML5Z..*RTL:XO9%()6 .()9E(T.S:03ED3D2#^1;#S$ALD\B#"332:6?LC/"5
MG+@:4CRGD;>CZ.AJ#D4 <SPPV1,L;-!89@IY:X9,IC:^!8$/"][5%.C6H-G;
M686"S:GNS:GN?JL67:YGC43I#G<0QN36\@ $N7K-YT#K+P\UJL%.')C6::]=
MI;$PZ0-1:TY%SLW.YN)*[J1X_;$KL%X1H]28R@T7VW55K.0B6.&4\P;1EHH*
M14"X)XD(";*""EQL\,#!84,8*][9AYXY6M>KENK#=K3U+#2Z"S$^&9H<6%T<
MC2UX#FD.:2"1F"".X<U;JV9J5F"W7<&3UY631.+6O#9(W!S26N!:X @<' @]
MT+#'_K_&,FPB9UY=Z.=/Q:;;K;:HZ,76%,@=R16F82#2(7LLE#(2IB(7&0T[
M(0QB9L,8L%GB-GG842V6/:PRG<P]V%SQN=3=%%"8Q(]KMW"6&-N\!#^!C9F=
M69R.9XE9%;$K=2^,3@>UMMLLLP>6-<W>3!XD.[<"S(B1V0RR&?#D%$<T:*P%
M/<D)\M/\M(-GVDM@LSDM9:DHOMEY)S=+&#INR<2!;"XF!%PC!I0-F#MPL<<C
M@HM\C-Q.MPZW"Q#9S#,3MLNVFVNR8X1 R2&[9KZ(@7.T-$,K  7.<79<7$^^
MSR"S:&T6)X=5=3JNK"N^8SOCFIUK&J5P#=;C-$\DAK0&YGWH'#+,YYA.>N:-
M+.KSLUN3U,\F$SL?I35:"ZKGSZTH(ZVS<$P\P5]64SHII56#*2XD!"5%,X9,
M#*2GD6,"BF,C0^0U7\1PJ.[@\^$M>YC756002/>Z1\<D 8ZM*][BY\ACEBB>
M]Q)>\M))U'-6,.Q22EB\.*N:U[FV7S3QL:V-DD<Y>VS$QC &,:^*21C6M 8S
M, -TC)8*[M*(?FQ;;4ESDTQ#<EFVJQ$Z5$9H/MZ)\:2"ILP0)93$]WMLH:0D
MM_H#:<V9LRW<G,@@C#DK%0%,ED6"#3R^-8V>H8C+%<Q& NMNAK,NQP6;#:EI
MU<B1C)XFF)EJ**8N,1FB!+0T/;D P9,./WJ$<U3#I@VH)K+Z;YZU=UNLRP"Q
M[H)2V1]:66+2V7<RD!V98[,ZC/SXAUAR*ZHN>;J3#)Q?AMRJ#L81DNI'B(*8
MMJ:*:;YPP9*%!@BZD%FEG!P<2QX,8 //*PV&&(N&.5MG9H5K4U.Q,PNEH3.G
MK$/<T,D?&Z)Q+6D!XT.(R<"!SRS6LKWK-6&Y!"\-CO1-AL@L:XOC9(V5H#G
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M=B&<I%@P>13,<JI1*%E6)'W"#TR-I*<K64([D@D73W8E%\5$N8LGFSI4J#@
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M;\WA]8GBF<1K^=I/].)UZ+:>ZC=[U5?.)?N)[GE'OG;\WA]8GBF<1K^=I/\
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M2B)1$HB41*(E$2B)1$HB41*(E$6(2#_^ O?_ ,H.7]RG:*6\Q\H^U5MX>?\
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MQL! \"E44].<V1'"Y)R&#A1NG)8DAFQT57C2<& ,H%D4P\%E'"5#!$(T5%.
MD<QQ"H9D#,?'#$8.^12 3R!/R#/[%"GE%.'WZ]6G'.<A/XWHIT/^"[Z)ZD\H
MIP^_7JTXYSD)_&]$T/\ @N^B>I/**</OUZM..<Y"?QO1-#_@N^B>I/**</OU
MZM..<Y"?QO1-#_@N^B>I/**</OUZM..<Y"?QO1-#_@N^B>I/**</OUZM..<Y
M"?QO1-#_ (+OHGJ3RBG#[]>K3CG.0G\;T30_X+OHGJ3RBG#[]>K3CG.0G\;T
M30_X+OHGJ3RBG#[]>K3CG.0G\;T30_X+OHGJ7G-_"1B6C6[FHJ+*T-[;:EO'
M8S6A9%6VNWFQL/#:LZG]&KK,)Z:_V2E)Q!XB'5933Q@$5\(A3#$P/CBW5U,2
MBN9YQ98B%<BU,=Q:X-(R.8.7@/\ 72MC7"F>'#DX>ND$/:]8;Q:5W?@29=\S
M2L$MG8/$Q7IA>(!0\\!NVPGO; ^2;W8D]D(!WK<,S#9:J+F+A8:XM\BI>'N<
M3I=Q/#WIY=SN+8QY13A]^O5IQSG(3^-Z*G0_X+OHGJ3RBG#[]>K3CG.0G\;T
M30_X+OHGJ3RBG#[]>K3CG.0G\;T30_X+OHGJ3RBG#[]>K3CG.0G\;T30_P""
M[Z)ZD\HIP^_7JTXYSD)_&]$T/^"[Z)ZD\HIP^_7JTXYSD)_&]$T/^"[Z)ZD\
MHIP^_7JTXYSD)_&]$T/^"[Z)ZD\HIP^_7JTXYSD)_&]$T/\ @N^B>I/**</O
MUZM..<Y"?QO1-#_@N^B>I60CN3(WEYJ$'W$T@LB4&.JBG0$QY1VZT%ZM12'3
M3@R>H@D'$VCZFD'!2!\N8(G0RYP3,J< &+#XAC!9X8E201P(R/05TDJSE"D$
MI":X)OF"+8;05E1NCI"W*L@-./$A55[%ACMTM-4G<KHY,\HV)EC!NY$J,*9L
M6 &'[%V(+//$I )X $GH S4%>44X??KU:<<YR$_C>BG0_P""[Z)ZD\HIP^_7
MJTXYSD)_&]$T/^"[Z)ZD\HIP^_7JTXYSD)_&]$T/^"[Z)ZD\HIP^_7JTXYSD
M)_&]$T/^"[Z)ZD\HIP^_7JTXYSD)_&]$T/\ @N^B>I/**</OUZM..<Y"?QO1
M-#_@N^B>I/**</OUZM..<Y"?QO1-#_@N^B>I/**</OUZM..<Y"?QO1-#_@N^
MB>I/**</OUZM..<Y"?QO1-#_ (+OHGJ6@;\(EST-WIT@.NR,MO\ 49S[#:R'
MC\E1HE(.Q4-JCF>+4. %2LHQRCD23Q,J"D>7$,D0<Z(D)Q4TIK+H9:$AIP5Q
M587$0KD>MKN+79'@?>GQ\E:G@UN'AX\/31"*X>5MV=,"LMNPOX5IX.8;-P?D
M8&E)YDB(R@A"F WO?$<NPT0JB,(H(%EVL:LW!54/# 53,7S*EX>]Q.EV7(>]
M/ =S_P"_"MJ'E%.'WZ]6G'.<A/XWHJ=#_@N^B>I/**</OUZM..<Y"?QO1-#_
M (+OHGJ3RBG#[]>K3CG.0G\;T30_X+OHGJ3RBG#[]>K3CG.0G\;T30_X+OHG
MJ3RBG#[]>K3CG.0G\;T30_X+OHGJ3RBG#[]>K3CG.0G\;T30_P""[Z)ZD\HI
MP^_7JTXYSD)_&]$T/^"[Z)ZD\HIP^_7JTXYSD)_&]$T/^"[Z)ZD\HIP^_7JT
MXYSD)_&]$T/^"[Z)ZE8J-I5B^96N ]X@DAA2LRS)LXGEG?&SP;SY:Y@^GB6!
M/D@%]L**HDBFR(U[!'"P9O(8L)>V V&&5^I1000<B"#T'@5\Y,EJ*H6;.3UF
M.3(^B9FXGRB5D[9,>;<8C9Q5#]A;D4W)>=*DE)5CYVP ]RA.YNQ@S8$6X(>?
M8\^H0 DY $GH'$JO/E%.'WZ]6G'.<A/XWHIT/^"[Z)ZD\HIP^_7JTXYSD)_&
M]$T/^"[Z)ZD\HIP^_7JTXYSD)_&]$T/^"[Z)ZD\HIP^_7JTXYSD)_&]$T/\
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MQ@YA:V!H;K^R&,+6Q&RSM^2B+CG6JV%-/-I*DW$%02E YW0/IAU'3S:>=/\
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M/B?'EQ/SYD?_ 'W-MR4E)B$F)J(B)I!'1D<@32DA(2B9=/3$I,3RX90@FII
MH&"4(D")0$(J3)E0@BY8N$&""'@'ACC8J5SZ(E$2B)1%J/WR_AI:"?-[NG^[
M]=Z*H?BN_P"'[5D%%2E$2B)1$HB41*(J!<0>=ID@UI:WAP<IM)&>$T[@0EKZ
M:5'LW##I02"%*&+I(FSQA')JR&=,7('B"8>RP)*R>:'+%C!, Z4S-6,@E4T
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M%$%-(8GRIGM0O<,IS(S()&?/(Y>'N>%6'3DY/1T\@D)! FEI262*IR8F)Q4
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M0YJO)FZU,]<:2*_W,6=SKLX'X^) 4%-<)HY-"*#]TWROKYXJ 73"(!<,H4'
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L(%WK/0OUH&#6>060G7FFZ '?J"#A8];CG?._7=6V-\<<KV*II /'HZE__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>g947560g60r81.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g60r81.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X5T/:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C8M8S V-R W.2XQ
M-3<W-#<L(#(P,34O,#,O,S M,C,Z-# Z-#(@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(*(" @(" @(" @(" @
M>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(@H@(" @
M(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S
M+S$N,2\B"B @(" @(" @(" @('AM;&YS.GAM<%109STB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+W0O<&<O(@H@(" @(" @(" @("!X;6QN<SIS=$1I
M;3TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+T1I;65N<VEO
M;G,C(@H@(" @(" @(" @("!X;6QN<SIS=$9N=#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+W-4>7!E+T9O;G0C(@H@(" @(" @(" @("!X;6QN<SIX
M;7!'/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R\B"B @(" @(" @
M(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O
M;6TO(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(*(" @(" @(" @(" @
M>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP
M92]297-O=7)C945V96YT(R(^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR
M,#(P+3 W+3$W5#$U.C W.C4V*S U.C,P/"]X;7 Z0W)E871E1&%T93X*(" @
M(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!);&QU<W1R871O<B!#0R R
M,#$U("A7:6YD;W=S*3PO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP
M.DUO9&EF>41A=&4^,C R,"TP-RTQ-U0Q-3HP-SHU-BLP-3HS,#PO>&UP.DUO
M9&EF>41A=&4^"B @(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,C M,#<M
M,3=4,34Z,#<Z-38K,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @(" @(" @
M(#QX;7 Z5&AU;6)N86EL<SX*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \>&UP1TEM9SIW:61T:#XR-38\+WAM<$=);6<Z
M=VED=&@^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.FAE:6=H=#XQ,C@\
M+WAM<$=);6<Z:&5I9VAT/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIF
M;W)M870^2E!%1SPO>&UP1TEM9SIF;W)M870^"B @(" @(" @(" @(" @(" @
M(#QX;7!'26UG.FEM86=E/B\Y:B\T04%14VM:2E)G04)!9T5!4T%"24%!1"\W
M44%S54=H=F1'.7IA1SEW241-=4U!0311:VQ.02LP04%!04%!0D%!4T%!04%!
M14$F(WA!.T%10DE!04%!05%!0B\K-$%$:T9K8C)*;$%'5$%!04%!068O8D%)
M44%"9U%%0D%514)G549"9VM'0E%92D-W9T="9V=,1$%O2T-W;TLF(WA!.T1"
M04U$07=-1$%W441!-%!%03A/1$)-5$9"451%>'=B1WAS8TAX.&9(>#AF2'@X
M9DAW14A"=V-.1$$P645"05E':%521E)O9DAX.&8F(WA!.TAX.&9(>#AF2'@X
M9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF
M2'@X9B\X04%%46=!9T%%04%W15(F(WA!.T%!25)!44U2068O14%A24%!04%(
M05%%0D%114%!04%!04%!04%!449!=TE'05%!2$-!:TM#=T5!06=)1$%114)!
M445!04%!04%!04$F(WA!.T%104-!=U%&0F=C24-1;TQ%04%#05%-1$%G44-"
M9V-$0D%)1T%N34)!9TU20D%!1DE227A15D5'13)%:6-9155-<$=H0GA7>%%I
M4$(F(WA!.U5T2&A->%II.$-2>6=V16Q1>E)4:W%+>5DS4$-.55%N:S9/>DYH
M9%5:2%1$,'5)24IO34I#:&=::$I21E)Q4S!6=$Y62T)R>30O4$4F(WA!.S%/
M5#!:6%=&;&%7,7AD6&PY5UHR:'!A;71S8E<U=EDS4C%D;F0T95AP-V9(,2MF
M,T]%:%EA2&E);4MI-'E.:F\K0VLU4U9L<&59;5HF(WA!.W%B;DHR96XU2VIP
M2U=M<#9I<'%Q=7-R839V;U)!04E#05%)1$)1545"45E%0T%-1&)114%!:$5$
M0D-%4TU514954DYH26=:>&=:17DF(WA!.V]B2'=&34A2-%-.0T962FEC=D5Z
M2D121&=H85-5>5=I63=,0T(S4%-.94I%9WAD56MW9TI#:&=:2FI:1D=I9&MD
M1E4S.'%/>G=Y9W F(WA!.S K4'IH2E-K=$U453504FQD65=6<&)81C%E6#%2
M;%IM9&]A5W!R8D<Q=6(R4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.
M:F\F(WA!.RM$;$I75VPU:5IM<'5C;EHV9FMQ3VMP86%N<4MM<7$V>71R<2MV
M+V%!07=$05%!0T5135)!1#A!.54T<3=&5T,V:G!(-75Y964S=DXF(WA!.TXQ
M=7AT9DM*4VE71GI%3&QW+V]C95)J4T<R:W V=GA5*W0K.6%F04975F589%%M
M,4QY+W!M;WIQ<7HS='!"8U-Q9TE14$Q'<G-&0DHF(WA!.TY+='1V:7%),4M+
M.6PP-C9I<UI6:'9:25I&=%IN1E9357%1:DU004Y1-'%X9E-V23)P479P=#-D
M*UE.4VEU.4]T2F)*3%<R=65D;38F(WA!.TU:1FAL;&IN:F8Q<#1O-48K3BMR
M2T-18U93<7@O2W)7;V)Y0S5U9DYL,6-Z3'!J-E1D6'!G4DPR4DI+35I&;C5-
M1EI'565M5U)Y4&DF(WA!.W%763AG<6QC+W=#5#-M=4ID27-D3C@Q5%=T:EHR
M5G)96%8S1S P1GE)-U=/-T1'1EE(469V2'5);6]Z,')'0S-/;D5Q<&Y.*U5&
M>6(F(WA!.VAP269.5W%32DQP12MI>G9E>4<U;EI*,VMK.68Q43!8-S%79%%#
M5E!W:6YE;U919B]+:DEF,#5P97%.<FLX-C9F8E=&=$QB,TU:;44F(WA!.S,Q
M04U#-4Q355%Y9SA'05=N0G!&,TUH64MS:R],6'E.3#5.,'$W,# S4S-%17,V
M5%%*1W9P>'!3,FAI;%I9>#A-6FUM:F55;W9W<GDF(WA!.V]017%S=7A6,DMU
M>%8R2W5X5FI8;E=X.#@S8TYM=FQ/+VAS2D5E43-R5&Q">FI-5$)%5&YB6&1'
M.5%G.'5I.3%C9D1I<70U679F34HF(WA!.W5B>E1D8VQT<FDW<V\W9'9R1G!'
M.%-V-G%T6&MR<RLY53=52'1I<68T<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98
M67$W1EA9<3=&6%DF(WA!.W$W1EA9<6M(;%,V9W1025=J6%9W,T-#1%,W85-6
M-D9Q2VQU<$IO;TI/=S9$1E5D*VXW2"]!2#%E9CE)5C4O,5-X5C,V9G-F.3E8
M;B\F(WA!.T%%:%AN+U9,1EAF<"MX+S,Q968Y258U+S%3>%9$<C5M9TXY2D$Q
M<&5I,U=*2&IU4'%6,U)N6FY$<%0P<2]#1E4O5&EQ22]4.6HO=G$F(WA!.S@O
M-E%R>B]Q;&ER=C O62\W-G90*VM+."]W0W%72W1(>D)99C<V=E K:T<X+W=#
M<5=+;S8R=4EB;3-I=5E(16M%>4Q*1DE/:DDT<7 F(WA!.TAZ0GA657A6,DMU
M>%8R2W5X5DI.3B\U4W)7+RM-3FPK<5A&53=X5C)+=7A6,DMU>%8R2W5X5C)+
M=7A6,DMU>%8R2W5X5C)+=DEF3F4F(WA!.V\V;DHO=T$U02M73DQ46#5B5%12
M84-A9E))-VDT:49W.4QL,5EX>&]);D99;#5C,S9$<#1Q=EAS5F1I<5)E54E)
M8FIY4&]537E"-&XF(WA!.S R>C5)96AP0VAX5E!C5F1I<G-69&ER<U9D:7$R
M4U=/2D1*2S9O9S9S>$%!<G0Q3TMO93!U3DQJ:FET3%=A14I';VIH:%(Q3D95
M54$F(WA!.T%"-T%9<6ES5F1I<G-6648U1"]-2S0X>BMB=DY':W$V9E8O3# W
M5S!K4G1F4F-/6EI),$EU1G4W;%IH4T)U6#=Q3VAP-S1Q>C-&56LF(WA!.S S
M+VQ+=&(O04]-3FPK<5A&53=X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMO3T16
M27!T4VXP.%)3<DYB>')+-W-L27ER<WER>&%U.5,F(WA!.VIF9&EQ37A61'DV
M:G X5C-(6GDS54UD,TM/559U,&ER27=R4W%O5'E/-'A615EQ.',X,C)D:B]Y
M=DAY;F-*<71X8F%N3&)T1VUN+U4F(WA!.S-L='!);VMU6&-M-6%72TY'6D=D
M84MR<TYT9W)'<7(Q4$97239X*U=(;#=6+TYK4&UA-VYV4F51>&U0-G9&8TY(
M07=-8E(Q;V\Y4E0F(WA!.WAF<6IR*TQ65E)N:W5W9V)Y9&]41G!Q;E1R46UK
M,&]'.$-D9S)+<'HK:C10-35V*U(X,R]!1%AI<G8P9D(O4$XO=T%J-78X06UV
M1E@F(WA!.V9O*T0K96(O04I(>F8X,31Q-SE(=V9Z>F8X:C5V*V$X5F0K:C10
M-35V*U(X,R].94MU+U(X2#@X,R])*V(O;79&6&LS;5 X04]/,',F(WA!.R]/
M5C<U4'0O3&PU<70Q8GI*071,-'%S<DY%:S)Y=5111&PS4&)--T9O6E1H>#)!
M1W,U041317-0>DQU1FYU6DEV2E4P8W$K:D]68E8F(WA!.TE)6D5393%%,%AW
M<WET.&-31G5N6#1F=&)95&]4+T](,CDY9'EI9FMZ=CA!3&IZ6%DK9"],<#%M
M1S)U8D5,4$IB3D)*9%-Y1W-D1%@F(WA!.VMR1%DX<WAS*T4T-6-*6E)L671L
M.%53>$IW57-2,2M.;6,O97A*>6QK=GA6-6PK5T=I-G9P4&Y4>F=,*S9U<FU#
M+W5N;G-5;'0W,4DF(WA!.UE9>&-43553865+3T(K46Q5<C95:C=E1DMS<7DS
M>G U2C!N>F9P839D<6-K.%5+;55Q.7-Y<2\W-D-3,V(W87E,.6E9:V)D85EQ
M:'8F(WA!.TMM:E=M:V$W<DYN87902D5)-TYQ,T4X<S=62WE#:6U6;31,='-I
M55)F,E9'1E=5-$9D:7)S5F1I<G-69&ER<U93;E=V365N86-'=&HF(WA!.U<W
M,4HT>3!';'=!>7IY-V)F06=C<6A/>&1H>$AC-'%W6#AQ=%@O34<O=T)%=F9R
M4&PR>#!D,79:,5=35#%R87 U:W-"8FA(36=I87$F(WA!.T)V555%0V<V6F)L
M:D5(,&TP0S)B2%1F3DTK,7AR561U=B],:&%,1R]Y-5A,,V%N+T%)1$MK<TLX
M=2]L:F,V9"M9975A-FUT87%*3"LF(WA!.T5F-E=Y5S0U<S!G3&]X6DI),T-"
M1CE0.3!O5E-13VU7>7DS15)O8DE!,UIR*VEV37-*+S!B6&97+W=#638Q:6PK
M+S9S8E X07IP-S$F(WA!.W%3>$A64BMA-F9M5F]%8T0R52MH*VA)8C9E2TU1
M:C!V5E0V=T=J;&QM;$15.4PP*T1(9G)T6$Q9.$A#8G9I-DE.,CE)>7!,>2]7
M<BLF(WA!.WEI+U!V4F):=E4K=7DV97%O>4XV8U%I2S-R3TIU0E)P2$QX<#93
M4V,P2'A%8U<V<7,K,&)Z1' R<V5T.5-&>79O8V5F,6TP=7)3;V4F(WA!.W9&
M:RMS>'AE;W T;C1K<4U65$Q&56PX:R]W1$M'84(O,GIR5"]K=VU+<&YE6#!.
M;W%T2W-R0FI196I$3$UF<$53=5(Y3TMQ3VXV>%HF(WA!.V%H>$YR-GI)>4-2
M2DAG;FE2;$Y+1EAK4E9.83=53TMO,T9867$W1EA9<2M/9GI:;FUG+TYR>DI0
M0DDP53!D-44X8W%%<7ES3&%%9W$F(WA!.W<S0D=D4#)A3'=!2'IC3$XY4U)$
M>EHU<4-S;S%M*S1U04A(,6UA:$%J35%"*TQT1V5(*W)T,'I,.$=(.#!F2G(T
M>C-V;W8X035X;B\F(WA!.T%02F13+SA!8E)U9BM)>#5Z9F%8.3A83G<O4TAR
M1UE,63=&6&M0-65A:G!M:2MB9E!M<C8U<E,R.$9Z9E)X0G12=44T5S1J=6)Y
M3TLF(WA!.T5Z>75N1FU64%5316]V0TYK<'EQ5&ER,75#94=E1T]E0U):65I6
M1'A3;U%Y<W)#<7-R1%EG:F]C5E-F5&8K57$Q=CA!-'<R6#9P8U8F(WA!.U1V
M1EA9<3=&5U X06Y,>FAP+VQE>70W=3EL=&]O-VED248K<WI.1'4W049H>&IL
M<45"-4UA0V=Y55EK.&Q*5C,X-6569WA34%4T3&TF(WA!.U5F-V]T1RMS>2\X
M04EU1#%(+T1)<6M0;F9Z:G%-4&Q857)J471&,4LK=6]O<6\S;WI765=R04TO
M>&U#-%!P:7)%4G%3865'*U1H14<F(WA!.U%"3D)"5RM3,#@R95EF2S)M,U=S
M>7DV2D1.1E8W0T9P1&1Y045J;DQD5&QP545G2$Y644LV9R]B.$=906M11&%H
M;&UN-E!P5VU7-W@F(WA!.U=6<VQV1R]X5$92.&-J56]7:V,Q9#)P*S!X2GE#
M5DQ14F]G='!0,%)X*W(K<2]Q8V564%5Q968R=2]+=&9F1E5Y>%8R2W5X5DQB
M='0F(WA!.T$O5$9S;'I(0S)R1DLR<G9%1VQ#0G%(:2]%:T%-9DA&57EX5C5F
M-75E>'-F>F,P<E9B,CET<F4R=&1.;6UM:6$P,'%3-4UC359Y-WDF(WA!.U(S
M16LT,591<3<X64E'6%DW-W925D%F.#1X45<P4&MF5D9T.51H,5I',6%2=G)-
M0WIQ0B]O='5O4B]R14YU-6-"9FE)56HS3TML;"LF(WA!.W,O;7 U6#!B>FA"
M-5<Q15A&=F1Z>$=B-C8X87)A2V=2;C-K6FQ:=G-%9D%P;V5T3592,VMV5610
M6'ED;U-T9%%Q>39D84%G>4M#0TDF(WA!.T4Y.%99<G)(-6]A;'!0;&ME67)W
M42]5,DLO=5E,5U-:,35T>%=R9E=),7 T<V%$0W%595AV>FEH:VTP;E%,5S1I
M37,P1FUL<SAL;V4F(WA!.TI%,79*26]:;'5Y3U-I,TMV5#EO9T-U.498<%AL
M+WI(8F%J;W1N93--.$56>%!'2&QJ1&="5S=G0FE334-O<3<Q:3)I:357.&M.
M>$HF(WA!.U=N<"MT1VTS:E5N1E5(<&YM9$QX<7E24E<X26573G!'=4EM26%*
M,FI0=V<Y0WEB67%M6#94,#,O04IA-&8K4FDO=T)C5F9(=C5U4U(F(WA!.WEF
M;6HU;65.9S9.9%(P6E-#1"]O<U!C6C%(6FXY>5!I-%=F-FU*6FYT3#9A+W=#
M8V),,GIH+TQY5DIP-#0S+U-.>65,=7%M;$4W134F(WA!.WDS85 Y.%A/=R]3
M2')C53!->6,T;E=23VY*0T=(,VI-1G18-'$K5G9/1C<U2FQF>EI:-D%R6'5R
M2G)V4%8Y3SAZ6&1T6E=C<F8V97,F(WA!.VI7:VM.>EEY=45E4G8W>5%M:%AA
M=4M8,&QR,VUJ>2\U8G1,85A68FM7<T9W-'0W54I(2DE8:S1L;&IJ4T9866QG
M=$951&,P03-)1TLF(WA!.T5U.'$V,W!/<S8Y<DXW<&0Q2&57<&ES,44P4G%T
M47-H<#@V2$-R2TU#=7A65'5B;3-T<F53-75:1FAT-%9-:S P:$-O:4M+<WI-
M9&<F(WA!.T%-5F5F95IV2E@O2W=L=&(S5DQ623E/=$IE5VPR5G=:23-K:5IK
M36LP,W!L6%@Q:U1I<U)0=W)U,WA':51H:VQ(:V%14F(P2T='2T<F(WA!.TI)
M;U573TI!1E)&1D%!3W=!>4-72V5E9DUU:TQO,2]P,$QF6'(P:%EP-V$S37HK
M9T=K5E=L=4AT9WI1<$5P3&YK5G%"5'9H5F(U5#$F(WA!.TA8;3AV5U56:F]Q
M<D5I1DDU<G$W9$DU1E9I0DMH2U1Z.$I+8VPU3#!)-UEQ;6,W961:65I#4#!B
M<#%&2D0Q;G9E3D(Q<%-Z<F=6:3,F(WA!.S5C,TAM92\P>39N<SE6=%=G4S1D
M2&AU25HW<&I/<$EN9%IE5FM65U=3<D%E;3%+,3(K>4-66EIZ.#5X+S=P,#8V
M;TXO,W,Y=%4O.$$F(WA!.TEU-'!407)&=$AM.#1$>G)Q378V17-5=5AT>4QK
M<WI126E,3V9Q>%,X5T]6-2]7575Z5FA8-TER>'!2:7)+=BMD>6MB<G Q<W1F
M0V4F(WA!.S1.1"]!3DDO5#AF8D%R1DY4:S@Q4F9M1&\Y<%!Q5G$W4W=#5TYO
M5#E55EE9-3%&,T<Q=$DY=S!R5$LP65$X+S)A9T1I95)6-DIG5C0F(WA!.W(U
M-3%,6&TO-7E+.'!A5%E3=U=K171M<W-L-CEJ85A%=T-M-FML:%,T:VHY94U4
M4E)'33A*4E1K5%1R5E-Z1#AP9DLO;G9Y,W!&+UDF(WA!.V5B9%5J,6E34S=-
M.6ID3&-81G<V>$UI<#92*W-+=D)6-%965DI'-7A1>G)&56PX:R]W1$M'84(O
M,GIR5"]K=VU+<U0X<R\X04A"<R\F(WA!.SE4*TIW;U101E4R.&EF.$%+26%6
M+W=!648O:F=+6&U(;7959DXO<&$S4&\Q+V1Y-FY(8S-I5T9O8FPT-&%X,T1P
M1VQ!.%E#:%8O;4<F(WA!.V)(2&=I64$Q=31%.#!H3W(R4T13=%0O37-A<$1B
M6$LS9')P:GIZ1S5U63<X<U95=TQ)2$-I5&M42F1.240X3W=P='9Y>5$P-'9K
M9S4F(WA!.WI83C=:-41U3&TT.'(R,&QZ3DIC5$-7-5%Z4W-78VE/-6M2951(
M<E)607I!>E)!:U%(37A%;4E*9DMV-7=F.$%K,5!-+W=$>D92+SDF(WA!.U%S
M3V1*,EHO8VHT=4YN*W!I1UHW4RMO4"MC6B\O2F13+W=$8E)U9BM)>#5Y,V%8
M.3A84'<O4TAR1UE,63=&6'I6-74P2#AW4'I),6XF(WA!.WI(;V0K64Y2,'93
M9%5A6%-B:E1P9$EU<GEY:%)P;W9Q-U%I-7-P1CEC1E=B,35!45EQ8U-E:6PY
M1%0V8EEA=G!S35=S861$36IO2&LF(WA!.W-R<$DU,5(S:DMS<$(U;U-&9&M*
M2&%V8D9#0C!M3T],>DYR16-A:$DP9W-64D9!0W%O5U5!041O0FEQ931Q,'I+
M<6QM24-G5DI/=T$F(WA!.T=+<U1N=G),5VQ'<39N4$AA*U5R6F<Y<W1Y4D=T
M-4MJ8VMN:S4P+V-Q4E=*9C)Z.&94:E96:E@U;BMC14]N,F)W,F=7=SE8;D9F
M6#$F(WA!.W9'16QU131V0DA(2&-V1$HV5'-0,W-N14QX<#A60U-#06=L4'!:
M=$-K-"\T;S@P5S X:D%&=%!J=5DW3S!"<'504U=4,5I2=C!L:V,F(WA!.TAW
M>%-P95DO3DAL4W@X<#-D=' X37!T3T-W>'!9>%A.<F)O6EA73E,Q,4-I4G=O
M<&%R2&PP0C8Y34U26G!"3D,Q8GEJ-6DQ1S8X=5<F(WA!.TDP>E$W<5-*54M*
M9%A6,T<P1&Q'2TUY>E!*3F-/:$EQ:D=,9&%5,GAK2TY+1%ET3G!O+T]D>D9)
M1&-A9G!)2VM64DIB-6QQ2V-L9&HF(WA!.UIQ0T]O<6A(>GE+5TUF;#=P4&UM
M,S R-F4R,38P=59A-&M$=WEI92]8,4DR2U!+2FUN:610<D1+6D].0TXV-VMK
M;6-Y0V1H5$=)234F(WA!.VTR5F984$XP02]E-EIA6%-J<3ET9$]K:#EX1DQ%
M<6HO04I'-4)K=S-19&9E6'HY<35S+TQ":3%/4T0P-5$P,&%44FE'6&0W<G%I
M0V,F(WA!.WE!>"MM>CAG=%(S-'I-9&=B66E7.4UY-&5C<FHW571H<'$Y0W%,
M3F90.'<W1WI52#5O8V=Y67AQ2&MY4U1Z-7!7;S-7;S-L,TQ(1W,F(WA!.VAU
M2'1!9E1.=DQY4T=+-&=J:FIH4V(Q2#E13E5S;V]4=FMX2V=1>$UB24PP2$E-
M;FYE=%=M<'0K8S)I6$5F;65#,7-&<S9395=7,48F(WA!.S1P<F=H3'9L24Y/
M0VQ:<6QO>4I/630K;3)X;TM+=E)-5F1I<5,K4V8K54TP1"]T;E=N+TIH3599
M;C5:+S0T3FXO<69X3T9#6C1Q;3,F(WA!.VM4+VQ%3DLO-'=,+T%"=T9,>GEB
M+V4O568K62LY+S9I<$TS1T0V039R4#A!5U=S=6%M9F9L-R]Y:6QV+T%-6C=Z
M+W%-;7I4-2]R3'0F(WA!.V-0,$(X<R]N0B\U3E1Z4"]!37A59B]53$1N4F1M
M9C-)*TQJ-2]Q66AM93!V<40O;D=F.$$X;#%,+W="=$<U+S1J2&Y,9'!F,WAC
M+T0F(WA!.SE)97-:9W1J<U9E4&9K<'!51FXU.2]-5S1I=C=/-V$X,41N2F(R
M<&Y-<T)7.'96-#-);&I25FM*0C)5:U5&96A"2W(R2$95:S S+VPF(WA!.TMT
M8B]!3TU.;"MQ6$95-WA6-$0K6C-0>D0K8C!/:3));75.4W-O-T=+3DDP:D9O
M<TUS:E,S4S-K:E)43T1W6D-U>%=H;U9.5U9P1&LF(WA!.V=V5&)$>5!Q9C%H
M8GDO,4E#.$93='I&1THW;$-D:45N=2]7:E)F84=#35E%;V9Z6BM7=6IA=&%1
M3$YA5#9R8W!+:&5A-G9*:7=I-7$F(WA!.UIL6&UX5E!54455:D,W,$]X1F-)
M:U%G9T9M5G!9,E9L14ER3S-J=#1G04%K4TMG,CEL07E+5W11=%=U-T=E,5=4
M,&I-:&I-;D5044TF(WA!.TM(-%1S9'-68C K,64Q<V],6C505DU+0E!5-&AA
M:&1H.$DR1S)+<2M+=7A6,DMO2T141$9Q;'AQ0G5P<$1C4G!%8F1X1C93<D=Z
M378F(WA!.TAI:79596\S5FHQ>%9'-'$W1EA9<3AG.#!A9'!Z+SA!3U-(;$LK
M9E5,94<X5%0U5E=W:U,W*W-3<4ER>6AI6EE7=&5)-3%B;DM',BLF(WA!.U96
M6'(K2W!"-6DQ1'IF86%P<%,V2G!C5V\V8DPY62]3>G9+:U5K9D=-1S-%6F0Q
M2'AU5'E01G5N5&5O5E$S:WDX,4YF2BMH0F103'$F(WA!.TY0=%%R97)'2VHP
M13-O8U931'EW4V1!<VE242MN=5!P3T9#85EQ:5!*5C5Q4RM63DQ74%1Z26=H
M040K<6DQ1RLY1&EL:$1--UAD*WHF(WA!.W)W8S,Q-E=3;TY$.6%K<4MJ3G9G
M*V=/<7HO5U<X=6%M6F528G)513AT47)&66UA350S;D=4,457=BML>3EJ=FUN
M>B]76&$T9F]$-6@F(WA!.R].;#58+TTO>DLP<V9P4T<V:C52,415+S!72'5.
M<S9,<WHK-4AX8V90.51&37HR;#E++S@T-#-..4@K6#!Q=U=:;E0Y25A"-6E2
M13,F(WA!.V]M,4=Z;'4P9C<T=61H*VM06')A4V%324Y.0UE(<6%X;&<S-')M
M0S)Q=4MV3&9Y;#%X<B]!33AE9C=*<#E3;4]N6'EO>5@K;T<Y9VHF(WA!.S5Z
M,TE#,G-*9V<K<G)34#=)6CEU27(X3S9R,$1Z3'%T,W!'9U@K<#)D:$QQ;#-A
M471,0G P2$PQ2C-58E)R>%=2<6XR52],1E5P.'$F(WA!.UAT+V4V-W).>&4R
M4G-*5VES=4U$3TAB9U9K25DP0SA382]:27%-2V]Z>G U;FDX=&58<FY5>D=B
M:38K1T14-TYF=%A&,TUE145+9V(F(WA!.R]'-49A9$)5.7-#;T1Y3C5'=$Y$
M,'%'6%59;V(S>DAC3SDU<6UQ3VET23DS3V5C=D(V5E9&4'=Q0E%52%1&5U8T
M<3=&6%EQ-T9867$F(WA!.S=&6%EQ-T9867$W1EA9<3=&54),;T=H5&%T1')-
M,FTR<VUR,C8K;D)Q3'=X=&-X;U%W-'!-5C5Q2T\R=U!C*T]+;R]&6%EQ:W9K
M;B\F(WA!.T%*47I14#A!=&Y7;B]*:$U666XU6B\T-$YN+W%F>$]&0UHT<6TS
M:U0O;$5.2R\T=TPO2$%5=E!*=CDW.5(O-6HW,R]Q2VMZ8UE0;T0F(WA!.W%S
M+S%L<DQM<&XS-64O.$%+2U<O+T=E."]W0V]Y8DY0;BMS=3%W+U%(>7HK8T@O
M:S%032\O359(+W="47-/9$8R6B]C:C1U4&XK<&DF(WA!.T=:-U,K;U K8UHO
M+T%#6%5V+V)2=68X06E-96-T,FPO9D9Z.% P:#9X;4,R3WA6:79L1#AT.40X
M<38U-6<Q;E1P<FU3-3AY5&DU=F\F(WA!.S4R:4UA3TAK:W!#<V-C6E56;6(W
M4E!B1E=667%K;6TO.'!6<F8O1T=Y+U9,:7%15U-F-'0X*U,V;DE/96=E57!*
M3%14;$YE32MQ:V,F(WA!.V)M96AP55=Y;C!5,BLR6$E/,DMS-GA6,DMU>%8R
M2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W!,-4HO=T-533!$+T%,
M6C$F(WA!.W O>5E41E=**U=F*T]$6B\V;CA4:%%M94MP=#5%+S521%-V*TU#
M+WAW1DQZ>6(O92]59BM9*SDO-FEP33-'1#9!-G)0.5IA>35Q6CDF(WA!.RM8
M=B]!0VEL=B]X;G90.$%Q36UZ5#4O<DQT8U P0CAS+VY"+S5.5'I0+WI&4B\X
M055,1&Y29&UF,TDK3&HU+W%9:&UE,'9Q1"]N1V8F(WA!.R]W06PQ3"\R,&)N
M+T%):DAN3&1P9C-X8R]$.4EE<UIG=&IS5F1I<G-6969E871C=C=,5W14,')2
M;E9F365U:7IS=$I*;V932E-:<#<F(WA!.W1L4%9,84E.261J5G5++W195EIJ
M-64P3%0Y03!3>C!B5&LT5V1J14EO9V%C;7!U>G524W)U>$Q-935*3T)5=WA6
M,DMU>%8R2W5X5C(F(WA!.TMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5FHS;5!Y
M-7)E<&%V<$]O86)R<S)K>#9C3&=4,FE)6EER:WIO15%Y25A21#9:0DDU<3-T
M>$\F(WA!.RM+;U144$MN;794.4]T8D-$>DUF4G,T631)<3)-2E!'2E%I.5<X
M0FA60E=F-65A-6%7,&1T1#5K8U)20VEG,F-*3D]V:FIA1F8O02\F(WA!.VU,
M+W%:1R\V431F-C0R<71P=FQ0>E)P,6A"63(S;5EI,W0Q0U)H<DM%;6<X5%A&
M2U5T*U9U<71,3DMF37-N2V%74UHO.45G*S-+-6LF(WA!.V%M+SAZ2$PT-FU5
M4E%A2F%E2DYL,R]+<DY6+S9M5U@O04M225 V-4PX,TYJ*U9G;6UL950O32ML
M,DM75G(U;5E123!J<4=S;T-A>7DF(WA!.TY),CEF-6Y/63AP8U)S=#A9,$M$
M0U!-2"]/3CEV<C)U6'5T6#-M5S8K=3,W<DI0-F1V07%C;%)9>'A&1%0T54=:
M;4AT1$IJ:G=X<6TF(WA!.TUS46MB2U@O05!1<6UL9CE43F4O.&E,9BMM5R]Y
M=&PX;5!G4EIR-4XO3$174$M/:TA3=$DX>E-#,6%:-7HV,7!!-V,U2U8S<4YV
M:'HF(WA!.T)Z6FIK;'A(;3)2:E%O37HP;3 Q2S)T;6HQ0RLO4T5X8W-S,W!*
M1%)A04)E2T5J<4-A*RM636MB:7)S5E,S>DIP5C5Q=6E85VXR9#@F(WA!.RMM
M,TTV9U(S<UA0:VQ'1$@K-V5'4VI!8U1W:U9Q2%IG9#A695<K579+3W)N.'=T
M5E5E6C)K,6)264I,92LQ04Y.8UA5<V0O2D908DDF(WA!.S!.-4,Q<$5S8V-(
M12]6,V%P*S%X3S)%;%AO4"M(9DTO+U4Q,V8O4TQ99CA!5D1!<59A:$(U:',Y
M9C!N4S503V-K8F%O='HV340R,7 F(WA!.S8X:C(V3$HK-D,R-5AI<3AU6EEJ
M.6UN6$95,2]W-S5N+W=#<')U+RMK5W<O-F]9<6LS;6=A-V].;F%83GHU,&QT
M;S=I.71R5#%,:3 F(WA!.W13;C<K44E11$AB4'A9:79%=%)19G1%1$95-2]W
M-S5N+W=#<')U+RMK5W<O-F]9<6=.97,Y93!J4G)V57)N>FIC45)7,%IC>7DR
M;&TF(WA!.UDQ4%)E66IT,F9J>4ER45EQ<"M7;W1B,3=23&)63%1Z9F1Y>%1"
M:V1V<4YT0U!6:&-X5$M)-3=A3U5C6D599D5O>%9-;C!$>DMI33<F(WA!.RMB
M3'-+;TQ-9G%T:G-"=68Y,%EQ>#=Y6'%/<&5:-V$W97DX-WDS8VQP3WE3;3-S
M<F1%5TM6:DIA9VUE,6I*:TYS>4=11%E055EQ>4PF(WA!.R]$=FUF+W%A-W8X
M03928D0O<6AI<D=.1S%Q-S%4>EIQ4&PV,S@X5'9E5U-T+V]:<TE9<FA7=#)#
M,T)F,6)227EL6F]V5%I'4$MP27$F(WA!.T)I<DHO=T1$=FUF+T%+;74W+S92
M8D0O<6AI<50O=T-)5&]F;D,P,')69DY$,TEN5EE7<W)U,%=&;FYU;D,R;C%E
M5T<S4DAQ56LU:FXF(WA!.SA09G9I<D\X5F1I<G-69&ER<U9D:7)S5F1I<G-6
M9&ER<U9D:7)S5F1I<G-69&ER<U9D:7%'9S!Z5&)E.75R-C-T25EB,BLY4#8W
M9%(F(WA!.WAO<W,S;W)X:CE6=T%Z.$9.1C5(661-5E)/2V]79E-D2W5,*S(Q
M1V5Z9VPQ0WE$:7IV2&I2<&]224],:4M1:FMN2F1M-&YF1E56:7$F(WA!.TAV
M.$%49$\Q1T993E%T66)Y1EA75EEP-#%L55-2;FMJ:%A"2$I4=40R>%9%67$X
M<SAX+VUD-7=G,6DT,%(O>3%V.58P;')L-TM7.%(F(WA!.VI*0DY%>D96:T5:
M=#)6:V5/:&)K47$Y2VYQ5EAE469Z0C%E9E4Y2SAU4F9L>&9E5TY-;3E5>7EM
M1C1B4S%(;V9705%&=#0T=C-K>%HF(WA!.TMC;$YA16EP-&A6-FYI<40P-U)T
M2#!W4VI48D<S<VA-5DUW=&]K:35L1D-+5S1"83A60556-UEQ:DU64RMY.'4K
M6#=#.6QV<DA43%,F(WA!.S%V6C)K864V9V=J:FQD<#)6<%,W<6]::DDP86QQ
M;F-G5C99<6U'2W!89&564$LY,W%A87)D85!9,T=Q4G1(2DAF>3(P3#-#=D1V
M17DF(WA!.WES<&-&4#)46&)T:7%A67%H:'%M;45!:3=H24\T26M4*W5+=2]3
M96TO=T1,6$0O>4U8*W5+=2]396TO.'1C4"]!0TU8*W5+=2]396TF(WA!.R]W
M1$Q81"]Y35@K=4MU+U-E;2\X=&-0+T%#35@K=4MU+U-E;2]W1$Q81"]Y35@K
M=4MU+U-E;2\X=&-0+T%#35@K=4MU+U-E;2]W1$PF(WA!.UA$+WE-6"MU2W4O
M4V5M+SAT8U O04--6"MU2W4O4V5M+W=$3%A$+WE-6"MU2W4O4V5M+SAT8U O
M04--6"MU2W4O4V5M+W=$3%A$+WDF(WA!.TU8*W5+=2]396TO.'1C4"]!0TU8
M*W5+=2]396TO=T1,6$0O>4U8*W5+=2]396TO.'1C4"]!0TU8*W5+=2]396TO
M=T1,6$0O>4U8*W4F(WA!.TMU+U-E;2\X=&-0+T%#35@K=4MU+U-E;2]W1$Q8
M1"]Y35@K=4MU+U-E;2\X=&-0+T%#35@K=4MU+U-E;2]W1$Q81"]Y35@K=4MU
M+U,F(WA!.V5M+SAT8U O04--6"MU2W4O4V5M+W=$3%A$+WE-6"MU2W4O4V5M
M+SAT8U O04--6"MU2W4O4V5M+W=$3%A$+WE-6"MU2W4O4V5M+S@F(WA!.W1C
M4"]!0TU8*W5+=2]396TO=T1,6$0O>4U8*W5+=2]396TO.'1C4"]!0TU8*W5+
M=2]396TO=T1,6$0O>4U8*W5+=2]396TO.'1C4"\F(WA!.T%#35@K=4MU+U-E
M;2]W1$Q81"]Y35@K=4MU+U-E;2\X=&-0+T%#35@K=4MU3W%A64%38G5%06)K
M;5)0-C1Q>&$U=G161C="83(Q.4HF(WA!.V$R.&5N5VMO:FI30G%V23!Q<U-:
M635$,&I8=FA6<5!59%I$,VM%;7!&=S)N6&-Y4S-2:&=32U-,,'=J=$Q&17!2
M4C9H3$U1861A67$F(WA!.WA3,3AR9FYH<&5N.%<X,E=.=6IZ;W!.>DTQ,395
M6FIE,VI62C=Q,6%2-4AK849J>3),,6]">4MK2WE8>3EE*UE%=4Y.,'DY.#,V
M6G$F(WA!.T8K2DI*8GE':T0S9'A!665)15EH*W)+;G S0WEB*VMA<4)5,416
M5E%L:#55+TUM,F<P44YQ<TQ4-F1B87!&9'9*95AK-&MM=3%6<DLF(WA!.UEH
M,%9::D,V.&%40F=Q:SA15%-I<6QP=6QF;E9$<3DO6E@R<U(S3VY0<#DS*VIT
M5D,R:3A,<#4V5W9Q>')B<35K4TQD:44Y4#)*>%8F(WA!.T-8;FQ0.#@W<#):
M+TY&<VM34WE00D)!>7=(:4IM94AL2W1M>F-H1U92<7%Y8F)O,V166&@X=F9N
M;75O1TYV34YK=6UY4T@Q2E9+4$TF(WA!.VE-4WI'1T]7>&5J9D9S2&QD96Y1
M8EEQ<&%0-6(O4&Q.9'-R;E=0361J8V%F0CE85V%+,TEJ-7%'6#8P6&DK<%5F
M,495.%)Z57%F<W,F(WA!.V]Q0W%Q,VYM8GI-9%%V;&HQ4U-+3TLW=5EO-#%I
M=&E&4TM:,%5684IM*WEV8S5S35=M:DM)2F-(3'%*4FM12%<W*V-.8V=T2&@Q
M6E0F(WA!.TY9-G=G36,Q=S%G6F]O-')E-5I0.45I+V9F04I2-E1R>%E.5G9S
M:DUB4$%2;%%C;D1->6I:55IB3'HW;VUK85A"9CA!;DA4.4MU3%$F(WA!.UA-
M;6]Y,T9W2D)D8S-!=&YK:W8T<&Y51C9#45)&1DA):$%0:$%O8E5V<V)(.'<O
M3B]L3S%E4%@W9CE.96Q/:S@Y=G%H:2MR1G)M45(F(WA!.U-L9$I8,$QJ,4EO
M+U1#<WDX2U9"-6<T<6YL.2M8;FY*3DQV-UA4=DU-.&LY,T)B4F5T3F4V:$4T
M94HS85)R95%Z6% Q53 Y26-U37 F(WA!.V-+5F5P6FYX5G)Y>C50.$%Z27-0
M358Q93,K<5)Y5W-K52\Q9&XQ0RMV0CE99$573C-S<%5H9T5F3E=C<$<V:U8T
M<7=58G%T83<U42\F(WA!.TY#-VQL:W1T6F=A95A4-')D<&9R5C=:46TT4U=#
M4C97='5'0TLO;WE!>7AY3$Q347%P5V=/2W0K6DY,+T%$:V=U6F)R43E54S1T
M-5HF(WA!.TQ72T141DYQ;V=I-$%4>D=3-71N:V9J26]01G!#5U%T4VIC84MQ
M*W$V1BMC8W9M27IA9#5I=%E.0UI:,BMR3VM8<7)*-G)T8DM+,FHF(WA!.VXP
M+U1%85-6:S5B<U%A.&-64VY3=DMV-3<R1C-(22]M2S!U-UI(:UIO2EIY=V1/
M4F5/3FUE=V0V2&M6<4=$2T\W:%%U2W5U+TLS-2\F(WA!.WE16$U3*V$W1C!U
M1#A0=W)#.&%M2V175T]32WI$3"LX94EQ>'%2>#<Y0W%R+VUN-6\X-F554'DU
M,#8X:G9O>')R6&-D=F184W!(2W F(WA!.U9K;&5N>%)2;U0X0V=S26QR,4-R
M5V=Y.49H:FMY8TUU5$1*27A&=DMV2R\U,R]M6&9E871$<TQR5E9K=&(S57)+
M,G59+W$Q<W9+2V4F(WA!.S5J:FM7<7AG:7%S9'=C,FUO-TYX47AM475W1VE'
M66LP.69S3D$X.&UE2S=B5F])8D<S,5<T=35F5#%+-W4P3G-%15AP<UI9;$AW
M=$<F(WA!.W=E26XP,5IM6F501E9Z4755;%=I-FXU*VHQ>4Q4-S=Z9%EA;%E,
M6C--=7!A:$AC86-0<3AZ4E-.0W)14G=14S!606MY=%=L0DIY<4\F(WA!.TY&
M55=V-6)E95HO<F(S6&U/-'0P97I-3FQ:46%H<51M3V9L27=:<F]Y4DUY.&U2
M*U)I3"]!3S8K6'!R>%E+=#AX95$O>DUU.5)V-VDF(WA!.W@Q:TYB>G9B;3-G
M1W V:EE2:%E.<6A);'58:EEX+T)*>&Q+>6XY-%%R0VU+<VDO44AN9S9%3$$V
M<$-3=6PR,70V9D]C5&TY:4DY95$F(WA!.S9I0TIE37%!<'I%4$U6-6EH1S9Q
M5%=0;% X,7)E=W8T,#%U0T,Y;71D4&AS8G,S3GAE3D9*8E)O;'I68G%*-$-*
M9410>DU*:UIM4$HF(WA!.W9S.%98859P=C4Q>39:<49R9C9R1$)Q54IH4WEV
M>4Q5>%1&3%-14U-):5<W;$DS=5=I-4-295=Z;&5)2W%&579U9DM(-3AZ,F5N
M1B\F(WA!.TY&;V(V3"]E.6MF,%DR-4)O,D-#2WI8;79$:7<U2T=$:S!904QI
M<4IU4$PO04]F:S)M<D)$-6MS3%,Y574U=6=)<&EX8EI9;4(P*TXF(WA!.T]#
M535C9V=9,7 K>GE:5D<V4&]N-7%7,G V:F5E6719=&)V4UI)3&A6=&]',D-H
M<&UH06DK<GAC6$-324,T;#-#,$MS84]&53=K,%<F(WA!.S)U6&=U;G5R*S!U
M0F%W5S!S54U!2V9U96)!+W9)2E17<W V1VU&5D<V.'-733EL9G='*W8U2DPR
M>75,1EI*<F5Q>')C9T)M0WA1=S@F(WA!.W%&0G-4:7%6,D@U569L-UDS83,P
M3FYD9G!"0D-S9#)5;C5+:T4P9'AX15E142](3D9Z9'5(26QM,S-W2S8Q+TQ4
M>7I:83EB8799>C,F(WA!.SA!=#-,9E5"0W=T<4=C6$954DEK-%!Z4D4U5E W
M<V-+9$-#<D]F,&A"+TI.+W=!:4IV.$%M:D%R=C!H0B]*3B]Y26TO-6]X5C,V
M46<F(WA!.R]K;2\U151F.#!9<3<Y25%F>51F.&E*=BMA359D*VM)4#5*=BM2
M13,O3D=+<U1U4$I7:GI85GAC0R\Q4TDS13!K-U)P0VY&5VQC>4TF(WA!.T8U
M5WI.4W)B5D]:16143TEO3DUS15-B2T,Q4#AS+TQ7<&%C9$YU-VDK=4Q35UHU
M<FM45R]*;41P0T]+,&=61C1T87AK3G=*<'E(-U<F(WA!.S%5.&AK8DQ/14)%
M54A82#5795-V.4]F5%)F-E!C86TP>C9J8S)K8E!,3S%Y-E!.>DXQ1&-G2R]P
M,$M+071#=W!2:FM'86$K579,3F@F(WA!.S5B;G5:27)Y*W9V<DU58V)Y6&1U
M9E=,4GI4>6QN94='1E<O,V\T<4](=W%O1F%D1E=39G!#1"M38B]K4DXO>E)I
M<G8P:$(O2DXO>4DF(WA!.VTO-6]X5C,V46<O:VTO-4549CA!3D=+=2]314@X
M:S,O04-);2]W0V%-5F0K:TE0-4IV.$%K4DXO>E)I<G8P:$(O2DXO>4EM+S5O
M>%8F(WA!.S,V46<O:VTO-4549C@P67%X,WHQ-5<P2'IN;SAE:S9O.3E"8GAZ
M<F-Q.7)%-G9Z4E=10W-K36DP;S4W6F)H>E-X>31O.#)-;V=I:7<F(WA!.WI3
M=GE".&AA8G$Q:'%C1C=R5'HV9F-W6&M+4TMP47E7.'%Y;T=#,G%N:5=15F]2
M;59K-U)Y>FE9;7%,05EO9S)M,% U4F512&576%4F(WA!.S=39E5:6EHW934O
M95%Z4G(V;&MR>#)Z34DQ57E&67!+4#9H6EA.4U8S<&U#,G%H+TQ0>2M%=4-T
M-W%-<S=7:E=.;$IC5S9U='1%,7 F(WA!.TQA.$DO5'0T;C1%5$8R578X5&IL
M,7)65FY9=C=C04%,4%%B8G=Z12]E57=+-SE)469Y5&8X:4IV*V%-5F0K:TE0
M-4IV*U)%,R].1TLF(WA!.W4O4T5(.&LS+TEI8B]M:D989G!#1"M38B]K4DXO
M=T$P67$W.4E19GE49CA!26EB+T%*;WA6,S919R]K;2]W0U)%,R].1TMQ1CEE
M4GDF(WA!.S)6>$9(2$U894HQ565H34MK<5%/<31Q+R\Y:ST\+WAM<$=);6<Z
M:6UA9V4^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \
M+W)D9CI!;'0^"B @(" @(" @(#PO>&UP.E1H=6UB;F%I;',^"B @(" @(" @
M(#QP9&8Z4')O9'5C97(^061O8F4@4$1&(&QI8G)A<GD@,3 N,#$\+W!D9CI0
M<F]D=6-E<CX*(" @(" @(" @/&1C.F9O<FUA=#YA<'!L:6-A=&EO;B]P;W-T
M<V-R:7!T/"]D8SIF;W)M870^"B @(" @(" @(#QD8SIC<F5A=&]R/@H@(" @
M(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3Y-96=A
M;B!"86QD=VEN/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @
M(" @(" @/"]D8SIC<F5A=&]R/@H@(" @(" @(" \9&,Z=&ET;&4^"B @(" @
M(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI('AM;#IL
M86YG/2)X+61E9F%U;'0B/F<V,'(X,3PO<F1F.FQI/@H@(" @(" @(" @(" \
M+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @(" @(#QD8SID
M97-C<FEP=&EO;CX*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M<F5P86ER(CY&:6QE($YA;64Z(" @
M(" @(" @(" @(" @9S8P<C@Q+F%I)B-X03M5<V5R;F%M93H@(" @(" @(" @
M(" @(')R,CDT,38U)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @(" Q-BU*
M=6PM,C R," Q-#HS,#HU,28C>$$[15-4(%1I;64Z(" @(" @(" @(" @(" Q
M-BU*=6PM,C R," P-3HP,#HU,28C>$$[4V-R:7!T(%9E<G-I;VXZ(" @(" @
M(" @,BXV)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" Q-BXP+C,F(WA!
M.T=R87!H:6,@='EP93H@(" @(" @(" @07)T=V]R:R8C>$$[)B-X03LJ*BI4
M:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A<V4@96YS=7)E
M(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O8V5S<RXJ*BHF
M(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T
M:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @5&EM97,M4F]M86XF(WA!.R @
M(" @(" @("!4:6UE<RU";VQD)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@8V]L
M;W)S(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @
M("!";&%C:R8C>$$[(" @(" @(" @($--64LF(WA!.R8C>$$[+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03M&
M:6QE($YA;64Z(" @(" @(" @(" @(" @9S8P<C@Q+F%I)B-X03M5<V5R;F%M
M93H@(" @(" @(" @(" @(')R-C S-S(X)B-X03M,;V-A;"!4:6UE.B @(" @
M(" @(" @(" Q-RU*=6PM,C R," Q-3HP-SHS.28C>$$[15-4(%1I;64Z(" @
M(" @(" @(" @(" Q-RU*=6PM,C R," P-3HS-SHS.28C>$$[4V-R:7!T(%9E
M<G-I;VXZ(" @(" @(" @,BXV)B-X03M);&QU<W1R871O<B!697)S:6]N.B @
M(" Q.2XP+C F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @07)T=V]R:R8C
M>$$[)B-X03LJ*BI4:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0
M;&5A<V4@96YS=7)E(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@
M<')O8V5S<RXJ*BHF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@
M<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @07)I86Q-
M5"8C>$$[(" @(" @(" @($%R:6%L350M0F]L9"8C>$$[)B-X03M4:&4@9F]L
M;&]W:6YG(&-O;&]R<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X
M03L@(" @(" @(" @0FQA8VLF(WA!.R @(" @(" @("!#35E+)B-X03LF(WA!
M.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+28C>$$[/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @
M(" @(" @/"]D8SID97-C<FEP=&EO;CX*(" @(" @(" @/'AM<%109SI.4&%G
M97,^,3PO>&UP5%!G.DY086=E<SX*(" @(" @(" @/'AM<%109SI(87-6:7-I
M8FQE5')A;G-P87)E;F-Y/D9A;'-E/"]X;7!44&<Z2&%S5FES:6)L951R86YS
M<&%R96YC>3X*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT
M/E1R=64\+WAM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/@H@(" @(" @(" \
M>&UP5%!G.DUA>%!A9V53:7IE(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @/'-T1&EM.G<^-30P+C P,# P,#PO<W1$:6TZ=SX*(" @
M(" @(" @(" @/'-T1&EM.F@^-S(P+C P,# P,#PO<W1$:6TZ:#X*(" @(" @
M(" @(" @/'-T1&EM.G5N:70^4&]I;G1S/"]S=$1I;3IU;FET/@H@(" @(" @
M(" \+WAM<%109SI-87A086=E4VEZ93X*(" @(" @(" @/'AM<%109SI&;VYT
M<SX*(" @(" @(" @(" @/')D9CI"86<^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \<W1&;G0Z9F]N=$YA;64^07)I86Q-5#PO<W1&;G0Z9F]N=$YA;64^"B @
M(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/D%R:6%L/"]S=$9N
M=#IF;VYT1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A
M8V4^4F5G=6QA<CPO<W1&;G0Z9F]N=$9A8V4^"B @(" @(" @(" @(" @(" @
M(#QS=$9N=#IF;VYT5'EP93Y/<&5N(%1Y<&4\+W-T1FYT.F9O;G14>7!E/@H@
M(" @(" @(" @(" @(" @(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SY697)S:6]N
M(#4N,C(\+W-T1FYT.G9E<G-I;VY3=')I;F<^"B @(" @(" @(" @(" @(" @
M(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT.F-O;7!O<VET93X*(" @
M(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&:6QE3F%M93YA<FEA;"YT=&8\
M+W-T1FYT.F9O;G1&:6QE3F%M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$YA;64^07)I86Q-
M5"U";VQD/"]S=$9N=#IF;VYT3F%M93X*(" @(" @(" @(" @(" @(" @/'-T
M1FYT.F9O;G1&86UI;'D^07)I86P@350\+W-T1FYT.F9O;G1&86UI;'D^"B @
M(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%C93Y";VQD/"]S=$9N=#IF
M;VYT1F%C93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/E1Y
M<&4@,3PO<W1&;G0Z9F]N=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N
M=#IV97)S:6]N4W1R:6YG/C P,2XP,#,\+W-T1FYT.G9E<G-I;VY3=')I;F<^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T
M1FYT.F-O;7!O<VET93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&
M:6QE3F%M93YA<FEA8E]?7RYP9F([(&%R:6%B7U]?+E!&33PO<W1&;G0Z9F]N
M=$9I;&5.86UE/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @/"]R9&8Z0F%G/@H@(" @(" @(" \+WAM<%109SI&;VYT<SX*(" @(" @
M(" @/'AM<%109SI0;&%T94YA;65S/@H@(" @(" @(" @(" \<F1F.E-E<3X*
M(" @(" @(" @(" @(" @/')D9CIL:3Y#>6%N/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D^36%G96YT83PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" \<F1F.FQI/D)L86-K/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E
M<3X*(" @(" @(" @/"]X;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @/'AM
M<%109SI3=V%T8VA'<F]U<',^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!.86UE/D1E9F%U;'0@4W=A
M=&-H($=R;W5P/"]X;7!'.F=R;W5P3F%M93X*(" @(" @(" @(" @(" @(" @
M/'AM<$<Z9W)O=7!4>7!E/C \+WAM<$<Z9W)O=7!4>7!E/@H@(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @
M(" \+WAM<%109SI3=V%T8VA'<F]U<',^"B @(" @(" @(#QX;7!-33I$;V-U
M;65N=$E$/GAM<"YD:60Z,S4Y.&(V83$M-#DQ,2TV9#0S+3EF.&8M-#8T-&$S
M-V,S839C/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ26YS
M=&%N8V5)1#YX;7 N:6ED.C,U.3AB-F$Q+30Y,3$M-F0T,RTY9CAF+30V-#1A
M,S=C,V$V8SPO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D]R
M:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.C,V14,T-3E%,T9#-T5!,3$X.38P
M.$9#.30T13$Q,$%$/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @
M(" @(#QX;7!-33I296YD:71I;VY#;&%S<SYD969A=6QT/"]X;7!-33I296YD
M:71I;VY#;&%S<SX*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A
M;F-E240^>&UP+FEI9#IC,S5D-C P,"TV96(X+3,V-#@M.61F9"TW9C4V-SEA
M.3!D8SD\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @(#QS=%)E9CID
M;V-U;65N=$E$/GAM<"YD:60Z8S,U9#8P,# M-F5B."TS-C0X+3ED9F0M-V8U
M-C<Y83DP9&,Y/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12
M968Z;W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z,S9%0S0U.44S1D,W14$Q
M,3@Y-C X1D,Y-#1%,3$P040\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*
M(" @(" @(" @(" @/'-T4F5F.G)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+W-T
M4F5F.G)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&
M<F]M/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D
M9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A
M=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II
M;G-T86YC94E$/GAM<"YI:60Z,S9%0S0U.44S1D,W14$Q,3@Y-C X1D,Y-#1%
M,3$P040\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IW:&5N/C(P,C M,#<M,394,30Z,S Z-#@K,#4Z,S \+W-T179T.G=H
M96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D
M;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E
M06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T
M179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T
M:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N
M:6ED.C,U.3AB-F$Q+30Y,3$M-F0T,RTY9CAF+30V-#1A,S=C,V$V8SPO<W1%
M=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^
M,C R,"TP-RTQ-U0Q-3HP-SHU-BLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@26QL=7-T
M<F%T;W(@0T,@,C Q-2 H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H
M86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \
M+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @/"]R
M9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
M !$( 2L"70,!$0 "$0$#$0'_Q  ?  $  @(# 0$! 0          " D&!P0%
M"@L# 0+_Q !=$   !@(! 0,%" P+ PD'!0$" P0%!@<  0@)$1(3%!48&5@6
M(2)WEZ?6UQ<C-3<X.5=XM+:WN HD,3)9='5YEIC8-D%V)3,T0DA2A[/'455A
M8Y6UU1HF)T56E/_$ !T! 0 " @,! 0             ! @,'! 4&" G_Q !2
M$0 " 0("! D%# 8'" (#     0(#$00A!1(Q408306%Q@9&AT2(RL;/P!Q0T
M-392<G1UDK+!"!95D[32%2,S0M/A\1<D5%9B<Y34)8(84Y7_V@ , P$  A$#
M$0 _ /?Q@# & , 8!%*[>859\?;%@T#LF-VBW-4X4L#<&V$D%6*:>C;U+#Y6
MGB\=?YJ:J3:4R!V,A;Z:K:(HW2=9$FT+4^SLN*L$@871R$VZ/;VY=O)<PJH.
MHGQ7M>O7*RG.P$-'L+7(XQ&CB.1+I%Z@<5"F=UC%+IK]:@U(9'MN6HYQ54WC
M<V8B4[D-V);U:UN?6MFD#&_,[8#BU;EONSV.S['^6\E? K'KRU(Z3+ZPGD,L
MB)J%*I$GE$"E#',(Z>L0F>$M2$O4>7.+::I1F_:E1 %(C4YGP#0 %[V"+-;5
M8S/ & , BMS LB;P6KF>+U*]DQZ[+TL2&473[X<U-S_N-2:;K#U4GL I@=R5
M#2^[J.JF.P[@-975,J;'9- 3FY>F/2JC2A"5MSV+-]7)U[.LT[%N7TF:>G\_
M<EIPAA([:IB%S6.W4Q2R4*:\@J.\*1?W2M[;0NLF;8O+5L3BJB>1=\<F5S3Q
M%Y'N,+V9R2-JI(M3F#"UW;//997=GFLKYY<YI#IO=3]7STG=C0U3'^-[,&"1
M)MDP3:1Y)R:\'8[:]Y U;+>VA]H2H26-NUH7>(<2'-W-/4]B82 D&_*-"91U
M;>=G\Z.KV9NYUS!U/;!>^I'(.&QG$OD>TUPAJR+N"*9.=, 3N[=,'*Z+$KQQ
MN"0OFK3&SE<57)BC#2=%)<GC1<E5O262F*TX48$B0D-7R5*ZY<K\R>7/F[KD
MRWF%\0+$Y05QU')]Q@OSDS/+RA$OXOBN6#R"RX%5L.CEIV4WV2V)9C).*Z*I
MDCKJ'TO7D1E#%"I3 [9F[I/U4PVGDT;)=HII:_GO;V]O1F:35TN6SVNVZ[>5
MW:^66>Q;#07+'JN&I>IIQCXW5CR!JJM*7JWE#'J6Y1-[[-X2USNS9Q-JMG4C
MTRIV%[5^?66H:N7((;&'Z9C(;&Z6W!839"FA>H70I>2K%HP\F3:?FMK)V6:L
M[KEVY<B3;R+&>3M^SR/<T^)="P]W7,\6#5?*#E9<"5O.*0*)S&J3C$8A4%K<
MUR,2K#$S&[SVUTTMD&T9(%1@X,R(QC.;%[FC4BJ7DR?0ETO._8FNLA!!^M78
M[E7]2V3:O%""TQ%>37%.X^2?&Y[>^38Y"RNJJAFF,O<_B=R+FVD$BFKF90SR
M=(^QJ8-#;/3%;,%.%UC;2^JEK&S"7!*]FW:6J[1WMI-9YO+9EGLNLR,DWZW5
MNWG0ELM51&<;ZNL$<GX[P!DLBC>03ER)D,"2W?R!K^I9!+E<2G/':L8\W#9X
M[)W4<>=UZJ0)2).<TB5,B@DL7>$ZJ35U*UI.THZM[1;RS;>S/=UEF? KD#;W
MV)N?D8M.;R&]7CA#RGOVG(/8DO1QQ%-;#@4$KJ$6;$D4Y4PJ/Q>..<T:]3!3
M%WAY9HTS <24+>M.;BUQJD1@K*S<6LM97:ODG=KJ65[9VWL@/T]^5G/&<SJO
MXJINUHY 3CEQTND_/"+-%W-3!%ZRIR\5%Z,]?[B3&JJ.$M4L;Z9'%ILW -C+
MB.52,3Q"%1K;($0WM=M,+22SLDE&3CE>[6>;3Y<MZV[$=)7?*[F/.^)'#RN9
M9R,DC-;_ ";ZI]X\4;6Y%06-0QJE+'6E>3F_5ZYLJQJD\>ED4ASD[IZV9HW$
MU#JQR4V.L E1&BW)> M:$+1O)VR4(R2;>UJ.UJSVRY+9\V1BRR\N;%X\'^+5
MCQ'F[<L!Y3VAR#F/!"OV2"PZCBZ]N&?PKD);414\@[*1/]6R1Y0(8O2U?O,X
ML)-!E;&T.2F'&MK0C9%C^2H(>WMN%DI-.*:24GG+*Z3LG=<KM=WWV>PN H2R
MK+@G/2\.'EA6-(;79@\4N-?):OI1)D[40\MRPYPF?'VVT2L#.A0(4R>7RFK(
M_9Q+6A3$-K9(IE,M-9"9N5)$"$5=M5/).[37-DUEUM=A9-@J, 8 P!@# & ,
M 8 P!@# & , KFFW5!XXUM*;0BL^C]WP\^N6*>/K,ZR"I7QL:+E#6MF0:F9:
MW4L8I. X2]<GM2S(#"F8UP;F!IEBV5-;M$W1[C.U#XG%M5\F>SEV73:[4F^;
M8[/(DO2/)NJ;XKA'9,;<UD51#E$]@CU&+%)1Q":1&>U=,'>!6'"I.R*EZ@M&
M_P 3EC&XM;@!$N<6X_0$[@VN"]L7(5J@0TT[/F?2GFFC?218D7IB5B!4F6I%
M >^0J2'E*4QP.W8>^2>2(91@>]K>N\ 0M=NMZ[>W6\$'(P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# (37?
MPG9KWY"5I?,FNBV&U!6<.?H4WTL@;ZB>:F=$$R\XH9Z]')9K5TJF<<FLVBK@
M*".LZ@<RB4N;H4!4PQEY8B'R2B>A*E9-66;3OG?*]N6W+?88A3/3-XP5I7#O
M6MCQ1MY5MKM)(3(MN/)^#519*AOW6%/0R@ZU0M+.37S)$V_<2JF!LD? \IH\
M"1/*Q7(7A[=URQ^5Z")<FW?9MR5TE=W=L][-$=%=B9(OQMO^,QEG:H[&X[U!
M>=3%'X^Q-Z1H9&)D:.0,J;VIG9VIO)3H&QJ;$"=.B;V]$G(2(DA!*9,2424
M 0GM_P#K#\,2W_!48 P#0-V\:JTO]RKM[G2FQ6U\JITD#S!'RM[:LRIGED<Y
M2Q&QA[5A<ZUE476+#%<?4K6@.UQRG29 Y.B9-HDMS7!/$IM7V9[TGZ4<ZBN/
M-;\=6>9LM<>[0XJP9ZY6;,'&>V//;0D#U-'=CCL<<7<^16)(I*]EZ5-4592S
M$*=<4@VJ(4.&DVE[@O4J0;OZ,DEZ#>'9K7\FM:P08N*$0L<J6SH<0BXYNY1=
M+"'&8B8&D4J7PM$XN#PBB"V0[2;=U472.[LZNB5@/6&-*=Q<W!<4D I6J33
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M<'?BD4?KI*L%I^?+Z4O2RV/!48 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MK\F=MW+R^O)L& QM;S"]:T68A2#+UHH!&M &06(.M$%"$63K0=Z^U%B$ O\
MF %L.M;V,1SL 8 P!@%2O1S^\1R8_O&N??[QLPP6EM7T8?@B6U8*C & , 8
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M;T\A[X/YOP-:!OWA?;/A:[H']\)Y[?\ IS9V=SLWKS6J[?$_[W;YX[- [/\
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MN"<T-.R^2W+&CTU2.,Y2LL?0.MW6'3,@:)=%F9L<$#@_O092*!RM$_O2%9&
MNKT:G>6=K71-D2IPRH9WN?=MX#<&>!>D-"1X.N>&_I+#8N>+T7/%5<6\,L-/
M#QH8J,\1.KB80QCK5H:M6I*#GA9NC9*<8]9P9TIC=*4,3+&*,G1J4XTZZIQI
M*IKQFYP:@E!RI:L&W&*=JBUL[-^H'UE7&%L^US]/R)IU0#_GPW+P^Y75NV$:
M_P!X]RR1TVEA*@D/O]Y2ADJI,'6MBV=W??S1QZ6SVY9Y9--]B;?<9M#NH7P/
ML!5YNB',GC&\/&AZ+,CX;OKI%)B#=]G84JC#C(4<@2&[WO6O"5-I)G>^#W>W
M6]8&K+<^QDKF9]9)&A*=(\\M3ZV'Z[2'%F<4CHA.UO6MZV4K0G'IS-=F];[0
M&;][>M_R;P0<:4J8PBC3^NFI[$EAZ!F<E\I5R@UO(C:./HD9RIX6/Y[J(+8G
M9TB D]2Y*'$0$1"0HXY4,!(!BT!4IP>YD=.*].1O(6"T)8U*2&RG2V$\PKAN
M:H>*+NLDB;#Q_I:+O[S6;F^1=A3RMO;Y#&9CY=N%+G38$2-?(!@VR*RW-3S<
M3HW2."I8?$8S 8W"4,9#C,)6Q.%KT*6*IV3U\/4JTX0KPLT]:E*4;-.^:*QJ
MTZCE&G5IU)4W:K&%2,Y4Y7:M4C&3<)96M))Y6Y"XG.$6& , 8!5C<7#B\ RZ
MSIW$>1O%ADK^>2INL:;&<DN"M;VC*(XHA[KN11!8&S(C:%#-S^AJL\HG5<.U
MIQF7R:()6YO5K)B\.*0U>H%DUED[K99VV]*?=:Y895D7E4.@S*PS>SGVXI41
MI8J>;#D+)$(VM?%+BN4N&@)6""LC!'&AE:RE);2P(DZ-4O*9D*'SV]R%ZVX/
MK@*FPL 8 P!@%2O1S^\1R8_O&N??[QLPP6EM7T8?@B6U8*C & , 8 P!@# &
M , 8 P!@# & , \NW+S^$53?C)RBO3CLR<,XM/T%,3HV$@F;IR0=H<KD0RF5
MF>!N HTDH&6DM0?^5PIPI]2!QWOP-F;-#W] #M/@?[D7"7AMHC^FM%8W0E#"
M^^J^#XO2&)QU+$<;0C3E.6IA]&XJGJ-58ZKXW6;3O%65^DTAI_ :,KK#8F.*
M=1TXU;T:5*<-64I17E2KTW>\'=:O6R/:;^%(VNM.TG1]/N&*U @&F!(3<L)&
M><(!!0SSQZ**XMC'L!)!1AQHM!["RBQF#WH !"UZB7Z.O#6"UIZ5X*1C=+6E
MC]*Q5Y-1BKO0J5W)I)<K:2S9PEPOT3)V5/2#>Y8:BWEF\EBN19F"2#^$LVM(
M)97]@>@;#DR.OEDF($4'E+(CTCDKEC 8V%I3'+T9"BD"A,20<M**V2J,5EE&
M!" D!8S=/_QVX:ZZA_2O!37<7-0]_P"E-=P32<E'^A;N*<HIRM9-I-W:'ZWZ
M)U7+B](6NEK>]Z.JGMLW[ZM=I72NGRFQ@_PH*Y1A;!@Z=\7&%Z,&2SB#RHE
M@NQI9P4QA39O7%C>EYA:@02!@2[-$$X02A:T/>@[J_T>>&2XR^F."2XE)UKZ
M1TG_ %2<=9.I_P#"_P!6G'RDY63CGLS)_6W17D_U.D?+RA_NM+RG>UH_[UY6
M>65\SJG/^%.VBT%. U_3]AI!C86J&L3#Y8R M42-$$P2@@9!W%TL1:@O98RQ
M%&[+V$S6P#[N];[,.+_1_P"&6#P6)Q]32?!BI0PN%K8R?$X[2<Y3HT*4JTN*
MOH:,)2E"+U+SC&3:O))W+4^%>BJE6G14,>IU*D*24L/124IR45K?[TVDFU?)
MM;CUM55-A675];V.)MTS"L"!0^;"9PJ]N 6H4JCS<^[;0K]ID6UND.U^TNE>
MT:3:G17C;3$=_P (&C#TIGN , 8 P!@%?G4W@:.?\47=,L= -08?9U)VFG-=
MJ7GO(6!+5U4VK%+!0M-M5!6(#)O+*G=54>*0SD;)K0H\U'[E*T8&]D5BT+1=
MGTW7(GGD[-['N*M>F>3Q4JGD5$CZUY/P3DG.#:15TLYZH:C+,<9].;/M^XR[
MTO>[N3LJ:6IZ984TMU@;5)*^(G3@TIH1#7!W:U\@<'A>E0G"TFVMC2;NKN]K
M965\\DU??MM9*WI-P8Q@# ."Z?<UQ_J*O]',P"JKH7?BE.#OQ2*/UTE6"T_/
ME]*7I9;'@J, 8 P!@# & , 8 P!@# & , 8 P!@# . ZNK6QMJ]Y>W) SL[4
MC4.#H[.JQ.WMK:@2%"/5+EZY682E1HTQ(!G*%*@TLDDH C#!A '>] >%K^$(
M<TE_(&Z:J@]3VG()/PR25J=MLD,2#+VFD+:OM++I*18J-OG>D37!+J,@$*#6
M@F\49>IA'HV;*GL2942[*W0I+O'W#=#\#-,::TM3X5QP.(Q%'"8>6A\%I*I&
M&$Q$I5*RQU34J3A2Q%?#PCAN*HSU[0JUZRIMTM>GYOA/B-)X7"4):/XV"G5F
ML35HQ<JM.*C'B5=*3A"I)SUI))ZT(1UEK6<]>@N]]1V\^*LW:XSR1BT%H&#V
MFLC%63:VZ4E5]V2Z(RX\S'RF+5G,7J[(/'4E>0M],,2-IK[$K$);W]:_Q9K5
MHFZ-A96SQGNFX'@WH[AII?"<%:E&>B:<J#4,-5X_"T,7*A3EC,/AJVM/7HTJ
M[DK*<XTJCG0BU&DHKL="U<96T;AJFD(R6)G&3;DE3G.FIM4YU(65IS@DWE%R
M6K-YR;=XGH46/*OMEQ<^>9D]T;[Q[)!I+57'&-% W_.);C^/M4U_8Z8L7O\
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MX[1N/GBL35I*E&G4IQ5*I*3Q'&.RDTXQ<81<=>T[3UU"T;>4OH Y\SGLQ@#
M& >4;DWQQMODYRNFDO8;UJ'JFUW37*<<HF?!M9=Q%8SVDX;!'U];))Q_,XWO
M,DUQTLP"!8%"D+L2WD$0EKZ)A3:TX/!#NJ5X,M]5+)P;2\I*][\M\FKJ^2;]
M%O5FG[/)R.Z1M,'P2NZFV$ =I]=P/81L)6Q%AV5K[7W2][!KN]@-[#K6\&(_
M; & , 8!4KT<_O$<F/[QKGW^\;,,%I;5]&'X(EM6"HP!@# & , 8 P!@# &
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M0B5IW1N@,I:4T)XK1!R3&A4)3(EQG95[C%7XUN4 "<UR&\'JZ)NVG!V<VRI
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M7-!+ALO>DQCDC0+&]:I1@-[NSR4JY(>87K82U!0MZ%H#2?F_E/\ _P"LX_\
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M>+-VV=R#YF6E9,'8>5L7XFK:(CS4],')NIY13;"AY"-,M2)&7=%P^R([&[
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M2ZLV_P A]@_GY,_AS[G3!ZU(/_GMO&'BE%6!P0%;][9),JY'3[DJD<%.@_\
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M#KL[1 [#?AZUVZ[=A[=:[==O\N"I61U(%S8X2+IY%$+$"W0^=)X_")4)U/>
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MUHS>O%[= WO6]:'_ #=]F_?][> ?-0ZI)I1_4HYPG$&%G$FWNL,*-*&$PLP
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M-A1!I5PYN1L:^,,\X;##FZ4EQ=0E$PJ'=&>:$]8@4 4>$M*4IR1C>7^>1NW
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M<Y6!^&X/ZUA_70/JG\6/P8N.7Q#U#^SZ/9^8YNXWQ@# & , 8!C,U K,ALM
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MC /F@]4[\9;SE^/I;^I4+S[@_1]^0#^W-)>JP9K'AA\:P^IT?65R!N;P/*C
M& =1(/N"]_V0Y?H1V=/PA^(-.?8^D_X*N<K _#<']:P_KH'U3^+'X,7'+XAZ
MA_9]'L_,<W<;XP!@# & , US;=?L5GUW*8:_PR SXEQ:U)S7&K.C39+H.JDB
M$H2R-*']B=D3@D5HT#X2A6"%I*8H(\'QDNP* %BT!49TTZGO.&W E>9EQ1<.
M.#!'.)\5JNZ'R6UQPYA:JU>3S--43P\3>H%O& *AZ7UN\M*F2AD)TL-CT=<
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MC]IX;U&+/;\ ?CJO]G5_XC"GIJS1!N$8!\T'JG?C+><OQ]+?U*A>?<'Z/OR
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MB]-\;B,-8'B52F0NIX4K6PQV/MRAV>WER4C^"G0-C:D4K59PO>*3D&#W[P<
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MP<'16(:I6<,0HW=M[S;&"!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MSI^$/Q!IS['TG_!5SE8'X;@_K6']= ^J?Q8_!BXY?$/4/[/H]GYCF[C?& ,
M8 P!@$-.?UA7-5G%:R)S0LHXT0^Q&33 -,]\N9 .+T4!A5/[<CE*.4O7GF.I
M4RUQCY[@BCQ;F^-;4I?3T*9R6$I#3!8)BDVDTVMT=NS*W7W%(O00.9UMQ7VN
M::6@D&,,@R4ESG%5<=9ZT5 ]GE2%ATA9Z?Y-+>8_*.K9#!PH-@.35C F6N=;
M VM[H-J)2Q("(H7GR9OK:;Z6M5._.[ODZ/4+@QC & <%T^YKC_45?Z.9@%57
M0N_%*<'?BD4?KI*L%I^?+Z4O2RV/!4TCR2Y UUQ5H>U>1-L.?FJOZCAKK,)
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M=:U@QGZX P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MZYAGYSZO0C/'S(],OR+9,J21EYK?@;<M?S9;Y_99*\$QVKI7I*'*J^]?6_\
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M,5FIU!">PU4DD,<=@FMZLK0M?5A;^].S?T>1=;SZ"ZK!C& , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!4KT
M<_O$<F/[QKGW^\;,,%I;5]&'X(EM6"I6)U)O]H^GC^?6;^Y-S2RT/.77Z&1+
MS)="_%$Y>9C , 8 P#"^&OX??-7\UO@9^TKGKF&?G/J]",\?,CTR_(MDRI)&
M7FM^!MRU_-EOG]EDKP3':NE>DH<JK[U];_\  4/_ %>;L^K\%\#PGU:AZJ!\
MW8OX7BOK%;UDC/<Y)QQ@# ,50?A5=/[\[HO]V_D9FOO=*^3]'[3PWJ,6>WX
M_'5?[.K_ ,1A3TU9H@W", ^:#U3OQEO.7X^EOZE0O/N#]'WY /[<TEZK!FL>
M&'QK#ZG1]97(&YO \J, 8!U$@^X+W_9#E^A'9T_"'X@TY]CZ3_@JYRL#\-P?
MUK#^N@?5/XL?@Q<<OB'J']GT>S\QS=QOC & , 8 P!@# & , 8!P73[FN/\
M45?Z.9@'FKX<WC84 Z)/3QHSCXL*)Y6\N8:MI"A%&P"/U!!+9#,7&S[Z=TY0
MO'!&:%KLIXG:M3HHXE1)2HA'3"S#I$F*,%VO+FWL4FWVY+K>7+;;9I,ORXV<
M?J]XK456/'RK$)J*$5=%T4=;#58@FNCTL"(Q:_2I_5!"#2Z32^0*W2425QV$
M(G!]=W!9L(?&[NA5MMMOE-X8(& , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MO_*AS$^H+ XN6Y?>CXCUZ?3!_+W._P#*AS$^H+ XN6Y?>CXCUZ?3!_+W._\
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M#BY[E]Z/B<[UZ?3!_+W._P#*AS$^H+ XN6Y?>CXCUZ?3!_+W._\ *AS$^H+
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M7)W<[)+C&E^DVZ'U2W:K\@U8(AKQ"]UJVN\ELY]:_9;//.^QVR+S<%!@# &
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M//GX4B<C0/;V]N@B3OOVMW;W]25][6W;9%KN"HP!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M[VJ^./RVUK])<"SW/L8],_A][5?''Y;:U^DN!9[GV,>F?P^]JOCC\MM:_27
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M5'HDTFCZA:F%W%*0AZ;3E2<?E12'N'IRU(C2A>6J"$?=, '?E1Q2?L\4P !
M?NMD<>;=]CB_,R#>U(46M+71"EWY8,Y"G D[#SR_XR-0YMI 2/\ G1'."$K0
M-C5D!, _ ^6Q5*VKWE3)H^G9VI8<W.CJ>\MQ+:VN"<\*50@7KC%(4J-80I&!
M.<E4&EGE'C"2, 3!:#L#$&:XZ\?;&EE4H)"FW-X:BB;@ZM*G^*^5)9HUNKRQ
MC8SS]@*?=C;&5>K6A:]J1-Y)98U>B@G%[$'M[=IUUX7]3W&Z% L6[YTV5]"S
M'QJC13ZZIW-62<_/8C@-+40F:$+BO/5KA)S]$%DI1]OA"[VPZUEH0G4DH4XR
MG.3M&$(N4I/<HI-M\R164HPBY3E&,4KN4FHQ2WMNR2Z2)OK8^GM[2<?_ ,'V
M7]"LY/O#'?\ !8O_ ,:M_(8??>$_XG#_ +ZG_,/6Q]/;VDX__@^R_H5CWACO
M^"Q?_C5OY![[PG_$X?\ ?4_YB0M \N..?*0V8$4':3-8RB :CPIDF;6]_;%3
M "5Z>MQPQ:ED#0T*/">-1Q\TC-)+-+'ML5!$,(@:UO!4I5:,M2M3J4IV3U:D
M)0E9WL]623L[.SM9V9EA4A4CKTYPJ1NUK0DI1NK-J\6U=)JZO=76\5KRJINV
M9\NKB'.LB-?2T<Z<X\O>(5*X_%[!::NF+?7UDO%;2EY:$3'.&J#S5W9X^^KF
M):I(\1Y9G1N$X,#NVNRK&9&FO;9?8GN;V^S.9%N2M>32VY73<8:;/=GZ$OB^
M,2:5D5)8H:I;)(UQYKDK@PF6T;' 5\:[)&]X0)SD1$@-. [FB9N[YS*-3 "V
M5\NU7[-IN5;)XTVJ#DCC(6- K3I5JU0E6NR!*H(1-J9,L<59Q)Z@LPI*@1K4
M:M:H&$)25,K3'GC+*/*&,0?Z-DD=),;"CG]E)->TXEC,4:ZH2S'=( ) QJFP
M S]"7IPA5)A"/2Z-*"%00+8M:.+V(#4-O\BH#33U%(D[M\YF=@3E$_NT5KBK
MH/(+!FSG'XH-I*E$I4-3"D.3L,48%+^PH'"2R1<S,VWA]9&!(L5/SRUMJL2D
MW=\BWM+;LVFGUG/RAMZK8J*-]PV4Z6@QVF_LL:KBEK&E$P84E)3")U]:R.?0
MXEA(D\"?(+.9M'XE((]*6IL>T#\H.;S4&CDQP0A9]&SOV<UK9WV6,=7]1ZA"
MC:QVPQ/D-.&^Y='$UB\PKCS:3TVRYV01M^E;_&D6Q1](M1RR)-$5E&IC%W9$
MWOD6<8V^-+TA1N38J3%A;;FE;;?IMUY[B2EHWK#:C:(BXR1JGSLXSIQ&UQ:(
M0:O9=.YLYJTL?<94ZZW%XLU.;DA3LC T.*YV6.):1(G/)3LQ1Q[\ZLS4X@E?
MVMZ35I/./C@M=J_0,\O>) T6.QTS(&:<L,(F3I7;4W\BU@&ZA02^;)V/;%$'
M"V7$Y(@B;6_JD3AM4Z,('A.TADL=&ZA9]G;V;3)*GY94W=,O*A4)72W3HZQ5
M_GD*6R6 3.(Q^S8%%)$RQ.33:LW^1LK<US2,,<@DT61K')I4&!,1RN*/R("J
M.2=A=W &FL_9/<]SR]K,WX3(6!2_N443OC0?*&9G9)"\1LER1FOS4P25;(&V
M./CDS@.$X(6A_<8G*4#(Y*4Y2-U6QI_2H3CSV=Q G$&BGKE73<?MTJEW%UD0
M91J2QB#.3VFA4K65[';"F[!J4PJO)-8B9I-B##-I7'34#JRL+DZD*#BWZ))%
M DSE-H:B?A-GMZ^J]K]N7;N9S)YR5KRO[08Z=7--GR:>/3&R2<QNKJI;%L5#
M'(W(Y"YQ=D?IH]PV./#/#FER>6-\(3+9$M;R1DLCNK[WDK<J-+"WM[;>HW:X
M/;*TC2ENKNUMABT\A*B+<%Z1$-6J5'@3)DR4"DTL2@]2I-+3D$E:&8<>8 HL
M(C!A#L0<7W51C2+3GN1L.FT3GYE"X>>&_P BV\>6;;_-.E?E'@;<_+];0^0:
M,\J\LUM-X7C:V# .2K?61O;RW9>\M2)J.*T>2YJW!(F;S2-IC%NCBUIQP$PR
MMHRC5>C F[!M,48?K?A $/0'Y%R2.G+7)N)?V4UP9@I1/" MT0C6M05NM;1"
M<DH3]GH0J];UM+M465I1K>ME=_MU@&JK/Y#5C4D243R4NC@KAJ-AEDD7R:+-
M"V5LK>VPL*7;WY:X,1:Q,G5Z,5:3(48S-*%ZM.L3)P#.2'@ &TS978T32K(\
MG"X^7(I)[HO)9"V \XQ9O]RY'CNOGV1I1&-++W!:&D3^<%1/E*\HY$7VJ"A@
M"!W[?)8X[ $8U/[*YEA"I&(;>ZH5@ @1!3"6"$),>9K04@5J,2D6]]A 5:;9
MNP:/*[X'XJ);%$A@RE<FCR4TI I=#2U#TVDF%MB),E6K'$8#%(1 0)$:Y$K4
MJQ:TG(3+$IYI@"E!(Q@?L9)(Z4I9T1K\RE+)"6,Y@2&.B$"E\)+)"H,-9R!'
MZ-<RRTXP'C&B >$)(@FBWH M"V!AM5V_7]T1DJ65\_$O#88J=4AI)@=HW5$<
MSOSQ&U/G%H4; X-X#G1B<PH3%9!0%Z<C2I+LP@81[!JV1E$SF$9KR'RN?S5X
M21V'0>-/LPEL@7[,TA8HS&6M4]/SPMV26:;I(V-2)6M4[**,,T20/N%C%V!V
M&W85O:ZU72RWK6]<SZKWK>NW6]$3#>MZW_)O6_<Q[^MYV:T)IEI-:(TFTTFF
ML!BVFGFFFJ5FFMC,+Q%!-IUZ*:R:=2%T]S\H>NIZ6?MGU9__ ,\P^C&3_0>F
MOV/I3_\ GXO_  1[XP__ .^C^]A_,;@HKJ6<%>3%B(*FHCDG [)L9T;79W;X
MFQ D!;FK;6--Y8[*R?.3*A3B*0)?MQ_V_0] ]\(1;][.-B='X_!QC+%X+%X6
M,VXPEB<-6H1G)*[C%U814FEFTFVEF7A4IU+\74A/55WJ3C*R;LKV;MF;1.Y9
M4V1;A=-&KI:&0&3DNJ]2;W 3/[&8;6.A>K$)K0=D^9?<>&7&P[870"7SIM!Y
M>,N+"<0S$PN/"XADL]O-?:MB=MFWV;V)G[S'E53<$M%%4DA=9$7(CG.O&%W>
M4$*E;K!(?)+>>3H[5$9FT\;FA1%HM(+%?RBF>,-3JYDJ3E[I&R5X4&Y?$MO8
M6?I[MIOE8]LK<I2(G!W:T*Q>H3I4*18X)$JE:J5Z5;2)DA!YP#5*A5I$MVG)
M) ,P[215LL(M)S>X(.)J5Q;;>A=M25@VU.BT+:V.>GENVWN+B,XY,! A6^4^
M3*UHU"<\@*5.:8>(X@XK1>QE#"$# +=O*OJ4CK!(9@K>5QDRD;?#H%&89''N
M<3.P)<Z-SF\H8Y"XK%T3F[OJ\3&RO<A7GD)PM;%&&1\E,@<&J-LKJZHPVFAG
M'GQ1;8PMK@:UV^?+5]NIJ+45 DIZ='70SV:KK>36^D8W6M_-0'TMO75I$7R9
M-<J1%KHD]L:8*UD?'$H?:$39]"M>[V>W)ERF.2#J/4''HT1*S8KR&<6TNQ&>
MGY$G:^/%JFO,%MJ1RN(0N,5K.V17'4;I&)=*G^P(*5%4*Y+HB2M\PC;TR*US
M.\(5QP:KYME]^2O?9?99DDGR]H?%ZE07#)V>P6!D=#HZ@015?7LK'9BE^E\C
M01*+Q<NND3:LE/NB>I"Z-K>G;]M^M)@JPN#D<B:B%BY.%L[>V\TR\\^>.+'%
M&:7*WB='HG!#:[P^M+955C.LIKM@H:4$PJ[)#9L7;XVH>X.RU?+%*=BDJQZ1
MD^.J-"?'RWM!H:P(6;[N5<NPS1LY=TF\6F@J9O=9.H=GB8N=;L4N#!)AJK7^
MS&6%KK$=Z\8[.VS:ACI*D$+:G=Z-3)'<Q ::S/;"E<#Y,S.C*D"SM?\ UMEZ
M;Y$@E,A8$;VTQE8^-"22/R%X=&./J7)&0]O+;'C&HE_<&IJ-."N<4+(:^LA3
MNK2$'$-ICPU@6&$B<$FC1!HNZ>55.4"[(V>Q721)U HLYS^0J8["I7+FVOZV
M97)"T.]DV0Y1MI<D4'@S<XN!12A^?SDA.TJ-_=R@&LL4E;BR"4K[/2EZ3N+F
MY#P"C%$*;I8AL%_?;"6O2*)1>L*SG=JRETU'&T+L_+_<]7[#('5*T-*,U+Y<
M[*TQ+>0H7($HU&E"U.68(M?_ %2])M7<G9"&-%(G1:7'FQ<@(<=#D_;'#TA)
MR';B(ES2O/D:AL6)4H#3%Z):60J0[3J0*BBA)S=  _V*3QL)+NH%(6,*>/@+
M-?CQ.R#1+(6:E N*,=S=J.XV@,1& 6%C6")"-*,"@.]DBT/8',+=FHU%IR*<
MV\QNV+NZ7EK$PT6Q;.TGT'2H)FR.]X^]$=GB=OC;T5V=_?=P#KTTLBJQ4B1)
M)-'U2US:_/C:D3/+<>J<&7W_ /EA$G*4B-5M?O;_ .4" &)/>W]NP#I7BQHJ
MT)4ZPM::_$FR5HBBGW*D#DIC2Z/.RQ)AO1;1M4-I0D$G$JUZY;HDA$C.*5'B
M 28 >P,/AG("M+$JZO+@A#FOD\+LU%5[E'3F9J6+G=(@MY-'5T15R1D( -RC
M1(&R4-+J_P"WDA+N/-8U"]T"G3)CC @U;:;+;Y9%G8>RVJ2Q]S,T845LMO>6
MY:/1I^C-DE[ F4F"T8=HDW90.SO&:*,V#6^X+L _8V1QX@],F.?F8E2M5Z;T
M:<UT0EGJU^S5Y&D28H9^C#U>SFIS)TF*",[9K<O+[G?1J-%@<4R81$EK0O9L
MICA3*YJP(&UW,>VP#6X+C#C4Y:)"O$JTD5JS%!!Q $Q!IAPSB32@@V,L8= 8
MM#+?K^>R:PH=''TE1)JPF2F"2UF5!VA7IWU'%(9,U(D"53LL]T:R&.?Q@PUW
M0EG( +%PT C]*DYI80M[=O@R@?\ A!W_ &1O_'O_ -%L&2GR]7YDT[@_$/6A
M_=(33]SERP1'^T7TU^(S!G^Y+7_9R+]&*S/'8NA>@XLMKZ7Z3L<D@TTU?C!.
M&/Q=<M_U>J?,=3DZ_P C+3V2Z8^B1+#F;2DQMM15BYBJ&$7)'H>HF)SRS'6S
M/./-V11]>T;$FC$XI*^*\&2^Q0]N3(Y&QS6+ <(T*5MDB:G9/*T:B&!CTIQF
M1.W-U)\]K/J]MD(''IU7C.X=:;M<0JXLJZW;BA"ZGIZ=3*0JI[+*UF$:Y*<D
MK>C;2&T)!#&V3.BZO(%/*2B1ER::VN66#**_5S)V:T#F9HPX6UK-6R5[M=2O
ME=[GT7R-86]TXN4UHR>Z''3/5#3N>,G/J+&+VQY@$;97YLY+,\S2U:H1ZC%&
M-UQ+AGE'PTZWS[8N2:@;9JC,5U\Q&1EN:!-@*2V9[8OLYKVYES;<R7;1T^T$
M.OIXM>OJUIJ%E%<X*TNJ).$79&B./3!1D<X7Q2C91%&OS1'DNV4QRLO4[<C8
MHW*"F=U;I"N>URG:YV6I<%6VTLWLSSVYO_(DA?7#"%7Y<5)V\^3JY(XNJ20N
MSLL8H5?/(6 ,DA0+8!.8>A2-C-6]OPJ-1!Z(<9B4Z/,M:H\=()4Q-Q\'?U2R
M..JA.4"DTFLL]Z3W;T]W5M1AW*BE[ND=A:LBDV"$3%?*.,MV<:7MEF\O60U-
M&E]DO,(?H980%B:-27;M&V)9'WY'.&%(G)?UJ1<PJ6 M>:@5I!@GE9[[[+[$
M_P#+F,8MCC9(Y%7=(UZ\<<JAY%Q'CPY(8HPL%DV*\,;G+(TCHAOA#?:#44%A
M60]EE">4NDBC#M#9>@E)944+,G49E**3[;XT:)3VYM-[LEMO;*[M^?:<IUXC
M3R4<3N)M!6:YQFV)!4M@<;Y);2J7N#G)6*3M%6R%N>9.W@7RE K=YL4D3I -
M;6KEZ4ISER="2ODVB%Z]<#0)V;VYII?E[(@=:W3U<JDK%#+F.%U/'&N(./*Y
MVM%LC<=?52.SH#8_48X\<CJGJ2=I*_KZ229TJIVH>KGFHK#,%&9,U51!WA<E
M1QI\A[6M2;C/KS].7Y#6WW>SJ\EJ_4W=;^8W=QTJF36_Q$ZF,<A-80>H2>4E
MB7XEIF.QPUU15HM(E_$RH*A2R=J=5L'AIZEC>K'CLG4/[^UPX#,K>BG]?&CY
M(R";7QVG?[<B]L@W9QN[VM??M?MGGOL8G>/3TMAWLB)%4M7M+PNMX2JX@.<+
M'%$E50H+0EHV[4ULV4@DAKG1<SM#<A6.0WIUKO546+5T9<'.1O;A/E!SF>X"
MD(*66=[Y\ZS5M^78WSG^%G32L!LBE8)83&ZECDK1U9?\8MMY:CPM*V:RJ?\
M,_BK?L#7/3LBCH%TJ+9H355G% 6O0AG,#N\)FIK*VC>ERE.(;RMGR=R=^\Q(
MSIQWFXL*N/-=9T;6#RR.O)QT=;*B\P.5R"_$][<EH];<699D!- VIR1HHU'F
M<+Q(]R-U?]()DP1)JAX%;(<X+V@64DMMWLZK+DSZ>K.YG#CPQO65/]_62Y\;
M:"BEQS";UY(:XDL6G[,TQUMK2D>2%<WC'JE+3L]6HWE-)+D' //UJVD]"=%K
ME.UC(D5(-PN$1)M:7MXD7V+.R3[6FNS=S=)P)ST]+AO.0WM.+8KFE_+[)J[J
M#(H%%'>1AGR>#V'R3K?@["*:=QN3C"T:-(^LR6@+*32N1,R(TR,F.J8B.+'U
M ['+ N7FS_*WYC62LL_[M^IMOT^UCN[#X 6HTR@X%0P&GV^K'";U'*UT48D5
M7-S^@>H=QSE-1NDKC3?:]-6W4K<Z+'QQ9VN5OCK7C],'*!:5FQI>C>D9*%<&
MMON\FNEWY<TVK?Z&IZEZ;G("',T/BDGK2B%\G+AW!6+)>0:6;&K)I2N^*,X,
MD\L%!T1E:MSHH2N3,24W5T5'E\53+G%8-OF;:Q1I( L8.6VS=FY-=:Y<[;B6
M'5V^\?0?YY-"?^9*<]#P3^4FA_KM/T2.BX2?$6E/JE3\B#&?2YH(8!(?I??A
M7<Z/BJX6?_=.6.:']TGY0T_LW#>NQ1N7@'\0R^T<5ZG"&ZJ4XW\BJND=0^<(
MC '5AXE5GR*@-9+4UE+4B^\%-P6% W"$N+N6.$*-UVGCU>0M1J=%+PR4Y;/W
MA.5']KV)G$]NFOSVC?7>SZ+7RY=^3OL[%V40XH3YEY:QVUF:JZJJ5O8;MN^S
M+&N6OY_+ULHY%UU9<+GK+$ZJF<&>D)YR96VS.6Q&Q94-RDBV&,,HJ=N<*Q:6
MXB<KVJ)";JULWDDK\F:;:?:N3)\R.EG/3^1V#R%F%PRZNJ@EFI%SLJV] N\F
M:FUYD)]'P3@Y":),BZLUQ85)OC$6^T2%X2Q/:L;,I:ENGL]1I8J-0 #6LN7)
M-+FN[^CO*W9SQOE-..;50SM4M;VM8DNE/#@NLG UJG9DEI:%P/ET_P B&Q4P
ML)I]VC#K"8O"%ALJD(8_8,,2UF4KE@[$1-T2W%5$I;.X+9M=_*W<JY7?EL^3
M/D>ZZNW:YN.,\BHMR7IJ)Q6T31TX]4A/JWDTU,KYU U#F3=.8C,H-)38Y)68
MU6WNFGYGE\9>B&<MZ:W-E>FZ0$KHB%@DHA6Y<N>U_;VRS(FPGIZ6*]7?#[?M
MR9.\1/?6;F;+[,;^/=UV?71\;L#D3:?%U^@T"C<LB88')9E#(Y7U*.B.6OSF
M3&BY%/$Z>6)XDV;=$J5D>VXF]DTN5IYI/8GV7O\ Y[Y9._%U#%Y3P=;:<9FF
M-U;Q@L>P9 ZLZUZ>%SH"/RCCW=%;I3TKB\F/+S*I&XS2PFYUD3O(G@YX=AJG
MJ0.KJXNQAVU8B^WG\4_R.';E3WJ5&I8Q-LFD?*:#V?(GE/.:RLN<1&B'R%01
MT;G@UL8*5LN@ZOKE\(;V]_-9&Y_(LMUE<G=(:6L.23<3RD5-<O!?Z=-UMYK7
M(80;@UR8A4&:J3<SZVE4;L,/!)ZLJRD4H6,YU;+^)SE789I$8Q$]0Q(=,&U\
MAU31*/5E) '1DW;\ZOLBF#"PDMR5&^B6TWS9V3SVIY]N;ZK7Y).<6X'R=/NF
M;W)ROK.'(9Z^QE_C$1E42N'4PB]9UX9+6IU:*?KV!;KZ-*6U._D(6V3VC8[P
M_NDCG\QBS-I6F;(DS0.(P<0[9)7MSI+/M=^;=TMFQ8APPA4/Y96#RL23JY%S
MQ-X5!8Z1"W2^>0KO$&M[C<EOI\D#BLBCW;[I7[[$'-+=*9'!ZM6P4$$IYRC2
MV15RU,SM*5QJ1[>WMZ1?*V78N;FO?+;M>QY&EIIQBNAXN2QV=K;H<=3EP\R>
M-',=\L53+%:65P\[CW#N/34LK1/!PQT_SXNE$FXQPLUL?P2-&V)HQ.I66X%I
MET39VZ5B;JW.DU;?>^=^:^[=SF*\D>+MP7K.29R@HZG(O:$H@=*QQ@Y"H[<F
M ;.XUO=;6?-I<\*VC14;(;Y>W-K/,%SE!MP]!#5DO?7N406T^[!5R1V3B$[9
M.]L[K?[=VU9F0\[^$SSRH<+%<T$:KN0+UG!+E#159+9OHHQ5$[PM9;!5E?RM
MJ..:',R-^:3(RK-,F;2(#^P&>%ML+'M0=O0E.V_:GV7\2)7(+CK'>-=VO-FK
M*@H^44%+9K8QD)H"11R4ME1$N<FXP<;*T#.EB>"TQ9T9C5EM3C3LVA\;CZF-
MDN\W@UE3;<3=5\J(*B+X%^F]MJV[6WRK*SOTKK4EZ[XE/=D\,^E'6%J5]&ER
M7CZP\<))>-:V6VDKDZ?W%<.9]6:^/JXX[H')(ZO3#94KCFSVEV++** VKU)I
MPCT0$ZB+;.;P:Y]^_K%[.5LKWM;I3[+$.Y#TU^3DVE,R<'Z/5"W(91">2L(E
M"9J<J[98M)S+CO\ J:U&E2Q-D/HJ-6,NC+BP0%R52T^[K3LV6CG#H,+:2E;0
MGO+I)-UEM><=NVROE>_/ELM8V;?W35LZ7+>3#54\8IQBKVRWR^5U=P3;@?#H
MFC;[5X>\0Z<*;G%FCD7/21Q(]6G3=F.LF\RHE9FD#PFD>BUSL]+4A C6R6VZ
MM=[<TY/?N:[#NE7##D$USB67-7M#\;XR6X*K+713BTYRDH^H$SN[\=X73[,]
M2W;+7[='U.IA)8\)=+6=BCY #H3&8H ]T+D;HZ$L8FZ2MGR9I6Y;NV?9DL[Y
M'%@W"^^:H9X6Z5A0E4M4MU5W+JK[0+<+9:&(<_GW*??'A].OMT50ZIR&-L:6
M-XHH$3-KA@82]16"GQ5C@Q)K+%DC*6"EMOOBUR^:I9;>6_CO.SK[IE*B'^#R
M2T*ZI.7/3-R@X^63('AV;V^1NBRI:DZ:-;\8%D7"M=8V)2J(2WU&'R0M45--
M RJ&=07*#MDNBLYN #ENNLGVN3>_=9&ES^G%RD),J]C2,=2$-E://%M9%7IB
M=*[;O,L0H?DHKMMUBKP[2:BIA;07!GC9@6^I&:IK$JF"H"G%<CE/:)*H*D0.
M2;;SSOVM6OMM=O:2JX>\-+,IRUJ[DTAK"H*N2UFQ<I6Z53FN9+MZD_(!5?MQ
M,-@Q,N3I00R-K"$,3;F8YVD Y.[/"A!,1MK=#@J&#;DX[$2:=[/:T[;K*W1G
M[6MG*WJ#?@$<WOS0N2O[&9I@0\^/TH^E'S D/_0D?]53_P#D@S]1\%\#PGU:
MAZJ!HJO_ &];_NU/QR.5G),1<?T!OQIU,?%E>_ZD!SYM_22^(N#?VMBOX,]O
MP)_M](?]BCZUGL/<X)RBFW+Y).;-J^&22AJLD9A_'A"UW-II2QA>KA:IC>KG
MGT&,KQ6MFEHJS7N31:(-XY4DBM>PYU.6MK:X3)>MD1?R";"RME>[VY<^S;LV
M<E[\Q@\ZXW<A9Q-9NGW%8$T0SD?:W"N^[,?16(L<7>G9'QQ>:D>;'KIF; PM
M$*?II"AI:-,M?2Y*ICA '>325_D+&S)F)M0283=6Y;I-=-[V?-M=^JU\[?MS
M$X+*^2EA6Y,5,/K*4;D7'>C:NKU;-2$ZISCTGA'(&:6;-5"0U2S.!C"F71UT
MC@4CHV'^6K'%$)(8!,4G >8"=K;;7=[9<BMRK<0=Y3\>B./4PLU_<*?J&Q:U
MLI'S!34Y1SO')H7!(TIL^K>)+6@?XHE@],V+&6FU'27UO8+8BKE(W-$XFS5,
M7U[KAU7JTD]:5(E/G>5MU[7;MF]EK7VI6S+$%=$7 FJ/@1-X,QQUQMWBA'(J
M<]5=.7]5%6F6MK_Q_<JAL",IY6@99,&,31B,?"WR,NRID<FA>K8EL2=#69NE
M)\H8A6ZN^>_BN6V?+NVK99Z7F'"6[+]N>+7U:)B.IUSMR(J^4R*&5+<$N;)5
M!J8IKC%RRK&+J45J19HAKFOM*5V;R*&KE2..EMS&WP "2-E2.2!:EBAV$W2O
M;/G:6>:Y.KEOU$D;)X=LS=1K755')%!"]3RUXI<BIL_6).YC,Y/,553\K*'M
M^R))*)W-'&62R22I57]6*&>.E.CB:E+ UQF)MXV2/(4);<">=W\V2[8M++I?
MYFT[-@U[-R^<3RLK*?;#V^IHTUHN.5@JZ^A55M3 !QC22>*X'8T#JIMN]BL5
MUBR&2JXJZ32RYG$44N?1%*&9F9]-*V*B%;*^7/G?ESV]&SD6^]ZW8WPEY.5G
M%I:* 16M5@K6JWEE3:*MI':T@7IZ(8[ZLTFQJ^>7.QG.'.K[;);4Z.T\?+;$
MH*%)U#S(&EHC3O,&]H$^G/\ ,LVF\WSWLKO+IR7(N]$@ZQICDLEY&PA;;M?Q
M23T?0A((7QK<FRWPIRX0SMU;&P-;=<LK@4!VLF%V3I$I?HR2>IF2=@K6 2IQ
M88NWF.[G,Y)+A6ZWN[VY;<[[_P O\MXV/PPA5D<G*QY+.,ZN1J=*]CLR:%$1
MCU\\A8Q%WA>_+*P4L:M%&XG;\?A$=9&\%=G%S*(((8;'K7.>$RJ?I'<]D3"/
M#6=K9=BOL:VVORY9Y<AJ+E_QONRRI+=AU2MD*>VSE!P]=>(<O<);*E<=,J<X
MUXL4UELQ,UIX\]>[5F*9[BFA[W&T:QF>%3O%X@V)31-[ZZO48$II6O?)WRY=
MEUMYEWG(Y2\?IE<HX8<OXP4M=**!L=RUY%D<_M^5QF1LA<Q25T&#V:TO;9&%
M+(U%GJX>KW,T/F%UL*&JDD8D]92DUP2/+*\"$[)YO.W(N?VY\TS)IAQ-D$_B
M?3YAELJXO>I7&F:LLCO%[L9$4[$V6XL?$*[Z9%,Q,#PB=43V^.UK3N-3#:5W
M[OD.]*GLM4)S:D@#1-UY65M965N3RD^RR:*TW_@H[<8*MXWRMTA%0>YNJ*CX
MDQ&^8,C;'XR#719%7SJ5N#P99R^)UM*S11IG=YK[O(W8TTB[@Q-LV9&;W5#C
M# L<9&V0MBZ!K-MY\K:WJ^[-;=EEV9$BJ1X[26Y>FE,ZA*K"&UX3:O)"Z9RS
M5F82\-D 2U2\<[)/9S<C9B'J(1AS,ATBK%.%?#]J81&DKTQ.K,>F8&-K<4Z1
M)*\?3[?D);=NRV?.DN^^WG,6LC@'>#UR1!,X'"Z>AM=QF](W-(@*(%U="FTF
MJ&WCSJFRF<2)#1B^X]V$@5K71H7M!%SL5/\ V."&XAEC)CL>L:B@NK/:VURW
MVWV[<URV:VM])V40Z<$YK]70P8+&ZHAS9#*IZ?S#9B6,FEL89)87&F:6L_69
M)%1;;'D^I(XK&^<I-,LC=Q>=WU2>XA<!H^[XIP.5]^V3^\O:YKBG.G3>\-@G
M'MJ*J>B*E<J*K_A' YHP0";&K6KD!(>/-]5U;,TLF2N!%>L0DZE S1.3IH8;
M(TC])G.1V?/2'A2E;DR%ZDPERNWFW=NU]JNFN^ZO;=R\F9UKPYOZ*)45IG\9
MJ(BU_)^0-9WG-00*QF&/Q*6QB&(IO$VJD*Z):*Q:R89%ZSB\]<G6,K)"2I-G
MLN]TLDE2IG>9HJ/:Q&MMY<FL]N=L^[>[<]CH ],FR9S'+>66] J,>9Q.F<D4
M7+/<QS!##G=[ZDW*'EQ+T#+(GJ%MCDE1FUQ;4$;RWE*TM:YU?FM:@4($"=&4
MH.!RV6NO]$O2GD?V^.G1=\C66=%*SA5*HZJF4CY0+8.R(B*N:3H69=4!X^L3
M*4J2V/1-PQ^+5R\OD#LESL5)5479K0&\JXRX,4EVE=Y&!,)4DLW>^6:YF^2Z
MN]FU\C,UIK@M=46MB.R&3UK3K2\)^1E2WV\\DVN9&N]L"C,"XI5]2LFJO2(V
M$)GM4=+I3'I$R*.V8%Q$^O)1(WQ62"4&%,KV]NC*V7MRL.2:VO8\N2[;>_DO
M?9M[2-'\(._[(W_CW_Z+8)I\O5^9-.X/Q#UH?W2$T_<Y<L$1_M%]-?B,P9_N
M2U_V<B_1BLSQV+H7H.++:^E^D[')(---7XP3AC\77+?]7JGS'4Y.O\C+3V2Z
M8^B1.R\[J>X+:M,5O'^Z3J1Q>\;KG2GR=*H5*ZMH&/19.]1QE&M+-3(7J1V!
M:]7)3' TDX1$7(E)*+21T4M[JVXS);)OG2[;^'MRQ?0]3%$EA:^6V!3[=5(C
MJJX_7C$TUBW_ $Y#&5[K3D6IL)!$MO$VF#O&HE&9ZSKZW>2GV%;<W<HTAP9S
MH_(7PT3LE9Q+B^3/-K)/DM?JS\4CF3;F/:<UI*C[MH=/2Z6%R7E=QTJ6U7<F
MU8I=BDB(61RDI.E'-DK]QJA0_P!?.#\_-MBO1CL].TP3*H(F:BR$T9>GA]3.
M,7$);[K)M9<S,TN>\>4D%Y(2V#0V'U]*X@+A1R<N2DH$V*'IPGEEW)3KMQV0
MQY',G!4A9D$7;'E]M9TA;+%HVH>AJ$I.Y8\2G:MX01F("4DUGEY44WN3UK^C
MVY8NP/G):*!?,4JN?.ML1JH_06L";2Z544[4>[/3!RQM>U*"M. $QA_9&18D
M1TV\Q=LL^,N:!O,?3'!J>:AEC\^/+'(%XPME??=+/9:SV\M]G7?<75X*C &
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M"Z,V/ K58T+D%"D/6P]'$3W,*E[$ZN*T1N?M=?Y6ZR36"!@# & , 8 P!@#
M& , 8 P!@# & , 8!$+J#?@$<WOS0N2O[&9I@M#SX_2CZ4?,"0_]"1_U5/\
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M1N"5&ZEM3PK&W*E*!:0G6:)..2*2P")&*MVDVMJE==3-6%=- D@HLDKG!SE
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M9T[T!H:3<GH^BW)MMZU;-MW;_M>5G^O_ -,IP(_*KR\^4RL?J4RW^U_W2/\
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MH\Z*VT:> .$9^UA1':%I4V-IZ0+N]^7;L1E;=3B5/>.[E7.(%6X_42:G:X8
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CZ]Q?G/\ V=A;3Y3Y3YI;_P#IGE'@^3_Q?PO%/\42DEL1_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>g947560g60u79.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g60u79.jpg
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M @,! 0             ! @,'! 4&" G_Q !7$0 "  ,#!@<+! X) P4!
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M"@6$PJ'"D.EI--155URI#$KDUKK?KU'SDCB.;+9/';!#B;8$HKH<FNO@K1'
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MX :3ON6NBI50Z6-.C74MYQ\/%B3!\ZVI7K:0G0F7PUNB^BR9"A04 H!0"@%
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M+?(%D=YNM*10%%9)]\=URP&.'!APTG2E;KE@JT6";I5])G#0J* 4 H!0"@%
M* 4 H!0"@% 0W\?#Q8DP?.MJ5ZVD)T+R^&MT7T63(4*"@% * 4 H!0"@% *
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M73KB=+N6)U><1Y.2RV8O0RL#@*:PS%RQOB'CEE;E0&/T*;^Z1;'.;-DP5M?
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M%10"@% * 4 H!0"@% * 4 H!0&,FE_Z*&OOS6-/ZN"H#)N@% * 4 H!0"@%
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M4*%10"@% * AOD3Q\>M7T:^P7\^(TH67 B\:'JC)D*%10"@% * 4 H!0"@%
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MD"3G P"K=1[F$((NJ7P"'Q5^-Y,2BHZJE7I1-N]N^F+V/!7N]WZME2AC% *
MA:X_4?N!X<,C9-P)DL2)'Z-'4?*SJ6VDQ#B0D$)2']L$,@C(#[6!TDZX[L]*
M,&3"L:;S<54$-QGL2)=PF3Z,5&2C@O ^_AN3JTK^5KV77U1'GQD#C#;VW*),
MKGD&!9(>,*:[0"7C70R5$6=DB2YW5GKL.O$556@1V,U_QJVE5^K 1TBB)^"$
MF36.@&VH'9[,U!15"RB.)API1WMUBNHDDJZ2HW18XK72M"X/'+MQ);ZUS9D[
MQ-(+:1WFS6ZZ<"W2\\6VJQ0K[(1%[D,3XRD:RB.ZOB[_ &J]TMRX/>5VY90L
ME\E/O;*A,&C54TM*D6M4X+U4KZS9MMW3JY]#MZ^72[.KL^/M[>KL^.AB%NZ=
M7/H=O7RZ79U=GQ]O;U=GQT MW3JY]#MZ^72[.KL^/M[>KL^.@%NZ=7/H=O7R
MZ79U=GQ]O;U=GQT MW3JY]#MZ^72[.KL^/M[>KL^.@%NZ=7/H=O7RZ79U=GQ
M]O;U=GQT MW3JY]#MZ^72[.KL^/M[>KL^.@%NZ=7/H=O7RZ79U=GQ]O;U=GQ
MT MW3JY]#MZ^72[.KL^/M[>KL^.@%NZ=7/H=O7RZ79U=GQ]O;U=GQT MW3JY
M]#MZ^72[.KL^/M[>KL^.@%NZ=7/H=O7RZ79U=GQ]O;U=GQT MW3JY]#MZ^72
M[.KL^/M[>KL^.@%NZ=7/H=O7RZ79U=GQ]O;U=GQT!C&S.Z>_!V"Y]#X -5.?
M+I=GN[VT[/C[>WJ[/CH#)RW=.KGT.WKY=+LZNSX^WMZNSXZ 6[IU<^AV]?+I
M=G5V?'V]O5V?'0"W=.KGT.WKY=+LZNSX^WMZNSXZ 6[IU<^AV]?+I=G5V?'V
M]O5V?'0"W=.KGT.WKY=+LZNSX^WMZNSXZ _JW/E_>Y<_U\N?+_\ OK[* _:
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MU@^E&UQR$R[H%2"M@UW)!6U! ''##'3A\K""T*.E;DTMC=6MNI&6U"!0"@%
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M#(V">C(Q0^KJQ[,,++$HF)1$ZI'Q[AE2)0R:%"!S QQ]]Q$__#6RG[E^XO\
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MZ5I2ZN#J8Z\)?47;Z%]@82<,[:7L_5UG07PW!-251[-F9HBD@Y.$FDY9B9Y
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M8:Y0R7-6+F!B@]RXP8U@#1?+H&"PUP\LK!& ,_[@P.?1$"R_NYXXWZJ&(Y%
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MLU7EL^? G/#S6S@^J;6=CDCC;)G/[)V\L]::./@\8?R,:_U&1K\V#<Y6= *
M4 H!0%LYGBF.9SB>0X?EU$+.*,I&:2TTWNCFSAE-"-MY5)B '[X*A$P3/))H
MJ'?OLDKD#A0^DG2Y=1)&BQHL"-@"='79>8/Z;:;:NP/*;FDM@;%2_L_-"@P<
MX_*O&?-FSNPSS8,28N!*6SK&9F!H[T&RS3;E(M\\JW]KQCIU23TGOU5%SM;
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M.5K-UM$5-$CTXHF4]2.+2FO'^Y.%.;*?GB>'/7. "\:=.%&U7^TFDL=;;O\
M1M-C.AC% * 4 H"&_CX>+$F#YUM2O6TA.A>7PUNB^BR9"A04!&SQ;?T&7K\]
MVE_KK:]4)6/HBZF<6N0<84 H!0"@++0GXU!M_1_2]ZQ<#5BCQ6[VLS2^ _&7
M4R9FJ%A0&GA[*C^$'AY_)K<'^-U=K>W<\^'=I\W<H?KF3#R^=_%"YY([.>:K
MU?;1J\4 H!0"@-Y3V,UXO=\^=A,'V;C:OSO^53\(>=?E2/L9)N3(G$^3N:P=
M<1L.5K\[04 H!0$"7'#8VLRT0@%X;"RK=EFTMF[61TQV<3@E3GYP+@\G1RU#
M(DJMYNIE\K-(;7Q[L:,WXOOI:Q+-HNS#+F9ZHL(QAZ)QNCY+B\&E?3DK>EMZ
M:INY5VZC+;A,-9-:>KCA($Y)CB0E,SL5L.?>"?$,9+<-1E%S]$DM8*O6*&7&
M;ESS<+51&NXRA\X"75+6NHBK0RTF9F4-22SAD1%CZ%BTV[L6U<V2;T*B@% *
M @&U+XB>R:K-$Q6W*">,6-\E'6TLR0[K,?THD=C2:\8KA.3AB*>M1[)JC(RR
M:EIUH\<!H)I<CO")V@XUI3?:*<;]U%-("FSHNX52ZNI-MJB;6M)77X/2>&TM
MW"VX,<;@\;Z$W3'+-FUFD&CP\YX;ZB4FR'GG$"N<.&YIC)2#,(J4\2!$VKIN
M .=@AE GAF7"-6N6SSL+;HT)<.C [TZQ0X-/!1;-YL=].W5U9=?/_P &?ZOV
M_P!WJ^+GV_JH8QT[?LSZ_P#\//\ T]7^- 0[[.Y6RXG<*\N?Z!T[=N.6/_S!
MZ_?_ %6M5X,7N]J(C^]__OV,NU64P"@% * 4!QN%1E:T'3I;EE^G9N[;JQRO
M;](=Z?KM:]N77V\^7;^R_+!%B][ZSDZH/$AZB3?IVORZLNN_+KPSM_Z\\>JW
M7VWY6[>OJO4$#IVORZLNN_+\C.W[.WGCU6Z^V_*W;U]5^0'F8\3F_/B2[UW_
M &[&.._7:]K_ )N-7MM?KM_]K]=?;W<^> 4SR]E'L+":SSRXUE<QD=I/,'ZW
MD>3% * 4!2SY_,IW_)A>^JS5>6SY\"<\/-;.#ZIM9V.2.-LF<_LG;RSUI(XR
MMX/6'U9=;-:]OR,^WVD(=M^CRM;K[;]5^OE?JOR_-@W.5GT[7Y=677?E^1G;
M]G;SQZK=?;?E;MZ^J_(!T[7Y=677?E^1G;]G;SQZK=?;?E;MZ^J_(#^J 4 H
M##'B),>.Y(T;VC9<L282AN.EF'G9=U2BII&3B3&0GII2RO@NJ;9#S",.M-+&
MR!;%0:9,3 ^Z28@S?3\\3JD7O82KFMZY->W40[\)AK0OGNP_WY$TIL9+;J_"
M,].-A04GZINO7&43J+(6UI >6U60CKAN&65VW"DY,5SM2*6-WH4<\;,.5TA/
M6"22FJ20$HB\6%&JM:-7I*+4Z);*K&^C:Y#96H8Q0"@% 0<<0#=O:?7O:]M-
MENF5*%]-VM&<3.67=DW#J(^)VCLD]Y'EYQLD=M+#\29*CA+8Z,CH!%KBJZZF
ME7V=03KL)&U9 !3L,S& O"DU5WN^B3H[E7"CK75A>J8LQ7XYN_,2.?6R;=0R
M,?;&%9$(39K>C#/%6@.04N%A#+7V1B)T'QRTNFDS!G&")LBFC%$@Z&>N J*P
MI5+*99FC(6%Q:7"ZJ*JPBNJJKO6L,39MZ=K\NK+KOR_(SM^SMYX]5NOMORMV
M]?5?D,0Z=K\NK+KOR_(SM^SMYX]5NOMORMV]?5?D!&SQ;,K7T:>G*V77-VF%
MNO#.W9NMKS?KYXVY?%>_*U[]5N=[7H2L?1%U,X]<@XPH!0"@% 65A._+BH-O
MMZ^'_+MNJU[]NQ<#=O*U^5OCORM;]=ZQ1XK=[69I? ?C+J9,QT[7Y=677?E^
M1G;]G;SQZK=?;?E;MZ^J_*A8=.U^75EUWY?D9V_9V\\>JW7VWY6[>OJOR T\
M?945[92#P\[VY_FUN#;KQRQO_P!]U<_5E:U_\>RM[=SSX=VGS=RA^N9,/+YW
M\4+GDCLYYJOU]M&KQ0"@% * WD_8S>5K</A\V_O=>V,P6ZL<KV_-N-?UVM>U
MK==NN]^7;U]5^7YW_*I^$/.ORI'V,DW)D3B?)W-8.N(V&^G:_+JRZ[\OR,[?
ML[>>/5;K[;\K=O7U7Y:_.T'3M?EU9==^7Y&=OV=O/'JMU]M^5NWKZK\@/VU^
M=N=N?^-KVO\ ^E[6O;_&U ?M :C/&.W=UTE[8M6TW>,?[<QA-L(E':RVI,D:
MR/K3%2!(S"G=G,L>2&0F%MBGNW4*1&>ZP$UK%CY$B6"6R#I:*<:25 M<L,">
M&6"%TTDX:/4U$\'=6BNO6V_!XT)S^%JU"K8U2(&[LN=6HX7Q(LB2*^5C9%UQ
MR]);DQ[O)<NJK\G+Z[$RHJ1_F1<HF8)=OD6WD4)I:$EIZ?<GB(7S,&!2/A/@
MZEWM4KM5Z3N)%Z%10"@% 8#0)PZ(2U^F(&:T5YSI(KD;C:?+*B=&F24U&16Q
M!3-DMU$W@^FU%)13(@JQ JXE9,20#2FZUIW.,NBI)!OD%LHC!BDA1-72EU,<
M,:5I7=5^TQHD3Q\>M7T:^P7\^(TH2N!%XT/5&3(4*B@(=MGO&=PKYAT[>L'K
M]5X,7N]J(C^]KQ_V679K*8!0"@% * ^'"G^ V=//KW=]8=ZU@BQ>]]9R7A!X
MD/42;U! H#S+^)UXR7>SSC'']G&K7V]W/G@%,\O91["PFL\\N-97,9':3S!^
MMY'DQ0"@% 4L^?S*=_R87OJLU7EL^? G/#S6S@^J;6=CDCC;)G/[)V\L]::.
M/@\8?R,:_P!1D:_-@W.5G0"@% * 4!#/QI]T((UAU]2XHV-AB9Y4C#:Y.?<:
MK"S$:NTVGX/\THHW!R:TL/MZ+K?;[.5,CZX44F>JJ!S(I@K-\<4T . 7S &?
M'Q0M FW<TFK[ZW[DDV_088\$9!077-L@3)8EN1)9HW'DFW:4Y; 2WJ=(L8H9
M269=:<DR2U6H4UF=J[B+(DJO((@]70ZEXID"?(L>Q EDB!A!IZ@+1X+@J^]0
MZ2=4KJJ)745U-5>C9FH8Q0"@% 8#[(\.F$MII"S>\E/.="B"NIC"1)2AMI2F
MI(<*3:C1D[!'HRDV46**14,3@*2N"YW,CM-2:)Y=3^BE.$VJIP89;$2HFE14
MQJG2]5N]AC/Q\/%B3!\ZVI7K:0G0M+X:W1?19,A0H* C9XMOZ#+U^>[2_P!=
M;7JA*Q]$74SBUR#C"@% * 4!9:$_&H-OZ/Z7O6+@:L4>*W>UF:7P'XRZF3,U
M0L* T\/94?P@\//Y-;@_QNKM;V[GGP[M/F[E#]<R8>7SOXH7/)'9SS5>K[:-
M7B@% * 4!O*>QFO%[OGSL)@^S<;5^=_RJ?A#SK\J1]C)-R9$XGR=S6#KB-AR
MM?G:"@% * UM^(=HYQ=-O9OE%MEI&@ET:**!Q)M&\&CR?X&G"9(6;B477_"&
M[$35F2WT=S/+WMUD  @2&E6 3Q"MP3(&60H&(R0Q00I8J+6TD]=U*Q);,4\"
M4?AF:NJ.GFJC<A!5B"*X1.(SH=:OFRH=E*3YB:&5ELZ$9]OLWM+J>EN\TM+6
M6.9E53[D2Z0G"VP+I(097D'@*QQ:43=6Z[4EZDVB0&A44 H!0"@(;Y$\?'K5
M]&OL%_/B-*%EP(O&AZHR9"A44!#ML]XSN%?,.G;U@]?JO!B]WM1$?WM>/^RR
M[-93 * 4 H!0'PX4_P !LZ>?7N[ZP[UK!%B][ZSDO"#Q(>HDWJ"!0'F7\3KQ
MDN]GG&./[.-6OM[N?/ *9Y>RCV%A-9YY<:RN8R.TGF#];R/)B@% * I9\_F4
M[_DPO?59JO+9\^!.>'FMG!]4VL[')'&V3.?V3MY9ZTT<?!XP_D8U_J,C7YL&
MYRLZ 4 H!0"@(NN)U&'$LEAIQBUN'A+$6145-'W@7GPR_P RDIJ^X&N<)H #
M92&.MKD-38G(AC,3W3V6%"[8"-A!C)URHHM["8ABT+A5=)-[*>V]=9A_PF.&
M3+6F,_29,4P0?!"([I"C)9;*Y.S.V9F:8Y6=JHH/!CKN3=6V6XXOBF)4)M'\
M&\*L'5EL-DBM%E1%14PF!BDGC^(0M'$FDDXJ)UHTDM]:MM[Z[S8%H8Q0"@%
M* AOX^'BQ)@^=;4KUM(3H7E\-;HOHLF0H4% 1L\6W]!EZ_/=I?ZZVO5"5CZ(
MNIG%KD'&% * 4 H"RT)^-0;?T?TO>L7 U8H\5N]K,TO@/QEU,F9JA84!IX>R
MH_A!X>?R:W!_C=7:WMW//AW:?-W*'ZYDP\OG?Q0N>2.SGFJ]7VT:O% * 4 H
M#>4]C->+W?/G83!]FXVK\[_E4_"'G7Y4C[&2;DR)Q/D[FL'7$;#E:_.T% *
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M% 66A/QJ#;^C^E[UBX&K%'BMWM9FE\!^,NIDS-4+"@-/#V5'\(/#S^36X/\
M&ZNUO;N>?#NT^;N4/US)AY?._BA<\D=G/-5ZOMHU>* 4 H!0&\I[&:\7N^?.
MPF#[-QM7YW_*I^$/.ORI'V,DW)D3B?)W-8.N(V'*U^=H* 4 H!0"@% * 4 H
M!0$-\B>/CUJ^C7V"_GQ&E"RX$7C0]49,A0J* AVV>\9W"OF'3MZP>OU7@Q>[
MVHB/[VO'_99=FLI@% * 4 H#X<*?X#9T\^O=WUAWK6"+%[WUG)>$'B0]1)O4
M$"@/,OXG7C)=[/.,<?V<:M?;W<^> 4SR]E'L+":SSRXUE<QD=I/,'ZWD>3%
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MYN9Y" ?:)L;;IF@VXR)OFX'JVE\PG$-S53:O,U")W9TN2]K%1SO@%:N[%A*
M.*/NQ-Q&&I%D \6;8I*^+X^-1DBO3;PTEHK7HT>')AR)ZE@9YK&CO&?6]J67
MM^<V=X?EI48D,.V"D4N#"<VAM+-EO-U(KO5Q3R+D\Q#IA;Q54(EB34 UHN7
M*7& S3Q\Q,1PPK+I2D=&TZU5;JI:J4O9D9X.^/+Y2W#7_=^GC^I%"/N>R/IA
M]P\'?'E\I;AK_N_3Q_4B@^Y[(^F'W&.[WT?XSS^FUMSXN;.\/S!\M6+'3$"8
M"0A&;"Z#DU'>[6F]%44T0%>I@R*KXK#,2,"AS ^$ "3R. YDQA!@Q@93:P#^
M;:HU'2M<5CAL._\ >A<:[RG.'IZ#9O\ QU4Z<6WU+W%=&3^+'^<O</>A<:[R
MG.'IZ#9O_'5-.+;ZE[AHR?Q8_P Y>X>]"XUWE.</3T&S?^.J:<6WU+W#1D_B
MQ_G+W#WH7&N\ISAZ>@V;_P =4TXMOJ7N&C)_%C_.7N'O0N-=Y3G#T]!LW_CJ
MFG%M]2]PT9/XL?YR]Q_,$:@<:W7=L.AI,'9SAZ#I;NE&3)=5<G#!LWJ)O%U2
MN[U)ZN@,H,5?*=@"DAK"J:P2B>8(PY0E8( 8V;$PR'SKB7K+NNCN22O6"]!>
MOP=\>7REN&O^[]/']2*$?<]D?3#[AX.^/+Y2W#7_ '?IX_J10?<]D?3#[B%6
M;/8Z?$(GR992G1\;7:F@O677@<>[J!08ZE0@AA+)XF1(C8)!$R</F29*P*<7
MO@ .>."8YW$RN/E;*V..S<TOE8SHS+R5%D?(\O)4=DBM<ZV-VVR3IT[YV?!*
M@C2CEVN1#H4DPZ*T*IN+OG5)=-E'(63<ISX;1:5:?G(94,E?-S8((="!Q1*J
M<N*^L;JZ[+BV7]E[W@\K/6+_ "+)O^JO3_;"Y^?D,W_]/M7\0.!]B.1?\;^G
M@_<C^R][P>5GK%_D63?]5/MA<_/R&;_^GVK^(#[$<B_XW]/!^Y']E[W@\K/6
M+_(LF_ZJ?;"Y^?D,W_\ 3[5_$!]B.1?\;^G@_<C^R][P>5GK%_D63?\ 53[8
M7/S\AF__ *?:OX@/L1R+_C?T\'[DX*G[%KW85DU02C6V>LUBJF1-IYBX3'DS
M 6P!P 0N+</._3MB)8,3*^&5\<K8Y<KWQRM;E?@Y4^77/7*V3<HY*M4G(:LN
M4[#:\GVERK#:8)JD6VSS+-.<J.*W1PPS%+FQ:$3@B4,5&X8DJ/-9\U\D6:?)
MM$O^F?.2)LN=!I3X'#IRHU'#I+YI55855555K1/FCQ-QW$-(2D4ELOPW+DT=
M-(I92X\ SL(-<LGE0B@%QL\9&PQS%N$#A<3/'##'+/G>V&-K\K:9/1?<]D?3
M#[CLO!WQY?*6X:_[OT\?U(H/N>R/IA]P\'?'E\I;AK_N_3Q_4B@^Y[(^F'W$
MOJ$&LA(B.$XS! VX0TI/#7324 ,62S*S@4!Q5#":6,B"F"Y 8]8<0F .*(,$
M7R##%$SSQRRN*':T H!0"@% * 4 H#4@XK1$(7>38(LX$P<WM&O-/A>A\+0[
MFE'SCJ+N%$VR5CVQ=H75 "HH:0JD2N7MA*ER!HH;Q9&88R[>Z,*5OD,L+>BJ
M4I6-Q+5="J:6K'#56FLD+XAVE/%'W4;\K0@@[ Z9-+6IWOED.=H(ZU%<KBRL
ME)L<OQJR,UB:\ZB#E,M\X<]T;4(XJPA) #!.)N8Y0#O082QL(5ABAAOI$XJ-
M8JEZ:V5P?27"\'?'E\I;AK_N_3Q_4B@^Y[(^F'W#P=\>7REN&O\ N_3Q_4B@
M^Y[(^F'W%FI^U&XV&R$8*422%LYP\P&LJN:-W89%;D&S>FJUE2+9*:,JMK$(
MV;?2D!@4$<[*1PU0+(IGF:2\SI0$4J,.&: !.6M4>O7#K5-A\_>A<:[RG.'I
MZ#9O_'56TXMOJ7N*Z,G\6/\ .7N'O0N-=Y3G#T]!LW_CJFG%M]2]PT9/XL?Y
MR]P]Z%QKO*<X>GH-F_\ '5-.+;ZE[AHR?Q8_SE[A[T+C7>4YP]/0;-_XZIIQ
M;?4O<-&3^+'^<O</>A<:[RG.'IZ#9O\ QU33BV^I>X:,G\6/\Y>XIMM:,\9M
MJ3H3V%3-GN']D_",3."&0 #4)38*W[M%RO!JO=1%S3\'H$:R6<5EGI.!8[91
MQ+A$LC@&9(00; <&&V\2R^:2:2CO:>*U5Y.4R-\'?'E\I;AK_N_3Q_4BH'W/
M9'TP^X>#OCR^4MPU_P!WZ>/ZD4'W/9'TP^XCQWIX0O%8XA:M$:U/.TND1(Y"
MI*0R#/M'\23"W@10),%8XKCNLX*CB<.1T0/*/T+VMR+YDK%K9J%AL3-S 5R_
MJ<T<[\JYE95CROD>&R1VN98YUAB5MDQSY/S,Z9)FQM02YTB)1Z4B#1BTVDM)
M.%U37"RA8+)E*S_T:TJ=\W\Y!-^YQPPQ:4"CA5[@B5*1NJI6J5ZOK@M_9>]X
M/*SUB_R+)O\ JK9?VPN?GY#-_P#T^U?Q Z3[$<B_XW]/!^Y']E[W@\K/6+_(
MLF_ZJ?;"Y^?D,W_]/M7\0'V(Y%_QOZ>#]R/[+WO!Y6>L7^19-_U4^V%S\_(9
MO_Z?:OX@/L1R+_C?T\'[D?V7O>#RL]8O\BR;_JI]L+GY^0S?_P!/M7\0'V(Y
M%_QOZ>#]R/[+WO!Y6>L7^19-_P!5/MA<_/R&;_\ I]J_B ^Q'(O^-_3P?N23
MW2OAR\830V)%2%X1V@T*.-!7?KAD8T*^H9FA>6;.!S$D8BHX!'4UW()?!.Q!
M0B5RQ;(EF*$)D/EF8%L)CB'J'+N6;9G#E>WY:MZDPVS*,]VBT*SP12Y*F.&&
M&DN"*.9%##2%7..)UK>>ALTBSV6SR;-*4WYN1 I<&E%"XM%5II/157?C1&77
M@[X\OE+<-?\ =^GC^I%=29_N>R/IA]P\'?'E\I;AK_N_3Q_4B@^Y[(^F'W$@
M.K:-M<AQTH$]Q7M"C]E/-V*1A,6H&:+K9;,!96:8BX)*><27BM+JJ*X0%<-P
M#G3P1S D,1-)8(1? 8N8$%%72O>UIRTKZJ&2-"!0"@% * 4 H#\M:UKWO:UK
M7ROSRO:UK7RO:UL;7O?]=[6M:W._ZK6MV6M0'[0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H#\O:U[VO>UKWQY]&][6O>W.W*_*_
M;;G;JOR[;=5 ?M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M 4 H"*Q][(NB.FNG/V2)[DQ%QD;8[86&8W8<2:WILMJXN4521,R<E)Y=,0&F
MYG.9L4CR*3BRLK*A;O?(T6-B9" =W +V$[<$DKZM+8L736RWOOV?_P T]X?_
M ..5Y_TBJ:/8^AD7?C0_G0^\S$B+*09RB]AS#'FUSP46-)+727@U#RE"L=(:
M@:0ULK@<("G497;)142S60(F/=R)\J ;+"6R"'"P$QRQM P+C>"R<_*B<?HJ
MBG[AH!X+)S\J)Q^BJ*?N&@'@LG/RHG'Z*HI^X: >"R<_*B<?HJBG[AH!X+)S
M\J)Q^BJ*?N&@'@LG/RHG'Z*HI^X: >"R<_*B<?HJBG[AH!X+)S\J)Q^BJ*?N
M&@'@LG/RHG'Z*HI^X: >"R<_*B<?HJBG[AH!X+)S\J)Q^BJ*?N&@'@LG/RHG
M'Z*HI^X: >"R<_*B<?HJBG[AH!X+)S\J)Q^BJ*?N&@'@LG/RHG'Z*HI^X: >
M"R<_*B<?HJBG[AH!X+)S\J)Q^BJ*?N&@'@LG/RHG'Z*HI^X: >"R<_*B<?HJ
MBG[AH!X+)S\J)Q^BJ*?N&@'@LG/RHG'Z*HI^X: JC79YKTC:_07(3J&*F70_
M(<C%YN0P2*XD28Z\Z&4B+:P,4)89B8$RHJ@>,9ERN&>>)<++ ''/*V%KW O'
M0"@% * 4 H#&:65B1E"9HMC-E2&)'*0OQ9.$@N%5)M5O.=3.G8]=4!H"&1!Q
M<A8X4)D>]I-<!D[W M<T9, )]L1@P@10Q@(Z&SO\@/-N-]X-2:]T7"UG6B)3
MD;2^D\.YW'4I<0%T@75$983#@,29 FT]33C18Z2,A99!CEAPQ<,KXYVO4T>Q
M]##N;3<-5<^^A]Y?>")X5-AGLY8Z9>Q\]MYY-1K)3U5$24]2"$4FA6RLJQ]#
M(JJ7[O& AX*P&2JF'2@OM?D/D7$!_P!];"V6-[Q1K%4)I=6YJM*IIW^AF5W@
MLG/RHG'Z*HI^X:$#P63GY43C]%44_<- /!9.?E1./T513]PT \%DY^5$X_15
M%/W#0#P63GY43C]%44_<- /!9.?E1./T513]PT \%DY^5$X_15%/W#0#P63G
MY43C]%44_<- /!9.?E1./T513]PT \%DY^5$X_15%/W#0#P63GY43C]%44_<
M- /!9.?E1./T513]PT \%DY^5$X_15%/W#0#P63GY43C]%44_<- /!9.?E1.
M/T513]PT \%DY^5$X_15%/W#0#P63GY43C]%44_<- /!9.?E1./T513]PT \
M%DY^5$X_15%/W#0#P63GY43C]%44_<- /!9.?E1./T513]PT!#AQ#-R]Q]0)
MH;$:,>:D)S)*Y%Z*^3!]UQ*S,U$%14W6]4 8H#=(LF%K$@RS9*#!VS+YC]W,
M&;Y#9!W"P#$W:T^FGL9L-4(% * 4 H"$:6?_ (FD?TB_$'_@=^JM!PEZ>ID1
M<"+<OI0F1-9C 6$BH9U \+31"[97W^WR^34BGW4C,5&EXZ I-T./'8-BC/=Q
M:_*Z5-T>,TZX0T#,1^1U@K&4IREVRGNU'/1VKO'''CG*_M/#%XTV\MSW']LN
M9MT6,EGI!!9\L+S,3V8QDK*+WU&DA2[)*B(FQKL"JF'2TU\46$E=:-J*ZSHQ
MN DNZ/68_'.4<B8A27=GR*X;&4 **]:]M;M2Y>5NEVRJ.T;6SO$ =V"B EL9
MN)(" ZU<D XES6^8ARST015G3LHBF2A V]&9<D&2(SC.(QY22AE9+5+1%D.C
MJ9M,;;J6%00Z<O3RODW741EX?>FWJIKM=68S/9*O.Z7,3T8Z@7<_MU%Z.LL!
MA; .E@%7ZD(RFD/X0+-\1NW$EX@E1C=TT1)<9I=;"H=Q"04U1"ZO)3K7HP9;
MK=1<G1/3V9FTL))3%S. 9_5&R3A>S^748;<5/PAR^NS<<BDU44D95V(<-')8
M!S*28F)45KZ>5$-R$FE12:0$5!4]:QV7U]F%^I'\2\YY%,;61FNM Y*#A9Y8
M6+&D6BHJSMD6:VSYPU,TELN:)(-/YL.%L1(:+1XV"2&\CS=F!H/!(=+5:Z/@
MQCA&THME:5PU/#?5<EU+WT4Y<#I9MF?=]MO:=Q8R;;6.,B/RLKFH\13D#R*Z
MEIY7C?7&&):;10%TI$C)!)6'DF3W>_HP)71FW>_1;^:4BAG'6C*0N8E)75]-
MZVM;,<'NK@<R)-IIP>DA3&TEE,21S[5B65W\ALXM#LC-PTWW.TY6=3$9K9*/
MA77S;>F9*6T1!(G!EIA$B@"DL9G3Z>9)I:RC(R6(:^*UU+^?5J98Y\;9[YLL
MTF(J5&83Y<0$1O!?<7<=89?1V_F^Q-3Y7G1FY-PTD/UX6/(9674&/8/4$Y;5
MVTK*#@-KK230U%VJ2>HHHE).^M/2MJ6O&Z^Y4U[4<F3Y;W*2ID1&TJ9N%#;3
M"ELNA+4RL>!IN6V6Y6*::A9?]M52+FX]7"F*:65.NW-M&%@NHG0R2NU2JZIJ
M&"4GK*!D(V;GZ,?^>4[1D[/;9J#H9"*Z&6L1FN/Z3(\4'IFNZX[#/-E)4=>]
MRU=<[Y%2E(%S' (^<BU([O?<?M-F] -';2T4<SB?>1IP1X_,WR):6I^N_%T]
M23?\T=:>V_W@=#,!4X_B/)&<3?UF2)'>!9V:VS;D&=GI$AB0GJ]H@;Y!1<+1
M,#A&)+;C6893-,,.$T6NJ*2(0.JSB,$#A *);7>\&L+J/HKZ=EY53QV>W/9$
MHH$;^#_W7@I4V,AK.!X)6N,IDV@^XO=LE1:B.)Q-Q;2'J\0V^I,%E/%Y*"EF
M= --HE[F4UU+3JL1!5VL;$))UW-J]8I<NW4E?O/A L\;5E=+Y:7W@2<+CD6(
MM)&*^FJZG=#,C1R[5#80&))$//B,W,WY$-FU"15]E+C08*LLO)(*$4MUJLA'
M4\$D&,0$!"$T55RQ>JMWM+C827N(GNE:;$<)*"\6.7$>+-BQ4<<;NIQ*9U.8
M[2A-9:<ANR1UB962@/O%^8N>1B&9RZJS2JV>2D\ZEK)M21%P@XA%U/2M>J_D
MU>DHI>7]J;3)!2W)&#G,+P!F+DH_$$?,J=F4P5D!VSDX&X_W\>>D73L_XC+C
MQ;%V+??Z^SYB4Y"35Q%1!TE,(M@\^ \R FZ]+EOQU<J7*E2CWW%QV0K36R7S
M'",ZWO(;P.N+=298]-&7H4*)F#FAPY +]D,@8((J2C(;:*-]K.]DMW)I+J:D
MV$*D2A]MX+!Y0=JV:5A%U-6'KK3EU:KMI(S0@4 H!0"@,<]/?T2-6O-SA'^6
M;8H#(R@% * 4 H!0&-+U_2JAWS:=K?YC:?T!%SHA^@]IKYJ>O'\HF?6>'!;E
MU&&/AQ>-%ULR"UO_ $_I#\SUA?SI?M8X\5N]K,L'WM^/^RBP3:7]J!'19OLE
M>V'-.!=?<8J#LD-[-K8.R$UKC;1Q62<39D6%9$+",-NK12.%][@AG]6YL#@]
MRL=ONQQ.!GI[6SC-4,4+7:[TMC576^N%:88[KM53.3<_?%.%#((<(FE!?2X^
ME4!;(G];9C+)"D^6EK/,\F,AX-P\ENQ:Q.-5XR\R(^8&*"JJ+=/>V#I5& @'
M'0XQ4ITE7Q\;":+;==K5;Z=2;OVK49HPB_\ :8Y-1MDR^5;:NP;D=@0";G;\
M/O"/L03T7/B$DN.SXZNL/UY))G"1FY);Z, $P\"V"GA'=U%OC9 D7'CF#I2Z
MNK6M:?)J/J*O;IYP_MZ;7F<Q$22$E$D@75P)B.D5Y&5A3 C2YAF!&B:TQVD3
MN%[NL0<$\58N8.J1D=0)JB<13"*<:5!%U5?575K=KWEBP'(^3<%[#MAHO#89
M!;ZC*+4QA!_/6/-BGG)";#1= U>)3$J#B#XMV91;E'Z\I="(XFW,A/<B3+.L
M]'W<VC'@>:(%RIN?3?3DV;^6I5Q*0-F4O6^"L(X;IA)>Z_)4QL]Q+4A,R:90
M,XQVPF9LFY6%)1E ?T@%I2;^$RJT:Q4;0TN27NM*31)2DGL8<XMK@20*,)N;
M=^S8L:78:DW6[56ACX^=R]Q8X;S@-/=!;#?.HK=6G<AJ^&MTPK"8\#_@MU1=
MQ%AFDI)?APRQDE)>$URJSCTDKJH(AAJ##3$Y4S)*[8>!-?"B=*5O:UKEY*5N
M3IT&3FQ\T[,Q_(#W+Q^AXCQVCM>"R#<,$H,>DBJ!YZ26\)/+/A:5'*BOA')D
MFRR&RQ&T2&!2F@YE!"6'ZF*BR062QQ)1AA"2NKM>M*Z[;OU[*8F-8>RN^KFA
MLL^%F)@R1]>]K&.HQNB0Q-[6=R:K'-&TB?UJ0"B]@]4QX)*.7G_!5A1/1K(2
M8=3CINS:..8=[$\0[B6E?1[=:_&HO5>=2R-B]LFZ2915WH<E.YMM=7?ZR^'>
M%K?L'B]6&.0BW<M52&N=; 3B(^^ S-&V1#ED<,D4P;YE6<J!WF 75W[$RDV
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MS0JBYW-%[-6%=9& !*#.(P=0R8H;I%)%P@ " CI+W!<6:>$"#@0R4[D\0@[
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MJ=-CI B#62/Y$@&%G4E- !6;[ B]A"OB.DAUE6&T<U01%2RJ4BEQSA1&3P<
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M;74(NF&UM%+*!0=61RBU8[=&,JB<$+D;(%U:R:HW31C0(09ZQ Y<KD+WL-T
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M6$U5$K]ZVW_RZ.1'203HI/4;28SGBZ'0PCYA(66L.<D)/D-\GWX@L=FO^?7
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J)!.)U& R81I25S(X94,<R9&P+X"6!P&,#B8X6S%$RR&2!)IU2=^S<?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>g947560g61k18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g61k18.jpg
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M-=$2D/-5Q+=CV-CF20GW%WWN5#Z4(DN+)QO>SM<V>H5% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@(P>#Q[!)K>,)KE_/DU%U"T]<NMEI^$_5U(D^J2HH!0"@
M% * 4 H!0"@% * 4 H!0"@% * ^)CZG'_P B+_4RH",S@P=RKT(^+TS/ZAFA
M:?AR\Z76R3FA44 H!0"@% * 4 H!0"@% * 4 H!0"@% 4U9_>=5^UI[\E%H"
M-_@T=ROT(>+FP_R,2A>IX<N<DRH4% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@(P>#Q[!)K>,)KE_/DU%U"T]<NMEI^$_5U(D^J2HH!0"@% * 4 H!0"@% *
M4 H!0"@% * ^)CZG'_R(O]3*@(S.#!W*O0CXO3,_J&:%I^'+SI=;).:%10"@
M% * 4 H!0"@% * 4 H!0"@% * 4!35G]YU7[6GOR46@(W^#1W*_0AXN;#_(Q
M*%ZGARYR3*A04 H!0"@% * 4 H!0"@% * 4 H!0"@% * C!X/'L$FMXPFN7\
M^3474+3URZV6GX3]74B3ZI*B@% * 4 H!0"@% * 4 H!0"@% * 4 H#XF/J<
M?_(B_P!3*@(S.#!W*O0CXO3,_J&:%I^'+SI=;).:%10"@% * 4 H!0"@% *
M4 H!0"@% * 4!35G]YU7[6GOR46@(W^#1W*_0AXN;#_(Q*%ZGARYR3*A04 H
M!0"@% * T6XBFMDIP_\ 38I:ASD;FY6P(O1E,P)GDW2 SA3!AY*OG6$=R7#*
M$X@P B&5KC" ^=8N0]NTQ$"OVU?5V'L?%\(-KX#8N!E1CC-I8B.&P\L1.5.B
MJDTVG4G"%248Y.[C"3\AAB<13PE"KB:W&[W1@ZD^)%2EQ5K9-QN_6B#IF^29
M7!(CI0F0Q.'D\'<[W.H I3?;;?GXDIK"NH&+W\J*DB)6&!!AL^QQS$$O;'L
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MY;WQZ\^5^G+ISZ]?Z* =ORWOCUY\K].73GUZ_P!% ?VV^W/;?O[=/Z=Z _M
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M0"@% * 4 H!0'Q,?4X_^1%_J94!&9P8.Y5Z$?%Z9G]0S0M/PY>=+K9)S0J*
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MT(^+TS/ZAFA:?AR\Z76R3FA44 H!0"@% * @H\D8=S0=/WZX)^7A.N>=R_\
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MP)"T]<NMD3\)^KJ7-U$JNV?ML>OM+]/!ZOK[O]%25&V?ML>OM+]/!ZOK[O\
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M-'9;J2@H!0$8/!X]@DUO&$UR_GR:BZA:>N76RT_"?JZD2?5)44 H!0"@% *
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MX9F<BP&65A1[%\! \A[A8YV"QSPR$[&V6-[@<8%0(*B<(=3#Q-1)"AFL S9
MR"<*B9@9"EQ\,#!?,0+/($<(4 7''.]PQ@Q \[8YX98V C8X,'<J]"/B],S^
MH9H6GX<O.EULDYH5(9V5[(_B!>-HW?S,](M:PT?/V(SJ:Q\WZTC-%7,Q0"@+
M2TZ=T">GB=-GYZW%64]5S=K-8:/G[$2NU0N04>2,.YH.G[]<$_+PG7/.Y?\
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M*47.,5:%:+<F\5:>=?;=T_*:^J)T#8KPBJ^8DG5/)XR3=#3$74A#@DE9MU\
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MV[/RNV/;WMV-K<]J @!A&>YQUKS?#,NM&67RH0A%+];3'=#J@9JR4A--ZGE
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M0XKF@ K  &50R7!#&4# (%K A#&\QA PK6#PRMA;L: JE * ^)CZG'_R(O\
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M/%S8?Y&)0O4\.7.294*$,$?^R%U_>-V0_-,TK5K#1\_8C.IK'S?K2,WU<S%
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MM:W+IT]_G6E/E]7:4JZ0YGULRO6AD* 4!CF.+;\1C3USO;;1SK9ORVY_VX]
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MV=Z=A/G%,];)J>M9M?:!'^+BU>:1W45^@% * 4 H"FK/[SJOVM/?DHM 1O\
M!H[E?H0\7-A_D8E"]3PY<Y)E0H0P1_[(77]XW9#\TS2M6L-'S]B,ZFL?-^M(
MS?5S,4 H"V--_L^I!\4!C?/.^:RGJN;M9M#P/TI=425>J%B![R1OW-9:^_K!
MORLRKGO<N_&#P3_.]#Y,SY6W/%&T/1JG8=#"O1,Z<% * MQX^M%T_<XN?%AJ
MN-\,O>APJ^#>W/HO%'[ME^,MG>G83YQ3/6[;W[P(?VG3/R("O-,[J*Q0"@%
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M2TZ=T">GB=-GYZW%64]5S=K-8:/G[$2NU0N04>2,.YH.G[]<$_+PG7/.Y?\
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M#M_PRU:?Z\2?Z#URK_J+P\_G?PA_O7%_YI^#[T[*_DS _P!FI^P?V,GP[?\
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M*U[QMKHT[W3NM4N;UDL[7.2V[=/,W$%M5>:P[333?">Q")6/UIKR0D>;V4:
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MP(044-.1D\HED Q1Q+BCB8%"((!? 087+(07/$.V0@F5\\[Y97O>@*K0"@%
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M^=4$D_B6.%S!0QD4-BV!,@# "7Q%"SPQ NZ@% * 4 H!0"@% * 4 H!0"@%
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M?"%[EYH)\5J(/DDGT+3\.7G2ZV2,T*B@% * 4 H!0"@% * 4 H!0"@% * 4
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M * 4 H!0"@,'ZF(,0=3FGB;M.SG5#Z$@3;%KWC%374H,(930B[R;Q]#LMIX
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M>O0F?AR\Y]9(SV6/ML>F_6W2V^]_>MM?\%Z%1V6/ML>F_6W2V^]_>MM?\%Z
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MF$LVGF&:(;P$*X*@)D$]ACED!F#>V56FG9EE9QXRO:]LU;DOR-F_M0!0"@%
M* 4 H!0"@% 1I:W=#.G&:5A=U$3?-DZ0LG-R/HY;SS4XREN\<M,^WX8E!;F&
M,U%R$,4%6S55QI26XQUQL"AYY&_/FR6 G$Q3^(.(PE-Z+J7+ER[S;O36:8QN
M$6$+&TK.N;F8&252:3)[Z<X[Q>;E%3W KD%?!T. V13#IE=0ELLHMQ2)J"<1
M448TD"(J@4+G4\<+$'>^>OVW&<J$$7?!8[EMHV^]F?\ ELZJ$RU?.^LE$H00
MSM3V57$:\:Z-/]WYH@K2GR^KM*U=*?FR^7(S16AB* 4!9T!=T'.>)LK_ #VM
MFLIZKF[6:PT?/V(EAJA<4 H!0"@% * 4 H!0$3NL#0SI<//=T:L)@U':DX'S
M.O6-7:HCQG,QQE-4*2VHTPXD8#A0VRG-=:43+XS;J@(W262;8ZIF\%$V&7+V
M#%$QP%DWDES:+GY?^"22*C;;/QA')UFO0[)#1-,1I#M>0E)=P="D^F^(@$,D
M=X*+D#P#P<"@Y4^Y=9.K6(8>*H:."G;!X>7]C85*'/O\!,U?>ED?Y'+- :Z<
M,/N;?#_\2S2]\RC)H3+5\[ZS>6A!"K#?K^U?>.-,OY.U:UAH^?L1G5\)>;'J
M,]5<S% * M_23[/'5=XH^B+YY-?-93U7-VLVAX'Z4NJ)*A5"QUW?),OL"(O\
M;:-OFQFJNS.X[^,G@OZ1COHG'GQN$/B7:']53^<43HXUZ"'4 H!0'T+_ %:F
M?;A&^-2=<-[HGO$X7_!W:WS.J?5V'XXV;Z71^4CUK*\X3N,4 H!0$2FKC2S.
M&H?52U$9,:#8;.G%S1X2194EU \[AGLHF4@-]K*8B/-ON>2S+#?A!NNXM'HK
M(;;QTO2N"E +CR<C;E:*76523186327EOIT>M>6S7)JB16#HXRB&)V3&N8+%
M!NSTH1)M:-F4/';,&#P/&QPCB2S3+C=YA$&/!C8'5@(5RK&9M;,*2A<YEYK[
M# 5?VOF7B\_6>[/N:7?BLU0&A?"%[EYH)\5J(/DDGT+3\.7G2ZV2,T*D+T;?
MPXZZ_&]4?S>]/-:PT?/V(SJ:Q\WZTBAZIV%*,GQ(KL.+RD;*HKJR-(3T09,<
M,D,I.76.KHBPFJ9%#?L5BBNMF. %1-I"B&I@HK@**:025VR.23\ET)?1[25U
M96]?9Y2L&HN[NK;K:^5/5?\ )IS,>A:<)LTGLS3&XIH:B*%%D<LM 0EM&:I4
M9#EMWMN'#++N:D]GFT3!+:S;1'\."[F84:5UG)(-);?<=R.+@;J2$!5QDU9M
M9:9=?-_R752,9N2B\V\FV[*]\G=-MK6[\A(5#;.7H\B6,V$Z%X!T.)EL1JM9
M:<)8F$GEE=1040DF&CQ8D "7#+EAA2V60&%@ <O*NPR$"P$RRQM9*R2W(S;3
M;:5DVW8N+3)[/J8O% A3YYYSK.>JYNUFT/WM^?\ 51*O5"10"@% * 4 H!0"
M@% 11:SM,TY:@M2L<I#:9K92(&<4<EF?+TPHPA#"0\DZRF_U \SW2F..2L6*
M]&<@BFVNL,)EOS3/J&;A]QNE\G//"(54JFN\<6327EY-W)NSY\UR+/,WXT^Q
M7>$H@9T6WP8EO0B$L%<1(V8PL;M,X&><2NKA*0#.&<CNS3EM4#4,%%WG+. Z
M&O.\TNN$$)/"5<$TF(;N[]?V1F6A!%WP6.Y;:-OO9G_ELZJ$RU?.^LE$H00S
MM3V57$:\:Z-/]WYH@K2GR^KM*U=*?FR^7(S16AB* 4!9T!=T'.>)LK_/:V:R
MGJN;M9K#1\_8B6&J%Q0"@% * 4 H!0"@% 0[:B-'TX:B]6CP3E%J,UB:;G$W
M$ ^HR,ADB"V:?KE:C;;YEL&)58[FE57:#_<*,\TRS;3@#&FY =[5C9(2UJ/]
M5;4<.5V< +77%7*[Z=/+9-+3).SY42HQBTLV%'#"8PA5GD<F:SFVUO,4>M<9
MD,,I9 2":5B69C,,++C':;6 Q*XAH+;%<"X(B)F)9-S5U*Y:YP85>;;Z\WZR
MW9]_@)FK[TLC_(Y9H#73AA]S;X?_ (EFE[YE&30F6KYWUF\M""%6&_7]J^\<
M:9?R=JUK#1\_8C.KX2\V/49ZJYF* 4!;^DGV>.J[Q1]$7SR:^:RGJN;M9M#P
M/TI=425"J%CKN^29?8$1?XVT;?-C-5=F=QW\9/!?TC'?1.//C<(?$NT/ZJG\
MXHG1QKT$.H!0"@/H7^K4S[<(WQJ3KAO=$]XG"_X.[6^9U3ZNP_'&S?2Z/RD>
MM97G"=QB@% * 4 H"VGGZSW9]S2[\5FJ T+X0O<O-!/BM1!\DD^A:?AR\Z76
MR1FA4A>C;^''77XWJC^;WIYK6&CY^Q&=36/F_6D9QJYF* 4!;&F3V?4Q>*!"
MGSSSG64]5S=K-X?O;\_ZJ)5ZH2* 4 H!0"@% * 4 H!0"@% 1=\%CN6VC;[V
M9_Y;.JA,M7SOK)1*$$,[4]E5Q&O&NC3_ '?FB"M*?+ZNTK5TI^;+Y<C-%:&(
MH!0%G0%W0<YXFRO\]K9K*>JYNUFL-'S]B)8:H7% * 4 H!0"@% * 4 H!0&)
M9]_@)FK[TLC_ ".6: UTX8?<V^'_ .)9I>^91DT)EJ^=]9O+0@A5AOU_:OO'
M&F7\G:M:PT?/V(SJ^$O-CU&>JN9B@% 6_I)]GCJN\4?1%\\FOFLIZKF[6;0\
M#]*75$E0JA8Z[ODF7V!$7^-M&WS8S579G<=_&3P7](QWT3CSXW"'Q+M#^JI_
M.*)T<:]!#J 4 H#Z%_JU,^W"-\:DZX;W1/>)PO\ @[M;YG5/J[#\<;-]+H_*
M1ZUE><)W&* 4 H!0%G2&Y%IG,-Y.QMLE=DEPMML+BVA1ZV#:*0<+W6$Q.,&T
MUJHIYR**0WR2FO' @4PF<6E0@EE1C. YTT"7#$SL'Q?;R$:9#BGZ>0H5D5R:
MHW-'NE)>195E_3L"FNF4D5X,UZ/R-6RVE-SY1C(:>E(9)[)B,*]"#:7AL$1+
M,(;X1W2UC9;,PAYFC MQ&_!3>5]-.3/[,R%PAL\+<+W03:^6-K_2M1#?;LK;
M[6:1#>_7O;7W\&U]^EZ"?AR\Z76R1GL\/;X\[7O;MK<[6WWOUZ6VOO?O;7\%
M"I#!&U[7G'77>U][7U>J%[7MTO;Z7K3SSK6&CY^Q&=36/F_6D9QJYF* 4!:^
MF7+&VOJ8;7RM:]]'\*WM:][6WM:9YSO>]M^]:W._@[]93U7-VLWA^]_I]B)5
MNSP]OCSM>]NVMSM;?>_7I;:^]^]M?P50D=GA[?'G:][=M;G:V^]^O2VU][][
M:_@H!V>'M\>=KWMVUN=K;[WZ]+;7WO[E_!0#L\/;X]-_56Z6ZWZ]+;7YT [/
M#V^/3?U5NGAZ]/=H!V>'M\>F_JK=/#UZ>[0#RS#V^'3?U5NGAZ]* =GA[?'I
MOZJW3P]>GNT!^K7M>V]K[VOSM>W2]O#0"@% 6X\'0G,=HNEZ+!=8-I+0;BVZ
M%0JWD15<R^93D!,-*QTNAMQ"*'UMP+ Q8H*&F(B.1.*JJ=R ()Y0P;, @Y@:
MVP5K0A^<41\J0H+IA=;C1]EHX?;%GLDAQX\6XZ5%AL^3T8F:*V<2PBF;+#!?
MC5<A7%.7#IHH IY$%@LF+!%032HEJUM'=75MUVNM&M_!6O;+A:Z-<L;VRQRC
M(]?'*U[7M>UWJZKVO:]N5[7MSM>W*]J"6KYWUDHM""&=J>RJXC7C71I_N_-$
M%:4^7U=I6KI3\V7RY&:*T,10"@+.@+N@YSQ-E?Y[6S64]5S=K-8:/G[$2PU0
MN* 4 H!0"@% * 4 H!0%BR=(*5%,>O&2%M)=B^E,M 4' <0F(UEAZO-9P( Y
M"8)38:B 6-JRZMJ OE91/(% ?W0P+AD.,6+8C&0@-0SFK6)IRTN3ZYRHRO&2
MDWTN>(D=+$E_%!9[V;<C,-LFRSE:YPH67UI"5#9+!61S>!MKN!P)8Q96)6P/
M>:LABP EJWK5US%1X8?<V^'_ .)9I>^91DT$M7SOK-Y:$$*L-^O[5]XXTR_D
M[5K6&CY^Q&=7PEYL>HSU5S,4 H"W])/L\=5WBCZ(OGDU\UE/5<W:S:'@?I2Z
MHDJ%4+'7=\DR^P(B_P ;:-OFQFJNS.X[^,G@OZ1COHG'GQN$/B7:']53^<43
MHXUZ"'4 H!0'T+_5J9]N$;XU)UPWNB>\3A?\'=K?,ZI]78?CC9OI='Y2/6LK
MSA.XQ0"@% * L&5&"#*L:ON-##J>;'*OYJ+C1-NZ.U@!NOMO$W GCIAM4:+@
M,$%3!"<!8L9%R2UC B.93#7E9TGY4; !&#!9>7G->X%TJLS2+IJ/P4S'>_GX
MQVHAK_H/QDX9DJ"@TD:S:+$ 6NA793'8J4"A #)PZQN:23:R;7%I;4E)7.B'
M<<0!+=W<Q1PA>Y>:"?%:B#Y))]"9^'+SI=;)&:%2%Z-OX<==?C>J/YO>GFM8
M:/G[$9U-8^;]:1G&KF8H!0%L:9/9]3%XH$*?//.=93U7-VLWA^]OS_JHE7JA
M(H!0"@% * 4 H!0"@% 6D_D=T.%C/) 8[NP8#S6VLOI#3?8B 5=6++<BDE&B
M:(Z[M@\<3R+ANWE$8LK8HIT\5)J>12Q(T.& ,)E8".Z .&!$C/@@O!VJ]+AG
M6R73I$79/).V5-/J!==5'R[$\J7>#^?(SS=DJ''G)KL/!FS:V^S2F0-9IPY%
MM$$X@@(J62 A9?;?ZV6XSO=-K*V3Y-V5LO(<3@J  A<+/1F$$"&&$'%YP(,/
M##''# (-Z.G$,/'&UK6MAACCCCCC:VV-L;6M:UK6J2):OG?62C]AA[3'G:UK
M]K;G:VVUNG2VUMK=[:W@H00TM2UK:JN(U:UMK6U71G:UK=+6]+\T0<JTI\OJ
M[2M72GYLOER,T5H8B@% 6; >..7$&.;VM?\ N-E>W.UK\OHVMB^W/W;6O[]K
M>"LIZKF[6:PT?/V(E@[##VF/.UK7[6W.UMMK=.EMK;6[VUO!5"X[##VF/.UK
M7[6W.UMMK=.EMK;6[VUO!0#L,/:8\[6M?M;<[6VVMTZ6VMM;O;6\% .PP]IC
MSM:U^UMSM;;:W3I;:VUN]M;P4 [##VF/.UK7[6W.UMMK=.EMK;6[VUO!0#L,
M/:8\[6M?M;<[6VVMTZ6VMM;O;6\% /*\/:8=-O4VZ6VVMTZ6VM^"U .PPY]I
MCSVW[6W/;IOR[W>H#]6M:W*UMK>"U * 4!B^:V:^I#B60F+&4G&H7?CN:RHW
MVS*Y!N%':I,!15 +E/1.DMX\I)!)06$P 489(\UGPBY52L5.C!F@RV10<2LG
MO(U3?#2@QGZ'52)-13'@S5*IPDR)O<<:/AVP(AIRFWU)X-VRZYG%GB['/*"T
MH2([74CXNM]2*<= C@>B_F IK%\SA,,<03QFFW%N-]S^+*V6Y&R?##PP]+;X
M?]^QQW^DLTO\^QMOSA1E;][O[WW\.]"):OG?6;R]AA[3'I>WJ;=+[[VZ=+[W
MWMW][^&A!"O#5K6?NKZUK;6MK&F2UK6Z6MYG:O*M8:/G[$9U?"7FQZC/57,Q
M0"@+>TE8XWUXZKM[6OMI'T1VMO:U]K7F/7S:]N?AMROX;=:RGJN;M9M#P/TI
M=424_L,/:8\K7M;M;<K7WWMTZ7WOO;O[W\-4+'7>\DR8XVT$Q?MCC;;5K&]K
M;6M;E]#*:K[<N]OSV\/.NS.X[^,G@OZ1COHG'GQN$/B7:']53^<43HY5Z"'4
M H!0'T+_ %:F?;A&^-2=<-[HGO$X7_!W:WS.J?5V'XXV;Z71^4CUJNPP]ICR
MM>UNUMRM??>W3I?>^]N_O?PUYPG<8[##VF/*U[6[6W*U]][=.E][[V[^]_#0
M'ZM:UK;6MM:W*UK=+6\% * 4 H"VGGZSW9]S2[\5FJ T+X0O<O-!/BM1!\DD
M^A:?AR\Z76R1FA4A>C;^''77XWJC^;WIYK6&CY^Q&=36/F_6D9QJYF* 4!;&
MF3V?4Q>*!"GSSSG64]5S=K-X?O;\_P"JB5>J$B@% * 4 H!0"@% * 4 H!0$
M7?!8[EMHV^]F?^6SJH3+5\[ZR42A!#.U/95<1KQKHT_W?FB"M*?+ZNTK5TI^
M;+Y<C-%:&(H!0%G0%W0<YXFRO\]K9K*>JYNUFL-'S]B)8:H7% * 4 H!0"@%
M * 4 H!0&)9]_@)FK[TLC_(Y9H#73AA]S;X?_B6:7OF49-"9:OG?6;RT((58
M;]?VK[QQIE_)VK6L-'S]B,ZOA+S8]1GJKF8H!0%OZ2?9XZKO%'T1?/)KYK*>
MJYNUFT/ _2EU1)4*H6.N[Y)E]@1%_C;1M\V,U5V9W'?QD\%_2,=]$X\^-PA\
M2[0_JJ?SBB='&O00Z@% * ^A?ZM3/MPC?&I.N&]T3WB<+_@[M;YG5/J[#\<;
M-]+H_*1ZUE><)W&* 4 H!0"@+:>?K/=GW-+OQ6:H#0OA"]R\T$^*U$'R23Z%
MI^'+SI=;)&:%2%Z-OX<==?C>J/YO>GFM8:/G[$9U-8^;]:1G&KF8H!0%L:9/
M9]3%XH$*?//.=93U7-VLWA^]OS_JHE7JA)C66)GB&!VD(_IOE*/8?8P*@121
M7E)SR;S%:X:JIY"8IR:(O.903$O ^?R"%Q)E,C5AS.0>=@0\[X9;2DV[)-MZ
M)*[?J0LWHKFL'IH/#8_C_P"C#X3<,_IG5N]U/^W/]67L)L]SZ&/30>&Q_'_T
M8?";AG],Z=[J?]N?ZLO8+/<^ACTT'AL?Q_\ 1A\)N&?TSIWNI_VY_JR]@L]S
MZ&?VW% X;-[VM;7_ *,+WO?:UOIFX9YWO_\ O.CIS2;<)I+-MQ=DM[R%GN?0
MS>>U[7M:]KVO:]K7M>U][7M?G:]KVY7M>W2]4(/[0"@% * 4 H"+O@L=RVT;
M?>S/_+9U4)EJ^=]9*)0@AG:GLJN(UXUT:?[OS1!6E/E]7:5JZ4_-E\N1FBM#
M$4 H"SH"[H.<\397^>ULUE/5<W:S6&CY^Q$L-4+GYSSPPQOEGECAC;;?+/*V
M.-M^5M[WO:W._2@/EYJ+?WP!_I@_^*@'FHM_? '^F#_XJ >:BW]\ ?Z8/_BH
M!YJ+?WP!_I@_^*@/OUZ4 H!0"@% * Q+/O\  3-7WI9'^1RS0&NG##[FWP__
M !+-+WS*,FA,M7SOK-Y:$$*L-^O[5]XXTR_D[5K6&CY^Q&=7PEYL>HSU5S,4
M H"W])/L\=5WBCZ(OGDU\UE/5<W:S:'@?I2ZHDJ%4+'7=\DR^P(B_P ;:-OF
MQFJNS.X[^,G@OZ1COHG'GQN$/B7:']53^<43HXUZ"'4 H!0'T+_5J9]N$;XU
M)UPWNB>\3A?\'=K?,ZI]78?CC9OI='Y2/6LKSA.XQ0"@% * 4!;3S]9[L^YI
M=^*S5 :%\(7N7F@GQ6H@^22?0M/PY>=+K9(S0J0O1M_#CKK\;U1_-[T\UK#1
M\_8C.IK'S?K2,XU<S% * MC3)[/J8O% A3YYYSK*>JYNUF\/WM^?]5$J]4)(
M"/)(_<YBWC%PU_M7'787<H_&)P4_.7_^:N?*VYXGVCZ-+Y4#HC5Z''3A-CJ\
MTUL'Z6^)LX<B5M%5X\?A@S"[J:)2V#IF^+A-%:9+VIQZ.!0N?S]&>4?S"04@
M513&+!Y,DX,M,DM8H$G>=1;IO@GPBQ_X0[46U]JXF5"%/;,=L87%SOA=B[37
M#&KLG@W@\/#O:^XUC]D3I2I4U-K&P5'&RXSJ=\ER;:."H_<>'^YJ%-3<L.\/
M.FDIXFA][EB,;4G)O]T[UB(R3FTN)[JFK6L4SB*PE$,=::=.KA84=M1FK8RF
MST05R)"271P)%1E73E$[H6%Z/7.54SYN>V(!(8[M'<$J.<@W5IL/%8^AZ33#
M":3N8#U[G^V=K;0X1\(*&.VABL915/%UEAJM655[/K4N$.U<-1H8_#2I0AL+
M'2V?'"1H;+PU3$4<3A*/W?.I&I/BNNV,-AZ."P<Z5&G3GQJ<7.,%#OT982C.
M4J4U)O$TN^\=RK34)0J2[THN.9!\\/6DZ/N>6?BXS7-N'/O)X8?!;A!]$XL^
M9LCQMLST_"?X],]<X#_F ?\ )!_U,:\V#N<^M * 4 H!0"@(N^"QW+;1M][,
M_P#+9U4)EJ^=]9*)0@AG:GLJN(UXUT:?[OS1!6E/E]7:5JZ4_-E\N1FBM#$4
M H"SH"[H.<\397^>ULUE/5<W:S6&CY^Q$L-4+D'/DB@L7.<+:52IL $T6'E'
M3T$.7,!8#@#!9S0S+9AB@BXY!B!Y6Y989XY8Y6Y7M>U<Q[GV&PV,X;\%\+B\
M/0Q6%Q&VL%2KX;$TJ=>A6I3JI2IUJ-6,J=2G)92A.,HR633/P;5J3I;-Q]2E
M.=.I#"5Y0J4Y.$X25.5I1E%J46N1IIH\^[T$LS_!%L?]@)7_ )2O[W_ ?@7_
M #0X+_W!LG_2'4WWVVK_ "GM#^VXG_,)3DC0YID-:"3$PG&"$#*8T!O/48'(
MH@Z:$U$PPT=8C5TQ%X>';%T7%-$NM-M:,O;!5%4<5_!<-I0(-[HMA"9GK#$8
M/@_0X;_>R7!;@;'9-/;>$V!/!2X,['5><,5P2Q7"66V%BW04XJAB*,<%*GQ/
MN?O,:LG^[6G'[].KC9[+[^MH[4>(EA:F+558_$N"=/'PP:PW>U4LW.,G4O?C
M\9Q7@Y/EZSM"VF6&--,1/V/8_)%I" 4H;;,NXG!\%8PCKTK::FI-@:>]4U2;
MB>WBBXIJIQQGV->)EAW-@K'Y0L4?ZDE/W*R9E' _ ["VQPCVK@<?P4X(RP$J
M>U\3LEPX+[%I1K8?9?"/%[&=3!U*=*IB)T:5*&'IX[[ZT<)B98^<IX&E5P/[
MH1M*MC,+@L/5H[1VFJREAX8CC;0Q4G&5?!PQ*51.48*3DYNDZ$JD.])*JXU<
MB(UQ,YH -]=&!:K;!&!1E,4(4)#3 Q A R0^88@8F!6V6&>&5K989XWMECE:
MV5KVO:UZYOPBX&<#Z'!_;M:CP4X-4:U'8VTZM*K2V%LNG4I5*>"KSIU*=2&%
M4H3A)*4)Q:E&24DTTF?+P.U=IRQN#C+:./E&6*P\91EC,0XRBZL$XR3J----
MIIJS63/6UBW^#*.?N$:/R?3Z\\#MXON@% * 4 H#$L^_P$S5]Z61_D<LT!KI
MPP^YM\/_ ,2S2]\RC)H3+5\[ZS>6A!"K#?K^U?>.-,OY.U:UAH^?L1G5\)>;
M'J,]5<S% * M_23[/'5=XH^B+YY-?-93U7-VLVAX'Z4NJ)*A5"QUW?),OL"(
MO\;:-OFQFJNS.X[^,G@OZ1COHG'GQN$/B7:']53^<43HXUZ"'4 H!0'T+_5J
M9]N$;XU)UPWNB>\3A?\ !W:WS.J?5V'XXV;Z71^4CUK*\X3N,4 H!0"@, :K
M9X)Z7=,T^:C#Z".ZBT(1(_9.NV"YRR<*XAV<VU!;*(5E'(N;Q3<%8V4 ("J-
MRANQ (QF<N4,^4^4""4KM+>TNEF@R%Q,4!&BB7D[54TEUHRE'TSR/IN5RFGJ
M*Y^U"LU?<R%%D:2B16DL2/HQ<KA;"4<:LR-4CGZ,B:>"*O$%L-./G"X%[ ">
M+?1JS5\VH^K-YVMR&M/#GXDFF> ]"&DB%953-3S9DF+H%CEDOAOX:(=9BY@C
M.5 ;Q,@JIV*PWX'5$12Q*F@A K'$I1.D1^Q[,N9%#O;*XM*+<I-.+3;:]W'E
M=^5FZ'IP&BC^^=4'P#-<GZO%"O%>^/Z\/VB,IDZ^(&1Y4U7N51;VIPNBR;J,
M./YE&_I*M8(MUAJ"P[#C4#4\BX$'B&4[+)>::\2\PJ@))0M8E8UD5L4-%!Q[
MQDDK.^OL*SIRE:SADK9SCO;W^4RIZ8[IL_ZJU._ BUE_^Q%6XZW/XO:4[S+?
M#]>/M'ICNFS_ *JU._ BUE_^Q%..MS^+VCO,M\/UX^T>F.Z;/^JM3OP(M9?_
M +$4XZW/XO:.\RWP_7C[2A09Q$-.K,U<R1*3C1M3I!C.#3C&# 25G'1+K'-Y
M&G6W)-E5Q+"9=-)06850,2B0YD4U8\8)!)YBYNY<L:&,ES0(-)--W6[VFL8-
M0XK<;\:_AQTLEO-_O3@-%']\ZH/@&:Y/U>*J.*]\?UX?M$17&PUN0UJ_T7@1
M'I[:VIQ]O_"9XT=N2&+HQU<M7"S?;PBUDKGO/1XPF@(][E;'"^Q6Q^YP?RS_
M ),7%[#/L>8]S_:V V'PRX/[6VI7>&P&!QO?L575*M6=.GWFK#C=ZH4ZM:?N
MI15J=.4L[VLF?@VKAJV*V;C</149U:U!PIQ=2G'C2<HNW&E-162>;:1U/?H1
MSE_%VU)_!VFG]!J_LC_K=W,_YQ3_ +GVY_\ FG6WX*[<_P#%I_VO!_YX^A'.
M7\7;4G\'::?T&I_UN[F?\XI_W/MS_P#-'X*[<_\ %I_VO!_YX^A'.7\7;4G\
M'::?T&I_UN[F?\XI_P!S[<__ #1^"NW/_%I_VO!_YY17)"\]*#>7B!33GJ3%
M-'493*%@OI>9F#\L,&"0P(.'9B,C /#LQ,\<>RSSQPQWWRRMC:][?!X5=V'N
M>;3X+\)-FX+;TZV,VAL';&"PE)[)VS357$XO9V(H4*;J5=GPI4^/5J0CQZDX
M0C?C3E&*;7[-G<&ML8?:&!KU<-3C2HXO#U:DEBL++BPIUH2G+BQK.3M%-VBF
MWHDWD>B:%Q?]%.(06.1G5!;+$/#&]OI#=<=]KVQM:]M[:>;VOM>W>Y5_$AV9
MQ7OC^O#]H^GIP&BC^^=4'P#-<GZO%!Q7OC^O#]HWRAV7&7.\;MJ5X]R<^;.=
MF"F(C9/)BO>-')?%(6E)OG?/-D2,WVJ\T/+SR2CEBN*T@I^1\EYF5"-C"8>)
M&S AJSL_B:>OE5T9,H0* QW+\H->$8FE":'OF<"9<11V]I/=XB<7Q-J ;78+
M:4W6OYD"N8H&!D[BE))O(J7R'!Q&'L&'D*';*^=@2N[+5Y(TDB;B>Z<W R'8
MY=1CG96B]PL>14F,W"T]0\MQ>V01%YSQ,P9S:=VZ[17*7;CDQ68RDILK Y1/
M,^>*2HAK:8;*7P2\#YP6<7>R3>5\DWHVGT--?\FC?"/X@^@R,^'#I08DCZU-
M*+!>[;CTZ1<+/>>H2)VRYT([F[W*:P*+""M.PDJ)IG(L8 ,8@'"H(MP1@A;8
M]@)AE<3*$[OW,M7R,D:]-!X:W^,$T5?"AA/]-J$<2?Y,OU7[")UM:]]#1?4I
MKU7Q]9&EH%#>>I>/E]H+(L^Q8&ENE"(Z'M'K0.K+=/YNJQ5:2BCK:[E;)E03
MA3)0!?;RVD"BXJ"6=+@:0:5[M+3EYRM6$VH6A-VB[VC+*\I/=N,M>F%:"?XZ
M^D[X0T2_I;5[K>NE&7>ZG_;G^K+V#TPK03_'7TG?"&B7]+:76]=*'>ZG_;G^
MK+V#TPK03_'7TG?"&B7]+:76]=*'>ZG_ &Y_JR]A:D)\0'0BD:Y#3O5=:&E1
M-:>6E!4;>+F/Z@HH*(&3A$E]O*@:%98'=8:?=8S30!E#!-L8\V9$@1#5@;@8
M99VSFTWD[Y=K-(4YI.\)+/EB]R\A)GZ:#PUO\8)HJ^%#"?Z;50OQ)_DR_5?L
M(>>.SKQT0S%PYY%8L2ZPM,$GO8]),%'R30CZ>8O>+G.$4:6VFIJYPJA-YT**
MH.52TTL9/J X17,(F3 &,F,@P0\\[<P[G^*PV"X;<%\7C,10PF%P^V<%5Q&)
MQ-6%"A0I0JISJ5JU24:=.G%9RG.2BEFVC\&U:-:KLW'TZ=*I4J3PM>,(0A*4
MI2E!I1C%)N3;=DDFSI)>CQD?X7MG_MQ-_P#,U_>GX>\!_P">/!?^_ME_ZHZG
M^\NU_P"2\?\ V2O^P7N)J)4!HU.0R+-Q\6(%%9Q<2A%8DBF<XX/.#'$/#%;.
M,G)7NVC*MCB"#:RB,F9F[6!"_=OW/#L?EXGA!W+<;B9XS&;9X!XO%U,-+!5,
M5B<?L"OB*F#E?C86=:K5G4EAI7?&H2DZ3N[Q=V?HIX#A%1@J=+"[7I4XS56,
M*=+%PC&HM*BC%)*:Y))7\IS75J;<+Z:[19#VGY<>#+C\K<DQ&BZ)/4%]LLLG
MD""6N5:B$JK1M+;Q>Y8N7+>4I)4H'8L7  MCY2"'ACKA>$_<SP6)Q>-P>W^!
M&$QF/EQ\=B\-M+8=#$XR?&<N/BJ]*M"KB)<:4I<:K*;XTI2O=MNM39NWZM.G
M2JX+:M2E25J5.='%3A35K6A&47&"ME:*666AB-Q/=F#M]=  =;<&&&1U,($(
M):3LQ!11"0^ 88>&)B^6>>>=[8X8XVOEEE>UK6O>]J_-PBX<<#*_!_;M"CPM
MX-5JU;8^TZ5&E2VYLVI4JU:F"KPITZ<(XERG.<VHPA%.4I-))MI%\%L?:L,9
MA)SV;CHQABL/*4I86LHQC&K!RE)N%DDDVV\DLSTV(XXF_#@(1XPB)[7WHQ)G
M2;,:Y0X4-:G(7+F2IHNAD03!8P *],!01P!<,PA@1,<1 Q,<L,\<<L;VMYYG
M;W$G^3+]5^PO/TT'AK?XP315\*&$_P!-J#B3_)E^J_8;4QA+$73:S$R1H:D=
MBRQ'RT*H ([YC=V(3W:"J.DGS*4J ISC;9]21SHJ:J$S:<?#+'!,RAXJ8*#V
M#'!$#Q$--.S33W/)F0*$"@,):D9W:FF*!Y5G][D5A5;$4,U6=RBC-T$L87UW
M,B';!/0$0(Z9)$;JRZIC$DA/R/G21 (V="%/'"I3 8<,2E=I;W;_ )\F\T:>
M7$7TZK>F&:3<[/F/=*,AEC.I" E",)PER,T!6.2E%B"$1<R&QUD9QEDJ0RER
M;N9:N4.MKRX:Q-W(8"@13SYK$I0<5\B;R6GE_P"&O48EX=G$2T L?0!H?9;T
MUP:1FD\&EI'TYMIU-5RZC8@0G&VG&AQ"T$Q:05]%4W@54DA92%(L93U-,4"Q
M<Z0.EQRIH (<+/#$3).[R>KY'O-R/3.^&W_C =%?PHH2_3:A%GN?0R(N*->&
MB!.>VJ8VH:Q-+I JX=5LL.- ,G)\BPJ MM]2 ;5D]=2!AW5@&HHYZX ]B:D3
MR&)F;@BV!&SN'GMI!I)W:6>_F*5(3;34)-<6.:BWR<QFOTP70;_'6TG?"(B3
M]+JO=;UTHIWNI_VY_JR]@],%T&_QUM)WPB(D_2ZEUO72AWNI_P!N?ZLO8/3!
M=!O\=;2=\(B)/TNI=;UTH=[J?]N?ZLO84/3!K_T)-_6EJ8=:]K1TI(K77]+^
MC]O(;C5=0D3)Z$LKS8E?6TI.1$2E8V[0B"@K-]/=C6/+2<4'%-I9-R()D\"
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MH\ICZ).+CH>F I@HI,FF&HEX:=XRU,'U1^I=FZ12V/*[V4XZ;2 :&L;/7,R
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M^W(77C'.E;)4<"'BP]/V2TTR(2HZ4?%KQS=4;28,!<T"HN!/L1N;1B(I:US
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MR*XA;*_EL6IG*/#+"<DI- 5?T>@N6$TAP+TKHXQ"+03;&2&D;*)SN/+EA2.
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MZ**>-I! RG'E4 F45$T8V(-4Y*G+1E&^L2-=$@NF1G.:6Y'9[7?H9Y(;FEI
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M>T>B/5-]9N /A*R+^J?09;WT+VCT1ZIOK-P!\)61?U3Z#+>^A>T>B/5-]9N
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MQO0\ ,BX/!YO$)>D@LUUHXBR'(6!MX&"UG200V.FA89+ADFV"9IT*HEP;O\
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M=/[)J >G??8Q?CI_9-0#T[[[&+\=/[)J >G??8Q?CI_9-0#T[[[&+\=/[)J
M>G??8Q?CI_9-0#T[[[&+\=/[)J VBT$ZMOIOYNU(/7Z'_P!#ST,17IH:WG9Z
M*_1;YNV=NJ%6\W>;?0VV?,W[X>9_,OF0Q_S/EOFC]T\KP$\BYWU1)2J$"@%
+* 4 H!0"@% ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>g947560g61r81.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g61r81.jpg
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MR/YJ\A^*B&VH<QMN*&/XIKE#7>M-<<EA4+DR1R2HQ*8WC9R8M4"X^8BGU]:
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M2&IRTJ?&NS=V7LD(P, \..RW;&.+CNFY)K.EG_9\<5NVLU>RXVSZZU@XQ=]
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M.PY1+W<@C2TK8HPG3&[Y@DR%7-SR,B,)0_CNNB(R"E9?(]83T#  LY>QPML
MK&GS.&,SBF3;LX18_HR^LW7V=8NOC#O^*\JN/>GN1T'#2N/1+<\" 3\"$FX%
M_')0+8'FF+E-F4&OT4K*W2ROG9F:%*$(S)1_:LCB)H_%BH<V0 96,R/21VS>
MH7M00(R!_FLU])FG^&Q*@"34 * %[VM:][WZEK?QO>_^EK?][T =1^A>EZTK
MMF/<BY9+XL8@0/4&R(4!U:B">K;-DW(C6&Y-EE],<?=DP.)QH*W-)$MS;2C4
M@C0&$)H%W M"\=+ECB+,[EW."HTF5NNY7[-!7,L_86D68WZ6+A:K(-?Q9Y-Y
M<$/[!F!N#HBI%K6; 7\//!=X/N-UT]BLB@AL\A+<CNX82@(]8RW1RL_&E"1!
M,>!$E"S(&2JQGU%ZR["/-^1W_P!\P@<EZ8/C4UCP<U!(GNO8+T[.N/D9$!6^
MJ)M&W9Z,;]WROQ\9; BJIL%AA)P<9G(F0A5VHS#-T?DC(-'PV2F$J#EE 9!]
M=BT]9'H3E=5ST?5Q.8WTGVA'4BUU$Y>F? R3>&U]R032(,"$.3$E+XCI_=Z_
M'QUL8DB+$IY#AL@GC)4HV%"<3Y('!WPZ62),:);G'0D(-)E^5K^JY7M["/V#
M:[CENY+?6OBDJ6!XQ>11/9^X-.S:-ID+ED!$VTML^5:PD-V)/)F/R?AS+J+V
MDL>=*,VRZ\?-BU'3=!UDLBF RM[C]I7_ ._\Q?-! 4 * (TW\<"_HU'?O244
M 26@#2/G-S,'\+(9J*4OHM&),IM_=XC20Y6<;8C>DX3&GY776S-BXR*5[#E@
MPJ##BDVFM'8A/%V@EVR4,#D\7&'\<% J2G*OZBN>:YZ2+,7Y^S.*;U7TN'$B
M=:RA\[F!F8ZS.2+5(3;YJ&KZYV5L-*,Q23; FFK(<]O.M90J4P4ZCLR>P$^"
MTZ@*-Y'MKK.(TE#@#XC*@0UX TF7K*]KYNJU_9?/V=8O,/T@G$Z0%=;A 6QC
MI@OM++/ ".&:DW,]=1I1/99+3"B>W4FVOE+Z'SPVX&-ZSSPW=\'V6,X!G(U>
MUB@8HV:!%C^C+K*Y6[<V?,-?M2=++Q_G,.!3">,9!KFTK$Z7SB\5!1O9FYYR
M:EFZHKNF; (6SBFKM8FBCXIWL:+FI-@L%3,8D^TE6+A 024$LS(3DGZNN^<B
MT';K_$NP_4+#9=)MQ7<7)E[S5<K"G@C1QC6A:!PO;.S9CM%MO;6LRVW&<8WJ
MF#ZS,3QPJT@$%D<K)H"1AYV%CH<V6ES:*)!W2=PC)/V7OG+-8['?..'OWI/.
M-6D8EL\DV(2F8S: Z*F6^X_#,]?[0AH/9<:A>OPNS"8F%[8D\ ;ZQ+2!M$I+
M'BA8$+D160Q]L5QR+A&ZK,@@U'F(S[!.2?O(CSD=KG;1>_UZQV+8WZ[''+_3
MKK6OU/\ UMU:"D1HY_-X9Z0/?\3DM $FH H/E1OAAQ=XW;RY&%8Z\EPW2.KY
MCLU]%Q[]$4^/M8@%=F5A+0DY;NT&*[[!K=!)TLU<)HY9VSS1SM:^-PDBN9%V
MF1>TQUJ0GIIM2E"C,?.=;D1PUOMV2ZKDTXTA+<N6&OFE@'&TQR2S/PTUH:(R
M8WL+,<!#JQ^=1\-&&I37;W)0O(KXAFCEPF$Y)WMVE?/]G2=NL_YC<R1=(QPY
MB)6XR3;:=@T,]5%]UL900UGMQ#7IO7(#6C+<9LM&=EY0/X/I26%:P(LIF^A\
M<DQ29H"'&.6<?[9P5;X!%CT==[6N5[WM^HXZ_2/\/68O7A@GLJ2A6>SUC%HU
M@?TKO4 08BP,HC4**RV=B3.M6)75VO6TLF45 8[*V6SB< =$#XS!G)7";BRE
M@6//ZM.<O9ISGIS%GS&)KN#E4-U'R%XO<?'&MIZ?><F)A*(FTV*T'V8:W@[B
M.:GVKM1NT*2%YA? [*CC/5)AHSB8--9T-'9YR"0/A#=2/LY* BN1G<LQ7MUG
MG(OYC:Z@@* (K!?$B&^BL>^Z&= $JH ZF-A=*M%M=\V'W#PAK >2<L-TZ*T=
MD='[EA.&RB!_?6OXW.@<M Z#?,FDRD.N(AA)4&FP)<'*O$HP/'EC[EGFR'N$
M4PJR3R25VD9Z#MF,RTZ+W+1ZR[1-]"=*QQBW;H49NMQ\)D1(HZ\T]L*;:Q1T
MGO>;3:,#=W,I$O"W,>%Q;5+DKM:+.WT-FHJ^PM9AI)"DG<0D-GI=C8:ZLD+.
M1'V@:3(_Q,R+.6>WYYCT9CSYR[19@7I).%DC)+L FZ,"35CIX9OPQ*&^O]I?
M!_&]4&=8?#.*DTMV3G",(#$5G^K>I-&\=DTD%2C,3FE_[%L[71;* R3T6SWM
M:Y7O>VB]].86!&>5T)VSI78&W>.D?F6[R4%>/X[GJY.-F]1;%<SML)!'6<.-
MQO> S7IB$/'X*4QJ3I/)8,'(KPXX-E I(N/(#+/PBUC(C,BOUZ2M>U\U[Z#T
M#F\2^1S;E/I_#:;>(KPS-O.]FZ[(#4Y"+F<=?&-63V0:^,G(-.@J385.8,7*
M1YVZC<J9,F"9)I>]E&+5=!5+$!E;]?;^@V7H($:2\<'_ *-"?O0U0!): -/>
M;?+5APTU-&]GD(P&E-I1MK7.I&;>3;$":HBHDAL8LH(9R&53^1#B@:-QP.JG
MVR6(/FMT6[7KULU$\4\KW"4E>_J(SS%?0-0-.=,GH381"!MIY$I7JX1.8N<)
MH35F@:V_KQL?#<G#G%AM@G/=41:2Q2^KY3.A+%[#]YFBT>UT9822/MUGS!^1
M20N$FD[&?66DCS'HN>D])=FGK&S,FZ27AS#"6Q0LKV5)P!O5Q6-!I$$*:2WP
MT-%WDQG!?6L84UP)5UGB0V\,,SH"9C;,WJEO,PMW@]=90@FQ[&[S""29Z+9[
M]96S:;G>Q?G83(3SGXOFMD0#4K'89/">;,#1(U%Q1'6NU0K!'*?1Z12N#QR7
MR0S"&$9UU/Y='(E)3$=UIL(Q%]A%F85[FSC*N6*>"@+'G]6G.7U;UZ!B+\MW
MS'FD,X@R+3YP%A*X#+I] -E7FD,+)2D/!64&6D)I[!1+UU(8G$%B\T6AT=.R
M!PV,G9=$90VQB;./(B9*6!8K7O\ B7XF?M/-?\!N;00(S-?$V6^C)[[J=T 2
M:@!0 H Z[N:O2 @^%6V>)T,F<&3+:\Y#2F: I[M%:66!M]+BH\[UW' ,D> L
MH\4QE+*0SK:$2C#E*YN-W$8OL2&*Q++_ ,E05$FY';275;3V^PKGUC3?3O30
M/]H:BA6RB_'0=!Y#+#$;%/-8O]L&R,HC^!_GQJWA$N_=D4M.M(TLB%RV5:<O
MV=S#<OD7$XPQN-5&O5YR-"31;KN74=M.8S[>TO9G]0V5PZ8O@<O$IE,V>SC+
ML1$)'!HYAU(8?8J2NVS#DUCD!D,1<%FPX61BLI,:ZFK0<>?$1C7',*AVWVMW
MQ12QT(R3_7W6^)>WU';F,^E1T8K/M@PAY MY-\XV\X_A=>V9ZDGA.5[GE7(+
M51K<X&*0F )1Y&2M#D>U\!+R"1L3R(YR)'@I,[+H"4 >63L&2?JZ[Y]&2=CO
M^9V*U[GH'\QW2'<"9GMW5<K&OC1N9E8G#89$-P9:FG2,?A,:Y2+7DD<ATHF[
MX"U:0-78<BTBW8F(Y(+CR0R4P=HPDC,4L/RS3!8['V%ISEGM;JZ[7T]E\XV'
MXI\W>._- 9+"N@Y63D*$-QBKTL@:C)V+/E(Y/ACPS 9>P9'63-PZC$U&#2;H
M"^ZQ-S?(819DF0Y^S7:X!!I-.GZMI^O9<AMK00% "@"+P?Q+B'HO'_NEI0!*
M* .FGFMTK4@XF<E"?'\#I&";->"M6:8V*.$D=T3*'[@VV;W)L':$%&ZOT'K.
M.<?=G!9Y/V'P9KDVXV4;#UXS,9F6;)%\U1:OR+<*R3<B.]BN9'FT6MG//HS]
M1':PN QTJ''J!83]+9MI&U(:_FV_Q,@:ZPANR]IMXO =$[=^!IY/]@/&FO@&
M,/0,S!P."Y-+)& S<RL2L&E$DC0$M*6P4Y)^VUM&>_\ V/\ [YA5<FZ8W5$(
MA?(LK*M2;0PGFBYER;!@H0% 24B*VU&^-/)H)QJD<EAL_=10='7+EH5FVNI1
M-@@_ RI"!LM5:)OI(XCYE1L$Y)GHMU?E<C,OT/V=5R&Y^DN;VAN06W]F:.UL
M0E[V?:BL01GS0M")"%'Q\J%?!QAV.E"+YHFD(D0HB<8ML!!O$6Z/)8$2<3QD
M 8.5),@@R,K'FS_7U;1UC;N@@* % "@!0!JPSX<Z380'DMKIL+*X".5YG<9O
M;1/MUIWR.'&\PUP<W:@3>([%P+'69WZ\(R5Q>IC'-K+W[8O;K::1-SN1]EK?
MD*[DG1W<?)3L:,;#)*[$P2"8:)6D6OV<S6;ZUV<:XR/5BFA9-LB,W8J*&CFM
MRJC<D-S&$08TTY%!,)8-D#0*,;-07.UNR_XYRL9?@?UI%3 .B3XV1<>R9@IK
MR 9.XP*T3'=7FU=G($B^G(MQIG<JGVDXMKG(K&GP]J!A!":2(0V:2<?*%"@%
M[9J;7)/DDR6(3E'^M_69VN9F>>YV+V?B)KK7HS- Z@.PLSKB7;ZB3>,1^-QF
M2@ FWCHP+M\1"9ALF<PEMN#M!!L7EZ<:/[:G-[((EQ+24"2N ">-I8$:-F"8
M1?JL6F^C1<K']=758;5<>='Q;C3I'66@H,7E1J$:CB@Z#0QW-2;,S(VL2!VS
M:QL(]*,1@A!ZVC87%E'1*N;'%WW'%L,2#E^_Q<OW(#,S,S/2>G\?]Q<M! C(
M'^:S7TF:?X;$J )-0 H C\MC0V:1630XPH02$2R/F8T55$$GH8JF-.CG(M\H
M,,#5FQ$20P:NE<F1)@X0>L7-DG359)=)//$ ZU=I]$CQ0,ZX7C6@M<P'CG/&
M.O8=KN+SN'QF1,6C=A MEZQVK$SDO#ZVGNI)),9M&Y5JJ/$HOLB\^"[,C!-<
MF2#3)OF5+MR0591]9F=\Y^PRZR/3<[EH,?ST-T3^BM7B=9F)^:EFQ=R0&9[%
MG!+9<>F.UM>-)@[V!R!E/)%.,24"IM.9GY=#(EL*4.7 -ELR=[#D!1'NK:82
M62)2J4-BH#49G?U6ZM%B+L["ZB(6T_Z-7B6]C0.,)0Z5"6L7C.NHK%R8+94^
M#2*-L-3[S5Y'Z_?!#[ ^B48'8[MY;.3-3B3CNDIA; 4X75%)X-,0BYWO^/47
M65C]I"+8=&/Q_D(*/1;:=Y/L"+:_W)M#:>MHRA+9O$HT&&['W<ZY"-8C)HN$
MEF,;EW>5L1^NC&I*N*'&\8>R&Q-XLN+4/IG0G*/268[6/UYK:3S^O3ISE;-;
M:;CII%#0>O2,2S/7E<@E.R]N[?F\H[F]QDSDYW/LR4[/DRS(1V^4N+#C'\HR
MC\='YD7RS*.AQ+9P\=N4EG*H09W]A%["^C_$7O00% "@"--_' OZ-1W[TE%
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MO0=(7A=UJ1L'#GR@/#"=(;]/*'LMU![ATYO<)>BU=_J.]!TA>%W6I&P<.?*
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M "@!0 H 4 * ,@)_FHS_ /4&7_W*56-4_P#+:C_R,O\ ^NX,YAC_ -2X>_\
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MV%["#+5V^XAM3#X>"@H%E'(XSP8BF"=DV[=.W4QPQM_TM;_I4BG2)10 H 4
M* % "@!0 H C('^:S7TF:?X;$J )-0 H 4 * % "@!0 H 4 * % &E/);F9I
M_B1,@..UD9>K>>QBV0+O6"-#%L;1DJ^L2[>[9*C.U[W[O,>UNL[-V7J+]=V/
ML>/7[?A?!-9Q<B:NDG#(H*F$O^5/K9.\@G3;R,EEW**S*\JYE;-IOFZCX3^&
MK!O!([1F<5HK"EUUN<Y!\U06IA$FG*B)D<>;LN-Q9WF,\6227E%EW-.25]=?
M#+<0?Z3;GV*%>]5;5S,8Q^]2._.[J.J^F7P0?X6+MBQ?FH>&6X@_TFW/L4*]
MZJ<S&,?O4COSNZATR^"#_"Q=L6+\U#PRW$'^DVY]BA7O53F8QC]ZD=^=W4.F
M7P0?X6+MBQ?FH>&6X@_TFW/L4*]ZJ<S&,?O4COSNZATR^"#_  L7;%B_-0\,
MMQ!_I-N?8H5[U4YF,8_>I'?G=U#IE\$'^%B[8L7YJ'AEN(/])MS[%"O>JG,Q
MC'[U([\[NH=,O@@_PL7;%B_-0\,MQ!_I-N?8H5[U4YF,8_>I'?G=U#IE\$'^
M%B[8L7YJ'AEN(/\ 2;<^Q0KWJIS,8Q^]2._.[J'3+X(/\+%VQ8OS488GTP_$
MAV_CKE)KMGL8LJY>.>NA@O'+L*H(R.P[':TIOU^?;#Y#JXWOC:R?7Y=6]\;8
MW<S&,?O4COSNZATR^"#_  L7;%B_-1F?#+<0?Z3;GV*%>]5.9C&/WJ1WYW=0
MZ9?!!_A8NV+%^:AX9;B#_2;<^Q0KWJIS,8Q^]2._.[J'3+X(/\+%VQ8OS4/#
M+<0?Z3;GV*%>]5.9C&/WJ1WYW=0Z9?!!_A8NV+%^:AX9;B#_ $FW/L4*]ZJ<
MS&,?O4COSNZATR^"#_"Q=L6+\U#PRW$'^DVY]BA7O53F8QC]ZD=^=W4.F7P0
M?X6+MBQ?FH>&6X@_TFW/L4*]ZJ<S&,?O4COSNZATR^"#_"Q=L6+\U#PRW$'^
MDVY]BA7O53F8QC]ZD=^=W4.F7P0?X6+MBQ?FH>&6X@_TFW/L4*]ZJ<S&,?O4
MCOSNZATR^"#_  L7;%B_-1@XQTPO$@1&X\*=M=L=M# 8D>Y[%#!>:7;#)@W;
M+=CSO*,;YI]D2RZS*^.-\L>I>^-NKU+.9C&/WJ1WYW=0Z9?!!_A8NV+%^:C.
M>&6X@_TFW/L4*]ZJ<S&,?O4COSNZATR^"#_"Q=L6+\U#PRW$'^DVY]BA7O53
MF8QC]ZD=^=W4.F7P0?X6+MBQ?FH>&6X@_P!)MS[%"O>JG,QC'[U([\[NH=,O
M@@_PL7;%B_-0\,MQ!_I-N?8H5[U4YF,8_>I'?G=U#IE\$'^%B[8L7YJ'AEN(
M/])MS[%"O>JG,QC'[U([\[NH=,O@@_PL7;%B_-1N3QMY:Z6Y5A#!C5!QXLZC
MKO!J>C4@9I")0*P7M>[)^Y%XNGF*@HA;%2S(BU<.&JBR+AJHHD\;KMT],Q+A
M&MX3?99JS"$HDH-<>3'6;T5TTYG&TNY*+.MW(UM+2E9)4E9$:%)4?<G!MPMX
M*X5H4R7A.<\MVG.DU/IE093#JD5*\[$AR*3KQ*BR+*)F2RXXTI:'&E*0\VMM
M.R]:R.S!&DO'!_Z-"?O0U0!): % "@!0 H 4 * (S-?$V6^C)[[J=T 2:@!0
M H 4 * % "@!0 H 4 * % $7@_B7$/1>/_=+2@"44 * % "@!0 H 4 * % "
M@!0 H 4 * % "@",@?YK-?29I_AL2H DU "@!0 H 4 * % "@!0 H 4 ><[I
MS/';CUZ+3_[VC5>BN G^[XE_SJ5_HJ ^>'].G^_<&O\ RF*O^MA\=$%=_#P,
M% "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H M32^Z-A:!V$#
MV;K,VJ%D@17J7M?KU1ID:KGA=^!/,;*)X$@I)-/%-VT4RQRQRQ1=M%FK]JT=
MH8JM46G8@IS]+J;!/QGR]1.LNI(^+D1W+&;3[1F9H61'F-2%DMM:T*VK!F,\
M0X Q#!Q-AF<N#4X*[9[KC3(RS2;\">P2DIDPI*4DEYE1D9&2'F5M2&F7F_8'
MP_Y@:]Y=:]PDD;S2"S4*DU;3Z N76"I*-DE<+VQ=-<KV3S)1PDHFJH',)I8X
MJXXJ,WB;4DU=M$O'>,<'5'"%1.-)(WX3YK53Z@E)DU):2>=*BSDU):(TD\R9
MF9&9+0:FEH6?V!X'N&'#W"[AXJE333!K<%+3=?H#CI+DTV2LC(G6C,DJDTV4
MI*U0IB4$2R)3+R6I+3S*-E$O'!_Z-"?O0U6H#MT26@!0 H 4 * % "@",S7Q
M-EOHR>^ZG= $FH 4 * % "@!0 H 4 * % "@!0!%X/XEQ#T7C_W2TH E% "@
M!0 H 4 * % "@!0 H 4 * % "@!0 H C('^:S7TF:?X;$J .F8CQ3Y7Q:=<D
MI=K+4<$0W_+)1R,E<,YMN-O-Q\XD6N-F3D0>U?HX?$'8 ZFN4UWKC#X,(TEM
M<0^U9K<O#8]/HG@5>'C;-$*[EUGFL6:U[&16,^JV?/FSF6D<P9H?I0I&7AV1
M_>NP85"FAR+(*!ATYU$\G+36Y7?N\UY.+V%(6L$?#))LJ.\<S&HP5Y'%;X,<
MI&R5>C"DBE@/OV>A%T]GZ]F:V<LU^W/;V#6U+472R[P";0UEL0W,%E T<U?
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M/GA_3I_OW!K_ ,IBK_K8?'1!7?P\#!0 H 4 * % "@!0 H 4 * % "@!0 H
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MD>QRL]>Q]>R99HUOVPNT32_YZ )50 H B\'\2XAZ+Q_[I:4 2B@!0 H 4 *
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M&EV0/KM&EL>UMSH+$P@R4S><@1Z[Y!':!O"?ZS?HFH\MMG6A*)-=9.X[$0)
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M)-0 H 4 * % "@!0 H 4 * % $:;^.!?T:COWI** )+0 H 4 * % "@!0 H
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MS^;PST@>_P")R6@"34 * % "@!0 H 4 * (K!?$B&^BL>^Z&= $JH 4 * %
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M:.2D"!.'C-L4DK5=VV35!8_=?27U?U:18DKWBA#]VZQTZ7B!=-';-S+"(S+
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M_6P^.B"N_AX&"@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4
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M,]"HA&I$,:1(8*CVHF..<19.#5LK@N6;U'[LW5H[?;G,Q"K<4N2QK+4(63[
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M '?$O^=2O]%0'SP_IT_W[@U_Y3%7_6P^.B"N_AX&"@!0 H 4 * % "@!0 H
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M0% "@!0 H 4 * % "@"+P?Q+B'HO'_NEI0!** % "@!0 H 4 * % "@!0 H
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M@!0 H 4 * % "@!0 H 4 1>#^)<0]%X_]TM* )10 H 4 * % "@!0 H 4 *
M% "@!0 H 4 * (R!_FLU])FG^&Q*@"34 * % "@!0 H 4 * % "@!0!UA\\>
M"Q;FA,X'D,V,.@'P=1@CBO9_&W,@[J]]96UT[I=KF!/:G:7>[GU_7]G[/VUA
MUO8NQ7[)V3@#'K6"FZHV[3'*AYQ7$6DVY28_%>3)D),C)3#V7E\>1D9&FV2>
MF^;S?P^< \SAGD88>BXDC4 L/,U=I:9%-=J!RCJ:Z<M*DFW,B\5Q/D)D9&2\
MOC"L:<D\K1+P&,K\XR/>S<E[X5V'SZQ-6Y&TV]R'GKH,5;]HM._AR3\W#P&,
MK\XR/>S<E[X4Y]8FK<C:;>Y!T&*M^T6G?PY)^;AX#&5^<9'O9N2]\*<^L35N
M1M-O<@Z#%6_:+3OX<D_-P\!C*_.,CWLW)>^%.?6)JW(VFWN0=!BK?M%IW\.2
M?FX> QE?G&1[V;DO?"G/K$U;D;3;W(.@Q5OVBT[^')/S</ 8ROSC(][-R7OA
M3GUB:MR-IM[D'08JW[1:=_#DGYN'@,97YQD>]FY+WPISZQ-6Y&TV]R#H,5;]
MHM._AR3\W#P&,K\XR/>S<E[X4Y]8FK<C:;>Y!T&*M^T6G?PY)^;C&O>A"E3)
MV':WY#1]2Y=^LQQSMKHCC9"Z(HB4NIEC>77[);+$=DC;&U\;VNK;/KKVPOCD
MY]8FK<C:;>Y!T&*M^T6G?PY)^;C)> QE?G&1[V;DO?"G/K$U;D;3;W(.@Q5O
MVBT[^')/S</ 8ROSC(][-R7OA3GUB:MR-IM[D'08JW[1:=_#DGYN'@,97YQD
M>]FY+WPISZQ-6Y&TV]R#H,5;]HM._AR3\W#P&,K\XR/>S<E[X4Y]8FK<C:;>
MY!T&*M^T6G?PY)^;AX#&5^<9'O9N2]\*<^L35N1M-O<@Z#%6_:+3OX<D_-P\
M!C*_.,CWLW)>^%.?6)JW(VFWN0=!BK?M%IW\.2?FX> QE?G&1[V;DO?"G/K$
MU;D;3;W(.@Q5OVBT[^')/S</ 8ROSC(][-R7OA3GUB:MR-IM[D'08JW[1:=_
M#DGYN,6$Z$.4F@H@QAR&C[?$L+8$\4,M=$5,D,7[1)U9')2TNPMG=.RML+YV
MPQME?'KK8X]7J6<^L35N1M-O<@Z#%6_:+3OX<D_-QE/ 8ROSC(][-R7OA3GU
MB:MR-IM[D'08JW[1:=_#DGYN'@,97YQD>]FY+WPISZQ-6Y&TV]R#H,5;]HM.
M_AR3\W#P&,K\XR/>S<E[X4Y]8FK<C:;>Y!T&*M^T6G?PY)^;AX#&5^<9'O9N
M2]\*<^L35N1M-O<@Z#%6_:+3OX<D_-P\!C*_.,CWLW)>^%.?6)JW(VFWN0=!
MBK?M%IW\.2?FX[!N$G1R0/B4\)3,V:;;,VJ]NX9#98L%[DL(J#63[$JSC@M=
M\44;$R6-U,"QM1WDZ59YXBV2;)GF1[I]>XWX2*ABY#<)AE5,I*,E;L-+_'.2
MWTG<ER74MM$MILR(V6"02$K+C5FM9-\5Z$X$?Z.5!X)'I-:G36L38K?XQB-5
MEPO)(]*@+3D+9IL5Q^2IJ5)(U%+G*=-U;)E%82PRJ3Y7V1UUJ/2(C27C@_\
M1H3]Z&J )+0 H 4 * % "@!0!&9KXFRWT9/?=3N@"34 * % "@!0 H 4 * %
M "@!0 H B\'\2XAZ+Q_[I:4 2B@!0 H 4 * % "@!0 H 4 * % "@!0 H 4
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MN$;Q@Z5-:U2I>T9?@!\HCVMYMFO?MO)/TJG1OI.L]1[A&\8.E36M4J7M&7X
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M "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@#)A/X&1%[?POW38?\
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M@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4
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M1$I*TF2DJ(E$9&1#NKT3JW#3NN 4%P==N6$-\4>S]3J=??&U_P"/_K_'^/\
M\_\ ][X ;&9W,S[1<5! 4 * % "@!0 H 4 1D#_-9KZ3-/\ #8E0!)J % "@
M!0 H 4 * % "@!0 H C3?QP+^C4=^])10!): % "@!0 H 4 * % $9.?S>&>
MD#W_ !.2T 2:@!0 H 4 * % "@!0!%8+XD0WT5CWW0SH E5 "@!0 H 4 * %
M $:2\<'_ *-"?O0U0!): % "@!0 H 4 * (S-?$V6^C)[[J=T 2:@!0 H 4
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M3G\WAGI ]_Q.2T 2:@!0 H 4 * % "@!0!%8+XD0WT5CWW0SH E5 "@!0 H
M4 * % $:2\<'_HT)^]#5 $EH 4 * % "@!0 H C,U\39;Z,GONIW0!)J % "
M@!0 H 4 * % "@!0 H 4 1>#^)<0]%X_]TM* )10 H 4 * % "@!0 H 4 *
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MC()+@RBIK/8>W-<-Q,;3F>KH$\FZ@,IJ H4V!B30@9&. 9!'249%SU)=[VD
MTVOG_+\"(ST7MI+U:<^89KDKSFY!Z'W-O6'JQW13>(00GT;Z^NEY%*SP= A%
M.6G)#>.EMC$MI3HDQ8"8,X;--6(.0JPF/2H="VN69I\M.G#O*/, $DC(CSYS
M7?\ !*2/^9W_ )"B]B]*Y/3>OX?M;4QW0VKADW-:9UW!]?[Q;.S9;86ZI/$S
M.R9_$!6P6&RM<0N/:N$Z[E6I)BYW<6Q="P\,5?F1L;E)Z:1"+)OP^OAU!DY[
M9^LSM?-GMHM?3<C*W9GTC<?CATCD4Y([EVMJ2,1:,C\=8[$BD1QD[G9V*+>5
M!9>\Y)AV#H 'D,)B[\I/&)KC5),R<!C^<A'918PE+ TY,LPAEJ@$&5B(^WX$
M?_\ 8OS_ ",^RB@@* % "@!0!Y].FL\<]">C$Y^]8]7I+@"_N^*/\ZD?Z*B.
M@>&O^\8=_P FI_ZX0Z0J]##HT* % "@!0 H 4 * % "@!0 H 4 * % "@!0
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MM>Z@0,W0 H 4 * % 'GTZ:SQST)Z,3G[UCU>DN +^[XH_P ZD?Z*B.@>&O\
MO&'?\FI_ZX0Z0J]##HT* % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 *
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M<R.&+QC:+D9LR&)*2%NW:QI2+Z4V V8,WJH6=+,! <<RB"N,LAS<Z B/\O\
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MA$7&/.6*ZK$E*22AM*&T(0FV:PHRP4 * % $:2\<'_HT)^]#5 $EH 4 * %
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M3C$SJMGA((6\*!YV@G"WZ)4(FQ&E<,09RT^_/?38\^G\18:'$30C0]#BC"!
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M8]'BHH%_K/\ D7Y>WUC;6@@* % "@!0!%X/XEQ#T7C_W2TH E% "@!0 H 4
M* % "@!0 H 4 * % "@!0 H C('^:S7TF:?X;$J )-0 H 4 * % "@!0 H 4
M * % $:;^.!?T:COWI** )+0 H 4 * % "@!0 H C)S^;PST@>_XG): )-0
MH 4 * % "@!0 H BL%\2(;Z*Q[[H9T 2J@!0 H 4 * % "@"-)>.#_T:$_>A
MJ@"2T * % "@!0 H 4 1F:^)LM]&3WW4[H DU "@!0 H 4 * % "@!0 H 4
M* (O!_$N(>B\?^Z6E $HH 4 * % "@!0 H 4 * % "@!0 H 4 * % $9 _S6
M:^DS3_#8E0!)J % "@!0 H 4 * % "@!0 H C3?QP+^C4=^])10!): % "@!
M0 H 4 * % $9.?S>&>D#W_$Y+0!)J % "@!0 H 4 * % $5@OB1#?16/?=#.
M@"54 * % "@!0 H 4 1I+QP?^C0G[T-4 26@!0 H 4 * % "@",S7Q-EOHR>
M^ZG= $FH 4 * % "@!0 H 4 * % "@!0!%X/XEQ#T7C_ -TM* )10 H 4 *
M% "@!0 H 4 * % "@!0 H 4 * (R!_FLU])FG^&Q*@"34 * % "@!0 H 4 *
M % "@!0!&F_C@7]&H[]Z2B@"2T * % "@!0 H 4 * (R<_F\,]('O^)R6@"3
M4 * % "@!0 H 4 * (K!?$B&^BL>^Z&= $JH 4 * % "@!0 H C27C@_]&A/
MWH:H DM "@!0 H 4 * % $9FOB;+?1D]]U.Z )-0 H 4 * % "@!0 H 4 *
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@PS=)8YX9X9.KXY898WOCECE:]LK7O:]KVO0!OQ0!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>g947560g70z93.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g70z93.jpg
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M[V3SA2L[N:&";1QBSY76\5?)JT&,AVE+$:0_N#8>O,.CZK6E<>-4''&,*O\
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M*+34HR3:::::;35#';2DK&V:E)-65HTTVFGJ2Q33P.OW^U>,_P G6+_A#?\
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MA+@TO;(X)'5H=$"D&C$ZUN<D!QZ-<D/+WH9*E,<:2:#>A &(.];P0?4P!@#
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MW=_X^7<WTQ>DOULRG/>/P%_<WT1]+TM_$KR:KY6>.K;YF[?L8$6,V^=;& ,
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M MOFK3T)'7)Y]/31@P!@# / S^#,_F"_N[REIX.T[$O19:'/CVH\4=F7XO\
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M%P-=HIXX!JJ^*4&!T3+>O:<C%VFIB]Z%Z-5JSL4SK5$[FD["86SO-^M0B!F
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MVU]BR_Q+N_\ I[G/_)+=SP]]4#]O_P"1-&^G>C:?)+Q-#Z3>.,#;6S2!V48
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M[6=4J)Q=$ZU+9<R&$PKC[X@O8WT1.#_UO>0+,4\UU>MF>'@UVY^C9ELN4)&
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M#Z=W=_[3MB8+SSCV(<$6U8*$!?*A\.#MOZ-MJ?HPNP3'-=:XF$YR#C# & ,
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M#5D"*>);&#GM^B4CE4$D2!LNYU07:@2SK5;%1>2%09T86V)O"MUG#D\2%:I
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M+BR=&"HP!@%2/D/\H:;A2R:\KY1#JP5D2ZO9=82V4W%=B6EF5;\C%/#<PPZ
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M@.71.6/:).K"'2A H4%+D@RE2<DP#^\3EW^%_*+];7S_ +I*T3HO_IMQR?\
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M3ZZ^IHX+EW)$EG;4D9)7V!U"[-:&3PF9)4NT7+:/14EKF9L%A0QR]LW\QI%
M]LLPB[$\!2&&C0KQ(-(7-,M;5"M&>%>A>?;Y3)_N>[*^>EU%_P (Y-__ .6L
M"JW+S^TD:Q-RIG9&=I6OCK)EC8V(&]7(WT#06]OZE&E*3GO+P7'VEA80.;F:
M6):O RL;.U!5'&A;VM DT4E*$'U< 8 P!@# & >(P , (LP 3"QZV$8!AT,
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M>M;5!R<9J%6I2C*.&*GU\ 8 P"H^1_'7J?\ JJ;L_:OI/!9<R7:CPF6X8*C
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M_54W9^U?2>"RYDNU'A,MPP5& , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MUZ1Z%Z0Z$T:@ZK_%'A,V!,%!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M&*0V&,#6SPR#1EE0MS+'DOKB1J7!<>K7+U!VQ#=:8)45%2N]O:WM;)3E$E$
MT604627K>]Z 4 )8-;WOT[WH(-:#K>]_AWOT?AW_ +<$'Z8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP"GCL:=?N>+NK+==D5Q6.MK.0\>5U756Q+KSH/F2'G.E^SF(5?[9>X5#(MM3
M<$I_GZ60.STI@TD=E*1K^3R]A+$0).+)52__ &?D44_4R/ORMTW\T5[_ /\
M.EY ?^T>3JS^]7YW]"FM#[Y_F_U))T2Y4%9O,=0]$6(+K6MG"V7:0Q=OK:']
ML>0>\WX4OC;W.FUP8(LG@<_)E\V$!IKV22H]2W0)$)!'6QS='%*D;VI:L!!9
MIIT]_+L\^9SW#ZVY'GJ9]5Q6[[^<28PW,KQ(-G=V]J-1C0S2&%1.Q&=Y6D/%
M^-YY+,KATXBSS\K;+^3T^G4*!4I(<TB]$E"CW,RL= <UEB2!'<=Z $O2H5R
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M]R!4_P#*WJ+\^'M3_O\ X ^Y J?^5O47Y\/:G_?_  !]R!4_\K>HOSX>U/\
MO_@'[<@JW-320$SH^2.1&,%N]*0YO=9;)'Z82(<=@W25LPV*HG242AQ=Y&^G
M-$98FAH+<GQU<712G0DC6K5)_KG#$O/R)]Z3).8(& , 8 P"O7L%:G(LZ)*)
M ZVF*&P3D;LR['"&UI>5MT7]MDDJR0\OF1_3R_5)+(LY+1)6J22IJ;=N^GE
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MYPUB];3N4]2*/RXV/"?6)B2/#T(2JTO5DG3VU]=<#U7CR(N,7<I.JE=.,['
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M0TZ?7\MM-2E/KN!:&H]Z\_L/N%_9 O%Q)19!-7],%$E%@**)+A-4@*+* '0
M%EEAN?0 %@!K00 #K00AUH.M:UK6L#4>]>?V&,OGG3X%DB!6UO=)=$+D#@E:
MV]P3"@=4$!<&IG<"W- RKQ)KH),6L(%1>]*6)4,UG7I#UC<O1*F]<M2GAJ/>
MO?R&KMY)^^:>O7M6Z+4B,;LINCTI_<Z^3T<C9XND>2?D2IX)'%?OB=LF3NA+
;]HN:%)J?V#BH]=*,@9GL3A&$%#)%427OF?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>g947560g95s99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947560g95s99.jpg
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MTX*C & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , U:_'5_K;=/(;A!_HK7:/E#\O7&\O5_\ Y8Y3.Y0@Z'K$:_\ AT :.0\W
M22/LI^]:]5=.ST.A>LY!"(9*M_-3;?532O\ _1M*8,8P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , C/VG^1QUG]6>^/NME6":=5TKM,7>+[YM;Q]
M_4JY>^Y.$X)K\.KRJNUDZ<%1@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & :NE0)%39X]O(7<C4G./?>5O,7T_ULV"3EB./
M V<Z]31NRK!2EE%ZV88!\JAEGT:5EE^@9B%Z5 #Z=B]&VAD?A*<YHI770DL^
M9FT&D5I7!(E7H5!*M$M3D*T:I.8$U.I2J2@G)U!!H-[ 82<4,!A1@-[", @B
M#O>MZW@QGL8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & 1G[3_(XZ
MS^K/?'W6RK!-.JZ5VF+O%]\VMX^_J5<O?<G"<$U^'5Y57:R=."HP!@# & ,
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M!$7)*V)82S/(Y>^M1!LD4I.<\\X4<%/^F6>_22PK!48 P!@# & , 8 P!@#
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M,(6H* I."V/#$\2:)0B0%IWMKTC=#6=WCI"Q@5*SV0:][ @ ]. JXW:<YDC
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M47[6M\K/;E_O33%8]&:T> W8A#T3YFM6]'Z,FE"+#<$# & , 8 P!@# & ,
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MW]T5;_8#_34XE,A8.7&>I.>J;EE>.C:E;8#3M4V5+K@Z?3VE#UKT5.I?*F=
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MNQ(M8',<)C\L,6O"-U:HI,.K:BC\G9$PVYR1D^YO;+)W]L7:,)&:8D=%16C
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MX$HUN@ZWHX@M:I  7XM'#U^/--JI=-3IJ454MTM/5-.&GT,SF9L@# & , 8
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MUHYSW&+OE\[<OW_,<X<T(.>H0K_$5>';PES9(#4HOWGPA#^3Z[>/E%<Q?O\
M1Q*2X;$H-R*V0+2ED/"8 &Q,):N>:GT_*TZ(3\Q[*/QV0RPU:9_[-M:S.V7X
MI02N#$;65H(OS>TK2# F$A8^7:_)8ZH=$J799>D2NUT%KRHCT#&9*CS#3!B#
M:X991S]>ONN!/QC8F2,-#='HTS-4>8&=(2@:&-C;TC2T-:%.'U"$3<VH"4Z)
M"D(!K024R8@HDL.O5  .OQ8*GU< KZ;?G59G_)]5E_6-MK!;]#_%^!PRG?\
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MU?')[I46.MG2SD5%+ 7%:E4.['4K/8%AV.UU)!55[&L<?@HI',RFJLY*RR.
MQ&TGH28S9[.HALK:X^["7,+7'S#MH5B %KHGGDLX_!QYTR&/!0KDGTK(G2*P
M/)-&*Y"S,DD61[NDOBN?P>W&.4HEAC>IKUVH1X=['@\@; B1/!AA[PR17:)6
M0C-BKJ<+86P35'_*_)52CIE+T?\ FX;!48 P"GCPR?Q7]P_RJ/?/WNBP6JU7
MDT>I27#X*FOS^Z(>C'RN>4(OS5'H\TJE'8;Q)H0]S)]3KE:6"1.OVYIF+FY1
MU*A7-OM+#4NYD='#E"U8) TA0/3\<@<C6DA(/F.0N2OZ:Y2LX!WE8IKIN5UW
M'2JJMBW2ZG310W2JJZLDDVDE-3E4P]>[J>Z#_9GD;$<K+#/%UVJ[-JU8VG10
M[E^XK=-5ZXJ:G1:HEU512W75L6DZ7<5=,;?#]Y*NLIC6+MR6@Y<7].2#F.!5
M QPJPH%+JOIJ-,U4*F9\AD.9KF46#-"E>I:A,KQ82V.];124#DK,$Y8\1QB7
M-)BZ1YNZ+D5<A<H+!T7_ (Q;KL6[]NMI4W*::ZKE&Q<I3:VD[;::RJI=+A.4
MOG[CNZ7_ &KY(JY2KPOQ*[:Q=[!WK2K=VW7<M6[-[OMBMTT-VZJ+]%+IJ^51
M<IKI=52V:G<=\(^4R>_ODD9X<YF;U7[TL;Y)+LZVE* D7[W9RIH967DZ,A<
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M@# & 5->='YIOM/]'4?^\F$YR')/TKR9]88+[S:(J\&OR*_49UBF>^#6!@#
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M:_(K]1G6*9[X-8& , [2/PW_ #6G"GU=H+_-#,_/W$?.+_[Z[Z]1M!9;F$#
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MF@4)UK<XHE!Z1:D/)4ICC230#%)->3AY/9H]5%SF"IC6Y_XGK7_1K.OZ+NN
M8.\??Y!?$?U1.;/N:A>13HNA=A-6KZ7VDN\D@@;W!R[T!U7%TM=USTA7])UT
M>NKZ0R-HD7.KA;\D=996EH1RTHTY-LF3WK5Z5E:!.T284#FR&QUW.5HRUXB7
M=(8M+TC%J6DY:;>Z&E^#)55,QVE'8,UM-S6%%;1L%.>Y#=YI#*X5U/'G).>X
M*3FLE'!UT]LM2UF-[8-*@5'CF#CIR4IS7 !* *G2$@0XG*4N=R^N%V&2,$#
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MK0WDIV]K:6MO3IT+<W(4Y"-"C()3)B2B2@ ")KU_PT>K27.X*F-;G_B>M?\
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M2O)GUA@OO-HBKP:_(K]1G6*9[X-8& , [2/PW_-:<*?5V@O\T,S\_<1\XO\
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M:8J>R*OC-<U)9#1#XFV/--M4I=@H%-95_+E)R][4OZ Y6<8YRA?H/K)PZ+(
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M8*G^IN>[CY[L]?"JL9M&A,9V$P5)=4T*3/S&OU=#&YSAM>37!1_I"LD8]:]
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M9E5;J\(VN.KTS:0>W:3#B.&6<Z=?6LI+;2\7C.?&,EEDE$I.8XZDMX;XB.(
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M@# & 4\>&3^*_N'^51[Y^]T6"U6J\FCU*2X?!48 P!@# & , 8 P!@# & ,
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M;Q]_4JY>^Y.$X)K\.KRJNUF-/*9_%+SI]>SD+[U6_/OY+^D<%_$VO71\6/\
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M4>^?O=%@M5JO)H]2DN'P5& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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ME,'R0O C5H4"3VA0G':<&R="))+$,S8Q#;;EYOW1(3! P!@# & , 8 P!@#
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ML3JWH3+$X(P1B&Q%B+TD2EHV./LB1/[<*MU<#7![='1R6 W,<RC?^,DE,$#
M(_W9SQ%KRDU%RB1O#VV*J%L*6V-'$K3\';2/+K+Z.MFB5B)["O1*S!($D>MU
MZ>D?N)B-2%\:VD1IYB$*M(I$IQ/.H?6G^!'^LO&SSI5D,KEDCAMF)IW6-+PN
MF(W;R*T9TURY(B@E2-E-,$Q2QM&^ZJU'+TD9:$:\D\J "9RY 4%W$T&J/6V,
M3M/3=,Q"XSVF6N5>7&OEY@LE&784OM&56_9RJV;!F4M;87'3'25GPV&0 LQK
MB==1F(0R/IQ1N Q\UTVV,9:V024U[D[TL6.3P=LH0W,9)0HRZ6_Q)38(& ,
M8 P!@%:4&\6/.L621=JD+E8$[8XI2<;I%&TKY4XQ#WEJBUH6):C=(U3M6Y\.
M?MO@WBRGMO5)RG0MD4-Q"(1K6): Q4,6VGS+.=.:'U]I[NO&%0!'1M*] (53
MVE)H-.V'U_ E#/!WL:1_9&RQVIH<'"XY#%7;H-W84GRHR-\%!76UEL2,E2*/
M/1;:06U&(%H;3SY]=>;=INX%D&"HP!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@$%/(S:$VJ'F8V6PR:K:O2*[
MIYLAMEVVW%LFUU24C/N@:WAETV2G5R5M>8ZQ_%2M7R2+CY4^-2YJAR71\L6E
M%DLHE!(M3$\<G"XN'"\[A1O*ZGOLR3/OC$ATLE?8B6F.C$C(-W+GSFX0ROSI
MTV/2N^D?-3S9TO<:?LF'5-'+_C]5HITWRS=?L[5/GUG^($84M9LX1(3A,)5/
M+*6M&X>4PI3<3I,K4S7T%WMT%3G-?*5A02&1:2S>U^1+:Z*GPKKC,CACNC5T
M;S4Q7H[L2R"PYV%J+2R9+37&,+V,QW5(H4Z+='E&/93&)K=Q$)MK3.%$-:QQ
M4\4UPX.5%ZUO,7T/4[!994MKOGN*2"LMWV[FRR2N5DE5K.%-;<J\O=.5S1<0
M-(V6[ZNBQD71SPP-RUP/"W.B.FI6^L\3$-U-:8N)V4U*TRYVI=2EK+Q<^$IF
MP="'X^4PN(2=404E4R.+L#\H3$;&(A.>[M21P.()V9O9FRB3% BR]CWL>P!U
ML6]B].\%#E& 5\)IO>J'R@_)D_6.@<J#D7&DUL6%5BT0\MG^+LJC%KTI%%<A
ME<K4NKNOE\E<3I'*RVX2%/%6%FBZAK:P1]<]$.TF>(WKA#_"/Q)RC3.5GTS[
M"OJS?*IU?"I/;JAIJ:AU\#K=9VX^H25ZFR"Y<Z0;B3JVM.>GY*H4)E>V8N5V
M8V6LTN[ >2FVT1E7&W5>L(D"9Y3,K/);949MIO9W;ZDVO,H\\[B1_+WD7L*]
M>S'#FZ21VJ6!N^#.S7)9#VA9+AW55(N8+^K*FH8AMA(ZB*CP%-Q1><#MMD$S
MHTY9<8=HZ6C]_;O=Y)(P=*5.TF_T5NU:;<-/=$=//D6^X*# *;)UTXK_  MM
M8\U0KK@Q,K1-()#<G/<H.JQA@2&$.=/3%7%*\@C6K8MVU95^3.;&QRYG!^9)
M&FCM:5-%SFQ^3CU+V5M>Q:/DS'0\YF5KN2C3>WZ,.7_Y/^L:TEW0A<*JVA'.
M%T\H[?\ @8,E.LC4G=D'%%1U7=+JH7FM2XIJ$KLIJL!;"&=&D(3%1MU0$3!0
MN?DNC8::)5*RSUV>"\*?0NB==QF/GKR5V!<_:"#G)XBU5QQE>Y1U&R#A9"^6
MFWE7C+SZ;"D\(E\](6:)C1K'?[;*C)[ CD;>VE AH$.D"F3'"='!L$;.3?DY
M[G*F.E9ST/(N3P5& , 8!"/R+6;/J>Y"LB?5Q)ED'>VV24PT/D_;TC4L6US6
M<OO.MH;<ED)@OK<[,B,VO:D?YM,M/+PV+FM@TR;?7!,:D;C@[$I2_,_/";2\
M[R("Q_KU9)/'4@=;#['351;FGF=JXS<3L]PN"+)U3Y'1]V5ES!8-A6 94=D0
MRIJ]Z#BM;1H#E>OR9',)^URUTCY):U\;$QHLU%41N66>3A-K52UTF/;8\ALN
M:O'53-C7%)^F^;IL[0'FC1-W&Q3G&K2>L+ALZHSG-1!8 XS"63QLI9GW-MBF
M5HS><U_$F"(0R)R#4<5NC&M(.4/?WD*F6XAZSX7R4G$N->:&S/O07<'17.O-
M/+$BB"ZC.@)_,>.KCOFR[5-$_BKJP'/G'G.,W _OM;$P<UJ3F,]QN)CL1&5F
MM)&QH0O38^)V]8G;A1YQ$))MY-9I+?$MZ\8\TO@1QM3S ]"U1'+"!+:^Y\BD
MAK=ZZ$]ZE\E<K)*K&8*:LY5YEZ<KFE(J:1L#R&Y+33=%NL79%2T\:%S)IN7O
MK-$5)[J!ACXLJ%Q>[)0VE+3;S6D;N*\]_5>R-1,8#!Y<K3DI%<JB$:D:I(FV
M,2=*H?&5$YG)R!&[$8(DDQ4(LK9@A#V (=CWL7IW@QO5[SE^ , 8 P#^9HMA
M*-$'?H$$L8M;_%OT;T'>];]&_3K?HWK_ (?Q8!3U8'4L>YKYXYHM[IGLOI]I
M<+ZA<.5H28+3E!3+:V6.5>MLUD!9#/%^67E8V-J<L]4<08L%LDLO1:?W@PWT
M>M]6#P6+Q]Y8?!8>[B;[IJK5JS2ZZW33G55"W*5+/@Y4Y7Y,Y%PE6/Y6QF&Y
M/P=%=NU5B<5<[U:5RZVK=#J;C:K::I6\C>O\PG&+6A6N;CW#W,B;VY(I7KUB
MCE.N2R$B-(2-0J4GF;X[] "2""QFF#W^(( "WO\ @SD;O<UR]8M7+U[DG&V[
M5FW7=NW*K-2IHMVZ77774]U--*=3>Y)FOX;X0.XK&8G#X3"]TO(]_$XJ_:PV
M'L6\735<O7[]RFU9M6Z9^57<N54T4K?4TBY?5-V*+6MZZSZ!]&]:WK_4WRO_
M  ;_ !Z__3/G"&X2N"]/M//R-6-]+/H']6^5OV9\"5P7I]H^1JQOI9] _JWR
MM^S/@2N"]/M'R-6-]+/H']6^5OV9\"5P7I]H^1JQOI9] _JWRM^S/@2N"]/M
M'R-6-]+/H']6^5OV9\"5P7I]H^1JQOI9] _JWRM^S/@2N"]/M'R-6-]+/H']
M6^5OV9\"5P7I]H^1JQOI9] _JWRM^S/@2N"]/M'R-6-]+/H']6^5OV9\"5P7
MI]H^1JQOI9] _JWRM^S/@2N"]/M'R-6-]+/H']6^5OV9\"5P7I]H^1JQOI9]
M _JWRM^S/@2N"]/M'R-6-]+/H']6^5OV9\"5P7I]H^1JQOI9] _JWRM^S/@2
MN"]/M'R-6-]+/H']6^5OV9\"5P7I]H^1JQOI9] _JWRM^S/@2N"]/M'R-6-]
M+/H']6^5OV9\"5P7I]H^1JQOI9] _JWRM^S/@2N"]/M'R-6-]+/H']6^5OV9
M\"5P7I]H^1JQOI9] _JWRM^S/@2N"]/M'R-6-]+/H']6^5OV9\"5P7I]H^1J
MQOI9] _JWRM^S/@2N"]/M($^1.4]%<P4I%Y]6765Q;?G>TF2'J]2*$<MNR+X
M(<(G-WH_V2<GG1"("KWR/H/4.V<((2?;E[+WLS0@!*X+T^TMWP0, 8 P!@#
M*L+N\C4JJR6]&ND?YZ1SCG/CJ:5U >F;95VZ5%IRSO4ZB]?SE\/JFHA5V_(;
M':JVA-H0]\EY\BLNM5:\U4YM4102)8U[]Z%E3,<:M%S2UGYT]S,-U'Y9IY?-
M^37G2JN=J=E4Z:)AT]#(^V$=9N"EXCBKF.V3JV5O72L<9N;7IRY[C=HH4*V0
M5>Z)=6F-]7F,T>&D3ENACZ@;X]_=[NAATPI;>YZ<5*C//@^!*'E[MN=="<OQ
M&]7FG:VAMG7'7SE9/._.D?Z2:)3,[68B(OI[;4*Q\FU;5 DB[R<Y%+&Y\T@:
M9>Q1MK3A?U#^LT,YL2B&DG$S&KCL]T5K7-WI174+%6:>]>0")LBBKE9S3=VV
M/HN:,S-7];KNI:[XRDQT0-9(57TFOB+6-*)2UR&153:T7I]N=ZYC"]6^-+BN
M-C#,_"ZI:T;3<-*-96TL]%"T:;:<::JU;F#JN8W%<-[41-:'04\[T.S5V[_Z
MG;5C]KMZ)KL)PGJ.-P>?G1:-LT;KNWD$9A+1.G>M8_(+%;F>#S^#.8I@(UU"
MB *-)).9F?1&?1G"?%,Q)T;Y"9Q3<QZ8)K_G1+:U6\2U]$;)ZIF[C<">OI6R
M,<GBKE8J]MIJ F5[*T-H2")5BW:FKXEE$XJAL5:6(X\QN[H\#/+3N/-P)2F,
M\WIE,[L^&>2R?FRG!<$\NTBMGI^1<QU30]43.2!M"^*JAH">I%Y4T3K*8A[K
M,&RQ+QKAOYY>76DZ:L8#87&X_/"72Q%2>7/#*Q_%M>-=[8H-E1+;62W:SN6>
M<;]"5'*G:TYORD";9L*I:OJJ2S9593=1%1Q_I%#.9G<+Q54@E40D[*C.G%6T
MBW,KD;*(R6E;-HS),WEM+RWO,A<(\'1J/0-).)Z7'^N95S&^]:2HR63*^FKB
MA T7LV.?6AG1AC3TI+)<P5K45.3WG%WZ$E-0"ET$2I#WB:S6[JXD"FN&FM*0
M;[#>(8[2);*ES&B@<FE@F&U$Y?)C+>TXF."3SS@MSI'K.<67T[<W-DYHU+7"
M^L8DEGS<_,]LL-H+-15ZGDFA\,36TS1J.HF6HYS8S''/E.@L(23.PEJZNUP7
M!_71M[1JV  JTDDY>?-"\SWQH](,?=&]RV15UEW17]+<[-EW)^8*(C'1'13R
M_P!R%5,H8X=,S;(.C<4JQJ'7,\+L:R7!CJ:;2 37('6M8<D3IF9O4SDMQ>=D
MH'O[^DE).)<2X64YY:YII9\Y%2"^9@ZW>@]473]'5Q-5,EGSG75;HSNEE39;
MSB<=S@CZ$AUIV;2R"AW]PK#GM\VZ-<!D%JI95.5<5D!Z@9$-D9R8#8I>_OZ2
M71"ESHGIQ:4)SFU^#)A<F=I3F^*]?YY;U5U-2"A595L5'4<-8>DR[%E5LSVC
MK2L>GK$9D">:5%1B!K&9,8 3N%;0KI,<_,L@3.$@(AAR,2%4*M1OG)/3BDUO
MY\RK\/<=64Y,+6O\KA9O2]70.:=7-MLQU'U!))'$XG!Z5HFLND^F)C7*^1P4
M# VV%(&MTAT27,,;J.!LEJ6"P*#@6X]5Z2VV$ZBT-PI<.(RU<M+*5.]IYPGE
MGD6JU!V;*;*ZK?\ G)[I$B(L@JF?+K@L[;K58YR^KJ^;YA%(C$WRU( Q1TE+
M3P;D#(G224RUK)U*Y))X[!IP;)F&$NT?5M 1#2V9G?&D9Q+C/.,IR6J)Z8*C
M & 1VZMZ$;>6Z)F%T.$5<YTH97&"Q2-0EH7(FI;+YY:=@Q6J:ZC.GAR"- R(
MWN=S6.MSF^JR51#&V*%CL8C6A1[2'"4I<=+\R4OT(K/NKRV3;G58OK:[>?J4
MKN[66YJ1KA_(EO79L>YL;(+?]4]!63 K0/Z!=>=R7Q(2%QYPG4 >8H\TNT*$
MDC&V*$;TX-2]$J5"RHE2FXAO3/)I-1.>JC//F<HYG6WDGO\ MA\X]+BW(E=M
M$1Z\B%BS-C?YWU')(P]1)GIA6SD6<YJ(XCY=?T+ZPJT#PFD50OB:4-R>RHRI
M;7AW)KXIQ 62(=,3GX.3R_UZ^#XF=+V[];J7L>B4R*"QNQ.?+J=U$6(OR*7!
M'UVT\N1M5@O+PUQ:&-3"]M4G01%'!" RYR?[#@*D;C+6%AKYIL22$/K*T"$I
MG//<N.[7=JH],%:EU=OPWJCG"3VQ<7";1)$U*0Z'6=(V![[!<JXCR3GWJ"@F
MJUH0T*Y9$8@S2F?V'>" ULII9S,D@,OA,ELP*"./,X7Q=4V2A4+*F'$YYKP9
M<I\-%&K<REN-B"+*2%L9CJQ,QJXRG5L30I3QM>C(;ET?(/;TYI3&M;TPS$R%
M6TEC"@4HTXQD)3DXR"AB+ '>Q0^[@# & , _D?\ ^H._Z(S_ /P+ -4'S$/;
M+'^'_%8XOSNULC>%C8"1+G=>D;4833>;FS116U2TTDC1AF];T6#8_6'O6]!U
MOT9NG<#B,/ANZ&W=Q-^SA[7Q3%4]\OW:+5O:=-,4[=RJFF7#A3+W'4_PTX''
M<H]PF*PW)^#Q6.Q+Y2Y-K6'P>'O8J^Z*+M;KK5JQ17<=-*:=56S%,YM&N#:5
MF5NNK*Q42*P80K6*X)+DJ1(EE;"H4JE*B/N!1"=.04O&:>>>:,!1))0!&&&"
M"  1"%K6^W^6N5N2KG(W*UNWRGR?<N7.3,?1111C<-57775A;M--%%--QU55
M55-*FE)MMI)-L\M=Q_<MW36.ZWN7OW^YWEVS9L]T7(EV]>N\D<H6[5JU;Y3P
MM=RY<N5X>FBW;MT)U5UU-4TTIU5-)-G8_P#4J:=*^;KB35J&2#F9U?O1;45#
M#ER::'D;2Z^&4T*4-9A3J1,E+%\)D1,YI.(=BI"8VF-9Y*\*<T'FP]_+7W]/
M-Q(HP]2E34K=\6>8KTF&JWBW%3[3+"CKWH R>-5-HW:G6MY*=&H\$<LX$-)M
M9=83ZIJ8QY;)_+J$ ^(8%%W6)E)T)0/5:3&>D;_-I&F_G,R<0R9^^1U@K6P#
MI?NSH8CD;XYE3&-SZ/+UU;R.Z+FC5/2I.BL E3((TV2Z)UX8[Q^KY9)))9M7
M1,4=C-CN3B[A32*0@UPTRX:PITX3KOURT/WS8)VJT,S@-E2>SI ^S3I&UD5=
MR&RTKV\/4O;4\:2S':T+LA84$89F ;<TR-2P)T".,PM,2@%'8>WI"4R%G #S
MCHSZW^$&*J>4"?NVK.<&MEZ)A3-$&VRXR[++*A71)<3O.2O<C@[AJ1Q^32F+
M)*%9ZPJ5(Q*8C3:6.R!9+I>"03)X9T++$T:IYL\2]%IYHRZ=\OJ670L+ L+R
M$-*-PFPUTQ?CVPB@Y&EK=]IZ*QN+.BFR.HK J6RHBYR,J)))&SQBM:+9XE:S
MLZ;?2WV..3@9/)-( 5NN3Q D&EIEOSF=%*>7%Y:;H6>;^Y3US=*733/8$<A,
MXF4HMUBYNA3I3SK-ZI;J8>6&^;.J*>O>VIJ2N<9C38YQ9KFA$6-AT@<4CNU!
M93$7O,GF28M1*GP,DTVLN:7*G/>MVZ4^@P7:U>RR9Z8&#D>OND&2MG,BB&V\
M&.ZVKJ"&)I#/1]A<PK6%Q7BL+W*>OBAII]!T:/HJR( >O;7:+KHZ.;2Q^+0,
MPFP$^+S6U$9;GOYVU'X&<G;BIX9S^;F^;GR>PS''J>2KY@AA,IN@$)K.DW>C
MKG7-]> 6.<[>9 ;7S992&*/.G>4N)"?X[R),V,J*/L8HY&4()Z[LMV4YKA&>
M;Z%UG).NPW&Z,L4-*KRP(];46E9JZG$U)/-W6W!I9&H]-ZT<!L4IDT1C];1Z
ME+=L%"C,C[--;BBE@U3 88;/0N#S)V5^F#84(72L\G,<_3DHW9SDLX(SF*K"
MB#+(7.:U3UY8RXUE;FNZX6U,72YD=L+I%9=LQ'&74A9$HO*G9;1#'%_C ]S^
M14RP26+;JQ#4\/ T2D:>%0!6)W+P>E1I&<\_"=\YHG8?&^G&_D>BX]SW/B7^
MRF8RD4DJE]U06?,,FD,4;9I$ V"J51BRGV-3N.G;BQ$AVO;; 4ND^61HHYMT
MXK)TM22 P1E+RC7)=&7I\WF.$]ZFO"J(5;"U33>RRPILQS2.DV514%Z1E-<T
MF['M<6+?KM>X[0C',I0JGD2/'L7/49D!X N+ZY/8%C\UM""22=H$KS1.]J=^
M6<:[W&63X'+ND'SJH-FH6VF'^81V$HF[F<@]0RU8P2\AX66ITPEJ^X7%>YR"
M-.PTYM7THXKK+$B;C&\F.N#4SRF6@6PQ(^QU_$*-^N?1DLNM\Y&..]+]1M-I
M5Q"+,D4V9'0=XP*I$C#ND41L=L^O7.P+88W:QK&F:*( 05O8DAC$(9G^/1]N
M>(0T+X\(V41V$O;++FUQB(G+/):3KIEDNOIB8;D^+V18O:$KEW1U25<S7JV0
M)W@5QP1E6P^L'HM0DTEY<5SN+RFOI<BI%Y;5CI*K3(% &Z5I;Z6.@ECPKAC7
M3L5FC8S3D84PH>6JU?/'%-<=^FNXX"WLG1]=S6(,1Q_34%K*"7_)/18T&IJ9
M6O+ 0)1./,2RLI>HHA@DX9GR)@95'+IC<4GKIY8&%IFM;NJ)O;6]TA+HTB<G
MPEK>]\4\^NOIDY(EZ \H;D6__"]='PZ:[K-M4&1%OJR;RB.,#HJH*#R0<EC2
M@BF5,0?I<3>CN\QM?&CNG)(($;*<H\35Z9UC"R<J1#V5SY_COC=$.4M6^!D^
MQK7[6A15@LD77W%-)I')<U1 Q*MYXWN%(Z?33RH6(5[1>TH334E;I/:T@@;W
M-)8[0Z'P:XVUH>ECF2DI!J0U6[-$G$9<V_?O<PL]%.7IF&C&B#H+MN9+WBO=
M/%AIK0(AE=EM</B%%/J1@51.QYM?<<>[/GMF3*G(@KKRR([4T.AEC1-BD++3
MZ5RLA$H80U>[()@WQ&."87NUO2YY:3F8SC>X,]3::W4QT9R"8TJK(=)L905H
M28C4QC#RAL*;])0CE]Y>:XA,YA"]B8'1S>W%>"P9DHBCK&DJM=*X SJQH??D
M1>QB(4N-SXY1,:]1]L(>_P!QU+8_&).I=38G8)*9'+ID@@%7JI-%I'2E'S'1
M;>G/HZ;L;\V1BSI!:\50+V= S+FQ$T)8[*'.62)H7O0A.666[G><]*W>;F(E
M3M-TI#Y;TI($7RB!.AD ZKG*2:O!UV("+&NHVZ:LF_$E>H6F5QUCJ-S*C2YN
M4U- D5-2:P6^;UT<Z(Y^BK1]F2J$/ *,N$J=^4/:<:[IW<ST9GCS.?DO0/\
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M!"*$.)REKG4/JE]ID[! P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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A# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
